PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	PG	WC	SC	GA	UT	PM
J	Sakuma, S; Matsumoto, S; Ishizuka, N; Mohri, K; Fukushima, M; Ohba, C; Kawakami, K				Sakuma, Shinji; Matsumoto, Satoshi; Ishizuka, Narimoto; Mohri, Kohta; Fukushima, Mayuko; Ohba, Chie; Kawakami, Kohsaku			Enhanced Boosting of Oral Absorption of Lopinavir Through Electrospray Coencapsulation with Ritonavir	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						boosting; oral absorption improvement; coaxial electrospray deposition; enteric-coated particle; lopinavir; ritonavir	GRAPEFRUIT JUICE; EXPRESSION CLONING; HEALTHY-VOLUNTEERS; P-GLYCOPROTEIN; DRUG-DELIVERY; IN-VIVO; DISSOLUTION; PROTEASE; RATS; PHARMACOKINETICS	In vivo activities of absorption enhancers coencapsulated with poorly absorptive drugs in the same enteric-coated particles were evaluated. Lopinavir [a substrate of cytochrome P450 3A (CYP3A)] and ritonavir (an inhibitor of CYP3A-mediatd metabolism) were used as a model drug and a model absorption enhancer, respectively. Lopinavir and ritonavir were encapsulated into enteric-coated particles as amorphous forms using coaxial electrospray deposition. The electrospray treatment resulted in dramatic improvement of dissolution profiles of both compounds, probably because of complete amorphization and superior dispersion efficiency of the particles. Poor absorption of lopinavir in rats was observed after oral administration of enteric-coated particles containing lopinavir alone. When the particles were coadministered with enteric-coated particles containing ritonavir alone, lopinavir absorption was boosted. The boosting effect was further enhanced when ritonavir was coencapsulated with lopinavir into the same enteric-coated particles. A significant increase in area under the plasma concentration-time curve reflected an extension of mean residence time rather than an elevation of C-max. Lopinavir absorption was improved presumably because lopinavir was always accompanied by a practical amount of ritonavir required for the boosting during the gastrointestinal transit of the particles. Not only did the electrospray coencapsulation technique improve drug absorption, but also increased trough concentration that might result in the reduction of the number of doses. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:2977-2985, 2015	[Sakuma, Shinji; Matsumoto, Satoshi; Ishizuka, Narimoto; Mohri, Kohta] Setsunan Univ, Fac Pharmaceut Sci, Hirakata, Osaka 5730101, Japan; [Fukushima, Mayuko; Ohba, Chie; Kawakami, Kohsaku] Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton, Tsukuba, Ibaraki 3050044, Japan	Sakuma, S (reprint author), Setsunan Univ, Fac Pharmaceut Sci, Hirakata, Osaka 5730101, Japan.	sakuma@pharm.setsunan.ac.jp; kawakami.kohsaku@nims.go.jp			(JSPS KAKENHI) from the Ministry of Education, Culture, Sports, Sciences, and Technology of Japan (MEXT) [25670016]; Health Labour Sciences Research Grant from the Ministry of Health, Labour, and Welfare of Japan; World Premier International Research Center (WPI) Initiative on Materials Nanoarchitectonics, MEXT, Japan	This work was financially supported in part by a grant-in-aid for scientific research (JSPS KAKENHI Grant No. 25670016) from the Ministry of Education, Culture, Sports, Sciences, and Technology of Japan (MEXT), Health Labour Sciences Research Grant from the Ministry of Health, Labour, and Welfare of Japan, and World Premier International Research Center (WPI) Initiative on Materials Nanoarchitectonics, MEXT, Japan. Japan Machinery is also acknowledged for the use of the flow-through cell apparatus.	Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; Zhang SL, 2011, MOL PHARMACEUT, V8, P807, DOI 10.1021/mp100401d; Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Ravi PR, 2012, PHYTOTHER RES, V26, P1490, DOI 10.1002/ptr.4593; Kataoka M, 2013, EUR J PHARM BIOPHARM, V85, P1317, DOI 10.1016/j.ejpb.2013.06.018; Heng D, 2008, PHARM RES-DORDR, V25, P1696, DOI 10.1007/s11095-008-9560-0; Petri N, 2006, INT J CLIN PHARM TH, V44, P71; Alonzo DE, 2011, J PHARM SCI-US, V100, P3316, DOI 10.1002/jps.22579; Kawakami K, 2010, INT J PHARMACEUT, V390, P250, DOI 10.1016/j.ijpharm.2010.02.018; Greiner B, 1999, J CLIN INVEST, V104, P147, DOI 10.1172/JCI6663; Ieiri I, 2012, J CLIN PHARMACOL, V52, P1078, DOI 10.1177/0091270011408612; Kumar GN, 2004, PHARM RES, V21, P1622, DOI 10.1023/B:PHAM.0000041457.64638.8d; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; AMIDON GL, 1995, PHARMACEUT RES, V12, P413, DOI 10.1023/A:1016212804288; Kawakami K, 2013, J PHARM SCI-US, V102, P518, DOI 10.1002/jps.23378; Ara R, 2008, HEALTH TECHNOL ASSES, V12, P1; Holmstock N, 2012, DRUG METAB DISPOS, V40, P1474; Kataoka M, 2013, DRUG METAB PHARMACOK, V28, P125, DOI 10.2133/dmpk.DMPK-12-RG-059; Kawakami K, 2013, INT J PHARMACEUT, V450, P123, DOI 10.1016/j.ijpharm.2013.04.006; Kawakami Kohsaku, 2015, Ther Deliv, V6, P339, DOI 10.4155/tde.14.116; Misaka S, 2013, J CLIN PHARMACOL, V53, P738, DOI 10.1002/jcph.95; Morishita M, 2006, J CONTROL RELEASE, V110, P587, DOI 10.1016/j.jconrel.2005.10.029; Nishimura T, 2007, DRUG METAB DISPOS, V35, P1275, DOI 10.1124/dmd.106.013037; Sai Y, 2004, DRUG DISCOV TODAY, V9, P712, DOI 10.1016/S1359-6446(04)03198-8; Sakuma S, 2007, J CONTROL RELEASE, V123, P195, DOI 10.1016/j.jconrel.2007.08.011; Shirasaka Y, 2013, J PHARM SCI-US, V102, P3418, DOI 10.1002/jps.23653; Shirasaka Y, 2008, DRUG METAB DISPOS, V36, P916, DOI 10.1124/dmd.107.020040; Strickley RG., 2007, ORAL LIPID BASED FOR, P1; Tamai I, 1996, ADV DRUG DELIVER REV, V20, P5, DOI 10.1016/0169-409X(95)00128-T; Tubic-Grozdanis M, 2008, PHARM RES-DORDR, V25, P1591, DOI 10.1007/s11095-007-9519-6; Hill A, 2009, AIDS, V23, P2237, DOI 10.1097/QAD.0b013e328332c3a5	33	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					2977	2985		10.1002/jps.24492		9	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200030		
J	Sakamoto, A; Matsumaru, T; Yamamura, N; Suzuki, S; Uchida, Y; Tachikawa, M; Terasaki, T				Sakamoto, Atsushi; Matsumaru, Takehisa; Yamamura, Norio; Suzuki, Shinobu; Uchida, Yasuo; Tachikawa, Masanori; Terasaki, Tetsuya			Drug Transporter Protein Quantification of Immortalized Human Lung Cell Lines Derived from Tracheobronchial Epithelial Cells (Calu-3 and BEAS2-B), Bronchiolar-Alveolar Cells (NCI-H292 and NCI-H441), and Alveolar Type II-like Cells (A549) by Liquid Chromatography-Tandem Mass Spectrometry	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						drug transport; membrane transporter; pulmonary drug delivery; cell lines; mass spectrometry; multidrug resistance-associated proteins; organic cation transporters (OCT); proteomics; pulmonary delivery; absorption	BLOOD-BRAIN-BARRIER; SIMULTANEOUS ABSOLUTE QUANTIFICATION; MULTIDRUG-RESISTANCE; UDP-GLUCURONOSYLTRANSFERASES; P-GLYCOPROTEIN; IN-VITRO; CYTOCHROME-P450 ENZYMES; PULMONARY ABSORPTION; PEPTIDE SELECTION; HUMAN PLATELETS	Understanding the mechanisms of drug transport in the human lung is an important issue in pulmonary drug discovery and development. For this purpose, there is an increasing interest in immortalized lung cell lines as alternatives to primary cultured lung cells. We recently reported the protein expression in human lung tissues and pulmonary epithelial cells in primary culture, (Sakamoto A, Matsumaru T, Yamamura N, Uchida Y, Tachikawa M, Ohtsuki S, Terasaki T. 2013. J Pharm Sci 102(9):3395-3406) whereas comprehensive quantification of protein expressions in immortalized lung cell lines is sparse. Therefore, the aim of the present study was to clarify the drug transporter protein expression of five commercially available immortalized lung cell lines derived from tracheobronchial cells (Calu-3 and BEAS2-B), bronchiolar-alveolar cells (NCI-H292 and NCI-H441), and alveolar type II cells (A549), by liquid chromatography-tandem mass spectrometry-based approaches. Among transporters detected, breast cancer-resistance protein in Calu-3, NCI-H292, NCI-H441, and A549 and OCTN2 in BEAS2-B showed the highest protein expression. Compared with data from our previous study,(Sakamoto A, Matsumaru T, Yamamura N, Uchida Y, Tachikawa M, Ohtsuki S, Terasaki T. 2013. J Pharm Sci 102(9):3395-3406) NCI-H441 was the most similar with primary lung cells from all regions in terms of protein expression of organic cation/carnitine transporter 1 (OCTN1). In conclusion, the protein expression profiles of transporters in five immortalized lung cell lines were determined, and these findings may contribute to a better understanding of drug transport in immortalized lung cell lines. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3029-3038, 2015	[Sakamoto, Atsushi; Matsumaru, Takehisa; Yamamura, Norio; Suzuki, Shinobu] Nippon Boehringer Ingelheim Pharmacokinet & Noncl, Kobe, Hyogo 6500047, Japan; [Sakamoto, Atsushi; Uchida, Yasuo; Tachikawa, Masanori; Terasaki, Tetsuya] Tohoku Univ, Grad Sch Pharmaceut Sci, Div Membrane Transport & Drug Targeting, Sendai, Miyagi 9808578, Japan	Sakamoto, A (reprint author), Nippon Boehringer Ingelheim Pharmacokinet & Noncl, Kobe, Hyogo 6500047, Japan.	atsushi.sakamoto@boehringer-ingelheim.com					Al-Jayyoussi G, 2013, J PHARM SCI-US, V102, P3382, DOI 10.1002/jps.23587; Foster KA, 1998, EXP CELL RES, V243, P359, DOI 10.1006/excr.1998.4172; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Florea BI, 2001, BRIT J PHARMACOL, V134, P1555, DOI 10.1038/sj.bjp.0704390; Sondergaard HB, 2008, PFLUG ARCH EUR J PHY, V456, P611, DOI 10.1007/s00424-007-0421-1; Niessen J, 2009, DRUG METAB DISPOS, V37, P1129, DOI 10.1124/dmd.108.024570; Horvath G, 2007, AM J RESP CELL MOL, V36, P53, DOI 10.1165/rcmb.2006-0230OC; Courcot E, 2012, DRUG METAB DISPOS, V40, P1953, DOI 10.1124/dmd.112.046896; Forbes B, 2003, INT J PHARM, V257, P161, DOI 10.1016/S0378-5173(03)00129-7; KOBAYASHI S, 1995, PHARMACEUT RES, V12, P1115, DOI 10.1023/A:1016295406473; Sung S, 2011, J CELL BIOCHEM, V112, P3015, DOI 10.1002/jcb.23226; Fehrenbach H, 1999, EUR RESPIR J, V14, P534, DOI 10.1034/j.1399-3003.1999.14c10.x; Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230; Ito K, 2011, J PHARM SCI-US, V100, P3939, DOI 10.1002/jps.22487; Endter S, 2009, J PHARM PHARMACOL, V61, P583, DOI 10.1211/jpp/61.05.0006; VANKALKEN CK, 1992, AM J PATHOL, V141, P1063; Sporty JL, 2008, EXPERT OPIN DRUG MET, V4, P333, DOI 10.1517/17425255.4.4.333 ; Uchida Y, 2011, J NEUROCHEM, V117, P333, DOI 10.1111/j.1471-4159.2011.07208.x; Nakamura T, 2010, MOL PHARMACEUT, V7, P187, DOI 10.1021/mp900206j; Scheffer GL, 2002, J CLIN PATHOL, V55, P332; Gonzalez RF, 2010, J HISTOCHEM CYTOCHEM, V58, P891, DOI 10.1369/jhc.2010.956433; Newton DA, 2006, J BIOL CHEM, V281, P5668, DOI 10.1074/jbc.M509314200; Schaefer O, 2012, DRUG METAB DISPOS, V40, P93, DOI 10.1124/dmd.111.042275; Kamiie J, 2008, PHARM RES, V25, P1469, DOI 10.1007/s11095-008-9532-4; Wang ZY, 2004, INT J PHARM, V269, P451, DOI 10.1016/j.ijpharm.2003.09.033; Bosquillon C, 2010, J PHARM SCI-US, V99, P2240, DOI 10.1002/jps.21995; Halldorsson S, 2007, IN VITRO CELL DEV-AN, V43, P283, DOI 10.1007/s11626-007-9050-4; Heijink IH, 2010, EUR RESPIR J, V35, P894, DOI 10.1183/09031936.00065809; Salomon JJ, 2012, EUR J PHARM BIOPHARM, V81, P351, DOI 10.1016/j.ejpb.2012.03.001; Hooijberg JH, 1999, CANCER RES, V59, P2532; Shlyonsky V, 2005, J BIOL CHEM, V280, P24181, DOI 10.1074/jbc.M413823200; Horvath G, 2007, J ALLERGY CLIN IMMUN, V120, P1103, DOI 10.1016/j.jaci.2007.08.034; Hukkanen J, 2000, AM J RESP CELL MOL, V22, P360; Haghi M, 2010, DRUG DEV IND PHARM, V36, P1207, DOI 10.3109/03639041003695113; LechaptZalcman E, 1997, EUR RESPIR J, V10, P1837, DOI 10.1183/09031936.97.10081837; Ohtsuki S, 2013, MOL PHARMACEUT, V10, P289, DOI 10.1021/mp3004308; Hamilton KO, 2001, J PHARMACOL EXP THER, V298, P1199; Ohtsuki S, 2012, DRUG METAB DISPOS, V40, P83, DOI 10.1124/dmd.111.042259; Mukherjee M, 2012, INT J PHARMACEUT, V426, P7, DOI 10.1016/j.ijpharm.2011.12.036; Niessen J, 2010, PHARMACOGENET GENOM, V20, P396, DOI 10.1097/FPC.0b013e32833997b0; van der Deen M, 2006, VIRCHOWS ARCH, V449, P682, DOI 10.1007/s00428-006-0240-3; Kawakami H, 2011, J PHARM SCI-US, V100, P341, DOI 10.1002/jps.22255; Tamai I, 2013, CURR OPIN PHARMACOL, V13, P859, DOI 10.1016/j.coph.2013.09.001; Budulac SE, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-60; Caterson AJ, 2005, INFECT IMMUN, V73, P1129; Salomon Johanna Jessica, 2012, Ther Deliv, V3, P735; Grainger CI, 2006, PHARM RES, V23, P1482, DOI 10.1007/s11095-006-0255-0; Hutter V, 2014, EUR J PHARM BIOPHARM, V86, P74, DOI 10.1016/j.ejpb.2013.06.010; Marinelli RA, 2005, J HEPATOL, V42, P592, DOI 10.1016/j.jhep.2005.01.001; Pawlowski KM, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-119; Ren XF, 2006, J GEN VIROL, V87, P1691, DOI 10.1099/vir.0.81749-0; Sakamoto A, 2013, J PHARM SCI-US, V102, P3395, DOI 10.1002/jps.23606; Sakamoto A, 2011, J PHARM SCI-US, V100, P4037, DOI 10.1002/jps.22591	53	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3029	3038		10.1002/jps.24381		10	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200034		
J	Tanaka, Y; Kitamura, Y; Maeda, K; Sugiyama, Y				Tanaka, Yuta; Kitamura, Yoshiaki; Maeda, Kazuya; Sugiyama, Yuichi			Quantitative Analysis of the ABCG2 c.421C > A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						pharmacogenetics; ABC transporters; pharmacokinetics; intestinal absorption; mathematical model	INTER-SUBJECT VARIABILITY; RECEPTOR-TYROSINE KINASE; COA REDUCTASE INHIBITORS; GENETIC POLYMORPHISMS; GRAPEFRUIT JUICE; PHYSIOLOGICAL-PARAMETERS; ORAL BIOAVAILABILITY; EFFLUX TRANSPORTERS; DRUG ABSORPTION; P-GLYCOPROTEIN	ABCG2 c.421C>A is one of the most frequent polymorphisms in ABCG2, which encodes the breast cancer resistance protein (BCRP). Clinical pharmacogenetic studies have shown that the plasma area under the concentration-time curve (AUC) values after oral administration of BCRP substrate drugs are significantly higher in subjects homozygous for the c.421C>A polymorphism (421AA) than in wild-type subjects (421CC). The aim of this study was to quantitatively estimate the in vivo decrease of BCRP function caused by the c.421C>A polymorphism based on clinical pharmacokinetic data. Assuming that the pharmacokinetic alteration is accounted for by intestinal BCRP, the ratio of the transport activity of the mutated BCRP to that of the wild-type was optimized by comparing calculations from an intestinal absorption model and clinical pharmacokinetic data. In conclusion, the in vivo intestinal BCRP transport activity in 421AA subjects is estimated to be approximately 23% of that in the 421CC subjects. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3039-3048, 2015	[Tanaka, Yuta; Kitamura, Yoshiaki] Kyorin Pharmaceut Co Ltd, Discovery Res Labs, Nogi, Tochigi, Japan; [Maeda, Kazuya] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Mol Pharmacokinet, Tokyo, Japan; [Sugiyama, Yuichi] RIKEN Res Cluster Innovat, RIKEN Innovat Ctr, Sugiyama Lab, Yokohama, Kanagawa, Japan	Tanaka, Y (reprint author), Kyorin Pharmaceut Co Ltd, Discovery Res Labs, Nogi, Tochigi, Japan.	yuuta.tanaka@mb.kyorin-pharm.co.jp					Adkison KK, 2008, BRIT J CLIN PHARMACO, V66, P233, DOI 10.1111/j.1365-2125.2008.03184.x; Akasaka K, 2010, CANCER CHEMOTH PHARM, V66, P691, DOI 10.1007/s00280-009-1211-6; Ieiri I, 2012, DRUG METAB PHARMACOK, V27, P85, DOI 10.2133/dmpk.DMPK-11-RV-098; Kondo C, 2004, PHARM RES, V21, P1895, DOI 10.1023/B:PHAM.0000045245.21637.d4; Li JB, 2011, DRUG METAB DISPOS, V39, P1196, DOI 10.1124/dmd.111.038075; Gardner ER, 2006, CLIN PHARMACOL THER, V80, P192, DOI 10.1016/j.clpt.2006.05.003; Tomita Y, 2013, CLIN PHARMACOL THER, V94, P37, DOI 10.1038/clpt.2012.221; Mizuarai S, 2004, INT J CANCER, V109, P238, DOI 10.1002/ijc.11669; Ieiri I, 2009, EXPERT OPIN DRUG MET, V5, P703, DOI 10.1517/17425250902976854; Sparreboom A, 2004, CLIN PHARMACOL THER, V76, P38, DOI 10.1016/j.clpt.2004.03.003; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Yu LX, 1996, ADV DRUG DELIVER REV, V19, P359, DOI 10.1016/0169-409X(96)00009-9; Ando H, 2005, BRIT J CLIN PHARMACO, V60, P494, DOI 10.1111/j.1365-2125.2005.02462.x; Cusatis G, 2006, J NATL CANCER I, V98, P1739, DOI 10.1093/jnci/djj469; Kobayashi D, 2005, DRUG METAB DISPOS, V33, P94, DOI 10.1124/dmd.104.001628; Urquhart BL, 2008, PHARMACOGENET GENOM, V18, P439, DOI 10.1097/FPC.0b013e3282f974dc; Zhu CY, 2002, EUR J MED CHEM, V37, P399, DOI 10.1016/S0223-5234(02)01360-0; Prasad B, 2013, J PHARM SCI-US, V102, P787, DOI 10.1002/jps.23436; Sparreboom A, 2005, CANCER BIOL THER, V4, P650; Ieiri I, 2007, CLIN PHARMACOL THER, V82, P541, DOI 10.1038/sj.clpt.6100190; Watanabe T, 2010, DRUG METAB DISPOS, V38, P215, DOI 10.1124/dmd.109.030254; Hirano M, 2005, MOL PHARMACOL, V68, P800, DOI 10.1124/mol.105.014019; Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028; Ho RH, 2007, PHARMACOGENET GENOM, V17, P647, DOI 10.1097/FPC.0b013e3280ef698f; Yamasaki Y, 2008, CLIN PHARMACOL THER, V84, P95, DOI 10.1038/sj.clpt.6100459; Morisaki K, 2005, CANCER CHEMOTH PHARM, V56, P161, DOI 10.1007/s00280-004-0931-x; Tomlinson B, 2010, CLIN PHARMACOL THER, V87, P558, DOI 10.1038/clpt.2009.232; Rudin CM, 2008, J CLIN ONCOL, V26, P1119, DOI 10.1200/JCO.2007.13.1128; DeSesso JM, 2001, FOOD CHEM TOXICOL, V39, P209, DOI 10.1016/S0278-6915(00)00136-8; Tamura M, 2012, NAGOYA J MED SCI, V74, P133; Lilja JJ, 1999, CLIN PHARMACOL THER, V66, P118, DOI 10.1053/cp.1999.v66.100453001; Li J, 2007, CANCER BIOL THER, V6, P432; Winiwarter S, 1998, J MED CHEM, V41, P4939, DOI 10.1021/jm9810102; Keskitalo JE, 2009, PHARMACOGENOMICS, V10, P1617, DOI [10.2217/pgs.09.85, 10.2217/PGS.09.85]; Uchimura T, 2010, BIOPHARM DRUG DISPOS, V31, P286, DOI 10.1002/bdd.711; Keskitalo JE, 2009, CLIN PHARMACOL THER, V86, P197, DOI 10.1038/clpt.2009.79; Kadono K, 2010, DRUG METAB DISPOS, V38, P1230, DOI 10.1124/dmd.109.029322; Martin PD, 2003, CLIN THER, V25, P2553, DOI 10.1016/S0149-2918(03)80316-8; Merino G, 2005, MOL PHARMACOL, V67, P1758, DOI 10.1124/mol.104.010439; Gertz M, 2010, DRUG METAB DISPOS, V38, P1147, DOI 10.1124/dmd.110.032649; Bolger MB, 2009, AAPS J, V11, P353, DOI 10.1208/s12248-009-9111-6; Chen WQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070341; DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122; Deguchi T, 2011, DRUG METAB DISPOS, V39, P820, DOI 10.1124/dmd.110.037457; Fukazawa I, 2004, BRIT J CLIN PHARMACO, V57, P448, DOI 10.1046/j.1365-2125.2003.02030.x; Hisaka A, 1998, J PHARMACOKINET BIOP, V26, P495, DOI 10.1023/A:1023294632129; HOENER BA, 1981, CLIN PHARMACOL THER, V29, P808; Ito K, 1999, PHARMACEUT RES, V16, P225, DOI 10.1023/A:1018872207437; Johnson MA, 1998, BRIT J CLIN PHARMACO, V46, P21, DOI 10.1046/j.1365-2125.1998.00044.x; Kim CO, 2012, J CARDIOVASC PHARM, V60, P49, DOI 10.1097/FJC.0b013e3182576098; Kim HS, 2007, BRIT J CLIN PHARMACO, V64, P645, DOI 10.1111/j.1365-2125.2007.02944.x; Kretz O, 2004, BRIT J CLIN PHARMACO, V58, P212, DOI 10.1111/j.1365-2125.2004.02117.x; LENNERNAS H, 1993, BRIT J CLIN PHARMACO, V35, P243; Li J, 2006, INVEST NEW DRUG, V24, P291, DOI 10.1007/s10637-006-5269-2; Matsushima S, 2005, J PHARMACOL EXP THER, V314, P1059, DOI 10.1124/jpet.105.085589; Mizuno T, 2012, DRUG METAB PHARMACOK, V27, P631, DOI 10.2133/dmpk.DMPK-12-RG-026; SINGHVI SM, 1990, BRIT J CLIN PHARMACO, V29, P239; Steeghs N, 2011, INVEST NEW DRUG, V29, P137, DOI 10.1007/s10637-009-9347-0; TSE FLS, 1992, J CLIN PHARMACOL, V32, P630; vansLeeuwen R, 1992, AIDS, V6, P1471; Zhou Q, 2013, PHARMAZIE, V68, P129, DOI 10.1691/ph.2013.2693; Zhou Q, 2012, ARZNEIMITTELFORSCH, V62, P519, DOI 10.1055/s-0032-1323696	62	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3039	3048		10.1002/jps.24366		10	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200035		
J	Kubo, Y; Ohtsuki, S; Uchida, Y; Terasaki, T				Kubo, Yoshiyuki; Ohtsuki, Sumio; Uchida, Yasuo; Terasaki, Tetsuya			Quantitative Determination of Luminal and Abluminal Membrane Distributions of Transporters in Porcine Brain Capillaries by Plasma Membrane Fractionation and Quantitative Targeted Proteomics	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						blood-brain barrier; transporter; membrane transport; localization; species differences; mass spectrometry; pharmacoproteomics (PPx); quantitative targeted absolute proteomics (QTAP); polarity	MICROVESSEL ENDOTHELIAL-CELLS; AMINO-ACID-TRANSPORT; ELECTRON-MICROSCOPIC IMMUNOGOLD; TO-BLOOD EFFLUX; P-GLYCOPROTEIN; GLUCOSE-TRANSPORTER; IN-VITRO; ULTRASTRUCTURAL-LOCALIZATION; BARRIER TRANSPORTERS; RESISTANCE PROTEIN	Abluminal or luminal localization of transporter in plasma membranes at the blood-brain barrier (BBB) is critical for their physiological and pharmacological roles. Therefore, the purpose of this study was to develop a new method to investigate membrane localization of transporters, through quantitative measurement of protein expression levels in fractionated plasma membrane prepared from porcine brain capillaries. Luminal-abluminal distribution ratios were calculated from the results of quantitative targeted absolute proteomics of fractionated membranes, after correction for cross-contamination based on measurements of luminal and abluminal membrane markers. BCRP expression was greater at the luminal membrane than at the abluminal membrane, supporting the usefulness of the distribution ratio as a quantitative indicator of localization. The distribution ratios suggested luminal-dominant localizations of GLUT1 and OATP3A1, and abluminal-dominant localizations of ABCA1 and FATP1. For OATP3A1, ABCA1 and FATP1, these results require reconsideration of their functions at the BBB. Species differences were examined using expression levels normalized to Na+/K+-ATPase. BCRP expression is dominant over multidrug resistance 1 expression in porcine BBB, as in other primates including humans. This methodology for quantitative measurement of protein localization is expected to improve our understanding of the roles of transporters at the BBB, and should be applicable to other polarized cells. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3060-3068, 2015	[Kubo, Yoshiyuki] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Pharmaceut, Sugitani, Toyama 9300194, Japan; [Ohtsuki, Sumio] Kumamoto Univ, Fac Life Sci, Dept Pharmaceut Microbiol, Kumamoto 8620973, Japan; [Uchida, Yasuo; Terasaki, Tetsuya] Tohoku Univ, Grad Sch Pharmaceut Sci, Div Membrane Transport & Drug Targeting, Aoba Ku, Sendai, Miyagi 9808578, Japan	Terasaki, T (reprint author), Tohoku Univ, Grad Sch Pharmaceut Sci, Div Membrane Transport & Drug Targeting, Aoba Ku, Sendai, Miyagi 9808578, Japan.	terasaki.tetsuya@m.tohoku.ac.jp			Global COE Program from the Japan Society for the Promotion of Science;  [KAKENHI: 24249011]	This study was supported in part by a Global COE Program from the Japan Society for the Promotion of Science and Grants-in-Aid for Scientific Research (A) (KAKENHI: 24249011). The authors thank Dr. Katsuaki Ito for his technical support and valuable discussions concerning isolation of porcine brain capillaries and the quantification of membrane proteins, and Dr. Ken Ohmine and Dr. Wataru Obuchi for their technical support during protein quantification with LC-MS/MS.	Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; PARDRIDGE WM, 1990, J PHARMACOL EXP THER, V253, P884; Zhang L, 1999, EXP BRAIN RES, V126, P509, DOI 10.1007/s002210050759; CORNFORD EM, 1994, J CEREBR BLOOD F MET, V14, P106; Mori S, 2003, J CEREBR BLOOD F MET, V23, P432, DOI 10.1097/01.WCB.0000050062.57184.75; Cooray HC, 2002, NEUROREPORT, V13, P2059, DOI 10.1097/00001756-200211150-00014; Ito K, 2011, J PHARM SCI-US, V100, P3939, DOI 10.1002/jps.22487; Asaba H, 2000, J NEUROCHEM, V75, P1907, DOI 10.1046/j.1471-4159.2000.0751907.x; Virgintino D, 2002, J HISTOCHEM CYTOCHEM, V50, P1671; Uchida Y, 2011, J NEUROCHEM, V117, P333, DOI 10.1111/j.1471-4159.2011.07208.x; Hori S, 2004, J NEUROCHEM, V90, P526, DOI 10.1111/j.1471-4159.2004.02537.x; Kim WS, 2006, NEUROREPORT, V17, P891, DOI 10.1097/01.wnr.0000221833.41340.cd; Leino RL, 1999, DEV BRAIN RES, V113, P47, DOI 10.1016/S0165-3806(98)00188-6; Shawahna R, 2011, MOL PHARMACEUT, V8, P1332, DOI 10.1021/mp200129p; Mitchell RW, 2009, J NEUROCHEM, V110, P1049, DOI 10.1111/j.1471-4159.2009.06199.x; Mitchell RW, 2011, J NEUROCHEM, V117, P735, DOI 10.1111/j.1471-4159.2011.07245.x; Panzenboeck U, 2002, J BIOL CHEM, V277, P42781, DOI 10.1074/jbc.M207601200; Gunn RN, 2012, J CEREBR BLOOD F MET, V32, P874, DOI 10.1038/jcbfm.2012.1; Kamiie J, 2008, PHARM RES, V25, P1469, DOI 10.1007/s11095-008-9532-4; BETZ AL, 1980, BRAIN RES, V192, P17, DOI 10.1016/0006-8993(80)91004-5; Zhang WD, 2003, FASEB J, V17, P2085, DOI 10.1096/fj.02-1131fje; FARRELL CL, 1991, P NATL ACAD SCI USA, V88, P5779, DOI 10.1073/pnas.88.13.5779; Tamai I, 2000, BIOCHEM BIOPH RES CO, V273, P251, DOI 10.1006/bbrc.2000.2922; Franke H, 2000, BRAIN RES PROTOC, V5, P248, DOI 10.1016/S1385-299X(00)00020-9; Ohtsuki S, 2013, MOL PHARMACEUT, V10, P289, DOI 10.1021/mp3004308; Ohtsuki S, 2007, PHARM RES, V24, P1745, DOI 10.1007/s11095-007-9374-5; Roberts LM, 2008, NEUROSCIENCE, V155, P423, DOI 10.1016/j.neuroscience.2008.06.015; Dauchy S, 2008, J NEUROCHEM, V107, P1518, DOI 10.1111/j.1471-4159.2008.05720.x; Kawakami H, 2011, J PHARM SCI-US, V100, P341, DOI 10.1002/jps.22255; Gao B, 2000, J PHARMACOL EXP THER, V294, P73; Bauer B, 2003, PHARMACEUT RES, V20, P1170, DOI 10.1023/A:1025040712857; DELPINO MMS, 1995, J BIOL CHEM, V270, P14913; DELPINO MMS, 1992, J BIOL CHEM, V267, P25951; Edmond J, 1998, J NEUROCHEM, V70, P1227; Gonzalez-Gonzalez IM, 2005, NEUROSCIENCE, V130, P61, DOI 10.1016/j.neuroscience.2004.09.023; Hatanaka T, 2000, BBA-BIOMEMBRANES, V1467, P1, DOI 10.1016/S0005-2736(00)00252-2; Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200; Hoshi Y, 2013, J PHARM SCI-US, V102, P3343, DOI 10.1002/jps.23575; Leino RL, 1997, J NEUROSCI RES, V49, P617; Nies AT, 2004, NEUROSCIENCE, V129, P349, DOI 10.1016/j.neuroscience.2004.07.051; Ohtsuki S, 2001, J PHARM SCI, V100, P3547; Patabendige A, 2013, BRAIN RES, V1521, P16, DOI 10.1016/j.brainres.2013.04.006; Simpson IA, 2001, J BIOL CHEM, V276, P12725, DOI 10.1074/jbc.M010897200; Tachikawa M, 2013, DRUG DELIVERY BRAINP, P23; Takanaga H, 2002, MOL PHARMACOL, V61, P1289, DOI 10.1124/mol.61.6.1289; Teifel M, 1996, EXP CELL RES, V228, P50, DOI 10.1006/excr.1996.0298; TSUJI A, 1992, LIFE SCI, V51, P1427, DOI 10.1016/0024-3205(92)90537-Y; Wells GAH, 2003, J GEN VIROL, V84, P1021, DOI 10.1099/vir.0.18788-0	48	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3060	3068		10.1002/jps.24398		9	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200037		
J	Tega, Y; Kubo, Y; Yuzurihara, C; Akanuma, SI; Hosoya, KI				Tega, Yuma; Kubo, Yoshiyuki; Yuzurihara, Chihiro; Akanuma, Shin-Ichi; Hosoya, Ken-Ichi			Carrier-Mediated Transport of Nicotine Across the Inner Blood-Retinal Barrier: Involvement of a Novel Organic Cation Transporter Driven by an Outward H+ Gradient	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						blood-retinal barrier; nicotine; organic cation transporter; membrane transport; transporters; membrane transporter; drug transport; in vitro models; TR-iBRB2 cells	GLUTAMATE-INDUCED EXCITOTOXICITY; MEMBRANE MONOAMINE TRANSPORTER; TISSUE DISTRIBUTION PATTERN; FUNCTIONAL-CHARACTERIZATION; ACETYLCHOLINE-RECEPTORS; GANGLION-CELLS; RAT; BRAIN; ANTIPORTER; IDENTIFICATION	The present study was carried out to investigate the blood-to-retina transport of nicotine across the inner blood-retinal barrier (BRB). Using the in vivo vascular injection method, the blood-to-retina influx clearance of nicotine across the BRB was determined as 131 L/(min?g retina), which is much higher than that of a nonpermeable paracellular marker, and blood-to-retina transport of nicotine was inhibited by organic cations such as pyrilamine and verapamil. The nicotine uptake by a conditionally immortalized rat retinal capillary endothelial cell line (TR-iBRB2 cells), an in vitro model of the inner BRB, exhibited time, temperature, and concentration dependence with a K-m of 492 M. These results suggest the involvement of a carrier-mediated transport process in nicotine transport in the inner BRB. The nicotine uptake by TR-iBRB2 cells was stimulated by an outwardly directed H+ gradient, and the uptake was significantly inhibited by bulky and hydrophobic cationic drugs, whereas inhibitors of organic cation transporters did not show inhibitory effect. These results suggest that the novel organic cation transport system driven by an outwardly directed H+ gradient is involved in the blood-to-retina transport of nicotine across the inner BRB. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3069-3075, 2015	[Tega, Yuma; Kubo, Yoshiyuki; Yuzurihara, Chihiro; Akanuma, Shin-Ichi; Hosoya, Ken-Ichi] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Pharmaceut, Toyama 930, Japan	Hosoya, KI (reprint author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Pharmaceut, Toyama 930, Japan.	hosoyak@pha.u-toyama.ac.jp			Japan Society for the Promotion of Science (JSPS) [25293036, 26460193]	This work was partly supported by a Grant-in-Aid for Scientific Research (B) (25293036) and Scientific Research (C) (26460193) from the Japan Society for the Promotion of Science (JSPS).	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Puchowicz MA, 2004, J CEREBR BLOOD F MET, V24, P449, DOI 10.1097/WCB.0000115096.40457.40; Okura T, 2011, J PHARM SCI-US, V100, P3924, DOI 10.1002/jps.22594; VanWert AL, 2010, BIOPHARM DRUG DISPOS, V31, P1, DOI 10.1002/bdd.693; Urakami Y, 1998, J PHARMACOL EXP THER, V287, P800; Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733; Hosoya K, 2010, PHARM RES-DORDR, V27, P2715, DOI 10.1007/s11095-010-0272-x; Tachikawa M, 2010, INVEST OPHTH VIS SCI, V51, P430, DOI 10.1167/iovs.09-4080; KEYSER KT, 1993, J NEUROSCI, V13, P442; Moretti M, 2004, MOL PHARMACOL, V66, P85, DOI 10.1124/mol.66.1.85; Tega Y, 2013, NEUROCHEM INT, V62, P173, DOI 10.1016/j.neuint.2012.11.014; Wehrwein E, 2004, INVEST OPHTH VIS SCI, V45, P1531, DOI 10.1167/iovs-03-0406; Kubo Y, 2014, MOL PHARMACEUT, V11, P3747, DOI 10.1021/mp500516j; LIGHTMAN SL, 1987, J PHYSIOL-LONDON, V389, P483; Kubo Y, 2013, PHARM RES-DORDR, V30, P847, DOI 10.1007/s11095-012-0926-y; Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X; Smith ML, 2014, MOL VIS, V20, P1328; Hosoya K, 2001, EXP EYE RES, V72, P163, DOI 10.1006/exer.2000.0941; Wu X, 2000, BBA-BIOMEMBRANES, V1466, P315, DOI 10.1016/S0005-2736(00)00189-9; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Itagaki S, 2012, DRUG METAB DISPOS, V40, P1138, DOI 10.1124/dmd.111.042432; Urakami Y, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000019413.78751.46; Ohta KY, 2006, DRUG METAB DISPOS, V34, P1868, DOI 10.1124/dmd.106.010876; Thompson SA, 2006, EXP EYE RES, V83, P1135, DOI 10.1016/j.exer.2006.05.022; Dom AM, 2011, INVEST OPHTH VIS SCI, V52, P4428, DOI 10.1167/iovs.10-5461; Picciotto MR, 2000, NEUROPSYCHOPHARMACOL, V22, P451, DOI 10.1016/S0893-133X(99)00146-3; Okura T, 2008, DRUG METAB DISPOS, V36, P2005, DOI 10.1124/dmd.108.022087; Iwamoto K, 2014, INVEST OPHTH VIS SCI, V55, P1078, DOI 10.1167/iovs.13-12688; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482; Brandt SK, 2011, NEUROSCIENCE, V172, P387, DOI 10.1016/j.neuroscience.2010.10.071; Fukada A, 2002, J PHARMACOL EXP THER, V302, P532, DOI 10.1124/jpet.102.034629; Fukada Atsuko, 2002, Drug Metab Pharmacokinet, V17, P554, DOI 10.2133/dmpk.17.554; Gourlay SG, 1997, CLIN PHARMACOL THER, V62, P453, DOI 10.1016/S0009-9236(97)90124-7; Hosoya K, 2004, INVEST OPHTH VIS SCI, V45, P1232, DOI 10.1167/iovs.03-0505; Hosoya K, 2005, EUR J PHARM BIOPHARM, V60, P227, DOI 10.1016/j.ejpb.2004.12.007; Hosoya KI, 2009, PHARM RES-DORD, V26, P2055, DOI 10.1007/s11095-009-9930-2; HUTCHINS JB, 1985, INVEST OPHTH VIS SCI, V26, P1550; Kubo Y, 2013, J PHARM SCI-US, V102, P3332, DOI 10.1002/jps.23535; Lin HY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050138; Ohkura Y, 2010, EXP EYE RES, V91, P387, DOI 10.1016/j.exer.2010.06.010; SPECTOR R, 1982, J NEUROCHEM, V38, P594, DOI 10.1111/j.1471-4159.1982.tb08669.x; Strang CE, 2005, AM J PHYSIOL-CELL PH, V289, pC644, DOI 10.1152/ajpcell.00633.2004; Takami K, 1998, J PHARMACOL EXP THER, V286, P676; Tega Y, 2015, DRUG METAB DISPOS, V43, P89, DOI 10.1124/dmd.114.061002; Tsuda M, 2007, AM J PHYSIOL-RENAL, V292, pF593, DOI 10.1152/ajprenal.00312.2006; Varghese SB, 2011, INVEST OPHTH VIS SCI, V52, P9445, DOI 10.1167/iovs.11-7874; Wood JPM, 2003, EXP EYE RES, V76, P505, DOI 10.1016/S0014-4835(02)00335-4; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879; Yoneyama D, 2010, EXP EYE RES, V90, P507, DOI 10.1016/j.exer.2010.01.003; Zevin S, 1998, J PHARM SCI, V87, P702, DOI 10.1021/js970455v	50	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3069	3075		10.1002/jps.24453		7	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200038		
J	Ohura, K; Nakada, Y; Kotani, S; Imai, T				Ohura, Kayoko; Nakada, Yuichiro; Kotani, Shunsuke; Imai, Teruko			Design of Fexofenadine Prodrugs Based on Tissue-Specific Esterase Activity and Their Dissimilar Recognition by P-Glycoprotein	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						bioavailability; membrane transport; metabolism; oral absorption; P-glycoprotein; prodrugs	HUMAN INTESTINAL-ABSORPTION; HUMAN LIVER-MICROSOMES; IN-VITRO; CARBOXYLESTERASE ISOZYMES; ORAL BIOAVAILABILITY; CATALYTIC-PROPERTIES; HYDROLASE ACTIVITY; CACO-2 CELLS; RAT-LIVER; TERFENADINE	The aim of this study was to develop a suitable prodrug for fexofenadine (FXD), a model parent drug, that is resistant to intestinal esterase but converted to FXD by hepatic esterase. Carboxylesterases (CESs), human carboxylesterase 1 (hCE1) and human carboxylesterase 2 (hCE2), are the major esterases in human liver and intestine, respectively. These two CESs show quite different substrate specificities, and especially, hCE2 poorly hydrolyzes prodrugs with large acyl groups. FXD contains a carboxyl group and is poorly absorbed because of low membrane permeability and efflux by P-glycoprotein (P-gp). Therefore, two potential FXD prodrugs, ethyl-FXD and 2-hydroxyethyl-FXD, were synthesized by substitution of the carboxyl group in FXD. Both derivatives were resistant to intestinal hydrolysis, indicating their absorption as intact prodrugs. Ethyl-FXD was hydrolyzed by hepatic hCE1, but 2-hydroxyethyl-FXD was not. Both derivatives showed high membrane permeability in human P-gp-negative LLC-PK1 cells. In LLC-GA5-COL300 cells overexpressing human P-gp, ethyl-FXD was transported by P-gp, but its efflux was easily saturated. Whereas 2-hydroxyethyl-FXD showed more efficient P-gp-mediated transport than FXD. Although the structure of 2-hydroxyethyl-FXD only differs from ethyl-FXD by substitution of a hydroxyl group, 2-hydroxyethyl-FXD is unsuitable as a prodrug. However, ethyl-FXD is a good candidate prodrug because of good intestinal absorption and hepatic conversion by hCE1. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3076-3083, 2015	[Ohura, Kayoko; Kotani, Shunsuke; Imai, Teruko] Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto, Japan; [Nakada, Yuichiro] Santen Pharmaceut Co Ltd, Osaka, Japan	Imai, T (reprint author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto, Japan.	iteruko@gpo.kumamoto-u.ac.jp					Kataoka M, 2011, EUR J PHARM SCI, V44, P544, DOI 10.1016/j.ejps.2011.09.007; Quinney SK, 2005, J PHARMACOL EXP THER, V313, P1011, DOI 10.1124/jpet.104.081265; Zdrazil B, 2012, MOL INFORM, V31, P599, DOI 10.1002/minf.201200059; Wang RW, 2000, DRUG METAB DISPOS, V28, P360; Imai T, 2010, CURR DRUG METAB, V11, P793, DOI 10.2174/138920010794328904; TANIGAWARA Y, 1992, J PHARMACOL EXP THER, V263, P840; Takai S, 1997, BIOL PHARM BULL, V20, P869; Alelyunas YW, 2009, EUR J PHARM SCI, V37, P172, DOI 10.1016/j.ejps.2009.02.007; Waring MJ, 2010, EXPERT OPIN DRUG DIS, V5, P235, DOI 10.1517/17460441003605098; Petri N, 2004, PHARM RES, V21, P1398, DOI 10.1023/B:PHAM.0000036913.90332.b1; Shi DS, 2006, J PHARMACOL EXP THER, V319, P1477, DOI 10.1124/jpet.106.111807; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; Humerickhouse R, 2000, CANCER RES, V60, P1189; Gleeson MP, 2008, J MED CHEM, V51, P817, DOI 10.1021/jm701122q; Satoh T, 2006, CHEM-BIOL INTERACT, V162, P195, DOI 10.1016/j.cbi.2006.07.001; Chen Chen, 2007, Drugs R D, V8, P301, DOI 10.2165/00126839-200708050-00004; Lappin G, 2010, EUR J PHARM SCI, V40, P125, DOI 10.1016/j.ejps.2010.03.009; LING KHJ, 1995, DRUG METAB DISPOS, V23, P631; Seelig A, 1998, EUR J BIOCHEM, V251, P252, DOI 10.1046/j.1432-1327.1998.2510252.x; Tang M, 2006, J PHARMACOL EXP THER, V319, P1467, DOI 10.1124/jpet.106.110577; Sherer EC, 2012, MOL INFORM, V31, P231, DOI 10.1002/minf.201100157; Klopman G, 1997, MOL PHARMACOL, V52, P323; Perloff MD, 2003, PHARMACEUT RES, V20, P1177, DOI 10.1023/A:1025092829696; Litman T, 1997, BBA-MOL BASIS DIS, V1361, P159, DOI 10.1016/S0925-4439(97)00026-4; Imai T, 2006, DRUG METAB PHARMACOK, V21, P173, DOI 10.2133/dmpk.21.173; Imai T, 2005, DRUG METAB DISPOS, V33, P1185, DOI 10.1124/dmd.105.004226; Zhao R, 2009, DRUG METAB DISPOS, V37, P529, DOI 10.1124/dmd.107.019893; Yasui-Furukori N, 2005, CLIN PHARMACOL THER, V77, P17, DOI 10.1016/j.clpt.2004.08.026; HEYMANN E, 1967, H-S Z PHYSIOL CHEM, V348, P609, DOI 10.1515/bchm2.1967.348.1.609; Imai T, 2006, DRUG METAB DISPOS, V34, P1734, DOI 10.1124/dmd.106.009381; Badwan AA, 1990, ANAL PROFILE DRUG SU, V19, P627; BLOCK W, 1978, BIOCHIM BIOPHYS ACTA, V524, P85, DOI 10.1016/0005-2744(78)90106-7; Fujiyama N, 2010, DRUG METAB DISPOS, V38, P2210, DOI 10.1124/dmd.110.034249; Giacomo BD, 1999, FARMACO, V54, P600; Hsiao P, 2007, DRUG METAB DISPOS, V36, P481, DOI 10.1124/dmd.107.018176; Imai T, 2010, J PESTIC SCI, V35, P229, DOI 10.1584/jpestics.R10-03; Jurima-Romet M, 1998, BRIT J CLIN PHARMACO, V45, P318, DOI 10.1046/j.1365-2125.1998.00681.x; Lalonde RL, 1996, PHARMACEUT RES, V13, P832, DOI 10.1023/A:1016036624935; Lin HX, 2005, EUR J PHARM SCI, V26, P203, DOI 10.1016/j.ejps.2005.06.003; Martin DE, 1997, J CLIN PSYCHOPHARM, V17, P451, DOI 10.1097/00004714-199712000-00003; MENTLEIN R, 1988, BIOCHIM BIOPHYS ACTA, V964, P319, DOI 10.1016/0304-4165(88)90032-3; Nozawa T, 2011, DRUG METAB DISPOS, V39, P1263, DOI 10.1124/dmd.110.037937; Ohura K, 2011, J PHARM SCI-US, V100, P3985, DOI 10.1002/jps.22628; Ohura K, 2012, J PHARM SCI-US, V101, P3264, DOI 10.1002/jps.23182; OKERHOLM RA, 1981, BIOPHARM DRUG DISPOS, V2, P185, DOI 10.1002/bdd.2510020211; Pleban K, 2004, BIOORG MED CHEM LETT, V14, P5823, DOI 10.1016/j.bmcl.2004.09.040; RODRIGUES AD, 1995, DRUG METAB DISPOS, V23, P765; Sato Y, 2012, DRUG METAB DISPOS, V40, P1389, DOI 10.1124/dmd.112.045054; Timmerman H, 2000, ALLERGY, V55, P5, DOI 10.1034/j.1398-9995.2000.055supp60005.x; Wang EJ, 2000, DRUG METAB DISPOS, V28, P522	50	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3076	3083		10.1002/jps.24467		8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200039		
J	Taguchi, K; Hashimoto, M; Ogaki, S; Watanabe, H; Takeoka, S; Ikeda, Y; Handa, M; Otagiri, M; Maruyama, T				Taguchi, Kazuaki; Hashimoto, Mai; Ogaki, Shigeru; Watanabe, Hiroshi; Takeoka, Shinji; Ikeda, Yasuo; Handa, Makoto; Otagiri, Masaki; Maruyama, Toru			Effect of Repeated Injections of Adenosine Diphosphate-Encapsulated Liposomes Coated with a Fibrinogen -Chain Dodecapeptide Developed as a Synthetic Platelet Substitute on Accelerated Blood Clearance in a Healthy and an Anticancer Drug-Induced Thrombocytopenia Rat Model	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						liposome; adenosine-diphosphate; dodecapeptide; accelerated blood clearance phenomenon; thrombocytopenia; platelet substitute; pegylation; disposition; clearance; pharmacokinetics	POLYETHYLENE-GLYCOL PEG; PEGYLATED LIPOSOMES; PHOSPHOLIPID-VESICLES; IN-VIVO; DOXORUBICIN; IGM; INDUCTION; ANTIBODY; THERAPY; VITRO	Adenosine diphosphate (ADP)-encapsulated liposomes coated with a fibrinogen -chain dodecapeptide [H12 (dodecapeptide ((400)HHLGGAKQAGDV(411)))-(ADP)-liposome] is a synthetic platelet substitute, in which the surface is covered with polyethylene glycol (PEG). It has been reported that repeated injections of PEGylated liposomes induce an accelerated blood clearance (ABC) phenomenon, which involves a loss in the long-circulation half-life of the material when administered repeatedly to the same animals. The objective of this study was to determine whether the ABC phenomenon was induced by repeated injections of H12-(ADP)-liposome in healthy and anticancer drug-induced thrombocytopenia model rats. The findings show that the ABC phenomenon was induced by healthy rats that were repeatedly injected with H12-(ADP)-liposomes at the interval of 5 days at a dose of 10 mg lipids/kg. The ABC phenomenon involves the production of anti-H12-(ADP)-liposome immunoglobulin M (IgM) and complement activation. On the other hand, when thrombocytopenia model rats were repeatedly injected with H12-(ADP)-liposomes under the same conditions, no ABC phenomenon, nor was any suppression of anti-H12-(ADP)-liposome IgM-mediated complement activation observed. We thus conclude that the repeated injection of H12-(ADP)-liposome treatment in rat model with anticancer drug-induced thrombocytopenia did not induce the ABC phenomenon. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3084-3091, 2015	[Taguchi, Kazuaki; Otagiri, Masaki] Sojo Univ, Fac Pharmaceut Sci, Nishi Ku, Kumamoto 8620082, Japan; [Hashimoto, Mai; Ogaki, Shigeru; Watanabe, Hiroshi; Otagiri, Masaki; Maruyama, Toru] Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Chuo Ku, Kumamoto 8620973, Japan; [Watanabe, Hiroshi; Maruyama, Toru] Kumamoto Univ, Ctr Clin Pharmaceut Sci, Chuo Ku, Kumamoto 8620973, Japan; [Takeoka, Shinji; Ikeda, Yasuo] Waseda Univ, Grad Sch Adv Sci & Engn, Dept Life Sci & Med Biosci, Shinjuku Ku, Tokyo 1628480, Japan; [Handa, Makoto] Keio Univ, Ctr Transfus Med & Cell Therapy, Shinjuku Ku, Tokyo 1608582, Japan; [Otagiri, Masaki] Sojo Univ, DDS Res Inst, Nishi Ku, Kumamoto 8620082, Japan	Maruyama, T (reprint author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Chuo Ku, Kumamoto 8620973, Japan.	tomaru@gpo.kumamoto-u.ac.jp			Ministry of Health, Labour and Welfare, Japan	We would like to thank Atsushi Fujiyama and Mami Doi at Waseda University for preparation of liposome samples. We also thank Hayato Ujihira at Kumamoto University for technical assistance in the present study. This work was supported in part by Health and Labor Sciences Research Grants (Research on Public Essential Drugs and Medical Devices) from the Ministry of Health, Labour and Welfare, Japan.	Abu Lila AS, 2013, J CONTROL RELEASE, V172, P38, DOI 10.1016/j.jconrel.2013.07.026; Abu Lila AS, 2013, BIOL PHARM BULL, V36, P1842; Nishikawa K, 2012, J THROMB HAEMOST, V10, P2137, DOI 10.1111/j.1538-7836.2012.04889.x; Ishida T, 2006, J CONTROL RELEASE, V112, P15, DOI 10.1016/j.jconrel.2006.01.005; Shimizu T, 2013, IMMUNOBIOLOGY, V218, P725, DOI 10.1016/j.imbio.2012.08.274; Okamura Y, 2010, J CONTROL RELEASE, V148, P373, DOI 10.1016/j.jconrel.2010.09.013; Ishida T, 2007, J CONTROL RELEASE, V122, P349, DOI 10.1016/j.jconrel.2007.05.015; Cheng TL, 1999, BIOCONJUGATE CHEM, V10, P520, DOI 10.1021/bc980143z; Abu Lila AS, 2014, J PHARM SCI-US, V103, P557, DOI 10.1002/jps.23823; Abu Lila AS, 2013, INT J PHARMACEUT, V456, P235, DOI 10.1016/j.ijpharm.2013.07.059; Suzuki T, 2012, INT J PHARMACEUT, V436, P636, DOI 10.1016/j.ijpharm.2012.07.049; Okamura Y, 2005, BIOCONJUGATE CHEM, V16, P1589, DOI 10.1021/bc050178g; Taguchi K, 2013, J PHARM SCI-US, V102, P3852, DOI 10.1002/jps.23692; Okamura Y, 2010, NANOMED-NANOTECHNOL, V6, P391, DOI 10.1016/j.nano.2009.07.004; Tokutomi K, 2011, INT J PHARMACEUT, V407, P151, DOI 10.1016/j.ijpharm.2011.01.014; Okamura Y, 2009, J THROMB HAEMOST, V7, P470, DOI 10.1111/j.1538-7836.2008.03269.x; Thushara RM, 2014, ARCH TOXICOL, V88, P185, DOI 10.1007/s00204-013-1185-3; Laverman P, 2001, J PHARMACOL EXP THER, V298, P607; Ishida T, 2006, J CONTROL RELEASE, V115, P251, DOI 10.1016/j.jconret.2006.08.017; Taguchi K, 2009, DRUG METAB DISPOS, V37, P2197, DOI 10.1124/dmd.109.028852; Taguchi K, 2013, DRUG METAB DISPOS, V41, P1584, DOI 10.1124/dmd.112.050005; Dams ETM, 2000, J PHARMACOL EXP THER, V292, P1071; Armstrong JK, 2007, CANCER-AM CANCER SOC, V110, P103, DOI 10.1002/cncr.22739; Cheng TL, 2000, BIOCONJUGATE CHEM, V11, P258, DOI 10.1021/bc990147j; Hagisawa K, 2014, TRANSFUSION, V55, P314; Hashimoto Y, 2014, TOXICOL APPL PHARM, V277, P30, DOI 10.1016/j.taap.2014.03.002; James N D, 1994, Clin Oncol (R Coll Radiol), V6, P294, DOI 10.1016/S0936-6555(05)80269-9; Li CL, 2012, J PHARM SCI-US, V101, P3864, DOI 10.1002/jps.23254; Liu YJ, 2011, J PHARMACOL TOX MET, V64, P238, DOI 10.1016/j.vascn.2011.07.003; Ma YL, 2012, EUR J PHARM SCI, V45, P539, DOI 10.1016/j.ejps.2011.11.014; Mayer M, 1961, COMPLEMENT COMPLEMEN, V2nd, P133; McGahan L, 2008, Issues Emerg Health Technol, P1; Suzuki T, 2014, INT J PHARMACEUT, V476, P205, DOI 10.1016/j.ijpharm.2014.09.047; ten Brink MH, 2014, DRUG DISCOV TODAY, V19, P1572, DOI 10.1016/j.drudis.2014.04.005; VERKADE HJ, 1991, BIOCHEM J, V275, P139; Xu H, 2015, DRUG DELIV, V22, P598, DOI 10.3109/10717544.2014.885998	36	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3084	3091		10.1002/jps.24418		8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200040		
J	Nakanishi, T; Ogawa, T; Yanagihara, C; Tamai, I				Nakanishi, Takeo; Ogawa, Tetsuro; Yanagihara, Chihiro; Tamai, Ikumi			Kinetic Evaluation of Determinant Factors for Cellular Accumulation of Protoporphyrin IX Induced by External 5-Aminolevulinic Acid for Photodynamic Cancer Therapy	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						metabolism; transport; cancer; pharmacodynamics; ABC transporter	DELTA-AMINOLEVULINIC-ACID; RESISTANCE PROTEIN; HUMAN-ERYTHROCYTES; CELLS; TRANSPORT; HEME; RAT; FERROCHELATASE; PORPHYRINS; PHOTOSENSITIZER	Five-aminolevulinic acid (ALA) is a prodrug to generate phototoxic protoporphyrin IX (PPIX) for photodynamic cancer therapy. It remains unclear how PPIX accumulates in cancer cells; therefore, we aimed to clarify determinant factors by assessing ALA uptake, PPIX biosynthesis, conversion of PPIX to heme (ferrochelatase activity), and PPIX efflux, independently, in 10 human cancer cell lines. ALA-induced PPIX accumulation was not correlated with ALA uptake clearance. ALA uptake rates were far greater than maximum conversion rates of ALA to PPIX in the five cell lines, where ALA uptake activity was detected. A negative correlation of PPIX accumulation with ferrochelatase activity was found, but not statistically significant among all cell lines. As PPIX accumulation was restored in MCF-7 and DU145 cells by adding an inhibitor of PPIX efflux transporter BCRP, a compartment model incorporating PPIX synthesis, ferrochelatase activity, and PPIX efflux, was established, and hybrid parameters ( index) calculated using the model were significantly correlated with ALA-induced PPIX accumulation (r = 0.90, p = 0.005). Accordingly, kinetic analyses indicate that ALA-induced PPIX levels are determined by the three processes of PPIX biosynthesis, conversion of PPIX to heme, and PPIX efflux, suggesting that index is a useful to predict ALA-induced PPIX accumulation. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3092-3100, 2015	[Nakanishi, Takeo; Ogawa, Tetsuro; Yanagihara, Chihiro; Tamai, Ikumi] Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan	Tamai, I (reprint author), Kanazawa Univ, Fac Pharmaceut Sci, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	tamai@p.kanazawa-u.ac.jp	TAMAI, Ikumi/D-8412-2015		 [21890084]	This work was supported by Grant-in-Aid for Scientific Research 21890084 (to T.N.). We also thank Dr. Hiroshi Matsui at University of Tsukuba for his constructive comments.	ANDERSON PM, 1980, J BIOL CHEM, V255, P1993; Doring F, 1998, J CLIN INVEST, V101, P2761, DOI 10.1172/JCI1909; KENNEDY JC, 1992, J PHOTOCH PHOTOBIO B, V14, P275, DOI 10.1016/1011-1344(92)85108-7; Ogino T, 2011, MOL CELL BIOCHEM, V358, P297, DOI 10.1007/s11010-011-0980-5; Hinnen P, 1998, BRIT J CANCER, V78, P679, DOI 10.1038/bjc.1998.559; ANDERSON PM, 1979, J BIOL CHEM, V254, P6924; Peng Q, 1997, CANCER-AM CANCER SOC, V79, P2282; Nakanishi T, 2006, CANCER RES, V66, P5007, DOI 10.1158/0008-5472.CAN-05-4572; Nakanishi T, 1997, CANCER RES, V57, P4118; Arakawa H, 2012, BIOCHEM PHARMACOL, V84, P1070, DOI 10.1016/j.bcp.2012.07.026; Nakanishi T, 2010, METHODS MOL BIOL, V637, P105, DOI 10.1007/978-1-60761-700-6_5; Ohgari Y, 2005, BIOCHEM PHARMACOL, V71, P42, DOI 10.1016/j.bcp.2005.10.019; HUA ZX, 1995, CANCER RES, V55, P1723; TULKENS P, 1978, BIOCHEM PHARMACOL, V27, P415, DOI 10.1016/0006-2952(78)90370-2; Krieg RC, 2000, PHOTOCHEM PHOTOBIOL, V72, P226, DOI 10.1562/0031-8655(2000)072<0226:CTSPIM>2.0.CO;2; Nakanishi T, 2003, CLIN CANCER RES, V9, P3320; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Kemmner W, 2008, FASEB J, V22, P500, DOI 10.1096/fj.07-8888com; Neumann J, 2003, J PHARMACOL EXP THER, V305, P219, DOI 10.1124/jpet.102.046573; Usuda J, 2010, LUNG CANCER, V67, P198, DOI 10.1016/j.lungcan.2009.04.002; Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200; Anderson CMH, 2010, J PHARMACOL EXP THER, V332, P220, DOI 10.1124/jpet.109.159822; Frolund S, 2010, BRIT J PHARMACOL, V159, P1339, DOI 10.1111/j.1476-5381.2009.00620.x; MALIK Z, 1987, BRIT J CANCER, V56, P589, DOI 10.1038/bjc.1987.246; Berg K, 1996, BRIT J CANCER, V74, P688, DOI 10.1038/bjc.1996.423; CHEEKS C, 1986, P SOC EXP BIOL MED, V181, P596; Garcia SC, 1998, GEN PHARMACOL, V31, P579, DOI 10.1016/S0306-3623(98)00038-X; Gibson SL, 2001, PHOTOCHEM PHOTOBIOL, V73, P312, DOI 10.1562/0031-8655(2001)073<0312:IAADRL>2.0.CO;2; Hiyama K, 2013, J PORPHYR PHTHALOCYA, V17, P36, DOI 10.1142/S1088424612501192; Inoue K, 2009, PATHOBIOLOGY, V76, P303, DOI 10.1159/000245896; Kobuchi H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050082; KONDO M, 1993, CELL BIOL TOXICOL, V9, P95, DOI 10.1007/BF00755143; Lee DI, 2007, ARCH BIOCHEM BIOPHYS, V464, P19, DOI 10.1016/j.abb.2007.03.040; Malik E, 2000, SURG ENDOSC-ULTRAS, V14, P452, DOI 10.1007/s004640000160; MAMET R, 1994, BIOCHEM MED METAB B, V52, P53, DOI 10.1006/bmmb.1994.1033; MCLOUGHLIN JL, 1984, GEN PHARMACOL, V15, P553, DOI 10.1016/0306-3623(84)90215-5; ROSSI E, 1988, CLIN CHEM, V34, P2481; VANHILLEGERSBERG R, 1992, GASTROENTEROLOGY, V103, P647	38	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3092	3100		10.1002/jps.24462		9	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200041		
J	Tanaka, Y; Goto, T; Kataoka, M; Sakuma, S; Yamashita, S				Tanaka, Yusuke; Goto, Takanori; Kataoka, Makoto; Sakuma, Shinji; Yamashita, Shinji			Impact of Luminal Fluid Volume on the Drug Absorption After Oral Administration: Analysis Based on In Vivo Drug Concentration-Time Profile in the Gastrointestinal Tract	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						biopharmaceutics classification system; gastrointestinal; luminal volume; oral absorption; osmolality; passive diffusion; permeability	INTESTINAL CONTENTS; FOOD; RAT; PERMEABILITY; AQUAPORIN-3; DISSOLUTION; METABOLISM; SIMULATION; EXPRESSION; PREDICTION	The objective of this study is to clarify the influence of fluid volume in the gastrointestinal (GI) tract on the oral drug absorption. In vivo rat luminal concentrations of FITC-dextran (FD-4), a nonabsorbable marker, and drugs (metoprolol and atenolol) after oral coadministration as solutions with different osmolarity were determined by direct sampling of residual water in each segment of the GI tract. The luminal FD-4 concentration after oral administration as hyposmotic solution was significantly higher than that after administration as isosmotic or hyperosmotic solution. As the change in FD-4 concentration reflects the change in the volume of luminal fluid, it indicated that the luminal volume was greatly influenced by osmolality of solution ingested orally. Then, fraction of drug absorbed (Fa) in these segments was calculated by comparing the area under the luminal concentration-time curve of FD-4 with those of drugs. Fa values of two model drugs in each GI segment decreased with increase in luminal fluid volume, and the impact of the fluid volume was marked for Fa of atenolol (a low permeable drug) than for that of metoprolol (a high permeable drug). These findings should be beneficial to assure the effectiveness and safety of oral drug therapy. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3120-3127, 2015	[Tanaka, Yusuke] Hiroshima Int Univ, Fac Pharmaceut Sci, Lab Pharmaceut Technol, Kure, Hiroshima 7370112, Japan; [Goto, Takanori] Kyowa Pharmaceut Ind Co Ltd, Depertment Corp Qual Assurance, Yodogawa Ku, Osaka 5320011, Japan; [Kataoka, Makoto; Yamashita, Shinji] Setsunan Univ, Fac Pharmaceut Sci, Lab Biopharmaceut, Hirakata, Osaka 5730101, Japan; [Sakuma, Shinji] Setsunan Univ, Fac Pharmaceut Sci, Lab Drug Delivery Syst, Hirakata, Osaka 5730101, Japan	Yamashita, S (reprint author), Setsunan Univ, Fac Pharmaceut Sci, Lab Biopharmaceut, Hirakata, Osaka 5730101, Japan.	shinji@pharm.setsunan.ac.jp					Schiller C, 2005, ALIMENT PHARM THERAP, V22, P971, DOI 10.1111/j.1365-2036.2005.02683.x; Yu LX, 1996, ADV DRUG DELIVER REV, V19, P359, DOI 10.1016/0169-409X(96)00009-9; Itoh A, 2003, J GASTROEN HEPATOL, V18, P203, DOI 10.1046/j.1440-1746.2003.02949.x; Asai M, 2006, BIOL PHARM BULL, V29, P991, DOI 10.1248/bpb.29.991; Sjogren E, 2014, EUR J PHARM SCI, V57, P99, DOI 10.1016/j.ejps.2014.02.010; Gu CH, 2007, PHARM RES, V24, P1118, DOI 10.1007/s11095-007-9236-1; Chen ML, 2007, PHARM RES, V24, P73, DOI 10.1007/s11095-006-9120-4; [Anonymous], 2006, MOL PHARMACEUT, DOI DOI 10.1021/MP0600182; Cvijic S, 2014, EUR J PHARM SCI, V61, P40, DOI 10.1016/j.ejps.2014.04.008; BORG KO, 1975, ACTA PHARMACOL TOX, V36, P125; Agre P, 2004, ANGEW CHEM INT EDIT, V43, P4278, DOI 10.1002/anie.200460804; Koyama Y, 1999, AM J PHYSIOL-CELL PH, V276, pC621; Kasim NA, 2004, MOL PHARMACEUT, V1, P85, DOI 10.1021/mp034006h; Sugano K, 2010, EUR J PHARM SCI, V40, P118, DOI 10.1016/j.ejps.2010.03.011; Kalantzi L, 2006, PHARM RES-DORDR, V23, P165, DOI 10.1007/s11095-005-8476-1; Kalantzi L, 2006, PHARM RES, V23, P1373, DOI 10.1007/s11095-006-0207-8; Vertzoni M, 2005, EUR J PHARM BIOPHARM, V60, P413, DOI 10.1016/j.ejpb.2005.03.002; Rege BD, 2001, J PHARM SCI, V90, P1776, DOI 10.1002/jps.1127; Gamsiz ED, 2010, PHARM RES-DORDR, V27, P2646, DOI 10.1007/s11095-010-0264-x; Gosgnach M, 2005, ANESTH ANALG, V100, P137, DOI 10.1213/01.ANE.0000140238.79041.73; Grefner N M, 2010, Tsitologiia, V52, P580; Leiper JB, 1998, INT J SPORTS MED, V19, pS129, DOI 10.1055/s-2007-971977; Masaoka Y, 2006, EUR J PHARM SCI, V29, P240, DOI 10.1016/j.ejps.2006.06.004; REEVES PR, 1978, XENOBIOTICA, V8, P305; Sakamoto S, 2006, MOL PHARMACEUT, V3, P275, DOI 10.1021/mp050101+; Takashima T, 2013, MOL PHARMACEUT, V10, P2261, DOI 10.1021/mp300469m; Tanabe H, 2007, BIOL PHARM BULL, V30, P552, DOI 10.1248/bpb.30.552; TEICHBERG S, 1978, PEDIATR RES, V12, P720, DOI 10.1203/00006450-197806000-00009; Wallace CJ, 2014, PHARM RES-DORDR, V31, P887, DOI 10.1007/s11095-013-1210-5; WICK AN, 1951, J AM PHARM ASSOC SCI, V40, P542	30	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3120	3127		10.1002/jps.24433		8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200043		
J	Noguchi, S; Nishimura, T; Fujibayashi, A; Maruyama, T; Tomi, M; Nakashima, E				Noguchi, Saki; Nishimura, Tomohiro; Fujibayashi, Ayasa; Maruyama, Tetsuo; Tomi, Masatoshi; Nakashima, Emi			Organic Anion Transporter 4-Mediated Transport of Olmesartan at Basal Plasma Membrane of Human Placental Barrier	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						organic anion transporters (OAT); placenta; pregnancy; membrane transporter; membrane transport; pharmacokinetics	II RECEPTOR BLOCKERS; ANGIOTENSIN-II; FUNCTIONAL-CHARACTERIZATION; ACID TRANSPORTERS; HIGH-AFFINITY; SULFATE; ANTAGONIST; PREGNANCY; SYSTEM; CELLS	Mechanisms regulating fetal transfer of olmesartan, an angiotensin-II receptor type 1 antagonist, are important as potential determinants of life-threatening adverse fetal effects. The purpose of this study was to examine the olmesartan transport mechanism through the basal plasma membrane (BM) of human syncytiotrophoblasts forming the placental barrier. Uptake of olmesartan by human placental BM vesicles was potently inhibited by dehydroepiandrosterone sulfate (DHEAS), estrone 3-sulfate, and bromosulfophthalein, which are all typical substrates of organic anion transporter (OAT) 4 localized at the BM of syncytiotrophoblasts, and was increased in the absence of chloride. In tetracycline-inducible OAT4-expressing cells, [H-3]olmesartan uptake was increased by tetracycline treatment. Olmesartan uptake via OAT4 was concentration dependent with a K-m of 20 M, and was increased in the absence of chloride. [H-3]Olmesartan efflux via OAT4 was also observed and was trans-stimulated by extracellular chloride and DHEAS. Thus, OAT4 mediates bidirectional transport of olmesartan and appears to regulate fetal transfer of olmesartan at the BM of syncytiotrophoblasts. Efflux transport of olmesartan via OAT4 from syncytiotrophoblasts to the fetal circulation might be facilitated in the presence of an inwardly directed physiological chloride gradient and extracellular DHEAS. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3128-3135, 2015	[Noguchi, Saki; Nishimura, Tomohiro; Fujibayashi, Ayasa; Tomi, Masatoshi; Nakashima, Emi] Keio Univ, Fac Pharm, Minato Ku, Tokyo 1058512, Japan; [Maruyama, Tetsuo] Keio Univ, Sch Med, Dept Obstet & Gynaecol, Shinjuku Ku, Tokyo 1058512, Japan	Tomi, M (reprint author), Keio Univ, Fac Pharm, Minato Ku, Tokyo 1058512, Japan.	tomi-ms@pha.keio.ac.jp			JSPS KAKENHI [26282028, 25560063, 23790199, 25860396]; MEXT-Supported Program for Strategic Research at Private Universities; Takeda Science Foundation	This study was supported in part by JSPS KAKENHI Grant Numbers 26282028, 25560063, 23790199, and 25860396. It was also funded in part by the MEXT-Supported Program for Strategic Research at Private Universities and the Takeda Science Foundation.	Alwan S, 2005, BIRTH DEFECTS RES A, V73, P123, DOI 10.1002/bdra.20102; Ugele B, 2003, AM J PHYSIOL-ENDOC M, V284, pE390, DOI 10.1152/ajprendo.00257.2002; Ekaratanawong S, 2004, J PHARMACOL SCI, V94, P297, DOI 10.1254/jphs.94.297; LAATIKAINEN T, 1980, J CLIN ENDOCR METAB, V50, P489; Hagos Y, 2007, J AM SOC NEPHROL, V18, P430, DOI 10.1681/ASN.2006040415; Ho RH, 2006, GASTROENTEROLOGY, V130, P1793, DOI 10.1053/j.gastro.2006.02.034; Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; Yamada A, 2007, DRUG METAB DISPOS, V35, P2166, DOI 10.1124/dmd.107.017459; Oppermann M, 2013, BRIT J CLIN PHARMACO, V75, P822, DOI 10.1111/j.1365-2125.2012.04388.x; Babu E, 2002, BBA-MOL CELL RES, V1590, P64, DOI 10.1016/S0167-4889(02)00187-8; Nishimura T, 2014, BBA-BIOMEMBRANES, V1838, P1306, DOI 10.1016/j.bbamem.2014.01.004; Schweigmann H, 2014, J STEROID BIOCHEM, V143, P259, DOI 10.1016/j.jsbmb.2014.03.013; Takeda M, 2002, EUR J PHARMACOL, V438, P137, DOI 10.1016/S0014-2999(02)01306-7; Gomez R A, 1998, Kidney Int Suppl, V67, pS12; Schutz S, 1996, AM J PATHOL, V149, P2067; Iwanaga T, 2007, J PHARMACOL EXP THER, V320, P211, DOI 10.1124/jpet.106.112755; Sato M, 2008, PHARM RES, V25, P639, DOI 10.1007/s11095-007-9401-6; Quan A, 2006, EARLY HUM DEV, V82, P23, DOI 10.1016/j.earlhumdev.2005.11.001; Nishimura T, 2010, PLACENTA, V31, P1003, DOI 10.1016/j.placenta.2010.08.003; St-Pierre MV, 2002, J CLIN ENDOCR METAB, V87, P1856, DOI 10.1210/jc.87.4.1856; Zhou FF, 2006, EUR J PHARM SCI, V27, P518, DOI 10.1016/j.ejps.2005.09.008; ILLSLEY NP, 1990, BIOCHIM BIOPHYS ACTA, V1029, P218, DOI 10.1016/0005-2736(90)90157-J; Sakairi A, 2008, HYPERTENS RES, V31, P2165, DOI 10.1291/hypres.31.2165; Wang HP, 2000, AM J PHYSIOL-CELL PH, V278, pC1019; Enomoto A, 2003, EUR J PHARMACOL, V466, P13, DOI 10.1016/S0014-2999(03)01530-9; GANAPATHY V, 1988, BIOCHEM J, V249, P179; Griine H, 1992, AM J PHYSIOL, V262, pF326; Hagos Y, 2012, PFLUG ARCH EUR J PHY, V464, P367, DOI 10.1007/s00424-012-1140-9; Jimenez V, 2004, PLACENTA, V25, P422, DOI 10.1016/j.placenta.2003.10.013; KELLEY LK, 1983, BIOCHIM BIOPHYS ACTA, V734, P91, DOI 10.1016/0005-2736(83)90079-2; Kiyohide F, 1976, STEROIDS, V27, P797, DOI 10.1016/0039-128X(76)90139-2; Kobayashi Y, 2005, J BIOL CHEM, V280, P32332, DOI 10.1074/jbc.M504246200; Laeis Petra, 2001, Journal of Hypertension, V19, pS21; Lopez MLSS, 2004, CURR OPIN NEPHROL HY, V13, P117, DOI 10.1097/01.mnh.0000109591.66112.0e; MATHUR RS, 1980, J CLIN ENDOCR METAB, V51, P1235; Nakagomi-Hagihara R, 2006, DRUG METAB DISPOS, V34, P862, DOI 10.1124/dmd.105.008888; Nishimura T, 2012, DRUG METAB PHARMACOK, V27, P439, DOI 10.2133/dmpk.DMPK-11-RG-103; Tomi M, 2014, PLACENTA, V35, P658, DOI 10.1016/j.placenta.2014.06.003; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879; Yamashita F, 2006, J PHARM PHARMACOL, V58, P1499, DOI 10.1211/jpp.58.11.0011; Zhang Q, 2010, PROTEOM CLIN APPL, V4, P538, DOI 10.1002/prca.200900048	41	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3128	3135		10.1002/jps.24434		8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200044		
J	Takahashi, K; Yoshisue, K; Chiba, M; Nakanishi, T; Tamai, I				Takahashi, Koichi; Yoshisue, Kunihiro; Chiba, Masato; Nakanishi, Takeo; Tamai, Ikumi			Involvement of Concentrative Nucleoside Transporter 1 in Intestinal Absorption of Trifluridine Using Human Small Intestinal Epithelial Cells	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						trifluridine; FTD; intestinal absorption; nucleoside transporters; CNT1; cancer; intestinal epithelia; transcellular transport	ORAL-DRUG ABSORPTION; CACO-2 CELLS; EXPRESSION; CLONING; PURINE; HCNT3; ACID	TAS-102, which is effective for refractory metastatic colorectal cancer, is a combination drug of anticancer trifluridine (FTD; which is derived from pyrimidine nucleoside) and FTD-metabolizing enzyme inhibitor tipiracil hydrochloride (TPI) at a molecular ratio of 1:0.5. To evaluate the intestinal absorption mechanism of FTD, the uptake and transcellular transport of FTD by human small intestinal epithelial cell (HIEC) monolayer as a model of human intestinal epithelial cells was investigated. The uptake and membrane permeability of FTD by HIEC monolayers were saturable, Na+-dependent, and inhibited by nucleosides. These transport characteristics are mostly comparable with those of concentrative nucleoside transporters (CNTs). Moreover, the uptake of FTD by CNT1-expressing Xenopus oocytes was the highest among human CNT transporters. The obtained K-m and V-max values of FTD by CNT1 were 69.0 M and 516 pmol/oocyte/30 min, respectively. The transcellular transport of FTD by Caco-2 cells, where CNT1 is heterologously expressed, from apical to basolateral side was greater than that by Mock cells. In conclusion, these results demonstrated that FTD exhibits high oral absorption by the contribution of human CNT1. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3146-3153, 2015	[Takahashi, Koichi; Yoshisue, Kunihiro; Chiba, Masato] Taiho Pharmaceut Co Ltd, Tsukuba Res Ctr, Pharmacokinet Res Labs, Tsukuba, Ibaraki, Japan; [Takahashi, Koichi; Nakanishi, Takeo; Tamai, Ikumi] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Pharmaceut Sci, Kanazawa, Ishikawa, Japan	Tamai, I (reprint author), Taiho Pharmaceut Co Ltd, Tsukuba Res Ctr, Pharmacokinet Res Labs, Tsukuba, Ibaraki, Japan.	tamai@p.kanazawa-u.ac.jp	TAMAI, Ikumi/D-8412-2015				SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Hayeshi R, 2008, EUR J PHARM SCI, V35, P383, DOI 10.1016/j.ejps.2008.08.004; Smith KM, 2005, J BIOL CHEM, V280, P25436, DOI 10.1074/jbc.M409454200; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058; FUJIWARA Y, 1970, MOL PHARMACOL, V6, P273; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707; Doi T, 2012, BRIT J CANCER, V107, P429, DOI 10.1038/bjc.2012.274; Ward JL, 1999, BBA-BIOMEMBRANES, V1419, P15, DOI 10.1016/S0005-2736(99)00045-0; ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P880, DOI 10.1016/0006-291X(91)91647-U; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; Meier Y, 2007, DRUG METAB DISPOS, V35, P590, DOI 10.1124/dmd.106.013342; Emura T, 2004, INT J MOL MED, V13, P545; Govindarajan R, 2007, AM J PHYSIOL-REG I, V293, pR1809, DOI 10.1152/ajpregu.00293.2007; LENNERNAS H, 1992, PHARMACEUT RES, V9, P1243, DOI 10.1023/A:1015888813741; Li LH, 2009, J CLIN PHARMACOL, V49, P661, DOI 10.1177/0091270009335002; MAEDA T, 2007, MOL PHARMACEUT, V4, P85, DOI DOI 10.1021/MP060082J; Okayama T, 2012, J PHARMACOL EXP THER, V340, P457, DOI 10.1124/jpet.111.186296; Owen RP, 2006, J BIOL CHEM, V281, P26675, DOI 10.1074/jbc.M513421200; Patil SD, 1997, AM J PHYSIOL-GASTR L, V272, pG1314; Rozehnal V, 2012, EUR J PHARM SCI, V46, P367, DOI 10.1016/j.ejps.2012.02.025; Shirasaka Y, 2013, J PHARM SCI-US, V102, P3418, DOI 10.1002/jps.23653; Sjoberg, 2013, EUR J PHARM SCI, V48, P166; Takenaka Toru, 2014, Drug Metab Dispos, V42, P1947, DOI 10.1124/dmd.114.059493; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879	24	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3146	3153		10.1002/jps.24455		8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200046		
J	Yamashita, S; Kataoka, M; Suzaki, Y; Imai, H; Morimoto, T; Ohashi, K; Inano, A; Togashi, K; Mutaguchi, K; Sugiyama, Y				Yamashita, Shinji; Kataoka, Makoto; Suzaki, Yuki; Imai, Hiromitsu; Morimoto, Takuya; Ohashi, Kyoichi; Inano, Akihiro; Togashi, Kazutaka; Mutaguchi, Kuninori; Sugiyama, Yuichi			An Assessment of the Oral Bioavailability of Three Ca-Channel Blockers Using a Cassette-Microdose Study: A New Strategy for Streamlining Oral Drug Development	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						clinical study; microdose; cassette dose; Nonlinear pharmacokinetics; bioavailability; first-pass metabolism; dose proportionality; oral absorption	NICARDIPINE HYDROCHLORIDE; GRAPEFRUIT JUICE; PHARMACOKINETICS; DILTIAZEM; METABOLISM; NIFEDIPINE; VOLUNTEERS; CLEARANCE; HUMANS; RATES	A cassette-microdose (MD) clinical study was performed to demonstrate its usefulness for identifying the most promising compound for oral use. Three Ca-channel blockers (nifedipine, nicardipine, and diltiazem) were chosen as model drugs. In the MD clinical study, a cassette-dose method was employed in which three model drugs were administered simultaneously. Both intravenous (i.v.) and oral (p.o.) administration studies were conducted to calculate the oral bioavailability (BA). For comparison, p.o. studies with therapeutic dose (ThD) levels were also performed. In all studies, blood concentrations of each drug were successfully determined using liquid chromatography-mass spectrometry with the lower limit of quantification of 0.2-2.0 pg/mL. Oral BA of nifedipine in the MD study was approximately 50% and in the same range with that obtained in the ThD study, whereas other two drugs showed significantly lower BA in the MD study, indicating a dose-dependent absorption. In addition, compared with the ThD study, absorption of nicardipine was delayed in the MD study. As a result, nifedipine was considered to be most promising for oral use. In conclusion, a cassette-MD clinical study is of advantage for oral drug development that enables to identify the candidate having desired properties for oral use. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3154-3161, 2015	[Yamashita, Shinji; Kataoka, Makoto] Setsunan Univ, Fac Pharmaceut Sci, Hirakata, Osaka 5730101, Japan; [Suzaki, Yuki; Imai, Hiromitsu; Morimoto, Takuya; Ohashi, Kyoichi] Oita Univ Hosp, Gen Clin Res Ctr, Oita, Japan; [Inano, Akihiro] Fukushima Med Univ Hosp, Clin Res Ctr, Fukushima, Fukushima 9601295, Japan; [Togashi, Kazutaka; Mutaguchi, Kuninori] Sumika Chem Anal Serv Ltd, Pharmaceut Business Div, Osaka 5540022, Japan; [Sugiyama, Yuichi] RIKEN Res Cluster Innovat, RIKEN Innovat Ctr, Sugiyama Lab, Yokohama Bio Ind Ctr,Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Yamashita, S (reprint author), Setsunan Univ, Fac Pharmaceut Sci, Hirakata, Osaka 5730101, Japan.	shinji@pharm.setsunan.ac.jp			New Energy and Industrial Technology Development Organization (NEDO)	This study is a part of the Research Project for the "Establishment of Evolutional Drug Development with the Use of Microdose Clinical Trial" sponsored by the New Energy and Industrial Technology Development Organization (NEDO).	Hay M, 2014, NAT BIOTECHNOL, V32, P40, DOI 10.1038/nbt.2786; Uno T, 2000, EUR J CLIN PHARMACOL, V56, P643, DOI 10.1007/s002280000235; Lappin G, 2013, EXPERT OPIN DRUG MET, V9, P817, DOI 10.1517/17425255.2013.786042; RAEMSCH KD, 1983, HYPERTENSION, V5, P18; Roberts SA, 2003, CURR OPIN DRUG DISC, V6, P66; HERMANN P, 1983, EUR J CLIN PHARMACOL, V24, P349, DOI 10.1007/BF00610053; SIETSEMA WK, 1989, INT J CLIN PHARM TH, V27, P179; Toutain PL, 2010, HANDB EXP PHARMACOL, V199, P19, DOI 10.1007/978-3-642-10324-7_2; Thorn M, 2005, BRIT J CLIN PHARMACO, V60, P54, DOI 10.1111/j.1365-2125.2005.02389.x; Lappin G, 2006, CLIN PHARMACOL THER, V80, P203, DOI 10.1016/j.clpt.2006.05.008; Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470; Maeda K, 2011, CLIN PHARMACOL THER, V90, P575, DOI 10.1038/clpt.2011.142; Holtbecker N, 1996, DRUG METAB DISPOS, V24, P1121; Tang HD, 2005, DRUG METAB DISPOS, V33, P1297, DOI 10.1124/dmd.105.004143; ECHIZEN H, 1986, CLIN PHARMACOKINET, V11, P425, DOI 10.2165/00003088-198611060-00002; Sugiyama Y, 2011, ADV DRUG DELIVER REV, V63, P494, DOI 10.1016/j.addr.2010.09.010; Takahashi M, 2009, J PHARM SCI-US, V98, P4343, DOI 10.1002/jps.21708; Lappin G, 2008, EXPERT OPIN DRUG MET, V4, P1499, DOI 10.1517/17425250802531767 ; Christensen H, 2002, EUR J CLIN PHARMACOL, V58, P515, DOI 10.1007/s00228-0516-8; GRAHAM DJM, 1985, BRIT J CLIN PHARMACO, V20, pS23; HIGUCHI S, 1980, XENOBIOTICA, V10, P447; ICH Harmonised Tripartite Guideline, 2009, GUID NONCL SAF STUD; Inotsume N, 1997, EUR J CLIN PHARMACOL, V52, P289, DOI 10.1007/s002280050292; KOLLE EU, 1983, ARZNEIMITTEL-FORSCH, V33-2, P972; Musther H, 2014, EUR J PHARM SCI, V57, P280, DOI 10.1016/j.ejps.2013.08.018; OCHS HR, 1984, KLIN WOCHENSCHR, V62, P303, DOI 10.1007/BF01716446; Richter O, 2004, CLIN PHARMACOL THER, V75, P172; U.S. Department of Health and Human Services, 2001, GUID IND BIOAN METH; WAGNER JG, 1987, BIOPHARM DRUG DISPOS, V8, P133, DOI 10.1002/bdd.2510080205; Yamane N, 2011, PHARM RES-DORDR, V28, P1963, DOI 10.1007/s11095-011-0423-8	30	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3154	3161		10.1002/jps.24499		8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200047		
J	Shimada, T; Nakanishi, T; Tajima, H; Yamazaki, M; Yokono, R; Takabayashi, M; Shimada, T; Sawamoto, K; Miyamoto, KI; Kitagawa, H; Ohta, T; Tamai, I; Sai, Y				Shimada, Takuya; Nakanishi, Takeo; Tajima, Hidehiro; Yamazaki, Maiko; Yokono, Rina; Takabayashi, Makiko; Shimada, Tsutomu; Sawamoto, Kazuki; Miyamoto, Ken-Ichi; Kitagawa, Hirohisa; Ohta, Tetsuo; Tamai, Ikumi; Sai, Yoshimichi			Saturable Hepatic Extraction of Gemcitabine Involves Biphasic Uptake Mediated by Nucleoside Transporters Equilibrative Nucleoside Transporter 1 and 2	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						transporters; cancer; hepatocytes; equilibrative nucleoside transporter; hepatic transport; kinetics	FUNCTIONAL-CHARACTERIZATION; PANCREATIC-CANCER; ARTERIAL INFUSION; RANDOMIZED-TRIAL; CLONING; CELLS; EXPRESSION; 5-FLUOROURACIL; CHEMOTHERAPY; METASTASES	Hepatic arterial infusion (HAI) chemotherapy with gemcitabine (GEM) is expected to be more effective and safer method to treat hepatic metastasis of pancreatic cancer compared with intravenous administration, because it affords higher tumor exposure with lower systemic exposure. Thus, a key issue for dose selection is the saturability of hepatic uptake of GEM. Therefore, we investigated GEM uptake in rat and human isolated hepatocytes. Hepatic GEM uptake involved high- and low-affinity saturable components with K-m values of micromolar and millimolar order, respectively. The uptake was inhibited concentration dependently by S-(4-nitrobenzyl)-6-thioinosine (NBMPR) and was sodium-ion-independent, suggesting a contribution of equilibrative nucleoside transporters (ENTs). The concentration dependence of uptake in the presence of 0.1 M NBMPR showed a single low-affinity binding site. Therefore, the high- and low-affinity sites correspond to ENT1 and ENT2, respectively. Our results indicate hepatic extraction of GEM is predominantly mediated by the low-affinity site (hENT2), and at clinically relevant hepatic concentrations of GEM, hENT2-mediated uptake would not be completely saturated. This is critical for HAI, because saturation of hepatic uptake would result in a marked increase of GEM concentration in the peripheral circulation, abrogating the advantage of HAI over intravenous administration in terms of severe adverse events. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3162-3169, 2015	[Shimada, Takuya; Yamazaki, Maiko; Yokono, Rina; Takabayashi, Makiko; Shimada, Tsutomu; Sawamoto, Kazuki; Miyamoto, Ken-Ichi; Sai, Yoshimichi] Kanazawa Univ, Univ Hosp, Dept Hosp Pharm, Kanazawa, Ishikawa 9208641, Japan; [Shimada, Takuya; Nakanishi, Takeo; Tamai, Ikumi] Kanazawa Univ, Fac Pharmaceut Sci, Dept Membrane Transport & Biopharmaceut, Kanazawa, Ishikawa 9201192, Japan; [Tajima, Hidehiro; Kitagawa, Hirohisa; Ohta, Tetsuo] Kanazawa Univ, Grad Sch Med Sci, Div Canc Med, Dept Surg Gastroenterol, Kanazawa, Ishikawa 9208641, Japan	Sai, Y (reprint author), Kanazawa Univ, Univ Hosp, Dept Hosp Pharm, Takara Machi, Kanazawa, Ishikawa 9208641, Japan.	sai-ys@staff.kanazawa-u.ac.jp	TAMAI, Ikumi/D-8412-2015; SAI, Yoshimichi/L-3828-2015	SAI, Yoshimichi/0000-0003-2954-1532	JSPS KAKENHI [23590173]	This study was supported in part by JSPS KAKENHI grant number 23590173.	Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058; Kemeny NE, 2006, J CLIN ONCOL, V24, P1395, DOI 10.1200/JCO.2005.03.8166; BREEDIS C, 1954, AM J PATHOL, V30, P969; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Mackey JR, 1999, J NATL CANCER I, V91, P1876, DOI 10.1093/jnci/91.21.1876; Wagner M, 2004, BRIT J SURG, V91, P586, DOI 10.1002/bjs.4484; ENSMINGER WD, 1983, SEMIN ONCOL, V10, P176; Ritzel MWL, 2001, MOL MEMBR BIOL, V18, P65, DOI 10.1080/09687680010026313; Mackey JR, 1998, CANCER RES, V58, P4349; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7; Sai Y, 2006, J PHARM SCI-US, V95, P336, DOI 10.1002/jps.20540; Govindarajan R, 2008, AM J PHYSIOL-GASTR L, V295, pG570, DOI 10.1152/ajpgi.00542.2007; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Pennycooke M, 2001, BIOCHEM BIOPH RES CO, V280, P951, DOI 10.1006/bbrc.2000.4205; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Blastik M, 2011, PANCREAS, V40, P478, DOI 10.1097/MPA.0b013e318205e332; Burris HA, 1997, J CLIN ONCOL, V15, P2403; DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122; De Vita VT., 2005, CANC PRINCIPLES PRAC, P945; ENSMINGER WD, 1978, CANCER RES, V38, P3784; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; McCullagh KJA, 1996, AM J PHYSIOL-ENDOC M, V271, pE143; Praff E., 1967, METHOD ENZYMOL, V10, P680; SCHWARZ LR, 1975, EUR J BIOCHEM, V55, P617, DOI 10.1111/j.1432-1033.1975.tb02199.x; Tajima H, 2013, MOL CLIN ONCOL, V1, P869; Tajima Hidehiro, 2013, Gan To Kagaku Ryoho, V40, P1668; Tajima H, 2010, EXP THER MED, V1, P987, DOI 10.3892/etm.2010.160; Tajima H, 2011, EXP THER MED, V2, P265, DOI 10.3892/etm.2011.190; Tse AN, 2009, CANCER CHEMOTH PHARM, V64, P935, DOI 10.1007/s00280-009-0945-5; van Riel JM, 2009, EUR J CANCER, V45, P2519, DOI 10.1016/j.ejca.2009.05.025; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	34	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3162	3169		10.1002/jps.24498		8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200048		
J	Mano, Y; Sugiyama, Y; Ito, K				Mano, Yoko; Sugiyama, Yuichi; Ito, Kiyomi			Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						clinical trial simulations; cytochrome P450; drug interactions; intestinal metabolism; pharmacokinetics; physiologically based pharmacokinetic modeling	IN-VITRO DATA; 1ST-PASS METABOLISM; P-GLYCOPROTEIN; KETOCONAZOLE; ERYTHROMYCIN; ABSORPTION; EVEROLIMUS; INHIBITORS; QUETIAPINE; VIVO	The purpose of this study was to predict the drug-drug interactions (DDIs) via CYP3A4 by estimating the extent of hepatic CYP3A4 inhibition based on a physiologically based pharmacokinetic (PBPK) model of both substrate and inhibitor and the increase in the intestinal availability (F-g) due to the enzyme inhibition. For the DDIs resulting from reversible inhibition of CYP3A4, the prediction using in vivo K-i values estimated from other clinical DDI studies and predicted in vivo K-i values calculated using the correlation between the log P and the in vivo K-i/in vitro K-i ratio was more accurate than that using in vitro K-i values. Incorporating inhibition of both intestinal and hepatic metabolism resulted in better prediction than that obtained considering inhibition in the liver alone, and all the DDIs (AUC increase by the inhibitor) were predicted within 2-fold accuracy when in vivo K-i values were used. In addition, F-g values were successfully back-calculated from the clinical DDI data based on the present model. In conclusion, the present PBPK model incorporating the in vivo K-i values was found to be useful for quantitative prediction of clinical DDIs and for estimation of the F-g values for CYP3A4 substrates for which intravenous data were not available. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3183-3193, 2015	[Mano, Yoko] Taisho Pharmaceut Co Ltd, Drug Safety & Pharmacokinet Labs, Pharmacokinet & Metab, Saitama 3319530, Japan; [Sugiyama, Yuichi] RIKEN, RIKEN Res Cluster Innovat, RIKEN Innovat Ctr, Sugiyama Lab, Kanagawa 2300045, Japan; [Ito, Kiyomi] Musashino Univ, Res Inst Pharmaceut Sci, Tokyo 2028585, Japan	Mano, Y (reprint author), Taisho Pharmaceut Co Ltd, Drug Safety & Pharmacokinet Labs, Pharmacokinet & Metab, Saitama 3319530, Japan.	y-mano@so.taisho.co.jp					Yang JS, 2008, CURR DRUG METAB, V9, P384, DOI 10.2174/138920008784746382; Kato M, 2008, PHARM RES-DORDR, V25, P1891, DOI 10.1007/s11095-008-9607-2; Choi MK, 2012, J PHARM PHARMACOL, V64, P1074, DOI 10.1111/j.2042-7158.2012.01498.x; Hisaka A, 2014, DRUG METAB DISPOS, V42, P1640, DOI 10.1124/dmd.114.059147; Fahmi OA, 2009, DRUG METAB DISPOS, V37, P1658, DOI 10.1124/dmd.108.026252; Poulin P, 2002, J PHARM SCI, V91, P129, DOI 10.1002/jps.10005; Varma MVS, 2010, J MED CHEM, V53, P1098, DOI 10.1021/jm901371v; Shoaf SE, 2011, J CLIN PHARMACOL, V51, P761, DOI 10.1177/0091270010376193; Yang JS, 2007, CURR DRUG METAB, V8, P676, DOI 10.2174/138920007782109733; Uchimura T, 2010, BIOPHARM DRUG DISPOS, V31, P286, DOI 10.1002/bdd.711; Sinha VK, 2012, BIOPHARM DRUG DISPOS, V33, P111, DOI 10.1002/bdd.1782; Williams JA, 2004, DRUG METAB DISPOS, V32, P1201, DOI 10.1124/dmd.104.000794; Paine MF, 2006, DRUG METAB DISPOS, V34, P880, DOI 10.1124/dmd.105.008672; Ekins S, 2002, MOL PHARMACOL, V61, P964, DOI 10.1124/mol.61.5.964; Cook CS, 2004, XENOBIOTICA, V34, P215, DOI 10.1080/00498230310001649341; Galetin A, 2008, EXPERT OPIN DRUG MET, V4, P909, DOI [10.1517/17425255.4.7.909 , 10.1517/17425250802188055]; Gertz M, 2008, CURR DRUG METAB, V9, P785, DOI 10.2174/138920008786049276; Grimm SW, 2006, BRIT J CLIN PHARMACO, V61, P58, DOI 10.1111/j.1365-2125.2005.02507.x; Kovarik JM, 2005, EUR J CLIN PHARMACOL, V61, P35, DOI 10.1007/s00228-004-0866-5; Kovarik JM, 2005, J CLIN PHARMACOL, V45, P514, DOI 10.1177/0091270005275368; Li KY, 2005, EUR J CLIN PHARMACOL, V60, P791, DOI 10.1007/s00228-004-0953-x; Nishimuta H, 2011, DRUG METAB PHARMACOK, V26, P592, DOI 10.2133/dmpk.DMPK-11-RG-034; Rostami-Hodjegan Amin, 2004, Drug Discov Today Technol, V1, P441, DOI 10.1016/j.ddtec.2004.10.002; ROWLAND YK, 2010, EUR J PHARM SCI, V39, P298; Sanchez RI, 2004, DRUG METAB DISPOS, V32, P1287, DOI 10.1124/dmd.104.000216; US Department of Health and Human Services. Food and Drug Administration. Guidance for Industry, 2012, GUID IND DRUG INT ST; Wakayama N, SILICO PREDICT UNPUB	27	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3183	3193		10.1002/jps.24495		11	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200050		
J	Matsuo, Y; Ishibashi, T; Shimamura, K; Wajima, T				Matsuo, Yumiko; Ishibashi, Toru; Shimamura, Kenji; Wajima, Toshihiro			Prediction of Pharmacokinetics and Pharmacodynamics of Doripenem in Pediatric Patients	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						antiinfectives; clinical pharmacokinetics; doripenem; Monte Carlo; pediatric; pharmacodynamics	ANTIMICROBIAL SUSCEPTIBILITY; MEROPENEM; BACTERIA; SIZE; TIME	The aim of this paper was to predict the pharmacokinetics of doripenem in pediatrics from adult pharmacokinetic data and to investigate dosing regimens in pediatrics using Monte-Carlo pharmacokinetics/pharmacodynamics (PK/PD) simulations prior to the initiation of pediatric clinical trials. The pharmacokinetics in pediatrics was predicted by using a previously reported approach for -lactam antibiotics. Monte-Carlo simulation was employed to assess dosing regimens in pediatrics based on the predicted pharmacokinetic profiles and the minimum inhibitory concentration (MIC) distributions of Haemophilus influenzae and Streptococcus pneumoniae, which frequently cause infectious pediatric diseases. The probabilities of attaining target time above MIC (40%T>MIC) were calculated for dosing regimens of 1-30 mg/kg with two or three times daily dosing (TID) based on simulations of 5000 pediatric patients and MICs. The results suggested 15 and 5 mg/kg TID would give approximately 90% or more probability of target attainment against Haemophilus influenzae and Streptococcus pneumoniae, respectively. The pediatric phase 3 study confirmed that pharmacokinetics in pediatrics could be well predicted by this method, indicating that the dosing regimen had been appropriately selected. The framework of dose selection for pediatric clinical trials based on predictions of pharmacokinetic profiles and PK/PD indices should be applicable to the development of other -lactam antibiotics for pediatric use. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3194-3198, 2015	[Matsuo, Yumiko; Ishibashi, Toru; Shimamura, Kenji; Wajima, Toshihiro] Shionogi & Co Ltd, Dept Clin Res, Clin Pharmacol & Pharmacokinet, Osaka, Japan	Wajima, T (reprint author), Shionogi & Co Ltd, Dept Clin Res, Clin Pharmacol & Pharmacokinet, Osaka, Japan.	toshihiro.wajima@shionogi.co.jp					Anderson BJ, 1997, CLIN PHARMACOKINET, V33, P313, DOI 10.2165/00003088-199733050-00001; Ambrose PG, 2007, CLIN INFECT DIS, V44, P79, DOI 10.1086/510079; Wajima T, 2004, J PHARM SCI-US, V93, P1890, DOI 10.1002/jps.20099; Nandy P, 2010, ANTIMICROB AGENTS CH, V54, P2354, DOI 10.1128/AAC.01649-09; Holford NHG, 1996, CLIN PHARMACOKINET, V30, P329; Zhanel GG, 2007, DRUGS, V67, P1027, DOI 10.2165/00003495-200767070-00006; BOXENBAUM H, 1982, J PHARMACOKINET BIOP, V10, P201, DOI 10.1007/BF01062336; Kuti JL, 2003, J CLIN PHARMACOL, V43, P1116, DOI 10.1177/0091270003257225; Boeckmann AJ, 1992, NONMEM USERS GUIDE; Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Food and Drug Administration, GUID IND EXP RESP RE; Ellis Jennifer M, 2006, Paediatr Drugs, V8, P131, DOI 10.2165/00148581-200608020-00005; FUJIMURA T, 2008, JPN J CHEMOTHER, V56, P543; Goldstein EJC, 2008, ANTIMICROB AGENTS CH, V52, P761, DOI 10.1128/AAC.01128-07; Kuti JL, 2004, ANTIMICROB AGENTS CH, V48, P2464, DOI 10.1128/AAC.48.7.2464-2470.2004; Kuwahara-Arai K, 2005, JPN J CHEMOTHER, V53, P17; Mahmood I., 2005, INTERSPECIES PHARMAC; Miwa H, 2005, JPN J CHEMOTHER, V53, P80; Nakashima M, 2005, JPN J CHEMOTHER, V53, P104; Shimamura K, 2007, J PHARM SCI-US, V96, P3125, DOI 10.1002/jps.20977; Sunakawa K, 2011, 51 ANN INT C ANT AG; Totsuka K, 2011, 51 ANN INT C ANT AG; Toyonaga Y, 2003, JPN J CHEMOTHER, V51, P762; Tsuji M, 2005, JPN J CHEMOTHER, V53, P1; Wajima T, 2010, 50 ANN INT C ANT AG; YOSHIDA I, 2008, JPN J CHEMOTHER, V56, P562	25	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3194	3198		10.1002/jps.24432		5	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200051		
J	Ebner, T; Ishiguro, N; Taub, ME				Ebner, Thomas; Ishiguro, Naoki; Taub, Mitchell E.			The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical SettingProposal of a Four Component Transporter Cocktail	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						ABC transporters; drug interaction; efflux pumps; inhibition; kinetics; organic anion transporters; organic anion-transporting polypeptide transporters; organic cation transporters; P-glycoprotein	ORGANIC ANION TRANSPORTERS; IN-VIVO EXTRAPOLATION; TOXIN EXTRUSION 1; P-GLYCOPROTEIN; FUNCTIONAL-CHARACTERIZATION; MEMBRANE TRANSPORTERS; HUMAN MULTIDRUG; HUMAN LIVER; VITRO; ROSUVASTATIN	Probe drug cocktails are used clinically to assess the potential for drug-drug interactions (DDIs), and in particular, DDIs resulting from coadministration of substrates and inhibitors of cytochrome P450 enzymes. However, a probe drug cocktail has not been identified to assess DDIs involving inhibition of drug transporters. We propose a cocktail consisting of the following substrates to explore the potential for DDIs caused by inhibition of key transporters: digoxin (P-glycoprotein, P-gp), rosuvastatin (breast cancer resistance protein, BCRP; organic anion transporting polypeptides, OATP), metformin (organic cation transporter, OCT; multidrug and toxin extrusion transporters, MATE), and furosemide (organic anion transporter, OAT). Furosemide was evaluated in vitro, and is a substrate of OAT1 and OAT3, with K-m values of 38.9 and 21.5 M, respectively. Furosemide was also identified as a substrate of BCRP, OATP1B1, and OATP1B3. Furosemide inhibited BCRP (50% inhibition of drug transport: 170 M), but did not inhibit OATP1B1, OATP1B3, OCT2, MATE1, and MATE2-K at concentrations below 300 M, and P-gp at concentrations below 2000 M. Conservative approaches for the estimation of the likelihood of in vivoDDIs indicate a remote chance of in vivo transporter inhibition by these probe drugs when administered at low single oral doses. This four component probe drug cocktail is therefore proposed for clinical evaluation. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3220-3228, 2015	[Ebner, Thomas] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Drug Metab & Pharmacokinet, Biberach, Germany; [Ishiguro, Naoki] Nippon Boehringer Ingelheim Co Ltd, Kobe Pharma Res Inst, Pharmacokinet & Nonclin Safety Dept, Kobe, Hyogo, Japan; [Taub, Mitchell E.] Boehringer Ingelheim Pharmaceut Inc, Drug Metab & Pharmacokinet, Ridgefield, CT USA	Ebner, T (reprint author), Boehringer Ingelheim Pharma GmbH & Co KG, Dept Drug Metab & Pharmacokinet, Biberach, Germany.	thomas.ebner@boehringer-ingelheim.com					Li JB, 2011, DRUG METAB DISPOS, V39, P1196, DOI 10.1124/dmd.111.038075; Bahn A, 2004, DRUG METAB DISPOS, V32, P424, DOI 10.1124/dmd.32.4.424; Ishiguro N, 2013, DRUG METAB DISPOS, V41, P149, DOI 10.1124/dmd.112.048470; Nies AT, 2011, HANDB EXP PHARMACOL, V201, P105, DOI 10.1007/978-3-642-14541-4_3; Reitman ML, 2011, CLIN PHARMACOL THER, V89, P234, DOI 10.1038/clpt.2010.271; Windass AS, 2007, J PHARMACOL EXP THER, V322, P1221, DOI 10.1124/jpet.107.125831; Baldes C, 2006, EUR J PHARM BIOPHARM, V62, P39, DOI 10.1016/j.ejpb.2005.06.001; Eyal S, 2009, PHARMACOL THERAPEUT, V123, P80, DOI 10.1016/j.pharmthera.2009.03.017; Tsuda M, 2009, J PHARMACOL EXP THER, V329, P185, DOI 10.1124/jpet.108.147918; Hasannejad H, 2004, J PHARMACOL EXP THER, V308, P1021, DOI 10.1124/jpet.103.059139; Annaert P, 2010, XENOBIOTICA, V40, P163, DOI 10.3109/00498250903509375; Hasegawa M, 2007, J AM SOC NEPHROL, V18, P37, DOI 10.1681/ASN.2005090966; Streetman DS, 2000, CLIN PHARMACOL THER, V68, P375, DOI 10.1067/mcp.2000.109519; Bentz J, 2013, DRUG METAB DISPOS, V41, P1347, DOI 10.1124/dmd.112.050500; Kullak-Ublick GA, 2001, GASTROENTEROLOGY, V120, P525, DOI 10.1053/gast.2001.21176; Kishimoto W, 2014, DRUG METAB DISPOS, V42, P257, DOI 10.1124/dmd.113.053769; Yoshida K, 2012, CLIN PHARMACOL THER, V91, P1053, DOI 10.1038/clpt.2011.351; Goh BC, 2010, CLIN PHARMACOL THER, V88, P652, DOI 10.1038/clpt.2010.158; Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028; Kitamura S, 2008, DRUG METAB DISPOS, V36, P2014, DOI 10.1124/dmd.108.021410; PENTIKAINEN PJ, 1979, EUR J CLIN PHARMACOL, V16, P195, DOI 10.1007/BF00562061; Benet LZ, 2011, AAPS J, V13, P519, DOI 10.1208/s12248-011-9290-9; Haegeli L, 2007, BRIT J CLIN PHARMACO, V64, P804, DOI 10.1111/j.1365-2125.2007.03035.x; Jamei M, 2014, CLIN PHARMACOKINET, V53, P73, DOI 10.1007/s40262-013-0097-y; Kunze A, 2014, J PHARM SCI-US, V103, P994, DOI 10.1002/jps.23851; Mease K, 2012, J PHARM SCI-US, V101, P1888, DOI 10.1002/jps.23069; ODLIND B, 1980, CLIN PHARMACOL THER, V27, P784; Ohtsuki S, 2012, DRUG METAB DISPOS, V40, P83, DOI 10.1124/dmd.111.042259; Prueksaritanont T, 2014, BRIT J CLIN PHARMACO, V78, P587, DOI 10.1111/bcp.12377; Simonson SG, 2004, CLIN PHARMACOL THER, V76, P167, DOI 10.1016/j.clpt.2004.03.010; Taub ME, 2011, DRUG METAB DISPOS, V39, P2093, DOI 10.1124/dmd.111.040816; Hirano M, 2004, J PHARMACOL EXP THER, V311, P139, DOI 10.1124/jpet.104.068056; Martin PD, 2003, CLIN THER, V25, P2553, DOI 10.1016/S0149-2918(03)80316-8; Lin XN, 2011, DRUG METAB DISPOS, V39, P265, DOI 10.1124/dmd.110.034629; Chu XY, 2007, J PHARMACOL EXP THER, V321, P673, DOI 10.1124/jpct.106.116517; Grun B, 2013, BRIT J CLIN PHARMACO, V76, P787, DOI 10.1111/bcp.12079; Beermann B, 1975, Eur J Clin Pharmacol, V9, P51; Brunton L.L., 2011, GOODMAN GILMANS PHAR; Dresser MJ, 2002, PHARMACEUT RES, V19, P1244, DOI 10.1023/A:1019870831174; European Medicines Agency, 2012, CPMPEWP56095 EUR MED; Frye RF, 1997, CLIN PHARMACOL THER, V62, P365, DOI 10.1016/S0009-9236(97)90114-4; Fuchs H, 2014, DRUG METAB DISPOS, V42, P1761, DOI 10.1124/dmd.114.058545; Haberer LJ, 2014, EUR J CLIN PHARMACOL, V70, P37, DOI 10.1007/s00228-013-1592-7; Hemauer SJ, 2010, AM J OBSTET GYNECOL, V202, P383; Ijzerman AP, 2013, MOL PHARM, V83, P1257; Juhasz V, 2013, J PHARM SCI-US, V102, P1683, DOI 10.1002/jps.23491; KOREN G, 1986, INT J CLIN PHARM TH, V24, P39; Li JB, 2013, J PHARM SCI-US, V102, P3436, DOI 10.1002/jps.23523; MASSON JP, 1978, KLIN WOCHENSCHR, V56, P1071, DOI 10.1007/BF01476555; Schwabedissen HEMZ, 2010, AM J PHYSIOL-RENAL, V298, pF997, DOI 10.1152/ajprenal.00431.2009; Ministry of Health Labor and Welfare Tokyo Japan, 2014, MHLW GUID DRUG INT D; Nader AM, 2014, J CLIN PHARMACOL, V54, P3, DOI 10.1002/jcph.200; Takeuchi K, 2014, DRUG METAB DISPOS, V42, P726, DOI 10.1124/dmd.113.054767; Umehara KI, 2007, XENOBIOTICA, V37, P618, DOI 10.1080/00498250701397705; US Food and Drug Administration, 2012, GUID IN PRESS; Zamek-Gliszczynski MJ, 2013, CLIN PHARMACOL THER, V94, P64, DOI 10.1038/clpt.2013.45	56	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	SEP	2015	104	9					3220	3228		10.1002/jps.24489		9	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CP4MV	WOS:000359857200054		
J	Kadokawa, J; Endo, R; Hatanaka, D; Yamamoto, K				Kadokawa, Jun-ichi; Endo, Ryo; Hatanaka, Daisuke; Yamamoto, Kazuya			Preparation of Chitin Nanofiber-Reinforced Cellulose Films Through Stepwise Regenerations from Individually Prepared Ion Gels	JOURNAL OF POLYMERS AND THE ENVIRONMENT			English	Article						Cellulose; Chitin nanofiber; Ionic liquid	COMPOSITE GELS; LIQUIDS; DISSOLUTION; CHITOSAN; POLYSACCHARIDES; MEDIA	In this study, we investigated the preparation of chitin nanofiber (CNF)-reinforced cellulose films through stepwise regeneration procedures from the respective ion gels with ionic liquids. Self-assembled CNF dispersions were prepared by regeneration from the chitin ion gel with the ionic liquid, 1-allyl-3-methylimidazolium bromide, using methanol, followed by dilution with adjusted amounts of methanol. Cellulose ion gels with the ionic liquid, 1-butyl-3-methylimidazolium chloride, were then prepared, soaked in the CNF dispersions, and centrifuged to simultaneously occur regeneration of cellulose and compatibilization with the CNFs. Soxhlet extraction with methanol and subsequent drying of the resulting materials gave the CNF/cellulose composite films. The IR and SEM results of the films indicated the presence of CNFs not only on the surfaces of the films but also inside the films. Powder X-ray diffraction patterns showed the amorphous structure of the cellulose in the film. Tensile testing of the films suggested the reinforcing effect of the CNFs on the mechanical properties of the films.	[Kadokawa, Jun-ichi; Endo, Ryo; Hatanaka, Daisuke; Yamamoto, Kazuya] Kagoshima Univ, Grad Sch Sci & Engn, Kagoshima 8900065, Japan	Kadokawa, J (reprint author), Kagoshima Univ, Grad Sch Sci & Engn, 1-21-40 Korimoto, Kagoshima 8900065, Japan.	kadokawa@eng.kagoshima-u.ac.jp					Kadokawa JI, 2009, CARBOHYD POLYM, V75, P180, DOI 10.1016/j.carbpol.2008.07.021; Pinkert A, 2009, CHEM REV, V109, P6712, DOI 10.1021/cr9001947; Kadokawa J, 2011, CARBOHYD POLYM, V84, P1408, DOI 10.1016/j.carbpol.2011.01.049; Prasad K, 2009, INT J BIOL MACROMOL, V45, P221, DOI 10.1016/j.ijbiomac.2009.05.004; Kurita K, 2006, MAR BIOTECHNOL, V8, P203, DOI 10.1007/s10126-005-0097-5; Zakrzewska ME, 2010, ENERG FUEL, V24, P737, DOI 10.1021/ef901215m; Turner MB, 2004, BIOMACROMOLECULES, V5, P1379, DOI 10.1021/bm049748q; Liebert T, 2008, BIORESOURCES, V3, P576; Butchosa N, 2013, GREEN CHEM, V15, P3404, DOI 10.1039/c3gc41700j; Jaworska MM, 2012, J POLYM ENG, V32, P67, DOI 10.1515/polyeng-2011-0145; Wang WT, 2010, J MACROMOL SCI B, V49, P528, DOI 10.1080/00222341003595634; Takegawa A, 2010, CARBOHYD POLYM, V79, P85, DOI 10.1016/j.carbpol.2009.07.030; Yamazaki S, 2009, ELECTROCHEM COMMUN, V11, P68, DOI 10.1016/j.elecom.2008.10.039; Swatloski RP, 2002, J AM CHEM SOC, V124, P4974, DOI 10.1021/ja025790m; Izawa H, 2009, J MATER CHEM, V19, P6969, DOI 10.1039/b916864h; Zhao DB, 2005, HELV CHIM ACTA, V88, P665, DOI 10.1002/hlca.200590046; Muzzarelli RAA, 2011, MAR DRUGS, V9, P1510, DOI 10.3390/md9091510; Rinaudo M, 2006, PROG POLYM SCI, V31, P603, DOI 10.1016/j.progpolymsci.2006.06.001; Feng L, 2008, J MOL LIQ, V142, P1, DOI 10.1016/j.molliq.2008.06.007; Klemm D, 2011, ANGEW CHEM INT EDIT, V50, P5438, DOI 10.1002/anie.201001273; Prasad K, 2009, J MATER CHEM, V19, P4088, DOI 10.1039/b903332g; Izawa H, 2010, J MATER CHEM, V20, P5235, DOI 10.1039/c0jm00595a; Kadokawa J, 2015, RSC ADV, V5, P12736, DOI 10.1039/c4ra15319g; Klemm D, 2005, ANGEW CHEM INT EDIT, V44, P3358, DOI 10.1002/anie.200460587; Turner MB, 2005, BIOMACROMOLECULES, V6, P2497, DOI 10.1021/bm050199d; Prasad K, 2009, MACROMOL BIOSCI, V9, P376, DOI 10.1002/mabi.200800179; Hatanaka D, 2014, INT J BIOL MACROMOL, V69, P35, DOI 10.1016/j.ijbiomac.2014.05.022; Pillai CKS, 2009, PROG POLYM SCI, V34, P641, DOI 10.1016/j.progpolymsci.2009.04.001; Setoyama M, 2014, J POLYM ENVIRON, V22, P298, DOI 10.1007/s10924-014-0642-2; Bochek AM, 2012, RUSS J APPL CHEM, V285, P1718; Huang Y, 2013, MACROMOL MATER ENG, V298, P3030; Kadokawa J, 2013, J POLYM ENVIRON, V21, P512, DOI 10.1007/s10924-012-0495-5; Kadokawa J, 2012, J POLYM ENVIRON, V20, P37, DOI 10.1007/s10924-011-0331-3; Kadokawa J, 2008, CARBOHYD RES, V348, P769; Mine S, 2010, J MATER CHEM, V20, P9220, DOI 10.1039/c0jm00984a; Muzzarelli R. A. A., 2012, POLYM SCI COMPREHENS, V10, P153; Schuerch C., 1986, ENCY POLYM SCI ENG, V13, P87; Setoyama M, 2013, J POLYM ENVIRON, V21, P795, DOI 10.1007/s10924-013-0580-4; Tajiri R., 2013, J BIOBASED MATER BIO, V7, P655, DOI DOI 10.1166/JBMB.2013.1393	39	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1566-2543	1572-8900		J POLYM ENVIRON	J. Polym. Environ.	SEP	2015	23	3					348	355		10.1007/s10924-015-0723-x		8	Engineering, Environmental; Polymer Science	Engineering; Polymer Science	CP6MU	WOS:000360002300008		
J	Tada, M; Uchida, H; Mizushima, J; Suzuki, T; Mimura, M; Nio, S				Tada, Mitsuhiro; Uchida, Hiroyuki; Mizushima, Jin; Suzuki, Takefumi; Mimura, Masaru; Nio, Shintaro			Antidepressant dose and treatment response in bipolar depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data	JOURNAL OF PSYCHIATRIC RESEARCH			English	Article						Affective switch; Antidepressants; Bipolar disorder; Dose; Response	PSYCHIATRY WFSBP GUIDELINES; WEEKLY SYMPTOMATIC STATUS; BIOLOGICAL TREATMENT; BRITISH-ASSOCIATION; WORLD FEDERATION; NATURAL-HISTORY; MOOD DISORDERS; II DISORDERS; MANIA; PSYCHOPHARMACOLOGY	The aim of this study is to evaluate whether an adjunct antidepressant therapy at a higher dose to a mood stabilizer would make a difference in the treatment of bipolar depression. This is a post-hoc analysis of the data from the randomized treatment for acute depression of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), in which patients with bipolar depression were randomly assigned to treatment with a mood stabilizer plus adjunctive antidepressant drugs or placebo. According to the highest dose received in the course of treatment, the subjects were divided into one of the following three groups: high-dose, low-dose and placebo groups. The primary and secondary outcomes were durable recovery (which was operationally defined as eight consecutive weeks with </ = 2 symptoms) and treatment-emergent affective switch (i.e. transition to mania or hypomania), respectively. In the evaluable 333 subjects, subjects in both the high-dose (n = 102) and placebo groups (n = 169) more significantly achieved durable recovery than the low-dose group (n = 62) (odds ratio = 3.013 [p = 0.009], 2.899 [p = 0.008], respectively). No significant association was found between the dose status and treatment-emergent affective switch (p = 0.614). The allocation to either high- and low-dose antidepressants was not randomized and the dose was guided by a case-by-case decision, which hampers to draw a firm conclusion on dose response issues and renders the findings as preliminary. Nevertheless, higher doses of adjunctive antidepressant drugs seem to have potential for yielding greater clinical improvement without increasing any risk of manic switch compared to lower doses, at least in carefully selected patients. The ClinicalTrials.gov identifier: NCT00012558. (C) 2015 Elsevier Ltd. All rights reserved.	[Tada, Mitsuhiro; Uchida, Hiroyuki; Mizushima, Jin; Suzuki, Takefumi; Mimura, Masaru; Nio, Shintaro] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan; [Uchida, Hiroyuki] Ctr Addict & Mental Hlth, Geriatr Psychiat Div, Toronto, ON, Canada; [Mizushima, Jin] Kyosai Tachikawa Hosp, Dept Psychiat, Tokyo, Japan; [Suzuki, Takefumi] Inokashira Hosp, Dept Psychiat, Tokyo, Japan; [Nio, Shintaro] Saiseikai Cent Hosp, Dept Psychiat, Tokyo 1080073, Japan	Nio, S (reprint author), Saiseikai Cent Hosp, Dept Psychiat, Minato Ku, 1-4-17 Mita, Tokyo 1080073, Japan.	shin@dd.catv.ne.jp	Uchida, Hiroyuki/I-4867-2015	Uchida, Hiroyuki/0000-0002-0628-7036	NIMH [N01MH80001]	Data used in the preparation of this article were obtained from the limited access datasets distributed from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) supported by the National Institute of Mental Health (NIMH). STEP-BD focused on non-psychotic bipolar disorder in adults seen in outpatient settings. One of the primary purposes of this research study was to determine whether adjunctive antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania. The study was supported by NIMH Contract #N01MH80001.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; American Psychiatric Association, 2010, PRACT GUID TREATM PA; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Grunze H, 2010, WORLD J BIOL PSYCHIA, V11, P81, DOI 10.3109/15622970903555881; Sachs GS, 2002, BIPOLAR DISORD, V4, P323, DOI 10.1034/j.1399-5618.2002.01195.x; Yatham LN, 2013, BIPOLAR DISORD, V15, P1, DOI 10.1111/bdi.12025; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Cipriani A, 2009, LANCET, V373, P746, DOI 10.1016/S0140-6736(09)60046-5; Leboyer M, 2010, J CLIN PSYCHIAT, V71, P1689, DOI 10.4088/JCP.10m06347yel; Gitlin MJ, 2011, J CLIN PSYCHIAT, V72, P692, DOI 10.4088/JCP.09m05291gre; Judd LL, 2005, ARCH GEN PSYCHIAT, V62, P1322, DOI 10.1001/archpsyc.62.12.1322; Angst J, 2013, EUR ARCH PSY CLIN N, V263, P425, DOI 10.1007/s00406-012-0380-1; Bauer M, 2013, WORLD J BIOL PSYCHIA, V14, P334, DOI 10.3109/15622975.2013.804195; Judd LL, 2003, ARCH GEN PSYCHIAT, V60, P261, DOI 10.1001/archpsyc.60.3.261; GITLIN MJ, 1995, AM J PSYCHIAT, V152, P1635; Goldberg JF, 2007, AM J PSYCHIAT, V164, P1348, DOI 10.1176/appi.ajp.2007.05122032; Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6; Sachs GS, 2007, NEW ENGL J MED, V356, P1711, DOI 10.1056/NEJMoa064135; Anderson IM, 2008, J PSYCHOPHARMACOL, V22, P343, DOI 10.1177/0269881107088441; Perlis RH, 2006, AM J PSYCHIAT, V163, P217, DOI 10.1176/appi.ajp.163.2.217; Dilsaver SC, 2011, J AFFECT DISORDERS, V129, P79, DOI 10.1016/j.jad.2010.08.030; Nierenberg AA, 2000, AM J PSYCHIAT, V157, P1423, DOI 10.1176/appi.ajp.157.9.1423; Kupka RW, 2007, BIPOLAR DISORD, V9, P531, DOI 10.1111/j.1399-5618.2007.00467.x; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Goodwin GM, 2009, J PSYCHOPHARMACOL, V23, P346, DOI 10.1177/0269881109102919; SCHWEIZER E, 1990, J CLIN PSYCHIAT, V51, P8; YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429; Judd LL, 2002, ARCH GEN PSYCHIAT, V59, P530, DOI 10.1001/archpsyc.59.6.530; De Dios C, 2012, J AFFECT DISORDERS, V143, P160, DOI 10.1016/j.jad.2012.05.047; Glue P, 1999, CLIN PHARMACOL THER, V66, P152; Dilsaver SC, 1997, PSYCHIAT RES, V73, P47, DOI 10.1016/S0165-1781(97)00109-1; Guy W., 1976, ASSESSMENT PSYCHOPHA; Joffe RT, 2005, ACTA PSYCHIAT SCAND, V112, P105, DOI 10.1111/j.1600-0447.2005.00583.x; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; Lavori PW, 2001, BIOL PSYCHIAT, V50, P792, DOI 10.1016/S0006-3223(01)01223-9; Michalak Erin, 2011, Chronic Illn, V7, P209, DOI 10.1177/1742395310395959; Schweizer E, 2001, INT CLIN PSYCHOPHARM, V16, P137, DOI 10.1097/00004850-200105000-00002; Sheehan DV, 1998, J CLIN PSYCHIAT S20, V59, P4; WATT DC, 1972, PSYCHOL MED, V2, P397	40	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3956	1879-1379		J PSYCHIATR RES	J. Psychiatr. Res.	SEP	2015	68						151	156		10.1016/j.jpsychires.2015.06.015		6	Psychiatry	Psychiatry	CP5WM	WOS:000359956100023		
J	Kishi, T; Matsunaga, S; Iwata, N				Kishi, Taro; Matsunaga, Shinji; Iwata, Nakao			Intramuscular olanzapine for agitated patients: A systematic review and meta-analysis of randomized controlled trials	JOURNAL OF PSYCHIATRIC RESEARCH			English	Article						Olanzapine intramuscular injection; Agitated patients; Efficacy; Safety; Meta-analysis	HALOPERIDOL PLUS PROMETHAZINE; DOUBLE-BLIND; RAPID TRANQUILIZATION; SCHIZOPHRENIA; PLACEBO; EFFICACY; ZIPRASIDONE; LORAZEPAM; SAFETY; ANTIPSYCHOTICS	We performed an updated systematic review and meta-analysis of randomized controlled trials (RCTs) of intramuscular (IM)-olanzapine (OLA-IM) versus controls in agitated patients. The risk ratio, number-needed-to-treat/harm, and standardized mean difference based on a random effects model were calculated. We identified 13 RCTs (19 comparisons) as follows: 7 comparisons with 1059 patients for OLA-IM versus placebo; 5 comparisons with 613 patients for OLA-IM versus haloperidol (HAL)-IM; 2 comparisons with 108 patients for OLA-IM versus ziprasidone (ZIP)-IM; 2 comparisons with 110 patients for OLA-IM versus HAL-IM plus midazolam; and 3 comparisons with 412 patients for OLA-IM versus HAL-IM plus promethazine, 2 comparisons with 355 patients for OLA-IM versus lorazepam-IM (LOR-IM); and 1 comparison with 67 patients for OLA-IM versus HAL-IM plus LOR-IM. OLA-IM was superior to placebo in both Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) and Agitation Calmness Evaluation Scale (ACES) scores 2 h after first injection, and had a comparable side effect profile, including over sedation, extrapyramidal symptoms, akathisia, and anticholinergic use. While there was no significant difference in PANSS-EC scores after 2 h between OLA-IM and HAL-IM, OLA-IM outperformed HAL-IM in ACES after 2 h. Compared with HAL-IM, OLA-IM was associated with fewer side effects, including anticholinergic use, akathisia, extrapyramidal symptoms, and dystonia, and marginally less QT prolongation compared with HAL-IM. Based on our findings, OLA-IM is preferable to HAL-IM for the treatment of agitated patients. However, comparator data for ZIP-IM, LOR-IM and HAL-IM combination therapy were insufficient. (C) 2015 Elsevier Ltd. All rights reserved.	[Kishi, Taro; Matsunaga, Shinji; Iwata, Nakao] Fujita Hlth Univ, Sch Med, Dept Psychiat, Toyoake, Aichi 4701192, Japan	Kishi, T (reprint author), Fujita Hlth Univ, Sch Med, Dept Psychiat, Toyoake, Aichi 4701192, Japan.	tarok@fujita-hu.ac.jp			GlaxoSmithKline; Otsuka	Dr Kishi has received speaker's honoraria from Abbott, Astellas, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Tanabe-Mitsubishi, Tsumura, Novartis, and Pfizer. Dr Matsunaga has received speaker's honoraria from Eisai, Janssen, Novartis, Daiichi Sankyo, Ono, Eli Lilly, Takeda, and Otsuka. Dr Iwata has received speaker's honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer and a research grant from GlaxoSmithKline and Otsuka.	KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261; Leucht S, 2013, LANCET, V382, P951, DOI 10.1016/S0140-6736(13)60733-3; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Chan EW, 2013, ANN EMERG MED, V61, P72, DOI 10.1016/j.annemergmed.2012.07.118; Wilson MP, 2012, J EMERG MED, V43, P889, DOI 10.1016/j.jemermed.2010.04.012; Satterthwaite TD, 2008, J CLIN PSYCHIAT, V69, P1869; Meehan KM, 2002, NEUROPSYCHOPHARMACOL, V26, P494, DOI 10.1016/S0893-133X(01)00365-7; Raveendran NS, 2007, BRIT MED J, V335, P865, DOI 10.1136/bmj.39341.608519.BE; Baldacara L, 2011, REV BRAS PSIQUIATR, V33, P30, DOI 10.1590/S1516-44462011000100008; Belgamwar RB, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003729.pub2; Breier A, 2002, ARCH GEN PSYCHIAT, V59, P441, DOI 10.1001/archpsyc.59.5.441; Chan HY, 2014, J CLIN PSYCHOPHARM, V34, P355, DOI 10.1097/JCP.0000000000000120; Citrome L, 2007, J CLIN PSYCHIAT, V68, P1876; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Guy W.B., 1970, MANUAL ECDEU ASSESSM; Hsu WY, 2010, J CLIN PSYCHOPHARM, V30, P230, DOI 10.1097/JCP.0b013e3181db8715; Huang CLC, 2015, J FORMOS MED ASSOC, V114, P438, DOI 10.1016/j.jfma.2015.01.018; Katagiri H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-20; Katagiri H., 2012, J NEW REMEDIES CLIN, V61, P30; Mantovani C, 2013, J CLIN PSYCHOPHARM, V33, P306, DOI 10.1097/JCP.0b013e3182900fd6; Meehan K, 2001, J CLIN PSYCHOPHARM, V21, P389, DOI 10.1097/00004714-200108000-00006; Miceli JJ, 2010, CLIN THER, V32, P472, DOI 10.1016/j.clinthera.2010.03.003; Moher D, 2009, BMJ-BRIT MED J, V21, P339, DOI DOI 10.1136/BMJ.B2535; Ono H., 2009, J NEW REMEDIES CLIN, V58, P163; Ono H., 2007, JAPANESE J CLIN PSYC, V10, P1063; Powney MJ, 2012, COCHRANE DB SYST REV, V11, DOI DOI 10.1002/14651858.CD009377.PUB2; Pratts M, 2014, ACTA PSYCHIAT SCAND, V130, P61, DOI 10.1111/acps.12262; Rueve Marie E, 2008, Psychiatry (Edgmont), V5, P34; Wilson Michael P, 2012, West J Emerg Med, V13, P26, DOI 10.5811/westjem.2011.9.6866; Wright P, 2001, AM J PSYCHIAT, V158, P1149, DOI 10.1176/appi.ajp.158.7.1149	30	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3956	1879-1379		J PSYCHIATR RES	J. Psychiatr. Res.	SEP	2015	68						198	209		10.1016/j.jpsychires.2015.07.005		12	Psychiatry	Psychiatry	CP5WM	WOS:000359956100029		
J	Okuno, H; Greene, J; Hasebe, H; Imao, H; Storalrz, A; Yoshida, A				Okuno, H.; Greene, J.; Hasebe, H.; Imao, H.; Storalrz, A.; Yoshida, A.			Foreword of the 27th world conference of the international nuclear target	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Editorial Material									[Okuno, H.; Hasebe, H.; Imao, H.; Yoshida, A.] RIKEN, Nishina Ctr Accelerator Based Sci, Wako, Saitama 3510198, Japan; [Greene, J.] Argonne Natl Lab, Div Phys, Argonne, IL 60439 USA; [Storalrz, A.] Univ Warsaw, Heavy Ion Lab, PL-02093 Warsaw, Poland	Okuno, H (reprint author), RIKEN, Nishina Ctr Accelerator Based Sci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	okuno@riken.jp						0	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					701	702		10.1007/s10967-015-4358-0		2	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000001		
J	Sugai, I; Oyaizu, M; Bessho, K; Tamii, A				Sugai, Isao; Oyaizu, Michihiro; Bessho, Kotaro; Tamii, Atsushi			Fabrication of isotopic and natural carbon foils by thermal cracking method and some issues	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Carbon foil; Target foil; Cracking foil; Thermal cracking carbon; CVD		Isotopic and natural carbon foils made by thermal cracking method are used for various purposes in nuclear physics experiments. An apparatus equipped with an oil free vacuum pumping system has been constructed to produce such foils on a resistively heated metallic Ta filament by the thermal cracking method. Properties of the foils such as accessible thickness and area, uniformity, purity and yield in the foil preparation were investigated. We also investigated the following issue during the foil production; when the Ta filament temperature was decreased after the cracking process, the cracked layer sometimes broke into pieces from the filament. Eventually, we could successfully fabricate enriched isotopic C-12 foils and natural carbon foils with thicknesses from 0.2 to 5 mg/cm(2) and with a dimension of 20 x 20 mm(2) or even larger.	[Sugai, Isao] High Energy Accelerator Res Org, Accelerator Lab, Tsukuba, Ibaraki 3050801, Japan; [Oyaizu, Michihiro] High Energy Accelerator Res Org, Inst Particle & Nucl Studies, Tsukuba, Ibaraki 3050801, Japan; [Bessho, Kotaro] High Energy Accelerator Res Org, Radiat Sci Ctr, Tsukuba, Ibaraki 3050801, Japan; [Tamii, Atsushi] Osaka Univ, Nucl Phys Res Ctr, Ibaraki 5670047, Japan	Sugai, I (reprint author), High Energy Accelerator Res Org, Accelerator Lab, Oho 1-1, Tsukuba, Ibaraki 3050801, Japan.	isao.sugai@kek.jp					[Anonymous], 2008, THERMOPHYSICAL PROPE; Makii H, 2009, PHYS REV C, V80, DOI 10.1103/PhysRevC.80.065802; Firestone RB, 1998, TABLE ISOTOPES, V8th; Makii H, 2007, PHYS REV C, V76, DOI 10.1103/PhysRevC.76.022801; Stoner JO, 2006, NUCL INSTRUM METH A, V561, P24, DOI 10.1016/j.nima.2005.12.189; Sugai I, 1971, INSJ132; Tamii A, 2014, E387 EXPT RES CTR NU	7	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					731	736		10.1007/s10967-015-3961-4		6	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000008		
J	Nakadaira, T				Nakadaira, T.			The graphite target for J-PARC neutrino beam-line	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Accelerator-based neutrino beam; High power target; High intensity proton accelerator		The graphite target of the J-PARC neutrino beam-line for the long base-line neutrino-oscillation experiment, T2K is developed. The graphite target is designed to withstand the exposure of high intensity protons beam from J-PARC accelerator. The Helium gas cooling is adopted to minimize the radiation damage of the graphite. J-PARC neutrino beam-line is operated from April 2009. The first target was used for 6.7 x 10(20) protons-on-target without significant trouble, while the maximum number of protons per pulse is 1.2 x 10(20) with 2.48 s cycle.	High Energy Accelerator Res Org KEK, J PARC Ctr, Inst Particle & Nucl Phys Studies, Tsukuba, Ibaraki 3050801, Japan	Nakadaira, T (reprint author), High Energy Accelerator Res Org KEK, J PARC Ctr, Inst Particle & Nucl Phys Studies, Tsukuba, Ibaraki 3050801, Japan.	nakadair@neutrino.kek.jp			MEXT/JSPS KAKENHI [19740162, 20039013, 23684016]	MEXT/JSPS KAKENHI Grant Numbers 19740162, 20039013 and 23684016, supports the development of J-PARC neutrino target and its upgrade. The development of J-PARC neutrino target is collaboration work with KEK, University of Kyoto, STFC Rutherford Appleton Laboratory, and T2K collaboration.	Abe K, 2011, NUCL INSTRUM METH A, V659, P106, DOI 10.1016/j.nima.2011.06.067; Abe K, 2014, PHYS REV LETT, V112, DOI 10.1103/PhysRevLett.112.061802; Abe K, 2013, PHYS REV D, V87, DOI 10.1103/PhysRevD.87.012001; ANSYS&REG; CFX, ANSYS CFX REL 12 1; Densham CJ, 2009, WE6RFP033 P PAC09 VA, P4; Densham CJ, 2010, THOA01 P HB2010 MORS, P560; Fukuda S, 2003, NUCL INSTRUM METH A, V501, P418, DOI 10.1016/S0168-9002(03)00425-X; Ichikawa AK, 2012, NUCL INSTRUM METH A, V690, P27, DOI 10.1016/j.nima.2012.06.045; Ishihara M, 1991, 91153 JAERIM; Nakadaira T, 2008, AIP CONF PROC, V981, P290, DOI 10.1063/1.2898964; Ueda T, 2004, THESIS KYOTO U KYOTO	11	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					777	782		10.1007/s10967-015-4120-7		6	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000015		
J	Yamagata, Y; Hirota, K; Ju, J; Wang, S; Morita, SY; Kato, J; Otake, Y; Taketani, A; Seki, Y; Yamada, M; Ota, H; Bautista, U; Jia, QG				Yamagata, Yutaka; Hirota, Katsuya; Ju, Jungmyoung; Wang, Sheng; Morita, Shin-ya; Kato, Jun-ichi; Otake, Yoshie; Taketani, Atsushi; Seki, Yoshichika; Yamada, Masako; Ota, Hideo; Bautista, Unico; Jia, Qinngan			Development of a neutron generating target for compact neutron sources using low energy proton beams	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Neutron-generating target; Compact neutron source; Blistering; Activation	HYDROGEN EMBRITTLEMENT; DIFFUSION; ALLOYS; PERFORMANCE; PERMEATION; BOUNDARY; ALUMINUM; METALS	A neutron generating target using a Be(p,n) reaction was developed for a RIKEN compact accelerator-driven neutron source (RANS). The major problem of targets using a low energy proton beam is blistering, which is actually due to hydrogen embrittlement caused by injected hydrogen. To avoid this problem, the authors have proposed a new target design with a hydrogen diffusible backing and its design was modeled using finite-element analysis (FEM) and Monte-Carlo ion injection simulation. Also, the mechanical strength and heat removal capability of the target were considered by FEM. Based on those simulations, a new target was manufactured and applied to RANS and operated for 1 year without any problems. Also, the residual radioactivity of the target was investigated by experiment and simulation.	[Yamagata, Yutaka; Ju, Jungmyoung; Wang, Sheng; Morita, Shin-ya; Kato, Jun-ichi; Otake, Yoshie; Taketani, Atsushi; Seki, Yoshichika; Yamada, Masako; Ota, Hideo] RIKEN, RIKEN Ctr Adv Photon, Wako, Saitama 3510198, Japan; [Hirota, Katsuya] Nagoya Univ, Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Bautista, Unico] Univ Tokyo, Tokai, Ibaraki 3191188, Japan; [Jia, Qinngan] Xi An Jiao Tong Univ, Xian 710049, Shaanxi, Peoples R China	Yamagata, Y (reprint author), RIKEN, RIKEN Ctr Adv Photon, Hirosawa 2-1, Wako, Saitama 3510198, Japan.	yamagata@riken.jp			Advanced Manufacturing Support Team, RIKEN Center for Advanced Photonics	The authors would like to express their gratitude for the advice from JCANS (Japan Collaboration on compact accelerator-driven neutron sources) members especially Prof. Y. Kiyanagi, Prof. H. M. Shimizu and Prof. Y. Iwashita. The authors would like to acknowledge the support from Advanced Manufacturing Support Team, RIKEN Center for Advanced Photonics.	Aleynik V, 2011, APPL RADIAT ISOTOPES, V69, P1635, DOI 10.1016/j.apradiso.2011.03.010; Astrelin VT, 2010, J NUCL MATER, V396, P43, DOI 10.1016/j.jnucmat.2009.10.051; Nambu T, 2007, J ALLOY COMPD, V446, P588, DOI 10.1016/j.jallcom.2007.02.063; ICHIMURA M, 1991, MATER T JIM, V32, P1109; Lavelle CM, 2008, NUCL INSTRUM METH A, V587, P324, DOI 10.1016/j.nima.2007.12.044; NISHIMURA C, 1991, MATER T JIM, V32, P501; BAUER HC, 1978, Z PHYS B CON MAT, V29, P17, DOI 10.1007/BF01354833; Bayanov B., 2006, Journal of Physics: Conference Series, V41, DOI 10.1088/1742-6596/41/1/051; Bayanov B, 2009, APPL RADIAT ISOTOPES, V67, pS282, DOI 10.1016/j.apradiso.2009.03.076; HAWKESWORTH MR, 1977, ATOM ENERGY REV, V15, P169; ISHIKAWA T, 1985, J PHYS CHEM SOLIDS, V46, P445, DOI 10.1016/0022-3697(85)90110-6; Kamata S, 2006, 2006 ANN M AT EN SOC; Kim IJ, 2005, NUCL INSTRUM METH B, V241, P917, DOI 10.1016/j.nimb.2005.07.170; Kiyanagi Y, 2006, NUCL INSTRUM METH A, V562, P561, DOI 10.1016/j.nima.2006.02.009; Kosako K, 1999, DEV DCHAIN SP CODE A; MOMOSE T, 1993, VACUUM, V44, P991, DOI 10.1016/0042-207X(93)90285-I; PSTAR program is provided by the National Institute of Stan- dards and Technology, 2011, PSTAR PROGRAM IS PRO; Sago T, 2013, J NUCL SCI TECHNOL, V50, P913; Wang S, 2012, 3 INT M UN COMP ACC; Waseda Y, 2000, HDB OF METALS; Wipf H, 2001, PHYS SCRIPTA, VT94, P43, DOI 10.1238/Physica.Topical.094a00043; Yamagata Y, 2013, RAD IND, V134, P16; YANO S, 1991, J NUCL MATER, V179, P779, DOI 10.1016/0022-3115(91)90204-K	23	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					787	794		10.1007/s10967-015-4059-8		8	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000017		
J	Takahashi, H; Agari, K; Aoki, K; Hagiwara, M; Hirose, E; Ieiri, M; Iwasaki, R; Katoh, Y; Minakawa, M; Muto, R; Naruki, M; Noumi, H; Sato, Y; Sawada, S; Shirakabe, Y; Suzuki, Y; Tanaka, KH; Toyoda, A; Watanabe, H; Yamanoi, Y				Takahashi, H.; Agari, K.; Aoki, K.; Hagiwara, M.; Hirose, E.; Ieiri, M.; Iwasaki, R.; Katoh, Y.; Minakawa, M.; Muto, R.; Naruki, M.; Noumi, H.; Sato, Y.; Sawada, S.; Shirakabe, Y.; Suzuki, Y.; Tanaka, K. H.; Toyoda, A.; Watanabe, H.; Yamanoi, Y.			Indirectly water-cooled production target at J-PARC hadron facility	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Production target; Hadron beam; Synchrotron; Secondary beam; Thermo-mechanical	TITANIUM-ALLOYS; IRRADIATION; TENSILE; SYSTEM	After the radioactive material leak accident at the J-PARC hadron experimental facility on May 23, 2013, we designed a new production target, which is capable of a primary proton beam with the energy of 30 GeV and power of 50 kW. It is made of gold and cooled by water through a copper block. For the countermeasures of the recurrence of the accident, the target is enclosed by an airtight chamber and helium gas is circulated to monitor the target soundness. In this paper, technical details of the new target design are presented.	[Takahashi, H.; Agari, K.; Aoki, K.; Hirose, E.; Ieiri, M.; Iwasaki, R.; Katoh, Y.; Minakawa, M.; Muto, R.; Sato, Y.; Sawada, S.; Shirakabe, Y.; Suzuki, Y.; Tanaka, K. H.; Toyoda, A.; Watanabe, H.; Yamanoi, Y.] KEK, Inst Particle & Nucl Studies, Tsukuba, Ibaraki 3050801, Japan; [Hagiwara, M.] KEK, Radiat Sci Ctr, Tsukuba, Ibaraki 3050801, Japan; [Naruki, M.] Kyoto Univ, Dept Phys, Sakyo Ku, Kyoto 6068502, Japan; [Noumi, H.] Osaka Univ, Nucl Phys Res Ctr, Osaka, Ibaraki 5670047, Japan	Takahashi, H (reprint author), KEK, Inst Particle & Nucl Studies, 1-1 Oho, Tsukuba, Ibaraki 3050801, Japan.	hitoshi.takahashi@kek.jp					Agari K, 2012, PROG THEOR EXP PHYS, DOI [10.1093/ptep/pts03402B008, DOI 10.1093/PTEP/PTS03402B008]; Marmy P, 2001, J NUCL MATER, V296, P155, DOI 10.1016/S0022-3115(01)00564-5; Rodchenkov BS, 2002, J NUCL MATER, V307, P421, DOI 10.1016/S0022-3115(02)01011-5; Sato T, 2013, J NUCL SCI TECHNOL, V50, P913, DOI 10.1080/00223131.2013.814553; GELLES DS, 1994, J NUCL MATER, V212, P29, DOI 10.1016/0022-3115(94)90030-2; Hirose E, 2006, IEEE T APPL SUPERCON, V16, P1342, DOI 10.1109/TASC.2005.864314; Krivosheev OE, 2000, P MONT CARL 2000 C L; Mokhov N. V., 1995, FERMILABFN628; Mokhov N. V., 2004, FERMILABCONF04053; Mokhov NV, 2003, FERMILABCONF03053; Moons F, 1996, J NUCL MATER, V233, P823, DOI 10.1016/S0022-3115(96)00139-0	11	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					803	809		10.1007/s10967-015-3940-9		7	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000019		
J	Makimura, S; Kawamura, N; Onizawa, S; Matsuzawa, Y; Tabe, M; Kobayashi, Y; Shimizu, R; Taniguchi, Y; Fujimori, H; Ikedo, Y; Kadono, R; Koda, A; Kojima, KM; Nishiyama, K; Nakamura, J; Shimomura, K; Strasser, P; Nakatsugawa, Y; Miyake, Y				Makimura, Shunsuke; Kawamura, N.; Onizawa, S.; Matsuzawa, Y.; Tabe, M.; Kobayashi, Y.; Shimizu, R.; Taniguchi, Y.; Fujimori, H.; Ikedo, Y.; Kadono, R.; Koda, A.; Kojima, K. M.; Nishiyama, K.; Nakamura, J.; Shimomura, K.; Strasser, P.; Nakatsugawa, Y.; Miyake, Y.			Development of muon rotating target at J-PARC/MUSE	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Proton beam; Muon target; Graphite target; Rotating target; High radiation; Bearing	J-PARC	A pulsed muon beam with unprecedented intensity will be generated by a 3-GeV 333-micro A proton beam on a muon target made of 20-mm thick isotropic graphite at J-PARC. The current muon target with a fixed target method has been utilized without replacements since the first muon beam generation on September of 2008 till June of 2014. However, the proton irradiation damage to graphite is significant for our case. To extend the lifetime, the developments of the muon rotating target, in which the radiation damage is distributed to a wider area, have been performed.	[Makimura, Shunsuke; Kawamura, N.; Kobayashi, Y.; Taniguchi, Y.; Fujimori, H.; Ikedo, Y.; Kadono, R.; Koda, A.; Kojima, K. M.; Nishiyama, K.; Nakamura, J.; Shimomura, K.; Strasser, P.; Nakatsugawa, Y.; Miyake, Y.] High Energy Accelerator Res Org KEK IMSS, Muon Sci Lab, Tokai, Ibaraki 3191195, Japan; [Makimura, Shunsuke; Kawamura, N.; Kobayashi, Y.; Taniguchi, Y.; Fujimori, H.; Ikedo, Y.; Kadono, R.; Koda, A.; Kojima, K. M.; Nishiyama, K.; Nakamura, J.; Shimomura, K.; Strasser, P.; Miyake, Y.] J PARC Ctr, Muon Sect, Mat & Life Sci Div, Tokai, Ibaraki 3191195, Japan; [Onizawa, S.; Matsuzawa, Y.; Shimizu, R.] Nippon Adv Technol Co Ltd NAT, Tokai, Ibaraki 3191112, Japan; [Tabe, M.] Seekel Co Ltd, Mito, Ibaraki 3100851, Japan	Makimura, S (reprint author), High Energy Accelerator Res Org KEK IMSS, Muon Sci Lab, Tokai, Ibaraki 3191195, Japan.	shunsuke.makimura@kek.jp					Iwase H, 2002, J NUCL SCI TECHNOL, V39, P1142, DOI 10.3327/jnst.39.1142; Kawamura N, 2009, NUCL INSTRUM METH A, V600, P114, DOI 10.1016/j.nima.2008.11.073; Makimura S, 2009, NUCL INSTRUM METH A, V600, P146, DOI 10.1016/j.nima.2008.11.110; Makimura S, 2007, P 4 ANN M PART ACC S, P868; Makimura S, 2014, J NUCL MATER, V450, P110, DOI 10.1016/j.jnucmat.2013.10.019; Makimura S, 2011, P 8 ANN M PART ACC S, P1188; Matsuo H, 1991, GRAPHITE, V150, P290	7	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					811	815		10.1007/s10967-015-3949-0		5	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000020		
J	Hasebe, H; Okuno, H; Kuboki, H; Imao, H; Fukunishi, N; Kase, M; Kamigaito, O				Hasebe, Hiroo; Okuno, Hiroki; Kuboki, Hironori; Imao, Hiroshi; Fukunishi, Nobuhisa; Kase, Masayuki; Kamigaito, Osamu			Development of rotating beryllium disk stripper	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Beryllium; Charge stripper; Stripper lifetime; Rotating stripper; Uranium beam		High-intensity uranium (U) ion beams are successfully provided at the RIKEN RI Beam Factory. We have attempted to extend the lifetime of the charge stripper as the U-beam intensity has increased. An attempt to enlarge the irradiated area using a rotating large carbon disk (C-disk) failed in 2006-2007 because no commercially available C-disk with 0.085 mm thickness met our requirements. In 2012, we tested a beryllium (Be) disk (0.1-mm-thick, diameter = 120 mm) as an alternative to the C-disk. The Be disk proved to be an adequate substitute, and has been successfully used during beam-time operation.	[Hasebe, Hiroo; Okuno, Hiroki; Kuboki, Hironori; Imao, Hiroshi; Fukunishi, Nobuhisa; Kase, Masayuki; Kamigaito, Osamu] RIKEN Nishina Ctr Accelerator Based Sci, Wako, Saitama 3510198, Japan	Hasebe, H (reprint author), RIKEN Nishina Ctr Accelerator Based Sci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	hasebe@riken.jp					Koyama R, 2013, NUCL INSTRUM METH A, V729, P788, DOI 10.1016/j.nima.2013.08.056; Ryuto H, 2006, NUCL INSTRUM METH A, V569, P697, DOI 10.1016/j.nima.2006.09.075	2	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					825	829		10.1007/s10967-015-4044-2		5	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000022		
J	Saha, PK; Yoshimoto, M; Hotchi, H; Harada, H; Okabe, K; Yamazaki, Y; Kinsho, M; Irie, Y				Saha, P. K.; Yoshimoto, M.; Hotchi, H.; Harada, H.; Okabe, K.; Yamazaki, Y.; Kinsho, M.; Irie, Y.			Measurement of continuous degradation of a stripper foil during ths operation with 300 kW beam power in the 3-GeV RCS of J-PARC	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Stripper foil; H- stripping injection; Foil degradation; J-PARC; Rapid cycling synchrotron		In the 3-GeV rapid cycling synchrotron of Japan Proton Accelerator Research Complex, we have clearly measured a continuous degradation of a stripper foil during more than 6 months operation with a beam power of 300 kW. A hybrid-type boron doped carbon stripper foil of 200 mu g/cm(2) was used for 181 MeV H- stripping injection. In order to know an absolute change of the foil thickness as well as information on the pinhole formation, we precisely measured an absolute change of the partially-stripped H-0 and the un-stripped H- waste beams. Two absolutely independent monitor systems were used and the results were found to be very consistent with each other. The foil thickness at the injected beam spot was measured to be gradually thickening and it was more than 10 % thicker at the end compared to the initial thickness, where the measurement accuracy was obtained to be better than 2 %. The missing un-stripped H- were also measured to be gradually increasing due to foil deformation and curling but there was however no clear indication of foil thinning or pinhole formation.	[Saha, P. K.; Yoshimoto, M.; Hotchi, H.; Harada, H.; Okabe, K.; Yamazaki, Y.; Kinsho, M.] Japan Atom Energy Agcy, J PARC Ctr, Tokai, Ibaraki 3191195, Japan; [Irie, Y.] KEK High Energy Accelerator Res Org, Tsukuba, Ibaraki 3050801, Japan	Saha, PK (reprint author), Japan Atom Energy Agcy, J PARC Ctr, Tokai, Ibaraki 3191195, Japan.	saha.pranab@j-parc.jp					[High-intensity Proton Accelerator Project Team Accelerator Technical Design Report for High Intensity Proton Accelerator Facility Project], 2003, 20032044 JAERI HIGH; Hotchi H, 2014, P 2014 INT PART ACC, P899; Saha PK, 2011, PHYS REV SPEC TOP-AC, V14, DOI 10.1103/PhysRevSTAB.14.072801; Saha PK, 2014, J RADIOANAL NUCL CH, V299, P1041, DOI 10.1007/s10967-013-2636-2; Saha PK, 2014, NUCL INSTRUM METH A, V776, P87; Spickermann T, 2008, P 42 ICFA ADV BEAM D, P262; Sugai I, 2006, NUCL INSTRUM METH A, V561, P16, DOI 10.1016/j.nima.2005.12.225	7	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					851	857		10.1007/s10967-015-4023-7		7	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000026		
J	Yamazaki, Y; Yoshimoto, M; Saha, PK; Kinsho, M; Taguchi, T; Yamamoto, S; Sugai, I				Yamazaki, Y.; Yoshimoto, M.; Saha, P. K.; Kinsho, M.; Taguchi, T.; Yamamoto, S.; Sugai, I.			Analyses and the effect of impurities contained in charge stripper foils for the 3-GeV RCS of J-PARC	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Stripper foil; Impurities; High power proton beam; J-PARC		In J-PARC, the 3 GeV rapid cycling synchrotron (RCS) applied hybrid type thick boron-doped carbon (HBC) foils as charge stripper in the multi-turn injection. Although HBC foils have successfully operated to provide a high-power beam for experimental users since the operation of the accelerator started, the deformation and radio-activation of the foils occurred as serious problems. We investigated the cause of the problems, as result we found that impurities in the foil led to these phenomena. In this report, we describe why impurities were mixed in the foil, and which kinds of impurities were found by various methods of analysis. The effect of impurities is also discussed.	[Yamazaki, Y.; Yoshimoto, M.; Saha, P. K.; Kinsho, M.] Japan Atom Energy Agcy, J PARC, Tokai, Ibaraki 3191195, Japan; [Taguchi, T.] Japan Atom Energy Agcy, Quantum Beam Sci Directorate, Tokai, Ibaraki 3191195, Japan; [Yamamoto, S.] Japan Atom Energy Agcy, Quantum Beam Sci Directorate, Takasaki, Gumma 3701292, Japan; [Sugai, I.] High Energy Accelerator Res Org KEK, Tshukuba, Ibaraki 3050801, Japan	Yamazaki, Y (reprint author), Japan Atom Energy Agcy, J PARC, 2-4 Shirane, Tokai, Ibaraki 3191195, Japan.	yamazaki.yoshio@jaea.go.jp					Sugai I, 2010, NUCL INSTRUM METH A, V613, P457, DOI 10.1016/j.nima.2009.10.003; Sugai I, 2006, NUCL INSTRUM METH A, V561, P16, DOI 10.1016/j.nima.2005.12.225; Sugai I, 2008, NUCL INSTRUM METH A, V590, P32, DOI 10.1016/j.nima.2008.02.079; Yamazaki Y, 2013, J PHYS CONF SER, V417, DOI 10.1088/1742-6596/417/1/012071; Yoshimoto M, 2013, J PHYS CONF SER, V417, DOI 10.1088/1742-6596/417/1/012073	5	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					859	864		10.1007/s10967-015-4106-5		6	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000027		
J	Yoshimoto, M; Yamazaki, Y; Saha, PK; Kinsho, M; Sugai, I; Irie, Y				Yoshimoto, Masahiro; Yamazaki, Yoshio; Saha, Pranab Kumar; Kinsho, Michikazu; Sugai, Isao; Irie, Yoshiro			Maintenance of radio-activated stripper foils in the 3 GeV RCS of J-PARC	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Stripper foil; Radio-activation at high-power proton beam; J-PARC		In the 3 GeV rapid cycling synchrotron (RCS) of the Japan proton accelerator research complex, we adopted the multi-turn charge exchange injection scheme using the stripper foils. After the fine beam tuning in the RCS, most of the beam losses occur at the foil only. However, the high residual doses were detected around the stripper foil, which cannot be explained by the direct scattering of the injected H- and circulating proton beams with the stripper foil. From the measurements and simulations, it is identified that secondary particles produced in the nuclear reactions with the foil had caused the high residual activity around there. The radio-activation of the foil itself and the high residual dose around the foil are intrinsic problems for all high power beam accelerators with stripping foil. A safe and efficient maintenance in the high radiation and narrow space in these accelerators is important. The foil maintenance under such an environment is required to keep staff radiation exposure as low as possible to reduce the risk of radioactive foil breakup or dispersion and to retrieve the foil without breaking for its analysis. We achieved a safe and efficient maintenance method to retrieve the radioactivated stripper foils.	[Yoshimoto, Masahiro; Yamazaki, Yoshio; Saha, Pranab Kumar; Kinsho, Michikazu] Japan Atom Energy Agcy, J PARC, Tokai, Ibaraki 3191195, Japan; [Sugai, Isao; Irie, Yoshiro] High Energy Accelerator Res Org KEK, Tsukuba, Ibaraki 3050801, Japan	Yoshimoto, M (reprint author), Japan Atom Energy Agcy, J PARC, 2-4 Shirane, Tokai, Ibaraki 3191195, Japan.	yoshimoto.masahiro@jaea.go.jp					Sato T, 2013, J NUCL SCI TECHNOL, V50, P913, DOI 10.1080/00223131.2013.814553; Hasegawa K, 2014, P J PARC S IN PRESS; Hotchi H, 2012, PROG THEOR EXP PHYS, V2012; J-PARC, 2010, J PARC ANN REP 2010, P10; Kamiya J, 2014, P IPAC14 DRESD GERM, P2338; Kato S, 2013, PHYS REV SPEC TOP-AC, V16, DOI 10.1103/PhysRevSTAB.16.071003; Kinsho M, 2006, J VAC SOC JPN, V49, P728; Murakami Y, 1982, RAD DATA BOOK, P403; PARIKH V, 1960, NUCL PHYS, V18, P646, DOI 10.1016/0029-5582(60)90432-6; Saha PK, 2014, J RADIOANAL NUCL CH, V299, P1041, DOI 10.1007/s10967-013-2636-2; Sugai I, 2006, NUCL INSTRUM METH A, V561, P16, DOI 10.1016/j.nima.2005.12.225; Valentin L, 1963, PHYS LETT, V7, P162; Yamakawa E, 2014, P J PARC S IN PRESS; Yamazaki Y, 2013, J PHYS CONF SER, V417, DOI 10.1088/1742-6596/417/1/012071; Yoshimoto M, 2013, J PHYS CONF SER, V417, DOI 10.1088/1742-6596/417/1/012073	15	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					865	873		10.1007/s10967-015-4138-x		9	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000028		
J	Sato, M; Iio, M; Ishimoto, S; Enomoto, S; Hashimoto, T; Suzuki, S; Iwasaki, M; Hayano, RS				Sato, M.; Iio, M.; Ishimoto, S.; Enomoto, S.; Hashimoto, T.; Suzuki, S.; Iwasaki, M.; Hayano, R. S.			Liquid He-3 target for an experimental search for nuclear anti-kaon bound states in J-PARC	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Liquid He-3; Saturated vapor pressure; Anti-kaon nuclear bound state		A liquid He-3 target system was successfully developed for experimental studies of the anti-kaon interaction with a nucleon at the J-PARC hadron facility. Pumped liquid He-4 with the temperature of 1.4 K is used to condense gaseous He-3 with a total volume of 400 L at atmospheric pressure and 21 A degrees C. A circulation of the liquid between a heat exchanger and a target cell works well for an effective heat transfer between them. The target system was stably operated in the first experiment at the K1.8BR beam line in May 2013.	[Sato, M.; Hashimoto, T.; Iwasaki, M.] RIKEN, RIKEN Nishina Ctr, Wako, Saitama 3510198, Japan; [Iio, M.; Ishimoto, S.; Enomoto, S.; Suzuki, S.] High Energy Accelerator Res Org KEK, Tsukuba, Ibaraki 3050801, Japan; [Iwasaki, M.] Tokyo Inst Technol, Dept Phys, Tokyo 1528551, Japan; [Hayano, R. S.] Univ Tokyo, Dept Phys, Tokyo 1130033, Japan	Sato, M (reprint author), RIKEN, RIKEN Nishina Ctr, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	m-sato@riken.jp	Iwasaki, Faculty of Science/M-8433-2014	Iwasaki, Faculty of Science/0000-0002-3460-9469			Agari K, 2012, PROG THEOR EXP PHYS, V687; Hayano RS, 2006, PROPOSAL J PARC 50 G; Iio M, 2012, NUCL INSTRUM METH A, V687, P1, DOI 10.1016/j.nima.2012.05.080; Iwasaki M, 2006, PROPOSAL J PARC 50 G; Sato M, 2009, NUCL INSTRUM METH A, V606, P233, DOI 10.1016/j.nima.2009.04.013	5	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					883	887		10.1007/s10967-015-4020-x		5	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000030		
J	Matsuzaki, T; Ishida, K; Iwasaki, M				Matsuzaki, T.; Ishida, K.; Iwasaki, M.			High-pressure solid hydrogen target for muon catalyzed fusion	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Muon catalyzed fusion; Solid hydrogen; High-pressure target; Fusion cycling rate; Muon loss probability; Muon reactivation	D-T; X-RAYS; MIXTURES; NEUTRONS	We have developed a high-pressure solid hydrogen target for muon-catalyzed fusion to study temperature dependence of fusion cycling rates and muon loss probabilities in solid hydrogen at higher temperature than the melting point. The constructed target is a simple standalone-system consisting of a solid hydrogen target, a high-pressure generator, an isolation valve and a buffer tank. The solid hydrogen target and high-pressure generator are independently cooled down and temperature-controlled by closed-cycle helium-refrigerators. In the performance test, the solid D-2 target was formed successfully at 33.6 K with applying D-2 gas pressure at 79 MPa.	[Matsuzaki, T.; Ishida, K.; Iwasaki, M.] RIKEN Nishina Ctr Accelerator Based Sci, Wako, Saitama 3510198, Japan	Matsuzaki, T (reprint author), RIKEN Nishina Ctr Accelerator Based Sci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	matsuzak@riken.jp	Iwasaki, Faculty of Science/M-8433-2014	Iwasaki, Faculty of Science/0000-0002-3460-9469	RIKEN Director's fund (RIKEN's strategic programs for RD)	We would like sincerely to appreciate Dr. A. J. Caffrey and Dr. J. Zmeskal for valuable discussions and suggestions on technical issues of high-pressure solid hydrogen target. We would also like to thank Mr. T. Kawaguchi for discussions during the designing, manufacturing and performance test. The present work was supported in part by RIKEN Director's fund (RIKEN's strategic programs for R&D).	Bom VR, 1999, HYPERFINE INTERACT, V118, P103, DOI 10.1023/A:1012688603918; Caffrey A. J., 1987, Muon Catalyzed Fusion, V1; Ishida K, 2005, NUCL PHYS B-PROC SUP, V149, P348, DOI 10.1016/j.nuclphysbps.2005.05.064; Ishida K, 1999, HYPERFINE INTERACT, V118, P203, DOI 10.1023/A:1012669527116; Ishida K, 2001, HYPERFINE INTERACT, V138, P225, DOI 10.1023/A:1020839926049; Jones Steven E, 1987, MUON CATAL FUSION, V1, P21; Kawamura N, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.043401; Perevozchikov VV, 1999, HYPERFINE INTERACT, V119, P353, DOI 10.1023/A:1012641004768; Petitjean C, 2001, HYPERFINE INTERACT, V138, P191, DOI 10.1023/A:1020883708302; SOUERS P. C., 1986, HYDROGEN PROPERTIES; Zmeskal J, 1990, MUON CATAL FUSION, P379	11	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					889	895		10.1007/s10967-015-4080-y		7	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000031		
J	Matsuda, Y; Tsumura, M; Sakaguchi, H; Terashima, S; Zenihiro, J; Kawabata, T; Otsu, H; Beaumel, D; Tian, Z; Maeda, Y; Gotanda, S; Kawakami, S; Aoi, N; Yamamoto, T				Matsuda, Y.; Tsumura, M.; Sakaguchi, H.; Terashima, S.; Zenihiro, J.; Kawabata, T.; Otsu, H.; Beaumel, D.; Tian, Z.; Maeda, Y.; Gotanda, S.; Kawakami, S.; Aoi, N.; Yamamoto, T.			Solid hydrogen target for missing mass spectroscopy in inverse kinematics	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Solid hydrogen; Para hydrogen; Thin target; Large target; Proton elastic scattering		By using para-hydrogen and a mechanical press made of neodymium magnets, we have succeeded in making a 1-mm-thick and 30-mm-diameter solid hydrogen target (SHT), and have measured elastic scattering of protons with radioactive ion beams at 300 MeV/u. We also succeeded in making not only a 0.5-mm-thick and 10-mm-diameter SHT but also a 2-mm-thick and 30-mm-diameter SHT to study excited-state properties of nuclei via (p,p') reactions, and quasi-free (p,p alpha) reactions at intermediate energies. The ortho-para converter and the simple mechanical press show possibilities for making SHTs which have various radii and thicknesses.	[Matsuda, Y.] Konan Univ, Dept Phys, Kobe, Hyogo 6588501, Japan; [Tsumura, M.; Kawabata, T.] Kyoto Univ, Dept Phys, Kyoto 6068502, Japan; [Sakaguchi, H.; Aoi, N.; Yamamoto, T.] Osaka Univ, Nucl Phys Res Ctr, Osaka 5670047, Japan; [Terashima, S.] Beihang Univ, Sch Phys & Nucl Energy Engn, Beijing 100191, Peoples R China; [Zenihiro, J.; Otsu, H.; Beaumel, D.; Tian, Z.] RIKEN Nishina Ctr, Wako, Saitama 3510198, Japan; [Beaumel, D.] Univ Paris 11, Inst Phys Nucl, IN2P3, CNRS, F-91406 Orsay, France; [Maeda, Y.; Gotanda, S.; Kawakami, S.] Miyazaki Univ, Dept Appl Phys, Miyazaki 8892192, Japan	Matsuda, Y (reprint author), Konan Univ, Dept Phys, Kobe, Hyogo 6588501, Japan.	matsu@rcnp.osaka-u.ac.jp			RI beam Factory [NP0709-RIBF40]; Japan Society for the Promotion of Science (JSPS) [23740164]; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan	The experiments of <SUP>10,11</SUP>C, and <SUP>20</SUP>O were performed as one of Research Projects with Heavy Ions at NIRS-HIMAC. The authors would like to express their gratitude to Dr. M. Kanazawa, Dr. T. Murakami, Dr. E. Takada, and the staff of Accelerator Engineering Corporation at the Heavy Ion Medical Accelerator in Chiba, Japan for their assistance with the experiments at HIMAC. The experiment of <SUP>70</SUP>Ni was carried out at GSI. The authors are grateful to the accelerator crews for providing the primary beam. The experiment of <SUP>16</SUP>C was carried out under Program No. NP0709-RIBF40 at the RI beam Factory operated by RIKEN Nishina Center, RIKEN and CNS, University of Tokyo. The authors are grateful to the RIBF accelerator crews for providing the primary beam. This work was supported by the Grant-in-Aid for Young Scientists B(23740164) from the Japan Society for the Promotion of Science (JSPS), and the Grant-in-Aid for the Global COE Programs "Weaving Science Web beyond Particle-Matter Hierarchy" and "The Next Generation of Physics, Spun from Universality and Emergence" from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.	Guenter A, 1964, J CHEM PHYS, V40, P3123; Ishimoto S, 2002, NUCL INSTRUM METH A, V480, P304, DOI 10.1016/S0168-9002(01)00951-2; Mate CF, 1978, PHYS REV B, V2, P2121; Matsuda Y, 2013, PHYS REV C, V87, DOI 10.1103/PhysRevC.87.034614; Matsuda Y, 2011, NUCL INSTRUM METH A, V643, P6, DOI 10.1016/j.nima.2011.04.017; Moriguchi T, 2010, NUCL INSTRUM METH A, V624, P27, DOI 10.1016/j.nima.2010.09.005; Obertelli A, 2011, EUR PHYS J A, V47, DOI 10.1140/epja/i2011-11105-5	7	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					897	901		10.1007/s10967-014-3903-6		5	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000032		
J	Sagara, K; Fujita, K; Yamaguchi, H; Tao, N; Ban, T; Hamamoto, K; Narikiyo, Y; Kodama, D; Mituzumi, T				Sagara, K.; Fujita, K.; Yamaguchi, H.; Tao, N.; Ban, T.; Hamamoto, K.; Narikiyo, Y.; Kodama, D.; Mituzumi, T.			A windowless gas target for low-energy He-4 (C-12, O-16) gamma experiment: improvement to reduce O-16 backgrounds	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Windowless gas target; He burning in stars; Rare O-16 events; O-16 backgrounds from target cell; Beam slits using gold foils		A blow-in type windowless thick He gas target has been developed to measure He-4(C-12,O-16) gamma cross section for astrophysical interests. We use a C-12 beam of energy from 6 to 2.8 MeV and detect O-16 recoils at forward angles. Numerous C-12 backgrounds have been rejected by particle identification techniques. O-16 backgrounds from the target are not many but fatally harmful. Our techniques to reduce the O-16 backgrounds are described.	[Sagara, K.; Fujita, K.; Yamaguchi, H.; Tao, N.; Ban, T.; Hamamoto, K.; Narikiyo, Y.; Kodama, D.; Mituzumi, T.] Kyushu Univ, Dept Phys, Fukuoka 8128581, Japan	Sagara, K (reprint author), Kyushu Univ, Dept Phys, Fukuoka 8128581, Japan.	sagara@phys.kyushu-u.ac.jp					Schurmann D, 2005, EUR PHYS J A, V26, P301, DOI 10.1140/epja/i2005-10175-2; Fujita K, 2013, FEW-BODY SYST, V54, P1603, DOI 10.1007/s00601-012-0558-0; Sagara K, 2008, NUCL INSTRUM METH A, V590, P194, DOI 10.1016/j.nima.2008.02.089; Sagara K, 1996, NUCL INSTRUM METH A, V378, P392, DOI 10.1016/0168-9002(96)00522-0	4	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					903	906		10.1007/s10967-015-4033-5		4	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000033		
J	Ota, S; Tokieda, H; Lee, CS; Watanabe, YN				Ota, S.; Tokieda, H.; Lee, C. S.; Watanabe, Y. N.			CNS active target (CAT) for missing mass spectroscopy with intense beams	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Deuterium; Gas target; Active target; THGEM; Time projection chamber	GASEOUS ELECTRON MULTIPLIERS; PRESSURE OPERATION	A new gaseous active target based on a time projection chamber, named CAT, is introduced. The remarkable feature is a dual gain THGEM to decrease the effective gain for the beam particles while keeping a high enough effective gain for the recoil particles. The measured effective gain of low gain region was a factor of one hundred smaller than that of high gain region. This technique provides a wide dynamic range in order to detect both the beam and recoil particles at the same time even with a very high intensity beam of more than 10(5) Hz.	[Ota, S.; Tokieda, H.; Lee, C. S.] Univ Tokyo, Ctr Nucl Study, Wako, Saitama 3510198, Japan; [Lee, C. S.] RIKEN Nishina Ctr Accelerator Based Sci, Wako, Saitama 3510198, Japan; [Watanabe, Y. N.] Univ Tokyo, Dept Phys, Tokyo 1138654, Japan	Ota, S (reprint author), Univ Tokyo, Ctr Nucl Study, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	ota@cns.s.u-tokyo.ac.jp					Fox SP, 2011, J PHYS CONF SER, V312, DOI 10.1088/1742-6596/312/5/052007; Lee CS, 2014, J INSTRUM, V9, DOI 10.1088/1748-0221/9/05/C05014; Ota S, 2014, P ARIS2014 IN PRESS; Ota S, 2013, CNSREP90, P70; Rodriguez-Tajes C, 2014, NUCL INSTRUM METH A, V768, P179, DOI 10.1016/j.nima.2014.08.046; Shalem C, 2006, NUCL INSTRUM METH A, V558, P475, DOI 10.1016/j.nima.2005.12.241; Shalem CK, 2006, NUCL INSTRUM METH A, V558, P468, DOI 10.1016/j.nima.2005.12.219	7	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					907	911		10.1007/s10967-015-4130-5		5	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000034		
J	Vascon, A; Wiehl, N; Runke, J; Drebert, J; Reich, T; Trautmann, N; Cremer, B; Kogler, T; Beyer, R; Junghans, AR; Eberhardt, K; Dullmann, CE				Vascon, A.; Wiehl, N.; Runke, J.; Drebert, J.; Reich, T.; Trautmann, N.; Cremer, B.; Koegler, T.; Beyer, R.; Junghans, A. R.; Eberhardt, K.; Duellmann, Ch. E.			Improving material properties and performance of nuclear targets for transmutation-relevant experiments	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Molecular plating; Improved layer properties; alpha-Particle spectroscopy; Pu-242; Transmutation		To improve the properties and performance of thin layers produced by molecular plating as targets for nuclear experiments investigations with lanthanide elements (i.e., natural Nd and Sm-147-enriched Sm) were carried out. Plating parameters like roughness of the deposition substrate, plating solvent, electrolyte concentration, and applied current density were varied. The influence of each parameter on the properties of the layers was studied by characterizing the deposits. The characterizations showed that nuclear targets perform differently depending on their layer properties. The results obtained from the investigations were applied for the quantitative preparation of homogeneous large-area (i.e., 42 cm(2)) Pu-242 targets to be used for transmutation-relevant experiments.	[Vascon, A.; Wiehl, N.; Drebert, J.; Reich, T.; Trautmann, N.; Eberhardt, K.; Duellmann, Ch. E.] Johannes Gutenberg Univ Mainz, Inst Nucl Chem, D-55099 Mainz, Germany; [Vascon, A.; Koegler, T.; Beyer, R.; Junghans, A. R.] Helmholtz Zentrum Dresden Rossendorf, D-01328 Dresden, Germany; [Wiehl, N.; Eberhardt, K.; Duellmann, Ch. E.] Helmholtz Inst Mainz, SHE Chem Res Sect, D-55099 Mainz, Germany; [Runke, J.; Duellmann, Ch. E.] GSI Helmholtzzentrum Schwerionenforsch GmbH, SHE Chem Dept, D-64291 Darmstadt, Germany; [Cremer, B.] Commiss European Communities, Joint Res Ctr, Inst Transuranium Elements, D-76125 Karlsruhe, Germany; [Koegler, T.] Tech Univ Dresden, D-01069 Dresden, Germany	Vascon, A (reprint author), Japan Atom Energy Agcy, Adv Sci Res Ctr, Tokai, Ibaraki 3191195, Japan.	vascon.alessio@jaea.go.jp			German Federal Ministry of Science and Education (BMBF) [02NUK13A, 02NUK13E]	The authors thank the staff of the TRIGA Mainz for performing the irradiations, Dr. T. Lauer for performing the coating of the Si wafers, and Prof. Dr. K. Lutzenkirchen as well as Dr. T. Wiss for facilitating the analyses of the Pu targets at the Institute for Transuranium Elements of the Joint Research Centre of the European Commission. A. Vascon acknowledges financial support from the German Federal Ministry of Science and Education (BMBF) under contract numbers 02NUK13A and 02NUK13E.		0	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					913	919		10.1007/s10967-014-3916-1		7	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000035		
J	Kurihara, T; Kobayashi, H; Matsumoto, H; Yoshioka, M				Kurihara, T.; Kobayashi, H.; Matsumoto, H.; Yoshioka, M.			Neutron target research and development for BNCT: direct observation of proton induced blistering using light-polarization and reflectivity changes	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Blistering; Polarization; Long distance microscope; In-situ observation; Neutron source; BNCT	COPPER	The blistering problem due to high power proton irradiation is a crucial issue for any neutron generation target. When a proton beam irradiates a metal, the protons stopped inside capture free electrons in the metal to form a hydrogen gas. Eventually, blisters and/or flakes appear on the surface as the pressure of the hydrogen gas rises enough to cause ruptures. An experimental setup for observation of the metal surface that would have high sensitivity and high spatial resolution was proposed, designed and implemented. The system observes light-polarization and reflectivity and has successfully detected blistering surface dynamics.	[Kurihara, T.; Kobayashi, H.; Matsumoto, H.; Yoshioka, M.] KEK, Accelerator Lab, Tsukuba, Ibaraki 3050801, Japan	Kurihara, T (reprint author), KEK, Accelerator Lab, Tsukuba, Ibaraki 3050801, Japan.	toshikazu.kurihara@kek.jp			JSPS [23340080]	The authors wish to thank A. Matsumura and other members of the Ibaraki BNCT group, University of Tsukuba, Hokkaido Univ., Japan Atomic Energy Agency, Mitsubishi Heavy Industries, ATOX, Nippon Advanced Technology and Ibaraki Prefectural Government. The authors thank A. Takagi for his support in operating the Cockcroft-Walton accelerator, Tsukuba, KEK. This work was supported by the JSPS Grant-in-Aid for Scientific Research (B) Grant Number 23340080.	Astrelin VT, 2010, J NUCL MATER, V396, P43, DOI 10.1016/j.jnucmat.2009.10.051; YADAVA RDS, 1980, J PHYS D APPL PHYS, V13, P2077, DOI 10.1088/0022-3727/13/11/017; ARMSTRONG TR, 1981, J NUCL MATER, V98, P338, DOI 10.1016/0022-3115(81)90160-4; Kobayashi H, 2012, P 12 INT PART ACC C; Takagi A, 2006, P EPAC 2006 ED SCOTL; Weaver R, 2003, AM LAB, V35, P55	6	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					935	942		10.1007/s10967-015-4056-y		8	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000038		
J	Yoshihashi, S; Yamamoto, K; Teranishi, N; Izawa, D; Okita, T; Hoashi, E; Horiike, H				Yoshihashi, Sachiko; Yamamoto, Kohei; Teranishi, Noriyuki; Izawa, Daisuke; Okita, Takafumi; Hoashi, Eiji; Horiike, Hiroshi			Optical property of lithium vapor evaporated in vacuum or cover-gas area	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Liquid lithium; Lithium vapor; Optical absorption characteristics; Molar absorbance coefficient	IFMIF; FLOW; JET	A liquid metal lithium (Li) jet will be employed as a target irradiated by an ion beam to generate a neutron field in an accelerator neutron source. In these applications, Li vapor, which is produced by a decrease in boiling temperature under vacuum condition and heat load due to beam irradiation, may cause degradation of the vacuum and contamination of the equipment. The present study is intended to develop a novel measurement method of Li vapor using the optical absorption characteristics. In this experiment, we were successful to obtain the molar absorbance coefficient of Li vapor.	[Yoshihashi, Sachiko; Yamamoto, Kohei; Teranishi, Noriyuki; Izawa, Daisuke; Okita, Takafumi; Hoashi, Eiji; Horiike, Hiroshi] Osaka Univ, Grad Sch Engn, Suita, Osaka 5650871, Japan	Yoshihashi, S (reprint author), Osaka Univ, Grad Sch Engn, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.	yoshihashi@fukui-ut.ac.jp					Nolen JA, 2005, REV SCI INSTRUM, V76, DOI 10.1063/1.1942530; Erdman PS, 2004, J QUANT SPECTROSC RA, V88, P447, DOI 10.1016/j.jqsrt.2004.04.018; Horiike H., 2014, P 16 INT C NEUTR CAP; Imao H, 2011, P 8 ANN M PART ACC S, P252; Kanemura T, 2008, FUSION ENG DES, V83, P1529, DOI 10.1016/j.fusengdes.2008.06.042; Kondo H, 2005, FUSION ENG DES, V75-79, P865, DOI 10.1016/j.fusengdes.2005.06.086; Yoshihashi-Suzuki S, 2012, FUSION ENG DES, V87, P1434, DOI 10.1016/j.fusengdes.2012.03.027	7	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	SEP	2015	305	3					953	956		10.1007/s10967-015-4304-1		4	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CP7PT	WOS:000360081000041		
J	Huang, FT				Huang, Futao			The Internationalization of Japan's Academy Across Research and Non-Research Universities	JOURNAL OF STUDIES IN INTERNATIONAL EDUCATION			English	Article						internationalization of the academy; Japan; national survey	PROFESSION	The purpose of this article is to look at the internationalization of both Japanese faculty members' teaching and research activities and their affiliated institutions, as well as their views on international connections between research universities and non-research universities based on major findings from the latest national survey which was implemented in 2011. The study begins with a brief introduction to the research framework and methodology. Then by dividing all Japanese universities into two typesresearch universities and non-research universitiesit examines important observations about the teaching and research activities which were undertaken by individual academics and occurred in their institutions, as well as individual academics' attitudes toward international issues. The study concludes by providing two major findings: First, the overall internationalization of Japan's universities is primarily concerned with the attraction of foreign students to Japanese campus and sending out Japanese students to other countries at an institutional level, while at an individual level, a majority of academics are still receptive to new ideas from foreign books and journals in comparison with their views on other international connections; second, there appears to be a much higher level of international activities in which respondents from research universities are involved and which are carried out in research universities. Furthermore, the study presents some implications for research, policy, and institutions.	[Huang, Futao] Hiroshima Univ, Hiroshima 7398512, Japan	Huang, FT (reprint author), Hiroshima Univ, Res Inst Higher Educ, Kagamiyama 1-2-2, Hiroshima 7398512, Japan.	futao@hiroshima-u.ac.jp					Altbach P. G., 1978, COMP PERSPECTIVES AC; Amano I., 1986, KOUTOU KYOUIKU NIHON; Huang FT, 2009, J STUD INT EDUC, V13, P143, DOI 10.1177/1028315308331101; Horie M, 2002, HIGH EDUC, V43, P65, DOI 10.1023/A:1012920215615; Arimoto A., 1996, DAIGAKU KYOUKYUSYOKU; Arimoto A., 2009, RIHE INT SEMINAR REP, V13; Goodman R., 2013, OXFORD STUDIES COMP; Goodman R., 2007, GLOBALISATION SOC ED, V5, P71, DOI DOI 10.1080/14767720601133413; Hoffman D. H., 2008, J STUD INT EDUC, V13, P347; Huang F., 2014, INT ACAD CHANGES REA; Huang F., 2011, RIHE INT SEMINAR REP, V17, P113; Huang F., 2007, UNESCO FORUM HIGHER, P81; Huang F., 2006, COE PUBLICATION SERI, V20, P195; Knight J., 2008, HIGHER ED TURMOIL CH, P21; Ministry of Education Culture Sports Science and Technology, 2011, JAP STAT ABSTR; Ministry of Education Culture Sports Science and Technology, 2013, KYOUIK SHIH NO KOK H; University Council, 2000, GUR JID NI MOT KOUT; Welch AR, 1997, HIGH EDUC, V34, P323, DOI 10.1023/A:1003071806217	18	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1028-3153	1552-7808		J STUD INT EDUC	J. Stud. Int. Educ.	SEP	2015	19	4					379	393		10.1177/1028315315574102		15	Education & Educational Research	Education & Educational Research	CP5JZ	WOS:000359918900005		
J	Sugamoto, Y; Hamamoto, Y; Kimura, M; Fukunaga, T; Tasaki, K; Asai, Y; Takeshita, N; Maruyama, T; Hosokawa, T; Tamachi, T; Aoyama, H; Matsubara, H				Sugamoto, Yuji; Hamamoto, Yasuyoshi; Kimura, Masayuki; Fukunaga, Toru; Tasaki, Kentaro; Asai, Yo; Takeshita, Nobuyoshi; Maruyama, Tetsuro; Hosokawa, Takashi; Tamachi, Tomohide; Aoyama, Hiromichi; Matsubara, Hisahiro			A Novel Method for Real-Time Audio Recording With Intraoperative Video	JOURNAL OF SURGICAL EDUCATION			English	Article						synchronous recording; laparoscopic surgery; wireless microphone; audiovisual education; teaching aids	RADIOFREQUENCY IDENTIFICATION; REGULATORY FRAMEWORK; MEDICAL DEVICES; COGNITIVE LOAD; SURGERY; SKILLS; INFORMATION	OBJECTIVE: Although laparoscopic surgery has become widespread, effective and efficient education in laparoscopic surgery is difficult. Instructive laparoscopy videos with appropriate annotations are ideal for initial training in laparoscopic surgery; however, the method we use at our institution for creating laparoscopy videos with audio is not generalized, and there have been no detailed explanations of any such method. Our objectives were to demonstrate the feasibility of low-cost simple methods for recording surgical videos with audio and to perform a preliminary safety evaluation when obtaining these recordings during operations. DESIGN: We devised a method for the synchronous recording of surgical video with real-time audio in which we connected an amplifier and a wireless microphone to an existing endoscopy system and its equipped video-recording device. We tested this system in 209 cases of laparoscopic surgery in operating rooms between August 2010 and July 2011 and prospectively investigated the results of the audiovisual recording method and examined intraoperative problems. SETTING: Numazu City Hospital in Numazu city, Japan. PARTICIPANTS: Surgeons, instrument nurses, and medical engineers. RESULTS: In all cases, the synchronous input of audio and video was possible. The recording system did not cause any inconvenience to the surgeon, assistants, instrument nurse, sterilized equipment, or electrical medical equipment. Statistically significant differences were not observed between the audiovisual group and control group regarding the operating time, which had been divided into 2 slots performed by the instructors or by trainees (p > 0.05). CONCLUSIONS: This recording method is feasible and considerably safe while posing minimal difficulty in terms of technology, time, and expense. We recommend this method for both surgical trainees who wish to acquire surgical skills effectively and medical instructors who wish to teach surgical skills effectively. (C) 2015 Association of Program Directors in Surgery. Published by Elsevier Inc. All rights reserved.)	[Sugamoto, Yuji; Kimura, Masayuki; Fukunaga, Toru; Tasaki, Kentaro; Asai, Yo; Takeshita, Nobuyoshi; Maruyama, Tetsuro; Hosokawa, Takashi; Tamachi, Tomohide] Numazu City Hosp, Dept Surg, Numazu, Shizuoka 4100302, Japan; [Hamamoto, Yasuyoshi] Numazu City Hosp, Dept Med Engn, Numazu, Shizuoka 4100302, Japan; [Aoyama, Hiromichi] Chiba East Hosp, Natl Hosp Org, Dept Surg, Chiba, Japan; [Matsubara, Hisahiro] Chiba Univ, Grad Sch Med, Dept Frontier Surg, Chiba, Japan	Sugamoto, Y (reprint author), Numazu City Hosp, Dept Surg, 550 Harunoki, Numazu, Shizuoka 4100302, Japan.	numazucityhosp@yahoo.co.jp					MOUSAVI SY, 1995, J EDUC PSYCHOL, V87, P319, DOI 10.1037/0022-0663.87.2.319; Brunken R, 2002, EXP PSYCHOL, V49, P109, DOI 10.1027//1618-3169.49.2.109; Gallagher AG, 2005, AM J SURG, V189, P76, DOI 10.1016/j.amjsurg.2004.04.008; Moreno R, 1999, J EDUC PSYCHOL, V91, P358, DOI 10.1037//0022-0663.91.2.358; O'Connor A, 2008, SURG ENDOSC, V22, P1614, DOI 10.1007/s00464-007-9645-6; Hariri S, 2004, MED EDUC, V38, P896, DOI 10.1111/j.1365-2929.2004.01897.x; Turnbull AMJ, 2014, SURV OPHTHALMOL, V59, P553, DOI 10.1016/j.survophthal.2014.01.006; Garcia-Retamero R, 2013, SOC SCI MED, V83, P27, DOI 10.1016/j.socscimed.2013.01.034; Campbell I K, 1982, J R Coll Gen Pract, V32, P548; Censi F, 2012, EXPERT REV MED DEVIC, V9, P283, DOI [10.1586/erd.12.4, 10.1586/ERD.12.4]; Dinscore Amanda, 2010, Medical Reference Services Quarterly, V29, P10, DOI 10.1080/02763860903484996; Ericsson KA, 2014, ACAD MED, V89, P17, DOI 10.1097/ACM.0000000000000049; Hall JC, 2002, AM J SURG, V184, P465, DOI 10.1016/S0002-9610(02)01007-3; Hong J, 2013, J AM ACAD DERMATOL, V68; Kakkilaya V, 2011, PEDIATRICS, V128, pE1511, DOI 10.1542/peds.2011-0597; Kyser KL, 2014, ACAD MED, V89, P71, DOI 10.1097/ACM.0000000000000048; Makoto Y, RECORDING SENIOR SUR; Mattei E, 2012, EXPERT REV MED DEVIC, V9, P289, DOI [10.1586/erd.12.5, 10.1586/ERD.12.5]; McEwen A, 2007, PEDIATR ANESTH, V17, P534, DOI 10.1111/j.1460-9592.2006.02173.x; Nageswari KS, 2004, ADV PHYSIOL EDUC, V28, P51, DOI 10.1152/advan.00013.2003; Ozyurda F, 2002, TEACH LEARN MED, V14, P189, DOI 10.1207/S15328015TLM1403_10; Pommergaard HC, 2013, UGESKRIFT LAEGER, V25, P876; Rafiq A, 2004, ANN SURG, V239, P567, DOI 10.1097/01.sla.0000118749.24645.45; RYAN ED, 1983, J SPORT PSYCHOL, V5, P419; Saab Bassem R, 2009, J Med Liban, V57, P226; Tolerton SK, 2012, J SURG EDUC, V69, P404, DOI 10.1016/j.jsurg.2011.10.017; Tri JL, 2007, MAYO CLIN PROC, V82, P282; Volandes AE, 2013, HEALTH EXPECT, V16, pE80, DOI 10.1111/j.1369-7625.2011.00727.x; Wallin MKEB, 2005, ANESTH ANALG, V101, P1393, DOI 10.1213/01.ANE.0000180216.83554.00	29	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1931-7204	1878-7452		J SURG EDUC	J. Surg. Educ.	SEP-OCT	2015	72	5					795	802		10.1016/j.jsurg.2015.03.020		8	Education, Scientific Disciplines; Surgery	Education & Educational Research; Surgery	CP4ZE	WOS:000359890300006		
J	Katayama, M; Miyahara, R; Watanabe, T; Yamagishi, H; Yamashita, S; Kizaki, T; Sugawara, Y; Inada, Y				Katayama, Misaki; Miyahara, Ryota; Watanabe, Toshiki; Yamagishi, Hirona; Yamashita, Shohei; Kizaki, Terue; Sugawara, Yoshimi; Inada, Yasuhiro			Development of dispersive XAFS system for analysis of time-resolved spatial distribution of electrode reaction	JOURNAL OF SYNCHROTRON RADIATION			English	Article						DXAFS; imaging; polychromator; Li ion secondary battery; reaction distribution	ABSORPTION FINE-STRUCTURE; SYNCHROTRON-RADIATION; BEHAVIOR; LIFEPO4	Apparatus for a technique based on the dispersive optics of X-ray absorption fine structure (XAFS) has been developed at beamline BL-5 of the Synchrotron Radiation Center of Ritsumeikan University. The vertical axis of the cross section of the synchrotron light is used to disperse the X-ray energy using a cylindrical polychromator and the horizontal axis is used for the spatially resolved analysis with a pixel array detector. The vertically dispersive XAFS (VDXAFS) instrument was designed to analyze the dynamic changeover of the inhomogeneous electrode reaction of secondary batteries. The line-shaped X-ray beam is transmitted through the electrode sample, and then the dispersed transmitted X-rays are detected by a two-dimensional detector. An array of XAFS spectra in the linear footprint of the transmitted X-ray on the sample is obtained with the time resolution of the repetition frequency of the detector. Sequential measurements of the space-resolved XAFS data are possible with the VDXAFS instrument. The time and spatial resolutions of the VDXAFS instrument depend on the flux density of the available X-ray beam and the size of the light source, and they were estimated as 1 s and 100 mm, respectively. The electrode reaction of the LiFePO4 lithium ion battery was analyzed during the constant current charging process and during the charging process after potential jumping.	[Katayama, Misaki; Miyahara, Ryota; Watanabe, Toshiki; Yamagishi, Hirona; Yamashita, Shohei; Inada, Yasuhiro] Ritsumeikan Univ, Dept Appl Chem, Kusatsu 5258577, Japan; [Kizaki, Terue; Sugawara, Yoshimi] Kohzu Precis Co Ltd, Kawasaki, Kanagawa 2158521, Japan	Inada, Y (reprint author), Ritsumeikan Univ, Dept Appl Chem, Kusatsu 5258577, Japan.	yinada@fc.ritsumei.ac.jp			Research and Development Initiative for Scientific Innovation of New Generation Battery (RISING) project from New Energy and Industrial Technology Development Organization (NEDO), Japan;  [2012G020];  [2014G542]	This work was partially supported by the Research and Development Initiative for Scientific Innovation of New Generation Battery (RISING) project from the New Energy and Industrial Technology Development Organization (NEDO), Japan. Some of the VDXAFS measurements were carried out under the approval of PF program advisory committee (Nos. 2012G020 and 2014G542).	Nakai I, 1997, J POWER SOURCES, V68, P536, DOI 10.1016/S0378-7753(97)02598-6; Katayama M, 2014, J POWER SOURCES, V269, P994, DOI 10.1016/j.jpowsour.2014.03.066; Leriche JB, 2010, J ELECTROCHEM SOC, V157, pA606, DOI 10.1149/1.3355977; Liu J, 2010, J PHYS CHEM LETT, V1, P2120, DOI 10.1021/jz100634n; Delmas C, 1997, J POWER SOURCES, V68, P120, DOI 10.1016/S0378-7753(97)02664-5; Ouvrard G, 2013, J POWER SOURCES, V229, P16, DOI 10.1016/j.jpowsour.2012.11.057; Katayama M, 2012, J SYNCHROTRON RADIAT, V19, P717, DOI 10.1107/S0909049512028282; MATSUSHITA T, 1981, JPN J APPL PHYS, V20, P2223, DOI 10.1143/JJAP.20.2223; Yoo S, 2015, ELECTROCHIM ACTA, V151, P270, DOI 10.1016/j.electacta.2014.10.106	9	0	0	INT UNION CRYSTALLOGRAPHY	CHESTER	2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND	1600-5775			J SYNCHROTRON RADIAT	J. Synchrot. Radiat.	SEP	2015	22		5				1227	1232		10.1107/S1600577515012990		6	Instruments & Instrumentation; Optics; Physics, Applied	Instruments & Instrumentation; Optics; Physics	CP8KK	WOS:000360142400012		
J	Tanaka, T				Tanaka, Takashi			SIMPLEX: simulator and postprocessor for free-electron laser experiments	JOURNAL OF SYNCHROTRON RADIATION			English	Article						free-electron laser; simulation	FEL SIMULATION; CODE; COHERENT	SIMPLEX is a computer program developed for simulating the amplification process of free-electron lasers (FELs). It numerically solves the so-called FEL equations describing the evolution of the radiation field and growth of microbunching while the electron beam travels along the undulator. In order to reduce the numerical cost, the FEL equations have been reduced to more convenient forms for numerical implementation by applying reasonable approximations. SIMPLEX is equipped with a postprocessor to facilitate the retrieval of desired information from the simulation results, which is crucial for practical applications such as designing the beamline and analyzing the experimental results.	RIKEN SPring 8 Ctr, Sayo, Hyogo 6795148, Japan	Tanaka, T (reprint author), RIKEN SPring 8 Ctr, Koto 1-1-1, Sayo, Hyogo 6795148, Japan.	ztanaka@spring8.or.jp	Tanaka, Takashi/N-1959-2014				BONIFACIO R, 1984, OPT COMMUN, V50, P373, DOI 10.1016/0030-4018(84)90105-6; Xie M, 2000, NUCL INSTRUM METH A, V445, P59, DOI 10.1016/S0168-9002(00)00114-5; Geloni G, 2011, J MOD OPTIC, V58, P1391, DOI 10.1080/09500340.2011.586473; Allaria E, 2012, NAT PHOTONICS, V6, P699, DOI [10.1038/nphoton.2012.233, 10.1038/NPHOTON.2012.233]; Ishikawa T, 2012, NAT PHOTONICS, V6, P540, DOI 10.1038/nphoton.2012.141; Saldin EL, 1999, NUCL INSTRUM METH A, V429, P233, DOI 10.1016/S0168-9002(99)00110-2; Feldhaus J, 1997, OPT COMMUN, V140, P341, DOI 10.1016/S0030-4018(97)00163-6; Emma P, 2010, NAT PHOTONICS, V4, P641, DOI [10.1038/nphoton.2010.176, 10.1038/NPHOTON.2010.176]; Tanaka T, 2001, J SYNCHROTRON RADIAT, V8, P1221, DOI 10.1107/S090904950101425X; BASTIAANS MJ, 1986, J OPT SOC AM A, V3, P1227, DOI 10.1364/JOSAA.3.001227; Campbell LT, 2012, PHYS PLASMAS, V19, DOI 10.1063/1.4752743; Chubar O., 1998, P EPAC 98, P1177; Faatz B, 1997, NUCL INSTRUM METH A, V393, P277, DOI 10.1016/S0168-9002(97)00492-0; Fawley WM, 2002, PHYS REV SPEC TOP-AC, V5, DOI 10.1103/PhysRevSTAB.5.070701; FREUND HP, 1995, PHYS REV E, V52, P5401, DOI 10.1103/PhysRevE.52.5401; Geloni G., 2010, 10008 DESY; Kim K.-J., 1989, AIP C P, V184, P565; Reicher S, 1999, NUCL INSTRUM METH A, V429, P243, DOI 10.1016/S0168-9002(99)00114-X; Shreiner D., 2013, OPENGL PROGRAMMING G; Smart J., 2005, CROSS PLATFORM GUI P; TRAN TM, 1989, COMPUT PHYS COMMUN, V54, P263, DOI 10.1016/0010-4655(89)90090-8; WALKER RP, 1992, REV SCI INSTRUM, V63, P392, DOI 10.1063/1.1142766; Wigner W., 1932, PHYS REV, V40, P749	23	0	0	INT UNION CRYSTALLOGRAPHY	CHESTER	2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND	1600-5775			J SYNCHROTRON RADIAT	J. Synchrot. Radiat.	SEP	2015	22		5				1319	1326		10.1107/S1600577515012850		8	Instruments & Instrumentation; Optics; Physics, Applied	Instruments & Instrumentation; Optics; Physics	CP8KK	WOS:000360142400025		
J	Kurihara, T; Yamashita, Y; Yoshida, Y; Takeishi, K; Itoh, S; Harimoto, N; Yoshizumi, T; Shirabe, K; Ikeda, T; Maehara, Y				Kurihara, Takeshi; Yamashita, Yo-ichi; Yoshida, Yoshihiro; Takeishi, Kazuki; Itoh, Shinji; Harimoto, Norifumi; Yoshizumi, Tomoharu; Shirabe, Ken; Ikeda, Tetsuo; Maehara, Yoshihiko			Indocyanine Green Fluorescent Imaging for Hepatic Resection of the Right Hepatic Vein Drainage Area	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							NAVIGATION SYSTEM; LIVER		[Kurihara, Takeshi; Yamashita, Yo-ichi; Yoshida, Yoshihiro; Takeishi, Kazuki; Itoh, Shinji; Harimoto, Norifumi; Yoshizumi, Tomoharu; Shirabe, Ken; Ikeda, Tetsuo; Maehara, Yoshihiko] Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Fukuoka 8128582, Japan	Kurihara, T (reprint author), Kyushu Univ, Dept Surg & Sci, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	t_kuri@surg2.med.kyushu-u.ac.jp					CHERRICK GR, 1960, J CLIN INVEST, V39, P592, DOI 10.1172/JCI104072; Hashimoto T, 2008, LIVER TRANSPLANT, V14, P872, DOI 10.1002/lt.21460; Taketomi A, 2012, SURG TODAY, V42, P46, DOI 10.1007/s00595-011-0021-8; Shirabe K, 1999, J AM COLL SURGEONS, V188, P304, DOI 10.1016/S1072-7515(98)00301-9; Uchiyama K, 2011, LANGENBECK ARCH SURG, V396, P1101, DOI 10.1007/s00423-011-0778-7; Nimura H, 2004, BRIT J SURG, V91, P575, DOI 10.1002/bjs.4470; Sano K, 2002, ANN SURG, V236, P241, DOI 10.1097/01.SLA.0000021845.89475.00; Aoki T, 2008, WORLD J SURG, V32, P1763, DOI 10.1007/s00268-008-9620-y; Cho A, 2004, J HEPATO-BILIARY-PAN, V11, P390, DOI 10.1007/s00534-004-0919-2; Kitai Toshiyuki, 2005, Breast Cancer, V12, P211, DOI 10.2325/jbcs.12.211; Makuuchi M, 1987, Surg Gynecol Obstet, V164, P68; Ninomiya M, 2015, BRIT J SURG, V102, P944, DOI 10.1002/bjs.9820; Taggart DP, 2003, ANN THORAC SURG, V75, P870, DOI 10.1016/S0003-4975(02)04669-6	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	SEP	2015	221	3					E49	E53		10.1016/j.jamcollsurg.2015.05.009		5	Surgery	Surgery	CP7UK	WOS:000360093800001		
J	Oda, T; Hashimoto, S; Shimomura, O; Yamada, K; Ohara, Y; Fukunaga, K; Oshiro, Y; Akashi, Y; Enomoto, T; Ohkohchi, N				Oda, Tatsuya; Hashimoto, Shinji; Shimomura, Osamu; Yamada, Keiichi; Ohara, Yusuke; Fukunaga, Kiyoshi; Oshiro, Yukio; Akashi, Yoshimasa; Enomoto, Tsuyoshi; Ohkohchi, Nobuhiro			Inter-Anastomosis Drainage Tube Between the Pancreas and Jejunum: A Novel Technique for Preventing Pancreatic Fistula after Pancreaticoduodenectomy	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							DUCT-TO-MUCOSA; PROSPECTIVE RANDOMIZED-TRIAL; BLUMGART ANASTOMOSIS; PANCREATICOJEJUNOSTOMY; COMPLICATIONS; SURGERY; INSTITUTION; DECREASE		[Oda, Tatsuya; Hashimoto, Shinji; Shimomura, Osamu; Yamada, Keiichi; Ohara, Yusuke; Fukunaga, Kiyoshi; Oshiro, Yukio; Akashi, Yoshimasa; Enomoto, Tsuyoshi; Ohkohchi, Nobuhiro] Univ Tsukuba, Dept Surg, Clin Sci, Fac Med, Tsukuba, Ibaraki 3058575, Japan	Oda, T (reprint author), Univ Tsukuba, Dept Surg, Clin Sci, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.	tatoda@md.tsukuba.ac.jp					Lillemoe KD, 2004, J GASTROINTEST SURG, V8, P766, DOI 10.1016/j.gassur.2004.06.011; Kennedy EP, 2007, J AM COLL SURGEONS, V204, P917, DOI 10.1016/j.jamcollsurg.2007.01.057; Kennedy EP, 2011, J HEPATO-BIL-PAN SCI, V18, P769, DOI 10.1007/s00534-011-0429-y; Berger AC, 2009, J AM COLL SURGEONS, V208, P738, DOI 10.1016/j.jamcollsurg.2008.12.031; Grutzmann R, 2012, SURGERY, V151, P612, DOI 10.1016/j.surg.2011.09.039; Grobmyer SR, 2010, J AM COLL SURGEONS, V210, P54, DOI 10.1016/j.jamcollsurg.2009.09.020; Fujii T, 2014, J GASTROINTEST SURG, V18, P1108, DOI 10.1007/s11605-014-2523-3; Bassi C, 2003, SURGERY, V134, P766, DOI 10.1016/S0039-6060(03)00345-3; Pessaux P, 2011, ANN SURG, V253, P879, DOI 10.1097/SLA.0b013e31821219af; Harnoss JC, 2014, SURGERY, V155, P47, DOI 10.1016/j.surg.2013.05.035; Kajiwara T, 2010, LANGENBECK ARCH SURG, V395, P707, DOI 10.1007/s00423-009-0547-z; Pratt WB, 2009, BRIT J SURG, V96, P641, DOI 10.1002/bjs.6614; Kleespies A, 2009, BRIT J SURG, V96, P741, DOI 10.1002/bjs.6634; Ansorge C, 2012, BRIT J SURG, V99, P1076, DOI 10.1002/bjs.8784; Fujino Y, 2007, SURG TODAY, V37, P860, DOI 10.1007/s00595-007-3507-7; Grobmyer SR, 2000, AM J SURG, V180, P117, DOI 10.1016/S0002-9610(00)00423-2; Kakita A, 2001, J Hepatobiliary Pancreat Surg, V8, P230, DOI 10.1007/s005340170022; Kim JH, 2009, WORLD J SURG, V33, P326, DOI 10.1007/s00268-008-9827-y; Knechtle WS, 2015, ANN SURG, V262, P273, DOI 10.1097/SLA.0000000000001042; Maharaj R, 2010, J AM COLL SURGEONS, V211, P143, DOI 10.1016/j.jamcollsurg.2010.03.023; Ohwada S, 1997, J AM COLL SURGEONS, V185, P190, DOI 10.1016/S1072-7515(01)00904-8; Roberts Keith J, 2015, Ann Surg, V261, P1191, DOI 10.1097/SLA.0000000000000997; Tanaka T, 2002, ARCH SURG-CHICAGO, V137, P1258, DOI 10.1001/archsurg.137.11.1258	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	SEP	2015	221	3					E55	E60		10.1016/j.jamcollsurg.2015.05.010		6	Surgery	Surgery	CP7UK	WOS:000360093800002		
J	Fukuda, S				Fukuda, Shin-ichi			Abenomics: Why was it so successful in changing market expectations?	JOURNAL OF THE JAPANESE AND INTERNATIONAL ECONOMIES			English	Article						Unconventional policy; Structural break; Stock price; Exchange rate; Intra-daily data	MONETARY-POLICY; INTEREST-RATES; STRUCTURAL-CHANGE; UNITED-STATES; JAPAN; ZERO; COMMITMENT; TOKYO	'Abenomics' refers to a new unconventional economic policy regime in Japan since late 2012. It consists of three arrows: unconventional monetary policy (the first arrow), expansionary fiscal policy (the second arrow), and economic growth strategies to encourage private investment (the third arrow). After the new regime started, both the stock and the foreign exchange markets reacted very favorably. The purpose of this paper is to investigate why the markets reacted to the new regime so favorably. Unlike orthodox arguments, we focus on asymmetric behavior between local and foreign investors after December 2012. We show that under the new regime, foreign investors were aggressive in purchasing Japanese stocks and in selling the Japanese yen, while local investors were not. By using high frequency intra-daily data, both structural break tests and regression analysis show that various news shocks had more significant impacts on the stock prices and exchange rates in nighttime than in daytime even if they were revealed in daytime. Noting that local investors tend to trade in daytime, while foreign investors tend to trade in nighttime, this implies that more dramatic market responses to the new regime happened in time zones when foreign investors were active. However, the asymmetry became less significant after the market crash on May 23, 2013. Faculty of Economics, University of Tokyo, 7-3-1 Hongo, Bunkyoku, Tokyo 113-0033, Japan. (C) 2015 Elsevier Inc. All rights reserved.	Univ Tokyo, Fac Econ, Bunkyo Ku, Tokyo 1130033, Japan	Fukuda, S (reprint author), Univ Tokyo, Fac Econ, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	sfukuda@e.u-tokyo.ac.jp			Ministry of Education, Science, Sports and Culture [26285044]; JSPS	I would like to thank Koichi Hamada, Masahiro Kawai, Etsuro Shioji, and other conference participants for their helpful comments. This research was supported by the Ministry of Education, Science, Sports and Culture, Grant-in-Aid for Scientific Research (B) 26285044 and JSPS Core-to-Core Program, B. Asia-Africa Science Platforms, JSPS Grant-in-Aid for Challenging Exploratory Research.	ANDREWS DWK, 1993, ECONOMETRICA, V61, P821, DOI 10.2307/2951764; Bai J, 2003, J APPL ECONOM, V18, P1, DOI 10.1002/jae.659; Koeda J, 2013, J JPN INT ECON, V29, P170, DOI 10.1016/j.jjie.2013.07.002; Gambacorta L, 2014, J MONEY CREDIT BANK, V46, P615, DOI 10.1111/jmcb.12119; Fujiwara I, 2006, J JPN INT ECON, V20, P434, DOI 10.1016/j.jjie.2006.02.001; Fukuda S, 2012, J BANK FINANC, V36, P3185, DOI 10.1016/j.jbankfin.2012.01.003; Honda Y., 2007, DISCUSSION PAPERS EC; Honda Y, 2014, JPN ECON REV, V65, P1, DOI 10.1111/jere.12036; IMF, 2013, 13253 IMF; ITO T, 1987, J MONETARY ECON, V19, P255, DOI 10.1016/0304-3932(87)90049-3; Kano T, 2015, J JPN INT ECON, V37, P21, DOI 10.1016/j.jjie.2015.05.002; Krugman P., 2013, NY TIMES; Lambert F., 2014, WP14152 IMF; Nakazono Y, 2013, JPN WORLD ECON, V25-26, P102, DOI 10.1016/j.japwor.2013.03.004; Oda N, 2008, J JPN INT ECON, V22, P34, DOI 10.1016/j.jjie.2007.03.002; Rogers J.H., 2014, ECON POLICY, V80, P749; Rosa C., 2012, 560 FRB; Shioji E, 2015, J JPN INT ECON, V37, P43, DOI 10.1016/j.jjie.2015.06.001; Tsutsui Y, 2010, JPN ECON REV, V61, P175, DOI 10.1111/j.1468-5876.2009.00480.x; Ueda K, 2013, ASIAN ECON POLICY R, V8, P252, DOI 10.1111/aepr.12026; Ueda K, 2012, J ECON PERSPECT, V26, P177, DOI 10.1257/jep.26.3.177; Krishnamurthy A, 2011, BROOKINGS PAP ECO AC, P215	22	1	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1583	1095-8681		J JPN INT ECON	J. Jpn. Inst. Econ.	SEP	2015	37				SI		1	20		10.1016/j.jjie.2015.05.006		20	Economics; International Relations	Business & Economics; International Relations	CP4YS	WOS:000359889100002		
J	Fukuda, S; Shioji, E				Fukuda, Shin-ichi; Shioji, Etsuro			Abenomics: Editor's Introduction	JOURNAL OF THE JAPANESE AND INTERNATIONAL ECONOMIES			English	Editorial Material									[Fukuda, Shin-ichi] Univ Tokyo, Tokyo 1138654, Japan; [Fukuda, Shin-ichi; Shioji, Etsuro] TCER, Tokyo, Japan; [Shioji, Etsuro] Hitotsubashi Univ, Kunitachi, Tokyo, Japan	Fukuda, S (reprint author), Univ Tokyo, Tokyo 1138654, Japan.							0	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1583	1095-8681		J JPN INT ECON	J. Jpn. Inst. Econ.	SEP	2015	37				SI		IV	V		10.1016/S0889-1583(15)00040-4		2	Economics; International Relations	Business & Economics; International Relations	CP4YS	WOS:000359889100001		
J	Kano, T; Morita, H				Kano, Takashi; Morita, Hiroshi			An equilibrium foundation of the Soros chart	JOURNAL OF THE JAPANESE AND INTERNATIONAL ECONOMIES			English	Article						Japanese yen/US dollar exchange rate; Soros chart; Random walk; Bayesian analysis	EXCHANGE-RATES; FUNDAMENTALS	The most prominent characteristic of the Japanese yen/U.S. dollar nominal exchange rate in the post-Plaza Accord era is near random-walk behavior sharing a common stochastic trend with the two-country monetary base differential augmented with excess reserves. In this paper, we develop a simple two-country incomplete-market model equipped with domestic reserve markets to structurally investigate this anecdotal evidence known as the Soros chart. In this model, we theoretically verify that a market discount factor close to one generates near random-walk behavior of an equilibrium nominal exchange rate in accordance with a permanent component of the augmented monetary base differential as an economic fundamental. Results of a Bayesian posterior simulation with post-Plaza Accord data of Japan and the United Stats plausibly support our model as a data generating process of the Japanese yen/U.S. dollar exchange rate. The model identifies the two-country differential in money demand shocks as the main generator of the sharp depreciation of the Japanese yen against the U.S. dollar under the Abenomics. We discuss data evidence that the identified money demand shocks are tightly correlated with longer-term interest rate differentials between the two countries. Hitotsubashi University, Tokyo Center for Economic Research, Japan; Japan Society for the Promotion of Science, Japan. (C) 2015 Elsevier Inc. All rights reserved.	[Kano, Takashi] Hitotsubashi Univ, Tokyo Ctr Econ Res, Kunitachi, Tokyo 1868601, Japan; [Morita, Hiroshi] Japan Soc Promot Sci, Tokyo, Japan	Kano, T (reprint author), Hitotsubashi Univ, Grad Sch Econ, Naka 2-1, Kunitachi, Tokyo 1868601, Japan.	tkano@econ.hit-u.ac.jp; hiroshi.morita1013@gmail.com			Japan Society for the Promotion of Science [24330060]	We would like to thank the editor Shin-ichi Fukuda, an anonymous referee, Kosuke Aoki, Ichiro Fukunaga, Takatoshi Ito, Kazuko Kano, Etsuro Shioji, and conference participants of TCER conference "Abenomics" for helpful and useful discussions and suggestions. Especially, we appreciate Kozo Ueda for his detailed comments on the early draft of this paper. The first author wishes to thank a grant-in-aid for scientific research from the Japan Society for the Promotion of Science (Number 24330060). We are solely responsible for any errors and misinterpretations of this paper.	Engel C, 2005, J POLIT ECON, V113, P485, DOI 10.1086/429137; BACKUS DK, 1993, J INT ECON, V35, P297, DOI 10.1016/0022-1996(93)90021-O; Balke NS, 2013, J INT ECON, V90, P1, DOI 10.1016/j.jinteco.2012.10.003; Engel Charles, 2014, HDB INT EC, V4, P453; Geweke J., 1999, ECONOMET REV, V18, P1, DOI 10.1080/07474939908800428; Hamilton J. D., 1994, TIME SERIES ANAL; Kano T., 2014, 201307 HIT U GRAD SC; MEESE RA, 1983, J INT ECON, V14, P3, DOI 10.1016/0022-1996(83)90017-X; Nason J. M., 2008, 200816 FED RES BANK; Sargent T., 1987, MACROECONOMIC THEORY; Sarno L, 2009, J MONEY CREDIT BANK, V41, P437, DOI 10.1111/j.1538-4616.2009.00212.x; Sims C. A., 2001, COMPUTATIONAL EC, V20, P1, DOI DOI 10.1023/A:1020517101123	12	2	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1583	1095-8681		J JPN INT ECON	J. Jpn. Inst. Econ.	SEP	2015	37				SI		21	42		10.1016/j.jjie.2015.05.002		22	Economics; International Relations	Business & Economics; International Relations	CP4YS	WOS:000359889100003		
J	Shioji, E				Shioji, Etsuro			Time varying pass-through: Will the yen depreciation help Japan hit the inflation target?	JOURNAL OF THE JAPANESE AND INTERNATIONAL ECONOMIES			English	Article						Exchange rate; Pass-through; Expected inflation; CPI by purchase frequency class; Time series analysis	EXCHANGE-RATE DYNAMICS; MONETARY-POLICY; PRICES; INFORMATION	This paper argues that the exchange rate could be a powerful transmission channel of the effects of ongoing "unconventional" monetary policies in Japan. It is shown that exchange rate pass-through to domestic prices, once considered near-extinct, has come back strong in recent years. This is especially true for those items that households purchase frequently. Evidence based on VARs as well as TVP-VARs indicates that a 25% depreciation of the yen would produce a 2% increase in the prices of those items. This could have an additional benefit of raising the public's expectation about future inflation, as their beliefs are often said to be influenced by their daily observations about prices of those items that they buy frequently. Department of Economics, Hitotsubashi University, 2-1 Naka, Kunitachi, Tokyo 186-8601, Japan. (C) 2015 Elsevier Inc. All rights reserved.	Hitotsubashi Univ, Dept Econ, Kunitachi, Tokyo 1868601, Japan	Shioji, E (reprint author), Hitotsubashi Univ, Dept Econ, 2-1 Naka, Kunitachi, Tokyo 1868601, Japan.	shioji@econ.hit-u.ac.jp			 [24223003];  [24530293]	Research for this paper has been partially funded by the Grant-in-aid for scientific research (S) 24223003, (C) 24530293. I would like to thank the editor, the referee for their most insightful comments on the previous version of the paper. Special thanks go to Taisuke Uchino (Daito Bunka University) for a series of discussion which has led to launching of this research project. I am also indebted to Jouchi Nakajima (Bank of Japan) for his suggestions, especially regarding matlab coding. I thank participants at the 5th GRIPS International Conference of Macroeconomics, Policy, "International Conference: Frontiers in Macroeconometrics" at Hitotsubashi University, my seminar talk at Gakushuin University, the Fall 2013 Meetings of the Japanese Economic Association, the Japan Society for Monetary Economics, the TCER Conference on the Abenomics, the Society for Nonlinear Dynamics, Econometrics 22nd Annual Symposium, especially the discussants Masahiro Higo, Masanori Ono, Takashi Kano. Needless to say, all the remaining errors are my own responsibility.	Campa JM, 2005, REV ECON STAT, V87, P679, DOI 10.1162/003465305775098189; Sims CA, 2003, J MONETARY ECON, V50, P665, DOI 10.1016/S0304-3932(03)00029-1; Goldberg PK, 1997, J ECON LIT, V35, P1243; Coibion O, 2012, J POLIT ECON, V120, P116, DOI 10.1086/665662; Betts C, 2000, J INT ECON, V50, P215, DOI 10.1016/S0022-1996(98)00036-1; Primiceri GE, 2005, REV ECON STUD, V72, P821, DOI 10.1111/j.1467-937X.2005.00353.x; OBSTFELD M, 1995, J POLIT ECON, V103, P624, DOI 10.1086/261997; Coibion O, 2010, 16537 NBER; Fukuda S, 2015, J JPN INT ECON, V37, P1, DOI 10.1016/j.jjie.2015.05.006; Hellerstein R., 2006, CURR ISSUES EC FINAN, V12; Hori M., 2013, HITOTSUB J ECON, V54, P17; Hosono K., 2013, J SOCIAL SCI, V64, P131; Ito T, 2008, J MONEY CREDIT BANK, V40, P1407, DOI 10.1111/j.1538-4616.2008.00165.x; Kano T, 2015, J JPN INT ECON, V37, P21, DOI 10.1016/j.jjie.2015.05.002; Kichian M., 2001, NATURE STABILITY CAN; Kim C. J., 1999, STATE SPACE MODELS R; Kuroda H, 2013, COMMUNICATION; Marazzi M., 2005, 833 FED RES SYST INT, V833; Nakajima J., 2011, MONET EC STUD, V29, P107; Nissay Institute, 2013, SHOULD WE UND HOUS I; Otani A., 2003, MONETARY EC STUDIES, V21, P53; Otani A., 2006, MONETARY EC STUDIES, V24, P61; Parsons CR, 2008, INT J FINANC ECON, V13, P174, DOI 10.1002/ijfe.337; Mankiw NG, 2002, Q J ECON, V117, P1295, DOI 10.1162/003355302320935034; Sekine T., 2006, 202 BIS; Shioji E., 2012, PUBLIC POLICY REV, V8, P67; Shioji E., 2007, 07J024 RIETI; Shioji E., 2009, BANK JAPAN WORKING P; Shioji E., 2010, KEIZAI KENKYU, V61, P47; Shioji E., 2011, COMMODITY PRICES MAR; Shioji E, 2014, ASIAN ECON POLICY R, V9, P120, DOI 10.1111/aepr.12053; Shirai S., 2014, COMMUNICATION; Ueda K, 2013, ASIAN ECON POLICY R, V8, P252, DOI 10.1111/aepr.12026; Ueda K, 2010, J JPN INT ECON, V24, P503, DOI 10.1016/j.jjie.2010.06.002; Ueno Y., 2014, UPDATING BEHAV UNPUB; Yoshida Y, 2010, INT REV ECON FINANC, V19, P3, DOI 10.1016/j.iref.2009.02.006	36	1	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1583	1095-8681		J JPN INT ECON	J. Jpn. Inst. Econ.	SEP	2015	37				SI		43	58		10.1016/j.jjie.2015.06.001		16	Economics; International Relations	Business & Economics; International Relations	CP4YS	WOS:000359889100004		
J	Fujiwara, I; Nakazono, Y; Ueda, K				Fujiwara, Ippei; Nakazono, Yoshiyuki; Ueda, Kozo			Policy regime change against chronic deflation? Policy option under a long-term liquidity trap	JOURNAL OF THE JAPANESE AND INTERNATIONAL ECONOMIES			English	Article						Monetary policy rule; Liquidity trap; Survey forecasts	MONETARY-POLICY; EXPECTATIONS; STABILITY; RULES; JAPAN; MODEL; END	The policy package known as Abenomics appears to have influenced the Japanese economy drastically, in particular, in the financial markets. In this paper, focusing on the aggressive monetary easing of Abenomics, the first arrow, we evaluate its role in guiding public perceptions on monetary policy stance through the management of expectations. In order to end chronic deflation, such as that which Japan has been suffering over the last two decades, policy regime change must be perceived by economic agents. Analysis using the QUICK survey system (QSS) monthly survey data shows that monetary policy reaction to inflation rates has been in a declining trend since the mid 2000s, implying intensified forward guidance well before Abenomics. However, Japan seems to have moved closer to a long-term liquidity trap, where even long-term bond yields are constrained by the zero lower bound. Consequently, no sizable difference in perceptions has been found before and after the introduction of Abenomics. Estimated changes in perceptions are not abrupt enough to satisfy "Sargent's (1982) criteria for regime change" termed by Eggertsson (2008). This poses a serious challenge to central banks: what is an effective policy option left under the long-term liquidity trap? RIM, Japan; Keio University, Japan; Australian National University, Australia; Yokohama City University, Japan; Waseda University, Japan. (C) 2015 Elsevier Inc. All rights reserved.	[Fujiwara, Ippei] RIETI, Tokyo, Japan; [Fujiwara, Ippei] Keio Univ, Tokyo 108, Japan; [Fujiwara, Ippei] Australian Natl Univ, Canberra, ACT 0200, Australia; [Nakazono, Yoshiyuki] Yokohama City Univ, Yokohama, Kanagawa, Japan; [Ueda, Kozo] Waseda Univ, Tokyo, Japan	Nakazono, Y (reprint author), Yokohama City Univ, Yokohama, Kanagawa, Japan.	ippei.fujiwara@anu.edu.au; nakazono@yokohama-cu.ac.jp; kozo.ueda@waseda.jp			RIETI	We thank the discussant, Kosuke Aoki, for invaluable inputs and have also benefited from discussions with Shin-ichi Fukuda, Etruso Shioji, Masahisa Fujita, Hideo Hayakawa, Yasuo Hirose, Takuji Kawamoto, Jinill Kim, Takushi Kurozumi, Colin McKenzie, Tsuyoshi Mihira, Tsutomu Miyagawa, Ryuzo Miyao, Masayuki Morikawa, Atsushi Nakajima, Jochi Nakajima, Koji Nakamura, Masao Ogaki, Yoshikiyo Sakai, Masaya Sakuragawa, Toshitaka Sekine, Mototsugu Shintani, Hajime Tomura, Kazuo Ueda, Masazumi Wakatabe, Tomoaki Yamada, Yohei Yamamoto, Tomoo Yoshida, and participants in the TCER-CIRJE-BIE conference on "Abenomics" and seminars at the Bank of Japan, Daiwa Institute of Research, Gakushuin University, JSRI, Kanagawa University, Keio University, RIETI, Waseda University and Yokohama City University. The authors also thank the QUICK corporation for permission to use panel data on each individual forecast. This research was conducted while Fujiwara was a visiting scholar at RIETI. Fujiwara thanks RIETI for their support and hospitality during this time.	Gagnon J, 2011, INT J CENT BANK, V7, P3; Benhabib J, 2002, J POLIT ECON, V110, P535, DOI 10.1086/339713; Cochrane JH, 2011, EUR ECON REV, V55, P2, DOI 10.1016/j.euroecorev.2010.11.002; Jung T, 2005, J MONEY CREDIT BANK, V37, P813, DOI 10.1353/mcb.2005.0053; Albanesi S, 2003, REV ECON STUD, V70, P715, DOI 10.1111/1467-937X.00264; Lubik TA, 2004, AM ECON REV, V94, P190, DOI 10.1257/000282804322970760; Wright JH, 2011, AM ECON REV, V101, P1514, DOI 10.1257/aer.101.4.1514; Joyce MAS, 2011, INT J CENT BANK, V7, P113; Rose AK, 2011, ECON J, V121, P652, DOI 10.1111/j.1468-0297.2010.02407.x; Orphanides A, 2000, J JPN INT ECON, V14, P327, DOI 10.1006/jjie.2000.0452; Aoki Kosuke, 2012, BANK JAPAN WORKING P, V12-E-8; Bank of Japan, 2014, MONTHL REP REC EC FI; Bauer Michael, 2013, FEDERAL RESERVE BANK, V2011-21; Bhattarai Saroj, 2014, TIME CONSISTEN UNPUB; Clarida R, 2000, Q J ECON, V115, P147, DOI 10.1162/003355300554692; Del Negro M., 2012, STAFF REPORTS FEDERA, V574; Eggertsson Gauti, 2003, BROOKINGS PAPERS EC, V1, P139; Eggertsson GB, 2008, AM ECON REV, V98, P1476, DOI 10.1257/aer.98.4.1476; Fujiki Hiroshi, 2002, MONETARY EC STUDIES, V20, P1; Fujiwara I, 2007, JPN WORLD ECON, V19, P329, DOI 10.1016/j.japwor.2006.05.003; Fukuda Shin-ichi, 2014, ABENOMICS WHY UNPUB; Hausman Joshua K., 2014, ABENOMICS PREL UNPUB; Kamada Koichiro, 2006, BANK JAPAN WORKING P, V06-E-17; Kato Ryo, 2004, BANK JAPAN WORKING P, V04-E-13; Kim Jinill, 2013, CAMA WORKING PAPERS, V2013-53; KOENIG EF, 1990, Q J ECON, V105, P399, DOI 10.2307/2937793; Kuroda H, 2013, COMMUNICATION; Kuroda Haruhiko, 2013, BANKS SEMIANNUAL REP; LEEPER EM, 1991, J MONETARY ECON, V27, P129, DOI 10.1016/0304-3932(91)90007-B; Nakazono Y, 2013, JPN WORLD ECON, V25-26, P102, DOI 10.1016/j.japwor.2013.03.004; Romer Christina, 2013, NBERMACRO ANN 2013; Sargent Thomas, 1981, STOPPING MODERATE IN; Sargent Thomas, 1982, INFLATION CAUSES EFF; Sugo T, 2008, J JPN INT ECON, V22, P476, DOI 10.1016/j.jjie.2007.09.002; Sugo T, 2008, ECON LETT, V100, P119, DOI 10.1016/j.econlet.2007.12.006; Tobin J., 1958, REV ECON STUD, V25, P65, DOI DOI 10.2307/2296205; Krishnamurthy A, 2011, BROOKINGS PAP ECO AC, P215; TEMIN P, 1990, EXPLOR ECON HIST, V27, P483, DOI 10.1016/0014-4983(90)90026-U; Woodford M, 1995, CARN ROCH CONF SERIE, V43, P1; Woodford M., 2012, CHANGING POLICY LAND, P185	40	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1583	1095-8681		J JPN INT ECON	J. Jpn. Inst. Econ.	SEP	2015	37				SI		59	81		10.1016/j.jjie.2015.05.005		23	Economics; International Relations	Business & Economics; International Relations	CP4YS	WOS:000359889100005		
J	Miyazawa, K; Yamada, J				Miyazawa, Kensuke; Yamada, Junji			The growth strategy of Abenomics and fiscal consolidation	JOURNAL OF THE JAPANESE AND INTERNATIONAL ECONOMIES			English	Article						Fiscal consolidation; Growth strategy; Demographic change	GOVERNMENT DEBT; JAPAN; SUSTAINABILITY; POLICY; RATES	Using a general equilibrium model with an overlapping generation structure, this study examines the impacts of a new Abenomics growth strategy on fiscal consolidation in Japan. Our simulation yielded the following results. (i) It is difficult to achieve the government target of fiscal consolidation by the year 2020 even when assuming that the growth strategy has the desired effects. (ii) Moreover, further economic and fiscal reforms are required from 2030 to 2070 because of accelerated population aging. (iii) However, population policy and an extended retirement age contribute to significant improvements in Japan's fiscal condition after 2070. (iv) In contrast, the promotion of productivity and the labor force participation rate have a lesser impact on fiscal reconstruction. Faculty of Economics, Kyushu University, 6-10-1 Hakosaki, Higashi-ku, Fukuoka 812-8581, Japan; Faculty of Economics, University of Toyama, 3190 Gofuku, Toyama 930-0055, Japan. (C) 2015 Elsevier Inc. All rights reserved.	[Miyazawa, Kensuke] Kyushu Univ, Fac Econ, Higashi Ku, Fukuoka 8128581, Japan; [Yamada, Junji] Toyama Univ, Fac Econ, Toyama 9300055, Japan	Yamada, J (reprint author), Toyama Univ, Fac Econ, 3190 Gofuku, Toyama 9300055, Japan.	kensuke.miyazawa@gmail.com; jyamada@eco.u-toyama.ac.jp			JSPS [24330094]	An earlier version of this paper was presented at the APEA and TCER conferences. We are grateful for the helpful comments of an anonymous reviewer, Tomoaki Yamada, Real Arai, and other participants. We also wish to express our appreciation to the Editor of this journal, Shin-ichi Fukuda. We would like to acknowledge financial support from JSPS Grant-in-Aid for Scientific Research (B) (24330094). Yamada is grateful for financial support by JSPS Grant-in-Aid for Challenging Exploratory Research and Core-to-Core Program (B), Asia-Africa Science Platforms.	Sakuragawa M, 2011, J JPN INT ECON, V25, P434, DOI 10.1016/j.jjie.2011.10.002; Doi T, 2011, J JPN INT ECON, V25, P414, DOI 10.1016/j.jjie.2011.09.006; Arai R, 2013, J JPN INT ECON, V30, P59, DOI 10.1016/j.jjie.2013.10.003; Braun RA, 2009, INT ECON REV, V50, P291; Braun R.A., 2014, FEDERAL RESERVE BANK, V2014-18, P1; Hansen G., 2013, 19431 NBER, P1; Imrohoroglu S., 2013, EC WORKING PAPER ARC, P1; Imrohoroglu S., 2011, MONET EC STUD I MONE, V29, P73; Kameda K, 2014, J JPN INT ECON, V32, P105, DOI 10.1016/j.jjie.2014.02.001; LUCAS RE, 1976, CARN ROCH CONF SERIE, V1, P19, DOI 10.1016/S0167-2231(76)80003-6; MENDOZA EG, 1994, J MONETARY ECON, V34, P297, DOI 10.1016/0304-3932(94)90021-3; Miyazawa K., 2013, JAPANESE CURRENT ACC; Yamada T, 2012, J ECON DYN CONTROL, V36, P63, DOI 10.1016/j.jedc.2011.07.001	13	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1583	1095-8681		J JPN INT ECON	J. Jpn. Inst. Econ.	SEP	2015	37				SI		82	99		10.1016/j.jjie.2015.05.004		18	Economics; International Relations	Business & Economics; International Relations	CP4YS	WOS:000359889100006		
J	Arai, Y; Ichimura, H; Kawaguchi, D				Arai, Yoichi; Ichimura, Hidehiko; Kawaguchi, Daiji			The educational upgrading of Japanese youth, 1982-2007: Are all Japanese youth ready for structural reforms?	JOURNAL OF THE JAPANESE AND INTERNATIONAL ECONOMIES			English	Article						Tertiary education; Youth employment; Japan	BIASED TECHNOLOGICAL-CHANGE; WAGE INEQUALITY; LABOR-MARKETS; UNITED-STATES; DEMAND; UNEMPLOYMENT; OECD	Are all Japanese youth ready for the structural reforms proposed as a supply-side policy of Abenomics? To answer this question, we assess how well Japanese youth have coped with the labor market's long-term structural changes, induced primarily by deepening interdependence with emerging economies and rapid technological progress over the last three decades. We examine the role of educational upgrading on the labor-market outcomes of youth between the ages of 25 and 29, using six waves of micro data from the Employment Status Survey spanning from 1982 to 2007. The analysis demonstrates that the demand growth for skilled labor relative to unskilled labor has been met by the educational upgrading of youth through the expansion of tertiary education, including education in vocational schools. Youth left behind the trend of educational upgrading, however, have suffered significantly from decreasing employment opportunities and deteriorated working conditions. National Graduate Institute for Policy Studies (GRIPS), Roppongi 7-22-1, Minato-ku, Tokyo 106-8677, Japan; Graduate School of Economics, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan; Graduate School of Economics, Hitotsubashi University, Naka 2-1, Kunitachi-shi, Tokyo 186-8601, Japan. (C) 2015 Elsevier Inc. All rights reserved.	[Arai, Yoichi] Natl Grad Inst Policy Studies GRIPS, Minato Ku, Tokyo 1068677, Japan; [Ichimura, Hidehiko] Univ Tokyo, Grad Sch Econ, Bunkyo Ku, Tokyo 1130033, Japan; [Kawaguchi, Daiji] Hitotsubashi Univ, Grad Sch Econ, Kunitachi, Tokyo 1868601, Japan	Kawaguchi, D (reprint author), Hitotsubashi Univ, Grad Sch Econ, Naka 2-1, Kunitachi, Tokyo 1868601, Japan.	yarai@grips.ac.jp; ichimura@e.u-tokyo.ac.jp; kawaguch@econ.hit-u.ac.jp			Japan Society for the Promotion of Science [22243020, 23330070, 23330079]	An earlier version of this paper was prepared for the conference on Abenomics hosted by Tokyo Center for Economic Research on March 7, 2014 at the University of Tokyo. We received valuable comments from the conference participants. We are especially grateful to Ayako Kondo, the formal discussant at the conference, for many helpful comments. We also gratefully acknowledge the comments from a referee that significantly improve the manuscript. This research was supported by Grants-in-Aid for Scientific Research Nos. 22243020, 23330070 and 23330079 from the Japan Society for the Promotion of Science. The full version of this paper including more figures is avaiable as IZA Discussion Paper under the same title.	Abe M, 2001, J JPN INT ECON, V15, P437, DOI 10.1006/jjie.2001.0492; Abe N., 2011, 2011J03 NAT I POP SO; Abe Y, 2010, JPN WORLD ECON, V22, P69, DOI 10.1016/j.japwor.2010.01.001; Abe Yukiko, 2010, Journal of Asian Economics, V21, DOI 10.1016/j.asieco.2009.12.003; Ahn S., 2008, COLUMBIA BUSINESS SC; Akabayashi H, 2011, J JPN INT ECON, V25, P183, DOI 10.1016/j.jjie.2011.07.003; Brickley JA, 2001, J CORP FINANC, V7, P367, DOI 10.1016/S0929-1199(01)00026-8; Johnson GE, 1997, J ECON PERSPECT, V11, P41; Barro RJ, 2013, J DEV ECON, V104, P184, DOI 10.1016/j.jdeveco.2012.10.001; Acemoglu D, 2001, NBER MACROECON ANN, V15, P9; BOUND J, 1992, AM ECON REV, V82, P371; Feenstra RC, 1996, AM ECON REV, V86, P240; ROTHSCHILD M, 1995, J POLIT ECON, V103, P573, DOI 10.1086/261995; Nickell S, 2005, ECON J, V115, P1, DOI 10.1111/j.1468-0297.2004.00958.x; Asano H, 2013, SCOT J POLIT ECON, V60, P360, DOI 10.1111/sjpe.12015; Berman E, 1998, Q J ECON, V113, P1245, DOI 10.1162/003355398555892; BERMAN E, 1994, Q J ECON, V109, P367, DOI 10.2307/2118467; BORJAS GJ, 1995, Q J ECON, V110, P1075, DOI 10.2307/2946649; Dill DD, 2004, HIGH EDU DYN, V6, P61; Feenstra RC, 1999, Q J ECON, V114, P907, DOI 10.1162/003355399556179; Genda Y., 2006, NAGGING SENSE JOB IN; Genda Y., 2007, JAPANESE J LABOUR ST, V567, P97; Hamanaka J., 2009, JAPANESE J LABOUR ST, V588, P34; Hamanaka J., 2013, UTILITY ED; Kambayashi R., 2013, PRIMCED DISCUSSION P; KATZ LF, 1992, Q J ECON, V107, P35, DOI 10.2307/2118323; Kawaguchi D., 2014, WINNING RACE TECHNOL; Korenman S, 2000, NBER COMPA LABOR MAR, P57; Krueger A.B., 1997, 5924 NBER; Kuroda S., 2003, MONET EC STUD, V21, P69; Levy F, 1996, AM ECON REV, V86, P258; Ling C., 2012, J JAPANESE INT EC, V26, P44; Machin S, 1998, Q J ECON, V113, P1215, DOI 10.1162/003355398555883; Mitani N., 2008, YOUNG WORKERS IN THE, P109; Miyamoto H., 2010, J JAPANESE INT EC, V23, P214; Miyoshi K, 2008, JPN WORLD ECON, V20, P479, DOI 10.1016/j.japwor.2007.06.003; Morikawa M., 2012, DISCUSSION PAPERS RI, V12009; Nagao Y., 2008, J JPN SOC ED SOCIOL, P85; Nakamura J., 2009, FOREIGN LABOR FORCE; Sachs J. D., 1994, BROOKINGS PAPERS EC, V1, P1; Sakurai K, 2004, JPN WORLD ECON, V16, P139, DOI 10.1016/s0922-1425(03)00023-9; Sakurai K, 2001, J JPN INT ECON, V15, P298, DOI 10.1006/jjie.2001.0473; Stiglitz J. E., 2000, EC PUBLIC SECTOR; Yamada K, 2015, J ECON INEQUAL, V13, P129, DOI 10.1007/s10888-014-9295-6	44	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1583	1095-8681		J JPN INT ECON	J. Jpn. Inst. Econ.	SEP	2015	37				SI		100	126		10.1016/j.jjie.2015.04.002		27	Economics; International Relations	Business & Economics; International Relations	CP4YS	WOS:000359889100007		
J	Nasu, H; Nimura, A; Yamaguchi, K; Akita, K				Nasu, H.; Nimura, A.; Yamaguchi, K.; Akita, K.			Distribution of the axillary nerve to the subacromial bursa and the area around the long head of the biceps tendon	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Axillary nerve; Subacromial bursa; Long head of the biceps; Capsule; Distribution; Macroscopic anatomy	SUPRASCAPULAR NERVE; PAIN; INNERVATION; TENODESIS; TENOTOMY; SURGERY; BRANCH	Patients with a shoulder disorder often complain of pain on the anterior or lateral aspect of the shoulder. Such pain has been thought to originate from the suprascapular nerve. However, taking into consideration the distinctive course of the axillary nerve, the axillary nerve is likely to supply branches to the structure around the shoulder joint. This study was conducted to clarify the division, course, and distribution of the branches which originate from the axillary nerve and innervate structures around the shoulder joint. The division, course, and distribution of the branches which originate from the axillary nerve and innervate structures around the shoulder joint were examined macroscopically by dissecting 20 shoulders of 10 adult Japanese cadavers. The thin branches from the anterior branch of the axillary nerve were distributed to the subacromial bursa and the area around the long head of the biceps tendon. The branches from the main trunk of the axillary nerve or the branch to the teres minor muscle were distributed to the infero-posterior part of the shoulder joint. The pain on the anterior or lateral aspect of the shoulder, which has been thought to originate from the suprascapular nerve, might be related to the thin branches which originate from the axillary nerve and innervate the subacromial bursa and the area around the long head of the biceps tendon. These results would be useful to consider the cause of the shoulder pain or to prevent the residual pain after the biceps tenodesis.	[Nasu, H.; Nimura, A.; Yamaguchi, K.; Akita, K.] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Clin Anat, Bunkyo Ku, Tokyo 1138510, Japan	Akita, K (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Clin Anat, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	akita.fana@tmd.ac.jp			Ministry of Education, Culture, Sports, Science and Technology [90622556]	This study was partly supported by a Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology (No. 90622556).	Aiyama S, 1973, HIROSAKI IGAKU, V24, P413; Boileau P, 2002, ARTHROSCOPY, V18, P1002, DOI 10.1053/jars.2002.36488; Szabo I, 2008, SPORTS MED ARTHROSC, V16, P180, DOI 10.1097/JSA.0b013e3181824f1e; Hsu AR, 2011, J SHOULDER ELB SURG, V20, P326, DOI 10.1016/j.jse.2010.08.019; Khan KM, 2000, BRIT J SPORT MED, V34, P81, DOI 10.1136/bjsm.34.2.81; Gelber PE, 2006, CLIN ANAT, V19, P304, DOI 10.1002/ca.20172; Ritchie ED, 1997, ANESTH ANALG, V84, P1306, DOI 10.1097/00000539-199706000-00024; Wittstein JR, 2011, AM J SPORT MED, V39, P857, DOI 10.1177/0363546510387512; Elser F, 2011, ARTHROSCOPY, V27, P581, DOI 10.1016/j.arthro.2010.10.014; Vorster W, 2008, J SHOULDER ELB SURG, V17, P500, DOI 10.1016/j.jse.2007.10.008; Aszmann OC, 1996, CLIN ORTHOP RELAT R, P202; Tosounidis T, 2013, J ORTHOP SCI, V18, P238, DOI 10.1007/s00776-012-0346-1; Lutton DM, 2011, CLIN ORTHOP RELAT R, V469, P1050, DOI 10.1007/s11999-010-1691-z; Alpantaki K, 2005, J BONE JOINT SURG AM, V87A, P1580, DOI 10.2106/JBJS.D.02840; Ball CM, 2003, J BONE JOINT SURG AM, V85A, P1497; Ebraheim Ebraheim NA, 2011, J SHOULDER ELB SURG, V20, P13; Frohse F, 1908, MUSKELN MENSCHLICHEN, P27; GARDNER E, 1948, ANAT REC, V102, P1, DOI 10.1002/ar.1091020102; Ide K, 1996, J Shoulder Elbow Surg, V5, P371, DOI 10.1016/S1058-2746(96)80069-3; Loukas M, 2009, SURG RADIOL ANAT, V31, P43, DOI 10.1007/s00276-008-0409-3; Mazzocca Augustus D, 2005, Arthroscopy, V21, P896; Morisawa Y, 1997, KANSESTU GEKA, V16, P917; Murakami M, 1997, KANSESTU GEKA, V16, P923; Ochiai N, 2010, KATAKANSESTU, V34, P569; Rauber A, 1870, KNOCHEN NERVEN OBERA, P13; Sander B, 2008, ARTHROSCOPY, V24, pe9, DOI 10.1016/j.arthro.2008.04.017; Soifer TBN, 1996, ARTHROSCOPY, V12, P182, DOI 10.1016/S0749-8063(96)90008-0; WRETE M, 1949, J NEUROSURG, V6, P351, DOI 10.3171/jns.1949.6.5.0351; Zhang Q, 2013, KNEE SURG SPORT TR A, DOI [10.1007/s0016701325878, DOI 10.1007/S0016701325878]	29	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	SEP	2015	23	9					2651	2657		10.1007/s00167-014-3112-4		7	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CP6ND	WOS:000360003300030		
J	Tasaki, A; Nimura, A; Mochizuki, T; Yamaguchi, K; Kato, R; Sugaya, H; Akita, K				Tasaki, Atsushi; Nimura, Akimoto; Mochizuki, Tomoyuki; Yamaguchi, Kumiko; Kato, Ryuichi; Sugaya, Hiroyuki; Akita, Keiichi			Anatomic observation of the running space of the suprascapular nerve at the suprascapular notch in the same direction as the nerve	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Suprascapular nerve; Suprascapular notch; Superior transverse scapular ligament; Subscapularis	ENTRAPMENT NEUROPATHY; VOLLEYBALL PLAYERS; COMPRESSION; GANGLION	The configuration of suprascapular notch was previously analysed from the anteroposterior viewing. However, the approach direction of the suprascapular nerve (SSN) to the inlet of the suprascapular notch is consistently craniocaudal and mediolateral. We propose a new method to observe the suprascapular notch according to the running course of the SSN. We reviewed the anatomic characteristics of the suprascapular notch in relation to the nerve. In 30 formalin-fixed cadaveric shoulders, the morphology of the suprascapular notch and the attachments of the superior transverse scapular ligament (STSL) were examined from both the anteroposterior and the nerve approach direction. The dimensions of the opening of the SSN passage were measured. By observing from the nerve approach direction, the inlet of the suprascapular notch was recognized to be a space-bordered by the medial wall of the coracoid process, the deep fascia of subscapularis, and the STSL. The STSL formed a sheet-like structure, which ran parallel to the nerve and also to the deep fascia of subscapularis. The attachment of the ligament to the coracoid process was located at the posteromedial corner rather than the medial side. Based on the present study, the space between the STSL and deep fascia of the subscapularis formed the space for the nerve to run through. As a clinical implication, this new method to assess the suprascapular notch in the nerve approach direction might develop the imaging techniques for evaluation of SSN entrapment.	[Tasaki, Atsushi; Nimura, Akimoto; Yamaguchi, Kumiko; Akita, Keiichi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Clin Anat, Bunkyo Ku, Tokyo 1138519, Japan; [Tasaki, Atsushi] St Lukes Int Med Ctr, Dept Orthopaed Surg, Tokyo, Japan; [Mochizuki, Tomoyuki] Tokyo Med & Dent Univ, Grad Sch, Dept Joint Reconstruct, Tokyo 1138519, Japan; [Kato, Ryuichi] Nokyo Kyosai Res Inst, Tokyo, Japan; [Sugaya, Hiroyuki] Funabashi Orthopaed Sports Med Ctr, Shoulder & Elbow Serv, Funabashi, Chiba, Japan	Nimura, A (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Clin Anat, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	nimura.orj@tmd.ac.jp			Ministry of Education, Culture, Sports(C) [24791525]; NokyoKyosai Research Institute (Agricultural Cooperative Insurance Research Institute)	This study was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports(C) (No. 24791525) and also by a Grant from NokyoKyosai Research Institute (Agricultural Cooperative Insurance Research Institute).	Kibler WB, 1998, AM J SPORT MED, V26, P325; Duparc F, 2010, SURG RADIOL ANAT, V32, P277, DOI 10.1007/s00276-010-0631-7; Shah AA, 2011, J SHOULDER ELB SURG, V20, P975, DOI 10.1016/j.jse.2010.10.032; WARNER JJP, 1992, J BONE JOINT SURG AM, V74A, P36; RENGACHARY SS, 1979, NEUROSURGERY, V5, P452; Ticker JB, 1998, J SHOULDER ELB SURG, V7, P472, DOI 10.1016/S1058-2746(98)90197-5; Bayramoglu A, 2003, KNEE SURG SPORT TR A, V11, P393, DOI 10.1007/s00167-003-0378-3; CLEIN LJ, 1975, J NEUROSURG, V43, P337, DOI 10.3171/jns.1975.43.3.0337; Cohen SB, 1997, CLIN ORTHOP RELAT R, P131; Cummins CA, 2000, J BONE JOINT SURG AM, V82A, P415; EDELSON JG, 1995, J BONE JOINT SURG BR, V77B, P505; FERRETTI A, 1987, J BONE JOINT SURG AM, V69A, P260; GANZHORN RW, 1981, J BONE JOINT SURG AM, V63, P492; HIRAYAMA T, 1981, CLIN ORTHOP RELAT R, P95; Kannan Usha, 2014, J Clin Diagn Res, V8, P7, DOI 10.7860/JCDR/2014/7836.4089; Natsis K, 2007, CLIN ANAT, V20, P135, DOI 10.1002/ca.20318; Oizumi N, 2012, J SHOULDER ELB SURG, V21, P759, DOI 10.1016/j.jse.2011.08.063; RENGACHARY SS, 1979, NEUROSURGERY, V5, P447; RINGEL SP, 1990, AM J SPORT MED, V18, P80, DOI 10.1177/036354659001800113; Romeo Anthony A, 2010, J Shoulder Elbow Surg, V19, P118, DOI 10.1016/j.jse.2010.01.006; Sandow MJ, 1998, J SHOULDER ELB SURG, V7, P516, DOI 10.1016/S1058-2746(98)90205-1; THOMPSON WAL, 1959, NEW ENGL J MED, V260, P1261, DOI 10.1056/NEJM195906182602503; Wang HJ, 2011, CLIN ANAT, V24, P47, DOI 10.1002/ca.21061; Witvrouw E, 2000, BRIT J SPORT MED, V34, P174, DOI 10.1136/bjsm.34.3.174	24	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	SEP	2015	23	9					2667	2673		10.1007/s00167-014-3129-8		7	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CP6ND	WOS:000360003300033		
J	Kotake-Nara, E; Yonekura, L; Nagao, A				Kotake-Nara, Eiichi; Yonekura, Lina; Nagao, Akihiko			Glyceroglycolipids Affect Uptake of Carotenoids Solubilized in Mixed Micelles by Human Intestinal Caco-2 Cells	LIPIDS			English	Article						Glyceroglycolipid; Lysoglyceroglycolipid; Carotenoid; beta-Carotene; Lutein; Mixed micelles; Caco-2; Lyso-lipid; Intercellular barrier integrity; Intestinal uptake	VISIBLE CIRCULAR-DICHROISM; BETA-CAROTENE; DIETARY CAROTENOIDS; BACTERIAL TRANSLOCATION; LUTEIN AGGREGATE; OPTICAL-ACTIVITY; EXCITED-STATES; LYSOPHOSPHATIDYLCHOLINE; CHOLESTEROL; PERMEABILITY	We previously reported that phospholipids markedly affected the uptake of carotenoids solubilized in mixed micelles by human intestinal Caco-2 cells. In the present study, we found that two classes of dietary glyceroglycolipids and the corresponding lysoglyceroglycolipids affected uptake of beta-carotene and lutein by differentiated Caco-2 cells. The levels of carotenoid uptake from micelles containing digalactosyldiacylglycerol or sulfoquinovosyldiacylglycerol were significantly lower than that from control micelles. On the other hand, the uptakes from micelles containing digalactosylmonoacylglycerol or sulfoquinovosylmonoacylglycerol were significantly higher than that from control micelles. In dispersed cells and Caco-2 cells with poor cell-to-cell adhesion, however, the levels of uptake from micelles containing these lyso-lipids were much lower than that from control micelles. The uptake levels from control micelles were markedly decreased depending on the development of cell-to-cell/cell-matrix adhesion in Caco-2 cells, but the uptake levels from the micelles containing these lyso-lipids were not substantially changed, suggesting that the intercellular barrier formed by cell-to-cell/cell-matrix adhesion inhibited the uptake from control micelles, but not from the lyso-lipid-containing micelles. The lyso-lipids appeared to enhance carotenoid uptake by decreasing the intercellular barrier integrity. The results showed that some types of glyceroglycolipids have the potential to modify the intestinal uptake of carotenoids.	[Kotake-Nara, Eiichi; Yonekura, Lina; Nagao, Akihiko] Natl Agr & Food Res Org, Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan	Kotake-Nara, E (reprint author), Natl Agr & Food Res Org, Natl Food Res Inst, 2-1-12 Kannondai, Tsukuba, Ibaraki 3058642, Japan.	ekotake@affrc.go.jp			JSPS KAKENHI [24500962]	This work was supported in part by JSPS KAKENHI Grant Number 24500962.	ANDERSSON L, 1995, J LIPID RES, V36, P1392; Frank HA, 2000, J PHYS CHEM B, V104, P4569, DOI 10.1021/jp000079u; Sawai T, 2002, PEDIATR SURG INT, V18, P591, DOI 10.1007/s00383-002-0860-x; Hashimoto H, 1996, JPN J APPL PHYS 1, V35, P281, DOI 10.1143/JJAP.35.281; Lambert D, 2007, CELL PHYSIOL BIOCHEM, V20, P495, DOI 10.1159/000107533; Kompauer I, 2006, PUBLIC HEALTH NUTR, V9, P472, DOI 10.1079/PHN2005868; Zsila F, 2001, CHIRALITY, V13, P446, DOI 10.1002/chir.1060; Stahl W, 2012, MOL NUTR FOOD RES, V56, P287, DOI 10.1002/mnfr.201100232; Sugawara T, 1999, LIPIDS, V34, P1231, DOI 10.1007/s11745-999-0476-3; Yonekura L, 2007, MOL NUTR FOOD RES, V51, P107, DOI 10.1002/mnfr.200600145; Takayanagi K, 2011, J AGR FOOD CHEM, V59, P12342, DOI 10.1021/jf202821u; BLUME G, 1990, BIOCHIM BIOPHYS ACTA, V1029, P91, DOI 10.1016/0005-2736(90)90440-Y; Doi N, 2011, DRUG METAB PHARMACOK, V26, P162, DOI 10.2133/dmpk.DMPK-10-RG-071; Yonekura L, 2006, LIPIDS, V41, P629, DOI 10.1007/s11745-006-5013-x; Francis SA, 1999, EUR J CELL BIOL, V78, P473; Kotake-Nara E, 2012, BIOSCI BIOTECH BIOCH, V76, P875, DOI 10.1271/bbb.110777; Marcotorchino J, 2012, MOL NUTR FOOD RES, V56, P725, DOI 10.1002/mnfr.201100623; Ramel F, 2012, PLANT PHYSIOL, V158, P1267, DOI 10.1104/pp.111.182394; Holst B, 2008, CURR OPIN BIOTECH, V19, P73, DOI 10.1016/j.copbio.2008.03.003; Kotake-Nara E, 2010, BIOSCI BIOTECH BIOCH, V74, P209, DOI 10.1271/bbb.90665; Zsila F, 2001, J PHYS CHEM B, V105, P9413, DOI 10.1021/jp011626u; Nagao A, 2013, BIOSCI BIOTECH BIOCH, V77, P1055, DOI 10.1271/bbb.130025; Tanaka T, 2012, MOLECULES, V17, P3202, DOI 10.3390/molecules17033202; Lambert D, 2005, BIOCHEM J, V387, P553, DOI 10.1042/BJ20041377; Maiani G, 2009, MOL NUTR FOOD RES, V53, pS194, DOI 10.1002/mnfr.200800053; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Billsten HH, 2005, J PHYS CHEM A, V109, P1521, DOI 10.1021/jp044847j; Kotake-Nara E, 2005, BIOSCI BIOTECH BIOCH, V69, P224, DOI 10.1271/bbb.69.224; Sanchez M, 2010, J COLLOID INTERF SCI, V341, P240, DOI 10.1016/j.jcis.2009.09.042; Avital S, 2006, BBA-BIOENERGETICS, V1757, P798, DOI 10.1016/j.bbabio.2006.05.038; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; Correa NM, 2001, J COLLOID INTERF SCI, V240, P573, DOI 10.1006/jcis.2001.7640; Foss BJ, 2005, CHEM PHYS LIPIDS, V135, P157, DOI 10.1016/j.chemphyslip.2005.02.006; GOUNARIS K, 1986, BIOCHEM J, V237, P313; Haynes MP, 2000, BIOCHEMISTRY-US, V39, P4508, DOI 10.1021/bi992125q; Krisko A, 2004, ANAL BIOCHEM, V331, P177, DOI 10.1016/j.ab.2004.03.048; Liu DZ, 1999, J PHARM SCI, V88, P1161, DOI 10.1021/js990094e; Muir LV, 1996, GASTROENTEROLOGY, V110, P1068, DOI 10.1053/gast.1996.v110.pm8612995; MURAKAMI N, 1994, TETRAHEDRON, V50, P1993; Nakae T, 1998, FOOD SCI TECHNOL INT, V4, P235; Nakano T, 2009, AM J PHYSIOL-GASTR L, V297, pG207, DOI 10.1152/ajpgi.90590.2008; Ohnishi T, 1978, B CHEM SOC JPN, V51, P1717; RALSTON E, 1980, BIOCHIM BIOPHYS ACTA, V597, P543, DOI 10.1016/0005-2736(80)90226-6; Richelle M, 2004, AM J CLIN NUTR, V80, P171; Sato Y, 2010, J AGR FOOD CHEM, V58, P7180, DOI 10.1021/jf100519x; Sawai T, 2001, PEDIATR SURG INT, V17, P269, DOI 10.1007/s003830100592; Sawai T, 2000, PEDIATR SURG INT, V16, P262, DOI 10.1007/s003830050741; Shirakura Y, 2011, J NUTR SCI VITAMINOL, V57, P426; Soontornchaiboon W, 2012, BIOL PHARM BULL, V35, P1137, DOI 10.1248/bpb.b12-00187; Stankewich MC, 1996, LIPIDS, V31, P817, DOI 10.1007/BF02522977; Sugawara T, 2001, J NUTR, V131, P2921; TAKAGI S, 1987, AGR BIOL CHEM TOKYO, V51, P1567; TAKAGI S, 1981, AGR BIOL CHEM TOKYO, V45, P1159; TAKAGI S, 1983, AGR BIOL CHEM TOKYO, V47, P1435; TAKAGI S, 1982, AGR BIOL CHEM TOKYO, V46, P2035; TAKAGI S, 1980, AGR BIOL CHEM TOKYO, V44, P2111; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; Zaripheh S, 2002, J NUTR, V132, p531S	58	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0024-4201	1558-9307		LIPIDS	Lipids	SEP	2015	50	9					847	860		10.1007/s11745-015-4033-9		14	Biochemistry & Molecular Biology; Nutrition & Dietetics	Biochemistry & Molecular Biology; Nutrition & Dietetics	CP6RB	WOS:000360014500003		
J	Kojima, H; Suzuki, Y; Ito, M; Kabayama, K				Kojima, Hisao; Suzuki, Yusuke; Ito, Masahiro; Kabayama, Kazuya			Structural Characterization of Neutral Glycosphingolipids from 3T3-L1 Adipocytes	LIPIDS			English	Article						Glycosphingolipids; 1,2-Dichloroethane wash; Adipocytes; Triacylglycerols; Liquid chromatography-tandem mass spectrometry	ADIPOSE-TISSUE; EXPRESSION; MEMBRANE; LIPIDS; CELLS	In recent years, obesity has been considered a pathological stage of early lifestyle-related diseases, and adipose tissue and adipocyte research has been active. Glycosphingolipids are involved in the pathogenesis of type 2 diabetes induced by insulin resistance, but the details of the glycosphingolipid molecular species composition of adipocytes have yet to be elucidated. We used 3T3-L1 adipocytes and the 1,2-dichloroethane-wash method to remove triacylglycerols, which are abundant in adipocytes, and analyzed the structures of glycosphingolipids, particularly neutral glycosphingolipids, using liquid chromatography-mass spectrometry.	[Kojima, Hisao; Ito, Masahiro] Ritsumeikan Univ, Coll Life Sci, Shiga, Japan; [Suzuki, Yusuke] Nihon Univ, Coll Sci & Technol, Tokyo 101, Japan; [Kabayama, Kazuya] Osaka Univ, Grad Sch Sci, Toyonaka, Osaka 5600043, Japan	Kabayama, K (reprint author), Osaka Univ, Grad Sch Sci, 1-1 Machikaneyama, Toyonaka, Osaka 5600043, Japan.	kaba@chem.sci.osaka-u.ac.jp			 [00399974]	We thank Dr. Akemi Suzuki, the chief of the Institute of Glycoscience in Tokai University, for helpful comments. This study was supported in part by a Grant-in-Aid for Young Scientists (B) (No. 00399974).	Messner MC, 2010, ADV EXP MED BIOL, V688, P156; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Galic S, 2010, MOL CELL ENDOCRINOL, V316, P129, DOI 10.1016/j.mce.2009.08.018; Kabayama K, 2007, P NATL ACAD SCI USA, V104, P13678, DOI 10.1073/pnas.0703650104; Wu DY, 2007, J IMMUNOL, V179, P4829; Hakomori SI, 2008, BBA-GEN SUBJECTS, V1780, P325, DOI 10.1016/j.bbagen.2007.08.015; Cawthorn WP, 2008, FEBS LETT, V582, P117, DOI 10.1016/j.febslet.2007.11.051; OHASHI M, 1979, LIPIDS, V14, P52, DOI 10.1007/BF02533566; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Boggs JA, 2008, BBA-GEN SUBJECTS, V1780, P445, DOI 10.1016/j.bbagen.2007.10.015; Kolter T., 2012, ISRN BIOCH, V2012, P1; Kuwahata H, 2014, E J SURF SCI NANOTEC, V12, P400; MCCLUER RH, 1989, LIPIDS, V24, P951, DOI 10.1007/BF02544540; OHASHI M, 1977, J BIOCHEM-TOKYO, V81, P1675; Ortegren U, 2004, EUR J BIOCHEM, V271, P2028, DOI 10.1111/j.1432-1033.2004.04117.x; Suzuki Y, 2012, J LIPID RES, V53, P599, DOI 10.1194/jlr.D020545; Tanabe A, 2009, BIOCHEM BIOPH RES CO, V379, P547, DOI 10.1016/j.bbrc.2008.12.086; Yamashita T, 2002, BBA-GEN SUBJECTS, V1573, P236, DOI 10.1016/S0304-4165(02)00389-6	18	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0024-4201	1558-9307		LIPIDS	Lipids	SEP	2015	50	9					913	917		10.1007/s11745-015-4035-7		5	Biochemistry & Molecular Biology; Nutrition & Dietetics	Biochemistry & Molecular Biology; Nutrition & Dietetics	CP6RB	WOS:000360014500009		
J	Omura, K; Adachi, Y; Kobayashi, Y; Sekiguchi, S; Zhou, B; Iida, T				Omura, Kaoru; Adachi, Yuuki; Kobayashi, Yuuki; Sekiguchi, Shoutaro; Zhou, Biao; Iida, Takashi			Chemical Synthesis of the Epimeric (23R)- and (23S)-Fluoro Derivatives of Bile Acids via Horner-Wadsworth-Emmons Reaction	LIPIDS			English	Article						Bile acid u Epimeric (23R)-/(23S)-fluoro-bile acids; Horner-Wadsworth-Emmons reaction; alpha-Fluoro-alpha,beta-unsaturated esterification	MEDICINAL CHEMISTRY; CONFIGURATION; FLUORINATION; TAURINE; GLYCINE; RATS	A method for the synthesis of two (23R)- and (23S)-epimeric pairs of 23-fluoro-3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholan-24-oic acid and 23-fluoro-3 alpha,7 alpha-dihydroxy-5 beta-cholan-24-oic acid is described. The key intermediates, 23,24-dinor-22-aldehyde peracetates were prepared from cholic and chenodeoxycholic acids via the 24-nor-22-ene, 24-nor-22 xi,23-epoxy, and 23,24-dinor-22-aldehyde derivatives. The Horner-Wadsworth-Emmons reaction of the 23,24-dinor-22-aldehydes using triethyl 2-fluoro-2-phosphonoacetate in the presence of LiCl and 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU), and subsequent hydrogenation of the resulting 23 xi-fluoro-22-ene ethyl esters, followed by hydrolysis, gave a mixture of the epimeric (23R)- and (23S)-fluorinated bile acids which were resolved efficiently by preparative RP-HPLC. The stereochemical configuration of the fluorine atom at C-23 in the newly synthesized compounds was confirmed directly by the X-ray crystallographic data. The H-1 and C-13 NMR spectral differences between the (23R)- and (23S)-epimers were also discussed.	[Omura, Kaoru; Adachi, Yuuki; Kobayashi, Yuuki; Sekiguchi, Shoutaro; Zhou, Biao; Iida, Takashi] Nihon Univ, Dept Chem, Coll Humanities & Sci, Setagaya Ku, Tokyo 1568550, Japan	Iida, T (reprint author), Nihon Univ, Dept Chem, Coll Humanities & Sci, Setagaya Ku, Tokyo 1568550, Japan.	takaiida@chs.nihon-u.ac.jp			Ministry of Education, Culture, Sports, Sciences and Technology of Japan [21550091]	This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Sciences and Technology of Japan (to T.I., 21550091) for 2012-2014.	Acebedo SL, 2011, STEROIDS, V76, P1016, DOI 10.1016/j.steroids.2011.04.004; Khan SN, 2007, BIOORG MED CHEM LETT, V17, P5139, DOI 10.1016/j.bmcl.2007.07.001; Hagmann WK, 2008, J MED CHEM, V51, P4359, DOI 10.1021/jm800219f; Jin Z, 2012, ALDRICHIM ACTA, V45, P67; Halperin SD, 2014, ANGEW CHEM INT EDIT, V53, P4690, DOI 10.1002/anie.201400420; FRIED J, 1954, J AM CHEM SOC, V76, P1455, DOI 10.1021/ja01634a101; BLANCHETTE MA, 1984, TETRAHEDRON LETT, V25, P2183, DOI 10.1016/S0040-4039(01)80205-7; Filler R, 2009, FUTURE MED CHEM, V1, P777, DOI [10.4155/fmc.09.65, 10.4155/FMC.09.65]; BATTA AK, 1979, J LIPID RES, V20, P935; CARLSON GL, 1977, STEROIDS, V30, P787, DOI 10.1016/S0039-128X(77)80024-X; Clerici C, 2006, TOXICOL APPL PHARM, V214, P199, DOI 10.1016/j.taap.2005.12.017; ISHIDA H, 1991, CHEM PHARM BULL, V39, P3153; Kakiyama G, 2004, J LIPID RES, V45, P567, DOI 10.1194/jlr.D300027-JLR200; KAYAHARA T, 1994, LIPIDS, V29, P289, DOI 10.1007/BF02536334; KIHIRA K, 1982, CHEM PHARM BULL, V30, P3040; Kuramoto T, 2000, CHEM PHARM BULL, V48, P53; Marson CM, 2002, SYNTHETIC COMMUN, V32, P2125, DOI 10.1081/SCC-120005419; Murata N, 2006, CHEM PHARM BULL, V54, P1567, DOI 10.1248/cpb.54.1567; Ogawa S, 2010, CHEM PHARM BULL, V58, P1103; Omura K, 2014, LIPIDS, V49, P1169, DOI 10.1007/s11745-014-3955-y; Reyes-Moreno M, 2009, EUR J MED CHEM, V44, P4567, DOI 10.1016/j.ejmech.2009.06.025; Sharma U, 2008, MED CHEM RES, V17, P326, DOI 10.1007/s00044-007-9068-x; Thomas MG, 1999, J CHEM SOC PERK T 1, P3191, DOI 10.1039/a904826j; Xia JB, 2003, TETRAHEDRON LETT, V44, P9295, DOI 10.1016/j.tetlet.2003.10.075	24	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0024-4201	1558-9307		LIPIDS	Lipids	SEP	2015	50	9					919	926		10.1007/s11745-015-4050-8		8	Biochemistry & Molecular Biology; Nutrition & Dietetics	Biochemistry & Molecular Biology; Nutrition & Dietetics	CP6RB	WOS:000360014500010		
J	Ju, Y; Tasaka, T; Yamauchi, H; Nakagawa, T				Ju, Yang; Tasaka, Takafumi; Yamauchi, Hayato; Nakagawa, Tomoki			Synthesis of Sn nanoparticles and their size effect on the melting point	MICROSYSTEM TECHNOLOGIES-MICRO-AND NANOSYSTEMS-INFORMATION STORAGE AND PROCESSING SYSTEMS			English	Article							FREE SOLDER; PARTICLES; TEMPERATURE; TIN	Recently, the use of Sn-Pb eutectic solder has been prohibited by restriction of the use of hazardous substances (RoHS), since Pb may have a bad influence on human and the environment. Instead, Tin-Silver-Copper (Sn-Ag-Cu) system is adopted as the lead free solder. However, the melting temperature of Sn-Ag-Cu is higher than that of Sn-Pb, which may induce damages in the electronic packages. To solve this problem, Sn nanoparticles were fabricated in this study. Morphology observation and component analysis of Sn nanoparticles were carried out by field emission scanning electron microscopy (FE-SEM), transmission electron microscopy (TEM) and energy dispersive X-ray (EDX) spectroscopy, respectively. The melting temperature of Sn nanoparticles was measured by differential scanning calorimeter (DSC822e). The lowest melting temperature of the present Sn nanoparticles is 440 K, which is approximately 65 K lower than that of the bulk Sn.	[Ju, Yang; Tasaka, Takafumi; Yamauchi, Hayato; Nakagawa, Tomoki] Nagoya Univ, Dept Mech Sci & Engn, Chikusa Ku, Nagoya, Aichi 4648603, Japan	Ju, Y (reprint author), Nagoya Univ, Dept Mech Sci & Engn, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.	ju@mech.nagoya-u.ac.jp			Japan Society for the Promotion of Science [23246024]	This work was supported by the Japan Society for the Promotion of Science under a Grant-in-Aid for Scientific Research (A) 23246024.	Andersson C, 2005, MAT SCI ENG A-STRUCT, V394, P20, DOI 10.1016/j.msea.2004.10.043; Zou CD, 2010, T NONFERR METAL SOC, V20, P248, DOI 10.1016/S1003-6326(09)60130-8; Lai SL, 1996, PHYS REV LETT, V77, P99, DOI 10.1103/PhysRevLett.77.99; BUFFAT P, 1976, PHYS REV A, V13, P2287, DOI 10.1103/PhysRevA.13.2287; CARROLL MA, 1987, MATER SCI TECH SER, V3, P1040; Koppes JP, 2012, MATER SCI ENG B-ADV, V177, P197, DOI 10.1016/j.mseb.2011.12.019; WRONSKI CRM, 1967, BRIT J APPL PHYS, V18, P1731, DOI 10.1088/0508-3443/18/12/308; Wu CW, 2008, POWDER TECHNOL, V188, P166, DOI 10.1016/j.powtec.2008.04.038	8	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0946-7076	1432-1858		MICROSYST TECHNOL	Microsyst. Technol.	SEP	2015	21	9			SI		1849	1854		10.1007/s00542-014-2397-z		6	Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied	Engineering; Science & Technology - Other Topics; Materials Science; Physics	CP5TW	WOS:000359948500006		
J	Abe, S; Hane, K				Abe, Syotaro; Hane, Kazuhiro			A silicon microring resonator with a nanolatch mechanism	MICROSYSTEM TECHNOLOGIES-MICRO-AND NANOSYSTEMS-INFORMATION STORAGE AND PROCESSING SYSTEMS			English	Article							GUIDE COUPLER SWITCH; WIRE WAVE-GUIDE; PHOTONICS; COMPACT; MODULATOR; FILTERS; POWER	A microring resonator with a waveguide latch mechanism is designed and fabricated on silicon-on-insulator wafer as switchable notch filter. The waveguide is 400 nm in width and 260 nm in thickness. The latch mechanism consists of three ultrasmall electrostatic comb-drive actuators with nano hooks. One of the actuators is used for moving busline waveguide to the microring and the other two actuators are used for latching the busline waveguide. The busline waveguide is decoupled from the microring in the switch-off state, and it is coupled to the microring in the switch-on state to filter at the resonant wavelength. The position of the busline waveguide is hold by the hooks of latches without applying voltage. The gap between the busline waveguide and the microring was approximately 108 nm after latching, which corresponded to an undercoupling condition of the microring resonator. Applying another voltage to the two latch actuators, the busline waveguide was released and returned to the initial switch-off state. The proposed nanolatch mechanism is useful for reconfigurable photonic circuits using microring resonators.	[Abe, Syotaro; Hane, Kazuhiro] Tohoku Univ, Dept Nanomech, Sendai, Miyagi 9808579, Japan	Hane, K (reprint author), Tohoku Univ, Dept Nanomech, Sendai, Miyagi 9808579, Japan.	hane2@hane.mech.tohoku.ac.jp			SCOPE; JSPS; muSIC	A part of this work was supported by SCOPE, JSPS and mu SIC. The fabrication was carried out in Micro/Nano Center of Tohoku University.	Abe S, 2013, IEEE PHOTONIC TECH L, V25, P675, DOI 10.1109/LPT.2013.2248354; Ko JS, 2002, APPL PHYS LETT, V81, P547, DOI 10.1063/1.1494462; Yamada H, 2006, IEEE J SEL TOP QUANT, V12, P1371, DOI 10.1109/JSTQE.2006.880611; Kiyat I, 2006, IEEE PHOTONIC TECH L, V18, P364, DOI 10.1109/LPT.2005.861951; Jalali B, 2006, J LIGHTWAVE TECHNOL, V24, P4600, DOI 10.1109/JLT.2006.885782; Geng MM, 2009, OPT EXPRESS, V17, P5502, DOI 10.1364/OE.17.005502; Little BE, 2000, IEEE PHOTONIC TECH L, V12, P323, DOI 10.1109/68.826928; Niehusmann J, 2004, OPT LETT, V29, P2861, DOI 10.1364/OL.29.002861; Green WMJ, 2007, OPT EXPRESS, V15, P17106, DOI 10.1364/OE.15.017106; Park S, 2011, OPT EXPRESS, V19, P13531, DOI 10.1364/OE.19.013531; Akihama Y, 2011, OPT EXPRESS, V19, P23658, DOI 10.1364/OE.19.023658; Xu QF, 2005, NATURE, V435, P325, DOI 10.1038/nature03569; Watts MR, 2011, OPT EXPRESS, V19, P21989, DOI 10.1364/OE.19.021989; Takahashi K, 2008, OPT EXPRESS, V16, P14421, DOI 10.1364/OE.16.014421; Goebuchi Y, 2008, OPT EXPRESS, V16, P535, DOI 10.1364/OE.16.000535; Little BE, 2004, IEEE PHOTONIC TECH L, V16, P2263, DOI 10.1109/LPT.2004.834525; Yao J, 2007, IEEE J SEL TOP QUANT, V13, P202, DOI 10.1109/JSTQE.2007.893743; Atabaki AH, 2010, OPT EXPRESS, V18, P18312, DOI 10.1364/OE.18.018312; Bulgan E, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2892677; Chu HM, 2014, IEEE PHOTONIC TECH L, V26, P1411, DOI 10.1109/LPT.2014.2326405; Hu T, 2013, IEEE PHOTONIC TECH L, V25, P2281, DOI 10.1109/LPT.2013.2285171; Ikeda T, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4809733; Ng HY, 2007, IEEE PHOTONIC TECH L, V19, P704, DOI 10.1109/LPT.2007.895420; Vorckel A, 2003, IEEE PHOTONIC TECH L, V15, P921, DOI 10.1109/LPT.2003.813419; Wang X, 2008, IEEE PHOTONIC TECH L, V20, P936, DOI 10.1109/LPT.2008.922907	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0946-7076	1432-1858		MICROSYST TECHNOL	Microsyst. Technol.	SEP	2015	21	9			SI		2019	2024		10.1007/s00542-014-2283-8		6	Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied	Engineering; Science & Technology - Other Topics; Materials Science; Physics	CP5TW	WOS:000359948500024		
J	Ikawa, M; Karita, K				Ikawa, Motohide; Karita, Keishiro			Relation between blood flow and tissue blood oxygenation in human fingertip skin	MICROVASCULAR RESEARCH			English	Article						Human; Skin; Blood flow; Oxygenation; Laser Doppler	NEAR-INFRARED SPECTROSCOPY; RED LASER LIGHTS; VASCULAR-RESPONSES; NONINVASIVE MEASURES; SYSTEMIC-SCLEROSIS; IN-VIVO; VOLUME; FOREARM; TENDON; REPRODUCIBILITY	Background: Tissue blood flow (BF) is thought to be involved in the regulation of tissue blood oxygenation (StO(2)). The purpose of the present study was to show the relation between BF and StO(2) by measuring them simultaneously under different conditions. Methods: Twenty-one healthy subjects (age 21-30 years) participated in this study. We measured BF and StO(2) in a small area of skin (fingertip, palm, forearm) simultaneously using a laser Doppler flowmeter and a tissue oxygenation monitor. Three measurements were made at rest while performing mental arithmetic and during constriction of the ipsilateral upper arm. Results: At rest, BF and StO(2) were higher in the fingertip than in the palm or forearm (p < 0.01). Performing mental arithmetic produced significant decreases in BF, oxygenated hemoglobin, and StO(2) in the fingertip (p < 0.05). Constriction of the ipsilateral upper arm produced significant decreases in BF and StO(2) (p < 0.05) and an increase in oxygenated hemoglobin (p < 0.05). Both procedures produced significant increases in deoxygenated hemoglobin (p < 0.05), which was in antiphase to the decrease in StO(2). Conclusions: BF decrease produced a significantly decreased StO(2) in fingertip skin. The results show that simultaneous measurement of BF and StO(2) is beneficial for showing the close relation between them. (C) 2015 Elsevier Inc. All rights reserved.	[Ikawa, Motohide] Tohoku Univ, Grad Sch Dent, Dept Oral Biol, Div Periodontol & Endodontol,Aoba Ku, Sendai, Miyagi 9808575, Japan; [Karita, Keishiro] Tohoku Univ, Grad Sch Dent, Dept Oral Hlth & Dev Sci, Div Oral Diag,Aoba Ku, Sendai, Miyagi 9808575, Japan	Ikawa, M (reprint author), Tohoku Univ, Grad Sch Dent, Dept Oral Biol, Div Periodontol & Endodontol,Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	ikawa@dent.tohoku.ac.jp			JSPS KAKENHI [C21592410, C24592859]	This work was financially supported by JSPS KAKENHI (grant numbers C21592410 and C24592859).	Abramson DI, 1940, AM HEART J, V19, P541, DOI 10.1016/S0002-8703(40)90195-8; O'Brien C, 2005, J APPL PHYSIOL, V98, P1334, DOI 10.1152/japplphysiol.00859.2004; Willard AL, 2012, J OPHTHALMOL, DOI 10.1155/2012/209538; Gerhard M, 1996, HYPERTENSION, V27, P849; WALLIN BG, 1988, ANNU REV PHYSIOL, V50, P565, DOI 10.1146/annurev.ph.50.030188.003025; Ferrari M, 2004, CAN J APPL PHYSIOL, V29, P463; FRANK KH, 1989, PHYS MED BIOL, V34, P1883, DOI 10.1088/0031-9155/34/12/011; Gao W, 2014, DIABETES VASC DIS RE, V11, P270, DOI 10.1177/1479164114533356; KHAN F, 1992, CLIN SCI, V82, P521; KESSLER M, 1976, ANESTHESIOLOGY, V45, P184, DOI 10.1097/00000542-197608000-00007; CHANCE B, 1992, AM J PHYSIOL, V262, pC766; MARIN J, 1995, MECH AGEING DEV, V79, P71, DOI 10.1016/0047-6374(94)01551-V; Benaron DA, 2004, ANESTHESIOLOGY, V100, P1469, DOI 10.1097/00000542-200406000-00019; Abbink EJ, 2001, VASC MED, V6, P203, DOI 10.1177/1358836X0100600401; Brummelen P.V., 1981, CLIN SCI, V60, P571; CALLISTER R, 1992, J PHYSIOL-LONDON, V454, P373; Chen CC, 2007, CLIN PHYSIOL FUNCT I, V27, P154, DOI 10.1111/j.1475-097X.2007.00731.x; Docherty J.R., 1985, CLIN SCI, V68, P133; Freccero C, 2003, MICROVASC RES, V66, P183, DOI 10.1016/j.mvr.2003.06.001; Hamaoka T, 1996, J APPL PHYSIOL, V81, P1410; Hayashi N, 2009, PHYSIOL BEHAV, V98, P441, DOI 10.1016/j.physbeh.2009.07.008; Herrick AL, 1998, ANN RHEUM DIS, V57, P70, DOI 10.1136/ard.57.2.70; Hess A, 2000, J NEUROSCI, V20, P3328; Johansson L, 2002, EUR J APPL PHYSIOL, V86, P394, DOI 10.1007/s00421-001-0562-4; Kakihana Y, 1998, MICROVASC RES, V56, P104, DOI 10.1006/mvre.1998.2097; Kanellakos GW, 2003, ANN PLAS SURG, V50, P387, DOI 10.1097/01.SAP.0000041487.47731.D0; Kashima S, 2003, OPT LASER TECHNOL, V35, P485, DOI 10.1016/S0030-3992(03)00066-5; KASHIMA S, 1992, JPN J APPL PHYS 1, V31, P4097, DOI 10.1143/JJAP.31.4097; KROGSTAD AL, 1995, J AUTONOM NERV SYST, V53, P215, DOI 10.1016/0165-1838(94)00178-M; Kubo K, 2009, J APPL PHYSIOL, V106, P412, DOI 10.1152/japplphysiol.91381.2008; Kubo K, 2008, ACTA PHYSIOL, V193, P257, DOI 10.1111/j.1748-1716.2008.01841.x; Kubo K, 2008, EUR J APPL PHYSIOL, V104, P859, DOI 10.1007/s00421-008-0841-4; Littleford RC, 1999, CLIN SCI, V96, P507, DOI 10.1042/CS19980341; Maxim PG, 2005, TECHNOL CANCER RES T, V4, P227; Mayrovitz HN, 2002, MICROVASC RES, V63, P227, DOI 10.1006/mvre.2001.2391; MESCON H, 1956, J INVEST DERMATOL, V27, P133, DOI 10.1038/jid.1956.85; Ohkubo M., 2009, DYN MED, V8; Partovi S, 2014, J MAGN RESON IMAGING, V40, P1408, DOI 10.1002/jmri.24503; Rida M., 2013, APPL MECH ENG, V2, P5; Schmidt WD, 2001, J INVEST DERMATOL, V116, P531, DOI 10.1046/j.1523-1747.2001.01297.x; SWAIN ID, 1989, PHYS MED BIOL, V34, P151, DOI 10.1088/0031-9155/34/2/001; Tanaka T, 2008, NEUROGASTROENT MOTIL, V20, P498, DOI 10.1111/j.1365-2982.2007.01039.x; Thorn CE, 2009, AM J PHYSIOL-HEART C, V296, pH1289, DOI 10.1152/ajpheart.01192.2008; WALLIN BG, 1990, J AUTONOM NERV SYST, V30, pS185	44	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0026-2862	1095-9319		MICROVASC RES	Microvasc. Res.	SEP	2015	101						135	142		10.1016/j.mvr.2015.07.006		8	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CP6WI	WOS:000360028500019		
J	Nariyama, M; Mori, M; Shimazaki, E; Ando, H; Ohnuki, Y; Abo, T; Yamane, A; Asada, Y				Nariyama, Megumi; Mori, Manami; Shimazaki, Emi; Ando, Hitoshi; Ohnuki, Yoshiki; Abo, Tokuhisa; Yamane, Akira; Asada, Yoshinobu			Functions of miR-1 and miR-133a during the postnatal development of masseter and gastrocnemius muscles	MOLECULAR AND CELLULAR BIOCHEMISTRY			English	Article						miRNA; HDAC4; MEF2; SRF; Skeletal muscles	SKELETAL-MUSCLE; IN-VIVO; EMBRYONIC-DEVELOPMENT; TRANSCRIPTION FACTOR; ANIMAL DEVELOPMENT; EXPRESSION; MICRORNAS; MOUSE; DIFFERENTIATION; PROLIFERATION	The present study investigated the function of miR-1 and miR-133a during the postnatal development of mouse skeletal muscles. The amounts of miR-1 and miR-133a were measured in mouse masseter and gastrocnemius muscles between 1 and 12 weeks after birth with real-time polymerase chain reaction and those of HDACs, MEF2, MyoD family, MCK, SRF, and Cyclin D1 were measured at 2 and 12 weeks with Western blotting. In both the masseter and gastrocnemius muscles, the amount of miR-1 increased between 1 and 12 weeks, whereas the amount of HADC4 decreased between 2 and 12 weeks. In the masseter muscle, those of MEF2, MyoD, Myogenin, and MCK increased between 2 and 12 weeks, whereas, in the gastrocnemius muscle, only those of MRF4 and MCK increased. The extent of these changes in the masseter muscle was greater than that in the gastrocnemius muscle. The amounts of miR-133a, SRF, and Cyclin D1 did not change significantly in the masseter muscle between 1 and 12 weeks after birth. By contrast, in the gastrocnemius muscle, the amounts of miR-133a and Cyclin D1 increased, whereas that of SRF decreased. Our findings suggest that the regulatory pathway of miR-1 via HDAC4 and MEF2 plays a more prominent role during postnatal development in the masseter muscle than in the gastrocnemius muscle, whereas that of miR-133a via SRF plays a more prominent role in the gastrocnemius muscle than in the masseter muscle.	[Nariyama, Megumi; Mori, Manami; Shimazaki, Emi; Asada, Yoshinobu] Tsurumi Univ, Sch Dent Med, Dept Pediat Dent, Tsurumi Ku, Yokohama, Kanagawa 2308501, Japan; [Ando, Hitoshi; Abo, Tokuhisa; Yamane, Akira] Tsurumi Univ, Sch Dent Med, Dept Biophys, Tsurumi Ku, Yokohama, Kanagawa 2308501, Japan; [Ohnuki, Yoshiki] Tsurumi Univ, Sch Dent Med, Dept Physiol, Tsurumi Ku, Yokohama, Kanagawa 2308501, Japan	Nariyama, M (reprint author), Tsurumi Univ, Sch Dent Med, Dept Pediat Dent, Tsurumi Ku, 2-1-3 Tsurumi, Yokohama, Kanagawa 2308501, Japan.	nariyama-m@tsurumi-u.ac.jp			JSPS KAKENHI [24792313, 20592190, 25463201, 23593053]	This study was supported by JSPS KAKENHI Grant Number 24792313 (MN), 20592190, 25463201 (AY), and 23593053 (YA). We thank Dr. Jim Cahill of ON-LINE EDIT Science Communications for help in the preparation of this manuscript.	Al-Khalili L, 2004, AM J PHYSIOL-CELL PH, V286, pC1410, DOI 10.1152/ajpcell.00444.2003; Chen JF, 2009, J CELL SCI, V122, P13, DOI 10.1242/jcs.041723; Lewis A, 2012, THORAX, V67, P26, DOI 10.1136/thoraxjnl-2011-200309; Liu N, 2007, P NATL ACAD SCI USA, V104, P20844, DOI 10.1073/pnas.0710558105; Liu N, 2010, DEV CELL, V18, P510, DOI 10.1016/j.devcel.2010.03.010; Callis TE, 2007, DNA CELL BIOL, V26, P219, DOI 10.1089/dna.2006.0556; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817; Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347; Ivey KN, 2008, CELL STEM CELL, V2, P219, DOI 10.1016/j.stem.2008.01.016; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Ludolph DC, 1995, FASEB J, V9, P1595; Torella D, 2011, CIRC RES, V109, P880, DOI 10.1161/CIRCRESAHA.111.240150; Callis TE, 2008, EXP BIOL MED, V233, P131, DOI 10.3181/0709-MR-237; Latronico MVG, 2007, CIRC RES, V101, P1225, DOI 10.1161/CIRCRESAHA.107.163147; McKinsey TA, 2000, NATURE, V408, P106; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; McCarthy JJ, 2008, BBA-GENE REGUL MECH, V1779, P682, DOI 10.1016/j.bbagrm.2008.03.001; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Dodou E, 2003, MECH DEVELOP, V120, P1021, DOI 10.1016/S0925-4773(03)00178-3; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Gao S, 2014, ATHEROSCLEROSIS, V232, P171, DOI 10.1016/j.atherosclerosis.2013.11.029; Xie CQ, 2011, STEM CELLS DEV, V20, P205, DOI 10.1089/scd.2010.0283; Yamane A, 2000, J DENT RES, V79, P1933; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324; Deng ZL, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-115; Gallagher IJ, 2010, GENOME MED, V2, DOI 10.1186/gm130; Jackson RJ, 2007, SCI STKE, V367, P1, DOI 10.1126/stke.3672007re1; Mcgee SL, 2011, J APPL PHYSIOL, V110, P258, DOI 10.1152/japplphysiol.00979.2010; Nariyama M, 2012, CELL BIOCHEM FUNCT, V30, P82, DOI 10.1002/cbf.1821; Townley-Tilson WHD, 2010, INT J BIOCHEM CELL B, V42, P1252, DOI 10.1016/j.biocel.2009.03.002; Yamane A, 2000, ARCH ORAL BIOL, V45, P71, DOI 10.1016/S0003-9969(99)00105-3; Yamane A, 2005, CELL TISSUE RES, V322, P183, DOI 10.1007/s00441-005-0019-x; Yamane A, 2002, ZOOL SCI, V19, P207, DOI 10.2108/zsj.19.207; Zhang HM, 2015, COMP BIOCHEM PHYS B, V179, P1, DOI 10.1016/j.cbpb.2014.08.005	36	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-8177	1573-4919		MOL CELL BIOCHEM	Mol. Cell. Biochem.	SEP	2015	407	1-2					17	27		10.1007/s11010-015-2450-y		11	Cell Biology	Cell Biology	CP3KX	WOS:000359778900003		
J	Iwatake, M; Okamoto, K; Tanaka, T; Tsukuba, T				Iwatake, Mayumi; Okamoto, Kuniaki; Tanaka, Takashi; Tsukuba, Takayuki			Punicalagin attenuates osteoclast differentiation by impairing NFATc1 expression and blocking Akt- and JNK-dependent pathways	MOLECULAR AND CELLULAR BIOCHEMISTRY			English	Article						Osteoclasts; Punicalagin; NFATc1	NF-KAPPA-B; CYSTEINE PROTEINASE; CATHEPSIN-K; POMEGRANATE JUICE; MOLECULAR-CLONING; HEME OXYGENASE-1; BONE-RESORPTION; GRANATUM L; RANKL; ACTIVATION	Punicalagin is a bioactive polyphenol that is classified as an ellagitannin. Although punicalagin has been shown to have various pharmacological effects, such as anti-oxidative, anti-inflammatory, and anti-tumor effects, no studies have reported the effects of punicalagin on osteoclasts (OCLs). In this study, we investigated the effects of punicalagin on OCL differentiation by receptor activator of nuclear factor kappa-B ligand in the murine monocytic RAW-D cell line and bone marrow-derived macrophages (BMMs). Treatment with punicalagin significantly inhibited OCL formation from RAW-D cells and BMMs and prevented bone resorption of BMM-derived OCLs. Moreover, punicalagin impaired multinucleation and actin-ring formation in OCLs, and decreased the protein levels of nuclear factor of activated T cells cytoplasmic-1 (NFATc1), which is a master regulator of OCL differentiation, and concomitantly reduced the expression levels of Src and cathepsin K, which are transcriptionally regulated by NFATc1. The effects of punicalagin on intracellular signaling during the OCL differentiation of BMMs indicated that punicalagin-treated OCLs displayed markedly reduced phosphorylation of Jun N-terminal kinase and Akt, and partially impaired phosphorylation of extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, and inhibitor of nuclear factor kappa-B alpha compared with untreated OCLs. Thus, punicalagin may affect bone metabolism by inhibiting OCL differentiation.	[Iwatake, Mayumi; Okamoto, Kuniaki; Tsukuba, Takayuki] Nagasaki Univ, Div Dent Pharmacol, Grad Sch Biomed Sci, Nagasaki 8528588, Japan; [Tanaka, Takashi] Nagasaki Univ, Div Nat Prod Chem, Grad Sch Biomed Sci, Bunkyo Ku, Nagasaki 8528521, Japan	Tsukuba, T (reprint author), Nagasaki Univ, Div Dent Pharmacol, Grad Sch Biomed Sci, Sakamoto 1-7-1, Nagasaki 8528588, Japan.	tsuta@nagasaki-u.ac.jp			 [25293383];  [15H05298];  [30264055]	We thank Dr. Kazuhisa Nishishita for providing recombinant RANKL, and Dr. Eiko Sakai for useful comments. This study was supported in part by Grants-in-Aid for Scientific Research (B) Grant Numbers 25293383, 15H05298, and for Exploratory Research Grant Number 30264055 (T.T).	Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; Lee SI, 2008, BIOCHEM BIOPH RES CO, V371, P799, DOI 10.1016/j.bbrc.2008.04.150; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Chen BS, 2012, AM J PHYSIOL-ENDOC M, V302, pE1142, DOI 10.1152/ajpendo.00003.2012; Olajide OA, 2014, MOL NUTR FOOD RES, V58, P1843, DOI 10.1002/mnfr.201400163; Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557; Delaisse JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood-2004-09-3662; Chen PS, 2006, TOXICOL LETT, V163, P44, DOI 10.1016/j.toxlet.2005.09.026; ELFORD PR, 1987, CALCIFIED TISSUE INT, V41, P151, DOI 10.1007/BF02563795; SATOMI H, 1993, BIOL PHARM BULL, V16, P787; Cerda B, 2003, EUR J NUTR, V42, P18, DOI 10.1007/s00394-003-0396-4; Xu XL, 2014, INFLAMMATION, V37, P956, DOI 10.1007/s10753-014-9816-2; Zwerina J, 2005, FASEB J, V19, P2011, DOI 10.1096/fj.05-4278fje; Kamiya T, 1998, J BIOCHEM-TOKYO, V123, P752; Zhang YH, 2001, J BIOL CHEM, V276, P563; Watanabe T, 2004, J ENDOCRINOL, V180, P193, DOI 10.1677/joe.0.1800193; Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; HAYMAN AR, 1994, J BIOL CHEM, V269, P1294; Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; Lin CC, 1998, J PHARM PHARMACOL, V50, P789; Maus M, 2013, J LEUKOCYTE BIOL, V93, P537, DOI 10.1189/jlb.0312169; Narahara S, 2012, CELL TISSUE RES, V348, P81, DOI 10.1007/s00441-012-1325-8; TANAKA T, 1986, CHEM PHARM BULL, V34, P650	32	1	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-8177	1573-4919		MOL CELL BIOCHEM	Mol. Cell. Biochem.	SEP	2015	407	1-2					161	172		10.1007/s11010-015-2466-3		12	Cell Biology	Cell Biology	CP3KX	WOS:000359778900017		
J	Sato, M; Hirose, K; Kashiwakura, I; Aoki, M; Kawaguchi, H; Hatayama, Y; Akimoto, H; Narita, Y; Takai, Y				Sato, Mariko; Hirose, Katsumi; Kashiwakura, Ikuo; Aoki, Masahiko; Kawaguchi, Hideo; Hatayama, Yoshiomi; Akimoto, Hiroyoshi; Narita, Yuichiro; Takai, Yoshihiro			LW6, a hypoxia-inducible factor 1 inhibitor, selectively induces apoptosis in hypoxic cells through depolarization of mitochondria in A549 human lung cancer cells	MOLECULAR MEDICINE REPORTS			English	Article						hypoxia-inducible factor 1 inhibitor; hypoxia; apoptosis; A549	HIGH LACTATE LEVELS; ANTITUMOR-ACTIVITY; HIF-1 INHIBITOR; HIF-1-ALPHA; ANGIOGENESIS; METASTASIS; EXPRESSION; DEATH; OXYGENATION; ADAPTATION	Hypoxia-inducible factor 1 (HIF-1) activates the transcription of genes that act upon the adaptation of cancer cells to hypoxia. LW6, an HIF-1 inhibitor, was hypothesized to improve resistance to cancer therapy in hypoxic tumors by inhibiting the accumulation of HIF-1 alpha. A clear anti-tumor effect under low oxygen conditions would indicate that LW6 may be an improved treatment strategy for cancer in hypoxia. In the present study, the HIF-1 inhibition potential of LW6 on the growth and apoptosis of A549 lung cancer cells in association with oxygen availability was evaluated. LW6 was observed to inhibit the expression of HIF-1a induced by hypoxia in A549 cells at 20 mM, independently of the von Hippel-Lindau protein. In addition, at this concentration, LW6 induced hypoxia-selective apoptosis together with a reduction in the mitochondrial membrane potential. The intracellular reactive oxygen species levels increased in LW6-treated hypoxic A549 cells and LW6 induced a hypoxia-selective increase of mitochondrial O2(center dot-). In conclusion, LW6 inhibited the growth of hypoxic A549 cells by affecting the mitochondria. The inhibition of the mitochondrial respiratory chain is suggested as a potentially effective strategy to target apoptosis in cancer cells.	[Sato, Mariko; Hirose, Katsumi; Aoki, Masahiko; Kawaguchi, Hideo; Hatayama, Yoshiomi; Akimoto, Hiroyoshi; Narita, Yuichiro; Takai, Yoshihiro] Hirosaki Univ, Grad Sch Med, Dept Radiol & Radiat Oncol, Hirosaki, Aomori 0368562, Japan; [Kashiwakura, Ikuo] Hirosaki Univ, Grad Sch Med, Dept Radiol Life Sci, Hirosaki, Aomori 0368564, Japan	Hirose, K (reprint author), Hirosaki Univ, Grad Sch Med, Dept Radiol & Radiat Oncol, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	khirose@cc.hirosaki-u.ac.jp		Aoki, Masahiko/0000-0002-3760-919X	JSPS KAKENHI [25861056]	The present study was supported by JSPS KAKENHI, Grant-in-Aid for Young Scientists (grant B; no. 25861056).	Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Theodoropoulos VE, 2004, EUR UROL, V46, P200, DOI 10.1016/j.eururo.2004.04.008; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200; Yeo EJ, 2003, J NATL CANCER I, V95, P516; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Lee K, 2010, BIOCHEM PHARMACOL, V80, P982, DOI 10.1016/j.bcp.2010.06.018; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Welsh S, 2004, MOL CANCER THER, V3, P233; Akakura N, 2001, CANCER RES, V61, P6548; Walenta S, 2000, CANCER RES, V60, P916; Sundfor K, 1998, BRIT J CANCER, V78, P822, DOI 10.1038/bjc.1998.586; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; [Anonymous], 2012, CANC STAT JAP 2012; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Brizel DM, 1996, CANCER RES, V56, P941; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Walenta S, 1997, AM J PATHOL, V150, P409; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Lee K, 2013, ANGEW CHEM INT EDIT, V52, P10286, DOI 10.1002/anie.201304987; Zhong H, 1999, CANCER RES, V59, P5830; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; Yeo EJ, 2006, CANCER RES, V66, P6345, DOI 10.1158/0008-5472.CAN-05-4460; Zhao Q, 2007, PANCREAS, V34, P242, DOI 10.1097/01.mpa.0000250135.95144.b6; Okamoto K, 2012, INT J MOL MED, V29, P541, DOI 10.3892/ijmm.2011.875; Pitson G, 2001, INT J RADIAT ONCOL, V51, P699, DOI 10.1016/S0360-3016(01)01662-5; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000	29	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	SEP	2015	12	3					3462	3468		10.3892/mmr.2015.3862		7	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	CP5OW	WOS:000359933900033		
J	Kuroyanagi, G; Tokuda, H; Yamamoto, N; Matsushima-Nishiwaki, R; Mizutani, J; Kozawa, O; Otsuka, T				Kuroyanagi, Gen; Tokuda, Haruhiko; Yamamoto, Naohiro; Matsushima-Nishiwaki, Rie; Mizutani, Jun; Kozawa, Osamu; Otsuka, Takanobu			Resveratrol amplifies BMP-4-stimulated osteoprotegerin synthesis via p38 MAP kinase in osteoblasts	MOLECULAR MEDICINE REPORTS			English	Article						resveratrol; osteoblast; bone morphogenetic protein-4; osteoprotegerin	VEGF SYNTHESIS; CYCLIC-AMP; CROSS-TALK; S6 KINASE; CELLS; DIFFERENTIATION; OSTEOCLAST; DISEASE; SIGNALS; MICE	Resveratrol is a naturally occurring polyphenol that possesses health-related properties, and is predominantly found in grapes and berries. Bone morphogenetic protein-4 (BMP-4) stimulates osteocalcin synthesis via p38 mitogen-activated protein (MAP) kinase in osteoblast-like MC3T3-E1 cells. The present study aimed to investigate the effects of resveratrol on BMP-4-induced osteoprotegerin (OPG) synthesis in MC3T3-E1 cells. Resveratrol alone had no effect on OPG expression levels, but significantly enhanced BMP-4-induced OPG release. In addition, resveratrol markedly amplified the mRNA expression levels of BMP-4-induced OPG. SB203580 is an inhibitor of p38 MAP kinase, which was shown to suppress BMP-4-stimulated OPG release. BMP-4-induced phosphorylation of p38 MAP kinase was also enhanced by resveratrol. Furthermore, SB203580 significantly reduced the resveratrol-induced amplification of BMP-4-stimulated OPG release. These results suggested that resveratrol was able to upregulate BMP-4-stimulated OPG synthesis via the amplification of p38 MAP kinase activity in osteoblasts.	[Kuroyanagi, Gen; Yamamoto, Naohiro; Mizutani, Jun; Otsuka, Takanobu] Nagoya City Univ, Grad Sch Med Sci, Dept Orthoped Surg, Nagoya, Aichi 4678601, Japan; [Kuroyanagi, Gen; Tokuda, Haruhiko; Yamamoto, Naohiro; Matsushima-Nishiwaki, Rie; Kozawa, Osamu] Gifu Univ, Grad Sch Med, Dept Pharmacol, Gifu 5011194, Japan; [Tokuda, Haruhiko] Natl Ctr Geriatr & Gerontol, Dept Clin Lab, Obu, Aichi 4748511, Japan	Tokuda, H (reprint author), Natl Ctr Geriatr & Gerontol, Dept Clin Lab, 7-430 Morioka Cho, Obu, Aichi 4748511, Japan.	tokuda@ncgg.go.jp			Ministry of Education, Science, Sports and Culture of Japan [19591042]; Foundation for Growth Science [23-9]; Ministry of Health, Labour and Welfare of Japan [25-4]	The authors of the present study are grateful for the technical assistance of Mrs. Yumiko Kurokawa (Department of Pharmacology, Gifu University Graduate School of Medicine). The present study was supported by grants from the Ministry of Education, Science, Sports and Culture of Japan (grant no. 19591042), the Foundation for Growth Science (grant no. 23-9), and the Ministry of Health, Labour and Welfare of Japan (grant no. 25-4).	Cai J, 2012, FEBS LETT, V586, P1993, DOI 10.1016/j.febslet.2012.04.030; Hofbauer LC, 1998, BIOCHEM BIOPH RES CO, V250, P776, DOI 10.1006/bbrc.1998.9394; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Jankun J, 1997, NATURE, V387, P561, DOI 10.1038/42381; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Simpson D, 2000, MOL VIS, V6, P178; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756-3282(01)00642-1; Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031-9422(00)00235-1; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Mizuno A, 2002, J BONE MINER METAB, V20, P337, DOI 10.1007/s007740200049; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365-2362.2012.02717.x; Kato K, 1996, J NEUROCHEM, V66, P946; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; KOZAWA O, 1992, EXP CELL RES, V198, P130, DOI 10.1016/0014-4827(92)90158-5; Kozawa O, 2002, J CELL BIOCHEM, V84, P583, DOI 10.1002/jcb.10056; Kondo A, 2014, INT J MOL MED, V33, P1013, DOI 10.3892/ijmm.2014.1626; Koo SH, 2006, CELL, V127, P1091, DOI 10.1016/j.cell.2006.11.034; Krause C, 2008, PRIMER METABOLIC BON, V7th; Kwan TS, 2004, CYTOKINE GROWTH F R, V15, P49; Tokuda H, 2003, AM J PHYSIOL-ENDOC M, V284, pE1202, DOI 10.1152/ajpendo.00300.2002	27	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	SEP	2015	12	3					3849	3854		10.3892/mmr.2015.3877		6	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	CP5OW	WOS:000359933900089		
J	Ootsuka, T; Nakanishi, A; Tsukamoto, I				Ootsuka, Tomoyo; Nakanishi, Atsuko; Tsukamoto, Ikuyo			Increase in osteoclastogenesis in an obese Otsuka Long-Evans Tokushima fatty rat model	MOLECULAR MEDICINE REPORTS			English	Article						bone resorption; osteoclastogenesis; c-fms; obese rodent model; OLETF rats	RESISTANT ACID-PHOSPHATASE; BONE-MARROW; OLETF RATS; GENE-EXPRESSION; FACTOR-RECEPTOR; KAPPA-B; C-FMS; DIET; DIFFERENTIATION; CELLS	In the present study, the effects of obesity on bone metabolism were investigated using a hyperphagic and obese rat model, the Otsuka Long-Evans Tokushima fatty (OLETF) rat, which exhibits normal glycemic control at 8 weeks of age. Body weight, food intake, fat mass, markers of bone resorption, the activities of tartrate-resistant acid phosphatase (TRAP) and cathepsin K, the number of osteoclasts in the proximal tibia, and the serum C-terminal crosslinking telopeptide level were higher in OLETF rats than those in control rats (Long-Evans Tokushima Otsuka; LETO). However, no differences in markers of bone formation, alkaline phosphatase activity, the number of osteoblasts in the proximal tibia or the serum osteocalcin level were observed. mRNA and protein levels of c-fms, receptor for activation of nuclear factor-kappa B (RANK), RANK ligand (RANKL), TRAP and cathepsin K were significantly increased in OLETF rats, although those levels of macrophage colony-stimulating factor (M-CSF) and osteoprotegerin (OPG) were similar to those in LETO rats. The level of serum tumor necrosis factor alpha (TNF alpha), and that of TNFa mRNA in bone, increased in association with the activation of NF kappa B. Furthermore, a frequency analysis and a colony formation assay respectively showed that the number of osteoclast precursors and the number of colony-forming cells induced by M-CSF each increased in OLETF rats compared with the control group. These results suggested that hyperphagia-induced obesity with normal glycemic control induces the upregulation of osteoclastogenesis that is associated with an increase in the expression of c-fms, RANK and RANKL, which is induced by TNFa, via the activation of NF kappa B.	[Ootsuka, Tomoyo; Nakanishi, Atsuko; Tsukamoto, Ikuyo] Nara Womens Univ, Dept Food Sci & Nutr, Nara 6308506, Japan; [Tsukamoto, Ikuyo] Hiroshima Int Univ, Dept Clin Nutr, Kure, Hiroshima 7370112, Japan	Tsukamoto, I (reprint author), Hiroshima Int Univ, Dept Clin Nutr, 5-1-1 Hirokoshingai, Kure, Hiroshima 7370112, Japan.	itsuka@cc.nara-wu.ac.jp					Xiao Y, 2010, NUTRITION, V26, P1188, DOI 10.1016/j.nut.2009.11.021; Zhao LJ, 2008, J BONE MINER RES, V23, P17, DOI 10.1359/JBMR.070813; Fehrendt H, 2014, INT J ENDOCRINOL, DOI 10.1155/2014/318924; Hie M, 2011, BONE, V49, P1152, DOI 10.1016/j.bone.2011.08.019; KAWANO K, 1992, DIABETES, V41, P1422, DOI 10.2337/diabetes.41.11.1422; Laye MJ, 2009, J PHYSIOL-LONDON, V587, P3729, DOI 10.1113/jphysiol.2009.172601; Schroeder M, 2009, AM J PHYSIOL-REG I, V297, pR1749, DOI 10.1152/ajpregu.00461.2009; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; GIBBS J, 1973, NATURE, V245, P323, DOI 10.1038/245323a0; Hsu YH, 2006, AM J CLIN NUTR, V83, P146; ZHANG DE, 1994, MOL CELL BIOL, V14, P373; Hie M, 2009, EUR J PHARMACOL, V621, P1, DOI 10.1016/j.ejphar.2009.08.025; Cao JJ, 2009, BONE, V44, P1097, DOI 10.1016/j.bone.2009.02.017; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Baek K, 2014, J CELL PHYSIOL, V229, P640, DOI 10.1002/jcp.24487; Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200; PARFITT AM, 1987, J BONE MINER RES, V2, P595; Park SY, 2005, ARCH BIOCHEM BIOPHYS, V436, P276, DOI 10.1016/j.abb.2005.01.010; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468; Halade GV, 2010, J NUTR BIOCHEM, V21, P1162, DOI 10.1016/j.jnutbio.2009.10.002; Moran TH, 2006, DEV PSYCHOBIOL, V48, P360, DOI 10.1002/dev.20149; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Singer P, 2008, INTENS CARE MED, V34, P1580, DOI 10.1007/s00134-008-1142-4; Bajotto G, 2004, LIFE SCI, V75, P2117, DOI 10.1016/j.lfs.2004.04.016; Bergman I, 1970, Clin Chim Acta, V27, P347, DOI 10.1016/0009-8981(70)90355-4; Bi S, 2001, AM J PHYSIOL-REG I, V281, pR254; Chen JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013704; Fujita D, 2003, PROSTAG LEUKOTR ESS, V68, P351, DOI 10.1016/S0952-3278(03)00027-9; Goto A, 2003, CALCIFIED TISSUE INT, V73, P180, DOI 10.1007/s00223-002-2040-3; Hayashi S, 1997, J CELL PHYSIOL, V170, P241, DOI 10.1002/(SICI)1097-4652(199703)170:3<241::AID-JCP4>3.0.CO;2-O; Hie M, 2007, BONE, V41, P1045, DOI 10.1016/j.bone.2007.08.030; Hie M, 2010, INT J MOL MED, V26, P611, DOI 10.3892/ijmm_00000506; Ishii J, 2008, J CELL BIOCHEM, V105, P896, DOI 10.1002/jcb.21886; KAWANO K, 1994, DIABETES RES CLIN PR, V24, pS317, DOI 10.1016/0168-8227(94)90269-0; Kyung TW, 2009, J NUTR, V139, P502, DOI 10.3945/jn.108.100032; Man ZW, 2000, METABOLISM, V49, P108, DOI 10.1016/S0026-0495(00)90913-2; Omi N, 1998, J NUTR SCI VITAMINOL, V44, P409; Patsch JM, 2011, METABOLISM, V60, P243, DOI 10.1016/j.metabol.2009.11.023; Sato T, 2001, J BONE MINER RES, V16, P2215, DOI 10.1359/jbmr.2001.16.12.2215	42	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	SEP	2015	12	3					3874	3880		10.3892/mmr.2015.3811		7	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	CP5OW	WOS:000359933900093		
J	Tanaka, M; Kijima, H; Shimada, H; Makuuchi, H; Ozawa, S; Inokuchi, S				Tanaka, Makiko; Kijima, Hiroshi; Shimada, Hideo; Makuuchi, Hiroyasu; Ozawa, Soji; Inokuchi, Sadaki			Expression of podoplanin and vimentin is correlated with prognosis in esophageal squamous cell carcinoma	MOLECULAR MEDICINE REPORTS			English	Article						podoplanin; vimentin; prognosis; esophagus; squamous cell carcinoma	EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR INVASION; CANCER-CELLS; E-CADHERIN; PROGRESSION	Podoplanin is a small membrane mucin, which is involved in cell migration and cancer cell invasion. However, the roles of podoplanin in esophageal squamous cell carcinoma (ESCC) are poorly understood. In the present study, 139 cases of surgically resected ESCC were analyzed and the clinicopathological significance of podoplanin membrane expression in ESCC was demonstrated. Podoplanin expression kvas positive in 66.2% (92/139) of ESCC samples; with weak expression in 32.4% (45/139), and strong expression in 33.8% (47/139). Membrane expression of podoplanin was significantly associated with tumor status (P=0.001), venous invasion (P=0.035) and Union for International Cancer Control stage (P=0.029). Patients who exhibited strong podoplanin expression, were shown to have a poorer prognosis [hazard ratio (HR), 3.949; 95% confidence interval (CI), 2.001-7.7941 Expression of vimentin, a mesenchymal marker, was detected in 49 cases (35.3%) and was associated with venous invasion (P=0.020). Vimentin-positive cases were also more likely to have a worse prognosis than vimentin-negative cases (HR, 2.161; 95% CI, 1.300-3.592). Podoplanin membrane expression was significantly correlated with vimentin cytoplasmic expression in ESCC (P<0.001). The present study confirmed that podoplanin and vimentin are independent predictors of mortality (HR, 3.084; 95% Cl, 1.543-6.164). These results suggest that podoplanin membrane expression results in epithelial-mesenchymal transition and promotes aggressive invasion in human ESCC.	[Tanaka, Makiko; Inokuchi, Sadaki] Tokai Univ, Sch Med, Dept Crit Care & Emergency Med, Isehara, Kanagawa 2591193, Japan; [Kijima, Hiroshi] Hirosaki Univ, Dept Pathol & Biosci, Grad Sch Med, Hirosaki, Aomori 0368562, Japan; [Shimada, Hideo; Makuuchi, Hiroyasu; Ozawa, Soji] Tokai Univ, Dept Gastroenterol Surg, Sch Med, Isehara, Kanagawa 2591193, Japan	Inokuchi, S (reprint author), Tokai Univ, Sch Med, Dept Crit Care & Emergency Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	inokuchi@is.icc.u-tokai.ac.jp					Wicki A, 2007, BRIT J CANCER, V96, P1, DOI 10.1038/sj.bjc.6603518; Yoneda M, 2013, ANTICANCER RES, V33, P2699; Shimada Y, 2009, CANCER SCI, V100, P2054, DOI 10.1111/j.1349-7006.2009.01295.x; Imamura M, 2001, J AM COLL SURGEONS, V192, P708; Kaneko MK, 2006, GENE, V378, P52, DOI 10.1016/j.gene.2006.04.023; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Jin H, 2010, BIOMED RES-TOKYO, V31, P105; Chino O, 2001, INT J MOL MED, V8, P359; Yuan P, 2006, CANCER, V107, P563, DOI 10.1002/cncr.22061; Tong L, 2012, DIS ESOPHAGUS, V25, P72, DOI 10.1111/j.1442-2050.2011.01211.x; Martin-Villar E, 2006, J CELL SCI, V119, P4541, DOI 10.1242/jcs.03218; Usami Y, 2008, J PATHOL, V215, P330, DOI 10.1002/path.2365; Dauphin M, 2013, LUNG CANCER, V81, P117, DOI 10.1016/j.lungcan.2013.03.011; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Myong NH, 2012, KOREAN J PATHOL, V46, P341, DOI 10.4132/KoreanJPathol.2012.46.4.341; Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010; Rahadiani N, 2010, ANN SURG ONCOL, V17, P1311, DOI 10.1245/s10434-009-0895-5; Ito E, 2012, J GASTROENTEROL, V47, P1279, DOI 10.1007/s00535-012-0587-y; Japanese Gastric Cancer Association, 1998, GASTRIC CANCER, V1, P10, DOI DOI 10.1007/S101209800016]; Le Bras GF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027063; Makuuchi H, 1997, Diagn Ther Endosc, V3, P211, DOI 10.1155/DTE.3.211; Oshiba G, 1999, ANTICANCER RES, V19, P4375; Shimada H, 2011, ESOPHAGUS-TOKYO, V8, P67, DOI 10.1007/s10388-011-0254-z; Sobin LH, 2009, TNM CLASSIFICATION M; Sudo T, 2013, ANN SURG ONCOL, V20, pS324, DOI 10.1245/s10434-012-2418-z; Suzuki H, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-287; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822	29	1	1	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	SEP	2015	12	3					4029	4036		10.3892/mmr.2015.3966		8	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	CP5OW	WOS:000359933900115		
J	Fukuyama, Y; Yuki, Y; Katakai, Y; Harada, N; Takahashi, H; Takeda, S; Mejima, M; Joo, S; Kurokawa, S; Sawada, S; Shibata, H; Park, EJ; Fujihashi, K; Briles, DE; Yasutomi, Y; Tsukada, H; Akiyoshi, K; Kiyono, H				Fukuyama, Y.; Yuki, Y.; Katakai, Y.; Harada, N.; Takahashi, H.; Takeda, S.; Mejima, M.; Joo, S.; Kurokawa, S.; Sawada, S.; Shibata, H.; Park, E. J.; Fujihashi, K.; Briles, D. E.; Yasutomi, Y.; Tsukada, H.; Akiyoshi, K.; Kiyono, H.			Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques	MUCOSAL IMMUNOLOGY			English	Article							CD4(+) T-CELLS; CONJUGATE VACCINE; NASOPHARYNGEAL COLONIZATION; MIR-17-SIMILAR-TO-92 FAMILY; INTRANASAL IMMUNIZATION; PROTECTIVE IMMUNITY; DELIVERY SYSTEM; CUTTING EDGE; DIFFERENTIATION; PSPA	We previously established a nanosized nasal vaccine delivery system by using a cationic cholesteryl group-bearing pullulan nanogel (cCHP nanogel), which is a universal protein-based antigen-delivery vehicle for adjuvant-free nasal vaccination. In the present study, we examined the central nervous system safety and efficacy of nasal vaccination with our developed cCHP nanogel containing pneumococcal surface protein A (PspA-nanogel) against pneumococcal infection in nonhuman primates. When [F-18-labeled PspA-nanogel was nasally administered to a rhesus macaque (Macaca mulatta), longer-term retention of PspA was noted in the nasal cavity when compared with administration of PspA alone. Of importance, no deposition of [F-18-PspA was seen in the olfactory bulbs or brain. Nasal PspA-nanogel vaccination effectively induced PspA-specific serum IgG with protective activity and mucosa] secretory IgA (SIgA) Ab responses in cynomolgus macaques (Macaca fascicularis). Nasal PspA-nanogel-induced immune responses were mediated through T-helper (Th) 2 and Th17 cytokine responses concomitantly with marked increases in the levels of miR181a and miR-326 in the serum and respiratory tract tissues, respectively, of the macaques. These results demonstrate that nasal PspA-nanogel vaccination is a safe and effective strategy for the development of a nasal vaccine for the prevention of pneumonia in humans.	[Fukuyama, Y.; Yuki, Y.; Mejima, M.; Joo, S.; Kurokawa, S.; Park, E. J.; Kiyono, H.] Univ Tokyo, Inst Med Sci, Div Mucosal Immunol, Minato Ku, Tokyo, Japan; [Yuki, Y.; Kiyono, H.] Univ Tokyo, Inst Med Sci, Int Res & Dev Ctr Mucosal Vaccine, Minato Ku, Tokyo, Japan; [Katakai, Y.] Corp Prod & Res Lab Primates, Tsukuba, Ibaraki, Japan; [Harada, N.; Tsukada, H.] Hamamatsu Photon KK, Cent Res Lab, PET Ctr, Hamamatsu, Shizuoka, Japan; [Takahashi, H.; Takeda, S.; Sawada, S.; Akiyoshi, K.] Kyoto Univ, Dept Polymer Chem, Grad Sch Engn, Nishikyo Ku, Kyoto, Japan; [Shibata, H.; Yasutomi, Y.] Natl Inst Biomed Innovat, Tsukuba Primate Res Ctr, Tsukuba, Ibaraki, Japan; [Fujihashi, K.] Univ Alabama Birmingham, Dept Pediat Dent, Immunobiol Vaccine Ctr, Birmingham, AL USA; [Fujihashi, K.] Univ Alabama Birmingham, Dept Microbiol, Immunobiol Vaccine Ctr, Birmingham, AL 35294 USA; [Briles, D. E.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	Yuki, Y (reprint author), Univ Tokyo, Inst Med Sci, Div Mucosal Immunol, Minato Ku, Tokyo, Japan.	yukiy@ims.u-tokyo.ac.jp; kiyono@ims.u-tokyo.ac.jp			Ministry of Health, Labour, and Welfare of Japan; Global Center of Excellence Program "Center of Education and Research for the Advanced Genome Based Medicine For personalized medicine, the control of worldwide infectious diseases "MEXT" Japan; Ministry of Education, Culture, Sports, Science, and Technology of Japan [23229004]; Core Research for Evolutional Science and Technology Program of the Japan Science and Technology Agency	This work was supported by the Ministry of Health, Labour, and Welfare of Japan (Y. Y.), Global Center of Excellence Program "Center of Education and Research for the Advanced Genome Based Medicine For personalized medicine, the control of worldwide infectious diseases "MEXT" Japan (Y.F. and H.K.), the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Grant-in-Aid for Scientific Research S [23229004], H.K.), and the Core Research for Evolutional Science and Technology Program of the Japan Science and Technology Agency (H.K.). We are grateful to Drs. Natsumi Takeyama, Koji Kashima, and Tatsuhiko Azegami and Mr. Yuji Suzuki for their useful discussions and technical support.	Fukuyama Y, 2011, J IMMUNOL, V186, P2454, DOI 10.4049/jimmunol.1002837; van Ginkel FW, 2000, J IMMUNOL, V165, P4778; Muljo SA, 2005, J EXP MED, V202, P261, DOI 10.1084/jem.20050678; Dagan R, 2013, CLIN INFECT DIS, V57, P952, DOI 10.1093/cid/cit428; Kang SG, 2013, NAT IMMUNOL, V14, P849, DOI 10.1038/ni.2648; Cobb BS, 2005, J EXP MED, V201, P1367, DOI 10.1084/jem.20050572; Ferreira DM, 2009, CLIN VACCINE IMMUNOL, V16, P636, DOI 10.1128/CVI.00395-08; Ayame H, 2008, BIOCONJUGATE CHEM, V19, P882, DOI 10.1021/bc700422s; Du CS, 2009, NAT IMMUNOL, V10, P1252, DOI 10.1038/ni.1798; Nguyen CT, 2011, VACCINE, V29, P5731, DOI 10.1016/j.vaccine.2011.05.095; Jackson LA, 2008, CLIN INFECT DIS, V47, P1328, DOI 10.1086/592691; Koralov SB, 2008, CELL, V132, P860, DOI 10.1016/j.cell.2008.02.020; Trzcinski K, 2008, INFECT IMMUN, V76, P2678, DOI 10.1128/IAI.00141-08; Hirota K, 2013, NAT IMMUNOL, V14, P372, DOI 10.1038/ni.2552; MCDANIEL LS, 1987, J EXP MED, V165, P381, DOI 10.1084/jem.165.2.381; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; Baumjohann D, 2013, NAT REV IMMUNOL, V13, P666, DOI 10.1038/nri3494; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Tan LP, 2009, LAB INVEST, V89, P708, DOI 10.1038/labinvest.2009.26; Li QJ, 2007, CELL, V129, P147, DOI 10.1016/j.cell.2007.03.008; Yuki Y, 2009, EXPERT REV VACCINES, V8, P1083, DOI [10.1586/erv.09.61, 10.1586/ERV.09.61]; Malley R, 2005, P NATL ACAD SCI USA, V102, P4848, DOI 10.1073/pnas.0501254102; Yuki Y, 2010, J IMMUNOL, V185, P5436, DOI 10.4049/jimmunol.1001789; Dagan R, 2002, J INFECT DIS, V185, P927, DOI 10.1086/339525; Nochi T, 2010, NAT MATER, V9, P572, DOI [10.1038/nmat2784, 10.1038/NMAT2784]; BERRY AM, 1989, INFECT IMMUN, V57, P2037; Kitano S, 2006, CLIN CANCER RES, V12, P7397, DOI 10.1158/1078-0432.CCR-06-1546; Briles DE, 2000, INFECT IMMUN, V68, P796, DOI 10.1128/IAI.68.2.796-800.2000; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Zhu S, 2013, J MOL MED, V91, P1039, DOI 10.1007/s00109-013-1043-z; Jaffar Z, 2009, J IMMUNOL, V182, P4507, DOI 10.4049/jimmunol.0900237; Janoff EN, 1999, J CLIN INVEST, V104, P1139, DOI 10.1172/JCI6310; McCool TL, 2002, J EXP MED, V195, P359, DOI 10.1084/jem.20011576; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; Baltimore D, 2008, NAT IMMUNOL, V9, P839, DOI 10.1038/ni.f.209; Chang KH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-173; Croney CM, 2012, CLIN VACCINE IMMUNOL, V19, P891, DOI 10.1128/CVI.05671-11; Fukuyama Y, 2010, J IMMUNOL, V185, P1755, DOI 10.4049/jimmunol.1000831; Fukuyama Y, 2012, EXPERT REV VACCINES, V11, P367; Illum L, 2004, J PHARM PHARMACOL, V56, P3, DOI 10.1211/0022357022764; Kong IG, 2013, INFECT IMMUN, V81, P1625, DOI 10.1128/IAI.00240-13; Kono M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027102; Lu YJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000159; Mizuno H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018388; Nuorti J. Pekka, 2010, Morbidity and Mortality Weekly Report, V59, P1; Oosterhuis-Kafeja F, 2007, VACCINE, V25, P2194, DOI 10.1016/j.vaccine.2006.11.032; Twigg Homer L 3rd, 2005, Proc Am Thorac Soc, V2, P417, DOI 10.1513/pats.200508-089JS; Wright AKA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003274; Yuki Y, 2013, BIOTECHNOL GENET ENG, V29, P61, DOI 10.1080/02648725.2013.801226	50	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1933-0219	1935-3456		MUCOSAL IMMUNOL	Mucosal Immunol.	SEP	2015	8	5					1144	1153				10	Immunology	Immunology	CP5WB	WOS:000359954600018		
J	Wu, XM; Kashino, K				Wu, Xiaomeng; Kashino, Kunio			Interest point selection by topology coherence for multi-query image retrieval	MULTIMEDIA TOOLS AND APPLICATIONS			English	Article						Interest point selection; Spatial topology; Delaunay triangulation; Multi-query image retrieval	SCALE; FEATURES; SEARCH	Although the bag-of-visual-words (BOVW) model in computer vision has been demonstrated successfully for the retrieval of particular objects, it suffers from limited accuracy when images of the same object are very different in terms of viewpoint or scale. Naively leveraging multiple views of the same object to query the database naturally alleviates this problem to some extent. However, the bottleneck appears to be the presence of background clutter, which causes significant confusion with images of different objects. To address this issue, we explore the structural organization of interest points within multiple query images and select those that derive from the tentative region of interest (ROI) to significantly reduce the negative contributions of confusing images. Specifically, we propose the use of a multi-layered undirected graph model built on sets of Hessian affine interest points to model the images' elastic spatial topology. We detect repeating patterns that preserve a coherent local topology, show how these redundancies are leveraged to estimate tentative ROIs, and demonstrate how this novel interest point selection approach improves the quality of visual matching. The approach is discriminative in distinguishing clutter from interest points, and at the same time, is highly robust as regards variation in viewpoint and scale as well as errors in interest point detection and description. Large-scale datasets are used for extensive experimentation and discussion.	[Wu, Xiaomeng; Kashino, Kunio] NTT Commun Sci Labs, Atsugi, Kanagawa 2430198, Japan	Wu, XM (reprint author), NTT Commun Sci Labs, 3-1 Morinosato Wakamiya, Atsugi, Kanagawa 2430198, Japan.	wu.xiaomeng@lab.ntt.co.jp; kashino.kunio@lab.ntt.co.jp					Jegou H, 2010, INT J COMPUT VISION, V87, P316, DOI 10.1007/s11263-009-0285-2; Zhang YM, 2011, PROC CVPR IEEE, P809; Arandjelovic R, 2012, PROC CVPR IEEE, P2911, DOI 10.1109/CVPR.2012.6248018; Wang XY, 2011, 2011 IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION (ICCV), P209; Wang ZH, 2011, 2011 IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION (ICCV), P603; Poullot S, 2010, MULTIMED TOOLS APPL, V47, P279, DOI 10.1007/s11042-009-0323-7; Torresani L, 2010, LECT NOTES COMPUT SC, V6311, P776, DOI 10.1007/978-3-642-15549-9_56; Mikolajczyk K, 2004, INT J COMPUT VISION, V60, P63, DOI 10.1023/B:VISI.0000027790.02288.f2; Wu Z, 2009, PROC CVPR IEEE, P25; Bay H, 2008, COMPUT VIS IMAGE UND, V110, P346, DOI 10.1016/j.cviu.2007.09.014; Cox IJ, 2000, IEEE T IMAGE PROCESS, V9, P20, DOI 10.1109/83.817596; Yang Y, 2011, 2011 IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION (ICCV), P1465; Chum O, 2011, PROC CVPR IEEE, P889, DOI 10.1109/CVPR.2011.5995601; Jegou H, 2008, LECT NOTES COMPUT SC, V5302, P304, DOI 10.1007/978-3-540-88682-2_24; Lowe DG, 2004, INT J COMPUT VISION, V60, P91, DOI 10.1023/B:VISI.0000029664.99615.94; Arandjelovic R., 2012, BRIT MACH VIS C, P1; Berg M., 2008, COMPUTATIONAL GEOMET; Gammeter S, 2009, IEEE I CONF COMP VIS, P614, DOI 10.1109/ICCV.2009.5459180; Heller KA, 2006, CVPR, V2, P2110; Kalantidis Y, 2011, ICMR, P20; Knopp J, 2010, LECT NOTES COMPUT SC, V6311, P748, DOI 10.1007/978-3-642-15549-9_54; Li FY, 2006, IEEE INT CONF ROBOT, P3405; Liu Z, 2012, ACM MULTIMEDIA, P199; Matas J, 2002, BIOMETHANIZATION ORG, P1; Over P, 2012, P TRECVID 2012 NIST; Philbin J., 2007, CVPR, P1; Philbin J., 2008, CVPR; Romberg S., 2013, IJMIR, V2, P243; Romberg S, 2011, ICMR, P25; Schindler G., 2007, CVPR; Shewchuk J. R., 1996, LECT NOTES COMPUTER, V1148, P203, DOI DOI 10.1007/BFB0014497; Sivic J., 2003, P 9 IEEE C COMP VIS, V2, P1470, DOI DOI 10.1109/ICCV.2003.1238663; Wang SY, 2012, NEUROCOMPUTING, V95, P117, DOI 10.1016/j.neucom.2011.05.043; Welzl E, 1997, COMP GEOM-THEOR APPL, V7, P361; Zhang W, 2012, ACM MULTIMEDIA, P609; Zhu CZ, 2012, ICMR, P52	36	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1380-7501	1573-7721		MULTIMED TOOLS APPL	Multimed. Tools Appl.	SEP	2015	74	17					7147	7180		10.1007/s11042-014-1957-7		34	Computer Science, Information Systems; Computer Science, Software Engineering; Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	CP7MI	WOS:000360071800026		
J	Yoshida, T; Sueyoshi, T; Suwazono, S; Suehara, M				Yoshida, Takeshi; Sueyoshi, Takeshi; Suwazono, Shugo; Suehara, Masahito			Three-tesla magnetic resonance neurography of the brachial plexus in cervical radiculopathy	MUSCLE & NERVE			English	Article						brachial plexopathy; cervical disk herniation; cervical radiculopathy; magnetic resonance neurography; neuralgic amyotrophy	DISC HERNIATION; MR NEUROGRAPHY	Introduction: There have been no reports of the use of 3-Tesla magnetic resonance neurography (3T MRN) to characterize cervical radiculopathy. In particular, there are no reports of MRN of brachial plexus involvement in patients with cervical radiculopathy. Methods: We reviewed retrospectively 12 consecutive patients with cervical radiculopathy who underwent 3T MRN. Results: The median age was 54.5 years. Eleven of 12 patients were men. The distribution of nerve-root signal abnormality was correlated with intervertebral foraminal stenosis and the presence of muscles that exhibited weakness and/or signs of denervation on electromyography. MRN abnormalities were found to extend into the distal part of the brachial plexus in 10 patients. Conclusion: This study demonstrates that MRN is potentially useful for diagnosis in patients with suspected cervical radiculopathy. Moreover, the finding of brachial plexus involvement on MRN may indicate a possible pathophysiological relationship between cervical radiculopathy and brachial plexopathy. Muscle Nerve 52:392-396, 2015	[Yoshida, Takeshi; Suwazono, Shugo; Suehara, Masahito] Okinawa Natl Hosp, Natl Hosp Org, Dept Neurol, Ginowan City, Okinawa, Japan; [Sueyoshi, Takeshi] Minei Daiichi Hosp, Dept Radiol, Urasoe City, Okinawa, Japan	Yoshida, T (reprint author), Okinawa Natl Hosp, Natl Hosp Org, Dept Neurol, Ganeko 3-20-14, Ginowan City, Okinawa, Japan.	yoshida_okinawahosp@yahoo.co.jp					Subhawong TK, 2012, SKELETAL RADIOL, V41, P15, DOI 10.1007/s00256-011-1143-1; Filler AG, 2004, NEUROL CLIN, V22, P643, DOI 10.1016/j.ncl.2004.03.005; OLMARKER K, 1993, SPINE, V18, P1425; Battie MC, 2012, SPINE J, V12, P932, DOI 10.1016/j.spinee.2012.08.020; Hakimi K, 2013, PHYS MED REH CLIN N, V24, P1, DOI 10.1016/j.pmr.2012.08.012; Benzel EC, 2012, CERVICAL SPINE; Carette S, 2005, NEW ENGL J MED, V353, P392, DOI 10.1056/NEJMcp043887; Caridi John M, 2011, HSS J, V7, P265; Chhabra A, 2013, AM J NEURORADIOL, V34, P486, DOI 10.3174/ajnr.A3287; Feinberg Joseph H, 2007, HSS J, V3, P106, DOI 10.1007/s11420-006-9028-x; Finsterer J., 2013, British Journal of Medicine and Medical Research, V3, P928; Goupille P, 2007, ARTHRITIS RHEUM, V56, P3887, DOI 10.1002/art.23051; Morgan G, 1998, NEUROLOGY, V50, P78; VANDEKELFT E, 1994, J NEUROL NEUROSUR PS, V57, P724, DOI 10.1136/jnnp.57.6.724; vansAlfen N, 2006, BRAIN, V129, P438; Wolff Michael W, 2002, Phys Med Rehabil Clin N Am, V13, P589, DOI 10.1016/S1047-9651(02)00008-6	16	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0148-639X	1097-4598		MUSCLE NERVE	Muscle Nerve	SEP	2015	52	3					392	396		10.1002/mus.24560		5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CP1XT	WOS:000359671800011		
J	Watanabe, K; Kouzaki, M; Moritani, T				Watanabe, Kohei; Kouzaki, Motoki; Moritani, Toshio			Heterogeneous neuromuscular activation within human rectus femoris muscle during pedaling	MUSCLE & NERVE			English	Article						bi-articular muscles; cycling; high-density surface electromyography; multichannel surface electromyography; neuromuscular compartment; quadriceps femoris muscle	MEDIAL GASTROCNEMIUS-MUSCLE; MYOELECTRIC MANIFESTATIONS; ELECTRICAL-STIMULATION; JOINT ANGLE; COORDINATION; FORCE; EMG; FATIGUE; PATTERN; GAIT	Introduction: We investigated the effect of workload and the use of pedal straps on the spatial distribution of neuromuscular activation within the rectus femoris (RF) muscle during pedaling movements. Methods: Eleven healthy men performed submaximal pedaling exercises on an electrically braked ergometer at different workloads and with or without pedal straps. During these tasks, surface electromyograms (SEMGs) were recorded from the RF using 36 electrode pairs, and central locus activation (CLA) was calculated along the longitudinal line of the muscle. Results: CLA moved markedly, indicating changes in spatial distribution of SEMG within the muscle, during a crank cycle under all conditions (P<0.05). There were significant differences in CLA among different workloads and between those with and without pedal straps (P<0.05). Conclusion: These results suggest that neuromuscular activation within the RF is regulated regionally by changes in workload and the use of pedal straps during pedaling. Muscle Nerve 52:404-411, 2015	[Watanabe, Kohei] Chukyo Univ, Sch Int Liberal Studies, Lab Neuromuscular Biomech, Showa Ku, Nagoya, Aichi 4668666, Japan; [Kouzaki, Motoki] Kyoto Univ, Grad Sch Human & Environm Studies, Neurophysiol Lab, Kyoto, Japan; [Moritani, Toshio] Kyoto Univ, Grad Sch Human & Environm Studies, Appl Physiol Lab, Kyoto, Japan	Watanabe, K (reprint author), Chukyo Univ, Sch Int Liberal Studies, Lab Neuromuscular Biomech, Showa Ku, Yagotohonmachi, Nagoya, Aichi 4668666, Japan.	wkohei@lets.chukyo-u.ac.jp			JSPS KAKENHI [24800071]	This research was supported in part by JSPS KAKENHI, a Grant-Aid for Research Activity Start-Up (No. 24800071).	Akima H, 2000, NEUROSCI LETT, V296, P133, DOI 10.1016/S0304-3940(00)01644-X; HENNEMAN E, 1965, J NEUROPHYSIOL, V28, P560; PRATT CA, 1991, EXP BRAIN RES, V85, P243, DOI 10.1007/BF00229404; Watanabe K, 2012, J ELECTROMYOGR KINES, V22, P251, DOI 10.1016/j.jelekin.2011.11.004; Doucet Barbara M., 2012, Yale Journal of Biology and Medicine, V85, P201; Balius R, 2009, BRIT J SPORT MED, V43, P818, DOI 10.1136/bjsm.2008.052332; Hug F, 2009, J ELECTROMYOGR KINES, V19, P182, DOI 10.1016/j.jelekin.2007.10.010; Gallina A, 2011, J ELECTROMYOGR KINES, V21, P929, DOI 10.1016/j.jelekin.2011.08.006; Watanabe K, 2009, EUR J APPL PHYSIOL, V106, P815, DOI 10.1007/s00421-009-1086-6; Vieira TMM, 2011, J PHYSIOL-LONDON, V589, P431, DOI 10.1113/jphysiol.2010.201806; Farina D, 2006, EXERC SPORT SCI REV, V34, P121, DOI 10.1249/00003677-200607000-00006; SCHENAU GJV, 1992, NEUROSCIENCE, V46, P197; Blemker SS, 2006, J BIOMECH, V39, P1383, DOI 10.1016/j.jbiomech.2005.04.012; Sheffler LR, 2007, MUSCLE NERVE, V35, P562, DOI 10.1002/mus.20758; Gyftopoulos S, 2008, AM J ROENTGENOL, V190, pW182, DOI 10.2214/AJR.07.2947; Akima H, 2004, EUR J APPL PHYSIOL, V91, P7, DOI 10.1007/s00421-003-0942-z; Li L, 1998, J APPL PHYSIOL, V85, P927; Farina D, 2001, IEEE ENG MED BIOL, V20, P62, DOI 10.1109/51.982277; Farina D, 2004, J APPL PHYSIOL, V96, P1486, DOI 10.1152/japplphysiol.01070.2003; ADAMS GR, 1992, J APPL PHYSIOL, V73, P1578; Neptune RR, 1998, J BIOMECH ENG-T ASME, V120, P334, DOI 10.1115/1.2797999; Staudenmann D, 2009, J ELECTROMYOGR KINES, V19, P882, DOI 10.1016/j.jelekin.2008.04.013; Dorel S, 2008, J ELECTROMYOGR KINES, V18, P857, DOI 10.1016/j.jelekin.2007.03.002; Belda-Lois JM, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-66; Ericson M, 1986, Scand J Rehabil Med Suppl, V16, P1; Farina D, 2004, ELECTROMYOGRAPHY PHY, P81, DOI 10.1002/0471678384.ch4; GREGOR RJ, 1985, J BIOMECH, V18, P307, DOI 10.1016/0021-9290(85)90286-6; Gregor R J, 1991, Exerc Sport Sci Rev, V19, P127; Hagio S, 2012, J BIOMECH, V45, P179, DOI 10.1016/j.jbiomech.2011.10.012; HASSELMAN CT, 1995, AM J SPORT MED, V23, P493, DOI 10.1177/036354659502300421; Hof AL, 2001, J BIOMECH, V34, P1085, DOI 10.1016/S0021-9290(01)00056-2; Holtermann A, 2008, ACTA PHYSIOL, V192, P559, DOI 10.1111/j.1748-1716.2007.01775.x; JORGE M, 1986, J BIOMECH, V19, P683, DOI 10.1016/0021-9290(86)90192-2; Merletti R, 2001, Exerc Sport Sci Rev, V29, P20, DOI 10.1097/00003677-200101000-00005; Neptune RR, 1997, J BIOMECH, V30, P1051, DOI 10.1016/S0021-9290(97)00071-7; Prilutsky BI, 2000, IEEE T REHABIL ENG, V8, P362, DOI 10.1109/86.867878; Raasch CC, 1997, J BIOMECH, V30, P595, DOI 10.1016/S0021-9290(96)00188-1; RYAN MM, 1992, J ELECTROMYOGR KINES, V2, P69, DOI 10.1016/1050-6411(92)90018-E; Saitou K, 2000, J Hum Ergol (Tokyo), V29, P35; Segal RL, 2005, ARCH PHYS MED REHAB, V86, P2013, DOI 10.1016/j.apmr.2005.04.012; Sung DH, 2003, ARCH PHYS MED REHAB, V84, P1028, DOI 10.1016/S0003-9993(03)00029-7; Watanabe K, 2014, MUSCLE NERVE, V50, P794, DOI 10.1002/mus.24232; Watanabe K, 2014, J BIOMECH, V47, P3502, DOI 10.1016/j.jbiomech.2014.09.001; Watanabe K, 2013, MUSCLE NERVE, V48, P226, DOI 10.1002/mus.23739; Yang DP, 1999, PLAST RECONSTR SURG, V104, P102, DOI 10.1097/00006534-199907000-00014	45	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0148-639X	1097-4598		MUSCLE NERVE	Muscle Nerve	SEP	2015	52	3					404	411		10.1002/mus.24544		8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CP1XT	WOS:000359671800013		
J	Honda, Y; Sakamoto, J; Nakano, J; Kataoka, H; Sasabe, R; Goto, K; Tanaka, M; Origuchi, T; Yoshimura, T; Okita, M				Honda, Yuichiro; Sakamoto, Junya; Nakano, Jiro; Kataoka, Hideki; Sasabe, Ryo; Goto, Kyo; Tanaka, Miho; Origuchi, Tomoki; Yoshimura, Toshiro; Okita, Minoru			Upregulation of interleukin-1/transforming growth factor-1 and hypoxia relate to molecular mechanisms underlying immobilization-induced muscle contracture	MUSCLE & NERVE			English	Article						fibrosis; hypoxia; IL-1; muscle contracture; TGF-1	COLLAGEN FIBRIL ARRANGEMENT; RAT SOLEUS MUSCLE; FACTOR-BETA; CONNECTIVE-TISSUE; LIVER FIBROSIS; JOINT MOBILITY; TGF-BETA; EXPRESSION; FIBROBLASTS; DISEASE	Introduction: In this study we investigated the molecular mechanism underlying muscle contracture in rats. Methods: The rats were divided into immobilization and control groups, and soleus muscles of the right and left sides were selected for analyses. Results: The levels of CD11b and -SMA protein, IL-1, and TGF-1 mRNA, and type I and III collagen protein and mRNA were significantly greater in the immobilization group than in the control group at all time-points. HIF-1 mRNA levels were significantly higher in the immobilization group at 4 weeks. Moreover, HIF-1, -SMA, and type I collagen levels were significantly higher at 4 weeks than at 1 and 2 weeks in the immobilization group. Conclusions: In the early stages of immobilization, upregulation of IL-1/TGF-1 via macrophages may promote fibroblast differentiation that could affect muscle contracture. The soleus muscle became hypoxic in the later stages of immobilization, suggesting that hypoxia influences the progression of muscle contracture. Muscle Nerve 52:419-427, 2015	[Honda, Yuichiro; Kataoka, Hideki; Sasabe, Ryo; Goto, Kyo; Origuchi, Tomoki; Yoshimura, Toshiro; Okita, Minoru] Nagasaki Univ, Grad Sch Biomed Sci, Unit Rehabil Sci, Dept Locomot Rehabil Sci, Nagasaki 8528520, Japan; [Honda, Yuichiro; Sasabe, Ryo] Nagasaki Univ Hosp, Dept Rehabil, Nagasaki, Japan; [Sakamoto, Junya; Nakano, Jiro; Tanaka, Miho] Nagasaki Univ, Grad Sch Biomed Sci, Unit Phys & Occupat Therapy Sci, Dept Phys Therapy Sci, Nagasaki 8528520, Japan	Okita, M (reprint author), Nagasaki Univ, Grad Sch Biomed Sci, Unit Rehabil Sci, Dept Locomot Rehabil Sci, Sakamoto 1-7-1, Nagasaki 8528520, Japan.	mokita@nagasaki-u.ac.jp			Ministry of Education, Science, Sports and Culture of Japan [21300200, 26882030]	This research was supported in part by a grant-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (21300200 and 26882030).	Zanotti S, 2007, MATRIX BIOL, V26, P615, DOI 10.1016/j.matbio.2007.06.004; WILLIAMS PE, 1988, ANN RHEUM DIS, V47, P1014, DOI 10.1136/ard.47.12.1014; Mauviel A, 2005, METH MOLEC MED, V117, P69; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Zhu SM, 2013, MUSCLE NERVE, V47, P711, DOI 10.1002/mus.23642; Gressner AM, 2006, J CELL MOL MED, V10, P76, DOI 10.1111/j.1582-4934.2006.tb00292.x; Piera-Velazquez S, 2010, ANN RHEUM DIS, V69, P2017, DOI 10.1136/ard.2009.127761; Andrews T, 2003, CLIN MICROBIOL REV, V16, P597, DOI 10.1128/CMR.16.4.597-621.2003; McCormick LL, 1999, J IMMUNOL, V163, P5693; Tzouvelekis A, 2007, AM J RESP CRIT CARE, V176, P1108, DOI 10.1164/rccm.200705-683OC; Khan R, 2006, IMMUNOLOGY, V118, P10, DOI 10.1111/j.1365-2567.2006.02336.x; Okita M, 2004, J MUSCLE RES CELL M, V25, P159, DOI 10.1023/B:JURE.0000035851.12800.39; Trudel G, 2000, ARCH PHYS MED REHAB, V81, P6, DOI 10.1016/S0003-9993(00)90213-2; Devi SL, 2010, EUR J PHARMACOL, V647, P161, DOI 10.1016/j.ejphar.2010.08.011; WILLIAMS PE, 1984, J ANAT, V138, P343; Comito G, 2012, CANCER LETT, V324, P31, DOI 10.1016/j.canlet.2012.04.025; Thom R, 2014, J BIOL CHEM, V289, P8810, DOI 10.1074/jbc.M114.554394; Gomes I, 2005, J ALLERGY CLIN IMMUN, V116, P796, DOI 10.1016/j.jaci.2005.06.031; Vesey DA, 2002, J LAB CLIN MED, V140, P342, DOI 10.1067/mlc.2002.128468; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Blaauboer ME, 2011, BIOCHEM BIOPH RES CO, V404, P23, DOI 10.1016/j.bbrc.2010.11.033; Chetty A, 2006, PEDIATR RES, V60, P389, DOI 10.1203/01.pdr.0000238257.15502.f4; Colwell AS, 2007, PLAST RECONSTR SURG, V119, P852, DOI 10.1097/01.prs.0000255541.39993.66; Haase VH, 2006, AM J PHYSIOL-RENAL, V291, P271; Hibino Itaru, 2008, J Jpn Phys Ther Assoc, V11, P1, DOI 10.1298/jjpta.11.1; Jarvinen TAH, 2002, J MUSCLE RES CELL M, V23, P245, DOI 10.1023/A:1020904518336; Magne H, 2011, J PHYSIOL-LONDON, V589, P511, DOI 10.1113/jphysiol.2010.201707; Matsumoto Y, 2014, ULTRASOUND MED BIOL, V40, P1578, DOI 10.1016/j.ultrasmedbio.2013.12.031; Negash AA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003330; NikolicPaterson DJ, 1996, SEMIN NEPHROL, V16, P583; Okita M, 2009, ULTRASOUND MED BIOL, V35, P237, DOI 10.1016/j.ultrasmedbio.2008.09.001; Robinson CM, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-74; Sarrazy V, 2011, WOUND REPAIR REGE S1, V19, P10; SHAH M, 1995, J CELL SCI, V108, P985; YUE TL, 1994, BIOCHEM BIOPH RES CO, V204, P1186, DOI 10.1006/bbrc.1994.2588	36	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0148-639X	1097-4598		MUSCLE NERVE	Muscle Nerve	SEP	2015	52	3					419	427		10.1002/mus.24558		9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CP1XT	WOS:000359671800015		
J	Medema, MH; Kottmann, R; Yilmaz, P; Cummings, M; Biggins, JB; Blin, K; de Bruijn, I; Chooi, YH; Claesen, J; Coates, RC; Cruz-Morales, P; Duddela, S; Dusterhus, S; Edwards, DJ; Fewer, DP; Garg, N; Geiger, C; Gomez-Escribano, JP; Greule, A; Hadjithomas, M; Haines, AS; Helfrich, EJN; Hillwig, ML; Ishida, K; Jones, AC; Jones, CS; Jungmann, K; Kegler, C; Kim, HU; Kotter, P; Krug, D; Masschelein, J; Melnik, AV; Mantovani, SM; Monroe, EA; Moore, M; Moss, N; Nutzmann, HW; Pan, GH; Pati, A; Petras, D; Reen, FJ; Rosconi, F; Rui, Z; Tian, ZH; Tobias, NJ; Tsunematsu, Y; Wiemann, P; Wyckoff, E; Yan, XH; Yim, G; Yu, FG; Xie, YC; Aigle, B; Apel, AK; Balibar, CJ; Balskus, EP; Barona-Gomez, F; Bechthold, A; Bode, HB; Borriss, R; Brady, SF; Brakhage, AA; Caffrey, P; Cheng, YQ; Clardy, J; Cox, RJ; De Mot, R; Donadio, S; Donia, MS; van der Donk, WA; Dorrestein, PC; Doyle, S; Driessen, AJM; Ehling-Schulz, M; Entian, KD; Fischbach, MA; Gerwick, L; Gerwick, WH; Gross, H; Gust, B; Hertweck, C; Hofte, M; Jensen, SE; Ju, JH; Katz, L; Kaysser, L; Klassen, JL; Keller, NP; Kormanec, J; Kuipers, OP; Kuzuyama, T; Kyrpides, NC; Kwon, HJ; Lautru, S; Lavigne, R; Lee, CY; Linquan, B; Liu, XY; Liu, W; Luzhetskyy, A; Mahmud, T; Mast, Y; Mendez, C; Metsa-Ketela, M; Micklefield, J; Mitchell, DA; Moore, BS; Moreira, LM; Muller, R; Neilan, BA; Nett, M; Nielsen, J; O'Gara, F; Oikawa, H; Osbourn, A; Osburne, MS; Ostash, B; Payne, SM; Pernodet, JL; Petricek, M; Piel, J; Ploux, O; Raaijmakers, JM; Salas, JA; Schmitt, EK; Scott, B; Seipke, RF; Shen, B; Sherman, DH; Sivonen, K; Smanski, MJ; Sosio, M; Stegmann, E; Sussmuth, RD; Tahlan, K; Thomas, CM; Tang, Y; Truman, AW; Viaud, M; Walton, JD; Walsh, CT; Weber, T; van Wezel, GP; Wilkinson, B; Willey, JM; Wohlleben, W; Wright, GD; Ziemert, N; Zhang, CS; Zotchev, SB; Breitling, R; Takano, E; Glockner, FO				Medema, Marnix H.; Kottmann, Renzo; Yilmaz, Pelin; Cummings, Matthew; Biggins, John B.; Blin, Kai; de Bruijn, Irene; Chooi, Yit Heng; Claesen, Jan; Coates, R. Cameron; Cruz-Morales, Pablo; Duddela, Srikanth; Duesterhus, Stephanie; Edwards, Daniel J.; Fewer, David P.; Garg, Neha; Geiger, Christoph; Gomez-Escribano, Juan Pablo; Greule, Anja; Hadjithomas, Michalis; Haines, Anthony S.; Helfrich, Eric J. N.; Hillwig, Matthew L.; Ishida, Keishi; Jones, Adam C.; Jones, Carla S.; Jungmann, Katrin; Kegler, Carsten; Kim, Hyun Uk; Koetter, Peter; Krug, Daniel; Masschelein, Joleen; Melnik, Alexey V.; Mantovani, Simone M.; Monroe, Emily A.; Moore, Marcus; Moss, Nathan; Nuetzmann, Hans-Wilhelm; Pan, Guohui; Pati, Amrita; Petras, Daniel; Reen, F. Jerry; Rosconi, Federico; Rui, Zhe; Tian, Zhenhua; Tobias, Nicholas J.; Tsunematsu, Yuta; Wiemann, Philipp; Wyckoff, Elizabeth; Yan, Xiaohui; Yim, Grace; Yu, Fengan; Xie, Yunchang; Aigle, Bertrand; Apel, Alexander K.; Balibar, Carl J.; Balskus, Emily P.; Barona-Gomez, Francisco; Bechthold, Andreas; Bode, Helge B.; Borriss, Rainer; Brady, Sean F.; Brakhage, Axel A.; Caffrey, Patrick; Cheng, Yi-Qiang; Clardy, Jon; Cox, Russell J.; De Mot, Rene; Donadio, Stefano; Donia, Mohamed S.; van der Donk, Wilfred A.; Dorrestein, Pieter C.; Doyle, Sean; Driessen, Arnold J. M.; Ehling-Schulz, Monika; Entian, Karl-Dieter; Fischbach, Michael A.; Gerwick, Lena; Gerwick, William H.; Gross, Harald; Gust, Bertolt; Hertweck, Christian; Hofte, Monica; Jensen, Susan E.; Ju, Jianhua; Katz, Leonard; Kaysser, Leonard; Klassen, Jonathan L.; Keller, Nancy P.; Kormanec, Jan; Kuipers, Oscar P.; Kuzuyama, Tomohisa; Kyrpides, Nikos C.; Kwon, Hyung-Jin; Lautru, Sylvie; Lavigne, Rob; Lee, Chia Y.; Linquan, Bai; Liu, Xinyu; Liu, Wen; Luzhetskyy, Andriy; Mahmud, Taifo; Mast, Yvonne; Mendez, Carmen; Metsa-Ketela, Mikko; Micklefield, Jason; Mitchell, Douglas A.; Moore, Bradley S.; Moreira, Leonilde M.; Mueller, Rolf; Neilan, Brett A.; Nett, Markus; Nielsen, Jens; O'Gara, Fergal; Oikawa, Hideaki; Osbourn, Anne; Osburne, Marcia S.; Ostash, Bohdan; Payne, Shelley M.; Pernodet, Jean-Luc; Petricek, Miroslav; Piel, Joern; Ploux, Olivier; Raaijmakers, Jos M.; Salas, Jose A.; Schmitt, Esther K.; Scott, Barry; Seipke, Ryan F.; Shen, Ben; Sherman, David H.; Sivonen, Kaarina; Smanski, Michael J.; Sosio, Margherita; Stegmann, Evi; Suessmuth, Roderich D.; Tahlan, Kapil; Thomas, Christopher M.; Tang, Yi; Truman, Andrew W.; Viaud, Muriel; Walton, Jonathan D.; Walsh, Christopher T.; Weber, Tilmann; van Wezel, Gilles P.; Wilkinson, Barrie; Willey, Joanne M.; Wohlleben, Wolfgang; Wright, Gerard D.; Ziemert, Nadine; Zhang, Changsheng; Zotchev, Sergey B.; Breitling, Rainer; Takano, Eriko; Gloeckner, Frank Oliver			Minimum Information about a Biosynthetic Gene cluster	NATURE CHEMICAL BIOLOGY			English	Editorial Material							NATURAL-PRODUCTS; DATABASE; DISCOVERY; SCALE; RESOURCE		[Medema, Marnix H.; Kottmann, Renzo; Yilmaz, Pelin; Gloeckner, Frank Oliver] Max Planck Inst Marine Microbiol, Microbial Genom & Bioinformat Res Grp, Bremen, Germany; [Cummings, Matthew; Breitling, Rainer; Takano, Eriko] Univ Manchester, Fac Life Sci, Manchester Inst Biotechnol,SYNBIOCHEM, Manchester Ctr Synthet Biol Fine & Special Chem, Manchester, Lancs, England; [Biggins, John B.; Brady, Sean F.] Rockefeller Univ, Howard Hughes Med Inst, Lab Genet Encoded Small Mol, New York, NY 10021 USA; [Blin, Kai; Kim, Hyun Uk; Nielsen, Jens; Weber, Tilmann] Tech Univ Denmark, Novo Nordisk Fdn Ctr Biosustainabil, Horsholm, Denmark; [de Bruijn, Irene; Raaijmakers, Jos M.] Netherlands Inst Ecol NIOO KNAW, Dept Microbial Ecol, Wageningen, Netherlands; [Chooi, Yit Heng; Tang, Yi] Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA USA; [Tang, Yi] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90024 USA; [Chooi, Yit Heng] Univ Western Australia, Sch Chem & Biochem, Perth, WA 6009, Australia; [Claesen, Jan; Fischbach, Michael A.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Claesen, Jan; Fischbach, Michael A.] Univ Calif San Francisco, Calif Inst Quantitat Biosci, San Francisco, CA 94143 USA; [Coates, R. Cameron; Hadjithomas, Michalis; Pati, Amrita; Kyrpides, Nikos C.; van Wezel, Gilles P.] Joint Genome Inst, Dept Energy DOE, Walnut Creek, CA USA; [Cruz-Morales, Pablo; Barona-Gomez, Francisco] CINVESTAV, IPN, Unidad Genom Avanzada Langebio, Evolut Metab Div Lab, Guanajuato, Mexico; [Duddela, Srikanth; Jungmann, Katrin; Krug, Daniel; Luzhetskyy, Andriy; Mueller, Rolf] Univ Saarland, Helmholtz Ctr Infect Res, Helmholtz Inst Pharmaceut Res, D-66123 Saarbrucken, Germany; [Duddela, Srikanth; Jungmann, Katrin; Krug, Daniel; Luzhetskyy, Andriy; Mueller, Rolf] Univ Saarland, Dept Pharmaceut Biotechnol, D-66123 Saarbrucken, Germany; [Duesterhus, Stephanie; Geiger, Christoph; Koetter, Peter; Entian, Karl-Dieter] Goethe Univ Frankfurt, Inst Mol Biosci, D-60054 Frankfurt, Germany; [Edwards, Daniel J.] Calif State Univ Chico, Dept Chem & Biochem, Chico, CA 95929 USA; [Fewer, David P.; Sivonen, Kaarina] Univ Helsinki, Dept Food & Environm Sci, Microbiol & Biotechnol Div, Helsinki, Finland; [Garg, Neha; Melnik, Alexey V.; Dorrestein, Pieter C.; Gerwick, William H.; Moore, Bradley S.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [Gomez-Escribano, Juan Pablo; Truman, Andrew W.; Wilkinson, Barrie] John Innes Ctr, Dept Mol Microbiol, Norwich, Norfolk, England; [Greule, Anja; Bechthold, Andreas] Univ Freiburg, Dept Pharmaceut Biol & Biotechnol, D-79106 Freiburg, Germany; [Haines, Anthony S.; Thomas, Christopher M.] Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England; [Helfrich, Eric J. N.; Piel, Joern] ETH, Inst Microbiol, CH-8092 Zurich, Switzerland; [Hillwig, Matthew L.; Liu, Xinyu] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA; [Ishida, Keishi; Tsunematsu, Yuta; Brakhage, Axel A.; Hertweck, Christian; Nett, Markus] Leibniz Inst Nat Product Res & Infect Biol HK, Jena, Germany; [Jones, Adam C.] Gordon & Betty Moore Fdn, Palo Alto, CA USA; [Jones, Carla S.] Roosevelt Univ, Sustainable Studies Program, Chicago, IL 60605 USA; [Kegler, Carsten; Tobias, Nicholas J.; Bode, Helge B.] Goethe Univ Frankfurt, Fachbereich Biowissensch, Merck Stiftungsprof Mol Biotechnol, D-60054 Frankfurt, Germany; [Kim, Hyun Uk] Korea Adv Inst Sci & Technol, BioInformat Res Ctr, Daejeon 305701, South Korea; [Masschelein, Joleen; Lavigne, Rob] Katholieke Univ Leuven, Lab Gene Technol, Heverlee, Belgium; [Masschelein, Joleen] Katholieke Univ Leuven, Lab Food Microbiol, Heverlee, Belgium; [Mantovani, Simone M.; Moss, Nathan; Dorrestein, Pieter C.; Gerwick, Lena; Gerwick, William H.; Moore, Bradley S.] Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA; [Monroe, Emily A.] William Paterson Univ, Dept Biol, Wayne, NJ USA; [Moore, Marcus; Tahlan, Kapil] Mem Univ Newfoundland, Dept Biol, St John, NF, Canada; [Nuetzmann, Hans-Wilhelm; Osbourn, Anne] John Innes Ctr, Dept Metab Biol, Norwich, Norfolk, England; [Pan, Guohui; Yan, Xiaohui; Shen, Ben] Scripps Res Inst, Dept Chem, Jupiter, FL USA; [Petras, Daniel; Suessmuth, Roderich D.] Tech Univ Berlin, Inst Chem, Berlin, Germany; [Reen, F. Jerry; O'Gara, Fergal] Natl Univ Ireland Univ Coll Cork, Sch Microbiol, BIOMERIT Res Ctr, Cork, Ireland; [Rosconi, Federico] IBCE, Dept Bioquim & Genom Microbianas, Montevideo, Uruguay; [Rui, Zhe] Univ Calif Berkeley, Energy Biosci Inst, Berkeley, CA 94720 USA; [Rui, Zhe] Univ Calif Berkeley, Dept Chem & Biomol Engn, Berkeley, CA 94720 USA; [Tian, Zhenhua; Liu, Wen] Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, Shanghai 200032, Peoples R China; [Tsunematsu, Yuta] Univ Shizuoka, Dept Pharmaceut Sci, Shizuoka 4228526, Japan; [Wiemann, Philipp; Keller, Nancy P.] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA; [Wyckoff, Elizabeth; Payne, Shelley M.] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA; [Wyckoff, Elizabeth; Payne, Shelley M.] Univ Texas Austin, Inst Cellular & Mol Biol, Austin, TX 78712 USA; [Yim, Grace; Wright, Gerard D.] McMaster Univ, Dept Biochem & Biomed Sci, MG DeGroote Inst Infect Dis Res, Hamilton, ON L8N 3Z5, Canada; [Yu, Fengan; Sherman, David H.] Univ Michigan, Life Sci Inst, Ann Arbor, MI 48109 USA; [Yu, Fengan; Sherman, David H.] Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; [Yu, Fengan; Sherman, David H.] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; [Yu, Fengan; Sherman, David H.] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; [Xie, Yunchang; Ju, Jianhua; Zhang, Changsheng] Chinese Acad Sci, South China Sea Inst Oceanol, RNAM Ctr Marine Microbiol, Key Lab Trop Marine Bioresources & Ecol,Guangdong, Guangzhou, Guangdong, Peoples R China; [Aigle, Bertrand] Univ Lorraine, Dynam Genomes & Adaptat Microbienne, Vandoeuvre Les Nancy, France; [Aigle, Bertrand] INRA, UMR 1128, Vandoeuvre Les Nancy, France; [Apel, Alexander K.; Gross, Harald; Gust, Bertolt; Kaysser, Leonard] Univ Tubingen, Inst Pharmazeut, Dept Pharmaceut Biol, Tubingen, Germany; [Apel, Alexander K.; Gross, Harald; Gust, Bertolt; Kaysser, Leonard; Stegmann, Evi; Wohlleben, Wolfgang; Ziemert, Nadine] Partner Site Tubingen, German Ctr Infect Res DZIF, Tubingen, Germany; [Balibar, Carl J.] Merck Res Labs, Infect Dis Res, Kenilworth, NJ USA; [Balskus, Emily P.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; [Bode, Helge B.] Goethe Univ Frankfurt, Buchmann Inst Mol Life Sci BMLS, D-60054 Frankfurt, Germany; [Borriss, Rainer] Humboldt Univ, Albrecht Thaer Inst, Fachbereich Phytomed, D-10099 Berlin, Germany; [Caffrey, Patrick] Univ Coll Dublin, UCD Sch Biomol & Biomed Sci, Dublin, Ireland; [Cheng, Yi-Qiang] Univ N Texas, Hlth Sci Ctr, UNT Syst Coll Pharm, Ft Worth, TX USA; [Clardy, Jon] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA USA; [Cox, Russell J.] Leibniz Univ Hannover, Inst Organ Chem, Hannover, Germany; [Cox, Russell J.] Univ Bristol, Sch Chem, Bristol, Avon, England; [De Mot, Rene] Univ Leuven, Fac Biosci Engn, Ctr Microbial & Plant Genet, Heverlee, Belgium; [Donadio, Stefano; Sosio, Margherita] Naicons Srl, Milan, Italy; [Donia, Mohamed S.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; [van der Donk, Wilfred A.; Mitchell, Douglas A.] Univ Illinois, Dept Chem, Urbana, IL USA; [van der Donk, Wilfred A.] Howard Hughes Med Inst, Chevy Chase, MD USA; [Dorrestein, Pieter C.] Univ Calif San Diego, Collaborat Mass Spectrometry Innovat Ctr, La Jolla, CA 92093 USA; [Doyle, Sean] Maynooth Univ, Dept Biol, Maynooth, Kildare, Ireland; [Driessen, Arnold J. M.] Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Microbiol, Groningen, Netherlands; [Driessen, Arnold J. M.] Univ Groningen, Zernike Inst Adv Mat, Groningen, Netherlands; [Ehling-Schulz, Monika] Univ Vet Med Vienna, Inst Microbiol, Dept Pathobiol, Funct Microbiol, Vienna, Austria; [Hertweck, Christian] Univ Jena, Jena, Germany; [Hofte, Monica] Univ Ghent, Fac Biosci Engn, Dept Crop Protect, B-9000 Ghent, Belgium; [Jensen, Susan E.] Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada; [Katz, Leonard] Univ Calif Emeryville, Synthet Biol Engn Res Ctr SynBERC, Emeryville, CA USA; [Klassen, Jonathan L.] Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT USA; [Keller, Nancy P.] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; [Kormanec, Jan] Slovak Acad Sci, Inst Mol Biol, Bratislava 84251, Slovakia; [Kuipers, Oscar P.] Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Genet, Groningen, Netherlands; [Kuzuyama, Tomohisa] Univ Tokyo, Biotechnol Res Ctr, Tokyo, Japan; [Kyrpides, Nikos C.] King Abdulaziz Univ, Fac Sci, Dept Biol Sci, Jeddah, Saudi Arabia; [Kwon, Hyung-Jin] Myongji Univ, Div Biosci & Bioinformat, Yongin, Gyeonggi Do, South Korea; [Lautru, Sylvie; Pernodet, Jean-Luc] Univ Paris 11, CNRS, CEA, Inst Integrat Biol Cell I2BC, Orsay, France; [Lee, Chia Y.] Univ Arkansas Med Sci, Dept Microbiol & Immunol, Little Rock, AR 72205 USA; [Linquan, Bai] Shanghai Jiao Tong Univ, State Key Lab Microbial Metab, Shanghai 200030, Peoples R China; [Linquan, Bai] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200030, Peoples R China; [Mahmud, Taifo] Oregon State Univ, Dept Pharmaceut Sci, Corvallis, OR 97331 USA; [Mast, Yvonne; Stegmann, Evi; Wohlleben, Wolfgang; Ziemert, Nadine] Univ Tubingen, Fac Sci, Interfaculty Inst Microbiol & Infect Med, Microbiology Biotechnol, Tubingen, Germany; [Mendez, Carmen; Salas, Jose A.] Univ Oviedo, Dept Biol Func, Oviedo, Spain; [Mendez, Carmen] Univ Oviedo, IUOPA, Oviedo, Spain; [Metsa-Ketela, Mikko] Univ Turku, Dept Biochem, Turku, Finland; [Micklefield, Jason] Univ Manchester, Sch Chem, Manchester, Lancs, England; [Moreira, Leonilde M.] Univ Lisbon, Inst Super Tecn, Inst Bioengn & Biosci, P-1699 Lisbon, Portugal; [Neilan, Brett A.] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia; [Nielsen, Jens] Chalmers, Dept Chem & Biol Engn, S-41296 Gothenburg, Sweden; [O'Gara, Fergal] Curtin Univ, Sch Biomed Sci, Perth, WA 6845, Australia; [Oikawa, Hideaki] Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido, Japan; [Osburne, Marcia S.] Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; [Ostash, Bohdan] Ivan Franko Natl Univ Lviv, Dept Genet & Biotechnol, Lvov, Ukraine; [Petricek, Miroslav] Acad Sci Czech Republic, Inst Microbiol, Prague, Czech Republic; [Ploux, Olivier] Univ Paris Diderot, CNRS, LIED, UMR 8236, Paris, France; [Schmitt, Esther K.] Novartis Inst BioMed Res, Basel, Switzerland; [Scott, Barry] Massey Univ, Inst Fundamental Sci, Palmerston North, New Zealand; [Seipke, Ryan F.] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Astbury Ctr Struct Mol Biol, Leeds, W Yorkshire, England; [Shen, Ben] Scripps Res Inst, Mol Therapeut & Nat Prod Lib Initiat, Jupiter, FL USA; [Smanski, Michael J.] Univ Minnesota Twin Cities, Dept Biochem Mol Biol & Biophys, St Paul, MN USA; [Smanski, Michael J.] Univ Minnesota Twin Cities, BioTechnol Inst, St Paul, MN USA; [Viaud, Muriel] INRA, Unite Biol & GEst Risques Agr BIOGER, Grignon, France; [Walton, Jonathan D.] Michigan State Univ, Dept Energy Great Lakes, Bioenergy Res Ctr, E Lansing, MI 48824 USA; [Walton, Jonathan D.] Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA; [Walsh, Christopher T.] Stanford Univ, Chemistry Engn & Med Human Hlth ChEM H Inst, Stanford, CA 94305 USA; [van Wezel, Gilles P.] Leiden Univ, Inst Biol, Mol Biotechnol, Leiden, Netherlands; [Willey, Joanne M.] Hofstra North Shore Long Isl Jewish Sch Med, Hempstead, NY USA; [Zotchev, Sergey B.] Norwegian Univ Sci & Technol, Dept Biotechnol, N-7034 Trondheim, Norway; [Gloeckner, Frank Oliver] Jacobs Univ Bremen, gGmbH, D-28759 Bremen, Germany	Medema, MH (reprint author), Max Planck Inst Marine Microbiol, Microbial Genom & Bioinformat Res Grp, Bremen, Germany.	marnix.medema@wur.nl	Moreira, Leonilde/C-6744-2011; Fewer, David/A-8704-2008; Weber, Tilmann/C-7159-2009; Ziemert, Nadine/H-1935-2015; de Bruijn, Irene/A-7437-2014; Fac Sci,  KAU,  Biol Sci Dept/L-4228-2013; 	Moreira, Leonilde/0000-0002-6838-4245; Fewer, David/0000-0003-3978-4845; Weber, Tilmann/0000-0002-8260-5120; de Bruijn, Irene/0000-0002-4889-3253; Medema, Marnix/0000-0002-2191-2821			Anand S, 2010, NUCLEIC ACIDS RES, V38, pW487, DOI 10.1093/nar/gkq340; Wilson MC, 2014, NATURE, V506, P58, DOI 10.1038/nature12959; Yamanaka K, 2014, P NATL ACAD SCI USA, V111, P1957, DOI 10.1073/pnas.1319584111; Yilmaz P, 2011, NAT BIOTECHNOL, V29, P415, DOI 10.1038/nbt.1823; Hastings J, 2013, NUCLEIC ACIDS RES, V41, pD456, DOI 10.1093/nar/gks1146; Charlop-Powers Z, 2014, CURR OPIN MICROBIOL, V19, P70, DOI 10.1016/j.mib.2014.05.021; Bork P, 2015, SCIENCE, V348, P873, DOI 10.1126/science.aac5605; Kersten RD, 2013, P NATL ACAD SCI USA, V110, pE4407, DOI 10.1073/pnas.1315492110; Shao ZY, 2013, ACS SYNTH BIOL, V2, P662, DOI 10.1021/sb400058n; Kersten RD, 2011, NAT CHEM BIOL, V7, P794, DOI 10.1038/nchembio.684; Gubbens J, 2014, CHEM BIOL, V21, P707, DOI 10.1016/j.chembiol.2014.03.011; Weber T, 2015, NUCLEIC ACIDS RES, V43, pW237, DOI 10.1093/nar/gkv437; Ichikawa N, 2013, NUCLEIC ACIDS RES, V41, pD408, DOI 10.1093/nar/gks1177; Wilson MC, 2013, CHEM BIOL, V20, P636, DOI 10.1016/j.chembiol.2013.04.011; Baranasic D, 2014, J IND MICROBIOL BIOT, V41, P461, DOI 10.1007/s10295-013-1322-2; Pence HE, 2010, J CHEM EDUC, V87, P1123, DOI 10.1021/ed100697w; Arnison PG, 2013, NAT PROD REP, V30, P108, DOI 10.1039/c2np20085f; Inokuma Y, 2013, NATURE, V495, P461, DOI 10.1038/nature11990; Field D, 2008, NAT BIOTECHNOL, V26, P541, DOI 10.1038/nbt1360; Cimermancic P, 2014, CELL, V158, P412, DOI 10.1016/j.cell.2014.06.034; Bento AP, 2014, NUCLEIC ACIDS RES, V42, pD1083, DOI 10.1093/nar/gkt1031; Charlop-Powers Z, 2015, ELIFE, V4, DOI 10.7554/eLife.05048; Conway KR, 2013, NUCLEIC ACIDS RES, V41, pD402, DOI 10.1093/nar/gks993; Doroghazi JR, 2014, NAT CHEM BIOL, V10, P963, DOI [10.1038/nchembio.1659, 10.1038/NCHEMBIO.1659]; Field D, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001088; Gilbert JA, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0069-1; Hadjithomas M, 2015, MBIO, V6, DOI 10.1128/mBio.00932-15; Khayatt BI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062136; Kopf A, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0066-5; Rottig M, 2011, NUCLEIC ACIDS RES, V39, pW362	30	3	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2015	11	9					625	631				7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CP5WC	WOS:000359954700003		
J	Ueoka, R; Uria, AR; Reiter, S; Mori, T; Karbaum, P; Peters, EE; Helfrich, EJN; Morinaka, BI; Gugger, M; Takeyama, H; Matsunaga, S; Piel, J				Ueoka, Reiko; Uria, Agustinus R.; Reiter, Silke; Mori, Tetsushi; Karbaum, Petra; Peters, Eike E.; Helfrich, Eric J. N.; Morinaka, Brandon I.; Gugger, Muriel; Takeyama, Haruko; Matsunaga, Shigeki; Piel, Joern			Metabolic and evolutionary origin of actin-binding polyketides from diverse organisms	NATURE CHEMICAL BIOLOGY			English	Article							NATURAL-PRODUCT DISCOVERY; SPONGE THEONELLA-SWINHOEI; IN-SITU HYBRIDIZATION; GENE-CLUSTER; CYTOTOXIC MACROLIDES; ANTIFUNGAL MACROLIDE; BACTERIAL SYMBIONT; SYNTHASES; IDENTIFICATION; CYANOBACTERIA	Actin-targeting macrolides comprise a large, structurally diverse group of cytotoxins isolated from remarkably dissimilar micro- and macroorganisms. In spite of their disparate origins and structures, many of these compounds bind actin at the same site and exhibit structural relationships reminiscent of modular, combinatorial drug libraries. Here we investigate biosynthesis and evolution of three compound groups: misakinolides, scytophycin-type compounds and luminaolides. For misakinolides from the sponge Theonella swinhoei WA, our data suggest production by an uncultivated 'Entotheonella' symbiont, further supporting the relevance of these bacteria as sources of bioactive polyketides and peptides in sponges. Insights into misakinolide biosynthesis permitted targeted genome mining for other members, providing a cyanobacterial luminaolide producer as the first cultivated source for this dimeric compound family. The data indicate that this polyketide family is bacteria-derived and that the unusual macrolide diversity is the result of combinatorial pathway modularity for some compounds and of convergent evolution for others.	[Ueoka, Reiko; Uria, Agustinus R.; Reiter, Silke; Karbaum, Petra; Peters, Eike E.; Helfrich, Eric J. N.; Morinaka, Brandon I.; Piel, Joern] ETH, Inst Microbiol, CH-8092 Zurich, Switzerland; [Mori, Tetsushi; Takeyama, Haruko] Waseda Univ, Ctr Adv Biomed Sci, Fac Sci & Engn, Tokyo, Japan; [Karbaum, Petra] Kekule Inst Organ Chem & Biochem, Bonn, Germany; [Gugger, Muriel] Inst Pasteur, Collect Cyanobacteries, Paris, France; [Matsunaga, Shigeki] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Aquat Nat Prod Chem, Tokyo, Japan	Piel, J (reprint author), ETH, Inst Microbiol, CH-8092 Zurich, Switzerland.	jpiel@ethz.ch		Uria, Agustinus R./0000-0002-9223-7464	SNF [IZLSZ3_149025]; EU (BlueGenics); EU (BluePharmTrain); Institut Pasteur; Alexander von Humboldt Research Fellowship; DAAD fellowship	We thank T. Wakimoto and K. Takada for providing sponge samples, D. Uemura for a generous sample of luminaolide, M. Wilson for sequence analysis and naming of 'Entotheonella serta', C. Maufrais and A. Criscuolo from the Bioinformatic Plateform of the Institut Pasteur for help in ANI calculation, and J. Pernthaler for helpful discussion and for providing material for CARD-FISH experiments. We are also grateful to Y.I. Park and J.-F. Humbert for the use of cyanobacterial genomes. This work was funded by grants of the SNF (IZLSZ3_149025), and the EU (BlueGenics and BluePharmTrain) to J.P., by the Institut Pasteur to M.G., by an Alexander von Humboldt Research Fellowship to R.U. and by a DAAD fellowship to A.R.U.	Wilson MC, 2014, NATURE, V506, P58, DOI 10.1038/nature12959; Jenner M, 2013, ANGEW CHEM INT EDIT, V52, P1143, DOI 10.1002/anie.201207690; Keatinge-Clay A, 2008, J MOL BIOL, V384, P941, DOI 10.1016/j.jmb.2008.09.084; Nguyen T, 2008, NAT BIOTECHNOL, V26, P225, DOI 10.1038/nbt1379; Allingham JS, 2006, CELL MOL LIFE SCI, V63, P2119, DOI 10.1007/s00018-006-6157-9; Poplau P, 2013, ANGEW CHEM INT EDIT, V52, P13215, DOI 10.1002/anie.201307406; Donia MS, 2011, P NATL ACAD SCI USA, V108, pE1423, DOI 10.1073/pnas.1111712108; Freeman MF, 2012, SCIENCE, V338, P387, DOI 10.1126/science.1226121; Partida-Martinez LP, 2005, NATURE, V437, P884, DOI 10.1038/nature03997; Pernthaler A, 2002, APPL ENVIRON MICROB, V68, P3094, DOI 10.1128/AEM.68.6.3094-3101.2002; Irschik H, 2010, CHEMBIOCHEM, V11, P1840, DOI 10.1002/cbic.201000313; Richter M, 2009, P NATL ACAD SCI USA, V106, P19126, DOI 10.1073/pnas.0906412106; Caffrey P, 2003, CHEMBIOCHEM, V4, P654, DOI 10.1002/cbic.200300581; Sudek S, 2007, J NAT PROD, V70, P67, DOI 10.1021/np060361d; Yang JY, 2012, J BACTERIOL, V194, P6023, DOI 10.1128/JB.00823-12; Binga EK, 2008, ISME J, V2, P233, DOI 10.1038/ismej.2008.10; Andrianasolo EH, 2005, ORG LETT, V7, P1375, DOI 10.1021/ol050188x; RASHID MA, 1995, J NAT PRODUCTS, V58, P1120, DOI 10.1021/np50121a025; Kohlhaas C, 2013, CHEM SCI, V4, P3212, DOI 10.1039/c3sc50540e; Piel J, 2010, NAT PROD REP, V27, P996, DOI 10.1039/b816430b; SASSE F, 1993, J ANTIBIOT, V46, P741; Schmidt EW, 2000, MAR BIOL, V136, P969, DOI 10.1007/s002270000273; Piel J, 2002, P NATL ACAD SCI USA, V99, P14002, DOI 10.1073/pnas.222481399; Piel J, 2004, P NATL ACAD SCI USA, V101, P16222, DOI 10.1073/pnas.0405976101; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1; Nakabachi A, 2013, CURR BIOL, V23, P1478, DOI 10.1016/j.cub.2013.06.027; ISHIBASHI M, 1986, J ORG CHEM, V51, P5300, DOI 10.1021/jo00376a047; YAMADA K, 1993, J AM CHEM SOC, V115, P11020, DOI 10.1021/ja00076a082; Jenke-Kodama H, 2005, MOL BIOL EVOL, V22, P2027, DOI 10.1093/molbev/msi193; Kitamura M, 2009, TETRAHEDRON LETT, V50, P6606, DOI 10.1016/j.tetlet.2009.09.065; Yilmaz LS, 2011, APPL ENVIRON MICROB, V77, P1118, DOI 10.1128/AEM.01733-10; Pistorius D, 2012, CHEMBIOCHEM, V13, P416, DOI 10.1002/cbic.201100575; Reid R, 2003, BIOCHEMISTRY-US, V42, P72, DOI 10.1021/bi0268706; Hertweck C, 2009, ANGEW CHEM INT EDIT, V48, P4688, DOI 10.1002/anie.200806121; Watrous J, 2012, P NATL ACAD SCI USA, V109, pE1743, DOI 10.1073/pnas.1203689109; KERNAN MR, 1987, TETRAHEDRON LETT, V28, P2809, DOI 10.1016/S0040-4039(00)96215-4; Schramm A, 2002, ENVIRON MICROBIOL, V4, P713, DOI 10.1046/j.1462-2920.2002.00364.x; O'Brien RV, 2014, J ANTIBIOT, V67, P89, DOI 10.1038/ja.2013.125; Wakimoto T, 2014, NAT CHEM BIOL, V10, P648, DOI [10.1038/nchembio.1573, 10.1038/NCHEMBIO.1573]; Fisch KM, 2009, NAT CHEM BIOL, V5, P494, DOI 10.1038/nchembio.176; Kubanek J, 2003, P NATL ACAD SCI USA, V100, P6916, DOI 10.1073/pnas.1131855100; Perrins RD, 2008, CHEM BIOL, V15, P287, DOI 10.1016/j.chembiol.2008.01.010; Berkhan G, 2014, ANGEW CHEM INT EDIT, V53, P14240, DOI 10.1002/anie.201407979; Bewley C. A., 1996, CELL MOL LIFE SCI, V52, P716; Bewley CA, 1998, ANGEW CHEM INT EDIT, V37, P2163; CARMELI S, 1990, J NAT PROD, V53, P1533, DOI 10.1021/np50072a021; DAURIA MV, 1994, TETRAHEDRON, V50, P4829, DOI 10.1016/S0040-4020(01)85019-5; Elshahawi SI, 2013, P NATL ACAD SCI USA, V110, pE295, DOI 10.1073/pnas.1213892110; Gaget V, 2015, SYST APPL MICROBIOL, V38, P141, DOI 10.1016/j.syapm.2015.02.004; GARCIAPICHEL F, 1991, J PHYCOL, V27, P395, DOI 10.1111/j.0022-3646.1991.00395.x; GUELLA G, 1989, HELV CHIM ACTA, V72, P237, DOI 10.1002/hlca.19890720207; Hrvatin S, 2007, J MICROBIOL METH, V68, P434, DOI 10.1016/j.mimet.2006.09.009; Jenner M, 2015, ANGEW CHEM INT EDIT, V54, P1817, DOI 10.1002/anie.201410219; Kampa A, 2013, P NATL ACAD SCI USA, V110, pE3129, DOI 10.1073/pnas.1305867110; MATSUNAGA S, 1986, J AM CHEM SOC, V108, P847, DOI 10.1021/ja00264a053; SAKAI R, 1986, CHEM LETT, P1499, DOI 10.1246/cl.1986.1499; SPIEGEL M, 1972, EXP CELL RES, V70, P423, DOI 10.1016/0014-4827(72)90155-3; Teta R, 2010, CHEMBIOCHEM, V11, P2506, DOI 10.1002/cbic.201000542; WETMUR JG, 1991, CRIT REV BIOCHEM MOL, V26, P227, DOI 10.3109/10409239109114069	59	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2015	11	9					705	+		10.1038/NCHEMBIO.1870		10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CP5WC	WOS:000359954700015		
J	Kubo, M				Kubo, Masato			TCF-1 and LEF-1 help launch the T-FH program	NATURE IMMUNOLOGY			English	Editorial Material							CELL DIFFERENTIATION; PATHWAY; FATE	Follicular helper T cells (T-FH cells) differentiate from naive T cells, but the picture of this differentiation process remains incomplete. Two studies now identify the related transcriptional regulators TCF-1 and LEF-1 as important early participants in this process.	[Kubo, Masato] Tokyo Univ Sci, Res Inst Biomed Sci, Chiba, Japan; [Kubo, Masato] RIKEN, Ctr Integrat Med Sci IMS, Yokohama, Kanagawa, Japan	Kubo, M (reprint author), Tokyo Univ Sci, Res Inst Biomed Sci, Chiba, Japan.	masato.kubo@riken.jp					Zaretsky AG, 2009, J EXP MED, V206, P991, DOI 10.1084/jem.20090303; Yu Q, 2009, NAT IMMUNOL, V10, P992, DOI 10.1038/ni.1762; Choi YS, 2015, NAT IMMUNOL, V16, P980, DOI 10.1038/ni.3226; Xu LF, 2015, NAT IMMUNOL, V16, P991, DOI 10.1038/ni.3229; Jeannet G, 2010, P NATL ACAD SCI USA, V107, P9777, DOI 10.1073/pnas.0914127107; Xue HH, 2012, ANN NY ACAD SCI, V1247, P16, DOI 10.1111/j.1749-6632.2011.06302.x; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Steinke FC, 2014, NAT IMMUNOL, V15, P646, DOI 10.1038/ni.2897; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Kali T., 2012, J EXP MED, V209, P2079; Nuneva R. I., 2009, SCIENCE, V325, P1001; Ueno H, 2015, NAT IMMUNOL, V16, P142, DOI 10.1038/ni.3054	13	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1529-2908	1529-2916		NAT IMMUNOL	Nat. Immunol.	SEP	2015	16	9					900	901				2	Immunology	Immunology	CP4UA	WOS:000359876900006		
J	du Plessis, MC; Shiino, H; Sugiyama, M				du Plessis, Marthinus Christoffel; Shiino, Hiroaki; Sugiyama, Masashi			Online Direct Density-Ratio Estimation Applied to Inlier-Based Outlier Detection	NEURAL COMPUTATION			English	Article								Many machine learning problems, such as nonstationarity adaptation, outlier detection, dimensionality reduction, and conditional density estimation, can be effectively solved by using the ratio of probability densities. Since the naive two-step procedure of first estimating the probability densities and then taking their ratio performs poorly, methods to directly estimate the density ratio from two sets of samples without density estimation have been extensively studied recently. However, these methods are batch algorithms that use the whole data set to estimate the density ratio, and they are inefficient in the online setup, where training samples are provided sequentially and solutions are updated incrementally without storing previous samples. In this letter, we propose two online density-ratio estimators based on the adaptive regularization of weight vectors. Through experiments on inlier-based outlier detection, we demonstrate the usefulness of the proposed methods.	[du Plessis, Marthinus Christoffel; Sugiyama, Masashi] Univ Tokyo, Dept Complex Sci & Engn, Bunkyo Ku, Tokyo 1130033, Japan; [Shiino, Hiroaki] Tokyo Inst Technol, Dept Comp Sci, Meguro Ku, Tokyo 1528552, Japan	du Plessis, MC (reprint author), Univ Tokyo, Dept Complex Sci & Engn, Bunkyo Ku, Tokyo 1130033, Japan.				JST CREST project; KAKENHI [25700022]	We thank Tomoya Sakai for his valuable comments. M.C.dP. was supported by the JST CREST project, and M.S. was supported by KAKENHI 25700022.	Kanamori T, 2009, J MACH LEARN RES, V10, P1391; Nguyen XL, 2010, IEEE T INFORM THEORY, V56, P5847, DOI 10.1109/TIT.2010.2068870; Bregman L. M., 1967, USSR COMP MATH MATH, V7, P200, DOI 10.1016/0041-5553(67)90040-7; Crammer K., 2009, ADV NEURAL INFORM PR, V22, P414; Haykin S., 2002, ADAPTIVE FILTER THEO; Hido S, 2011, KNOWL INF SYST, V26, P309, DOI 10.1007/s10115-010-0283-2; Izbicki R., 2014, P 17 INT C ART INT S, P420; Sugiyama M, 2012, ADAPT COMPUT MACH LE, P1; Sugiyama M, 2012, DENSITY RATIO ESTIMATION IN MACHINE LEARNING, P1, DOI 10.1017/CBO9781139035613; Sugiyama M, 2012, ANN I STAT MATH, V64, P1009, DOI 10.1007/s10463-011-0343-8; Vapnik V., 1998, STAT LEARNING THEORY	11	0	0	MIT PRESS	CAMBRIDGE	ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA	0899-7667	1530-888X		NEURAL COMPUT	Neural Comput.	SEP	2015	27	9					1899	1914		10.1162/NECO_a_00761		16	Computer Science, Artificial Intelligence; Neurosciences	Computer Science; Neurosciences & Neurology	CP7TS	WOS:000360091800004		
J	Li, ZN; Ding, SX; Li, YJ				Li, Zhenni; Ding, Shuxue; Li, Yujie			A Fast Algorithm for Learning Overcomplete Dictionary for Sparse Representation Based on Proximal Operators	NEURAL COMPUTATION			English	Article							LINEAR INVERSE PROBLEMS; THRESHOLDING ALGORITHM; MATRIX FACTORIZATION; NONNEGATIVE MATRIX; REGRESSION; SHRINKAGE; DESIGN	We present a fast, efficient algorithm for learning an overcomplete dictionary for sparse representation of signals. The whole problem is considered as a minimization of the approximation error function with a coherence penalty for the dictionary atoms and with the sparsity regularization of the coefficient matrix. Because the problem is nonconvex and nonsmooth, this minimization problem cannot be solved efficiently by an ordinary optimization method. We propose a decomposition scheme and an alternating optimization that can turn the problem into a set of minimizations of piecewise quadratic and univariate subproblems, each of which is a single variable vector problem, of either one dictionary atom or one coefficient vector. Although the subproblems are still nonsmooth, remarkably they become much simpler so that we can find a closed-form solution by introducing a proximal operator. This leads to an efficient algorithm for sparse representation. To our knowledge, applying the proximal operator to the problem with an incoherence term and obtaining the optimal dictionary atoms in closed form with a proximal operator technique have not previously been studied. The main advantages of the proposed algorithm are that, as suggested by our analysis and simulation study, it has lower computational complexity and a higher convergence rate than state-of-the-art algorithms. In addition, for real applications, it shows good performance and significant reductions in computational time.	[Li, Zhenni; Li, Yujie] Univ Aizu, Grad Sch Comp Sci & Engn, Aizu Wakamatsu, Fukushima 9658580, Japan; [Ding, Shuxue] Univ Aizu, Fac Comp Sci & Engn, Aizu Wakamatsu, Fukushima 9658580, Japan	Li, ZN (reprint author), Univ Aizu, Grad Sch Comp Sci & Engn, Aizu Wakamatsu, Fukushima 9658580, Japan.	lizhenni2012@gmail.com; sding@u-aizu.ac.jp; d8152102@u-aizu.ac.jp			Japan Society for the Promotion of Science [26-10950]	This work was supported by the Japan Society for the Promotion of Science under grant no. 26-10950.	Aharon M, 2006, IEEE T SIGNAL PROCES, V54, P4311, DOI 10.1109/TSP.2006.881199; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267; Yaghoobi M, 2009, IEEE T SIGNAL PROCES, V57, P4800, DOI 10.1109/TSP.2009.2026610; Rakotomamonjy A, 2013, IEEE T SIGNAL PROCES, V61, P5495, DOI 10.1109/TSP.2013.2278158; Kazerouni A, 2013, IEEE SIGNAL PROC LET, V20, P249, DOI 10.1109/LSP.2013.2242061; Elad M, 2006, IEEE T IMAGE PROCESS, V15, P3736, DOI 10.1109/TIP.2006.881969; Lee DD, 1999, NATURE, V401, P788; Chen SSB, 2001, SIAM REV, V43, P129, DOI 10.1137/S003614450037906X; Chartrand R, 2008, INT CONF ACOUST SPEE, P3869, DOI 10.1109/ICASSP.2008.4518498; Selesnick IW, 2005, IEEE SIGNAL PROC MAG, V22, P123, DOI 10.1109/MSP.2005.1550194; Lin T, 2012, INT C PATT RECOG, P1237; MALLAT SG, 1993, IEEE T SIGNAL PROCES, V41, P3397, DOI 10.1109/78.258082; Tropp JA, 2004, IEEE T INFORM THEORY, V50, P2231, DOI 10.1109/TIT.2004.834793; Adler A, 2012, IEEE T AUDIO SPEECH, V20, P922, DOI 10.1109/TASL.2011.2168211; Yaghoobi M, 2009, IEEE T SIGNAL PROCES, V57, P2178, DOI 10.1109/TSP.2009.2016257; Dai W, 2012, IEEE T SIGNAL PROCES, V60, P6340, DOI 10.1109/TSP.2012.2215026; Sigg CD, 2012, IEEE SIGNAL PROC LET, V19, P861, DOI 10.1109/LSP.2012.2223757; Kreutz-Delgado K, 2003, NEURAL COMPUT, V15, P349, DOI 10.1162/089976603762552951; Engan K, 1999, INT CONF ACOUST SPEE, P2443; Combettes PL, 2005, MULTISCALE MODEL SIM, V4, P1168, DOI 10.1137/050626090; Elad M, 2010, P IEEE, V98, P972, DOI 10.1109/JPROC.2009.2037655; Mairal J, 2010, J MACH LEARN RES, V11, P19; Baraniuk RG, 2007, IEEE SIGNAL PROC MAG, V24, P118, DOI 10.1109/MSP.2007.4286571; Lewicki MS, 2000, NEURAL COMPUT, V12, P337, DOI 10.1162/089976600300015826; Hyvarinen A, 1999, IEEE T NEURAL NETWOR, V10, P626, DOI 10.1109/72.761722; Jafari MG, 2011, IEEE J-STSP, V5, P1025, DOI 10.1109/JSTSP.2011.2157892; Daubechies I, 2004, COMMUN PUR APPL MATH, V57, P1413, DOI 10.1002/cpa.20042; Skretting K, 2010, IEEE T SIGNAL PROCES, V58, P2121, DOI 10.1109/TSP.2010.2040671; Bao C., 2014, P EUR C COMP VIS, P302; Bao C. L., 2014, P IEEE C COMP VIS PA, P3858; Beck A, 2009, SIAM J IMAGING SCI, V2, P183, DOI 10.1137/080716542; Caiafa C. F., 2012, NEURAL COMPUT, V1, P1; Cichocki A, 2009, IEICE T FUND ELECTR, VE92A, P708, DOI 10.1587/transfun.E92.A.708; Combettes P. L., 2010, ARXIV09123522V4; Efron B, 2004, ANN STAT, V32, P407; Elad M, 2010, SPARSE AND REDUNDANT REPRESENTATIONS, P3, DOI 10.1007/978-1-4419-7011-4_1; Engan K, 1999, P NORSIG, V99, P65; Fadili MJ, 2009, COMPUT J, V52, P64, DOI 10.1093/comjnl/bxm055; Lee H., 2007, ADV NEURAL INFORM PR, V19, P801; Mailhe B, 2012, 2012 IEEE INTERNATIONAL CONFERENCE ON ACOUSTICS, SPEECH AND SIGNAL PROCESSING (ICASSP), P3573; MOREAU JJ, 1962, CR HEBD ACAD SCI, V255, P2897; Wang J., 2014, IEEE INT C IM PROC; Wang Z, 2004, IEEE T IMAGE PROCESS, V13, P600, DOI 10.1109/TIP.2003.819861	43	0	0	MIT PRESS	CAMBRIDGE	ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA	0899-7667	1530-888X		NEURAL COMPUT	Neural Comput.	SEP	2015	27	9					1951	1982		10.1162/NECO_a_00763		32	Computer Science, Artificial Intelligence; Neurosciences	Computer Science; Neurosciences & Neurology	CP7TS	WOS:000360091800006		
J	Yoshida, K; Xu, M; Natsubori, A; Mimura, M; Takata, N; Tanaka, KF				Yoshida, Keitaro; Xu, Ming; Natsubori, Akiyo; Mimura, Masaru; Takata, Norio; Tanaka, Kenji F.			Identification of the extent of cortical spreading depression propagation by Npas4 mRNA expression	NEUROSCIENCE RESEARCH			English	Article						Immediate early gene; DC-potential shift; Multichannel extracellular recording; In vivo	FOCAL CEREBRAL-ISCHEMIA; PERIINFARCT DEPOLARIZATIONS; TRIGEMINAL NUCLEUS; BRAIN; MIGRAINE; RAT; MECHANISMS; CORTEX; TRANSIENTS; RELEVANCE	Cortical spreading depression (CSD) is a phenomenon associated with a propagating large shift in direct current (DC) potential followed by suppression of electrophysiological activity. For temporal analysis of CSD propagation, electrophysiological recording is the most reliable tool. However, it is difficult to completely identify the spatial area of the brain influenced by CSD, because recording sites are technically limited. Histological post hoc identification of activated neurons by labeling the induction of an immediate early gene (IEG) could determine areas of CSD propagation. We found that cortical application of potassium chloride induced expression of Npas4 IEG mRNA in the ipsilateral dorsal cortex. Interestingly, induction of Npas4 was never observed in the ipsilateral hippocampus and there was a clear boundary to the area of Npas4 expression. To determine whether the boundary of the area of Npas4 mRNA expression was the limit of CSD propagation, we recorded local field potentials from multiple sites that crossed the boundary of Npas4 expression. We found that the area of Npas4 mRNA expression coincided with the area of DC-potential shift propagation. We propose that induction of Npas4 identifies the area influenced by CSD propagation. (C) 2015 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.	[Yoshida, Keitaro; Xu, Ming; Natsubori, Akiyo; Mimura, Masaru; Takata, Norio; Tanaka, Kenji F.] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo 1608582, Japan	Tanaka, KF (reprint author), Keio Univ, Sch Med, Dept Neuropsychiat, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	kftanaka@keio.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) [25115726, 25116523]; MEXT [23680042]; General collaborative project at the National Institute for Physiological Sciences (NIPS) [2012-8, 2013-7]; Takeda Science Foundation; Joint Usage/Research Program of Medical Research Institute, Tokyo Medical and Dental University	This work was supported by grants from Grant-in-Aid for Scientific Research on Innovative Areas "Mesoscopic Neurocircuitry" from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) to N.T. (25115726), "Microendophenotype" to K.F.T. (25116523), Grant-in-Aid for Young Scientists (A) from MEXT to K.F.T. (23680042), General collaborative project at the National Institute for Physiological Sciences (NIPS) to N.T. (2012-8, 2013-7), Takeda Science Foundation to K.F.T. and the Joint Usage/Research Program of Medical Research Institute, Tokyo Medical and Dental University to K.F.T.	Takano K, 1996, ANN NEUROL, V39, P308, DOI 10.1002/ana.410390307; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Lin YX, 2008, NATURE, V455, P1198, DOI 10.1038/nature07319; GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154; OKA H, 1977, BRAIN, V100, P287, DOI 10.1093/brain/100.2.287; Puelles L, 2000, J COMP NEUROL, V424, P409, DOI 10.1002/1096-9861(20000828)424:3<409::AID-CNE3>3.0.CO;2-7; HANSEN AJ, 1980, ACTA PHYSIOL SCAND, V108, P355, DOI 10.1111/j.1748-1716.1980.tb06544.x; Kunkler PE, 2003, HIPPOCAMPUS, V13, P835, DOI 10.1002/hipo.10139; Ramamoorthi K, 2011, SCIENCE, V334, P1669, DOI 10.1126/science.1208049; MOSKOWITZ MA, 1993, J NEUROSCI, V13, P1167; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Merkler D, 2009, ANN NEUROL, V66, P355, DOI 10.1002/ana.21746; LAURITZEN M, 1995, NEUROREPORT, V6, P1271; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Dietz RM, 2008, J NEUROSCI, V28, P8014, DOI 10.1523/JNEUROSCI.0765-08.2008; Bepari AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052783; BURES J, 1974, MECH APPL LEAOS SPRE; Carmo R J, 1972, Brain Res, V39, P515; Eikermann-Haerter K, 2011, J NEUROSCI, V31, P5755, DOI 10.1523/JNEUROSCI.5346-10.2011; FIFKOVA E, 1964, PHYSIOL BOHEMOSLOV, V13, P1; FIFKOVA E, 1974, J NEUROBIOL, V5, P469, DOI 10.1002/neu.480050508; Gniel HM, 2010, J NEUROPHYSIOL, V104, P3203, DOI 10.1152/jn.00922.2009; Gorji A, 2001, BRAIN RES REV, V38, P33, DOI 10.1016/S0165-0173(01)00081-9; GUEDES RCA, 1987, EXP BRAIN RES, V69, P113; HERRERA DG, 1990, BRAIN RES, V510, P166, DOI 10.1016/0006-8993(90)90747-Y; Hossmann KA, 1996, CEREBROVAS BRAIN MET, V8, P195; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721; KOROLEVA VI, 1980, ELECTROEN CLIN NEURO, V48, P1, DOI 10.1016/0013-4694(80)90038-3; LAURITZEN M, 1987, TRENDS NEUROSCI, V10, P8, DOI 10.1016/0166-2236(87)90115-9; Matsushima K, 1996, J CEREBR BLOOD F MET, V16, P221; Moldestad O, 2009, J NEUROSCI METH, V176, P57, DOI 10.1016/j.jneumeth.2008.08.015; Ohta K, 2001, STROKE, V32, P535; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Piper RD, 1996, CEPHALALGIA, V16, P87, DOI 10.1046/j.1468-2982.1996.1602087.x; SUGAYA E, 1975, J NEUROPHYSIOL, V38, P822; FIFKOVA E, 1964, EXP NEUROL, V9, P355, DOI 10.1016/0014-4886(64)90070-6; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007	37	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-0102	1872-8111		NEUROSCI RES	Neurosci. Res.	SEP	2015	98						1	8		10.1016/j.neures.2015.04.003		8	Neurosciences	Neurosciences & Neurology	CP5XW	WOS:000359959800001		
J	Shibuta, S; Morita, T; Kosaka, J; Kamibayashi, T; Fujino, YJ				Shibuta, Satoshi; Morita, Tomotaka; Kosaka, Jun; Kamibayashi, Takahiko; Fujino, Yuji			Only extra-high dose of ketamine affects L-glutamate-induced intracellular Ca2+ elevation and neurotoxicity	NEUROSCIENCE RESEARCH			English	Article; Proceedings Paper	Annual Meeting of Society-for-Neuroscience	NOV 19, 2014	Washington, DC	Soc Neuroscience		Developing brain; Intracellular calcium; Ketamine; L-glutamate; Neuron; Thiopental sodium	METHYL-D-ASPARTATE; DEVELOPING RAT-BRAIN; PROLONGED HYPOXIC EPISODES; OXIDE-INDUCED CYTOTOXICITY; NITRIC-OXIDE; THIOPENTONE SODIUM; IN-VITRO; APOPTOTIC NEURODEGENERATION; MEDIATED NEUROTOXICITY; FOREBRAIN CULTURE	The neurotoxic effects of anesthetics on the developing brain are a concern. Although most of the anesthetics are GABA(A) agonists or NMDA antagonists, the differences in these effects on prospective glutamate-neurotoxicity in the brain is not fully understood. We examined the degree of L-glutamate-induced intracellular calcium ([Ca2+]i) elevation and neurotoxicity in neurons exposed to anesthetics. Primary cortical neurons from E17 rats were preincubated with 1-100 mu M of ketamine or thiopental sodium (TPS) for the first 72 h of culturing. Two weeks later, the neurons were exposed to L-glutamate. The extent of glutamate toxicity was evaluated using Ca2+ -imaging and morphological experiments. Preincubation with 100 mu M ketamine but not with other concentrations of ketamine and TPS for the first 72 h in culture significantly enhanced L-glutamate-induced [Ca2+]i elevation 2 weeks later. Morphology experiments showed that vulnerability to L-glutamate-mediated neurotoxicity was only altered in neurons preincubated with 100 mu M ketamine but not with TPS. Although preincubation with high concentration of ketamine showed enhancement of L-glutamate-induced [Calli elevation 2 weeks later, long-term exposure to TPS or ketamine at clinical doses during developmental periods may not result in a dose-related potentiation of exogenous glutamate-induced neurotoxicity, once the intravenous anesthetics are discontinued. (C) 2015 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.	[Shibuta, Satoshi; Morita, Tomotaka; Kamibayashi, Takahiko; Fujino, Yuji] Osaka Univ, Grad Sch Med D7, Dept Anesthesiol & Intens Care Med, Suita, Osaka 5650871, Japan; [Kosaka, Jun] Int Univ Hlth & Welf, Ctr Med Sci, Ohtawara, Tochigi 3248501, Japan	Shibuta, S (reprint author), Osaka Univ, Grad Sch Med D7, Dept Anesthesiol & Intens Care Med, 2-2,Yamadaoka, Suita, Osaka 5650871, Japan.	shibuta@anes.med.osaka-u.ac.jp; acpe0193@mac.com; junksk@iuhw.ac.jp; kamib@anes.med.osaka-u.ac.jp; fujino@anes.med.osaka-u.ac.jp					Yan J, 2014, J NEUROSURG ANESTH, V26, P155, DOI 10.1097/ANA.0000000000000027; Zou XJ, 2009, TOXICOL SCI, V108, P149, DOI 10.1093/toxsci/kfn270; Wang C, 2005, NEUROSCIENCE, V132, P967, DOI 10.1016/j.neuroscience.2005.01.053; Soriano SG, 2010, ANESTHESIOLOGY, V112, P1155, DOI 10.1097/ALN.0b013e3181d3e0c2; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; Edwards DA, 2010, ANESTHESIOLOGY, V112, P567, DOI 10.1097/ALN.0b013e3181cf9138; Shibuta S, 1998, BRIT J PHARMACOL, V124, P804, DOI 10.1038/sj.bjp.0701884; Fredriksson A, 2007, ANESTHESIOLOGY, V107, P427, DOI 10.1097/01.anes.0000278892.62305.9c; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; Liu F, 2013, TOXICOL SCI, V131, P548, DOI 10.1093/toxsci/kfs296; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Zhao YL, 2011, ANESTH ANALG, V113, P1152, DOI 10.1213/ANE.0b013e318230b3fd; Pearson RA, 2004, EUR J NEUROSCI, V19, P2435, DOI 10.1111/j.1460-9568.2004.03338.x; Shibuta S, 2006, BRIT J ANAESTH, V97, P517, DOI 10.1093/bja/ael192; Liu JR, 2012, ANESTHESIOLOGY, V117, P64, DOI 10.1097/ALN.0b013e31825ae693; Slikker W, 2007, TOXICOL SCI, V98, P145, DOI 10.1093/toxsci/kfm084; Tassonyi E, 2002, BRAIN RES BULL, V57, P133, DOI 10.1016/S0361-9230(01)00740-7; Autry AE, 2011, NATURE, V475, P91, DOI 10.1038/nature10130; Olney JW, 2002, BRAIN PATHOL, V12, P488; Flood P, 2000, ANESTHESIOLOGY, V92, P1418, DOI 10.1097/00000542-200005000-00033; Holmes GL, 2002, NEUROREPORT, V13, pA3, DOI 10.1097/00001756-200201210-00002; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876; Leinekugel X, 1999, Adv Neurol, V79, P189; Liu Fang, 2011, Curr Neuropharmacol, V9, P256, DOI 10.2174/157015911795017155; lkonomidou C, 1999, SCIENCE, V283, P70; Nunez JL, 2003, EXP NEUROL, V181, P258, DOI 10.1016/S0014-4886(03)00053-0; Poulter MO, 1997, J NEUROCHEM, V68, P631; Sekiguchi-Tonosaki M, 2009, AM J PHYSIOL-CELL PH, V296, pC1195, DOI 10.1152/ajpcell.00423.2008; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; Shibuta S, 2003, J NEUROL SCI, V215, P31, DOI 10.1016/S0022-510X(03)00180-1; Shibuta S, 2000, J NEUROL SCI, V174, P9, DOI 10.1016/S0022-510X(99)00324-X; Shibuta S, 2010, BRIT J ANAESTH, V104, P52, DOI 10.1093/bja/aep320; Sinner B, 2011, TOXICOLOGY, V290, P96, DOI 10.1016/j.tox.2011.08.022; Turner CP, 2012, NEUROSCIENCE, V210, P384, DOI 10.1016/j.neuroscience.2012.02.015; Varathan S, 2003, J NEUROSCI RES, V72, P613, DOI 10.1002/jnr.10608; Varathan S, 2001, J NEUROSCI RES, V65, P583, DOI 10.1002/jnr.1188; Varathan S, 2002, J NEUROSCI RES, V68, P352, DOI 10.1002/jnr.10237; Wang C, 2000, J PHARMACOL EXP THER, V294, P287; Wang C, 2006, TOXICOL SCI, V91, P192, DOI 10.1093/toxsci/kfj144; Wei HF, 2011, ANESTH ANALG, V113, P972, DOI 10.1213/ANE.0b013e3182323261; Wei HF, 2013, PROG NEURO-PSYCHOPH, V47, P156, DOI 10.1016/j.pnpbp.2013.05.009; WEISS J, 1986, BRAIN RES, V380, P186, DOI 10.1016/0006-8993(86)91447-2; Zhan RZ, 1998, BRIT J ANAESTH, V81, P932	43	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-0102	1872-8111		NEUROSCI RES	Neurosci. Res.	SEP	2015	98						9	16		10.1016/j.neures.2015.04.005		8	Neurosciences	Neurosciences & Neurology	CP5XW	WOS:000359959800002		
J	Kawaguchi, A; Sato, M; Kimura, M; Ichinohe, T; Tazaki, M; Shibukawa, Y				Kawaguchi, Aya; Sato, Masaki; Kimura, Maki; Ichinohe, Tatsuya; Tazaki, Masakazu; Shibukawa, Yoshiyuki			Expression and function of purinergic P2Y(12) receptors in rat trigeminal ganglion neurons	NEUROSCIENCE RESEARCH			English	Article						Ca2+ signal; Neuropathic pain; Orofacial; Pain; Purinergic receptor; Trigeminal ganglion neuron	NEUROPATHIC PAIN; MOLECULAR-MECHANISMS; PLATELET-FUNCTION; PHOSPHOLIPASE-C; ADP RECEPTORS; P2Y RECEPTORS; NERVE INJURY; CELLS; CALCIUM; PATHOPHYSIOLOGY	Purinergic receptors play key signaling roles in neuropathic pain in the orofacial region, which is innervated by trigeminal ganglion (TG) neurons. The neuropathology of purinergic P2Y(12) receptors is well characterized in glia; however, their physiological role in TG neurons remains to be fully elucidated. The present study investigated the expression and function of P2Y(12) receptors in rat TG neurons. P2Y(12) receptor immunoreactivity was intense in the soma, dendrites, and axons, and colocalized with a pan-neuronal marker, neurofilament H, isolectin B4, and substance P. In the presence of extracellular Ca2+, 2-methylthio-ADP (an agonist of P2Y(1),(12),(13) receptors) transiently increased intracellular free Ca2+ concentrations ([Ca2+]1), an effect that was abolished by P2Y12 receptor antagonists. In the absence of extracellular Ca2+, ryanodine receptor/channel inhibitors diminished the 2-methylthio-ADP-induced increases in [Call. A sarcoplasmic reticulum Ca2+-ATPase (SERCA) inhibitor gradually increased [Ca2+], and after a plateau, application of 2-MeS-ADP induced a rapid and transient, but additive increase in [Ca2+](i). An adenylate cyclase inhibitor transiently increased [Ca2+](i), while a phosphodiesterase inhibitor prevented the 2-methylthio-ADP-induced increase in [Ca2+](i). Our study shows that P2Y(12) receptors are expressed in TG neurons, and act via a cAMP-dependent pathway to release intracellular Ca2+ from ryanodine-sensitive Ca2+ stores. (C) 2015 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.	[Kawaguchi, Aya; Ichinohe, Tatsuya] Tokyo Dent Coll, Dept Dent Anesthesiol, Tokyo 1010061, Japan; [Sato, Masaki; Kimura, Maki; Tazaki, Masakazu; Shibukawa, Yoshiyuki] Tokyo Dent Coll, Dept Physiol, Tokyo 1010061, Japan	Shibukawa, Y (reprint author), Tokyo Dent Coll, Dept Physiol, Tokyo 1010061, Japan.	yshibuka@tdc.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [23592751, 26861559, 25861762]	This research was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (grant #23592751/26861559/25861762).	Zhang KH, 2014, NATURE, V509, P115, DOI 10.1038/nature13083; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; Pausch MH, 2004, BIOCHEM BIOPH RES CO, V324, P171, DOI 10.1016/j.bbrc.2004.09.034; Burnstock Geoffrey, 2013, Keio Journal of Medicine, V62, P63, DOI 10.2302/kjm.2013-0003-RE; Mizuta K, 2011, AM J RESP CELL MOL, V45, P1232, DOI 10.1165/rcmb.2011-0088OC; Zhang J, 2014, NATURE, V509, P119, DOI 10.1038/nature13288; Ceruti S, 2008, CELL CALCIUM, V43, P576, DOI 10.1016/j.ceca.2007.10.003; Cervero F, 1996, PAIN, V68, P13, DOI 10.1016/S0304-3959(96)03165-X; Dussor G, 2009, BRAIN RES REV, V60, P24, DOI 10.1016/j.brainresrev.2008.12.013; Kim YC, 2005, BIOCHEM PHARMACOL, V70, P266, DOI 10.1016/j.bcp.2005.04.021; Kobayashi K, 2008, J NEUROSCI, V28, P2892, DOI 10.1523/JNEUROSCI.5589-07.2008; Lymperopoulos A, 2013, CIRC RES, V113, P739, DOI 10.1161/CIRCRESAHA.113.300308; Villa G, 2010, NEURON GLIA BIOL, V6, P31, DOI 10.1017/S1740925X10000086; Moskvina E, 2003, J NEUROSCI, V23, P7479; Abbracchio MP, 2006, PHARMACOL REV, V58, P281, DOI 10.1124/pr.58.3.3; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Tozaki-Saitoh H, 2008, J NEUROSCI, V28, P4949, DOI 10.1523/JNEUROSCI.0323-08.2008; Ruan HZ, 2003, HISTOCHEM CELL BIOL, V120, P415, DOI 10.1007/s00418-003-0579-3; Balghi H, 2006, J GEN PHYSIOL, V127, P171, DOI 10.1085/jgp.200509456; Fried K, 2001, NEUROSCIENTIST, V7, P155; Gachet C, 1997, THROMB HAEMOSTASIS, V78, P271; Bodor ET, 2003, MOL PHARMACOL, V64, P1210, DOI 10.1124/mol.64.5.1210; Bugrim AE, 1999, CELL CALCIUM, V25, P219, DOI 10.1054/ceca.1999.0027; Carrasquero Luz María G, 2005, Purinergic Signal, V1, P153, DOI 10.1007/s11302-005-6211-3; Giachini FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091890; Hayashi T, 1997, J NEURAL TRANSM, V104, P811, DOI 10.1007/BF01285550; Katagiri A, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-23; Kubista H, 2003, BRIT J PHARMACOL, V138, P343, DOI 10.1038/sj.bjp.0705037; Kuroda H, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-22; Langer I, 2005, CELL SIGNAL, V17, P17, DOI 10.1016/j.cellsig.2004.05.009; Li N, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-21; Malin SA, 2010, MOL PAIN, V15, P21; Moheimani F, 2012, INT J HEMATOL, V96, P572, DOI 10.1007/s12185-012-1188-5; Murugappan S, 2006, FRONT BIOSCI, V11, P1977, DOI 10.2741/1939; Ochoa JL, 2009, NEUROLOGY, V72, P1282, DOI 10.1212/01.wnl.0000346325.50431.5f; Pinheiro AR, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-70; Rossi B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039983; Salinska E, 2008, NEUROSCI LETT, V432, P137, DOI 10.1016/j.neulet.2007.12.013; Simon J, 2002, J BIOL CHEM, V277, P31390, DOI 10.1074/jbc.M110714200; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Unterberger U, 2002, BRIT J PHARMACOL, V135, P673, DOI 10.1038/sj.bjp.0704514; Villa G, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-89; von Kugelgen I, 2008, PHARM MAMMALIAN P2X	43	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-0102	1872-8111		NEUROSCI RES	Neurosci. Res.	SEP	2015	98						17	27		10.1016/j.neures.2015.04.008		11	Neurosciences	Neurosciences & Neurology	CP5XW	WOS:000359959800003		
J	Kondo, T; Yoshihara, Y; Yoshino-Saito, K; Sekiguchi, T; Kosugi, A; Miyazaki, Y; Nishimura, Y; Okano, HJ; Nakamura, M; Okano, H; Isa, T; Ushiba, J				Kondo, Takahiro; Yoshihara, Yamato; Yoshino-Saito, Kimika; Sekiguchi, Tornofumi; Kosugi, Akito; Miyazaki, Yuta; Nishimura, Yukio; Okano, Hirotaka J.; Nakamura, Masaya; Okano, Hideyuki; Isa, Tadashi; Ushiba, Junichi			Histological and electrophysiological analysis of the corticospinal pathway to forelimb motoneurons in common marmosets	NEUROSCIENCE RESEARCH			English	Article						Corticospinal tract; Common marmoset; Non-human primate; Manual dexterity; Motoneuron; Segmental interneuron	PRIMARY MOTOR CORTEX; UPPER-LIMB MOTONEURONS; SPINAL-CORD-INJURY; NEUROSCIENCE RESEARCH; DESCENDING PATHWAYS; SENSORIMOTOR CORTEX; NONHUMAN PRIMATE; BROWN-SEQUARD; MONKEYS; PROJECTIONS	Using histological and electrophysiological methods, we identified the neuroanatomical properties of the common marmoset corticospinal tract (CST), which underlies hand/arm motor control. Biotinylated dextran amine (BDA) was injected into the primary motor cortex to anterogradely label CST axons in the cervical segments, revealing that most CST axons descend in the contralateral dorsolateral funiculus (DLF; 85.0%), and some in the ipsilateral DLF (10.7%). Terminal buttons were mainly found in the contralateral lamina VII of the gray matter, but projection to lamina IX, where forelimb motoneurons are located, was rare. Bilateral projections were more abundant than found in the rat CST, resembling the CST organization of other primates. Intracellular recordings were made from 57 forelimb motoneurons on the contralateral side to stimulation, which revealed no monosynaptic excitatory postsynaptic potentials (EPSPs), but di- or polysynaptic EPSPs and inhibitory synaptic potentials were commonly found. Local field potentials showed monosynaptic excitation mainly in laminae VII, where abundant BDA-labeled CST terminals were observed. These results suggest that direct corticomotoneuronal projection is absent in common marmosets but di -or oligosynaptic effects would be mediated by spinal interneurons. (C) 2015 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.	[Kondo, Takahiro; Yoshino-Saito, Kimika; Okano, Hideyuki] Keio Univ, Sch Med, Dept Physiol, Tokyo 160, Japan; [Yoshihara, Yamato; Sekiguchi, Tornofumi; Kosugi, Akito; Miyazaki, Yuta] Keio Univ, Grad Sch Sci & Technol, Sch Fundamental Sci & Technol, Kanagawa, Japan; [Yoshino-Saito, Kimika] Japan Soc Promot Sci, Tokyo, Japan; [Nishimura, Yukio; Isa, Tadashi] Natl Inst Physiol Sci, Dept Dev Physiol, Aichi, Japan; [Okano, Hirotaka J.] Jikei Univ, Sch Med, Div Regenerat Med, Tokyo, Japan; [Nakamura, Masaya] Keio Univ, Sch Med, Dept Orthopaed Surg, Tokyo, Japan; [Ushiba, Junichi] Keio Univ, Dept Biosci & Informat, Fac Sci & Technol, Kanagawa, Japan; [Ushiba, Junichi] Keio Univ, Sch Med, Dept Rehabil Med, Tokyo, Japan	Ushiba, J (reprint author), Keio Univ, Dept Biosci & Informat, Fac Sci & Technol, Kanagawa, Japan.	ushiba@brain.bio.keio.ac.jp	Okano, Hideyuki/J-5973-2013		Japan Orthopaedics and Traumatology Research Foundation, Inc. [245]; JSPS Fellows [23-40018]; Japan Science and Technology Agency (JST); Keio Gijuku Academic Development Funds	This work was supported by grants of Japan Orthopaedics and Traumatology Research Foundation, Inc. No. 245 to Y.K., Grant-in-Aid for JSPS Fellows (23-40018) to Y. K., Research Center Network for Realization of Regenerative Medicine from the Japan Science and Technology Agency (JST) to H.O., and Keio Gijuku Academic Development Funds to J. U.	Ando K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046371; Brus-Ramer M, 2007, J NEUROSCI, V27, P13793, DOI 10.1523/JNEUROSCI.3489-07.2007; Sasaki E, 2009, NATURE, V459, P523, DOI 10.1038/nature08090; Schieber MH, 2004, J APPL PHYSIOL, V96, P2293, DOI 10.1152/japplphysiol.01063.2003; REXED B, 1954, J COMP NEUROL, V100, P297, DOI 10.1002/cne.901000205; Burman KJ, 2008, J COMP NEUROL, V506, P860, DOI 10.1002/cne.21580; NUDO RJ, 1992, J NEUROSCI, V12, P2918; HEFFNER RS, 1983, BRAIN BEHAV EVOLUT, V23, P165, DOI 10.1159/000121494; Rosenzweig ES, 2009, J COMP NEUROL, V513, P151, DOI 10.1002/cne.21940; Alstermark B, 2004, J NEUROPHYSIOL, V91, P1832, DOI 10.1152/jn.00820.2003; Isa T, 2007, PHYSIOLOGY, V22, P145, DOI 10.1152/physiol.00045.2006; Lemon RN, 2005, MUSCLE NERVE, V32, P261, DOI 10.1002/mus.20333; Alstermark B, 2012, ANNU REV NEUROSCI, V35, P559, DOI 10.1146/annurev-neuro-062111-150527; Okano H, 2012, SEMIN FETAL NEONAT M, V17, P336, DOI 10.1016/j.siny.2012.07.002; Takei T, 2010, J NEUROSCI, V30, P17041, DOI 10.1523/JNEUROSCI.4297-10.2010; BORTOFF GA, 1993, J NEUROSCI, V13, P5105; Nakajima K, 2000, J NEUROPHYSIOL, V84, P698; Kinoshita M, 2012, NATURE, V487, P235, DOI 10.1038/nature11206; PALMER E, 1992, J PHYSIOL-LONDON, V448, P397; Belmonte JCI, 2015, NEURON, V86, P617, DOI 10.1016/j.neuron.2015.03.021; Morecraft RJ, 2013, J COMP NEUROL, V521, P4205, DOI 10.1002/cne.23410; Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547; Kishi N, 2014, DEV GROWTH DIFFER, V56, P53, DOI 10.1111/dgd.12109; NATHAN PW, 1990, BRAIN, V113, P303, DOI 10.1093/brain/113.2.303; Spinozzi G, 2004, AM J PHYS ANTHROPOL, V125, P30, DOI 10.1002/ajpa.10362; Iwanami A, 2005, J NEUROSCI RES, V80, P172, DOI 10.1002/jnr.20435; ALSTERMARK B, 1990, EXP BRAIN RES, V80, P1; Emborg ME, 2007, ILAR J, V48, P339; Rosenzweig ES, 2010, NAT NEUROSCI, V13, P1505, DOI 10.1038/nn.2691; Bihel E, 2010, J CEREBR BLOOD F MET, V30, P273, DOI 10.1038/jcbfm.2009.209; Burish MJ, 2008, J COMP NEUROL, V507, P1151, DOI 10.1002/cne.21596; Higo N, 2009, J COMP NEUROL, V516, P493, DOI 10.1002/cne.22121; Hikishima K., 2015, RADIOLOGY; ILLERT M, 1976, EXP BRAIN RES, V26, P509; Isa Tadashi, 2013, Front Neurol, V4, P191, DOI 10.3389/fneur.2013.00191; LITTLE JW, 1985, PARAPLEGIA, V23, P39; Puentes S., 2015, NEUROSCIENCE, V285, P400; ROTH EJ, 1991, PARAPLEGIA, V29, P582; ROUILLER EM, 1991, EXP NEUROL, V114, P53, DOI 10.1016/0014-4886(91)90084-P; Takemi M, 2014, BEHAV BRAIN RES, V275, P259, DOI 10.1016/j.bbr.2014.09.020; Tanaka H, 2004, NEUROSCI RES, V49, P113, DOI 10.1016/j.neures.2004.02.001; Umeda T, 2010, J NEUROPHYSIOL, V104, P1707, DOI 10.1152/jn.00968.2009; Yamamoto T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065701; Yoshino-Saito K, 2010, NEUROSCIENCE, V171, P1164, DOI 10.1016/j.neuroscience.2010.10.007	44	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-0102	1872-8111		NEUROSCI RES	Neurosci. Res.	SEP	2015	98						35	44		10.1016/j.neures.2015.05.001		10	Neurosciences	Neurosciences & Neurology	CP5XW	WOS:000359959800005		
J	Murata, Y; Higo, N; Oishi, T; Isa, T				Murata, Yumi; Higo, Noriyuki; Oishi, Takao; Isa, Tadashi			Increased expression of the growth-associated protein-43 gene after primary motor cortex lesion in macaque monkeys	NEUROSCIENCE RESEARCH			English	Article						Functional recovery; In situ hybridization; Perilesional area; Plastic changes; Ventral premotor cortex	SUBSTRATE MESSENGER-RNA; IN-SITU HYBRIDIZATION; BEHAVIORAL RECOVERY; MANUAL DEXTERITY; CEREBRAL-CORTEX; NORTHERN BLOT; BRAIN-INJURY; SPINAL-CORD; GAP-43; REORGANIZATION	We recently showed that changes of brain activity in the ipsilesional ventral premotor cortex (PMv) and perilesional primary motor cortex (M1) of macaque monkeys were responsible for recovery of manual dexterity after lesioning M1. To investigate whether axonal remodeling is associated with M1 lesion-induced changes in brain activity, we assessed gene expression of growth-associated protein-43 (GAP-43) in motor and premotor cortices. Increased expression was observed in the PMv during the period just after recovery and in the perilesional M1 during the plateau phase of recovery. Time-dependent and brain region-specific remodeling may play a role in functional recovery after lesioning M1. (C) 2015 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.	[Murata, Yumi; Higo, Noriyuki] Natl Inst Adv Ind Sci & Technol, Human Informat Res Inst, Tsukuba, Ibaraki 3058568, Japan; [Higo, Noriyuki] Japan Sci & Technol Agcy JST, Precursory Res Embryon Sci & Technol PRESTO, Kawaguchi, Saitama 3320012, Japan; [Higo, Noriyuki; Oishi, Takao; Isa, Tadashi] Japan Sci & Technol Agcy JST, CREST, Kawaguchi, Saitama 3320012, Japan; [Oishi, Takao] Kyoto Univ, Primate Res Inst, Dept Cellular & Mol Biol, Inuyama, Aichi 4848506, Japan; [Isa, Tadashi] Natl Inst Physiol Sci, Dept Dev Physiol, Okazaki, Aichi 4448585, Japan	Higo, N (reprint author), Natl Inst Adv Ind Sci & Technol, Human Informat Res Inst, Syst Neurosci Grp, Tsukuba, Ibaraki 3058568, Japan.	n.higo@aist.go.jp			Japan Society for the Promotion of Science (JSPS) Research Fellowship for Young Scientists; Precursory Research for Embryonic Science and Technology (PRESTO); Core Research for Evolutional Science and Technology (CREST) programs of the Japan Science and Technology Agency (JST)	We are grateful to Ms. M. Arikawa and Ms. A. Muramatsu for their excellent technical assistance, and to Dr. Y. Abe, Dr. S. Goto, and Mr. T. Takasu for their excellent care of the animals. This work was supported by a Japan Society for the Promotion of Science (JSPS) Research Fellowship for Young Scientists, and by grants from the Precursory Research for Embryonic Science and Technology (PRESTO) and the Core Research for Evolutional Science and Technology (CREST) programs of the Japan Science and Technology Agency (JST).	Murata Y, 2008, J NEUROPHYSIOL, V99, P773, DOI 10.1152/jn.01001.2007; Carmichael ST, 2005, EXP NEUROL, V193, P291, DOI 10.1016/j.expneurol.2005.01.004; Denny JB, 2006, CURR NEUROPHARMACOL, V4, P293, DOI 10.2174/157015906778520782; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; JONES EG, 1994, J NEUROSCI, V14, P611; TETZLAFF W, 1991, J NEUROSCI, V11, P2528; Borra E, 2010, J COMP NEUROL, V518, P2570, DOI 10.1002/cne.22353; STROEMER RP, 1995, STROKE, V26, P2135; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Rosenzweig ES, 2010, NAT NEUROSCI, V13, P1505, DOI 10.1038/nn.2691; Biernaskie J, 2001, J NEUROSCI, V21, P5272; Bendotti C, 1997, EUR J NEUROSCI, V9, P93, DOI 10.1111/j.1460-9568.1997.tb01357.x; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; Friel KM, 2000, NEUROREHAB NEURAL RE, V14, P187; Higo N, 2004, NEUROSCIENCE, V129, P167, DOI 10.1016/j.neuroscience.2004.07.039; Higo N, 2009, J COMP NEUROL, V516, P493, DOI 10.1002/cne.22121; Higo N, 2000, J NEUROSCI, V20, P6030; Higo N, 2004, CEREB CORTEX, V14, P1134, DOI 10.1093/cercor/bhh073; Higo N, 2007, BRAIN RES, V1171, P30, DOI 10.1016/j.brainres.2007.07.054; LINDA H, 1992, EXP BRAIN RES, V91, P284; MAYHEW TM, 1992, J NEUROCYTOL, V21, P313, DOI 10.1007/BF01191700; Murata Y, 2015, J NEUROSCI, V35, P84, DOI 10.1523/JNEUROSCI.1737-14.2015; Murata Y, 2005, NEUROSCIENCE, V136, P497, DOI 10.1016/j.neuroscience.2005.08.034; PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263; VANDERZEE CEEM, 1989, J NEUROSCI, V9, P3505; Weaver LC, 1997, NEUROSCIENCE, V81, P535, DOI 10.1016/S0306-4522(97)00151-6	28	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-0102	1872-8111		NEUROSCI RES	Neurosci. Res.	SEP	2015	98						64	69		10.1016/j.neures.2015.04.007		6	Neurosciences	Neurosciences & Neurology	CP5XW	WOS:000359959800009		
J	Sawai, N; Iijima, N; Ozawa, H; Matsuzaki, T				Sawai, Nobuhiko; Iijima, Norio; Ozawa, Hitoshi; Matsuzaki, Toshiyuki			Neurokinin B- and kisspeptin-positive fibers as well as tuberoinfundibular dopaminergic neurons directly innervate periventricular hypophyseal dopaminergic neurons in rats and mice (vol 84, pg 10, 2014)	NEUROSCIENCE RESEARCH			English	Correction									[Sawai, Nobuhiko; Matsuzaki, Toshiyuki] Gunma Univ, Dept Anat & Cell Biol, Grad Sch Med, Maebashi, Gunma 3718511, Japan; [Iijima, Norio; Ozawa, Hitoshi] Nippon Med Sch, Grad Sch Med, Dept Anat & Neurobiol, Bunkyo Ku, Tokyo 1138602, Japan	Sawai, N (reprint author), Gunma Univ, Dept Anat & Cell Biol, Grad Sch Med, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan.	nsawai@gunma-u.ac.jp					Sawai N, 2014, NEUROSCI RES, V84, P10, DOI 10.1016/j.neures.2014.05.002	1	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-0102	1872-8111		NEUROSCI RES	Neurosci. Res.	SEP	2015	98						70	74		10.1016/j.neures.2015.06.009		5	Neurosciences	Neurosciences & Neurology	CP5XW	WOS:000359959800010		
J	Sujitha, V; Murugan, K; Paulpandi, M; Panneerselvam, C; Suresh, U; Roni, M; Nicoletti, M; Higuchi, A; Madhiyazhagan, P; Subramaniam, J; Dinesh, D; Vadivalagan, C; Chandramohan, B; Alarfaj, AA; Munusamy, MA; Barnard, DR; Benelli, G				Sujitha, Vasu; Murugan, Kadarkarai; Paulpandi, Manickam; Panneerselvam, Chellasamy; Suresh, Udaiyan; Roni, Mathath; Nicoletti, Marcello; Higuchi, Akon; Madhiyazhagan, Pari; Subramaniam, Jayapal; Dinesh, Devakumar; Vadivalagan, Chithravel; Chandramohan, Balamurugan; Alarfaj, Abdullah A.; Munusamy, Murugan A.; Barnard, Donald R.; Benelli, Giovanni			Green-synthesized silver nanoparticles as a novel control tool against dengue virus (DEN-2) and its primary vector Aedes aegypti	PARASITOLOGY RESEARCH			English	Article						Botanical insecticides; Mosquito-borne diseases; Moringa oleifera; silver nanoparticles; Aedes aegypti; cytotoxicity	OLEIFERA LEAF EXTRACT; MORINGA-OLEIFERA; ANOPHELES-STEPHENSI; DIPTERA-CULICIDAE; PREDATION EFFICIENCY; ESSENTIAL OILS; FILARIASIS; MALARIA; BIOSYNTHESIS; MOSQUITOS	Dengue is an arthropod-borne viral infection mainly vectored through the bite of Aedes mosquitoes. Recently, its transmission has strongly increased in urban and semi-urban areas of tropical and sub-tropical regions worldwide, becoming a major international public health concern. There is no specific treatment for dengue. Its prevention and control solely depends on effective vector control measures. In this study, we proposed the green-synthesis of silver nanoparticles (AgNP) as a novel and effective tool against the dengue serotype DEN-2 and its major vector Aedes aegypti. AgNP were synthesized using the Moringa oleifera seed extract as reducing and stabilizing agent. AgNP were characterized using a variety of biophysical methods including UV-vis spectroscopy, Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDX), X-ray diffraction (XRD), and sorted for size categories. AgNP showed in vitro antiviral activity against DEN-2 infecting vero cells. Viral titer was 7 log(10) TCID50/ml in control (AgNP-free), while it dropped to 3.2 log(10) TCID50/ml after a single treatment with 20 mu l/ml of AgNP. After 6 h, DEN-2 yield was 5.8 log(10) PFU/ml in the control, while it was 1.4 log(10) PFU/ml post-treatment with AgNP (20 mu l/ml). AgNP were highly effective against the dengue vector A. aegypti, with LC50 values ranging from 10.24 ppm (I instar larvae) to 21.17 ppm (pupae). Overall, this research highlighted the concrete potential of green-synthesized AgNP in the fight against dengue and its primary vector A. aegypti. Further research on structure-activity relationships of AgNP against other dengue serotypes is urgently required.	[Sujitha, Vasu; Murugan, Kadarkarai; Paulpandi, Manickam; Panneerselvam, Chellasamy; Suresh, Udaiyan; Roni, Mathath; Madhiyazhagan, Pari; Subramaniam, Jayapal; Dinesh, Devakumar; Vadivalagan, Chithravel; Chandramohan, Balamurugan] Bharathiar Univ, Div Entomol, Dept Zool, Sch Life Sci, Coimbatore 641046, Tamil Nadu, India; [Nicoletti, Marcello] Univ Roma La Sapienza, Dept Environm Biol, I-00185 Rome, Italy; [Higuchi, Akon] Natl Res Inst Child Hlth & Dev, Dept Reprod, Tokyo 1578535, Japan; [Alarfaj, Abdullah A.; Munusamy, Murugan A.] King Saud Univ, Dept Bot & Microbiol, Coll Sci, Riyadh 11451, Saudi Arabia; [Barnard, Donald R.] USDA ARS, Ctr Med Agr & Vet Entomol, Gainesville, FL 32608 USA; [Benelli, Giovanni] Univ Pisa, Dept Agr Food & Environm, I-56124 Pisa, Italy	Benelli, G (reprint author), Univ Pisa, Dept Agr Food & Environm, Via Borghetto 80, I-56124 Pisa, Italy.	g.benelli@sssup.it	Benelli, Giovanni/A-9100-2013; 	Benelli, Giovanni/0000-0001-8971-6010	Deanship of Scientific Research at King Saud University [RGP-1435-057]; University Grant Commission of New Delhi	We are grateful to Prof. Heinz Mehlhorn and the anonymous reviewers for improving an earlier version of the manuscript. We would like to thank the Deanship of Scientific Research at King Saud University for its financial support (project no. RGP-1435-057). Dr. Jayapal Subramaniam is supported by the University Grant Commission of New Delhi (UGC-BSR-RFSMS-Research Fellowship in Science for Meritorious Students). We also thank the Research and Development Centre of Bharathiar University for providing instrumentation facilities.	Ali GH, 2004, INT J ENVIRON STUD, V61, P699, DOI 10.1080/0020723042000189877; Vasanth K, 2014, COLLOID SURFACE B, V117, P354, DOI 10.1016/j.colsurfb.2014.02.052; Rajakumar G, 2011, ACTA TROP, V118, P196, DOI 10.1016/j.actatropica.2011.03.003; Murugan K, 2015, EXP PARASITOL, V153, P129, DOI 10.1016/j.exppara.2015.03.017; Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2; Murrell S, 2011, BIOTECHNOL ADV, V29, P239, DOI 10.1016/j.biotechadv.2010.11.008; Dinesh D, 2015, PARASITOL RES, V114, P1519, DOI 10.1007/s00436-015-4336-z; Sathyavathi R, 2011, J NANOSCI NANOTECHNO, V11, P2031, DOI 10.1166/jnn.2011.3581; Rajan R, 2015, IND CROP PROD, V70, P356, DOI 10.1016/j.indcrop.2015.03.015; Muthukumaran U, 2015, PARASITOL RES, V114, P1817, DOI 10.1007/s00436-015-4368-4; Krishnaraj C, 2010, COLLOID SURFACE B, V76, P50, DOI 10.1016/j.colsurfb.2009.10.008; Murugan K, 2015, PARASITOL RES, V114, P2243, DOI 10.1007/s00436-015-4417-z; Hemingway J, 2000, ANNU REV ENTOMOL, V45, P371, DOI 10.1146/annurev.ento.45.1.371; Magudapathy P, 2001, PHYSICA B, V299, P142, DOI 10.1016/S0921-4526(00)00580-9; Panneerselvam C, 2012, PARASITOL RES, V111, P2241, DOI 10.1007/s00436-012-3073-9; Miura N, 2009, BIOCHEM BIOPH RES CO, V390, P733, DOI 10.1016/j.bbrc.2009.10.039; Hu RL, 2014, GENET MOL RES, V13, P7022, DOI 10.4238/2014.March.19.2; Prasad T. N. V. K. V., 2011, Asian Pacific Journal of Tropical Biomedicine, V1, P439, DOI 10.1016/S2221-1691(11)60096-8; Shameli K, 2012, MOLECULES, V17, P8506, DOI 10.3390/molecules17078506; Amer A, 2006, PARASITOL RES, V99, P478, DOI 10.1007/s00436-006-0184-1; Suresh U, 2015, PARASITOL RES, V114, P1551, DOI 10.1007/s00436-015-4339-9; Agra-Neto AC, 2014, PARASITOL RES, V113, P175, DOI 10.1007/s00436-013-3640-8; Amer A, 2006, PARASITOL RES, V99, P466, DOI 10.1007/s00436-006-0182-3; Guevara AP, 1999, MUTAT RES-GEN TOX EN, V440, P181, DOI 10.1016/S1383-5718(99)00025-X; Park S, 2014, APPL ENVIRON MICROB, V80, P2343, DOI [10.1128/AEM.03427-13, 10.1128/AEM.03427]; Sukirtha R, 2012, PROCESS BIOCHEM, V47, P273, DOI 10.1016/j.procbio.2011.11.003; Chuang PH, 2007, BIORESOURCE TECHNOL, V98, P232, DOI 10.1016/j.biortech.2005.11.003; Vivek R, 2012, PROCESS BIOCHEM, V47, P2405, DOI 10.1016/j.procbio.2012.09.025; Prabhu K., 2011, Asian Pacific Journal of Tropical Biomedicine, V1, P124, DOI 10.1016/S2221-1691(11)60009-9; Fayaz AM, 2010, NANOMED-NANOTECHNOL, V6, P103, DOI 10.1016/j.nano.2009.04.006; Kora AJ, 2010, CARBOHYD POLYM, V82, P670, DOI 10.1016/j.carbpol.2010.05.034; Benelli G, 2015, PARASITOL RES, V114, P391, DOI 10.1007/s00436-014-4286-x; Benelli G, 2015, PARASITOL RES, V114, P227, DOI 10.1007/s00436-014-4183-3; Bharali Rupjyoti, 2003, Asian Pac J Cancer Prev, V4, P131; CACERES A, 1992, J ETHNOPHARMACOL, V36, P233, DOI 10.1016/0378-8741(92)90049-W; Elchiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1; Finney DJ, 1971, PROBIT ANAL, P68, DOI DOI 10.1007/BF02431962; Goodsell DS, 2004, BIONANOTECHNOLOGY LE; Kalwar NH, 2013, APPL CATAL A-GEN, V453, P54, DOI 10.1016/j.apcata.2012.12.005; Kumar P., 2012, NANO BIOMED ENG, V4, P12, DOI DOI 10.5101/NBE.V4IL.P12-16; Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1; Mahalakshmi Abirami V, 2013, J MICROBIOL BIOTECHN, V3, P54; Mori Y, 2013, NANOSCALE RES LETT, V8, P1; Noginov MA, 2006, APPL PHYS B, V86, P458; Speshock Janice L., 2010, Journal of Nanobiotechnology, V8, P19, DOI 10.1186/1477-3155-8-19; Vaseeharan B, 2012, MATER LETT, V82, P171; Vaseeharan B, 2012, NANOTECHNOL DEV, V2, P12; Vinoth B, 2012, INT J RES BIOL SCI, V2, P98; WHO, 2012, HDB INT VECT MAN; World Health Organization (WHO), 2015, DENG SEV DENG	50	5	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0932-0113	1432-1955		PARASITOL RES	Parasitol. Res.	SEP	2015	114	9					3315	3325		10.1007/s00436-015-4556-2		11	Parasitology	Parasitology	CP4PW	WOS:000359865600016		
J	Austrup, J; Ntais, P; Christodoulou, V; Dedet, JP; Pratlong, F; Karanis, P; Antoniou, M				Austrup, Johannes; Ntais, Pantelis; Christodoulou, Vasiliki; Dedet, Jean-Pierre; Pratlong, Francine; Karanis, Panagiotis; Antoniou, Maria			Frequency of MDR 1-related p-gp overexpression in Greek Leishmania isolates (vol 113, pg 1225, 2014)	PARASITOLOGY RESEARCH			English	Correction									[Austrup, Johannes; Karanis, Panagiotis] Univ Cologne, Ctr Anat, Sch Med, Lab Med & Mol Parasitol,Inst 2, D-50931 Cologne, Germany; [Ntais, Pantelis; Antoniou, Maria] Univ Crete, Fac Med, Lab Clin Bacteriol Parasitol Zoonoses & Geog Med, Iraklion, Greece; [Christodoulou, Vasiliki] Vet Serv Cyprus, Nicosia, Cyprus; [Dedet, Jean-Pierre; Pratlong, Francine] Univ Montpellier I, Montpellier & French Natl Reference Ctr Leishmani, Hosp Univ Ctr CHRU, Fac Med,Lab Parasitol Mycol,CNRS 5290 IRD 224, Montpellier, France; [Dedet, Jean-Pierre; Pratlong, Francine] Univ Montpellier 2, UMR BMIVEGEC, Montpellier, France; [Karanis, Panagiotis] Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Obihiro, Hokkaido, Japan	Austrup, J (reprint author), Univ Cologne, Ctr Anat, Sch Med, Lab Med & Mol Parasitol,Inst 2, D-50931 Cologne, Germany.	johannesaustrup@gmail.com					JOHANNES J, 2014, PARASITOL RES, V113, P1225, DOI DOI 10.1007/S00436-014-3761-8	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0932-0113	1432-1955		PARASITOL RES	Parasitol. Res.	SEP	2015	114	9					3565	3565		10.1007/s00436-015-4572-2		1	Parasitology	Parasitology	CP4PW	WOS:000359865600044		
J	Sato, M; Ogura, M; Kamei, K; Ishikura, K; Ito, S				Sato, Mai; Ogura, Masao; Kamei, Koichi; Ishikura, Kenji; Ito, Shuichi			REFRACTORY STEROID-DEPENDENT NEPHROTIC SYNDROME UNDER B CELL DEPLETION AFTER RITUXIMAB TREATMENT	PEDIATRIC NEPHROLOGY			English	Meeting Abstract									[Sato, Mai; Ogura, Masao; Kamei, Koichi; Ishikura, Kenji] Natl Ctr Child Hlth & Dev, Div Nephrol & Rheumatol, Tokyo, Japan; [Ito, Shuichi] Yokohama City Univ, Sch Med, Dept Pediat, Tokyo, Japan								0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0931-041X	1432-198X		PEDIATR NEPHROL	Pediatr. Nephrol.	SEP	2015	30	9				O - 47	1560	1560				1	Pediatrics; Urology & Nephrology	Pediatrics; Urology & Nephrology	CP2ZC	WOS:000359745600069		
J	Ohtomo, Y; Umino, D; Takada, M; Fujinaga, S; Niijima, S				Ohtomo, Yoshiyuki; Umino, Daisuke; Takada, Masaru; Fujinaga, Shuichiro; Niijima, Shinichi			ATOMOXETINE AMELIORATES NOCTURNAL ENURESIS IN PATIENTS WITH MILD ADHD	PEDIATRIC NEPHROLOGY			English	Meeting Abstract									[Ohtomo, Yoshiyuki; Umino, Daisuke; Niijima, Shinichi] Juntendo Univ Nerima Hosp, Dept Pediat, Tokyo, Japan; [Takada, Masaru] Musashi Murayama Hosp, Dept Pediat, Tokyo, Japan; [Fujinaga, Shuichiro] Saitama Childrens Med Ctr, Div Nephrol, Tokyo, Japan								0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0931-041X	1432-198X		PEDIATR NEPHROL	Pediatr. Nephrol.	SEP	2015	30	9				P - 30	1576	1576				1	Pediatrics; Urology & Nephrology	Pediatrics; Urology & Nephrology	CP2ZC	WOS:000359745600119		
J	Okamoto, S; Sakama, T; Niimura, F; Mochizuki, H				Okamoto, Shojiro; Sakama, Takashi; Niimura, Fumio; Mochizuki, Hiroyuki			RENAL FUNCTION OF THE BABIES UPON THE DIAGNOSIS OF CONGENITAL URETHRAL STENOSIS	PEDIATRIC NEPHROLOGY			English	Meeting Abstract									[Okamoto, Shojiro; Sakama, Takashi] Tokai Univ Hachioji Hosp, Dept Pediat, Tokyo, Japan; [Niimura, Fumio; Mochizuki, Hiroyuki] Tokai Univ, Dept Pediat, Tokyo 151, Japan								0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0931-041X	1432-198X		PEDIATR NEPHROL	Pediatr. Nephrol.	SEP	2015	30	9				P - 92	1594	1594				1	Pediatrics; Urology & Nephrology	Pediatrics; Urology & Nephrology	CP2ZC	WOS:000359745600181		
J	Leifheit-Nestler, M; Basaran, M; Alesutan, I; Kuro-o, M; Voelkl, J; Lang, F; Haffner, D				Leifheit-Nestler, Maren; Basaran, Melis; Alesutan, Ioana; Kuro-o, Makoto; Voelkl, Jakob; Lang, Florian; Haffner, Dieter			CARDIAC EXPRESSION LEVELS OF FIBROBLAST GROWTH FACTOR 23 CORRELATE WITH LEFT VENTRICULAR HYPERTROPHY IN KLOTHO-HYPOMORPHIC MICE	PEDIATRIC NEPHROLOGY			English	Meeting Abstract									[Leifheit-Nestler, Maren; Basaran, Melis; Haffner, Dieter] Hannover Med Sch, Dept Pediat Kidney Liver & Metab Dis, Hannover, Germany; [Alesutan, Ioana; Voelkl, Jakob; Lang, Florian] Univ Tubingen, Dept Physiol, Tubingen, Germany; [Kuro-o, Makoto] Jichi Med Univ, Ctr Mol Med, Shimotsuke, Japan								0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0931-041X	1432-198X		PEDIATR NEPHROL	Pediatr. Nephrol.	SEP	2015	30	9				P - 118	1601	1602				2	Pediatrics; Urology & Nephrology	Pediatrics; Urology & Nephrology	CP2ZC	WOS:000359745600207		
J	Ishikura, K; Uemura, O; Hamasaki, Y; Ito, S; Hattori, M; Tanaka, R; Ohashi, Y; Nakanishi, K; Harada, R; Mikami, N; Nakai, H; Kaneko, T; Iijima, K; Honda, M				Ishikura, Kenji; Uemura, Osamu; Hamasaki, Yuko; Ito, Shuichi; Hattori, Motoshi; Tanaka, Ryojiro; Ohashi, Yasuo; Nakanishi, Koichi; Harada, Ryoko; Mikami, Naoaki; Nakai, Hideo; Kaneko, Tetsuji; Iijima, Kazumoto; Honda, Masataka			URINE beta 2-MICROGLOBULIN AS A SENSITIVE DIAGNOSTIC MARKER IN CHILDREN WITH CKD STAGE 3-5	PEDIATRIC NEPHROLOGY			English	Meeting Abstract									[Ishikura, Kenji; Uemura, Osamu; Hamasaki, Yuko; Ito, Shuichi; Hattori, Motoshi; Tanaka, Ryojiro; Ohashi, Yasuo; Nakanishi, Koichi; Harada, Ryoko; Mikami, Naoaki; Nakai, Hideo; Kaneko, Tetsuji; Iijima, Kazumoto; Honda, Masataka] Pediat Ckd Study Grp Japan, Tokyo, Japan								0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0931-041X	1432-198X		PEDIATR NEPHROL	Pediatr. Nephrol.	SEP	2015	30	9				P - 131	1606	1606				1	Pediatrics; Urology & Nephrology	Pediatrics; Urology & Nephrology	CP2ZC	WOS:000359745600220		
J	Miyazaki, K; Nishi, H; Enya, T; Miyazawa, T; Sugimoto, K; Yanagida, H; Okada, M; Takemura, T				Miyazaki, Kohei; Nishi, Hitomi; Enya, Takuji; Miyazawa, Tomoki; Sugimoto, Keisuke; Yanagida, Hidehiko; Okada, Mitsuru; Takemura, Tsukasa			BENEFICIAL EFFECTS OF TONSILLECTOMY FOR CLINICOPATHOLOGICAL FINDING AND CLINICAL OUTCOME OF CHILDHOOD IGA NEPHROPATY (IGAN) IN JAPAN	PEDIATRIC NEPHROLOGY			English	Meeting Abstract									[Miyazaki, Kohei; Nishi, Hitomi; Enya, Takuji; Miyazawa, Tomoki; Sugimoto, Keisuke; Yanagida, Hidehiko; Okada, Mitsuru; Takemura, Tsukasa] Kinki Univ, Sch Med, Osaka 589, Japan								0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0931-041X	1432-198X		PEDIATR NEPHROL	Pediatr. Nephrol.	SEP	2015	30	9				P - 146	1610	1611				2	Pediatrics; Urology & Nephrology	Pediatrics; Urology & Nephrology	CP2ZC	WOS:000359745600235		
J	Hashimoto, J; Hamada, R; Yamamoto, K; Hada, I; Mikami, N; Kubota, W; Terano, C; Harada, R; Ishikura, K; Hataya, H; Honda, M				Hashimoto, Junya; Hamada, Riku; Yamamoto, Kazuna; Hada, Ichiro; Mikami, Naoaki; Kubota, Wataru; Terano, Chikako; Harada, Ryoko; Ishikura, Kenji; Hataya, Hiroshi; Honda, Masataka			RELATIONSHIP BETWEEN PROTEINURIA AND DECREASE OF ESTIMATED GLOMERULAR FILTRATION RATE IN LONG TERM OUTCOMES OF CHILDREN WITH SHIGATOXIN-ASSOCIATED HEMOLYTIC UREMIC SYNDROME	PEDIATRIC NEPHROLOGY			English	Meeting Abstract									[Hashimoto, Junya; Hamada, Riku; Yamamoto, Kazuna; Hada, Ichiro; Mikami, Naoaki; Kubota, Wataru; Terano, Chikako; Harada, Ryoko; Hataya, Hiroshi; Honda, Masataka] Tokyo Metropolitan Childrens Med Ctr, Dept Nephrol, Tokyo, Japan; [Ishikura, Kenji] Natl Ctr Child Hlth & Dev, Dept Nephrol & Rheumatol, Tokyo, Japan								0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0931-041X	1432-198X		PEDIATR NEPHROL	Pediatr. Nephrol.	SEP	2015	30	9				P - 256	1647	1647				1	Pediatrics; Urology & Nephrology	Pediatrics; Urology & Nephrology	CP2ZC	WOS:000359745600345		
J	Nozu, K; Kamiyoshi, N; Matsunoshita, N; Minamikawa, S; Yamamura, T; Ninchoji, T; Tanaka, R; Nakanishi, K; Yoshikawa, N; Iijima, K				Nozu, Kandai; Kamiyoshi, Naohiro; Matsunoshita, Natsuki; Minamikawa, Shogo; Yamamura, Tomohiko; Ninchoji, Takeshi; Tanaka, Ryojiro; Nakanishi, Koichi; Yoshikawa, Norishige; Iijima, Kazumoto			GENETIC, PATHOLOGICAL AND CLINICAL BACKGROUNDS IN AUTOSOMAL DOMINANT ALPORT SYNDROME	PEDIATRIC NEPHROLOGY			English	Meeting Abstract									[Nozu, Kandai; Kamiyoshi, Naohiro; Matsunoshita, Natsuki; Minamikawa, Shogo; Yamamura, Tomohiko; Ninchoji, Takeshi; Iijima, Kazumoto] Kobe Univ, Kobe, Hyogo 657, Japan; [Tanaka, Ryojiro] Kobe Childrens Hosp, Kobe, Hyogo, Japan; [Nakanishi, Koichi; Yoshikawa, Norishige] Wakayama Med Univ, Wakayama, Japan								0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0931-041X	1432-198X		PEDIATR NEPHROL	Pediatr. Nephrol.	SEP	2015	30	9				P - 319	1669	1669				1	Pediatrics; Urology & Nephrology	Pediatrics; Urology & Nephrology	CP2ZC	WOS:000359745600407		
J	Miyazawa, T; Enya, T; Nishi, H; Sugimoto, K; Yanagida, H; Okada, M; Takemura, T				Miyazawa, Tomoki; Enya, Takuji; Nishi, Hitomi; Sugimoto, Keisuke; Yanagida, Hidehiko; Okada, Mitsuru; Takemura, Tsukasa			DYSFUNCTION OF ECT2 GENE MAY CAUSE TUBULOINTERSTITIAL INJURY LEADING TO SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS IN THE MOUSE MODEL OF KIDNEY INJURY WITH ARISTOLOCHIC ACID ADMINISTRATION	PEDIATRIC NEPHROLOGY			English	Meeting Abstract									[Miyazawa, Tomoki; Enya, Takuji; Nishi, Hitomi; Sugimoto, Keisuke; Yanagida, Hidehiko; Okada, Mitsuru; Takemura, Tsukasa] Kinki Univ, Fac Med, Dept Pediat, Osaka, Japan								0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0931-041X	1432-198X		PEDIATR NEPHROL	Pediatr. Nephrol.	SEP	2015	30	9				P - 371	1687	1687				1	Pediatrics; Urology & Nephrology	Pediatrics; Urology & Nephrology	CP2ZC	WOS:000359745600459		
J	Yoshida, Y; Hamasaki, Y; Takahashi, Y; Kubota, M; Hashimoto, J; Yonekura, T; Nihei, H; Hyoudo, Y; Itabashi, Y; Muramastu, M; Kawamura, T; Shishido, S; Aikawa, A				Yoshida, Yasuhiro; Hamasaki, Yuko; Takahashi, Yusuke; Kubota, Mai; Hashimoto, Junya; Yonekura, Takashi; Nihei, Hiroshi; Hyoudo, Youji; Itabashi, Yoshihiro; Muramastu, Masaki; Kawamura, Takeshi; Shishido, Seiichiro; Aikawa, Atsushi			CHANGE IN ANTIBODY TITERS FOR MEASLES, RUBELLA, MUMPS, AND VARICELLA IN CHILDREN RECEIVING KIDNEY TRANSPLANTATION	PEDIATRIC NEPHROLOGY			English	Meeting Abstract									[Yoshida, Yasuhiro; Hamasaki, Yuko; Takahashi, Yusuke; Kubota, Mai; Hashimoto, Junya; Shishido, Seiichiro] Toho Univ, Fac Med Toho, Dept Pediat Nephrol, Toho, Japan; [Yonekura, Takashi; Nihei, Hiroshi; Hyoudo, Youji; Itabashi, Yoshihiro; Muramastu, Masaki; Kawamura, Takeshi; Aikawa, Atsushi] Toho Univ, Fac Med Toho, Dept Nephrol, Toho, Japan								0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0931-041X	1432-198X		PEDIATR NEPHROL	Pediatr. Nephrol.	SEP	2015	30	9				P - 457	1718	1718				1	Pediatrics; Urology & Nephrology	Pediatrics; Urology & Nephrology	CP2ZC	WOS:000359745600545		
J	Aksoy, GK; Koyun, M; Gemici, A; IchIda, K; Aliosmanoglu, I; Dinckan, A; Akman, S				Aksoy, Gulsah Kaya; Koyun, Mustafa; Gemici, Atilla; IchIda, KImIyoshI; Aliosmanoglu, Ibrahim; Dinckan, Ayhan; Akman, Sema			SUCCESSFUL KIDNEY TRANSPLANTATION IN A PATIENT WITH HEREDITARY XANTHINURIA	PEDIATRIC NEPHROLOGY			English	Meeting Abstract									[Aksoy, Gulsah Kaya; Koyun, Mustafa; Gemici, Atilla; Akman, Sema] Akdeniz Univ, Fac Med, Pediat Nephrol Dept, TR-07058 Antalya, Turkey; [IchIda, KImIyoshI] Tokyo Univ Pharm & Life Sci, Dept Pathophysiol, Tokyo, Japan; [Aliosmanoglu, Ibrahim; Dinckan, Ayhan] Akdeniz Univ, Fac Med, Dept Gen Surg, TR-07058 Antalya, Turkey								0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0931-041X	1432-198X		PEDIATR NEPHROL	Pediatr. Nephrol.	SEP	2015	30	9				P - 472	1723	1723				1	Pediatrics; Urology & Nephrology	Pediatrics; Urology & Nephrology	CP2ZC	WOS:000359745600560		
J	Takeyama, E; Tanaka, M; Fujishiro, J; Kitagawa, N; Iwanaka, T; Tanaka, Y				Takeyama, Eriko; Tanaka, Mio; Fujishiro, Jun; Kitagawa, Norihiko; Iwanaka, Tadashi; Tanaka, Yukichi			A case of alpha-fetoprotein-producing gastric cancer in a child presenting with rupture of multiple liver metastases	PEDIATRIC SURGERY INTERNATIONAL			English	Article						Alpha-fetoprotein-producing gastric cancer; Children; Metastasis; Liver	CLINICOPATHOLOGICAL FEATURES; BETA-CATENIN; CARCINOMA; ADENOCARCINOMA; EXPRESSION	We report a 14-year-old boy with alpha-fetoprotein-producing gastric cancer (AFPGC) who was found with ruptured metastatic tumor in the liver. AFPGC is exceedingly rare in pediatric age. It often shows metastases to the liver and should be included in differential diagnoses of liver tumors with increased serum AFP.	[Takeyama, Eriko; Tanaka, Mio; Tanaka, Yukichi] Kanagawa Childrens Med Ctr, Dept Pathol, Minami Ku, Yokohama, Kanagawa 2328555, Japan; [Takeyama, Eriko; Fujishiro, Jun; Iwanaka, Tadashi] Univ Tokyo, Dept Pediat Surg, Tokyo, Japan; [Kitagawa, Norihiko] Kanagawa Childrens Med Ctr, Dept Surg, Yokohama, Kanagawa 2328555, Japan	Takeyama, E (reprint author), Kanagawa Childrens Med Ctr, Dept Pathol, Minami Ku, Mutsukawa 2-138-4, Yokohama, Kanagawa 2328555, Japan.	erikotakeyama-tky@umin.ac.jp					Liu XW, 2010, J SURG ONCOL, V102, P249, DOI 10.1002/jso.21624; Zhou YN, 2002, WORLD J GASTROENTERO, V8, P987; Uozaki H, 2008, INT J CLIN EXP PATHO, V1, P198; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#; Chiba N, 2005, ANTICANCER RES, V25, P2965; Curtis JL, 2008, J PEDIATR SURG, V43, P1487, DOI 10.1016/j.jpedsurg.2007.11.016; Emir S, 2014, TURKISH J PEDIATR, V56, P88; Furuya Y, 2011, J CLIN ONCOL, V29, pE647, DOI 10.1200/JCO.2011.34.9670; Harting Matthew T, 2004, J Pediatr Surg, V39, pe8, DOI 10.1016/j.jpedsurg.2004.04.043; MCGILL TW, 1993, J PEDIATR SURG, V28, P1620, DOI 10.1016/0022-3468(93)90120-A; Michalek J, 2000, PEDIATR HEMAT ONCOL, V17, P511, DOI 10.1080/08880010050120881; Nakamura T, 1999, J SURG ONCOL, V71, P214, DOI 10.1002/(SICI)1096-9098(199908)71:4<214::AID-JSO2>3.0.CO;2-D; Subbiah V, 2011, PEDIATR BLOOD CANCER, V57, P524, DOI 10.1002/pbc.23051	13	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0179-0358	1437-9813		PEDIATR SURG INT	Pediatr. Surg. Int.	SEP	2015	31	9					885	888		10.1007/s00383-015-3724-x		4	Pediatrics; Surgery	Pediatrics; Surgery	CP4DG	WOS:000359831600015		
J	Okahara, S; Tsuji, T; Ninomiya, S; Miyamoto, S; Takahashi, H; Soh, Z; Sueda, T				Okahara, S.; Tsuji, T.; Ninomiya, S.; Miyamoto, S.; Takahashi, H.; Soh, Z.; Sueda, T.			Hydrodynamic characteristics of a membrane oxygenator: modeling of pressure-flow characteristics and their influence on apparent viscosity	PERFUSION-UK			English	Article						cardiopulmonary bypass; oxygenator; blood viscosity; pressure gradient; pressure-flow characteristics	CARDIOPULMONARY BYPASS; HUMAN BLOOD; RHEOLOGY; MICROCIRCULATION	The viscosity obtained from pressure-flow characteristics of an oxygenator may help to detect factors that change oxygenator resistance. The objective of this study was to model pressure-flow characteristics of a membrane oxygenator with an integrated arterial filter and to quantify their influence on apparent viscosity of non-Newtonian fluids. One Newtonian fluid (glycerin solution) and two non-Newtonian fluids (whole bovine blood and a human red blood cell suspension) were perfused through an oxygenator and their pressure-flow characteristics examined systematically. Four resistance parameters for the pressure gradient characteristics approximation equation were obtained by the least squares method from the relational expression of pressure-flow characteristics and viscosity. For all three fluids, a non-linear flow to pressure change was observed with a coefficient of determination of almost 1 by exponential approximation. The glycerin solution had a higher pressure gradient (10-70%) than the other fluids; the apparent viscosity of the non-Newtonian fluids was around 35% lower than the static one measured by a torsional oscillation viscometer. Overall, our study demonstrated that the influence on the apparent viscosity of non-Newtonian fluids can be quantified by pressure gradient differences in a membrane oxygenator with an integrated arterial filter.	[Okahara, S.] Hiroshima Univ, Grad Sch Engn, Dept Syst Cybernet, Hiroshima, Japan; [Tsuji, T.; Soh, Z.] Hiroshima Univ, Inst Engn, Dept Syst Cybernet, Hiroshima, Japan; [Ninomiya, S.] Hiroshima Int Univ, Dept Clin Engn, Hiroshima, Japan; [Okahara, S.; Miyamoto, S.; Takahashi, H.] Hiroshima Univ Hosp, Dept Clin Engn, Hiroshima 7348551, Japan; [Sueda, T.] Hiroshima Univ Hosp, Dept Cardiovasc Surg, Hiroshima 7348551, Japan	Okahara, S (reprint author), Hiroshima Univ Hosp, Dept Clin Engn, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	okahara@hiroshima-u.ac.jp	Tsuji, Toshio/D-6210-2011	Tsuji, Toshio/0000-0002-7689-3963			RAND PW, 1964, J APPL PHYSIOL, V19, P117; Fedosov DA, 2010, MICROCIRCULATION, V17, P615, DOI 10.1111/j.1549-8719.2010.00056.x; REINHART WH, 1986, BLOOD, V67, P1110; MERRILL EW, 1963, BIOPHYS J, V3, P199; Maeda N, 1996, JPN J PHYSIOL, V46, P1, DOI 10.2170/jjphysiol.46.1; WHITMORE RL, 1967, NATURE, V215, P123, DOI 10.1038/215123a0; Popel AS, 2005, ANNU REV FLUID MECH, V37, P43, DOI 10.1146/annurev.fluid.37.042604.133933; Fisher AR, 2003, PERFUSION-UK, V18, P25, DOI 10.1191/0267659103pf635oa; Ganushchak Y, 2006, PERFUSION-UK, V21, P373, DOI 10.1177/0267659106074003; Hoffman JW, 2002, PERFUSION-UK, V17, P391, DOI 10.1191/0267659102pf601cr; London M, 1997, CLIN HEMORHEOL MICRO, V17, P93; Okamura N, 2010, JPN J EXTRA CORPOREA, V37, P347; PRIES AR, 1992, AM J PHYSIOL, V263, pH1770; Ranucci M, 2014, PHYSL REP, V2, DOI 10.14814/phy2.12065.; Travagli V, 2008, CLIN HEMORHEOL MICRO, V38, P65; Tsuji T, 1984, Tokyo Ika Shika Daigaku Iyo Kizai Kenkyusho Hokoku, V18, P67; Wickramasinghe SR, 2002, BIOTECHNOL PROGR, V18, P867, DOI 10.1021/bp010192h	17	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0267-6591	1477-111X		PERFUSION-UK	Perfusion-UK	SEP	2015	30	6					478	483		10.1177/0267659114562101		6	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Cardiovascular System & Cardiology	CP6MD	WOS:000360000600008		
J	Ishizawa, J; Kojima, K; Hail, N; Tabe, Y; Andreeff, M				Ishizawa, Jo; Kojima, Kensuke; Hail, Numsen, Jr.; Tabe, Yoko; Andreeff, Michael			Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein	PHARMACOLOGY & THERAPEUTICS			English	Review						CRM1; Nuclear export; SINE; Hematological malignancies; KPT-330; Ribosomal biogenesis	ACUTE MYELOID-LEUKEMIA; MANTLE CELL LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; LEPTOMYCIN-B; SELECTIVE INHIBITORS; NUCLEOCYTOPLASMIC TRANSPORT; SCHIZOSACCHAROMYCES-POMBE; STRUCTURAL BASIS; TYROSINE KINASE	Nucleocytoplasmic trafficking of proteins/RNAs is essential to normal cellular function. Indeed, accumulating evidence suggests that cancer cells escape anti-neoplastic mechanisms and benefit from pro-survival signals via the dysregulation of this system. The nuclear exporter chromosome region maintenance 1 (CRM1) protein is the only protein in the karyopherin-beta protein family that contributes to the trafficking of numerous proteins and RNAs from the nucleus. It is considered to be an oncogenic, anti-apoptotic protein in transformed cells, since it reportedly functions as a gatekeeper for cell survival, including affecting p53 function, and ribosomal biogenesis. Furthermore, abnormally high expression of CRMI is correlated with poor patient prognosis in various malignancies. Therapeutic targeting of CRM1 has emerged as a novel cancer treatment strategy, starting with a clinical trial with leptomycin B, the original specific inhibitor of CRM1, followed by development of several next-generation small molecules. ITT-330, a novel member of the CRMI -selective inhibitors of nuclear export (SINE) class of compounds, is currently undergoing clinical evaluation for the therapy of various malignancies. Results from these trials suggest that SINE compounds may be particularly useful against hematological malignancies, which often become refractory to standard chemotherapeutic agents. (C) 2015 Elsevier Inc. All rights reserved.	[Ishizawa, Jo; Kojima, Kensuke; Hail, Numsen, Jr.; Andreeff, Michael] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Mol Hematol & Therapy, Houston, TX 77030 USA; [Kojima, Kensuke] Saga Univ, Dept Med, Hematol Resp Med & Oncol, Saga 840, Japan; [Tabe, Yoko] Juntendo Univ, Sch Med, Dept Clin Lab Med, Tokyo 113, Japan	Andreeff, M (reprint author), 1515 Holcombe Blvd,Unit 448, Houston, TX 77070 USA.	mandreef@mdanderson.org			National Institutes of Health [CA49639, 100632, CA136411, CA16672]; Paul and Maly Haas Chair in Genetics; Japan Society for the Promotion of Science	This work was supported in part by grants from the National Institutes of Health (CA49639, 100632, CA136411, and CA16672), the Paul and Maly Haas Chair in Genetics (all to M.A.), and the Japan Society for the Promotion of Science Postdoctoral Fellowship for Research Abroad Award (to J. I.)	ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Culjkovic B, 2006, J CELL BIOL, V175, P415, DOI 10.1083/jcb.200604099; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Kohler A, 2007, NAT REV MOL CELL BIO, V8, P761, DOI 10.1038/nrm2255; Yanada M, 2005, LEUKEMIA, V19, P1345, DOI 10.1038/sj.leu.2403838; HAYAKAWA Y, 1995, J ANTIBIOT, V48, P954; Noske A, 2008, CANCER, V112, P1733, DOI 10.1002/cncr.23354; Falini B, 2006, BLOOD, V107, P4514, DOI 10.1182/blood-2005-11-4745; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Havelange V, 2014, BLOOD, V123, P2412, DOI 10.1182/blood-2013-10-532374; Etchin J, 2013, LEUKEMIA, V27, P66, DOI 10.1038/leu.2012.219; Newlands ES, 1996, BRIT J CANCER, V74, P648, DOI 10.1038/bjc.1996.415; Zhang KJ, 2013, EXP HEMATOL, V41, P67, DOI 10.1016/j.exphem.2012.09.002; Wach JY, 2010, BIOORG MED CHEM LETT, V20, P2843, DOI 10.1016/j.bmcl.2010.03.049; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Lucas CM, 2011, BLOOD, V117, P6660, DOI 10.1182/blood-2010-08-304477; Lapalombella R, 2012, BLOOD, V120, P4621, DOI 10.1182/blood-2012-05-429506; Kojima K, 2013, BLOOD, V121, P4166, DOI 10.1182/blood-2012-08-447581; Turner JG, 2009, CANCER RES, V69, P6899, DOI 10.1158/0008-5472.CAN-09-0484; Xu DR, 2012, MOL BIOL CELL, V23, P3673, DOI 10.1091/mbc.E12-01-0045; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Shen AG, 2009, NEUROSURGERY, V65, P153, DOI 10.1227/01.NEU.0000348550.47441.4B; Schmidt J, 2013, LEUKEMIA, V27, P2357, DOI 10.1038/leu.2013.172; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Ranganathan P, 2012, BLOOD, V120, P1765, DOI 10.1182/blood-2012-04-423160; Santagata S, 2013, SCIENCE, V341, P250, DOI 10.1126/science.1238303; Huang WY, 2009, CLIN INVEST MED, V32, pE315; Turner JG, 2012, BIOCHEM PHARMACOL, V83, P1021, DOI 10.1016/j.bcp.2011.12.016; Yoshimura M, 2014, CANCER SCI, V105, P795, DOI 10.1111/cas.12430; Turner JG, 2004, J CELL SCI, V117, P3061, DOI 10.1242/jcs.01147; Inoue H, 2013, J UROLOGY, V189, P2317, DOI 10.1016/j.juro.2012.10.018; Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796; Tiedemann RE, 2012, CANCER RES, V72, P757, DOI 10.1158/0008-5472.CAN-11-2781; Dong XH, 2009, NATURE, V458, P1136, DOI 10.1038/nature07975; HAMAMOTO T, 1985, J ANTIBIOT, V38, P1573; Van der Watt PJ, 2009, INT J CANCER, V124, P1829, DOI 10.1002/ijc.24146; Shao CX, 2011, CANCER CHEMOTH PHARM, V67, P1369, DOI 10.1007/s00280-010-1434-6; Thomas F, 2003, J CELL SCI, V116, P2409, DOI 10.1242/jcs.00464; Tai YT, 2014, LEUKEMIA, V28, P155, DOI 10.1038/leu.2013.115; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Yao Y, 2009, ONCOL REP, V21, P229, DOI 10.3892/or_00000213; Takenaka Y, 2004, MOL CELL BIOL, V24, P4395, DOI 10.1128/MCB.24.10.4395-4406.2004; Meissner T, 2004, FEBS LETT, V576, P27, DOI 10.1016/j.febslet.2004.08.056; Aloisi A, 2006, BLOOD, V107, P1591, DOI 10.1182/blood-2005-05-2123; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Monecke T, 2009, SCIENCE, V324, P1087, DOI 10.1126/science.1173388; Long JT, 2010, BLOOD, V116, P71, DOI 10.1182/blood-2010-01-261628; Sakakibara K, 2011, BLOOD, V118, P3922, DOI 10.1182/blood-2011-01-333138; Meani N, 2009, EXPERT REV ANTICANC, V9, P1283, DOI [10.1586/era.09.84, 10.1586/ERA.09.84]; Bonazzi S, 2007, ANGEW CHEM INT EDIT, V46, P8707, DOI 10.1002/anie.200703134; Jin LH, 2010, CANCER LETT, V299, P161, DOI 10.1016/j.canlet.2010.08.015; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; Etchin J, 2013, BRIT J HAEMATOL, V161, P117, DOI 10.1111/bjh.12231; Fukuda M, 1997, NATURE, V390, P308; Dong XH, 2009, NAT STRUCT MOL BIOL, V16, P558, DOI 10.1038/nsmb.1586; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; Li ZL, 2009, CELL CYCLE, V8, P2703; Daelemans D, 2002, P NATL ACAD SCI USA, V99, P14440, DOI 10.1073/pnas.212285299; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Bai BY, 2013, NUCLEUS-AUSTIN, V4, P315, DOI 10.4161/nucl.25342; Brown J Martin, 2003, Cancer Biol Ther, V2, P477; Burzlaff A, 2003, APPL MICROBIOL BIOT, V62, P174, DOI 10.1007/s00253-003-1300-0; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Eiring AM, 2008, BLOOD, V111, P816, DOI 10.1182/blood-2007-05-090472; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Gademann K, 2011, CURR DRUG TARGETS, V12, P1574; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/S1355838201016089; Golomb L, 2012, MOL CELL, V45, P222, DOI 10.1016/j.molcel.2011.11.022; Granneman S, 2005, CURR OPIN CELL BIOL, V17, P281, DOI 10.1016/j.ceb.2005.04.001; JEWERS K, 1974, STEROIDS, V24, P203, DOI 10.1016/0039-128X(74)90103-2; Khutornenko AA, 2010, P NATL ACAD SCI USA, V107, P12828, DOI 10.1073/pnas.0910885107; KOMIYAMA K, 1985, J ANTIBIOT, V38, P427; Kuruvilla J., 2013, BLOOD, V122; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; London CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087585; Mutka S. C., 2009, CANCER RES, V69, P510; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Raska I, 2004, BIOL CELL, V96, P579, DOI 10.1016/j.biolcel.2004.04.015; Savona M., 2013, BLOOD, V122; Tabe Y., 2013, BLOOD, V122; Van Neck T, 2008, BIOORGAN MED CHEM, V16, P9487, DOI 10.1016/j.bmc.2008.09.051; Walker CJ, 2013, BLOOD, V122, P3034, DOI 10.1182/blood-2013-04-495374; Whitman SP, 2008, BLOOD, V111, P1552, DOI 10.1182/blood-2007-08-107946; Wu CH, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000090	87	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0163-7258			PHARMACOL THERAPEUT	Pharmacol. Ther.	SEP	2015	153						25	35		10.1016/j.pharmthera.2015.06.001		11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CP4WE	WOS:000359882500003		
J	Okazaki, Y; Nishizawa, T; Takano, K; Ohnishi, M; Mimura, T; Saito, K				Okazaki, Yozo; Nishizawa, Tomoko; Takano, Kouji; Ohnishi, Miwa; Mimura, Tetsuro; Saito, Kazuki			Induced accumulation of glucuronosyldiacylglycerol in tomato and soybean under phosphorus deprivation	PHYSIOLOGIA PLANTARUM			English	Article							PHOSPHATE STARVATION; SULFOLIPID BIOSYNTHESIS; ARABIDOPSIS-THALIANA; UDP-SULFOQUINOVOSE; PLASMA-MEMBRANE; DIACYLGLYCEROL SULFOQUINOVOSYLTRANSFERASE; CHLOROPLAST ENVELOPES; GENOME SEQUENCE; CHARA-CORALLINA; GENE	Glucuronosyldiacylglycerol (GlcADG) is a plant glycolipid that accumulates in Arabidopsis and rice in response to phosphorus (P) starvation. It has been suggested that GlcADG functions to mitigate the stress induced by P depletion. Biosynthesis of GlcADG requires sulfolipid (SQDG) synthase, which is coded for in plant genomes. This indicates the possibility that GlcADG may be a general constituent of membrane lipids in plants. In this study, we investigated the SQDG synthases found in the genomes of higher plants, ferns, mosses, algae and cyanobacteria. In addition, we analyzed GlcADG accumulation, and the expression of SQDG synthase homologs in tomato and soybean plants grown under P-limited conditions. LC-MS analysis of lipids from these plants confirmed that GlcADG accumulated during P deprivation, as previously observed in Arabidopsis and rice. We also observed upregulation of SQDG synthase transcripts in these plants during P deprivation. These data suggest that GlcADG is present not only in model plants, but also in various other plant species, and that this lipid molecule performs an important physiological function as a mitigator of P-deprivation stress in plants.	[Okazaki, Yozo; Nishizawa, Tomoko; Takano, Kouji; Saito, Kazuki] RIKEN, Ctr Sustainable Resource Sci, Metabol Res Grp, Yokohama, Kanagawa 2300045, Japan; [Ohnishi, Miwa; Mimura, Tetsuro] Kobe Univ, Grad Sch Sci, Dept Biol, Kobe, Hyogo 6578501, Japan; [Saito, Kazuki] Chiba Univ, Grad Sch Pharmaceut Sci, Chiba 2608675, Japan	Saito, K (reprint author), RIKEN, Ctr Sustainable Resource Sci, Metabol Res Grp, Yokohama, Kanagawa 2300045, Japan.	kazuki.saito@riken.jp	Saito, Kazuki/D-2670-2009		Strategic International Collaborative Research Program of Japan Science and Technology Agency (Metabolomics for a Low Carbon Society, JST-NSF); Competitive Program for Creative Science and Technology of RIKEN (Integrated Lipidology); Japan Advanced Plant Science Network	This work was supported in part by grant aid from the Strategic International Collaborative Research Program of Japan Science and Technology Agency (Metabolomics for a Low Carbon Society, JST-NSF), and Competitive Program for Creative Science and Technology of RIKEN (Integrated Lipidology). This work was also supported by the Japan Advanced Plant Science Network.	Gaude N, 2007, PLANT J, V49, P729, DOI 10.1111/j.1365-313X.2006.02992.x; Benning C, 2005, J BIOL CHEM, V280, P2397, DOI 10.1074/jbc.R400032200; Andersson MX, 2005, J BIOL CHEM, V280, P27578, DOI 10.1074/jbc.M503273200; Sanda S, 2001, J BIOL CHEM, V276, P3941, DOI 10.1074/jbc.M008200200; Schmutz J, 2010, NATURE, V463, P178, DOI 10.1038/nature08670; Gaude N, 2008, PLANT J, V56, P28, DOI 10.1111/j.1365-313X.2008.03582.x; Okazaki Y, 2009, PLANT CELL, V21, P892, DOI 10.1105/tpc.108.063925; Nakamura Y, 2009, P NATL ACAD SCI USA, V106, P20978, DOI 10.1073/pnas.0907173106; Kobayashi K, 2009, PLANT J, V57, P322, DOI 10.1111/j.1365-313X.2008.03692.x; Misson J, 2005, P NATL ACAD SCI USA, V102, P11934, DOI 10.1073/pnas.0505266102; Nakamura Y, 2005, J BIOL CHEM, V280, P7469, DOI 10.1074/jbc.M408799200; FUJIWARA T, 1992, PLANT PHYSIOL, V99, P263, DOI 10.1104/pp.99.1.263; Kobayashi K, 2006, PLANT J, V47, P238, DOI 10.1111/j.1365-313X.2006.02778.x; Jouhet J, 2004, J CELL BIOL, V167, P863, DOI 10.1083/jcb.200407022; Awai K, 2001, P NATL ACAD SCI USA, V98, P10960, DOI 10.1073/pnas.181331498; Sato S, 2012, NATURE, V485, P635, DOI 10.1038/nature11119; Andersson MX, 2003, FEBS LETT, V537, P128, DOI 10.1016/S0014-5793(03)00109-1; Okazaki Y, 2014, PLANT J, V79, P584, DOI 10.1111/tpj.12556; Emanuelsson O, 1999, PROTEIN SCI, V8, P978; Kimbara J, 2013, PLANT CELL PHYSIOL, V54, P1535, DOI 10.1093/pcp/pct100; Le DT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046487; Yu B, 2002, P NATL ACAD SCI USA, V99, P5732, DOI 10.1073/pnas.082696499; Kelly AA, 2002, J BIOL CHEM, V277, P1166, DOI 10.1074/jbc.M110066200; Matyash V, 2008, J LIPID RES, V49, P1137, DOI 10.1194/jlr.D700041-JLR200; Fettke J, 2011, PLANT PHYSIOL, V155, P1723, DOI 10.1104/pp.110.168716; BIELESKI RL, 1973, ANNU REV PLANT PHYS, V24, P225, DOI 10.1146/annurev.pp.24.060173.001301; Hackel A, 2006, PLANT J, V45, P180, DOI 10.1111/j.1365-313X.2005.02572.x; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; Giavalisco P, 2011, PLANT J, V68, P364, DOI 10.1111/j.1365-313X.2011.04682.x; Essigmann B, 1998, P NATL ACAD SCI USA, V95, P1950, DOI 10.1073/pnas.95.4.1950; Benning Christoph, 2008, V27, P185; Benning C, 1998, ANNU REV PLANT PHYS, V49, P53, DOI 10.1146/annurev.arplant.49.1.53; BIELESKI RL, 1968, PLANT PHYSIOL, V43, P1297, DOI 10.1104/pp.43.8.1297; Eichenberger W, 1997, PHYTOCHEMISTRY, V45, P1561, DOI 10.1016/S0031-9422(97)00201-X; EICHENBERGER W, 1994, J PLANT PHYSIOL, V144, P272; ERGLE DR, 1959, PLANT PHYSIOL, V34, P476, DOI 10.1104/pp.34.4.476; Guler S, 2000, J BACTERIOL, V182, P543, DOI 10.1128/JB.182.2.543-545.2000; Haines TH, 1973, LIPIDS BIOMEMBRANES, P197; Mimura T, 1998, J EXP BOT, V49, P13, DOI 10.1093/jexbot/49.318.13; MIMURA T, 1990, BOT ACTA, V103, P408; Mudd JB, 1987, LIPIDS STRUCTURE FUN, P275; Oikawa A, 2011, PLANT PHYSIOL, V157, P544, DOI 10.1104/pp.111.183772; Okazaki Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2512; Okazaki Y., 2013, METABOLOMICS S1, V9, P121, DOI [10.1007/s11306-011-0318-z, DOI 10.1007/S11306-011-0318-Z]; Oono Y, 2013, PLANT MOL BIOL, V83, P523, DOI 10.1007/s11103-013-0106-4; ROSSAK M, 1995, J BIOL CHEM, V270, P25792; SEIFERT U, 1992, BOT ACTA, V105, P197; Tietje C, 1998, PLANTA, V206, P72, DOI 10.1007/s004250050375	48	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0031-9317	1399-3054		PHYSIOL PLANTARUM	Physiol. Plant.	SEP	2015	155	1			SI		33	42		10.1111/ppl.12334		10	Plant Sciences	Plant Sciences	CP4ND	WOS:000359858100005		
J	d'Ischia, M; Wakamatsu, K; Cicoira, F; Di Mauro, E; Garcia-Borron, JC; Commo, S; Galvan, I; Ghanem, G; Kenzo, K; Meredith, P; Pezzella, A; Santato, C; Sarna, T; Simon, JD; Zecca, L; Zucca, FA; Napolitano, A; Ito, S				d'Ischia, Marco; Wakamatsu, Kazumasa; Cicoira, Fabio; Di Mauro, Eduardo; Carlos Garcia-Borron, Jose; Commo, Stephane; Galvan, Ismael; Ghanem, Ghanem; Kenzo, Koike; Meredith, Paul; Pezzella, Alessandro; Santato, Clara; Sarna, Tadeusz; Simon, John D.; Zecca, Luigi; Zucca, Fabio A.; Napolitano, Alessandra; Ito, Shosuke			Melanins and melanogenesis: from pigment cells tohuman health and technological applications	PIGMENT CELL & MELANOMA RESEARCH			English	Review						melanogenesis control; bioelectronics; antioxidants; polydopamine; dermocosmetic applications; melanosomes; extracutaneous melanins	AGOUTI SIGNALING PROTEIN; HUMAN SUBSTANTIA-NIGRA; PARAMAGNETIC-RESONANCE SPECTROSCOPY; INDUCED DNA-DAMAGE; CUTTLEFISH SEPIA-OFFICINALIS; AVIAN MELANOCORTIN SYSTEM; HUMAN HAIR PHEOMELANIN; ION BINDING-SITES; PARKINSONS-DISEASE; HUMAN BRAIN	During the past decade, melanins and melanogenesis have attracted growing interest for a broad range of biomedical and technological applications. The burst of polydopamine-based multifunctional coatings in materials science is just one example, and the list may be expanded to include melanin thin films for organic electronics and bioelectronics, drug delivery systems, functional nanoparticles and biointerfaces, sunscreens, environmental remediation devices. Despite considerable advances, applied research on melanins and melanogenesis is still far from being mature. A closer intersectoral interaction between research centers is essential to raise the interests and increase the awareness of the biomedical, biomaterials science and hi-tech sectors of the manifold opportunities offered by pigment cells and related metabolic pathways. Starting from a survey of biological roles and functions, the present review aims at providing an interdisciplinary perspective of melanin pigments and related pathway with a view to showing how it is possible to translate current knowledge about physical and chemical properties and control mechanisms into new bioinspired solutions for biomedical, dermocosmetic, and technological applications.	[d'Ischia, Marco; Pezzella, Alessandro; Napolitano, Alessandra] Univ Naples Federico II, Dept Chem Sci, Naples, Italy; [Wakamatsu, Kazumasa; Ito, Shosuke] Fujita Hlth Univ, Sch Hlth Sci, Dept Chem, Toyoake, Aichi, Japan; [Cicoira, Fabio] Ecole Polytech, Dept Chem Engn, Montreal, PQ H3C 3A7, Canada; [Di Mauro, Eduardo] Ecole Polytech, Dept Engn Phys, Montreal, PQ H3C 3A7, Canada; [Carlos Garcia-Borron, Jose] Univ Murcia, IMIB Arrixaca, Sch Med, Murcia, Spain; [Commo, Stephane] LOreal Rech & Innovat, Aulnay Sous Bois, France; [Galvan, Ismael] CSIC, Estac Biol Donana, Dept Ecol Evolutiva, Seville, Spain; [Ghanem, Ghanem] Univ Libre Bruxelles, Inst J Bordet, LOCE, Brussels, Belgium; [Kenzo, Koike] Kao Corp, Dev Res Hair Care Prod, Sumida Ku, Tokyo, Japan; [Meredith, Paul] Univ Queensland, Sch Math & Phys, Ctr Organ Photon & Elect, Brisbane, Qld, Australia; [Sarna, Tadeusz] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Biophys, Krakow, Poland; [Simon, John D.] Univ Virginia, Dept Chem, Milan, Italy; [Zecca, Luigi; Zucca, Fabio A.] Natl Res Council Italy, Inst Biomed Technol, Milan, Italy	d'Ischia, M (reprint author), Univ Naples Federico II, Dept Chem Sci, Naples, Italy.	dischia@unina.it	Pezzella, Alessandro/E-1440-2011; d'Ischia, Marco/C-9837-2011; Napolitano, Alessandra /E-9761-2011; Zucca, Fabio/O-4368-2015	Pezzella, Alessandro/0000-0001-6925-922X; d'Ischia, Marco/0000-0002-7184-0029; Zucca, Fabio/0000-0003-1230-1129	Ramon y Cajal fellowship from Spanish Ministry of Economy and Competitiveness [RYC-2012-10237]	This review is a consensus document prepared by members of the EuMelaNet special interest group of the European Society for Pigment Cell Research (ESPCR). IG is supported by a Ramon y Cajal fellowship (RYC-2012-10237) from the Spanish Ministry of Economy and Competitiveness'. Additional information on specific topics addressed in this paper with relevant references is provided as Supporting Information.	Abbas M, 2011, J PHYS CHEM B, V115, P11199, DOI 10.1021/jp2033577; Ambrico M, 2014, ADV FUNCT MATER, V24, P7161, DOI 10.1002/adfm.201401377; Ambrico M, 2011, ADV MATER, V23, P3332, DOI 10.1002/adma.201101358; Ambrico M, 2015, J MATER CHEM C, V3, P6413, DOI 10.1039/c5tc00570a; Ambrico M, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.4729754; Fei B, 2008, CARBON, V46, P1795, DOI 10.1016/j.carbon.2008.06.049; ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; Adachi K, 2005, PIGM CELL RES, V18, P465, DOI 10.1111/j.1600-0749.2005.00272.x; Briganti S, 2003, PIGM CELL RES, V16, P101, DOI 10.1034/j.1600-0749.2003.00029.x; Gauden M, 2008, J AM CHEM SOC, V130, P17038, DOI 10.1021/ja806345q; Russo GL, 2003, BIOCHEM BIOPH RES CO, V308, P293, DOI 10.1016/S0006-291X(03)01379-2; Wakamatsu K, 2012, PIGM CELL MELANOMA R, V25, P434, DOI 10.1111/j.1755-148X.2012.01011.x; Hornykiewicz O, 1987, Adv Neurol, V45, P19; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; d'Ischia M, 2009, ANGEW CHEM INT EDIT, V48, P3914, DOI 10.1002/anie.200803786; Lee H, 2007, SCIENCE, V318, P426, DOI 10.1126/science.1147241; Wakamatsu K, 2003, J NEUROCHEM, V86, P1015, DOI 10.1046/j.1471-4159.2003.01917.x; Sanchez-Mas J, 2004, PIGM CELL RES, V17, P386, DOI 10.1111/j.1600-0749.2004.00160.x; CHEDEKEL MR, 1978, P NATL ACAD SCI USA, V75, P5395, DOI 10.1073/pnas.75.11.5395; Wunsche J, 2013, ADV FUNCT MATER, V23, P5591, DOI 10.1002/adfm.201300715; Vavricka CJ, 2014, INSECT SCI, V21, P13, DOI 10.1111/1744-7917.12038; Casadevall A, 2000, CURR OPIN MICROBIOL, V3, P354, DOI 10.1016/S1369-5274(00)00103-X; Raper HS, 1927, BIOCHEM J, V21, P89; Meredith P, 2004, PHOTOCHEM PHOTOBIOL, V79, P211, DOI 10.1562/0031-8655(2004)079<0211:RCRQYF>2.0.CO;2; Zecca L, 2002, FEBS LETT, V510, P216, DOI 10.1016/S0014-5793(01)03269-0; Arck PC, 2006, FASEB J, V20, P1567, DOI 10.1096/fj.05-4039fje; Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x; Ju KY, 2013, BIOMACROMOLECULES, V14, P3491, DOI 10.1021/bm4008138; Simon JD, 2010, ACCOUNTS CHEM RES, V43, P1452, DOI 10.1021/ar100079y; Ito S, 2011, PIGM CELL MELANOMA R, V24, P63, DOI 10.1111/j.1755-148X.2010.00755.x; d'Ischia M, 2011, EUR J ORG CHEM, P5501, DOI 10.1002/ejoc.201100796; Tadokoro T, 2003, FASEB J, V17, P1177, DOI 10.1096/fj.02-0865fje; Suzuki I, 1997, J INVEST DERMATOL, V108, P838, DOI 10.1111/1523-1747.ep12292572; Hong L, 2006, PHOTOCHEM PHOTOBIOL, V82, P1475, DOI 10.1562/2006-03-14-RA-846; Ito S, 2003, PIGM CELL RES, V16, P230, DOI 10.1034/j.1600-0749.2003.00037.x; Nosanchuk JD, 2003, CELL MICROBIOL, V5, P203, DOI 10.1046/j.1462-5814.2003.00268.x; Bernsmann F, 2011, LANGMUIR, V27, P2819, DOI 10.1021/la104981s; Ju KY, 2011, BIOMACROMOLECULES, V12, P625, DOI 10.1021/bm101281b; D'Orazio JA, 2006, NATURE, V443, P340, DOI 10.1038/nature05098; Boswell T, 2005, PEPTIDES, V26, P1733, DOI 10.1016/j.peptides.2004.11.039; Panzella L, 2013, ANGEW CHEM INT EDIT, V52, P12684, DOI 10.1002/anie.201305747; Bettinger CJ, 2009, BIOMATERIALS, V30, P3050, DOI 10.1016/j.biomaterials.2009.02.018; Abdel-Malek ZA, 2009, PIGM CELL MELANOMA R, V22, P635, DOI 10.1111/j.1755-148X.2009.00598.x; Bothma JP, 2008, ADV MATER, V20, P3539, DOI 10.1002/adma.200703141; Garcia-Borron JC, 2014, PIGM CELL MELANOMA R, V27, P699, DOI 10.1111/pcmr.12257; Bush WD, 2006, P NATL ACAD SCI USA, V103, P14785, DOI 10.1073/pnas.0604010103; Kanetsky PA, 2002, AM J HUM GENET, V70, P770, DOI 10.1086/339076; Waite JH, 2008, NAT MATER, V7, P8, DOI 10.1038/nmat2087; Zecca L, 2004, P NATL ACAD SCI USA, V101, P9843, DOI 10.1073/pnas.0403495101; Wielgus AR, 2005, PIGM CELL RES, V18, P454, DOI 10.1111/j.1600-0749.2005.00268.x; Takeuchi S, 2004, P NATL ACAD SCI USA, V101, P15076, DOI 10.1073/pnas.0403994101; Qu WG, 2010, J PHYS CHEM C, V114, P13010, DOI 10.1021/jp104492f; Eisenman HC, 2012, APPL MICROBIOL BIOT, V93, P931, DOI 10.1007/s00253-011-3777-2; Liu Y, 2003, PIGM CELL RES, V16, P606, DOI 10.1046/j.1600-0749.2003.00098.x; Commo S, 2012, INT J COSMETIC SCI, V34, P102, DOI 10.1111/j.1468-2494.2011.00691.x; Prota G, 1998, EXP EYE RES, V67, P293, DOI 10.1006/exer.1998.0518; Liu Y, 2003, PIGM CELL RES, V16, P72, DOI 10.1034/j.1600-0749.2003.00009.x; Napolitano A, 2014, PIGM CELL MELANOMA R, V27, P721, DOI 10.1111/pcmr.12262; Solano F, 2006, PIGM CELL RES, V19, P550, DOI 10.1111/j.1600-0749.2006.00334.x; MCGEER PL, 1988, NEUROLOGY, V38, P1285; Mostert AB, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.3688491; Dadachova E, 2008, CURR OPIN MICROBIOL, V11, P525, DOI 10.1016/j.mib.2008.09.013; Kobayashi N, 1998, J INVEST DERMATOL, V110, P806, DOI 10.1046/j.1523-1747.1998.00178.x; Meredith P, 2006, PIGM CELL RES, V19, P572, DOI 10.1111/j.1600-0749.2006.00345.x; Ito S, 2013, PIGM CELL MELANOMA R, V26, P357, DOI 10.1111/pcmr.12078; Capozzi V, 2006, THIN SOLID FILMS, V511, P362, DOI 10.1016/j.tsf.2005.12.065; Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1; Meng S, 2008, BIOPHYS J, V94, P2095, DOI 10.1529/biophysj.107.121087; Shao QM, 2012, J BIOL CHEM, V287, P14270, DOI 10.1074/jbc.M112.354548; POLACHECK I, 1988, J GEN MICROBIOL, V134, P1037; Ito S, 2011, PIGM CELL MELANOMA R, V24, P605, DOI 10.1111/j.1755-148X.2011.00864.x; Clusella Trullas S, 2007, J THERM BIOL, V32, P235, DOI 10.1016/j.jtherbio.2007.01.003; Kang SM, 2012, ADV FUNCT MATER, V22, P2949, DOI 10.1002/adfm.201200177; Bonilla C, 2005, HUM GENET, V116, P402, DOI 10.1007/s00439-004-1251-2; Cerda-Reverter JM, 2011, EUR J PHARMACOL, V660, P53, DOI 10.1016/j.ejphar.2010.10.108; Galvan I, 2009, P R SOC B, V276, P3089, DOI 10.1098/rspb.2009.0774; Tran ML, 2006, BIOPHYS J, V90, P743, DOI 10.1529/biophysj.105.069096; Sulzer D, 2000, P NATL ACAD SCI USA, V97, P11869, DOI 10.1073/pnas.97.22.11869; Corani A, 2014, J AM CHEM SOC, V136, P11626, DOI 10.1021/ja501499q; Kim YJ, 2013, P NATL ACAD SCI USA, V110, P20912, DOI 10.1073/pnas.1314345110; Derby CD, 2014, MAR DRUGS, V12, P2700, DOI 10.3390/md12052700; Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6; Weis E, 2006, ARCH OPHTHALMOL-CHIC, V124, P54, DOI 10.1001/archopht.124.1.54; Mitra D, 2012, NATURE, V491, P449, DOI 10.1038/nature11624; Zecca L, 2008, ACTA NEUROPATHOL, V116, P47, DOI 10.1007/s00401-008-0361-7; Plonka PM, 2006, ACTA BIOCHIM POL, V53, P429; Dreyer DR, 2012, LANGMUIR, V28, P6428, DOI 10.1021/la204831b; ZECCA L, 1993, J NEURAL TRANSM-PARK, V5, P203, DOI 10.1007/BF02257675; Liu Y, 2005, PHOTOCHEM PHOTOBIOL, V81, P135, DOI 10.1562/2004-08-03-RA-259.1; McGraw KJ, 2008, PIGM CELL MELANOMA R, V21, P133, DOI 10.1111/j.1755-148X.2008.00454.x; Land EJ, 2003, PIGM CELL RES, V16, P487, DOI 10.1034/j.1600-0749.2003.00082.x; Zhang W, 2011, NEUROTOX RES, V19, P63, DOI 10.1007/s12640-009-9140-z; Liu Y, 2004, PIGM CELL RES, V17, P262, DOI 10.1111/j.1600-0749.2004.00140.x; KORYTOWSKI W, 1990, J BIOL CHEM, V265, P12410; BONSER RHC, 1995, CONDOR, V97, P590, DOI 10.2307/1369048; Nappi AJ, 2005, INSECT BIOCHEM MOLEC, V35, P443, DOI 10.1016/j.ibmb.2005.01.014; Samokhvalov A, 2005, PHOTOCHEM PHOTOBIOL, V81, P145, DOI 10.1562/2004-07-23-RC-245.1; Yamamura K, 1996, CANCER RES, V56, P3546; Simon JD, 2008, J PHYS CHEM B, V112, P13201, DOI 10.1021/jp804248h; Jiang S, 2010, FREE RADICAL BIO MED, V48, P1144, DOI 10.1016/j.freeradbiomed.2010.01.033; Sulzer D, 2008, J NEUROCHEM, V106, P24, DOI 10.1111/j.1471-4159.2008.05385.x; Meredith P, 2013, REP PROG PHYS, V76, DOI 10.1088/0034-4885/76/3/034501; Fujii R, 2000, PIGM CELL RES, V13, P300, DOI 10.1034/j.1600-0749.2000.130502.x; Stark KB, 2005, J PHYS CHEM B, V109, P1970, DOI 10.1021/jp046710z; Swope VB, 2012, J INVEST DERMATOL, V132, P2255, DOI 10.1038/jid.2012.135; Mueller KP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087372; Orive AG, 2011, NANOSCALE, V3, P1708, DOI 10.1039/c0nr00911c; delMarmol V, 1996, J INVEST DERMATOL, V107, P698, DOI 10.1111/1523-1747.ep12365591; Nishimura EK, 2005, SCIENCE, V307, P720, DOI 10.1126/science.1099593; Gallas JM, 1999, BIOPHYS J, V77, P1135; Riley PA, 1997, INT J BIOCHEM CELL B, V29, P1235, DOI 10.1016/S1357-2725(97)00013-7; Ward WC, 2007, J LIPID RES, V48, P1457, DOI 10.1194/jlr.C700008-JLR200; Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003; Liu YL, 2014, CHEM REV, V114, P5057, DOI 10.1021/cr400407a; Ito S, 2006, P NATL ACAD SCI USA, V103, P14647, DOI 10.1073/pnas.0606879103; Edge R, 2006, PIGM CELL RES, V19, P443, DOI 10.1111/j.1600-0749.2006.00327.x; Mostert AB, 2012, P NATL ACAD SCI USA, V109, P8943, DOI 10.1073/pnas.1119948109; Aime S, 1997, BBA-MOL BASIS DIS, V1361, P49, DOI 10.1016/S0925-4439(97)00014-8; Langfelder K, 2003, FUNGAL GENET BIOL, V38, P143, DOI 10.1016/S1087-1845(02)00526-1; Korkina LG, 2007, CELL MOL BIOL, V53, P15, DOI 10.1170/T772; Sendoel A, 2010, NATURE, V465, P577, DOI 10.1038/nature09141; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; WAITE JH, 1981, SCIENCE, V212, P1038, DOI 10.1126/science.212.4498.1038; Inomata K, 2009, CELL, V137, P1088, DOI 10.1016/j.cell.2009.03.037; Schioth HB, 2003, GENOMICS, V81, P504, DOI 10.1016/S0888-7543(03)00028-4; Peles DN, 2009, J PHYS CHEM B, V113, P11346, DOI 10.1021/jp904138n; Clancy CMR, 2001, BIOCHEMISTRY-US, V40, P13353, DOI 10.1021/bi010786t; Hong L, 2007, J PHYS CHEM B, V111, P7938, DOI 10.1021/jp071439h; Kauser S, 2011, J INVEST DERMATOL, V131, P979, DOI 10.1038/jid.2010.397; Chen SG, 2009, BIOINORG CHEM APPL, DOI 10.1155/2009/901563; Brenner M, 2008, PHOTOCHEM PHOTOBIOL, V84, P539, DOI 10.1111/j.1751-1097.2007.00226.x; Zucca FA, 2014, NEUROTOX RES, V25, P13, DOI 10.1007/s12640-013-9435-y; Tarabella G, 2013, J MATER CHEM B, V1, P3843, DOI 10.1039/c3tb20639d; FELIX CC, 1978, BIOCHEM BIOPH RES CO, V84, P335, DOI 10.1016/0006-291X(78)90175-4; Wunsche J, 2015, CHEM MATER, V27, P436, DOI 10.1021/cm502939r; d'Ischia M, 2013, PIGM CELL MELANOMA R, V26, P616, DOI 10.1111/pcmr.12121; Meredith P, 2006, SOFT MATTER, V2, P37, DOI 10.1039/b511922g; Ito S, 2011, MELANINS AND MELANOSOMES: BIOSYNTHESIS, BIOGENESIS, PHYSIOLOGICAL, AND PATHOLOGICAL FUNCTIONS, P167; Greco G, 2011, CHEM COMMUN, V47, P10308, DOI 10.1039/c1cc13731j; Jacobson ES, 2000, CLIN MICROBIOL REV, V13, P708, DOI 10.1128/CMR.13.4.708-717.2000; Arzillo M, 2012, BIOMACROMOLECULES, V13, P2379, DOI 10.1021/bm3006159; TSE DCS, 1976, J MED CHEM, V19, P37, DOI 10.1021/jm00223a008; Samokhvalov A, 2004, PHOTOCHEM PHOTOBIOL, V80, P84, DOI 10.1562/2004-01-18-RA-047.1; Wolnicka-Glubisz A, 2012, EXP DERMATOL, V21, P537, DOI 10.1111/j.1600-0625.2012.01511.x; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; Ito S, 2008, PHOTOCHEM PHOTOBIOL, V84, P582, DOI 10.1111/j.1751-1097.2007.00238.x; Hong S, 2012, ADV FUNCT MATER, V22, P4711, DOI 10.1002/adfm.201201156; Kreuer KD, 2004, CHEM REV, V104, P4637, DOI 10.1021/cr020715f; Zecca L, 2008, J NEUROCHEM, V106, P1866, DOI 10.1111/j.1471-4159.2008.05541.x; Goncalves RCR, 2012, WORLD J MICROB BIOT, V28, P1467, DOI 10.1007/s11274-011-0948-3; Smit N, 2009, INT J MOL SCI, V10, P5326, DOI 10.3390/ijms10125326; Ozeki H, 1997, BBA-GEN SUBJECTS, V1336, P539, DOI 10.1016/S0304-4165(97)00068-8; Zecca L, 2000, J NEUROCHEM, V74, P1758, DOI 10.1046/j.1471-4159.2000.0741758.x; Bridelli MG, 2006, BIOPHYS CHEM, V119, P137, DOI 10.1016/j.bpc.2005.06.004; Zecca L, 2008, P NATL ACAD SCI USA, V105, P17567, DOI 10.1073/pnas.0808768105; Schweitzer AD, 2010, INT J RADIAT ONCOL, V78, P1494, DOI 10.1016/j.ijrobp.2010.02.020; Garcia TS, 2004, ECOL APPL, V14, P1055, DOI 10.1890/02-5288; Andersen SO, 2010, INSECT BIOCHEM MOLEC, V40, P166, DOI 10.1016/j.ibmb.2009.10.007; Huang GS, 2007, BIOSENS BIOELECTRON, V23, P319, DOI 10.1016/j.bios.2007.04.011; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Greco G, 2009, PIGM CELL MELANOMA R, V22, P319, DOI 10.1111/j.1755-148X.2009.00561.x; Borges CR, 2001, ANAL BIOCHEM, V290, P116, DOI 10.1006/abio.2000.4976; Roulin A, 2013, J HERPETOL, V47, P258, DOI 10.1670/12-028; Wakamatsu K, 2008, PIGM CELL MELANOMA R, V21, P97, DOI 10.1111/j.1755-148X.2007.00415.x; Hida T, 2009, PIGM CELL MELANOMA R, V22, P623, DOI 10.1111/j.1755-148X.2009.00582.x; Schmaler-Ripcke J, 2009, APPL ENVIRON MICROB, V75, P493, DOI 10.1128/AEM.02077-08; DUFFY PE, 1965, J NEUROPATH EXP NEUR, V24, P398, DOI 10.1097/00005072-196507000-00003; Candille SI, 2007, SCIENCE, V318, P1418, DOI 10.1126/science.1147880; Della Vecchia NF, 2013, ADV FUNCT MATER, V23, P1331, DOI 10.1002/adfm.201202127; Wunsche J, 2013, J MATER CHEM B, V1, P3836, DOI 10.1039/c3tb20630k; Cooksey CJ, 1997, J BIOL CHEM, V272, P26226, DOI 10.1074/jbc.272.42.26226; Araujo M, 2014, INT J PHARMACEUT, V469, P140, DOI 10.1016/j.ijpharm.2014.04.051; Ball V., 2013, ADV CHEM ENG SCI, V3, P1; Bamford AJ, 2010, ETHOLOGY, V116, P1163, DOI 10.1111/j.1439-0310.2010.01834.x; BARDEN H, 1971, J NEUROPATH EXP NEUR, V30, P650, DOI 10.1097/00005072-197110000-00009; Bloisi F., 2011, J APPL PHYS, V110; Bloisi F, 2011, APPL PHYS A-MATER, V105, P619, DOI 10.1007/s00339-011-6603-x; Borovansky J, 2011, MELANINS AND MELANOSOMES: BIOSYNTHESIS, BIOGENESIS, PHYSIOLOGICAL, AND PATHOLOGICAL FUNCTIONS, P343; Bortolotti G. R., 2006, BIRD COLORATION, V2, P3; BOULTON M, 1991, PROG RETIN RES, V11, P125, DOI 10.1016/0278-4327(91)90027-Y; Bridelli MG, 2010, J PHYS CHEM B, V114, P9381, DOI 10.1021/jp101833k; Burke JM, 2011, MOL VIS, V17, P2864; Burtt J. E. H., 2004, CONDOR, V106, P681; Bush WD, 2009, PHOTOCHEM PHOTOBIOL, V85, P387, DOI 10.1111/j.1751-1097.2008.00476.x; Buszman E, 2003, PHARMAZIE, V58, P507; Cebrian C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4633; CHEDEKEL MR, 1982, PHOTOCHEM PHOTOBIOL, V35, P881, DOI 10.1111/j.1751-1097.1982.tb02663.x; Cheli Y, 2009, J BIOL CHEM, V284, P18699, DOI 10.1074/jbc.M109.005819; Clark KD, 2013, J BIOL CHEM, V288, P14476, DOI 10.1074/jbc.M113.459222; Coelho SG, 2009, PIGM CELL MELANOMA R, V22, P238, DOI 10.1111/j.1755-148X.2009.00550.x; Commo S, 2004, PIGM CELL RES, V17, P488, DOI 10.1111/j.1600-0749.2004.00170.x; Commo S, 2004, BRIT J DERMATOL, V150, P435, DOI 10.1046/j.1365-2133.2004.05787.x; COWEN D, 1986, J NEUROPATH EXP NEUR, V45, P205, DOI 10.1097/00005072-198605000-00001; Crippa R., 1989, CHEM MELANINS, V36, P255; DAMATO RJ, 1986, SCIENCE, V231, P987, DOI 10.1126/science.3080808; d'Ischia M, 2014, ACCOUNTS CHEM RES, V47, P3541, DOI 10.1021/ar500273y; da Silva MIN, 2004, J APPL PHYS, V96, P5803, DOI 10.1063/1.1803629; Della Vecchia NF, 2015, J MATER CHEM C, V3, P6525, DOI 10.1039/c5tc00672d; DEMATTEI M, 1986, NEUROSCI LETT, V72, P37, DOI 10.1016/0304-3940(86)90614-2; Diaz P, 2005, LANGMUIR, V21, P5924, DOI 10.1021/la0469755; Di Cristo C, 2007, EUR J NEUROSCI, V26, P1599, DOI 10.1111/j.1460-9568.2007.05765.x; DUNN PE, 1986, ANNU REV ENTOMOL, V31, P321; Engelen M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048490; ENOCHS WS, 1993, J NEUROCHEM, V61, P68, DOI 10.1111/j.1471-4159.1993.tb03538.x; Fiore G, 2004, BIOCHEM J, V378, P785, DOI 10.1042/BJ20031864; Fiore G, 2009, PIGM CELL MELANOMA R, V22, P857, DOI 10.1111/j.1755-148X.2009.00626.x; FRONCISZ W, 1980, ARCH BIOCHEM BIOPHYS, V202, P289, DOI 10.1016/0003-9861(80)90430-0; Gallone A, 2007, HISTOL HISTOPATHOL, V22, P1065; Galvan I, 2011, J EVOLUTION BIOL, V24, P988, DOI 10.1111/j.1420-9101.2011.02231.x; Galvan I, 2011, J EVOLUTION BIOL, V24, P999, DOI 10.1111/j.1420-9101.2011.02232.x; Galvan I, 2011, OECOLOGIA, V165, P827, DOI 10.1007/s00442-010-1860-5; Galvan I, 2009, PIGM CELL MELANOMA R, V22, P339, DOI 10.1111/j.1755-148X.2009.00559.x; Ghiani S, 2008, MAGN RESON CHEM, V46, P471, DOI 10.1002/mrc.2202; Grande JM, 2004, ARDEOLA, V51, P375; Guerrero D, 2012, Ann Dermatol Venereol, V139 Suppl 4, pS166, DOI 10.1016/S0151-9638(12)70130-8; Guo SL, 2008, PHOTOCHEM PHOTOBIOL, V84, P671, DOI 10.1111/j.1751-1097.2008.00331.x; HARSANYI ZP, 1980, EXPERIENTIA, V36, P291, DOI 10.1007/BF01952282; Hellstrom AR, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002285; Hong L, 2006, PHOTOCHEM PHOTOBIOL, V82, P1265, DOI 10.1562/2006-02-23-RA-809; ITO S, 1988, BIOCHEM PHARMACOL, V37, P1707, DOI 10.1016/0006-2952(88)90432-7; ITO S, 1977, EXPERIENTIA, V33, P1118, DOI 10.1007/BF01946005; Jastrzebska M, 2010, J MATER SCI, V45, P5302, DOI 10.1007/s10853-010-4575-4; Kaczara P, 2012, PIGM CELL MELANOMA R, V25, P804, DOI 10.1111/pcmr.12008; KASTNER A, 1992, J NEUROCHEM, V59, P1080, DOI 10.1111/j.1471-4159.1992.tb08350.x; Kawasaki A, 2008, PIGM CELL MELANOMA R, V21, P56, DOI 10.1111/j.1755-148X.2007.00420.x; Kaxiras E, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.218102; Kim IG, 2011, ELECTROCHIM ACTA, V56, P2954, DOI 10.1016/j.electacta.2010.12.095; Koike K., 2013, Jpn Tokkyo Koho, Patent No. [JP5363703B220131211, 5363703]; Koike K., 2010, FRAGRANCE J, V38, P16; Lamoreux L. M., 2010, COLORS MICE MODEL GE; LARSSON BS, 1993, PIGM CELL RES, V6, P127, DOI 10.1111/j.1600-0749.1993.tb00591.x; Le Pape E, 2009, P NATL ACAD SCI USA, V106, P1802, DOI 10.1073/pnas.0806753106; Li F, 2011, ANAL METHODS-UK, V3, P1601, DOI 10.1039/c1ay05126a; Liebscher J, 2013, LANGMUIR, V29, P10539, DOI 10.1021/la4020288; LINDQUIST NG, 1988, NEUROSCI LETT, V93, P1, DOI 10.1016/0304-3940(88)90002-X; Lopez-Serrano D, 2004, GENE, V342, P179, DOI 10.1016/j.gene.2004.08.003; MANIMALA M, 1986, J ELECTROCHEM SOC, V133, P1987, DOI 10.1149/1.2109088; MARS U, 1995, PIGM CELL RES, V8, P194, DOI 10.1111/j.1600-0749.1995.tb00663.x; Marsden C D, 1983, J Neural Transm Suppl, V19, P121; Michard Q, 2008, FREE RADICAL BIO MED, V45, P1002, DOI 10.1016/j.freeradbiomed.2008.06.030; Michard Q, 2008, FREE RADICAL BIO MED, V44, P1023, DOI 10.1016/j.freeradbiomed.2007.11.021; Moreau MF, 2005, NUCL MED BIOL, V32, P377, DOI 10.1016/j.nucmedbio.2005.02.004; Mula G, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-377; Nakamura Y., 2012, SEIBUTSU-KOGAKU KAIS, V90, P115; Napolitano A, 1996, J MED CHEM, V39, P5192, DOI 10.1021/jm9605243; Negro JJ, 2006, COMP BIOCHEM PHYS A, V143, P78, DOI 10.1016/j.cbpa.2005.10.028; Ninh C, 2014, BIOMATER SCI-UK, V2, P766, DOI 10.1039/c3bm60321k; Oliveira HP, 2000, J MATER CHEM, V10, P371, DOI 10.1039/a908736b; Orive AG, 2009, ELECTROCHIM ACTA, V54, P1589, DOI 10.1016/j.electacta.2008.09.046; Palumbo A, 2000, J BIOL CHEM, V275, P16885, DOI 10.1074/jbc.M909509199; Palumbo A, 1997, MELANOMA RES, V7, P478, DOI 10.1097/00008390-199712000-00006; PALUMBO A, 1994, BIOCHEM J, V299, P839; Palumbo A, 2003, PIGM CELL RES, V16, P517, DOI 10.1034/j.1600-0749.2003.00080.x; Panhard S, 2012, BRIT J DERMATOL, V167, P865, DOI 10.1111/j.1365-2133.2012.11095.x; Pannkuk EL, 2010, FUNCT ECOL, V24, P347, DOI 10.1111/j.1365-2435.2009.01634.x; Panzella L, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12199; Patel KR, 1996, J INVERTEBR PATHOL, V67, P120, DOI 10.1006/jipa.1996.0018; Pezzella A, 2015, MATER HORIZ, V2, P212, DOI 10.1039/c4mh00097h; Pezzella A, 1996, TETRAHEDRON, V52, P7913, DOI 10.1016/0040-4020(96)00362-6; Pezzella A, 2013, MAT SCI ENG C-MATER, V33, P347, DOI 10.1016/j.msec.2012.08.049; Prota G., 1992, MELANINS MELANOGENES; Reale S, 2012, J MASS SPECTROM, V47, P49, DOI 10.1002/jms.2025; Riley PA, 2003, PIGM CELL RES, V16, P548, DOI 10.1034/j.1600-0749.2003.00069.x; Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088; Sangaletti L, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.174203; SARNA T, 1980, ARCH BIOCHEM BIOPHYS, V202, P304, DOI 10.1016/0003-9861(80)90431-2; SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R; Schreiber RW, 2006, CONDOR, V108, P736, DOI 10.1650/0010-5422(2006)108[736:PODTAG]2.0.CO;2; Serpentini CL, 2000, ELECTROCHIM ACTA, V45, P1663, DOI 10.1016/S0013-4686(99)00388-6; Siegrist W, 1997, J RECEPT SIGNAL TR R, V17, P75, DOI 10.3109/10799899709036595; Smit NPM, 1997, J INVEST DERMATOL, V109, P796, DOI 10.1111/1523-1747.ep12340980; Solano F., 2014, NEW J SCI, V2014, DOI [10. 1155/2014/498276, DOI 10.1155/2014/498276]; Sono K, 2012, BIOINORG CHEM APPL, DOI 10.1155/2012/361803; Sturm RA, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-248; Subianto S, 2005, POLYMER, V46, P11505, DOI 10.1016/j.polymer.2005.10.068; Sugumaran H, 2002, PIGM CELL RES, V15, P2, DOI 10.1034/j.1600-0749.2002.00056.x; Takeuchi S, 2003, ANN NY ACAD SCI, V994, P366; TRIAS J, 1989, CAN J MICROBIOL, V35, P1037; Wakamatsu K., 2012, PIGM CELL MELANOMA R, V25, P793; Wang A, 2009, J PHYS CHEM B, V113, P10480, DOI 10.1021/jp905417w; Ward WC, 2009, ARCH BIOCHEM BIOPHYS, V484, P94, DOI 10.1016/j.abb.2009.01.013; Watt AAR, 2009, SOFT MATTER, V5, P3754, DOI 10.1039/b902507c; Wenczl E, 1998, J INVEST DERMATOL, V111, P678, DOI 10.1046/j.1523-1747.1998.00357.x; Wilms H, 2003, FASEB J, V17, P500, DOI 10.1096/fj.02-0314fje; Wolfram L. J., 1970, SOC COSMET CHEM, V21, P875; Zecca L, 1996, NEUROSCIENCE, V73, P407, DOI 10.1016/0306-4522(96)00047-4; ZECCA L, 1994, J NEUROCHEM, V62, P1097; ZECCA L, 1992, BIOCHIM BIOPHYS ACTA, V1138, P6, DOI 10.1016/0925-4439(92)90144-C	288	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-1471	1755-148X		PIGM CELL MELANOMA R	Pigment Cell Melanoma Res.	SEP	2015	28	5					520	544		10.1111/pcmr.12393		25	Oncology; Cell Biology; Dermatology	Oncology; Cell Biology; Dermatology	CP3WG	WOS:000359812800005		
J	Galvan, I; Jorge, A; Edelaar, P; Wakamatsu, K				Galvan, Ismael; Jorge, Alberto; Edelaar, Pim; Wakamatsu, Kazumasa			Insects synthesize pheomelanin	PIGMENT CELL & MELANOMA RESEARCH			English	Letter							CATECHOLAMINES; NEUROMELANIN; BOETTGERI; EUMELANIN; CYSTEINE; PATHWAY; SKIN		[Galvan, Ismael] CSIC, Dept Evolutionary Ecol, Donana Biol Stn, E-41080 Seville, Spain; [Jorge, Alberto] CSIC, Natl Museum Nat Sci, Madrid, Spain; [Edelaar, Pim] Pablo de Olavide Univ, Dept Mol Biol & Biochem Engn, Seville, Spain; [Wakamatsu, Kazumasa] Fujita Hlth Univ Sch Hlth Sci, Dept Chem, Toyoake, Aichi, Japan	Galvan, I (reprint author), CSIC, Dept Evolutionary Ecol, Donana Biol Stn, E-41080 Seville, Spain.	galvan@ebd.csic.es		Wakamatsu, Kazumasa/0000-0003-1748-9001			Wakamatsu K, 2012, PIGM CELL MELANOMA R, V25, P792, DOI 10.1111/pcmr.12014; Bush WD, 2006, P NATL ACAD SCI USA, V103, P14785, DOI 10.1073/pnas.0604010103; Mitra D, 2012, NATURE, V491, P449, DOI 10.1038/nature11624; Galvan I, 2012, BIOESSAYS, V34, P565, DOI 10.1002/bies.201200017; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Napolitano A, 2011, CURR MED CHEM, V18, P1832; Ito S, 2011, MELANINS AND MELANOSOMES: BIOSYNTHESIS, BIOGENESIS, PHYSIOLOGICAL, AND PATHOLOGICAL FUNCTIONS, P167; Wolnicka-Glubisz A, 2012, EXP DERMATOL, V21, P537, DOI 10.1111/j.1600-0625.2012.01511.x; Zecca L, 2008, P NATL ACAD SCI USA, V105, P17567, DOI 10.1073/pnas.0808768105; Speiser DI, 2014, J NAT HIST, V48, P2899, DOI 10.1080/00222933.2014.959572; Roulin A, 2013, J HERPETOL, V47, P258, DOI 10.1670/12-028; Ito S, 2003, PIGM CELL RES, V16, P523, DOI 10.1034/j.1600-0749.2003.00072.x; Galván Ismael, 2013, Pigment Cell Melanoma Res, V26, P917, DOI 10.1111/pcmr.12140; Sugumaran H, 2002, PIGM CELL RES, V15, P2, DOI 10.1034/j.1600-0749.2002.00056.x	14	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-1471	1755-148X		PIGM CELL MELANOMA R	Pigment Cell Melanoma Res.	SEP	2015	28	5					599	602		10.1111/pcmr.12397		4	Oncology; Cell Biology; Dermatology	Oncology; Cell Biology; Dermatology	CP3WG	WOS:000359812800010		
J	Fujisaki, K; Abe, Y; Ito, A; Saitoh, H; Yoshida, K; Kanzaki, H; Kanzaki, E; Utsushi, H; Yamashita, T; Kamoun, S; Terauchi, R				Fujisaki, Koki; Abe, Yoshiko; Ito, Akiko; Saitoh, Hiromasa; Yoshida, Kentaro; Kanzaki, Hiroyuki; Kanzaki, Eiko; Utsushi, Hiroe; Yamashita, Tetsuro; Kamoun, Sophien; Terauchi, Ryohei			Rice Exo70 interacts with a fungal effector, AVR-Pii, and is required for AVR-Pii-triggered immunity	PLANT JOURNAL			English	Article						AVR-Pii; effector-triggered immunity; Exo70; avirulence effector; decoy; helper	BLAST RESISTANCE GENE; MAGNAPORTHE-ORYZAE; DISEASE RESISTANCE; PATHOGEN EFFECTORS; EXOCYST; GENOME; CELLS; ARABIDOPSIS; INFECTION; RESPONSES	Vesicle trafficking including the exocytosis pathway is intimately associated with host immunity against pathogens. However, we still have insufficient knowledge about how it contributes to immunity, and how pathogen factors affect it. In this study, we explore host factors that interact with the Magnaporthe oryzae effector AVR-Pii. Gel filtration chromatography and co-immunoprecipitation assays identified a 150kDa complex of proteins in the soluble fraction comprising AVR-Pii and OsExo70-F2 and OsExo70-F3, two rice Exo70 proteins presumably involved in exocytosis. Simultaneous knockdown of OsExo70-F2 and F3 totally abrogated Pii immune receptor-dependent resistance, but had no effect on Pia- and Pik-dependent resistance. Knockdown levels of OsExo70-F3 but not OsExo70-F2 correlated with reduction of Pii function, suggesting that OsExo70-F3 is specifically involved in Pii-dependent resistance. Under our current experimental conditions, over-expression of AVR-Pii or knockdown of OsExo70-F2 and -F3 genes in rice did not affect the virulence of compatible isolates of M.oryzae. AVR-Pii interaction with OsExo70-F3 appears to play a crucial role in immunity triggered by Pii, suggesting a role for OsExo70 as a decoy or helper in Pii/AVR-Pii interactions.	[Fujisaki, Koki; Abe, Yoshiko; Ito, Akiko; Saitoh, Hiromasa; Kanzaki, Hiroyuki; Kanzaki, Eiko; Utsushi, Hiroe; Terauchi, Ryohei] Iwate Biotechnol Res Ctr, Kitakami, Iwate, Japan; [Yoshida, Kentaro] Kobe Univ, Org Adv Sci & Technol, Kobe, Hyogo 657, Japan; [Yamashita, Tetsuro] Iwate Univ, Fac Agr, Morioka, Iwate 020, Japan; [Kamoun, Sophien] Sainsbury Lab, Norwich, Norfolk, England	Terauchi, R (reprint author), Iwate Biotechnol Res Ctr, Kitakami, Iwate, Japan.	terauchi@ibrc.or.jp			Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry, Japan [23113009]; Japan Society for the Promotion of Science (KAKENHI) [15H05779]; Japan Society for the Promotion of Science KAKENHI [26850029, 26292027]	We thank Hanae Kaku (Department of Life Science, Meiji University) for the CEBiP antibody, Seiji Tsuge (Graduate School of Life and Environmental Science, Kyoto Prefectural University) for X. oryzae T7174, Yoshitaka Takano (Graduate School of Agriculture, Kyoto University) for C. orbiculare 104T, Yasin Dagdas (Department of Life Science, The Sainsbury Labolatory) for kind comments on the paper, and the members of our laboratory for discussions and general assistance. R.T. thanks the Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry, Japan [Grant-in-aid for MEXT (Scientific Research on Innovative Areas) 23113009)] and the Japan Society for the Promotion of Science (KAKENHI grant number 15H05779). K.F. was supported by Japan Society for the Promotion of Science KAKENHI grant number 26850029, and H.K. was supported by Japan Society for the Promotion of Science KAKENHI grant number 26292027.	Rooney HCE, 2005, SCIENCE, V308, P1783, DOI 10.1126/science.1111404; Dean RA, 2005, NATURE, V434, P980, DOI 10.1038/nature03449; Jia Y, 2000, EMBO J, V19, P4004, DOI 10.1093/emboj/19.15.4004; Takagi H, 2013, NEW PHYTOL, V200, P276, DOI 10.1111/nph.12369; Deslandes L, 2012, TRENDS PLANT SCI, V17, P644, DOI 10.1016/j.tplants.2012.06.011; Takahashi M, 2013, J BIOL CHEM, V288, P13821, DOI 10.1074/jbc.M112.448902; Adam L, 1996, PLANT J, V9, P341, DOI 10.1046/j.1365-313X.1996.09030341.x; Takahashi Y, 2007, PLANT J, V49, P1030, DOI 10.1111/j.1365-313X.2006.03022.x; Inada N, 2014, PLANT CELL PHYSIOL, V55, P672, DOI 10.1093/pcp/pcu046; Miki D, 2004, PLANT CELL PHYSIOL, V45, P490, DOI 10.1093/pcp/pch048; Saunders DGO, 2012, PLANT CELL, V24, P3420, DOI 10.1105/tpc.112.099861; Munson M, 2006, NAT STRUCT MOL BIOL, V13, P577, DOI 10.1038/nsmb1097; Okuyama Y, 2011, PLANT J, V66, P467, DOI 10.1111/j.1365-313X.2011.04502.x; Kimura A, 2001, PLANT CELL, V13, P1945, DOI 10.1105/tpc.13.8.1945; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Kanzaki H, 2012, PLANT J, V72, P894, DOI 10.1111/j.1365-313X.2012.05110.x; Cesari S, 2013, PLANT CELL, V25, P1463, DOI 10.1105/tpc.112.107201; Yoshida K, 2009, PLANT CELL, V21, P1573, DOI 10.1105/tpc.109.066324; Sharma S, 2013, PLANT J, V74, P701, DOI 10.1111/tpj.12148; Hagiwara Y, 2003, EMBO J, V22, P344, DOI 10.1093/emboj/cdg033; Tamiru M, 2014, NEW PHYTOL, V202, P116, DOI 10.1111/nph.12630; Schornack S, 2009, MOL PLANT PATHOL, V10, P795, DOI 10.1111/j.1364-3703.2009.00593.x; van der Hoorn RAL, 2008, PLANT CELL, V20, P2009, DOI 10.1105/tpc.108.060194; Zarsky V, 2013, CURR OPIN PLANT BIOL, V16, P726, DOI 10.1016/j.pbi.2013.10.013; Kaku H, 2006, P NATL ACAD SCI USA, V103, P11086, DOI 10.1073/pnas.0508882103; Dodds PN, 2010, NAT REV GENET, V11, P539, DOI 10.1038/nrg2812; Pecenkova T, 2011, J EXP BOT, V62, P2107, DOI 10.1093/jxb/erq402; Christensen AH, 1996, TRANSGENIC RES, V5, P213, DOI 10.1007/BF01969712; Stegmann M, 2012, PLANT CELL, V24, P4703, DOI 10.1105/tpc.112.104463; Zhang Y, 2010, J INTEGR PLANT BIOL, V52, P138, DOI 10.1111/j.1744-7909.2010.00929.x; Dean R, 2012, MOL PLANT PATHOL, V13, P414, DOI 10.1111/j.1364-3703.2011.00783.x; Cvrkova F., 2012, FRONT PLANT SCI, V3, P159; desWit P. J., 2009, MOL PLANT PATHOL, V10, P735; Matsumoto T, 2005, NATURE, V436, P793, DOI 10.1038/nature03895; Kanzaki H, 2014, METHODS MOL BIOL, V1127, P269, DOI 10.1007/978-1-62703-986-4_20; Liu WD, 2013, MOL PLANT, V6, P605, DOI 10.1093/mp/sst015; Saitoh H, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002711; Stegmann Martin, 2013, Plant Signal Behav, V8, pe27421, DOI 10.4161/psb.27421; Takeda T, 2010, APPL MICROBIOL BIOT, V88, P1113, DOI 10.1007/s00253-010-2781-2; Win J, 2012, Cold Spring Harb Symp Quant Biol, V77, P235, DOI 10.1101/sqb.2012.77.015933; Zhao T, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004945	41	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0960-7412	1365-313X		PLANT J	Plant J.	SEP	2015	83	5					875	887		10.1111/tpj.12934		13	Plant Sciences	Plant Sciences	CP7WQ	WOS:000360100200011		
J	Cheynier, V; Yoshida, K; Martens, S				Cheynier, Veronique; Yoshida, Kumi; Martens, Stefan			Focus issue on polyphenols	PLANTA			English	Editorial Material									[Cheynier, Veronique] INRA, Sci Oenol UMR1083, F-34060 Montpellier, France; [Yoshida, Kumi] Nagoya Univ, Grad Sch Informat Sci, Nagoya, Aichi 4648601, Japan; [Martens, Stefan] Fdn Edmund Mach, Ctr Ric & Innovaz, Dept Food Qual & Nutr, I-38010 San Michele All Adige, TN, Italy	Martens, S (reprint author), Fdn Edmund Mach, Ctr Ric & Innovaz, Dept Food Qual & Nutr, Via E Mach 1, I-38010 San Michele All Adige, TN, Italy.	cheynier@supagro.inra.fr; yoshidak@is.nagoya-u.ac.jp; stefan.martens@fmach.it						0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0032-0935	1432-2048		PLANTA	Planta	SEP	2015	242	3					507	507		10.1007/s00425-015-2379-0		1	Plant Sciences	Plant Sciences	CP4DJ	WOS:000359831900001		
J	Kanbayashi, T; Miyafuji, H				Kanbayashi, Toru; Miyafuji, Hisashi			Topochemical and morphological characterization of wood cell wall treated with the ionic liquid, 1-ethylpyridinium bromide	PLANTA			English	Article						1-Ethylpyridinium bromide; Cell wall; Ionic liquid; Microscopy; Raman microscopy; Wood	FT-RAMAN-SPECTROSCOPY; 1-ETHYL-3-METHYLIMIDAZOLIUM CHLORIDE; REACTION BEHAVIOR; CLEAN TECHNOLOGY; JAPANESE BEECH; DISSOLUTION; LIGNIN; SPRUCE; CELLULOSE; PRETREATMENT	[EtPy][Br] is more reactive toward lignin than toward the PSs in wood cell walls, and [EtPy][Br] treatment results in inhomogenous changes to the cell wall's ultrastructural and chemical components. The effects of the ionic liquid 1-ethylpyridinium bromide ([EtPy][Br]), which prefers to react with lignin rather than cellulose on the wood cell walls of Japanese cedar (Cryptomeria japonica), were investigated from a morphology and topochemistry point of view. The [EtPy][Br] treatment induced cell wall swelling, the elimination of warts, and the formation of countless pores in the tracheids. However, many of the pit membranes and the cellulose crystalline structure remained unchanged. Raman microscopic analyses revealed that chemical changes in the cell walls were different for different layers and that the lignin in the compound middle lamella and the cell corner resists interaction with [EtPy][Br]. Additionally, the interaction of [EtPy][Br] with the wood cell wall is different to that of other types of ionic liquid.	[Kanbayashi, Toru; Miyafuji, Hisashi] Kyoto Prefectural Univ, Grad Sch Life & Environm Sci, Div Environm Sci, Sakyo Ku, Kyoto 6068522, Japan	Miyafuji, H (reprint author), Kyoto Prefectural Univ, Grad Sch Life & Environm Sci, Div Environm Sci, Sakyo Ku, Hangi Cho, Kyoto 6068522, Japan.	miyafuji@kpu.ac.jp			Kyoto Prefectural University (KPU) Academic Promotion Fund; JSPS [25450246]	The authors wish to thank the Kyoto Municipal Institute of Industrial Technology and Culture for assistance with the Raman microscopic analyses. This research was partly supported by the Kyoto Prefectural University (KPU) Academic Promotion Fund and a Grant-in-Aid for Scientific Research (c) (25450246) from the JSPS for which the authors are grateful.	Agarwal U. P., 1999, ADV LIGNOCELLULOSICS, P201; Agarwal UP, 2000, ACS SYM SER, V742, P250; Miyafuji H, 2012, J WOOD SCI, V58, P222, DOI 10.1007/s10086-011-1245-3; WHITING P, 1982, WOOD SCI TECHNOL, V16, P261; Kanbayashi T, 2013, J WOOD SCI, V59, P410, DOI 10.1007/s10086-013-1343-5; Agarwal UP, 1997, APPL SPECTROSC, V51, P1648, DOI 10.1366/0003702971939316; Nakamura A, 2010, J WOOD SCI, V56, P256, DOI 10.1007/s10086-009-1081-x; TERASHIMA N, 1988, WOOD SCI TECHNOL, V22, P259; Nakamura A, 2010, HOLZFORSCHUNG, V64, P289, DOI 10.1515/HF.2010.042; Miyafuji H, 2009, J WOOD SCI, V55, P215, DOI 10.1007/s10086-009-1020-x; Viell J, 2011, HOLZFORSCHUNG, V65, P519, DOI 10.1515/HF.2011.072; Lee SH, 2009, BIOTECHNOL BIOENG, V102, P1368, DOI 10.1002/bit.22179; MOK WSL, 1992, IND ENG CHEM RES, V31, P1157, DOI 10.1021/ie00004a026; Agarwal UP, 2008, HOLZFORSCHUNG, V62, P667, DOI 10.1515/HF.2008.112; Chundawat SPS, 2011, ENERG ENVIRON SCI, V4, P973, DOI 10.1039/c0ee00574f; Swatloski RP, 2002, J AM CHEM SOC, V124, P4974, DOI 10.1021/ja025790m; Rogers RD, 2003, SCIENCE, V302, P792, DOI 10.1126/science.1090313; Zhang H, 2005, MACROMOLECULES, V38, P8272, DOI 10.1021/ma0505676; Zhao YL, 2008, BIOTECHNOL BIOENG, V99, P1320, DOI 10.1002/bit.21712; Earle MJ, 2000, PURE APPL CHEM, V72, P1391, DOI 10.1351/pac200072071391; Agarwal UP, 2011, J WOOD CHEM TECHNOL, V31, P324, DOI 10.1080/02773813.2011.562338; Akim LG, 2001, CAN J CHEM, V79, P201, DOI 10.1139/cjc-79-2-201; WILEY JH, 1987, CARBOHYD RES, V160, P113, DOI 10.1016/0008-6215(87)80306-3; Fort DA, 2007, GREEN CHEM, V9, P63, DOI 10.1039/b607614a; Donaldson LA, 2001, PHYTOCHEMISTRY, V57, P859, DOI 10.1016/S0031-9422(01)00049-8; Yamazaki J, 2006, J WOOD SCI, V52, P527, DOI 10.1007/s10086-005-0798-4; Zhang X, 2014, MICROSC RES TECHNIQ, V77, P609, DOI 10.1002/jemt.22379; Jansen S, 1998, IAWA J, V19, P347; Kilpelainen I, 2007, J AGR FOOD CHEM, V55, P9142, DOI 10.1021/jf071692e; Taherzadeh MJ, 1997, IND ENG CHEM RES, V36, P4659, DOI 10.1021/ie9700831; Kosan B, 2008, CELLULOSE, V15, P59, DOI 10.1007/s10570-007-9160-x; Agarwal UP, 1998, J WOOD CHEM TECHNOL, V18, P381, DOI 10.1080/02773819809349587; Kanbayashi T, 2014, J WOOD SCI, V60, P152, DOI 10.1007/s10086-014-1389-z; Corrales RCNR, 2012, BIOTECHNOL BIOFUELS, V5, DOI 10.1186/1754-6834-5-36; DONALDSON LA, 1987, WOOD SCI TECHNOL, V21, P227; Edwards HGM, 1997, SPECTROCHIM ACTA A, V53, P2383, DOI 10.1016/S1386-1425(97)00178-9; Freemantle M, 1998, CHEM ENG NEWS, V76, P32, DOI 10.1021/cen-v076n013.p032; Harada H, 1985, BIOSYNTHESIS BIODEGR, P1; Honglu X., 2006, HOLZFORSCHUNG, V60, P509, DOI 10.1515/HF.2006.084; Ji Z, 2014, BIORESOURCES, V9, P4159; Kanbayashi T, 2015, HOLZFORSCHUNG, V69, P273, DOI 10.1515/hf-2014-0060; Lucas M, 2011, BIORESOURCE TECHNOL, V102, P4518, DOI 10.1016/j.biortech.2010.12.087; PISKORZ J, 1988, RESEARCH IN THERMOCHEMICAL BIOMASS CONVERSION, P557; Schenzel K, 2001, CELLULOSE, V8, P49, DOI 10.1023/A:1016616920539; Scott JAN, 1970, CELL CHEM TECHNOL, V4, P83; Seddon KR, 1997, J CHEM TECHNOL BIOT, V68, P351, DOI 10.1002/(SICI)1097-4660(199704)68:4<351::AID-JCTB613>3.0.CO;2-4; Sheldon R, 2001, CHEM COMMUN, P2399, DOI 10.1039/b107270f; WILKES JS, 1992, J CHEM SOC CHEM COMM, P965, DOI 10.1039/c39920000965; Yokoo T, 2014, J WOOD SCI, V60, P339, DOI 10.1007/s10086-014-1409-z	49	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0032-0935	1432-2048		PLANTA	Planta	SEP	2015	242	3					509	518		10.1007/s00425-014-2235-7		10	Plant Sciences	Plant Sciences	CP4DJ	WOS:000359831900002		
J	Morita, Y; Ishiguro, K; Tanaka, Y; Iida, S; Hoshino, A				Morita, Yasumasa; Ishiguro, Kanako; Tanaka, Yoshikazu; Iida, Shigeru; Hoshino, Atsushi			Spontaneous mutations of the UDP-glucose:flavonoid 3-O-glucosyltransferase gene confers pale- and dull-colored flowers in the Japanese and common morning glories	PLANTA			English	Article						Anthocyanin; Flavonoid; Flower pigmentation; Ipomoea	ACYLATED PELARGONIDIN GLYCOSIDES; RED-PURPLE FLOWERS; IPOMOEA-PURPUREA; ANTHOCYANIN BIOSYNTHESIS; PHARBITIS-NIL; MOLECULAR CHARACTERIZATION; TRANSPOSABLE ELEMENTS; PEONIDIN GLYCOSIDES; BLUE ANTHOCYANIN; REGULATORY GENE	UDP-glucose:flavonoid 3- O -glucosyltransferase is essential for maintaining proper production quantity, acylation, and glucosylation of anthocyanin, and defects cause pale and dull flower pigmentation in morning glories. The Japanese (Ipomoea nil) and the common (I. purpurea) morning glory display bright blue and dark purple flowers, respectively. These flowers contain acylated and glucosylated anthocyanin pigments, and a number of flower color mutants have been isolated in I. nil. Of these, the duskish mutants of I. nil produce pale- and dull-colored flowers. We found that the Duskish gene encodes UDP-glucose:flavonoid 3-O-glucosyltransferase (3GT). The duskish-1 mutation is a frameshift mutation caused by a 4-bp insertion, and duskish-2 is an insertion of a DNA transposon, Tpn10, at 1.3 kb upstream of the 3GT start codon. In the duskish-2 mutant, excision of Tpn10 is responsible for restoration of the expression of the 3GT gene. The recombinant 3GT protein displays expected 3GT enzymatic activities to catalyze 3-O-glucosylation of anthocyanidins in vitro. Anthocyanin analysis of a duskish-2 mutant and its germinal revertant showing pale and normal pigmented flowers, respectively, revealed that the mutation caused around 80 % reduction of anthocyanin accumulation. We further characterized two I. purpurea mutants showing pale brownish-red flowers, and found that they carry the same frameshift mutation in the 3GT gene. Most of the flower anthocyanins in the mutants were previously found to be anthocyanidin 3-O-glucosides lacking several caffeic acid and glucose moieties that are attached to the anthocyanins in the wild-type plants. These results indicated that 3GT is essential not only for production, but also for proper acylation and glucosylation, of anthocyanin in the morning glories.	[Morita, Yasumasa; Iida, Shigeru; Hoshino, Atsushi] Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan; [Morita, Yasumasa] Meijo Univ, Fac Agr, Kasugai, Aichi 4860804, Japan; [Ishiguro, Kanako; Tanaka, Yoshikazu] Suntory Global Innovat Ctr Ltd, Mishima, Shizuoka 6188503, Japan; [Iida, Shigeru] Univ Shizuoka, Grad Sch Pharmaceut Sci, Grad Sch Nutr & Environm Sci, Shizuoka 4228526, Japan; [Hoshino, Atsushi] Grad Univ Adv Studies, SOKENDAI, Dept Basic Biol, Okazaki, Aichi 4448585, Japan	Morita, Y (reprint author), Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan.	ymorita@meijo-u.ac.jp; hoshino@nibb.ac.jp	Hoshino, Atsushi/F-3822-2012	Hoshino, Atsushi/0000-0003-1926-5028	Ministry of Education, Culture, Sports, Science and Technology [17207002, 18770041]	We thank Dr. Norio Saito for his participation in valuable discussions, Miwako Matsumoto, Chisato Matsuda, Ryoko Nakamura, Tomoyo Takeuchi, and Kazuyo Ito for their technical assistance, and the NIBB Model Plant Research Facility and the NIBB Functional Genomics Facility for the technical support. We also thank the National Bioresource Project Morning Glory and Dr. Eiji Nitasaka for Ipomoea seeds. This work was supported by grants, Grant-in-Aid for Scientific Research (No. 17207002 to S. I. and No. 18770041 to A. H.) from the Ministry of Education, Culture, Sports, Science and Technology.	Chen WH, 2011, PLANT CELL REP, V30, P1007, DOI 10.1007/s00299-011-1006-1; Kubo H, 2007, J PLANT RES, V120, P445, DOI 10.1007/s10265-006-0067-7; Petrussa E, 2013, INT J MOL SCI, V14, P14950, DOI 10.3390/ijms140714950; Zufall RA, 2003, J HERED, V94, P442, DOI 10.1093/jhered/esg098; Ogata J, 2005, NATURE, V435, P757, DOI 10.1038/nature435757a; Conti E, 2005, CURR OPIN CELL BIOL, V17, P316, DOI 10.1016/j.ceb.2005.04.005; Winkel BSJ, 2004, ANNU REV PLANT BIOL, V55, P85, DOI 10.1146/annurev.arplant.55.031903.141714; Behm-Ansmant I, 2007, FEBS LETT, V581, P2845, DOI 10.1016/j.febslet.2007.05.027; Matsuba Y, 2010, PLANT CELL, V22, P3374, DOI 10.1105/tpc.110.077487; Morita Y, 2006, PLANT CELL PHYSIOL, V47, P457, DOI 10.1093/pcp/pcj012; Iida S, 2004, ADV BIOPHYS, V38, P141, DOI 10.1016/S0065-227X(04)80136-9; Sijen T, 2001, CURR BIOL, V11, P436, DOI 10.1016/S0960-9822(01)00116-6; INAGAKI Y, 1994, PLANT CELL, V6, P375; SAITO N, 1995, PHYTOCHEMISTRY, V40, P1283, DOI 10.1016/0031-9422(95)00369-I; Tanaka Y, 2008, PLANT J, V54, P733, DOI 10.1111/j.1365-313X.2008.03447.x; Tohge T, 2005, PLANT J, V42, P218, DOI 10.1111/j.1365-313X.2005.02371.x; Fukuchi-Mizutani M, 2003, PLANT PHYSIOL, V132, P1652, DOI 10.1104/pp.102.018242; Chang SM, 2005, GENETICS, V170, P1967, DOI 10.1534/genetics.104.034975; Chopra S, 2006, SCI FLAVONOIDS, P147; DOONER HK, 1977, BIOCHEM GENET, V15, P509, DOI 10.1007/BF00520194; FEDOROFF NV, 1984, P NATL ACAD SCI-BIOL, V81, P3825, DOI 10.1073/pnas.81.12.3825; Fukada-Tanaka S, 2000, NATURE, V407, P581, DOI 10.1038/35036683; Habu Y, 1998, PLANT J, V16, P371, DOI 10.1046/j.1365-313x.1998.00308.x; Hagiwara T, 1956, B RES COLL AGR VET S, V5, P34; Hagiwara T, 1954, B RES COLLEGE AGR VE, V3, P1; Hoshino A, 2009, J PLANT RES, V122, P215, DOI 10.1007/s10265-008-0202-8; Hoshino A, 2003, PLANT CELL PHYSIOL, V44, P990, DOI 10.1093/pcp/pcg143; Iida S, 1999, ANN NY ACAD SCI, V870, P265, DOI 10.1111/j.1749-6632.1999.tb08887.x; IMAI YOSHITAKA, 1935, ZEITSCHR INDUKT ABSTAMM U VERERBUNGSL, V68, P242, DOI 10.1007/BF01953610; Imai Y, 1931, J GENET, V24, P203, DOI 10.1007/BF02983854; Inagaki Y, 1999, GENE, V226, P181, DOI 10.1016/S0378-1119(98)00571-X; KONDO T, 1987, TETRAHEDRON LETT, V28, P2273, DOI 10.1016/S0040-4039(00)96099-4; LARSON RL, 1977, BIOCHEM GENET, V15, P153, DOI 10.1007/BF00484558; LU TS, 1992, PHYTOCHEMISTRY, V31, P289, DOI 10.1016/0031-9422(91)83056-Q; LU TS, 1992, PHYTOCHEMISTRY, V31, P659; Lu YQ, 2012, PLANT METHODS, V8, DOI 10.1186/1746-4811-8-9; Morita Y, 2005, PLANT J, V42, P353, DOI 10.1111/j.1365-313X.2005.02383.x; Morita Y, 2014, PLANT J, V78, P294, DOI 10.1111/tpj.12469; Neuffer MG, 1997, MUTANTS MAIZE; Ohnishi Makoto, 2005, Plant and Cell Physiology, V46, P259, DOI 10.1093/pcp/pci028; Park KI, 2007, PLANT J, V49, P641, DOI 10.1111/j.1365-313X.2006.02988.x; Saito N, 1996, PHYTOCHEMISTRY, V43, P1365, DOI 10.1016/S0031-9422(96)00501-8; Saito N, 2005, PHYTOCHEMISTRY, V66, P1852, DOI 10.1016/j.phytochem.2005.04.042; Saito N, 1998, PHYTOCHEMISTRY, V49, P875, DOI 10.1016/S0031-9422(98)00185-X; Toki K, 2001, HETEROCYCLES, V55, P1241; Toki K, 2004, HETEROCYCLES, V63, P1449; Toki K, 2001, HETEROCYCLES, V55, P2261; Yamazaki M, 1999, J BIOL CHEM, V274, P7405, DOI 10.1074/jbc.274.11.7405	48	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0032-0935	1432-2048		PLANTA	Planta	SEP	2015	242	3					575	587		10.1007/s00425-015-2321-5		13	Plant Sciences	Plant Sciences	CP4DJ	WOS:000359831900007		
J	Noda, S; Koshiba, T; Hattori, T; Yamaguchi, M; Suzuki, S; Umezawa, T				Noda, Soichiro; Koshiba, Taichi; Hattori, Takefumi; Yamaguchi, Masatoshi; Suzuki, Shiro; Umezawa, Toshiaki			The expression of a rice secondary wall-specific cellulose synthase gene, OsCesA7, is directly regulated by a rice transcription factor, OsMYB58/63	PLANTA			English	Article						Cellulose; Lignin; Lignocellulose; Oryza sativa; Transcriptional regulation; Transcription factor	LIGNIN BIOSYNTHETIC-PATHWAY; CELL-WALL; FUNCTIONAL-CHARACTERIZATION; COEXPRESSION NETWORK; ARABIDOPSIS-THALIANA; VESSEL FORMATION; DIRECT TARGET; ORYZA-SATIVA; NAC; DOMAIN	A rice MYB transcription factor, OsMYB58/63, was found to directly upregulate the expression of a rice secondary wall-specific cellulose synthase gene, cellulose synthase A7 ( OsCesA7 ); in contrast, the Arabidopsis putative orthologs AtMYB58 and AtMYB63 have been shown to specifically activate lignin biosynthesis. Although indirect evidence has shown that grass plants are similar to but partially different from dicotyledonous ones in transcriptional regulation of lignocellulose biosynthesis, little is known about the differences. This study showed that a rice MYB transcription factor, OsMYB58/63, directly upregulated the expression of a rice secondary wall-specific cellulose synthase gene, cellulose synthase A7 (OsCesA7). Gene co-expression analysis showed that, in rice, OsMYB58/63 and several rice MYB genes were co-expressed with genes encoding lignocellulose biosynthetic enzymes. The expression levels of OsMYB55/61, OsMYB55/61-L, OsMYB58/63, and OsMYB42/85 were commonly found to be high in culm internodes and nodes. All four MYB transcription factors functioned as transcriptional activators in yeast cells. OsMYB58/63 most strongly transactivated the expression of OsCesA7 in rice protoplasts. Moreover, recombinant OsMYB58/63 protein was bound to two distinct cis-regulatory elements, AC-II and SMRE3, in the OsCesA7 promoter. This is in sharp contrast to the role of Arabidopsis orthologs, AtMYB58 and AtMYB63, which had been reported to specifically activate lignin biosynthesis. The promoter analysis revealed that AC elements, which are the binding sites for MYB58 and MYB63, were lacking in cellulose and xylan biosynthetic genes in Arabidopsis, but present in cellulose, xylan, and lignin biosynthetic genes in rice, implying that the difference of transcriptional regulation between rice and Arabidopsis is due to the distinct composition of promoters. Our results provide a new insight into transcriptional regulation in grass lignocellulose biosynthesis.	[Noda, Soichiro; Koshiba, Taichi; Hattori, Takefumi; Suzuki, Shiro; Umezawa, Toshiaki] Kyoto Univ, Res Inst Sustainable Humanosphere, Uji, Kyoto 6110011, Japan; [Yamaguchi, Masatoshi] Saitama Univ, Inst Environm Sci & Technol, Saitama 3388570, Japan; [Yamaguchi, Masatoshi] Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan; [Umezawa, Toshiaki] Kyoto Univ, Inst Sustainabil Sci, Uji, Kyoto 6110011, Japan	Suzuki, S (reprint author), Kyoto Univ, Res Inst Sustainable Humanosphere, Uji, Kyoto 6110011, Japan.	shiro-s@rish.kyoto-u.ac.jp			Japan Society for the Promotion of Science (JSPS) [22780161, 25450241]; "Advanced Low Carbon Technology Research and Development Program (ALCA)"	We thank Ms. Kumiko Murata for technical assistance in cultivating rice plants. We appreciate Dr. Koji Yamaguchi and Dr. Tsutomu Kawasaki of Kinki University, Japan, and Dr. Shingo Sakamoto and Dr. Nobutaka Mitsuda of the National Institute of Advanced Industrial Science and Technology (AIST), Japan, for technical advice about protoplast preparation and PEG-mediated transfection. Seeds of O. sativa L. ssp. japonica cv. Nipponbare were a generous gift from the Shiga Prefecture Agricultural Technology Promotion Center, Shiga, Japan. The vectors pH35GS and pBD-GAL4-GWRFC were the kind gifts of Dr. Taku Demura of the Nara Institute of Science and Technology, Japan; and the vectors p35SG, p190LUC, and pPTRL were the kind gifts of Dr. N. Mitsuda and Dr. Masaru Takagi of AIST. Rice Oc suspension cells and rice full-length cDNA clones were provided by RIKEN Bioresouce Center and the National Institute of Agrobiological Sciences, Japan, respectively. This work was partly supported by Grants-in-Aid for Young Scientists (B) (No. 22780161) and for Scientific Research (C) (No. 25450241) from the Japan Society for the Promotion of Science (JSPS); and a grant from the "Advanced Low Carbon Technology Research and Development Program (ALCA)", managed by the Japan Science and Technology Agency. A part of this study was conducted using the Development and Assessment of Sustainable Humanosphere/Forest Biomass Analytical System (DASH/FBAS) at the Research Institute for Sustainable Humanosphere, Kyoto University, Japan.	Wang HZ, 2012, MOL PLANT, V5, P297, DOI 10.1093/mp/ssr098; Yamaguchi K, 2012, PLANT J, V70, P389, DOI 10.1111/j.1365-313X.2011.04874.x; Suzuki S, 2006, PLANT PHYSIOL, V142, P1233, DOI 10.1104/pp.106.086678; Tanaka K, 2003, PLANT PHYSIOL, V133, P73, DOI 10.1104/pp.103.022442; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Hiratsu K, 2002, FEBS LETT, V514, P351, DOI 10.1016/S0014-5793(02)02435-3; Aohara T, 2009, PLANT CELL PHYSIOL, V50, P1886, DOI 10.1093/pcp/pcp133; Stracke R, 2001, CURR OPIN PLANT BIOL, V4, P447, DOI 10.1016/S1369-5266(00)00199-0; Zhou JL, 2009, PLANT CELL, V21, P248, DOI 10.1105/tpc.108.063321; Ko JH, 2009, PLANT J, V60, P649, DOI 10.1111/j.1365-313X.2009.03989.x; Demura T, 2010, CURR OPIN PLANT BIOL, V13, P299, DOI 10.1016/j.pbi.2010.03.002; Zhong RQ, 2008, PLANT CELL, V20, P2763, DOI 10.1105/tpc.108.061325; McCarthy RL, 2009, PLANT CELL PHYSIOL, V50, P1950, DOI 10.1093/pcp/pcp139; BABA A, 1986, PLANT CELL PHYSIOL, V27, P463; Gui JS, 2011, PLANT PHYSIOL, V157, P574, DOI 10.1104/pp.111.178301; Zhao KM, 2014, BMC PLANT BIOL, V14, DOI 10.1186/1471-2229-14-135; Hirano K, 2013, PLANT CELL PHYSIOL, V54, P1791, DOI 10.1093/pcp/pct122; Yamaguchi M, 2010, PLANT CELL, V22, P1249, DOI 10.1105/tpc.108.064048; Zhong RQ, 2006, PLANT CELL, V18, P3158, DOI 10.1105/tpc.106.047399; Zhong RQ, 2011, PLANT CELL PHYSIOL, V52, P1856, DOI 10.1093/pcp/pcr123; Ohashi-Ito K, 2010, PLANT CELL, V22, P3461, DOI 10.1105/tpc.110.075036; Mitsuda N, 2007, PLANT CELL, V19, P270, DOI 10.1105/tpc.106.047043; Zhong RQ, 2010, PLANT PHYSIOL, V152, P1044, DOI 10.1104/pp.109.148270; Vogel J, 2008, CURR OPIN PLANT BIOL, V11, P301, DOI 10.1016/j.pbi.2008.03.002; Fujimoto SY, 2000, PLANT CELL, V12, P393, DOI 10.1105/tpc.12.3.393; Shen H, 2012, NEW PHYTOL, V193, P121, DOI 10.1111/j.1469-8137.2011.03922.x; Kim WC, 2012, PLANT MOL BIOL, V78, P489, DOI 10.1007/s11103-012-9880-7; Zhao QA, 2010, PLANT J, V63, P100, DOI 10.1111/j.1365-313X.2010.04223.x; Legay S, 2007, PLANT SCI, V173, P542, DOI 10.1016/j.plantsei.2007.08.007; Zhang KW, 2006, PLANT PHYSIOL, V140, P972, DOI 10.1104/pp.105.073007; Chiniquy D, 2012, P NATL ACAD SCI USA, V109, P17117, DOI 10.1073/pnas.1202079109; Taylor NG, 2004, CELLULOSE, V11, P329, DOI 10.1023/B:CELL.0000046405.11326.a8; Fornale S, 2010, PLANT J, V64, P633, DOI 10.1111/j.1365-313X.2010.04363.x; Raes J, 2003, PLANT PHYSIOL, V133, P1051, DOI 10.1104/pp.103.026484; Zhong RQ, 2012, PLANT CELL PHYSIOL, V53, P368, DOI 10.1093/pcp/pcr185; Rennie EA, 2014, CURR OPIN BIOTECH, V26, P100, DOI 10.1016/j.copbio.2013.11.013; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Zhong R, 2007, PLANT CELL, V19, P2776, DOI 10.1105/tpc.107.053678; Kubo M, 2005, GENE DEV, V19, P1855, DOI 10.1101/gad.1331305; Graham RL, 2007, AGRON J, V99, P1, DOI 10.2134/argonj2005.0222; Goicoechea M, 2005, PLANT J, V43, P553, DOI 10.1111/j.1365-313X.2005.02480.x; Silveira RL, 2015, J PHYS CHEM LETT, V6, P206, DOI 10.1021/jz502298q; HATTON D, 1995, PLANT J, V7, P859, DOI 10.1046/j.1365-313X.1995.07060859.x; Ohtani M, 2011, PLANT J, V67, P499, DOI 10.1111/j.1365-313X.2011.04614.x; Yamaguchi M, 2008, PLANT J, V55, P652, DOI 10.1111/j.1365-313X.2008.03533.x; Bromley JR, 2013, PLANT J, V74, P423, DOI 10.1111/tpj.12135; Cao PJ, 2012, RICE, V5, DOI 10.1186/1939-8433-5-17; Handakumbura PP, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00074; Hirano K, 2013, PLANT CELL PHYSIOL, V54, P1803, DOI 10.1093/pcp/pct121; Hussey SG, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00325; Ko JH, 2012, MOL PLANT, V5, P961, DOI 10.1093/mp/sss076; Koshiba T, 2013, PLANT BIOTECHNOL-NAR, V30, P157, DOI 10.5511/plantbiotechnology.13.0219a; Lee C, 2014, PLANT SIGNAL BEHAV, V9; Lemmon ZH, 2014, PLOS GENET, V10; Noda S, 2013, PLANT BIOTECHNOL-NAR, V30, P169, DOI 10.5511/plantbiotechnology.13.0304a; Noda S, 2013, PLANT BIOTECHNOL-NAR, V30, P503, DOI 10.5511/plantbiotechnology.13.0905b; Taylor-Teeples M., 2014, NATURE, V517, P571, DOI [10.1038/nature14099, DOI 10.1038/NATURE14099]; Umezawa T, 2010, PHYTOCHEM REV, V9, P1, DOI 10.1007/s11101-009-9155-3; Yamamura M, 2013, PLANT BIOTECHNOL-NAR, V30, P25, DOI 10.5511/plantbiotechnology.12.1127a; Yokoyama KD, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003771; Yoshida K, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00383	61	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0032-0935	1432-2048		PLANTA	Planta	SEP	2015	242	3					589	600		10.1007/s00425-015-2343-z		12	Plant Sciences	Plant Sciences	CP4DJ	WOS:000359831900008		
J	Jyske, TM; Suuronen, JP; Pranovich, AV; Laakso, T; Watanabe, U; Kuroda, K; Abe, H				Jyske, Tuula M.; Suuronen, Jussi-Petteri; Pranovich, Andrey V.; Laakso, Tapio; Watanabe, Ugai; Kuroda, Katsushi; Abe, Hisashi			Seasonal variation in formation, structure, and chemical properties of phloem in Picea abies as studied by novel microtechniques	PLANTA			English	Article						Carbohydrates; Laser microdissection; Microtomography; Phloem parenchyma; Phenolics; Stilbene glucosides	NORWAY SPRUCE PINACEAE; SITCHENSIS BONG CARR; STILBENE GLUCOSIDES; PARENCHYMA CELLS; CAMBIAL ACTIVITY; DEFENSE RESPONSES; FUNGAL-INFECTION; WOOD FORMATION; SCOTS PINE; BARK	Phloem production and structural development were interlinked with seasonal variation in the primary and secondary metabolites of phloem. Novel microtechniques provided new perspectives on understanding phloem structure and chemistry. To gain new insights into phloem formation in Norway spruce (Picea abies), we monitored phloem cell production and seasonal variation in the primary and secondary metabolites of inner bark (non-structural carbohydrates and phenolic stilbene glucosides) during the 2012 growing season in southern and northern Finland. The structure of developing phloem was visualised in 3D by synchrotron X-ray microtomography. The chemical features of developing phloem tissues isolated by laser microdissection were analysed by chemical microanalysis. Within-year phloem formation was associated with seasonal changes in non-structural carbohydrates and phenolic extractive contents of inner bark. The onset of phloem cell production occurred in early and mid-May in southern and northern Finland, respectively. The maximal rate of phloem production and formation of a tangential band of axial phloem parenchyma occurred in mid-June, when total non-structural carbohydrates peaked (due to the high amount of starch). In contrast, soluble sugar content dropped during the most active growth period and increased in late summer and winter. The 3D visualisation showed that the new axial parenchyma clearly enlarged from June to August. Sub-cellular changes appeared to be associated with accumulation of stilbene glucosides and soluble sugars in the newest phloem. Stilbene glucosides also increased in inner bark during late summer and winter. Our findings may indicate that stilbene biosynthesis in older phloem predominantly occurs after the formation of the new band(s) of axial parenchyma. The complementary use of novel microtechniques provides new perspectives on the formation, structure, and chemistry of phloem.	[Jyske, Tuula M.; Laakso, Tapio] Nat Resources Inst Finland Luke, New Business Opportun, Vantaa 01370, Finland; [Suuronen, Jussi-Petteri] ESRF European Synchrotron, F-38043 Grenoble 9, France; [Suuronen, Jussi-Petteri] Univ Helsinki, Dept Phys, FIN-00014 Helsinki, Finland; [Pranovich, Andrey V.] Abo Akad Univ, Proc Chem Ctr, SF-20500 Turku, Finland; [Watanabe, Ugai] Chiba Inst Technol, Dept Life & Environm Sci, Chiba 2750016, Japan; [Kuroda, Katsushi; Abe, Hisashi] Forestry & Forest Prod Res Inst, Tsukuba, Ibaraki 3058687, Japan	Jyske, TM (reprint author), Nat Resources Inst Finland Luke, New Business Opportun, Jokiniemenkuja 1, Vantaa 01370, Finland.	tuula.jyske@luke.fi			Academy of Finland [250299]; JSPS KAKENHI [26-04395]; JSPS [P14395]	We thank the staff of the Finnish Forest Research Institute, and several students and trainees, for assisting in field and laboratory work. We also thank Dr. P. Saranpaa, Dr. H. Makinen, and Prof. B. Holmbom for their help designing of the study. We are grateful to the Electron Microscopy Unit of the Institute of Biotechnology, University of Helsinki, for providing laboratory facilities and help in sample preparation. We acknowledge the European Synchrotron Radiation Facility (ESRF) for providing beam time for the mu CT measurements, and are grateful for P. Tafforeau and C. Soriano for their help in using beamline ID19. P. Ahvenainen, A. Kallonen, A. Meaney, and K. Pirkkalainen of the Department of Physics, University of Helsinki, provided valuable assistance in carrying out the mu CT experiments. Prof. R. Serimaa is acknowledged for her help designing the study and participating in the mu CT experiment. This study was carried out under the framework of the COST FP1106 network STReESS and funded by the post-doctoral research grant from the Academy of Finland (no. 250299). This work was also supported by JSPS KAKENHI Grant No. 26-04395 and JSPS post-doctoral Grant No. P14395.	ALFIERI FJ, 1968, AM J BOT, V55, P518, DOI 10.2307/2440583; Krogell J, 2012, NORD PULP PAP RES J, V27, P6; Gricar J, 2014, TREE PHYSIOL, V34, P869, DOI 10.1093/treephys/tpu026; Deslauriers A, 2014, ANN BOT-LONDON, V114, P335, DOI 10.1093/aob/mcu111; Sala A, 2012, TREE PHYSIOL, V32, P764, DOI 10.1093/treephys/tpr143; Chong JL, 2009, PLANT SCI, V177, P143, DOI 10.1016/j.plantsci.2009.05.012; Latva-Maenpaa H, 2013, TREES-STRUCT FUNCT, V27, P131, DOI 10.1007/s00468-012-0780-x; McDowell N, 2008, NEW PHYTOL, V178, P719, DOI 10.1111/j.1469-8137.2008.02436.x; Begum S, 2013, PHYSIOL PLANTARUM, V147, P46, DOI 10.1111/j.1399-3054.2012.01663.x; Hammerbacher A, 2011, PLANT PHYSIOL, V157, P876, DOI 10.1104/pp.111.181420; Gruber A, 2013, TREE PHYSIOL, V33, P1076, DOI 10.1093/treephys/tpt088; Van Bel AJE, 2003, PLANT CELL ENVIRON, V26, P125, DOI 10.1046/j.1365-3040.2003.00963.x; Oribe Y, 2003, TREES-STRUCT FUNCT, V17, P185, DOI 10.1007/s00468-002-0231-1; Froelich DR, 2011, PLANT CELL, V23, P4428, DOI 10.1105/tpc.111.093179; Prislan P, 2013, AGR FOREST METEOROL, V180, P142, DOI 10.1016/j.agrformet.2013.06.001; Rossi S, 2006, NEW PHYTOL, V170, P301, DOI 10.1111/j.1469-8137.2006.01660.x; Hoch G, 2002, OIKOS, V98, P361, DOI 10.1034/j.1600-0706.2002.980301.x; Sevanto S, 2014, PLANT CELL ENVIRON, V37, P153, DOI 10.1111/pce.12141; Nishizawa A, 2008, PLANT PHYSIOL, V147, P1251, DOI 10.1104/pp.108.122465; Deslauriers A, 2009, TREE PHYSIOL, V29, P1223, DOI 10.1093/treephys/tpp061; Franceschi VR, 2000, AM J BOT, V87, P314, DOI 10.2307/2656627; Nagy NE, 2000, AM J BOT, V87, P302, DOI 10.2307/2656626; Begum S, 2010, ANN BOT-LONDON, V106, P885, DOI 10.1093/aob/mcq185; Li SH, 2012, CHEMBIOCHEM, V13, P2707, DOI 10.1002/cbic.201200547; Manach C, 2004, AM J CLIN NUTR, V79, P727; Ryan MG, 2014, TREE PHYSIOL, V34, P1, DOI 10.1093/treephys/tpt123; KOZLOWSKI TT, 1992, BOT REV, V58, P107, DOI 10.1007/BF02858600; Rossi M, 2013, CHEM-BIOL INTERACT, V206, P175, DOI 10.1016/j.cbi.2013.09.013; Spicer R, 2014, J EXP BOT, V65, P1829, DOI 10.1093/jxb/ert459; Franceschi VR, 2005, NEW PHYTOL, V167, P353, DOI 10.1111/j.1469-8137.2005.01436.x; Jyske T, 2014, AGR FOREST METEOROL, V194, P241, DOI 10.1016/j.agrformet.2014.04.015; Giovannelli A, 2011, DENDROCHRONOLOGIA, V29, P177, DOI 10.1016/j.dendro.2011.01.001; Franceschi VR, 1998, AM J BOT, V85, P601, DOI 10.2307/2446529; WOODWARD S, 1988, PHYSIOL MOL PLANT P, V33, P127, DOI 10.1016/0885-5765(88)90049-5; Henttonen HM, 2009, CAN J FOREST RES, V39, P606, DOI 10.1139/X08-203; Simard S, 2013, TREE PHYSIOL, V33, P913, DOI 10.1093/treephys/tpt075; Krokene P, 2008, TREE PHYSIOL, V28, P29; Rossi S, 2006, IAWA J, V27, P89; Robb EL, 2014, PHYTOCHEMISTRY, V98, P164, DOI 10.1016/j.phytochem.2013.11.019; Antonova GF, 2008, RUSS J DEV BIOL+, V39, P207, DOI 10.1134/S1062360408040024; Antonova G F, 2006, Ontogenez, V37, P368; Baek K.R., 2012, J AGR CHEM ENV, V1, P34; Brodersen CR, 2013, IAWA J, V34, P408, DOI 10.1163/22941932-00000033; Cochard H, 2015, PLANT CELL ENVIRON, V38, P201, DOI 10.1111/pce.12391; Evert R., 2006, ESAUS PLANT ANATOMY; Gricar J, 2008, RUSS J PLANT PHYSL+, V55, P538, DOI 10.1134/S102144370804016X; HERMS DA, 1992, Q REV BIOL, V67, P283, DOI 10.1086/417659; Jyske T, 2015, NEW PHYTOL, V205, P102, DOI 10.1111/nph.12973; Jyske T, 2014, BIOMASS BIOENERG, V71, P216, DOI 10.1016/j.biombioe.2014.10.005; KENDALL EJ, 1989, PHYSIOL PLANTARUM, V76, P86, DOI 10.1111/j.1399-3054.1989.tb05457.x; Krekling T, 2000, FLORA, V195, P354; Larson P, 1994, VASCULAR CAMBIUM DEV; Latva-Maenpaa H, 2014, HOLZFORSCHUNG, V68, P1, DOI 10.1515/hf-2013-0020; Leroux O, 2009, J MICROSC-OXFORD, V233, P1, DOI 10.1111/j.1365-2818.2008.03088.x; Liu J-L, 2011, MOLECULES, V16, P710; Makinen H, 2003, TREE PHYSIOL, V23, P959; Martinez-Vilalta J, 2014, TREE PHYSIOL, V34, P215, DOI 10.1093/treephys/tpu010; Massad TJ, 2014, NEW PHYTOL, V203, P607, DOI 10.1111/nph.12811; Rossi Sergio, 2003, Dendrochronologia, V21, P33, DOI 10.1078/1125-7865-00034; Solhaug KA, 1990, SCAND J FOREST RES, V5, P59, DOI 10.1080/02827589009382593; Sundberg A., 1996, NORD PULP PAP RES J, V11, P226; SUNDBERG B, 1993, TREE PHYSIOL, V12, P347; TROCKENBRODT M, 1990, IAWA BULL, V11, P141; Truernit E, 2014, J EXP BOT, V65, P1681, DOI 10.1093/jxb/ert445; Tsuyama T, 2013, PLANT PHYSIOL, V162, P918, DOI 10.1104/pp.113.214957; UNDERWOOD CDT, 1991, EUR J FOREST PATHOL, V21, P279; UNDERWOOD CDT, 1991, PHYTOCHEMISTRY, V30, P2183; VANBEL AJE, 1990, J EXP BOT, V41, P631, DOI 10.1093/jxb/41.6.631; Whetten RW, 1998, ANNU REV PLANT PHYS, V49, P585, DOI 10.1146/annurev.arplant.49.1.585; Witzell J, 2008, CAN J FOREST RES, V38, P2711, DOI 10.1139/X08-112; ZEIDE B, 1993, FOREST SCI, V39, P594	71	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0032-0935	1432-2048		PLANTA	Planta	SEP	2015	242	3					613	629		10.1007/s00425-015-2347-8		17	Plant Sciences	Plant Sciences	CP4DJ	WOS:000359831900010		
J	Deguchi, A; Tatsuzawa, F; Hosokawa, M; Doi, M; Ohno, S				Deguchi, Ayumi; Tatsuzawa, Fumi; Hosokawa, Munetaka; Doi, Motoaki; Ohno, Sho			Tobacco streak virus (strain dahlia) suppresses post-transcriptional gene silencing of flavone synthase II in black dahlia cultivars and causes a drastic flower color change	PLANTA			English	Article						Cyanidin; Dahlia variabilis; FNS II; PTGS; Silencing suppressor	SEED TRANSMISSION; MOSAIC-VIRUS; NICOTIANA-BENTHAMIANA; TRANSCRIPTION FACTOR; 2B PROTEIN; VARIABILIS; ANTHOCYANINS; TEMPERATURE; GLYCOSIDES; PLANTS	Tobacco streak virus suppressed post-transcriptional gene silencing and caused a flower color change in black dahlias, which supported the role of cyanidin-based anthocyanins for black flower appearance. Black flower color of dahlia (Dahlia variabilis) has been attributed, in part, to the high accumulation of cyanidin-based anthocyanins that occurs when flavone synthesis is reduced because of post-transcriptional gene silencing (PTGS) of flavone synthase II (DvFNS). There are also purple-flowering plants that have emerged from a black cultivar 'Kokucho'. We report that the purple color is not caused by a mutation, as previously thought, but by infection with tobacco streak virus (TSVdahlia), which suppresses the PTGS of DvFNS. When TSVdahlia was eliminated from the purple-flowering 'Kokucho' by leaf primordia-free shoot apical meristem culture, the resulting flowers were black. TSVdahlia-infected purple flowers had lower numbers of siRNAs to DvFNS than black flowers, suggesting that TSVdahlia has a silencing suppressor. The graft inoculation of other black cultivars with TSVdahlia altered their flower color drastically except for 'Fidalgo Blacky', a very deep black cultivar with the highest amount of cyanidin-based anthocyanins. The flowers of all six TSVdahlia-infected cultivars accumulated increased amounts of flavones and reduced amounts of cyanidin-based anthocyanins. 'Fidalgo Blacky' remained black despite the change in pigment accumulation, and the amounts of cyanidin-based anthocyanins in its TSVdahlia-infected plants were still higher than those of other cultivars. We propose that black flower color in dahlia is controlled by two different mechanisms that increase the amount of cyanidin-based anthocyanins: DvFNS PTGS-dependent and -independent mechanisms. If both mechanisms occur simultaneously, the flower color will be blacker than if only a single mechanism is active.	[Deguchi, Ayumi; Hosokawa, Munetaka; Doi, Motoaki; Ohno, Sho] Kyoto Univ, Grad Sch Agr, Lab Vegetable & Ornamental Hort, Sakyo Ku, Kyoto 6068502, Japan; [Tatsuzawa, Fumi] Iwate Univ, Fac Agr, Morioka, Iwate 0208550, Japan	Ohno, S (reprint author), Kyoto Univ, Grad Sch Agr, Lab Vegetable & Ornamental Hort, Sakyo Ku, Kyoto 6068502, Japan.	sohno@kais.kyoto-u.ac.jp			JSPS KAKENHI [14J01993]	This work was supported by JSPS KAKENHI Grant-in-Aid for JSPS Fellows Grant Number 14J01993.	Shimura H, 2013, VIROLOGY, V442, P180, DOI 10.1016/j.virol.2013.04.015; Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739; Hosokawa M, 2004, PLANT CELL REP, V22, P859, DOI 10.1007/s00299-004-0770-6; Szittya G, 2003, EMBO J, V22, P633, DOI 10.1093/emboj/cdg74; Ayabe Shin-ichi, 2006, Phytochemistry Reviews, V5, P271, DOI 10.1007/s11101-006-9007-3; Duan CG, 2012, PLANT CELL, V24, P259, DOI 10.1105/tpc.111.092718; Hosokawa M, 2008, J JPN SOC HORTIC SCI, V77, P341, DOI 10.2503/jjshs1.77.341; Davies KM, 1998, PLANT J, V13, P259, DOI 10.1046/j.1365-313X.1998.00029.x; Grotewold E, 2006, ANNU REV PLANT BIOL, V57, P761, DOI 10.1146/annurev.arplant.57.032905.105248; ASEN S, 1972, PHYTOCHEMISTRY, V11, P1139, DOI 10.1016/S0031-9422(00)88467-8; Martens S, 2005, PHYTOCHEMISTRY, V66, P2399, DOI 10.1016/j.phytochem.205.07.013; Ohno S, 2013, PLANTA, V238, P331, DOI 10.1007/s00425-013-1897-x; Ghoshal B, 2014, VIROLOGY, V456, P188, DOI 10.1016/j.virol.2014.03.026; Takeda A, 2002, FEBS LETT, V532, P75, DOI 10.1016/S0014-5793(02)03632-3; Tanaka Y, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0432; Chellappan P, 2005, PLANT PHYSIOL, V138, P1828, DOI 10.1104/pp.105.066563; NORDSTROM CG, 1956, ARCH BIOCHEM BIOPHYS, V60, P329, DOI 10.1016/0003-9861(56)90435-0; Ohno S, 2011, PLANTA, V234, P945, DOI 10.1007/s00425-011-1456-2; Senda M, 2004, PLANT CELL, V16, P807, DOI 10.1105/tpc.019885; Tanaka Y, 2008, PLANT J, V54, P733, DOI 10.1111/j.1365-313X.2008.03447.x; Ohno S, 2011, J EXP BOT, V62, P5105, DOI 10.1093/jxb/err216; [Anonymous], 1962, PHYSIOL PLANTARUM, DOI DOI 10.1111/J.1399-3054.1962.TB08052.X; CLAUSEN J., 1930, HEREDITAS, V13, P342; CORNELISSEN BJC, 1984, NUCLEIC ACIDS RES, V12, P2427, DOI 10.1093/nar/12.5.2427; Deguchi A, 2013, PLANTA, V237, P1325, DOI 10.1007/s00425-013-1848-6; DEKKER EL, 1993, J GEN VIROL, V74, P881, DOI 10.1099/0022-1317-74-5-881; FISCHER D, 1988, ARCH BIOCHEM BIOPHYS, V264, P40, DOI 10.1016/0003-9861(88)90567-X; GHANEKAR AM, 1974, PHYTOPATHOLOGY, V64, P112; Halbwirth H, 2008, NAT PROD COMMUN, V3, P1259; HARBORNE JB, 1990, PHYTOCHEMISTRY, V29, P2899, DOI 10.1016/0031-9422(90)87101-Y; Hunter DA, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-412; JOHNSON HA, 1984, PLANT DIS, V68, P390, DOI 10.1094/PD-69-390; Lesnaw JA, 2000, PLANT DIS, V84, P1052, DOI 10.1094/PDIS.2000.84.10.1052; Markham KR, 2004, Z NATURFORSCH C, V59, P625; Naka T, 2007, B NARA AGR EXP STA, V38, P17; NORDSTROM CG, 1953, J CHEM SOC, P2764, DOI 10.1039/jr9530002764; NORDSTROM CG, 1958, ARCH BIOCHEM BIOPHYS, V73, P220, DOI 10.1016/0003-9861(58)90257-1; Padmanabhan C, 2014, GENOME ANNOUNC, V2, DOI [10.1128/genomeA.01138-14, DOI 10.1128/GENOMEA.01138-14]; Schlangen K, 2010, ARCH BIOCHEM BIOPHYS, V494, P40, DOI 10.1016/j.abb.2009.11.015; Scott SW, 1998, ARCH VIROL, V143, P1187, DOI 10.1007/s007050050366; Sharman M, 2009, PLANT DIS, V93, P708, DOI 10.1094/PDIS-93-7-0708; Sharman M, 2013, ARCH VIROL, V158, P1637, DOI 10.1007/s00705-013-1628-4; Tatsuzawa F, 2012, J JPN SOC HORTIC SCI, V81, P91; Teycheney PY, 2001, J GEN VIROL, V82, P1239; Thill J, 2012, BMC PLANT BIOL, V12, DOI 10.1186/1471-2229-12-225; Wimmer G, 1998, PHYTOCHEMISTRY, V47, P1013	46	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0032-0935	1432-2048		PLANTA	Planta	SEP	2015	242	3					663	675		10.1007/s00425-015-2365-6		13	Plant Sciences	Plant Sciences	CP4DJ	WOS:000359831900013		
J	Chen, DD; Arakawa, K; Xu, CH				Chen, Dingding; Arakawa, Kazuo; Xu, Changheng			Reduction of void content of vacuum-assisted resin transfer molded composites by infusion pressure control	POLYMER COMPOSITES			English	Article							CARBON/EPOXY COMPOSITES; MECHANICAL-PROPERTIES; MOLDING PROCESSES; BUBBLE-GROWTH; VARTM PROCESS; FLOW; MODEL; PERFORMANCE; VALIDATION; SIMULATION	Vacuum-assisted resin transfer molding is a promising technique for making large and complex composite structures. However, void formation remains a problem. Two primary contributors to void formation, non-uniform resin flow and continuous evaporation of resin under low pressure, were experimentally studied. Improved pressure control at the vent is proposed to reduce the void content of the manufactured composite material: at the start of the resin infusion, the pressure at the vent is set to the full vacuum of the equipment, while after the resin has saturated all of the reinforcements, the pressure at the vent is increased slightly. The full vacuum at the start of infusion avoids air entrapment, and the slightly higher pressure later in the process restrains the resin evaporation. A lower void content is obtained. POLYM. COMPOS., 36:1629-1637, 2015. (c) 2014 Society of Plastics Engineers	[Chen, Dingding; Xu, Changheng] Kyushu Univ, Interdisciplinary Grad Sch Engn Sci, Fukuoka 8168580, Japan; [Arakawa, Kazuo] Kyushu Univ, Appl Mech Res Inst, Fukuoka 8168580, Japan	Chen, DD (reprint author), Kyushu Univ, Interdisciplinary Grad Sch Engn Sci, Fukuoka 8168580, Japan.	dingding.mail@163.com	Kyushu, RIAM/F-4018-2015		Japan Society for the Promotion of Science [23656605]; Collaborative Research Program of the Research Institute for Applied Mechanics, Kyushu University	Contract grant sponsor: Japan Society for the Promotion of Science; contract grant number: #23656605; contract grant sponsor: the Collaborative Research Program of the Research Institute for Applied Mechanics, Kyushu University.	Alms JB, 2010, COMPOS STRUCT, V92, P2811, DOI 10.1016/j.compstruct.2010.04.007; Govignon Q, 2010, COMPOS PART A-APPL S, V41, P45, DOI 10.1016/j.compositesa.2009.07.007; Simacek P, 2012, COMPOS PART A-APPL S, V43, P370, DOI 10.1016/j.compositesa.2011.10.002; Matsuzaki R, 2011, COMPOS PART A-APPL S, V42, P550, DOI 10.1016/j.compositesa.2011.01.014; Kuentzer N, 2007, COMPOS PART A-APPL S, V38, P802, DOI 10.1016/j.compositesa.2006.08.005; Hagstrand PO, 2005, COMPOS PART A-APPL S, V36, P705, DOI 10.1016/j.compositesa.2004.03.007; Sul IH, 2012, POLYM ENG SCI, V52, P1733, DOI 10.1002/pen.23112; Kang MK, 2000, COMPOS SCI TECHNOL, V60, P2427, DOI 10.1016/S0266-3538(00)00036-1; Park CH, 2011, COMPOS PART A-APPL S, V42, P658, DOI 10.1016/j.compositesa.2011.02.005; Govignon Q, 2008, COMPOS PART A-APPL S, V39, P1412, DOI 10.1016/j.compositesa.2008.05.005; Mathur R, 2001, POLYM COMPOSITE, V22, P477, DOI 10.1002/pc.10553; [Anonymous], 2011, D3171 ASTM; [Anonymous], 2011, D2584 ASTM; Huang H, 2005, COMPOS SCI TECHNOL, V65, P1964, DOI 10.1016/j.compscitech.2005.02.019; Johnson RJ, 2003, COMPOS SCI TECHNOL, V63, P2201, DOI 10.1016/S0266-3538(03)00179-9; DeValve C, 2013, COMPOS PART A-APPL S, V51, P22, DOI 10.1016/j.compositesa.2013.03.016; Fu BR, 2009, INT J HEAT MASS TRAN, V52, P767, DOI 10.1016/j.ijheatmasstransfer.2008.07.018; Govignon Q, 2013, J COMPOS MATER, V47, P1479, DOI 10.1177/0021998312448500; Hamidi YK, 2005, COMPOS SCI TECHNOL, V65, P1306, DOI 10.1016/j.compscitech.2005.01.001; Hernandez S, 2013, COMPOS SCI TECHNOL, V85, P73, DOI 10.1016/j.compscitech.2013.06.005; Johnson RJ, 2007, COMPOS SCI TECHNOL, V67, P669, DOI 10.1016/j.compscitech.2006.04.012; Kedari VR, 2011, J COMPOS MATER, V45, P2727, DOI 10.1177/0021998311415442; LUNDSTROM TS, 1994, POLYM COMPOSITE, V15, P25, DOI 10.1002/pc.750150105; Nalla AR, 2007, COMPOS PART A-APPL S, V38, P1058, DOI 10.1016/j.compositesa.2006.06.021; Paciornik S, 2009, J COMPOS MATER, V43, P101, DOI 10.1177/0021998308098234; Parnas RS, 2005, POLYM COMPOSITE, V26, P477, DOI 10.1002/pc.20121; Santulli C, 2002, SCI ENG COMPOS MATER, V10, P77; Scott AE, 2014, COMPOS SCI TECHNOL, V90, P147, DOI 10.1016/j.compscitech.2013.11.004; Seon G, 2013, COMPOS SCI TECHNOL, V89, P194, DOI 10.1016/j.compscitech.2013.10.006; Song YS, 2008, POLYM COMPOSITE, V29, P390, DOI 10.1002/pc.20326; Takeda F., 2005, TECH REV MITSUBISHI, V42, P1; Tuladhar TR, 2004, CHEM ENG SCI, V59, P5997, DOI 10.1016/j.ces.2004.07.054; Zhu HY, 2011, J MATER SCI TECHNOL, V27, P69, DOI 10.1016/S1005-0302(11)60028-5	33	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0272-8397	1548-0569		POLYM COMPOSITE	Polym. Compos.	SEP	2015	36	9					1629	1637		10.1002/pc.23071		9	Materials Science, Composites; Polymer Science	Materials Science; Polymer Science	CP7NJ	WOS:000360074600008		
J	Dong, YB; Ni, QQ				Dong, Yubing; Ni, Qing-Qing			Effect of vapor-grown carbon nanofibers and in situ hydrolyzed silica on the mechanical and shape memory properties of water-borne epoxy composites	POLYMER COMPOSITES			English	Article							BIOMEDICAL APPLICATIONS; THERMOMECHANICAL CHARACTERIZATION; POLYMER NANOCOMPOSITES; SYNTACTIC FOAM; DRY ADHESIVES; PERFORMANCE; NANOTUBES; PHASE	Vapor-grown carbon nanofiber (VGCNF)/water-borne epoxy (WEP) and SiO2/WEP composites were successfully synthesized via freeze drying and hot-press molding. VGCNFs were mixed directly with a WEP emulsion, while SiO2 was synthesized by in situ hydrolysis of TEOS solution (3-triethoxysilylpropylamine (KH550): tetraethoxysilane (TEOS): absolute ethanol=1:5:20, w/w/w) dispersed in the WEP emulsion. WEP composites were obtained from these mixtures by freeze drying and compressing under a pressure of 10 MPa at 120 degrees C for 2 h. The morphology and mechanical properties of the WEP composites were investigated by transmission electron microscopy, scanning electron microscopy, dynamic mechanical analysis and tensile testing. The shape memory (SM) properties of the WEP composites were evaluated by fold-deploy SM testing. The effects of filler content and recovery temperature on the SM properties were revealed through systematic variation. The results confirmed that VGCNF and in situ hydrolyzed SiO2 were homogenously dispersed and incorporated into the WEP matrices. Thus, significant improvements in the mechanical and SM properties of the composites were achieved. POLYM. COMPOS., 36:1712-1720, 2015. (c) 2014 Society of Plastics Engineers	[Dong, Yubing] Shinshu Univ, Fac Text Sci & Technol, Ueda, Nagano 3868576, Japan; [Ni, Qing-Qing] Shinshu Univ, Dept Funct Machinery & Mech, Ueda, Nagano 3868576, Japan; [Ni, Qing-Qing] Zhejiang Sci Tech Univ, Minist Educ, Key Lab Adv Text Mat & Mfg Technol, Hangzhou 310018, Zhejiang, Peoples R China	Ni, QQ (reprint author), Shinshu Univ, Dept Funct Machinery & Mech, 3-15-1 Tokida, Ueda, Nagano 3868576, Japan.	niqq@shinshu-u.ac.jp					Zhang QL, 2013, SOL ENERG MAT SOL C, V117, P259, DOI 10.1016/j.solmat.2013.06.020; Huang WM, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1880448; Small W, 2010, J MATER CHEM, V20, P3356, DOI 10.1039/b923717h; Rodriguez ED, 2011, ACS APPL MATER INTER, V3, P152, DOI 10.1021/am101012c; Habault D, 2013, CHEM SOC REV, V42, P7244, DOI 10.1039/c3cs35489j; Han XJ, 2012, MACROMOL RAPID COMM, V33, P1055, DOI 10.1002/marc.201200153; Kunzelman J, 2008, J MATER CHEM, V18, P1082, DOI 10.1039/b718445j; Xiao XC, 2010, J MATER CHEM, V20, P3508, DOI 10.1039/c0jm00307g; Zhang CS, 2007, COMPOS STRUCT, V78, P153, DOI 10.1016/j.compstruct.2005.08.029; Xie T, 2009, MACROMOL RAPID COMM, V30, P1823, DOI 10.1002/marc.200900409; Zhang YM, 2011, J MATER CHEM, V21, P9073, DOI 10.1039/c1jm11022e; Kumar KSS, 2013, REACT FUNCT POLYM, V73, P421, DOI 10.1016/j.reactfunctpolym.2012.06.009; Lendlein A, 2002, SCIENCE, V296, P1673, DOI 10.1126/science.1066102; Meng H, 2013, POLYMER, V54, P2199, DOI 10.1016/j.polymer.2013.02.023; Li GQ, 2010, POLYMER, V51, P755, DOI 10.1016/j.polymer.2009.12.002; Al-Saleh MH, 2011, COMPOS PART A-APPL S, V42, P2126, DOI 10.1016/j.compositesa.2011.08.005; Leng JS, 2011, PROG MATER SCI, V56, P1077, DOI 10.1016/j.pmatsci.2011.03.001; Thevenot J, 2013, CHEM SOC REV, V42, P7099, DOI 10.1039/c3cs60058k; Li GG, 2010, COMPOS SCI TECHNOL, V70, P1419, DOI 10.1016/j.compscitech.2010.04.026; Jung YC, 2010, CARBON, V48, P1598, DOI 10.1016/j.carbon.2009.12.058; Zhang CS, 2007, COMPOS SCI TECHNOL, V67, P2973, DOI 10.1016/j.compscitech.2007.05.011; Dong YB, 2013, COMPOS SCI TECHNOL, V76, P8, DOI 10.1016/j.compscitech.2012.12.011; Al-Saleh MH, 2009, CARBON, V47, P2, DOI 10.1016/j.carbon.2008.09.039; Endo M, 2006, APPL PHYS A-MATER, V82, P559, DOI 10.1007/s00339-005-3398-7; Lendlein A, 2005, NATURE, V434, P879, DOI 10.1038/nature03496; Rousseau IA, 2010, J MATER CHEM, V20, P3431, DOI 10.1039/b923394f; Ma MM, 2013, SCIENCE, V339, P186, DOI 10.1126/science.1230262; Sharifi S, 2013, BIOMATERIALS, V34, P8105, DOI 10.1016/j.biomaterials.2013.07.061; Liu YJ, 2009, COMPOS SCI TECHNOL, V69, P2064, DOI 10.1016/j.compscitech.2008.08.016; Serrano MC, 2012, MACROMOL BIOSCI, V12, P1156, DOI 10.1002/mabi.201200097; Xu LB, 2011, CHINESE J CHEM, V29, P703, DOI 10.1002/cjoc.201190144; DiOrio AM, 2011, SOFT MATTER, V7, P68, DOI 10.1039/c0sm00487a; Xu JW, 2006, POLYMER, V47, P457, DOI 10.1016/j.polymer.2005.11.035; Lendlein A, 2010, J MATER CHEM, V20, P3332, DOI 10.1039/c004361n; Ragosta G, 2005, POLYMER, V46, P10506, DOI 10.1016/j.polymer.2005.08.028; Ni QQ, 2007, COMPOS STRUCT, V81, P176, DOI 10.1016/j.compstruct.2006.08.017; Raza MA, 2012, CARBON, V50, P84, DOI 10.1016/j.carbon.2011.08.010; Boesel LF, 2010, ADV MATER, V22, P2125, DOI 10.1002/adma.200903200; Tang ZH, 2013, COMPOS SCI TECHNOL, V75, P15, DOI 10.1016/j.compscitech.2012.11.019; Meng H, 2013, J MATER CHEM A, V1, P7838, DOI 10.1039/c3ta10716g; Hu JL, 2012, PROG POLYM SCI, V37, P1720, DOI 10.1016/j.progpolymsci.2012.06.001; Viry L, 2010, J MATER CHEM, V20, P3487, DOI 10.1039/b924430a; Chen CM, 2013, ADV FUNCT MATER, V23, P3813, DOI 10.1002/adfm.201300052; Dong YB, 2013, J COLLOID INTERF SCI, V391, P8, DOI 10.1016/j.jcis.2012.08.072; Yan BB, 2013, EUR POLYM J, V49, P366, DOI 10.1016/j.eurpolymj.2012.09.026; Liu YY, 2010, MAT SCI ENG A-STRUCT, V527, P2510, DOI 10.1016/j.msea.2009.12.014; Cai Y, 2013, COMPOS PART A-APPL S, V53, P16, DOI 10.1016/j.compositesa.2013.05.016; Ding J, 2014, POLYM COMPOSITE, V35, P412, DOI 10.1002/pc.22675; Huang W. M., 2010, J MATER CHEM, V20, P3368; Kai Y., 2014, RSC ADV, V4, P2961; Lan X, 2009, SMART MATER STRUCT, V18, DOI 10.1088/0964-1726/18/2/024002; Lee SK, 2011, J POLYM SCI POL CHEM, V49, P634, DOI 10.1002/pola.24473; MAURITZ KA, 1989, MACROMOLECULES, V22, P1730, DOI 10.1021/ma00194a038; Prima MD, 2010, MECH MATER, V42, P304	54	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0272-8397	1548-0569		POLYM COMPOSITE	Polym. Compos.	SEP	2015	36	9					1712	1720		10.1002/pc.23082		9	Materials Science, Composites; Polymer Science	Materials Science; Polymer Science	CP7NJ	WOS:000360074600018		
J	Molla, MZ; Mizukoshi, N; Furukawa, H; Ogomi, Y; Pandey, SS; Ma, T; Hayase, S				Molla, Md. Zaman; Mizukoshi, Norihiro; Furukawa, Hiroaki; Ogomi, Yuhei; Pandey, Shyam S.; Ma, Tingli; Hayase, Shuzi			Transparent conductive oxide-less back contact dye-sensitized solar cells using cobalt electrolyte	PROGRESS IN PHOTOVOLTAICS			English	Article						TCO-less; cobalt electrolyte; recombination; surface passivation; dye-sensitized solar cells	HIGH-EFFICIENCY; ORGANIC-DYES; TIO2; ELECTRICITY; CONVERSION; SUBSTRATE; DESIGN	Transparent conductive oxide-less (TCO-less) dye-sensitized solar cells (DSSCs) have been fabricated and characterized using nanoporous TiO2-coated stainless steel metal mesh as flexible photoanode and cobalt bipyridyl complex (Co(bpy))-based one electron redox shuttle electrolyte. Attempts have been made towards enhancing the efficiency of TCO-less DSSCs to match with their TCO-based DSSC counterparts. It has been found that surface protection of metal mesh is highly required for enhancing the efficiency of TCO-less DSSCs specially using cobalt electrolytes as confirmed by dark current-voltage characteristics. Photocurrent action spectra clearly reveal that TCO-based DSSCs using (Co(bpy)) electrolyte exhibits photon harvesting (incident photon to current conversion efficiency (IPCE) 52%) in the 370-450nm wavelength region as compared to photon harvesting at peak absorption of the dye (IPCE 56% at 550nm), which is almost the same (IPCE 47%) in the 400-610nm wavelength region for TCO-less DSSCs. Under similar experimental conditions, replacing indoline dye D-205 to porphyrin-based dye YD2-o-C8 led to the enhancement in the photoconversion efficiency from 3.33% to 4.84% under simulated solar irradiation. Copyright (c) 2014 John Wiley & Sons, Ltd.	[Molla, Md. Zaman; Furukawa, Hiroaki; Ogomi, Yuhei; Pandey, Shyam S.; Ma, Tingli; Hayase, Shuzi] Kyushu Inst Technol, Grad Sch Life Sci & Syst Engn, Kitakyushu, Fukuoka 8080196, Japan; [Mizukoshi, Norihiro] Godo Shigen Sangyo Co Ltd, Chiba 2994333, Japan	Molla, MZ (reprint author), Kyushu Inst Technol, Grad Sch Life Sci & Syst Engn, 2-4 Hibikino, Kitakyushu, Fukuoka 8080196, Japan.	zaman-molla@edu.life.kyutech.ac.jp; hayase@life.kyutech.ac.jp			Strategic Promotion of Innovative Research and Development (S-Innovation) program of Japan Science and Technology under the Japanese government	This work has been supported by the Strategic Promotion of Innovative Research and Development (S-Innovation) program of Japan Science and Technology under the Japanese government.	Marchena MJ, 2013, J PHYS CHEM C, V117, P11906, DOI 10.1021/jp401399j; Mosconi E, 2012, J AM CHEM SOC, V134, P19438, DOI 10.1021/ja3079016; NAZEERUDDIN MK, 1993, J AM CHEM SOC, V115, P6382, DOI 10.1021/ja00067a063; Greijer H, 2001, RENEW ENERG, V23, P27, DOI 10.1016/S0960-1481(00)00111-7; Yella A, 2011, SCIENCE, V334, P629, DOI 10.1126/science.1209688; Vijayakumar V, 2011, SOL ENERG MAT SOL C, V95, P2120, DOI 10.1016/j.solmat.2011.03.010; Horiuchi T, 2004, J AM CHEM SOC, V126, P12218, DOI 10.1021/ja0488277; Frank AJ, 2004, COORDIN CHEM REV, V248, P1165, DOI 10.1016/j.ccr.2004.03.015; Kang MG, 2006, SOL ENERG MAT SOL C, V90, P574, DOI 10.1016/j.solmat.2005.04.025; Bernard MC, 2003, J ELECTROCHEM SOC, V150, pE155, DOI 10.1149/1.1543951; Gratzel M, 2004, J PHOTOCH PHOTOBIO A, V164, P3, DOI 10.1016/j.jphotochem.2004.02.023; Hagfeldt A, 2000, ACCOUNTS CHEM RES, V33, P269, DOI 10.1021/ar980112j; OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0; Kern R, 2002, ELECTROCHIM ACTA, V47, P4213, DOI 10.1016/S0013-4686(02)00444-9; Islam A, 2003, J PHOTOCH PHOTOBIO A, V158, P131, DOI 10.1016/S1010-6030(03)00027-3; Fuke N, 2007, JPN J APPL PHYS 2, V46, pL420, DOI 10.1143/JJAP.46.L420; Feldt SM, 2010, J AM CHEM SOC, V132, P16714, DOI 10.1021/ja1088869; Wang MK, 2012, ENERG ENVIRON SCI, V5, P9394, DOI 10.1039/c2ee23081j; Liang M, 2007, J PHYS CHEM C, V111, P4465, DOI 10.1021/jp067930a; Fuke N, 2008, CHEM MATER, V20, P4974, DOI 10.1021/cm800797v; Fan X, 2007, APPL PHYS LETT, V90; Hore S, 2005, APPL PHYS LETT, V87; Ito S, 2006, CHEM COMMUN, P4004, DOI 10.1039/b608279c; Kashiwa Y, 2008, APPL PHYS LETT, V92; Kroon JM, 2007, PROG PHOTOVOLTAICS, V15, P1, DOI 10.1002/pip.707; Lagemaat J.V.D., 2000, J PHYS CHEM B, V104, P2044; Topic M, 2010, CURR APPL PHYS, V10, pS425, DOI 10.1016/j.cap.2010.02.042; Yoshida Y., 2009, APPL PHYS LETT, V94	28	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1062-7995	1099-159X		PROG PHOTOVOLTAICS	Prog. Photovoltaics	SEP	2015	23	9					1100	1109		10.1002/pip.2526		10	Energy & Fuels; Materials Science, Multidisciplinary; Physics, Applied	Energy & Fuels; Materials Science; Physics	CP4QW	WOS:000359868400004		
J	Nakazawa, S; Murai, T; Miyauchi, M; Kotani, M; Ikeda, K				Nakazawa, Shunsuke; Murai, Takeshi; Miyauchi, Masanori; Kotani, Manato; Ikeda, Kazuhito			Behavioral and neurophysiological effects of Ro 10-5824, a dopamine D4 receptor partial agonist, in common marmosets	PSYCHOPHARMACOLOGY			English	Article						Non-human primate; Dopamine D4 receptor (D4R); Electroencephalography (EEG); Gamma oscillations; Object retrieval detour task (ORD task); Cognition; Attention deficit hyperactivity disorder (ADHD)	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; GAMMA-BAND RESPONSES; EXECUTIVE FUNCTION; PREFRONTAL CORTEX; WORKING-MEMORY; OSCILLATIONS; SCHIZOPHRENIA; ASSOCIATION; RATS	Growing evidence suggests that dopamine D4 receptors (D4Rs) are involved in controlling executive functions. We have previously demonstrated that Ro 10-5824, a D4R partial agonist, improves the performance of common marmosets in the object retrieval detour (ORD) task. However, the neural mechanisms underlying this improvement are unknown. We investigated the behavioral and neurophysiological effects of Ro 10-5824 in common marmosets. The effects of Ro 10-5824 on cognitive function were evaluated using the ORD task. The neurophysiological effects of Ro 10-5824 were investigated by quantitative electroencephalography, especially on baseline gamma band activity in the frontal cortex. The effects of Ro 10-5824 on spontaneous locomotion were also assessed. Systemic administration of Ro 10-5824 at 3 mg/kg significantly increased the success rate in the ORD task. At doses of 1 and 3 mg/kg, Ro 10-5824 increased baseline gamma band activity in the frontal cortex. Ro 10-5824 had no effect on spontaneous locomotion. Activation of D4R by Ro 10-5824 improves the success rate in the ORD task and increases baseline gamma band activity in the frontal cortex without affecting locomotion in common marmosets. These findings highlight the role of D4R in gamma oscillations of non-human primates. As gamma oscillations are thought to be involved in attention and behavioral inhibition, our results suggest D4R agonists may improve these cognitive functions by modulating baseline gamma band activity in the frontal cortex.	[Nakazawa, Shunsuke; Murai, Takeshi; Miyauchi, Masanori; Kotani, Manato; Ikeda, Kazuhito] Sumitomo Dainippon Pharma Co Ltd, Drug Dev Res Labs, Suita, Osaka 5640053, Japan	Ikeda, K (reprint author), Sumitomo Dainippon Pharma Co Ltd, Drug Dev Res Labs, 33-94 Enoki Cho, Suita, Osaka 5640053, Japan.	kazuhito-ikeda@ds-pharma.co.jp			Sumitomo Dainippon Pharma Co., Ltd.	We wish to thank Keiko Nakamichi for her assistance in analyzing qEEG data and Yuji Ogi and Masaru Ikejiri for their technical assistance in conducting experiments in common marmosets. This study was funded by Sumitomo Dainippon Pharma Co., Ltd. All animal procedures comply with the current relevant laws of Japan.	Jones NC, 2012, INT J NEUROPSYCHOPH, V15, P657, DOI 10.1017/S1461145711000848; Newman JD, 2009, BRAIN RES REV, V62, P1, DOI 10.1016/j.brainresrev.2009.09.001; Herrmann CS, 2005, CLIN NEUROPHYSIOL, V116, P2719, DOI 10.1016/j.clinph.2005.07.007; Cardin JA, 2009, NATURE, V459, P663, DOI 10.1038/nature08002; Benchenane K, 2011, CURR OPIN NEUROBIOL, V21, P475, DOI 10.1016/j.conb.2011.01.004; DIAMOND A, 1990, ANN NY ACAD SCI, V608, P637, DOI 10.1111/j.1749-6632.1990.tb48913.x; Murai T, 2013, BEHAV BRAIN RES, V246, P125, DOI 10.1016/j.bbr.2013.02.019; Nakako T, 2013, BEHAV BRAIN RES, V249, P109, DOI 10.1016/j.bbr.2013.04.012; Gallinat J, 2004, CLIN NEUROPHYSIOL, V115, P1863, DOI 10.1016/j.clinph.2004.03.013; Takahashi H, 2012, J CEREBR BLOOD F MET, V32, P1248, DOI 10.1038/jcbfm.2011.194; Keizer AW, 2010, NEUROIMAGE, V49, P3404, DOI 10.1016/j.neuroimage.2009.11.023; Li DW, 2006, HUM MOL GENET, V15, P2276, DOI 10.1093/hmg/ddl152; Uhlhaas PJ, 2010, NAT REV NEUROSCI, V11, P100, DOI 10.1038/nrn2774; Brown VJ, 2002, TRENDS NEUROSCI, V25, P340, DOI 10.1016/S0166-2236(02)02164-1; Lewis DA, 2012, TRENDS NEUROSCI, V35, P57, DOI 10.1016/j.tins.2011.10.004; Powell SB, 2003, NEUROPHARMACOLOGY, V44, P473, DOI 10.1016/S0028-3908(02)00412-4; Herrmann CS, 2001, NEUROSCI BIOBEHAV R, V25, P465, DOI 10.1016/S0149-7634(01)00027-6; MeadorWoodruff JH, 1996, NEUROPSYCHOPHARMACOL, V15, P17, DOI 10.1016/0893-133X(95)00150-C; Browman KE, 2005, PHARMACOL BIOCHEM BE, V82, P148, DOI 10.1016/j.pbb.2005.08.002; Khan ZU, 1998, J COMP NEUROL, V402, P353, DOI 10.1002/(SICI)1096-9861(19981221)402:3<353::AID-CNE5>3.0.CO;2-4; Brioni JD, 2004, P NATL ACAD SCI USA, V101, P6758, DOI 10.1073/pnas.0308292101; Yordanova J, 2001, CLIN NEUROPHYSIOL, V112, P1096, DOI 10.1016/S1388-2457(01)00524-7; Herrmann CS, 2010, NEUROSCI BIOBEHAV R, V34, P981, DOI 10.1016/j.neubiorev.2009.09.001; Gandal MJ, 2012, NEUROPHARMACOLOGY, V62, P1504, DOI 10.1016/j.neuropharm.2011.02.007; Smucny J, 2014, TRENDS PHARMACOL SCI, V35, P397, DOI 10.1016/j.tips.2014.05.001; Nieoullon A, 2002, PROG NEUROBIOL, V67, P53, DOI 10.1016/S0301-0082(02)00011-4; Barry RJ, 2010, CLIN NEUROPHYSIOL, V121, P1871, DOI 10.1016/j.clinph.2010.04.022; Gandal MJ, 2010, BIOL PSYCHIAT, V68, P1100, DOI 10.1016/j.biopsych.2010.09.031; Uylings HBM, 2003, BEHAV BRAIN RES, V146, P3, DOI 10.1016/j.bbr.2003.09.028; Demiralp T, 2007, CEREB CORTEX, V17, P1007, DOI 10.1093/cereor/bhl011; Happe F, 2006, BRAIN COGNITION, V61, P25, DOI 10.1016/j.bandc.2006.03.004; Faraone SV, 2001, AM J PSYCHIAT, V158, P1052, DOI 10.1176/appi.ajp.158.7.1052; Andersson RH, 2012, P NATL ACAD SCI USA, V109, P13118, DOI 10.1073/pnas.1201011109; Young JW, 2011, BEHAV BRAIN RES, V222, P183, DOI 10.1016/j.bbr.2011.03.054; Mrzljak L, 1996, NATURE, V381, P245, DOI 10.1038/381245a0; Arnsten AF, 2005, BEHAV BRAIN FUNCT, V1, P2, DOI 10.1186/1744-9081-1-2; Barry RJ, 2009, NEUROPHARMACOLOGY, V57, P702, DOI 10.1016/j.neuropharm.2009.08.003; Bastin J, 2012, NEUROIMAGE, V63, P339, DOI 10.1016/j.neuroimage.2012.07.011; Fox Michael D, 2010, Front Syst Neurosci, V4, P19, DOI 10.3389/fnsys.2010.00019; Friel PN, 2007, ALTERN MED REV, V12, P146; Furth KE, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00102; Karch S, 2012, J PSYCHIATR RES, V46, P1515, DOI 10.1016/j.jpsychires.2012.07.017; Kocsis B, 2014, BRAIN STRUCT FUNCT, V219, P2173, DOI 10.1007/s00429-013-0607-6; Murai T, 2014, BEHAV BRAIN RES, V261, P26, DOI 10.1016/j.bbr.2013.11.036; Noland JS, 2012, CHILD NEUROPSYCHOL, V18, P506, DOI 10.1080/09297049.2011.628307; Ptacek R, 2011, MED SCI MONITOR, V17, pRA215; Salari N, 2014, EXP BRAIN RES, V232, P3353, DOI 10.1007/s00221-014-4023-9; van Wingerden M, 2010, J NEUROSCI, V30, P10025, DOI 10.1523/JNEUROSCI.0222-10.2010; Zhong P, 2014, CEREB CORTEX, DOI [10.1093/cercor/bhu190, DOI 10.1093/CERCOR/BHU190]	49	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0033-3158	1432-2072		PSYCHOPHARMACOLOGY	Psychopharmacology	SEP	2015	232	17					3287	3295		10.1007/s00213-015-3978-y		9	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	CP1TS	WOS:000359659600016		
J	Nishimura, A; Minegishi, Y; Kwamura, K; Ichino, A; Uchiyama, K				Nishimura, Akito; Minegishi, Yohjiroh; Kwamura, Keiko; Ichino, Asako; Uchiyama, Katsufumi			Efficacy of certolizumab pegol: a case study in a patient with rheumatoid arthritis on maintenance hemodialysis	RHEUMATOLOGY INTERNATIONAL			English	Article							METHOTREXATE; ETANERCEPT; COMBINATION		[Nishimura, Akito; Minegishi, Yohjiroh; Kwamura, Keiko; Ichino, Asako; Uchiyama, Katsufumi] Shizuoka PWFAC Shimizu Kosei Hosp, Shimizu Ku, Shizuoka, Shizuoka 4240114, Japan	Nishimura, A (reprint author), Shizuoka PWFAC Shimizu Kosei Hosp, Shimizu Ku, Iharacho 578-1, Shizuoka, Shizuoka 4240114, Japan.	94080@smz.ja-shizuoka.or.jp					Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140-6736(04)15640-7; Yamamoto K, 2014, MOD RHEUMATOL, V24, P552, DOI 10.3109/14397595.2013.843764; Iwamoto M, 2011, RHEUMATOL INT, V31, P559, DOI 10.1007/s00296-010-1430-5; Nakamura M, 1999, J RHEUMATOL, V26, P1424; Singh R, 2002, J RHEUMATOL, V29, P636; Sugioka Y, 2008, MOD RHEUMATOL, V18, P293, DOI 10.1007/s10165-008-0041-4; van Vollenhoven RF, 2003, ARTHRITIS RES THER, V5, pR347, DOI 10.1186/ar1005	7	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8172	1437-160X		RHEUMATOL INT	Rheumatol. Int.	SEP	2015	35	9					1601	1602		10.1007/s00296-015-3225-1		2	Rheumatology	Rheumatology	CP4EG	WOS:000359834200023		
J	Kamata, Y; Minota, S				Kamata, Yasuyuki; Minota, Seiji			Successful treatment of a patient with SAPHO syndrome with certolizumab pegol	RHEUMATOLOGY INTERNATIONAL			English	Letter									[Kamata, Yasuyuki; Minota, Seiji] Jichi Med Univ, Div Rheumatol & Clin Immunol, Shimotsuke, Tochigi 3290498, Japan	Kamata, Y (reprint author), Jichi Med Univ, Div Rheumatol & Clin Immunol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	y.kamata@jichi.ac.jp; sminota@jichi.ac.jp					Nguyen MT, 2012, SEMIN ARTHRITIS RHEU, V42, P254, DOI 10.1016/j.semarthrit.2012.05.006; Sieper J, 2009, ANN RHEUM DIS, V68, P1, DOI 10.1136/ard.2008.104018; CHAMOT AM, 1987, REV RHUM, V54, P187; BENHAMOU CL, 1988, CLIN EXP RHEUMATOL, V6, P109	4	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8172	1437-160X		RHEUMATOL INT	Rheumatol. Int.	SEP	2015	35	9					1607	1608		10.1007/s00296-015-3263-8		2	Rheumatology	Rheumatology	CP4EG	WOS:000359834200025		
J	Hashiba, K; Fukui, K				Hashiba, K.; Fukui, K.			Effect of Water on the Deformation and Failure of Rock in Uniaxial Tension	ROCK MECHANICS AND ROCK ENGINEERING			English	Article						Uniaxial tension test; Uniaxial compression test; Stress-strain curve; Effect of water; Crack extension resistance curve	STRENGTH; DEFORMABILITY; MOISTURE; CHALK	To design and construct underground structures, it is essential to understand the mechanical properties of rock in not only compression but also tension. It is well known that water is one of the important factors affecting the deformation and failure of rock. In this study, laboratory tests and numerical simulations were conducted to understand the effect of water on rock properties in uniaxial tension. In the experiments, a testing machine previously used for uniaxial tension tests in dry conditions was modified for tests in wet conditions. Using this machine, complete stress-strain curves from the pre- to postpeak regions of water-saturated specimens in uniaxial tension were obtained. The results for granite, tuff, and two types of andesite showed that the stress-strain curves in wet conditions have a lower initial slope and lower strength than those in dry conditions, and they are strongly nonlinear in the prepeak region. Comparing the changes in the results for uniaxial tension versus compression due to water, it was found that the reduction rate of uniaxial tensile strength was greater than that of uniaxial compressive strength, while the ratio between the reduction rates was almost constant for various rocks. In numerical simulations, the stress-strain curves in the prepeak region under dry and wet conditions could be reproduced by crack extension models under uniaxial tensile stress. Numerical analyses indicated that the nonlinearity of the stress-strain curves is probably due to the longer crack extension in wet compared with dry conditions.	[Hashiba, K.; Fukui, K.] Univ Tokyo, Dept Syst Innovat, Bunkyo Ku, Tokyo 1138656, Japan	Hashiba, K (reprint author), Univ Tokyo, Dept Syst Innovat, Bunkyo Ku, Tokyo 1138656, Japan.	hashiba@sys.t.u-tokyo.ac.jp					KIRBY SH, 1984, J GEOPHYS RES, V89, P3991, DOI 10.1029/JB089iB06p03991; GUNSALLUS KL, 1984, INT J ROCK MECH MIN, V21, P233, DOI 10.1016/0148-9062(84)92680-9; BELL FG, 1977, ENG GEOL, V11, P217, DOI 10.1016/0013-7952(77)90003-5; HAWKINS AB, 1992, Q J ENG GEOL, V25, P115, DOI 10.1144/GSL.QJEG.1992.025.02.05; Okubo S, 1996, INT J ROCK MECH MIN, V33, P549, DOI 10.1016/0148-9062(96)00024-1; Erguler ZA, 2009, INT J ROCK MECH MIN, V46, P355, DOI 10.1016/j.ijrmms.2008.07.002; BROCH E, 1972, INT J ROCK MECH MIN, V9, P669, DOI 10.1016/0148-9062(72)90030-7; Chu SY, 1995, J MIN MAT P I JAP, V111, P31; Fukui K, 1991, J MIN MAT I JPN, V107, P416; Hashiba K, 2015, ROCK MECH ROCK ENG, V48, P859, DOI 10.1007/s00603-014-0597-6; HAWKES I, 1973, INT J ROCK MECH MIN, V10, P493, DOI 10.1016/0148-9062(73)90001-6; Ishii E, 2011, ENG GEOL, V122, P215, DOI 10.1016/j.enggeo.2011.05.007; KRANZ RL, 1980, J GEOPHYS RES, V85, P1854, DOI 10.1029/JB085iB04p01854; Nishimatsu Y, 1977, J MMIJ, V93, P185; Ojo O, 1990, MIN SCI TECHNOL, V10, P145, DOI [10.1016/0167-9031(90)90158-O, DOI 10.1016/0167-9031(90)90158-O]; Okamura H, 1976, SENKEI HAKAI RIKIGAK; Okubo S, 1984, J SOC MATER SCI JPN, V33, P882; Okubo S., 1992, Journal of the Society of Materials Science, Japan, V41; Ouchterlony F, 1982, SM ARCH, V7, P131; Parate NS, 1973, T SOC MIN ENG, V254, P127; Sanada H, 2009, J MINING MAT PROCESS, V125, P521, DOI DOI 10.2473/JOURNALOFMMIJ.125.521; Talesnick ML, 2001, INT J ROCK MECH MIN, V38, P543, DOI 10.1016/S1365-1609(01)00024-7; The Japan Society of Mechanical Engineers, 1989, GANS HAK RIK SON OY; VANEECKHOUT EM, 1976, INT J ROCK MECH MIN, V13, P61	24	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0723-2632	1434-453X		ROCK MECH ROCK ENG	Rock Mech. Rock Eng.	SEP	2015	48	5					1751	1761		10.1007/s00603-014-0674-x		11	Engineering, Geological; Geosciences, Multidisciplinary	Engineering; Geology	CP6OJ	WOS:000360006700001		
J	Ishikawa, T				Ishikawa, Takashi			Untitled	SAMPE JOURNAL			English	Editorial Material									Nagoya Univ, Dept Aerosp Engn, Grad Sch Engn, Nagoya, Aichi 4648601, Japan	Ishikawa, T (reprint author), Nagoya Univ, Dept Aerosp Engn, Grad Sch Engn, Nagoya, Aichi 4648601, Japan.	ishikawa@nuae.nagoya-u.ac.jp						0	0	0	SAMPE PUBLISHERS	COVINA	1161 PARKVIEW DRIVE, COVINA, CA 91722 USA	0091-1062			SAMPE J	Sampe J.	SEP-OCT	2015	51	5					2	2				1	Engineering, Multidisciplinary; Materials Science, Multidisciplinary	Engineering; Materials Science	CP9AW	WOS:000360187100001		
J	Lima, A; Lopez, A; van Genderen, ME; Hurtado, FJ; Angulo, M; Grignola, JC; Shono, A; van Bommel, J				Lima, Alexandre; Lopez, Alejandra; van Genderen, Michel E.; Hurtado, Francisco Javier; Angulo, Martin; Grignola, Juan C.; Shono, Atsuko; van Bommel, Jasper			Interrater Reliability and Diagnostic Performance of Subjective Evaluation of Sublingual Microcirculation Images by Physicians and Nurses: A Multicenter Observational Study	SHOCK			English	Article							SEPTIC SHOCK; SEVERE SEPSIS; RESUSCITATION; PERFUSION; PROTOCOL; FAILURE	Introduction: This was a cross-sectional multicenter study to investigate the ability of physicians and nurses from three different countries to subjectively evaluate sublingual microcirculation images and thereby discriminate normal from abnormal sublingual microcirculation based on flow and density abnormalities. Methods: Forty-five physicians and 61 nurses (mean age, 36 +/- 10 years; 44 males) from three different centers in The Netherlands (n = 61), Uruguay (n = 12), and Japan (n = 33) were asked to subjectively evaluate a sample of 15 microcirculation videos randomly selected from an experimental model of endotoxic shock in pigs. All videos were first analyzed offline using the A.V.A. software by an independent, experienced investigator and were categorized as good, bad, or very bad microcirculation based on the microvascular flow index, perfused capillary density, and proportion of perfused capillaries. Then, the videos were randomly assigned to the examiners, who were instructed to subjectively categorize each image as good, bad, or very bad. An interrater analysis was performed, and sensitivity and specificity tests were calculated to evaluate the proportion of A.V.A. score abnormalities that the examiners correctly identified. Results: The kappa statistics indicated moderate agreement in the evaluation of microcirculation abnormalities using three categories, i.e., good, bad, or very bad (kappa = 0.48), and substantial agreement using two categories, i.e., normal (good) and abnormal (bad or very bad) (kappa = 0.66). There was no significant difference between the kappa three and kappa two statistics. We found that the examiner's subjective evaluations had good diagnostic performance and were highly sensitive (84%; 95% confidence interval, 81%-86%) and specific (87%; 95% confidence interval, 84%-90%) for sublingual microcirculatory abnormalities as assessed using the A.V.A. software. Conclusions: The subjective evaluations of sublingual microcirculation by physicians and nurses agreed well with a conventional offline analysis and were highly sensitive and specific for sublingual microcirculatory abnormalities.	[Lima, Alexandre; van Genderen, Michel E.; van Bommel, Jasper] Univ Rotterdam Hosp, Erasmus MC, Dept Intens Care, Rotterdam, Netherlands; [Lopez, Alejandra; Hurtado, Francisco Javier; Angulo, Martin; Grignola, Juan C.] Univ Republica, Sch Med, Univ Hosp, Dept Pathophysiol, Montevideo, Uruguay; [Shono, Atsuko] Shimane Univ, Dept Anesthesiol, Fac Med, Matsue, Shimane, Japan	Lima, A (reprint author), Univ Med Ctr Rotterdam, Dept Intens Care, Erasmus MC, Room H-602,POB 2040, NL-3000 CA Rotterdam, Netherlands.	a.pintolima@erasmusmc.nl					Viera AJ, 2005, FAM MED, V37, P360; de Backer D, 2006, CRIT CARE MED, V34, P1918, DOI 10.1097/01.CCM.0000220498.48773.3C; van Genderen ME, 2012, CRIT CARE MED, V40, P2287, DOI 10.1097/CCM.0b013e31825333b2; He XR, 2012, CRIT CARE MED, V40, P2833, DOI 10.1097/CCM.0b013e31825b88ba; Massey MJ, 2013, J CRIT CARE, V28, P913, DOI 10.1016/j.jcrc.2013.06.015; Trzeciak S, 2008, INTENS CARE MED, V34, P2210, DOI 10.1007/s00134-008-1193-6; Ospina-Tascon G, 2010, INTENS CARE MED, V36, P949, DOI 10.1007/s00134-010-1843-3; den Uil CA, 2010, EUR HEART J, V31, P3032, DOI 10.1093/eurheartj/ehq324; De Backer D, 2006, CRIT CARE MED, V34, P403, DOI 10.1097/01.CCM.0000198107.61493.5A; Sakr Y, 2004, CRIT CARE MED, V32, P1825, DOI 10.1097/01.CCM.0000138558.16257.3F; De Backer D, 2013, CRIT CARE MED, V41, P791, DOI 10.1097/CCM.0b013e3182742e8b; Boerma EC, 2010, CRIT CARE MED, V38, P93, DOI 10.1097/CCM.0b013e3181b02fc1; Arnold RC, 2009, INTENS CARE MED, V35, P1761, DOI 10.1007/s00134-009-1517-1; Bezemer R, 2012, CRIT CARE, V16, DOI 10.1186/cc11236; De Backer D, 2007, CRIT CARE, V11, P101, DOI DOI 10.1186/CC6118; Hallgren KA, 2012, TUTOR QUANT METHODS, V8, P23; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Pozo MO, 2012, CRIT CARE RESPRACT, V102483, P2012	18	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	SEP	2015	44	3					239	244		10.1097/SHK.0000000000000401		6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	CP6FU	WOS:000359981300008		
J	Miyazaki, H; Kinoshita, M; Ono, S; Seki, S; Saitoh, D				Miyazaki, Hiromi; Kinoshita, Manabu; Ono, Satoshi; Seki, Shuhji; Saitoh, Daizoh			Burn-Evoked Reactive Oxygen Species Immediately After Injury are Crucial to Restore the Neutrophil Function Against Postburn Infection in Mice	SHOCK			English	Article							ACUTE LUNG INJURY; SUPEROXIDE-DISMUTASE; STAPHYLOCOCCUS-AUREUS; BACTERIAL-INFECTION; LIPID-PEROXIDATION; OXIDATIVE STRESS; KUPFFER CELLS; FREE-RADICALS; SUBSTANCE-P; ACTIVATION	Although reactive oxygen species (ROS) basically play beneficial roles to maintain host homeostasis against external disturbance/stress including infection, excessive ROS generation by activated neutrophils can sometimes cause organ damage. We investigated the role of burn-induced ROS generation in the injured hosts, focusing on postburn infection. C57BL/6 mice received a 20% full-thickness burn injury. In these mice, the burn-induced ROS generation was inhibited during and immediately after injury by pretreatment with superoxide dismutase (at 1 h before and immediately before injury), or the subsequent ROS production was inhibited posttreatment with superoxide dismutase (at 1 and 2 h after injury), which could not scavenge the ROS produced immediately after injury. As expected, inhibition of ROS production during/immediately after injury reduced the burn-induced pulmonary damage at 6 h, whereas inhibition of the subsequent ROS production did not lead to any improvements. Burn injury rendered the mice susceptible to bacterial infection at 5 days after injury and impaired bactericidal activity of neutrophils. Nevertheless, inhibition of the ROS production during/immediately after injury did not improve the burn-induced susceptibility to infection or the neutrophil dysfunction. Interestingly, inhibition of the subsequent ROS production potently restored the neutrophil functions and hematopoietic function of the bone marrow myelocytes, thereby improving the postburn infection. Thus, although the inhibition of burn-evoked ROS generation is effective against burn-induced organ injury, it may be ineffective against postburn infection. Preservation of the immediate burn-evoked ROS production, but the inhibition of subsequent ROS production, may be crucial to protect against postburn infection.	[Miyazaki, Hiromi; Saitoh, Daizoh] Natl Def Med Coll, Res Inst, Div Traumatol, Tokorozawa, Saitama 359, Japan; [Kinoshita, Manabu; Seki, Shuhji] Natl Def Med Coll, Dept Immunol & Microbiol, Tokorozawa, Saitama 359, Japan; [Ono, Satoshi] Tokyo Med Univ, Hachioji Med Ctr, Div Crit Care Med, Tokyo 1608402, Japan	Kinoshita, M (reprint author), Natl Def Med Coll, Dept Immunol & Microbiol, 3-2 Namiki, Tokorozawa, Saitama 359, Japan.	manabu@ndmc.ac.jp			Japan Society for the Promotion of Science [25293369, 26462773]	This study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (grants 25293369 and 26462773).	Ami K, 2002, J IMMUNOL, V169, P4437; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; Kinoshita M, 2000, EUR SURG RES, V32, P337, DOI 10.1159/000052215; Horton JW, 2003, TOXICOLOGY, V189, P75, DOI 10.1016/S0300-483X(03)00154-9; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; Sio SWS, 2008, J IMMUNOL, V180, P8333; Ritter C, 2003, INTENS CARE MED, V29, P1380, DOI 10.1007/s00134-003-1833-9; Adediran SG, 2010, AM J PHYSIOL-REG I, V299, pR918, DOI 10.1152/ajpregu.00132.2010; Hu ZH, 2004, AM J PHYSIOL-CELL PH, V286, pC170, DOI 10.1152/ajpcell.00187.2003; Parihar A, 2008, BURNS, V34, P6, DOI 10.1016/j.burns.2007.04.009; Tanaka H, 2000, ARCH SURG-CHICAGO, V135, P326, DOI 10.1001/archsurg.135.3.326; Miyazaki H, 2011, BURNS, V37, P1208, DOI 10.1016/j.burns.2011.04.010; Yano H, 2012, INFECT IMMUN, V80, P4409, DOI 10.1128/IAI.00787-12; Rafla K, 2011, BURNS, V37, P5, DOI 10.1016/j.burns.2009.06.198; Kinoshita M, 2011, INFECT IMMUN, V79, P2670, DOI 10.1128/IAI.01298-10; ZOR U, 1993, BIOCHEM J, V295, P879; Droge W, 2002, PHYSIOL REV, V82, P47; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Fialkow L, 2007, FREE RADICAL BIO MED, V42, P153, DOI 10.1016/j.freeadbiomed.2006.09.030; Bhatia M, 1998, P NATL ACAD SCI USA, V95, P4760, DOI 10.1073/pnas.95.8.4760; Chitnis D, 1996, J LEUKOCYTE BIOL, V59, P835; Inatsu A, 2009, HEPATOLOGY, V49, P2044, DOI 10.1002/hep.22888; Kinoshita M, 2006, J IMMUNOL, V177, P4627; Kinoshita M, 2013, J LEUKOCYTE BIOL, V93, P689, DOI 10.1189/jlb.1012502; Koizumi T, 2006, ARCH SURG-CHICAGO, V141, P992, DOI 10.1001/archsurg.141.10.992; MASON AD, 1986, ARCH SURG-CHICAGO, V121, P1027; Masuda Y, 2006, J CLIN BIOCHEM NUTR, V38, P25, DOI 10.3164/jcbn.38.25; Sahib A S, 2010, Ann Burns Fire Disasters, V23, P199; SAITOH D, 1994, AM J EMERG MED, V12, P142, DOI 10.1016/0735-6757(94)90233-X; SAITOH D, 1995, AM J EMERG MED, V13, P37, DOI 10.1016/0735-6757(95)90238-4; SAITOH D, 1993, AM J EMERG MED, V11, P355, DOI 10.1016/0735-6757(93)90167-A; SMITH RM, 1991, BLOOD, V77, P673; Tanaka Hideharu, 1992, Journal of Burn Care and Rehabilitation, V13, P567, DOI 10.1097/00004630-199209000-00010; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Yabe Y, 2001, J PHARMACOL EXP THER, V298, P894	36	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	SEP	2015	44	3					252	257		10.1097/SHK.0000000000000404		6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	CP6FU	WOS:000359981300010		
J	Kawada, T				Kawada, Tomoyuki			Sleep characteristics of children with Williams syndrome in relation to saliva melatonin and cortisol	SLEEP MEDICINE			English	Letter							ADULTS		[Kawada, Tomoyuki] Nippon Med Sch, Dept Hyg & Publ Hlth, Tokyo 1138602, Japan	Kawada, T (reprint author), Nippon Med Sch, Dept Hyg & Publ Hlth, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.	kawada@nms.ac.jp					Goldman SE, 2009, J INTELL DISABIL RES, V53, P182, DOI 10.1111/j.1365-2788.2008.01140.x; Bodizs R, 2014, RES DEV DISABIL, V35, P3226, DOI 10.1016/j.ridd.2014.07.056; Katsumata Masao, 2009, Nihon Eiseigaku Zasshi, V64, P811; Kawada T, 2012, APPL ERGON, V43, P266, DOI 10.1016/j.apergo.2011.03.009; Kay DB, 2015, J SLEEP RES, V24, P32, DOI 10.1111/jsr.12220; Lense Miriam Diane, 2013, Am J Intellect Dev Disabil, V118, P201, DOI 10.1352/1944-7558-118.3.201; Sniecinska-Cooper AM, 2015, SLEEP MED, V16, P94, DOI 10.1016/j.sleep.2014.09.003	7	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	SEP	2015	16	9					1176	1176		10.1016/j.sleep.2015.05.007		1	Clinical Neurology	Neurosciences & Neurology	CP6RA	WOS:000360014400023		
J	Ashraf, J; Pandey, R; de Jong, W; Nagar, B				Ashraf, Jawaid; Pandey, Rajiv; de Jong, Wil; Nagar, Bhuvnesh			Factors Influencing Farmers' Decisions to Plant Trees on Their Farms in Uttar Pradesh, India	SMALL-SCALE FORESTRY			English	Article						Agroforestry; Binary logistic regression; Socio-ecological system; Subsistence farming	AGROFORESTRY ADOPTION; FOREST OWNERS; PROGRAM; ZONE	Increasing tree planting on farms is beneficial to increase the supply of forest functions including provision or raw materials, sequestration of carbon and wildlife habitat. Tree planting decisions by farmers are governed by the knowledge base of farm households, and other factors if the farmers are rational decision-makers under their given resource endowments. A recent surge of tree planting in several states in northern India, though inadequate, coincided with efforts by national and state forest agencies to promote tree planting. This paper reports on the results of a survey into tree plantations of 176 randomly selected households distributed in 34 villages in Western Uttar Pradesh based on demographic data and other factors potentially associated with tree planting decisions. The data were used to develop a binary logistic regression model, to identify which factors influence tree planting decisions. The factors found to correlate positively and significantly with tree planting include size of landholding, overall annual income, area of irrigated land and prior experience with tree planting. It is hypothesized that the lack of significance of other factors including family size and education level was probably due to the relatively homogeneous sample. The result can be used to devise policies to promote tree planting among famers in Uttar Pradesh and possibly other states and other countries.	[Ashraf, Jawaid] Forest Res Inst, Dehra Dun, Uttar Pradesh, India; [Pandey, Rajiv; Nagar, Bhuvnesh] HNB Garhwal Univ, Srinagar, Jammu & Kashmir, India; [de Jong, Wil] Kyoto Univ, Kyoto, Japan	Pandey, R (reprint author), HNB Garhwal Univ, Srinagar, Jammu & Kashmir, India.	rajivfri@yahoo.com			Indian Council of Forestry Education and Research (ICFRE)	The authors acknowledge the Indian Council of Forestry Education and Research (ICFRE) for their generous funding support.	Ghadim AKA, 1999, AGR ECON, V21, P145, DOI 10.1016/S0169-5150(99)00023-7; Adelman I, 1988, COMP PATTERNS EC DEV, P1850; Agresti A, 1996, INTRO CATEGORICAL DA; Alavalapati JRR, 1995, AGROFOREST SYST, V32, P1, DOI 10.1007/BF00713844; Neupane RP, 2002, AGR SYST, V72, P177, DOI 10.1016/S0308-521X(01)00066-X; Boon TE, 2004, SCAND J FOREST RES, V19, P45, DOI 10.1080/14004080410034056; Lonnstedt L, 2012, SMALL-SCALE FOR, V11, P407, DOI 10.1007/s11842-011-9187-6; Emtage N, 2007, ENVIRON MANAGE, V40, P481, DOI 10.1007/s00267-005-0359-z; Puri S, 2004, AGROFOREST SYST, V61-2, P437, DOI 10.1023/B:AGFO.0000029014.66729.e0; Thangata PH, 2003, AGR SYST, V78, P57, DOI 10.1016/S0308-521X(03)00032-5; Adesina AA, 2000, AGR ECOSYST ENVIRON, V80, P255, DOI 10.1016/S0167-8809(00)00152-3; Bhojvaid PP, 2013, TRANSITION SUSTAINAB; Buyinza M, 2008, ENV RES J, V2, P131; Chandra J. P., 2001, Indian Forester, V127, P51; Dhiman RC, 2012, LMA CONV J, V8, P85; Dwivedi RP, 2007, INDIAN RES J EXTENSI, V7, P18; Elham Faham, 2008, AM J AGR BIOL SCI, V3, P451; Emtage N., 2006, Australasian Journal of Environmental Management, V13, P79; FSI, 2009, IND STAT FOR REP; Hoch L, 2009, INT FOREST REV, V11, P1; Jain SK, 2000, AGROFOREST SYST, V49, P255, DOI 10.1023/A:1006388128069; Joshi AK, 2011, SMALL-SCALE FOR, V10, P83, DOI 10.1007/s11842-010-9133-z; MoE&F, 2012, REG REG REG FELL TRA; Negi YS, 1993, THESIS U CALIFORNIA; Ozioma AF, 2011, ASIAN J AGR RURAL DE, V2, P1; Pande SK, 2004, RAP PUBLICATION, P81; Place F, 2012, AGROFORESTRY BIODIVE, P113; Prasad K, 2003, 12 WORLD FOR C UNPUB; Ranjit Raina, 2011, Journal of Resources, Energy, and Development, V8, P67; SAS Institute Inc, 2008, SAS 9 1 3 INT PLATF, V3rd; Selter A, 2008, SMALL-SCALE FOR, V8, P25; Sharma SK, 2009, AGR BIOL J N INDIA, V1, P343; Sidibe M, 2005, AGR WATER MANAGE, V71, P211; Siriri D, 2000, AGROFORESTRY TRENDS; Sood KK, 2008, INDIAN J FOR, V3, P559; Suyanto S, 2005, AGROFOREST SYST, V65, P1, DOI 10.1007/s10457-004-1413-1; Zomer R. J., 2007, 122 IWMI	37	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1873-7617	1873-7854		SMALL-SCALE FOR	Small-Scale For.	SEP	2015	14	3					301	313		10.1007/s11842-015-9289-7		13	Forestry	Forestry	CP7OU	WOS:000360078400003		
J	Jemali, NJNB; Shiba, M; Zawawi, AA				Jemali, Noor Janatun Naim Binti; Shiba, Masami; Zawawi, Azita Ahmad			Strategic Forest Management Options for Small-Scale Timber Harvesting on Okinawa Island, Japan	SMALL-SCALE FORESTRY			English	Article						HARVEST model; Alternative harvesting methods; Subtropical; Sustainable yield; Yambaru Forest	DIVERSITY; PATTERNS	Forest-related activities are important as the economic and social drivers for local residents in Okinawa Island. Therefore, strategic timber management planning is a prerequisite to achieve a sustainable timber yield and optimize forest resource utilization. In this study, the practicability of the Timber Harvest Simulation Model (HARVEST) developed by Eric Gustafson from USDA was tested with the aim of assessing the spatial pattern consequence of timber management plans in the subtropical Yambaru Forest of Okinawa Island. HARVEST evaluates options for timber harvesting by providing comparable predictions of age effect, forest spatial distribution and forest edge habitat, as well as patch structure in a targeted forest type and management area. The timber harvest simulation in 2.1 % of the Yambaru timber production areas was investigated using two alternative cutting methods (clustered and dispersed). It was found that small-area clear-cut harvesting, mimicked by a clustered method, was the practical harvesting practice in Yambaru with an estimated timber volume 12 % higher than that from the selective-logging mimicked by the dispersed method. The mean patch size of the harvested area and forest edge habitat were significantly correlated with timber harvesting method. In spite of some limitations quantified in the model, information generated from HARVEST model was applicable and practical for many forest stakeholders and effective for time-and-cost consideration.	[Jemali, Noor Janatun Naim Binti; Zawawi, Azita Ahmad] Kagoshima Univ, United Grad Sch Agr Sci, Korimoto 8908580, Japan; [Shiba, Masami] Univ Ryukyus, Fac Agr, Nishihara, Okinawa 9030213, Japan; [Jemali, Noor Janatun Naim Binti] Univ Malaysia Kelantan, Fac Earth Sci, Jeli 17600, Kelantan, Malaysia	Jemali, NJNB (reprint author), Kagoshima Univ, United Grad Sch Agr Sci, Korimoto 8908580, Japan.	idiana0303@yahoo.com			Ministry of Education of Malaysia; United Graduate School of Kagoshima University [148]	We would like to thank the Forestry Department of Okinawa Prefecture and Eric Gustafson for providing advice, assistance and comments during this research. The financial support from the Ministry of Education of Malaysia and the Female Research Grant (No. 148) from the United Graduate School of Kagoshima University is much appreciated.	Gustafson EJ, 2007, LANDSCAPE ECOL, V22, P141, DOI 10.1007/s10980-006-9017-y; Shifley SR, 2008, FOREST ECOL MANAG, V254, P474, DOI 10.1016/j.foreco.2007.08.030; Pinedo-Vasquez M, 2001, HUM ECOL, V29, P219, DOI 10.1023/A:1011064031078; RIPPLE WJ, 1991, BIOL CONSERV, V57, P73, DOI 10.1016/0006-3207(91)90108-L; Bremer LL, 2010, BIODIVERS CONSERV, V19, P3893, DOI 10.1007/s10531-010-9936-4; Department of Agriculture Forestry and Fisheries ( DAFF) of Okinawa Prefecture, 2011, ANN REP FOR FOR OK; Forestry Agency, 2012, FOR WHIT PAP UNPUB; Fujii S, 2010, J FOREST RES-JPN, V15, P289, DOI 10.1007/s10310-010-0191-z; Gustafson EJ, 1998, ECOSYSTEMS, V1, P484, DOI 10.1007/s100219900044; Gustafson EJ, 1996, J ENVIRON MANAGE, V46, P77, DOI 10.1006/jema.1996.0008; Gustafson EJ, 2002, COMPUT ELECTRON AGR, V33, P179, DOI 10.1016/S0168-1699(02)00008-X; Gustafson EJ, 2005, HARVEST WINDOWS V6 1, P273; Ito Y, 2003, P IUFRO KAN 2003 FOR, P11; Ito Y, 1997, PLANT ECOL, V133, P125, DOI 10.1023/A:1009748016272; IUCN, 2013, IUCN REDL THREAT BIR; Jemali NJN, 2013, J JPN FOR ENG, V28, P99; Kubota Y, 2005, BIODIVERS CONSERV, V14, P879, DOI 10.1007/s10531-004-0657-4; Leefers LA, 2003, MANAG FOR ECOSYST, V7, P165; LI H, 1993, LANDSCAPE ECOL, V8, P63, DOI 10.1007/BF00129867; Okinawa Development Agency, 2003, DAMS YAMB OP MAN; Shinohara T, 1996, SCI B FACULTY AGR, V43, P31; Shinohara T, 1999, SCI B FAC AGR U RYUK, V46, P37; Tang SM, 1997, LANDSCAPE URBAN PLAN, V39, P1, DOI 10.1016/S0169-2046(97)00072-8	23	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1873-7617	1873-7854		SMALL-SCALE FOR	Small-Scale For.	SEP	2015	14	3					351	362		10.1007/s11842-015-9292-z		12	Forestry	Forestry	CP7OU	WOS:000360078400006		
J	Tripathi, BM; Kim, M; Tateno, R; Kim, W; Wang, JJ; Lai-Hoe, A; Ab Shukor, NA; Rahim, RA; Go, R; Adams, JM				Tripathi, Binu M.; Kim, Mincheol; Tateno, Ryunosuke; Kim, Woosung; Wang, Jianjun; Lai-Hoe, Ang; Ab Shukor, Nor Aini; Rahim, Raha A.; Go, Rusea; Adams, Jonathan M.			Soil pH and biome are both key determinants of soil archaeal community structure	SOIL BIOLOGY & BIOCHEMISTRY			English	Article						Ammonia oxidizing archaea; Biome; Community assembly; Soil pH; 16S rRNA gene	AMMONIA-OXIDIZING ARCHAEA; PHYLOGENETIC BETA DIVERSITY; MICROBIAL COMMUNITIES; MESOPHILIC CRENARCHAEOTA; NICHE CONSERVATISM; ARABLE SOIL; BACTERIAL; CULTIVATION; ABUNDANCE; PATTERNS	The mechanisms underlying community composition and diversity of soil archaea are poorly understood. We compared both total archaea and ammonia oxidizing archaea (AOA) using 16S rRNA and amoA genes pyrosequencing respectively, in two different biomes: tropics (Malaysia), and temperate (Korea and Japan). Despite differences in characteristics of these biomes, we found that at the broad taxonomic level the dominant archaeal lineages are the same, except in certain instances (16S rRNA gene: group 1.1a Thaumarchaeota; amoA gene: Nitrososphaera and Nitrosotalea lineages). However, at the OTU level, both total archaea and AOA communities showed biome-specific patterns, indicating that at lower taxonomic levels biome differences are also important. In both biomes, total archaeal diversity showed a negative correlation with pH, but a hump-shaped curve for AOA diversity, peaking at similar to pH 6.0. Within each biome, pH also emerged as the delimiting factor determining variation in community composition of both total archaea and AOA. Communities from each biome clustered separately, even at analogous pH levels. At the 0Th level, certain shared OTUs did occur at approximately the same pH range in both biomes. We found that closely related OTUs of both total archaea and AOA respectively tended to co-occur, suggesting that in evolutionary terms these closely related lineages have conserved very similar ecological requirements. This predictability also strongly suggests that soil archaeal community assembly has strongly deterministic aspect. Overall, our findings emphasize that soil archaeal communities are to large extent predictable and structured by both biome and by soil chemical environment, especially pH. (C) 2015 Elsevier Ltd. All rights reserved.	[Tripathi, Binu M.; Kim, Woosung; Adams, Jonathan M.] Seoul Natl Univ, Coll Nat Sci, Dept Biol Sci, Seoul 151742, South Korea; [Kim, Mincheol] KOPRI, Korea Polar Res Inst, Inchon, South Korea; [Tateno, Ryunosuke] Kyoto Univ, Filed Sci Educ & Res Ctr, Sakyo Ku, Kyoto 6068502, Japan; [Wang, Jianjun] Chinese Acad Sci, Nanjing Inst Geog & Limnol, State Key Lab Lake Sci & Environm, Nanjing, Jiangsu, Peoples R China; [Lai-Hoe, Ang] FRIM, Div Forest Biotechnol, Kepong, Malaysia; [Ab Shukor, Nor Aini; Adams, Jonathan M.] Univ Putra Malaysia, Inst Trop Forestry & Forest Prod INTROP, Serdang 43400, Malaysia; [Rahim, Raha A.] Univ Putra Malaysia, Inst Biosci, Fac Biotechnol & Biomol Sci, Serdang 43400, Malaysia; [Go, Rusea] Univ Putra Malaysia, Fac Sci, Dept Biol, Serdang 43400, Malaysia	Adams, JM (reprint author), Seoul Natl Univ, Coll Nat Sci, Dept Biol Sci, 1 Gwanak Ro, Seoul 151742, South Korea.	jonadams@snu.ac.kr			National Research Foundation (NRF) grant - Korean government, Ministry of Education, Science and Technology (MEST) [NRF-2013-031400]	This work was partly supported by a grant from the National Research Foundation (NRF) grant funded by the Korean government, Ministry of Education, Science and Technology (MEST) (NRF-2013-031400). The authors declare no conflict of interest.	Hu HW, 2013, J SOIL SEDIMENT, V13, P1439, DOI 10.1007/s11368-013-0726-y; Treusch AH, 2005, ENVIRON MICROBIOL, V7, P1985, DOI 10.1111/j.1462-2920.2005.00906.x; Nicol GW, 2008, ENVIRON MICROBIOL, V10, P2966, DOI 10.1111/j.1462-2920.2008.01701.x; Tang SYY, 2013, BIOINFORMATICS, V29, P114, DOI 10.1093/bioinformatics/bts636; Brochier-Armanet C, 2008, NAT REV MICROBIOL, V6, P245, DOI 10.1038/nrmicro1852; Fierer N, 2006, P NATL ACAD SCI USA, V103, P626, DOI 10.1073/pnas.0507535103; Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1111/j.1442-9993.2001.01070.pp.x; Losos JB, 2008, ECOL LETT, V11, P995, DOI 10.1111/j.1461-0248.2008.01229.x; Kim JG, 2012, ENVIRON MICROBIOL, V14, P1528, DOI 10.1111/j.1462-2920.2012.02740.x; Graham CH, 2008, ECOL LETT, V11, P1265, DOI 10.1111/j.1461-0248.2008.01256.x; Fine PVA, 2011, ECOGRAPHY, V34, P552, DOI 10.1111/j.1600-0587.2010.06548.x; Chu HY, 2010, ENVIRON MICROBIOL, V12, P2998, DOI 10.1111/j.1462-2920.2010.02277.x; Lauber CL, 2009, APPL ENVIRON MICROB, V75, P5111, DOI 10.1128/AEM.00335-09; Santoro AE, 2011, SCIENCE, V333, P1282, DOI 10.1126/science.1208239; Bates ST, 2011, ISME J, V5, P908, DOI 10.1038/ismej.2010.171; Peres-Neto PR, 2006, ECOLOGY, V87, P2614, DOI 10.1890/0012-9658(2006)87[2614:VPOSDM]2.0.CO;2; de la Torre JR, 2008, ENVIRON MICROBIOL, V10, P810, DOI 10.1111/j.1462-2920.2007.01506.x; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Angel R, 2010, ISME J, V4, P553, DOI 10.1038/ismej.2009.136; Kowalchuk GA, 2001, ANNU REV MICROBIOL, V55, P485, DOI 10.1146/annurev.micro.55.1.485; Dray S, 2006, ECOL MODEL, V196, P483, DOI 10.1016/j.ecolmodel.2006.02.015; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; ODEN NL, 1986, SYST ZOOL, V35, P608, DOI 10.2307/2413120; Cavender-Bares J, 2009, ECOL LETT, V12, P693, DOI 10.1111/j.1461-0248.2009.01314.x; Auguet JC, 2010, ISME J, V4, P182, DOI 10.1038/ismej.2009.109; Blanchet FG, 2008, ECOLOGY, V89, P2623, DOI 10.1890/07-0986.1; Wang JJ, 2013, ISME J, V7, P1310, DOI 10.1038/ismej.2013.30; Gubry-Rangin C, 2011, P NATL ACAD SCI USA, V108, P21206, DOI 10.1073/pnas.1109000108; Rousk J, 2010, ISME J, V4, P1340, DOI 10.1038/ismej.2010.58; Pester M, 2012, ENVIRON MICROBIOL, V14, P525, DOI 10.1111/j.1462-2920.2011.02666.x; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Hur M, 2011, APPL ENVIRON MICROB, V77, P7611, DOI 10.1128/AEM.06102-11; Tripathi BM, 2013, FEMS MICROBIOL ECOL, V86, P303, DOI 10.1111/1574-6941.12163; Stegen JC, 2012, ISME J, V6, P1653, DOI 10.1038/ismej.2012.22; Stahl DA, 2012, ANNU REV MICROBIOL, V66, P83, DOI 10.1146/annurev-micro-092611-150128; Bengtson P, 2012, APPL ENVIRON MICROB, V78, P5906, DOI 10.1128/AEM.01476-12; LEGENDRE P, 1994, EVOLUTION, V48, P1487, DOI 10.2307/2410243; Cao HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052853; Cao P, 2012, FEMS MICROBIOL ECOL, V80, P146, DOI 10.1111/j.1574-6941.2011.01280.x; Diniz JAF, 2010, GLOBAL ECOL BIOGEOGR, V19, P916, DOI 10.1111/j.1466-8238.2010.00562.x; Ghosh P., 2005, Tropical Ecology, V46, P173; Kim O. S., 2012, INT J SYST EVOL MICR, V62, P716, DOI DOI 10.1099/IJS.0.038075-0; Konneke M, 2005, NATURE, V437, P543, DOI 10.1038/nature03911; Lehtovirta-Morley LE, 2011, P NATL ACAD SCI USA, V108, P15892, DOI 10.1073/pnas.1107196108; R Development CoreTeam, 2008, R LANG ENV STAT COMP; Singh D., 2012, PLOS ONE, V7; Touma M., 2011, P NATL ACAD SCI USA, V108, P8420; Zhalnina K, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00210	48	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0038-0717			SOIL BIOL BIOCHEM	Soil Biol. Biochem.	SEP	2015	88						1	8		10.1016/j.soilbio.2015.05.004		8	Soil Science	Agriculture	CP4VL	WOS:000359880600001		
J	Makita, N; Fujii, S				Makita, Naoki; Fujii, Saori			Tree species effects on microbial respiration from decomposing leaf and fine root litter	SOIL BIOLOGY & BIOCHEMISTRY			English	Article						CO2 efflux; Heterotrophic respiration; Litter quality; Mass loss; Morphology	BELOW-GROUND LITTER; ORGANIC-MATTER; TEMPERATURE SENSITIVITY; ABOVEGROUND LITTER; METABOLIC QUOTIENT; CURRENT KNOWLEDGE; SOIL RESPIRATION; GLOBAL PATTERNS; QUALITY; CARBON	Tree species have an impact on decomposition processes of woody litter, but the effects of different tree species on microbial heterotrophic respiration derived from decomposing litter are still unclear. Here we used leaf and fine root litter of six tree species differing in chemical and morphological traits in a temperate forest and elucidated the effects of tree species on the relationships between litter-derived microbial respiration rates and decomposition rates and morphological traits, including specific leaf area (cm(2) g(-1)) and specific root length (m g(-1)) of litter at the same site. Litterbags set in forest soil were sequentially collected five times over the course of 18 months. During litter decomposition, microbial respiration from leaf and fine root litter differed among the six tree species. Temporal changes in the remaining mass and morphology (specific leaf area and specific root length) were observed, and the magnitude of these changes differed among species. Positive correlations were observed between respiration and mass loss or morphology across species. These results revealed that litter mass loss and morphological dynamics during decomposition jointly enhanced microbial respiration, and these carbon-based litter traits explained species differences in,decomposition of leaves and fine roots. In conclusion, tree species influenced the magnitude and direction of microbial respiration during leaf/fine root litter decomposition. Tree species also affected the relationship between microbial respiration and litter decomposition through direct effects of litter traits and indirect effects mediated by regulation of heterotroph requirements. (C) 2015 Elsevier Ltd. All rights reserved.	[Makita, Naoki; Fujii, Saori] Kyoto Univ, Grad Sch Agr, Kyoto 6068502, Japan; [Makita, Naoki] Kansai Res Ctr, Forestry & Forest Prod Res Inst, Kyoto 6120855, Japan; [Fujii, Saori] Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Yokohama, Kanagawa 2408501, Japan	Makita, N (reprint author), Kansai Res Ctr, Forestry & Forest Prod Res Inst, Kyoto 6120855, Japan.	makita701@gmail.com			Fujiwara Natural History Foundation;  [PD 13J09602]	The authors acknowledge Ms. Shoko Oguchi, Ms. Ayumi Kawamura, Ms. Waka Saito, Ms. Rie Takagi, and staffs of the Kamigamo Experimental Station, Kyoto University for helpful supports in field and laboratory experiments. The authors also acknowledge Dr. Yoshiko Kosugi for constructive suggestions on this study and Prof. Helja-Sisko Helmisaari and Dr. Mike Starr for insightful comments to an earlier version of the manuscript. The authors also thank to two reviewers for their constructive comments and suggestions for the manuscript. This work was funded by Grant-in Aid for Japan Society for the Promotion of Science fellows (PD 13J09602) to NM and the Fujiwara Natural History Foundation to SF.	Anderson JM, 1999, FUNCT ECOL, V13, P116, DOI 10.1046/j.1365-2435.1999.00014.x; ANDERSON TH, 1993, SOIL BIOL BIOCHEM, V25, P393, DOI 10.1016/0038-0717(93)90140-7; Angers DA, 1997, PLANT SOIL, V189, P197, DOI 10.1023/A:1004207219678; Cornwell WK, 2008, ECOL LETT, V11, P1065, DOI 10.1111/j.1461-0248.2008.01219.x; Cornelissen JHC, 1999, NEW PHYTOL, V143, P191, DOI 10.1046/j.1469-8137.1999.00430.x; Kalbitz K, 2000, SOIL SCI, V165, P277, DOI 10.1097/00010694-200004000-00001; Finer L, 2011, FOREST ECOL MANAG, V262, P2008, DOI 10.1016/j.foreco.2011.08.042; Papa S, 2008, APPL SOIL ECOL, V40, P401, DOI 10.1016/j.apsoil.2008.06.013; Curtis PS, 2002, AGR FOREST METEOROL, V113, P3, DOI 10.1016/S0168-1923(02)00099-0; Fanin N, 2011, SOIL BIOL BIOCHEM, V43, P1014, DOI 10.1016/j.soilbio.2011.01.018; Wright IJ, 2004, NATURE, V428, P821, DOI 10.1038/nature02403; Conant RT, 2011, GLOBAL CHANGE BIOL, V17, P3392, DOI 10.1111/j.1365-2486.2011.02496.x; Langley JA, 2006, ECOL LETT, V9, P955, DOI 10.1111/j.1461-0248.2006.00948.x; Makita N, 2012, TREE PHYSIOL, V32, P303, DOI 10.1093/treephys/tps008; Aponte C, 2013, FOREST ECOL MANAG, V309, P36, DOI 10.1016/j.foreco.2013.05.035; Frey SD, 2008, SOIL BIOL BIOCHEM, V40, P2904, DOI 10.1016/j.soilbio.2008.07.020; Kuroiwa M, 2011, J FOREST RES-JPN, V16, P363, DOI 10.1007/s10310-011-0287-0; Gill RA, 2000, NEW PHYTOL, V147, P13, DOI 10.1046/j.1469-8137.2000.00681.x; Fioretto A, 2007, APPL SOIL ECOL, V36, P32, DOI 10.1016/j.apsoil.2006.11.006; Langley JA, 2003, ECOLOGY, V84, P2302, DOI 10.1890/02-0282; Fujii S, 2010, SOIL BIOL BIOCHEM, V42, P2224, DOI 10.1016/j.soilbio.2010.08.022; Cornelissen JHC, 2014, J ECOL, V102, P269; Manzoni S, 2008, SCIENCE, V321, P684, DOI 10.1126/science.1159792; Sulzman EW, 2005, BIOGEOCHEMISTRY, V73, P231, DOI 10.1007/s10533-004-7314-6; Goebel M, 2011, ECOL MONOGR, V81, P89, DOI 10.1890/09-2390.1; Freschet GT, 2013, J ECOL, V101, P943, DOI 10.1111/1365-2745.12092; Fortunel C, 2009, ECOLOGY, V90, P598, DOI 10.1890/08-0418.1; Smith SW, 2014, NEW PHYTOL, V203, P851, DOI 10.1111/nph.12845; Talbot JM, 2012, BIOGEOCHEMISTRY, V108, P279, DOI 10.1007/s10533-011-9599-6; Garcia-Palacios P, 2013, ECOL LETT, V16, P1045, DOI 10.1111/ele.12137; Davidson EA, 2006, NATURE, V440, P165, DOI 10.1038/nature04514; Gusewell S, 2009, FUNCT ECOL, V23, P211, DOI 10.1111/j.1365-2435.2008.01478.x; Bond-Lamberty B, 2004, GLOBAL CHANGE BIOL, V10, P1756, DOI 10.1111/j.1365-2486.2004.00816.x; Silver WL, 2001, OECOLOGIA, V129, P407; Chen H, 2000, FOREST ECOL MANAG, V138, P51, DOI 10.1016/S0378-1127(00)00411-4; BEARE MH, 1990, SOIL BIOL BIOCHEM, V22, P585, DOI 10.1016/0038-0717(90)90002-H; Prescott CE, 2013, FOREST ECOL MANAG, V309, P19, DOI 10.1016/j.foreco.2013.02.034; de Graaff MA, 2013, SOIL BIOL BIOCHEM, V58, P198, DOI 10.1016/j.soilbio.2012.11.015; Fierer N, 2005, ECOLOGY, V86, P320, DOI 10.1890/04-1254; Fontaine S, 2007, NATURE, V450, P277, DOI 10.1038/nature06275; Kazakou E, 2009, ANN BOT-LONDON, V104, P1151, DOI 10.1093/aob/mcp202; Berg B., 2008, PLANT LITTER DECOMPO; Birouste M, 2012, ANN BOT-LONDON, V109, P463, DOI 10.1093/aob/mcr297; Brechet L, 2009, PLANT SOIL, V319, P235, DOI 10.1007/s11104-008-9866-z; COUTEAUX MM, 1995, TRENDS ECOL EVOL, V10, P63, DOI 10.1016/S0169-5347(00)88978-8; Falloon P., 2009, INTEGRATED METHODOLO, P221; Fujii S., 2015, TREES IN PRESS; Harmon ME, 2011, J GEOPHYS RES-BIOGEO, V2005-2012, P116; Heal O. W., 1997, P3; Hobbie SE, 2006, ECOLOGY, V87, P2288, DOI 10.1890/0012-9658(2006)87[2288:TSEODA]2.0.CO;2; IUSS Working Group WRB, 2006, WORLD SOIL RES REP, V103; Kawamura A., 2013, Plant Root, V7, P77, DOI 10.3117/plantroot.7.77; Leppalammi-Kujansuu J, 2014, FOREST ECOL MANAG, V326, P79, DOI 10.1016/j.foreco.2014.03.039; Luo Y., 2006, SOIL RESPIRATION ENV, P107, DOI 10.1016/B978-012088782-8/50006-1; Makita N, 2015, PLANT SOIL, V393, P283, DOI 10.1007/s11104-015-2491-8; Makita N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117694; Prescott CE, 2010, BIOGEOCHEMISTRY, V101, P1; R Development Core Team, 2014, R LANG ENV STAT COMP; RAICH JW, 1992, TELLUS B, V44, P81, DOI 10.1034/j.1600-0889.1992.t01-1-00001.x; Spaldonova A, 2014, APPL SOIL ECOL, V83, P186, DOI 10.1016/j.apsoil.2014.04.012; Suzuki Y, 2013, SOIL BIOL BIOCHEM, V57, P116, DOI 10.1016/j.soilbio.2012.07.020; Swift M.J., 1979, DECOMPOSITION TERRES; Wardle DA, 1995, SOIL BIOL BIOCHEM, V27, P1601, DOI 10.1016/0038-0717(95)00093-T	63	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0038-0717			SOIL BIOL BIOCHEM	Soil Biol. Biochem.	SEP	2015	88						39	47		10.1016/j.soilbio.2015.05.005		9	Soil Science	Agriculture	CP4VL	WOS:000359880600006		
J	Lei, YB; Zhou, J; Xiao, HF; Duan, BL; Wu, YH; Korpelainen, H; Li, CY				Lei, Yanbao; Zhou, Jun; Xiao, Haifeng; Duan, Baoli; Wu, Yanhong; Korpelainen, Helena; Li, Chunyang			Soil nematode assemblages as bioindicators of primary succession along a 120-year-old chronosequence on the Hailuogou Glacier forefield, SW China	SOIL BIOLOGY & BIOCHEMISTRY			English	Article						Bioavailable phosphorus; Hailuogou Glacier Chronosequence; Nematode assemblages; Nematode ecological indices; Plant succession; Retrogression	EDGE XANES SPECTROSCOPY; COMMUNITY STRUCTURE; PHOSPHORUS LIMITATION; EXTRACTION METHOD; GONGGA MOUNTAIN; FOOD-WEB; DIVERSITY; SPECIATION; PRODUCTIVITY; ECOSYSTEMS	Successional dynamics in terrestrial ecosystems is important for interactions between aboveground and belowground subsystems. In this study, nematode communities in a Hailuogou Glacier Chronosequence from seven stages were investigated to determine whether changes in soil phosphorus (P) and nematode assemblages parallel those observed in aboveground communities, and whether the primary succession in this chronosequence has entered a retrogressive phase after 120 years of succession. The initial 40-year succession, including stages 2, 3 and 4, can be viewed as a build-up phase. Especially at stage 3, vegetation succession from grassland to forest accelerated the accumulation of plant litter and bioavailable P, paralleled with a sharp increase in nematode abundance. The mature phases covering stages 5, 6 and 7 displayed most balanced nematode communities, in which abundance, taxon richness, maturity index and structure index were at highest. However, the last stage 7 appeared to show some retrogressive characteristics, as suggested by the reduced bioavailability of P and a significant decrease in nematode densities, along with the disappearance of some rare genera of nematodes from higher trophic guilds, resulting in decreases in the nematode channel ratio, plant parasite index and enrichment index. Thus, the Hailuogou Glacier Chronosequence may enter its retrogressive phase during the next decade or century. A bacterial-based nematode energy channel dominated the chronosequence during the development; by contrast, a fungivore-based channel was activated at the early and late stages, because fungivores are better adapted to nutrient-poor environments. Our results demonstrated that different nematode guilds have contrasting responses to chronosequence stages, possibly due to their different responses to bottom-up and top-down controls. Furthermore, soil nematode communities could be used as sensitive bioindicators of soil health in glacial-retreat areas. (C) 2015 Elsevier Ltd. All rights reserved.	[Lei, Yanbao; Zhou, Jun; Duan, Baoli; Wu, Yanhong] Chinese Acad Sci, Inst Mt Hazards & Environm, Key Lab Mt Surface Proc & Ecol Regulat, Chengdu 610041, Peoples R China; [Li, Chunyang] Zhejiang A&F Univ, State Key Lab Subtrop Silviculture, Nurturing Stn, Linan 311300, Zhejiang, Peoples R China; [Lei, Yanbao] Tokyo Univ Agr & Technol, Dept Environm Sci Biosphere, Fuchu, Tokyo 1838509, Japan; [Xiao, Haifeng] Chinese Acad Sci, Xishuangbanna Trop Bot Garden, Key Lab Trop Forest Ecol, Mengla 666303, Peoples R China; [Korpelainen, Helena] Univ Helsinki, Dept Agr Sci, FIN-00014 Helsinki, Finland	Li, CY (reprint author), Zhejiang A&F Univ, State Key Lab Subtrop Silviculture, Nurturing Stn, Linan 311300, Zhejiang, Peoples R China.	licy@zafu.edu.cn	Li, Chunyang/D-6254-2013		National Science Foundation of China [31370607]; Chinese Academy of Sciences [SDSQB-2012-01, SDS0-135-1207]; Japan Society for the Promotion of Science [P13080]	The authors are grateful to the Gongga Mountain Alpine Ecosystem Observation Station, Chinese Academy of Sciences for logistic support, Dr. Lei YU and Mr. Quan LAN for assistance in collecting samples, and Professor Douglas A. Schaefer for insightful suggestions and comments to improve our manuscript. This work was supported by the National Science Foundation of China (No. 31370607), Chinese Academy of Sciences (Nos. SDSQB-2012-01, SDS0-135-1207) and Japan Society for the Promotion of Science, Postdoctoral Fellowship for Foreign Researchers (No. P13080).	Alexander EB, 1996, GEODERMA, V72, P1, DOI 10.1016/0016-7061(96)00021-3; Prietzel J, 2013, GEOCHIM COSMOCHIM AC, V108, P154, DOI 10.1016/j.gca.2013.01.029; Ugarte CM, 2013, SOIL BIOL BIOCHEM, V64, P103, DOI 10.1016/j.soilbio.2013.03.035; Bongers T, 1999, TRENDS ECOL EVOL, V14, P224, DOI 10.1016/S0169-5347(98)01583-3; Richardson SJ, 2004, OECOLOGIA, V139, P267, DOI 10.1007/s00442-004-1501-y; Vitousek PM, 2010, ECOL APPL, V20, P5, DOI 10.1890/08-0127.1; Zhao J, 2014, SOIL BIOL BIOCHEM, V75, P1, DOI 10.1016/j.soilbio.2014.03.019; Fontaine S, 2003, SOIL BIOL BIOCHEM, V35, P837, DOI 10.1016/S0038-0717(03)00123-8; Bradford MA, 2002, SCIENCE, V298, P615, DOI 10.1126/science.1075805; WALKER TW, 1976, GEODERMA, V15, P1, DOI 10.1016/0016-7061(76)90066-5; Walker LR, 2010, J ECOL, V98, P725, DOI 10.1111/j.1365-2745.2010.01664.x; Yeates GW, 2003, BIOL FERT SOILS, V37, P199, DOI 10.1007/s00374-003-0586-5; De Deyn GB, 2005, TRENDS ECOL EVOL, V20, P625, DOI 10.1016/j.tree.2005.08.009; DuPont ST, 2009, APPL SOIL ECOL, V41, P157, DOI 10.1016/j.apsoil.2008.10.004; Doblas-Miranda E, 2008, SOIL BIOL BIOCHEM, V40, P1069, DOI 10.1016/j.soilbio.2007.11.026; Van Der Putten WH, 2003, ECOLOGY, V84, P2269, DOI 10.1890/02-0284; McSorley R, 2004, APPL SOIL ECOL, V27, P55, DOI 10.1016/j.apsoil.2004.02.005; Zhou J, 2013, GEODERMA, V195, P251, DOI [10.1016/j.geoderma2012.12.010, 10.1016/j.geoderma.2012.12.010]; He L, 2008, CATENA, V72, P259, DOI 10.1016/j.catena.2007.05.010; van der Heijden MGA, 2008, ECOL LETT, V11, P296, DOI 10.1111/j.1461-0248.2007.01139.x; Prietzel J, 2013, EUR J SOIL SCI, V64, P260, DOI 10.1111/ejss.12032; Ferris H, 2001, APPL SOIL ECOL, V18, P13, DOI 10.1016/S0929-1393(01)00152-4; Yeates GW, 1999, AGR ECOSYST ENVIRON, V74, P113, DOI 10.1016/S0167-8809(99)00033-X; Li ZX, 2010, QUATERN INT, V218, P166, DOI 10.1016/j.quaint.2008.09.005; De Deyn GB, 2003, NATURE, V422, P711, DOI 10.1038/nature01548; De Mesel I, 2004, ENVIRON MICROBIOL, V6, P733, DOI 10.1111/j.1462-2920.2004.00610.x; Bardgett R.D., 2002, ZOOLOGY, V105, P365; Bremner J. M., 1996, Methods of soil analysis. Part 3 - chemical methods., P1085; BROOKES PC, 1985, SOIL BIOL BIOCHEM, V17, P837, DOI 10.1016/0038-0717(85)90144-0; Carrascosa M, 2014, EUR J SOIL BIOL, V62, P49, DOI 10.1016/j.ejsobi.2014.02.009; Dumig A, 2011, GEODERMA, V163, P83, DOI 10.1016/j.geoderma.2011.04.006; Eskelinen A, 2009, OECOLOGIA, V161, P113, DOI 10.1007/s00442-009-1362-5; Goransson H, 2011, SOIL BIOL BIOCHEM, V43, P1333, DOI 10.1016/j.soilbio.2011.03.006; Hanel L., 1998, NEMATODE COMMUNITIES, P95; LAJTHA K, 1988, ECOLOGY, V69, P24, DOI 10.2307/1943157; Luo J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042354; Maynard D.G., 2006, SOIL SAMPLING METHOD, P863; Mikola J, 1998, OIKOS, V82, P158, DOI 10.2307/3546926; Murphy J., 1962, ANAL CHIM ACTA, V27, P31, DOI DOI 10.1016/S0003-2670(00)88444-5; Nelson D. W., 1982, METHODS SOIL ANAL, V2, P539; Oksanen JF, 2010, VEGAN COMMUNITY ECOL; PICKETT S T A, 1989, P110; R Development Core Team, 2010, R LANG ENV STAT COMP; Stirling GR, 2008, AUSTRALAS PLANT PATH, V37, P123, DOI 10.1071/AP07090; Sun XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082468; TOWNSHEND J. L., 1963, NEMATOLOGICA, V9, P106; Wardle D. A., 2002, COMMUNITIES ECOSYSTE; Williamson WM, 2005, SOIL BIOL BIOCHEM, V37, P1289, DOI 10.1016/j.soilbio.2004.11.025; Xiao HF, 2014, SOIL BIOL BIOCHEM, V76, P161, DOI 10.1016/j.soilbio.2014.05.012; Yang Y, 2014, FOREST ECOL MANAG, V312, P10, DOI 10.1016/j.foreco.2013.10.028; YEATES GW, 1993, J NEMATOL, V25, P315; Yin W Y, 1998, PICTORIAL KEYS SOIL; Zhang SH, 2010, J ENVIRON SCI-CHINA, V22, P1418, DOI 10.1016/S1001-0742(09)60269-2	53	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0038-0717			SOIL BIOL BIOCHEM	Soil Biol. Biochem.	SEP	2015	88						362	371		10.1016/j.soilbio.2015.06.013		10	Soil Science	Agriculture	CP4VL	WOS:000359880600041		
J	Nishibori, E; Hyodo, H; Kimura, K; Takata, M				Nishibori, Eiji; Hyodo, Hiroshi; Kimura, Kaoru; Takata, Masaki			Revisit: High resolution charge density study of alpha-rhombohedral boron using third-generation SR data at SPring-8	SOLID STATE SCIENCES			English	Article						alpha-rhombohedral boron; X-ray charge density study; SPring-8	POWDER DIFFRACTION DATA; VISUALIZATION; BONDS	Experimental charge density of alpha-rhombohedral boron (alpha-B-12) by a Maximum entropy method (MEM) has been re-investigated using the high resolution powder diffraction data measured at third-generation synchrotron radiation (SR) source, SPring-8. The present MEM charge density has many discrepancies from the previous MEM charge densities reported by Fujimori et al. and Hosoi et al. The data-resolution dependence of the MEM charge density was investigated using the present data. We found that diffraction data with d > 0.4 angstrom resolution range were needed to reveal qualitative bonding nature of alpha-B-12 at 100 K. The peculiar bonding natures, such as a bend B-B bond and a propeller-shaped bond, which were found in the previous studies have disappeared by using d > 0.4 angstrom. The bonding nature of MEM charge density using the full data with d > 0.327 angstrom d-spacing range is well agreed with those of theoretical calculations. The present study suggests that resolution test is important for an accurate charge density study of boron related materials. (C) 2015 Elsevier Masson SAS. All rights reserved.	[Nishibori, Eiji] Univ Tsukuba, Tsukuba Res Ctr Interdiscriplinary Mat Sci TIMS, Fac Pure & Appl Sci, Div Phys, Tsukuba, Ibaraki 3058571, Japan; [Nishibori, Eiji] Univ Tsukuba, Ctr Integrated Res Fundamental Sci & Engn, Tsukuba, Ibaraki 3058571, Japan; [Nishibori, Eiji; Takata, Masaki] RIKEN, RIKEN SPring Ctr 8, Struct Mat Sci Lab, Sayo, Hyogo 6795148, Japan; [Hyodo, Hiroshi] Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; [Kimura, Kaoru; Takata, Masaki] Univ Tokyo, Dept Adv Mat Sci, Kashiwa, Chiba 2778561, Japan	Nishibori, E (reprint author), Univ Tsukuba, Tsukuba Res Ctr Interdiscriplinary Mat Sci TIMS, Fac Pure & Appl Sci, Div Phys, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058571, Japan.	nishibori.eiji.ga@u.tsukuba.jp			 [25600148]	This work was supported by G Grant-in-Aid for Challenging Exploratory Research (no. 25600148). We thank Dr. Kato for experimental help at SPing-8 BL44B2. The synchrotron radiation experiments were performed at BL44B2 in SPring-8 with the approval of RIKEN (Proposal No. 20140077).	Albert B, 2009, ANGEW CHEM INT EDIT, V48, P8640, DOI 10.1002/anie.200903246; Tanaka H, 2002, J APPL CRYSTALLOGR, V35, P282, DOI 10.1107/S002188980200050X; Takata M, 2008, ACTA CRYSTALLOGR A, V64, P232, DOI 10.1107/S010876730706521X; Ohno A, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.064119; Nishibori E, 2007, ACTA CRYSTALLOGR A, V63, P43, DOI 10.1107/S0108767306047210; Kato K, 2010, AIP CONF PROC, V1234, P875, DOI 10.1063/1.3463354; Will G, 2001, Z ANORG ALLG CHEM, V627, P2100, DOI 10.1002/1521-3749(200109)627:9<2100::AID-ZAAC2100>3.0.CO;2-G; SAKA T, 1986, ACTA CRYSTALLOGR A, V42, P469, DOI 10.1107/S0108767386098860; Fujimori M, 1999, PHYS REV LETT, V82, P4452, DOI 10.1103/PhysRevLett.82.4452; Corcoran J. B., 1973, P ANSS 73 P 1 S SIM, P46; Hosoi S, 2007, J PHYS SOC JPN, V76, DOI 10.1143/JPSJ.76.044602; KOBAYASHI M, 1988, J MATER SCI, V23, P4392, DOI 10.1007/BF00551937; Larson A. C., 1990, GSAS GEN STRUCTURE; LEE S, 1990, PHYS REV B, V42, P1316, DOI 10.1103/PhysRevB.42.1316; Maki S, 2013, J APPL CRYSTALLOGR, V46, P649, DOI 10.1107/S002188981300592X; Mondal S, 2013, PHYS REV B, V88, DOI 10.1103/PhysRevB.88.024118; Petricek V., 2006, CRYSTALLOGRAPHIC COM; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Shirai K, 2011, J PHYS SOC JPN, V80, DOI 10.1143/JPSJ.80.084601; Svendsen H, 2010, ACTA CRYSTALLOGR A, V66, P458, DOI 10.1107/S0108767310014236	20	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1293-2558	1873-3085		SOLID STATE SCI	Solid State Sci.	SEP	2015	47						27	31		10.1016/j.solidstatesciences.2015.02.007		5	Chemistry, Inorganic & Nuclear; Chemistry, Physical; Physics, Condensed Matter	Chemistry; Physics	CP7ZM	WOS:000360109200007		
J	Takagiwa, Y; Miyazaki, Y; Yoshida, T; Yanagihara, D; Ueda, S; Kitahara, K; Kimura, K				Takagiwa, Y.; Miyazaki, Y.; Yoshida, T.; Yanagihara, D.; Ueda, S.; Kitahara, K.; Kimura, K.			Thermoelectric properties of (alpha-, delta-, zeta-) Ti-Ru-B approximants for the decagonal quasicrystal	SOLID STATE SCIENCES			English	Article						Quasicrystals; Borides; Thermoelectric properties; Decagonal phase; Pseudogap; Electronic density of states	INTERMETALLIC COMPOUNDS; PHASE; BORON; SUBSTITUTION; IMPROVEMENT; PSEUDOGAP; BORIDES; FIGURE; MERIT; MG	The electronic structure and the thermoelectric properties of (alpha-, delta-, zeta-) Ti-Ru-B approximants related to its decagonal quasicrystal phase were investigated. The band structure calculation reveals that they form pseudogaps in the electronic density of states across the Fermi level. The samples were synthesized by arc-melting, followed by spark plasma sintering. The electrical conductivity at 373 K varies from 1600 to 4200 Omega(-1) cm(-1) and their temperature coefficients are negative. All measured compounds show n-type properties, judging from the sign of the Seebeck coefficient; however, the magnitudes are rather low of less than 25 mu V K-1. The phonon thermal conductivity at 373 K have a range 3-5 W m(-1) K-1 resulting from complex crystal structures with large unit cell volumes. The maximum dimensionless figure-of-merit of 0.008 is evaluated at 773 K for delta-Ti-Ru-B. (C) 2015 Elsevier Masson SAS. All rights reserved.	[Takagiwa, Y.; Yoshida, T.; Yanagihara, D.; Ueda, S.; Kitahara, K.; Kimura, K.] Univ Tokyo, Dept Adv Mat Sci, Kashiwa, Chiba 2778561, Japan; [Miyazaki, Y.] Osaka Univ, Grad Sch Engn, Suita, Osaka 5650871, Japan	Takagiwa, Y (reprint author), Univ Tokyo, Dept Adv Mat Sci, Kashiwa, Chiba 2778561, Japan.	takagiwa@phys.mm.t.u-tokyo.ac.jp			Thermal & Electric Energy Technology Foundation (TEET); KAKENHI from JSPS [24360262, 26709051]	This work is supported by the Thermal & Electric Energy Technology Foundation (TEET) and KAKENHI Grant No. 24360262 and Grant No. 26709051 from JSPS.	Smontara A, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.104204; Toberer ES, 2011, J MATER CHEM, V21, P15843, DOI 10.1039/c1jm11754h; FUJIWARA T, 1991, PHYS REV LETT, V66, P333, DOI 10.1103/PhysRevLett.66.333; Fokwa BPT, 2012, ANGEW CHEM INT EDIT, V51, P1702, DOI 10.1002/anie.201106798; Wang H, 2014, ENERG ENVIRON SCI, V7, P804, DOI 10.1039/c3ee43438a; Mizutani U, 2013, PHILOS MAG, V93, P3353, DOI 10.1080/14786435.2013.805276; Takeuchi T, 2009, J ELECTRON MATER, V38, P1354, DOI 10.1007/s11664-009-0662-1; Takagiwa Y, 2010, MATER TRANS, V51, P988, DOI 10.2320/matertrans.E-M2010807; Nolas GS, 2000, APPL PHYS LETT, V77, P1855, DOI 10.1063/1.1311597; Saramat A, 2006, J APPL PHYS, V99, DOI 10.1063/1.2163979; Tromp HJ, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.016401; SHECHTMAN D, 1984, PHYS REV LETT, V53, P1951, DOI 10.1103/PhysRevLett.53.1951; Snyder GJ, 2008, NAT MATER, V7, P105, DOI 10.1038/nmat2090; Bobnar M, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.024205; Brgoch J, 2012, J SOLID STATE CHEM, V196, P168, DOI 10.1016/j.jssc.2012.06.010; Dian-lin Z., 1991, PHYS REV LETT, V66, P2778, DOI 10.1103/PhysRevLett.66.2778; Dolinsek J, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.064208; Dolinsek J, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.174207; Edagawa K., 2001, MAT SCI ENG A-STRUCT, V312, P283; Fokwa BPT, 2011, EUR J INORG CHEM, P3926, DOI 10.1002/ejic.201100315; Fokwa BPT, 2009, Z ANORG ALLG CHEM, V635, P2258, DOI 10.1002/zaac.200900192; Fokwa BPT, 2011, INORG CHEM, V50, P3332, DOI 10.1021/ic102148x; Hermus M, 2014, CHEM MATER, V26, P1967, DOI 10.1021/cm500237h; Takagiwa Y, 2014, SCI TECHNOL ADV MAT, V15, DOI 10.1088/1468-6996/15/4/044802; Macia E, 2012, CRIT REV SOLID STATE, V37, P215, DOI 10.1080/10408436.2012.703978; Maruyama S, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4758297; Mihalkovic M, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.095507; Misse PRN, 2010, Z ANORG ALLG CHEM, V636, P1013, DOI 10.1002/zaac.200900569; Misse PRN, 2012, J SOLID STATE CHEM, V192, P331, DOI 10.1016/j.jssc.2012.04.041; Miyazaki Y., UNPUB; Miyazaki Y, 2007, PHILOS MAG, V87, P2701, DOI 10.1080/14786430701361446; Miyazaki Y, 2010, J PHYS SOC JPN, V79, DOI 10.1143/JPSJ.79.073601; Miyazaki Y., 2008, PHILOS MAG, V89, P1935; Nishino Y, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.094425; Sahara R, 2014, SCI TECHNOL ADV MAT, V15, DOI 10.1088/1468-6996/15/3/035012; SCHWEITZER K, 1985, Z ANORG ALLG CHEM, V530, P127, DOI 10.1002/zaac.19855301115; Shu-yuan L., 1990, PHYS REV B, V41, P9625, DOI 10.1103/PhysRevB.41.9625; Souma S, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.027202; Takagiwa Y, 2013, J APPL PHYS, V113, DOI 10.1063/1.4775602; Takagiwa Y, 2009, Z KRISTALLOGR, V224, P79, DOI 10.1524/zkri.2009.1080; Takagiwa Y, 2008, J APPL PHYS, V104, DOI 10.1063/1.2990772; Takagiwa Y., J ELECTON MAT, DOI [10.1007/s11664-014-3423e8, DOI 10.1007/S11664-014-3423E8]; TAKEDA M, 1993, PHYS REV B, V48, P13159, DOI 10.1103/PhysRevB.48.13159; Takeda M, 2006, J SOLID STATE CHEM, V179, P2823, DOI 10.1016/j.jssc.2006.01.025	44	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1293-2558	1873-3085		SOLID STATE SCI	Solid State Sci.	SEP	2015	47						32	38		10.1016/j.solidstatesciences.2015.02.008		7	Chemistry, Inorganic & Nuclear; Chemistry, Physical; Physics, Condensed Matter	Chemistry; Physics	CP7ZM	WOS:000360109200008		
J	Morito, H; Anzai, J; Kimura, T; Yamane, H				Morito, Haruhiko; Anzai, Jun; Kimura, Takuma; Yamane, Hisanori			Synthesis of NaB5C bulk ceramics by reaction sintering	SOLID STATE SCIENCES			English	Article						Sodium carbaboride; Ceramics; Reaction sintering; Strength	LOW-TEMPERATURE SYNTHESIS; EARTH-METAL BOROCARBIDES; CRYSTAL-STRUCTURE; CUBIC CARBABORIDES; BORIDE CARBIDES; BORON-CARBON; SIC CERAMICS; NA FLUX; CHEMISTRY; SODIUM	Bulk ceramics of NaB5C were prepared by heating compact bodies of amorphous boron (B) and carbon black (C) powders with Na at 1073 K. The obtained bulk ceramics retained the rectangular shape of their original compacts. The obtained samples had a density of 80.1 +/- 0.6% of the theoretical density of NaB5C. NaB5C bulk ceramics were also prepared by heating compacts comprised of B and C powders and Na. The addition of Na to the starting compact bodies increased the relative bulk density to 83.5 +/- 0.4%. A fracture bending strength of 195 MPa was measured for the NaB5C bulk sample prepared from the compact of Na, B, and C. (C) 2015 Elsevier Masson SAS. All rights reserved.	[Morito, Haruhiko; Anzai, Jun; Kimura, Takuma; Yamane, Hisanori] Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	Morito, H (reprint author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	morito@tagen.tohoku.ac.jp					Adasch V, 2007, CHEM-EUR J, V13, P3450, DOI 10.1002/chem.200601002; Albert B, 1998, CHEM COMMUN, P2373, DOI 10.1039/a806994h; Albert B, 1999, CHEM MATER, V11, P3406, DOI 10.1021/cm991130d; Albert B, 1999, INORG CHEM, V38, P6159, DOI 10.1021/ic9907821; [Anonymous], 2008, FUNDAMENTALS APPL BO; Meyer FD, 1997, J ALLOY COMPD, V252, P98, DOI 10.1016/S0925-8388(96)02721-1; Hayun S, 2009, J EUR CERAM SOC, V29, P3395, DOI 10.1016/j.jeurceramsoc.2009.07.007; Vojteer N, 2006, ANGEW CHEM INT EDIT, V45, P165, DOI 10.1002/anie.200502325; Babizhetskyy V., 2007, J SOLID STATE CHEM, V180; Babizhetskyy V, 2009, Z ANORG ALLG CHEM, V635, P737, DOI 10.1002/zaac.200900021; Babizhetskyy V, 2007, SOLID STATE SCI, V9, P1126, DOI 10.1016/j.solidstatesciences.2007.07.027; Babizhetskyy V, 2012, J SOLID STATE CHEM, V191, P121, DOI 10.1016/j.jssc.2012.02.062; Bauer J, 1998, COORDIN CHEM REV, V178, P723, DOI 10.1016/S0010-8545(98)00106-4; Bidaud E, 2000, J SOLID STATE CHEM, V154, P286, DOI 10.1006/jssc.2000.8851; Carroll K. G., 1954, NATURE, V20, P4437; FISHEL NA, 1969, J INORG NUCL CHEM, V31, P891, DOI 10.1016/0022-1902(69)80043-6; Yamane H, 2008, J CERAM SOC JPN, V116, P163, DOI 10.2109/jcersj2.116.163; Kawamura F, 2008, J AM CERAM SOC, V91, P51, DOI 10.1111/j.1551-2916.2007.02021.x; Matkovich V.I., 1977, BORON REFRACTORY BOR; Morito H, 2008, MATER TRANS, V49, P1929, DOI 10.2320/matertrans.MAW200859; SMITH GS, 1965, ACTA CRYSTALLOGR, V19, P668, DOI 10.1107/S0365110X65004061; SMITH PK, 1967, J INORG NUCL CHEM, V29, P375, DOI 10.1016/0022-1902(67)80040-X; WORLE M, 1994, J ALLOY COMPD, V216, P75, DOI 10.1016/0925-8388(94)91045-6; Yamada T, 2009, JPN J APPL PHYS, V48, DOI 10.1143/JJAP.48.100209; Yamane H, 2011, J EUR CERAM SOC, V31, P409, DOI 10.1016/j.jeurceramsoc.2010.10.025	25	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1293-2558	1873-3085		SOLID STATE SCI	Solid State Sci.	SEP	2015	47						39	42		10.1016/j.solidstatesciences.2015.03.013		4	Chemistry, Inorganic & Nuclear; Chemistry, Physical; Physics, Condensed Matter	Chemistry; Physics	CP7ZM	WOS:000360109200009		
J	Fujima, T; Arimatsu, H; Miura, S; Yokoyama, S; Takagi, K				Fujima, Takuya; Arimatsu, Hideki; Miura, Shota; Yokoyama, Shun; Takagi, Ken-ichi			n-p Type variation in thermoelectric AlMgB14-based materials by raw material mixture ratio	SOLID STATE SCIENCES			English	Article						Thermoelectric properties; AlMgB14; Spark plasma sintering; Seebeck coefficient; Electrical conductivity; Rietveld refinement	BETA-RHOMBOHEDRAL BORON; RICH SOLIDS; MGALB14; GENERATION; MECHANISM; CARBIDE; BORIDES; SYSTEM	We controlled the sign of Seebeck coefficient of AlMgB14-based thermoelectric materials by changing the raw material ratio for spark plasma sintering. The raw material powders of Al, Mg and B were mixed by V-shape mixer then sintered at 1773 K. Some sintered samples exhibited negative Seebeck coefficients and the others did positive as established for stoichiometric AlMgB14. The temperature dependence of electrical conductivity was different from each other type. Rietveld refinement for XRD results about the samples revealed that Mg site in the AlMgB14-lattice was occupied more for negative materials than the p-type ones and the negative samples had more valence electron than the other. (C) 2015 Elsevier Masson SAS. All rights reserved.	[Fujima, Takuya; Arimatsu, Hideki; Miura, Shota; Yokoyama, Shun] Tokyo City Univ, Dept Mech Engn, Setagaya Ku, Tokyo 1588557, Japan; [Takagi, Ken-ichi] Tokyo City Univ, Adv Res Lab, Setagaya Ku, Tokyo 1580082, Japan	Fujima, T (reprint author), Tokyo City Univ, Dept Mech Engn, Setagaya Ku, 1-28-1 Tamazutsumi, Tokyo 1588557, Japan.	tfujima@tcu.ac.jp			Iwatani Naoji Fundation	Our heartfelt appreciation goes to professors K. Kimura and Y. Takagiwa (Graduate School of Frontier Science, The University of Tokyo) for the support of the sample preparation. We also sincerely thank the Iwatani Naoji Fundation for their financial support.	Nakayama T, 2000, J SOLID STATE CHEM, V154, P13, DOI 10.1006/jssc.2000.8804; KORSUKOVA MM, 1992, J ALLOY COMPD, V187, P39, DOI 10.1016/0925-8388(92)90518-E; Mori T, 2007, J APPL PHYS, V101, DOI 10.1063/1.2730571; Takeda M, 2004, J SOLID STATE CHEM, V177, P471, DOI 10.1016/j.jssc.2003.02.005; Kim H, 2011, MATER TRANS, V52, P41, DOI 10.2320/matertrans.M2010272; Izumi F, 2007, SOL ST PHEN, V130, P15; Emin D, 2006, J SOLID STATE CHEM, V179, P2791, DOI 10.1016/j.jssc.2006.01.014; Roberts DJ, 2009, INT J REFRACT MET H, V27, P556, DOI 10.1016/j.ijrmhm.2008.07.009; BOUCHACOURT M, 1985, J MATER SCI, V20, P1237, DOI 10.1007/BF01026319; Dai D, 2011, RENEW ENERG, V36, P3530, DOI 10.1016/j.renene.2011.06.012; WOOD C, 1984, PHYS REV B, V29, P4582, DOI 10.1103/PhysRevB.29.4582; Omer SA, 1998, SOL ENERG MAT SOL C, V53, P67, DOI 10.1016/S0927-0248(98)00008-7; Miura S, 2014, J PHYS CHEM SOLIDS, V75, P951, DOI 10.1016/j.jpcs.2014.04.009; Qiu K, 2008, J POWER SOURCES, V180, P884, DOI 10.1016/j.jpowsour.2008.02.073; Mori T, 2006, J SOLID STATE CHEM, V179, P2908, DOI 10.1016/j.jssc.2006.03.030; Higashi I., 1994, JJAP SERIES, V10, P52; Hill JM, 2003, J MAGN MAGN MATER, V265, P23, DOI 10.1016/S0304-8853(03)00220-8; Ioffe A.F., 1957, SEMICONDUCTOR THERMO; Killander Anders, 1996, P 15 INT C THERM PAS, P390; Koumoto K., 2013, THERMOELECTRIC NANOM; Maruyama S, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4758297; Matkovich V. I., 1970, J EC ACTA CRYST B, V26, P616; Mott N. F., 1971, ELECT PROCESSES NONC; Rowe DM, 2012, THERMOELECT ENERG; Rowe D.M., 1995, CRC HDB THERMOELECTR; Shklovskii B I, 1984, ELECT PROPERTIES DOP; Sun YY, 2011, MATER LETT, V65, P2158, DOI 10.1016/j.matlet.2011.04.053; WERHEIT H, 1995, MAT SCI ENG B-SOLID, V29, P228, DOI 10.1016/0921-5107(94)04023-W	28	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1293-2558	1873-3085		SOLID STATE SCI	Solid State Sci.	SEP	2015	47						51	54		10.1016/j.solidstatesciences.2015.03.015		4	Chemistry, Inorganic & Nuclear; Chemistry, Physical; Physics, Condensed Matter	Chemistry; Physics	CP7ZM	WOS:000360109200011		
J	Sumiyoshi, A; Hyodo, H; Sato, Y; Terauchi, M; Kimura, K				Sumiyoshi, A.; Hyodo, H.; Sato, Y.; Terauchi, M.; Kimura, K.			Good reproductive preparation method of Li-intercalated hexagonal boron nitride and transmission electron microscopy - Electron energy loss spectroscopy analysis	SOLID STATE SCIENCES			English	Article						Hexagonal boron nitride; Alkali metal intercalation; X-ray diffraction; Electrical conductivity; Transmission electron microscopy; Electron energy loss spectroscopy	NANOTUBES	A Li-intercalated hexagonal boron nitride (Li-h-BNIC) phase was synthesized using a highly reproducible method that involves annealing an Li3N and h-BN mixture at 1220 K. Powder X-ray diffraction, electrical conductivity measurements, transmission electron microscopy (TEM) and electron energy loss spectroscopy were performed. The stacking of BN atomic layers in the Li-h-BNIC phase is not the same as the two-layer stacking periodicity of h-BN. TEM observation suggests the existence of incommensurate periodicity along the intralayer direction. From the low-loss and core-loss spectra, the Li-h-BNIC phase is not metal as predicted by the first-principle calculations. Satellite peaks of 1 s to pi* transition in the B K-edge core-loss spectrum indicate the presence of N atom vacancies modified by O atoms in the h-BN atomic layer. (C) 2015 Elsevier Masson SAS. All rights reserved.	[Sumiyoshi, A.; Kimura, K.] Univ Tokyo, Dept Adv Mat Sci, Tokyo 1138654, Japan; [Hyodo, H.; Sato, Y.; Terauchi, M.] Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Sendai, Miyagi 980, Japan	Kimura, K (reprint author), Univ Tokyo, Dept Adv Mat Sci, Tokyo 1138654, Japan.	bkimura@phys.mm.t.u-tokyo.ac.jp			Japan Society for the Promotion of Science [23-5556]; Scientific Research on Priority Areas of New Materials Science Using Regulated Nano Spaces, KAKENHI from MEXT [19051005]	One of the authors (A.S.) was supported by Research Fellowships of the Japan Society for the Promotion of Science (No. 23-5556) for Young Scientists. This work was partly supported by Scientific Research on Priority Areas of New Materials Science Using Regulated Nano Spaces, KAKENHI No. 19051005 from MEXT.	Altintas B, 2011, EUR PHYS J B, V79, P301, DOI 10.1140/epjb/e2010-10660-4; Petravic M, 2010, PHYS CHEM CHEM PHYS, V12, P15349, DOI 10.1039/c0cp00984a; Dresselhaus MS, 2002, ADV PHYS, V51, P1, DOI 10.1080/00018730110113644; Izumi F, 2007, SOL ST PHEN, V130, P15; DOLL GL, 1989, J APPL PHYS, V66, P2554, DOI 10.1063/1.344219; Sato Y, 2011, ULTRAMICROSCOPY, V111, P1381, DOI 10.1016/j.ultramic.2011.05.003; Caretti I, 2011, J APPL PHYS, V110, DOI 10.1063/1.3602996; Choi HC, 2005, J PHYS CHEM B, V109, P7007, DOI 10.1021/jp0464425; Hemraj-Benny T, 2005, PHYS CHEM CHEM PHYS, V7, P1103, DOI 10.1039/b415423a; Jimenez I., 1997, PHYS REV B, V55, P25; Kovtyukhova NI, 2013, J AM CHEM SOC, V135, P8372, DOI 10.1021/ja403197h; Li L, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-417; Nagatochi T., 2011, PHYS REV B, V83, P1; Niibe M, 2010, J VAC SCI TECHNOL A, V28, P1157, DOI 10.1116/1.3474913; Oba F., 2010, PHYS REV B, V81, P20; Otani M., 2010, PHYS REV B, V81, P3; Preobrajenski AB, 2009, NANO LETT, V9, P2780, DOI 10.1021/nl901316p; Sakamoto M, 1986, J MATER RES, V1, P685, DOI 10.1557/JMR.1986.0685; Shen CP, 1999, J SOLID STATE CHEM, V147, P74, DOI 10.1006/jssc.1999.8176; Sumiyoshi A, 2012, J SOLID STATE CHEM, V187, P208, DOI 10.1016/j.jssc.2012.01.002; Sumiyoshi A, 2010, J PHYS CHEM SOLIDS, V71, P569, DOI 10.1016/j.jpcs.2009.12.038; YAMANE H, 1987, J SOLID STATE CHEM, V71, P1, DOI 10.1016/0022-4596(87)90135-6	22	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1293-2558	1873-3085		SOLID STATE SCI	Solid State Sci.	SEP	2015	47						68	72		10.1016/j.solidstatesciences.2015.04.011		5	Chemistry, Inorganic & Nuclear; Chemistry, Physical; Physics, Condensed Matter	Chemistry; Physics	CP7ZM	WOS:000360109200014		
J	Murakami, S; Ninomiya, W; Sakamoto, E; Shibata, T; Akiyama, H; Tashiro, F				Murakami, Shigekazu; Ninomiya, Wataru; Sakamoto, Erina; Shibata, Tatsuhiro; Akiyama, Hirotada; Tashiro, Fumio			SRY and OCT4 Are Required for the Acquisition of Cancer Stem Cell-Like Properties and Are Potential Differentiation Therapy Targets	STEM CELLS			English	Article						SRY; OCT4; Cancer stem cells; Hepatocellular carcinomas	LIVER-CANCER; HEPATOCELLULAR-CARCINOMA; DRUG-RESISTANCE; SELF-RENEWAL; EXPRESSION; PLURIPOTENCY; GROWTH; CARCINOGENESIS; IDENTIFICATION; CD133(+)	The acquisition of stemness is a hallmark of aggressive human hepatocellular carcinoma (hHCC). The stem cell marker OCT4 is frequently expressed in HCCs, and its expression correlates with those of putative cancer stem cell (CSC) markers and CSC properties. Here, we describe a novel mechanism of CSC maintenance by SRY through OCT4. We previously reported that Sry is involved in tumor malignancy in rodent HCCs. However, the oncogenic function of SRY in hHCCs is poorly understood. Ectopic expression of SRY increased multiple stem cell factors, including OCT4 and CD13. The OCT4 promoter contained SRY-binding sites that were directly activated by SRY. In HCC-derived cells, SRY knockdown decreased OCT4 expression and cancer stem-like phenotypes such as self-renewal, chemoresistance, and tumorigenicity. Conversely, OCT4 and SRY overexpression promoted cancer stem-like phenotypes. OCT4 knockdown in SRY clones downregulated the self-renewal capacity and chemoresistance. These data suggest that SRY is involved in the maintenance of cancer stem-like characteristics through OCT4. Moreover, CSCs of HCC-derived cells differentiated into Tuj1-positive neuron-like cells by retinoic acid. Noteworthily, SRY was highly expressed in some hHCC patients. Taken together, our findings imply a novel therapeutic strategy against CSCs of hHCCs.	[Murakami, Shigekazu; Ninomiya, Wataru; Sakamoto, Erina; Akiyama, Hirotada; Tashiro, Fumio] Tokyo Univ Sci, Dept Biol Sci & Technol, Katsushika Ku, Niiju Ku, Tokyo 1258585, Japan; [Shibata, Tatsuhiro] Natl Canc Ctr, Res Inst, Chuo Ku, Div Canc Genom, Tokyo 104, Japan	Tashiro, F (reprint author), Tokyo Univ Sci, Dept Biol Sci & Technol, Katsushika Ku, 1 Niijuku, Tokyo 1258585, Japan.	ftashir@rs.noda.tus.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology [70089332, 23701104, 25870775]	We thank Drs. T. Kawase, T. Sato, and T. Yamada for their advice and discussions. This work was supported by the Ministry of Education, Culture, Sports, Science, and Technology Grants-in-Aid for Scientific research under Grants 70089332, 23701104, and 25870775.	Bian CB, 2011, EMBO J, V30, P2829, DOI 10.1038/emboj.2011.193; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Gambelli F, 2012, CELL BIOL INT, V36, P29, DOI 10.1042/CBI20110013; Chambers I, 2009, DEVELOPMENT, V136, P2311, DOI 10.1242/dev.024398; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Zhang LX, 2012, CANCER RES, V72, P4276, DOI 10.1158/0008-5472.CAN-12-1013; Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Zhang X, 2013, ONCOGENE, V32, P2249, DOI 10.1038/onc.2012.237; Iida H, 2012, INT J ONCOL, V40, P71, DOI 10.3892/ijo.2011.1207; Kamiya D, 2011, NATURE, V470, P503, DOI 10.1038/nature09726; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Kim JB, 2009, CELL, V136, P411, DOI 10.1016/j.cell.2009.01.023; Babaie Y, 2007, STEM CELLS, V25, P500, DOI 10.1634/stemcells.2006-0426; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; Wang XQ, 2010, HEPATOLOGY, V52, P528, DOI 10.1002/hep.23692; Yang N, 2011, CELL STEM CELL, V9, P517, DOI 10.1016/j.stem.2011.11.015; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Bourguignon LYW, 2012, J BIOL CHEM, V287, P32800, DOI 10.1074/jbc.M111.308528; Ronen D, 2014, CELL REP, V8, P923, DOI 10.1016/j.celrep.2014.07.013; Hay DC, 2004, STEM CELLS, V22, P225, DOI 10.1634/stemcells.22-2-225; Liu KC, 2013, ONCOTARGET, V4, P2366; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Kurabe N, 2007, ONCOGENE, V26, P5626, DOI 10.1038/sj.onc.1210349; Bidlingmaier S, 2008, J MOL MED, V86, P1025, DOI 10.1007/s00109-008-0357-8; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Jia Q, 2013, CELL REPROGRAM, V15, P143, DOI 10.1089/cell.2012.0048; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Bradford ST, 2009, HUM MOL GENET, V18, P3429, DOI 10.1093/hmg/ddp283; Buhring HJ, 1999, ANN NY ACAD SCI, V872, P25, DOI 10.1111/j.1749-6632.1999.tb08450.x; Garg Minal, 2009, Critical Reviews in Oncogenesis, V15, P65; Hammerle B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076761; Hersmus R, 2009, EUR J HUM GENET, V17, P1642, DOI 10.1038/ejhg.2009.96; Jin VX, 2007, GENOME RES, V17, P807, DOI 10.1101/gr.6006107; Kang TW, 2014, SCI REP-UK, V4, DOI 10.1038/srep05546; Katoh H, 2007, GASTROENTEROLOGY, V133, P1475, DOI 10.1053/j.gastro.2007.08.038; Kim Ran-Ju, 2011, Lab Anim Res, V27, P147, DOI 10.5625/lar.2011.27.2.147; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Malik Babar, 2012, Front Biosci (Elite Ed), V4, P2142; Mark Manuel, 2009, Nucl Recept Signal, V7, pe002, DOI 10.1621/nrs.07002; Minami K, 2014, ANTICANCER RES, V34, P4767; Mitchell CL, 2002, MOL GENET METAB, V77, P217, DOI 10.1016/S1096-7192(02)00165-8; Murakami S, 2013, ONCOGENE, V33, P2978; Park SJ, 2006, CANCER GENET CYTOGEN, V166, P56, DOI 10.1016/j.cancergencyto.2005.08.022; Sterneckert J, 2012, STEM CELLS, V30, P15, DOI 10.1002/stem.765; Yokoyama M, 2008, J BIOSCI BIOENG, V106, P46, DOI 10.1263/jbb.106.46; Yuan FJ, 2010, MOL CELL BIOCHEM, V343, P155, DOI 10.1007/s11010-010-0509-3	51	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	SEP	2015	33	9					2652	2663		10.1002/stem.2059		12	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	CP6SQ	WOS:000360018900002		
J	Aiyama, Y; Tsunekawa, N; Kishi, K; Kawasumi, M; Suzuki, H; Kanai-Azuma, M; Kurohmaru, M; Kanai, Y				Aiyama, Yoshimi; Tsunekawa, Naoki; Kishi, Kasane; Kawasumi, Miyuri; Suzuki, Hitomi; Kanai-Azuma, Masami; Kurohmaru, Masamichi; Kanai, Yoshiakira			A Niche for GFR alpha 1-Positive Spermatogonia in the Terminal Segments of the Seminiferous Tubules in Hamster Testes	STEM CELLS			English	Article						Glial cell line-derived neurotrophic factor; Glial cell line-derived neurotrophic factor family receptor-alpha 1; Sertoli valve; Niche; Spermatogonial stem cell	GERMLINE STEM-CELLS; SELF-RENEWAL; MOUSE TESTES; DROSOPHILA TESTIS; UNDIFFERENTIATED SPERMATOGONIA; RECIPIENT TESTES; SERTOLI-CELLS; NORMAL MICE; SPERMATOGENESIS; TRANSPLANTATION	In invertebrate species such as flies and nematodes, germline stem cells are maintained in a niche environment, which is restricted to the terminal end of the tubular structure in the gonads. In mice, spermatogonial stem cells (SSCs), a subpopulation of A(single) GFR alpha 1 (glial cell line-derived neurotrophic factor [GDNF] family receptor-alpha 1)-positive spermatogonia, are widely distributed along the longitudinal axis in the convoluted seminiferous tubules, preferentially juxtaposed to the interstitial vasculature. However, whether this area is the only SSC niche is not known. In this study, we identified a valve-like terminal segment of the seminiferous tubules, the Sertoli valve (SV), adjacent to the rete testis as another niche for GFR alpha 1-positive spermatogonia in hamsters. Here, we show that the SV epithelium is composed of the modified Sertoli cells that are still capable of proliferation and missing most spermatogenic activities in the adult stage. The SV epithelium constitutively expresses GDNF, a major niche factor for SSCs, and supports the stable proliferation and selective maintenance of an A(single) subpopulation of GFR alpha 1-positive spermatogonia in hamsters. The SV region of hamster seminiferous tubules has features that are similar to the stem cell niche in invertebrate gonads. Therefore, we propose that the SV may be a novel niche for A(single) GFR alpha 1-positive spermatogonia potentially including a SSC population, at the terminal segments of the seminiferous tubules in hamsters.	[Aiyama, Yoshimi; Tsunekawa, Naoki; Kishi, Kasane; Kurohmaru, Masamichi; Kanai, Yoshiakira] Univ Tokyo, Dept Vet Anat, Bunkyo Ku, Tokyo 1138657, Japan; [Kawasumi, Miyuri; Suzuki, Hitomi; Kanai-Azuma, Masami] Tokyo Med & Dent Univ, Dept Expt Anim Model Human Dis, Ctr Expt Anim, Bunkyo Ku, Tokyo, Japan	Kanai, Y (reprint author), Univ Tokyo, Dept Vet Anat, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.	aykanai@mail.ecc.u-tokyo.ac.jp					Amoyel M, 2013, DEVELOPMENT, V140, P56, DOI 10.1242/dev.086413; Nagano M, 1999, BIOL REPROD, V60, P1429, DOI 10.1095/biolreprod60.6.1429; Sharpe RM, 2003, REPRODUCTION, V125, P769, DOI 10.1530/rep.0.1250769; Hofmann MC, 2005, DEV BIOL, V279, P114, DOI 10.1016/j.ydbio.2004.12.006; Tadokoro Y, 2002, MECH DEVELOP, V113, P29, DOI 10.1016/S0925-4773(02)00004-7; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; Michel M, 2012, DEVELOPMENT, V139, P2663, DOI 10.1242/dev.075242; Ketola I, 2002, EUR J ENDOCRINOL, V147, P397, DOI 10.1530/eje.0.1470397; Oatley MJ, 2011, BIOL REPROD, V84, P639, DOI 10.1095/biolreprod.110.087320; Clouthier DE, 1996, NATURE, V381, P418, DOI 10.1038/381418a0; Ogawa T, 2003, BIOL REPROD, V68, P316, DOI 10.1095/biolreprod.102.004549; Leatherman JL, 2008, CELL STEM CELL, V3, P44, DOI 10.1016/j.stem.2008.05.001; Aloisio GM, 2014, J CLIN INVEST, V124, P3929, DOI 10.1172/JCI75943; Nagano M, 2002, FERTIL STERIL, V78, P1225, DOI 10.1016/S0015-0282(02)04345-5; Kubota H, 2004, P NATL ACAD SCI USA, V101, P16489, DOI 10.1073/pnas.0407063101; Kawase E, 2004, DEVELOPMENT, V131, P1365, DOI 10.1242/dev.01025; Yoshida S, 2007, SCIENCE, V317, P1722, DOI 10.1126/science.1144885; Janke C, 2011, NAT REV MOL CELL BIO, V12, P773, DOI 10.1038/nrm3227; Kent J, 1996, DEVELOPMENT, V122, P2813; Suzuki H, 2009, DEV BIOL, V336, P222, DOI 10.1016/j.ydbio.2009.10.002; de Cuevas M, 2011, DEVELOPMENT, V138, P2861, DOI 10.1242/dev.056242; Ryu BY, 2005, P NATL ACAD SCI USA, V102, P14302, DOI 10.1073/pnas.0506970102; Phillips BT, 2010, PHILOS T R SOC B, V365, P1663, DOI 10.1098/rstb.2010.0026; Matson CK, 2011, NATURE, V476, P101, DOI 10.1038/nature10239; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; Shivdasani AA, 2003, CURR BIOL, V13, P2065, DOI 10.1016/j.cub.2003.10.063; Oatley JA, 2008, ANNU REV CELL DEV BI, V24, P263, DOI 10.1146/annurev.cellbio.24.110707.175355; Ryu BY, 2006, STEM CELLS, V24, P1505, DOI 10.1634/stemcells.2005-0580; Oatley JM, 2009, DEVELOPMENT, V136, P1191, DOI 10.1242/dev.032243; Yoshida S, 2010, DEV GROWTH DIFFER, V52, P311, DOI 10.1111/j.1440-169X.2010.01174.x; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Oatley JM, 2012, PHYSIOL REV, V92, P577, DOI 10.1152/physrev.00025.2011; Savitt J, 2012, STEM CELLS, V30, P732, DOI 10.1002/stem.1028; Brinster RL, 2002, SCIENCE, V296, P2174, DOI 10.1126/science.1071607; Combes AN, 2009, DEV DYNAM, V238, P1033, DOI 10.1002/dvdy.21925; Nagano M, 2001, BIOL REPROD, V64, P1409, DOI 10.1095/biolreprod64.5.1409; Chan F, 2014, GENE DEV, V28, P1351, DOI 10.1101/gad.240465.114; Naughton CK, 2006, BIOL REPROD, V74, P314, DOI 10.1095/biolreprod.105.047365; Yang QE, 2013, J CELL SCI, V126, P1009, DOI 10.1242/jcs.119826; Kidokoro T, 2005, DEV BIOL, V278, P511, DOI 10.1016/j.ydbio.2004.11.006; Nakagawa T, 2010, SCIENCE, V328, P62, DOI 10.1126/science.1182868; Yoshida S, 2012, REPRODUCTION, V144, P293, DOI 10.1530/REP-11-0320; White-Cooper H, 2010, PHILOS T R SOC B, V365, P1465, DOI 10.1098/rstb.2009.0323; Ahmed EA, 2009, BIOL REPROD, V80, P1084, DOI 10.1095/biolreprod.108.071662; De Rooij DG, 2009, MICROSC RES TECHNIQ, V72, P580, DOI 10.1002/jemt.20699; De Rooij DG, 2012, J ANDROL, V33, P1085, DOI 10.2164/jandrol.112.016832; Hayashi Y, 2009, J CELL BIOL, V187, P473, DOI 10.1083/jcb.200904118; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Gonczy P, 1996, DEVELOPMENT, V122, P2437; Bunt SM, 2004, GENESIS, V39, P84, DOI 10.1002/gene.20030; Campos-Junior PH, 2012, BIOL REPROD, V86, p[155, 151]; Chen LY, 2014, ENDOCRINOLOGY; Davies EL, 2008, COLD SH Q B, V73, P137, DOI 10.1101/sqb.2008.73.063; Dobrinski I, 1999, BIOL REPROD, V61, P1331, DOI 10.1095/biolreprod61.5.1331; Dobrinski I, 2000, MOL REPROD DEV, V57, P270, DOI 10.1002/1098-2795(200011)57:3<270::AID-MRD9>3.0.CO;2-Z; Dovere L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059431; Hara K, 2014, CELL STEM CELL, V14, P658, DOI 10.1016/j.stem.2014.01.019; Hess RA, 2005, SERTOLI CELL BIOL, P19, DOI 10.1016/B978-012647751-1/50004-0; Hofmann MC, 2008, MOL CELL ENDOCRINOL, V288, P95, DOI 10.1016/j.mce.2008.04.012; Kanatsu-Shinohara M, 2008, BIOL REPROD, V78, P611, DOI 10.1095/biolreprod.107.065615; Kanatsu-Shinohara M, 2005, BIOL REPROD, V72, P985, DOI 10.1095/biolreprod.104.036400; Kanatsu-Shinohara M, 2011, BIOL REPROD, V84, P97, DOI 10.1095/biolreprod.110.086462; Kanatsu-Shinohara M, 2003, BIOL REPROD, V69, P612, DOI 10.1095/biloreprod.103.017012; Kanatsu-Shinohara M, 2012, CELL STEM CELL, V11, P567, DOI 10.1016/j.stem.2012.06.011; Komai Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06175; Morimoto H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007909; Mouw JK, 2014, NAT REV MOL CELL BIO, V15, P771, DOI 10.1038/nrm3902; Nagai R, 2012, DEV DYNAM, V241, P1374, DOI 10.1002/dvdy.23824; Ogawa T, 1999, BIOL REPROD, V60, P515, DOI 10.1095/biolreprod60.2.515; Ren LQ, 2006, ENDOCRINE, V30, P151, DOI 10.1385/ENDO:30:2:151; Russell LD, 1993, SERTOLI CELL, P1; Sarrazin S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004952; Sato T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028367; Spradling A, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a002642; Tainosho S, 2011, MED MOL MORPHOL, V44, P34, DOI 10.1007/s00795-010-0501-8; Takahashi K, 2007, INT J ANDROL, V30, P21, DOI 10.1111/j.1365-2605.2006.00704.x; Williams C. S. F., 1976, PRACTICAL GUIDE LAB; Yeh JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040002; Yuan HB, 2010, CURR OPIN CELL BIOL, V22, P730, DOI 10.1016/j.ceb.2010.08.013; Zhang L, 2011, SPERMATOGENESIS, V1, P186, DOI DOI 10.4161/SPMG.1.3.17760	81	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	SEP	2015	33	9					2811	2824		10.1002/stem.2065		14	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	CP6SQ	WOS:000360018900015		
J	Nguyen, TM; Arthur, A; Panagopoulos, R; Paton, S; Hayball, JD; Zannettino, ACW; Purton, LE; Matsuo, K; Gronthos, S				Nguyen, Thao M.; Arthur, Agnieszka; Panagopoulos, Romana; Paton, Sharon; Hayball, John D.; Zannettino, Andrew C. W.; Purton, Louise E.; Matsuo, Koichi; Gronthos, Stan			EphB4 Expressing Stromal Cells Exhibit an Enhanced Capacity for Hematopoietic Stem Cell Maintenance	STEM CELLS			English	Article						Haematopoietic stem cells; Bone marrow stromal cells; EphB; ephrinB; Mesenchymal stem cells	BONE-MARROW NICHE; IN-VIVO; FLT3 LIGAND; PROGENITORS; DISTINCT; INTERLEUKIN-6; MOBILIZATION; BLOOD; MOUSE; MICROENVIRONMENT	The tyrosine kinase receptor, EphB4, mediates cross-talk between stromal and hematopoietic populations during bone remodeling, fracture repair and arthritis, through its interactions with the ligand, ephrin-B2. This study demonstrated that transgenic EphB4 mice (EphB4 Tg), over-expressing EphB4 under the control of collagen type-1 promoter, exhibited higher frequencies of osteogenic cells and hematopoietic stem/progenitor cells (HSC), correlating with a higher frequency of long-term culture-initiating cells (LTC-IC), compared with wild type (WT) mice. EphB4 Tg stromal feeder layers displayed a greater capacity to support LTC-IC in vitro, where blocking EphB4/ephrin-B2 interactions decreased LTC-IC output. Similarly, short hairpin RNA-mediated EphB4 knockdown in human bone marrow stromal cells reduced their ability to support high ephrin-B2 expressing CD34(+) HSC in LTC-IC cultures. Notably, irradiated EphB4 Tg mouse recipients displayed enhanced bone marrow reconstitution capacity and enhanced homing efficiency of transplanted donor hematopoietic stem/progenitor cells relative to WT controls. Studies examining the expression of hematopoietic supportive factors produced by stromal cells indicated that CXCL12, Angiopoietin-1, IL-6, FLT-3 ligand, and osteopontin expression were more highly expressed in EphB4 Tg stromal cells compared with WT controls. These findings indicate that EphB4 facilitates stromal-mediated support of hematopoiesis, and constitute a novel component of the HSC niche.	[Nguyen, Thao M.; Arthur, Agnieszka; Panagopoulos, Romana; Paton, Sharon; Gronthos, Stan] Univ Adelaide, Sch Med Sci, Fac Hlth Sci, Mesenchymal Stem Cell Lab, Adelaide, SA 5000, Australia; [Nguyen, Thao M.; Zannettino, Andrew C. W.; Gronthos, Stan] Univ Adelaide, Sch Med Sci, Fac Hlth Sci, Ctr Stem Cell Res, Adelaide, SA 5000, Australia; [Zannettino, Andrew C. W.] Univ Adelaide, Sch Med Sci, Fac Hlth Sci, Myeloma Res Lab, Adelaide, SA 5000, Australia; [Nguyen, Thao M.; Hayball, John D.] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia; [Nguyen, Thao M.; Hayball, John D.] Univ S Australia, Sansom Inst, Adelaide, SA 5001, Australia; [Nguyen, Thao M.; Arthur, Agnieszka; Zannettino, Andrew C. W.; Gronthos, Stan] South Australian Hlth & Med Res Inst, Canc Theme, Adelaide, SA, Australia; [Arthur, Agnieszka] SA Pathol, Div Haematol, Adelaide, SA, Australia; [Purton, Louise E.] Univ Melbourne, St Vincents Inst Med Res, Stem Cell Regulat Unit, Melbourne, Vic, Australia; [Purton, Louise E.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia; [Matsuo, Koichi] Keio Univ, Sch Med, Lab Cell & Tissue Biol, Tokyo, Japan	Gronthos, S (reprint author), Univ Adelaide, Sch Med Sci, Fac Hlth Sci, Mesenchymal Stem Cell Lab, Adelaide, SA 5000, Australia.	stan.gronthos@adelaide.edu.au	Matsuo, Koichi/K-5695-2012	Matsuo, Koichi/0000-0002-1490-8955	University of South Australia Post graduate Award; Royal Adelaide Hospital Mary Overton Fellowship; NHMRC Project [1023390]	We thank the staff at the Detmold Family Imaging Facility, Kate Pilkington and Rebecca Salmon, for their invaluable flow cytometric advice, the staff at the Radiation Oncology Department, Royal Adelaide Hospital, Josef-Binh Nguyen, for the use of Linac X-ray irradiator, Dr. Hayley Ramshaw at the SA Pathology, and Dr. Iain Comerford at the University of Adelaide for their invaluable advice on bone marrow transplantation. This work was supported by the University of South Australia Post graduate Award, Royal Adelaide Hospital Mary Overton Fellowship and NHMRC Project Grant #1023390.	Akashi K, 1999, COLD SPRING HARB SYM, V64, P1, DOI 10.1101/sqb.1999.64.1; Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369; Hemming S, 2014, STEM CELLS, V32, P802, DOI 10.1002/stem.1573; Winkler IG, 2010, BLOOD, V116, P375, DOI 10.1182/blood-2009-07-233437; Okubo T, 2006, EXP HEMATOL, V34, P330, DOI 10.1016/j.exphem.2005.12.003; Valverde-Franco G, 2012, ARTHRITIS RHEUM-US, V64, P3614, DOI 10.1002/art.34638; Noll JE, 2014, HAEMATOLOGICA, V99, P163, DOI 10.3324/haematol.2013.090977; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Nguyen TM, 2013, STEM CELLS DEV, V22, P2751, DOI 10.1089/scd.2012.0676; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Shen Y, 2012, CURR OPIN HEMATOL, V19, P250, DOI 10.1097/MOH.0b013e328353c714; Hoggatt J, 2013, STEM CELLS, V31, P2599, DOI 10.1002/stem.1574; Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984; Purton LE, 2007, CELL STEM CELL, V1, P263, DOI 10.1016/j.stem.2007.08.016; Kitamura T, 2008, AM J PHYSIOL-CELL PH, V294, pC189, DOI 10.1152/ajpcell.00314.2007; Kim S, 2010, J IMMUNOL, V184, P1143, DOI 10.4049/jimmunol.0902447; Short Brenton J., 2009, V482, P259, DOI 10.1007/978-1-59745-060-7_16; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Arthur A, 2011, BONE, V48, P533, DOI 10.1016/j.bone.2010.10.180; Xing WR, 2010, MOL CELL BIOL, V30, P711, DOI 10.1128/MCB.00610-09; Wada N, 2009, J CELL PHYSIOL, V219, P667, DOI 10.1002/jcp.21710; Levesque JP, 2010, LEUKEMIA, V24, P1979, DOI 10.1038/leu.2010.214; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Askmyr M, 2009, TRENDS ENDOCRIN MET, V20, P303, DOI 10.1016/j.tem.2009.03.004; Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293; Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012; Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885; Goldman DC, 2009, BLOOD, V114, P4393, DOI 10.1182/blood-2009-02-206433; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Kunkel EJ, 2003, NAT REV IMMUNOL, V3, P822, DOI 10.1038/nri1203; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Salvucci O, 2006, BLOOD, V108, P2914, DOI 10.1182/blood-2006-05-023341; Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood-2004-11-4422; Haylock DN, 2006, BRIT J HAEMATOL, V134, P467, DOI 10.1111/j.1365.2141.2006.06218.x; Ansel KM, 2001, CURR OPIN IMMUNOL, V13, P172, DOI 10.1016/S0952-7915(00)00201-6; Arthur A, 2013, J BONE MINER RES, V28, P926, DOI 10.1002/jbmr.1821; BERNAD A, 1994, IMMUNITY, V1, P725, DOI 10.1016/S1074-7613(94)80014-6; Bianco P, 2015, BONE, V70, P2, DOI 10.1016/j.bone.2014.08.011; Bordeaux-Rego P, 2010, STEM CELLS DEV, V19, P413, DOI 10.1089/scd.2009.0098; Fisher L W, 1995, Acta Orthop Scand Suppl, V266, P61; Grassinger J, 2011, METHODS MOL BIOL, V750, P197, DOI 10.1007/978-1-61779-145-1_14; Gronthos Stan, 2008, V449, P45, DOI 10.1007/978-1-60327-169-1_3; Hamada K, 2003, ARTERIOSCL THROM VAS, V23, P190, DOI 10.1161/01.ATV.0000055440.89758.C2; Joseph C, 2013, CELL STEM CELL, V13, P520, DOI 10.1016/j.stem.2013.10.010; Kovacevic-Filipovic M, 2007, J CELL PHYSIOL, V212, P68, DOI 10.1002/jcp.21003; Liu M, 2012, BASIC CELL CULT PROT, P241; Luis MAC, 2009, LEUKEMIA RES, V33, P395; LYMAN SD, 1994, STEM CELLS, V12, P99; LYMAN SD, 1995, INT J HEMATOL, V62, P63; Metcalf D, 2007, IMMUNITY, V26, P669, DOI 10.1016/j.immuni.2007.05012; Nikhil S, 2011, CHEM BIOL, V18, P361; Prevost N, 2004, BLOOD, V103, P1348, DOI 10.1182/blood-2003-06-1781; Saint-Vis B, 2004, BLOOD, V102, P4431; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; Ting MJ, 2008, OPEN HEMATOL J, V2, P103, DOI 10.2174/1874276900802010103; Williams Brenda, 2009, V482, P93, DOI 10.1007/978-1-59745-060-7_6; YIN T, 2006, AM SOC CLIN INVEST, V116, P1195, DOI DOI 10.1172/JCI28568; Zlotoff DA, 2008, SEMIN IMMUNOPATHOL, V30, P371, DOI 10.1007/s00281-008-0133-4	62	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	SEP	2015	33	9					2838	2849		10.1002/stem.2069		12	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	CP6SQ	WOS:000360018900017		
J	Kim, KH; Umakoshi, T; Abe, Y; Kawamura, M; Kiba, T				Kim, Kyung Ho; Umakoshi, Tomoyuki; Abe, Yoshio; Kawamura, Midori; Kiba, Takayuki			Growth behavior of Al-doped zinc oxide microrods with times	SUPERLATTICES AND MICROSTRUCTURES			English	Article						ZnO; Microrods; Growth; Morphology; Time; pH	ZNO NANOROD ARRAYS; HYDROTHERMAL GROWTH; OPTICAL-PROPERTIES; SIZE; MECHANISM; DEVICES; RODS; CU	We investigated the growth behavior of Al-doped zinc oxide (ZnO) microrods grown on ZnO seed layers at various growth times. During the initial 3 h (region I), the randomly oriented microrods grew on the surface of the substrate because of the weak acidity of the initial solution (pH similar to 5.5). Between 3 h and 6 h (region II), when the pH was close to neutrality, a dominant growth of Al-doped ZnO (AZO) microrods with tapered shape occurred. After that the vertical growth of the microrods reached a certain equilibrium, a selective etching of the side nonpolar plane, rather than the top polar plane, dominantly occurred between 6 h and 12 h (region III), thus leading to the formation of the microrods of cylindrical shape. From 12 h to 24 h (region IV), the pH value was saturated, and the morphology of the microrods did not significantly change. As a result, owing to the change of the pH value, the growth behavior of the AZO microrods appeared significantly different when increasing the time. (C) 2015 Elsevier Ltd. All rights reserved.	[Kim, Kyung Ho; Umakoshi, Tomoyuki; Abe, Yoshio; Kawamura, Midori; Kiba, Takayuki] Kitami Inst Technol, Dept Mat Sci & Engn, Kitami, Hokkaido 0908507, Japan	Kim, KH (reprint author), Kitami Inst Technol, Dept Mat Sci & Engn, 165 Koen Cho, Kitami, Hokkaido 0908507, Japan.	khkim@mail.kitami-it.ac.jp		Kiba, Takayuki/0000-0001-6543-2558			Amin G., 2011, J NANOMATER, V2011; Yang LL, 2009, J ALLOY COMPD, V469, P623, DOI 10.1016/j.jallcom.2008.08.002; Bao JM, 2006, NANO LETT, V6, P1719, DOI 10.1021/nl061080t; Yan XD, 2008, CRYST GROWTH DES, V8, P2406, DOI 10.1021/cg7012599; Li F, 2004, ANGEW CHEM INT EDIT, V43, P5238, DOI 10.1002/anie.200460783; Kim S, 2013, B KOREAN CHEM SOC, V34, P1205, DOI 10.5012/bkcs.2013.34.4.1205; Huang BR, 2013, APPL SURF SCI, V280, P945, DOI 10.1016/j.apsusc.2013.05.112; Kim JH, 2006, ADV MATER, V18, P2453, DOI 10.1002/adma.200600257; Zhang LJ, 2013, INORG CHEM, V52, P10167, DOI 10.1021/ic401646t; Polsongkram D, 2008, PHYSICA B, V403, P3713, DOI 10.1016/j.physb.2008.06.020; Sun JC, 2013, APPL SURF SCI, V276, P782, DOI 10.1016/j.apsusc.2013.03.171; Fang T.-H., 2009, J APPL PHYS, V105; Jin Z., 2014, 21 INT DISPL WORKSH; Kim KH, 2015, SUPERLATTICE MICROST, V77, P101, DOI 10.1016/j.spmi.2014.11.015; Kim KH, 2014, SUPERLATTICE MICROST, V75, P455, DOI 10.1016/j.spmi.2014.08.004; Kolodziejczak-Radzimska A, 2014, MATERIALS, V7, P2833, DOI 10.3390/ma7042833; Liu YS, 2015, J ALLOY COMPD, V629, P84, DOI 10.1016/j.jallcom.2014.12.139; Ozgur U, 2005, J APPL PHYS, V98, DOI 10.1063/1.1992666; She G.-W., 2008, APPL PHYS LETT, V92; Zhang SM, 2015, MATER LETT, V148, P1, DOI 10.1016/j.matlet.2015.02.050; Zheng ZK, 2013, SCI REP-UK, V3, DOI 10.1038/srep02434	21	0	0	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0749-6036			SUPERLATTICE MICROST	Superlattices Microstruct.	SEP	2015	85						743	746		10.1016/j.spmi.2015.07.003		4	Physics, Condensed Matter	Physics	CP4SP	WOS:000359873200084		
J	Zhu, YH; Wang, MY; Shi, M; Huang, J; Zhu, XJ; Yin, HH; Guo, XL; Egawa, T				Zhu, Youhua; Wang, Meiyu; Shi, Min; Huang, Jing; Zhu, Xiaojun; Yin, Haihong; Guo, Xinglong; Egawa, Takashi			Correlation on GaN epilayer quality and strain in GaN-based LEDs grown on 4-in. Si(111) substrate	SUPERLATTICES AND MICROSTRUCTURES			English	Article						GaN-LEDs; XRD; Raman scattering; CL; Strain	CHEMICAL-VAPOR-DEPOSITION; LIGHT-EMITTING DIODES; HIGH-PERFORMANCE; THIN-FILMS; BLUE; HETEROSTRUCTURE; SAPPHIRE; NITRIDE; SILICON; STRESS	GaN-based LEDs with different thickness of n-GaN have been grown on 4-in. Si(111) substrate by metal-organic chemical vapor deposition. Quality of GaN epilayer has been evaluated by X-ray diffraction (XRD). Strain information in the structure has been directly investigated by means of micro-Raman scattering. It can be concluded that the compressive strain has varied to a tensile one with increasing n-GaN thickness from 0.5 to 2.0 mu m. As a result, in a sample with a 2 mu m n-GaN thickness, the tensile stress of GaN epilayer was calculated to be 0.44 GPa. Moreover, the strain states of GaN epilayer have been revealed from the variations of its a- and c-lattice constants, which have been calculated using XRD results. In addition, emission peak shift of GaN epilayer has been confirmed by cathodoluminescence measurement, and light output power of LEDs has also been measured. Nevertheless, some correlations in this study would inspire researcher to design much more reasonable GaN-LEDs structures in future. Crown Copyright (C) 2015 Published by Elsevier Ltd. All rights reserved.	[Zhu, Youhua; Wang, Meiyu; Shi, Min; Huang, Jing; Zhu, Xiaojun; Yin, Haihong; Guo, Xinglong] Nantong Univ, Sch Elect & Informat, Nantong 226019, Peoples R China; [Zhu, Youhua; Egawa, Takashi] Nagoya Inst Technol, Res Ctr Nanodevice & Syst, Nagoya, Aichi 4668555, Japan	Wang, MY (reprint author), Nantong Univ, Sch Elect & Informat, SeYuan Rd 9, Nantong 226019, Peoples R China.	wmy123@ntu.edu.cn			NSF of China [61204018]; Natural Science Foundation of Jiangsu Province [BK20130392, BK20141239]; Foundation for University Natural Science Foundation of Jiangsu Province, China [13KJB510030]; "The Six Top Talents" of Jiangsu Province [2013-XCL-013]; Foundation for Nantong University Natural Science [03080666, 14Z003]	The authors acknowledge financial support from the NSF of China (Grant No. 61204018), Natural Science Foundation of Jiangsu Province (Grant Nos. BK20130392 and BK20141239), and Foundation for University Natural Science Foundation of Jiangsu Province, China (Grant No. 13KJB510030). This work has also been supported by the "The Six Top Talents" of Jiangsu Province (Grant No. 2013-XCL-013) and the Foundation for Nantong University Natural Science (Grant Nos. 03080666 and 14Z003).	Zhu YH, 2009, J APPL PHYS, V106, DOI 10.1063/1.3273311; Mo CL, 2005, J CRYST GROWTH, V285, P312, DOI 10.1016/j.jcrysgro.2005.08.046; Zhang BS, 2007, J CRYST GROWTH, V298, P725, DOI 10.1016/j.jcrysgro.2006.10.170; Kisielowski C, 1996, PHYS REV B, V54, P17745, DOI 10.1103/PhysRevB.54.17745; Romano LT, 2000, J APPL PHYS, V87, P7745, DOI 10.1063/1.373529; Tripathy S, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2814062; Zheng XH, 2003, J CRYST GROWTH, V250, P345, DOI [10.1016/S0022-0248(02)02465-X, 10.1016/S0022-0248(02)024645-X]; Li J, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2199492; Tripathy S, 2002, J APPL PHYS, V92, P3503, DOI 10.1063/1.1502921; Dadgar A, 2002, APPL PHYS LETT, V80, P3670, DOI 10.1063/1.1479455; Ruvimov S, 1996, APPL PHYS LETT, V69, P990, DOI 10.1063/1.117105; Zhao DG, 2003, APPL PHYS LETT, V83, P677, DOI 10.1063/1.1592306; Krost A, 2003, PHYS STATUS SOLIDI A, V200, P26, DOI 10.1002/pssa.200303428; Zhu DD, 2011, J APPL PHYS, V109, DOI 10.1063/1.3530602; Lu L, 2011, J APPL PHYS, V109, DOI 10.1063/1.3596592; Polian A, 1996, J APPL PHYS, V79, P3343, DOI 10.1063/1.361236; Deng DM, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3427438; Raghavan S, 2005, J APPL PHYS, V98, DOI 10.1063/1.1978991; HIRAMATSU K, 1993, JPN J APPL PHYS 1, V32, P1528, DOI 10.1143/JJAP.32.1528; Cheng K, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2928224; Dadgar A, 2002, PHYS STATUS SOLIDI A, V192, P308, DOI 10.1002/1521-396X(200208)192:2<308::AID-PSSA308>3.0.CO;2-M; DETCHPROHM T, 1992, JPN J APPL PHYS 2, V31, pL1454; Egawa T, 2002, JPN J APPL PHYS 2, V41, pL663, DOI 10.1143/JJAP.41.L663; Egawa T, 2005, IEEE ELECTR DEVICE L, V26, P169, DOI 10.1109/LED.2004.842642; GIANNINI C, 1994, SOLID STATE COMMUN, V91, P635, DOI 10.1016/0038-1098(94)90562-2; Harima H, 2002, J PHYS-CONDENS MAT, V14, pR967, DOI 10.1088/0953-8984/14/38/201; Ishikawa H, 1999, JPN J APPL PHYS 2, V38, pL492, DOI 10.1143/JJAP.38.L492; Lee L., 1998, J APPL PHYS, V83, P5787; Lu YA, 2003, J CRYST GROWTH, V247, P91, DOI 10.1016/S0022-0248(02)01953-X; Bairamov BH, 1999, PHYS REV B, V60, P16741, DOI 10.1103/PhysRevB.60.16741; NAKAMURA S, 1994, APPL PHYS LETT, V64, P1687, DOI 10.1063/1.111832; Weber W. H., 2000, RAMAN SCATTERING MAT; Zhang BS, 2004, J CRYST GROWTH, V270, P316, DOI 10.1016/j.jcrysgro.2004.06.040; Zhang JC, 2004, J CRYST GROWTH, V268, P24, DOI 10.1016/j.jcrysgro.2004.04.102; Zhang L, 2010, J APPL PHYS, V108, DOI 10.1063/1.3493115; Zhu D, 2009, PROC SPIE, V7231, DOI 10.1117/12.814919	36	1	1	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0749-6036			SUPERLATTICE MICROST	Superlattices Microstruct.	SEP	2015	85						798	805		10.1016/j.spmi.2015.05.052		8	Physics, Condensed Matter	Physics	CP4SP	WOS:000359873200091		
J	Maruyama, D; Chaki, T; Omote, M; Hirata, N; Yamauchi, M; Yamakage, M				Maruyama, Daisuke; Chaki, Tomohiro; Omote, Masahito; Hirata, Naoyuki; Yamauchi, Masanori; Yamakage, Michiaki			Movements of the double-lumen endotracheal tube due to lateral position with head rotation and tube fixation: a Thiel-embalmed cadaver study	SURGICAL AND RADIOLOGIC ANATOMY			English	Article						Double-lumen endotracheal tube (DLT); Thiel-embalmed cadaver; Lateral position; Head rotation	ONE-LUNG VENTILATION; ENDOBRONCHIAL TUBE; NECK; DISPLACEMENT; PATIENT; MALPOSITION; PLACEMENT; DEPTH	Following successful double-lumen endotracheal tube (DLT) insertion for pulmonary surgery, the body position of a patient is changed from supine to lateral. This change occasionally leads to the malposition of the DLT and difficulty in differential lung ventilation. In this study, we investigated movements of the DLT induced by change in body position from supine to lateral, using Thiel-embalmed cadavers. Thiel-embalmed cadavers retain full flexibility of the body and preservation of natural colours, using novel preservation techniques. After the tip of the DLT was directly fixed with forceps at the appropriate position in the bronchus, the DLT depth was measured at the lip in supine and lateral positions. The depth of DLT insertion measured at the lip in right (25.2 +/- A 0.3 cm; mean +/- A SEM) and left (25.1 +/- A 0.3 cm) lateral positions was significantly increased compared to the supine position (24.7 +/- A 0.3 cm). We recommend that the depth of DLT insertion should be advanced by approximately 0.5 cm from the best position, before changing from the supine to lateral position.	[Maruyama, Daisuke; Chaki, Tomohiro; Omote, Masahito; Hirata, Naoyuki; Yamakage, Michiaki] Sapporo Med Univ, Dept Anesthesiol, Sch Med, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; [Yamauchi, Masanori] Tohoku Univ, Sch Med, Dept Anesthesiol & Perioperat Med, Aoba Ku, Sendai, Miyagi 9808575, Japan	Maruyama, D (reprint author), Sapporo Med Univ, Dept Anesthesiol, Sch Med, Chuo Ku, South 1 West 16, Sapporo, Hokkaido 0608543, Japan.	d.maruyama@sapmed.ac.jp					Giger U, 2008, SURG ENDOSC, V22, P901, DOI 10.1007/s00464-007-9502-7; BENUMOF JL, 1987, ANESTHESIOLOGY, V67, P729, DOI 10.1097/00000542-198711000-00018; THIEL W, 1992, ANN ANAT, V174, P185; RILEY RH, 1992, ANESTH ANALG, V75, P1071, DOI 10.1213/00000539-199212000-00040; HARTREY R, 1995, ANAESTHESIA, V50, P682, DOI 10.1111/j.1365-2044.1995.tb06093.x; Bregy A, 2008, J NEUROSURG, V108, P567, DOI 10.3171/JNS/2008/108/3/0567; Klein U, 1998, ANESTHESIOLOGY, V88, P346, DOI 10.1097/00000542-199802000-00012; SAITO S, 1985, ANESTHESIOLOGY, V62, P696, DOI 10.1097/00000542-198505000-00041; Weiss M, 2006, BRIT J ANAESTH, V96, P486, DOI 10.1093/bja/ael014; Seo JH, 2012, CAN J ANESTH, V59, P437, DOI 10.1007/s12630-012-9679-7; Inoue S, 2004, BRIT J ANAESTH, V92, P195, DOI 10.1093/bja/aeh055; BRODSKY JB, 1985, ANESTHESIOLOGY, V62, P667, DOI 10.1097/00000542-198505000-00028; Bessa Júnior Roberto Cardoso, 2005, Rev Bras Anestesiol, V55, P660, DOI 10.1590/S0034-70942005000600009; BRODSKY JB, 1991, ANESTH ANALG, V73, P570; Cadiere GB, 2011, ANN SURG ONCOL, V18, P838, DOI 10.1245/s10434-010-1330-7; Desiderio DP, 1997, J CARDIOTHOR VASC AN, V11, P595, DOI 10.1016/S1053-0770(97)90011-2; DONN SM, 1980, PEDIATR RADIOL, V9, P37, DOI 10.1007/BF00973968; GOODMAN LR, 1976, AM J ROENTGENOL, V127, P433; Ikeda M, 1996, ANESTHESIOLOGY, V84, P1234, DOI 10.1097/00000542-199605000-00026; McLeod G, 2010, ULTRASOUND, V18, P125; Pruszkowski O, 2007, BRIT J ANAESTH, V98, P539, DOI 10.1093/bja/aem039; ROTSCHILD A, 1991, AM J DIS CHILD, V145, P1007; Sharma K, 2009, ANAESTHESIA, V64, P383, DOI 10.1111/j.1365-2044.2008.05796.x; Slinger PD, 2010, MILLERS ANESTHESIA, P1835; Yoon TG, 2005, CAN J ANAESTH, V52, P413	25	0	0	SPRINGER FRANCE	PARIS	22 RUE DE PALESTRO, PARIS, 75002, FRANCE	0930-1038	1279-8517		SURG RADIOL ANAT	Surg. Radiol. Anat.	SEP	2015	37	7					841	844		10.1007/s00276-014-1411-6		4	Anatomy & Morphology; Radiology, Nuclear Medicine & Medical Imaging; Surgery	Anatomy & Morphology; Radiology, Nuclear Medicine & Medical Imaging; Surgery	CP4EJ	WOS:000359834500015		
J	Aslan, F; Seren, AR; Akpinar, Z; Guven, AC; Ekinci, N; Alper, E; Cekic, C; Unsal, B; Yamamoto, H				Aslan, Fatih; Seren, Ali Riza; Akpinar, Zehra; Guven, Aylin Cakir; Ekinci, Nese; Alper, Emrah; Cekic, Cem; Unsal, Belkis; Yamamoto, Hironori			The usage of overtube has a favorable effect on endoscopic submucosal dissection	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Endoscopic submucosal dissection; Overtube; Dissection speed	EARLY GASTRIC-CANCER; ASPIRATION PNEUMONIA; TERM OUTCOMES; SEDATION; PROPOFOL; COMPLICATIONS; NEOPLASIA; FIBROSIS; TUMORS; CARE	Endoscopic submucosal dissection (ESD) may be very time consuming, and depending on the anesthesia, the contents of the stomach may reflux to the esophagus and cause the patient to aspirate. To prevent these situations, many practitioners suggest using an overtube, but no study has been done to evaluate the effect of the use of an overtube while performing the ESD procedure. Our aim was to investigate the effects of performing an upper gastrointestinal ESD with and without overtube. Records of patients who underwent ESD were evaluated for histopathological results, complications, speed of dissection, dosages of anesthetic medications, and number of suctions performed during the procedure. The patients were classified into two depending on whether an overtube was used or not. There were a total of 58 patients on which 63 upper gastrointestinal ESD procedures were performed. Regarding age, gender, localization of the lesions, duration of the procedures, dosage of propofol, histopathological results, rate of complete resection, and rate of en-bloc resection, there was no difference between the two groups (p > 0,05). But the size of the lesions, the size of the resected specimen, and the speed of dissection were statistically different in two groups (p = 0.018, p < 0.001, p < 0.001, respectively).The need for suction during the procedure was much lower in the overtube group than those with no overtube (p < 0.001). We conclude that using an overtube during an upper gastrointestinal ESD decreases the need for suction, favors the speed of dissection, and eases the comfort of the procedure.	[Aslan, Fatih; Akpinar, Zehra; Alper, Emrah; Cekic, Cem; Unsal, Belkis] Katip Celebi Univ, Ataturk Training & Res Hosp, Gastroenterol Klin, Gastroenterol, TR-35360 Izmir, Turkey; [Seren, Ali Riza; Guven, Aylin Cakir] Katip Celebi Univ, Ataturk Training & Res Hosp, Anesthesiol & Reanimat, TR-35360 Izmir, Turkey; [Ekinci, Nese] Katip Celebi Univ, Ataturk Training & Res Hosp, Pathol, TR-35360 Izmir, Turkey; [Yamamoto, Hironori] Jichi Med Univ, Endoscop Res & Int Educ, Shimotsuke, Tochigi, Japan	Aslan, F (reprint author), Katip Celebi Univ, Ataturk Training & Res Hosp, Gastroenterol Klin, Gastroenterol, Basin Sitesi, TR-35360 Izmir, Turkey.	drfatihaslan@hotmail.com					Tierney WM, 2009, GASTROINTEST ENDOSC, V70, P828, DOI 10.1016/j.gie.2009.06.014; Jeong JY, 2012, GASTROINTEST ENDOSC, V76, P59, DOI 10.1016/j.gie.2012.03.172; Chirica M, 2010, J VISC SURG, V147, pE117, DOI 10.1016/j.jviscsurg.2010.08.003; Yamamoto H, 2007, NAT CLIN PRACT GASTR, V4, P511, DOI 10.1038/ncpgasthep0906; Repici A, 2010, GASTROINTEST ENDOSC, V71, P715, DOI 10.1016/j.gie.2009.11.020; Park CH, 2013, SURG ENDOSC, V27, P2760, DOI 10.1007/s00464-013-2804-z; Matsumoto A, 2010, SCAND J GASTROENTERO, V45, P1329, DOI 10.3109/00365521.2010.495416; Marik PE, 2011, CURR OPIN PULM MED, V17, P148, DOI 10.1097/MCP.0b013e32834397d6; Yamamoto H, 2012, NAT REV GASTRO HEPAT, V9, P519, DOI 10.1038/nrgastro.2012.97; Sasaki T, 2012, ENDOSCOPY, V44, P584, DOI 10.1055/s-0032-1306776; Draganov PV, 2013, GASTROINTEST ENDOSC, V78, P677, DOI 10.1016/j.gie.2013.07.033; Akasaka T, 2011, DIGEST ENDOSC, V23, P73, DOI 10.1111/j.1443-1661.2010.01062.x; Tanabe S, 2014, GASTRIC CANCER, V17, P130, DOI 10.1007/s10120-013-0241-2; Eisen GM, 2002, GASTROINTEST ENDOSC, V55, P784, DOI 10.1016/S0016-5107(02)70404-5; Bassi GS, 2004, J PROSTHET DENT, V91, P459, DOI 10.1016/j.prosdent.2004.02.018; BLEACH NR, 1993, CLIN OTOLARYNGOL, V18, P303, DOI 10.1111/j.1365-2273.1993.tb00853.x; Carrasco G, 2000, CRIT CARE, V4, P217, DOI 10.1186/cc697; Chun SY, 2012, GUT LIVER, V6, P464, DOI 10.5009/gnl.2012.6.4.464; Coman Roxana M, 2013, World J Gastrointest Endosc, V5, P369, DOI 10.4253/wjge.v5.i8.369; Gotoda T, 2014, GASTRIC CANCER, V17, P686, DOI 10.1007/s10120-013-0336-9; Luers JC, 2012, DEUT MED WOCHENSCHR, V137, P1045, DOI 10.1055/s-0032-1304952; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; Monkemuller K, 2010, FRONT GASTROINT RES, V27, P1; Muguruma N, 2012, ENDOSCOPY, V44, pE225, DOI 10.1055/s-0032-1309351; Park CH, 2013, DIGEST DIS SCI, V58, P540, DOI 10.1007/s10620-012-2376-0; Tagaito Y, 1998, ANESTHESIOLOGY, V88, P1459, DOI 10.1097/00000542-199806000-00007; Tierney WM, 2003, GASTROINTESTINAL END, V58, pS3; Toyonaga T, 2010, Acta Chir Iugosl, V57, P41; Watari J, 2012, GASTROINTEST ENDOSC, V76, P1116, DOI 10.1016/j.gie.2012.07.043	29	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	SEP	2015	29	9					2561	2568		10.1007/s00464-014-3968-x		8	Surgery	Surgery	CP6PG	WOS:000360009100015		
J	Cuesta, MA; Weijs, TJ; Bleys, RLAW; van Hillegersberg, R; Henegouwen, MIV; Gisbertz, SS; Ruurda, JP; Straatman, J; Osugi, H; van der Peet, DL				Cuesta, Miguel A.; Weijs, Teus J.; Bleys, Ronald L. A. W.; van Hillegersberg, Richard; Henegouwen, Mark I. van Berge; Gisbertz, Suzanne S.; Ruurda, Jelle P.; Straatman, Jennifer; Osugi, Harushi; van der Peet, Donald L.			A new concept of the anatomy of the thoracic oesophagus: the meso-oesophagus. Observational study during thoracoscopic esophagectomy	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article; Proceedings Paper	ISDE Congress	2014	Vancouver, CANADA	ISDE		Oesophagus; Meso-oesophagus; Anatomy; Surgical resection; Thoracoscopy	CANCER	During thoracoscopic oesophageal surgery, we observed not previously described fascia-like structures. Description of similar structures in rectal cancer surgery was of paramount importance in improving the quality of resection. Therefore, we aimed to describe a new comprehensive concept of the surgical anatomy of the thoracic oesophagus with definition of the meso-oesophagus. We retrospectively evaluated 35 consecutive unedited videos of thoracoscopic oesophageal resections for cancer, to determine the surgical anatomy of the oesophageal fascia's vessels and lymphatic drainage. The resulting concept was validated in a prospective study, including 20 patients at three different centres. Additional confirmation was sought by a histologic study of a cadaver's thorax. A thin layer of connective tissue around the infracarinal oesophagus, involving the lymph nodes at the level of the carina, was observed during thoracoscopic esophagectomy in 32 of the 35 patients included in the retrospective study and in 19 of the 20 patients included in the prospective study. A thick fascia-like structure from the upper thoracic aperture to the lower thoracic aperture was visualized in all patients. This fascia is encountered between the descending aorta and left aspect of the infracarinal oesophagus. Above the carina it expands on both sides of the oesophagus to lateral mediastinal structures. This fascia contains oesophageal vessels, lymph vessels and nodes and nerves. The histologic study confirmed these findings. Here we described the concept of the "meso-oesophagus". Applying the description of the meso-oesophagus will create a better understanding of the oesophageal anatomy, leading to more adequate and reproducible surgery.	[Cuesta, Miguel A.; Straatman, Jennifer; van der Peet, Donald L.] Vrije Univ Amsterdam, Med Ctr, Dept Surg, NL-1081 HV Amsterdam, Netherlands; [Weijs, Teus J.; Bleys, Ronald L. A. W.] Univ Med Ctr, Dept Anat, Utrecht, Netherlands; [van Hillegersberg, Richard; Ruurda, Jelle P.] Univ Med Ctr, Dept Surg, Utrecht, Netherlands; [Henegouwen, Mark I. van Berge; Gisbertz, Suzanne S.] Univ Amsterdam, Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands; [Osugi, Harushi] Osaka City Univ, Sch Med, Dept Surg Gastroenterol, Osaka 558, Japan	Cuesta, MA (reprint author), Vrije Univ Amsterdam, Med Ctr, Dept Surg, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	ma.cuesta@vumc.nl	Weijs, Teus/B-9101-2013	Weijs, Teus/0000-0002-1814-5537			Luketich JD, 2012, ANN SURG, V256, P95, DOI 10.1097/SLA.0b013e3182590603; Biere SSAY, 2012, LANCET, V379, P1887, DOI 10.1016/S0140-6736(12)60516-9; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Brugger PC, 2011, ULTRASOUND OBST GYN, V38, P568, DOI 10.1002/uog.9002; Metzger R, 2011, SEMIN PEDIATR SURG, V20, P136, DOI 10.1053/j.sempedsurg.2011.03.004; SALASSA JR, 1977, ANN THORAC SURG, V24, P100; HEALD RJ, 1986, LANCET, V1, P1479; Bancroft JD, 1984, MANUAL HISTOLOGICAL; DAVIS EDD, 1948, ANN ROY COLL SURG, V3, P139; Gray H, 2000, ANATOMY HUMAN BODY; Healy JE, 1969, SYNOPSIS CLIN ANATOM; Izon AS, 2013, ANN SURG ONCOL, V20, P788, DOI 10.1245/s10434-012-2659-x; Kluth D, 2003, PEDIAT SURG, V12, P3; Liebermann-Meffert D, 2001, DIS ESOPHAGUS, V14, P81, DOI 10.1046/j.1442-2050.2001.00160.x; MARCHAND P, 1951, THORAX, V6, P359, DOI 10.1136/thx.6.4.359; Matsubara T, 1998, J AM COLL SURGEONS, V187, P238, DOI 10.1016/S1072-7515(98)00159-8; Netter FH, 1948, CIBA COLLECTION MED, V5th; Oezcelik A, 2011, THORAC SURG CLIN, V21, P289, DOI 10.1016/j.thorsurg.2011.01.003; Pinotti HW, 1999, ACESSO AO ESOFAGO TO; Riddell AM, 2007, AM J ROENTGENOL, V188, P37; Rouviere H, 1930, PRECIS ANATOMIE DISS; Sato T, 1992, COLOR ATLAS SURG ANA; Spalteholz W, 1903, HANDATLAS ANATOMIE M; Testut L, 1895, TRAITE ANATOMIE HUMA; Vesalius A, 1998, FABRIC HUMAN BODY	25	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	SEP	2015	29	9					2576	2582		10.1007/s00464-014-3972-1		7	Surgery	Surgery	CP6PG	WOS:000360009100017		
J	Scholvinck, DW; Herrero, LA; Goto, O; Meijer, SL; Neuhaus, H; Schumacher, B; Bergman, JJGHM; Weusten, BLAM				Scholvinck, D. W.; Herrero, L. Alvarez; Goto, O.; Meijer, S. L.; Neuhaus, H.; Schumacher, B.; Bergman, J. J. G. H. M.; Weusten, B. L. A. M.			Efficacy and safety of a novel submucosal lifting gel used for endoscopic submucosal dissection: a study in a porcine model	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Endoscopic submucosal dissection; Injection fluid; Gastric neoplasia; Swine	MUCOSAL RESECTION; LEARNING-CURVE; HYDROXYPROPYL METHYLCELLULOSE; FLUID CUSHION; INJECTION; EMR; TRIAL; NEOPLASMS; BLOOD	Endoscopic submucosal dissection (ESD) is technically demanding. A viscous gel for submucosal lifting might induce mechanical submucosal dissection facilitating easier and safer ESD. In 12 female pigs (median 64 kg), ESDs of simulated lesions were performed at the posterior wall and greater curvature in the gastric body (one ESD per location) with randomly assigned injection fluids: gel or control fluid (0.9 % saline with hydroxypropyl methylcellulose 3 mg/ml [7:1] and indigo carmine droplets). Additionally, 10 cc gel was injected into the submucosa at the anterior wall without ESD to assess effects of inappropriate injection. Pigs were euthanized at day 0, 3 or 28. In four additional pigs (euthanized day 3 or 28) 10 cc gel was injected into the muscularis propria (MP) after four endoscopic mucosal resections in the gastric body. Both fluid groups showed equal ESD-procedure times (28 [gel] vs. 26 min [control]) and complications. Gel-ESDs required less accessory interchanges (3.5 vs. 5.5; p = 0.01). Mechanical dissection after circumferential incision was achieved in 25 % of gel-ESDs; none in control-ESDs. The severity of inflammation and fibrosis was equal in both fluid groups. Normal architecture and vital mucosa were found after inappropriate submucosal injection. MP-injections resulted in one transmural hematoma (day 3), and intramuscular encapsulation in 25 % of the sites (day 28). A pig's stomach differs from the human stomach. The mechanical dissection properties of the gel may reduce the need for submucosal dissection during ESD. The gel is safe when advertently injected in the submucosa and MP. The porcine model appeared suboptimal to evaluate the true mechanical dissection properties of the gel.	[Scholvinck, D. W.; Herrero, L. Alvarez; Weusten, B. L. A. M.] St Antonius Hosp, Dept Gastroenterol & Hepatol, NL-3435 CM Nieuwegein, Netherlands; [Scholvinck, D. W.; Herrero, L. Alvarez; Bergman, J. J. G. H. M.; Weusten, B. L. A. M.] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands; [Goto, O.] Keio Univ, Ctr Canc, Sch Med, Div Res & Dev Minimally Invas Treatment, Tokyo, Japan; [Meijer, S. L.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Neuhaus, H.] Evangel Krankenhaus Dusseldorf, Dept Gastroenterol, Dusseldorf, Germany; [Schumacher, B.] Elisabeth Hosp, Dept Internal Med & Gastroenterol, Essen, Germany	Scholvinck, DW (reprint author), St Antonius Hosp, Dept Gastroenterol & Hepatol, Koekoekslaan 1, NL-3435 CM Nieuwegein, Netherlands.	d.scholvink@antoniusziekenhuis.nl			Cook Medical, Limerick, Ireland	The authors thank Elly van Zwol, Sanne Hackmann, Alwin Blankestijn, and Hester de Bruin for their biotechnical assistance. This study was supported by Cook Medical, Limerick, Ireland. Prof. J.J.G.H.M. Bergman is a consultant for Cook Medical and received speaker fees from Cook Medical. Prof. H. Neuhaus is a consultant for Cook Medical.	Akagi T, 2011, GASTROINTEST ENDOSC, V74, P1026, DOI 10.1016/j.gie.2011.07.042; Probst A, 2012, ENDOSCOPY, V44, P660, DOI 10.1055/s-0032-1309403; Cao Y, 2009, ENDOSCOPY, V41, P751, DOI 10.1055/s-0029-1215053; Lenz Luciano, 2010, Arquivos de Gastroenterologia, V47, P184, DOI 10.1590/S0004-28032010000200013; Park YM, 2011, SURG ENDOSC, V25, P2666, DOI 10.1007/s00464-011-1627-z; Lian JJ, 2012, GASTROINTEST ENDOSC, V76, P763, DOI 10.1016/j.gie.2012.06.014; Yamamoto H, 2008, GASTROINTEST ENDOSC, V67, P830, DOI 10.1016/j.gie.2007.07.039; Feitoza AB, 2003, GASTROINTEST ENDOSC, V57, P41, DOI 10.1067/mge.2003.25; Hotta K, 2010, DIGEST ENDOSC, V22, P302, DOI 10.1111/j.1443-1661.2010.01005.x; Fujishiro M, 2004, ENDOSCOPY, V36, P579, DOI 10.1055/s-2004-814517; Moss A, 2010, AM J GASTROENTEROL, V105, P2375, DOI 10.1038/ajg.2010.319; Uraoka T, 2005, GASTROINTEST ENDOSC, V61, P736, DOI 10.1016/S0016-5107(05)00321-4; Kakushima N, 2006, ENDOSCOPY, V38, P991, DOI 10.1055/s-2006-944808; Chandrasekhara V, 2013, SURG ENDOSC, V27, P3039, DOI 10.1007/s00464-013-2813-y; Fernandez-Esparrach G, 2009, GASTROINTEST ENDOSC, V69, P1135, DOI 10.1016/j.gie.2008.07.032; Giday SA, 2006, ENDOSCOPY, V38, P1230, DOI 10.1055/s-2006-944971; Khashab MA, 2013, GASTROENTEROLOGY, V144, P505, DOI 10.1053/j.gastro.2013.01.005; Kodashima S, 2006, J CLIN GASTROENTEROL, V40, P378, DOI 10.1097/00004836-200605000-00004; Lee SH, 2006, GASTROINTEST ENDOSC, V64, P691, DOI 10.1016/j.gie.2006.07.032; Mitchell RN, 2003, ROBBINS BASIC PATHOL, P61; Samarasena JB, 2013, GASTROINTEST ENDOSC, V77, pAB189; Sato T, 2006, DIS COLON RECTUM, V49, P1636, DOI 10.1007/s10350-006-0680-5; Saxena P, 2014, ENDOSCOPY, V46, P605, DOI 10.1055/s-0034-1365406; Zhao JB, 2008, J BIOMECH, V41, P3441, DOI 10.1016/j.jbiomech.2008.09.008	24	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	SEP	2015	29	9					2651	2660		10.1007/s00464-014-3985-9		10	Surgery	Surgery	CP6PG	WOS:000360009100028		
J	Yamada, T; Hirota, M; Tsutsui, S; Kato, M; Takahashi, T; Yasuda, K; Sumiyama, K; Tsujii, M; Takehara, T; Mori, M; Doki, Y; Nakajima, K				Yamada, Takuya; Hirota, Masashi; Tsutsui, Shusaku; Kato, Motohiko; Takahashi, Tsuyoshi; Yasuda, Kazuhiro; Sumiyama, Kazuki; Tsujii, Masahiko; Takehara, Tetsuo; Mori, Masaki; Doki, Yuichiro; Nakajima, Kiyokazu			Gastric endoscopic submucosal dissection under steady pressure automatically controlled endoscopy (SPACE); a multicenter randomized preclinical trial	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						SPACE; ESD; Early gastric cancer; GI; Endoscopy; Technical	CO2 INSUFFLATION; SURGERY NOTES	Steady pressure automatically controlled endoscopy (SPACE) is a new modality that eliminates on-demand insufflation but enables automatic insufflation in the gastrointestinal tract. Though its use in porcine esophageal ESD was reported to be promising, its applicability and potential effectiveness to gastric procedures have not been evaluated. The aims were (1) to evaluate feasibility and safety of SPACE in the stomach, and (2) to assess its potential advantages over conventional endoscopy in preventing "blind insufflation"-related complications. A multicenter randomized preclinical animal study. Laboratories at three universities. Experiment 1: Gastric ESD was attempted in the swine (n = 17), under either SPACE or manual insufflation. Experiment 2: Gastroscopy was performed for 10 min in the perforated stomach (n = 10) under either SPACE or manual insufflation. Experiment 1: ESD time, energy device activation time, number of forceps exchanges, specimen size, en block resection rate, vital signs and any intraoperative adverse events. Experiment 2: Intra-gastric and intra-abdominal pressures, vital signs, and any adverse events. Experiment 1: Gastric ESD was completed in all animals. ESD time tended to be shorter in SPACE than in the control, though the difference was not significant (p = 0.18). Experiment 2: Although both intra-gastric and intra-abdominal pressures remained within preset values in SPACE, they showed excessive elevation in control. An animal study with small sample size. SPACE is feasible and safe for complicated and lengthy procedures such as gastric ESD, and is potentially effective in preventing serious consequences related to excessive blind insufflation.	[Yamada, Takuya; Kato, Motohiko; Tsujii, Masahiko; Takehara, Tetsuo] Osaka Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Osaka, Japan; [Hirota, Masashi; Nakajima, Kiyokazu] Osaka Univ, Ctr Adv Med Engn & Informat, Div Collaborat Res Next Generat Endoscop Interven, Suita, Osaka 5650871, Japan; [Hirota, Masashi; Takahashi, Tsuyoshi; Mori, Masaki; Doki, Yuichiro; Nakajima, Kiyokazu] Osaka Univ, Dept Surg Gastroenterol, Grad Sch Med, Osaka, Japan; [Tsutsui, Shusaku] Itami City Hosp, Dept Gastroenterol & Hepatol, Itami, Hyogo, Japan; [Yasuda, Kazuhiro] Tenshindo Hetsugi Hosp, Dept Surg, Oita, Japan; [Sumiyama, Kazuki] Jikei Univ, Dept Endoscopy, Minato, Tokyo, Japan	Nakajima, K (reprint author), Osaka Univ, Ctr Adv Med Engn & Informat, Div Collaborat Res Next Generat Endoscop Interven, 2-2,M-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yamtak@gh.med.osaka-u.ac.jp; knakajima@gesurg.med.osaka-u.ac.jp			Top, Co., Ltd. (Tokyo, Japan); Fujifilm Corp. (Tokyo, Japan)	The co-author Kiyokazu Nakajima has received research funding from Top, Co., Ltd. (Tokyo, Japan) and Fujifilm Corp. (Tokyo, Japan).	Meireles O, 2007, SURG ENDOSC, V21, P998, DOI 10.1007/s00464-006-9167-7; Chung IK, 2009, GASTROINTEST ENDOSC, V69, P1228, DOI 10.1016/j.gie.2008.09.027; Imagawa A, 2006, ENDOSCOPY, V38, P987, DOI 10.1055/s-2006-944716; McGee MF, 2007, SURG ENDOSC, V21, P672, DOI 10.1007/s00464-006-9124-5; Nakajima K, 2010, GASTROINTEST ENDOSC, V72, P1036, DOI 10.1016/j.gie.2010.07.002; Navarro-Ripoll R, 2012, GASTROINTEST ENDOSC, V76, P388, DOI 10.1016/j.gie.2011.10.015; von Delius S, 2007, ENDOSCOPY, V39, P854, DOI 10.1055/s-2007-966920	7	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	SEP	2015	29	9					2748	2755		10.1007/s00464-014-4001-0		8	Surgery	Surgery	CP6PG	WOS:000360009100040		
J	Teshima, J; Miyata, G; Kamei, T; Nakano, T; Abe, S; Katsura, K; Taniyama, Y; Sakurai, T; Hikage, M; Nakamura, T; Takaya, K; Zuguchi, M; Okamoto, H; Youhei, O; Ohuchi, N				Teshima, Jin; Miyata, Go; Kamei, Takashi; Nakano, Toru; Abe, Shigeo; Katsura, Kazunori; Taniyama, Yusuke; Sakurai, Tadashi; Hikage, Makoto; Nakamura, Takanobu; Takaya, Kai; Zuguchi, Masashi; Okamoto, Hiroshi; Youhei, Ozawa; Ohuchi, Noriaki			Comparison of short-term outcomes between prone and lateral decubitus positions for thoracoscopic esophagectomy	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Surgical; Technical; Thoracoscopy; GI; Cancer	MINIMALLY INVASIVE ESOPHAGECTOMY; SQUAMOUS-CELL CARCINOMA; MEDIASTINAL LYMPHADENECTOMY; NERVE PARALYSIS; MOBILIZATION; STAGE	Prone thoracoscopic esophagectomy was introduced at our institution from 2012. This study describes our experiences of the main differences between thoracoscopic esophagectomy in the prone and traditional left lateral decubitus positions together with an analysis of the short-term surgical outcomes. In total, 87 patients undergoing thoracoscopic esophagectomy between January 2012 and October 2013 at Tohoku University Hospital were enrolled; of these, 54 and 33 patients were operated in the prone (Group P) and lateral decubitus (Group L) positions, respectively. The background of the patients was similar, and there was no in-hospital mortality. There were no significant differences between the groups in terms of whole surgical duration, thoracic duration, and number of dissected lymph nodes. Total blood loss and thoracic estimated blood loss were significantly lower in Group P than Group L. Furthermore, postoperative pulmonary complications, intensive care unit stay, and hospital stay were significantly lower in Group P. Thoracoscopic esophagectomy in the prone position is feasible and safe. The prone position technique may be superior to conventional lateral decubitus position esophagectomy.	[Teshima, Jin; Miyata, Go; Kamei, Takashi; Nakano, Toru; Abe, Shigeo; Katsura, Kazunori; Taniyama, Yusuke; Sakurai, Tadashi; Hikage, Makoto; Nakamura, Takanobu; Takaya, Kai; Zuguchi, Masashi; Okamoto, Hiroshi; Youhei, Ozawa] Tohoku Univ, Grad Sch Med, Div Adv Surg Sci & Technol, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Ohuchi, Noriaki] Tohoku Univ, Grad Sch Med, Div Surg Oncol, Sendai, Miyagi 9808575, Japan	Teshima, J (reprint author), Tohoku Univ, Grad Sch Med, Div Adv Surg Sci & Technol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	jintesshy@yahoo.co.jp					Akaishi T, 1996, J THORAC CARDIOV SUR, V112, P1533, DOI 10.1016/S0022-5223(96)70012-0; Ng JM, 2011, CURR OPIN ANESTHESIO, V24, P37, DOI 10.1097/ACO.0b013e32834141f7; Ando N, 2012, ANN SURG ONCOL, V19, P68, DOI 10.1245/s10434-011-2049-9; Noshiro H, 2010, SURG ENDOSC, V24, P2965, DOI 10.1007/s00464-010-1072-4; Baba M, 1999, J AM COLL SURGEONS, V188, P231, DOI 10.1016/S1072-7515(98)00295-6; Yatabe T, 2013, SURG TODAY, V43, P386, DOI 10.1007/s00595-012-0375-6; Luketich JD, 2003, ANN SURG, V238, P486, DOI 10.1097/01.sla.0000089858.40725.68; Palanivelu C, 2006, J AM COLL SURGEONS, V203, P7, DOI 10.1016/j.jamcollsurg.2006.03.016; Fabian T, 2008, SURG ENDOSC, V22, P2485, DOI 10.1007/s00464-008-9799-x; Kato K, 2011, INT J RADIAT ONCOL, V81, P684, DOI 10.1016/j.ijrobp.2010.06.033; Yatabe T, 2010, J ANESTH, V24, P803, DOI 10.1007/s00540-010-0968-4; Taniyama Y, 2013, ANN THORAC SURG, V95, P1930, DOI 10.1016/j.athoracsur.2013.03.069; Gockel I, 2005, EJSO, V31, P277, DOI 10.1016/j.rjso.2004.10.007; Hulscher JBF, 1999, BRIT J SURG, V86, P1583, DOI 10.1046/j.1365-2168.1999.01333.x; Chang Andrew C, 2009, Thorac Surg Clin, V19, P333, DOI 10.1016/j.thorsurg.2009.06.002; Cuschieri A, 1992, J R Coll Surg Edinb, V37, P7; Cuschieri A, 1994, Endosc Surg Allied Technol, V2, P21; Ichikawa H, 2013, ANN SURG, V257, P873, DOI 10.1097/SLA.0b013e31826c87cd; Shitara Kohei, 2009, Gastrointest Cancer Res, V3, P66	19	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	SEP	2015	29	9					2756	2762		10.1007/s00464-014-4003-y		7	Surgery	Surgery	CP6PG	WOS:000360009100041		
J	Mori, H; Kobara, H; Nishiyama, N; Fujihara, S; Matsunaga, T; Ayaki, M; Chiyo, T; Masaki, T				Mori, Hirohito; Kobara, Hideki; Nishiyama, Noriko; Fujihara, Shintaro; Matsunaga, Tae; Ayaki, Maki; Chiyo, Taiga; Masaki, Tsutomu			Simple and reliable treatment for post-EMR artificial ulcer floor with snare cauterization for 10-to 20-mm colorectal polyps: a randomized prospective study (with video)	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Endoscopic mucosal resection; Delayed bleeding prevention; Snare cauterization; Clip closure; Medical costs	ENDOSCOPIC SUBMUCOSAL DISSECTION; COLONOSCOPIC POLYPECTOMY; LARGE SESSILE; DIAGNOSIS	Comparative studies on wound surface treatments after endoscopic mucosal resection (EMR) of 10- to 20-mm colorectal polyps have not been reported. We conducted a prospective trial of postoperative hemorrhage prevention measures after EMR of such polyps. Of 138 patients (397 polyps) who had undergone EMR, 62 patients (148 polyps) with 10- to 20-mm colorectal polyps were enrolled. Using the sealed envelope method, the subjects were randomly assigned to either a snare cauterization (75 polyps) or clip closure group (73 polyps). The primary assessment item was the wound surface treatment time (from immediately after polyp resection to wound surface treatment completion). The secondary assessment items were the incidence of delayed bleeding, perforation incidence 1-7 days after EMR, and difference in medical costs between the groups (University Hospital Medical Information Network: No. 000013473). The time required for wound surface treatment completion was 3.26 +/- A 1.57 min in the snare cauterization group and 12.7 +/- A 2.92 min in the clip closure group, thus demonstrating a significant difference (P = 0.0001). Delayed bleeding was observed in two patients in the clip group, but was not observed in the snare cauterization group (P = 0.098). The clip group required the use of 720 clips that cost \523,410, US $5,163.50, or a,not sign3,665.5. After EMR of with 10- to 20-mm colorectal polyps, snare cauterization was superior to clip closure in terms of procedure time, and medical costs, and not inferior to clip closure in terms of the preventing effect of delayed bleeding.	[Mori, Hirohito; Kobara, Hideki; Nishiyama, Noriko; Fujihara, Shintaro; Matsunaga, Tae; Ayaki, Maki; Chiyo, Taiga; Masaki, Tsutomu] Kagawa Univ, Fac Med, Dept Gastroenterol & Neurol, Miki, Kagawa 7610793, Japan; [Mori, Hirohito] Ehime Rosai Hosp, Dept Surg Gastroenterol, Niihama, Ehime 7928550, Japan	Mori, H (reprint author), Kagawa Univ, Fac Med, Dept Gastroenterol & Neurol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	hiro4884@med.kagawa-u.ac.jp					Liaquat H, 2013, GASTROINTEST ENDOSC, V77, P401, DOI 10.1016/j.gie.2012.10.024; Kaminski MF, 2014, ENDOSCOPY, V46, P435, DOI 10.1055/s-0034-1365348; Oka S, 2010, DIGEST ENDOSC, V22, P376, DOI 10.1111/j.1443-1661.2010.01016.x; Zauber AG, 2012, NEW ENGL J MED, V366, P687, DOI 10.1056/NEJMoa1100370; Repici A, 2012, ENDOSCOPY, V44, P27, DOI 10.1055/s-0031-1291387; Tanaka S, 2013, DIGEST ENDOSC, V25, P107, DOI 10.1111/den.12016; Horiuchi A, 2014, GASTROINTEST ENDOSC, V79, P417, DOI 10.1016/j.gie.2013.08.040; Shioji K, 2003, GASTROINTEST ENDOSC, V57, P691, DOI 10.1067/mge.2003.193; Uraoka T, 2013, J GASTROEN HEPATOL, V28, P406, DOI 10.1111/jgh.12099; Wanders LK, 2013, LANCET ONCOL, V14, P1337, DOI 10.1016/S1470-2045(13)70509-6; Jang HW, 2014, DIGEST DIS SCI, V59, P1520, DOI 10.1007/s10620-014-3090-x; Kim Bong Jin, 2014, Korean J Gastroenterol, V63, P276; Wallace MB, 2014, GASTROINTEST ENDOSC, VS0016-5107, P01795	13	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	SEP	2015	29	9					2818	2824		10.1007/s00464-014-3983-y		7	Surgery	Surgery	CP6PG	WOS:000360009100050		
J	Nakagiri, T; Inoue, M; Shintani, Y; Funaki, S; Kawamura, T; Minami, M; Ohta, M; Kadota, Y; Shiono, H; Okumura, M				Nakagiri, Tomoyuki; Inoue, Masayoshi; Shintani, Yasushi; Funaki, Soichiro; Kawamura, Tomohiro; Minami, Masato; Ohta, Mitsunori; Kadota, Yoshihisa; Shiono, Hiroyuki; Okumura, Meinoshin			Improved procedures and comparative results for video-assisted thoracoscopic extended thymectomy for myasthenia gravis	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Video-assisted thoracoscopic extended thymectomy (VATS-ET); Myasthenia gravis (MG); Thymoma; Indications; Minimal invasive surgery; Anti-acetylcholine receptor	SURGERY; THYMOMA	We previously introduced video-assisted thoracoscopic ET (VATS-ET) as a therapeutic option for MG with acceptable results. We have conducted further investigations to improve the procedure without deterioration of operative results, including myasthenia gravis (MG) remission rate and palliation rate. Here, we report the details of our current procedure, as well as surgical results and patient outcomes as compared with the original VATS-ET procedure. From January 2002 to September 2013, we performed a VATS-ET procedure with an anterior chest wall lifting method for 77 patients who had MG with or without a thymoma. During that period, we investigated the appropriate indications and improved the procedure. Our current indication for this procedure is MG with the anti-acetylcholine receptor antibody or sero-negative type, or MG with a thymoma < 5 cm in diameter without invasion to adjacent organs. With our procedure, the thymus and surrounding tissue are sufficiently resected using a bilateral thoracoscopic surgical method without neck incision. Remission and palliation rates were found to be equivalent to those obtained with the original VATS-ET procedure. VATS-ET is suitable for select patients with MG with or without a thymoma. In addition, our current method has shown to be effective while also offering cosmetic advantages as compared with the original, neck incision needed, VATS-ET method.	[Nakagiri, Tomoyuki; Inoue, Masayoshi; Shintani, Yasushi; Funaki, Soichiro; Kawamura, Tomohiro; Minami, Masato; Okumura, Meinoshin] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Suita, Osaka 5650871, Japan; [Ohta, Mitsunori; Kadota, Yoshihisa] Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Gen Thorac Surg, Habikino, Osaka, Japan; [Shiono, Hiroyuki] Kinki Univ, Fac Med, Nara Hosp, Dept Gen Thorac Surg, Ikoma, Nara, Japan	Nakagiri, T (reprint author), Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, 2-2 L5 Yamadaoka, Suita, Osaka 5650871, Japan.	gilly64@thoracic.med.osaka-u.ac.jp					Shiono H, 2009, SURG LAPARO ENDO PER, V19, P424, DOI 10.1097/SLE.0b013e3181c48242; Shigemura N, 2006, SURG ENDOSC, V20, P1614, DOI 10.1007/s00464-005-0614-7; Kimura T, 2013, EUR J CARDIO-THORAC, V44, pE214, DOI 10.1093/ejcts/ezt305; Koezuka S, 2013, ANN THORAC SURG, V95, pE67, DOI 10.1016/j.athoracsur.2012.08.065; MASAOKA A, 1981, ANN NY ACAD SCI, V377, P755, DOI 10.1111/j.1749-6632.1981.tb33773.x; Ohta M, 2003, ANN THORAC SURG, V76, P1310, DOI 10.1016/S0003-4975(03)00445-4; Yoshida S, 2011, ANN THORAC SURG, V92, P2246, DOI 10.1016/j.athoracsur.2011.05.031; Yu L, 2012, ANN THORAC SURG, V93, P240, DOI 10.1016/j.athoracsur.2011.04.043	8	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	SEP	2015	29	9					2859	2865		10.1007/s00464-014-3964-1		7	Surgery	Surgery	CP6PG	WOS:000360009100056		
J	Nishikawa, T; Urabe, D; Adachi, M; Isobe, M				Nishikawa, Toshio; Urabe, Daisuke; Adachi, Masaatsu; Isobe, Minoru			Multifunctionality of the N-Trichloroacetyl Group Developed in the Synthesis of Tetrodotoxin, a Puffer Fish Toxin	SYNLETT			English	Article						protecting groups; tetrodotoxin; trichloroacetamide; neighboring-group effects; protecting-group transformations	STEREOCONTROLLED SYNTHESIS; UNNATURAL ANALOG; NATURAL-PRODUCTS; REARRANGEMENT; (-)-5,11-DIDEOXYTETRODOTOXIN; (-)-TETRODOTOXIN; INTERMEDIATE; 8,11-DIDEOXYTETRODOTOXIN; CYCLIZATION; PACTAMYCIN	This account describes a serendipitous discovery and the development of unique reactions associated with trichloroacetamide during synthetic studies of tetrodotoxin in our laboratory. The reactions include site-selective hydroxylation using the neighboring-group participation of trichloroacetamide, guanidinylation from a trichloroacetamide, protecting-group transformation, and removal of the N-trichloroacetyl group. These studies indicate the importance of the total synthesis of densely functionalized natural products as a field for the development of new reactions. 1 Introduction 2 Improvement of the Conditions for the Overman Rearrangement to Introduce Trichloroacetamide 3 Site-Selective Hydroxylation Using the Neighboring-Group Participation of Trichloroacetamide 4 Guanidine Synthesis 5 Protecting-Group Transformation of the N-Trichloroacetyl Group 6 New Deprotection Conditions for the Removal of the N-Trichloroacetyl Group 7 Conclusion	[Nishikawa, Toshio; Adachi, Masaatsu] Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Urabe, Daisuke] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; [Isobe, Minoru] Natl Sun Yat Sen Univ, Dept Chem, Kaohsiung 80424, Taiwan	Nishikawa, T (reprint author), Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.	nisikawa@agr.nagoya-u.ac.jp; minoru@mail.nsysu.edu.tw			MEXT; JST; Naito Foundation; Sumitomo Foundation; Nagase Science and Technology Foundation; Daiichi Sankyo Foundation	We gratefully thank all our co-workers for their significant contributions to the chemistry described in this account. Financial support provided by a Grand-in-Aid on the Innovative Area 'Chemical Biology of Natural Products',<SUP>32</SUP> Specially Promoted Research from MEXT, Presto 'Synthesis and Control' from JST, the Naito Foundation, the Sumitomo Foundation, the Nagase Science and Technology Foundation, and the Daiichi Sankyo Foundation is gratefully acknowledged.	Adachi M, 2014, CHEM-EUR J, V20, P1247, DOI 10.1002/chem.201304110; Adachi M, 2014, CHEM LETT, V43, P1719, DOI 10.1246/cl.140684; Adachi M, 2013, J ORG CHEM, V78, P1699, DOI 10.1021/jo302773f; Nie LD, 2013, TETRAHEDRON-ASYMMETR, V24, P638, DOI 10.1016/j.tetasy.2013.04.016; Narahashi T, 2008, P JPN ACAD B-PHYS, V84, P147, DOI 10.2183/pjab/84.147; Overman LE, 2005, ORG REACTIONS, V66, P1; Moczydlowski EG, 2013, TOXICON, V63, P165, DOI 10.1016/j.toxicon.2012.11.026; Diaba F, 2012, CHEM COMMUN, V48, P8799, DOI 10.1039/c2cc34133f; Schelhaas M, 1996, ANGEW CHEM INT EDIT, V35, P2056, DOI 10.1002/anie.199620561; Nishikawa T, 2001, TETRAHEDRON, V57, P3875, DOI 10.1016/S0040-4020(01)00258-7; Young IS, 2009, NAT CHEM, V1, P193, DOI [10.1038/nchem.216, 10.1038/NCHEM.216]; Nishikawa T, 1998, J ORG CHEM, V63, P188, DOI 10.1021/jo9713924; Takahashi K, 2012, ORG LETT, V14, P1644, DOI 10.1021/ol300431n; OVERMAN LE, 1974, J AM CHEM SOC, V96, P597, DOI 10.1021/ja00809a054; Satake Y, 2014, CHEM-ASIAN J, V9, P1922, DOI 10.1002/asia.201402202; Ueda M, 2012, CHEM LETT, V41, P658, DOI 10.1246/cl.2012.658; Li Q, 2013, ORG LETT, V15, P2601, DOI 10.1021/ol4007713; Asai M, 2001, TETRAHEDRON, V57, P4543, DOI 10.1016/S0040-4020(01)00382-9; ATANASSOVA IA, 1987, SYNTHESIS-STUTTGART, P734; Donohoe TJ, 1999, J ORG CHEM, V64, P2980, DOI 10.1021/jo982468e; Eguchi T, 1997, J SYN ORG CHEM JPN, V55, P814; Hoffmann RW, 2006, SYNTHESIS-STUTTGART, P3531, DOI 10.1055/s-2006-950311; Kang SH, 2005, CHEM REV, V105, P4537, DOI 10.1021/cr040608g; Kociensld P. J., 2005, PROTECTING GROUPS; Matsumoto N, 2012, RSC ADV, V2, P9448, DOI 10.1039/c2ra21060f; NAGASHIMA H, 1984, J CHEM SOC CHEM COMM, P652, DOI 10.1039/c39840000652; Nishikawa T, 2002, ORG LETT, V4, P2679, DOI 10.1021/ol026177a; Nishikawa T, 1999, TETRAHEDRON, V55, P4325, DOI 10.1016/S0040-4020(99)00140-4; Nishikawa T, 2006, ORG LETT, V8, P3263, DOI 10.1021/ol061123c; Nishikawa T, 1999, ANGEW CHEM INT EDIT, V38, P3081, DOI 10.1002/(SICI)1521-3773(19991018)38:20<3081::AID-ANIE3081>3.0.CO;2-6; Nishikawa T, 2013, CHEM REC, V13, P286, DOI 10.1002/tcr.201200025; Nishikawa T, 2004, CHEM-EUR J, V10, P452, DOI 10.1002/chem.200305111; Nishikawa T, 2010, B CHEM SOC JPN, V83, P66, DOI 10.1246/bcsj.20090223; Oishi T, 2002, ORG LETT, V4, P151, DOI 10.1021/ol0171620; Saicio RN, 2014, TETRAHEDRON, V70, P8183, DOI 10.1016/j.tet.2014.06.025; Satake Y, 2010, SYNTHESIS-STUTTGART, P1992, DOI 10.1055/s-0029-1218747; Seigal BA, 2005, J AM CHEM SOC, V127, P16329, DOI 10.1021/ja055806j; TAKEDA K, 1992, TETRAHEDRON LETT, V33, P7145, DOI 10.1016/S0040-4039(00)60858-4; Tsujimoto T, 2005, SYNLETT, P433, DOI 10.1055/s-2004-837223; Urabe D, 2006, CHEM-ASIAN J, V1, P125, DOI 10.1002/asia.200600038; Urabe D, 2004, TETRAHEDRON LETT, V45, P9405, DOI 10.1016/j.tetlet.2004.10.099; WEYGAND F, 1970, CHEM BER-RECL, V103, P2437, DOI 10.1002/cber.19701030816; Wuts P., 2014, GREENES PROTECTIVE G; Xu C, 2012, J ORG CHEM, V77, P6307, DOI 10.1021/jo300776d; YAMAMOTO N, 1994, CHEM LETT, P2299, DOI 10.1246/cl.1994.2299	45	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0936-5214	1437-2096		SYNLETT	Synlett	SEP	2015	26	14					1930	1939		10.1055/s-0034-1380781		10	Chemistry, Organic	Chemistry	CP6LH	WOS:000359998200003		
J	Monguchi, Y; Ichikawa, T; Netsu, M; Hattori, T; Mizusaki, T; Sawama, Y; Sajiki, H				Monguchi, Yasunari; Ichikawa, Tomohiro; Netsu, Moeko; Hattori, Tomohiro; Mizusaki, Tomoteru; Sawama, Yoshinari; Sajiki, Hironao			Tertiary-Amino-Functionalized Resin-Supported Palladium Catalyst for the Heterogeneous Suzuki-Miyaura Reaction of Aryl Chlorides	SYNLETT			English	Article						arenes; aryl chlorides; cross-coupling; heterogeneous catalysis; palladium	COUPLING REACTIONS; LIGAND-FREE; CARBON-CARBON; SYNTHETIC ADSORBENT; AQUEOUS-MEDIA; WATER; NANOPARTICLES; SONOGASHIRA; EFFICIENT; HECK	A palladium catalyst supported on a tertiary-amino-functionalized resin bearing N,N-dimethylamino substituents on the polystyrene-divinylbenzene-based resin was developed. The catalyst was effectively used for the ligand-free Suzuki-Miyaura reactions of less-reactive chloroarenes with arylboronic acids. No leached palladium species were detected in the reaction media after the reaction.	[Monguchi, Yasunari; Ichikawa, Tomohiro; Netsu, Moeko; Hattori, Tomohiro; Sawama, Yoshinari; Sajiki, Hironao] Gifu Pharmaceut Univ, Organ Chem Lab, Gifu 5011196, Japan; [Mizusaki, Tomoteru] NE Chemcat Corp, Catalyst Dev Ctr, Chem Catalysts R&D Dept, Ibaraki 3060608, Japan	Monguchi, Y (reprint author), Gifu Pharmaceut Univ, Organ Chem Lab, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.	monguchi@gifu-pu.ac.jp; sajiki@gifu-pu.ac.jp					Choudary BM, 2002, J AM CHEM SOC, V124, P14127, DOI 10.1021/ja026975w; MIYAURA N, 1995, CHEM REV, V95, P2457, DOI 10.1021/cr00039a007; Das P, 2011, TETRAHEDRON LETT, V52, P1176, DOI 10.1016/j.tetlet.2011.01.009; Jin MJ, 2010, ANGEW CHEM INT EDIT, V49, P1119, DOI 10.1002/anie.200905626; Phan NTS, 2006, ADV SYNTH CATAL, V348, P609, DOI 10.1002/adsc.200505473; McNamara CA, 2002, CHEM REV, V102, P3275, DOI 10.1021/cr0103571; Lamblin M, 2010, ADV SYNTH CATAL, V352, P33, DOI 10.1002/adsc.200900765; Sayah R, 2007, ADV SYNTH CATAL, V349, P373, DOI 10.1002/adsc.200600286; Lee DH, 2009, ADV SYNTH CATAL, V351, P2912, DOI 10.1002/adsc.200900495; LeBlond CR, 2001, ORG LETT, V3, P1555, DOI 10.1021/ol015850d; Monguchi Y, 2012, CHEMCATCHEM, V4, P546, DOI 10.1002/cctc.201100345; Wu L, 2006, ORG LETT, V8, P3605, DOI 10.1021/ol0614424; Yin LX, 2007, CHEM REV, V107, P133, DOI 10.1021/cr0505674; Yuan BZ, 2010, ANGEW CHEM INT EDIT, V49, P4054, DOI 10.1002/anie.201000576; Climent MJ, 2011, CHEM REV, V111, P1072, DOI 10.1021/cr1002084; Maegawa T, 2007, CHEM-EUR J, V13, P5937, DOI 10.1002/chem.200601795; Tagata T, 2003, J ORG CHEM, V68, P9412, DOI 10.1021/jo034970r; Yamada YMA, 2012, J AM CHEM SOC, V134, P3190, DOI 10.1021/ja210772v; Li G, 2011, GREEN CHEM, V13, P2939, DOI 10.1039/c1gc15757d; Karimi B, 2011, INORG CHEM, V50, P6063, DOI 10.1021/ic2000766; Monguchi Y, 2009, CHEM-EUR J, V15, P834, DOI 10.1002/chem.200801989; Choi M, 2009, ANGEW CHEM INT EDIT, V48, P3673, DOI 10.1002/anie.200806334; Kitamura Y, 2007, TETRAHEDRON, V63, P10596, DOI 10.1016/j.tet.2007.08.017; Arvela RK, 2005, ORG LETT, V7, P2101, DOI 10.1021/0503384; Choi M., 2009, ANGEW CHEM, V121, P3727; Ciriminna R, 2012, RSC ADV, V2, P10798, DOI 10.1039/c2ra21298f; Hattori T, 2015, CATALYSTS, V5, P18, DOI 10.3390/catal5010018; Jin M.J., 2010, ANGEW CHEM, V122, P1137; Kitamura Y, 2007, CHEM COMMUN, P5069, DOI 10.1039/b712207a; Kitamura Y, 2010, ADV SYNTH CATAL, V352, P718, DOI 10.1002/adsc.200900638; Kogan V, 2002, ORG LETT, V4, P3529, DOI 10.1021/ol026689p; Molnár Árpád, 2011, Chem Rev, V111, P2251, DOI 10.1021/cr100355b; Ohtaka A, 2013, CHEMCATCHEM, V5, P2167, DOI 10.1002/cctc.201300204; Pandarus V, 2013, ORG PROCESS RES DEV, V17, P1492, DOI 10.1021/op400118f; Sajiki H, 2005, J CHEM RES-S, P344; Sajiki H., 2005, SYNTHESIS-STUTTGART, P537; Sajiki H, 2005, SYNTHESIS-STUTTGART, P852; Sajiki H., 2004, J CHEM RES, P593; Schweizer S, 2007, ORG LETT, V9, P3777, DOI 10.1021/ol701460z; Yuan B., 2010, ANGEW CHEM, V122, P4148	40	1	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0936-5214	1437-2096		SYNLETT	Synlett	SEP	2015	26	14					2014	2018		10.1055/s-0034-1380443		5	Chemistry, Organic	Chemistry	CP6LH	WOS:000359998200017		
J	Hamasaka, G; Tsuji, H; Uozumi, Y				Hamasaka, Go; Tsuji, Hiroaki; Uozumi, Yasuhiro			Organoborane-Catalyzed Hydrogenation of Unactivated Aldehydes with a Hantzsch Ester as a Synthetic NAD(P)H Analogue	SYNLETT			English	Article						alcohols; aldehydes; hydrogenation; NADH analogues; organoboranes	ASYMMETRIC TRANSFER HYDROGENATION; NADH MODEL-COMPOUND; CARBONYL-COMPOUNDS; ZINC ION; ALPHA,BETA-UNSATURATED ALDEHYDES; BIOMIMETIC REDUCTION; AROMATIC-ALDEHYDES; HYDRIDE DONORS; BRONSTED ACID; METAL-FREE	We have developed a method for the hydrogenation of unactivated aldehydes, using a Hantzsch ester as a NAD(P)H analogue in the presence of an electron-deficient triarylborane as a Lewis acid catalyst. Thus, tris[3,5-bis(trifluoromethyl)phenyl]borane efficiently catalyzes the hydrogenation of aliphatic aldehydes with a Hantzsch ester in 1,4-dioxane at 100 degrees C to give the corresponding aliphatic primary alcohols in up to 97% yield. Aromatic aldehydes also undergo the hydrogenation, even at 25 degrees C, to furnish the corresponding aromatic primary alcohols in up to 100% yield.	[Hamasaka, Go; Tsuji, Hiroaki; Uozumi, Yasuhiro] Inst Mol Sci, Okazaki, Aichi 4448787, Japan; [Hamasaka, Go; Tsuji, Hiroaki; Uozumi, Yasuhiro] SOKENDAI, Okazaki, Aichi 4448787, Japan; [Uozumi, Yasuhiro] RIKEN Ctr Sustainable Resource Sci, Green Nanocatalysis Res Team, Wako, Saitama 3510198, Japan	Uozumi, Y (reprint author), Inst Mol Sci, 5-1 Higashiyama, Okazaki, Aichi 4448787, Japan.			Hamasaka, Go/0000-0001-9582-0324	JST-ACCEL program; JST-CREST program	This research project was supported by JST-ACCEL and JST-CREST programs.	Piers WE, 1997, CHEM SOC REV, V26, P345, DOI 10.1039/cs9972600345; Zheng C, 2012, CHEM SOC REV, V41, P2498, DOI 10.1039/c1cs15268h; Yang JW, 2005, ANGEW CHEM INT EDIT, V44, P108, DOI 10.1002/anie.200462432; Chatterjee I, 2015, ANGEW CHEM INT EDIT, V54, P1965, DOI 10.1002/anie.201409246; Mahdi T, 2014, J AM CHEM SOC, V136, P15809, DOI 10.1021/ja508829x; Jarboe LR, 2011, APPL MICROBIOL BIOT, V89, P249, DOI 10.1007/s00253-010-2912-9; McSkimming A, 2013, CHEM SOC REV, V42, P5439, DOI 10.1039/c3cs35466k; Webb JD, 2010, CHEM-EUR J, V16, P4895, DOI 10.1002/chem.200903005; FUKUZUMI S, 1986, TETRAHEDRON, V42, P1021, DOI 10.1016/S0040-4020(01)87507-4; Piers WE, 2005, ADV ORGANOMET CHEM, V52, P1, DOI 10.1016/S0065-3055(04)52001-4; Dimitrijevic E, 2013, ACS CATAL, V3, P945, DOI 10.1021/cs4000848; Oestreich M, 2015, CHEM SOC REV, V44, P2202, DOI 10.1039/c4cs00451e; Scott DJ, 2014, J AM CHEM SOC, V136, P15813, DOI 10.1021/ja5088979; Rueping M, 2011, GREEN CHEM, V13, P1084, DOI 10.1039/c1gc15027h; Kataoka M, 2003, APPL MICROBIOL BIOT, V62, P437, DOI 10.1007/s00253-003-1347-y; You SL, 2007, CHEM-ASIAN J, V2, P820, DOI 10.1002/asia.200700081; Erker G, 2005, DALTON T, P1883, DOI 10.1039/b503688g; AWANO H, 1985, J CHEM SOC CHEM COMM, P994, DOI 10.1039/c39850000994; Berg J.M., 2002, BIOCHEMISTRY; CAZIN J, 1986, TETRAHEDRON LETT, V27, P2375, DOI 10.1016/S0040-4039(00)84533-5; CREIGHTO.DJ, 1971, J AM CHEM SOC, V93, P6314, DOI 10.1021/ja00752a079; CREIGHTON DJ, 1976, J AM CHEM SOC, V98, P4619, DOI 10.1021/ja00431a047; DELOUX L, 1993, CHEM REV, V93, P763, DOI 10.1021/cr00018a007; Duggan PJ, 2002, J CHEM SOC PERK T 1, P1325, DOI 10.1039/b006767i; DUPAS G, 1982, TETRAHEDRON LETT, V23, P5141, DOI 10.1016/S0040-4039(00)85780-9; ENGBERSEN JFJ, 1988, BIOORG CHEM, V16, P215, DOI 10.1016/0045-2068(88)90010-7; FUKUZUMI S, 1985, J CHEM SOC CHEM COMM, P1069, DOI 10.1039/c39850001069; GELBARD G, 1992, J ORG CHEM, V57, P1789, DOI 10.1021/jo00032a035; Herrington TJ, 2012, DALTON T, V41, P9019, DOI 10.1039/c2dt30384a; Hoffmann S, 2005, ANGEW CHEM INT EDIT, V44, P7424, DOI 10.1002/anie.200503062; HOOD RA, 1979, J CHEM SOC CHEM COMM, P163, DOI 10.1039/c39790000163; HUGHES M, 1978, J INORG NUCL CHEM, V40, P703, DOI 10.1016/0022-1902(78)80395-9; Ishihara K, 1999, EUR J ORG CHEM, P527; Ishihara K, 2005, BORONIC ACIDS: PREPARATION AND APPLICATIONS IN ORGANIC SYNTHESIS AND MEDICINE, P377, DOI 10.1002/3527606548.ch10; ISHIKAWA M, 1990, J CHEM SOC CHEM COMM, P1353, DOI 10.1039/c39900001353; KURODA K, 1993, J CHEM SOC PERK T 1, P547, DOI 10.1039/p19930000547; Mathis R., 1981, TETRAHEDRON LETT, V22, P55; OHNISHI Y, 1978, TETRAHEDRON LETT, P4033; OHNO A, 1982, TETRAHEDRON LETT, V23, P3185, DOI 10.1016/S0040-4039(00)88591-3; Ouellet SG, 2007, ACCOUNTS CHEM RES, V40, P1327, DOI 10.1021/ar7001864; Rabinovitch-Deere CA, 2013, CHEM REV, V113, P4611, DOI 10.1021/cr300361t; Rueping M, 2010, SYNLETT, P852, DOI 10.1055/s-0029-1219528; SHINKAI S, 1979, TETRAHEDRON LETT, P1397; SHIRAI M, 1975, B CHEM SOC JPN, V48, P1079, DOI 10.1246/bcsj.48.1079; Yang JW, 2004, ANGEW CHEM INT EDIT, V43, P6660, DOI 10.1002/anie.200461816; Yang JW, 2006, ORG LETT, V8, P5653, DOI 10.1021/ol0624373	46	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0936-5214	1437-2096		SYNLETT	Synlett	SEP	2015	26	14					2037	2041		10.1055/s-0034-1378846		5	Chemistry, Organic	Chemistry	CP6LH	WOS:000359998200022		
J	Fujino, K; Obara, M; Ikegaya, T; Tamura, K				Fujino, Kenji; Obara, Mari; Ikegaya, Tomohito; Tamura, Kenichi			Genetic shift in local rice populations during rice breeding programs in the northern limit of rice cultivation in the world	THEORETICAL AND APPLIED GENETICS			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; LOW-TEMPERATURE GERMINABILITY; ALLELIC DIVERSITY CHANGES; QUANTITATIVE TRAIT LOCUS; CONTROLLING HEADING DATE; ORYZA-SATIVA L.; 10 GENOME TYPES; ARABIDOPSIS-THALIANA; GENUS ORYZA; IDENTIFICATION	The rapid accumulation of pre-existing mutations may play major roles in the establishment and shaping of adaptability for local regions in current rice breeding programs. The cultivated rice, Oryza sativa L., which originated from tropical regions, is now grown worldwide due to the concerted efforts of breeding programs. However, the process of establishing local populations and their origins remain unclear. In the present study, we characterized DNA polymorphisms in the rice variety KITAAKE from Hokkaido, one of the northern limits of rice cultivation in the world. Indel polymorphisms were attributed to transposable element-like insertions, tandem duplications, and non-TE deletions as the original mutation events in the NIPPONBARE and KITAAKE genomes. The allele frequencies of the KITAAKE alleles markedly shifted to the current variety types among the local population from Hokkaido in the last two decades. The KITAAKE alleles widely distributed throughout wild rice and cultivated rice over the world. These have accumulated in the local population from Hokkaido via Japanese landraces as the ancestral population of Hokkaido. These results strongly suggested that combinations of pre-existing mutations played a role in the establishment of adaptability. This approach using the re-sequencing of local varieties in unique environmental conditions will be useful as a genetic resource in plant breeding programs in local regions.	[Fujino, Kenji; Obara, Mari; Ikegaya, Tomohito; Tamura, Kenichi] Natl Agr Res Org, NARO Hokkaido Agr Res Ctr, Sapporo, Hokkaido 0628555, Japan	Fujino, K (reprint author), Natl Agr Res Org, NARO Hokkaido Agr Res Ctr, Sapporo, Hokkaido 0628555, Japan.	kfujino@affrc.go.jp			Ministry of Agriculture, Forestry and Fisheries of Japan (Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry)	This work was supported in part by a grant from the Ministry of Agriculture, Forestry and Fisheries of Japan (Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry).	Huang XH, 2012, NATURE, V490, P497, DOI 10.1038/nature11532; Fujino K, 2008, P NATL ACAD SCI USA, V105, P12623, DOI 10.1073/pnas.0805303105; Zhu QH, 2005, NEW PHYTOL, V167, P249, DOI 10.1111/j.1469-8137.2005.01406.x; Fu YB, 2003, CROP SCI, V43, P1989; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/nmeth.1363, 10.1038/NMETH.1363]; Ammiraju JSS, 2006, GENOME RES, V16, P140, DOI 10.1101/gr.3766306; Gunther T, 2010, THEOR APPL GENET, V121, P157, DOI 10.1007/s00122-010-1299-4; Le Clerc V, 2005, THEOR APPL GENET, V110, P294, DOI 10.1007/s00122-004-1834-2; Ebana K, 2008, BREEDING SCI, V58, P281, DOI 10.1270/jsbbs.58.281; Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336; Fujino K, 2013, THEOR APPL GENET, V126, P611, DOI 10.1007/s00122-012-2005-5; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Arai-Kichise Y, 2011, PLANT CELL PHYSIOL, V52, P274, DOI 10.1093/pcp/pcr003; Kojima Y, 2005, BREEDING SCI, V55, P431, DOI 10.1270/jsbbs.55.431; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Shinada H, 2014, THEOR APPL GENET, V127, P995, DOI 10.1007/s00122-014-2274-2; Nagasaki H, 2010, BREEDING SCI, V60, P648, DOI 10.1270/jsbbs.60.648; Roussel V, 2005, THEOR APPL GENET, V111, P162, DOI 10.1007/s00122-005-2014-8; Alonso-Blanco C, 1999, P NATL ACAD SCI USA, V96, P4710, DOI 10.1073/pnas.96.8.4710; Ammiraju JSS, 2008, PLANT CELL, V20, P3191, DOI 10.1105/tpc.108.063727; Fujino K, 2004, THEOR APPL GENET, V108, P794, DOI 10.1007/s00122-003-1509-4; Arai-Kichise Y, 2014, PLOS ONE, V21; Buntjer JB, 1997, PHYLOGENETIC COMPUTE; DILDAY RH, 1990, CROP SCI, V30, P905; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Fujino K, 2005, MOL GENET GENOMICS, V273, P150, DOI 10.1007/s00438-005-1131-z; Fujino K, 2005, THEOR APPL GENET, V111, P393, DOI 10.1007/s00122-005-2035-3; Fujino K, 2011, THEOR APPL GENET, V123, P1089, DOI 10.1007/s00122-011-1650-4; Fujino K, 2005, BREEDING SCI, V55, P141, DOI 10.1270/jsbbs.55.141; Fujino K, 2011, PLANT MOL BIOL, V75, P1, DOI 10.1007/s11103-010-9697-1; Fujino K, 2008, BREEDING SCI, V58, P367, DOI 10.1270/jsbbs.58.367; Matsumoto T, 2005, NATURE, V436, P793, DOI 10.1038/nature03895; Kim H, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-2-r45; Kim SL, 2013, J EXP BOT, V64, P4169, DOI 10.1093/jxb/ert226; Nonoue Y, 2008, THEOR APPL GENET, V116, P715, DOI 10.1007/s00122-007-0704-0; Nordborg Magnus, 2005, PLoS Biol, V3, pe196, DOI 10.1371/journal.pbio.0030196; Schmid KJ, 2003, GENOME RES, V13, P1250, DOI 10.1101/gr.728603; Yamamoto T, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-267	40	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0040-5752	1432-2242		THEOR APPL GENET	Theor. Appl. Genet.	SEP	2015	128	9					1739	1746		10.1007/s00122-015-2543-8		8	Agronomy; Plant Sciences; Genetics & Heredity; Horticulture	Agriculture; Plant Sciences; Genetics & Heredity	CP4EW	WOS:000359835800007		
J	Han, LJ; Chen, J; Mace, ES; Liu, YS; Zhu, MJ; Yuyama, N; Jordan, DR; Cai, HW				Han, Lijie; Chen, Jun; Mace, Emma S.; Liu, Yishan; Zhu, Mengjiao; Yuyama, Nana; Jordan, David R.; Cai, Hongwei			Fine mapping of qGW1, a major QTL for grain weight in sorghum	THEORETICAL AND APPLIED GENETICS			English	Article							BICOLOR L. MOENCH; QUANTITATIVE TRAIT LOCI; SEED SIZE; SSR MARKERS; RICE; GENE; YIELD; GENOME; SEQUENCE; ENCODES	We detected seven QTLs for 100-grain weight in sorghum using an F (2) population, and delimited qGW1 to a 101-kb region on the short arm of chromosome 1, which contained 13 putative genes. Sorghum is one of the most important cereal crops. Breeding high-yielding sorghum varieties will have a profound impact on global food security. Grain weight is an important component of grain yield. It is a quantitative trait controlled by multiple quantitative trait loci (QTLs); however, the genetic basis of grain weight in sorghum is not well understood. In the present study, using an F-2 population derived from a cross between the grain sorghum variety SA2313 (Sorghum bicolor) and the Sudan-grass variety Hiro-1 (S. bicolor), we detected seven QTLs for 100-grain weight. One of them, qGW1, was detected consistently over 2 years and contributed between 20 and 40 % of the phenotypic variation across multiple genetic backgrounds. Using extreme recombinants from a fine-mapping F-3 population, we delimited qGW1 to a 101-kb region on the short arm of chromosome 1, containing 13 predicted gene models, one of which was found to be under purifying selection during domestication. However, none of the grain size candidate genes shared sequence similarity with previously cloned grain weight-related genes from rice. This study will facilitate isolation of the gene underlying qGW1 and advance our understanding of the regulatory mechanisms of grain weight. SSR markers linked to the qGW1 locus can be used for improving sorghum grain yield through marker-assisted selection.	[Han, Lijie; Chen, Jun; Liu, Yishan; Zhu, Mengjiao; Cai, Hongwei] China Agr Univ, Dept Plant Genet & Breeding, Coll Agron & Biotechnol, Beijing 100193, Peoples R China; [Han, Lijie; Chen, Jun; Liu, Yishan; Zhu, Mengjiao; Cai, Hongwei] Minist Agr, Beijing Key Lab Crop Genet Improvement & Genome, Beijing 100193, Peoples R China; [Mace, Emma S.] Dept Agr & Fisheries, Warwick, Qld 4370, Australia; [Yuyama, Nana; Cai, Hongwei] Japan Grassland Agr & Forage Seed Assoc, Forage Crop Res Inst, Nasushiobara, Tochigi 3292742, Japan; [Jordan, David R.] Univ Queensland, Queensland Alliance Agr & Food Innovat, Warwick, Qld 4370, Australia	Cai, HW (reprint author), China Agr Univ, Dept Plant Genet & Breeding, Coll Agron & Biotechnol, 2 Yuanmingyuan West Rd, Beijing 100193, Peoples R China.	caihw@cau.edu.cn					Abe Y, 2010, GENES GENET SYST, V85, P327, DOI 10.1266/ggs.85.327; Paterson AH, 2009, NATURE, V457, P551, DOI 10.1038/nature07723; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; Cheng WH, 1996, PLANT CELL, V8, P971, DOI 10.1105/tpc.8.6.971; Feltus FA, 2006, THEOR APPL GENET, V112, P1295, DOI 10.1007/s00122-006-0232-3; PATERSON AH, 1995, SCIENCE, V269, P1714, DOI 10.1126/science.269.5231.1714; Murray SC, 2008, CROP SCI, V48, P2165, DOI 10.2135/cropsci2008.01.0016; Wang E, 2008, NAT GENET, V40, P1370, DOI 10.1038/ng.220; Zhang XJ, 2012, P NATL ACAD SCI USA, V109, P21534, DOI 10.1073/pnas.1219776110; Sun LJ, 2013, J INTEGR PLANT BIOL, V55, P938, DOI 10.1111/jipb.12062; Ishimaru K, 2013, NAT GENET, V45, P707, DOI 10.1038/ng.2612; Nakagawa H, 2012, PLANT PHYSIOL, V158, P1208, DOI 10.1104/pp.111.187567; Hibberd JM, 2008, CURR OPIN PLANT BIOL, V11, P228, DOI 10.1016/j.pbi.2007.11.002; Voorrips RE, 2002, J HERED, V93, P77, DOI 10.1093/jhered/93.1.77; Bowers JE, 2003, GENETICS, V165, P367; Song XJ, 2007, NAT GENET, V39, P623, DOI 10.1038/ng2014; Manly KF, 2001, MAMM GENOME, V12, P930, DOI 10.1007/s00335-001-1016-3; TANKSLEY SD, 1993, ANNU REV GENET, V27, P205, DOI 10.1146/annurev.ge.27.120193.001225; Wang SK, 2012, NAT GENET, V44, P950, DOI 10.1038/ng.2327; Srinivas G, 2009, THEOR APPL GENET, V118, P1439, DOI 10.1007/s00122-009-0993-6; Rampling LR, 2001, AUST J AGR RES, V52, P1131, DOI 10.1071/AR01027; Yonemaru J, 2009, DNA RES, V16, P187, DOI 10.1093/dnares/dsp005; Bednarek J, 2012, J EXP BOT, V63, P5945, DOI 10.1093/jxb/ers249; Shiringani AL, 2010, THEOR APPL GENET, V121, P323, DOI 10.1007/s00122-010-1312-y; Weng JF, 2008, CELL RES, V18, P1199, DOI 10.1038/cr.2008.307; Li ML, 2009, MOL BREEDING, V24, P41, DOI 10.1007/s11032-009-9270-2; Li YB, 2011, NAT GENET, V43, P1266, DOI 10.1038/ng.977; Mace ES, 2011, THEOR APPL GENET, V123, P169, DOI 10.1007/s00122-011-1575-y; Schnable PS, 2009, SCIENCE, V326, P1112, DOI 10.1126/science.1178534; Fan CH, 2006, THEOR APPL GENET, V112, P1164, DOI 10.1007/s00122-006-0218-1; Rami JF, 1998, THEOR APPL GENET, V97, P605, DOI 10.1007/s001220050936; Zhang L, 2012, NEW PHYTOL, V195, P574, DOI 10.1111/j.1469-8137.2012.04194.x; Shomura A, 2008, NAT GENET, V40, P1023, DOI 10.1038/ng.169; Tilman D, 2001, SCIENCE, V292, P281, DOI 10.1126/science.1057544; Khush GS, 2005, PLANT MOL BIOL, V59, P1, DOI 10.1007/s11103-005-2159-5; Tuinstra MR, 1997, MOL BREEDING, V3, P439, DOI 10.1023/A:1009673126345; Brown PJ, 2006, THEOR APPL GENET, V113, P931, DOI 10.1007/s00122-006-0352-9; Charcosset A, 1996, THEOR APPL GENET, V93, P1193, DOI 10.1007/BF00223450; Darvasi A, 1997, MAMM GENOME, V8, P67, DOI 10.1007/s003359900353; Diouf J, 2009, POPUL DEV REV, V35, P837; DUNNINGTON EA, 1992, POULTRY SCI, V71, P1251; Gilbert N, 2009, NATURE, DOI [10.1038/news.2009.585, DOI 10.1038/NEWS.2009.585]; Hillel J, 1990, ANIM BIOTECHNOL, V2, P201; Matsumoto T, 2005, NATURE, V436, P793, DOI 10.1038/nature03895; Kitagawa K, 2010, PLANT CELL PHYSIOL, V51, P1315, DOI 10.1093/pcp/pcq092; Li Q, 2010, BMC PLANT BIOL, V10, DOI 10.1186/1471-2229-10-143; Mace ES, 2013, NATURE COMMUN, V4; MARANVILLE JW, 1977, AGRON J, V69, P329; McCouch SR, 1997, RICE GENET NEWSLETT, V14, P11, DOI DOI 10.1007/S10681-005-0449-2; Mullet JE, 2012, US Patent, Patent No. 8309793; Paterson A.H., 2008, INT J PLANT GENOMICS; PEREIRA MG, 1995, REV BRAS GENET, V18, P249; PLOTSKY Y, 1993, ANIM GENET, V24, P105; Rajkumar Fakrudin B, 2013, PHYSL MOL BIOL PLANT, V19, P409; Sakhi S, 2013, EUPHYTICA, V193, P433, DOI 10.1007/s10681-013-0963-6; Segami S, 2012, RICE, V5, DOI 10.1186/1939-8433-5-4; Shehzad T, 2015, EUPHYTICA, V203, P17, DOI 10.1007/s10681-014-1243-9; Upadhyaya HD, 2012, EUPHYTICA, V187, P401, DOI 10.1007/s10681-012-0726-9; Zhang D, 2015, G3-GENES GENOM GENET, V5, P1117, DOI 10.1534/g3.115.017590; Zuo JR, 2014, ANNU REV GENET, V48, P99, DOI 10.1146/annurev-genet-120213-092138	60	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0040-5752	1432-2242		THEOR APPL GENET	Theor. Appl. Genet.	SEP	2015	128	9					1813	1825		10.1007/s00122-015-2549-2		13	Agronomy; Plant Sciences; Genetics & Heredity; Horticulture	Agriculture; Plant Sciences; Genetics & Heredity	CP4EW	WOS:000359835800013		
J	Wakita, M; Kotani, N; Akaike, N				Wakita, Masahito; Kotani, Naoki; Akaike, Norio			Tetrodotoxin abruptly blocks excitatory neurotransmission in mammalian CNS	TOXICON			English	Article						Tetrodotoxin; External Na+; Neurotransmission; 'Synaptic-bouton' preparation; Focal electrical stimulation	PRESYNAPTIC NERVE-TERMINALS; RAT HIPPOCAMPAL-NEURONS; CA2+-PERMEABLE AMPA; RECEPTOR CHANNELS; SODIUM-CHANNELS; RELEASE; TRANSMISSION; GLUTAMATE; MODULATION; POTASSIUM	The present study utilised a 'synaptic bouton' preparation of mechanically isolated rat hippocampal CA3 pyramidal neurons, which permits direct physiological and pharmacological quantitative analyses at the excitatory and inhibitory single synapse level. Evoked excitatory and inhibitory postsynaptic currents (eEPSCs and eIPSCs) were generated by focal paired-pulse electrical stimulation of single boutons. The sensitivity of eEPSC to tetrodotoxin (TTX) was higher than that of the voltage-dependent Na+ channel whole-cell current (I-Na) in the postsynaptic CA3 soma membrane. The synaptic transmission was strongly inhibited by 3 nM TTX, at which concentration the I-Na was hardly suppressed. The IC50 values of eEPSC and I-Na for TTX were 2.8 and 37.9 nM, respectively, and complete inhibition was 3-10 nM for eEPSC and 1000 nM for I-Na. On the other hand, both eEPSC and eIPSC were equally and gradually inhibited by decreasing the external Na+ concentration ([Na](o)), which decreases the Na+ gradient across the cell membrane. The results indicate that TTX at 3-10 nM could block most of voltage-dependent Na+ channels on presynaptic nerve terminal, resulting in abruptly inhibition of action potential dependent excitatory neurotransmission. (C) 2015 Elsevier Ltd. All rights reserved.	[Wakita, Masahito; Akaike, Norio] Kumamoto Kinoh Hosp, Jyuryokai, Med Corp, Res Div Clin Pharmacol,Kita Ku, Kumamoto 8608518, Japan; [Wakita, Masahito; Akaike, Norio] Kumamoto Hlth Sci Univ, Res Div Life Sci, Kita Ku, Kumamoto 8615598, Japan; [Kotani, Naoki; Akaike, Norio] Kitamoto Hosp, Res Div Neurophysiol, Koshigaya 3430821, Japan	Akaike, N (reprint author), Kumamoto Hlth Sci Univ, Res Div Life Sci, Kita Ku, 325 Izumi Machi, Kumamoto 8615598, Japan.	akaike@kumamoto-hsu.ac.jp			Kumamoto Kinoh hospital; Kumamoto Health Science University	This work was supported by Grants-in-Aid from Kumamoto Kinoh hospital and Kumamoto Health Science University for M. Wakita and N. Akaike, respectively.	Aldana BI, 2012, J NEUROCHEM, V121, P197, DOI 10.1111/j.1471-4159.2012.07674.x; Engel D, 2005, NEURON, V45, P405, DOI 10.1016/j.neuron.2004.12.048; Wakita M, 2014, J PHARMACOL EXP THER, V348, P246, DOI 10.1124/jpet.113.208751; Wakita M, 2013, EUR J PHARMACOL, V718, P63, DOI [10.1016/j.ejphar.2013.09.018, 10.1010/j.ejphar.2013.09.018]; BLAUSTEIN MP, 1975, J PHYSIOL-LONDON, V247, P589; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547; MURASE K, 1989, NEUROSCI LETT, V103, P56, DOI 10.1016/0304-3940(89)90485-0; Westphalen RI, 2010, J NEUROCHEM, V113, P1611, DOI 10.1111/j.1471-4159.2010.06722.x; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; KOH DS, 1995, J PHYSIOL-LONDON, V485, P383; Koike M, 1997, NEUROSCI RES, V29, P27, DOI 10.1016/S0168-0102(97)00067-9; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325; Akaike N, 2003, TRENDS PHARMACOL SCI, V24, P44, DOI 10.1016/S0165-6147(02)00010-X; Wakita M, 2012, J PHARMACOL EXP THER, V341, P809, DOI 10.1124/jpet.111.189126; Lai J, 2004, ANNU REV PHARMACOL, V44, P371, DOI 10.1146/annurev.pharmtox.44.101802.121627; Maeda M, 2009, J NEUROPHYSIOL, V101, P1103, DOI 10.1152/jn.90483.2008; Akaike N, 2002, NEUROSCI RES, V42, P187, DOI 10.1016/S0168-0102(01)00320-0; BLAUSTEIN MP, 1975, J PHYSIOL-LONDON, V247, P617; Cotman C. W., 1976, J PHYSL, V245, P475; Jang IS, 2005, NEUROSCIENCE, V135, P737, DOI 10.1016/j.neuroscience.2005.06.030; Koyama S, 2002, LIFE SCI, V72, P375, DOI 10.1016/S0024-3205(02)02280-4; KRUEGER BK, 1980, J GEN PHYSIOL, V76, P287, DOI 10.1085/jgp.76.3.287; Murakami N, 2002, BRAIN RES, V951, P121, DOI 10.1016/S0006-8993(02)03148-7	24	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0041-0101			TOXICON	Toxicon	SEP 1	2015	103						12	18		10.1016/j.toxicon.2015.05.003		7	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	CP4YK	WOS:000359888300002		
J	Oyama, E; Takahashi, H				Oyama, Etsuko; Takahashi, Hidenobu			Purification and characterization of two high molecular mass snake venom metalloproteinases (P-III SVMPs), named SV-PAD-2 and HR-Ele-1, from the venom of Protobothrops elegans (Sakishima-habu)	TOXICON			English	Article						Snake venom; Metalloproteinases; Anti-coagulant	TRIMERESURUS-FLAVOVIRIDIS VENOM; PLATELET-AGGREGATION; CROTALUS-ATROX; CDNA CLONING; APOPTOSIS; PROTEINS; FAMILY; METALLOENDOPEPTIDASES; INSIGHTS; TOXINS	We herein identified two high molecular mass metalloproteinases, named SV-PAD-2 and HR-Ele-1, in the venom of Protobothrops elegans. HR-Ele-1 appeared as a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) regard under reducing and non-reducing conditions, and the molecular mass of this protease was approximately 60 kDa under reducing conditions. On the other hand, the molecular masses of SV-PAD-2 on SDS-PAGE were 110 kDa under the non-reducing condition and 52 kDa under the reducing condition. These SVMPs exhibited fibrinogenolytic and enzymatic activities against synthetic substrates for matrix metalloproteinases (MMPs) and the insulin B-chain, and were both inhibited by EDTA. SV-PAD-2 inhibited ADP- and collagen-induced platelet aggregation, with IC50 values of 240 nM and 185 nM, respectively. HR-Ele-1 exhibited hemorrhagic activity, and its minimum hemorrhagic dose (MHD) was 0.05 mu g in the guinea pig. (C) 2015 Elsevier Ltd. All rights reserved.	[Oyama, Etsuko] Meiji Pharmaceut Univ, Dept Hyg Chem, Tokyo 2048588, Japan; [Takahashi, Hidenobu] Meiji Pharmaceut Univ, Tokyo 2048588, Japan	Oyama, E (reprint author), Meiji Pharmaceut Univ, Dept Hyg Chem, 2-522-1 Noshio, Tokyo 2048588, Japan.	oyama@my-pharm.ac.jp					Takeda S, 2012, BBA-PROTEINS PROTEOM, V1824, P164, DOI 10.1016/j.bbapap.2011.04.009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Kang TS, 2011, FEBS J, V278, P4544, DOI 10.1111/j.1742-4658.2011.08115.x; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; Trummal K, 2005, TOXICON, V46, P46, DOI 10.1016/j.toxicon.2005.03.008; Masuda S, 1997, BIOCHEM BIOPH RES CO, V235, P59, DOI 10.1006/bbrc.1997.6728; Fox JW, 2008, FEBS J, V275, P3016, DOI 10.1111/j.1742-4658.2008.06466.x; Fox JW, 2005, TOXICON, V45, P969, DOI 10.1016/j.toxicon.2005.02.012; TAKEYA H, 1992, J BIOL CHEM, V267, P14109; BJARNASON JB, 1978, BIOCHEMISTRY-US, V17, P3395, DOI 10.1021/bi00609a033; Doolittle R. F., 1967, BIOCHIM BIOPHYS ACTA, V118, P456; Kikushima E, 2008, TOXICON, V52, P589, DOI 10.1016/j.toxicon.2008.06.027; Kishimoto M, 2002, TOXICON, V40, P1369, DOI 10.1016/S0041-0101(02)00179-4; Lee C.-Y, 1979, HDB EXPT PHARM, V52, P480; Masuda S, 2001, EUR J BIOCHEM, V268, P3339, DOI 10.1046/j.1432-1327.2001.02246.x; Masuda S, 2000, BIOCHEM BIOPH RES CO, V278, P197, DOI 10.1006/bbrc.2000.3770; OBRIEN JR, 1964, J CLIN PATHOL, V17, P275, DOI 10.1136/jcp.17.3.275; OMORISATOH T, 1979, BIOCHIM BIOPHYS ACTA, V580, P392, DOI 10.1016/0005-2795(79)90151-X; Oyama E, 2009, TOXICON, V53, P706, DOI 10.1016/j.toxicon.2009.02.016; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; Sajevic T, 2013, BIOCHIMIE, V95, P1158, DOI 10.1016/j.biochi.2013.01.003; Samel M, 2012, TOXICON, V60, P648, DOI 10.1016/j.toxicon.2012.03.023; TAKEYA H, 1993, METHOD ENZYMOL, V223, P365; TAKEYA H, 1990, J BIOL CHEM, V265, P16068; Wan SG, 2006, TOXICON, V47, P480, DOI 10.1016/j.toxicon.2006.01.006	26	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0041-0101			TOXICON	Toxicon	SEP 1	2015	103						30	38		10.1016/j.toxicon.2015.06.010		9	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	CP4YK	WOS:000359888300004		
J	Isozaki, T; Ishii, S; Nishimi, S; Nishimi, A; Oguro, N; Seki, S; Miura, Y; Miwa, Y; Oh, K; Toyoshima, Y; Nakamura, M; Inagaki, K; Kasama, T				Isozaki, Takeo; Ishii, Sho; Nishimi, Shinichiro; Nishimi, Airi; Oguro, Nao; Seki, Shinya; Miura, Yoko; Miwa, Yusuke; Oh, Koei; Toyoshima, Yoichiro; Nakamura, Masanori; Inagaki, Katsunori; Kasama, Tsuyoshi			A disintegrin and metalloprotease-10 is correlated with disease activity and mediates monocyte migration and adhesion in rheumatoid arthritis	TRANSLATIONAL RESEARCH			English	Article							MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; NECROSIS-FACTOR; SYNOVIAL FIBROBLASTS; CHEMOTACTIC CYTOKINE; TNF-ALPHA; ANTI-TNF; FRACTALKINE; ADAM10; CHEMOKINE; ADAM-10	A disintegrin and metalloproteases (ADAMs) are a family of proteins that have been reported to be involved in several inflammatory conditions. We examined the secretion of ADAM-10 in biological fluids from patients with rheumatoid arthritis (RA) and the role it plays in monocyte migration. ADAM-10 levels were measured using enzyme-linked immunosorbent assays and immunofluorescence. To examine the role of ADAM-10 in RA synovial fluids (SFs), we studied THP-1 (human acute monocyte leukemia cell line) and monocyte chemotaxis. To determine whether ADAM-10 plays a role in cell proliferation in the RA synovium, we assayed the proliferation of ADAM-10 small interfering RNA (siRNA)-transfected RA fibroblast-like synoviocytes (FLSs). The ADAM-10 level in RA serum was significantly higher than that in normal serum and was correlated with a disease activity score of 28. ADAM-10-depleted RA SFs showed a decrease in THP-1 and monocyte migratory activity compared with that of sham-depleted controls. ADAM-10 siRNA inhibited monocyte adhesion to RA FLSs. Finally, blocking ADAM-10 secretion in RA FLSs resulted in decreased production of fractalkine/CX3CL1 and vascular endothelial cell growth factor. These data indicate that ADAM-10 plays a role in monocyte migration in RA and suggest that targeting ADAM-10 may provide a method of decreasing inflammation and potentially treating other inflammatory diseases.	Showa Univ Sch Med, Dept Med, Shinagawa Ku, Tokyo, Japan; Showa Univ Sch Med, Dept Orthoped, Shinagawa Ku, Tokyo, Japan	Isozaki, T (reprint author), Showa Univ Sch Med, Dept Med, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428666, Japan.	t.isozaki@med.showa-u.ac.jp					Ludwig A, 2005, COMB CHEM HIGH T SCR, V8, P161, DOI 10.2174/1386207053258488; Lee A, 2013, ARTHRITIS RHEUM-US, V65, P928, DOI 10.1002/art.37853; Weinblatt ME, 2003, ARTHRITIS RHEUM, V48, P35, DOI 10.1002/art.10697; Gomez-Reino JJ, 2012, ANN RHEUM DIS, V71, P382, DOI 10.1136/annrheumdis-2011-200302; Huber LC, 2006, RHEUMATOLOGY, V45, P669, DOI 10.1093/rheumatology/kel065; KOCH AE, 1994, J CLIN INVEST, V94, P1012, DOI 10.1172/JCI117414; BRENNAN FM, 1989, LANCET, V2, P244; Schulz B, 2008, CIRC RES, V102, P1192, DOI 10.1161/CIRCRESAHA.107.169805; Ruth JH, 2006, ARTHRITIS RHEUM, V54, P765, DOI 10.1002/art.21662; KOCH AE, 1994, J CLIN INVEST, V93, P921, DOI 10.1172/JCI117097; Wang YY, 2011, J SURG ONCOL, V103, P116, DOI 10.1002/jso.21781; Matsunawa M, 2006, ARTHRITIS RHEUM, V54, P3408, DOI 10.1002/art.22208; Badolato R, 1996, SEMIN ARTHRITIS RHEU, V26, P526, DOI 10.1016/S0049-0172(96)80041-2; Chatzidionysiou K, 2013, SCAND J RHEUMATOL, V42, P190, DOI 10.3109/03009742.2012.729607; Abel S, 2004, J IMMUNOL, V172, P6362; Rocks N, 2008, BIOCHIMIE, V90, P369, DOI 10.1016/j.biochi.2007.08.008; Isozaki T, 2013, ARTHRITIS RHEUM-US, V65, P98, DOI 10.1002/art.37755; Grabowska MM, 2012, CELL SIGNAL, V24, P532, DOI 10.1016/j.cellsig.2011.10.004; Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001; Ruth JH, 2001, ARTHRITIS RHEUM, V44, P1568, DOI 10.1002/1529-0131(200107)44:7<1568::AID-ART280>3.0.CO;2-1; Hong KJ, 2014, J CELL PHYSIOL, V229, P191, DOI 10.1002/jcp.24434; Tanida S, 2009, CYTOKINE, V47, P112, DOI 10.1016/j.cyto.2009.05.009; Volin MV, 2001, AM J PATHOL, V159, P1521, DOI 10.1016/S0002-9440(10)62537-0; Choy EHS, 2001, NEW ENGL J MED, V344, P907; Hanyuda M, 2003, RHEUMATOLOGY, V42, P1390, DOI 10.1093/rheumatology/keg391; Hurst LA, 2012, NEUROSCI LETT, V521, P52, DOI 10.1016/j.neulet.2012.05.057; Isozaki T, 2013, ARTHRITIS RHEUM-US, V65, P1736, DOI 10.1002/art.37981; Nagara Y, 2012, BIOCHEM BIOPH RES CO, V417, P462, DOI 10.1016/j.bbrc.2011.11.140; Oh ST, 2008, BRIT J DERMATOL, V158, P1371, DOI 10.1111/j.1365-2133.2008.08513.x; Plasencia C, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4258; Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093; Ruth JH, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3055; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Yang K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083853	34	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1931-5244	1878-1810		TRANSL RES	Transl. Res.	SEP	2015	166	3					244	253		10.1016/j.trsl.2015.02.005		10	Medical Laboratory Technology; Medicine, General & Internal; Medicine, Research & Experimental	Medical Laboratory Technology; General & Internal Medicine; Research & Experimental Medicine	CP4VV	WOS:000359881600004		
J	Meng, HX; Li, HN; Geng, JS; Ohe, R; Yu, XY; E, XQ; Ye, F; Yang, SR; Kato, T; Zhang, L; Ishida, A; Ohta, N; Jin, XM; Kakehata, S; Geng, JS; Yamakawa, M				Meng, Hong-Xue; Li, Hui-Ning; Geng, Jia-Shi; Ohe, Rintaro; Yu, Xiao-Yu; E, Xiao-Qiang; Ye, Fei; Yang, Su-Ran; Kato, Tomoya; Zhang, Lei; Ishida, Akihiro; Ohta, Nobuo; Jin, Xiao-Ming; Kakehata, Seiji; Geng, Jing-Shu; Yamakawa, Mitsunori			Decreased expression of follicular dendritic cell-secreted protein correlates with increased immunoglobulin A production in the tonsils of individuals with immunoglobulin A nephropathy	TRANSLATIONAL RESEARCH			English	Article							IGA NEPHROPATHY; B-CELLS; FDC-SP; OXFORD CLASSIFICATION; TONSILLECTOMY; PROGRESSION; DEPOSITION; DISEASE	Immunoglobulin A nephropathy (IgAN) is characterized by a qualitative abnormality of IgA in the circulation and IgA deposition in the renal mesangium. Recent research has indicated that pathogenic IgA may originate from affected tonsils. Follicular dendritic cell-secreted protein (FDC-SP), a small novel secretory protein that may regulate the induction of B-cell responses, has been suggested to control IgA production. Given this background, this study investigated the expression of FDC-SP and its correlation with IgA production in the tonsils of IgAN patients. lmmunohisto-chemistry and reverse transcription-polymerase chain reaction were used to compare the expression of FDC-SP in the tonsils of IgAN patients with tonsillitis and of non-IgAN patients with chronic tonsillitis. The location of FDC-SP in tonsillar tissue was confirmed by double immunofluorescence. We found that FDC-SP expression significantly decreased and was correlated negatively with enhanced IgA production in the tonsils of IgAN patients. FDC-SP secreted by follicular dendritic cells may act on germinal center B cells and participate in the modulation of IgA generation in the tonsils. Our study demonstrated that FDC-SP may be involved in IgA production in the tonsils of IgAN patients, making this protein an attractive candidate immunomodulator, and highlighting a promising strategy for therapeutic intervention in IgAN.	Harbin Med Univ Canc Hosp, Dept Pathol, Harbin, Peoples R China; Yamagata Univ Fac Med, Dept Pathol Diagnost, Yamagata, Japan; Hei Longjiang Univ Chinese Med, Dept Pathol, Affiliated Hosp 1, Harbin, Peoples R China; Harbin Med Univ Canc Hosp, Dept Radiol, Harbin, Peoples R China; Harbin Med Univ, Dept Orthoped, Affiliated Hosp 1, Harbin, Peoples R China; Harbin Med Univ, Dept Pathol, Harbin, Peoples R China; Yamagata Univ Fac Med, Dept Otolaryngol Head & Neck Surg, Yamagata, Japan	Meng, HX (reprint author), Harbin Med Univ Canc Hosp, Dept Pathol, 150 Haping Rd, Harbin, Peoples R China.	menghongxue15@163.com; k-moh@med.id.yamagata-u.ac.jp			Japan, Hai-Yan Foundation of Harbin Medical University Cancer Hospital [25460451]; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry; National Nature Science Foundation of China [81372785, 81301530, 81300584]	This work was supported by a Grant-in-Aid for Scientific Research (c) (25460451) in Japan, Hai-Yan Foundation of Harbin Medical University Cancer Hospital (Hong-Xue Meng), the Project Sponsored by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (Hong-Xue Meng), and National Nature Science Foundation of China (No. 81372785, No. 81301530, and No. 81300584, Hong-Xue Meng).	Al-Alwan M, 2007, J IMMUNOL, V178, P7859; Takemori T, 2014, EUR J IMMUNOL, V44, P1258, DOI 10.1002/eji.201343716; Zou YR, 2013, ADV IMMUNOL, V118, P1, DOI 10.1016/B978-0-12-407708-9.00001-7; Daha MR, 2013, NEPHROL DIAL TRANSPL, V28, P794, DOI 10.1093/ndt/gfs445; Huang HD, 2010, J NEPHROL, V23, P202; Macpherson AJ, 2012, TRENDS IMMUNOL, V33, P160, DOI 10.1016/j.it.2012.02.002; Brandtzaeg P, 2010, IMMUNOL INVEST, V39, P303, DOI 10.3109/08820131003680369; Cattran DC, 2009, KIDNEY INT, V76, P534, DOI 10.1038/ki.2009.243; Roberts ISD, 2009, KIDNEY INT, V76, P546, DOI 10.1038/ki.2009.168; Liu YY, 2014, INT UROL NEPHROL, V46, P1153, DOI 10.1007/s11255-013-0606-9; Matysiak-Budnik T, 2008, J EXP MED, V205, P143, DOI 10.1084/jem.20071204; El Shikh MEM, 2010, TRENDS IMMUNOL, V31, P205, DOI 10.1016/j.it.2010.03.002; Maeda I, 2012, NEPHROL DIAL TRANSPL, V27, P2806, DOI 10.1093/ndt/gfs053; Cerutti A, 2008, NAT REV IMMUNOL, V8, P421, DOI 10.1038/nri2322; Duan ZY, 2013, AM J NEPHROL, V38, P241, DOI 10.1159/000354646; El Shikh MEM, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00292; Hone A, 2003, AM J KIDNEY DIS, V42, P486; Hou S, 2014, MUCOSAL IMMUNOL, V7, P948, DOI 10.1038/mi.2013.113; Lafayette RA, 2014, TRANSL RES, V163, P3, DOI 10.1016/j.trsl.2013.08.007; Marshall AJ, 2002, J IMMUNOL, V169, P2381; Masieri S, 2013, CURR MED RES OPIN, V2, P203; Meng Hongxue, 2012, J Clin Exp Hematop, V52, P161; Moriyama T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091756; Nagasawa Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081636; Nakata J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089707; Ponticelli C, 2012, NEPHROL DIAL TRANSPL, V27, P2610, DOI 10.1093/ndt/gfs093; Sato Y, 1996, ACTA OTO-LARYNGOL, P189; Suzuki Y, 2014, CLIN EXP NEPHROL, V18, P770, DOI 10.1007/s10157-013-0921-6; Wang Y, 2014, TRANSPL P, V46, P607, DOI 10.1016/j.transproceed.2013.11.066; Yanagawa H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098081	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1931-5244	1878-1810		TRANSL RES	Transl. Res.	SEP	2015	166	3					281	291		10.1016/j.trsl.2015.04.004		11	Medical Laboratory Technology; Medicine, General & Internal; Medicine, Research & Experimental	Medical Laboratory Technology; General & Internal Medicine; Research & Experimental Medicine	CP4VV	WOS:000359881600007		
J	Akasaka, M; Osawa, T; Ikegami, M				Akasaka, Munemitsu; Osawa, Takeshi; Ikegami, Makihiko			The role of roads and urban area in occurrence of an ornamental invasive weed: a case of Rudbeckia laciniata L	URBAN ECOSYSTEMS			English	Article						Biological invasion; Distribution; Landscape planning; National park; Risk management	PLANT INVASIONS; SPECIES ATTRIBUTES; DISPERSAL; DISTRIBUTIONS; PERFORMANCE; FOREST; EXTENT; SIZE	Road density and proportion of urban area are considered to be useful indicators of invasion risk from non-native plants. However, the mechanisms behind the relationship between these indicators and establishment of non-native species have rarely been addressed explicitly. To identify these mechanisms, we used a species distribution model (MaxEnt) for an invasive ornamental weed Rudbeckia laciniata using road density and proportion of urban area as explanatory variables, along with soil moisture and solar radiation. Overall model performance is relatively high (AUC = 0.91). Road density explained most R. laciniata occurrence, followed by the proportion of urban area. The occurrence probability of R. laciniata increased monotonically with road density, but the rates of increase constantly fell. The occurrence probability also increased with urban area when the proportion of urban area was small, but started to decrease when the proportion of urban area reached 0.2. Our results suggest that both road density and proportion of urban area are important factors in determining R. laciniata establishment but work differently.	[Akasaka, Munemitsu] Tokyo Univ Agr & Technol, Inst Agr, Fuchu, Tokyo 1838509, Japan; [Akasaka, Munemitsu] Univ Queensland, Sch Biol Sci, Brisbane, Qld 4072, Australia; [Osawa, Takeshi] Natl Inst Agroenvironm Sci, Tsukuba, Ibaraki 3058604, Japan; [Ikegami, Makihiko] Lincoln Univ, Bioprotect Res Ctr, Canterbury 7647, New Zealand	Akasaka, M (reprint author), Tokyo Univ Agr & Technol, Inst Agr, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.	mail2muu@gmail.com					Akasaka M, 2012, J VEG SCI, V23, P33, DOI 10.1111/j.1654-1103.2011.01332.x; Akasaka M, 2005, J VEG SCI, V16, P647, DOI 10.1658/1100-9233(2005)016[0647:TSPIMA]2.0.CO;2; Sullivan JJ, 2005, NEW ZEAL J ECOL, V29, P1; Lockwood JL, 2005, TRENDS ECOL EVOL, V20, P223, DOI 10.1016/j.tree.2005.02.004; Hijmans RJ, 2000, CONSERV BIOL, V14, P1755, DOI 10.1046/j.1523-1739.2000.98543.x; Collingham YC, 2000, J APPL ECOL, V37, P13, DOI 10.1046/j.1365-2664.2000.00556.x; Richardson DM, 2007, DIVERS DISTRIB, V13, P126, DOI 10.1111/j.1472-4642.2006.00314.x; Hernandez PA, 2006, ECOGRAPHY, V29, P773, DOI 10.1111/j.0906-7590.2006.04700.x; Kadoya T, 2009, BIOL CONSERV, V142, P1011, DOI 10.1016/j.biocon.2009.01.012; Mack RN, 2001, BIOSCIENCE, V51, P95, DOI 10.1641/0006-3568(2001)051[0095:HAGPDG]2.0.CO;2; Callaway RM, 2000, SCIENCE, V290, P521, DOI 10.1126/science.290.5491.521; Chytry M, 2008, ECOLOGY, V89, P1541, DOI 10.1890/07-0682.1; Von der Lippe M, 2007, CONSERV BIOL, V21, P986, DOI 10.1111/j.1523-1739.2007.00722.x; Austin M, 2007, ECOL MODEL, V200, P1, DOI 10.1016/j.ecolmodel.2006.07.005; Wichmann MC, 2009, P R SOC B, V276, P523, DOI 10.1098/rspb.2008.1131; Foxcroft LC, 2008, ENVIRON MANAGE, V41, P32, DOI 10.1007/s00267-007-9027-9; Gelbard JL, 2003, CONSERV BIOL, V17, P420, DOI 10.1046/j.1523-1739.2003.01408.x; Gavier-Pizarro GI, 2010, ECOL APPL, V20, P1913, DOI 10.1890/09-2168.1; Phillips SJ, 2008, ECOGRAPHY, V31, P161, DOI 10.1111/j.0906-7590.2008.5203.x; Phillips SJ, 2006, ECOL MODEL, V190, P231, DOI 10.1016/j.ecolmodel.2005.03.026; Parendes LA, 2000, CONSERV BIOL, V14, P64, DOI 10.1046/j.1523-1739.2000.99089.x; Gasso N, 2009, DIVERS DISTRIB, V15, P50, DOI 10.1111/j.1472-4642.2008.00501.x; Borsic Igor, 2008, Natura Croatica, V17, P55; EPPO, 2009, EPPO REPORTING SERVI; Fu P, 2000, SOLAR ANAL 1 0 USER; Godefroid S, 2003, LANDSCAPE URBAN PLAN, V65, P169, DOI 10.1016/S0169-2046(03)00013-6; Holle B. V., 2005, ECOLOGY, V86, P3212, DOI DOI 10.1890/05-0427; Kanagawa plant research comittees, 2001, FLOR KAN 2001; Kim DW, 2007, KOREAN J APIC, V22, P9; Koike F, 2006, ASSESSMENT CONTROL B; Kolbek J, 1996, FOLIA GEOBOT PHYTOTX, V31, P207, DOI 10.1007/BF02812064; Kondo Toshihiro, 1999, Diversity and Distributions, V5, P223, DOI 10.1046/j.1472-4642.1999.00056.x; Margules CR, 2007, ECOL BIODIVERS CONS, P1; Osawa T., 2009, Japanese Journal of Conservation Ecology, V14, P37; Osawa T., 2007, Japanese Journal of Conservation Ecology, V12, P151; Osawa T., 2008, Japanese Journal of Conservation Ecology, V13, P179; Phillips S., 2005, BRIEF TUTORIAL MAXEN; Ripley BD, 2002, MODERN APPL STAT S; Statistics Hakone, 2014, STAT HAK; Torok K., 2003, Biological Invasions, V5, P349, DOI 10.1023/B:BINV.0000005570.19429.73; Usda NRCS, 2007, PLANTS DAT; von der Lippe M, 2008, DIVERS DISTRIB, V14, P18, DOI 10.1111/j.1472-4642.2007.00401.x; Walter J., 2005, NEOBIOTA, V6, P13; Wilson J. P., 2000, TERRAIN ANAL PRINCIP	44	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1083-8155	1573-1642		URBAN ECOSYST	Urban Ecosyst.	SEP	2015	18	3					1021	1030		10.1007/s11252-015-0466-4		10	Biodiversity Conservation; Ecology; Environmental Sciences; Urban Studies	Biodiversity & Conservation; Environmental Sciences & Ecology; Urban Studies	CP6SF	WOS:000360017700023		
J	Nagamine, E; Hirayama, K; Matsuda, K; Okamoto, M; Ohmachi, T; Kadosawa, T; Taniyama, H				Nagamine, E.; Hirayama, K.; Matsuda, K.; Okamoto, M.; Ohmachi, T.; Kadosawa, T.; Taniyama, H.			Diversity of Histologic Patterns and Expression of Cytoskeletal Proteins in Canine Skeletal Osteosarcoma	VETERINARY PATHOLOGY			English	Article						canine; osteosarcoma; cytoskeleton; pleomorphism; head; appendicular; immunohistochemistry	FIBRILLARY ACIDIC PROTEIN; EPITHELIOID OSTEOSARCOMA; APPENDICULAR OSTEOSARCOMA; PROGNOSTIC-FACTORS; BETA-CATENIN; FEATURES; BONE; RELEVANCE; TUMORS; DOGS	Osteosarcoma (OS), the most common bone tumor, includes OS of the head (OSH) and appendicular OS (OSA). In dogs, it is classified into 6 histologic subtypes: osteoblastic, chondroblastic, fibroblastic, telangiectatic, giant cell, and poorly differentiated. This study investigated the significance of the histologic classification relevant to clinical outcome and the histologic and immunohistochemical relationships between pleomorphism and expression of cytoskeletal proteins in 60 cases each of OSH and OSA. Most neoplasms exhibited histologic diversity, and 64% of OS contained multiple subtypes. In addition to the above 6 subtypes, myxoid, round cell, and epithelioid subtypes were observed. Although the epithelioid subtypes were observed in only OSH, no significant difference in the frequency of other subtypes was observed. Also, no significant relevance was observed between the clinical outcome and histologic subtypes. Cytokeratin (CK) was expressed in both epithelioid and sarcomatoid tumor cells in various subtypes, and all CK-positive tumor cells also expressed vimentin. Vimentin and a-smooth muscle actin (SMA) were expressed in all subtypes. A few SMA-positive spindle-shaped tumor cells exhibited desmin expression. Glial fibrillary acidic protein-positive tumor cells were observed in many subtypes, and some of these cells showed neurofilament expression. Although OSH exhibited significantly stronger immunoreactivity for SMA than OSA, no significant difference in other cytoskeletal proteins was observed. Some tumor cells had cytoskeletal protein expression compatible with the corresponding histologic subtypes, such as CK in the epithelioid subtype and SMA in the fibroblastic subtype. Thus, canine skeletal OS is composed of pleomorphic and heterogenous tumor cells as is reflected in the diversity of histologic patterns and expression of cytoskeletal proteins.	[Nagamine, E.; Hirayama, K.; Matsuda, K.; Okamoto, M.; Taniyama, H.] Rakuno Gakuen Univ, Sch Vet Med, Dept Vet Pathol, Ebetsu, Hokkaido 069, Japan; [Ohmachi, T.] PATHO LABO, Ito, Shizuoka, Japan; [Kadosawa, T.] Rakuno Gakuen Univ, Sch Vet Med, Dept Small Anim Clin Sci, Ebetsu, Hokkaido 069, Japan	Taniyama, H (reprint author), Rakuno Gakuen Univ, Sch Vet Med, Dept Vet Pathol, 582 Bunkyodai Midorimachi, Ebetsu, Hokkaido 069, Japan.	taniyama@rakuno.ac.jp					Hemingway F, 2012, VIRCHOWS ARCH, V460, P525, DOI 10.1007/s00428-012-1235-x; Bongiovanni L, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-78; Barresi V, 2006, ARCH PATHOL LAB MED, V130, P1208; Shoeneman JK, 2012, CANCER RES, V72, P249, DOI 10.1158/0008-5472.CAN-11-2315; DEXTER DL, 1978, CANCER RES, V38, P3174; Selvarajah GT, 2012, VET J, V193, P412, DOI 10.1016/j.tvjl.2012.02.009; Millanta F, 2012, J COMP PATHOL, V147, P153, DOI 10.1016/j.jcpa.2012.02.003; KNECHT CD, 1978, J AM VET MED ASSOC, V172, P72; Barut F, 2009, TURK NEUROSURG, V19, P417; Kirpensteijn J, 2002, VET PATHOL, V39, P240, DOI 10.1354/vp.39-2-240; HAMMER AS, 1995, J AM ANIM HOSP ASSOC, V31, P321; MISDORP W, 1979, J NATL CANCER I, V62, P537; Boerman I, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-56; BRODEY RS, 1969, CLIN ORTHOP RELAT R, P54; Carlos-Bregni R, 2008, ORAL SURG ORAL MED O, V105, P47; COHEN D, 1974, CANCER RES, V34, P2859; Dernell WS, 1998, J AM ANIM HOSP ASSOC, V34, P11; FRAZIER K, 1991, J AM VET MED ASSOC, V198, P432; HASEGAWA T, 1993, ARCH PATHOL LAB MED, V117, P295; Hasegawa T, 1997, CANCER DETECT PREV, V21, P280; HASEGAWA T, 1991, HUM PATHOL, V22, P583, DOI 10.1016/0046-8177(91)90236-I; HEYMAN SJ, 1992, VET SURG, V21, P304, DOI 10.1111/j.1532-950X.1992.tb00069.x; Kalil RK, 2013, WHO CLASSIFICATION T, P291; KASANTIKUL V, 1989, J SURG ONCOL, V41, P22, DOI 10.1002/jso.2930410109; Kaveri H, 2009, BRIT J ORAL MAX SURG, V47, P143, DOI 10.1016/j.bjoms.2008.07.188; KRAMER K, 1993, CANCER, V71, P2977, DOI 10.1002/1097-0142(19930515)71:10<2977::AID-CNCR2820711015>3.0.CO;2-U; Kruse MA, 2012, VET PATHOL, V50, P704; Loukopoulos P, 2007, J COMP PATHOL, V136, P65, DOI 10.1016/j.jcpa.2006.11.005; Loukopoulos P, 2003, VET PATHOL, V40, P237, DOI 10.1354/vp.40-3-237; Okada K, 2001, HUM PATHOL, V32, P726, DOI 10.1053/hupa.2001.25585; Okada K, 2003, J CLIN PATHOL, V56, P831, DOI 10.1136/jcp.56.11.831; Okada K, 2003, J CLIN PATHOL, V56, P742, DOI 10.1136/jcp.56.10.742; Oliveira AM, 2013, BONE, V4th, P289; Rinaggio J, 2007, HEAD NECK-J SCI SPEC, V29, P705, DOI 10.1002/hed.20575; Rosenberg AE, 2013, WHO CLASSIFICATION T, P282; Ru G, 1998, VET J, V156, P31, DOI 10.1016/S1090-0233(98)80059-2; Santos GC, 2009, MODERN PATHOL, V22, P1321, DOI 10.1038/modpathol.2009.99; Selvarajah GT, 2013, CELL STRESS CHAPERON, V18, P607, DOI 10.1007/s12192-013-0414-2; Slayter MV, 1994, WHO INT HISTOLOGIC C, V1; Stein TJ, 2011, VET COMP ONCOL, V9, P65, DOI 10.1111/j.1476-5829.2010.00236.x; Thompson K. G., 2002, Tumors in domestic animals, P245, DOI 10.1002/9780470376928.ch5; Yamamura H, 1998, INT J CANCER, V79, P245, DOI 10.1002/(SICI)1097-0215(19980619)79:3<245::AID-IJC6>3.0.CO;2-P	42	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	SEP	2015	52	5					977	984		10.1177/0300985815574006		8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	CP7PC	WOS:000360079200020		
J	Niu, QG; Takemura, Y; Kubota, K; Li, YY				Niu, Qigui; Takemura, Yasuyuki; Kubota, Kengo; Li, Yu-You			Comparing mesophilic and thermophilic anaerobic digestion of chicken manure: Microbial community dynamics and process resilience	WASTE MANAGEMENT			English	Article						Microbial community dynamic; Ammonia inhibition; Functional resilient; Chicken manure fermentation	MUNICIPAL SOLID-WASTE; POPULATION-DYNAMICS; MOORELLA-THERMOACETICA; METHANE FERMENTATION; SP-NOV; AMMONIA; STABILITY; INHIBITION; TEMPERATURE; METABOLISM	While methane fermentation is considered as the most successful bioenergy treatment for chicken manure, the relationship between operational performance and the dynamic transition of archaeal and bacterial communities remains poorly understood. Two continuous stirred-tank reactors were investigated under thermophilic and mesophilic conditions feeding with 10%TS. The tolerance of thermophilic reactor on total ammonia nitrogen (TAN) was found to be 8000 mg/L with free ammonia (FA) 2000 mg/L compared to 16,000 mg/L (FA1500 mg/L) of mesophilic reactor. Biomethane production was 0.29 L/gV S-in in the steady stage and decreased following TAN increase. After serious inhibition, the mesophilic reactor was recovered successfully by dilution and washing stratagem compared to the unrecoverable of thermophilic reactor. The relationship between the microbial community structure, the bioreactor performance and inhibitors such as TAN, FA, and volatile fatty acid was evaluated by canonical correspondence analysis. The performance of methanogenic activity and substrate removal efficiency were changed significantly correlating with the community evenness and phylogenetic structure. The resilient archaeal community was found even after serious inhibition in both reactors. Obvious dynamics of bacterial communities were observed in acidogenic and hydrolytic functional bacteria following TAN variation in the different stages. (C) 2015 Elsevier Ltd. All rights reserved.	[Niu, Qigui; Takemura, Yasuyuki; Kubota, Kengo; Li, Yu-You] Tohoku Univ, Grad Sch Engn, Dept Civil & Environm Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Li, Yu-You] Xian Univ Architecture & Technol, Key Lab Northwest Water Resource Environm & Ecol, MOE, Xian, Peoples R China	Li, YY (reprint author), Tohoku Univ, Grad Sch Engn, Dept Civil & Environm Engn, Aoba Ku, 6-6-06 Aza Aoba, Sendai, Miyagi 9808579, Japan.	yyli@epl1.civil.tohoku.ac.jp		, Qigui/0000-0001-9061-3844	Japan Society for the Promotion of Science (JSPS) [26.04044]	This work was partially supported by Japan Society for the Promotion of Science (JSPS: 26.04044).; The first author gratefully acknowledges support through Japan Society for the Promotion of Science (JSPS) for a postdoctoral support.	Rajagopal R, 2013, BIORESOURCE TECHNOL, V143, P632, DOI 10.1016/j.biortech.2013.06.030; Werner JJ, 2011, P NATL ACAD SCI USA, V108, P4158, DOI 10.1073/pnas.1015676108; Fisher E, 2008, ANN NY ACAD SCI, V1125, P230, DOI 10.1196/annals.1419.006; Niu QG, 2013, BIORESOURCE TECHNOL, V137, P358, DOI 10.1016/j.biortech.2013.03.080; McMahon KD, 2004, BIOTECHNOL BIOENG, V87, P823, DOI 10.1002/bit.20192; Fernandez A, 1999, APPL ENVIRON MICROB, V65, P3697; ELSDEN SR, 1976, ARCH MICROBIOL, V107, P283, DOI 10.1007/BF00425340; LaPara TM, 2002, WATER RES, V36, P638, DOI 10.1016/S0043-1354(01)00277-9; Lau IWC, 1997, WATER RES, V31, P2626, DOI 10.1016/S0043-1354(97)00110-3; Drake HL, 2004, RES MICROBIOL, V155, P422, DOI 10.1016/j.resmic.2004.03.003; Pender S, 2004, WATER RES, V38, P619, DOI 10.1016/j.watres.2003.10.055; Zhu YT, 2010, BIORESOURCE TECHNOL, V101, P6432, DOI 10.1016/j.biortech.2010.03.041; Wasserfallen A, 2000, INT J SYST EVOL MICR, V50, P43; Hansen KH, 1998, WATER RES, V32, P5, DOI 10.1016/S0043-1354(97)00201-7; Warnick TA, 2002, INT J SYST EVOL MICR, V52, P1155, DOI 10.1099/ijs.0.02125-0; McMahon KD, 2001, WATER RES, V35, P1817, DOI 10.1016/S0043-1354(00)00438-3; Hashsham SA, 2000, APPL ENVIRON MICROB, V66, P4050, DOI 10.1128/AEM.66.9.4050-4057.2000; Niu QG, 2013, BIORESOURCE TECHNOL, V146, P223, DOI 10.1016/j.biortech.2013.07.038; Kobayashi T, 2009, BIORESOURCE TECHNOL, V100, P4981, DOI 10.1016/j.biortech.2009.05.043; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Goberna M, 2009, APPL ENVIRON MICROB, V75, P2566, DOI 10.1128/AEM.02260-08; Angenent LT, 2002, WATER RES, V36, P4648, DOI 10.1016/S0043-1354(02)00199-9; Briones A, 2003, CURR OPIN BIOTECH, V14, P270, DOI 10.1016/S0958-1669(03)00065-X; Allison SD, 2008, P NATL ACAD SCI USA, V105, P11512, DOI 10.1073/pnas.0801925105; Angenent LT, 2004, TRENDS BIOTECHNOL, V22, P477, DOI 10.1016/j.tibtech.2004.07.001; Kadam PC, 1996, APPL ENVIRON MICROB, V62, P4486; CAYOL JL, 1995, INT J SYST BACTERIOL, V45, P201; Jiang B, 2009, ARCH MICROBIOL, V191, P123, DOI 10.1007/s00203-008-0435-x; JSWA, 1997, JAP STAND METH EX WA; Niu Q., 2014, J CHEM TECHNOL BIOTE; Rydzak T., 2012, BMC MICROBIOL, V12; Tabatabaei Meisam, 2009, Electron. J. Biotechnol., V12, P12	32	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0956-053X			WASTE MANAGE	Waste Manage.	SEP	2015	43						114	122		10.1016/j.wasman.2015.05.012		9	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	CP4ST	WOS:000359873600012		
J	Hidaka, T; Wang, F; Tsumori, J				Hidaka, Taira; Wang, Feng; Tsumori, Jun			Comparative evaluation of anaerobic digestion for sewage sludge and various organic wastes with simple modeling	WASTE MANAGEMENT			English	Article						Anaerobic digestion; Sewage sludge; Organic waste; Digested sludge; Mathematical model	ACTIVATED-SLUDGE; CO-DIGESTION; BMP TESTS; ADM1; BIODEGRADABILITY; PRETREATMENT; PERFORMANCE; CALIBRATION; INHIBITION; HYDROLYSIS	Anaerobic co-digestion of sewage sludge and other organic wastes, such as kitchen garbage, food waste, and agricultural waste, at a wastewater treatment plant (WWTP) is a promising method for both energy and material recovery. Substrate characteristics and the anaerobic digestion performance of sewage sludge and various organic wastes were compared using experiments and modeling. Co-digestion improved the value of digested sewage sludge as a fertilizer. The relationship between total and soluble elemental concentrations was correlated with the periodic table: most Na and K (alkali metals) were soluble, and around 20-40% of Mg and around 10-20% of Ca (alkaline earth metals) were soluble. The ratio of biodegradable chemical oxygen demand of organic wastes was 65-90%. The methane conversion ratio and methane production rate under mesophilic conditions were evaluated using a simplified mathematical model. There was reasonably close agreement between the model simulations and the experimental results in terms of methane production and nitrogen concentration. These results provide valuable information and indicate that the model can be used as a pre-evaluation tool to facilitate the introduction of co-digestion at WWTPs. (C) 2015 Elsevier Ltd. All rights reserved.	[Hidaka, Taira; Wang, Feng; Tsumori, Jun] Publ Works Res Inst, Recycling Res Team, Mat & Resources Res Grp, Tsukuba, Ibaraki 3058516, Japan	Hidaka, T (reprint author), Publ Works Res Inst, Recycling Res Team, Mat & Resources Res Grp, 1-6 Minamihara, Tsukuba, Ibaraki 3058516, Japan.	hidaka@pwri.go.jp					Esposito G, 2011, WASTE MANAGE, V31, P2527, DOI 10.1016/j.wasman.2011.07.024; Yasui H, 2008, WATER RES, V42, P249, DOI 10.1016/j.watres.2007.07.004; Rajagopal R, 2013, BIORESOURCE TECHNOL, V143, P632, DOI 10.1016/j.biortech.2013.06.030; Girault R, 2012, WATER RES, V46, P4099, DOI 10.1016/j.watres.2012.04.028; Dabrowska L, 2012, CHEMOSPHERE, V88, P168, DOI 10.1016/j.chemosphere.2012.02.073; Rodriguez J, 2006, WATER SCI TECHNOL, V54, P101, DOI 10.2166/wst.2006.531; Mottet A, 2010, CHEM ENG J, V160, P488, DOI 10.1016/j.cej.2010.03.059; Astals S, 2013, WATER RES, V47, P6033, DOI 10.1016/j.watres.2013.07.019; Alzate ME, 2012, BIORESOURCE TECHNOL, V123, P488, DOI 10.1016/j.biortech.2012.06.113; Donoso-Bravo A, 2009, WATER SCI TECHNOL, V60, P9, DOI 10.2166/wst.2009.316; Souza TSO, 2013, WATER RES, V47, P3244, DOI 10.1016/j.watres.2013.03.041; Navaneethan N, 2011, WATER SCI TECHNOL, V63, P2916, DOI 10.2166/wst.2011.557; Cabbai V, 2013, WASTE MANAGE, V33, P1626, DOI 10.1016/j.wasman.2013.03.020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Di Maria F, 2014, WASTE MANAGE, V34, P1603, DOI 10.1016/j.wasman.2014.05.017; Takashima M, 2011, WATER ENVIRON RES, V83, P339, DOI 10.2175/106143010X12780288628895; APHA-American Public Health Association AWWA - American Water Works Association WEF - Water Environment Federation, 1995, STANDARD METHODS EXA; Batstone D.J., 2002, ANAEROBIC DIGESTION; Chen Y, 2008, BIORESOURCE TECHNOL, V99, P4044, DOI 10.1016/j.biortech.2007.01.057; Derbal K, 2009, BIORESOURCE TECHNOL, V100, P1539, DOI [10.1016/j.biortech.2008.07.064, 10.1016/j.biortcch.2008.07.064]; Donoso-Bravo A, 2012, WATER SCI TECHNOL, V66, P2378, DOI 10.2166/wst.2012.408; Hidaka T, 2013, BIORESOURCE TECHNOL, V149, P177, DOI 10.1016/j.biortech.2013.09.033; JSWA (Japan Sewage Works Association), 2012, ANN REP SWE SYST JAP, V67; JSWA (Japan Sewage Works Association), 2003, GUID SEW SYST OP; Nagare H, 2012, WATER SCI TECHNOL, V66, P1110, DOI 10.2166/wst.2012.291; Naka D., 2012, JPN J WATER TREAT BI, V48, P81; NILIM (National Institute for Land and Infrastructure Management) Ministry of Land Infrastructure Transport and Tourism Japan, 2013, 1 NILIM BDASH MIN LA; Sewerage and Wastewater Management Department Ministry of Land Infrastructure Transport and Tourism Japan, 2013, MUN WAST P; Sui PZ, 2011, WATER RES, V45, P2029, DOI 10.1016/j.watres.2010.12.011; WEF (Water Environment Federation) and ASCE (American Society of Civil Engineers), 2009, DES MUN WAST TREATMM, VFifth	30	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0956-053X			WASTE MANAGE	Waste Manage.	SEP	2015	43						144	151		10.1016/j.wasman.2015.04.026		8	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	CP4ST	WOS:000359873600016		
J	Zhou, JZ; Wu, SM; Pan, Y; Zhang, LG; Cao, ZB; Zhang, XQ; Yonemochi, S; Hosono, S; Wang, Y; Oh, K; Qian, GR				Zhou, Jizhi; Wu, Simiao; Pan, Yun; Zhang, Lingen; Cao, Zhenbang; Zhang, Xiaoqiao; Yonemochi, Shinichi; Hosono, Shigeo; Wang, Yao; Oh, Kokyo; Qian, Guangren			Enrichment of heavy metals in fine particles of municipal solid waste incinerator (MSWI) fly ash and associated health risk	WASTE MANAGEMENT			English	Article						MSWI fly ash; Different particle size; Heavy metal; Health risk	POLLUTION CONTROL RESIDUES; CHEMICAL SPECIATION; PARTICULATE MATTER; ELEMENT BEHAVIOR; TRACE-METALS; CHINA; COMBUSTION; EMISSIONS; EXPOSURE; DUST	During the pretreatment and recycling processes, the re-suspended dust from municipal solid waste incinerator (MSWI) fly ash might pose a significant health risk to onsite workers due to its toxic heavy metal content. In this work, the morphological and mineralogical characteristics of fly ash in different particle sizes are presented. The concentrations of seven trace elements (Zn, Pb, Cu, Cd, Cr, Fe and Mn) in these samples were determined. The results show that volatile metals, such as Zn, Pb, Cu and Cd, were easily concentrated in the fine particles, especially in Dp2.5-1 and Dp1, with soluble and exchangeable substances as the main chemical species. The health risk assessment illustrated that the cumulative hazard indexes for non-carcinogenic metals in Dp10-5, Dp5-2.5, Dp2.5-1, and Dp1 were 1.69, 1.41, 1.78 and 2.64, respectively, which were higher than the acceptable threshold values (1.0). The cumulative carcinogenic risk was also higher than the threshold value (10(-6)). For the onsite workers, the relatively apparent non-carcinogenic and carcinogenic effects were from Pb and Cr, respectively. The above findings suggest that fine-grained fly ash contained a considerable amount of heavy metals and exhibited a great health risk. (C) 2015 Published by Elsevier Ltd.	[Zhou, Jizhi; Wu, Simiao; Pan, Yun; Zhang, Lingen; Cao, Zhenbang; Zhang, Xiaoqiao; Wang, Yao; Qian, Guangren] Shanghai Univ, Sch Environm & Chem Engn, Shanghai 200444, Peoples R China; [Yonemochi, Shinichi; Hosono, Shigeo; Oh, Kokyo] Ctr Environm Sci Saitama, Kazo, Saitama 3470115, Japan	Oh, K (reprint author), Ctr Environm Sci Saitama, 914 Kamitanadar, Kazo, Saitama 3470115, Japan.	o.kokyo@pref.saitama.lg.jp; grqian@shu.edu.cn			National Public Benefit (Environmental Research) Foundation of China [201209026]; Shanghai Leading Academic Disciplines [S30109]	This project is financially supported by National Public Benefit (Environmental Research) Foundation of China (No. 201209026) and Shanghai Leading Academic Disciplines (S30109). We also appreciate the support of instruments and equipment provided by the center for environmental science in Saitama, Japan.	Alvim-Ferraz MCM, 2005, WASTE MANAGE, V25, P638, DOI 10.1016/j.wasman.2004.07.017; Ram SS, 2014, MITIG ADAPT STRAT GL, V19, P499, DOI 10.1007/s11027-012-9445-8; Wu K, 2012, CEMENT CONCRETE COMP, V34, P322, DOI 10.1016/j.cemconcomp.2011.11.016; Zheng N, 2010, SCI TOTAL ENVIRON, V408, P726, DOI 10.1016/j.scitotenv.2009.10.075; Kubonova L, 2013, WASTE MANAGE, V33, P2322, DOI 10.1016/j.wasman.2013.05.022; Shi HS, 2009, J HAZARD MATER, V164, P750, DOI 10.1016/j.jhazmat.2008.08.077; Nelson PF, 2010, FUEL, V89, P810, DOI 10.1016/j.fuel.2009.03.002; Wu SM, 2015, FUEL, V158, P764, DOI 10.1016/j.fuel.2015.06.003; Tian HZ, 2012, ENVIRON SCI TECHNOL, V46, P10364, DOI 10.1021/es302343s; Feng XD, 2009, INT J ENVIRON SCI TE, V6, P337; Quina MJ, 2008, J HAZARD MATER, V152, P853, DOI 10.1016/j.jhazmat.2007.07.055; Pan Y, 2013, J HAZARD MATER, V261, P269, DOI 10.1016/j.jhazmat.2013.07.038; Qian GG, 2006, J HAZARD MATER, V129, P274, DOI 10.1016/j.jhazmat.2005.09.003; Sukandar S, 2006, ENVIRON POLLUT, V144, P726, DOI 10.1016/j.envpol.2006.02.010; Zheng N, 2010, ATMOS ENVIRON, V44, P3239, DOI 10.1016/j.atmosenv.2010.06.002; Chen B, 2013, ATMOS ENVIRON, V71, P234, DOI 10.1016/j.atmosenv.2013.02.013; Vejahati F, 2010, FUEL, V89, P904, DOI 10.1016/j.fuel.2009.06.013; Wang CC, 2013, J HAZARD MATER, V262, P179, DOI 10.1016/j.jhazmat.2013.08.044; Buhre BJP, 2006, FUEL, V85, P185, DOI 10.1016/j.fuel.2005.04.031; Belevi H, 2000, ENVIRON SCI TECHNOL, V34, P2507, DOI 10.1021/es991079e; Espinosa AJF, 2002, ATMOS ENVIRON, V36, P773; Tang Q, 2013, FUEL, V107, P315, DOI 10.1016/j.fuel.2013.01.009; He LY, 2008, ENVIRON SCI TECHNOL, V42, P4461, DOI 10.1021/es7022658; Quina MJ, 2008, WASTE MANAGE, V28, P2097, DOI 10.1016/j.wasman.2007.08.030; Belevi H, 2000, ENVIRON SCI TECHNOL, V34, P2501, DOI 10.1021/es991078m; Zereini F, 2005, ENVIRON SCI TECHNOL, V39, P2983, DOI 10.1021/es040040t; Buonanno G, 2015, WASTE MANAGE, V37, P75, DOI 10.1016/j.wasman.2014.03.008; Cetin B, 2012, WASTE MANAGE, V32, P965, DOI 10.1016/j.wasman.2011.12.012; De Boom A, 2015, WASTE MANAGE, V39, P179, DOI 10.1016/j.wasman.2015.01.040; EPA U.S, 1991, RISK ASS GUID SUP B, VI; EPA U.S, 2011, INT RISK INF SYST IR; EPA U.S, 1996, EXP FACT HDB; EPA U.S, 1989, RISK ASS GUID SUP H, V1; EPA U.S, 2001, 9355 EPA US OSWER; Gomez D, 2007, MICROCHEM J, V85, P276, DOI 10.1016/j.microc.2006.06.018; Haiying Z., 2010, PROCESS SAF ENVIRON, V88, P114; Li MG, 2010, J HAZARD MATER, V174, P586, DOI 10.1016/j.jhazmat.2009.09.092; Lind T, 2007, FUEL PROCESS TECHNOL, V88, P737, DOI 10.1016/j.fuproc.2007.03.004; Pancras JP, 2013, SCI TOTAL ENVIRON, V448, P2, DOI 10.1016/j.scitotenv.2012.11.083; Perin G., 1985, HEAVY METAL ENV, V2, P454; Schoof R, 2003, GUID INCORPORATING 1; Shim YS, 2003, WASTE MANAGE, V23, P851, DOI 10.1016/S0956-053X(02)00163-0; Sorum L, 2004, FUEL, V83, P1703, DOI 10.1016/j.fuel.2004.03.002; U. S. Environmental Protection Agency, 2004, RISK ASS GUID SUP E, VI; Wang Y, 2015, ECOTOX ENVIRON SAFE, V111, P177, DOI 10.1016/j.ecoenv.2014.09.030; Zhu ZM, 2013, J HAZARD MATER, V246, P189, DOI 10.1016/j.jhazmat.2012.12.024	46	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0956-053X			WASTE MANAGE	Waste Manage.	SEP	2015	43						239	246		10.1016/j.wasman.2015.06.026		8	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	CP4ST	WOS:000359873600026		
J	Asakura, H				Asakura, Hiroshi			Sulfate and organic matter concentration in relation to hydrogen sulfide generation at inert solid waste landfill site - Limit value for gypsum	WASTE MANAGEMENT			English	Article						Landfill site; Waste gypsum board; Hydrogen sulfide; Sulfate; Organic matter; Limit value	CONSTRUCTION; ADSORPTION; FINES; FLUX; GAS	In order to suggest a limit value for gypsum (CaSO4) for the suppression of hydrogen sulfide (H2S) generation at an inert solid waste landfill site, the relationship between raw material (SO4 and organic matter) for H2S generation and generated H2S concentration, and the balance of raw material (SO4) and product (H2S) considering generation and outflow were investigated. SO4 concentration should be less than approximately 100 mg-SO4/L in order to suppress H2S generation to below 2000 ppm. Total organic carbon (TOC) concentration should be less than approximately 200 mg-C/L assuming a high SO4 concentration. The limit value for 504 in the ground is 60 mg-SO4/kg with 0.011 wt% as gypsum dihydrate, i.e., approximately 1/10 of the limit value in inert waste as defined by the EU Council Decision (560 mg-SO4/kg-waste). The limit value for SO4 in inert waste as defined by the EU Council Decision is high and TOC is strictly excluded. The cumulative amount of SO4 outflow through the liquid phase is much larger than that through the gas phase. SO4 concentration in pore water decreases with time, reaching half the initial concentration around day 100. SO4 reduction by rainfall can be expected in the long term. (C) 2015 Elsevier Ltd. All rights reserved.	Nagasaki Univ, Grad Sch Fisheries & Environm Sci, Nagasaki 8528521, Japan	Asakura, H (reprint author), Nagasaki Univ, Grad Sch Fisheries & Environm Sci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	asakura_hiroshi@yahoo.co.jp			Japan Society for the Promotion of Science (JSPS) [25740039]	This research was supported by a Grant-in-Aid for Young Scientists B (25740039) from the Japan Society for the Promotion of Science (JSPS). Special thanks are extended to Takeaki Eiro and Shumpei Kitazaki.	American Chemical Society, 2006, REAG CHEM SPEC PROC, P242; KARGE HG, 1978, J COLLOID INTERF SCI, V64, P522, DOI 10.1016/0021-9797(78)90394-6; Fang JJ, 2012, WASTE MANAGE, V32, P1401, DOI 10.1016/j.wasman.2012.02.013; REIFFENSTEIN RJ, 1992, ANNU REV PHARMACOL, V32, P109, DOI 10.1146/annurev.pharmtox.32.1.109; Lopez A, 2014, WASTE MANAGE, V34, P1446, DOI 10.1016/j.wasman.2014.04.004; Moulin FJM, 2002, TOXICOL SCI, V66, P7, DOI 10.1093/toxsci/66.1.7; Eun S, 2007, WASTE MANAGE, V27, P220, DOI 10.1016/j.wasman.2005.12.019; Xu QY, 2010, WASTE MANAGE, V30, P660, DOI 10.1016/j.wasman.2009.10.022; Adib F, 1999, J COLLOID INTERF SCI, V214, P407, DOI 10.1006/jcis.1999.6200; Asakura H, 2009, WASTE MANAGE, V29, P1877, DOI 10.1016/j.wasman.2008.12.019; Bergersen O, 2014, WASTE MANAGE, V34, P141, DOI 10.1016/j.wasman.2013.09.012; EC, 2002, OJ L, V11, P32; EC, 1999, OJ L, V182, P5; Inoue Y, 2005, MECH STRONG HYDROGEN, P188; Jang YC, 2001, ADV ENVIRON RES, V5, P203, DOI 10.1016/S1093-0191(00)00056-3; Lee S, 2006, WASTE MANAGE, V26, P526, DOI 10.1016/j.wasman.2005.10.010; Masamoto H, 2012, WASTE MANAGE RES, V23, P144; Milby TH, 1999, AM J IND MED, V35, P192, DOI 10.1002/(SICI)1097-0274(199902)35:2<192::AID-AJIM11>3.0.CO;2-C; Naruoka T., 2004, J NATL ENV RES, V29, P14; Ono Y, 2003, WASTE MANAGE RES, V14, P248; Sagara H., 2009, CHEM ENG CALCULATION, P105; Townsend T., 2005, C D WASTE LANDFILL F; Townsend T, 2004, SCI TOTAL ENVIRON, V332, P1, DOI 10.1016/j.scitotenv.2004.03.11; Yue E., 2014, WASTE MANAGE, V34, P1041	24	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0956-053X			WASTE MANAGE	Waste Manage.	SEP	2015	43						328	334		10.1016/j.wasman.2015.06.018		7	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	CP4ST	WOS:000359873600036		
J	Kuwada, H; Hashimoto, K; Ishihara, Y; Fujiwara, T				Kuwada, Hayato; Hashimoto, Kenji; Ishihara, Yasunori; Fujiwara, Toru			The consistency and absolute consistency problems of XML schema mappings between restricted DTDs	WORLD WIDE WEB-INTERNET AND WEB INFORMATION SYSTEMS			English	Article						XML; Schema mapping; Consistency; Absolute consistency	SATISFIABILITY	Consistency of XML schema mappings, which means that some document conforming to the source schema can be mapped into a document conforming to the target schema, is an essentially necessary property. It is also important for XML schema mappings to be absolutely consistent, that is, every document conforming to the source schema can be mapped into a document conforming to the target schema. As a known result, consistency of a mapping between general DTDs is EXPTIME-complete even if the class of document patterns for defining mappings is restricted to downward axes and qualifiers. In addition, the known tractability result is only on a restricted class of document patterns under restricted DTDs called nested-relational DTDs. Moreover, there are few known results on the tractability of absolute consistency. In this paper, we discuss the consistency and absolute consistency problems under restricted DTDs called disjunction-capsuled DTDs, which were proposed by Ishihara et al, and their extended classes. We first show that for many document pattern classes, both problems are solvable in polynomial time under disjunction-capsuled DTDs. Then, we show that our results are extended to some superclasses of disjunction-capsuled DTDs, which are also proper superclasses of nested-relational DTDs.	[Kuwada, Hayato; Ishihara, Yasunori; Fujiwara, Toru] Osaka Univ, Osaka, Japan; [Hashimoto, Kenji] Nagoya Univ, Nagoya, Aichi 4648601, Japan	Kuwada, H (reprint author), Osaka Univ, Osaka, Japan.	h-kuwada@ist.osaka-u.ac.jp; k-hasimt@is.nagoya-u.ac.jp; ishihara@ist.osaka-u.ac.jp; fujiwara@ist.osaka-u.ac.jp			Japan Society for the Promotion of Science [23500120]	The authors thank Mr. Yohei Kusunoki of Osaka University for his insightful comments and suggestions on deciding XPath validity under DC-DTDs. This research is supported in part by Grant-in-Aid for Scientific Research (C) 23500120 from Japan Society for the Promotion of Science.	Amano S, 2009, PODS'09: PROCEEDINGS OF THE TWENTY-EIGHTH ACM SIGMOD-SIGACT-SIGART SYMPOSIUM ON PRINCIPLES OF DATABASE SYSTEMS, P33, DOI 10.1145/1559795.1559801; Arenas M., 2008, J ACM, V55; Arenas M., 2010, RELATIONAL XML DATA; Benedikt M., 2008, J ACM, V55; Ishihara Y, 2012, PROCEEDINGS OF THE TWELFTH INTERNATIONAL WORKSHOP ON WEB INFORMATION AND DATA MANAGEMENT, P11; Ishihara Y, 2010, LECT NOTES COMPUT SC, V6309, P33, DOI 10.1007/978-3-642-15684-7_4; Ishihara Y, 2009, LECT NOTES COMPUT SC, V5708, P68, DOI 10.1007/978-3-642-03793-1_5; Kuwada H., 2013, LECT NOTES COMPUTER, P228; Montazerian M, 2007, LECT NOTES COMPUT SC, V4704, P17; Bojanczyk M, 2011, J ACM, V58, DOI 10.1145/1989727.1989731; World Wide Web Consortium (W3C), 1999, XML PATH LANGUAGE XP	11	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1386-145X	1573-1413		WORLD WIDE WEB	World Wide Web	SEP	2015	18	5			SI		1443	1461		10.1007/s11280-014-0285-1		19	Computer Science, Information Systems; Computer Science, Software Engineering	Computer Science	CP7PA	WOS:000360079000013		
J	Ohtori, S; Orita, S; Yamauchi, K; Eguchi, Y; Ochiai, N; Kishida, S; Kuniyoshi, K; Aoki, Y; Nakamura, J; Ishikawa, T; Miyagi, M; Kamoda, H; Suzuki, M; Kubota, G; Sakuma, Y; Oikawa, Y; Inage, K; Sainoh, T; Sato, J; Shiga, Y; Abe, K; Fujimoto, K; Kanamoto, H; Toyone, T; Inoue, G; Takahashi, K				Ohtori, Seiji; Orita, Sumihisa; Yamauchi, Kazuyo; Eguchi, Yawara; Ochiai, Nobuyasu; Kishida, Shunji; Kuniyoshi, Kazuki; Aoki, Yasuchika; Nakamura, Junichi; Ishikawa, Tetsuhiro; Miyagi, Masayuki; Kamoda, Hiroto; Suzuki, Miyako; Kubota, Gou; Sakuma, Yoshihiro; Oikawa, Yasuhiro; Inage, Kazuhide; Sainoh, Takeshi; Sato, Jun; Shiga, Yasuhiro; Abe, Koki; Fujimoto, Kazuki; Kanamoto, Hiroto; Toyone, Tomoaki; Inoue, Gen; Takahashi, Kazuhisa			Efficacy of Direct Injection of Etanercept into Knee Joints for Pain in Moderate and Severe Knee Osteoarthritis	YONSEI MEDICAL JOURNAL			English	Article						Etanercept; knee osteoarthritis; pain	NECROSIS-FACTOR-ALPHA; NEUROPATHIC PAIN; DOUBLE-BLIND; TANEZUMAB; NERVE; HERNIATION; ARTHRITIS; SCIATICA; THERAPY; SAFETY	Purpose: Osteoarthritic (OA) pain is largely considered to be inflammatory pain. However, during the last stage of knee OA, sensory nerve fibers in the knee are shown to be significantly damaged when the subchondral bone junction is destroyed, and this can induce neuropathic pain. Several authors have reported that tumor necrosis factor-alpha (TNF alpha) in a knee joint plays a crucial role in pain modulation. The purpose of the current study was to evaluate the efficacy of etanercept, a TNF alpha inhibitor, for pain in knee OA. Materials and Methods: Thirty-nine patients with knee OA and a 2-4 Kellgren-Lawrence grading were evaluated in this prospective study. Patients were divided into two groups; hyaluronic acid (HA) and etanercept injection. All patients received a single injection into the knee. Pain scores were evaluated before and 4 weeks after injection using a visual analogue scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and they were compared between the groups. Results: Before injection, VAS and WOMAC scores were not significantly different between the groups (p>0.05). Significant pain relief was found in the etanercept group at 1 and 2 weeks by VAS, and at 4 weeks by WOMAC score, compared with the HA group (p<0.05). No adverse events were observed in either group. Conclusion: Direct injection of etanercept into OA knee joints was an effective treatment for pain in moderate and severe OA patients. Furthermore, this finding suggests that TNF alpha is one factor that induces OA pain.	[Ohtori, Seiji; Orita, Sumihisa; Yamauchi, Kazuyo; Eguchi, Yawara; Ochiai, Nobuyasu; Kishida, Shunji; Kuniyoshi, Kazuki; Aoki, Yasuchika; Nakamura, Junichi; Ishikawa, Tetsuhiro; Miyagi, Masayuki; Kamoda, Hiroto; Suzuki, Miyako; Kubota, Gou; Sakuma, Yoshihiro; Oikawa, Yasuhiro; Inage, Kazuhide; Sainoh, Takeshi; Sato, Jun; Shiga, Yasuhiro; Abe, Koki; Fujimoto, Kazuki; Kanamoto, Hiroto; Toyone, Tomoaki; Inoue, Gen; Takahashi, Kazuhisa] Chiba Univ, Dept Orthopaed Surg, Grad Sch Med, Chiba 2608670, Japan	Ohtori, S (reprint author), Chiba Univ, Dept Orthopaed Surg, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	sohtori@faculty.chiba-u.jp					Hochman JR, 2010, ARTHRIT CARE RES, V62, P1019, DOI 10.1002/acr.20142; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Nelson AE, 2014, SEMIN ARTHRITIS RHEU, V43, P701, DOI 10.1016/j.semarthrit.2013.11.012; Ohtori S, 2012, YONSEI MED J, V53, P801, DOI 10.3349/ymj.2012.53.4.801; Ohtori S, 2012, SPINE, V37, P439, DOI 10.1097/BRS.0b013e318238af83; Walsh DA, 2010, RHEUMATOLOGY, V49, P1852, DOI 10.1093/rheumatology/keq188; VANDERKRAAN PM, 1989, AM J PATHOL, V135, P1001; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Ivanavicius SP, 2007, PAIN, V128, P272, DOI 10.1016/j.pain.2006.12.022; Ohtori S, 2004, J PAIN, V5, P385, DOI 10.1016/j.jpain.2004.06.004; Lane NE, 2010, NEW ENGL J MED, V363, P1521, DOI 10.1056/NEJMoa0901510; Olmarker K, 1998, SPINE, V23, P2538, DOI 10.1097/00007632-199812010-00008; Korhonen T, 2004, SPINE, V29, P2115, DOI 10.1097/01.brs.0000141179.58778.6c; Balanescu AR, 2014, ANN RHEUM DIS, V73, P1665, DOI 10.1136/annrheumdis-2012-203164; Ochiai N, 2007, OSTEOARTHR CARTILAGE, V15, P1093, DOI 10.1016/j.joca.2007.03.01; Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion, 2008, ARTHR TYP OV; Maksymowych WP, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4044; Nagashima H, 2011, OSTEOARTHR CARTILAGE, V19, P1405, DOI 10.1016/j.joca.2011.09.006; Ogino S, 2009, CLIN RHEUMATOL, V28, P1395, DOI 10.1007/s10067-009-1258-0; Orita S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-144	20	0	0	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	SEP 1	2015	56	5					1379	1383		10.3349/ymj.2015.56.5.1379		5	Medicine, General & Internal	General & Internal Medicine	CP4XP	WOS:000359886200028		
J	Sakane, M; Tatsumi, M; Kim, T; Hori, M; Onishi, H; Nakamoto, A; Eguchi, H; Nagano, H; Wakasa, K; Hatazawa, J; Tomiyama, N				Sakane, Makoto; Tatsumi, Mitsuaki; Kim, Tonsok; Hori, Masatoshi; Onishi, Hiromitsu; Nakamoto, Atsushi; Eguchi, Hidetoshi; Nagano, Hiroaki; Wakasa, Kenichi; Hatazawa, Jun; Tomiyama, Noriyuki			Correlation between apparent diffusion coefficients on diffusion-weighted MRI and standardized uptake value on FDG-PET/CT in pancreatic adenocarcinoma	ACTA RADIOLOGICA			English	Article						Apparent diffusion coefficient; diffusion-weighted imaging (DWI); magnetic resonance imaging (MRI); standardized uptake value; PET/CT; pancreatic adenocarcinoma	POSITRON-EMISSION-TOMOGRAPHY; NEOADJUVANT CHEMOTHERAPY; F-18-FDG UPTAKE; CANCER; TRIAL; RADIOCHEMOTHERAPY; CHEMORADIATION; RADIOTHERAPY; CELLULARITY; PREDICTION	Background: Diffusion-weighted magnetic resonance imaging (DW-MRI) and 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography/computed tomography (PET/CT) is increasingly recognized as important for assessing tumor malignancy in oncology. Apparent diffusion coefficient (ADC) and standardized uptake value (SUV) are negatively correlated in some types of cancer based on tumor aggressiveness. Purpose: To evaluate relationships between ADC of magnetic resonance imaging and SUV of PET/CT in pancreatic adenocarcinomas. Material and Methods: Twenty-nine patients histopathologically diagnosed with pancreatic adenocarcinomas were evaluated. ADC maps were generated from 3 T-MRI using b values (b = 0, 800 s/mm(2)). PET/CT was performed 60 min after intravenous injection of FDG (3.7 MBq/kg). The margins of tumors on DW-MRI and PET/CT were assessed to measure ADC and SUV of tumor appropriately. For tumors considered well-marginated, minimal and mean ADC as well as maximal and mean SUV were measured. The correlation of ADC and SUV were statistically evaluated and survival period stratified on ADC and SUV also evaluated. Results: Twenty-two tumors on DW-MRI and 25 on PET/CT were deemed well-marginated. Minimal ADC was significantly and negatively correlated with maximal and mean SUV (r = -0.61, P = 0.0040; r = -0.66, P = 0.0015), and mean ADC also showed significantly and negatively correlation with maximal and mean SUV (r = -0.50, P = 0.024; r = -0.54, P = 0.012). There was no significant difference on overall survival stratified on ADC and SUV. Conclusion: ADC and SUV were significantly correlated in pancreatic adenocarcinomas, although no significant findings were observed in overall survival.	[Sakane, Makoto; Kim, Tonsok; Hori, Masatoshi; Onishi, Hiromitsu; Nakamoto, Atsushi; Tomiyama, Noriyuki] Osaka Univ, Dept Radiol, Grad Sch Med, Suita, Osaka 5650871, Japan; [Tatsumi, Mitsuaki; Hatazawa, Jun] Osaka Univ, Dept Nucl Med & Tracer Kinet, Grad Sch Med, Suita, Osaka 5650871, Japan; [Eguchi, Hidetoshi; Nagano, Hiroaki] Osaka Univ, Dept Surg, Grad Sch Med, Suita, Osaka 5650871, Japan; [Wakasa, Kenichi] Osaka City Univ, Grad Sch Med, Dept Diagnost Pathol, Osaka 558, Japan	Tatsumi, M (reprint author), Osaka Univ, Dept Radiol, Grad Sch, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	m-tatsumi@radiol.med.osaka-u.ac.jp					Nakata B, 2001, INT J ONCOL, V19, P53; Feuerlein S, 2009, AM J ROENTGENOL, V193, P1070, DOI 10.2214/AJR.08.2093; Muraoka N, 2008, J MAGN RESON IMAGING, V27, P1302, DOI 10.1002/jmri.21340; Schellenberg D, 2010, INT J RADIAT ONCOL, V77, P1420, DOI 10.1016/j.ijrobp.2009.06.049; Guiu B, 2011, EUR RADIOL, V21, P463, DOI 10.1007/s00330-010-2017-y; De Gaetano AM, 2012, ABDOM IMAGING, V37, P983, DOI 10.1007/s00261-012-9845-y; Maemura K, 2006, J HEPATO-BILIARY-PAN, V13, P435, DOI 10.1007/s00534-006-1102-8; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Ma C, 2014, MAGN RESON IMAGING, V32, P125, DOI 10.1016/j.mri.2013.10.005; Kubota K, 2001, ANN NUCL MED, V15, P471, DOI 10.1007/BF02988499; Benard F, 2003, SEMIN NUCL MED, V33, P148, DOI 10.1053/snuc.2003.127304; Higashi T, 1998, J NUCL MED, V39, P1727; Palmer DH, 2007, ANN SURG ONCOL, V14, P2088, DOI 10.1245/s10434-007-9384-x; Imamura M, 2004, SURGERY, V136, P1003, DOI 10.1016/j.surg.2004.04.030; Kanauchi N, 2009, EUR J CARDIO-THORAC, V35, P706, DOI 10.1016/j.ejcts.2008.12.039; Wang JC, 2001, RADIOLOGY, V220, P621, DOI 10.1148/radiol.2202010063; Wong CS, 2012, EUR J RADIOL, V81, P2122, DOI 10.1016/j.ejrad.2011.09.003; Gu J, 2011, MOL IMAGING BIOL, V13, P1020, DOI 10.1007/s11307-010-0433-7; Setsompop K, 2006, MAGN RESON MED, V56, P1163, DOI 10.1002/mrm.21042; Ansary-Moghaddam A, 2006, CANCER EPIDEM BIOMAR, V15, P2435, DOI 10.1158/1055-9965.EPI-06-0368; Heinrich S, 2008, ANN SURG, V248, P1014, DOI 10.1097/SLA.0b013e318190a6da; Delbeke D, 1999, J NUCL MED, V40, P1784; Shinya S, 2008, WORLD J GASTROENTERO, V14, P5478, DOI 10.3748/wjg.14.5478; Kitagawa Y, 2003, EUR J NUCL MED MOL I, V30, P63, DOI 10.1007/s00259-002-0978-z; Ho KC, 2009, EUR J NUCL MED MOL I, V36, P200, DOI 10.1007/s00259-008-0936-5; Doi R, 2008, SURG TODAY, V38, P1021, DOI 10.1007/s00595-007-3745-8; Dzik-Jurasz A, 2002, LANCET, V360, P307, DOI 10.1016/S0140-6736(02)09520-X; Koh DM, 2007, AM J ROENTGENOL, V188, P1001, DOI 10.2214/AJR.06.0601; Omary MB, 2007, J CLIN INVEST, V117, P50, DOI 10.1172/JCI30082; Fukukura Y, 2012, RADIOLOGY, V263, P732, DOI [10.1148/radiol.120111222, 10.1148/radiol.12111222]; Hayashida Y, 2006, AM J NEURORADIOL, V27, P1419; Avril N, 2004, J NUCL MED, V45, P930; Bos R, 2002, J CLIN ONCOL, V20, P379, DOI 10.1200/JCO.20.2.379; Fatemi-Ardekani Ali, 2009, Critical Reviews in Biomedical Engineering, V37, P495; Fléjou Jean-François, 2011, Ann Pathol, V31, pS27, DOI 10.1016/j.annpat.2011.08.001; Grassetto G, 2011, AM J CLIN ONCOL-CANC, V34, P111, DOI 10.1097/COC.0b013e3181d275a0; Hayano K, 2013, J HEPATO-BIL-PAN SCI, V20, P243, DOI 10.1007/s00534-011-0491-5; Kittaka H, 2013, WORLD J SURG, V37, P169, DOI 10.1007/s00268-012-1775-x; Maschauer S, 2004, J NUCL MED, V45, P455; Niwa T, 2009, BRIT J RADIOL, V82, P28, DOI 10.1259/bjr/43911400; Tjomsland V, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/212810	41	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0284-1851	1600-0455		ACTA RADIOL	Acta Radiol.	SEP	2015	56	9					1034	1041		10.1177/0284185114549825		8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CO9KP	WOS:000359495000002		
J	Ibukuro, K; Takeguchi, T; Fukuda, H; Mori, M; Abe, S; Tobe, K				Ibukuro, Kenji; Takeguchi, Takaya; Fukuda, Hozumi; Mori, Masaya; Abe, Shoko; Tobe, Kimiko			An analysis of initial and follow-up CT findings in intramural hematoma, aortic double-lumen dissection, and mixed type lesions	ACTA RADIOLOGICA			English	Article						Intramural hematoma; aortic dissection; ulcer-like lesion; vasa vasorum; entry tear	VASA VASORUM; ULCER; PROJECTIONS; MANAGEMENT	Background: Although the clinical presentation of intramural hematoma (IMH) and aortic double-lumen dissection (AD) is similar, the imaging results and subsequent clinical course of the two lesions differ. Purpose: To compare the clinical and radiological findings of IMH, AD, and mixed type lesions. Material and Methods: Forty-two patients with IMH, 38 with AD, and 10 with mixed type lesions were imaged with post-contrast-enhanced CT. The most proximal ulcer-like lesions and entry tears and the distal ends of the IMH and AD were evaluated. The interval change of the intramural hematoma, ulcer-like lesion, and false lumen was observed. The pathological findings of the aorta were evaluated in 15 patients. Results: The most proximal ulcer-like lesion and entry tear were located in the arch to the descending aorta in 27 (64.2%) of the 42 patients with IMH and in 24 (63.1%) of the 38 patients with AD. The distal extension was located at the iliac arteries in six (14.3%) patients with IMH and in 31 (81.6%) patients with AD (P < 0.001). The intramural hematomas regressed in 29 (93.5%) of 31 patients, and the ulcer-like lesion progressed in 14 (70%) of 20 patients with IMH. The clinical features of the mixed type lesions resembled those of AD, rather than IMH. The intramural hematoma or dissection was observed within the outer media in all lesion types on histopathology. Conclusion: There is a distinct difference between IMH and AD in distal extension; however, the locations of the lesions are pathologically the same in the media of the aorta.	[Ibukuro, Kenji; Takeguchi, Takaya; Fukuda, Hozumi; Mori, Masaya; Abe, Shoko; Tobe, Kimiko] Mitsui Mem Hosp, Tokyo 1018643, Japan	Ibukuro, K (reprint author), Mitsui Mem Hosp, Chiyoda Ku, 1 Kandaizumicho, Tokyo 1018643, Japan.	kj-ibkr@qd6.so-net.ne.jp					Song JK, 1999, AM J CARDIOL, V83, P937, DOI 10.1016/S0002-9149(98)01058-3; Wu MT, 2011, RADIOLOGY, V258, P705, DOI 10.1148/radiol.10101270; Williams DM, 2006, J VASC INTERV RADIOL, V17, P765, DOI 10.1097/01.RVI.0000209217.94558.81; Eggebrecht H, 2009, EUR J VASC ENDOVASC, V38, P659, DOI 10.1016/j.ejvs.2009.09.001; Osada H, 2013, EUR J CARDIO-THORAC, V43, pE82, DOI 10.1093/ejcts/ezs640; Sueyoshi E, 1997, J COMPUT ASSIST TOMO, V21, P931, DOI 10.1097/00004728-199711000-00016; Evangelista A, 2005, CIRCULATION, V111, P1063, DOI 10.1161/01.CIR.0000156444.26393.80; Bosma MS, 2009, AM J ROENTGENOL, V193, P895, DOI 10.2214/AJR.08.2073; CLARKE JA, 1965, THORAX, V20, P76, DOI 10.1136/thx.20.1.76; Daily P O, 1970, Ann Thorac Surg, V10, P237; DEBAKEY ME, 1965, J THORAC CARDIOV SUR, V49, P130; Harris KM, 2012, CIRCULATION, V126, pS91, DOI 10.1161/CIRCULATIONAHA.111.084541; Jang YM, 2008, CLIN RADIOL, V63, P201, DOI 10.1016/j.crad.2007.07.020; Kaji S, 2003, CIRCULATION, V108, P307, DOI 10.1161/01.cir.0000087425.86049.74; Lansman SL, 2010, J THORAC CARDIOV SUR, V140, pS92, DOI 10.1016/j.jtcvs.2010.07.062; Macura KJ, 2003, AM J ROENTGENOL, V181, P309; Moizumi Y, 2004, J THORAC CARDIOV SUR, V127, P421, DOI 10.1016/j.jtcvs.2003.09.016; Monnin-Bares V, 2009, J VASC INTERV RADIOL, V20, P713, DOI 10.1016/j.jvir.2009.02.013; Sousa AD, 1960, RADIOLOGY, V75, P91; Sueyoshi E, 2002, RADIOLOGY, V224, P536, DOI 10.1148/radiol.2242011009; TISNADO J, 1980, AM J ROENTGENOL, V135, P719	21	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0284-1851	1600-0455		ACTA RADIOL	Acta Radiol.	SEP	2015	56	9					1091	1099		10.1177/0284185114549824		9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CO9KP	WOS:000359495000009		
J	Sakamoto, H; Matsushita, S; Hyodo, K; Tokunaga, C; Sato, F; Hiramatsu, Y				Sakamoto, Hiroaki; Matsushita, Shonosuke; Hyodo, Kazuyuki; Tokunaga, Chiho; Sato, Fujio; Hiramatsu, Yuji			A new technique of in vivo synchrotron radiation coronary microangiography in the rat	ACTA RADIOLOGICA			English	Article						Cardiac; angiography; animal investigations; ischemia/infarction		Background: Previously, in our laboratory, synchrotron radiation coronary microangiography (SRCA) using Langendorff-perfused rat hearts could visualize a coronary artery of 50 mu m in diameter. However, in vivo rat SRCA poses the problem of compromised temporal resolution due to the rapid heart rate of rats. Purpose: To establish a simple method of in vivo rat SRCA with bradycardia induced by intravenous injection of adenosine triphosphate disodium hydrate (ATP). Material and Methods: SRCA was performed at the Photon Factory of the High Energy Accelerator Research Organization (Tsukuba, Japan). Eight male Wistar rats were anesthetized. A catheter for injecting the contrast material was inserted into the carotid artery. Temporary bradycardia was induced by an intravenous bolus injection of 5 mg of ATP, and SRCA was performed immediately thereafter. Results: After ATP administration, the average heart rate decreased from 388 to 73 beats per minute. As a result, we could detect a coronary artery as small as 45 mu m in diameter. Conclusion: Our SRCA system which has a high resolution of 9 mu m per pixel could detect a coronary artery as small as 45 mu m in diameter in the in vivo rat.	[Sakamoto, Hiroaki; Tokunaga, Chiho; Sato, Fujio; Hiramatsu, Yuji] Univ Tsukuba, Dept Cardiovasc Surg, Fac Med, Tsukuba, Ibaraki 3058575, Japan; [Matsushita, Shonosuke] Tsukuba Univ Technol, Fac Hlth Sci, Tsukuba, Ibaraki, Japan; [Hyodo, Kazuyuki] High Energy Accelerator Res Org, Photon Factory, Tsukuba, Ibaraki, Japan	Sakamoto, H (reprint author), Univ Tsukuba, Cardiovasc Surg, Fac Med, Tennodai 1-1-1, Tsukuba, Ibaraki 3058575, Japan.	sakamotoh@md.tsukuba.ac.jp					Akishima S, 2007, CIRC J, V71, P418, DOI 10.1253/circj.71.418; Shirai M, 2013, CIRC RES, V112, P209, DOI 10.1161/CIRCRESAHA.111.300096; Bashore TM, 2001, J AM COLL CARDIOL, V37, P2170, DOI 10.1016/S0735-1097(01)01346-8; Matsushita S, 2008, EUR J RADIOL, V68, pS84, DOI 10.1016/j.ejrad.2008.04.044; Plaschke K, 2006, BRIT J ANAESTH, V96, P310, DOI 10.1093/bja/ael002; Raithel D, 2009, J VASC SURG, V49, P1067; Sato F, 2008, CIRC J, V72, P1367, DOI 10.1253/circj.72.1367	7	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0284-1851	1600-0455		ACTA RADIOL	Acta Radiol.	SEP	2015	56	9					1105	1107		10.1177/0284185114549570		3	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CO9KP	WOS:000359495000011		
J	Tatsumi, K; Yamashiki, Y				Tatsumi, Kenichi; Yamashiki, Yosuke			Effect of irrigation water withdrawals on water and energy balance in the Mekong River Basin using an improved VIC land surface model with fewer calibration parameters	AGRICULTURAL WATER MANAGEMENT			English	Article						VIC model; Irrigation water withdrawals; Runoff; Bowen Ratio; Surface temperature; Mekong River	SPACE-TIME CLIMATE; HYDROLOGIC MODEL; GLOBAL OPTIMIZATION; UNITED-STATES; GREAT-PLAINS; PART II; RESOLUTION; IMPACTS; VARIABILITY; STREAMFLOW	We present a detailed analysis of the effect of agricultural irrigation water abstraction on surface water, energy state and flux, using a model simulation to predict changes in Bowen Ratio, surface temperature and water resources within the Mekong River Basin. Using the Variable Infiltration Capacity (VIC) macroscale hydrological model including the infiltration, surface runoff, subsurface runoff, drainage from the soil layer, and irrigation scheme, together with the most recently available and accurate geophysical, geological and meteorological forcing datasets, we carried out the hydrological simulation on three calibration parameters. The multi-objective complex evolution (MOCOM-UA) optimizer was used to calibrate the model, which revealed a significant decrease in Bowen Ratio due to irrigation water withdrawal: this in turn affected surface temperature. We conclude that (1) the performance of the improved model was generally good, with an overall Nash-Sutcliffe Efficiency of 0.86 for the validation period 1986-1993; (2) the volume-based total Net Irrigation Water Requirement was about 24 x 10(9) m(3)/year for the period 1979-2000; (3) including the irrigation water withdrawals from runoff, river channels and dams decreases the total monthly runoff by 32% compared to the "no irrigation" baseline; (4) the period-averaged Bowen Ratio decreased by 6.8% in the dry season as a result of irrigation effects; (5) this significant decrease in Bowen Ratio resulted in a decrease in average surface temperature of 9.3 x 10(-2)% and a maximum of 4.8% over irrigated areas during the dry season. (C) 2015 Elsevier B.V. All rights reserved.	[Tatsumi, Kenichi] Tokyo Univ Agr & Technol, Dept Environm & Agr Engn, Fuchu, Tokyo 1838509, Japan; [Yamashiki, Yosuke] Kyoto Univ, Grad Sch Adv Integrated Studies Human Survivabil, Sakyo Ku, Kyoto 6068501, Japan	Tatsumi, K (reprint author), Tokyo Univ Agr & Technol, Dept Environm & Agr Engn, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.	tatsumi.kenichi@gmail.com					Abdulla FA, 1996, J GEOPHYS RES-ATMOS, V101, P7449, DOI 10.1029/95JD02416; Alpert P, 2006, GLOBAL PLANET CHANGE, V54, P202, DOI 10.1016/j.gloplacha.2006.03.015; Moriasi DN, 2007, T ASABE, V50, P885; Bowling LC, 2004, J HYDROMETEOROL, V5, P745, DOI 10.1175/1525-7541(2004)005<0745:POBSIA>2.0.CO;2; Liang X, 1994, J GEOPHYS RES-ATMOS, V99, P14415, DOI 10.1029/94JD00483; Masson V, 2003, J CLIMATE, V16, P1261, DOI 10.1175/1520-0442-16.9.1261; New M, 1999, J CLIMATE, V12, P829, DOI 10.1175/1520-0442(1999)012<0829:RTCSTC>2.0.CO;2; Wu H, 2012, WATER RESOUR RES, V48, DOI 10.1029/2012WR012313; Mishra V, 2011, GLOBAL PLANET CHANGE, V75, P155, DOI 10.1016/j.gloplacha.2010.11.003; Boucher O, 2004, CLIM DYNAM, V22, P597, DOI 10.1007/s00382-004-0402-4; Nijssen B, 2001, CLIMATIC CHANGE, V50, P143, DOI 10.1023/A:1010616428763; Yapo PO, 1998, J HYDROL, V204, P83, DOI 10.1016/S0022-1694(97)00107-8; Tang Q, 2009, HYDROL EARTH SYST SC, V13, P617; Maurer EP, 2002, J CLIMATE, V15, P3237, DOI 10.1175/1520-0442(2002)015<3237:ALTHBD>2.0.CO;2; Nijssen B, 1997, WATER RESOUR RES, V33, P711, DOI 10.1029/96WR03517; Engel B, 2007, J AM WATER RESOUR AS, V43, P1223, DOI 10.1111/j.1752-1688.2007.00105.x; Tatsumi K, 2011, HYDROL PROCESS, V25, P2715, DOI 10.1002/hyp.8012; Haddeland I, 2007, HYDROL EARTH SYST SC, V11, P1035; Huffman GJ, 2001, J HYDROMETEOROL, V2, P36, DOI 10.1175/1525-7541(2001)002<0036:GPAODD>2.0.CO;2; New M, 2000, J CLIMATE, V13, P2217, DOI 10.1175/1520-0442(2000)013<2217:RTCSTC>2.0.CO;2; Haddeland I, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026047; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Dirmeyer PA, 2006, B AM METEOROL SOC, V87, P1381, DOI 10.1175/BAMS-87-10-1381; Kingston DG, 2011, HYDROL EARTH SYST SC, V15, P1459, DOI 10.5194/hess-15-1459-2011; Costa-Cabral MC, 2008, HYDROL PROCESS, V22, P1731, DOI 10.1002/hyp.6740; Pielke RA, 2007, TELLUS B, V59, P587, DOI 10.1111/j.1600-0889.2007.00251.x; SEGAL M, 1995, MON WEATHER REV, V123, P383, DOI 10.1175/1520-0493(1995)123<0383:SEOTEO>2.0.CO;2; Mitchell TD, 2005, INT J CLIMATOL, V25, P693, DOI 10.1002/joc.1181; Nijssen B, 2001, J CLIMATE, V14, P1790, DOI 10.1175/1520-0442(2001)014<1790:GREOSM>2.0.CO;2; Jackson RB, 2001, ECOL APPL, V11, P1027, DOI 10.1890/1051-0761(2001)011[1027:WIACW]2.0.CO;2; Douglas EM, 2009, GLOBAL PLANET CHANGE, V67, P117, DOI 10.1016/j.gloplacha.2008.12.007; DUAN QY, 1993, J OPTIMIZ THEORY APP, V76, P501, DOI 10.1007/BF00939380; Sheffield J, 2006, J CLIMATE, V19, P3088, DOI 10.1175/JCLI3790.1; Schubert SD, 2004, J CLIMATE, V17, P485, DOI 10.1175/1520-0442(2004)017<0485:COLDIT>2.0.CO;2; Haddeland I, 2006, J HYDROL, V324, P210, DOI 10.1016/j.jhydrol.2005.09.028; DUCOUDRE NI, 1993, J CLIMATE, V6, P248, DOI 10.1175/1520-0442(1993)006<0248:SANSOP>2.0.CO;2; Hanasaki N, 2006, J HYDROL, V327, P22, DOI 10.1016/j.jhydrol.2005.11.011; DUAN QY, 1992, WATER RESOUR RES, V28, P1015, DOI 10.1029/91WR02985; Castro CL, 2007, J CLIMATE, V20, P3866, DOI 10.1175/JCLI4212.1; Nijssen B, 2001, J CLIMATE, V14, P3307, DOI 10.1175/1520-0442(2001)014<3307:PTDOGR>2.0.CO;2; Lohmann D, 1996, TELLUS A, V48, P708, DOI 10.1034/j.1600-0870.1996.t01-3-00009.x; Fischer G, 2007, TECHNOL FORECAST SOC, V74, P1083, DOI 10.1016/j.techfore.2006.05.021; Wu HA, 2011, WATER RESOUR RES, V47, DOI 10.1029/2009WR008871; Park D, 2014, J HYDROL, V515, P267, DOI 10.1016/j.jhydrol.2014.05.004; AQUASTAT, 2014, IRR WAT REQ WAT WITH; Balascio CC, 1998, T ASAE, V41, P615; Belay A.A., 2010, J WATER RESOUR PROT, V2, P61; BOSCH JM, 1982, J HYDROL, V55, P3, DOI 10.1016/0022-1694(82)90117-2; Bowling LC, 2010, J HYDROMETEOROL, V11, P276, DOI 10.1175/2009JHM1084.1; Champeaux JL, 2005, METEOROL APPL, V12, P29, DOI 10.1017/S1350482705001519; Chase TN, 1999, J GEOPHYS RES-ATMOS, V104, P16673, DOI 10.1029/1999JD900118; Cherkauer KA, 1999, J GEOPHYS RES-ATMOS, V104, P19599, DOI 10.1029/1999JD900337; Corey A.T., 1966, J IRRIGATION DRAINAG, V92, P61; Doll P., 2002, WATER RESOUR RES, V38, P81, DOI DOI 10.1029/2001WR000355; Ehrgott M., 2005, LECTURE NOTES EC MAT, V491; Elsner M.M., 2010, MACROSCALE HYDROLOGI; EROS Data Center, 1996, GTOP030 USGS; FAO. Food and Agriculture Organization of the United Nations, 1998, 56 FAO; Frenken I., 2012, IRRIGATION WATER REQ; Gesch D.B., 1999, EOS T AM GEOPHYS UN, V80, P69, DOI DOI 10.1029/99EO00050; GRDC, 2014, GLOB RUN DAT CTR REP; Gupta HV, 1999, J HYDROL ENG, V4, P135, DOI 10.1061/(ASCE)1084-0699(1999)4:2(135); Henriksen HJ, 2008, J HYDROL, V348, P224, DOI 10.1016/j.jhydrol.2007.09.056; Hibbert A. R., 1983, JAWRA J AM WATER RES, V19, P375, DOI 10.1111/j.1752-1688.1983.tb04594.x; Hufman G.J., 2003, AM METEOROL SCI; Kotsuki, 2013, THESIS KYOTO U; Liu Y., 2004, J HYDROMETEOROL, V6, P156; Maidment D. R., 1993, HDB HYDROLOGY; MATHEUSSEN B, 2000, HYP, V3, P2, DOI DOI 10.1002/(SICI)1099-1085(20000415)14:5<867::AID-HYP975>3.0.CO;2-5; Maurer EP, 2001, J GEOPHYS RES-ATMOS, V106, P17841, DOI 10.1029/2000JD900828; Mekong River Comission (MRC), 1997, MEKONG RIVER BASIN D; Nachtergaele F., 2012, HARMONIZED WORLD SOI; Nash J. E., 1970, J HYDROL, V10, P282, DOI [10.1016/0022-1694(70)90255-6, DOI 10.1016/0022-1694(70)90255-6]; Pielke RA, 2007, AGR FOREST METEOROL, V142, P234, DOI 10.1016/j.agrformet.2006.06.012; Piper B.S., 1991, IAHS PUBL, V201, P45; Portmann F., 2008, 06 U FRANKF I PHYS G; Portmann FT, 2010, GLOBAL BIOGEOCHEM CY, V24, DOI 10.1029/2008GB003435; Rossi C. G., 2009, International Agricultural Engineering Journal, V18, P1; Sheffield J, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD008288; Someth P., 2012, ANNEX C CROP WATER R; Stackhouse PW, 2004, GEWEX NEWS, V14, P10; Stull R. B., 1988, INTRO BOUNDARY LAYER; Tang CL, 2012, GLOBAL PLANET CHANGE, V88-89, P32, DOI 10.1016/j.gloplacha.2012.03.002; Tesemma Z.K., 2014, HYDROL EARTH SYST SC, V11, P10515, DOI [10.5194/hessd-11-10515-2014, DOI 10.5194/HESSD-11-10515-2014]; Thompson JR, 2013, J HYDROL, V486, P1, DOI 10.1016/j.jhydrol.2013.01.029; Yamaushi K., 2014, PADDY WATER ENVIRON, V12, P227; Yorozu K., 2014, J JSCE, V70, P1	87	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-3774	1873-2283		AGR WATER MANAGE	Agric. Water Manage.	SEP	2015	159						92	106		10.1016/j.agwat.2015.05.011		15	Agronomy; Water Resources	Agriculture; Water Resources	CO7HK	WOS:000359330000009		
J	Matsumoto, T; Yamazaki, M; Takahashi, H; Kajita, S; Suzuki, E; Tsuruta, T; Saegusa, M				Matsumoto, Toshihide; Yamazaki, Masaaki; Takahashi, Hiroyuki; Kajita, Sabine; Suzuki, Erina; Tsuruta, Tomoko; Saegusa, Makoto			Distinct beta-Catenin and PIK3CA Mutation Profiles in Endometriosis-Associated Ovarian Endometrioid and Clear Cell Carcinomas	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						beta-Catenin; PIK3CA; Endometriosis; Ovarian endometrioid carcinoma; Ovarian clear cell carcinoma	SQUAMOUS DIFFERENTIATION; MOLECULAR PATHOGENESIS; OXIDATIVE STRESS; CANCER; EXPRESSION; TUMORS; FREQUENCY; PATHWAY; ORIGIN; CTNNB1	Objectives: We focused on the differences in molecular mechanisms in the early stages of endometriosis-associated ovarian endometrioid carcinoma (OEMCa) and ovarian clear cell carcinoma (OCCCa). Methods: Alterations in the beta-catenin and PIK3CA genes, as well as expression of their associated markers, were investigated. Results: Mutations in exon 3 of the beta-catenin gene were identified in 21 (60%) of 35 OEMCas. The mutations were also detected in the coexisting nonatypical (52.4%) and atypical (73.3%) endometriosis, and the single-nucleotide substitutions were identical in most cases. In contrast, the mutations were not identified in any of the OCCCas and their coexisting endometriosis. PIK3CA mutations were observed in 11 (31.4%) of 35 OEMCas and 10 (35.7%) of 28 OCCCas. Ten of 11 OEMCas had PIK3CA mutations in exon 9, and eight of 10 OCCCas had them in exon 20. The same mutations were also detected in the coexisting nonatypical and/or atypical endometriosis in three OEMCas and four OCCCas. In addition, significant differences in the expression of pAkt, hepatocyte nuclear factor 1 beta, hypoxiainducible factor 1 alpha, p65, and inducible nitric oxide synthase were evident between the two types of tumors and their coexisting endometriosis. Conclusions: Distinct molecular events may occur in relatively early stages of tumorigenesis of endometriosisassociated OEMCas and OCCCas.	[Matsumoto, Toshihide; Yamazaki, Masaaki; Takahashi, Hiroyuki; Kajita, Sabine; Suzuki, Erina; Tsuruta, Tomoko; Saegusa, Makoto] Kitasato Univ, Sch Med, Dept Pathol, Sagamihara, Kanagawa 2520374, Japan	Saegusa, M (reprint author), Kitasato Univ, Sch Med, Dept Pathol, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520374, Japan.	msaegusa@med.kitasato-u.ac.jp					Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Saegusa M, 2009, AM J PATHOL, V174, P2107, DOI 10.2353/ajpath.2009.081018; Saegusa M, 2001, J PATHOL, V194, P59, DOI 10.1002/path.856; Fukunaga M, 1997, HISTOPATHOLOGY, V30, P249, DOI 10.1046/j.1365-2559.1997.d01-592.x; Sato N, 2000, CANCER RES, V60, P7052; Erzen M, 1998, EUR J GYNAECOL ONCOL, V19, P553; Prowse AH, 2006, INT J CANCER, V119, P556, DOI 10.1002/ijc.21845; Saegusa M, 2004, AM J PATHOL, V164, P1739, DOI 10.1016/S0002-9440(10)63732-7; Kuo KT, 2009, AM J PATHOL, V174, P1597, DOI 10.2353/ajpath.2009.081000; Palacios J, 1998, CANCER RES, V58, P1344; Kobayashi H, 2009, ONCOL REP, V22, P233, DOI 10.3892/or_00000429; Stern RC, 2001, INT J GYNECOL PATHOL, V20, P133, DOI 10.1097/00004347-200104000-00004; Prat J, 2014, INT J GYNECOL OBSTET, V124, P1, DOI 10.1016/j.ijgo.2013.10.001; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Rudd ML, 2011, CLIN CANCER RES, V17, P1331, DOI 10.1158/1078-0432.CCR-10-0540; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Veras E, 2009, AM J SURG PATHOL, V33, P844, DOI 10.1097/PAS.0b013e31819c4271; Yamaguchi K, 2008, CLIN CANCER RES, V14, P32, DOI 10.1158/1078-0432.CCR-07-1614; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Yamamoto S, 2011, J PATHOL, V225, P189, DOI 10.1002/path.2940; Nishida M, 2000, GYNECOL OBSTET INVES, V50, P18, DOI 10.1159/000052874; Marquez RT, 2005, CLIN CANCER RES, V11, P6116, DOI 10.1158/1078-0432.CCR-04-2509; Wright K, 1999, INT J CANCER, V82, P625, DOI 10.1002/(SICI)1097-0215(19990827)82:5<625::AID-IJC1>3.0.CO;2-2; Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246; Dinulescu DM, 2005, NAT MED, V11, P531; Du Q, 2013, CANCER RES, V73, P6526, DOI 10.1158/0008-5472.CAN-13-1620; Longacre TA, 2014, WHO CLASS TUM FEM RE, P11; McConechy MK, 2014, MODERN PATHOL, V27, P128, DOI 10.1038/modpathol.2013.107; Oliva E, 2006, J PATHOL, V208, P708, DOI 10.1002/path.1923; Olive DL, 2003, SEMIN REPROD MED, V21, P209; Saegusa M, 2005, LAB INVEST, V85, P768, DOI 10.1038/labinvest.3700273; Saegusa M, 2001, BRIT J CANCER, V84, P209, DOI 10.1054/bjoc.2000.1581; Seagusa M, 2008, J PATHOL, V216, P521; Shigetomi H, 2012, GYNECOL ENDOCRINOL, V28, P897, DOI 10.3109/09513590.2012.683071; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Takahashi H, 2014, HUM PATHOL, V45, P33, DOI 10.1016/j.humpath.2013.06.020; Seidman JD, 1996, INT J GYNECOL PATHOL, V15, P1, DOI 10.1097/00004347-199601000-00001	39	0	0	AMER SOC CLINICAL PATHOLOGY	CHICAGO	2100 W HARRISON ST, CHICAGO, IL 60612 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	SEP	2015	144	3					452	463		10.1309/AJCPZ5T2POOFMQVN		12	Pathology	Pathology	CO9FE	WOS:000359477800011		
J	Amano, K; Morita, T; Tatara, R; Katayama, H; Aiki, S; Kitada, N; Fumimoto, H; Sato, E				Amano, Koji; Morita, Tatsuya; Tatara, Ryohei; Katayama, Hirofumi; Aiki, Sayo; Kitada, Namiki; Fumimoto, Hiromi; Sato, Emi			Assessment of Intervention by a Palliative Care Team Working in a Japanese General Hospital: A Retrospective Study	AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE			English	Article						palliative care team; inpatient hospice; patient with cancer; opioid prescription; length of stay	CANCER-PATIENTS; CONTROLLED-TRIAL; LATE REFERRALS; IMPROVE; LIFE; END; CONSULTATION; FAMILIES; UNITS; PAIN	Our objective was to explore the effectiveness of a palliative care team (PCT) by investigating potential differences in opioid prescription between patients who had had PCT involvement before admission to an inpatient hospice and those who had not. A total of 221 patients met the criteria; they were divided into an intervention group (n = 140) and a control group (n = 81). The daily dose of opioid before admission to the hospice was significantly higher in the intervention group (P < .001). The difference between the maximum opioid dose and the initial dose, the rate of increase in opioids until death, and the length of stay in the hospice were not significantly different between the groups. A PCT contributes to more appropriate use of opioids before admission to a hospice.	[Amano, Koji; Tatara, Ryohei] Osaka City Gen Hosp, Dept Palliat Med, Palliat Care Team, Osaka 5340021, Japan; [Morita, Tatsuya] Seirei Mikatahara Gen Hosp, Dept Palliat & Support Care, Palliat Care Team, Shizuoka, Japan; [Morita, Tatsuya] Seirei Mikatahara Gen Hosp, Seirei Hosp, Shizuoka, Japan; [Katayama, Hirofumi; Aiki, Sayo] Osaka City Gen Hosp, Dept Palliat Med, Osaka 5340021, Japan; [Kitada, Namiki; Fumimoto, Hiromi; Sato, Emi] Osaka City Gen Hosp, Palliat Care Team, Osaka 5340021, Japan	Amano, K (reprint author), Osaka City Gen Hosp, Dept Palliat Med, Palliat Care Team, Miyakojima Ku, 2-13-22 Miyakojima Hondori, Osaka 5340021, Japan.	kojiamano4813@gmail.com					Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Morita T, 2009, J PAIN SYMPTOM MANAG, V38, P191, DOI 10.1016/j.jpainsymman.2008.09.011; Higginson IJ, 2002, J PAIN SYMPTOM MANAG, V23, P96, DOI 10.1016/S0885-3924(01)00406-7; Morita T, 2005, J CLIN ONCOL, V23, P2637; Simon S, 2009, PALLIATIVE MED, V23, P23, DOI 10.1177/0269216308098802; Hanks GW, 2002, BRIT J CANCER, V87, P733, DOI 10.1038/sj.bjc.6600522; Morita T, 2013, LANCET ONCOL, V14, P638, DOI 10.1016/S1470-2045(13)70127-X; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; ELLERSHAW JE, 1995, PALLIATIVE MED, V9, P145, DOI 10.1177/026921639500900205; Fine PG, 2009, J PAIN SYMPTOM MANAG, V38, P418, DOI 10.1016/j.jpainsymman.2009.06.002; Higginson IJ, 2003, J PAIN SYMPTOM MANAG, V25, P150, DOI 10.1016/S0885-3924(02)00599-7; Higginson IJ, 2010, CANCER J, V16, P423, DOI 10.1097/PPO.0b013e3181f684e5; Carvajal A, 1997, MED CLIN-BARCELONA, V109, P281; Centeno Carlos, 2009, BMC Palliat Care, V8, P2, DOI 10.1186/1472-684X-8-2; de Santiago A, 2012, SUPPORT CARE CANCER, V20, P2199, DOI 10.1007/s00520-012-1476-x; Higginson IJ, 1997, J PAIN SYMPTOM MANAG, V14, P29, DOI 10.1016/S0885-3924(97)00006-7; Hospice PalliativeCare Japan, 2013, TIM TREND PALL CAR U; Ida E, 2002, PALLIATIVE MED, V16, P179, DOI 10.1191/0269216302pm511oa; Iwase Satoru, 2007, Am J Hosp Palliat Care, V24, P29, DOI 10.1177/1049909106295302; Jack B, 2004, PALLIATIVE MED, V18, P46, DOI 10.1191/0269216304pm846oa; Jacobs LG, 2002, J PAIN SYMPTOM MANAG, V24, P299, DOI 10.1016/S0885-3924(02)00492-X; Japanese Society for Palliative Medicine, 2013, NUMB REG PALL CAR TE; Maeyama E, 2003, SUPPORT CARE CANCER, V11, P509, DOI 10.1007/s00520-003-0465-5; Morita T, 2005, J PAIN SYMPTOM MANAG, V29, P595, DOI 10.1016/j.jpainsymann.2004.11.008; Morita T, 2002, PALLIATIVE MED, V16, P185, DOI 10.1191/0269216302pm524oa; National Comprehensive Cancer Network Prevention and Treatment of Cancer-Related Infection, 2009, NCCN CLIN PRACT GUID; World Health Organization, 1996, CANC PAIN REL GUID O; World Health Organization, 1990, WHO TECHN REP SER, P804	28	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-9091	1938-2715		AM J HOSP PALLIAT ME	Am. J. Hosp. Palliat. Med.	SEP	2015	32	6					600	603		10.1177/1049909114532340		4	Health Care Sciences & Services	Health Care Sciences & Services	CO8JS	WOS:000359415600005		
J	Yoshida, S; Miyashita, M; Morita, T; Akizuki, N; Akiyama, M; Shirahige, Y; Ichikawa, T; Eguchi, K				Yoshida, Saran; Miyashita, Mitsunori; Morita, Tatsuya; Akizuki, Nobuya; Akiyama, Miki; Shirahige, Yutaka; Ichikawa, Takayuki; Eguchi, Kenji			Strategies for Development of Palliative Care From the Perspectives of General Population and Health Care Professionals: A Japanese Outreach Palliative Care Trial of Integrated Regional Model Study	AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE			English	Article						development; palliative care; strategy; knowledge; informational resource; Japan	END-OF-LIFE; KNOWLEDGE; BARRIERS; PAIN; INFORMATION; COUNTRIES; ATTITUDES	This study primarily aimed to identify future actions required to promote palliative care in Japan. The future actions regarded as effective by the general population were improve physicians' skill in palliative care (61%), create a counseling center for cancer (61%), and improve nurses' skill in palliative care (60%). In contrast, future actions regarded as effective by the health care professionals were set up a Web site that provides information about cancer (72%), promote consultation with specialists in palliative care (71%), and open an outpatient department specializing in palliative care (70%). The results suggest (1) development and maintenance of settings; (2) enhancement of palliative care education and training programs for health care providers; and (3) improvement in distributing information about cancer and regional palliative care resources to the general population.	[Yoshida, Saran] Natl Canc Ctr, Ctr Canc control & Informat Serv, Tokyo, Japan; [Miyashita, Mitsunori] Tohoku Univ, Grad Sch Med, Dept Palliat Nursing Hlth Sci, Sendai, Miyagi, Japan; [Morita, Tatsuya] Seirei Mikatahara Gen Hosp, Dept Palliat & Support Care, Hamamatsu, Shizuoka, Japan; [Akizuki, Nobuya] Chiba Canc Ctr, Psycho Oncol Div, Chiba 2608717, Japan; [Akiyama, Miki] Keio Univ, Fac Policy Management, Tokyo, Japan; [Shirahige, Yutaka] Shirahige Clin, Nagasaki, Japan; [Ichikawa, Takayuki] Univ Tokyo, Grad Sch Engn, Dept Architecture, Tokyo, Japan; [Eguchi, Kenji] Teikyo Univ, Sch Med, Dept Internal Med & Med Oncol, Tokyo 173, Japan	Yoshida, S (reprint author), Natl Canc Ctr, Ctr Canc control & Informat Serv, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	saryoshi@ncc.go.jp		Yoshida, Saran/0000-0003-4055-2267	Third Term Comprehensive Control Research for Cancer Health and Labor Sciences Research Grant	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Grant in aid: This study was funded by the Third Term Comprehensive Control Research for Cancer Health and Labor Sciences Research Grant.	Mack JW, 2012, J CLIN ONCOL, V30, P4387, DOI 10.1200/JCO.2012.43.6055; Yamagishi A, 2008, AM J HOSP PALLIAT ME, V25, P412, DOI 10.1177/1049909108318568; Hesse BW, 2005, ARCH INTERN MED, V165, P2618, DOI 10.1001/archinte.165.22.2618; Miyashita M, 2007, J PALLIAT MED, V10, P390, DOI 10.1089/jpm.2006.0154; Morita T, 2006, J PAIN SYMPTOM MANAG, V31, P306, DOI 10.1016/j.jpainsymman.2005.09.004; Visentin M, 2001, J PAIN SYMPTOM MANAG, V22, P925, DOI 10.1016/S0885-3924(01)00355-4; Sanjo M, 2008, J PAIN SYMPTOM MANAG, V35, P275, DOI 10.1016/j.jpainsymman.2007.04.021; Lynch T, 2009, J PAIN SYMPTOM MANAG, V37, P305, DOI 10.1016/j.jpainsymman.2008.03.011; McCaffery M, 1997, J PAIN SYMPTOM MANAG, V14, P175, DOI 10.1016/S0885-3924(97)00170-X; Bingley A, 2009, J PAIN SYMPTOM MANAG, V37, P287, DOI 10.1016/j.jpainsymman.2008.02.014; Dart J, 2008, AUST HEALTH REV, V32, P186; Goepp JG, 2008, AM J HOSP PALLIAT ME, V25, P309, DOI 10.1177/1049909108319265; Ida E, 2002, PALLIATIVE MED, V16, P179, DOI 10.1191/0269216302pm511oa; LARUE F, 1995, CANCER, V76, P2375, DOI 10.1002/1097-0142(19951201)76:11<2375::AID-CNCR2820761129>3.0.CO;2-C	14	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-9091	1938-2715		AM J HOSP PALLIAT ME	Am. J. Hosp. Palliat. Med.	SEP	2015	32	6					604	610		10.1177/1049909114532341		7	Health Care Sciences & Services	Health Care Sciences & Services	CO8JS	WOS:000359415600006		
J	Tanabe, K; Sawada, K; Shimada, M; Kadoya, S; Endo, N; Ishiguro, K; Takashima, R; Amemiya, Y; Fujikawa, Y; Ikezaki, T; Takeuchi, M; Kitazawa, H; Iida, H; Koseki, S; Morita, T; Sasaki, K; Kashii, T; Murakami, N				Tanabe, Kouichi; Sawada, Koichiro; Shimada, Masanari; Kadoya, Shinichi; Endo, Naoki; Ishiguro, Kaname; Takashima, Rumi; Amemiya, Yoko; Fujikawa, Yasunaga; Ikezaki, Tomoaki; Takeuchi, Miyako; Kitazawa, Hidenori; Iida, Hiroyuki; Koseki, Shiro; Morita, Tatsuya; Sasaki, Koji; Kashii, Tatsuhiko; Murakami, Nozomu			Evaluation of A Novel Information-Sharing Instrument for Home-Based Palliative Care: A Feasibility Study	AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE			English	Article						patient-held records; information sharing; regional clinical referral pathway; home-based palliative care; multidisciplinary team care; daily record production	CANCER CARE; JAPAN; RECORDS	Aim:To examine the feasibility and usefulness of a novel region-based pathway: the Regional Referral Clinical Pathway for Home-Based Palliative Care.Method:This was a feasibility study to evaluate the frequency of variances and the perceived usefulness of pathway using in-depth interviews. All patients with cancer referred to the palliative care team between 2011 and 2013 and received home care services were enrolled.Result:A total of 44 patients were analyzed, and pathway was completed in all the patients. The target outcome was achieved in 61.4% while some variances occurred in 54.5%. Nine categories were identified as the usefulness of the pathway, such as reviewing and sharing information and promoting communication, education, motivation, and relationships.Conclusion:This novel pathway is feasible and seems to be useful.	[Tanabe, Kouichi; Kashii, Tatsuhiko] Toyama Univ Hosp, Dept Med Oncol, Toyama, Toyama 9300194, Japan; [Sawada, Koichiro; Shimada, Masanari; Kadoya, Shinichi; Endo, Naoki; Ishiguro, Kaname; Takashima, Rumi; Amemiya, Yoko; Fujikawa, Yasunaga; Ikezaki, Tomoaki; Takeuchi, Miyako; Kitazawa, Hidenori; Iida, Hiroyuki] Saiseikai Takaoka Hosp, Board Palliat Care, Toyama, Japan; [Koseki, Shiro] Takaoka Med Serv Reg, Home Palliat Care Comm, Takaoka, Toyama, Japan; [Morita, Tatsuya] Seirei Mikatahara Hosp, Dept Palliat & Support Care, Shizuoka, Japan; [Sasaki, Koji] Kyowa Hakko Kirin Co Ltd, Tokyo, Japan; [Murakami, Nozomu] Kanazawa Med Univ, Himi Municipal Hosp, Dept Gen & Digest Surg, Uchinada, Ishikawa, Japan	Tanabe, K (reprint author), Toyama Univ Hosp, Dept Med Oncol, 2630 Sugitani, Toyama, Toyama 9300194, Japan.	tanabeko-mi@umin.ac.jp			Japan Society for the Promotion of Science (JSPS) [25460892]; University of Toyama	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Foundations providing research grants: This study is supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) 25460892 and an administrative grant from the University of Toyama for our study.	Ikegami N, 2011, LANCET, V378, P1106, DOI 10.1016/S0140-6736(11)60828-3; Borras JM, 2014, EUR J CANCER, V50, P475, DOI 10.1016/j.ejca.2013.11.012; Yamagishi A, 2012, SUPPORT CARE CANCER, V20, P2575, DOI 10.1007/s00520-011-1373-8; Morita T, 2013, LANCET ONCOL, V14, P638, DOI 10.1016/S1470-2045(13)70127-X; Fukui S, 2011, J PAIN SYMPTOM MANAG, V42, P882, DOI 10.1016/j.jpainsymman.2011.02.024; Chinone Y, 2008, JPN J PALLIAT MED, V10, P247; Chinone Y, 2007, JPN J PALLIAT MED, V9, P102; Funada C, 2007, JPN J PALLIAT MED, V9, P139; Gysels M, 2007, HEALTH EXPECT, V10, P75, DOI 10.1111/j.1369-7625.2006.00415.x; Imada K, 2009, GLOSSARIES CLIN PATH, V1st, P1; Katsuo S, 2009, GLOSSARIES CLIN PATH, V1st, P47; Ko H, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2009.037531; Komura K, 2013, PALLIATIVE MED, V27, P179, DOI 10.1177/0269216311431758; Krippendorff K, 1980, CONTENT ANAL INTRO I; Morita T, 2013, CURR OPIN SUPPORT PA, V7, P207, DOI 10.1097/SPC.0b013e3283612241; Overill S, 2003, CARE DYING PATHWAY E, P1; Shima Y, 2013, JPN J HOSP PALLIAT C, V23, P108; Shimozuma K, 2007, JPN J PALLIAT MED, V9, P131; Tadokoro Kaori, 2006, Gan To Kagaku Ryoho, V33 Suppl 2, P338; Tsuneto S, 2013, JPN J CLIN ONCOL, V43, P17, DOI 10.1093/jjco/hys188; Wiggans MG, 2013, HPB SURG, V2013, DOI [10.1155/2013/861681, DOI 10.1155/2013/861681]	21	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-9091	1938-2715		AM J HOSP PALLIAT ME	Am. J. Hosp. Palliat. Med.	SEP	2015	32	6					611	619		10.1177/1049909114533141		9	Health Care Sciences & Services	Health Care Sciences & Services	CO8JS	WOS:000359415600007		
J	Yamaguchi, M; Tezuka, Y; Takeda, K; Shetty, V				Yamaguchi, Masaki; Tezuka, Yuki; Takeda, Kazunori; Shetty, Vivek			Disposable collection kit for rapid and reliable collection of saliva	AMERICAN JOURNAL OF HUMAN BIOLOGY			English	Article							BIOMARKERS; DIAGNOSIS; CORTISOL	ObjectivesTo describe and evaluate disposable saliva collection kit for rapid, reliable, and reproducible collection of saliva samples. MethodsThe saliva collection kit comprised of a saliva absorbent swab and an extractor unit was used to retrieve whole saliva samples from 10 subjects. The accuracy and precision of the extracted volumes (3, 10, and 30 l) were compared to similar volumes drawn from control samples obtained by passive drool. Additionally, the impact of kit collection method on subsequent immunoassay results was verified by assessing salivary cortisol levels in the samples and comparing them to controls. ResultsThe recovered volumes for the whole saliva samples were 3.850.28, 10.79 +/- 0.95, and 31.18 +/- 1.72 l, respectively (CV=8.76%) and 2.91 +/- 0.19, 9.75 +/- 0.43, and 29.64 +/- 0.91 l, respectively, (CV=6.36%) for the controls. There was a close correspondence between the salivary cortisol levels from the saliva samples obtained by the collection kit and the controls (R-2>0.96). ConclusionsThe disposable saliva collection kit allows accurate and repeatable collection of fixed amounts of whole saliva and does not interfere with subsequent measurements of salivary cortisol. The simple collection process, lack of elaborate specimen recovery steps, and the short turnaround time (<3 min) should render the kit attractive to test subjects and researchers alike. Am. J. Hum. Biol. 27:720-723, 2015. (c) 2015 Wiley Periodicals, Inc.	[Yamaguchi, Masaki; Tezuka, Yuki] Iwate Univ, Grad Sch Engn, Biomed Engn & Robot Lab, Morioka, Iwate 0208551, Japan; [Takeda, Kazunori] Univ Tsukuba, Grad Course Disabil Sci, Tsukuba, Ibaraki 3058577, Japan; [Shetty, Vivek] Univ Calif Los Angeles, UCLA Sch Dent, Sect Oral & Maxillofacial Surg, Los Angeles, CA 90095 USA	Yamaguchi, M (reprint author), Iwate Univ, Grad Sch Engn, Biomed Engn & Robot Lab, 4-3-5 Ueda, Morioka, Iwate 0208551, Japan.	masakiy@iwate-u.ac.jp			'Ministry of Education, Culture, Sports, Science and Technology' Japan [25350517]	Contract grant sponsor: Grants from the 'Ministry of Education, Culture, Sports, Science and Technology' Japan; Contract grant number: 25350517.	Granger DA, 2007, PHYSIOL BEHAV, V92, P583, DOI 10.1016/j.physbeh.2007.05.004; KIRSCHBAUM C, 1994, PSYCHONEUROENDOCRINO, V19, P313, DOI 10.1016/0306-4530(94)90013-2; Shirtcliff EA, 2001, PSYCHONEUROENDOCRINO, V26, P165, DOI 10.1016/S0306-4530(00)00042-1; MANDEL ID, 1993, ANN NY ACAD SCI, V694, P1, DOI 10.1111/j.1749-6632.1993.tb18336.x; Kaushik A, 2014, BIOSENS BIOELECTRON, V53, P499, DOI 10.1016/j.bios.2013.09.060; Granger DA, 2012, BIOL RES NURS, V14, P347, DOI 10.1177/1099800412443892; Zhang AH, 2012, APPL BIOCHEM BIOTECH, V168, P1718, DOI 10.1007/s12010-012-9891-5; Hellhammer DH, 2009, PSYCHONEUROENDOCRINO, V34, P163, DOI 10.1016/j.psyneuen.2008.10.026; Koh DSQ, 2007, OCCUP ENVIRON MED, V64, P202, DOI 10.1136/oem.2006.026567; Yamaguchi M, 2012, DISTRIBUTED DIAGNOSI, P1	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1042-0533	1520-6300		AM J HUM BIOL	Am. J. Hum. Biol.	SEP-OCT	2015	27	5					720	723		10.1002/ajhb.22696		4	Anthropology; Biology	Anthropology; Life Sciences & Biomedicine - Other Topics	CP1ZX	WOS:000359677700018		
J	Miura, T; Ban, D; Tanaka, S; Mogushi, K; Kudo, A; Matsumura, S; Mitsunori, Y; Ochiai, T; Tanaka, H; Tanabe, M				Miura, Tomoya; Ban, Daisuke; Tanaka, Shinji; Mogushi, Kaoru; Kudo, Atsushi; Matsumura, Satoshi; Mitsunori, Yusuke; Ochiai, Takanori; Tanaka, Hiroshi; Tanabe, Minoru			Distinct clinicopathological phenotype of hepatocellular carcinoma with ethoxybenzyl-magnetic resonance imaging hyperintensity: association with gene expression signature	AMERICAN JOURNAL OF SURGERY			English	Article						Hepatocellular carcinoma; EOB-MRI; Gd-EOB-DTPA-enhanced MRI	GD-EOB-DTPA; FOCAL LIVER-LESIONS; ENHANCED MR-IMAGES; HEPATOBILIARY PHASE; INITIAL-EXPERIENCE; INTENSITY; TRANSPORTERS; DIAGNOSIS; FEATURES; MDCT	BACKGROUND: Although hepatocellular carcinoma (HCC) is mostly a lower intensity lesion in the hepatobiliary phase on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging, some HCCs were shown as a higher intensity lesion (high HCC). This study aimed to reveal the clinicopathological and biological properties of high HCC. METHODS: Patients who underwent curative hepatectomy as the first treatment for HCC were included. HCC was defined as high HCC if the ratio between the signal intensity of the HCC and the background liver was greater than or equal to 1.0. We retrospectively performed clinicopathological and global gene expression analyses. RESULTS: Of the 77 patients, 14 had high HCC. Serum protein induced by vitamin K absence or antagonist II levels in high HCC were lower, and the high HCCs were well differentiated. The 3-year disease-free survival rates in high HCC and low HCC patients were 90% and 54%, respectively (P = .035). Overall survival did not differ significantly. Global gene expression analysis revealed that SLCO1B3 was upregulated in high HCC. CONCLUSIONS: Clinicopathological analysis revealed low-grade malignancy in high HCCs compared with low HCCs. The expression of SLCO1B3 was key to the hyperintensity in the hepatobiliary phase of ethoxybenzyl-diethylenetriamine pentaacetic acid magnetic resonance imaging. (C) 2015 Elsevier Inc. All rights reserved.	[Miura, Tomoya; Ban, Daisuke; Kudo, Atsushi; Matsumura, Satoshi; Mitsunori, Yusuke; Ochiai, Takanori; Tanabe, Minoru] Tokyo Med & Dent Univ, Grad Sch Med, Dept Hepatobiliary & Pancreat Surg, Tokyo, Japan; [Tanaka, Shinji] Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Oncol, Tokyo, Japan; [Mogushi, Kaoru; Tanaka, Hiroshi] Tokyo Med & Dent Univ, Med Res Inst, Dept Bioinformat, Tokyo, Japan	Ban, D (reprint author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Hepatobiliary & Pancreat Surg, Tokyo, Japan.	d-ban.msrg@tmd.ac.jp			Ministry of Education, Culture, Sports, Science & Technology of Japan [A25253081, C25462082]; Ministry of Health, Labour and Welfare, Japan	This work was supported by Grant-in-Aid for Scientific Research on Innovative Areas, Scientific Research (A25253081) and (C25462082) from the Ministry of Education, Culture, Sports, Science & Technology of Japan, and Health & Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan.	Kitao A, 2011, EUR RADIOL, V21, P2056, DOI 10.1007/s00330-011-2165-8; Tsuboyama T, 2010, RADIOLOGY, V255, P824, DOI 10.1148/radiol.10091557; Ooka Y, 2013, MAGN RESON IMAGING, V31, P748, DOI 10.1016/j.mri.2012.10.028; Park Y, 2010, KOREAN J RADIOL, V11, P433, DOI 10.3348/kjr.2010.11.4.433; Baek CK, 2012, CLIN RADIOL, V67, P148, DOI 10.1016/j.crad.2011.08.011; Sano K, 2011, RADIOLOGY, V261, P834, DOI 10.1148/radiol.11101840; Bashir MR, 2013, J MAGN RESON IMAGING, V37, P398, DOI 10.1002/jmri.23818; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Huppertz A, 2004, RADIOLOGY, V230, P266, DOI 10.1148/radiol.2301020269; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Kitao A, 2012, RADIOLOGY, V265, P780, DOI 10.1148/radiol.12120226; Murakata A, 2011, ANN SURG, V253, P94, DOI 10.1097/SLA.0b013e3181f9bc00; Zollner G, 2005, LIVER INT, V25, P367, DOI 10.1111/j.1478-3231.2005.01033.x; Asayama Y, 2011, EUR J RADIOL, V80, pE243, DOI 10.1016/j.ejrad.2010.10.032; Huppertz A, 2005, RADIOLOGY, V234, P468, DOI 10.1148/radiol.2342040278; Nies AT, 2001, INT J CANCER, V94, P492, DOI 10.1002/ijc.1498; Marrero JA, 2005, LIVER TRANSPLANT, V11, P281, DOI 10.1002/lt.20357; Aihara A, 2010, J HEPATOL, V52, P63, DOI 10.1016/j.jhep.2009.10.013; Narita M, 2009, J GASTROENTEROL, V44, P793, DOI 10.1007/s00535-009-0056-4; Yoneda N, 2013, JPN J RADIOL, V31, P480, DOI 10.1007/s11604-013-0224-6; Yoo SH, 2013, ANN SURG ONCOL, V20, P2893, DOI 10.1245/s10434-013-3001-y; Fujita M, 1996, JMRI-J MAGN RESON IM, V6, P472, DOI 10.1002/jmri.1880060310; Cabrera R, 2010, ALIMENT PHARM THER, V31, P461, DOI 10.1111/j.1365-2036.2009.04200.x; Kitao A, 2010, RADIOLOGY, V256, P817, DOI 10.1148/radiol.10092214; Tanimoto A, 2009, EUR RADIOL, V19, pS975, DOI 10.1007/s00330-009-1624-y; Lee SA, 2011, MAGN RESON IMAGING, V29, P83, DOI 10.1016/j.mri.2010.07.019; Liver Cancer Study Group of Japan, 2010, GEN RUL CLIN PATH ST; Ohama H, 2014, J GASTROENTEROL, V49, P1051; Smyth G. K., 2004, APPL GENET MOL BIOL, V3, DOI DOI 10.2202/1544-6115.1027; Vander BS, 2005, J PATHOL, V207, P471	30	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	SEP	2015	210	3					561	569		10.1016/j.amjsurg.2015.03.027		9	Surgery	Surgery	CP0WN	WOS:000359597500022		
J	Saito, T; Liu, W; Chew, STH; Ti, LK				Saito, T.; Liu, W.; Chew, S. T. H.; Ti, L. K.			Incidence of and risk factors for difficult ventilation via a supraglottic airway device in a population of 14480 patients fromSouth-East Asia	ANAESTHESIA			English	Article							OBSTRUCTIVE SLEEP-APNEA; LARYNGEAL MASK; INTUBATION; MANAGEMENT; PREDICTION; GUIDELINES; GENDER; TIME	Difficult airway practice guidelines include the use of a supraglottic airway device as part of the armamentarium to provide and maintain ventilation and oxygenation. We retrospectively reviewed 14480 patients aged 18years who underwent general anaesthesia. We identified 74 (0.5%) patients whose lungs were identified as having been difficult to ventilate via a supraglottic airway device, and 29 (0.2%) patients in whom device placement failed. Multivariate analysis identified four risk factors for difficult ventilation via a supraglottic airway device: male sex (OR 1.75, 95% CI 1.07-2.86, p=0.02); age >45years (OR 1.70, 95% CI 1.01-2.86, p=0.04); short thyromental distance (OR 4.35, 95% CI 2.31-8.17, p<0.001); and limited neck movement (OR 2.75, 95% CI 1.02-7.44, p=0.04). Adverse respiratory events including oxygen desaturation, hypercapnoea, laryngospasm, and bronchospasm occurred in 17 patients (22%). The incidence of difficult ventilation via a supraglottic airway device was 0.5% in a large cohort of South-East Asian patients.	[Saito, T.] Dokkyo Med Univ, Koshigaya Hosp, Dept Anaesthesia, Saitama, Japan; [Liu, W.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anaesthesia, Singapore 117548, Singapore; [Chew, S. T. H.] Singapore Gen Hosp, Dept Anaesthesia, Singapore, Singapore; [Ti, L. K.] Natl Univ Hlth Syst, Dept Anaesthesia, Singapore, Singapore	Saito, T (reprint author), Dokkyo Med Univ, Koshigaya Hosp, Dept Anaesthesia, Saitama, Japan.	s-tomo@dokkyomed.ac.jp					Kheterpal S, 2006, ANESTHESIOLOGY, V105, P885, DOI 10.1097/00000542-200611000-00007; Timmermann A, 2011, ANAESTHESIA, V66, P45, DOI 10.1111/j.1365-2044.2011.06934.x; Mohsenin V, 2001, CHEST, V120, P1442, DOI 10.1378/chest.120.5.1442; ElGanzouri AR, 1996, ANESTH ANALG, V82, P1197, DOI 10.1097/00000539-199606000-00017; Ramachandran SK, 2012, ANESTHESIOLOGY, V116, P1217, DOI 10.1097/ALN.0b013e318255e6ab; Henderson JJ, 2004, ANAESTHESIA, V59, P675, DOI 10.1111/j.1365-2044.2004.03831.x; Isono S, 2011, ANESTHESIOLOGY, V114, P7, DOI 10.1097/ALN.0b013e318201c8b9; Lam B, 2005, THORAX, V60, P504, DOI 10.1136/thx.2004.031591; GUILLEMINAULT C, 1988, CHEST, V93, P104, DOI 10.1378/chest.93.1.104; Mohsenin V, 2003, SLEEP MED, V4, P523, DOI 10.1016/S1389-9457(03)00168-0; Puhringer FK, 2008, ANESTHESIOLOGY, V109, P188, DOI 10.1097/ALN.0b013e31817f5bc7; Shiga T, 2005, ANESTHESIOLOGY, V103, P429, DOI 10.1097/00000542-200508000-00027; Abramson Z, 2009, J CRANIOFAC SURG, V20, P657, DOI 10.1097/SCS.0b013e318193d521; Caplan RA, 2003, ANESTHESIOLOGY, V98, P1269; Apfelbaum Jeffrey L, 2013, Anesthesiology, V118, P251, DOI 10.1097/ALN.0b013e31827773b2; Asai T, 1998, BRIT J ANAESTH, V80, P617; BRIMACOMBE J, 1993, ANAESTHESIA, V48, P347, DOI 10.1111/j.1365-2044.1993.tb06968.x; Diemunsch P, 2008, ANN FR ANESTH, V27, P3, DOI 10.1016/j.annfar.2007.10.028; Hashimoto Y, 2015, ANAESTHESIA, V69, P878; MCCRORY CR, 1995, ANESTH ANALG, V81, P1001, DOI 10.1097/00000539-199511000-00018; Norskov AK, 2015, ANAESTHESIA, V70, P272, DOI 10.1111/anae.12955; Patel A, 2015, ANAESTHESIA, V70, P323, DOI 10.1111/anae.12923; Qudaisat IY, 2011, EUR J ANAESTH, V28, P600, DOI 10.1097/EJA.0b013e328347cdd9; Randell T, 1996, ACTA ANAESTH SCAND, V40, P1016; World Health Organization, 2015, GLOB HLTH OBS MEAN B	25	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	SEP	2015	70	9					1079	1083		10.1111/anae.13153		5	Anesthesiology	Anesthesiology	CP1ZS	WOS:000359677200011		
J	Hasaba, Y; Yasuda, CI; Wada, S				Hasaba, Yukari; Yasuda, Chiaki I.; Wada, Satoshi			Reason for being single: some males do not guard receptive females in the hermit crab Pagurus filholi	ANIMAL BEHAVIOUR			English	Article						allocation; growth; hermit crab; mating behaviour; Pagurus	MALE-MALE COMPETITION; MALE-MALE CONTESTS; MALE MATE CHOICE; SEXUAL SIGNAL; EXPERIENCE; MIDDENDORFFII; NIGROFASCIA; PREFERENCE; BEHAVIOR; SUCCESS	In animals that reproduce sexually, males are often under strong selection to maximize the number of mating opportunities. However, in some iteroparous species, males do not always maximize the allocation of time and energy to the present mating opportunity. Male hermit crabs of the genus Pagurus show precopulatory guarding as a mate acquisition strategy. Although almost all males within this genus guard and compete for receptive females, males of Pagurus filholi differ in how likely they are to do so. To examine the factors explaining the absence of guarding behaviour in P. filholi, a laboratory experiment was conducted that focused on whether either of two receptive females was guarded by solitary males that had been found not paired in the field, had lost a previous male-male contest or had copulated with other females. Solitary males showed a significantly lower frequency of guarding than males with experience of losing or of copulation. In the solitary group, males that moulted within 5 days after the experimental trial did not guard females, and the moulting frequency of nonguarding males was significantly higher than that of guarding males. In further analysis, smaller solitary males were shown to be less likely to guard females. The results of the experiment suggest that males of P. filholi may not always invest as much as possible in the present mating opportunity but may temporarily invest in growth during the 8-month mating season. (C) 2015 The Association for the Study of Animal Behaviour. Published by Elsevier Ltd. All rights reserved.	[Hasaba, Yukari; Yasuda, Chiaki I.; Wada, Satoshi] Hokkaido Univ, Grad Sch Fisheries Sci, Lab Marine Biol & Biodivers, Hakodate, Hokkaido 0418611, Japan	Yasuda, CI (reprint author), Hokkaido Univ, Grad Sch Fisheries Sci, Lab Marine Biol & Biodivers, 3-1-1 Minato Cho, Hakodate, Hokkaido 0418611, Japan.	chiaki.y.0210@gmail.com			 [KAKENHI 25440228]	We are grateful to Professor S. Goshima, Professor Y. Watanuki and Dr. C. Norman for their invaluable comments on the manuscript and for Ms N. Kaga for help with the experiment. We thank the anonymous referees for their extensive comments and contributions that improved the manuscript. We also thank the members of the laboratory of Marine Biology and Biodiversity for their support. This study was partly supported by Grants-in-Aid for Scientific Research (KAKENHI 25440228) to S. W.	Andersson M., 1994, SEXUAL SELECTION; Hsu YY, 2006, BIOL REV, V81, P33, DOI 10.1017/S146479310500686X; Heino M, 1999, J EVOLUTION BIOL, V12, P423; Yasuda C, 2012, ANIM BEHAV, V84, P385, DOI 10.1016/j.anbehav.2012.05.007; Wada S, 2007, MAR BIOL, V152, P1263, DOI 10.1007/s00227-007-0773-2; Yasuda C, 2011, MAR BIOL, V158, P2327, DOI 10.1007/s00227-011-1736-1; Scharf I, 2013, EVOL BIOL, V40, P169, DOI 10.1007/s11692-012-9213-4; Kasumovic MM, 2009, ANIM BEHAV, V77, P1533, DOI 10.1016/j.anbehav.2009.02.026; Hsu YY, 1999, ANIM BEHAV, V57, P903, DOI 10.1006/anbe.1998.1049; Rutte C, 2006, TRENDS ECOL EVOL, V21, P16, DOI 10.1016/j.tree.2005.10.014; Perez-Staples D, 2010, ETHOLOGY, V116, P778, DOI 10.1111/j.1439-0310.2010.01790.x; Bollache L, 2004, BEHAV PROCESS, V66, P131, DOI 10.1016/j.beproc.2004.01.010; Christy JH, 2006, ANIM BEHAV, V71, P1239, DOI 10.1016/j.anbehav.2005.11.008; Christy JH, 2001, BEHAVIOUR, V138, P1065, DOI 10.1163/156853901753287145; Goshima S, 1998, ECOL RES, V13, P151, DOI 10.1046/j.1440-1703.1998.00254.x; Goshima S., 2006, BIOL ANOMURA 2 CRUST, V6, P87; Goshima Seiji, 1996, Crustacean Research, V25, P86; Judge KA, 2010, BEHAV ECOL SOCIOBIOL, V64, P1971, DOI 10.1007/s00265-010-1008-y; Kawaminami T, 2015, J ETHOL, V33, P25, DOI 10.1007/s10164-014-0411-7; Matsuo K., 2015, MARINE ECOL IN PRESS; Muramatsu D, 2010, ETHOL ECOL EVOL, V22, P87, DOI 10.1080/03949370903516040; Nakazawa M., 2014, PACKAGE FMSB COMPREH; Okamura S, 2010, J ETHOL, V28, P323, DOI 10.1007/s10164-009-0188-2; R Core Team, 2012, R LANG ENV STAT COMP; Stearns S. C., 1992, EVOLUTION LIFE HIST; Suzuki Y, 2012, MAR BIOL, V159, P1991, DOI 10.1007/s00227-012-1986-6; Tanikawa Daisuke, 2012, Japanese Journal of Benthology, V67, P15; Wada Satoshi, 1995, Crustacean Research, V24, P23; Wada S, 2011, BEHAV ECOL, V22, P114, DOI 10.1093/beheco/arq183; Wada Satoshi, 2008, Crustacean Research, V37, P67; Wada S, 1999, J EXP MAR BIOL ECOL, V239, P289, DOI 10.1016/S0022-0981(99)00045-3; Yasuda CI, 2015, BEHAV ECOL SOCIOBIOL, V69, P1287, DOI 10.1007/s00265-015-1941-x; Yasuda CI, 2014, ANIM BEHAV, V96, P49, DOI 10.1016/j.anbehav.2014.07.021; Yoshii Kenji, 2009, Japanese Journal of Benthology, V64, P25	34	0	0	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0003-3472	1095-8282		ANIM BEHAV	Anim. Behav.	SEP	2015	107						1	5		10.1016/j.anbehav.2015.06.003		5	Behavioral Sciences; Zoology	Behavioral Sciences; Zoology	CP1DM	WOS:000359616500002		
J	Pitiwittayakul, N; Yukphan, P; Sintuprapa, W; Yamada, Y; Theeragool, G				Pitiwittayakul, Nittaya; Yukphan, Pattaraporn; Sintuprapa, Wilawan; Yamada, Yuzo; Theeragool, Gunjana			Identification of acetic acid bacteria isolated in Thailand and assigned to the genus Acetobacter by groEL gene sequence analysis	ANNALS OF MICROBIOLOGY			English	Article						Acetic acid bacteria; Acetobacter strains; groEL gene sequences; 16S rRNA gene sequences	RIBOSOMAL-RNA GENE; TRANSCRIBED SPACER RESTRICTION; SP-NOV.; SPECIES IDENTIFICATION; PHYLOGENETIC ANALYSIS; ALPHA-PROTEOBACTERIA; POLYPHASIC TAXONOMY; DIFFERENTIATION; GLUCONOBACTER; STRAINS	Twenty-three strains of acetic acid bacteria were isolated by an enrichment culture approach from fruits, flowers, mushrooms, and fermented rice products collected in Thailand. All were assigned to the genus Acetobacter and examined taxonomically for 16S rRNA gene and groEL gene sequences. Based on analysis of 16S rRNA gene and groEL gene sequences, the strains isolated were divided into ten groups: Group 1 comprised four isolates identified as A. tropicalis, Group 2 consisted of three isolates identified as A. indonesiensis, Group 3 had two isolates identified as A. persici, Group 4 was two isolates (A. orientalis), Group 5 was one isolate (A. cibinongensis), Group 6 contained three isolates (A. pasteurianus), Group 7 was one isolate of A. papayae, Group 8 was two isolates identified as A. fabarum, Group 9 was one isolate of A. okinawensis, and Group 10 was four isolates identified as A. ghanensis.	[Pitiwittayakul, Nittaya; Theeragool, Gunjana] Kasetsart Univ, Interdisciplinary Grad Program Genet Engn, Grad Sch, Bangkok 10900, Thailand; [Yukphan, Pattaraporn; Yamada, Yuzo] Natl Sci & Technol Dev Agcy, BIOTEC Culture Collect, Natl Ctr Genet Engn & Biotechnol BIOTEC, Klong Luang Pathum Thani 12120, Thailand; [Sintuprapa, Wilawan] Kasetsart Univ, Dept Biotechnol, Fac Agroind, Ladyaowchatuchak Bangkok 10900, Thailand; [Yamada, Yuzo] Japan Int Cooperat Agcy, Shibuya Ku, Tokyo 1518558, Japan; [Yamada, Yuzo] Shizuoka Univ, Suruga ku, Shizuoka 4228529, Japan; [Theeragool, Gunjana] Kasetsart Univ, Fac Sci, Dept Microbiol, Bangkok 10900, Thailand	Theeragool, G (reprint author), Kasetsart Univ, Fac Sci, Dept Microbiol, Bangkok 10900, Thailand.	fscignt@ku.ac.th			Strategic Scholarship/Fellowships Research Network from the Office of the Higher Education Commission, Ministry of Education [82/2549]; Japan Society for the Promotion of Science (JSPS); National Research Council of Thailand (NRCT)	This work was supported financially by the Strategic Scholarship/Fellowships Research Network from the Office of the Higher Education Commission, Ministry of Education (Grant no. 82/2549). Sincere thanks are also due to Mr. Richard James Goldrick, Department of Foreign Languages, Kasetsart University for English editing of this manuscript. A part of this work was carried out through collaboration in the Core to Core Program supported by the Japan Society for the Promotion of Science (JSPS) and the National Research Council of Thailand (NRCT).	AMEYAMA M, 1981, J BACTERIOL, V145, P814; Cleenwerck I, 2008, INT J FOOD MICROBIOL, V125, P2, DOI 10.1016/j.ijfoodmicro.2007.04.017; Huang CH, 2014, J SCI FOOD AGR, V94, P213, DOI 10.1002/jsfa.6231; STACKEBRANDT E, 1994, INT J SYST BACTERIOL, V44, P846; Teng LJ, 2001, J CLIN MICROBIOL, V39, P3326, DOI 10.1128/JCM.39.9.3326-3331.2001; Cleenwerck I, 2010, INT J SYST EVOL MICR, V60, P2277, DOI 10.1099/ijs.0.018465-0; Naser SM, 2005, MICROBIOL-SGM, V151, P2141, DOI 10.1099/mic.0.27840-0; Karenlampi RI, 2004, J CLIN MICROBIOL, V42, P5731, DOI 10.1128/JCM.42.12.5731-5738.2004; Glazunova OO, 2009, INT J SYST EVOL MICR, V59, P2317, DOI [10.1099/ijs.0.005488-0, 10.1099/ijs-0.005488-0]; YAMADA Y, 1969, J GEN APPL MICROBIOL, V15, P181, DOI 10.2323/jgam.15.181; COLWELL RR, 1970, J BACTERIOL, V104, P410; Tanasupawat S, 2011, J GEN APPL MICROBIOL, V57, P159; Ventura M, 2004, APPL ENVIRON MICROB, V70, P6197, DOI 10.1128/AEM.70.10.6197-6209.2004; Yamada Y, 2008, INT J FOOD MICROBIOL, V125, P15, DOI 10.1016/j.ijfoodmicro.2007.11.077; ASAI T, 1964, J GEN APPL MICROBIOL, V10, P95, DOI 10.2323/jgam.10.95; Kommanee J, 2008, ANN MICROBIOL, V58, P319; Jian WY, 2001, INT J SYST EVOL MICR, V51, P1633; Cleenwerck I, 2008, INT J SYST EVOL MICR, V58, P2180, DOI 10.1099/ijs.0.65778-0; Saeki A, 1997, BIOSCI BIOTECH BIOCH, V61, P138; Iino T, 2012, J GEN APPL MICROBIOL, V58, P235; Greenberg DE, 2006, INT J SYST EVOL MICR, V56, P2609, DOI 10.1099/ijs.0.64412-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Shin SC, 2011, SCIENCE, V334, P670, DOI 10.1126/science.1212782; OKUMURA H, 1985, AGR BIOL CHEM TOKYO, V49, P1011; Yamada Y, 1999, J GEN APPL MICROBIOL, V45, P23, DOI 10.2323/jgam.45.23; Azuma Y, 2009, NUCLEIC ACIDS RES, V37, P5768, DOI 10.1093/nar/gkp612; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Blaiotta G, 2008, APPL ENVIRON MICROB, V74, P208, DOI 10.1128/AEM.01711-07; Chang YH, 2003, APPL ENVIRON MICROB, V69, P4502, DOI 10.1128/AEM.69.8.4502.4510.2003; Chen HJ, 2008, J MED MICROBIOL, V57, P432, DOI 10.1099/jmm.0.47628-0; De Ley J., 1984, BERGEYS MANUAL SYSTE, V1, P267; Devereux R, 1995, MOL MICROBIAL ECOLOG, P331; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.2307/2408678; Hall T. A., 1999, NUCL ACIDS S SER, V4, P95, DOI DOI 10.1111/J.1469-8137.2009.02874.X; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Lee JH, 2003, J CLIN MICROBIOL, V41, P2952, DOI 10.1128/JCM.41.7.2952-2960.2003; Lisdiyanti P, 2002, INT J SYST EVOL MICR, V52, P813, DOI 10.1099/ijs.0.01982-0; Seearunruangchai A, 2004, J GEN APPL MICROBIOL, V50, P47, DOI 10.2323/jgam.50.47; Swings J, 1992, PROKARYOTES, V3, P2268; Swings J, 1992, SOC APPL BACTERIOLOG, V29, P103; Tanasupawat S, 2009, MICROBES ENVIRON, V24, P135, DOI 10.1264/jsme2.ME08564; Tanasupawat S, 2011, J SCI FOOD AGR, V91, P2652, DOI 10.1002/jsfa.4506; Teng JL, 2002, J CLIN MICROBIOL, V40, P3172; Vissert Hooft F, 1925, THESIS TU MEINEMA	44	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1590-4261	1869-2044		ANN MICROBIOL	Ann. Microbiol.	SEP	2015	65	3					1557	1564		10.1007/s13213-014-0994-9		8	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CO7YM	WOS:000359379800036		
J	Nishida, T				Nishida, Toshirou			The Role of Endoscopy in the Diagnosis of Gastric Gastrointestinal Stromal Tumors	ANNALS OF SURGICAL ONCOLOGY			English	Editorial Material							SUBMUCOSAL TUMORS; GIST; GUIDELINES; MANAGEMENT; LESIONS		Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan	Nishida, T (reprint author), Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan.	tnishida@east.ncc.go.jp					HEDENBRO JL, 1991, SURG ENDOSC-ULTRAS, V5, P20, DOI 10.1007/BF00591381; Dinis-Ribeiro M, 2012, ENDOSCOPY, V44, P74, DOI 10.1055/s-0031-1291491; Joensuu H, 2013, LANCET, V382, P973, DOI 10.1016/S0140-6736(13)60106-3; Nishida T, 2008, INT J CLIN ONCOL, V13, P416, DOI 10.1007/s10147-008-0798-7; Demetri GD, 2010, J NATL COMPR CANC NE, V8, pS1; ESMO/European Sarcoma Network Working Group, 2014, ANN ONCOL, V25, piii21, DOI 10.1093/annonc/mdu255; Miyazaki Y, 2013, EUR J CANCER, V49, P2681, DOI 10.1016/j.ejca.2013.04.006; Nishida T, 2013, DIGEST ENDOSC, V25, P479, DOI 10.1111/den.12149; Polkowski M, 2005, ENDOSCOPY, V37, P635, DOI 10.1055/s-861422; Poveda A, 2014, CANCER CHEMOTH PHARM, V74, P883, DOI 10.1007/s00280-014-2547-0; Yamamoto K, 2015, ANN SURG ONCOL, V22, P232, DOI 10.1245/s10434-014-3971-4	11	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1068-9265	1534-4681		ANN SURG ONCOL	Ann. Surg. Oncol.	SEP	2015	22	9					2810	2811		10.1245/s10434-015-4520-5		2	Oncology; Surgery	Oncology; Surgery	CO8NA	WOS:000359425000002		
J	Matsunaga, H; Tanaka, S; Aihara, A; Ogawa, K; Matsumura, S; Ban, D; Ochiai, T; Irie, T; Kudo, A; Nakamura, N; Arii, S; Tanabe, M				Matsunaga, Hiroko; Tanaka, Shinji; Aihara, Arihiro; Ogawa, Kousuke; Matsumura, Satoshi; Ban, Daisuke; Ochiai, Takanori; Irie, Takumi; Kudo, Atsushi; Nakamura, Noriaki; Arii, Shigeki; Tanabe, Minoru			A Novel Therapeutic Combination Sequentially Targeting Aurora B and Bcl-xL in Hepatocellular Carcinoma	ANNALS OF SURGICAL ONCOLOGY			English	Article							CANCER-THERAPY; ONCOGENE ADDICTION; SOLID TUMORS; PHASE-I; INHIBITOR; RECURRENCE; SORAFENIB; HEPATECTOMY; MECHANISMS; RATIONALE	Effective therapeutic combinations targeting the oncogenic pathway still are unknown in human hepatocellular carcinoma (HCC). The authors previously identified aberrant expression of aurora B kinase as the independent predictor for the lethal recurrence of HCC, showing that AZD1152 induced in vitro and in vivo apoptosis with polyploidy in human HCC cells. In this preclinical study, the combined effects of molecular-targeted therapies were evaluated based on the cellular response of aurora B inhibition. This study analyzed the expression of Bcl-2 family proteins in polyploidization induced by AZD1152 and the in vitro synergistic effects of AZD1152 with control of the Bcl-2 family pathway in human HCC cells. The in vivo effects of the combination therapy targeting the specific molecules were evaluated using subcutaneous tumor xenograft models. The findings showed that Bcl-xL was specifically overexpressed in AZD1152-induced polyploid HCC cells. The combination of AZD1152 followed by Bcl-xL/2 inhibitor ABT263 induced synergistically cellular apoptosis (p < 0.001) and growth inhibition (p < 0.0001). Interestingly, the reverse sequential administration of AZD1152 combined with pretreatment of ABT263 was less effective than the original one. In vivo studies using tumor xenografts of human HCC cells showed that combination therapy of ABT263 after AZD1152 pretreatment induced significant intratumoral apoptosis (p < 0.05) and remarkable anti-tumor effects (p < 0.05) without a severe adverse effect compared with the monotherapy. Based on Bcl-xL overexpression in polyploidy induced by aurora B inhibition, the rationale for therapeutic combinations targeting aurora B and Bcl-xL was demonstrated in the authors' preclinical studies, leading to a promising novel approach for the mechanism-based treatment of human HCC.	[Matsunaga, Hiroko; Aihara, Arihiro; Ogawa, Kousuke; Matsumura, Satoshi; Ban, Daisuke; Ochiai, Takanori; Irie, Takumi; Kudo, Atsushi; Nakamura, Noriaki; Arii, Shigeki; Tanabe, Minoru] Tokyo Med & Dent Univ, Grad Sch Med, Dept Hepatobiliary Pancreat Surg, Tokyo, Japan; [Tanaka, Shinji] Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Oncol, Tokyo, Japan	Matsunaga, H (reprint author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Hepatobiliary Pancreat Surg, Tokyo, Japan.	tanaka.monc@tmd.ac.jp			Ministry of Education, Culture, Sports, Science & Technology of Japan; Ministry of Health Labour & Welfare of Japan	We thank AstraZeneca for kindly providing us with AZD1152 and AZD1152-HQPA for experimental studies. We also thank Drs. Andrew Foxley and Kate Owen (AstraZeneca) for their helpful review of our manuscript. This work was supported by Grant-in-Aid for Scientific Research on Innovative Areas; Scientific Research (A) from the Ministry of Education, Culture, Sports, Science & Technology of Japan; and a Health & Labour Sciences Research Grant from the Ministry of Health Labour & Welfare of Japan.	Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Finn RS, 2013, J HEPATOL, V59, P1271, DOI 10.1016/j.jhep.2013.07.029; Carvajal RD, 2006, CLIN CANCER RES, V12, P6869, DOI 10.1158/1078-0432.CCR-06-1405; Wilson WH, 2010, LANCET ONCOL, V11, P1149, DOI [10.1016/S1470-2045(10)70261-8, 10.1016/S1470.2045(10)70261.8]; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Yap TA, 2013, J CLIN ONCOL, V31, P1592, DOI 10.1200/JCO.2011.37.6418; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Rudin CM, 2012, CLIN CANCER RES, V18, P3163, DOI 10.1158/1078-0432.CCR-11-3090; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Aihara A, 2010, J HEPATOL, V52, P63, DOI 10.1016/j.jhep.2009.10.013; Vogel C, 2007, CANCER RES, V67, P339, DOI 10.1158/0008-5472.CAN-06-2548; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Tanaka S, 2008, BRIT J SURG, V95, P611, DOI 10.1002/bjs.6011; Sherman M, 2008, NEW ENGL J MED, V359, P2045, DOI 10.1056/NEJMe0807581; Hikita H, 2010, HEPATOLOGY, V52, P1310, DOI 10.1002/hep.23836; Tanaka S, 2012, SEMIN ONCOL, V39, P486, DOI 10.1053/j.seminoncol.2012.05.005; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Tanaka S, 2006, J NATL CANCER I, V98, P491, DOI 10.1093/jnci/djj105; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Thomas MB, 2009, J CLIN ONCOL, V27, P843, DOI 10.1200/JCO.2008.18.3301; Arii S, 2010, HEPATOL RES, V40, P667, DOI 10.1111/j.1872-034X.2010.00673.x; Villanueva A, 2011, GASTROENTEROLOGY, V140, P1410, DOI 10.1053/j.gastro.2011.03.006; Casredo M, 2004, ONCOGENE, V23, P2825; Finn RS, 2013, SEMIN LIVER DIS, V33, pS11, DOI 10.1055/s-0033-1333632; Hemandez-Gea V, 2013, GASTROENTEROLOGY, V114, P512; Lachenmayer Anja, 2010, Dig Liver Dis, V42 Suppl 3, pS264, DOI 10.1016/S1590-8658(10)60515-4; Laplante M, 2012, CELL, V149, P149; Marquardt JU, 2014, CANCER CELL, V25, P550, DOI 10.1016/j.ccr.2014.04.002; Nicholas K, 2004, NAT REV CANCER, V4, P927; Petricoin EF, 2005, J CLIN ONCOL, V23, P3614, DOI 10.1200/JCO.2005.02.509; Raymond E, 2014, INVEST NEW DRUG, V32, P94, DOI 10.1007/s10637-013-9950-y; Roulston A, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004113; Shah OJ, 2010, P NATL ACAD SCI USA, V107, P12634, DOI 10.1073/pnas.0913615107; Shen YJ, 2005, J HISTOCHEM CYTOCHEM, V53, P725, DOI 10.1369/jhc.4A6545.2005; Tanaka S, 2007, J AM COLL SURGEONS, V204, P1, DOI 10.1016/j.jamcollsurg.2006.10.004; Wrzesinski SH, 2011, CLIN LIVER DIS, V15, P423, DOI 10.1016/j.cld.2011.03.002; Zhu AX, 2011, CANCER-AM CANCER SOC, V117, P5094, DOI 10.1002/cncr.26165	41	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1068-9265	1534-4681		ANN SURG ONCOL	Ann. Surg. Oncol.	SEP	2015	22	9					3079	3086		10.1245/s10434-014-4292-3		8	Oncology; Surgery	Oncology; Surgery	CO8NA	WOS:000359425000039		
J	Kishida, N; Hibi, T; Itano, O; Okabayashi, K; Shinoda, M; Kitago, M; Abe, Y; Yagi, H; Kitagawa, Y				Kishida, Norihiro; Hibi, Taizo; Itano, Osamu; Okabayashi, Koji; Shinoda, Masahiro; Kitago, Minoru; Abe, Yuta; Yagi, Hiroshi; Kitagawa, Yuko			Validation of Hepatectomy for Elderly Patients with Hepatocellular Carcinoma	ANNALS OF SURGICAL ONCOLOGY			English	Article							LIVER RESECTION; SURGICAL OUTCOMES; PREOPERATIVE ASSESSMENT; GERIATRIC ASSESSMENT; FRAILTY; OLDER; SURGERY; CIRRHOSIS	The safety and feasibility of hepatectomy for hepatocellular carcinoma (HCC) in the elderly population have not been defined to date. A single-center, retrospective cohort study was conducted with 104 patients who underwent hepatectomy for HCC from 2005 to 2010. The patients were divided into two groups, the elderly group (age, a parts per thousand yen75 years; n = 22) and the nonelderly group (age, < 75 years; n = 82), for comparison of short- and long-term outcomes. More patients were categorized as preoperative Eastern Cooperative Oncology Group (ECOG) performance status 1 in the elderly group (32 %) than in the nonelderly group (6 %) (P = 0.003). Complications with a Clavien-Dindo classification of grade 3a or higher were more frequently observed in the elderly group (41 %) than in the nonelderly group (17 %) (P = 0.006). Multivariate logistic regression showed ECOG performance status 1 as the only independent predictor of complications classified as Clavien-Dindo grade 3a or higher. The in-hospital mortality rates were similar between the two groups (P = 0.20). During a median follow-up period of 47 months, the unadjusted 5-year recurrence-free survival rates were similar in the elderly (25 %) and nonelderly (33 %) groups (P = 0.80). Multiple tumors and high alpha-fetoprotein levels emerged as independent negative indicators of recurrence-free survival using multivariate Cox analyses. The adjusted risk for recurrence was not elevated in the elderly group (hazard ratio [HR], 0.92; 95 % confidence interval [CI] 0.50-1.68; P = 0.78). Despite the more frequent occurrence of complications with a Clavien-Dindo grade of 3a or higher among the elderly patients undergoing hepatectomy for HCC, their mortality and recurrence rates were comparable with those of the nonelderly patients. Therefore, age alone is not a determinant of surgical candidacy for HCC.	[Kishida, Norihiro; Hibi, Taizo; Itano, Osamu; Okabayashi, Koji; Shinoda, Masahiro; Kitago, Minoru; Abe, Yuta; Yagi, Hiroshi; Kitagawa, Yuko] Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 160, Japan	Kishida, N (reprint author), Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 160, Japan.	taizohibi@z3.keio.jp; itano@z8.keio.jp					Reddy SK, 2011, J AM COLL SURGEONS, V212, P787, DOI 10.1016/j.jamcollsurg.2010.12.048; Kanazawa A, 2013, SURG ENDOSC, V27, P2592, DOI 10.1007/s00464-013-2795-9; Portolani N, 2011, JPN J CLIN ONCOL, V41, P1358, DOI 10.1093/jjco/hyr154; Shimada H, 2013, J AM MED DIR ASSOC, V14, P518, DOI 10.1016/j.jamda.2013.03.010; Robinson TN, 2009, ANN SURG, V250, P449, DOI 10.1097/SLA.0b013e3181b45598; Yamada S, 2012, HEPATOL RES, V42, P454, DOI 10.1111/j.1872-034X.2011.00952.x; Hamaker ME, 2012, LANCET ONCOL, V13, pE437, DOI 10.1016/S1470-2045(12)70259-0; Tsujita E, 2012, HEPATO-GASTROENTEROL, V59, P1553, DOI 10.5754/hge09485; Huang J, 2009, J GASTROINTEST SURG, V13, P1627, DOI 10.1007/s11605-009-0933-4; MAKUUCHI M, 1993, SEMIN SURG ONCOL, V9, P298, DOI 10.1002/ssu.2980090404; Dagher I, 2010, J AM COLL SURGEONS, V211, P16, DOI 10.1016/j.jamcollsurg.2010.03.012; Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2; Cheung TT, 2013, ANN SURG, V257, P506, DOI 10.1097/SLA.0b013e31827b947a; Menon KV, 2006, J AM COLL SURGEONS, V203, P677, DOI 10.1016/j.jamcollsurg.2006.07.025; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Melloul E, 2012, WORLD J SURG, V36, P2161, DOI 10.1007/s00268-012-1621-1; Chow WB, 2012, J AM COLL SURGEONS, V215, P453, DOI 10.1016/j.jamcollsurg.2012.06.017; Dale W, 2014, ANN SURG, V259, P960, DOI 10.1097/SLA.0000000000000226; Nanashima A, 2011, J SURG ONCOL, V104, P284, DOI 10.1002/jso.21932; Makary MA, 2010, J AM COLL SURGEONS, V210, P901, DOI 10.1016/j.jamcollsurg.2010.01.028; De La Fuente SG, 2013, J SURG ONCOL, V107, P865, DOI 10.1002/jso.23335; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Han Ho-Seong, 2013, Liver Cancer, V2, P25, DOI 10.1159/000346224; Memeo R, 2014, WORLD J SURG, V38, P2919, DOI 10.1007/s00268-014-2659-z; Revenig LM, 2013, J AM COLL SURGEONS, V217, P665, DOI 10.1016/j.jamcollsurg.2013.06.012; The French METAVIR Cooperative Study Group, 1994, HEPATOLOGY, V20, P15, DOI DOI 10.1002/HEP.1840200104.PUBMED:8020885; Tsujita E, 2010, SURGERY, V147, P696, DOI 10.1016/j.surg.2009.10.054	27	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1068-9265	1534-4681		ANN SURG ONCOL	Ann. Surg. Oncol.	SEP	2015	22	9					3094	3101		10.1245/s10434-014-4350-x		8	Oncology; Surgery	Oncology; Surgery	CO8NA	WOS:000359425000041		
J	Okamura, A; Takeuchi, H; Matsuda, S; Ogura, M; Miyasho, T; Nakamura, R; Takahashi, T; Wada, N; Kawakubo, H; Saikawa, Y; Kitagawa, Y				Okamura, Akihiko; Takeuchi, Hiroya; Matsuda, Satoru; Ogura, Masaharu; Miyasho, Taku; Nakamura, Rieko; Takahashi, Tsunehiro; Wada, Norihito; Kawakubo, Hirofumi; Saikawa, Yoshiro; Kitagawa, Yuko			Factors Affecting Cytokine Change After Esophagectomy for Esophageal Cancer	ANNALS OF SURGICAL ONCOLOGY			English	Article							MINIMALLY INVASIVE ESOPHAGECTOMY; THORACIC ESOPHAGECTOMY; ENTERAL NUTRITION; SURGICAL STRESS; INDUCED IMMUNOSUPPRESSION; PULMONARY COMPLICATIONS; PROTEASE INHIBITOR; CONTROLLED-TRIAL; PRONE POSITION; SURGERY	Esophagectomy for esophageal cancer is one of the most invasive operative procedures. Surgical stress induces the release of proinflammatory cytokines, and overproduction induces a systemic inflammatory response syndrome, which may lead to acute lung injury and multiple organ dysfunction syndrome. In addition, surgical stress may cause immunosuppression, which may affect not only perioperative mortality but also long-term survival. Between 2006 and 2013, levels of perioperative serum cytokines were evaluated in 90 patients who underwent esophagectomy for esophageal carcinoma. The serum interleukin (IL)-6, IL-8, and IL-10 levels were measured by enzyme-linked immunosorbent assays. We reviewed and assessed medical records, including cytokine profiles, and determined the factors affecting postoperative serum cytokine levels. These cytokine levels peaked on postoperative day 1 and decreased gradually. Of the clinicopathologic factors, a thoracoscopic approach was a significant factor in attenuating IL-6 and IL-8 levels on postoperative day 1 in multivariate analysis, and a longer operative time was a significant factor in increasing these levels. During postoperative days 3-7, the thoracoscopic approach and early enteral nutrition were significant factors in attenuating serum cytokine changes in multivariate analysis, and postoperative infectious complications were significant factors in increasing these levels. The thoracoscopic approach and early enteral nutrition could attenuate the cytokine change after esophagectomy, and a longer operative time and postoperative infectious complication could increase it. We should undertake strategies to minimize the surgical stress to reduce potential short-term and long-term consequences for patients.	[Okamura, Akihiko; Takeuchi, Hiroya; Matsuda, Satoru; Ogura, Masaharu; Nakamura, Rieko; Takahashi, Tsunehiro; Wada, Norihito; Kawakubo, Hirofumi; Saikawa, Yoshiro; Kitagawa, Yuko] Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan; [Miyasho, Taku] Rakuno Gakuen Univ, Sch Vet Med, Hokkaido, Japan	Okamura, A (reprint author), Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan.	htakeuchi@a6.keio.jp					Takagi K, 2000, NUTRITION, V16, P355, DOI 10.1016/S0899-9007(00)00231-8; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Takeuchi H, 2010, WORLD J SURG, V34, P277, DOI 10.1007/s00268-009-0331-9; Biere SSAY, 2012, LANCET, V379, P1887, DOI 10.1016/S0140-6736(12)60516-9; Haga Y, 1997, CRIT CARE MED, V25, P1994, DOI 10.1097/00003246-199712000-00016; Dapri G, 2008, SURG ENDOSC, V22, P1060, DOI 10.1007/s00464-007-9697-7; BONE RC, 1992, CRIT CARE MED, V20, P724, DOI 10.1097/00003246-199206000-00002; DUIGNAN JP, 1986, BRIT J SURG, V73, P238, DOI 10.1002/bjs.1800730328; Ogawa K, 2000, SURGERY, V127, P329, DOI 10.1067/msy.2000.103498; KHANSARI DN, 1990, IMMUNOL TODAY, V11, P170, DOI 10.1016/0167-5699(90)90069-L; Briez N, 2012, BRIT J SURG, V99, P1547, DOI 10.1002/bjs.8931; Tsujimoto H, 2012, SURGERY, V151, P667, DOI 10.1016/j.surg.2011.12.006; Hogan BV, 2011, SURG-J R COLL SURG E, V9, P38, DOI 10.1016/j.surge.2010.07.011; Shakhar G, 2003, ANN SURG ONCOL, V10, P972, DOI 10.1245/ASO.2003.02.007; WAKEFIELD CH, 1993, BRIT J SURG, V80, P205, DOI 10.1002/bjs.1800800224; Safranek PM, 2010, BRIT J SURG, V97, P1845, DOI 10.1002/bjs.7231; Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; Couper G, 2011, P NUTR SOC, V70, P316, DOI 10.1017/S0029665111000553; Watanabe M, 2013, SURG TODAY, V43, P237, DOI 10.1007/s00595-012-0300-z; Biere SSAY, 2009, MINERVA CHIR, V64, P121; Cuschieri A, 1992, J R Coll Surg Edinb, V37, P7; Frick VO, 2012, ONCOL REP, V27, P258, DOI 10.3892/or.2011.1493; Fujita T, 2012, EUR SURG RES, V48, P79, DOI 10.1159/000336574; Goldberg RF, 2013, SURG ENDOSC, V27, P553, DOI 10.1007/s00464-012-2479-x; Kaburagi T, 2014, WORLD J SURG, V38, P410, DOI 10.1007/s00268-013-2258-4; Kawakubo Hirofumi, 2013, Korean J Thorac Cardiovasc Surg, V46, P241, DOI 10.5090/kjtcs.2013.46.4.241; Kotani J, 1999, ARCH SURG-CHICAGO, V134, P287, DOI 10.1001/archsurg.134.3.287; Lin E, 1999, INTENS CARE MED, V25, P255, DOI 10.1007/s001340050832; Morita M, 2008, DIS ESOPHAGUS, V21, P30, DOI 10.1111/j.1442-2050.2007.00725.x; Ono S, 1999, AM J SURG, V177, P78, DOI 10.1016/S0002-9610(98)00300-6; Sato N, 2002, DIGEST SURG, V19, P300, DOI 10.1159/000064578; Sato N, 2002, ANN SURG, V236, P184, DOI 10.1097/01.SLA.0000022025.67985.53; Shyamsundar M, 2014, ANN SURG, V259, P26, DOI 10.1097/SLA.0b013e31829d686b; Sobin LH, 2009, TNM CLASSIFICATION M; Suda K, 2007, DIS ESOPHAGUS, V20, P478, DOI 10.1111/j.1442-2050.2007.00699.x; Takeuchi Hiroya, 2013, Gen Thorac Cardiovasc Surg, V61, P513, DOI 10.1007/s11748-013-0258-9; Tsujimoto H, 2013, J SURG RES, V182, pE61, DOI 10.1016/j.jss.2012.11.015; Weijs TJ, 2015, CLIN NUTR, V34, P1, DOI 10.1016/j.clnu.2014.07.011; Xiao-Bo Y, 2014, MINERVA CHIR, V69, P37; Zhang LM, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-84	40	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1068-9265	1534-4681		ANN SURG ONCOL	Ann. Surg. Oncol.	SEP	2015	22	9					3130	3135		10.1245/s10434-014-4348-4		6	Oncology; Surgery	Oncology; Surgery	CO8NA	WOS:000359425000045		
J	Kadota, K; Villena-Vargas, J; Nitadori, J; Sima, CS; Jones, DR; Travis, WD; Adusumilli, PS				Kadota, Kyuichi; Villena-Vargas, Jonathan; Nitadori, Jun-ichi; Sima, Camelia S.; Jones, David R.; Travis, William D.; Adusumilli, Prasad S.			Tumoral CD10 Expression Correlates with Aggressive Histology and Prognosis in Patients with Malignant Pleural Mesothelioma	ANNALS OF SURGICAL ONCOLOGY			English	Article							I LUNG ADENOCARCINOMA; PHASE-II; COLORECTAL-CANCER; BREAST-CARCINOMA; PLUS CISPLATIN; CELL CARCINOMA; GRADING SYSTEM; SURVIVAL; DOXORUBICIN; THERAPY	Currently, tumor-node-metastasis stage and histologic type are the established prognostic factors for malignant pleural mesothelioma, whereas no prognostic markers have been established for clinical practice. We investigated the prognostic value of CD10, a metalloproteinase that can promote cancer aggressiveness through enzymatic degradation and intracellular signaling crosstalk, in malignant pleural mesothelioma. CD10 immunostaining was performed for 176 cases of malignant pleural mesothelioma (epithelioid, 148; biphasic, 14; sarcomatoid, 14), and its expression was dichotomized as negative (no staining) or positive (any staining). Epithelioid tumors were classified as pleomorphic subtype when cytologic pleomorphism was a parts per thousand yen10 % of the tumor. Overall survival (OS) was analyzed by log-rank tests and Cox proportional hazard models. Tumoral CD10 expression was identified in 42 % of epithelioid non-pleomorphic tumors, 57 % of epithelioid pleomorphic tumors, 79 % of biphasic tumors, and 93 % of sarcomatoid tumors (p < 0.001). Positive CD10 expression was correlated with higher mitotic count (p = 0.002). Overall survival for patients with positive CD10 expression was significantly shorter than that for patients with negative CD10 expression in all patients (p = 0.001) and in patients with epithelioid tumor (p = 0.04). On multivariate analysis, CD10 expression was an independent prognostic factor for all patients (hazard ratio 1.48; p = 0.019). Tumoral CD10 expression correlated with aggressive histologic types and higher mitotic activity and is an independent prognostic factor for patients with malignant pleural mesothelioma.	[Kadota, Kyuichi; Villena-Vargas, Jonathan; Nitadori, Jun-ichi; Jones, David R.; Adusumilli, Prasad S.] Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, New York, NY 10021 USA; [Kadota, Kyuichi; Travis, William D.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Kadota, Kyuichi] Kagawa Univ, Fac Med, Dept Diagnost Pathol, Takamatsu, Kagawa 760, Japan; [Sima, Camelia S.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; [Adusumilli, Prasad S.] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, New York, NY 10021 USA	Kadota, K (reprint author), Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, 1275 York Ave, New York, NY 10021 USA.	adusumip@mskcc.org			National Institutes of Health [R21 CA164568-01A1, R21 CA164585-01A1, R01 CA136705-06, U54 CA137788, P30 CA008748, P50 CA086438-13]; US Department of Defense [PR101053, LC110202]; Commonwealth Foundation for Cancer Research; Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center	The authors' laboratory work is supported in part by Grants from the National Institutes of Health (R21 CA164568-01A1, R21 CA164585-01A1, R01 CA136705-06, U54 CA137788, P30 CA008748, and P50 CA086438-13), the US Department of Defense (PR101053 and LC110202), Mr. William H. Goodwin and Mrs. Alice Goodwin, the Commonwealth Foundation for Cancer Research, and the Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center. We thank Joe Dycoco of the Memorial Sloan Kettering Thoracic Surgery Service for assisting with the Thoracic Surgery Service's malignant pleural mesothelioma database; Irina Linkov, Avani Giri, and Louie Lopez of the Memorial Sloan Kettering Pathology Core Facility for their help in making the tissue microarray and for technical assistance with immunohistochemistry; and David Sewell and Alex Torres of the Memorial Sloan Kettering Thoracic Surgery Service for their editorial assistance.	Suzuki K, 2013, J CLIN ONCOL, V31, P490, DOI 10.1200/JCO.2012.45.2052; Flores RM, 2007, J THORAC ONCOL, V2, P957, DOI 10.1097/JTO.0b013e31815608d9; Khanh DT, 2011, CANCER SCI, V102, P1724, DOI 10.1111/j.1349-7006.2011.01987.x; Desmedt C, 2012, CLIN CANCER RES, V18, P1004, DOI 10.1158/1078-0432.CCR-11-0383; Scherpereel A, 2011, EUR RESPIR J, V37, P129, DOI 10.1183/09031936.00037310; Kadota K, 2012, MODERN PATHOL, V25, P1117, DOI 10.1038/modpathol.2012.58; Kadota K, 2011, J THORAC ONCOL, V6, P896, DOI 10.1097/JTO.0b013e318211127a; Ho ME, 2013, MODERN PATHOL, V26, P849, DOI 10.1038/modpathol.2012.238; Fleischmann A, 2011, VIRCHOWS ARCH, V458, P741, DOI 10.1007/s00428-011-1084-z; Iwaya K, 2002, VIRCHOWS ARCH, V440, P589, DOI 10.1007/s00428-002-0639-4; Burt BM, 2012, CLIN CANCER RES, V18, P1568, DOI 10.1158/1078-0432.CCR-11-1808; Krug LM, 2009, J CLIN ONCOL, V27, P3007, DOI 10.1200/JCO.2008.20.3943; Kuniyasu H, 2010, GUT, V59, P348, DOI 10.1136/gut.2009.178376; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Yoshizawa A, 2010, CLIN CANCER RES, V16, P240, DOI 10.1158/1078-0432.CCR-09-0986; Kadota K, 2012, MODERN PATHOL, V25, P260, DOI 10.1038/modpathol.2011.146; Kadota K, 2012, J THORAC ONCOL, V7, P1192, DOI 10.1097/JTO.0b013e3182519d96; Fukusumi T, 2014, BRIT J CANCER, V111, P506, DOI 10.1038/bjc.2014.289; Fujimoto Y, 2005, DIS COLON RECTUM, V48, P1883, DOI 10.1007/s10350-005-0141-6; Butnor KJ, 2006, ARCH PATHOL LAB MED, V130, P823; Righi L, 2010, J CLIN ONCOL, V28, P1534, DOI 10.1200/JCO.2009.25.9275; Rusch VW, 2012, J THORAC ONCOL, V7, P1631, DOI 10.1097/JTO.0b013e31826915f1; Arrieta O, 2012, BRIT J CANCER, V106, P1027, DOI 10.1038/bjc.2012.44; Biasoli I, 2005, HISTOPATHOLOGY, V46, P328, DOI 10.1111/j.1365-2559.2005.02099.x; Bilalovic N, 2004, AM J CLIN PATHOL, V121, P34, DOI 10.1309/TNKL7GDC66R9WPV5; Dall'Era Marc A, 2007, BMC Urol, V7, P3, DOI 10.1186/1471-2490-7-3; Greene FL, 2002, AJCC CANC STAGING MA; Kim HS, 2010, HISTOPATHOLOGY, V56, P708, DOI 10.1111/j.1365-2559.2010.03534.x; McIntosh GG, 1999, AM J PATHOL, V154, P77, DOI 10.1016/S0002-9440(10)65253-4; Pan C, 2003, CANCER RES, V63, P5526; Ravel D, 2008, CLIN CANCER RES, V14, P1258, DOI 10.1158/1078-0432.CCR-07-1165; SHIPP MA, 1993, BLOOD, V82, P1052; Sugarbaker DJ, 1999, J THORAC CARDIOV SUR, V117, P54, DOI 10.1016/S0022-5223(99)70469-1; Sugarbaker DJ, 1999, J THORAC CARDIOVASC, V117, P63; Suzuki K, 2011, CANCER IMMUNOL IMMUN, V60, P1721, DOI 10.1007/s00262-011-1073-8; Turner AJ, 1997, FASEB J, V11, P355	36	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1068-9265	1534-4681		ANN SURG ONCOL	Ann. Surg. Oncol.	SEP	2015	22	9					3136	3143		10.1245/s10434-015-4374-x		8	Oncology; Surgery	Oncology; Surgery	CO8NA	WOS:000359425000046		
J	Kim, R; Yamauchi, T; Husain, K; Sebti, S; Malafa, M				Kim, Richard; Yamauchi, Teruo; Husain, Kazim; Sebti, Said; Malafa, Mokenge			Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells	ANTICANCER RESEARCH			English	Article						AKT inhibitor; gemcitabine; pancreatic cancer	TRICYCLIC NUCLEOSIDE; EXPRESSION; RESISTANCE; CARCINOMA; SURVIVAL; ACTIVATION; APOPTOSIS; ONCOGENE; KINASE; GROWTH	Background: Pancreatic cancer is a highly lethal cancer due to early metastasis and resistance to current chemotherapeutic agents. Abnormal protein kinase B (AKT) activation is an important mechanism of chemoresistance to gemcitabine, the most widely used agent in pancreatic cancer. Material and Methods: In the study, we tested the hypothesis that combining an AKT inhibitor with gemcitabine would augment anti-tumor activity. We treated human pancreatic cancer MiaPaCa-2 cells with gemcitabine and the AKT inhibitor triciribine, alone and in combination, and evaluated treatment effects using trypan blue assay, 3[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium (MTT) assay, and cell death enzyme-linked immunosorbant assay. Colorimetric data of MTT assay were computationally analyzed for synergism of the combination therapy by CalcuSyn2 (Biosoft, Great Shelford, Cambridge, UK). Results: Both gemcitabine and triciribine inhibited cell growth in a dose-dependent manner. Triciribine synergistically enhanced the cytotoxic activity of gemcitabine. The combination index (CI) provides the synergistic, additive, or antagonistic effects of the two-drug combination. CI at the 50% effective dose at 1: 500 ratio of gemcitabine to triciribine was 0.74, indicating the synergistic effect of the drugs. The combination treatment with the non-apoptotic dose of each agent distinctly induced apoptosis, with gemcitabine in combination with triciribine, synergistically inhibiting pancreatic cancer cell growth and inducing apoptosis. Conclusion: These findings support the use of triciribine to overcome activated AKT-mediated resistance of pancreatic cancer to gemcitabine.	[Kim, Richard; Malafa, Mokenge] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL 33612 USA; [Yamauchi, Teruo] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Drug Discovery, Tampa, FL 33612 USA; [Husain, Kazim; Sebti, Said] St Lukes Int Hosp, Div Med Oncol, Dept Internal Med, Tokyo, Japan; [Husain, Kazim; Sebti, Said] Univ S Florida, Dept Oncol Sci, Tampa, FL USA; [Husain, Kazim; Sebti, Said] Univ S Florida, Dept Mol Med, Tampa, FL USA	Kim, R (reprint author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, 12902 Magnolia Dr FOB-2, Tampa, FL 33612 USA.	Richard.Kim@moffitt.org					Garrett CR, 2011, INVEST NEW DRUG, V29, P1381, DOI 10.1007/s10637-010-9479-2; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Yamamoto S, 2004, CLIN CANCER RES, V10, P2846, DOI 10.1158/1078-0432.CCR-02-1441; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; MILLER WE, 1995, J VIROL, V69, P4390; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Wang QF, 2014, INT J ONCOL, V44, P1277, DOI 10.3892/ijo.2014.2271; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Burris HA, 1997, J CLIN ONCOL, V15, P2403; Dieterle A, 2009, INT J CANCER, V125, P932, DOI 10.1002/ijc.24374; FEUN LG, 1993, AM J CLIN ONCOL-CANC, V16, P506, DOI 10.1097/00000421-199312000-00010; Jetzt A, 2003, CANCER RES, V63, P6697; MOORE EC, 1989, BIOCHEM PHARMACOL, V38, P4037; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R	18	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4599	4604				6	Oncology	Oncology	CO7AX	WOS:000359311000006		
J	Nukatsuka, M; Nakagawa, F; Takechi, T				Nukatsuka, Mamoru; Nakagawa, Fumio; Takechi, Teiji			Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts	ANTICANCER RESEARCH			English	Article						TAS-102; oxaliplatin; colorectal cancer; gastric cancer; 5-FU resistance	DNA STRAND BREAKS; PHASE-III TRIAL; ANTITUMOR-ACTIVITY; CELL-LINES; THYMIDINE PHOSPHORYLASE; 1ST-LINE THERAPY; NON-INFERIORITY; OPEN-LABEL; IN-VIVO; PLUS	TAS-102 is a novel oral nucleoside antitumor agent consisting of trifluridine (FTD) and the thymidine phosphorylase inhibitor tipiracil hydrochloride (at a molar ratio of 1:0.5) that was approved in Japan in 2014 for the treatment of unresectable advanced or recurrent colorectal cancer. In the present study, the enhancement of therapeutic efficacy using a combination of TAS-102 and oxaliplatin was evaluated in a xenograft-bearing nude mouse model of colorectal and gastric cancer. TAS-102 was orally administered twice-a-day from day 1 to 14, and oxaliplatin was administered intravenously on days 1 and 8. The in vivo growth-inhibitory activity was evaluated based on the tumor volume and the growth-delay period, was estimated based on the period required to reach a tumor volume five-times greater than the initial volume (RTV5). The tumor growth-inhibitory activity and RTV5 in mice administered TAS-102 with oxaliplatin were significantly superior to those associated with either monotherapy in mice with colorectal (HCT 116, SW-48; p<0.001) and gastric cancer (SC-2, MKN74; p<0.001). MKN74/5FU, a 5-fluorouracil-resistant MKN74 sub-line, was sensitive to both FTD and oxaliplatin in vitro. In vivo, TAS-102 alone was effective in MKN74/5FU, and its antitumor activity was significantly enhanced in combination with oxaliplatin (p<0.001). No significant decrease in body weight or toxicity was observed compared to either monotherapy. The present pre-clinical findings indicate that combination of TAS-102 and oxaliplatin is a promising treatment option for colorectal or gastric cancer, and can be utilized in both chemo-naive tumors and recurrent tumors after 5-fluorouracil treatment.	[Nukatsuka, Mamoru; Takechi, Teiji] Taiho Pharmaceut Co Ltd, Translat Res Lab, Tokushima Res Ctr, Tokushima, Tokushima 7710194, Japan; [Nakagawa, Fumio] Taiho Pharmaceut Co Ltd, Appl Pharmacol Lab, Tokushima Res Ctr, Tokushima, Tokushima 7710194, Japan	Nukatsuka, M (reprint author), Taiho Pharmaceut Co Ltd, Translat Res Lab, 224-2 Ebisuno Hiraishi,Kawauchi Cho, Tokushima, Tokushima 7710194, Japan.	m-nukatsuka@taiho.co.jp					Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Cassidy J, 2011, BRIT J CANCER, V105, P58, DOI 10.1038/bjc.2011.201; DEXTER DL, 1972, CANCER RES, V32, P247; Becouarn Y, 1998, J CLIN ONCOL, V16, P2739; Emura T, 2005, INT J ONCOL, V27, P449; Yamada Y, 2013, LANCET ONCOL, V14, P1278, DOI 10.1016/S1470-2045(13)70490-X; Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325; Emura T, 2004, INT J ONCOL, V25, P571; BRATTAIN MG, 1981, CANCER RES, V41, P1751; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Utsugi T, 2013, JPN J CLIN ONCOL, V43, P945, DOI 10.1093/jjco/hyt131; Woynarowski JM, 2000, MOL PHARMACOL, V58, P920; ARMAND JP, 1995, EUR J CANCER, V31A, P1283, DOI 10.1016/0959-8049(95)00212-2; Bauer P, 1998, STAT MED, V17, P2133, DOI 10.1002/(SICI)1097-0258(19980930)17:18<2133::AID-SIM901>3.0.CO;2-2; Matsuoka K, 2015, MOL CANCER THER, V14, P1004, DOI 10.1158/1535-7163.MCT-14-0236; Murakami Y, 2000, INT J ONCOL, V17, P277; Nakamura A, 2014, GASTRIC CANCER, V17, P188, DOI 10.1007/s10120-013-0249-7; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Balin-Gauthier D, 2006, CANCER CHEMOTH PHARM, V57, P709, DOI 10.1007/s00280-005-0123-3; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; Yoshino T, 2012, LANCET ONCOL, V13, P993, DOI 10.1016/S1470-2045(12)70345-5; SAOTOME K, 1989, TOXICOL IN VITRO, V3, P317, DOI 10.1016/0887-2333(89)90039-8; Emura T, 2004, INT J MOL MED, V13, P249; Sobrero AF, 2008, J CLIN ONCOL, V26, P2311, DOI 10.1200/JCO.2007.13.1193; Temmink OH, 2007, BRIT J CANCER, V96, P231, DOI 10.1038/sj.bjc.6603549; Hong YS, 2012, LANCET ONCOL, V13, P1125, DOI 10.1016/S1470-2045(12)70363-7; Chen WJ, 2014, EXP THER MED, V7, P461, DOI 10.3892/etm.2013.1449; Emura T, 2004, INT J MOL MED, V13, P545; EXTRA JM, 1990, CANCER CHEMOTH PHARM, V25, P299, DOI 10.1007/BF00684890; Faivre S, 2003, BIOCHEM PHARMACOL, V66, P225, DOI 10.1016/S0006-2952(03)00260-0; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fukushima M, 2000, BIOCHEM PHARMACOL, V59, P1227, DOI 10.1016/S0006-2952(00)00253-7; INABA M, 1986, JPN J CANCER RES, V77, P190; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; Nukatsuka M, 2015, ANTICANCER RES, V35, P1437; Sobrero AF, 1995, CLIN CANCER RES, V1, P955; SOBRERO AF, 1993, J NATL CANCER I, V85, P1937, DOI 10.1093/jnci/85.23.1937; Suzuki N, 2011, INT J ONCOL, V39, P263, DOI 10.3892/ijo.2011.1003; Tanaka N, 2014, ONCOL REP, V32, P2319, DOI 10.3892/or.2014.3487; Yamada Y, 2015, ANN ONCOL, V26, P141, DOI 10.1093/annonc/mdu472	43	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4605	4615				11	Oncology	Oncology	CO7AX	WOS:000359311000007		
J	Harada, K; Baba, Y; Ishimoto, T; Kosumi, K; Tokunaga, R; Izumi, D; Ohuchi, M; Nakamura, K; Kiyozumi, Y; Kurashige, J; Iwagami, S; Miyamoto, Y; Sakamoto, Y; Yoshida, N; Oki, E; Watanabe, M; Baba, H				Harada, Kazuto; Baba, Yoshifumi; Ishimoto, Takatsugu; Kosumi, Keisuke; Tokunaga, Ryuma; Izumi, Daisuke; Ohuchi, Mayuko; Nakamura, Kenichi; Kiyozumi, Yuki; Kurashige, Junji; Iwagami, Shiro; Miyamoto, Yuji; Sakamoto, Yasuo; Yoshida, Naoya; Oki, Eiji; Watanabe, Masayuki; Baba, Hideo			Suppressor microRNA-145 Is Epigenetically Regulated by Promoter Hypermethylation in Esophageal Squamous Cell Carcinoma	ANTICANCER RESEARCH			English	Article						Cancer epigenetics; esophageal squamous cell carcinoma; microRNA; DNA methylation	DOWN-REGULATION; CANCER-CELLS; DNA METHYLATION; C-MYC; MIR-145; GROWTH; METASTASIS; INVASION; P53; EXPRESSION	Background/Aim: DNA methylation is a common epigenetic change in cancer. However, microRNA (miRNA) regulation by epigenetic alteration, especially CpG island hypermethylation, remains poorly understood in esophageal squamous cell carcinoma (ESCC). Materials and Methods: miRNAs which were up-regulated after de-methylation with 5-aza-2'-deoxycytidine (5-AZA) were analyzed using the Human miFinder 384HC miScript miRNA PCR Array. The DNA methylation level was evaluated by bisulfite-pyrosequencing assay. Results: In two of the cell lines, 20 miRNAs, including miR-145-5p, were found to be up-regulated by more than three-fold after 5-AZA treatment. The miRNA-145 promoter was significantly more hypermethylated in the cancer tissues than in matched normal adjacent esophageal epithelial mucosa (p=0.0042; paired t-test). Moreover, the miRNA-145-5p expression levels were significantly lower in cancerous tissues (p=0.0024). Conclusion: miRNA-145 expression in ESCC seems to be regulated by hypermethylation of the miRNA-145 promoter region.	[Harada, Kazuto; Baba, Yoshifumi; Ishimoto, Takatsugu; Kosumi, Keisuke; Tokunaga, Ryuma; Izumi, Daisuke; Ohuchi, Mayuko; Nakamura, Kenichi; Kiyozumi, Yuki; Kurashige, Junji; Iwagami, Shiro; Miyamoto, Yuji; Sakamoto, Yasuo; Yoshida, Naoya; Baba, Hideo] Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Kumamoto 8608556, Japan; [Oki, Eiji] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, Fukuoka 812, Japan; [Watanabe, Masayuki] Canc Inst Hosp, Dept Surg Gastroenterol, Koto Ku, Tokyo, Japan	Baba, Y (reprint author), Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	y-baba@kumamoto-u.ac.jp					Yu CC, 2013, CANCER RES, V73, P3425, DOI 10.1158/0008-5472.CAN-12-3840; Iwagami S, 2012, ANN SURG ONCOL, V19, P2726, DOI 10.1245/s10434-011-2176-3; Wang F, 2013, ONKOLOGIE, V36, P754, DOI 10.1159/000356978; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Pagliuca A, 2013, ONCOGENE, V32, P4806, DOI 10.1038/onc.2012.495; Melo S, 2011, P NATL ACAD SCI USA, V108, P4394, DOI 10.1073/pnas.1014720108; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354; Hamano R, 2011, CLIN CANCER RES, V17, P3029, DOI 10.1158/1078-0432.CCR-10-2532; Chen XD, 2012, INT J CANCER, V130, P1607, DOI 10.1002/ijc.26171; Ishimoto T, 2014, CARCINOGENESIS, V35, P1003, DOI 10.1093/carcin/bgt402; Kano M, 2010, INT J CANCER, V127, P2804, DOI 10.1002/ijc.25284; Tang MJ, 2013, ONCOTARGETS THER, V6, P833, DOI 10.2147/OTT.S40080; Sachdeva M, 2010, AM J TRANSL RES, V2, P170; Song JH, 2012, GASTROENTEROLOGY, V143, P35, DOI 10.1053/j.gastro.2012.05.003; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Suh SO, 2011, CARCINOGENESIS, V32, P772, DOI 10.1093/carcin/bgr036; Chiou GY, 2012, J CONTROL RELEASE, V159, P240, DOI 10.1016/j.jconrel.2012.01.014; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Guo Y, 2008, CANCER RES, V68, P26, DOI 10.1158/0008-5472.CAN-06-4418; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Tanaka K, 2013, ANN SURG ONCOL, V20, pS607, DOI 10.1245/s10434-013-3093-4; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178; Baba Y, 2014, CLIN CANCER RES, V20, P1114, DOI 10.1158/1078-0432.CCR-13-1645; Cui XB, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-20; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Haapa-Paananen S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060930; Inoue N, 2010, ONCOL LETT, V1, P527, DOI 10.3892/ol_00000093; Ko MA, 2012, ANN THORAC SURG, V94, P1094, DOI 10.1016/j.athoracsur.2012.04.145; Liu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033987; Muller CI, 2006, CURR PHARM BIOTECHNO, V7, P315, DOI 10.2174/138920106778521523; Schee K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-505; Sobin LH, 2010, INT UNION CANC TNM C; Zhu ZW, 2014, FEBS LETT, V588, P3180, DOI 10.1016/j.febslet.2014.06.059	39	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4617	4624				8	Oncology	Oncology	CO7AX	WOS:000359311000008		
J	Shimura, T; Toiyama, Y; Tanaka, K; Saigusa, S; Kitajima, T; Kondo, S; Okigami, M; Yasuda, H; Ohi, M; Araki, T; Inoue, Y; Uchida, K; Mohri, Y; Kusunoki, M				Shimura, Tadanobu; Toiyama, Yuji; Tanaka, Koji; Saigusa, Susumu; Kitajima, Takahito; Kondo, Satoru; Okigami, Masato; Yasuda, Hiromi; Ohi, Masaki; Araki, Toshimitsu; Inoue, Yasuhiro; Uchida, Keiichi; Mohri, Yasuhiko; Kusunoki, Masato			Angiopoietin-like Protein 2 as a Predictor of Early Recurrence in Patients After Curative Surgery for Gastric Cancer	ANTICANCER RESEARCH			English	Article						Angiopoietin-like protein 2; ANGPTL2; immunohistochemistry; gastric cancer	METASTASIS; INFLAMMATION; ANGPTL2; CARCINOGENESIS; CHEMOTHERAPY; STATISTICS; BIOMARKER; CELLS	Background: Angiopoietin-like protein-2 (ANGPTL2) mediates chronic inflammation. Tumor cell-derived ANGPTL2 promotes tumor invasion and angiogenesis. ANGPTL2 expression has not been fully investigated in gastric cancer (GC). Materials and Methods: ANGPTL2 expression in 354 patients with GC was assessed by immunohistochemistry (IHC). IHC scores were calculated, and the association of ANGPTL2 with clinicopathological factors and patient outcomes was evaluated. Results: Immunoreactive ANGPTL2 protein was expressed mainly in GC cell cytoplasm. Kaplan-Meier analysis showed that high expression of ANGPTL2 indicated significantly poorer overall disease-free survival (DFS). Among patients with curatively resected GC, multivariate analysis for DFS revealed that high ANGPTL2 expression (p<0.01), advanced T-stage (p=0.015), lymph node metastasis (p<0.01), and advanced Unio Internationalis Contra Cancrum (UICC) stage (p<0.01) were independent risk factors for poor DFS. Conclusion: High cytoplasmic ANGPTL2 expression in GC tissue was associated with tumor progression, invasion, metastasis, and poor prognosis. ANGPTL2 may be a useful marker for detecting early postoperative recurrence in patients with GC.	[Shimura, Tadanobu; Toiyama, Yuji; Tanaka, Koji; Saigusa, Susumu; Kitajima, Takahito; Kondo, Satoru; Okigami, Masato; Yasuda, Hiromi; Ohi, Masaki; Araki, Toshimitsu; Inoue, Yasuhiro; Uchida, Keiichi; Mohri, Yasuhiko; Kusunoki, Masato] Mie Univ, Grad Sch Med, Dept Gastrointestinal & Pediat Surg, Tsu, Mie 5148507, Japan	Shimura, T (reprint author), Mie Univ, Grad Sch Med, Dept Gastrointestinal & Pediat Surg, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	t-shimura@clin.medic.mie-u.ac.jp					Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Endo M, 2012, CANCER RES, V72, P1784, DOI 10.1158/0008-5472.CAN-11-3878; Allgayer H, 1997, BRIT J SURG, V84, P1651, DOI 10.1002/bjs.1800841206; Sasaki H, 2012, ONCOL LETT, V4, P1325, DOI 10.3892/ol.2012.924; Oike Y, 2004, INT J HEMATOL, V80, P21, DOI 10.1532/ijh97.04034; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Tabata M, 2009, CELL METAB, V10, P178, DOI 10.1016/j.cmet.2009.08.003; Lee HJ, 2013, BIOCHEM BIOPH RES CO, V430, P981, DOI 10.1016/j.bbrc.2012.11.127; Okada T, 2010, AM J PATHOL, V176, P2309, DOI 10.2353/ajpath.2010.090865; Yoshinaga T, 2015, MOL MED REP, V11, P2653, DOI 10.3892/mmr.2014.3040; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Correa P, 2007, GASTROENTEROLOGY, V133, P659, DOI 10.1053/j.gastro.2007.06.026; Washington K, 2010, ANN SURG ONCOL, V17, P3077, DOI 10.1245/s10434-010-1362-z; Kikuchi R, 2008, CANCER RES, V68, P5067, DOI 10.1158/0008-5472.CAN-08-0062; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Aoi J, 2011, CANCER RES, V71, P7502, DOI 10.1158/0008-5472.CAN-11-1758; Carbone C, 2014, ONCOTARGET; Endo M, 2014, INT J BIOL MARKER, V29, P239; Gao L, 2015, J GASTROEN HEPATOL, V30, P396, DOI 10.1111/jgh.12702; Ide S, 2015, ANN SURG ONCOL; Odagiri H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004612; Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252; Sato R, 2015, ONCOL REP, V33, P58, DOI 10.3892/or.2014.3586; Toiyama Y, 2014, CLIN CANCER RES, V20, P6175, DOI 10.1158/1078-0432.CCR-14-0007	25	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4633	4639				7	Oncology	Oncology	CO7AX	WOS:000359311000010		
J	Matsumoto, T; Suetsugu, A; Shibata, Y; Nakamura, N; Aoki, H; Kunisada, T; Tsurumi, H; Shimizu, M; Hoffman, RM				Matsumoto, Takuro; Suetsugu, Atsushi; Shibata, Yuhei; Nakamura, Nobuhiko; Aoki, Hitomi; Kunisada, Takahiro; Tsurumi, Hisashi; Shimizu, Masahito; Hoffman, Robert M.			A Color-coded Imageable Syngeneic Mouse Model of Stromal-cell Recruitment by Metastatic Lymphoma	ANTICANCER RESEARCH			English	Article						RFP; C57/BL6-GFP mice; malignant lymphoma; liver metastasis; imaging	PANCREATIC-CANCER SPECIMENS; TRANSGENIC NUDE-MOUSE; PROMOTE TUMOR-GROWTH; FLUORESCENT PROTEINS; REAL-TIME; HOST; MICROENVIRONMENT; MICE; ANGIOGENESIS; FIBROBLASTS	Aim: A syngeneic color-coded imageable lymphoma model has been developed to visualize recruitment of host stromal cells by malignant lymphoma during metastasis. The EL4 cell line was previously derived from a lymphoma induced in a C57/BL6 mouse by 9,10-dimethyl-1,2-benzanthracene. Materials and Methods: EL4 lymphoma cells expressing red fluorescent protein (EL4-RFP) were initially established. EL4-RFP cells were subsequently injected into the tail vein of C57/BL6-GFP transgenic mice. Results: EL4-RFP metastasis was observed in the lymph nodes of the upper mediastinum and in the liver 28 days after cell injection. Large EL4-RFP liver metastases in C57/BL6-GFP mice contained GFP-expressing stromal cells derived from the host. In addition, EL4-RFP lymphoma metastasis was formed in peri-gastric lymph nodes, which were also enriched in host GFP-expressing cells. Furthermore, EL4-RFP lymphoma cells were also observed in the peripheral blood and bone marrow of C57/BL6-GFP transgenic mice, where they were associated with GFP-expressing host cells. Conclusion: Lymph node, liver and bone marrow metastases were found approximately 4 weeks after transplantation and all RFP-expressing metastases were highly enriched in GFP-expressing host stromal cells. This model of malignant lymphoma can be used to study early tumor development, metastasis, and the role of the stroma, as well as for discovery and evaluation of novel therapeutics for this treatment-resistant disease.	[Matsumoto, Takuro; Suetsugu, Atsushi; Shibata, Yuhei; Nakamura, Nobuhiko; Aoki, Hitomi; Kunisada, Takahiro; Tsurumi, Hisashi; Shimizu, Masahito] Gifu Univ, Grad Sch Med, Gifu, Japan; [Suetsugu, Atsushi; Hoffman, Robert M.] AntiCancer Inc, San Diego, CA 92111 USA; [Suetsugu, Atsushi; Hoffman, Robert M.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA	Hoffman, RM (reprint author), AntiCancer Inc, 7917 Ostrow St, San Diego, CA 92111 USA.	asue@gifu-u.ac.jp; all@anticancer.com					Hoffman RM, 2006, NAT PROTOC, V1, P775, DOI 10.1038/nprot.2006.109; Suetsugu A, 2012, J CELL BIOCHEM, V113, P2290, DOI 10.1002/jcb.24099; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Suetsugu A, 2012, ANTICANCER RES, V32, P31; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Bouvet M, 2006, CANCER RES, V66, P11293, DOI 10.1158/0008-5472.CAN-06-2662; Hoffman RM, 2006, NAT PROTOC, V1, P1429, DOI 10.1038/nprot.2006.223; Suetsugu A, 2012, ANTICANCER RES, V32, P3063; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Suetsugu A, 2011, J CELL BIOCHEM, V112, P949, DOI 10.1002/jcb.23011; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Yang M, 2007, CANCER RES, V67, P5195, DOI 10.1158/0008-5472.CAN-06-4590; Menen RS, 2012, IN VIVO, V26, P565; Suetsugu A, 2012, ANTICANCER RES, V32, P1175; Yang M, 2004, CANCER RES, V64, P8651, DOI 10.1158/0008-5472.CAN-04-3118; Egeblad M, 2008, DIS MODEL MECH, V1, P155, DOI 10.1242/dmm.000596; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Hoffman RM, 2006, NAT PROTOC, V1, P928, DOI 10.1038/nprot.2006.119; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Yang M, 2003, P NATL ACAD SCI USA, V100, P14259, DOI 10.1073/pnas.2436101100; Uchugonova A, 2013, J CELL BIOCHEM, V114, P99, DOI 10.1002/jcb.24305; Uehara F, 2014, J CELL BIOCHEM, V115, P1490, DOI 10.1002/jcb.24799; Yang M, 2009, J CELL BIOCHEM, V106, P279, DOI 10.1002/jcb.21999; Amoh Y, 2005, CANCER RES, V65, P5352, DOI 10.1158/0008-5472.CAN-05-0821; Hiroshima Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103382; Momiyama M, 2012, J SURG RES, V178, P280, DOI 10.1016/j.jss.2012.03.020; Pietras K, 2008, PLOS MED, V5, P123, DOI 10.1371/journal.pmed.0050019; Hoffman RM, 2014, METHODS MOL BIOL, V1194, P353, DOI 10.1007/978-1-4939-1215-5_20; Snyder CS, 2013, PANCREAS, V42, P952, DOI 10.1097/MPA.0b013e31828643df; Tran Cao HS, 2009, J CELL BIOCHEM, V107, P328; Yamauchi K, 2012, ANTICANCER RES, V32, P39; Zielinski MR, 2004, J APPL PHYSIOL, V96, P2249, DOI 10.1152/japplphysiol.01210.2003	32	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4647	4654				8	Oncology	Oncology	CO7AX	WOS:000359311000012		
J	Hayashi, T; Horiuchi, A; Sano, K; Yaegashi, N; Konishi, I				Hayashi, Takuma; Horiuchi, Akiko; Sano, Kenji; Yaegashi, Nobuo; Konishi, Ikuo			Uterine Leiomyosarcoma Tumorigenesis in Lmp2-deficient Mice: Involvement of Impaired Anti-oncogenic Factor IRF1	ANTICANCER RESEARCH			English	Article						LMP2; IRF1; IFN-gamma; uterine leiomyosarcoma; smooth muscle cell	NF-KAPPA-B; CALPONIN H1; CYCLIN-E; EXPRESSION; PROTEASOME; P53; INTERFERON; UTERUS; TUMORS; LMP2	Background/Aim: Uterine leiomyosarcoma (Ut-LMS) is a highly metastatic smooth muscle neoplasm. We have previously reported that low molecular mass protein2 Lmp2-deficient mice spontaneously developed Ut-LMS, which implicated this protein as an anti-oncogenic candidate. We also suggested that LMP2 may negatively regulate Ut-LMS independently of its role in the proteasome. Initially described as a transcription factor able to activate the expression of interferon-gamma (IFN-gamma)-responsive genes, interferon regulatory factor-1 (IRF1) has been shown to play roles in the immune response, and tumor suppression. The aim of this study was to elucidate the molecular mechanism of sarcomagenesis of Ut-LMS using human and mouse uterine tissues. Materials and Methods: The expression of the IFN-gamma signal molecules, IRF1 and -2, STAT1, and LMP2, -3, -7 and -10 were examined by western blot analysis, electrophoretic mobility shift assay and immunohistochemistry in human and mouse uterine tissues. Physiological significance of IRF1 in sarcomagenesis of Ut-LMS was demonstrated by xenograft studies. Results: In the present study, several lines of evidence indicated that although treatment with IFN-gamma strongly induced the activation of STAT1 as a transcriptional activator, its target molecule, IRF1, was not clearly produced in Lmp2-deficient uterine smooth muscle cells (Ut-SMCs). Conclusion: Defective expression of IRF1 in the IFN-gamma-induced signaling molecules may result in the malignant transformation of Ut-SMCs. The modulation of LMP2 may lead to new therapeutic approaches in human Ut-LMS.	[Hayashi, Takuma] Shinshu Univ, Grad Sch Med, Dept Immunol & Infect Dis, Matsumoto, Nagano 3908621, Japan; [Horiuchi, Akiko] Horiuchi Ladies Clin, Matsumoto, Nagano, Japan; [Sano, Kenji] Shinshu Univ Hosp, Dept Lab Med, Matsumoto, Nagano, Japan; [Yaegashi, Nobuo] Tohoku Univ, Dept Obstet & Gynecol, Grad Sch Med, Sendai, Miyagi 980, Japan; [Konishi, Ikuo] Kyoto Univ, Dept Obstet & Gynecol, Grad Sch Med, Kyoto, Japan; [Hayashi, Takuma] Japan Sci & Technol Agcy JST, Promoting Business Using Adv Technol, Chiyoda Ku, Tokyo, Japan	Hayashi, T (reprint author), Shinshu Univ, Grad Sch Med, Dept Immunol & Infect Dis, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	yoyoyo224@hotmail.com			Ministry of Education, Culture, Science and Technology; Foundation of Osaka Cancer Research; Ichiro Kanehara Foundation of the Promotion of Medical Science and Medical Care; Foundation for the Promotion of Cancer Research; Kanzawa Medical Research Foundation; Shinshu Medical Foundation; Takeda Foundation for Medical Science	We sincerely thank Professor Susumu Tonegawa (Picower Institute for Learning and Memory, M.I.T.) and Professor Luc Van Kaer (Vanderbilt University Medical Center) for their research assistance. This study was supported in part by grants from the Ministry of Education, Culture, Science and Technology, The Foundation of Osaka Cancer Research, The Ichiro Kanehara Foundation of the Promotion of Medical Science and Medical Care, The Foundation for the Promotion of Cancer Research, The Kanzawa Medical Research Foundation, The Shinshu Medical Foundation, and The Takeda Foundation for Medical Science.	HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Wu TI, 2006, GYNECOL ONCOL, V100, P166, DOI 10.1016/j.ygyno.2005.08.010; Dusenbery KE, 2004, GYNECOL ONCOL, V94, P191, DOI 10.1016/j.ygyno.2004.04.001; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; Konstantinova IM, 2008, INT REV CEL MOL BIO, V267, P59, DOI 10.1016/S1937-6448(08)00602-3; Hayashi T, 2012, FEBS LETT, V586, P1824, DOI 10.1016/j.febslet.2012.05.029; Wang JS, 2006, CELL MOL IMMUNOL, V3, P255; Akhan SE, 2005, GYNECOL ONCOL, V99, P36, DOI 10.1016/j.ygyno.2005.05.019; Zhai YL, 1999, INT J GYNECOL PATHOL, V18, P20, DOI 10.1097/00004347-199901000-00004; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Ylisaukko-oja SK, 2006, INT J CANCER, V119, P283, DOI 10.1002/ijc.21798; Sherr CJ, 2000, CANCER RES, V60, P3689; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; Lassot I, 2007, MOL CELL, V25, P369, DOI 10.1016/j.molcel.2006.12.020; Amant F, 2009, LANCET ONCOL, V10, P1188, DOI 10.1016/S1470-2045(09)70226-8; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; Brooks Sandra E., 2004, Gynecologic Oncology, V93, P204, DOI 10.1016/j.ygyno.2003.12.029; Brucet M, 2004, GENES IMMUN, V5, P25; Cabrera CM, 2003, TISSUE ANTIGENS, V61, P211, DOI 10.1034/j.1399-0039.2003.00020.x; Hayashi T, 2006, ONCOGENE, V25, P4016, DOI 10.1038/sj.onc.1209434; HAYASHI T, 2014, TUMORI, V100, P509; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; Hayashi T, 2002, CANCER RES, V62, P24; Horiuchi A, 1998, LAB INVEST, V78, P839; Kanamori T, 2003, MOL HUM REPROD, V9, P709, DOI 10.1093/molehr/gag088; Liang SX, 2001, ARCH PATHOL LAB MED, V125, P1231; Lin JF, 2008, CURR ONCOL REP, V10, P512, DOI 10.1007/s11912-008-0077-9; Lodish H, 2004, MOL CELL BIOL, V5, P66; Miettinen M, 2006, HISTOPATHOLOGY, V48, P97, DOI 10.1111/j.1365-2559.2005.02292.x; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Venkatraman L, 2003, J CLIN PATHOL, V56, P233, DOI 10.1136/jcp.56.3.233; Wang HX, 2004, BIOL REPROD, V71, P1317, DOI 10.1095/biolreprod.104.030213; Wang L, 2003, GYNECOL ONCOL, V90, P402, DOI 10.1016/S0090-8258(03)00274-9; Yanagi S, 2000, BIOCHEM BIOPH RES CO, V279, P568, DOI 10.1006/bbrc.2000.3969; Zaloudek CJ, 2002, BLAUSTEINS PATHOLOGY, P561	40	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4665	4679				15	Oncology	Oncology	CO7AX	WOS:000359311000014		
J	Hotta, K; Ueyama, J; Tatsumi, Y; Tsukiyama, I; Sugiura, Y; Saito, H; Matsuura, K; Hasegawa, T				Hotta, Kazuo; Ueyama, Jun; Tatsumi, Yasuaki; Tsukiyama, Ikuto; Sugiura, Yuka; Saito, Hiroko; Matsuura, Katsuhiko; Hasegawa, Takaaki			Lack of Contribution of Multidrug Resistance-associated Protein and Organic Anion-transporting Polypeptide to Pharmacokinetics of Regorafenib, a Novel Multi-Kinase Inhibitor, in Rats	ANTICANCER RESEARCH			English	Article						Regorafenib; disposition; multidrug resistance-associated protein; organic anion-transporting polypeptide; hepatic uptake; biliary excretion; protein-binding	METASTATIC COLORECTAL-CANCER; HEPATOCYTE CANALICULAR ISOFORM; CETUXIMAB PLUS IRINOTECAN; BILIARY-EXCRETION; CONJUGATED HYPERBILIRUBINEMIA; PHASE-3 TRIAL; MUTANT RATS; BAY 73-4506; METABOLITES; GLUCURONIDE	We investigated whether hepatic multidrug resistance-associated protein 2 (ABCC2) is involved in the hepatobiliary excretion of regorafenib, a novel multi-kinase inhibitor, using Sprague-Dawley (SD) rats and Eisai hyperbilirubinemic rats (EHBR) lacking the efflux transporter ABCC2. The involvement of organic anion-transporting polypeptide 1 (OATP1; OATP in humans) and OATP2 in the hepatic uptake of regorafenib and their protein levels in the liver were also investigated in the two rat groups. When regorafenib (5 mg/kg) was administered intravenously, the plasma concentrations of regorafenib were higher in EHBR than those in SD rats. However, the slope of the plasma concentration-time curves was the same for the two groups. Although the apparent biliary clearance of regorafenib in EHBR was lower than that of SD rats, no significant difference in the biliary excretion rate was observed between them, suggesting that regorafenib is not a substrate for ABCC2 and is not excreted into bile by ABCC2. It was also found that the contribution of biliary excretion to the systemic elimination of regorafenib is small. The protein-binding profiles of regorafenib were found to be linear in both rat groups. The binding potency, which was very high in both rat groups (>99.5%), was significantly higher in EHBR than that in SD rats. No significant differences in the plasma concentrations of unbound regorafenib were observed between the two rat groups, suggesting that the differences observed in the pharmacokinetic behaviors of regorafenib between the two rat groups were due to differences in protein-binding. When the protein levels of hepatic OATP1 and OATP2 were measured by immunoblot analysis, the expression of both transporters in EHBR was less than 40% of that in SD rats. The present results suggest that regorafenib is not a substrate for OATP1 and OATP2. These findings suggest the possibility that ABCC2-mediated hepatobiliary excretion and OATP1/OATP2-mediated hepatic uptake do not play important roles in the disposition of regorafenib.	[Hotta, Kazuo; Tsukiyama, Ikuto; Matsuura, Katsuhiko; Hasegawa, Takaaki] Aichi Med Univ, Sch Med, Dept Hosp Pharm, Nagakute, Aichi 4801195, Japan; [Ueyama, Jun; Sugiura, Yuka] Nagoya Univ, Grad Sch Med, Dept Pathophysiol Lab Sci, Higashi Ku, Nagoya, Aichi 4648601, Japan; [Tatsumi, Yasuaki] Aichi Gakuin Univ, Sch Pharm, Dept Med, Chikusa Ku, Nagoya, Aichi 464, Japan; [Saito, Hiroko] Meijo Univ, Fac Pharm, Tempaku Ku, Nagoya, Aichi 468, Japan	Hasegawa, T (reprint author), Aichi Med Univ, Sch Med, Dept Hosp Pharm, Nagakute, Aichi 4801195, Japan.	takahase@aichi-med-u.ac.jp					Abe F, 2008, LIFE SCI, V83, P229, DOI 10.1016/j.lfs.2008.06.013; Neuvonen PJ, 2006, CLIN PHARMACOL THER, V80, P565, DOI 10.1016/j.clpt.2006.09.003; Hirosawa N, 2011, TOXICOL LETT, V203, P28, DOI 10.1016/j.toxlet.2011.02.016; Buchler M, 1996, J BIOL CHEM, V271, P15091; Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864; Strumberg D, 2012, BRIT J CANCER, V106, P1722, DOI 10.1038/bjc.2012.153; Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091; Schinkel AH, 2003, ADV DRUG DELIVER REV, V55, P3, DOI 10.1016/S0169-409X(02)00169-2; Hagenbuch B, 2004, PFLUG ARCH EUR J PHY, V447, P653, DOI 10.1007/s00424-003-1168-y; Keppler D, 1997, ADV ENZYME REGUL, V37, P321, DOI 10.1016/S0065-2571(96)00013-1; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Hu S, 2014, BRIT J CANCER, V110, P894, DOI 10.1038/bjc.2013.811; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Chu XY, 1997, CANCER RES, V57, P1934; Hirano M, 2005, MOL PHARMACOL, V68, P800, DOI 10.1124/mol.105.014019; Kuroda M, 2004, J GASTROEN HEPATOL, V19, P146, DOI 10.1111/j.1440-1746.2004.03275.x; Chen DS, 2014, CLIN CANCER RES, V20, P3472, DOI 10.1158/1078-0432.CCR-13-2944; [Anonymous], 2012, CLIN PHARM BIOPH REV; Zimmerman EI, 2013, CLIN CANCER RES, V19, P1458, DOI 10.1158/1078-0432.CCR-12-3306; Jedlitschky G, 1997, BIOCHEM J, V327, P305; Dallas S, 2006, PHARMACOL REV, V58, P140, DOI 10.1124/pr.58.2.3; Schmieder R, 2014, INT J CANCER, V135, P1487, DOI 10.1002/ijc.28669; Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1; Stringer AM, 2008, CANCER BIOL THER, V7, P1919, DOI 10.4161/cbt.7.12.6940; Chu XY, 1997, J PHARMACOL EXP THER, V281, P304; Arakawa-Todo M, 2013, ANTICANCER RES, V33, P5043; HOSOKAWA S, 1992, LAB ANIM SCI, V42, P27; Keppler D, 1997, BIOL CHEM, V378, P787; Khurana Varun, 2014, Drug Metabolism and Drug Interactions, V29, P179, DOI 10.1515/dmdi-2013-0062; Khurana Varun, 2014, Drug Metabolism and Drug Interactions, V29, P249, DOI 10.1515/dmdi-2014-0014; Mikami T, 1986, CONGENITAL ANOM, V26, P250; Newton DJ, 2005, LIFE SCI, V77, P1106, DOI 10.1016/j.lfs.2005.01.020; Sasabe H, 1998, J PHARMACOL EXP THER, V284, P1033; Takasuna K, 1998, CANCER CHEMOTH PHARM, V42, P280, DOI 10.1007/s002800050818; TAKENAKA O, 1995, J PHARMACOL EXP THER, V274, P1362; TAKENAKA O, 1995, PHARMACEUT RES, V12, P1746, DOI 10.1023/A:1016278008658	36	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4681	4689				9	Oncology	Oncology	CO7AX	WOS:000359311000015		
J	Emoto, M; Yoshihisa, H; Yano, K; Choijamts, B; Tsugu, H; Tachibana, K; Aizawa, M				Emoto, Makoto; Yoshihisa, Hajime; Yano, Kyoko; Choijamts, Batsuren; Tsugu, Hitoshi; Tachibana, Katsuro; Aizawa, Mamoru			Advanced Chemoembolization by Anti-angiogenic Calcium-Phosphate Ceramic Microspheres Targeting the Vascular Heterogeneity of Cancer Xenografts	ANTICANCER RESEARCH			English	Article						Chemoembolization; vascular heterogeneity; anti-angiogenic therapy; ceramics; microsphere; drug delivery system (DDS); TNP-470; uterine sarcoma; carcinosarcoma	HUMAN UTERINE CARCINOSARCOMA; PARTICULATE EMBOLIC MATERIAL; TRANSITIONAL-CELL CARCINOMA; INHIBITOR TNP-470 AGM-1470; SPRAY-PYROLYSIS TECHNIQUE; TUMOR-GROWTH; HYDROXYAPATITE CERAMICS; APATITE FIBERS; DRUG-DELIVERY; AGENT TNP-470	The purpose of the present study was to develop an advanced method of anti-angiogenic chemoembolization to target morphological vascular heterogeneity in tumors and further the therapeutic efficacy of cancer treatment. This new chemoembolization approach was designed using resorbable calcium-phosphate ceramic microspheres (CPMs), in a mixture of three different sizes, which were loaded with an anti-angiogenic agent to target the tumor vasculature in highly angiogenic solid tumors in humans in vivo. The human uterine carcinosarcoma cell line, FU-MMT-3, was used in this study because the tumor is highly aggressive and exhibits a poor response to radiotherapy and chemotherapeutic agents that are in current use. CPMs loaded with TNP-470, an anti-angiogenic agent, were injected into FU-MMT-3 xenografts in nude mice three times per week for 8 weeks. The treatment with TNP-470-loaded CPMs of three different diameters achieved a greater suppression of tumor growth in comparison to treatment with single-size TNP-470-loaded CPMs alone, and the control. Severe loss of body weight was not observed in any mice treated with any size of TNP-470-loaded CPMs. These results suggest that treatment with a mixture of differently-sized anti-angiogenic CPMs might be more effective than treatment with CPMs of a single size. This advanced chemoembolization method, which incorporated an anti-angiogenic agent to target the morphological vascular heterogeneity of tumors may contribute to effective treatment of locally advanced or recurrent solid tumors.	[Emoto, Makoto; Choijamts, Batsuren] Int Univ Hlth & Welf, Dept Hlth & Welf, Fukuoka 8140001, Japan; [Yoshihisa, Hajime; Aizawa, Mamoru] Meiji Univ, Sch Sci & Technol, Dept Appl Chem, Tama Ku, Kawasaki, Kanagawa, Japan; [Yano, Kyoko; Tsugu, Hitoshi] Fukuoka Univ, Dept Pathol, Fac Med, Jonan Ku, Nanakuma, Fukuoka, Japan; [Tachibana, Katsuro] Fukuoka Univ, Dept Anat, Fac Med, Jonan Ku, Nanakuma, Fukuoka, Japan; [Emoto, Makoto] Fukuoka Sanno Hosp, Div Gynecol Prevent Med, Sawara Ku, Fukuoka, Japan	Emoto, M (reprint author), Int Univ Hlth & Welf, Fukuoka Sanno Hosp, Div Gynecol Prevent Med, Sawara Ku, 3-6-45 Momochihama, Fukuoka 8140001, Japan.	emoto1209@gmail.com; mamorua@meiji.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [11671164]	This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 11671164).	Aizawa M, 2008, KEY ENG MAT, V361-363, P1215; Aizawa M, 1999, J MATER SCI, V34, P2865, DOI 10.1023/A:1004635418655; Aizawa M, 2006, PHOSPHORUS RES B, V20, P61, DOI 10.3363/prb.20.61; Checkley D, 2003, BRIT J CANCER, V89, P1889, DOI 10.1038/sj.bjc.6601386; Aizawa M, 2005, BIOMATERIALS, V26, P3427, DOI 10.1016/j.biomaterials.2004.09.044; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Kawata M, 2004, J MATER SCI-MATER M, V15, P817, DOI 10.1023/B:JMSM.0000032823.66093.aa; Nahari D, 2007, MOL CANCER THER, V6, P1329, DOI 10.1158/1535-7163.MCT-06-0554; Matsumura Y, 2008, ADV DRUG DELIVER REV, V60, P899, DOI 10.1016/j.addr.2007.11.010; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Emoto M, 2003, GYNECOL ONCOL, V89, P88, DOI 10.1016/S0090-8258(02)00155-5; Yuan HP, 1999, BIOMATERIALS, V20, P1799, DOI 10.1016/S0142-9612(99)00075-7; Acharya S, 2005, LANCET ONCOL, V6, P961, DOI 10.1016/S1470-2045(05)70463-0; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Emoto M, 2007, CANCER SCI, V98, P929, DOI 10.1111/j.1349-7006.00474.x; Emoto M, 2010, CANCER SCI, V101, P984, DOI 10.1111/j.1349-7006.2009.01479.x; Emoto M, 2004, GYNECOL ONCOL, V95, P474, DOI 10.1016/j.ygyno.2004.08.042; Emoto M, 1997, VIRCHOWS ARCH, V431, P249, DOI 10.1007/s004280050096; Inoue K, 2003, CLIN CANCER RES, V9, P886; Inoue K, 2002, CLIN CANCER RES, V8, P2389; Kawashita M, 2003, BIOMATERIALS, V24, P2955, DOI 10.1016/S0142-9612(03)00094-2; Kubo M, 2003, AM J NEURORADIOL, V24, P1545; Kubo M, 2003, AM J NEURORADIOL, V24, P1540; Miura S, 2004, CANCER LETT, V203, P45, DOI 10.1016/j.canlet.2003.08.020; Morisue H, 2009, J BIOMED MATER RES A, V90A, P811, DOI 10.1002/jbm.a.32147; Naganuma Y, 2011, CANCER SCI, V102, P1545, DOI 10.1111/j.1349-7006.2011.01998.x; Nagayama M, 2006, DENT MATER J, V25, P219; Ohno T, 2006, KEY ENG MATER, V309-311, P235; Petersen LK, 2008, EXPERT OPIN DRUG DEL, V5, P837, DOI [10.1517/17425247.5.8.837 , 10.1517/17425240802291652]; Victor SP, 2008, J MATER SCI-MATER M, V19, P283, DOI 10.1007/s10856-006-0044-7; YANASE T, 1993, CANCER RES, V53, P2566; Yoshida T, 1998, CANCER RES, V58, P3751; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P6427, DOI 10.1073/pnas.97.12.6427	34	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4757	4764				8	Oncology	Oncology	CO7AX	WOS:000359311000024		
J	Hata, M; Miyagi, E; Koike, I; Numazaki, R; Asai-Sato, M; Kasuya, T; Kaizu, H; Mukai, Y; Hirahara, F; Inoue, T				Hata, Masaharu; Miyagi, Etsuko; Koike, Izumi; Numazaki, Reiko; Asai-Sato, Mikiko; Kasuya, Takeo; Kaizu, Hisashi; Mukai, Yuki; Hirahara, Fumiki; Inoue, Tomio			Radiation Therapy for Para-Aortic Lymph Node Metastasis from Uterine Cervical Cancer	ANTICANCER RESEARCH			English	Article						Cervical cancer; para-aortic lymph node metastasis; radiation therapy; squamous cell carcinoma; uterine cervix	GYNECOLOGIC-ONCOLOGY-GROUP; POSITRON-EMISSION-TOMOGRAPHY; EXTENDED-FIELD IRRADIATION; COMPUTED-TOMOGRAPHY; CONCOMITANT CHEMOTHERAPY; CISPLATIN CHEMOTHERAPY; GROUP RTOG; CARCINOMA; RADIOTHERAPY; TOXICITY	Aim: To evaluate the efficacy of radiation therapy for para-aortic lymph node metastases from uterine cervical cancer and to identify an optimal radiation regimen. Patients and Methods: A total of 80 metastatic para-aortic lymph nodes, ranging from 11-50 mm (median=20 mm) on computed tomography, in 22 patients with squamous cell carcinoma of the uterine cervix were initially treated with radiation therapy. Total radiation doses for para-aortic lymph node metastases were 40-61.2 Gy (median=50.4 Gy) in 1.8-2 Gy fractions. Results: Eight out of the 22 patients remained alive at a median follow-up of 32 months. Seven irradiated lymph nodes, 20-50 mm in diameter, in four patients progressed after irradiation at total doses of 44-50.4 Gy. No metastatic lymph nodes administered >50.4 Gy (median=55.8 Gy) exhibited progression after irradiation. All metastatic lymph nodes <= 25 mm in diameter irradiated with 50 or 50.4 Gy were controlled. The 3-year lymph node progression-free rates were 78% in the cohort of 22 patients and 89% considering all 80 metastatic lymph nodes. Apart from transient hematological reactions, two patients developed grade 3 or more therapy-related toxicities, including radiation proctitis in one and hemorrhagic cystitis and colitis in another. Conclusion: Radiation therapy can effectively control para-aortic lymph node metastases in patients with uterine cervical cancer. A total dose of 50.4 Gy in 1.8 Gy fractions is sufficient to control metastatic lymph nodes <= 25 mm in diameter, whereas a higher dose (approximately 55.8 Gy) may be required for larger nodes.	[Hata, Masaharu] Yokohama City Univ, Div Radiat Oncol, Dept Oncol, Grad Sch Med, Yokohama, Kanagawa 2360004, Japan; [Miyagi, Etsuko] Yokohama City Univ, Div Gynecol Oncol, Dept Oncol, Grad Sch Med, Yokohama, Kanagawa 2360004, Japan; [Hata, Masaharu; Koike, Izumi; Kasuya, Takeo; Kaizu, Hisashi; Mukai, Yuki; Inoue, Tomio] Yokohama City Univ, Grad Sch Med, Dept Radiol, Yokohama, Kanagawa 2360004, Japan; [Miyagi, Etsuko; Numazaki, Reiko; Asai-Sato, Mikiko; Hirahara, Fumiki] Yokohama City Univ, Grad Sch Med, Dept Obstet & Gynecol, Yokohama, Kanagawa 2360004, Japan	Hata, M (reprint author), Yokohama City Univ, Div Radiat Oncol, Dept Oncol, Grad Sch Med,Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	mhata@syd.odn.ne.jp					Kim YS, 2009, INT J RADIAT ONCOL, V74, P1522, DOI 10.1016/j.ijrobp.2008.10.024; Walker JL, 2009, GYNECOL ONCOL, V112, P78, DOI 10.1016/j.ygyno.2008.09.035; Esthappan J, 2008, INT J RADIAT ONCOL, V72, P1134, DOI 10.1016/j.ijrobp.2008.02.063; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; BERMAN ML, 1984, GYNECOL ONCOL, V19, P8, DOI 10.1016/0090-8258(84)90151-3; Green JA, 2001, LANCET, V358, P781, DOI 10.1016/S0140-6736(01)05965-7; Varia MA, 1998, INT J RADIAT ONCOL, V42, P1015, DOI 10.1016/S0360-3016(98)00267-3; Grigsby PW, 2001, INT J RADIAT ONCOL, V51, P982, DOI 10.1016/S0360-3016(01)01723-0; MATSUKUMA K, 1989, GYNECOL ONCOL, V33, P168, DOI 10.1016/0090-8258(89)90544-1; Rose PG, 1999, J CLIN ONCOL, V17, P41; Jensen LG, 2013, INT J GYNECOL CANCER, V23, P119, DOI 10.1097/IGC.0b013e3182749114; BenedettiPanici P, 1996, GYNECOL ONCOL, V62, P19, DOI 10.1006/gyno.1996.0184; BANDY LC, 1985, OBSTET GYNECOL, V65, P73; BRENNER DE, 1982, CANCER, V50, P2323, DOI 10.1002/1097-0142(19821201)50:11<2323::AID-CNCR2820501117>3.0.CO;2-2; CAMILIEN L, 1988, GYNECOL ONCOL, V30, P209, DOI 10.1016/0090-8258(88)90026-1; Coronel JA, 2013, INT J GYNECOL CANCER, V23, P884, DOI 10.1097/IGC.0b013e3182915c69; EMAMI B, 1991, INT J RADIAT ONCOL, V21, P109; Belhadj H, 2014, INT J GYNECOL OBSTET, V125, P97, DOI 10.1016/j.ijgo.2014.02.003; Halperin EC, 2013, PRINCIPLES PRACTICE, VSixth; Hamm B, 2007, MED RADIOL DIAGN IMA, P1; Hata M, 2013, GYNECOL ONCOL, V131, P99, DOI 10.1016/j.ygyno.2013.07.085; Hata M, AM J CLIN ONCOL; Hata M, 2012, ONCOLOGY-BASEL, V83, P67, DOI 10.1159/000337985; Jang H, 2013, J GYNECOL ONCOL, V24, P229, DOI 10.3802/jgo.2013.24.3.229; Jones B, 2009, CLIN ONCOL-UK, V21, P56, DOI 10.1016/j.clon.2008.10.009; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kazumoto T, 2011, INT J GYNECOL CANCER, V21, P1465, DOI 10.1097/IGC.0b013e318226f657; KING LA, 1986, AM J OBSTET GYNECOL, V155, P960; Lin WC, 2003, GYNECOL ONCOL, V89, P73, DOI 10.1016/S0090-8258(03)00058-1; National Cancer Institute, 2015, CERV CANC CERV CANC; Scheidler J, 1997, JAMA-J AM MED ASSOC, V278, P1096, DOI 10.1001/jama.278.13.1096; Small W, 2011, INT J GYNECOL CANCER, V21, P1266, DOI 10.1097/IGC.0b013e31822c2769; Sobin LH, 2010, TNM CLASSIFICATION M; Stanic S, 2013, INT J GYNECOL CANCER, V23, P592, DOI 10.1097/IGC.0b013e318286aa68; The National Comprehensive Cancer Network, 2015, NCCN CLIN PRACT GUID; Tod M. C., 1938, BRIT J RADIOL, V11, P809; VAS W, 1985, CT-J COMPUT TOMOGR, V9, P359; Verma J, 2014, INT J RADIAT ONCOL, V88, P357, DOI 10.1016/j.ijrobp.2013.09.053; VILLASANTA U, 1983, OBSTET GYNECOL, V62, P218; WHITLEY NO, 1982, RADIOLOGY, V142, P439; World Health Organization, 2012, GLOBOCAN 2012 EST IN; Wu SY, 2014, RADIAT RES, V55, P129	42	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4849	4854				6	Oncology	Oncology	CO7AX	WOS:000359311000035		
J	Yamamoto, M; Kawano, H; Yamaguchi, S; Egashira, A; Minami, K; Taguchi, K; Ikeda, Y; Morita, M; Toh, Y; Okamura, T				Yamamoto, Manabu; Kawano, Hiroyuki; Yamaguchi, Shohei; Egashira, Akinori; Minami, Kazuhito; Taguchi, Kenichi; Ikeda, Yasuharu; Morita, Masaru; Toh, Yasushi; Okamura, Takeshi			Comparison of Neoadjuvant Chemotherapy to Surgery Followed by Adjuvant Chemotherapy in Japanese Patients with Peritoneal Lavage Cytology Positive for Gastric Carcinoma	ANTICANCER RESEARCH			English	Article						Gastric carcinoma; peritoneal washing; neoadjuvant chemotherapy	PROGNOSTIC-SIGNIFICANCE; CANCER PATIENTS; INTRAPERITONEAL CHEMOTHERAPY; WASHING CYTOLOGY; CELLS; S-1; DISSEMINATION; CISPLATIN; DOCETAXEL; SURVIVAL	Background: Therapeutic strategies for positive peritoneal lavage cytology [CY(+)] findings have not yet been established. The aim of the present study was to compare the effects of neoadjuvant systemic chemotherapy and surgery followed by S-1 adjuvant chemotherapy for treating gastric carcinoma in patients with CY(+) status without peritoneal metastasis. Patients and Methods: Twenty-three patients with CY(+) status without peritoneal metastasis who underwent curative surgery for gastric carcinoma between October 1999 and December 2014 were included in the study. Ten patients received neoadjuvant systemic chemotherapy followed by surgery, whereas 13 patients underwent surgery, in nine cases followed by S-1 adjuvant chemotherapy. Results: The 5-year survival in both groups was 15%, and no significant difference was observed. However, the prognosis for patients with CY(-) status after neoadjuvant systemic chemotherapy was significantly better than that of patients who were still CY(+) after neoadjuvant systemic chemotherapy (p<0.01). Among all patients, the prognosis of those with less than clinical N2 disease was significantly better than that of patients with clinical N3 (p<0.01). In multivariate analysis, clinical lymph node metastasis was the only independent prognostic factor for CY(+) patients without peritoneal metastasis (p<0.05). Conclusion: The prognosis of gastric carcinoma with CY(+) without peritoneal metastasis is still stage IV disease and is dependent on the degree of clinical lymph node metastasis, in spite of therapeutic treatment.	[Yamamoto, Manabu; Kawano, Hiroyuki; Yamaguchi, Shohei; Egashira, Akinori; Minami, Kazuhito; Ikeda, Yasuharu; Morita, Masaru; Toh, Yasushi; Okamura, Takeshi] Kyushu Natl Canc Ctr, Dept Surg Gastroenterol, Minami Ku, Fukuoka 8111395, Japan; [Taguchi, Kenichi] Kyushu Natl Canc Ctr, Dept Pathol, Minami Ku, Fukuoka 8111395, Japan	Yamamoto, M (reprint author), Kyushu Natl Canc Ctr, Dept Surg Gastroenterol, Minami Ku, 3-1-1 Notame, Fukuoka 8111395, Japan.	yamamoto.m@nk-cc.go.jp					La Torre M, 2010, EJSO-EUR J SURG ONC, V36, P982, DOI 10.1016/j.ejso.2010.06.007; Kodera Y, 2012, GASTRIC CANCER, V15, P335, DOI 10.1007/s10120-012-0156-3; Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI [10.1016/S1470-2045(08)70035-4, 10.1016/S1470-204S(08)70035-4]; Miyashiro I, 2005, WORLD J SURG, V29, P1131, DOI 10.1007/s00268-005-7703-6; Bando E, 1999, AM J SURG, V178, P256, DOI 10.1016/S0002-9610(99)00162-2; Mezhir JJ, 2010, ANN SURG ONCOL, V17, P3173, DOI 10.1245/s10434-010-1183-0; HAGIWARA A, 1993, CANCER RES, V53, P687; Brigand C, 2004, DIGEST DIS, V22, P366, DOI 10.1159/000083600; Lee SD, 2012, BRIT J SURG, V99, P397, DOI 10.1002/bjs.7812; Fushida S, 2009, ANTI-CANCER DRUG, V20, P752, DOI 10.1097/CAD.0b013e32832ec02b; Yamamoto M, 2009, HEPATO-GASTROENTEROL, V56, P261; Coccolini F, 2014, EJSO-EUR J SURG ONC, V40, P12, DOI 10.1016/j.ejso.2013.10.019; Lorenzen S, 2010, ANN SURG ONCOL, V17, P2733, DOI 10.1245/s10434-010-1090-4; Homma Y, 2010, ANN SURG ONCOL, V17, P455, DOI 10.1245/s10434-009-0764-2; Badgwell B, 2008, ANN SURG ONCOL, V15, P2684, DOI 10.1245/s10434-008-0055-3; Isobe Y, 2011, GASTRIC CANCER, V14, P301, DOI 10.1007/s10120-011-0085-6; Association JGC., 2011, GASTRIC CANCER, V14, P101; Emoto S, 2015, ANN SURG ONCOL, V22, P780; Kitayama J, 2014, SURG ONCOL, V23, P99, DOI 10.1016/j.suronc.2014.03.004; Koizumi W, 2014, J CANCER RES CLIN, V140, P319, DOI 10.1007/s00432-013-1563-5; Martharu G, 2011, BRIT J SURG, V98, P1225; Ministry for Health, 2012, CANC INC; Sobin LH, 2010, TNM CLASSIFICATION M; The General Rules for Gastric Cancer Study, 1993, GEN RUL GASTR CANC S, V12th; Yamamoto M, 2006, SURG TODAY, V36, P835, DOI 10.1007/s00595-006-3253-2; Yonemura Yutaka, 2007, Recent Results Cancer Res, V169, P11; Yonemura Y, 2012, INT J SURG ONCOL, V2012	27	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4859	4863				5	Oncology	Oncology	CO7AX	WOS:000359311000037		
J	Morinaga, S; Murakawa, M; Katayama, Y; Yamaoku, K; Aoyama, T; Kanazawa, A; Higuchi, A; Shiozawa, M; Kobayashi, S; Ueno, M; Morimoto, M				Morinaga, Soichiro; Murakawa, Masaaki; Katayama, Yusuke; Yamaoku, Koichiro; Aoyama, Toru; Kanazawa, Amane; Higuchi, Akio; Shiozawa, Manabu; Kobayashi, Satoshi; Ueno, Makoto; Morimoto, Manabu			Glasgow Prognostic Score Predicts Clinical Outcomes in Patients with Pancreatic Cancer Undergoing Adjuvant Gemcitabine Monotherapy After Curative Surgery	ANTICANCER RESEARCH			English	Article						Glascow prognostic score; clinical outcome; pancreatic cancer; gemcitabine monotherapy; curative surgery	SYSTEMIC INFLAMMATORY RESPONSE; COLORECTAL-CANCER; DUCTAL ADENOCARCINOMA; LYMPHOCYTE RATIO; SURVIVAL; CHEMOTHERAPY; RESECTION	Background/Aim: The Glasgow Prognostic Score (GPS), an inflammation-based prognostic score, has been shown to predict the clinical outcomes of a variety of cancer types. The aim of this study was to determine whether the GPS predicts clinical outcomes of patients with pancreatic cancer treated with adjuvant chemotherapy after surgery. Patients and Methods: Forty patients resected for pancreatic cancer who underwent adjuvant gemcitabine monotherapy after curative surgery were included. The GPS was measured prior to adjuvant therapy and correlated with clinical outcomes. Results: The disease-free survival (DFS) and overall survival (OS) in patients with an elevated GPS (GPS1 or GPS2) were significantly poorer (p=0.001 and p=0.035, respectively, by log-rank test) than patients with a GPS of 0. An elevated GPS was found to be independently associated with poor DFS (p=0.002, by Cox regression model). Conclusion: The pre-adjuvant GPS may predict clinical outcome in patients with pancreatic cancer undergoing adjuvant chemotherapy after surgery.	[Morinaga, Soichiro; Murakawa, Masaaki; Katayama, Yusuke; Yamaoku, Koichiro; Aoyama, Toru; Kanazawa, Amane; Higuchi, Akio; Shiozawa, Manabu] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Asahi Ku, Yokohama, Kanagawa 2418515, Japan; [Kobayashi, Satoshi; Ueno, Makoto; Morimoto, Manabu] Kanagawa Canc Ctr, Dept Gastrointestinal Med, Asahi Ku, Yokohama, Kanagawa 2418515, Japan	Morinaga, S (reprint author), Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Asahi Ku, 2-3-2 Nakao, Yokohama, Kanagawa 2418515, Japan.	morinagas@kcch.jp			Kanagawa Health Foundation	This work was partially supported by grants from the Kanagawa Health Foundation.	Oettle H, 2013, JAMA-J AM MED ASSOC, V310, P1473, DOI 10.1001/jama.2013.279201; Dutta S, 2011, ANN SURG ONCOL, V18, P2808, DOI 10.1245/s10434-011-1676-5; Jamieson NB, 2011, ANN SURG ONCOL, V18, P2318, DOI 10.1245/s10434-011-1560-3; Forrest LM, 2005, BRIT J CANCER, V92, P1834, DOI 10.1038/sj.bjc.6602591; Smith RA, 2009, AM J SURG, V197, P466, DOI 10.1016/j.amjsurg.2007.12.057; Guthrie GJK, 2013, CRIT REV ONCOL HEMAT, V88, P218, DOI 10.1016/j.critrevonc.2013.03.010; Crozier J, 2006, BRIT J CANCER, V94, P1833, DOI 10.1038/sj.bjc.6603185; FALCONER JS, 1995, CANCER, V75, P2077, DOI 10.1002/1097-0142(19950415)75:8<2077::AID-CNCR2820750808>3.0.CO;2-9; Bugada D, 2014, BIOMED RES INT, DOI 10.1155/2014/142425; Jamieson NB, 2005, BRIT J CANCER, V92, P21, DOI 10.1038/sj.bjc.6602305; Chua W, 2011, BRIT J CANCER, V104, P1288, DOI 10.1038/bjc.2011.100; Glen P, 2006, PANCREATOLOGY, V6, P450, DOI 10.1159/000094562; Laird BJ, 2013, CLIN CANCER RES, V19, P5456, DOI 10.1158/1078-0432.CCR-13-1066; Roxburgh CSD, 2011, ANN SURG ONCOL, V18, P997, DOI 10.1245/s10434-010-1410-8; Crumley ABC, 2006, BRIT J CANCER, V94, P637, DOI 10.1038/sj.bjc.6602998; Martin HL, 2014, INTERN MED J, V44, P676, DOI 10.1111/imj.12453; McMillan DC, 2008, P NUTR SOC, V67, P257; Roxburgh C, 2011, INT J COLORECTAL DIS, V26, P483, DOI 10.1007/s00384-010-1120-5; Sobin LH, 2009, TNM CLASSIFICATION M	19	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4865	4870				6	Oncology	Oncology	CO7AX	WOS:000359311000038		
J	Yoshida, Y; Ogura, K; Hiratsuka, A; Aisu, N; Yamada, T; Kojima, D; Tanimura, S; Ogata, K; Hara, S; Mogi, A; Takamatsu, Y; Tamura, K; Mishima, H; Yamashita, Y				Yoshida, Yoichiro; Ogura, Kenichiro; Hiratsuka, Akira; Aisu, Naoya; Yamada, Teppei; Kojima, Daibo; Tanimura, Syu; Ogata, Kentaro; Hara, Shuuji; Mogi, Ai; Takamatsu, Yasushi; Tamura, Kazuo; Mishima, Hideyuki; Yamashita, Yuichi			5-Fluorouracil Chemotherapy for Dihydropyrimidine Dehydrogenase-deficient Patients: Potential of the Dose-escalation Method	ANTICANCER RESEARCH			English	Article						Dihydropyrimidine dehydrogenase; DPD; 5-fluorouracil; DPYD deficiency; cancer; capecitabine	COLORECTAL-CANCER PATIENTS; BLOOD MONONUCLEAR-CELLS; RANDOMIZED-TRIAL; MOLECULAR-BASIS; DPD DEFICIENCY; TOXICITY; FLUOROURACIL; IDENTIFICATION; MUTATIONS; THERAPY	Background: Dihydropyrimidine dehydrogenase (DPD) degrades approximately 85% of administered 5-fluorouracil (5-FU). With a reported high mortality rate, chemotherapy is generally contraindicated for patients with DPD deficiency. Patients and Methods: Chemotherapy was initiated for a 73-year-old man with DPD deficiency. Capecitabine was administered in incrementally increasing doses, beginning with a single pill while monitoring plasma 5-FU concentration, and neutrophil and platelet counts. Results: DPD protein level was 2.35 U/mg. After increasing the capecitabine dose to 1,800 mg, oxaliplatin and bevacizumab were added. Subsequent DPD protein measurement showed that the level had increased to approximately 12-fold the one before chemotherapy. Sequencing of all 23 exons of DPYD gene revealed a mutation of guanine to thymine in exon 11 (1156G>T). Conclusion: This is the first report to indicate that DPD activity can be induced. These findings may provide early indications of a new method for chemotherapy for DPD-deficient patients.	[Yoshida, Yoichiro; Aisu, Naoya; Yamada, Teppei; Kojima, Daibo; Tanimura, Syu; Yamashita, Yuichi] Fukuoka Univ, Fac Med, Dept Surg Gastroenterol, Fukuoka 8140180, Japan; [Ogata, Kentaro; Hara, Shuuji] Fukuoka Univ, Fac Pharmaceut Sci, Fukuoka 8140180, Japan; [Mogi, Ai; Takamatsu, Yasushi; Tamura, Kazuo] Fukuoka Univ, Dept Internal Med, Div Oncol Hematol & Infect Dis, Fukuoka 8140180, Japan; [Ogura, Kenichiro; Hiratsuka, Akira] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Drug Metab & Mol Toxicol, Tokyo, Japan; [Mishima, Hideyuki] Aichi Med Univ, Ctr Canc, Nagakute, Aichi 48011, Japan	Yoshida, Y (reprint author), Fukuoka Univ, Fac Med, Dept Surg Gastroenterol, Jonan Ku, 7-45-1 Nanakuma, Fukuoka 8140180, Japan.	yy4160@yahoo.co.jp					Yang CG, 2011, CANCER CHEMOTH PHARM, V67, P49, DOI 10.1007/s00280-010-1282-4; Andre T, 2003, J CLIN ONCOL, V21, P2896, DOI 10.1200/JCO.2003.10.065; Wei XX, 1996, J CLIN INVEST, V98, P610, DOI 10.1172/JCI118830; LU ZH, 1993, CANCER RES, V53, P5433; Ogura K, 2005, CLIN CANCER RES, V11, P5104, DOI 10.1158/1078-0432.CCR-05-0217; Yoshida Y, 2015, SUPPORT CARE CANCER, V23, P1623, DOI 10.1007/s00520-014-2518-3; ETIENNE MC, 1995, J CLIN ONCOL, V13, P1663; van Kuilenburg ABP, 2000, CLIN CANCER RES, V6, P4705; van Kuilenburg ABP, 2001, CLIN CANCER RES, V7, P1149; Chazal M, 1996, CLIN CANCER RES, V2, P507; FLEMING RA, 1992, CANCER RES, V52, P2899; Boisdron-Celle M, 2007, CANCER LETT, V249, P271, DOI 10.1016/j.canlet.2006.09.006; deGramont A, 1997, J CLIN ONCOL, V15, P808; Johnson MR, 1999, CLIN CANCER RES, V5, P2006; HEGGIE GD, 1987, CANCER RES, V47, P2203; Caudle KE, 2013, CLIN PHARMACOL THER, V94, P640, DOI 10.1038/clpt.2013.172; Swen JJ, 2011, CLIN PHARMACOL THER, V89, P662, DOI 10.1038/clpt.2011.34; ETIENNE MC, 1994, J CLIN ONCOL, V12, P2248; Chen J, 2010, BIOANALYSIS, V2, P2011, DOI 10.4155/bio.10.152; Ezzeldin Hany, 2004, Clin Colorectal Cancer, V4, P181, DOI 10.3816/CCC.2004.n.018; GONZALEZ FJ, 1995, TRENDS PHARMACOL SCI, V16, P325, DOI 10.1016/S0165-6147(00)89065-3; FERNANDEZSALGUERO P, 1995, BIOCHEM PHARMACOL, V50, P1015, DOI 10.1016/0006-2952(95)00231-N; Hoque MO, 2001, INT J ONCOL, V19, P953; Kobayashi H, 2005, ORAL ONCOL, V41, P38, DOI 10.1016/j.oraloncology.2004.06.003; Kouwaki M, 1998, CLIN CANCER RES, V4, P2999; TUCHMAN M, 1985, CANCER RES, V45, P5553; WOODCOCK TM, 1980, CANCER, V45, P1135, DOI 10.1002/1097-0142(19800315)45:5+<1135::AID-CNCR2820451318>3.0.CO;2-Q; Yamashita T, 2014, MOL CLIN ONCOL, V2, P429; YOKOTA H, 1994, J BIOL CHEM, V269, P23192; Yoshida Y, 2015, INT J CLIN ONCOL, V20, P332, DOI 10.1007/s10147-014-0703-5; Yoshida Y, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-39	31	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4881	4887				7	Oncology	Oncology	CO7AX	WOS:000359311000041		
J	Ohira, M; Kubo, N; Yamashita, Y; Sakurai, K; Toyokawa, T; Tanaka, H; Muguruma, K; Hirakawa, K				Ohira, Masaichi; Kubo, Naoshi; Yamashita, Yoshito; Sakurai, Katsunobu; Toyokawa, Takahiro; Tanaka, Hiroaki; Muguruma, Kazuya; Hirakawa, Kosei			Impact of Chemoradiation-induced Myelosuppression on Prognosis of Patients with Locally Advanced Esophageal Cancer After Chemoradiotherapy Followed by Esophagectomy	ANTICANCER RESEARCH			English	Article						Esophageal cancer; myelosuppression; chemoradiation	SQUAMOUS-CELL CARCINOMA; TUMOR-INFILTRATING LYMPHOCYTES; RADICAL ESOPHAGECTOMY; BREAST-CANCER; SURGERY; COMPLICATIONS; CHEMOTHERAPY; DOCETAXEL; CISPLATIN; OUTCOMES	Background: The prognosis of patients with locally advanced esophageal squamous cell carcinoma (LAESC) is extremely poor. The impact of adverse effects of chemoradiotherapy (CRT), particularly myelosuppression, on postoperative long-term results has remained unclear. Patients and Methods: A total of 44 patients with LAESC who underwent CRT followed by esophagectomy were enrolled. We compared long-term survival by various clinical variables, including myelosuppression (Grade 3 and 4 leukopenia) due to CRT, response to CRT, performance status, postoperative complications, and pathological nodal status. Finally, multivariate analysis of prognostic factors was assessed by the Cox proportional hazards model. Results: The mean age of patients was 62.8 years and the male/female ratio was 32/9. The response rate to CRT was 75% (33/44), which included five cases with complete response and 28 cases with partial response. Grade 3 and 4 leukopenia was 43% (19/44). Mortality and postoperative pneumonia occurred in 3 (7.3%) and 14 cases (31.8%), respectively. Multivariate analysis demonstrated that myelosuppression was a significant negative prognostic factor in overall survival (OS) [hazard ratio (HR)=4.758, p=0.005]. The 5-year OS rate was significantly poorer in the group with myelosuppression than in the group without (15.4% vs. 69.0%, p=0.003). Discontinuation of the preoperative CRT schedule and dose reduction of chemotherapeutic agents was significantly more frequent in the group with myelosuppression than in the group without (p=0.003), and peripheral lymphocyte counts after surgery was significantly lower, which may explain poor prognosis in the group with myelosuppression. Conclusion: Preoperative CRT-induced myelosuppression has a negative impact on the prognosis of patients with LAESC. Our findings indicate that a careful postoperative follow-up is required for patients who develop myelosuppression after neoadjuvant CRT followed by curative resection for locally advanced esophageal cancer.	[Ohira, Masaichi; Kubo, Naoshi; Sakurai, Katsunobu; Toyokawa, Takahiro; Tanaka, Hiroaki; Muguruma, Kazuya; Hirakawa, Kosei] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Osaka 5458585, Japan; [Yamashita, Yoshito] Osaka City Gen Hosp, Dept Surg Gastroenterol, Osaka, Japan	Kubo, N (reprint author), Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	k-naoshi@med.osaka-cu.ac.jp					Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Kubo N, 2014, ANTICANCER RES, V34, P2399; Stahl M, 2005, J CLIN ONCOL, V23, P2310, DOI 10.1200/JCO.2005.00.034; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Mariette C, 2007, LANCET ONCOL, V8, P545, DOI 10.1016/S1470-2045(07)70172-9; Nakamura K, 2013, JPN J CLIN ONCOL, V43, P752, DOI 10.1093/jjco/hyt061; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Pimiento JM, 2013, ANN SURG ONCOL, V20, P2706, DOI 10.1245/s10434-013-2885-x; Hennies S, 2014, DIS ESOPHAGUS, V27, P146, DOI 10.1111/dote.12067; Forrest LM, 2003, BRIT J CANCER, V89, P1028, DOI 10.1038/sj.bjc.6601242; Yamasaki M, 2011, ONCOLOGY-BASEL, V80, P307, DOI 10.1159/000329806; [Anonymous], 2006, COMM TERM CRIT ADV E; Shimoji H, 2013, WORLD J SURG, V37, P2180, DOI 10.1007/s00268-013-2074-x; Bosch DJ, 2014, ANN SURG ONCOL, V21, P605, DOI 10.1245/s10434-013-3316-8; Hasegawa T, 2015, J GASTROINTEST SURG, V19, P226, DOI 10.1007/s11605-014-2686-y; Huang SH, 2015, CANCER-AM CANCER SOC, V121, P545, DOI 10.1002/cncr.29100; Ibrahim EM, 2014, BREAST CANCER RES TR, V148, P467, DOI 10.1007/s10549-014-3185-2; Japan Esophageal Society, 2009, ESOPHAGUS, V6, P1; Li X, 2014, ONCOTARGETS THER, V7, P1829, DOI [10.2147/OTT.S69227, 10.2147/OTT.869227]; McKenzie S, 2011, ANN SURG ONCOL, V18, P551, DOI 10.1245/s10434-010-1314-7; Miyoshi N, 2009, J SURG ONCOL, V99, P302, DOI 10.1002/jso.21235; Sobin LH, 2002, UICC TNM CLASSIFICAT	25	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4889	4895				7	Oncology	Oncology	CO7AX	WOS:000359311000042		
J	Ohira, M; Kubo, N; Masuda, G; Yamashita, Y; Sakurai, K; Toyokawa, T; Tanaka, H; Muguruma, K; Hirakawa, K				Ohira, Masaichi; Kubo, Naoshi; Masuda, Go; Yamashita, Yoshito; Sakurai, Katsunobu; Toyokawa, Takahiro; Tanaka, Hiroaki; Muguruma, Kazuya; Hirakawa, Kosei			Glasgow Prognostic Score as a Prognostic Clinical Marker in T4 Esophageal Squamous Cell Carcinoma	ANTICANCER RESEARCH			English	Article						T4 Esophageal cancer; Glasgow Prognostic Score; Prognostic Nutritional Index	CANCER; SURGERY; CHEMORADIOTHERAPY; CHEMORADIATION; PREDICTOR; SURVIVAL; INDEX	Patients with clinical T4 esophageal squamous cell carcinoma (ESCC) have an unfavorable prognosis, mainly indicated by the response to chemoradiotherapy (CRT), crucial to estimating long-term survival. Other prognostic measures include systemic inflammatory or immunonutritional indices such as the Glasgow Prognostic Score (GPS) and Prognostic Nutritional Index (PNI) that have not been sufficiently documented. Patients and Methods: This study retrospectively evaluated 91 patients with T4 ESCC treated at our Hospital between 2000 and 2013. All patients initially received CRT, including 5-fluorouracil (5FU) and cisplatin or nedaplatin with concurrent 2-Gy/fraction radiation (total dose, 40-60 Gy). Curative tumor resection was undertaken in suitable patients on completing CRT. Patients were classified as GPS0, GPS1, or GPS2 based on C-reactive protein (CRP) <= 10 mg/l and albumin >= 35 g/l, CRP >10 mg/l or albumin <35 g/l, or CRP >10 mg/l and albumin <35 g/l, respectively. PNI was calculated as 10-times the serum albumin (g/dl)+0.005xtotal lymphocyte count (/mm(3)). The impact of the pre-treatment GPS and PNI on the prognosis of patients with T4 ESCC was investigated in univariate and multivariate analyses. Results: Sixty (67%) patients responded to CRT (9 complete responses and 51 partial responses). Forty-one (45%) patients also underwent surgical resection of the residual tumor. The overall 5-year survival rate and median survival time were 27.0% and 11.8 months, respectively. In the cohort of CRT-plus-surgical resection, the 5-year survival rate was significantly higher than in the groups treated with CRT-alone (51.1% vs. 6.5%; p < 0.01). On multivariate analysis, good response to CRT [hazard ratio (HR) = 0.449, p < 0.01], GPS1/2 (HR = 2.151, p = 0.015), and surgical resection (HR= 0.282, p < 0.01) were significant prognostic factors, whereas PNI was not. Conclusion: The GPS is a useful, simple survival marker for patients with T4 ESCC undergoing multimodal therapy.	[Ohira, Masaichi; Kubo, Naoshi; Masuda, Go; Sakurai, Katsunobu; Toyokawa, Takahiro; Tanaka, Hiroaki; Muguruma, Kazuya; Hirakawa, Kosei] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Osaka 5458585, Japan; [Yamashita, Yoshito] Osaka City Gen Hosp, Dept Surg Gastroenterol, Osaka, Japan	Kubo, N (reprint author), Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	k-naoshi@med.osaka-cu.ac.jp					Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118; Feng JF, 2014, THER CLIN RISK MANAG, V10, P1, DOI 10.2147/TCRM.S56159; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Stahl M, 2005, J CLIN ONCOL, V23, P2310, DOI 10.1200/JCO.2005.00.034; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Maeda K, 2014, WORLD J SURG, V38, P1217, DOI 10.1007/s00268-013-2386-x; Nakamura M, 2014, SURG TODAY, V44, P875, DOI 10.1007/s00595-013-0628-z; Pimiento JM, 2013, ANN SURG ONCOL, V20, P2706, DOI 10.1245/s10434-013-2885-x; Zhang WC, 2014, ANN THORAC SURG, V98, P513, DOI 10.1016/j.athoracsur.2014.03.015; [Anonymous], 2006, COMM TERM CRIT ADV E; Forrest LM, 2003, BRIT J CANCER, V89, P1028, DOI 10.1038/sj.bjc.6601242; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Vashist YK, 2011, ANN SURG ONCOL, V18, P1130, DOI 10.1245/s10434-010-1383-7; Kobayashi T, 2008, SURGERY, V144, P729, DOI 10.1016/j.surg.2008.08.015; Shimoji H, 2013, WORLD J SURG, V37, P2180, DOI 10.1007/s00268-013-2074-x; Nozoe T, 2010, SURG TODAY, V40, P440, DOI 10.1007/s00595-009-4065-y; Feng JF, 2014, SAUDI J GASTROENTERO, V20, P48, DOI 10.4103/1319-3767.126319; Han U, 2003, DIS ESOPHAGUS, V20, P379; Japan Esophageal Society, 2009, ESOPHAGUS, V6, P1; Kanda M, 2011, BRIT J SURG, V98, P268, DOI 10.1002/bjs.7305; Nakamura T, 1998, Dis Esophagus, V11, P35; Onodera T, 1984, Nihon Geka Gakkai Zasshi, V85, P1001; Sobin LH, 2002, UICC TNM CLASSIFICAT	24	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4897	4901				5	Oncology	Oncology	CO7AX	WOS:000359311000043		
J	Niibe, Y; Yamashita, H; Sekiguchi, K; Takahashi, W; Shiraishi, K; Okuma, K; Terahara, A; Kawamori, J; Nakagawa, K				Niibe, Yuzuru; Yamashita, Hideomi; Sekiguchi, Kenji; Takahashi, Wataru; Shiraishi, Kenshiro; Okuma, Kae; Terahara, Atsuro; Kawamori, Jiro; Nakagawa, Keiichi			Stereotactic Body Radiotherapy Results for Pulmonary Oligometastases: A Two-Institution Collaborative Investigation	ANTICANCER RESEARCH			English	Article						Pulmonary oligometastases; SBRT; oligo-recurrence; sync-oligometastases	UTERINE CERVICAL-CARCINOMA; COLORECTAL-CANCER; OLIGO-RECURRENCE; METASTASES; THERAPY; TUMORS	Aim: The current study investigated outcomes and prognostic factors of pulmonary oligometastases at two Institutions. Patients and Methods: SBRT (stereotactic body radiotherapy) as performed for pulmonary oligometastases from January 2004 to April 2014, and patients with a biologically effective dose (BED10) >= 75 Gy were registered in the study. Control of the primary tumor was not a criterion: we included both oligo-recurrence and sync-oligometastases. Results: A total of 34 patients were enrolled in the study. The median overall survival was 20 months (range = 1-119 months) and the 2-year overall survival rate was 65.7% [95% confidence interval (CI) = 48.3-83.1%]. The two-year local control rate was 79.1% (95% CI = 62.4-95.8%). Stratified by oligo status, the 2-year overall survival rate of the oligo-recurrence group was 68.5% (95% CI = 50.3-86.7%), while that of the group with sync-oligometastases was 50.0% (95% CI = 1.0-99.0%). These rates were significantly different (p = 0.037). No grade 5 early-or late-adverse events were recognized in the current study. Conclusion: SBRT for pulmonary oligometastases achieved good results and there was no serious adverse event. The oligo-recurrence group, in particular, achieved fairly good results.	[Niibe, Yuzuru] Toho Univ, Omori Med Ctr, Dept Radiol, Ota Ku, Tokyo 1438541, Japan; [Yamashita, Hideomi; Takahashi, Wataru; Shiraishi, Kenshiro; Okuma, Kae; Terahara, Atsuro; Nakagawa, Keiichi] Tokyo Univ Hosp, Dept Radiol, Bunkyo Ku, Tokyo 113, Japan; [Niibe, Yuzuru; Sekiguchi, Kenji; Terahara, Atsuro; Kawamori, Jiro] St Lukes Int Hosp, Dept Radiat Oncol, Chuo Ku, Tokyo, Japan	Niibe, Y (reprint author), Toho Univ, Omori Med Ctr, Dept Radiol, Ota Ku, 6-11-1 Omorinishi, Tokyo 1438541, Japan.	yniibe-toho@umin.org			JSPS KAKENHI [21791209, 25461926]	This study was supported partly by grant-in-aid from JSPS KAKENHI Grant Number 21791209 and 25461926.	Niibe Y, 2010, JPN J CLIN ONCOL, V40, P107, DOI 10.1093/jjco/hyp167; Takeda A, 2011, RADIOTHER ONCOL, V101, P255, DOI 10.1016/j.radonc.2011.05.033; Watanabe T, 2012, INT J CLIN ONCOL, V17, P1, DOI 10.1007/s10147-011-0315-2; [Anonymous], 1997, J THORAC CARDIOVASC, V113, P37; HELLMAN S, 1995, J CLIN ONCOL, V13, P8; Huang F, 2014, RADIAT ONCOL, V9, DOI 10.1186/s13014-014-0230-6; Inoue T, 2012, PULM MED, V2012, DOI DOI 10.1155/2012/369820; Niibe Y, 2003, INT J GYNECOL CANCER, V13, P849, DOI 10.1111/j.1525-1438.2003.13397.x; Niibe Y, 2009, INT J RADIAT ONCOL, V66, P1366; Niibe Y, 2006, GYNECOL ONCOL, V103, P435, DOI 10.1016/j.ygyno.2006.03.034; Niibe Y, 2012, PULM MED, V2012, DOI DOI 10.1155/2012/261096; Niibe Y, 2003, ANTICANCER RES, V23, P4157; Onishi H, 2012, PULM MED, V2012, DOI DOI 10.1155/2012/713073; Sole CV, AN SURG ONC IN PRESS; Takahashi W, 2012, PULM MED, V2012; Takahashi W, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-68	16	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4903	4908				6	Oncology	Oncology	CO7AX	WOS:000359311000044		
J	Yoshitake, T; Shioyama, Y; Asai, K; Nakamura, K; Sasaki, T; Ohga, S; Kamitani, T; Yamaguchi, T; Ohshima, K; Matsumoto, K; Kawanami, S; Honda, H				Yoshitake, Tadamasa; Shioyama, Yoshiyuki; Asai, Kaori; Nakamura, Katsumasa; Sasaki, Tomonari; Ohga, Saiji; Kamitani, Takeshi; Yamaguchi, Toshihiro; Ohshima, Kaori; Matsumoto, Keiji; Kawanami, Satoshi; Honda, Hiroshi			Impact of Interstitial Changes on Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Lung Cancer	ANTICANCER RESEARCH			English	Article						Radiation pneumonitis; stereotactic radiation therapy; interstitial changes	PROSPECTIVE PHASE-II; RADIOTHERAPY; TUMORS; KL-6; FRACTIONS; TOXICITY; DISEASE; GRADE; RISK	Aim: The aim of the present study was to evaluate the impact of interstitial changes (IC) on radiation pneumonitis (RP) after stereotactic body radiation therapy (SBRT) for lung cancer. Patients and Methods: We analyzed 260 consecutive patients with primary lung cancer treated with SBRT. According to the presence or absence of IC on the pre-treatment computed tomography, patients were divided into two groups: an IC group (n = 18) and a non-IC group (n = 242). Results: RP of grade 2 or more was observed in 9 (50.0%) and 14 (6.7%) patients in the IC and non-IC group, respectively. All three patients with grade 5 RP were in the IC group. As indicated by multivariate analysis, the presence of IC was the only significant predictive factor of RP of grade 2 or more. Conclusion: The presence of IC was a significant indicator of grade 2 or more RP after SBRT for patients with lung cancer.	[Yoshitake, Tadamasa] Kyushu Univ, Grad Sch Med Sci, Dept Comprehens Clin Oncol, Higashi Ku, Fukuoka 8128582, Japan; [Asai, Kaori; Nakamura, Katsumasa; Sasaki, Tomonari; Ohga, Saiji; Kamitani, Takeshi; Yamaguchi, Toshihiro; Ohshima, Kaori; Matsumoto, Keiji; Kawanami, Satoshi; Honda, Hiroshi] Kyushu Univ, Grad Sch Med Sci, Dept Clin Radiol, Higashi Ku, Fukuoka 8128582, Japan; [Shioyama, Yoshiyuki] Kyushu Int Heavy Ion Beam Therapy Ctr, Tosu, Saga, Japan	Yoshitake, T (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Comprehens Clin Oncol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	yoshitake@radiol.med.kyushu-u.ac.jp			JSPS KAKENHI [26461894]	This work was supported in part by JSPS KAKENHI grants number 26461894.	Yamaguchi S, 2013, LUNG CANCER, V82, P260, DOI 10.1016/j.lungcan.2013.08.024; Baumann P, 2009, J CLIN ONCOL, V27, P3290, DOI 10.1200/JCO.2008.21.5681; Ong CL, 2010, RADIOTHER ONCOL, V97, P431, DOI 10.1016/j.radonc.2010.10.003; Song JW, 2011, EUR RESPIR J, V37, P356, DOI 10.1183/09031936.00159709; Fakiris AJ, 2009, INT J RADIAT ONCOL, V75, P677, DOI 10.1016/j.ijrobp.2008.11.042; Guckenberger M, 2010, RADIOTHER ONCOL, V97, P65, DOI 10.1016/j.radonc.2010.04.027; Nagata Y, 2005, INT J RADIAT ONCOL, V63, P1427, DOI 10.1016/j.ijrobp.2005.05.034; Borst GR, 2009, RADIOTHER ONCOL, V91, P307, DOI 10.1016/j.radonc.2009.02.003; Wulf J, 2004, INT J RADIAT ONCOL, V60, P186, DOI 10.1016/j.ijrobp.2004.06.060; Barriger RB, 2012, INT J RADIAT ONCOL, V82, P457, DOI 10.1016/j.ijrobp.2010.08.056; Ohnishi H, 2002, AM J RESP CRIT CARE, V165, P378; Ueki N, 2015, J THORAC ONCOL, V10, P116, DOI 10.1097/JTO.0000000000000359; Sanuki N, 2012, J RADIAT RES, V53, P110, DOI 10.1269/jrr.110142; Chang JY, 2015, LANCET ONCO IN PRESS; Hara R, 2004, CHEST, V125, P340, DOI 10.1378/chest.125.1.340; Iwata H, 2011, RADIOTHER ONCOL, V101, P267, DOI 10.1016/j.radonc.2011.05.031; National Cancer Institute, 2009, NIH PUBLICATION; Nuyttens JJ, 2015, INT J RADIAT ONCOL, V91, P337, DOI 10.1016/j.ijrobp.2014.10.021; Shioyama Yoshiyuki, 2005, Radiat Med, V23, P407; Stauder MC, 2011, RADIOTHER ONCOL, V99, P166, DOI 10.1016/j.radonc.2011.04.002; van den Blink B, 2010, PULM PHARMACOL THER, V23, P515, DOI 10.1016/j.pupt.2010.08.001; Yamashita H, 2007, RADIAT ONCOL, V2, DOI 10.1186/1748-717X-2-21; Yamashita H, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-32; Yamashita Hideomi, 2014, World J Radiol, V6, P708, DOI 10.4329/wjr.v6.i9.708; Yoshitake T, 2008, RADIAT MED, V26, P50, DOI 10.1007/s11604-007-0189-4	25	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4909	4913				5	Oncology	Oncology	CO7AX	WOS:000359311000045		
J	Tsubamoto, H; Sonoda, T; Ikuta, S; Tani, S; Inoue, K; Yamanaka, N				Tsubamoto, Hiroshi; Sonoda, Takashi; Ikuta, Shinichi; Tani, Satoshi; Inoue, Kayo; Yamanaka, Naoki			Impact of Itraconazole After First-line Chemotherapy on Survival of Patients with Metastatic Biliary Tract Cancer	ANTICANCER RESEARCH			English	Article						biliary tract cancer; second-line chemotherapy; itraconazole	PHASE-II TRIAL; PANCREATIC-CANCER; HEDGEHOG PATHWAY; COMBINATION CHEMOTHERAPY; P-GLYCOPROTEIN; CELL CARCINOMA; BREAST-CANCER; RESISTANCE; GEMCITABINE; ANTIFUNGAL	Aim: We evaluated the efficacy and safety of itraconazole after first-line chemotherapy in patients with metastatic biliary tract cancer (BTC). Patients and Methods: We retrospectively reviewed data from patients with histologically-diagnosed BTC with distant metastases who had received one or more lines of chemotherapy and subsequent itraconazole chemotherapy. Results: Among 28 enrolled patients, 26 (93%) received docetaxel (35 mg/m(2)), gemcitabine (1,000 mg/m(2)), and carboplatin (AUC4) on day 1 and oral itraconazole solution (400 mg) on days -2 to 2, repeated every 2 weeks. Two patients received docetaxel plus itraconazole with irinotecan. Two complete responses and 14 partial responses were observed, with a response rate of 57%. The median overall survival was 12.0 months. During 160 cycles, 21 (75%) and 17 (61%) patients had grade 3/4 neutropenia and thrombocytopenia, respectively. Two patients (7%) experienced febrile neutropenia. Conclusion: Combination chemotherapy with itraconazole after first-line chemotherapy is promising for patients with metastatic BTC.	[Tsubamoto, Hiroshi; Sonoda, Takashi; Inoue, Kayo] Meiwa Hosp, Dept Med Oncol, Nishinomiya, Hyogo 6638186, Japan; [Ikuta, Shinichi; Yamanaka, Naoki] Meiwa Hosp, Dept Surg, Nishinomiya, Hyogo 6638186, Japan; [Tsubamoto, Hiroshi; Inoue, Kayo] Hyogo Coll Med, Dept Obstet & Gynecol, Nishinomiya, Hyogo 6638501, Japan; [Tani, Satoshi] Kohnan Hosp, Dept Med Oncol, Higashinada Ku, Kobe, Hyogo, Japan	Tsubamoto, H (reprint author), Meiwa Hosp, Dept Med Oncol, Agenaruo 4-31, Nishinomiya, Hyogo 6638186, Japan.	tsuba@hyo-med.ac.jp					Xie GZ, 2012, INT J ONCOL, V40, P1171, DOI 10.3892/ijo.2011.1275; Kim J, 2010, CANCER CELL, V17, P388, DOI 10.1016/j.ccr.2010.02.027; Hong SP, 2009, INT J CANCER, V125, P2323, DOI [10.1002/ijc.24573, 10.1002/ijc.2403]; Huang FT, 2012, INT J ONCOL, V41, P1707, DOI 10.3892/ijo.2012.1597; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Tsubamoto H, 2014, ANTICANCER RES, V34, P2007; Tsubamoto H, 2014, ANTICANCER RES, V34, P3839; Okusaka T, 2010, BRIT J CANCER, V103, P469, DOI 10.1038/sj.bjc.6605779; Kim DJ, 2014, J CLIN ONCOL, V32, P745, DOI 10.1200/JCO.2013.49.9525; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Kim J, 2013, CANCER CELL, V23, P23, DOI 10.1016/j.ccr.2012.11.017; Antonarakis ES, 2013, ONCOLOGIST, V18, P163, DOI 10.1634/theoncologist.2012-314; Rudin CM, 2013, J THORAC ONCOL, V8, P619, DOI 10.1097/JTO.0b013e31828c3950; Matsushita S, 2014, CANCER SCI, V105, P272, DOI 10.1111/cas.12354; Sharma A, 2010, J CLIN ONCOL, V28, P4581, DOI 10.1200/JCO.2010.29.3605; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Tsubamoto H, 2014, ANTICANCER RES, V34, P2481; De Jesus-Acosta A, 2014, J CLIN ONCOL, V32; Hwang RF, 2012, MOL CANCER RES, V10, P1147, DOI 10.1158/1541-7786.MCR-12-0022; Iida N, 2001, BIOL PHARM BULL, V24, P1032, DOI 10.1248/bpb.24.1032; Japanese Ministry of Health Labor and Welfare, 2012, STAT INV RES; Kethlreddy S, 2007, EXPERT OPIN DRUG MET, V3, P573, DOI 10.1517/17425225.3.4.573; Kiesslich T, 2014, MOL CELL BIOCHEM, V396, P257, DOI 10.1007/s11010-014-2161-9; Lamarca A, 2014, ANN ONCOL, V25, P2328, DOI 10.1093/annonc/mdu162; Li JM, 2012, SURG TODAY, V42, P770, DOI 10.1007/s00595-012-0157-1; Shirakawa K, 1999, JPN J CANCER RES, V90, P1380; Takara K, 1999, BIOL PHARM BULL, V22, P1355; Tsubamoto H, ANTICANCER RES; Wang M, 2011, INT J CANCER, V128, P72, DOI 10.1002/ijc.25317; Yao J, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13208	31	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4923	4927				5	Oncology	Oncology	CO7AX	WOS:000359311000047		
J	Haruki, K; Shiba, H; Horiuchi, T; Shirai, Y; Iwase, R; Fujiwara, Y; Furukawa, K; Misawa, T; Yanaga, K				Haruki, Koichiro; Shiba, Hiroaki; Horiuchi, Takashi; Shirai, Yoshihiro; Iwase, Ryota; Fujiwara, Yuki; Furukawa, Kenei; Misawa, Takeyuki; Yanaga, Katsuhiko			Preoperative Change in Peripheral Blood Monocyte Count May Predict Long-term Outcomes After Pancreaticoduodenectomy for Bile Duct Cancer	ANTICANCER RESEARCH			English	Article						Bile duct cancer; monocyte; immune supression; systemic inflammatory response	PROGNOSTIC SCORE; SURGICAL RESECTION; RADICAL RESECTION; CARCINOMA; SURVIVAL; LYMPHOCYTE; RATIO; CHOLANGIOCARCINOMA; IMPACT; CELLS	Background/Aim: The perioperative immunological response predicts long-term outcomes after resection for malignant tumors. The aim of the study was to evaluate the significance of perioperative change in the peripheral blood monocyte count regarding therapeutic outcome after pancreaticoduodenectomy for bile duct cancer. Patients and Methods: The study comprised of 51 patients who had undergone pancreaticoduodenectomy for bile duct cancer between January 2000 and December 2012. We retrospectively investigated the relation between perioperative change in peripheral blood monocyte count and disease-free as well as overall survival. Results: In multivariate analysis, advanced TNM stage, and decrease in monocyte count on postoperative day 1 in comparison with those before surgery were independent and significant predictors of poor diseasefree survival and overall survival (p = 0.014 and 0.004, and 0.010 and 0.006, respectively). Conclusion: Perioperative change in peripheral blood monocyte count is an independent and significant indicator of therapeutic outcome after pancreaticoduodenectomy in patients with bile duct cancer.	[Haruki, Koichiro; Shiba, Hiroaki; Horiuchi, Takashi; Shirai, Yoshihiro; Iwase, Ryota; Fujiwara, Yuki; Furukawa, Kenei; Misawa, Takeyuki; Yanaga, Katsuhiko] Jikei Univ, Sch Med, Dept Surg, Tokyo 1058461, Japan	Haruki, K (reprint author), Jikei Univ, Sch Med, Dept Surg, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.	haruki@jikei.ac.jp					Stotz M, 2014, BRIT J CANCER, V110, P435, DOI 10.1038/bjc.2013.785; Jaiswal M, 2000, CANCER RES, V60, P184; Woo SM, 2007, ANN SURG ONCOL, V14, P3195, DOI 10.1245/s10434-007-9537-y; Jang JY, 2005, ANN SURG, V241, P77, DOI 10.1097/01.sla.0000150166.94732.88; McNamara MG, 2014, EUR J CANCER, V50, P1581, DOI 10.1016/j.ejca.2014.02.015; Miyakawa S, 2009, J HEPATO-BILIARY-PAN, V16, P1, DOI 10.1007/s00534-008-0015-0; Hernandez J, 2008, ANN SURG ONCOL, V15, P807, DOI 10.1245/s10434-007-9756-2; Fujiwara Y, 2014, ANTICANCER RES, V34, P5163; McMillan DC, 2008, P NUTR SOC, V67, P257, DOI 10.1017/S0029665108007131; Braga M, 2002, SURGERY, V132, P805, DOI 10.1067/msy.2002.128350; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Proctor MJ, 2011, BRIT J CANCER, V104, P726, DOI 10.1038/sj.bjc.6606087; Haruki K, 2012, J SURG ONCOL, V106, P31, DOI 10.1002/jso.23033; Higuchi R, 2010, SURGERY, V148, P7, DOI 10.1016/j.surg.2009.11.018; Hong SM, 2009, SURGERY, V146, P250, DOI 10.1016/j.surg.2009.02.023; Iwase R, 2013, ANTICANCER RES, V33, P3439; Japanese Society of Biliary Surgery, 2003, CLASS BIL TRACT CARC, V5th; Kamposioras K, 2014, BRIT J SURG, V101, P89, DOI 10.1002/bjs.9367; McMillan DC, 2003, BRIT J SURG, V90, P215, DOI 10.1002/bjs.4038; Oshikiri T, 2003, J SURG ONCOL, V84, P224, DOI 10.1002/jso.10321; Shiba H, 2015, WORLD J SURG, V39, P753, DOI 10.1007/s00268-014-2844-0; Shiba H, 2013, ANTICANCER RES, V33, P2715; Suzuki D, 2010, SURGERY, V148, P573, DOI 10.1016/j.surg.2010.01.017; Taketomi A, 1998, CANCER, V83, P58, DOI 10.1002/(SICI)1097-0142(19980701)83:1<58::AID-CNCR8>3.0.CO;2-A	24	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					4961	4966				6	Oncology	Oncology	CO7AX	WOS:000359311000053		
J	Korehisa, S; Ohgaki, K; Yukaya, T; Zaitu, Y; Tsuda, Y; Kasagi, Y; Ando, K; Nakashima, Y; Imamura, Y; Saeki, H; Oki, E; Maehara, Y				Korehisa, Shotaro; Ohgaki, Kippei; Yukaya, Takafumi; Zaitu, Yoko; Tsuda, Yasuo; Kasagi, Yuta; Ando, Koji; Nakashima, Yuichiro; Imamura, Yu; Saeki, Hiroshi; Oki, Eiji; Maehara, Yoshihiko			Laparoscopic Total Gastrectomy for RGC: Four Case Reports	ANTICANCER RESEARCH			English	Article						RGC; total gastrectomy; laparoscopic surgery	REMNANT GASTRIC-CANCER; CARCINOMA; RESECTION; EXPERIENCE; BENIGN; STUMP	Surgery for RGC can generally be difficult because of the severity of intra-abdominal adhesion due to past gastrectomy. Laparoscopic gastrectomy for RGC has been reported in some cases, but the adequacy of this procedure is still unclear. Herein we report four cases of RGC that underwent laparoscopic gastrectomy at our Hospital and discuss the benefit of the laparoscopic approach for RGC.	[Korehisa, Shotaro; Ohgaki, Kippei; Yukaya, Takafumi; Zaitu, Yoko; Tsuda, Yasuo; Kasagi, Yuta; Ando, Koji; Nakashima, Yuichiro; Imamura, Yu; Saeki, Hiroshi; Oki, Eiji; Maehara, Yoshihiko] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan	Oki, E (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	okieiji@surg2.med.kyushu-ac.jp					Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Cho HJ, 2009, SURG LAPARO ENDO PER, V19, P57; Corcione F, 2008, SURG LAPARO ENDO PER, V18, P502, DOI 10.1097/SLE.0b013e31817f460b; Kim HS, 2014, SURG LAPARO ENDO PER, V24, P177, DOI 10.1097/SLE.0b013e31828f6bfb; Kodera Y, 1996, J AM COLL SURGEONS, V182, P1; Kwon IG, 2014, SURG ENDOSC, V28, P2452, DOI 10.1007/s00464-014-3496-8; Nagai E, 2014, SURG ENDOSC, V28, P289, DOI 10.1007/s00464-013-3186-y; OVASKA JT, 1986, ANN CHIR GYNAECOL FE, V75, P192; Ozaki I, 2010, WORLD J SURG, V34, P1548; Qian F, 2010, SURG ENDOSC, V24, P3205, DOI 10.1007/s00464-010-1116-9; Shinohara T, 2013, LANGENBECK ARCH SURG, V398, P341, DOI 10.1007/s00423-012-0979-8; Son SY, 2015, GASTRIC CANCER, V18, P177, DOI 10.1007/s10120-014-0339-1; Tsunoda S, 2014, GASTRIC CANC; UICC International Union against Cancer, 2009, TNM CLASSIFICATION M, V7th; WELVAART K, 1982, J SURG ONCOL, V21, P104, DOI 10.1002/jso.2930210208; Yamada H, 2005, SURG LAPARO ENDO PER, V15, P226, DOI 10.1097/01.sle.0000174546.41307.02	16	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					5023	5026				4	Oncology	Oncology	CO7AX	WOS:000359311000060		
J	Kitagawa, Y; Urata, S; Mizokami, A; Nakashima, K; Koshida, K; Nakashima, T; Miyazaki, K; Namiki, M				Kitagawa, Yasuhide; Urata, Satoko; Mizokami, Atsushi; Nakashima, Kazuyoshi; Koshida, Kiyoshi; Nakashima, Takao; Miyazaki, Kimiomi; Namiki, Mikio			Simple Risk Stratification to Detect Prostate Cancer with High Gleason Score in Repeat Biopsies in a Population Screening Follow-up Study	ANTICANCER RESEARCH			English	Article						prostate cancer; repeat biopsy; percentage free PSA; PSA velocity; population screening; Gleason score >= 7	ANTIGEN LEVELS; 2.1-10.0 NG/ML; PSA RATIO; MEN; PROBABILITY; VALIDATION; GUIDELINES; DIAGNOSIS; NOMOGRAM; COHORT	Background: To investigate the clinical usefulness of percentage free prostate-specific antigen (%fPSA) and PSA velocity (PSAV) for detecting prostate cancer in repeat biopsies in a population-based screening cohort. Patients and Methods: In total, 178 men with serum PSA levels within 2.1-10 ng/ml who underwent repeat biopsies after initial negative biopsy results, were enrolled. Prostate cancer detection rates with a Gleason score of 7 or more according to age, serum PSA, % fPSA, and PSAV were investigated. The cumulative probability of detecting cancer according to risk factors was also investigated. Results: Out of 178 men who underwent repeat biopsy, 48 (27.0%) were diagnosed with prostate cancer during the observation period, and pathological examination revealed prostate cancer with a Gleason score of 7 or more in 17 patients (35.4%). In the multivariate logistic regression analysis, % fPSA <= 12 at repeat biopsy and PSAV >0.40 ng/ml/year were determined to be independent risk factors for prostate cancer, and % fPSA <= 12 at initial biopsy and PSAV >0.40 for cancer of Gleason score 7 or greater. The cumulative probabilities of developing high-grade cancer after 5 years were 55.8% and 4.0% in men with % fPSA <= 12 at initial biopsy and PSAV >0.40, and in men without both, respectively. There was a statistically significant difference in probabilities between groups by the log-rank test. Conclusion: The present results demonstrated that % fPSA and PSAV were predictors of prostate cancer with a Gleason score of 7 or more in repeat biopsy after a negative initial biopsy on a population follow-up basis.	[Kitagawa, Yasuhide; Urata, Satoko; Mizokami, Atsushi; Namiki, Mikio] Kanazawa Univ, Grad Sch Med Sci, Dept Integrat Canc Therapy & Urol, Kanazawa, Ishikawa 9208640, Japan; [Nakashima, Kazuyoshi; Koshida, Kiyoshi; Nakashima, Takao; Miyazaki, Kimiomi] Kanazawa Med Assoc, Kanazawa, Ishikawa, Japan	Kitagawa, Y (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Integrat Canc Therapy & Urol, Takaramachi 13-1, Kanazawa, Ishikawa 9208640, Japan.	yasukita@med.kanazawa-u.ac.jp					Moussa AS, 2010, BJU INT, V106, P1309, DOI 10.1111/j.1464-410X.2010.09362.x; Roehl KA, 2002, J UROLOGY, V167, P2435, DOI 10.1016/S0022-5347(05)64999-3; Aus G, 2005, ARCH INTERN MED, V165, P1857, DOI 10.1001/archinte.165.16.1857; Heidenreich A, 2014, EUR UROL, V65, P124, DOI 10.1016/j.eururo.2013.09.046; Zaytoun OM, 2011, INT J UROL, V18, P557, DOI 10.1111/j.1442-2042.2011.02798.x; Arumainayagam N, 2013, RADIOLOGY, V268, P761, DOI 10.1148/radiol.13120641; Djavan B, 2002, EUR UROL, V42, P93, DOI 10.1016/S0302-2838(02)00256-7; O'Dowd GJ, 2000, UROLOGY, V55, P553, DOI 10.1016/S0090-4295(00)00447-7; Benecchi L, 2008, J UROLOGY, V180, P146, DOI 10.1016/j.juro.2008.03.043; Candas B, 2006, J UROLOGY, V175, P510, DOI 10.1016/S0022-5347(05)00165-5; Naito S, 2010, INT J UROL, V17, P830, DOI 10.1111/j.1442-2042.2010.02613.x; Ito K, 2003, UROLOGY, V62, P64, DOI 10.1016/S0090-4295(03)00135-3; Ito K, 2005, CANCER, V103, P242, DOI 10.1002/cncr.20739; Keetch DW, 1996, J UROLOGY, V156, P428, DOI 10.1016/S0022-5347(01)65868-3; Kitagawa Y, 2011, INT J UROL, V18, P592, DOI 10.1111/j.1442-2042.2011.02796.x; Kitagawa Y, 2014, J CANCER RES CLIN, V140, P53, DOI 10.1007/s00432-013-1543-9; Kobori Y, 2008, INT J CLIN ONCOL, V13, P229, DOI 10.1007/s10147-007-0742-2; Morgan TO, 1996, UROLOGY, V48, P76, DOI 10.1016/S0090-4295(96)00615-2; Okada K, 2010, INT J UROL, V17, P541, DOI 10.1111/j.1442-2042.2010.02517.x; Sakura M, 2010, UROLOGY, V77, P915; Sawada K, 2014, INT J UROL, V21, P560, DOI 10.1111/iju.12380; Vickers AJ, 2010, J UROLOGY, V184, P907, DOI 10.1016/j.juro.2010.05.029; Wittekind CH, 1997, TNM CLASS MAL TUM, VFifth, P170	23	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					5031	5036				6	Oncology	Oncology	CO7AX	WOS:000359311000062		
J	Shibutani, M; Maeda, K; Nagahara, H; Ohtani, H; Sakurai, K; Yamazoe, S; Kimura, K; Toyokawa, T; Amano, R; Kubo, N; Tanaka, H; Muguruma, K; Ohira, M; Hirakawa, K				Shibutani, Masatsune; Maeda, Kiyoshi; Nagahara, Hisashi; Ohtani, Hiroshi; Sakurai, Katsunobu; Yamazoe, Sadaaki; Kimura, Kenjiro; Toyokawa, Takahiro; Amano, Ryosuke; Kubo, Naoshi; Tanaka, Hiroaki; Muguruma, Kazuya; Ohira, Masaichi; Hirakawa, Kosei			Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer	ANTICANCER RESEARCH			English	Article						Colorectal cancer; unresectable; prognosis; neutrophil to lymphocyte ratio; C-reactive protein; Glasgow prognostic score	C-REACTIVE PROTEIN; LYMPHOCYTE RATIO; 1ST-LINE TREATMENT; PROGNOSTIC SCORE; GASTRIC-CANCER; POOR SURVIVAL; NEUTROPHIL; FLUOROURACIL	Background: Markers of systemic inflammation, such as the neutrophil to lymphocyte ratio (NLR), C-reactive protein (CRP) level and Glasgow prognostic score (GPS), have been reported to be useful prognostic indicators for various types of cancers. However, most of the existing reports investigated the preoperative status, and the significance of markers of systemic inflammation remains unclear in patients with unresectable metastatic colorectal cancer. The aim of the present retrospective study was to evaluate the significance of markers of systemic inflammation for predicting the prognosis and chemotherapeutic outcomes and monitoring the progression of the tumor in patients with unresectable metastatic colorectal cancer receiving palliative chemotherapy. Patients and Methods: A total of 110 patients with unresectable metastatic colorectal cancer who underwent palliative chemotherapy for metastatic tumors were enrolled in the study. We evaluated the relationships between the survival/chemotherapeutic response and pre-/post-treatment markers of systemic inflammation. The pre-treatment markers of systemic inflammation were measured within one week before the initiation of chemotherapy and the post-treatment markers of systemic inflammation were measured eight weeks after initiation of chemotherapy. Results: The overall survival rates were significantly worse in the group with high pre-treatment NLR/CRP/GPS, and that with high post-treatment CRP/GPS; the progression-free survival rate was significantly worse in the high post-treatment CRP group. As for chemotherapeutic response, patients with a low post-treatment CRP level had a significantly higher disease control rate than those with a high post-treatment CRP level. Moreover, the patients with a high pre-treatment CRP level and normalization after treatment exhibited better overall and progression-free survival rates and had a significantly higher disease control rate than those with high pre-and posttreatment CRP levels. Conclusion: Pre-treatment markers of systemic inflammation are useful for predicting prognosis in patients with unresectable metastatic colorectal cancer who receive palliative chemotherapy. Moreover, the CRP level can be used as a marker for predicting chemotherapeutic outcome and monitoring the progression of the tumor.	[Shibutani, Masatsune; Maeda, Kiyoshi; Nagahara, Hisashi; Ohtani, Hiroshi; Sakurai, Katsunobu; Yamazoe, Sadaaki; Kimura, Kenjiro; Toyokawa, Takahiro; Amano, Ryosuke; Kubo, Naoshi; Tanaka, Hiroaki; Muguruma, Kazuya; Ohira, Masaichi; Hirakawa, Kosei] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, Osaka, Osaka 5458585, Japan	Shibutani, M (reprint author), Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, 1-4-3 Asahi Machi, Osaka, Osaka 5458585, Japan.	fbxbj429@ybb.ne.jp					Parkin DM, 2005, CA-CANCER J CLIN, V55, P74; de Gramont A, 2000, J CLIN ONCOL, V18, P2938; Kishiki T, 2013, AM J SURG, V206, P234, DOI 10.1016/j.amjsurg.2012.07.051; Shibutani M, 2013, ANTICANCER RES, V33, P3291; Forrest LM, 2005, BRIT J CANCER, V92, P1834, DOI 10.1038/sj.bjc.6602591; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Shimada H, 2010, GASTRIC CANCER, V13, P170, DOI 10.1007/s10120-010-0554-3; Heikkila K, 2007, J EPIDEMIOL COMMUN H, V61, P824, DOI 10.1136/jech.2006.051292; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Ishizuka M, 2013, AM J SURG, V205, P22, DOI 10.1016/j.amjsurg.2012.04.012; Maeda K, 2013, ANTICANCER RES, V33, P5567; Chua W, 2011, BRIT J CANCER, V104, P1288, DOI 10.1038/bjc.2011.100; Nozoe T, 2011, AM J SURG, V201, P186, DOI 10.1016/j.amjsurg.2010.01.030; Nozoe T, 2008, SURG TODAY, V38, P597, DOI 10.1007/s00595-007-3680-8; Ceze N, 2011, CANCER CHEMOTH PHARM, V68, P1305, DOI 10.1007/s00280-011-1610-3; Neal CP, 2009, EUR J CANCER, V45, P56, DOI 10.1016/j.ejca.2008.08.019; Zimmerman MA, 2003, ARCH SURG-CHICAGO, V138, P220, DOI 10.1001/archsurg.138.2.220; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Ishizuka M, 2012, ANN SURG ONCOL, V19, P3422, DOI 10.1245/s10434-012-2384-5; Cho IR, 2014, GASTRIC CANCER, V17, P703, DOI 10.1007/s10120-013-0330-2; Ishizuka M, 2009, ANN SURG, V250, P268, DOI 10.1097/SLA.0b013e3181b16e24; Kitayama J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-64; Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260; Zacharakis M, 2010, ANTICANCER RES, V30, P653	25	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					5037	5046				10	Oncology	Oncology	CO7AX	WOS:000359311000063		
J	Shoji, H; Yamada, Y; Okita, N; Takashima, A; Honma, Y; Iwasa, S; Kato, K; Hamaguchi, T; Shimada, Y				Shoji, Hirokazu; Yamada, Yasuhide; Okita, Natsuko; Takashima, Atsuo; Honma, Yoshitaka; Iwasa, Satoru; Kato, Ken; Hamaguchi, Tetsuya; Shimada, Yasuhiro			Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance	ANTICANCER RESEARCH			English	Article						Gastric cancer; FGFR2 amplification; chemotherapy; prognosis	GROWTH-FACTOR; STOMACH-CANCER; K-SAM; MUTATIONS; CARCINOMA; HER2; ADENOCARCINOMA; SURVIVAL; MET	Background: Fibroblast growth factors and their receptors regulate key cellular functions, such as proliferation, differentiation and survival. Herein, we studied the prevalence and prognostic role of fibroblast growth factor receptor 2 (FGFR2) amplification in patients with advanced gastric cancer (AGC) who received systemic chemotherapy. Patients and Methods: The gene copy number of FGFR2 was investigated in 80 patients with AGC who received systemic chemotherapy. FGFR2 gene status was assessed by dual-color fluorescence in- situ hybridization. Results: Among 80 patients, FGFR2 amplification was observed in seven cases (11.5%). Patients with FGFR2 amplification had significantly shorter overall survival (OS) than did those without FGFR2 amplification (9.1 vs. 16.5 months; p = 0.037). In multivariate analysis, disease status and number of metastatic sites were associated with worse OS (p = 0.015 and p = 0.009, respectively). FGFR2 amplification tended to be correlated with a poorer outcome (p = 0.080). Conclusion: FGFR2 amplification tended to result in a shorter survival period compared to cases without amplification.	[Shoji, Hirokazu; Yamada, Yasuhide; Okita, Natsuko; Takashima, Atsuo; Honma, Yoshitaka; Iwasa, Satoru; Kato, Ken; Hamaguchi, Tetsuya; Shimada, Yasuhiro] Natl Canc Ctr, Gastrointesinal Med Oncol Div, Chuo Ku, Tokyo 1040045, Japan	Yamada, Y (reprint author), Natl Canc Ctr, Gastrointesinal Med Oncol Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	yamada0304@aol.com					Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI [10.1016/S1470-2045(08)70035-4, 10.1016/S1470-204S(08)70035-4]; Matsuda T, 2012, JPN J CLIN ONCOL, V42, P139, DOI 10.1093/jjco/hyr184; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Hattori Y, 1996, CLIN CANCER RES, V2, P1373; Jang JH, 2001, CANCER RES, V61, P3541; Taylor JG, 2009, J CLIN INVEST, V119, P3395, DOI 10.1172/JCI39703; Toyokawa T, 2009, ONCOL REP, V21, P875, DOI 10.3892/or_00000297; Xie L, 2013, CLIN CANCER RES, V19, P2572, DOI 10.1158/1078-0432.CCR-12-3898; Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229; Jung EJ, 2012, HUM PATHOL, V43, P1559, DOI 10.1016/j.humpath.2011.12.002; Lieu C, 2011, CLIN CANCER RES, V17, P6130, DOI 10.1158/1078-0432.CCR-11-0659; [Anonymous], 2011, GASTRIC CANC, V14, P101; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Liu YJ, 2014, BRIT J CANCER, V110, P1169, DOI 10.1038/bjc.2014.61; Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149; Al-Ahmadie HA, 2011, J PATHOL, V224, P270, DOI 10.1002/path.2892; Su X, 2014, BRIT J CANCER, V110, P967, DOI 10.1038/bjc.2013.802; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Cappellen D, 1999, NAT GENET, V23, P18; Hofmann M, 2008, HISTOPATHOLOGY, V52, P797, DOI 10.1111/j.1365-2559.2008.03028.x; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Takeda M, 2007, CLIN CANCER RES, V13, P3051, DOI 10.1158/1078-0432.CCR-06-2743; Dutt A, 2008, P NATL ACAD SCI USA, V105, P8713, DOI 10.1073/pnas.0803379105; Chau Ian, 2004, J Clin Oncol, V22, P2395, DOI 10.1200/JCO.2004.08.154; Lee J, 2007, ANN ONCOL, V18, P886, DOI 10.1093/annonc/mdl501; Matsumoto K, 2012, BRIT J CANCER, V106, P727, DOI 10.1038/bjc.2011.603; Nagatsuma AK, 2015, GASTRIC CANCER, V18, P227, DOI 10.1007/s10120-014-0360-4; NAKATANI H, 1990, JPN J CANCER RES, V81, P707	29	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					5055	5061				7	Oncology	Oncology	CO7AX	WOS:000359311000065		
J	Nozawa, H; Nishikawa, T; Tanaka, T; Tanaka, J; Kiyomatsu, T; Kawai, K; Hata, K; Kazama, S; Yamaguchi, H; Ishihara, S; Sunami, E; Kitayama, J; Watanabe, T				Nozawa, Hiroaki; Nishikawa, Takeshi; Tanaka, Toshiaki; Tanaka, Junichiro; Kiyomatsu, Tomomichi; Kawai, Kazushige; Hata, Keisuke; Kazama, Shinsuke; Yamaguchi, Hironori; Ishihara, Soichiro; Sunami, Eiji; Kitayama, Joji; Watanabe, Toshiaki			Large Colorectal Carcinoma Is Predictive of Recurrence After Adjuvant Chemotherapy Using Oxaliplatin	ANTICANCER RESEARCH			English	Article						Colorectal cancer; oxaliplatin; adjuvant chemotherapy; recurrence; tumor size	III COLON-CANCER; MISMATCH REPAIR STATUS; DISEASE-FREE SURVIVAL; FOLFOX CHEMOTHERAPY; STAGE-II; MUCINOUS HISTOLOGY; NSABP C-07; FLUOROURACIL; TRIAL; LEUCOVORIN	Aim: The postoperative administration of oxaliplatin reduces the frequency of relapse in selected patients with colorectal cancer following surgical resection. However, factors associated with recurrence despite adjuvant therapy are largely unknown. Patients and Methods: We investigated 68 patients who were pathologically diagnosed with stage II or III colorectal cancer and received oxaliplatin-including chemotherapy, FOLFOX (5-fluorouracil, folinic acid and oxaliplatin) or CapeOX (capecitabine and oxaliplatin), after curative surgery. Results: Nineteen patients developed recurrence during the median follow-up period of 17.8 months. Multivariate analyses using the Cox proportional-hazards model revealed that primary tumor size >= 45 mm was a significant predictor of recurrence (hazard ratio = 3.16, 95% confidence interval = 1.06-11.54, p = 0.039). A primary tumor of 45 mm or more in size was associated with poor recurrence-free survival. Conclusion: Our results suggest that large colorectal carcinoma needs to be recognized as a high-risk factor for recurrence even after surgery and subsequent treatment with oxaliplatin.	[Nozawa, Hiroaki; Nishikawa, Takeshi; Tanaka, Toshiaki; Tanaka, Junichiro; Kiyomatsu, Tomomichi; Kawai, Kazushige; Hata, Keisuke; Kazama, Shinsuke; Yamaguchi, Hironori; Ishihara, Soichiro; Sunami, Eiji; Kitayama, Joji; Watanabe, Toshiaki] Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, Tokyo 1138655, Japan	Nozawa, H (reprint author), Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	hiroanozawa-gi@umin.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labor and Welfare of Japan	This study was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the Ministry of Health, Labor and Welfare of Japan.	Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771; Li P, 2013, BRIT J CANCER, V108, P1238, DOI 10.1038/bjc.2013.83; de Gramont A, 2000, J CLIN ONCOL, V18, P2938; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Lee DW, 2013, BRIT J CANCER, V108, P1978, DOI 10.1038/bjc.2013.232; Zaanan A, 2011, CLIN CANCER RES, V17, P7470, DOI 10.1158/1078-0432.CCR-11-1048; Yothers G, 2011, J CLIN ONCOL, V29, P3768, DOI 10.1200/JCO.2011.36.4539; Sinicrope FA, 2013, J CLIN ONCOL, V31, P3664, DOI 10.1200/JCO.2013.48.9591; Haller DG, 2011, J CLIN ONCOL, V29, P1465, DOI 10.1200/JCO.2010.33.6297; Lembersky BC, 2006, J CLIN ONCOL, V24, P2059, DOI 10.1200/JCO.2005.04.7498; Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974; Twelves C, 2012, ANN ONCOL, V23, P1190, DOI 10.1093/annonc/mdr366; Yoon HH, 2014, CLIN CANCER RES, V20, P3033, DOI 10.1158/1078-0432.CCR-13-3140; Chang MH, 2011, CANCER CHEMOTH PHARM, V68, P317, DOI 10.1007/s00280-010-1496-5; Diaz-Rubio E, 2002, ANN ONCOL, V13, P558, DOI 10.1093/annonc/mdf065; LABIANCA R, 1995, LANCET, V345, P939; Kim SH, 2013, ANN SURG ONCOL, V20, P3407, DOI 10.1245/s10434-013-3169-1; National Comprehensive Cancer Network (NCCN), NCCN CLIN PRACT GUID	20	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					5073	5078				6	Oncology	Oncology	CO7AX	WOS:000359311000067		
J	Furukawa, K; Shiba, H; Shirai, Y; Horiuchi, T; Iwase, R; Haruki, K; Fujiwara, Y; Misawa, T; Yanaga, K				Furukawa, Kenei; Shiba, Hiroaki; Shirai, Yoshihiro; Horiuchi, Takashi; Iwase, Ryota; Haruki, Koichiro; Fujiwara, Yuki; Misawa, Takeyuki; Yanaga, Katsuhiko			Negative Impact of Preoperative Endoscopic Biliary Drainage on Prognosis of Pancreatic Ductal Adenocarcinoma After Pancreaticoduodenectomy	ANTICANCER RESEARCH			English	Article						Pancreatic cancer; pancreaticoduodenectomy; endoscopic biliary drainage	OBSTRUCTIVE-JAUNDICE; STENT INSERTION; CANCER; COMPLICATIONS; RESECTION	Background/Aim: Patients with obstructive jaundice due to cancer of the pancreatic head often undergo preoperative endoscopic biliary drainage (EBD). The aim of the study was to evaluate the long-term impact of preoperative EBD following pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma. Patients and Methods: We studied 106 patients who underwent PD for pancreatic ductal adenocarcinoma between May 2000 and November 2013 at the Jikei University Hospital. We retrospectively examined perioperative findings as predictors of prognosis and the relationship between preoperative EBD and recurrence rate as well as overall survival. Results: In univariate analysis, significant factors associated with poor disease-free survival consisted of the presence of EBD (p = 0.0213), poor tumor differentiation (p = 0.0023) and tumor-node-metastasis (TNM) classification IV (p = 0.0027), while significant factors associated with poor overall survival consisted of the presence of EBD (p = 0.0047), poor tumor differentiation (p < 0.0001), TNM classification IV (p = 0.0031) and microscopic or macroscopic residual tumor (p = 0.0184). In multivariate analysis, poor tumor differentiation (p= 0.0033) and TNM classification IV (p = 0.0020) were independent factors for poor disease-free survival, while the presence of EBD (p = 0.0435), poor tumor differentiation (p = 0.0009), TNM classification IV (p = 0.0447) and microscopic or macroscopic residual tumor (p = 0.0184) were independent factors for poor overall survival. Conclusion: Preoperative EBD may have a negative impact on prognosis after PD for pancreatic ductal adenocarcinoma.	[Furukawa, Kenei; Shiba, Hiroaki; Shirai, Yoshihiro; Horiuchi, Takashi; Iwase, Ryota; Haruki, Koichiro; Fujiwara, Yuki; Misawa, Takeyuki; Yanaga, Katsuhiko] Jikei Univ, Sch Med, Dept Surg, Tokyo 1058461, Japan	Furukawa, K (reprint author), Jikei Univ, Sch Med, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.	k-furukawa@jikei.ac.jp					Bassi C, 2005, SURGERY, V138, P8, DOI 10.1016/j.surg.2005.05.001; Han SS, 2006, PANCREAS, V32, P271, DOI 10.1097/01.mpa.0000202953.87740.93; Watt AM, 2007, ANN SURG, V246, P24, DOI 10.1097/01.sla.0000261124.72687.72; Howard TJ, 2006, J GASTROINTEST SURG, V10, P1338, DOI 10.1016/j.gassur.2006.09.008; van der Gaag NA, 2009, J GASTROINTEST SURG, V13, P814, DOI 10.1007/s11605-008-0618-4; Uwagawa T, 2013, AM J CLIN ONCOL-CANC, V36, P44, DOI 10.1097/COC.0b013e31823a53b2; van der Gaag NA, 2010, NEW ENGL J MED, V362, P129, DOI 10.1056/NEJMoa0903230; SPEER AG, 1987, LANCET, V2, P57; Cascinu S, 2009, ANN ONCOL, V20, P37, DOI 10.1093/annonc/mdp123; Fang Y, 2012, COCHRANE DB SYST REV, V9, DOI DOI 10.1002/14651858.CD005444.PUB3; Japanese Pancreas Society, 2009, GEN RUL STUD PANCR C; Kimmings AN, 2000, GUT, V46, P725, DOI 10.1136/gut.46.5.725; Marudiachalam K, 2007, BRIT J SURG, V94, P1151, DOI 10.1002/bjs.5790; Sabbagh C, 2013, ANN SURG, V258, P107, DOI 10.1097/SLA.0b013e31827e30ce; Saxena P, 2015, DIGEST ENDOSC, V27, P265, DOI 10.1111/den.12394; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; TREDE M, 1988, ANN SURG, V207, P39, DOI 10.1097/00000658-198801000-00009	17	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0250-7005	1791-7530		ANTICANCER RES	Anticancer Res.	SEP	2015	35	9					5079	5083				5	Oncology	Oncology	CO7AX	WOS:000359311000068		
J	Mei, XL; Xia, Y; Sasano, H; Gao, HW				Mei, Xianglin; Xia, Yang; Sasano, Hironobu; Gao, Hongwen			Sinonasal yolk sac (Endodermal sinus) tumor in an adult female - A case report and review of the literature	APMIS			English	Article						Yolk sac tumor; endodermal sinus tumor; transitional cell carcinoma; sinonasal; adult	GERM-CELL TUMORS; CARCINOMA; HEAD	Yolk sac tumor (YST), also known as endodermal sinus tumor, is a highly malignant germ cell tumor that is extremely rare in the sinonasal region, especially in adults. To the best of our knowledge, only five such cases have been reported till date (four men, one woman). We present a case of sinonasal YST admixed with transitional cell carcinoma in a 58-year-old female. Magnetic resonance imaging revealed a mass in the right ethmoid fissure infiltratinginto the posterior and anterior ethmoid sinuses and nasopharynx. Positron emission tomography examination showed a maximum standardized uptake value of 6.8. Histological examination of the biopsy specimen revealed two distinct features, YST and transitional cell carcinoma, with evidence of mutual transition that indicated the composite nature of the tumor. Immunohistochemical analysis revealed positive immunoreactivity for Sal-like protein 4, -fetoprotein and glypican3, and negative immunoreactivity for placental alkaline phosphatase, CD30 and CD117 in the YST component. P40 and P63 were detected only in transitional cell carcinoma component. The tumor was subsequently excised and four cycles of adjuvant chemotherapy at intervals of 3weeks were administered. At 8months after surgery, there was no evidence of tumor recurrence or metastasis. We have also presented a literature review on YST in sinusoids.	[Mei, Xianglin; Xia, Yang; Gao, Hongwen] Jilin Univ, Hosp 2, Dept Pathol, Changchun 130041, Peoples R China; [Sasano, Hironobu] Tohoku Univ, Sch Med, Dept Anat, Pathol Lab, Sendai, Miyagi 980, Japan	Gao, HW (reprint author), Jilin Univ, Hosp 2, Dept Pathol, 218 Ziqiang St, Changchun 130041, Peoples R China.	gaohongwen@jlu.edu.cn					Nogales FF, 2014, ARCH PATHOL LAB MED, V138, P351, DOI 10.5858/arpa.2012-0547-RA; Mui WH, 2014, ONCOL LETT, V7, P199; Gonzalez-Roibon N, 2013, HUM PATHOL, V44, P1293, DOI 10.1016/j.humpath.2012.10.017; Bernbeck B, 2009, PEDIATR BLOOD CANCER, V52, P223, DOI 10.1002/pbc.21752; Chuang HC, 2014, FETAL PEDIATR PATHOL, V33, P127, DOI 10.3109/15513815.2013.839013; DEHNER LP, 1983, HUM PATHOL, V14, P493, DOI 10.1016/S0046-8177(83)80004-5; Devaney KO, 1997, ANN OTO RHINOL LARYN, V106, P254; Filho Bernardo Cunha Araujo, 2008, Am J Otolaryngol, V29, P250, DOI 10.1016/j.amjoto.2007.09.001; Kawahara M, 2009, INT J CLIN ONCOL, V14, P537, DOI 10.1007/s10147-009-0880-9; MANIVEL C, 1986, ARCH PATHOL LAB MED, V110, P198; Mishra A, 2008, HEAD NECK-J SCI SPEC, V30, P539, DOI 10.1002/hed.20711; Thomas J, 2011, ANN DIAGN PATHOL, V15, P135, DOI 10.1016/j.anndiagpath.2010.01.004; Zhang Y, 2012, PEDIATR SURG INT, V28, P1157, DOI 10.1007/s00383-012-3173-8	13	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0903-4641	1600-0463		APMIS	APMIS	SEP	2015	123	9					810	814		10.1111/apm.12409		5	Immunology; Microbiology; Pathology	Immunology; Microbiology; Pathology	CP2IV	WOS:000359701600011		
J	Tsurumaru, H; Hashimoto, S; Okizaki, K; Kanesaki, Y; Yoshikawa, H; Yamakawa, T				Tsurumaru, Hirohito; Hashimoto, Syougo; Okizaki, Kouhei; Kanesaki, Yu; Yoshikawa, Hirofumi; Yamakawa, Takeo			A Putative Type III Secretion System Effector Encoded by the MA20_12780 Gene in Bradyrhizobium japonicum Is-34 Causes Incompatibility with Rj(4) Genotype Soybeans	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							GRAM-NEGATIVE BACTERIA; FUNCTIONAL-ANALYSIS; LEGUME NODULES; NODULATION; PROTEINS; CULTIVARS; RHIZOBIA; RJ4; COMPATIBILITY; SPECIFICITY	The nodulation of Bradyrhizobium japonicum Is-34 is restricted by Rj(4) genotype soybeans (Glycine max). To identify the genes responsible for this incompatibility, Tn5 mutants of B. japonicum Is-34 that were able to overcome this nodulation restriction were obtained. Analysis of the Tn5 mutants revealed that Tn5 was inserted into a region containing the MA20_12780 gene. In addition, direct disruption of this gene using marker exchange overcame the nodulation restriction by Rj(4) genotype soybeans. The MA20_12780 gene has a tts box motif in its upstream region, indicating a possibility that this gene encodes a type III secretion system (T3SS) effector protein. Bioinformatic characterization revealed that the MA20_12780 protein contains the small ubiquitin-like modifier (SUMO) protease domain of the C48 peptidase (ubiquitin-like protease 1 [Ulp1]) family. The results of the present study indicate that a putative T3SS effector encoded by the MA20_12780 gene causes the incompatibility with Rj(4) genotype soybeans, and they suggest the possibility that the nodulation restriction of B. japonicum Is-34 may be due to Rj(4) genotype soybeans recognizing the putative T3SS effector (MA20_12780 protein) as a virulence factor.	[Tsurumaru, Hirohito] Tohoku Univ, Grad Sch Life Sci, Sendai, Miyagi 980, Japan; [Tsurumaru, Hirohito; Hashimoto, Syougo; Okizaki, Kouhei] Kyushu Univ, Fac Agr, Grad Sch Bioresource & Bioenvironm Sci, Fukuoka 812, Japan; [Kanesaki, Yu; Yoshikawa, Hirofumi] Tokyo Univ Agr, Genome Res Ctr, NODAI Res Inst, Tokyo, Japan; [Yoshikawa, Hirofumi] Tokyo Univ Agr, Dept Biosci, Tokyo, Japan; [Yamakawa, Takeo] Kyushu Univ, Fac Agr, Dept Biosci & Biotechnol, Fukuoka 812, Japan	Tsurumaru, H (reprint author), Tohoku Univ, Grad Sch Life Sci, Sendai, Miyagi 980, Japan.	tsurumaru@ige.tohoku.ac.jp			Cooperative Research Grant of the Genome Research for BioResource, NODAI Genome Research Center, Tokyo University of Agriculture	This work was supported by a Cooperative Research Grant of the Genome Research for BioResource, NODAI Genome Research Center, Tokyo University of Agriculture.	Albareda M, 2009, EUR J AGRON, V30, P205, DOI 10.1016/j.eja.2008.10.002; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; ISHIZUKA J, 1991, SOIL SCI PLANT NUTR, V37, P15; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; Chaudhuri RR, 2008, NUCLEIC ACIDS RES, V36, pD543, DOI 10.1093/nar/gkm928; HERRERO M, 1990, J BACTERIOL, V172, P6557; VEST G, 1972, CROP SCI, V12, P692; Tsurumaru H, 2008, SOIL SCI PLANT NUTR, V54, P197, DOI 10.1111/j.1747-0765.2007.00225.x; Kim JG, 2011, MOL PLANT PATHOL, V12, P715, DOI [10.1111/j.1364-3703.2011.00706.x, 10.1111/J.1364-3703.2011.00706.X]; Devine TE, 1996, PLANT SOIL, V186, P173, DOI 10.1007/BF00035072; COLE MA, 1973, ANTIMICROB AGENTS CH, V4, P248; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Okazaki S, 2010, MOL PLANT MICROBE IN, V23, P223, DOI 10.1094/MPMI-23-2-0223; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Okazaki S, 2009, FEMS MICROBIOL LETT, V295, P88, DOI 10.1111/j.1574-6968.2009.01593.x; Hotson A, 2003, MOL MICROBIOL, V50, P377, DOI 10.1046/j.1365-2958.2003.03730.x; Okazaki S, 2013, P NATL ACAD SCI USA, V110, P17131, DOI 10.1073/pnas.1302360110; Prell J, 2006, TRENDS MICROBIOL, V14, P161, DOI 10.1016/j.tim.2006.02.005; Zehner S, 2008, MOL PLANT MICROBE IN, V21, P1087, DOI 10.1094/MPMI-21-8-1087; Gourion B, 2014, TRENDS PLANT SCI; Hall T. A., 1999, NUCL ACIDS S SER, V4, P95, DOI DOI 10.1111/J.1469-8137.2009.02874.X; Hayashi M, 2014, PLANT CELL PHYSIOL, V55, P1679, DOI 10.1093/pcp/pcu099; Hayashi M, 2011, BREEDING SCI, V61, P544, DOI 10.1270/jsbbs.61.544; Isawa T, 1999, APPL ENVIRON MICROB, V65, P3493; ISHIZUKA J, 1991, SOIL SCI PLANT NUTR, V37, P23; Kambara K, 2009, MOL MICROBIOL, V71, P92, DOI 10.1111/j.1365-2958.2008.06507.x; Leonard LT, 1943, J BACTERIOL, V45, P523; Okazaki K, 2014, MICROBES ENVIRON, V29, P220, DOI 10.1264/jsme2.ME13182; SADOWSKY MJ, 1990, PLANT SOIL, V129, P53, DOI 10.1007/BF00011691; Sakai M, 1997, SOIL SCI PLANT NUTR, V43, P395; Shiina Y, 2014, MICROBES ENVIRON, V29, P420, DOI 10.1264/jsme2.ME14130; Simon R, 1983, NAT BIOTECHNOL, V1, P784, DOI DOI 10.1038/NBT1183-784; Smith TJ, 2002, APPL ENVIRON MICROB, V68, P5265, DOI 10.1128/AEM.68.11.5265-5273.2002; Tang F, 2014, MOL BREEDING, V33, P691, DOI 10.1007/s11032-013-9985-y; Tsurumaru H, 2014, GENOME ANNOUNC, V2; Yang Y, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S1-S47	36	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	SEP	2015	81	17					5812	5819		10.1128/AEM.00823-15		8	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CO6HY	WOS:000359259000017		
J	Ojima, Y; Nguyen, MH; Yajima, R; Taya, M				Ojima, Yoshihiro; Minh Hong Nguyen; Yajima, Reiki; Taya, Masahito			Flocculation of Escherichia coli Cells in Association with Enhanced Production of Outer Membrane Vesicles	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							GRAM-NEGATIVE BACTERIA; HIGH-LEVEL EXPRESSION; CELLULOSE SYNTHESIS; ENVELOPE STRESS; PROTEIN	Microbial flocculation is a phenomenon of aggregation of dispersed bacterial cells in the form of flocs or flakes. In this study, the mechanism of spontaneous flocculation of Escherichia coli cells by overexpression of the bcsB gene was investigated. The flocculation induced by overexpression of bcsB was consistent among the various E. coli strains examined, including the K-12, B, and O strains, with flocs that resembled paper scraps in structure being about 1 to 2 mm. The distribution of green fluorescent protein- labeled E. coli cells within the floc structure was investigated by three-dimensional confocal laser scanning microscopy. Flocs were sensitive to proteinase K, indicating that the main component of the flocs was proteinous. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and nano-liquid chromatography tandem mass spectrometry analyses of the flocs strongly suggested the involvement of outer membrane vesicles (OMVs) in E. coli flocculation. The involvement of OMVs in flocculation was supported by transmission electron microscopy observation of flocs. Furthermore, bcsB-induced E. coli flocculation was greatly suppressed in strains with hypovesiculation phenotypes (Delta dsbA and Delta dsbB strains). Thus, our results demonstrate the strong correlation between spontaneous flocculation and enhanced OMV production of E. coli cells.	[Ojima, Yoshihiro; Minh Hong Nguyen; Yajima, Reiki; Taya, Masahito] Osaka Univ, Grad Sch Engn Sci, Div Chem Engn, Toyonaka, Osaka 560, Japan	Ojima, Y (reprint author), Osaka Univ, Grad Sch Engn Sci, Div Chem Engn, Toyonaka, Osaka 560, Japan.	ojima@cheng.es.osaka-u.ac.jp			Japan Society for the Promotion of Science [2425]	One of the authors (M.H.N.) acknowledges financial support from a Research Fellowship for Young Scientists from the Japan Society for the Promotion of Science (no. 2425, 2011).	Saka K, 2005, DNA RES, V12, P63, DOI 10.1093/dnares/12.1.63; Rehn G, 2013, J BIOTECHNOL, V165, P138, DOI 10.1016/j.jbiotec.2013.03.014; Dibb-Fuller MP, 2001, J MED MICROBIOL, V50, P759; Omadjela O, 2013, P NATL ACAD SCI USA, V110, P17856, DOI 10.1073/pnas.1314063110; Morgan JLW, 2013, NATURE, V493, P181, DOI 10.1038/nature11744; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Mashburn-Warren L, 2008, GEOBIOLOGY, V6, P214, DOI 10.1111/j.1472-4669.2008.00157.x; Morimura S, 1997, J FERMENT BIOENG, V83, P271, DOI 10.1016/S0922-338X(97)80991-9; Gujrati V, 2014, ACS NANO, V8, P1525, DOI 10.1021/nn405724x; Salehizadeh H, 2001, BIOTECHNOL ADV, V19, P371, DOI 10.1016/S0734-9750(01)00071-4; Yang Z, 2014, ENVIRON SCI TECHNOL, V48, P6867, DOI 10.1021/es500415v; GUZMAN LM, 1995, J BACTERIOL, V177, P4121; Inaba K, 2009, J BIOCHEM, V146, P591, DOI 10.1093/jb/mvp102; McBroom AJ, 2007, MOL MICROBIOL, V63, P545, DOI 10.1111/j.1365-2958.2006.05522.x; LIPINSKA B, 1990, J BACTERIOL, V172, P1791; McBroom AJ, 2006, J BACTERIOL, V188, P5385, DOI 10.1128/JB.00498-06; Kadokura H, 2010, ANTIOXID REDOX SIGN, V13, P1231, DOI 10.1089/ars.2010.3187; Schwechheimer C, 2013, BIOCHEMISTRY-US, V52, P3031, DOI 10.1021/bi400164t; Schwechheimer C, 2013, J BACTERIOL, V195, P4161, DOI 10.1128/JB.02192-12; Lee EY, 2007, PROTEOMICS, V7, P3143, DOI 10.1002/pmic.200700196; Baba Tomoya, 2006, Mol Syst Biol, V2; Fennessey CM, 2010, APPL ENVIRON MICROB, V76, P2425, DOI 10.1128/AEM.03066-09; MISSIAKAS D, 1994, EMBO J, V13, P2013; NAKAMURA J, 1976, AGR BIOL CHEM TOKYO, V40, P619; Nguyen MH, 2014, J BIOSCI BIOENG, V118, P400, DOI 10.1016/j.jbiosc.2014.03.005; Schembri MA, 2003, J BACTERIOL, V185, P2236, DOI 10.1128/JB.185.7.2236-2242.2003; TAGO Y, 1977, APPL ENVIRON MICROB, V34, P308	27	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	SEP	2015	81	17					5900	5906		10.1128/AEM.01011-15		7	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CO6HY	WOS:000359259000025		
J	Zhao, DW; Wang, LH; Xu, LJ; Wang, Z				Zhao, Dawei; Wang, Lianhai; Xu, Lijuan; Wang, Zhen			Finding another yourself in multiplex networks	APPLIED MATHEMATICS AND COMPUTATION			English	Article						Multiplex networks; Similarity; Epidemic dynamics	INTERDEPENDENT NETWORKS; COMPLEX NETWORKS; DIFFUSION; DYNAMICS; IMPACT	Recently multiplex networks have attracted a great deal of attent ons in the science of complex networks, since they provide more natural and reasonable way to describe realistic complex systems. However, one of the biggest challenges for this issue is the lack of real world multiplex data, which is mainly caused by the difficulty to distinguish who the replicas of nodes in different network layers (namely, finding another yourself (FAY) problem). In this paper, we consider two kinds of epidemic spreading models named SIR DIAL model and SIR-NIAL model, and propose methods to solve the FAY problem based on the replica similarity during the epidemic process. To acquire high accuracy, our methods need to observe the spreading information of as many epidemics as possible, and record state information of nodes at as many time steps as possible during the epidemic spreading process with SIR DIAL model; but just the final results after the epidemic spreading process ends in SIR-NIAL model. (C) 2015 Elsevier Inc. All rights reserved.	[Zhao, Dawei; Wang, Lianhai; Xu, Lijuan] Natl Supercomp Ctr Jinan, Shandong Comp Sci Ctr, Shandong Prov Key Lab Comp Network, Jinan 250014, Peoples R China; [Wang, Zhen] Kyushu Univ, Interdisciplinary Grad Sch Engn Sci, Kasuga, Fukuoka 8168580, Japan	Zhao, DW (reprint author), Natl Supercomp Ctr Jinan, Shandong Comp Sci Ctr, Shandong Prov Key Lab Comp Network, Jinan 250014, Peoples R China.	zhaodw@sdas.org; zhenwang0@gmail.com	Wang, Zhen/H-5017-2011; zhao, dawei/O-2023-2013	zhao, dawei/0000-0002-2172-8274	Natural Science Foundation of Shandong Province [ZR2014FM003, ZR2013FM025, ZR2013FQ001, ZR2011FQ030]; Shandong Province Outstanding Young Scientists Research Award Fund Project [BS2014DX007, BS2013DX010]; Shandong Academy of Sciences Youth Fund Project [2013QN007]	This paper was supported by the Natural Science Foundation of Shandong Province (Grant No. ZR2014FM003, ZR2013FM025, ZR2013FQ001, ZR2011FQ030), the Shandong Province Outstanding Young Scientists Research Award Fund Project (Grant No. BS2014DX007, BS2013DX010), and the Shandong Academy of Sciences Youth Fund Project (Grant No. 2013QN007).	Boccaletti S, 2014, PHYS REP, V544, P1, DOI 10.1016/j.physrep.2014.07.001; Chang LL, 2015, APPL MATH COMPUT, V256, P540, DOI 10.1016/j.amc.2015.01.052; Perc M, 2013, CHAOS SOLITON FRACT, V56, P1, DOI 10.1016/j.chaos.2013.06.002; Singh J, 2005, MANAGE SCI, V51, P756, DOI 10.1287/mnsc.1040.0349; Dickison M, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.066109; Meloni S, 2009, P NATL ACAD SCI USA, V106, P16897, DOI 10.1073/pnas.0907121106; Kurant M, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.138701; Cozzo E, 2013, PHYS REV E, V88, DOI 10.1103/PhysRevE.88.050801; Hess B, 2000, PHYS REV E, V62, P8438, DOI 10.1103/PhysRevE.62.8438; Arenas A, 2008, PHYS REP, V469, P93, DOI 10.1016/j.physrep.2008.09.002; Buldyrev SV, 2010, NATURE, V464, P1025, DOI 10.1038/nature08932; Saumell-Mendiola A, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.026106; Szell M, 2010, P NATL ACAD SCI USA, V107, P13636, DOI 10.1073/pnas.1004008107; Kim JY, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.058702; Mucha PJ, 2010, SCIENCE, V328, P876, DOI 10.1126/science.1184819; Zhao DW, 2014, PHYS LETT A, V378, P770, DOI 10.1016/j.physleta.2014.01.014; Nicosia V, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.058701; Barrat A., 2008, DYNAMICAL PROCESSES; Battiston F, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.032804; Gao B, 2013, PHYS REV E, V88, DOI 10.1103/PhysRevE.88.062706; Gomez S, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.028701; Gomez-Gardenes J., 2012, SCI REP, V2, P602; Grabowski A, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.031908; Liao H., 2014, ARXIV14098481; Newman M E J, 2010, NETWORKS INTRO; Pastor-Satorras R., 2014, ARXIV14082701; Perc M, 2014, APPL MATH COMPUT, V249, P19, DOI 10.1016/j.amc.2014.10.044; Salehi M., 2014, ARXIV14054329V5; Sharma R., 2014, ARXIV14097623; Son SW, 2012, EPL-EUROPHYS LETT, V97, DOI 10.1209/0295-5075/97/16006; Sun F, 2012, NONLINEAR DYNAM, V67, P1457, DOI 10.1007/s11071-011-0081-8; Wang L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021197; Wang Z, 2013, SCI REP-UK, V3, DOI 10.1038/srep01183; Wang Z., 2015, EUR PHYS J B, V88, P1, DOI DOI 10.1140/EPJB/E2015-60270-7; Wang Z, 2013, SCI REP-UK, V3, DOI 10.1038/srep03055; Wang Z, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.011149; Yuan WJ, 2013, PHYS REV E, V88, DOI 10.1103/PhysRevE.88.022818; Zeng A, 2013, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2013/11/P11010; Zhao DW, 2013, MATH PROBL ENG, DOI 10.1155/2013/896187; Zhao DW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112018; Zhao DW, 2014, PHYS SCRIPTA, V89, DOI 10.1088/0031-8949/89/01/015203	41	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0096-3003	1873-5649		APPL MATH COMPUT	Appl. Math. Comput.	SEP 1	2015	266						599	604		10.1016/j.amc.2015.05.099		6	Mathematics, Applied	Mathematics	CO6XC	WOS:000359300100050		
J	Matsumoto, Y; Yasutake, Y; Takeda, Y; Tamura, T; Yokota, A; Wada, M				Matsumoto, Yu; Yasutake, Yoshiaki; Takeda, Yuki; Tamura, Tomohiro; Yokota, Atsushi; Wada, Masaru			Structural insights into the substrate stereospecificity of D-threo-3-hydroxyaspartate dehydratase from Delftia sp HT23: a useful enzyme for the synthesis of optically pure L-threo- and D-erythro-3-hydroxyaspartate	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Article						D-threo-3-Hydroxyaspartate dehydratase; Delftia sp HT23; Alanine racemase; Pyridoxal 5 '-phosphate; Enzymatic optical resolution	D-SERINE DEHYDRATASE; BETA-HYDROXYASPARTATE DERIVATIVES; GLUTAMATE TRANSPORTER BLOCKERS; PYRIDOXAL-PHOSPHATE ENZYMES; AMINO-ACID TRANSPORTERS; PSEUDOMONAS SP T62; X-RAY-DIFFRACTION; L-THREO-3-HYDROXYASPARTATE DEHYDRATASE; SACCHAROMYCES-CEREVISIAE; CHICKEN KIDNEY	d-threo-3-Hydroxyaspartate dehydratase (d-THA DH) is a fold-type III pyridoxal 5'-phosphate-dependent enzyme, isolated from a soil bacterium of Delftia sp. HT23. It catalyzes the dehydration of d-threo-3-hydroxyaspartate (d-THA) and l-erythro-3-hydroxyaspartate (l-EHA). To elucidate the mechanism of substrate stereospecificity, crystal structures of d-THA DH were determined in complex with various ligands, such as an inhibitor (d-erythro-3-hydroxyaspartate (d-EHA)), a substrate (l-EHA), and the reaction intermediate (2-amino maleic acid). The C (beta) -OH of l-EHA occupied a position close to the active-site Mg2+, clearly indicating a possibility of metal-assisted C (beta) -OH elimination from the substrate. In contrast, the C (beta) -OH of an inhibitor was bound far from the active-site Mg2+. This suggests that the substrate specificity of d-THA DH is determined by the orientation of the C (beta) -OH at the active site, whose spatial arrangement is compatible with the 3R configuration of 3-hydroxyaspartate. We also report an optically pure synthesis of l-threo-3-hydroxyaspartate (l-THA) and d-EHA, promising intermediates for the synthesis of beta-benzyloxyaspartate, by using a purified d-THA DH as a biocatalyst for the resolution of racemic dl-threo-3-hydroxyaspartate (dl-THA) and dl-erythro-3-hydroxyaspartate (dl-EHA). Considering 50 % of the theoretical maximum, efficient yields of l-THA (38.9 %) and d-EHA (48.9 %) as isolated crystals were achieved with > 99 % enantiomeric excess (e.e.). The results of nuclear magnetic resonance signals verified the chemical purity of the products. We were directly able to isolate analytically pure compounds by the recrystallization of acidified reaction mixtures (pH 2.0) and thus avoiding the use of environmentally harmful organic solvents for the chromatographic purification.	[Matsumoto, Yu; Takeda, Yuki; Yokota, Atsushi; Wada, Masaru] Hokkaido Univ, Lab Microbial Physiol, Res Fac Agr, Kita Ku, Sapporo, Hokkaido 0608589, Japan; [Yasutake, Yoshiaki; Tamura, Tomohiro] Natl Inst Adv Ind Sci & Technol, Bioprod Res Inst, Toyohira Ku, Sapporo, Hokkaido 0628517, Japan	Wada, M (reprint author), Hokkaido Univ, Lab Microbial Physiol, Res Fac Agr, Kita Ku, Kita 9,Nishi 9, Sapporo, Hokkaido 0608589, Japan.	y-yasutake@aist.go.jp; wada@chem.agr.hokudai.ac.jp			Institute for Fermentation, Osaka (IFO)	Authors would like to thank Dr. Eri Fukushi and Mr. Yusuke Takata of the GC-MS & NMR Laboratory (Research Faculty of Agriculture, Hokkaido University) for assistance with the NMR spectral measurements. We are grateful to Dr. Toshihiro Watanabe (Research Faculty of Agriculture, Hokkaido University) for conducting the ICP-MS analysis. Authors also acknowledge the technical staff at Photon Factory (PF) for their kind support in the X-ray diffraction experiments. This work was financially supported in part by a grant-in-aid from the Institute for Fermentation, Osaka (IFO). Synchrotron radiation experiments were conducted under the approval of 2012G576 at PF.	Shigeri Y, 2004, BRAIN RES REV, V45, P250, DOI 10.1016/j.brainsrev.2004.04.004; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Toney MD, 2005, ARCH BIOCHEM BIOPHYS, V433, P279, DOI 10.1016/j.abb.2004.09.037; Shimamoto K, 1998, MOL PHARMACOL, V53, P195; Ito T, 2012, FEBS J, V279, P612, DOI 10.1111/j.1742-4658.2011.08451.x; Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314; Ito T, 2008, BIOCHEM J, V409, P399, DOI 10.1042/BJ20070642; Nakashima N, 2004, APPL ENVIRON MICROB, V70, P5557, DOI 10.1128/AEM.70.9.5557.5568.2004; Shigeri Y, 2001, J NEUROCHEM, V79, P297, DOI 10.1046/j.1471-4159.2001.00588.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Battye TGG, 2011, ACTA CRYSTALLOGR D, V67, P271, DOI 10.1107/S0907444910048675; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Antolini L, 1997, J ORG CHEM, V62, P8784, DOI 10.1021/jo971285+; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; Shimamoto K, 2008, CHEM REC, V8, P182, DOI 10.1002/tcr.20145; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Shimamoto K, 2004, MOL PHARMACOL, V65, P1008, DOI 10.1124/mol.65.4.1008; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Bionda N, 2012, AMINO ACIDS, V42, P285, DOI 10.1007/s00726-010-0806-x; Cardillo G, 1999, SYNLETT, P1727; DeLano W. L., 2002, PYMOL; DENG JG, 1995, J AM CHEM SOC, V117, P7824, DOI 10.1021/ja00134a035; Hara R, 2010, J BIOTECHNOL, V150, pS373, DOI 10.1016/j.jbiotec.2010.09.450; KANEKO T, 1963, B CHEM SOC JPN, V36, P899, DOI 10.1246/bcsj.36.899; Khalaf JK, 2008, AMINO ACIDS, V35, P507, DOI 10.1007/s00726-007-0595-z; Liu JQ, 2003, APPL MICROBIOL BIOT, V62, P53, DOI 10.1007/s00253-003-1238-2; Maeda T, 2010, J BIOCHEM, V148, P705, DOI 10.1093/jb/mvq106; Matsumoto Y, 2013, ACTA CRYSTALLOGR F, V69, P1131, DOI 10.1107/S1744309113023956; Murakami T, 2009, J BIOCHEM, V145, P661, DOI 10.1093/jb/mvp023; Nakashima N, 2004, BIOTECHNOL BIOENG, V86, P136, DOI 10.1002/bit.20024; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Shimamoto K, 2000, BIOORG MED CHEM LETT, V10, P2407, DOI 10.1016/S0960-894X(00)00487-X; Strieker M, 2008, CHEMBIOCHEM, V9, P374, DOI 10.1002/cbic.200700557; Tanaka H, 2011, J BIOL CHEM, V286, P27548, DOI 10.1074/jbc.M110.201160; Tanaka H, 2008, J BIOCHEM, V143, P49, DOI 10.1093/jb/mvm203; Wada M, 1999, FEMS MICROBIOL LETT, V179, P147, DOI 10.1111/j.1574-6968.1999.tb08720.x; Wada M, 2003, FEMS MICROBIOL LETT, V225, P189, DOI 10.1016/S0378-1097(03)00484-1	41	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598	1432-0614		APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	SEP	2015	99	17					7137	7150		10.1007/s00253-015-6479-3		14	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CP2WY	WOS:000359739600016		
J	Matsutani, M; Ito, K; Azuma, Y; Ogino, H; Shirai, M; Yakushi, T; Matsushita, K				Matsutani, Minenosuke; Ito, Kohei; Azuma, Yoshinao; Ogino, Hidetaka; Shirai, Mutsunori; Yakushi, Toshiharu; Matsushita, Kazunobu			Adaptive mutation related to cellulose producibility in Komagataeibacter medellinensis (Gluconacetobacter xylinus) NBRC 3288	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Article						Acetic acid bacteria; Komagataeibacter; Cellulose synthase gene	COMPLETE GENOME SEQUENCE; ACETIC-ACID BACTERIA; BURROWS-WHEELER TRANSFORM; ACETOBACTER-XYLINUM; READ ALIGNMENT; PHYLOGENETIC ANALYSIS; MAXIMUM-LIKELIHOOD; PELLICLE FORMATION; VINEGAR; IDENTIFICATION	Gluconacetobacter xylinus (formerly Acetobacter xylinum and presently Komagataeibacter medellinensis) is known to produce cellulose as a stable pellicle. However, it is also well known to lose this ability very easily. We investigated the on and off mechanisms of cellulose producibility in two independent cellulose-producing strains, R1 and R2. Both these strains were isolated through a repetitive static culture of a non-cellulose-producing K. medellinensis NBRC 3288 parental strain. Two cellulose synthase operons, types I and II, of this strain are truncated by the frameshift mutation in the bcsBI gene and transposon insertion in the bcsCII gene, respectively. The draft genome sequencing of R1 and R2 strains revealed that in both strains the bcsBI gene was restored by deletion of a nucleotide in its C-rich region. This result suggests that the mutations in the bcsBI gene are responsible for the on and off mechanism of cellulose producibility. When we looked at the genomic DNA sequences of other Komagataeibacter species, several non-cellulose-producing strains were found to contain similar defects in the type I and/or type II cellulose synthase operons. Furthermore, the phylogenetic relationship among cellulose synthase genes conserved in other bacterial species was analyzed. We observed that the cellulose genes in the Komagataeibacter shared sequence similarities with the gamma-proteobacterial species but not with the alpha-proteobacteria and that the type I and type II operons could be diverged from a same ancestor in Komagataeibacter.	[Matsutani, Minenosuke; Ito, Kohei; Yakushi, Toshiharu; Matsushita, Kazunobu] Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan; [Azuma, Yoshinao] Kinki Univ, Biol Oriented Sci & Technol, Wakayama 6496493, Japan; [Ogino, Hidetaka; Shirai, Mutsunori] Yamaguchi Univ, Dept Microbiol & Immunol, Grad Sch Med, Ube, Yamaguchi 755, Japan	Matsushita, K (reprint author), Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan.	kazunobu@yamaguchi-u.ac.jp			Advanced Low Carbon Technology Research and Development Program (ALCA)	We thank Haruo Suzuki (Yamaguchi University) for his skillful technical assistance in phylogenetic analyses. This work was financially supported by the Advanced Low Carbon Technology Research and Development Program (ALCA).	Andres-Barrao C, 2011, J BACTERIOL, V193, P2670, DOI 10.1128/JB.00229-11; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Salichos L, 2013, NATURE, V497, P327, DOI 10.1038/nature12130; SAXENA IM, 1995, J BACTERIOL, V177, P5276; SAXENA IM, 1994, J BACTERIOL, V176, P5735; Castresana J, 2000, MOL BIOL EVOL, V17, P540; Steiner P, 2001, APPL ENVIRON MICROB, V67, P5474, DOI 10.1128/AEM.67.12.5474-5481.2001; Chawla PR, 2009, FOOD TECHNOL BIOTECH, V47, P107; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Talavera G, 2007, SYSTEMATIC BIOL, V56, P564, DOI 10.1080/10635150701472164; Chouaia B, 2014, GENOME BIOL EVOL, V6, P912, DOI 10.1093/gbe/evu062; Zogaj X, 2001, MOL MICROBIOL, V39, P1452, DOI 10.1046/j.1365-2958.2001.02337.x; Deeraksa A, 2006, BIOSCI BIOTECH BIOCH, V70, P2536, DOI 10.1271/bbb.60143; Iguchi M, 2000, J MATER SCI, V35, P261, DOI 10.1023/A:1004775229149; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Yamada Y, 2012, J GEN APPL MICROBIOL, V58, P397; Kawai S, 2013, APPL ENVIRON MICROB, V79, P1654, DOI 10.1128/AEM.03152-12; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Castro C, 2013, INT J SYST EVOL MICR, V63, P1119, DOI 10.1099/ijs.0.043414-0; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Hu SQ, 2010, P NATL ACAD SCI USA, V107, P17957, DOI 10.1073/pnas.1000601107; Yamada Y, 2014, INT J SYST EVOL MICR, V64, P1670, DOI 10.1099/ijs.0.054494-0; Matsutani M, 2013, J BIOTECHNOL, V165, P109, DOI 10.1016/j.jbiotec.2013.03.006; Deeraksa A, 2005, MICROBIOL-SGM, V151, P4111, DOI 10.1099/mic.0.28350-0; da Silva ACR, 2002, NATURE, V417, P459, DOI 10.1038/417459a; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Ogino H, 2011, J BACTERIOL, V193, P6997, DOI 10.1128/JB.06158-11; Deng Y, 2013, J BACTERIOL, V195, P5072, DOI 10.1128/JB.00767-13; Sokollek SJ, 1998, INT J SYST BACTERIOL, V48, P935; Sukumaran J, 2010, BIOINFORMATICS, V26, P1569, DOI 10.1093/bioinformatics/btq228; Yu XC, 1996, INT J BIOL MACROMOL, V19, P145, DOI 10.1016/0141-8130(96)01109-9; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Shoda M, 2005, BIOTECHNOL BIOPROC E, V10, P1, DOI 10.1007/BF02931175; Kumagai A, 2011, BIOMACROMOLECULES, V12, P2815, DOI 10.1021/bm2005615; Azuma Y, 2009, NUCLEIC ACIDS RES, V37, P5768, DOI 10.1093/nar/gkp612; Nair D, 2011, J BACTERIOL, V193, P2332, DOI 10.1128/JB.00027-11; Trcek J, 2000, APPL MICROBIOL BIOT, V53, P289, DOI 10.1007/s002530050023; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; BEPPU T, 1993, ANTON LEEUW INT J G, V64, P121; Bertalan M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-450; COUCHERON DH, 1991, J BACTERIOL, V173, P5723; Du XJ, 2011, J BACTERIOL, V193, P3395, DOI 10.1128/JB.05147-11; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Hyatt D, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-119; Kubiak K, 2014, J BIOTECHNOL, V176, P18, DOI 10.1016/j.jbiotec.2014.02.006; Lam HM, 2010, NAT GENET, V42, P1053; Iyer PR, 2010, J BACTERIOL, V192, P4256, DOI 10.1128/JB.00588-10; Matsutani M, 2014, BBA-BIOENERGETICS, V1837, P1810, DOI 10.1016/j.bbabio.2014.05.355; MAYER R, 1991, P NATL ACAD SCI USA, V88, P5472, DOI 10.1073/pnas.88.12.5472; Navarro RR, 1999, J GEN APPL MICROBIOL, V45, P7, DOI 10.2323/jgam.45.7; Sievers M, 1992, SYST APPL MICROBIOL, V15, P386; Suzuki H, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-38; TAKEMURA H, 1991, J BACTERIOL, V173, P7070; Umeda Y, 1999, DNA Res, V6, P109, DOI 10.1093/dnares/6.2.109; YAMADA Y, 1969, AGR BIOL CHEM TOKYO, V33, P1659	61	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598	1432-0614		APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	SEP	2015	99	17					7229	7240		10.1007/s00253-015-6598-x		12	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CP2WY	WOS:000359739600023		
J	Natsuki, T; Matsuyama, N; Ni, QQ				Natsuki, Toshiaki; Matsuyama, Nobuhiro; Ni, Qing-Qing			Vibration analysis of carbon nanotube-based resonator using nonlocal elasticity theory	APPLIED PHYSICS A-MATERIALS SCIENCE & PROCESSING			English	Article								Carbon nanotubes (CNTs) are nanomaterials with extremely favorable mass sensor properties. In this paper, we propose that CNTs under clamped boundary condition and an axial tensile load are considered as CNT-based resonators. Moreover, the resonant frequencies and frequency shifts of the CNTs with attached nanomass are investigated based on vibration analysis, which used the nonlocal Euler-Bernoulli beam model. Using the present methods, we analyze and discuss the effects of the aspect ratio, the concentrated mass and the axial force on the resonant frequency of the CNTs. The results indicate that the CNT beam under the axial tensile loads could provide higher sensitivity as nanomechanical mass sensor.	[Natsuki, Toshiaki; Ni, Qing-Qing] Shinshu Univ, Fac Text Sci & Technol, Ueda, Nagano 3868567, Japan; [Natsuki, Toshiaki] Shinshu Univ, Inst Carbon Sci & Technol, Nagano 3808553, Japan; [Matsuyama, Nobuhiro] Shinshu Univ, Grad Sch Sci & Technol, Ueda, Nagano 3868576, Japan	Natsuki, T (reprint author), Shinshu Univ, Fac Text Sci & Technol, 3-15-1 Tokida, Ueda, Nagano 3868567, Japan.	natsuki@shinshu-u.ac.jp					Amirian B, 2013, SHOCK VIB, V20, P821, DOI 10.3233/SAV-130787; Narendar S, 2009, COMP MATER SCI, V47, P526, DOI 10.1016/j.commatsci.2009.09.021; Mehdipour I, 2011, COMP MATER SCI, V50, P1830, DOI 10.1016/j.commatsci.2011.01.025; Natsuki T, 2010, PHYS LETT A, V374, P2670, DOI 10.1016/j.physleta.2010.04.040; Poncharal P, 1999, SCIENCE, V283, P1513, DOI 10.1126/science.283.5407.1513; Treacy MMJ, 1996, NATURE, V381, P678, DOI 10.1038/381678a0; Wang LF, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.195412; Mehdipour I, 2012, COMP MATER SCI, V55, P136, DOI 10.1016/j.commatsci.2011.11.036; Shen ZB, 2012, PHYSICA E, V44, P1169, DOI 10.1016/j.physe.2012.01.005; Lassagne B, 2008, NANO LETT, V8, P3735, DOI 10.1021/nl801982v; Elishakoff I, 2011, Journal of Nanotechnology in Engineering and Medicine, V2, DOI 10.1115/1.4003734; Govind S., 2014, INT J ADV MECH ENG, V4, P331; Kis A., 2008, T R SOC A, V366, P1591; Lee HL, 2010, NANOSCALE RES LETT, V5, P1774, DOI 10.1007/s11671-010-9709-8; Li CY, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.073405; Li XF, 2015, ULTRASONICS, V55, P75, DOI 10.1016/j.ultras.2014.08.002; Lozovik YE, 2006, J EXP THEOR PHYS+, V103, P449, DOI 10.1134/S1063776106090159; Natsuki T, 2014, APPL PHYS A-MATER, V116, P1001, DOI 10.1007/s00339-014-8289-3; Patel AM, 2014, PROC TECH, V14, P290, DOI 10.1016/j.protcy.2014.08.038; Patel A.M., 2014, P MAT SCI, V5, P482; Wang ZL, 2000, PURE APPL CHEM, V72, P209, DOI 10.1351/pac200072010209	21	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0947-8396	1432-0630		APPL PHYS A-MATER	Appl. Phys. A-Mater. Sci. Process.	SEP	2015	120	4					1309	1313		10.1007/s00339-015-9398-3		5	Materials Science, Multidisciplinary; Physics, Applied	Materials Science; Physics	CO8RD	WOS:000359437200010		
J	Shaalan, NM; Rashad, M; Yamazaki, T				Shaalan, N. M.; Rashad, M.; Yamazaki, T.			Sensing performance of SnO2 film fabricated by sputtering deposition	APPLIED PHYSICS A-MATERIALS SCIENCE & PROCESSING			English	Article							THIN-FILMS; GAS SENSORS; PHYSICAL-PROPERTIES; NO2 SENSORS; MICROSTRUCTURE; TEMPERATURE; NANOSTRUCTURES; ELECTRODES; MORPHOLOGY; OXIDES	The effects of in situ-deposition temperature and post-deposition annealing on the microstructure of the sputtered SnO2 thin film are studied. These effects on the performance of the resulting gas-sensing devices have been characterized. For in situ-deposition temperature, the film was deposited on a heated substrate, while for post-deposition annealing, the film was deposited on an unheated substrate and then annealed it at various temperatures. Microstructure changes in SnO2 film were induced at various temperatures. Both films of in situ heating and post-annealing evoked only partial crystallization, especially at low temperatures, and the crystallinity was enhanced with high temperatures. SEM images confirmed that the grains and pores of the film changed with the thermal treatment. In consequence of the post-annealing, the pores grew wider; however, they grew narrow in the case of in situ heating. The film annealed at low temperature yielded high-response device to NO2 gas compared with that annealed at higher temperature. The sensing devices fabricated by in situ deposition showed highest response.	[Shaalan, N. M.; Yamazaki, T.] Toyama Univ, Grad Sch Sci & Engn, Toyama 9308555, Japan; [Shaalan, N. M.; Rashad, M.] Univ Assiut, Dept Phys, Fac Sci, Assiut 71516, Egypt; [Rashad, M.] Univ Tabuk, Dept Phys, Fac Sci, Tabuk 71491, Saudi Arabia	Shaalan, NM (reprint author), Toyama Univ, Grad Sch Sci & Engn, 3190 Gofuku, Toyama 9308555, Japan.	nshaalan@aun.edu.eg; mohamed.ahemed24@sceince.au.edu.eg; yamazaki@eng.u-toyama.ac.jp					Ahn H, 2010, MATER CHEM PHYS, V124, P563, DOI 10.1016/j.matchemphys.2010.07.012; Francioso L, 2006, SENSOR ACTUAT B-CHEM, V114, P646, DOI 10.1016/j.snb.2005.03.124; Kolmakov A, 2004, ANNU REV MATER RES, V34, P151, DOI 10.1146/annurev.matsci.34.040203.112141; Hwang IS, 2010, SENSOR ACTUAT B-CHEM, V148, P595, DOI 10.1016/j.snb.2010.05.052; Ruhland B, 1998, SENSOR ACTUAT B-CHEM, V50, P85, DOI 10.1016/S0925-4005(98)00160-9; Sharma A, 2011, SENSOR ACTUAT B-CHEM, V156, P743, DOI 10.1016/j.snb.2011.02.033; Sharma A, 2012, SENSOR ACTUAT B-CHEM, V161, P1114, DOI 10.1016/j.snb.2011.10.014; Liu ZF, 2007, SENSOR ACTUAT B-CHEM, V128, P173, DOI 10.1016/j.snb.2007.06.001; Leo G, 1999, SENSOR ACTUAT B-CHEM, V58, P370, DOI 10.1016/S0925-4005(99)00098-2; Tamaki J, 2006, SENSOR ACTUAT B-CHEM, V117, P353, DOI 10.1016/j.snb.2005.11.005; Shen YB, 2008, THIN SOLID FILMS, V516, P5111, DOI 10.1016/j.tsf.2007.12.139; FAGLIA G, 1994, SENSOR ACTUAT B-CHEM, V19, P497, DOI 10.1016/0925-4005(93)01056-A; Kanan SM, 2009, SENSORS-BASEL, V9, P8158, DOI 10.3390/s91008158; SBERVEGLIERI G, 1992, SENSOR ACTUAT B-CHEM, V8, P79, DOI 10.1016/0925-4005(92)85012-L; Son B, 2004, ENVIRON RES, V94, P291, DOI 10.1016/j.envres.2003.08.004; Shaalan NM, 2011, SENSOR ACTUAT B-CHEM, V153, P11, DOI 10.1016/j.snb.2010.09.070; Korotcenkov G, 2008, MAT SCI ENG R, V61, P1, DOI 10.1016/j.mser.2008.02.001; Bilgin V, 2004, MATER LETT, V58, P3686, DOI 10.1016/j.matlet.2004.07.023; Bonn Germany, 2003, REP WHO WORK GROUP H, P1; Hayashi M, 2009, SENSOR ACTUAT B-CHEM, V141, P465, DOI 10.1016/j.snb.2009.07.035; Jie Z., 2006, SENSOR ACTUAT B-CHEM, V115, P460; Ke C, 2011, CURR APPL PHYS, V11, pS306, DOI 10.1016/j.cap.2010.11.067; Khan AF, 2009, APPL SURF SCI, V255, P8562, DOI 10.1016/j.apsusc.2009.06.020; Korotcenkov G, 2002, MAT SCI ENG C-BIO S, V19, P73, DOI 10.1016/S0928-4931(01)00445-3; Korotkov RY, 2006, THIN SOLID FILMS, V502, P79, DOI 10.1016/j.tsf.2005.07.248; Lekshmy SS, 2013, APPL SURF SCI, V274, P95, DOI 10.1016/j.apsusc.2013.02.109; Minami T, 2005, SEMICOND SCI TECH, V20, pS35, DOI 10.1088/0268-1242/20/4/004; Pelleg J, 2006, PHYSICA B, V381, P118, DOI 10.1016/j.physb.2005.12.260; Reddy AS, 2013, J PHYS CHEM SOLIDS, V74, P825, DOI 10.1016/j.jpcs.2013.01.023; SBERVEGLIERI G, 1991, SENSOR ACTUAT B-CHEM, V4, P457, DOI 10.1016/0925-4005(91)80151-9; Serventi AM, 2003, J PHYS CHEM SOLIDS, V64, P2097, DOI 10.1016/S0022-3697(03)00262-2; Shaalan NM, 2011, SENSOR ACTUAT B-CHEM, V156, P784, DOI 10.1016/j.snb.2011.02.039; Sing K., 1985, PURE APPL CHEM, V5714, P603, DOI DOI 10.1351/PAC198557040603; Wei BY, 2004, SENSOR ACTUAT B-CHEM, V101, P81, DOI 10.1016/j.snb.2004.02.028; WILLIAMS G, 1993, SENSOR ACTUAT B-CHEM, V16, P349, DOI 10.1016/0925-4005(93)85208-R; Yamazaki T, 2006, JPN J APPL PHYS 1, V45, P9180, DOI 10.1143/JJAP.45.9180; YAMAZOE N, 1991, SENSOR ACTUAT B-CHEM, V5, P7, DOI 10.1016/0925-4005(91)80213-4; YLINAMPA A, 1993, SENSOR ACTUAT B-CHEM, V14, P602, DOI 10.1016/0925-4005(93)85110-V	38	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0947-8396	1432-0630		APPL PHYS A-MATER	Appl. Phys. A-Mater. Sci. Process.	SEP	2015	120	4					1555	1563		10.1007/s00339-015-9355-1		9	Materials Science, Multidisciplinary; Physics, Applied	Materials Science; Physics	CO8RD	WOS:000359437200036		
J	Georgarakis, K; Dudina, DV; Mali, VI; Anisimov, AG; Bulina, NV; Jorge, AM; Yavari, AR				Georgarakis, Konstantinos; Dudina, Dina V.; Mali, Vyacheslav I.; Anisimov, Alexander G.; Bulina, Natalia V.; Jorge, Alberto Moreira, Jr.; Yavari, Alain R.			Crystallization of Fe83B17 amorphous alloy by electric pulses produced by a capacitor discharge	APPLIED PHYSICS A-MATERIALS SCIENCE & PROCESSING			English	Article							METALLIC-GLASS; FE-B; FE23B6 PHASE; NANOCRYSTALLIZATION; CONSOLIDATION; KINETICS; BEHAVIOR; FE80B20; DENSITY; FIELD	Heating of conductive materials by electric current is used in many technological processes. Application of electric pulses to metallic glasses induces their fast crystallization, which is an interesting and complex phenomenon. In this work, crystallization of the Fe83B17 amorphous alloy induced by pulses of electric current produced has been studied using X-ray diffraction and transmission electron microscopy. Ribbons of the alloy were directly subjected to single pulses of electric current 250 mu s long formed by a capacitor discharge. As the value of integral I(2)dt was increased from 0.33 to 2.00 A(2) s, different crystallization stages could be observed. The crystallization began through the formation of the nuclei of alpha-Fe. At high values of integral I(2)dt, alpha-Fe and tetragonal and orthorhombic Fe3B and Fe23B6 were detected in the crystallized ribbons with crystallites of about 50 nm. Thermal annealing of the ribbons at 600 degrees C for 2 min resulted in the formation of alpha-Fe and tetragonal Fe3B. It was concluded that pulses of electric current produced by a capacitor discharge induced transformation of the Fe83B17 amorphous phase into metastable crystalline products.	[Georgarakis, Konstantinos] Tohoku Univ, WPI AIMR, Aoba Ku, Sendai, Miyagi 9808577, Japan; [Georgarakis, Konstantinos; Jorge, Alberto Moreira, Jr.; Yavari, Alain R.] Sci & Ingn Mat & Proc SIMAP CNRS, Inst Polytech Grenoble INPG, F-38402 St Martin Dheres, France; [Dudina, Dina V.; Bulina, Natalia V.] Russian Acad Sci, Siberian Branch, Inst Solid State Chem & Mechanochem, Novosibirsk 630128, Russia; [Dudina, Dina V.] Novosibirsk State Univ, Novosibirsk 630090, Russia; [Mali, Vyacheslav I.; Anisimov, Alexander G.] Russian Acad Sci, Siberian Branch, Lavrentyev Inst Hydrodynam, Novosibirsk 630090, Russia; [Jorge, Alberto Moreira, Jr.] Univ Fed Sao Carlos, Dept Mat Sci & Engn, BR-13565905 Sao Carlos, SP, Brazil	Dudina, DV (reprint author), Russian Acad Sci, Siberian Branch, Inst Solid State Chem & Mechanochem, Kutateladze Str 18, Novosibirsk 630128, Russia.	dina1807@gmail.com	Georgarakis, Konstantinos/K-1939-2015; Georgarakis, Konstantinos/E-6390-2010		Institute of Solid State Chemistry and Mechanochemistry SB RAS, Novosibirsk, Russia; JSPS [25820340]	This work was partially supported by the basic research funds of the Institute of Solid State Chemistry and Mechanochemistry SB RAS, Novosibirsk, Russia. KG acknowledges support from JSPS KAKENHI (Grant Number 25820340).	Al-Heniti SH, 2009, J ALLOY COMPD, V484, P177, DOI 10.1016/j.jallcom.2009.05.076; Olevsky EA, 2013, MATERIALS, V6, P4375, DOI 10.3390/ma6104375; HEROLD U, 1980, J MAGN MAGN MATER, V19, P152, DOI 10.1016/0304-8853(80)90580-6; Palumbo M, 2003, INTERMETALLICS, V11, P1293, DOI 10.1016/S0966-9795(03)00171-7; Liu WS, 2006, J ALLOY COMPD, V420, P171, DOI 10.1016/j.jallcom.2005.10.045; Yiu P, 2014, MATER LETT, V136, P353, DOI 10.1016/j.matlet.2014.08.052; Stoica M, 2009, J ALLOY COMPD, V483, P632, DOI 10.1016/j.jallcom.2007.11.150; Dudina DV, 2010, COMPOS PART A-APPL S, V41, P1551, DOI 10.1016/j.compositesa.2010.07.004; Johnson WL, 2011, SCIENCE, V332, P828, DOI 10.1126/science.1201362; Torrens-Serra J, 2008, REV ADV MATER SCI, V18, P464; Aljerf M, 2012, MAT SCI ENG A-STRUCT, V532, P325, DOI 10.1016/j.msea.2011.10.098; Nakamura T, 2002, MATER TRANS, V43, P1918, DOI 10.2320/matertrans.43.1918; Dudina DV, 2009, COMPOS SCI TECHNOL, V69, P2734, DOI 10.1016/j.compscitech.2009.08.001; Ichitsubo T, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.052201; Yurlova MS, 2014, J MATER SCI, V49, P952, DOI 10.1007/s10853-013-7805-8; Barinov VA, 2009, PHYS MET METALLOGR+, V108, P50, DOI 10.1134/S0031918X09070072; Bataev I.A., 2012, SURF COAT TECH, V207, P253; Cho J.Y., 2012, J ALLOY COMPD, V536S, P78; Dudina DV, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-512; Duhamel C, 2009, J ALLOY COMPD, V483, P243, DOI 10.1016/j.jallcom.2008.08.132; GREER AL, 1982, ACTA METALL MATER, V30, P171, DOI 10.1016/0001-6160(82)90056-6; Hirata A, 2008, INTERMETALLICS, V16, P491, DOI 10.1016/j.intermet.2007.11.006; INAL OT, 1980, J MATER SCI, V15, P1947, DOI 10.1007/BF00550620; KHAN Y, 1991, Z METALLKD, V82, P703; LaGrange T, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3125429; Lomovsky OI, 2013, INORG MATER+, V49, P564, DOI 10.1134/S002016851306006X; Massalski TB, 1986, BINARY ALLOY PHASE D; Matko I., 2014, J ALLOYS COMPD S, V615S, P462; Mizuno A, 2012, ISIJ INT, V52, P770; Oliveira M., 2000, MAT T JIM, V41, P1501; RAY R, 1977, SCRIPTA METALL MATER, V11, P973, DOI 10.1016/0036-9748(77)90249-6; Singh AK, 2014, JOM-US, V66, P1080, DOI 10.1007/s11837-014-0974-3; Soliman AA, 2004, THERMOCHIM ACTA, V413, P57, DOI 10.1016/j.tca.2003.11.001; Suryanarayana C., BULK METALLIC GLASSE, P200; Svec P, 2014, J ALLOY COMPD, V590, P87, DOI 10.1016/j.jallcom.2013.12.055; Tang JC, 2005, J PHYS D APPL PHYS, V38, P729, DOI 10.1088/0022-3727/38/5/010; Trudeau ML, 1996, MATER SCI FORUM, V225, P689; Yavari A. R., 1986, Journal of Materials Research, V1, DOI 10.1557/JMR.1986.0746; Yavari AR, 2002, J NON-CRYST SOLIDS, V304, P44, DOI 10.1016/S0022-3093(02)01002-5	39	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0947-8396	1432-0630		APPL PHYS A-MATER	Appl. Phys. A-Mater. Sci. Process.	SEP	2015	120	4					1565	1572		10.1007/s00339-015-9356-0		8	Materials Science, Multidisciplinary; Physics, Applied	Materials Science; Physics	CO8RD	WOS:000359437200037		
J	Wolter, B; Yamashita, J				Wolter, Brent; Yamashita, Junko			Processing collocations in a second language: A case of first language activation?	APPLIED PSYCHOLINGUISTICS			English	Article							LEXICAL DECISION; EYE-MOVEMENTS; ACQUISITION; AGE; FREQUENCY; LEARNERS; ENGLISH; WORDS; REPRESENTATION; PROBABILITIES	This study investigated the possible influence of first language (L1) collocational patterns on second language (L2) collocational processing. A lexical decision task was used to assess whether collocational patterns acceptable in the L1 but not the L2 would still be activated when processing language entirely in the L2. The results revealed no such activation. Furthermore, L2 speakers did not produce accelerated processing for control collocations that were acceptable in the L2 but not the L1. Based on these findings, we put forth some theoretical suggestions regarding recent research indicating accelerated processing for congruent over incongruent collocations. Finally, our NS control group revealed some unexpected tendencies that cannot be easily accounted for with our current understanding of L1 language processing.	[Wolter, Brent] Idaho State Univ, Pocatello, ID 83209 USA; [Yamashita, Junko] Nagoya Univ, Nagoya, Aichi 4648601, Japan	Wolter, B (reprint author), Idaho State Univ, Dept English & Philosophy, 921 South 8th Ave,Stop 8056, Pocatello, ID 83209 USA.	woltbren@isu.edu					CARROLL JB, 1973, Q J EXP PSYCHOL, V25, P85, DOI 10.1080/14640747308400325; Sunderman G, 2006, STUD SECOND LANG ACQ, V28, P387, DOI 10.1017/S0272263106060177; Howarth P, 1998, APPL LINGUIST, V19, P24, DOI 10.1093/applin/19.1.24; Ellis AW, 2000, J EXP PSYCHOL LEARN, V26, P1103, DOI 10.1037/0278-7393.26.5.1103; Marinis T, 2005, STUD SECOND LANG ACQ, V27, P53, DOI 10.1017/S0272263105050035; Schoonbaert S, 2009, MEM COGNITION, V37, P569, DOI 10.3758/MC.37.5.569; Wang M, 2003, COGNITION, V87, P129, DOI 10.1016/S0010-0277(02)00232-9; Jiang N, 2000, APPL LINGUIST, V21, P47, DOI 10.1093/applin/21.1.47; Tomasello M, 2000, COGN LINGUIST, V11, P61; Jones LL, 2012, CUR ISS PSYCHOL LANG, P44; Nesselhauf N, 2003, APPL LINGUIST, V24, P223, DOI 10.1093/applin/24.2.223; Yamashita J, 2010, TESOL QUART, V44, P647, DOI 10.5054/tq.2010.235998; MEYER DE, 1971, J EXP PSYCHOL, V90, P227, DOI 10.1037/h0031564; Lucas M, 2000, PSYCHON B REV, V7, P618, DOI 10.3758/BF03212999; COLLINS AM, 1975, PSYCHOL REV, V82, P407, DOI 10.1037//0033-295X.82.6.407; Jiang N, 2011, LANG LEARN, V61, P940, DOI 10.1111/j.1467-9922.2010.00627.x; Rastle K, 2002, Q J EXP PSYCHOL-A, V55, P1339, DOI 10.1080/02724980244000099; Ghyselinck M, 2004, ACTA PSYCHOL, V115, P43, DOI 10.1016/j.actpsy.2003.11.002; Lemhofer K, 2004, MEM COGNITION, V32, P533, DOI 10.3758/BF03195845; Wolter B, 2011, APPL LINGUIST, V32, P430, DOI 10.1093/applin/amr011; Wolter B, 2013, STUD SECOND LANG ACQ, V35, P451, DOI 10.1017/S0272263113000107; Brysbaert M, 2000, ACTA PSYCHOL, V104, P215, DOI 10.1016/S0001-6918(00)00021-4; Monaghan J, 2002, J EXP PSYCHOL LEARN, V28, P183, DOI 10.1037//0278.7393.28.1.183; McDonald SA, 2003, VISION RES, V43, P1735, DOI 10.1016/S0042-6989(03)00237-2; Ralph MAL, 2006, VIS COGN, V13, P928, DOI 10.1080/13506280544000110; MANELIS L, 1977, MEM COGNITION, V5, P690, DOI 10.3758/BF03197417; Izura C, 2011, J MEM LANG, V64, P32, DOI 10.1016/j.jml.2010.09.002; McDonald SA, 2003, PSYCHOL SCI, V14, P648, DOI 10.1046/j.0956-7976.2003.psci_1480.x; Myerson J, 1997, ACTA PSYCHOL, V96, P83, DOI 10.1016/S0001-6918(97)00002-4; Brysbaert M, 2010, BILING-LANG COGN, V13, P359, DOI 10.1017/S1366728909990344; Baayen R. H., 2008, ANAL LINGUISTIC DATA; Bahns J., 1993, SYSTEM, V21, P101, DOI DOI 10.1016/0346-251X(93)90010-E; Bahns J, 1993, ELT J, V47, P56, DOI 10.1093/elt/47.1.56; Barfield A., 2009, RES COLLOCATIONS ANO; Bybee J. L., 2001, FREQUENCY EMERGENCE, P337; Bybee J. R, 2007, FREQUENCY USE ORG LA; Chomsky N., 1965, ASPECTS THEORY SYNTA; Chwilla DJ, 2002, MEM COGNITION, V30, P217, DOI 10.3758/BF03195282; Cowie A. P., 1998, PHRASEOLOGY THEORY A; Davies Mark, 2008, CORPUS CONT AM ENGLI; Durrant P, 2010, CORPUS LINGUIST LING, V6, P125, DOI 10.1515/CLLT.2010.006; Ellis N., 2009, EXPLORING LEXIS GRAM, DOI [10.1075/scl.35, DOI 10.1075/SCL.35]; Fan M, 2009, SYSTEM, V37, P110, DOI 10.1016/j.system.2008.06.004; Firth J. R., 1957, SELECTED PAPERS JR F; FISCHLER I, 1977, MEM COGNITION, V5, P335, DOI 10.3758/BF03197580; Gabrys-Biskup D., 1992, VOCABULARY APPL LING, P85; Gass S., 1988, STUDIES THEORETICAL, V8, P384, DOI [10.1007/978-94-009-2733-9_21, DOI 10.1007/978-94-009-2733-9_21]; Goldberg A., 2006, CONSTRUCTIONS WORK N; Granger S., 1998, PHRASEOLOGY THEORY A; Gyllstad H., 2007, THESIS LUND U; Hoey M., 2005, LEXICAL PRIMING NEW; Hunston S., 2002, CORPORA APPL LINGUIS; Izura C., 2002, PSICOLOGICA, V23, P245; Izura C, 2004, J MEM LANG, V50, P165, DOI 10.1016/j.jml.2003.09.004; JACET Committee of Basic Words Revision, 2003, JACET LIST 8000 BAS; Jackendoff Ray, 1983, SEMANTICS COGNITION; Jiang JY, 2009, RESEARCHING COLLOCATIONS IN ANOTHER LANGUAGE: MULTIPLE INTERPRETATIONS, P99; Jiang N, 2004, MOD LANG J, V88, P416, DOI 10.1111/j.0026-7902.2004.00238.x; Jiang N., 2012, CONDUCTING REACTION; Kasper Gabriele, 1992, SECOND LANG RES, V8, P203, DOI 10.1177/026765839200800303; Kellerman E, 1979, STUDIES 2ND LANGUAGE, V2, P37, DOI DOI 10.1017/S0272263100000942; KIRSNER K, 1980, Q J EXP PSYCHOL, V32, P585, DOI 10.1080/14640748008401847; Langacker R. W., 2000, USAGE BASED MODELS L; Langacker R. W., 1988, TOPICS COGNITIVE LIN, DOI [10.1075/cilt.50, DOI 10.1075/CILT.50]; Langacker R. W., 1987, FDN COGNITIVE GRAMMA; Levelt William J. M., 1989, SPEAKING INTENTION A; MacWhinney B., 2000, USAGE BASED MODELS L, P121; McDonough K, 2009, SECOND LANG ACQUIS R, P1; McNamara T. P., 2004, SEMANTIC PRIMING PER; Meara P., 1990, EUROCENTRES VOCABULA; Nation I. S. P., 2001, LEARNING VOCABULARY; Papadopoulou D, 2003, STUDIES 2 LANGUAGE A, V24, P501; Perea M, 2002, ACTA PSYCHOL, V110, P103, DOI 10.1016/S0001-6918(01)00074-9; Pinker Steven, 1989, LEARNABILITY COGNITI; R Core Team, 2012, R LANG ENV STAT COMP; Schmitt N., 2004, FORMULAIC SEQUENCES, DOI [10.1075/lllt.9, DOI 10.1075/LLLT.9]; Sinclair J., 1991, CORPUS CONCORDANCE C; Siyanova-Chanturia A, 2011, J EXP PSYCHOL LEARN, V37, P776, DOI 10.1037/a0022531; Tesniere L, 1959, ELEMENTS SYNTAXE STR; Tomasello M., 2003, CONSTRUCTING LANGUAG; Van Loon-Vervoom W. A., 1988, COGNITIVE NEUROPSYCH, P99, DOI 10.1007/978-94-009-1391-2; Wray A., 2008, FORMULAIC LANGUAGE P; Wray A., 2002, FORMULAIC LANGUAGE L	83	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0142-7164	1469-1817		APPL PSYCHOLINGUIST	Appl. Psycholinguist.	SEP	2015	36	5					1193	1221		10.1017/S0142716414000113		29	Linguistics; Psychology, Experimental	Linguistics; Psychology	CO6RO	WOS:000359284100007		
J	Ikeno, H; Apel, M; Zouboulis, C; Luger, TA; Bohm, M				Ikeno, Hiroshi; Apel, Mara; Zouboulis, Christos; Luger, Thomas A.; Boehm, Markus			L-Ascorbyl-2-phosphate attenuates NF-kappa B signaling in SZ95 sebocytes without affecting IL-6 and IL-8 secretion	ARCHIVES OF DERMATOLOGICAL RESEARCH			English	Article						Sebocytes; Ascorbyl-2-phosphate; Cytokines; Acne	INTERLEUKIN-8 GENE-EXPRESSION; MELANOCYTE-STIMULATING HORMONE; PROSTAGLANDIN E-2 PRODUCTION; ACNE-VULGARIS; PROPIONIBACTERIUM-ACNES; PROTEIN-KINASE; IN-VITRO; CYTOKINE; PATHOGENESIS; ACTIVATION	Acne is the most common inflammatory skin disease. Interleukin-1 (IL-1) is at the beginning of the cytokine signaling cascade and may be involved in the pathogenesis of this disorder. It activates redox-sensitive transcription factors, which induce IL-6 and IL-8 expression. Interestingly, l-ascorbyl-2-phosphate (APS) was shown to have beneficial effects in patients with acne vulgaris. The mechanism of action of this agent remains unknown. Here, we investigated if APS attenuates IL-1 beta- or TNF-alpha-mediated IL-6 and IL-8 expression in SZ95 sebocytes, whereas TNF-alpha was used as control. We also explored NF-kappa B activation which is known to orchestrate IL-1 beta- and TNF-alpha-mediated cytokine expression in many cell types. Both IL-1 beta and TNF-alpha increased IL-6 and IL-8 mRNA expression in SZ95 sebocytes. However, only IL-1 beta induced IL-6 and IL-8 secretion. IL-1 beta but not TNF-alpha activated NF-kappa B canonical signaling as demonstrated by I kappa-B alpha phosphorylation and degradation as well as by nuclear accumulation of NF-kappa B/p65. Concomitant treatment of SZ95 sebocytes with APS attenuated the effect of IL-1 beta and TNF-alpha on IL-6 and IL-8 gene expression as well as on IL-1 beta-mediated NF-kappa B signaling. In contrast, APS failed to reduce IL-1 beta-mediated IL-6 and IL-8 secretion, presumably by maintained IL-1 beta-mediated p38 activation, which is known to control IL-8 secretion. Our findings shed light into the impact of IL-1 beta on the inflammatory cytokine response and its molecular mechanisms in human sebocytes. Our data further suggest that the beneficial effect of APS in acne patients involves attenuation of NF-kappa B signaling but not reduction of IL-6 or IL-8 secretion.	[Ikeno, Hiroshi] Ikeno Clin Dermatol & Dermatol Surg, Chuo Ku, Tokyo, Japan; [Apel, Mara; Luger, Thomas A.; Boehm, Markus] Univ Munster, Dept Dermatol, D-48149 Munster, Germany; [Zouboulis, Christos] Dessau Med Ctr, Dept Dermatol Venereol Allergol & Immunol, Dessau, Germany	Ikeno, H (reprint author), Ikeno Clin Dermatol & Dermatol Surg, Chuo Ku, Ginza 1-14-4, Tokyo, Japan.	ikenoderma@nifty.com					Kurokawa I, 2009, EXP DERMATOL, V18, P821, DOI 10.1111/j.1600-0625.2009.00890.x; INGHAM E, 1992, J INVEST DERMATOL, V98, P895, DOI 10.1111/1523-1747.ep12460324; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Graham GM, 2004, BRIT J DERMATOL, V150, P421, DOI 10.1046/j.1365-2133.2004.05762.x; Bowie AG, 2000, J IMMUNOL, V165, P7180; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Zouboulis CC, 1999, J INVEST DERMATOL, V113, P1011, DOI 10.1046/j.1523-1747.1999.00771.x; Jeremy AHT, 2003, J INVEST DERMATOL, V121, P20, DOI 10.1046/j.1523-1747.2003.12321.x; Alestas T, 2006, J MOL MED-JMM, V84, P75, DOI 10.1007/s00109-005-0715-8; DINARELLO CA, 1994, FASEB J, V8, P1314; Kokot A, 2009, ENDOCRINOLOGY, V150, P3197, DOI 10.1210/en.2008-1315; Ottaviani M, 2006, J INVEST DERMATOL, V126, P2430, DOI 10.1038/sj.jid.5700434; Brenner M, 2009, BRIT J DERMATOL, V161, P1199, DOI 10.1111/j.1365-2133.2009.09404.x; Kistowska M, 2014, J INVEST DERMATOL, V134, P677, DOI 10.1038/jid.2013.438; AKIRA S, 1992, CIBA F SYMP, V167, P47; VOWELS BR, 1995, INFECT IMMUN, V63, P3158; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Ghodsi SZ, 2009, J INVEST DERMATOL, V129, P2136, DOI 10.1038/jid.2009.47; Melnik BC, 2013, EXP DERMATOL, V22, P311, DOI 10.1111/exd.12142; Chaudhary LR, 1996, J BIOL CHEM, V271, P16591; Choi JJ, 2011, J DERMATOL SCI, V65, P179; Elmore Amy R, 2005, Int J Toxicol, V24 Suppl 2, P51; Guy R, 1996, J INVEST DERMATOL, V106, P176, DOI 10.1111/1523-1747.ep12329907; Ikeno H, 2011, J COSMET DERMATOL-US, V10, P240, DOI 10.1111/j.1473-2165.2011.00570.x; Kobayashi S, 1996, PHOTOCHEM PHOTOBIOL, V64, P224, DOI 10.1111/j.1751-1097.1996.tb02447.x; Mastrofrancesco A, 2010, J IMMUNOL, V185, P1903, DOI 10.4049/jimmunol.0902298; Melnik BC, 2013, EXP DERMATOL, V22, P502, DOI 10.1111/exd.12172; Miyazawa K, 1998, J BIOL CHEM, V273, P7620, DOI 10.1074/jbc.273.13.7620; Nayama S, 1999, BIOL PHARM BULL, V22, P1301; Tochio T, 2009, J COSMET DERMATOL-US, V8, P152, DOI 10.1111/j.1473-2165.2009.00437.x; Vlahopoulos S, 1999, BLOOD, V94, P1878; Woolery-Lloyd H, 2010, J COSMET DERMATOL-US, V9, P22, DOI 10.1111/j.1473-2165.2010.00480.x; Zhang QW, 2006, J INVEST DERMATOL, V126, P42, DOI 10.1038/sj.jid.5700028; Zhang QW, 2006, EXP DERMATOL, V15, P769, DOI 10.1111/j.1600-0625.2006.00458.x	34	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-3696	1432-069X		ARCH DERMATOL RES	Arch. Dermatol. Res.	SEP	2015	307	7					595	605		10.1007/s00403-015-1565-z		11	Dermatology	Dermatology	CP3XE	WOS:000359815300006		
J	Hisada, T; Endoh, K; Kuriki, K				Hisada, Takayoshi; Endoh, Kaori; Kuriki, Kiyonori			Inter- and intra-individual variations in seasonal and daily stabilities of the human gut microbiota in Japanese	ARCHIVES OF MICROBIOLOGY			English	Article						Human gut microbiota; Inter-individual variations; Intra-individual variations; Next-generation sequencing; Seasonal and daily stabilities	COLORECTAL-CANCER; OBESITY; BIFIDOBACTERIA; ENTEROTYPES; POPULATION; DYSBIOSIS; FREQUENCY; FOOD	Relationships between human gut microbiota, dietary habits, and health/diseases are the subject of epidemiological and clinical studies. However, the temporal stability and variability of the bacterial community in fecal samples remain unclear. In this study, middle-aged Japanese male and female volunteers (n = 5 each) without disease were recruited from the Sakura Diet Study. Fecal samples and lifestyle information were collected in every quarter and at each defecation for 7 continuous days. Next-generation sequencing of 16S rDNA and hierarchical clustering showed no time trend and intra-individual differences in both fecal sample sets. Significant inter-individual variations in seasonal and daily fecal sample sets were detected for 24 and 23 out of 39 selected dominant genera (> 0.1 % of the total human gut microbiota; occupation rate > 85 %), respectively. Intra- to inter-individual variance ratios in 26 and 35 genera were significantly < 1.0 for seasonal and daily stabilities. Seasonal variation in fermented milk consumption might be associated with Bifidobacterium composition, but not with Lactobacillus. For most of the dominant genera in the human gut microbiota, inter-individual variations were significantly larger than intra-individual variations. Further studies are warranted to determine the contributions of human gut microbiota to nutritional metabolism, health promotion, and prevention/development of diseases.	[Hisada, Takayoshi; Endoh, Kaori; Kuriki, Kiyonori] Univ Shizuoka, Grad Sch Nutr & Environm Sci, Publ Hlth Lab, Suruga Ku, Shizuoka 4228526, Japan; [Hisada, Takayoshi] TechnoSuruga Lab Co Ltd, Shimizu Ku, Shizuoka 4240065, Japan	Kuriki, K (reprint author), Univ Shizuoka, Grad Sch Nutr & Environm Sci, Publ Hlth Lab, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.	kuriki@u-shizuoka-ken.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [26350154]; Danone Institute of Japan Foundation	We are grateful to H. Takada as medical doctor; E. Inaba, M. Ohba, E. Kimoto, Y. Masui, A. Nishiyama, and M. Tsubouchi as nurses; S. Yamashita and Y. Kariya as medical laboratory technologists; and Y. Takatsuka, S. Kawaguchi, and C. Kurita as research assistants. We are also grateful to Dr. T. Kunihiro for his constructive comments on this study and to Dr. S. Takahashi and Dr. J. Tomita for their analytical support for the NGS analysis. This study was supported by a Grant-in-Aid for Scientific Research C (No. 26350154) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the Danone Institute of Japan Foundation for financial support through the 2014 DIJF Research Grant.	Ahn J, 2013, JNCI-J NATL CANCER I, V105, P1907, DOI 10.1093/jnci/djt300; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; Faith JJ, 2013, SCIENCE, V341, P44, DOI 10.1126/science.1237439; Gillevet P, 2010, CHEM BIODIVERS, V7, P1065, DOI 10.1002/cbdv.200900322; Wu N, 2013, MICROB ECOL, V66, P462, DOI 10.1007/s00248-013-0245-9; Schwabe RF, 2013, NAT REV CANCER, V13, P800, DOI 10.1038/nrc3610; BEATON GH, 1979, AM J CLIN NUTR, V32, P2546; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/nature4441022a; Tokudome Y, 2005, J EPIDEMIOL, V15, P135, DOI 10.2188/jea.15.135; Shokralla S, 2012, MOL ECOL, V21, P1794, DOI 10.1111/j.1365-294X.2012.05538.x; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Petry N, 2012, AM J CLIN NUTR, V96, P325, DOI 10.3945/ajcn.112.035717; Matsumoto K, 2010, J BIOSCI BIOENG, V110, P547, DOI 10.1016/j.jbiosc.2010.05.016; Tjalsma H, 2012, NAT REV MICROBIOL, V10, P575, DOI 10.1038/nrmicro2819; Nagashima K, 2003, APPL ENVIRON MICROB, V69, P1251, DOI 10.1128/AEM.69.2.1251-1262.2003; Fukuda K, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-49; Ohtani N, 2014, CANCER RES, V74, P1885, DOI 10.1158/0008-5472.CAN-13-3501; Wang TT, 2012, ISME J, V6, P320, DOI 10.1038/ismej.2011.109; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Lahti L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5344; Martinez I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069621; McCoy AN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053653; Nakamura S, 2002, J JPN ASS DIETARY FI, V6, P73, DOI 10.11217/jjdf1997.6.73; Nam YD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022109; Ogawa K, 1999, EUR J CLIN NUTR, V53, P781, DOI 10.1038/sj.ejcn.1600845; Qin J, 2012, NATURE, V464, P59, DOI 10.1038/nature08821; Quail MA, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-341; Rajilic-Stojanovic M, 2012, ENVIRON MICROBIOL, V15, P1146; Saito Y, 2002, CURR MICROBIOL, V44, P368, DOI 10.1007/s00284-001-0012-x; Sheflin AM, 2014, CURR ONCOL REP, V16, DOI 10.1007/s11912-014-0406-0; Shiozaki A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111374; Takahashi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105592; Tokudome Yuko, 2002, J Epidemiol, V12, P85; Veiga P, 2014, SCI REP-UK, V4, DOI 10.1038/srep06328; Walters WA, 2014, FEBS LETT, V588, P4223, DOI 10.1016/j.febslet.2014.09.039	37	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0302-8933	1432-072X		ARCH MICROBIOL	Arch. Microbiol.	SEP	2015	197	7					919	934		10.1007/s00203-015-1125-0		16	Microbiology	Microbiology	CP2XE	WOS:000359740200006		
J	Romanenko, LA; Tanaka, N; Svetashev, VI; Kurilenko, VV; Mikhailov, VV				Romanenko, Lyudmila A.; Tanaka, Naoto; Svetashev, Vassilii I.; Kurilenko, Valeriya V.; Mikhailov, Valery V.			Flavobacterium maris sp nov isolated from shallow sediments of the Sea of Japan	ARCHIVES OF MICROBIOLOGY			English	Article						Flavobacterium maris sp nov.; Marine sediments; Biodiversity; The Sea of Japan	EMENDED DESCRIPTION; GENUS FLAVOBACTERIUM; FAMILY FLAVOBACTERIACEAE; DEOXYRIBONUCLEIC-ACID; BACTERIUM; GELIDILACUS; WATER	An aerobic, gram-negative, yellow-pigmented, and non-motile bacterium designated KMM 9535(T) was isolated from a marine sediment sample obtained from the Sea of Japan seashore and subjected to a phylogenetic and phenotypic study. On the basis of 16S rRNA gene sequence analysis, strain KMM 9535(T) was placed to the genus Flavobacterium sharing the highest sequence similarities to Flavobacterium ahnfeltiae KCTC 32467(T) (99.3 %), Flavobacterium jumunjinense KCTC 23618(T) (96.5 %), Flavobacterium ponti KCTC 22802(T) (96.3 %), Flavobacterium urocaniciphilum JCM 19142(T) (96.1 %), and Flavobacterium gelidilacus LMG 21477(T) (95.8 %). The DNA-DNA hybridization value between strain KMM 9535(T) and the closest related F. ahnfeltiae KCTC 32467(T) was 33 %. Strain KMM 9535(T) grew at 5-36 A degrees C and in the presence of 0-3 % (w/v) NaCl. It contained MK-6 as the predominant menaquinone, and the major fatty acids were iso-C-15:0, iso-C-17:1, iso-C-15:1, and iso-C-17:0 3-OH. The DNA G+C content was 28.8 mol%. On the basis of the results obtained, it is proposed strain KMM 9535(T) to be classified as a novel species of the genus Flavobacterium, Flavobacterium maris sp. nov., with the type strain of the species KMM 9535(T) (=NRIC 0920(T) = KCTC 42093(T)).	[Romanenko, Lyudmila A.; Kurilenko, Valeriya V.; Mikhailov, Valery V.] Russian Acad Sci, GB Elyakov Pacific Inst Bioorgan Chem, Far Eastern Branch, Vladivostok 690022, Russia; [Tanaka, Naoto] Tokyo Univ Agr, NODAI Culture Collect Ctr, Setagaya Ku, Tokyo 1568502, Japan; [Svetashev, Vassilii I.] Russian Acad Sci, Inst Marine Biol, Far Eastern Branch, Vladivostok 690041, Russia; [Mikhailov, Valery V.] Far Eastern Fed Univ, Vladivostok 690091, Russia	Romanenko, LA (reprint author), Russian Acad Sci, GB Elyakov Pacific Inst Bioorgan Chem, Far Eastern Branch, Prospect 100 Let Vladivostoku 159, Vladivostok 690022, Russia.	lro@piboc.dvo.ru			RSF "Biodiversity and biotechnological potential of marine bacteria and fungi" [14-14-00030]	We would like to thank Dr. Claudine Vereecke, BCCM (TM)/LMG Bacteria Collection, Ghent University, Belgium, and Dr. Jung-Sook Lee, the Korean Collection for Type Cultures (KCTC), Biological Resource Center (BRC), Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea, and Dr. Moriya Ohkuma, JCM, Japan Collection of Microorganisms, Japan, for providing Flavobacterium type strains for comparative analyses. This study was supported by a grant from the RSF "Biodiversity and biotechnological potential of marine bacteria and fungi" no. 14-14-00030.	Joung Y, 2013, INT J SYST EVOL MICR, V63, P3937, DOI 10.1099/ijs.0.045286-0; Yoon JH, 2011, INT J SYST EVOL MICR, V61, P81, DOI 10.1099/ijs.0.017582-0; Kim OS, 2012, INT J SYST EVOL MICR, V62, P716, DOI 10.1099/ijs.0.038075-0; Bruns A, 2001, INT J SYST EVOL MICR, V51, P1997; Kang JY, 2013, INT J SYST EVOL MICR, V63, P1633, DOI 10.1099/ijs.0.044495-0; STACKEBRANDT E, 1994, INT J SYST BACTERIOL, V44, P846; EZAKI T, 1989, INT J SYST BACTERIOL, V39, P224; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; Romanenko LA, 2004, INT J SYST EVOL MICR, V54, P669, DOI 10.1099/ijs.0.02846-0; Bernardet JF, 2002, INT J SYST EVOL MICR, V52, P1049, DOI 10.1099/ijs.0.02136-0; Shida O, 1997, INT J SYST BACTERIOL, V47, P289; Pruesse E, 2012, BIOINFORMATICS, V28, P1823, DOI 10.1093/bioinformatics/bts252; Bowman JP, 2000, INT J SYST EVOL MICR, V50, P1861; Bernardet JF, 1996, INT J SYST BACTERIOL, V46, P128; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI 10.1093/molbev/mst197; FAUTZ E, 1980, FEMS MICROBIOL LETT, V8, P87, DOI 10.1111/j.1574-6968.1980.tb05056.x; COLLINS MD, 1984, ARCH MICROBIOL, V137, P247, DOI 10.1007/BF00414552; Dong K, 2013, INT J SYST EVOL MICR, V63, P886, DOI 10.1099/ijs.0.039974-0; Bergey D. H., 1923, BERGEYS MANUAL DETER, P97; Bernardet J.F., 2011, BERGEYS MANUAL SYSTE, V4, P112; Fujii D, 2014, INT J SYST EVOL MICR, V64, P1488, DOI 10.1099/ijs.0.054312-0; Nedashkovskaya OI, 2014, ARCH MICROBIOL, V196, P745, DOI 10.1007/s00203-014-1010-2; Owen J, 1969, BIOPOLYMERS, V7, P503; Romanenko LA, 2007, INT J SYST EVOL MICR, V57, P457, DOI 10.1099/ijs.0.64662-0; Romanenko LA, 2013, INT J SYST EVOL MICR, V63, P3079, DOI 10.1099/ijs.0.046607-0; Sasser M., 1990, 101 MIDI; Smibert Robert M., 1994, P607; Van Trappen S, 2003, INT J SYST EVOL MICR, V53, P1241, DOI 10.1099/ijs.0.02583-0	28	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0302-8933	1432-072X		ARCH MICROBIOL	Arch. Microbiol.	SEP	2015	197	7					941	947		10.1007/s00203-015-1128-x		7	Microbiology	Microbiology	CP2XE	WOS:000359740200008		
J	Sonoda, K; Yamamoto, T; Motomura, G; Nakashima, Y; Yamaguchi, R; Iwamoto, Y				Sonoda, Kazuhiko; Yamamoto, Takuaki; Motomura, Goro; Nakashima, Yasuharu; Yamaguchi, Ryosuke; Iwamoto, Yukihide			Outcome of transtrochanteric rotational osteotomy for posttraumatic osteonecrosis of the femoral head with a mean follow-up of 12.3 years	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						Osteonecrosis of the femoral head; Trauma; Femoral neck fracture; Hip dislocation; Transtrochanteric rotational osteotomy	TRAUMATIC POSTERIOR DISLOCATION; NONTRAUMATIC AVASCULAR NECROSIS; HIP; FRACTURES; NECK	This study examined the outcomes of applying transtrochanteric rotational osteotomy (TRO) for posttraumatic osteonecrosis of the femoral head (ON). We retrospectively reviewed 28 hips in 28 patients (male, n = 17; female n = 11) with a mean age of 34.8 years (12-61 years) at the time of TRO. Transtrochanteric anterior rotational osteotomy (ARO) was used when the lesion was localized on the anterior aspect of the femoral head, and transtrochanteric posterior rotational osteotomy (PRO) was indicated in patients with lesions limited to the posterior aspect of the femoral head. The mean follow-up period was 12.3 years (5.0-21.3 years). We investigated the patients' clinical and radiological factors, including age, sex, body mass index, preoperative Harris Hip Score (HHS), type of antecedent trauma, preoperative stage, and postoperative intact ratio (the ratio of the intact articular surface of the femoral head to the weight-bearing surface of the acetabulum). We divided the patients into a hip-survival group and a conversion-to-total hip arthroplasty (THA) group and then compared these factors between the two groups. At the final follow-up, 22 hips had survived with a mean HHS of 85.8. The remaining six hips underwent THA at a mean of 10.2 years after TRO. The preoperative stage was correlated with hip survival. Furthermore, the postoperative intact ratio was significantly lower in the conversion-to-THA group. Based on the receiver operating characteristic curve, a ratio of less than 33.6 % was found to be associated with the need to convert to THA. TRO to correct posttraumatic ON resulted in favorable midterm results. The possible risk factors for conversion to THA were an advanced preoperative stage and a postoperative intact ratio of less than 33.6 %.	[Sonoda, Kazuhiko; Yamamoto, Takuaki; Motomura, Goro; Nakashima, Yasuharu; Yamaguchi, Ryosuke; Iwamoto, Yukihide] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Higashi Ku, Fukuoka 8128582, Japan	Yamamoto, T (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yamataku@ortho.med.kyushu-u.ac.jp			Japan Agency for Medical Research and Development, AMED	This work was partially supported by a Research Grant for Intractable Diseases from Japan Agency for Medical Research and Development, AMED. We would like to thank Junji Kishimoto (Department of Research and Development of Next Generation Medicine Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan) for his helpful advice on the statistical analysis.	Abbas AA, 2008, J ORTHOP TRAUMA, V22, P63, DOI 10.1097/BOT.0b013e31815aba30; Zhao G, 2013, J ORTHOP SCI, V18, P277, DOI 10.1007/s00776-012-0347-0; Atsumi T, 2006, J BONE JOINT SURG AM, V88A, P42, DOI 10.2106/JBJS.F.00767; Bachiller FGC, 2002, CLIN ORTHOP RELAT R, P87; Altman RD, 2004, OSTEOARTHR CARTILAGE, V12, P515, DOI 10.1016/j.joca.2004.04.004; Zhao G, 2012, J ORTHOP SCI, V17, P390, DOI 10.1007/s00776-012-0238-4; Koo KH, 2001, J BONE JOINT SURG BR, V83B, P83, DOI 10.1302/0301-620X.83B1.10914; MONT MA, 1995, J BONE JOINT SURG AM, V77A, P459; Zahiri CA, 1998, J ARTHROPLASTY, V13, P890, DOI 10.1016/S0883-5403(98)90195-4; Ha YC, 2010, J BONE JOINT SURG AM, V92A, P314, DOI 10.2106/JBJS.H.01020; UPADHYAY SS, 1983, J BONE JOINT SURG BR, V65, P150; Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x; LUYAO GL, 1994, J BONE JOINT SURG AM, V76A, P15; STEWART MJ, 1954, J BONE JOINT SURG AM, V36-A, P315; Sugioka Y, 2008, CLIN ORTHOP RELAT R, V466, P1104, DOI 10.1007/s11999-008-0192-9; Zlotorowicz M, 2013, BONE JOINT J, V95B, P1453, DOI 10.1302/0301-620X.95B11.32383; HARRIS WH, 1969, J BONE JOINT SURG AM, VA 51, P737; OHZONO K, 1991, J BONE JOINT SURG BR, V73, P68; UPADHYAY SS, 1981, J BONE JOINT SURG BR, V63, P548; SAITO S, 1988, J BONE JOINT SURG BR, V70, P78; Dwyer AJ, 2006, INT ORTHOP, V30, P224, DOI 10.1007/s00264-005-0056-9; EPSTEIN HC, 1973, CLIN ORTHOP RELAT R, P116; MCNEIL BJ, 1975, NEW ENGL J MED, V293, P211, DOI 10.1056/NEJM197507312930501; Miyanishi K, 2000, J BONE JOINT SURG BR, V82B, P512, DOI 10.1302/0301-620X.82B4.10065; Sugano Nobuhiko, 2002, J Orthop Sci, V7, P601, DOI 10.1007/s007760200108; SUGIOKA Y, 1992, CLIN ORTHOP RELAT R, P111; SUGIOKA Y, 1982, CLIN ORTHOP RELAT R, P115; Togrul E, 2005, INJURY, V36, P123, DOI 10.1016/j.injury.2004.04.010	28	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0936-8051	1434-3916		ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	SEP	2015	135	9					1257	1263		10.1007/s00402-015-2282-y		7	Orthopedics; Surgery	Orthopedics; Surgery	CP3XI	WOS:000359815800009		
J	Nakase, J; Goshima, K; Numata, H; Oshima, T; Takata, Y; Tsuchiya, H				Nakase, Junsuke; Goshima, Kenichi; Numata, Hitoaki; Oshima, Takeshi; Takata, Yasushi; Tsuchiya, Hiroyuki			Precise risk factors for Osgood-Schlatter disease	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						Osgood-Schlatter disease; Risk factor; Prospective cohort study; Muscle tightness		A number of studies have examined the risk factors for Osgood-Schlatter disease (OSD). Studies on risk factors have not necessarily accurately demonstrated the risk factors of this disease because they were not prospective cohort studies or the populations in the studies were not categorized by the skeletal maturation of the tibial tuberosity. We can identify the precise risk factors for OSD by performing a prospective cohort study of a group of asymptomatic patients in particular times of adolescent using ultrasonography. In the present study, we aimed to investigate the precise risk factors for OSD. For all examinations, we used a 3-stage classification for tibial tuberosity development observed on ultrasonography: sonolucent (stage S), individual (stage I), and connective stages (stage C). Among 150 players with 300 knees, we included 37 male players with 70 knees at asymptomatic stage I on the first examination. We re-examined the included knees 1 year after the first examination and compared 10 knees with OSD (OSD group) and 60 knees without OSD (control group). Height, body weight, body mass index, tightness of the quadriceps femoris and hamstring muscles, muscle strength during knee extension, and flexion were assessed during the first medical examination. The incidence of OSD was 14.3 % in this 1-year cohort study. A significant difference was found in body weight, quadriceps muscle tightness, and muscle tightness and strength during knee extension between the 2 groups. The precise risk factors for OSD were increased, namely the quadriceps femoris muscle tightness and strength during knee extension and flexibility of the hamstring muscles, using logistic regression analysis. This information may be useful for teaching quadriceps stretching in preadolescent male football players with stage I.	[Nakase, Junsuke; Numata, Hitoaki; Oshima, Takeshi; Takata, Yasushi; Tsuchiya, Hiroyuki] Kanazawa Univ, Sch Med, Dept Orthopaed Surg, Kanazawa, Ishikawa 9200934, Japan; [Goshima, Kenichi] Toyama Municipal Hosp, Dept Orthopaed Surg, Toyama, Japan	Nakase, J (reprint author), Kanazawa Univ, Sch Med, Dept Orthopaed Surg, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.	nakase1007@yahoo.co.jp					Stark T, 2011, PM&R, V3, P472, DOI 10.1016/j.pmrj.2010.10.025; Gholve PA, 2007, CURR OPIN PEDIATR, V19, P44, DOI 10.1097/MOP.0b013e328013dbea; KUJALA UM, 1985, AM J SPORT MED, V13, P236, DOI 10.1177/036354658501300404; de Lucena GL, 2011, AM J SPORT MED, V39, P415, DOI 10.1177/0363546510383835; Czyrny Z, 2010, MED ULTRASON, V12, P323; DEFLAVIIS L, 1989, SKELETAL RADIOL, V18, P193; EHRENBORG GOSTA, 1961, ACTA CHIR SCAND, V121, P315; EHRENBORG GOSTA, 1962, ACTA CHIR SCAND, V124, P89; EHRENBORG G, 1962, Acta Chir Scand Suppl, VSuppl 288, P1; Hirano A, 2002, SKELETAL RADIOL, V31, P334, DOI 10.1007/s00256-002-0486-z; Nakase J, 2014, KNEE SURG SPORT TR A, V22, P195, DOI 10.1007/s00167-012-2353-3; OGDEN JA, 1976, CLIN ORTHOP RELAT R, P180; Osgood RE, 1903, BOSTON MED SURG J, V148, P0114; Sarcevic Z, 2008, KNEE SURG SPORT TR A, V16, P726, DOI 10.1007/s00167-008-0529-7; Schlatter C, 1903, BRUNS BEITR KLIN CHI, V38, P874; Vreju F, 2010, MED ULTRASON, V12, P336	16	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0936-8051	1434-3916		ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	SEP	2015	135	9					1277	1281		10.1007/s00402-015-2270-2		5	Orthopedics; Surgery	Orthopedics; Surgery	CP3XI	WOS:000359815800011		
J	Matsumoto, S; Matsumoto, K; Iida, H				Matsumoto, Shigemi; Matsumoto, Kazu; Iida, Hiroki			Transdermal fentanyl patch improves post-operative pain relief and promotes early functional recovery in patients undergoing primary total knee arthroplasty: a prospective, randomised, controlled trial	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						Transdermal fentanyl patch; Post-operative pain; Total knee arthroplasty; Early functional recovery; NSAIDs	QUALITY-OF-LIFE; DOUBLE-BLIND; CONTROLLED ANALGESIA; ORTHOPEDIC-SURGERY; PLACEBO; INFILTRATION; REPLACEMENT; ANESTHESIA; MANAGEMENT; MORPHINE	The aim of the present study was to evaluate the efficacy and safety of a 12.5 mu g/h transdermal fentanyl patch (TFP). Fifty-two patients scheduled for primary total knee arthroplasty (TKA) were recruited in the study. They were randomly divided into two groups: patients provided with a transdermal fentanyl patch (Group TFP) and those provided with non-steroid anti-inflammatory drugs (Group NSAID). The patients in the TFP and NSAID groups had mean ages of 70.1 years (range 36-86 years) and 73.5 years (range 32-86 years), respectively. Post-operative pain intensity was measured using the visual analogue scale both at rest and during movement (mVAS). We also evaluated lower leg functional recovery and adverse events. The mean mVAS scores were not different between the two groups on post-operative day 4, but were significantly smaller in the TFP group than in the NSAID group on post-operative days 7 (p = 0.0026) and 14 (p = 0.007). Muscle strength recovered faster in the TFP group than in the NSAID group, the percentage of pre-operative strength being significantly greater in the former than in the latter on post-operative days 7 (p = 0.027) and 14 (p = 0.047). Furthermore, there were no remarkable adverse events in patients using TFP. We conclude that a 12.5 mu g/h TFP can improve post-operative pain relief and promotes early functional recovery following total knee arthroplasty.	[Matsumoto, Shigemi; Iida, Hiroki] Gifu Univ, Dept Anesthesiol & Pain Med, Grad Sch Med, Gifu 5011194, Japan; [Matsumoto, Kazu] Gifu Univ, Dept Orthopaed Surg, Grad Sch Med, Gifu 5011194, Japan	Iida, H (reprint author), Gifu Univ, Dept Anesthesiol & Pain Med, Grad Sch Med, 1-1 Yanagido, Gifu 5011194, Japan.	iida@gifu-u.ac.jp					Abrisham SMJ, 2014, KNEE SURG SPORT TR A, V22, P1580, DOI 10.1007/s00167-012-2287-9; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; KILBRIDE M, 1994, DIS COLON RECTUM, V37, P1070, DOI 10.1007/BF02049805; NormanTaylor FH, 1996, J BONE JOINT SURG BR, V78B, P74; Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a; BROOME IJ, 1995, ANAESTHESIA, V50, P300, DOI 10.1111/j.1365-2044.1995.tb04603.x; Rodgers A, 2000, BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Minville V, 2008, J CLIN ANESTH, V20, P280, DOI 10.1016/j.jclinane.2007.12.013; Singelyn FJ, 1998, ANESTH ANALG, V87, P88, DOI 10.1097/00000539-199807000-00019; MODIG J, 1983, ANESTH ANALG, V62, P174; LEHMANN KA, 1991, EUR J CLIN PHARMACOL, V41, P17, DOI 10.1007/BF00280100; Apfel CC, 2012, BRIT J ANAESTH, V109, P742, DOI 10.1093/bja/aes276; VANBASTELAERE M, 1995, J CLIN ANESTH, V7, P26, DOI 10.1016/0952-8180(94)00000-T; Meding JB, 2012, CLIN ORTHOP RELAT R, V470, P144, DOI 10.1007/s11999-011-2123-4; Lombardi AV, 2004, CLIN ORTHOP RELAT R, P125, DOI 10.1097/01.blo.000147701.24029.cc; Fischer HBJ, 2008, ANAESTHESIA, V63, P1105, DOI 10.1111/j.1365-2044.2008.05565.x; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; Hawker G, 1998, J BONE JOINT SURG AM, V80A, P163; Maheshwari AV, 2009, CLIN ORTHOP RELAT R, V467, P1418, DOI 10.1007/s11999-009-0728-7; Harden RN, 2003, PAIN, V106, P393, DOI 10.1016/j.pain.2003.08.009; Andersen KV, 2010, ACTA ORTHOP, V81, P606, DOI 10.3109/17453674.2010.519165; Carli F, 2010, BRIT J ANAESTH, V105, P185, DOI 10.1093/bja/aeq112; Chelly JE, 2003, ORTHOPEDICS, V26, pS865; Cheville A, 2001, J BONE JOINT SURG AM, V83A, P572; Fu P, 2009, KNEE, V16, P80; GOURLAY GK, 1990, PAIN, V40, P21, DOI 10.1016/0304-3959(90)91046-L; Koh IJ, 2012, KNEE, V19, P253, DOI 10.1016/j.knee.2011.03.007; MIGUEL R, 1995, ANESTHESIOLOGY, V83, P470, DOI 10.1097/00000542-199509000-00005; Parker DA, 2009, J ARTHROPLASTY, V24, P918, DOI 10.1016/j.arth.2008.05.001; Parvataneni Hari K, 2007, Instr Course Lect, V56, P125; Parvizi J, 2012, J BONE JOINT SURG AM, V94A, P1441, DOI 10.2106/JBJS.9416edit; SEBEL PS, 1987, EUR J CLIN PHARMACOL, V32, P529, DOI 10.1007/BF00637682	32	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0936-8051	1434-3916		ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	SEP	2015	135	9					1291	1297		10.1007/s00402-015-2265-z		7	Orthopedics; Surgery	Orthopedics; Surgery	CP3XI	WOS:000359815800013		
J	Ishii, Y; Noguchi, H; Sato, J; Todoroki, K; Toyabe, SI				Ishii, Yoshinori; Noguchi, Hideo; Sato, Junko; Todoroki, Koji; Toyabe, Shin-Ichi			Rotational alignment of tibial components in mobile-bearing TKA: posterior substituted vs. PCL retaining	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						Knee arthroplasty; Rotational alignment; Tibial prosthesis; Mobile-bearing TKA; Tibial tubercle	TOTAL KNEE ARTHROPLASTY; LOWER-EXTREMITY ALIGNMENT; TRANSEPICONDYLAR AXIS; IMPLANT ALIGNMENT; FEMORAL COMPONENT; SCREW-HOME; REPLACEMENT; KINEMATICS; COVERAGE; POSITION	The medial border of the tibial tubercle (MBTT) is one of the fixed anatomic landmarks for tibial component setting during total knee arthroplasty (TKA). In mobile-bearing TKA using a tibial cut first technique, the final tibial component rotation can be guided by the position it achieves following several flexion-extension cycles. In this study, tibial component angle (TCA) and tibial rotational angle (TRA) were determined in dependence of retention or resection of the posterior cruciate ligament (PCL). The TCA and TRA were examined in 206 patients who underwent primary TKA (PCL retaining: 104 knees, PCL substituting: 102 knees). The tibial component rotation was intraoperatively setting between the parallel to the axis of the most medial aspect of the tibial tubercle as the anterior anatomic landmark and the center of the tibial component as the posterior landmark at the maximum coverage with the osteotomized tibial plateau with its adjustment after several knee flexion-extension exercises. A postoperative quantitative three-dimensional computed tomography technique was used for measurements by a single observer. The TCA showed a divergence of 0.21A degrees external to the MBTT in the PCL-retaining design and 1.62A degrees internal divergence in the PCL-substituting design. The TRA showed an internal divergence of 0.88A degrees in the PCL-retaining design and an internal divergence of 2.12A degrees in the PCL-substituting design. There were no significant differences between the two designs. The MBTT might be regarded as a reliable landmark for obtaining an acceptable tibial rotational setting in mobile-bearing TKA despite PCL retention.	[Ishii, Yoshinori; Noguchi, Hideo; Sato, Junko; Todoroki, Koji] Ishii Orthopaed & Rehabil Clin, Gyoda, Saitama 3610037, Japan; [Toyabe, Shin-Ichi] Niigata Univ, Div Informat Sci & Biostat, Grad Sch Med & Dent Sci, Niigata, Niigata 9518520, Japan	Ishii, Y (reprint author), Ishii Orthopaed & Rehabil Clin, 1089 Shimo Oshi, Gyoda, Saitama 3610037, Japan.	ishii@sakitama.or.jp					Akagi M, 2005, CLIN ORTHOP RELAT R, P172, DOI 10.1097/01.blo.0000160027.52481.32; Siston RA, 2006, CLIN ORTHOP RELAT R, P65, DOI 10.1097/01.blo.0000229335.36900.a0; Mantas J P, 1992, J Arthroplasty, V7, P531; Aglietti P, 2008, CLIN ORTHOP RELAT R, V466, P2751, DOI 10.1007/s11999-008-0452-8; BERGER RA, 1993, CLIN ORTHOP RELAT R, P40; Huddleston JI, 2005, CLIN ORTHOP RELAT R, P101, DOI 10.1097/01.blo.0000185448.43622.77; Hutter EE, 2013, CLIN ORTHOP RELAT R, V471, P1646, DOI 10.1007/s11999-013-2822-0; Kawahara S, 2014, KNEE SURG SPORT TR A, V22, P1070, DOI 10.1007/s00167-013-2468-1; Ishii Y, 2011, KNEE SURG SPORT TR A, V19, P2002, DOI 10.1007/s00167-011-1395-2; Dennis DA, 2005, CLIN ORTHOP RELAT R, P88, DOI 10.1097/01.blo.0000185464.23505.6e; Mikashima Y, 2013, KNEE, V20, P422, DOI 10.1016/j.knee.2013.06.005; Uehara K, 2002, CLIN ORTHOP RELAT R, P196; Kobayashi K, 2009, J BIOMECH, V42, P2818, DOI 10.1016/j.jbiomech.2009.08.022; Cates HE, 2008, J ARTHROPLASTY, V23, P1057, DOI 10.1016/j.arth.2007.09.019; Graw BP, 2010, CLIN ORTHOP RELAT R, V468, P2734, DOI 10.1007/s11999-010-1330-8; Sato T, 2004, J ARTHROPLASTY, V19, P620, DOI 10.1016/j.arth.2003.12.063; Eckhoff D G, 1994, J Arthroplasty, V9, P73, DOI 10.1016/0883-5403(94)90140-6; Matziolis G, 2007, J BONE JOINT SURG AM, V89A, P236, DOI 10.2106/JBJS.F.00386; Dalury DF, 2001, CLIN ORTHOP RELAT R, P150; Martin S, 2014, CLIN ORTHOP RELAT R, V472, P121, DOI 10.1007/s11999-013-3047-y; Ikeuchi M, 2007, J BONE JOINT SURG BR, V89B, P45, DOI 10.1302/0301-620X.89B1.17728; Churchill DL, 1998, CLIN ORTHOP RELAT R, P111; Puloski SKT, 2001, J BONE JOINT SURG AM, V83A, P390; Nagamine R, 2003, CLIN ORTHOP RELAT R, P218, DOI 10.1097/01.blo.0000053163.71678.da; Matsui Y, 2005, CLIN ORTHOP RELAT R, P147, DOI 10.1097/01.blo.0000150465.29883.83; Ariumi A, 2010, J ORTHOP SCI, V15, P64, DOI 10.1007/s00776-009-1414-z; Banks SA, 2004, CLIN ORTHOP RELAT R, P187, DOI 10.1097/01.blo.0000138956.04316.ac; Dalury David F, 2003, J Knee Surg, V16, P215; ECKHOFF DG, 1995, CLIN ORTHOP RELAT R, P28; INCAVO SJ, 1994, CLIN ORTHOP RELAT R, P81; Insall JN, 2001, SURG KNEE, V3rd, P1553; Insall JN, 1993, SURG KNEE, V2, P739; Ishii Y, 2011, J ARTHROPLASTY, V26, P255, DOI 10.1016/j.arth.2010.05.023; Ishii Y, 1999, CLIN ORTHOP RELAT R, P181; Ishii Y, 1996, J ORTHOP SCI, V1, P313, DOI 10.1007/BF02348841; Ishii Y, 2007, KNEE, V14, P269, DOI 10.1016/j.knee.2007.04.002; Kawahara S, 2012, KNEE SURG SPORT TR A, V20, P2073, DOI 10.1007/s00167-011-1826-0; Komistek RD, 2004, CLIN ORTHOP RELAT R, P207, DOI 10.1097/01.blo.0000147135.60185.39; Lutzner J, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-57; MERKOW RL, 1985, J BONE JOINT SURG AM, V67A, P1321; MORELAND JR, 1988, CLIN ORTHOP RELAT R, P49; Sahin N, 2013, KNEE SURG SPORT TR A, V21, P2384, DOI 10.1007/s00167-012-2120-5; Stiehl JB, 1999, J ARTHROPLASTY, V14, P293, DOI 10.1016/S0883-5403(99)90054-2; WESTRICH GH, 1994, CLIN ORTHOP RELAT R, P163; Yoshioka K, 1989, J ORTHOP RES, V7, P132	45	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0936-8051	1434-3916		ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	SEP	2015	135	9					1299	1305		10.1007/s00402-015-2275-x		7	Orthopedics; Surgery	Orthopedics; Surgery	CP3XI	WOS:000359815800014		
J	Imazato, T; Kanematsu, M; Kishikawa, N; Ohyama, K; Hino, T; Ueki, Y; Maehata, E; Kuroda, N				Imazato, Takahiro; Kanematsu, Mariko; Kishikawa, Naoya; Ohyama, Kaname; Hino, Takako; Ueki, Yukitaka; Maehata, Eisuke; Kuroda, Naotaka			Determination of acrolein in serum by high-performance liquid chromatography with fluorescence detection after pre-column fluorogenic derivatization using 1,2-diamino-4,5-dimethoxybenzene	BIOMEDICAL CHROMATOGRAPHY			English	Article						acrolein; lipid peroxidation; high-performance liquid chromatography; fluorescence detection; fluorogenic derivatization; 1; 2-diamino-4; 5-dimethoxybenzene	ALIPHATIC-ALDEHYDES; LIPID-PEROXIDATION; OXIDATIVE STRESS; RENAL-FAILURE; PROTEIN; PLASMA; RELEVANT; DISEASE	Acrolein is a major unsaturated aldehyde that is generated during the lipid peroxidation process. The measurement of acrolein in biological samples should be useful to estimate the degree of lipid peroxidation and to evaluate the effect of hazardous properties of acrolein on human health. In this study, a highly sensitive and selective high-performance liquid chromatography with fluorescence detection method was developed for the determination of acrolein in human serum. The proposed method involves the pre-column fluorogenic derivatization of acrolein with 1,2-diamino-4,5-dimethoxybenzene (DDB) as a reagent. The fluorescent derivative of acrolein could be detected clearly without any interfering reagent blank peaks because DDB does not have intrinsic fluorescence itself, and the detection limit was 10nM (signal-to-noise ratio=3). The proposed method could selectively detect acrolein in human serum with a simple protein precipitation treatment. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Imazato, Takahiro; Kanematsu, Mariko; Kishikawa, Naoya; Ohyama, Kaname; Hino, Takako; Kuroda, Naotaka] Nagasaki Univ, Grad Sch Biomed Sci, Dept Environm & Pharmaceut Sci, Nagasaki 852, Japan; [Imazato, Takahiro; Ueki, Yukitaka] Sasebo Chuo Hosp, Sasebo, Japan; [Maehata, Eisuke] Showa Univ, Fujigaoka Hosp, Yokohama, Kanagawa 227, Japan	Kuroda, N (reprint author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Environm & Pharmaceut Sci, Nagasaki 852, Japan.	n-kuro@nagasaki-u.ac.jp					Ali MFB, 2014, J CHROMATOGR B, V953, P147, DOI 10.1016/j.jchromb.2014.02.009; LoPachin RM, 2009, CHEM RES TOXICOL, V22, P1499, DOI 10.1021/tx900147g; Igarashi K, 2006, AMINO ACIDS, V31, P477, DOI 10.1007/s00726-006-0264-7; Casella IG, 2004, J AGR FOOD CHEM, V52, P5816, DOI 10.1021/jf049440q; Shibamoto T, 2006, J PHARMACEUT BIOMED, V41, P12, DOI 10.1016/j.jpba.2006.01.047; Osorio VM, 2011, J CHROMATOGR A, V1218, P3332, DOI 10.1016/j.chroma.2010.11.068; Stevens JF, 2008, MOL NUTR FOOD RES, V52, P7, DOI 10.1002/mnfr.200700412; Saiki R, 2009, STROKE, V40, P3356, DOI 10.1161/STROKEAHA.109.553248; Sakata K, 2003, BIOCHEM BIOPH RES CO, V305, P143, DOI 10.1016/S0006-291X(03)00716-2; Andreoli R, 2003, RAPID COMMUN MASS SP, V17, P637, DOI 10.1002/rcm.960; Furuhata A, 2003, J BIOL CHEM, V278, P48658, DOI 10.1074/jbc.M309401200; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Ellis EM, 2007, PHARMACOL THERAPEUT, V115, P13, DOI 10.1016/j.pharmthera.2007.03.015; Noiri E, 2002, FREE RADICAL BIO MED, V33, P1651, DOI 10.1016/S0891-5849(02)01138-3; Garrett MC, 2008, BRIT J NEUROSURG, V22, P546, DOI 10.1080/02688690802072945; Bohnenstengel F, 1997, J CHROMATOGR B, V692, P163, DOI 10.1016/S0378-4347(96)00457-4; Casella IG, 2005, J CHROMATOGR A, V1063, P129, DOI 10.1016/j.chroma.2004.11.098; Colak E., 2008, J MED BIOCHEM, V27, P1, DOI 10.2478/v10011-007-0049-x; Medina-Navarro R, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-201; NAKAMURA M, 1982, ANAL CHIM ACTA, V134, P39, DOI 10.1016/S0003-2670(01)84175-1; Paci A, 2000, J CHROMATOGR B, V739, P239, DOI 10.1016/S0378-4347(99)00485-5; Pocernich CB, 2003, NEUROTOX RES, V5, P515; Tanuma N, 2008, BRAIN DEV-JPN, V30, P402, DOI 10.1016/j.braindev.2007.12.001; Togashi M, 2010, ORG LETT, V12, P1704, DOI 10.1021/ol1002219; TOTH B, 1988, In Vivo (Attiki), V2, P209; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Wright CI, 2006, NEUROBIOL AGING, V27, P361, DOI 10.1016/j.neurobiolaging.2005.01.014	27	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-3879	1099-0801		BIOMED CHROMATOGR	Biomed. Chromatogr.	SEP	2015	29	9					1304	1308		10.1002/bmc.3422		5	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	CP4OJ	WOS:000359861400002		
J	Kawanishi, M; Yano, I; Yoshimura, K; Yamamoto, T; Hashi, S; Masuda, S; Kondo, T; Takaori-Kondo, A; Matsubara, K				Kawanishi, Misaki; Yano, Ikuko; Yoshimura, Kazuaki; Yamamoto, Takashi; Hashi, Sachiyo; Masuda, Satohiro; Kondo, Tadakazu; Takaori-Kondo, Akifumi; Matsubara, Kazuo			Sensitive and validated LC-MS/MS methods to evaluate mycophenolic acid pharmacokinetics and pharmacodynamics in hematopoietic stem cell transplant patients	BIOMEDICAL CHROMATOGRAPHY			English	Article						mycophenolic acid; IMPDH; LC-MS; MS; therapeutic drug monitoring	5'-MONOPHOSPHATE DEHYDROGENASE-ACTIVITY; BLOOD MONONUCLEAR-CELLS; NONRADIOACTIVE DETERMINATION; CLINICAL PHARMACOKINETICS; MOFETIL; RECIPIENTS; ASSAY	Monitoring of pharmacodynamics in addition to pharmacokinetics is one of strategies to individualize mycophenolate mofetil therapy. The purpose of this study was to develop sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods for evaluation of the pharmacokinetics and pharmacodynamics of mycophenolic acid (MPA). Concentrations of mycophenolic acid glucuronide (MPAG), mycophenolic acid acyl-glucuronide, as well as unbound MPA and MPAG, were determined, and inosine-5-monophosphate dehydrogenase activity was calculated by measuring concentrations of produced xanthosine-5-monophosphate (XMP) and intracellular adenosine-5-monophosphate after incubation of peripheral blood mononuclear cell (PBMC) lysates. A metal-free Mastro(TM) column and two gradient patterns were used to improve the quantification limit of XMP to 0.1 m. In the clinical MPA concentration range, the linearity of the calibration curve, inter- and intra-day precision and accuracy satisfied the relevant US Food and Drug Administration guidelines. The MPA concentrations in hematopoietic stem cell transplant (HSCT) patients determined by the enzyme assay and the present LC-MS/MS method showed a good correlation (r(2) = 0.95, p < 0.001). In this study, we report sensitive and validated LC-MS/MS methods to evaluate the pharmacokinetics and pharmacodynamics of MPA, which are sufficiently sensitive to assess small quantities of PBMC lysates collected shortly after HSCT. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Kawanishi, Misaki; Yano, Ikuko; Yoshimura, Kazuaki] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Clin Pharm & Educ, Kyoto 6068501, Japan; [Kawanishi, Misaki; Yano, Ikuko; Yoshimura, Kazuaki; Yamamoto, Takashi; Hashi, Sachiyo; Masuda, Satohiro; Matsubara, Kazuo] Kyoto Univ Hosp, Dept Clin Pharmacol & Therapeut, Kyoto 606, Japan; [Kondo, Tadakazu; Takaori-Kondo, Akifumi] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto 6068501, Japan	Yano, I (reprint author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Clin Pharm & Educ, Sakyo Ku, Kyoto 6068501, Japan.	iyano@kuhp.kyoto-u.ac.jp	Masuda, Satohiro/E-6691-2010	Masuda, Satohiro/0000-0002-3589-5989	JSPS KAKENHI [24928023, 25460210, 26927010]	This work was supported in part by JSPS KAKENHI grant numbers 24928023, 25460210, and 26927010.	Glander P, 2012, CLIN CHIM ACTA, V413, P1391, DOI 10.1016/j.cca.2011.08.027; Bullingham RES, 1998, CLIN PHARMACOKINET, V34, P429, DOI 10.2165/00003088-199834060-00002; Delavenne X, 2011, CLIN CHIM ACTA, V412, P59, DOI 10.1016/j.cca.2010.09.041; Allison AC, 2000, IMMUNOPHARMACOLOGY, V47, P85, DOI 10.1016/S0162-3109(00)00188-0; Shipkova M, 2003, THER DRUG MONIT, V25, P1, DOI 10.1097/00007691-200302000-00001; Staatz CE, 2007, CLIN PHARMACOKINET, V46, P13, DOI 10.2165/00003088-200746010-00002; Glander P, 2009, THER DRUG MONIT, V31, P351, DOI 10.1097/FTD.0b013e31819c3f3d; Glander P, 2001, CLIN BIOCHEM, V34, P543, DOI 10.1016/S0009-9120(01)00267-3; Glander P, 2004, AM J TRANSPLANT, V4, P2045, DOI 10.1111/j.1600-6143.2004.00617.x; Kaufman DB, 2004, AM J TRANSPLANT, V4, P38, DOI 10.1111/j.1600-6135.2004.00397.x; Laverdiere I, 2012, ANAL CHEM, V84, P216, DOI 10.1021/ac202404y; Li H, 2014, BIOL BLOOD MARROW TR, V20, P1121, DOI 10.1016/j.bbmt.2014.03.032; Maiguma T, 2010, J CLIN PHARM THER, V35, P79, DOI 10.1111/j.1365-2710.2009.01072.x; Minagawa K, 2012, INT J HEMATOL, V96, P10, DOI 10.1007/s12185-012-1086-x; NOWAK I, 1995, CLIN CHEM, V41, P1011; Shaw LM, 2001, CLIN BIOCHEM, V34, P17, DOI 10.1016/S0009-9120(00)00184-3; US_Food_and_Drug_Administration, 2013, GUID IND BIOAN METH	17	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-3879	1099-0801		BIOMED CHROMATOGR	Biomed. Chromatogr.	SEP	2015	29	9					1309	1316		10.1002/bmc.3423		8	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	CP4OJ	WOS:000359861400003		
J	Mano, Y; Sakamaki, K; Ueno, T; Kita, K; Ishii, T; Hotta, K; Kusano, K				Mano, Yuji; Sakamaki, Kenji; Ueno, Takuya; Kita, Kenji; Ishii, Takuho; Hotta, Koichiro; Kusano, Kazutomi			Validation of a hydrophilic interaction ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of gemcitabine in human plasma with tetrahydrouridine	BIOMEDICAL CHROMATOGRAPHY			English	Article						UPLC-MS; MS; gemcitabine; tetrahydrouridine; validation; human	LC-MS/MS METHOD; METABOLITE	A simple and reproducible bioanalytical method for the determination of gemcitabine in human plasma treated with tetrahydrouridine (THU) was developed and validated using a hydrophilic interaction ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS). To prevent deamination of gemcitabine, blood was treated with THU, and the plasma samples obtained after centrifugation were used in this study. Gemcitabine and gemcitabine-C-13, N-15(2) used as an internal standard, were extracted from human plasma treated with THU using a 96-well Hybrid SPE-Precipitation plate. Extracts were chromatographed on a hydrophilic interaction chromatography column with isocratic elution. Detection was performed using Quattro Premier with positive electrospray ionization multiple reaction monitoring mode. The standard curve ranged from 10 to 10,000ng/mL without carryover. No significant interferences were detected in blank plasma and no interferences by 2-2-difluoro-2-deoxyuridine, a metabolite of gemcitabine. Accuracy and precision in the intra-batch reproducibility study using quality control samples with three THU levels did not exceed +/- 5.4 and 7.3%, respectively, and the inter-batch reproducibility results also met the criteria. Stability of gemcitabine was ensured in whole blood and plasma as well as stability of THU in solutions. The UPLC-MS/MS method developed was successfully validated and can be applied for gemcitabine bioanalysis in clinical studies. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Mano, Yuji; Hotta, Koichiro; Kusano, Kazutomi] Eisai & Co Ltd, Anal Grp, Tsukuba Div, Tsukuba, Ibaraki 3002635, Japan; [Sakamaki, Kenji; Ueno, Takuya; Kita, Kenji; Ishii, Takuho] Sunplanet Co Ltd, Tsukuba Div, Anal Grp, Tsukuba, Ibaraki 3002635, Japan	Mano, Y (reprint author), Eisai & Co Ltd, Biopharmaceut Assessment Core Funct Unit, Drug Metab & Pharmacokinet, 3-1 5-Chome, Tsukuba, Ibaraki 3002635, Japan.	y2-mano@hhc.eisai.co.jp					ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491; Pucci V, 2009, J PHARMACEUT BIOMED, V50, P867, DOI 10.1016/j.jpba.2009.05.037; Little JL, 2006, J CHROMATOGR B, V833, P219, DOI 10.1016/j.jchromb.2006.02.011; Bowen C, 2009, J CHROMATOGR B, V877, P2123, DOI 10.1016/j.jchromb.2009.06.002; Hui YF, 1997, AM J HEALTH-SYST PH, V54, P162; Kirstein MN, 2006, J CHROMATOGR B, V835, P136, DOI 10.1016/j.jchromb.2006.03.023; Liu YH, 2008, TALANTA, V77, P412, DOI 10.1016/j.talanta.2008.07.004; Marangon E, 2008, J MASS SPECTROM, V43, P216, DOI 10.1602/jms.1293; Pisano R, 2005, J PHARMACEUT BIOMED, V38, P738, DOI 10.1016/j.jpba.2005.01.039; Wang LZ, 2003, THER DRUG MONIT, V25, P552, DOI 10.1097/00007691-200310000-00003	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-3879	1099-0801		BIOMED CHROMATOGR	Biomed. Chromatogr.	SEP	2015	29	9					1343	1349		10.1002/bmc.3429		7	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	CP4OJ	WOS:000359861400008		
J	Mano, Y; Asakawa, Y; Kita, K; Ishii, T; Hotta, K; Kusano, K				Mano, Yuji; Asakawa, Yoshiki; Kita, Kenji; Ishii, Takuho; Hotta, Koichiro; Kusano, Kazutomi			Validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of flecainide in human plasma and its clinical application	BIOMEDICAL CHROMATOGRAPHY			English	Article						UPLC-MS; MS; flecainide; validation; ISR; hemolysis	SUPRAVENTRICULAR TACHYCARDIA; SERUM FLECAINIDE; CHILDREN; THERAPY	A simple and reproducible bioanalytical method for the determination of flecainide in human plasma was developed and validated using an ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS) to obtain higher sensitivity than the current available methods. After simple protein precipitation, flecainide and a stable isotope-labeled internal standard (IS) were chromatographed on an Acquity UPLC BEH C-18 column (2.1 x 100 mm, 1.7 mu m) with isocratic elution of mobile phase consisting of 45% methanol containing 0.1% formic acid at a flow rate 0.25 mL/min. Detection was performed in positive electrospray ionization by monitoring the selected ion transitions at m/z 415.4/301.1 for flecainide and m/z 419.4/305.1 for the IS. The method was validated according to current bioanalytical method validation guidelines. The calibration standard curve was linear from 2.5 to 1000 ng/mL using 0.1 mL of plasma. No significant interferences were detected in blank human plasma. Accuracy and precision in the intra- and inter-batch reproducibility study were within acceptance criteria. Neither hemolysis effects nor matrix effects were observed. The UPLC-MS/MS method developed was successfully applied to determine plasma flecainide concentrations to support clinical studies and incurred sample reanalysis also ensured the reproducibility of the method. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Mano, Yuji; Hotta, Koichiro; Kusano, Kazutomi] Eisai & Co Ltd, Biopharmaceut Assessment Core Funct Unit, Drug Metab & Pharmacokinet, Tsukuba, Ibaraki 3002635, Japan; [Asakawa, Yoshiki; Kita, Kenji; Ishii, Takuho] Sunplanet Co Ltd, Tsukuba Div, Anal Grp, Tsukuba, Ibaraki 3002635, Japan	Mano, Y (reprint author), Eisai & Co Ltd, Biopharmaceut Assessment Core Funct Unit, Drug Metab & Pharmacokinet, 1-3 5-Chome, Tsukuba, Ibaraki 3002635, Japan.	y2-mano@hhc.eisai.co.jp					FENRICH AL, 1995, J AM COLL CARDIOL, V25, P1195, DOI 10.1016/0735-1097(94)00513-P; Breindahl T, 2000, J CHROMATOGR B, V746, P249, DOI 10.1016/S0378-4347(00)00343-1; Doki K, 2004, J PHARMACEUT BIOMED, V35, P1307, DOI 10.1016/j.jpba.2004.04.009; FISCHER C, 1992, THER DRUG MONIT, V14, P433, DOI 10.1097/00007691-199210000-00015; Nakagawa R, 2002, J PHARMACEUT BIOMED, V30, P171, DOI 10.1016/S0731-7085(02)00224-8; Price JF, 2002, J AM COLL CARDIOL, V39, P517, DOI 10.1016/S0735-1097(01)01773-9; Sohns C, 2014, CARDIOVASC THER, V32, P7, DOI 10.1111/1755-5922.12052; Takada M, 2005, J CLIN PHARM THER, V30, P5, DOI 10.1111/j.1365-2710.2004.00612.x; WARD DE, 1986, AM J CARDIOL, V57, P787, DOI 10.1016/0002-9149(86)90614-4; WREN C, 1987, BRIT HEART J, V57, P171; ZEIGLER V, 1988, AM J CARDIOL, V62, pD41	11	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-3879	1099-0801		BIOMED CHROMATOGR	Biomed. Chromatogr.	SEP	2015	29	9					1399	1405		10.1002/bmc.3437		7	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	CP4OJ	WOS:000359861400016		
J	Hara, S; Uchiyama, M; Yoshinari, M; Matsumoto, T; Jimi, S; Togawa, A; Takata, T; Takamatsu, Y				Hara, Shuuji; Uchiyama, Masanobu; Yoshinari, Masami; Matsumoto, Taichi; Jimi, Shiro; Togawa, Atsushi; Takata, Tohru; Takamatsu, Yasushi			A simple high-performance liquid chromatography for the determination of linezolid in human plasma and saliva	BIOMEDICAL CHROMATOGRAPHY			English	Article						linezolid; HPLC-UV; plasma; saliva; therapeutic drug monitoring	HUMAN SERUM; VALIDATION; SAFETY	Linezolid is an antimicrobial agent for the treatment of multiresistant Gram-positive infections. A practical high-performance liquid chromatography method was developed for the determination of linezolid in human plasma and saliva. Linezolid and an internal standard (o-ethoxybenzamide) were extracted from plasma and saliva with ethyl acetate and analyzed on a Capcell Pak C-18 MG column with UV detection at 254nm. The calibration curve was linear through the range 0.5-50 mu g/mL using a 200L sample volume. The intra- and interday precisions were all <6.44% for plasma and 5.60% for saliva. The accuracies ranged from 98.8 to 110% for both matrices. The mean recoveries of linezolid were 80.8% for plasma and 79.0% for saliva. This method was used to determine the plasma and saliva concentrations of linezolid in healthy volunteers who were orally administered a 600mg dose of linezolid. Our liquid-liquid extraction procedure is easy and requires a small volume of plasma or saliva (200L). This small volume can be advantageous in clinical pharmacokinetic studies, especially if children participate. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Hara, Shuuji; Yoshinari, Masami; Matsumoto, Taichi] Fukuoka Univ, Fac Pharmaceut Sci, Fukuoka 8140180, Japan; [Uchiyama, Masanobu] Fukuoka Univ Hosp, Dept Pharm, Fukuoka, Japan; [Jimi, Shiro] Fukuoka Univ, Dept Med, Cent Lab Pathol & Morphol, Fukuoka 8140180, Japan; [Togawa, Atsushi; Takata, Tohru; Takamatsu, Yasushi] Fukuoka Univ, Dept Med, Div Med Oncol Hematol & Infect Dis, Fukuoka 8140180, Japan	Hara, S (reprint author), Fukuoka Univ, Fac Pharmaceut Sci, 8-19-1 Jonan Ku, Fukuoka 8140180, Japan.	harashu@fukuoka-u.ac.jp					Bolhuis MS, 2013, ANTIMICROB AGENTS CH, V57, P3676, DOI 10.1128/AAC.00558-13; Pea F, 2012, J ANTIMICROB CHEMOTH, V67, P2034, DOI 10.1093/jac/dks153; Pea F, 2010, ANTIMICROB AGENTS CH, V54, P4605, DOI 10.1128/AAC.00177-10; Cattaneo D, 2013, INT J ANTIMICROB AG, V41, P586, DOI 10.1016/j.ijantimicag.2013.02.020; Cios A, 2013, ACTA POL PHARM, V70, P631; Fortuna S, 2013, BIOMED CHROMATOGR, V27, P1489, DOI 10.1002/bmc.2947; Kitahashi T, 2002, J PHARMACEUT BIOMED, V30, P1411, DOI 10.1016/S0731-7085(02)00475-2; lasMarca G, 2012, J PHARMACEUT BIOMED, V67-68, P86; Ross LE, 2011, J CHEMOTHERAPY, V23, P71; Traunmuller F, 2010, J CHROMATOGR SCI, V48, P325; Vinh DC, 2009, J INFECTION, V59, pS59, DOI 10.1016/S0163-4453(09)60009-8; Zander J, 2014, CLIN CHEM LAB MED, V52, P381, DOI 10.1515/cclm-2013-0594	12	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-3879	1099-0801		BIOMED CHROMATOGR	Biomed. Chromatogr.	SEP	2015	29	9					1428	1431		10.1002/bmc.3441		4	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	CP4OJ	WOS:000359861400020		
J	Tashima, T				Tashima, Toshihiko			The structural use of carbostyril in physiologically active substances	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Carbostyril; 2-Quinolinone; 2-Quinolone; Drug design; Building block; Scaffold; Fragment	BIOLOGICAL EVALUATION; DRUG DISCOVERY; INHIBITORS; DERIVATIVES; DESIGN; GLANCE; 3,4-DIHYDROQUINOLIN-2(1H)-ONE; TANKYRASES; OXIDE; PDK1	Carbostyril (2-quinolinone, 2-quinolone) is an important structural component frequently used in natural products and in physiologically active substances including drugs. It is a 2-ring condensed heterocyclic compound containing several positions that can be replaced by arbitrary substituent groups and is used as a chemical building block, scaffold, fragment, and pharmacophore in drug design or discovery. Since the number of compounds that can be designed using carbostyril is exceedingly large, the steric structures of carbostyril derivatives can be adjusted to the unique, spatially oriented shape of, for example, the active sites of pharmaceutical target molecules. Moreover, the internal amide of the carbostyril unit exhibits distinctive features because of the fixed cis form of the lactam amide group. Because carbostyril has been used as a component in drugs and other bioactive compounds over time, carbostyril derivatives may improve absorption, distribution, metabolism, excretion, and toxicity (ADMET). Therefore, carbostyril derivatives have enormous potential. In this review, the potential and advantages of the use of carbostyril and its related molecular skeletons, such as 3,4-dihydrocarbostyril, are discussed by focusing on the physiologically active substances in which they are incorporated. (C) 2015 Elsevier Ltd. All rights reserved.	Nippon Pharmaceut Chem Co Ltd, Higashiosaka, Osaka 5770056, Japan	Tashima, T (reprint author), Nippon Pharmaceut Chem Co Ltd, 2-8-18 Chodo, Higashiosaka, Osaka 5770056, Japan.	t-tashima@nichiri.co.jp					Shaw PE, 2002, EMBO REP, V3, P521, DOI 10.1093/embo-reports/kvf118; O'Brien NJ, 2014, BIOORGAN MED CHEM, V22, P3781, DOI 10.1016/j.bmc.2014.04.037; [Anonymous], 1998, ANGEW CHEM INT EDIT, DOI DOI 10.1002/(SICI)1521-3773(19980316)37:5<576::AID-ANIE576>3.0.CO;2-L; Larsson EA, 2013, J MED CHEM, V56, P4497, DOI 10.1021/jm400211f; Acker TM, 2013, J MED CHEM, V56, P6434, DOI 10.1021/jm400652r; Lehtio L, 2013, FEBS J, V280, P3576, DOI 10.1111/febs.12320; BURGI HB, 1974, TETRAHEDRON, V30, P1563, DOI 10.1016/S0040-4020(01)90678-7; Hinderaker MP, 2003, PROTEIN SCI, V12, P1188, DOI 10.1110/ps.0241903; Sessa WC, 2004, J CELL SCI, V117, P2427, DOI 10.1242/jcs.01165; Naik M, 2014, J MED CHEM, V57, P5419, DOI 10.1021/jm5005978; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Wyllie DJA, 2013, NEUROPHARMACOLOGY, V74, P4, DOI 10.1016/j.neuropharm.2013.01.016; Mungrue IN, 2004, J CELL SCI, V117, P2627, DOI 10.1242/jcs.01187; Ekici OD, 2008, PROTEIN SCI, V17, P2023, DOI 10.1110/ps.035436.108; Lowenstein CJ, 2004, J CELL SCI, V117, P2865, DOI 10.1042/jcs.01166; Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a; Chen IL, 2013, EUR J MED CHEM, V59, P227, DOI 10.1016/j.ejmech.2012.11.016; Kalkhambkar RG, 2008, EUR J MED CHEM, V43, P2178, DOI 10.1016/j.ejmech.2007.08.007; Kraus JM, 2010, J MED CHEM, V53, P3887, DOI 10.1021/jm9013136; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Meiring L, 2013, BIOORG MED CHEM LETT, V23, P5498, DOI 10.1016/j.bmcl.2013.08.071; OCHIAI E, 1948, YAKUGAKU ZASSHI, V68, P88; Ochiai E., 1955, YAKUGAKU ZASSHI, V75, P213; Ochiai E., 1947, YAKUGAKU ZASSHI, V67, P87; OCHIAI E, 1948, YAKUGAKU ZASSHI, V68, P109; Ochiai E., 1956, YAKUGAKU ZASSHI, V76, P1421; Priya N, 2010, BIOORGAN MED CHEM, V18, P4085, DOI 10.1016/j.bmc.2010.04.011; Ramnauth J, 2011, J MED CHEM, V54, P5562, DOI 10.1021/jm200648s; Riordan JF, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-225; SCHWARTZMAN L. H., 1950, JOUR ORGANIC CHEM, V15, P517, DOI 10.1021/jo01149a011; SMITH JN, 1954, BIOCHEM J, V56, P325; Tashima T, 2014, BIOORGAN MED CHEM, V22, P3720, DOI 10.1016/j.bmc.2014.05.001	32	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	SEP 1	2015	25	17					3415	3419		10.1016/j.bmcl.2015.06.027		5	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CN9XD	WOS:000358802900002		
J	Takeuchi, J; Ohnishi, T; Okamoto, M; Todoroki, Y				Takeuchi, Jun; Ohnishi, Toshiyuki; Okamoto, Masanori; Todoroki, Yasushi			The selectivity of 6-nor-ABA and 7 '-nor-ABA for abscisic acid receptor subtypes	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Abscisic acid; PYR/PYL/RCAR receptor; Agonist	ABA-INDEPENDENT INHIBITION; MOLECULAR-BASIS; PYL PROTEINS; COMPLEX; FAMILY	Abscisic acid (ABA), a plant hormone, is involved in many plant development processes and environmental stress responses that are regulated by a Pyrabactin Resistant 1 (PYR)/Pyrabactin Resistant-Like (PYL)/Regulatory Component of ABA Receptor (RCAR) receptor protein-mediated signal transduction pathway. In Arabidopsis thaliana, PYL proteins constitute a 14-member family comprising two distinct subclasses: dimeric receptors (PYR1 and PYL1-PYL3) and monomeric receptors (PYL4-PYL13). The individual contributions of PYL subclasses/subtypes with specific physiological actions are still poorly understood; consequently, the development of PYL subclass/subtype-selective agonists should be useful to reveal the different functions of these receptors. In this study, we focused on the ABA analogs 6-norABA and 70-nor-ABA, which were expected to function as monomeric receptor-selective agonists on the basis of crystal structures of PYL-ABA complexes and sequence alignments of PYL subtypes. In a protein phosphatase 2C (PP2C) assay, the agonist activities of both analogs were lower than those of ABA toward all tested PYL proteins, regardless of subclass/subtype. Nevertheless, we found that 6-nor-ABA acts as a selective agonist at the physiological level: it induced stomatal closure but did not inhibit seed germination and root growth. On the basis of observed inhibitory activity against PP2C among different PYL subtypes, this biological effect of 6-nor-ABA may be attributed to the activity of that agonist on PYL5 and/or PYL6. (C) 2015 Elsevier Ltd. All rights reserved.	[Takeuchi, Jun; Ohnishi, Toshiyuki; Todoroki, Yasushi] Shizuoka Univ, Grad Sch Agr, Suruga Ku, Shizuoka 4228529, Japan; [Ohnishi, Toshiyuki; Todoroki, Yasushi] Shizuoka Univ, Res Inst Green Sci & Technol, Suruga Ku, Shizuoka 4228529, Japan; [Okamoto, Masanori] Tottori Univ, Arid Land Res Ctr, Tottori 6800001, Japan; [Todoroki, Yasushi] Shizuoka Univ, Grad Sch Sci & Technol, Suruga Ku, Shizuoka 4228529, Japan	Todoroki, Y (reprint author), Shizuoka Univ, Grad Sch Agr, Suruga Ku, 836 Ohya, Shizuoka 4228529, Japan.	todoroki.yasushi@shizuoka.ac.jp	Okamoto, Masanori/G-9503-2013				Santiago J, 2009, PLANT J, V60, P575, DOI 10.1111/j.1365-313X.2009.03981.x; Melcher K, 2009, NATURE, V462, P602, DOI 10.1038/nature08613; Hao Q, 2011, MOL CELL, V42, P662, DOI 10.1016/j.molcel.2011.05.011; Miyazono K, 2009, NATURE, V462, P609, DOI 10.1038/nature08583; Gonzalez-Guzman M, 2012, PLANT CELL, V24, P2483, DOI 10.1105/tpc.112.098574; Yin P, 2009, NAT STRUCT MOL BIOL, V16, P1230, DOI 10.1038/nsmb.1730; Ma Y, 2009, SCIENCE, V324, P1064, DOI 10.1126/science.1172408; Santiago J, 2012, PLANT SCI, V182, P3, DOI 10.1016/j.plantsci.2010.11.014; Park SY, 2009, SCIENCE, V324, P1068, DOI 10.1126/science.1173041; Takeuchi J, 2014, NAT CHEM BIOL, V10, P477, DOI [10.1038/nchembio.1524, 10.1038/NCHEMBIO.1524]; Dupeux F, 2011, EMBO J, V30, P4171, DOI 10.1038/emboj.2011.294; Cutler SR, 2010, ANNU REV PLANT BIOL, V61, P651, DOI 10.1146/annurev-arplant-042809-112122; Fuchs S, 2014, P NATL ACAD SCI USA, V111, P5741, DOI 10.1073/pnas.1322085111; Shing TKM, 2006, ORG LETT, V8, P3149, DOI 10.1021/ol0612298; Okamoto M, 2013, P NATL ACAD SCI USA, V110, P12132, DOI 10.1073/pnas.1305919110; Zhao Y, 2013, CELL RES, V23, P1380, DOI 10.1038/cr.2013.149; Cao MJ, 2013, CELL RES, V23, P1043, DOI 10.1038/cr.2013.95; Merlot S, 2002, PLANT J, V30, P601, DOI 10.1046/j.1365-313X.2002.01322.x; Antoni R., 2012, PLANT PHYSIOL, V161, P931; Cossy J, 2001, TETRAHEDRON, V57, P5173, DOI 10.1016/S0040-4020(01)00357-X; Benson CL, 2015, PHYTOCHEMISTRY, V113, P96, DOI 10.1016/j.phytochem.2014.03.017; Finkelstein Ruth, 2013, Arabidopsis Book, V11, pe0166, DOI 10.1199/tab.0166; Li WQ, 2013, CELL RES, V23, P1369, DOI 10.1038/cr.2013.143; NANZYO M, 1977, AGR BIOL CHEM TOKYO, V41, P1711; Sun DM, 2012, BIOCHEM BIOPH RES CO, V418, P122, DOI 10.1016/j.bbrc.2011.12.145; Todoroki Y., 2002, STUDIES NATURAL PROD, V27, P321; Ueno K, 2005, BIOORGAN MED CHEM, V13, P3359, DOI 10.1016/j.bmc.2005.03.015; Winska K, 2010, TETRAHEDRON-ASYMMETR, V21, P670, DOI 10.1016/j.tetasy.2010.02.031	28	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	SEP 1	2015	25	17					3507	3510		10.1016/j.bmcl.2015.06.088		4	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CN9XD	WOS:000358802900017		
J	Yoneyama, T; Arai, MA; Sadhu, SK; Ahmed, F; Ishibashi, M				Yoneyama, Tatsuro; Arai, Midori A.; Sadhu, Samir K.; Ahmed, Firoj; Ishibashi, Masami			Hedgehog inhibitors from Withania somnifera	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Hedgehog signaling pathway; Inhibitor; Natural product; Withania somnifera	MEDIATED TRANSCRIPTIONAL INHIBITORS; SMALL-MOLECULE INHIBITORS; SIGNALING PATHWAY; WITHAFERIN; WITHANOLIDES; CONSTITUENTS; CYCLOPAMINE; BLOCKS; DUN	The hedgehog (Hh) signaling pathway performs an important role in embryonic development and in cellular proliferation and differentiation. However, aberrant activation of the Hh signaling pathway is associated with tumorigenesis. Hh signal inhibition was evaluated using a cell-based assay system that targets GLI1-mediated transcription. Activity-guided isolation of the Withania somnifera MeOH extract led to the isolation of six compounds: withaferin A (1) and its derivatives (2-6). Compounds 1 and 2 showed strong inhibition of Hh/GLI1-mediated transcriptional activity with IC50 values of 0.5 and 0.6 mu M, respectively. Compounds 1, 2, 3, and 6 were cytotoxic toward human pancreatic (PANC-1), prostate (DU145) and breast (MCF7) cancer cells. Furthermore, 1 also inhibited GLI1-DNA complex formation in EMSA. (C) 2015 Elsevier Ltd. All rights reserved.	[Yoneyama, Tatsuro; Arai, Midori A.; Ishibashi, Masami] Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan; [Sadhu, Samir K.] Khulna Univ, Sch Life Sci, Pharm Discipline, Khulna 9208, Bangladesh; [Ahmed, Firoj] Univ Dhaka, Dept Pharmaceut Chem, Dhaka 1000, Bangladesh	Arai, MA (reprint author), Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2608675, Japan.	midori_arai@chiba-u.jp; mish@chiba-u.jp	Ishibashi, Masami /E-5328-2015; Arai, Midori/O-4613-2015	Ishibashi, Masami /0000-0002-2839-1045; 	JSPS [26305001, 26293022, 25670045]; MEXT [23102008]	We are very grateful to Drs. Fritz Aberger and Gerhard Regl (University of Salzburg) for providing us with tetracycline-regulated HaCaT cells, Dr. Rune Toftgard (Karolinska Institute) for the 12GLI-RE-TKO luciferase plasmid, Dr. Bert Vogelstein (Howard Hughes Medical Institute) and Dr. Hiroshi Sasaki (RIKEN) for the human GLI1 plasmid. This study was supported by KAKENHI Grant Numbers 26305001, 26293022, and 25670045 from JSPS, and 23102008 from MEXT (a Grant-in-Aid for Scientific Research on Innovative Areras in 'Chemical Biology of Natural Products').	Atwood SX, 2012, J CELL BIOL, V199, P193, DOI 10.1083/jcb.201207140; Svenda J, 2015, ANGEW CHEM INT EDIT, V54, P5596, DOI 10.1002/anie.201500112; Arai MA, 2013, MOL BIOSYST, V9, P1012, DOI 10.1039/c3mb25567k; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Stanton BZ, 2009, NAT CHEM BIOL, V5, P154, DOI 10.1038/nchembio.142; Williams JA, 2003, P NATL ACAD SCI USA, V100, P4616, DOI 10.1073/pnas.0732813100; LAVIE D, 1965, J ORG CHEM, V30, P1774, DOI 10.1021/jo01017a015; Arai MA, 2008, BIOORGAN MED CHEM, V16, P9420, DOI 10.1016/j.bmc.2008.09.053; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; KIRSON I, 1970, TETRAHEDRON, V26, P2209, DOI 10.1016/S0040-4020(01)92800-5; Incardona JP, 1998, DEVELOPMENT, V125, P3553; Petrova E, 2013, NAT CHEM BIOL, V9, P247, DOI [10.1038/nchembio.1184, 10.1038/NCHEMBIO.1184]; Petrova R, 2014, DEVELOPMENT, V141, P3445, DOI 10.1242/dev.083691; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Rifai Y, 2010, J NAT PROD, V73, P995, DOI 10.1021/np1000818; Firestone AJ, 2012, NATURE, V484, P125, DOI 10.1038/nature10936; Arai MA, 2011, ORG BIOMOL CHEM, V9, P1133, DOI 10.1039/c0ob00677g; Zhang HP, 2011, J NAT PROD, V74, P2532, DOI 10.1021/np200635r; Xu YM, 2009, BIOORGAN MED CHEM, V17, P2210, DOI 10.1016/j.bmc.2008.10.091; Rifai Y, 2011, BIOORG MED CHEM LETT, V21, P718, DOI 10.1016/j.bmcl.2010.11.126; KUPCHAN SM, 1969, J ORG CHEM, V34, P3858, DOI 10.1021/jo01264a027; Hosoya T, 2008, CHEMBIOCHEM, V9, P1082, DOI 10.1002/cbic.200700511; Arai MA, 2014, BEILSTEIN J ORG CHEM, V10, P134, DOI 10.3762/bjoc.10.10; Li YW, 2012, EXPERT OPIN THER TAR, V16, P49, DOI 10.1517/14728222.2011.617367; Mishra L C, 2000, Altern Med Rev, V5, P334; NITTALA SS, 1981, PHYTOCHEMISTRY, V20, P2735, DOI 10.1016/0031-9422(81)85277-6; Pasca di Magliano M, 2003, NAT REV CANCER, V3, P903, DOI DOI 10.1038/NRC1229; Trinh TN, 2014, MEDCHEMCOMM, V5, P117, DOI 10.1039/c3md00334e	28	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	SEP 1	2015	25	17					3541	3544		10.1016/j.bmcl.2015.06.081		4	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CN9XD	WOS:000358802900024		
J	Hayashi, J; Hamada, T; Sasaki, I; Nakagawa, O; Wada, S; Urata, H				Hayashi, Junsuke; Hamada, Tomoko; Sasaki, Ikumi; Nakagawa, Osamu; Wada, Shun-ichi; Urata, Hidehito			Synthesis of novel cationic spermine-conjugated phosphotriester oligonucleotide for improvement of cell membrane permeability	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Cationic oligonucleotide; Phosphotriester; Spermine; Cellular uptake	OLIGODEOXYRIBONUCLEOTIDE ETHYL PHOSPHOTRIESTERS; TRANSFER RIBONUCLEIC-ACID; ALKYL PHOSPHOTRIESTERS; COMPLEX-FORMATION; HYBRIDIZATION; DINUCLEOTIDES	A spermine-conjugated ethyl phosphotriester oligonucleotide was obtained by solid-phase synthesis based on phosphoramidite chemistry. The ethyl phosphotriester linkage was robust to exonuclease digestion and stable in fetal bovine serum. Cell membrane permeability of the spermine-conjugated ethyl phosphotriester oligonucleotide was studied by fluorescence experiments. The effective cell penetrating potency of the spermine-conjugated ethyl phosphotriester oligonucleotide was determined by confocal laser scanning microscopy and measurement of intracellular fluorescence intensity. (C) 2015 Elsevier Ltd. All rights reserved.	[Hayashi, Junsuke; Hamada, Tomoko; Sasaki, Ikumi; Nakagawa, Osamu; Wada, Shun-ichi; Urata, Hidehito] Osaka Univ Pharmaceut Sci, Takatsuki, Osaka 5691094, Japan	Urata, H (reprint author), Osaka Univ Pharmaceut Sci, 4-20-1 Nasahara, Takatsuki, Osaka 5691094, Japan.	urata@gly.oups.ac.jp					KUIJPERS WHA, 1990, NUCLEIC ACIDS RES, V18, P5197, DOI 10.1093/nar/18.17.5197; Voirin E, 2007, NAT PROTOC, V2, P1360, DOI 10.1038/nprot.2007.177; Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010; Pons B, 2006, CHEMBIOCHEM, V7, P1173, DOI 10.1002/cbic.200600178; Nothisen M, 2009, J AM CHEM SOC, V131, P17730, DOI 10.1021/ja908017e; HAYAKAWA Y, 1995, J ORG CHEM, V60, P925, DOI 10.1021/jo00109a024; Dias N, 2002, MOL CANCER THER, V1, P347; MILLER PS, 1971, J AM CHEM SOC, V93, P6657, DOI 10.1021/ja00753a054; Noir R, 2008, J AM CHEM SOC, V130, P13500, DOI 10.1021/ja804727a; BARRETT JC, 1974, BIOCHEMISTRY-US, V13, P4897, DOI 10.1021/bi00721a004; Bologna JC, 2002, ANTISENSE NUCLEIC A, V12, P33, DOI 10.1089/108729002753670247; Deglane G, 2006, CHEMBIOCHEM, V7, P684, DOI 10.1002/cbic.200500433; Fraley AW, 2006, J AM CHEM SOC, V128, P10763, DOI 10.1021/ja060873e; Jain M. L., 2011, CHEM REV, V112, P1284; Meade BR, 2014, NAT BIOTECHNOL, V32, P1256, DOI 10.1038/nbt.3078; Miller P. S., 1988, BIOCHEMISTRY-US, V13, P4887; MILLER PS, 1974, BIOCHEMISTRY-US, V13, P4887, DOI 10.1021/bi00721a003; Polushin NN, 2000, NUCLEIC ACIDS RES, V28, P3125, DOI 10.1093/nar/28.16.3125	18	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	SEP 1	2015	25	17					3610	3615		10.1016/j.bmcl.2015.06.071		6	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CN9XD	WOS:000358802900038		
J	Singh, SB; Kaelin, DE; Meinke, PT; Wu, J; Miesel, L; Tan, CM; Olsen, DB; Lagrutta, A; Fukuda, H; Kishii, R; Takei, M; Takeuchi, T; Takano, H; Ohata, K; Kurasaki, H; Nishimura, A; Shibata, T; Fukuda, Y				Singh, Sheo B.; Kaelin, David E.; Meinke, Peter T.; Wu, Jin; Miesel, Lynn; Tan, Christopher M.; Olsen, David B.; Lagrutta, Armando; Fukuda, Hideyuki; Kishii, Ryuta; Takei, Masaya; Takeuchi, Tomoko; Takano, Hisashi; Ohata, Kohei; Kurasaki, Haruaki; Nishimura, Akinori; Shibata, Takeshi; Fukuda, Yasumichi			Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5)	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Antibacterial; Broad-spectrum; Bacterial topoisomerase inhibitors; Gyrase inhibitors; ParC inhibitors	IIA TOPOISOMERASES; POTENT INHIBITORS; SAR; DERIVATIVES	Oxabicyclooctane linked novel bacterial topoisomerase inhibitors (NBTIs) are new class of recently reported broad-spectrum antibacterial agents. They target bacterial DNA gyrase and topoisomerase IV and bind to a site different than quinolones. They show no cross-resistance to known antibiotics and provide opportunity to combat drug-resistant bacteria. A structure activity relationship of the C-2 substituted ether analogs of 1,5-naphthyridine oxabicyclooctane-linked NBTIs are described. Synthesis and antibacterial activities of a total of 63 analogs have been summarized representing alkyl, cyclo alkyl, fluoro alkyl, hydroxy alkyl, amino alkyl, and carboxyl alkyl ethers. All compounds were tested against three key strains each of Gram-positive and Gram-negative bacteria as well as for hERG binding activities. Many key compounds were also tested for the functional hERG activity. Six compounds were evaluated for efficacy in a murine bacteremia model of Staphylococcus aureus infection. Significant tolerance for the ether substitution (including polar groups such as amino and carboxyl) at C-2 was observed for S. aureus activity however the same was not true for Enterococcus faecium and Gram-negative strains. Reduced c log D generally showed reduced hERG activity and improved in vivo efficacy but was generally associated with decreased overall potency. One of the best compounds was hydroxy propyl ether (16), which mainly retained the potency, spectrum and in vivo efficacy of AM8085 associated with the decreased hERG activity and improved physical property. (C) 2015 Elsevier Ltd. All rights reserved.	[Singh, Sheo B.; Kaelin, David E.; Meinke, Peter T.; Wu, Jin; Miesel, Lynn; Tan, Christopher M.] Merck Res Labs, Kenilworth, NJ 07033 USA; [Olsen, David B.; Lagrutta, Armando] Merck Res Labs, West Point, PA 19486 USA; [Fukuda, Hideyuki; Kishii, Ryuta; Takei, Masaya; Takeuchi, Tomoko; Takano, Hisashi; Ohata, Kohei; Kurasaki, Haruaki; Nishimura, Akinori; Shibata, Takeshi; Fukuda, Yasumichi] Kyorin Pharmaceut Co Ltd, Nogi, Tochigi 3290114, Japan	Singh, SB (reprint author), SBS Pharma Consulting LLC, Edison, NJ 08820 USA.	sheo.singh.215@gmail.com; yasumichi.fukuda@gmail.com					Miles TJ, 2013, BIOORG MED CHEM LETT, V23, P5437, DOI 10.1016/j.bmcl.2013.07.013; Ross JE, 2014, J CLIN MICROBIOL, V52, P2629, DOI 10.1128/JCM.00656-14; Black MT, 2008, ANTIMICROB AGENTS CH, V52, P3339, DOI 10.1128/AAC.00496-08; Mitton-Fry MJ, 2013, BIOORG MED CHEM LETT, V23, P2955, DOI 10.1016/j.bmcl.2013.03.047; Miles TJ, 2011, BIOORG MED CHEM LETT, V21, P7483, DOI 10.1016/j.bmcl.2011.09.114; Reck F, 2011, J MED CHEM, V54, P7834, DOI 10.1021/jm2008826; Gomez L, 2007, BIOORG MED CHEM LETT, V17, P2723, DOI 10.1016/j.bmcl.2007.03.003; Bax BD, 2010, NATURE, V466, P935, DOI 10.1038/nature09197; Reck F, 2012, J MED CHEM, V55, P6916, DOI 10.1021/jm300690s; Black MT, 2009, CURR OPIN INVEST DR, V10, P804; Singh SB, 2014, ACS MED CHEM LETT, V5, P609, DOI 10.1021/ml500069w; Miles TJ, 2011, BIOORG MED CHEM LETT, V21, P7489, DOI 10.1016/j.bmcl.2011.09.117; Wiener JJM, 2007, BIOORG MED CHEM LETT, V17, P2718, DOI 10.1016/j.bmcl.2007.03.004; Singh SB, 2015, BIOORG MED CHEM LETT, V25, P2409, DOI 10.1016/j.bmcl.2015.04.002; Singh SB, 2015, BIOORG MED CHEM LETT, V25, P1831, DOI 10.1016/j.bmcl.2015.03.044	15	2	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	SEP 1	2015	25	17					3630	3635		10.1016/j.bmcl.2015.06.061		6	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CN9XD	WOS:000358802900042		
J	Singh, SB; Kaelin, DE; Wu, J; Miesel, L; Tan, CM; Meinke, PT; Olsen, DB; Lagrutta, A; Wei, CQ; Liao, YG; Peng, XJ; Wang, X; Fukuda, H; Kishii, R; Takei, M; Yajima, M; Shibue, T; Shibata, T; Ohata, K; Nishimura, A; Fukuda, Y				Singh, Sheo B.; Kaelin, David E.; Wu, Jin; Miesel, Lynn; Tan, Christopher M.; Meinke, Peter T.; Olsen, David B.; Lagrutta, Armando; Wei, Changqing; Liao, Yonggang; Peng, Xuanjia; Wang, Xiu; Fukuda, Hideyuki; Kishii, Ryuta; Takei, Masaya; Yajima, Masanobu; Shibue, Taku; Shibata, Takeshi; Ohata, Kohei; Nishimura, Akinori; Fukuda, Yasumichi			Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6)	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Antibacterial; Broad-spectrum; Bacterial topoisomerase inhibitors; Gyrase inhibitors; ParC inhibitors	IIA TOPOISOMERASES; POTENT INHIBITORS; SAR; DERIVATIVES	Oxabicyclooctane linked 1,5-naphthyridinyl-pyridoxazinones are novel broad-spectrum bacterial topoisomerase inhibitors (NBTIs) targeting bacterial DNA gyrase and topoisomerase IV at a site different than quinolones. Due to lack of cross-resistance to known antibiotics they present excellent opportunity to combat drug-resistant bacteria. A structure activity relationship of the pyridoxazinone moiety is described in this Letter. Chemical synthesis and activities of NBTIs with substitutions at C-3, C-4 and C-7 of the pyridoxazinone moiety with halogens, alkyl groups and methoxy group has been described. In addition, substitutions of the linker NH proton and its transformation into amide analogs of AM-8085 and AM-8191 have been reported. Fluoro, chloro, and methyl groups at C-3 of the pyridoxazinone moiety retained the potency and spectrum. In addition, a C-3 fluoro analog showed 4-fold better oral efficacy (ED50 3.9 mg/kg) as compared to the parent AM-8085 in a murine bacteremia model of infection of Staphylococcus aureus. Even modest polarity (e.g., methoxy) is not tolerated at C-3 of the pyridoxazinone unit. The basicity and NH group of the linker is important for the activity when CH2 is at the linker position-8. However, amides (with linker position-8 ketone) with a position-7 NH or N-methyl group retained potency and spectrum suggesting that neither basicity nor hydrogen-donor properties of the linker amide NH is essential for the activity. This would suggest likely an altered binding mode of the linker position-7,8 amide containing compounds. The amides showed highly improved hERG (functional IC50 > 30 mu M) profile. (C) 2015 Elsevier Ltd. All rights reserved.	[Singh, Sheo B.; Kaelin, David E.; Wu, Jin; Miesel, Lynn; Tan, Christopher M.; Meinke, Peter T.] Merck Res Labs, Kenilworth, NJ 07033 USA; [Olsen, David B.; Lagrutta, Armando] Merck Res Labs, West Point, PA 19486 USA; [Wei, Changqing; Liao, Yonggang; Peng, Xuanjia; Wang, Xiu] WuXi AppTec, Shanghai, Peoples R China; [Fukuda, Hideyuki; Kishii, Ryuta; Takei, Masaya; Yajima, Masanobu; Shibue, Taku; Shibata, Takeshi; Ohata, Kohei; Nishimura, Akinori; Fukuda, Yasumichi] Kyorin Pharmaceut Co Ltd, Nogi, Tochigi 3290114, Japan	Singh, SB (reprint author), SBS Pharma Consulting LLC, Edison, NJ 08820 USA.	sheo.singh.215@gmail.com; yasumichi.fukuda@gmail.com					Miles TJ, 2013, BIOORG MED CHEM LETT, V23, P5437, DOI 10.1016/j.bmcl.2013.07.013; Ross JE, 2014, J CLIN MICROBIOL, V52, P2629, DOI 10.1128/JCM.00656-14; Black MT, 2008, ANTIMICROB AGENTS CH, V52, P3339, DOI 10.1128/AAC.00496-08; Mitton-Fry MJ, 2013, BIOORG MED CHEM LETT, V23, P2955, DOI 10.1016/j.bmcl.2013.03.047; Miles TJ, 2011, BIOORG MED CHEM LETT, V21, P7483, DOI 10.1016/j.bmcl.2011.09.114; Reck F, 2011, J MED CHEM, V54, P7834, DOI 10.1021/jm2008826; Gomez L, 2007, BIOORG MED CHEM LETT, V17, P2723, DOI 10.1016/j.bmcl.2007.03.003; Bax BD, 2010, NATURE, V466, P935, DOI 10.1038/nature09197; Reck F, 2012, J MED CHEM, V55, P6916, DOI 10.1021/jm300690s; Black MT, 2009, CURR OPIN INVEST DR, V10, P804; Singh SB, 2014, ACS MED CHEM LETT, V5, P609, DOI 10.1021/ml500069w; Miles TJ, 2011, BIOORG MED CHEM LETT, V21, P7489, DOI 10.1016/j.bmcl.2011.09.117; Wiener JJM, 2007, BIOORG MED CHEM LETT, V17, P2718, DOI 10.1016/j.bmcl.2007.03.004; Singh SB, 2015, BIOORG MED CHEM LETT, V25, P2409, DOI 10.1016/j.bmcl.2015.04.002; Singh SB, 2015, BIOORG MED CHEM LETT, V25, P1831, DOI 10.1016/j.bmcl.2015.03.044; Singh SB, 2015, BIOORG MED CHEM LETT, V25, P3630, DOI 10.1016/j.bmcl.2015.06.061; Singh SB, 2015, BIOORG MED CHEM LETT, V25, P2473, DOI 10.1016/j.bmcl.2015.04.063	17	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	SEP 1	2015	25	17					3636	3643		10.1016/j.bmcl.2015.06.057		8	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CN9XD	WOS:000358802900043		
J	Aoyama, H; Ijuin, R; Kato, JY; Urushiyama, S; Tetsuhashi, M; Hashimoto, Y; Yokomatsu, T				Aoyama, Hiroshi; Ijuin, Ryosuke; Kato, Jun-ya; Urushiyama, Sarasa; Tetsuhashi, Masashi; Hashimoto, Yuichi; Yokomatsu, Tsutomu			Discovery of non-competitive thrombin inhibitor derived from competitive tryptase inhibitor skeleton: Shift in molecular recognition resulted from skeletal conversion of carboxylate into phosphonate	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Serine protease; Thrombin; Tryptase; Aryl phosphonate ester; Non-competitive inhibitor	BLOOD-COAGULATION; CELL-DEATH; ESTERS; SPHINGOMYELINASE; APOPTOSIS	A novel series of terminal and internal phosphonate esters based on our previously developed aryl carboxylate- type tryptase selective inhibitor 1 was synthesized. The potency of these synthesized compounds was assessed in vitro with an enzyme inhibition assay using three available serine proteases, that is, tryptase, trypsin, and thrombin. The internal phosphonate derivative 6 showed potent thrombin inhibitory activity with an IC50 value of 1.0 mu M, whereas it exhibited no or only weak tryptase and trypsin inhibition at 10 mu M. The Lineweaver-Burk plot analysis indicates that the inhibition pattern of thrombin with 6 is non-competitive in spite of the fact that the lead carboxylate compound 1 is competitive inhibitor. Therefore, the skeletal conversion of the carboxylate into a phosphonate alters the mode of molecular recognition of these inhibitors by thrombin. (C) 2015 Elsevier Ltd. All rights reserved.	[Aoyama, Hiroshi; Ijuin, Ryosuke; Kato, Jun-ya; Urushiyama, Sarasa; Yokomatsu, Tsutomu] Tokyo Univ Pharm & Life Sci, Sch Pharm, Hachioji, Tokyo 1920392, Japan; [Tetsuhashi, Masashi; Hashimoto, Yuichi] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Aoyama, H (reprint author), Tokyo Univ Pharm & Life Sci, Sch Pharm, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.	aoyamahr@toyaku.ac.jp			Japan Society for the Promotion of Science (JSPS) [25460155]	The work described in this Letter was partially supported by JSPS Grant-in-Aid for Scientific Research (C) 25460155 from Japan Society for the Promotion of Science (JSPS).	Winiarski L, 2012, J MED CHEM, V55, P6541, DOI 10.1021/jm300599x; Kobayashi SD, 2005, ARCH IMMUNOL THER EX, V53, P505; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; Mansat V, 1997, FASEB J, V11, P695; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Jackson DS, 1998, J MED CHEM, V41, P2289, DOI 10.1021/jm970543s; Amin K, 2012, RESP MED, V106, P9, DOI 10.1016/j.rmed.2011.09.007; Pietrusewicz E, 2009, J ENZYM INHIB MED CH, V24, P1229, DOI 10.3109/14756360902781512; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Tanaka KA, 2009, ANESTH ANALG, V108, P1433, DOI 10.1213/ane.0b013e31819bcc9c; Audoly L., 2002, WO Patent, Patent No. [032422 A2, 032422]; Berg J.M., 2002, BIOCHEMISTRY; Bhargat S., 2007, J ORG CHEM, V72, P1263; Brown C. M., 2010, CHEM BIOL, V18, P48; Brown J. M., 2007, CLIN EXP ALLERGY, V38, P4; FREEMAN HJ, 1978, ANNU REV MED, V29, P99, DOI 10.1146/annurev.me.29.020178.000531; Jones P. A., 2009, WO Patent, Patent No. [106564 A2, 106564]; Tetsuhashi M, 2010, BIOORGAN MED CHEM, V18, P5323, DOI 10.1016/j.bmc.2010.05.037; Walker B, 2000, BIOCHEM BIOPH RES CO, V276, P1235, DOI 10.1006/bbrc.2000.3597; Yokomatsu T, 2001, BIOORG MED CHEM LETT, V11, P1277, DOI 10.1016/S0960-894X(01)00179-2; Yokomatsu T, 2003, BIOORG MED CHEM LETT, V13, P229, DOI 10.1016/S0960-894X(02)00888-0	21	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	SEP 1	2015	25	17					3676	3680		10.1016/j.bmcl.2015.06.039		5	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CN9XD	WOS:000358802900051		
J	Yamamoto, S; Fei, JH; Okochi, M; Shimizu, K; Yusa, A; Kondo, N; Iwata, H; Nakanishi, H; Honda, H				Yamamoto, Shuhei; Fei, Jiahui; Okochi, Mina; Shimizu, Kazunori; Yusa, Akiko; Kondo, Naoto; Iwata, Hiroji; Nakanishi, Hayao; Honda, Hiroyuki			Efficient capturing of circulating tumor cells using a magnetic capture column and a size-selective filter	BIOPROCESS AND BIOSYSTEMS ENGINEERING			English	Article						Circulating tumor cell; Cancer; Magnetic separation; Nanoparticles	BREAST-CANCER; GENE-EXPRESSION; PROSTATE-CANCER; CULTURE ARRAY; COLON-CANCER; FORCE; NANOPARTICLES; ERYTHROCYTES; SURFACE; MARKER	Detecting and analyzing circulating tumor cells (CTCs) in the blood of cancer patients is a promising approach for the early diagnosis of metastasis. Previously, we developed a size-selective filter for capturing CTCs, but its use was time consuming, particularly for capturing CTCs from large volumes of blood. In the present study, we describe the use of a magnetic capture column for rapid and efficient isolation of CTCs, which were magnetically labeled with magnetite cationic liposomes. In the capturing process, large volumes of blood containing magnetically labeled cancer cells were introduced into the column at a high flow rate to capture the cells, which were then added into the filter at a low flow rate. Our results show that the combined use of the column and filter decreased the required time for the spiked cancer cell capture, and the recovery rate of the spiked cancer cells from blood was significantly higher using the combination process (80.7 %) than that using the filter alone (64.7 %). Moreover, almost twice the number of CTCs could be captured from the blood of metastatic model mice using the combination process. These results suggest that the developed process would be useful for the rapid and efficient isolation of CTCs.	[Yamamoto, Shuhei; Fei, Jiahui; Shimizu, Kazunori; Honda, Hiroyuki] Nagoya Univ, Grad Sch Engn, Dept Biotechnol, Nagoya, Aichi 4648603, Japan; [Okochi, Mina] Tokyo Inst Technol, Grad Sch Sci & Engn, Dept Chem Engn, Tokyo 1528552, Japan; [Yusa, Akiko] Aichi Sci & Technol Fdn, Knowledge Hub Aichi, Prior Res Projects, Seto, Japan; [Yusa, Akiko; Nakanishi, Hayao] Aichi Canc Ctr Res Inst, Div Oncol Pathol, Nagoya, Aichi, Japan; [Kondo, Naoto; Iwata, Hiroji] Aichi Canc Ctr Cent Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan	Honda, H (reprint author), Nagoya Univ, Grad Sch Engn, Dept Biotechnol, Nagoya, Aichi 4648603, Japan.	honda@nubio.nagoya-u.ac.jp	Shimizu, Kazunori/B-7553-2008		AICHI priority research project, Japan [27-D-D7019]	This work was supported by AICHI priority research project (No. 27-D-D7019), Japan.	Al-Soud Waleed Abu, 2001, Journal of Clinical Microbiology, V39, P485, DOI 10.1128/JCM.39.2.485-493.2001; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Hosokawa M, 2010, ANAL CHEM, V82, P6629, DOI 10.1021/ac101222x; Shimizu K, 2007, J BIOMED MATER RES B, V82B, P471, DOI 10.1002/jbm.b.30752; Desitter I, 2011, ANTICANCER RES, V31, P427; Kang JH, 2012, LAB CHIP, V12, P2175, DOI 10.1039/c2lc40072c; Sieuwerts AM, 2009, J NATL CANCER I, V101, P61, DOI 10.1093/jnci/djn419; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Okochi M, 2013, BIOTECHNOL PROGR, V29, P135, DOI 10.1002/btpr.1642; Zhang Y, 2008, BIOMED MICRODEVICES, V10, P321, DOI 10.1007/s10544-007-9139-2; Thalgott M, 2013, J CANCER RES CLIN, V139, P755, DOI 10.1007/s00432-013-1377-5; Liu MC, 2009, J CLIN ONCOL, V27, P5153, DOI 10.1200/JCO.2008.20.6664; Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/S0046-8177(03)00502-1; Okochi M, 2009, LAB CHIP, V9, P3378, DOI 10.1039/b909304d; Vona G, 2000, AM J PATHOL, V156, P57, DOI 10.1016/S0002-9440(10)64706-2; WALL J, 1995, J CELL SCI, V108, P2673; Vona G, 2004, HEPATOLOGY, V39, P792, DOI 10.1002/hep.20091; Lu CY, 2013, BRIT J CANCER, V108, P791, DOI 10.1038/bjc.2012.595; Lucci A, 2012, LANCET ONCOL, V13, P688, DOI 10.1016/S1470-2045(12)70209-7; Shimizu K, 2007, J BIOSCI BIOENG, V103, P472, DOI 10.1263/jbb.103.472; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Krebs MG, 2012, J THORAC ONCOL, V7, P306, DOI 10.1097/JTO.0b013e31823c5c16; Bengtsson AM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-336; Chung J, 2012, ADV HEALTHC MATER, V1, P432, DOI 10.1002/adhm.201200046; Hosokawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067466; Imai Y, 2013, WORLD J GASTROENTERO, V19, P3957, DOI 10.3748/wjg.v19.i25.3957; Ino K, 2009, BIOTECHNOL BIOENG, V102, P882, DOI 10.1002/bit.22104; Ito H, 2010, J BIOSCI BIOENG, V109, P182, DOI 10.1016/j.jbiosc.2009.07.006; Kai H, 1996, AM J PHYSIOL-LUNG C, V271, pL484; Khazan N, 2013, NAT SCI, V5, P38; Nadal R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3180; Nakanishi H, 2003, CANCER SCI, V94, P112, DOI 10.1111/j.1349-7006.2003.tb01361.x; Okochi M, 2011, J BIOSCI BIOENG, V112, P635, DOI 10.1016/j.jbiosc.2011.08.003; Ozkumur E, 2013, SCI TRANSL MED, V5, P179, DOI DOI 10.1126/SCITRANSLMED.3005616; PASQUALE L, 1986, J GEN PHYSIOL, V88, P697, DOI 10.1085/jgp.88.6.697; Sandri MT, 2010, ANN SURG ONCOL, V17, P1539, DOI 10.1245/s10434-010-0918-2; Shimizu K, 2007, BIOTECHNOL BIOENG, V96, P803, DOI 10.1002/bit.21094; Takao M, 2011, CYTOM PART A, V79A, P107, DOI 10.1002/cyto.a.21014; Wu LY, 2012, PROSTATE, V72, P1532, DOI 10.1002/pros.22508; Yamamoto S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103502; Yusa A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088821	41	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1615-7591	1615-7605		BIOPROC BIOSYST ENG	Bioprocess. Biosyst. Eng.	SEP	2015	38	9					1693	1704		10.1007/s00449-015-1412-9		12	Biotechnology & Applied Microbiology; Engineering, Chemical	Biotechnology & Applied Microbiology; Engineering	CP2XK	WOS:000359740900007		
J	Li, J; Zhu, Y; Zhuang, LP; Otsuka, Y; Nakamura, M; Goodell, B; Sonoki, T; He, Z				Li, Jian; Zhu, Yuan; Zhuang, Liangpeng; Otsuka, Yuichiro; Nakamura, Masaya; Goodell, Barry; Sonoki, Tomonori; He, Zhen			A novel approach to recycle bacterial culture waste for fermentation reuse via a microbial fuel cell-membrane bioreactor system	BIOPROCESS AND BIOSYSTEMS ENGINEERING			English	Article						Wastewater reuse; Fermentation culture waste; Microbial fuel cell; Membrane bioreactor; 2-pyrone-4,6-dicarboxylic acid; Energy recovery	BIOELECTROCHEMICAL SYSTEMS; WATER TREATMENT; ACID PRODUCTION; PROTOCATECHUATE; RECOVERY; DEGRADATION; IMPROVEMENT; RESISTANCE; PUTIDA; LIGNIN	Biochemical production processes require water and nutrient resources for culture media preparation, but aqueous waste is generated after the target products are extracted. In this study, culture waste (including cells) produced from a lab-scale fermenter was fed into a microbial fuel cell-membrane bioreactor (MFC-MBR) system. Electrical energy was generated via the interaction between the microbial consortia and the solid electrode in the MFC. The treated wastewater was reclaimed in this process which was reused as a solvent and a nutrient source in subsequent fermentation. Polarization testing showed that the MFC produced a maximum current density of 37.53 A m(-3) with a maximum power density of 5.49 W m(-3). The MFC was able to generate 0.04 kWh of energy per cubic meter of culture waste treated. The lab-scale fermenters containing pure cultures of an engineered Pseudomonas spp. were used to generate 2-pyrone-4,6-dicarboxylic acid (PDC), a high value platform chemical. When the MFC-MBR-treated wastewater was used for the fermenter culture medium, a specific bacterial growth rate of 1.00 +/- A 0.05 h(-1) was obtained with a PDC production rate of 708.11 +/- A 64.70 mg PDC L-1 h(-1). Comparable values for controls using pure water were 0.95 +/- A 0.06 h(-1) and 621.01 +/- A 22.09 mg PDC L-1 h(-1) (P > 0.05), respectively. The results provide insight on a new approach for more sustainable bio-material production while at the same time generating energy, and suggest that the treated wastewater can be used as a solvent and a nutrient source for the fermentation production of high value platform chemicals.	[Li, Jian; He, Zhen] Virginia Polytech Inst & State Univ, Dept Civil & Environm Engn, Blacksburg, VA 24061 USA; [Zhu, Yuan; Zhuang, Liangpeng; Goodell, Barry] Virginia Polytech Inst & State Univ, Dept Sustainable Biomat, Blacksburg, VA 24061 USA; [Zhu, Yuan] Beijing Forestry Univ, MOE Key Lab Wooden Mat Sci & Applicat, Beijing 100083, Peoples R China; [Otsuka, Yuichiro; Nakamura, Masaya] Forestry & Forest Prod Res Inst, Tsukuba, Ibaraki 3058687, Japan; [Sonoki, Tomonori] Hirosaki Univ, Fac Agr & Life Sci, Dept Biochem & Mol Biol, Hirosaki, Aomori 0368561, Japan	Goodell, B (reprint author), Virginia Polytech Inst & State Univ, Dept Sustainable Biomat, Blacksburg, VA 24061 USA.	goodell@vt.edu; sonoki@hirosaki-u.ac.jp; zhenhe@vt.edu	He, Zhen/D-1275-2009	He, Zhen/0000-0001-6302-6556	Hirosaki University Grant for Exploratory Research by Young Scientists; USDA-Hatch Multistate project [S1041]; China Scholarship Council [201406510014]; National Science Foundation [1358145]	This work was supported in part by Hirosaki University Grant for Exploratory Research by Young Scientists, the USDA-Hatch Multistate project S1041, Scholarship from China Scholarship Council (#201406510014) and a grant from National Science Foundation (#1358145).	Ang WL, 2015, DESALINATION, V363, P2, DOI 10.1016/j.desal.2014.03.008; Asano T, 2004, WATER RES, V38, P1941, DOI 10.1016/J.watres.2004.01.023; Wang X, 2009, ENVIRON SCI TECHNOL, V43, P6870, DOI 10.1021/es900997w; Rosa PRF, 2014, BIORESOURCE TECHNOL, V161, P10, DOI 10.1016/j.biortech.2014.03.020; Arimi MM, 2015, BIOMASS BIOENERG, V75, P101, DOI 10.1016/j.biombioe.2015.02.011; He Z, 2006, ENVIRON SCI TECHNOL, V40, P5212, DOI 10.1021/es060394f; KATAYAMA Y, 1987, MOKUZAI GAKKAISHI, V33, P77; Otsuka Y, 2006, APPL MICROBIOL BIOT, V71, P608, DOI 10.1007/s00253-005-0203-7; Li WW, 2014, ENERG ENVIRON SCI, V7, P911, DOI 10.1039/c3ee43106a; Sheldon RA, 2014, GREEN CHEM, V16, P950, DOI 10.1039/c3gc41935e; Borole AP, 2011, BIOFUEL BIOPROD BIOR, V5, P28, DOI 10.1002/bbb.265; Passanha P, 2014, BIORESOURCE TECHNOL, V163, P287, DOI 10.1016/j.biortech.2014.04.068; Sun ZY, 2007, APPL MICROBIOL BIOT, V74, P69, DOI 10.1007/s00253-006-0655-4; Bunani S, 2015, DESALINATION, V364, P68, DOI 10.1016/j.desal.2014.07.030; Ge Z., 2013, ENV SCI TECHNOL LETT, V1, P137; Hughes MN, 1998, METALS MICROORGANISM; Kelly PT, 2014, BIORESOURCE TECHNOL, V153, P351, DOI 10.1016/j.biortech.2013.12.046; Matos C, 2014, SCI TOTAL ENVIRON, V493, P463, DOI 10.1016/j.scitotenv.2014.05.129; Mohsen MS, 2003, DESALINATION, V152, P281, DOI 10.1016/S0011-9164(02)01075-5; Nges IA, 2015, BIOCHEM ENG J, V94, P106, DOI 10.1016/j.bej.2014.11.023; Nozzi NE, 2014, METAB ENG, V25, P174, DOI 10.1016/j.ymben.2014.07.007; Qin MH, 2014, ENVIRON SCI TECH LET, V1, P437, DOI 10.1021/ez500280c; Sato O, 2014, J BIOSCI BIOENG, V119, P543; Smith AL, 2012, BIORESOURCE TECHNOL, V122, P149, DOI 10.1016/j.biortech.2012.04.055; Sonoki T, 2014, J BIOTECHNOL, V192, P71, DOI 10.1016/j.jbiotec.2014.10.027; Vardon DR, 2015, ENERG ENVIRON SCI, V8, P617, DOI [10.1039/c4ee03230f, 10.1039/C4EE03230F]; Wang CX, 2014, PROCESS BIOCHEM, V49, P1245, DOI 10.1016/j.procbio.2014.04.009; Xu K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100731; Yadav S, 2014, BIORESOURCE TECHNOL, V152, P377, DOI 10.1016/j.biortech.2013.11.022; Yan Q, 2014, BIOCHEM ENG J, V91, P92, DOI 10.1016/j.bej.2014.08.002; YANO K, 1980, J BACTERIOL, V143, P552	31	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1615-7591	1615-7605		BIOPROC BIOSYST ENG	Bioprocess. Biosyst. Eng.	SEP	2015	38	9					1795	1802		10.1007/s00449-015-1420-9		8	Biotechnology & Applied Microbiology; Engineering, Chemical	Biotechnology & Applied Microbiology; Engineering	CP2XK	WOS:000359740900017		
J	Nakagawa, Y; Takagi, K; Genjima, R; Koumoto, K				Nakagawa, Yuichi; Takagi, Kotomi; Genjima, Ryutaro; Koumoto, Kazuya			Significance of anionic functional group in betaine-type metabolite analogs on the facilitation of enzyme reactions	BIOPROCESS AND BIOSYSTEMS ENGINEERING			English	Article						Carboxybetaine; Cellular metabolite; Enzyme activation; Metabolite analog; Sulfobetaine	IONIC LIQUIDS; LACTATE-DEHYDROGENASE; ALPHA-GLUCOSIDASE; STABILIZATION; COMPATIBILITY; STABILITY; PROLINE; AGENTS; SUGARS	Using synthetic sulfobetaine library, the enzyme activation behavior has been investigated. Comparison of enzyme activation behavior revealed that sulfobetaines equally facilitate enzyme reactions, being consistent with that of carboxybetaines. The subsequent kinetic and solution property analyses clarified that both the kinetic parameter and hydration property changes are identical with those of carboxybetaines, indicating that the difference in the anionic functional group of the betaine structure scarcely affects the enzyme activation. On the other hand, comparison of carboxy- or sulfo-betaines with tetraalkylammonium salts, whose counteranion binds to the ammonium cation intermolecularly, revealed that the activation ability for enzymes of tetraalkylammonium salts is considerably smaller than that of carboxy- or sulfo-betaines. These findings give us a hint to design the useful betaine-type enzyme activators.	[Nakagawa, Yuichi; Takagi, Kotomi; Genjima, Ryutaro; Koumoto, Kazuya] Konan Univ, Dept Nanobiochem, FIRST, Chuo Ku, Kobe, Hyogo 6500047, Japan	Koumoto, K (reprint author), Konan Univ, Dept Nanobiochem, FIRST, Chuo Ku, 7-1-20 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	koumoto@center.konan-u.ac.jp			Noguchi Institute, Japan [NJ201005]	This work was supported in part by Grants-in-Aid for scientific research from the Noguchi Institute, Japan (NJ201005).	Totani K, 2008, J AM CHEM SOC, V130, P2101, DOI 10.1021/ja077570k; Wang AJ, 1996, BIOPHYS J, V71, P2117; BOWLUS RD, 1979, J EXP ZOOL, V208, P137, DOI 10.1002/jez.1402080202; Itoh T, 2006, CHEM-EUR J, V12, P9228, DOI 10.1002/chem.200601043; Yancey PH, 2005, J EXP BIOL, V208, P2819, DOI 10.1242/jeb.01730; Moniruzzaman M, 2010, BIOCHEM ENG J, V48, P295, DOI 10.1016/j.bej.2009.10.002; Rodrigues RC, 2013, CHEM SOC REV, V42, P6290, DOI 10.1039/c2cs35231a; Goldfeder M, 2014, APPL MICROBIOL BIOT, V98, P545, DOI 10.1007/s00253-013-5395-7; BROWN AD, 1972, J GEN MICROBIOL, V72, P589; CARPENTER JF, 1987, BIOCHIM BIOPHYS ACTA, V923, P109, DOI 10.1016/0304-4165(87)90133-4; Sola-Penna M, 1998, ARCH BIOCHEM BIOPHYS, V360, P10, DOI 10.1006/abbi.1998.0906; Arnold FH, 2010, DIRECTED ENZYME EVOL; Chiappe C, 2006, TETRAHEDRON LETT, V47, P5089, DOI 10.1016/j.tetlet.2006.05.072; Chilson OP, 2003, EUR J BIOCHEM, V270, P4823, DOI 10.1046/j.1432-1033.2003.03881.x; Deguchi E, 2011, BIOORGAN MED CHEM, V19, P3128, DOI 10.1016/j.bmc.2011.04.003; Kaftzik N, 2002, ORG PROCESS RES DEV, V6, P553, DOI 10.1021/op0255231; KouMoto K, 2008, TETRAHEDRON, V64, P168, DOI 10.1016/j.tet.2007.10.060; Lutz S, 2012, PROTEIN ENG HDB; Mejri M, 2001, CARBOHYD POLYM, V45, P161, DOI 10.1016/S0144-8617(00)00316-7; Nakagawa Y, 2014, TETRAHEDRON, V70, P5895, DOI 10.1016/j.tet.2014.06.028; Vasudevamurthy MK, 2008, BIOPOLYMERS, V91, P85; VUILLARD L, 1995, BIOCHEM J, V305, P337	22	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1615-7591	1615-7605		BIOPROC BIOSYST ENG	Bioprocess. Biosyst. Eng.	SEP	2015	38	9					1811	1817		10.1007/s00449-015-1422-7		7	Biotechnology & Applied Microbiology; Engineering, Chemical	Biotechnology & Applied Microbiology; Engineering	CP2XK	WOS:000359740900019		
J	Chihara, D; Asano, N; Ohmachi, K; Kinoshita, T; Okamoto, M; Maeda, Y; Mizuno, I; Matsue, K; Uchida, T; Nagai, H; Nishikori, M; Nakamura, S; Ogura, M; Suzuki, R				Chihara, Dai; Asano, Naoko; Ohmachi, Ken; Kinoshita, Tomohiro; Okamoto, Masataka; Maeda, Yoshinobu; Mizuno, Ishikazu; Matsue, Kosei; Uchida, Toshiki; Nagai, Hirokazu; Nishikori, Momoko; Nakamura, Shigeo; Ogura, Michinori; Suzuki, Ritsuro			Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan	BRITISH JOURNAL OF HAEMATOLOGY			English	Article						mantle cell lymphoma; MIPI; rituximab; prognostic factor	NON-HODGKINS-LYMPHOMA; GENE-EXPRESSION; RETROSPECTIVE ANALYSIS; UNITED-STATES; PHASE-II; INDEX; SURVIVAL; VALIDATION; SOX11; CYCLOPHOSPHAMIDE	Mantle cell lymphoma (MCL) is essentially incurable with conventional chemotherapy. The MCL International Prognostic Index (MIPI) is a validated specific prognostic index, but was derived from patients with advanced-stage disease primarily in the pre-rituximab era. We analysed 501 MCL patients (median age, 67years; range 22-90) treated with rituximab-containing chemotherapy, and evaluated the prognostic factors adjusted by the treatment. Five-year overall survival (OS) in the low, intermediate and high MIPI groups was 74%, 70% and 35%, respectively. Additional to MIPI risk factors, multivariate analysis revealed that low serum albumin and bone-marrow involvement were also significantly associated with a poor outcome. The revised-MIPI (R-MIPI) was constructed using six factors, namely age, performance status, white blood cell count, serum lactate dehydrogenase, bone-marrow involvement and serum albumin, which is divided into four prognostic groups. Five-year OS in low, low-intermediate (L-I), high-intermediate (H-I) and high R-MIPI groups was 92%, 75%, 61% and 19%, respectively. Hazard ratio for OS of L-I, H-I and high risk to low risk patients were 54, 83 and 330, respectively. R-MIPI, a new prognostic index with easy application to the general patient population, shows promise for identifying low- and high-risk MCL patients in the rituximab era.	[Chihara, Dai] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Chihara, Dai] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi 464, Japan; [Asano, Naoko; Nakamura, Shigeo] Nagoya Univ, Grad Sch Med, Dept Pathol, Nagoya, Aichi 4648601, Japan; [Asano, Naoko; Nakamura, Shigeo] Nagoya Univ, Grad Sch Med, Clin Labs, Nagoya, Aichi 4648601, Japan; [Ohmachi, Ken] Tokai Univ, Sch Med, Dept Haematol & Oncol, Isehara, Kanagawa 25911, Japan; [Kinoshita, Tomohiro] Aichi Canc Ctr Hosp, Dept Haematol & Cell Therapy, Nagoya, Aichi 464, Japan; [Okamoto, Masataka] Fujita Hlth Univ, Sch Med, Dept Haematol & Med Oncol, Toyoake, Aichi 47011, Japan; [Maeda, Yoshinobu] Okayama Univ, Dept Haematol & Oncol, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan; [Mizuno, Ishikazu] Hyogo Canc Ctr, Div Haematol, Dept Med, Akashi, Hyogo, Japan; [Matsue, Kosei] Kameda Med Ctr, Dept Haematol, Kamogawa, Japan; [Uchida, Toshiki] Nagoya Daini Red Cross Hosp, Dept Haematol & Oncol, Nagoya, Aichi, Japan; [Nagai, Hirokazu] Natl Hosp Org, Nagoya Med Ctr, Dept Haematol, Nagoya, Aichi, Japan; [Nishikori, Momoko] Kyoto Univ, Grad Sch Med, Dept Haematol & Oncol, Kyoto, Japan; [Ogura, Michinori] Suzuka Natl Hosp, Dept Haematol & Lab Med, Suzuka, Japan; [Suzuki, Ritsuro] Nagoya Univ, Grad Sch Med, Dept HSCT Data Management & Biostat, Nagoya, Aichi 4648601, Japan	Chihara, D (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dchihara-kob@umin.ac.jp	Nakamura, Shigeo/I-1571-2012				Abrahamsson A, 2014, BLOOD, V124, P1288, DOI 10.1182/blood-2014-03-559930; Kluin-Nelemans HC, 2012, NEW ENGL J MED, V367, P520, DOI 10.1056/NEJMoa1200920; Chihara D, 2014, BRIT J HAEMATOL, V164, P536, DOI 10.1111/bjh.12659; Navarro A, 2012, CANCER RES, V72, P5307, DOI 10.1158/0008-5472.CAN-12-1615; Romaguera JE, 2005, J CLIN ONCOL, V23, P7013, DOI 10.1200/JCO.2005.01.1825; Hartmann EM, 2010, BLOOD, V116, P953, DOI 10.1182/blood-2010-01-263806; Solal-Celigny P, 2004, BLOOD, V104, P1258, DOI 10.1182/blood-2003-12-4434; Nygren L, 2012, BLOOD, V119, P4215, DOI 10.1182/blood-2011-12-400580; Hoster E, 2014, J CLIN ONCOL, V32, P1338, DOI 10.1200/JCO.2013.52.2466; Sehn LH, 2007, BLOOD, V109, P1857, DOI 10.1182/blood-2006-08-038257; Morton LM, 2006, BLOOD, V107, P265, DOI 10.1182/blood-2005-06-2508; Ambinder AJ, 2013, CANCER-AM CANCER SOC, V119, P1570, DOI 10.1002/cncr.27898; Cheson BD, 1999, J CLIN ONCOL, V17, P1244; Iqbal J, 2012, BLOOD, V119, P4939, DOI 10.1182/blood-2011-07-370122; Romaguera JE, 2010, BRIT J HAEMATOL, V150, P200, DOI 10.1111/j.1365-2141.2010.08228.x; Federico M, 2009, J CLIN ONCOL, V27, P4555, DOI 10.1200/JCO.2008.21.3991; Orchard J, 2003, BLOOD, V101, P4975, DOI 10.1182/blood-2002-06-1864; Steyerberg EW, 2003, J CLIN EPIDEMIOL, V56, P441, DOI 10.1016/S0895-4356(03)00047-7; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; Fernandez V, 2010, CANCER RES, V70, P1408, DOI 10.1158/0008-5472.CAN-09-3419; SHIPP MA, 1993, NEW ENGL J MED, V329, P987; desJong D., 2007, J CLIN ONCOL, V25, P805; Eve HE, 2009, LEUKEMIA LYMPHOMA, V50, P1709, DOI [10.1080/10428190903186494, 10.3109/10428190903186494]; Hartmann E, 2008, J CLIN ONCOL, V26, P4966, DOI 10.1200/JCO.2007.12.0410; Hoster E, 2008, BLOOD, V111, P558, DOI 10.1182/blood-2007-06-095331; Katzenberger T, 2006, BLOOD, V107, P3407, DOI 10.1182/blood-2005-10-4079; Newson RB, 2010, STATA J, V10, P339; Nordstrom L, 2014, BRIT J HAEMATOL, V166, P98, DOI 10.1111/bjh.12854; Oki Y, 2008, CANCER SCI, V99, P179, DOI 10.1111/j.1349-7006.2007.00662.x; POLISSAR L, 1982, MED CARE, V20, P959, DOI 10.1097/00005650-198209000-00008; Salek D, 2014, LEUKEMIA LYMPHOMA, V55, P802, DOI 10.3109/10428194.2013.815349; Smith SD, 2010, AM J HEMATOL, V85, P454, DOI 10.1002/ajh.21705; Swerdlow S, 2008, WHO CLASSIFICATION T; van de Schans SAM, 2010, HAEMATOL-HEMATOL J, V95, P1503, DOI 10.3324/haematol.2009.021113; Vose Julie M, 2013, Am J Hematol, V88, P1082, DOI 10.1002/ajh.23615; Williams ME, 2013, HEMATOL-AM SOC HEMAT, P568	36	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1048	1365-2141		BRIT J HAEMATOL	Br. J. Haematol.	SEP	2015	170	5					657	668		10.1111/bjh.13486		12	Hematology	Hematology	CP0ZU	WOS:000359606400006		
J	Tiligada, E; Ishii, M; Riccardi, C; Spedding, M; Simon, HU; Teixeira, MM; Cuervo, MLC; Holgate, ST; Levi-Schaffer, F				Tiligada, Ekaterini; Ishii, Masaru; Riccardi, Carlo; Spedding, Michael; Simon, Hans-Uwe; Teixeira, Mauro Martins; Chovel Cuervo, Mario Landys; Holgate, Stephen T.; Levi-Schaffer, Francesca			The expanding role of immunopharmacology: IUPHAR Review 16	BRITISH JOURNAL OF PHARMACOLOGY			English	Review							HISTAMINE H-4 RECEPTOR; CONCISE GUIDE; DRUG TARGETS; THERAPEUTIC ANTIBODIES; INTERNATIONAL UNION; KINASE INHIBITORS; IN-VIVO; PHARMACOLOGY; IMMUNE; INFLAMMATION	Drugs targeting the immune system such as corticosteroids, antihistamines and immunosuppressants have been widely exploited in the treatment of inflammatory, allergic and autoimmune disorders during the second half of the 20th century. The recent advances in immunopharmacological research have made available new classes of clinically relevant drugs. These comprise protein kinase inhibitors and biologics, such as monoclonal antibodies, that selectively modulate the immune response not only in cancer and autoimmunity but also in a number of other human pathologies. Likewise, more effective vaccines utilizing novel antigens and adjuvants are valuable tools for the prevention of transmissible infectious diseases and for allergen-specific immunotherapy. Consequently, immunopharmacology is presently considered as one of the expanding fields of pharmacology. Immunopharmacology addresses the selective regulation of immune responses and aims to uncover and exploit beneficial therapeutic options for typical and non-typical immune system-driven unmet clinical needs. While in the near future a number of new agents will be introduced, improving the effectiveness and safety of those currently in use is imperative for all researchers and clinicians working in the fields of immunology, pharmacology and drug discovery. The newly formed ImmuPhar () is the Immunopharmacology Section of the International Union of Basic and Clinical Pharmacology (IUPHAR, ). ImmuPhar provides a unique international expert-lead platform that aims to dissect and promote the growing understanding of immune (patho)physiology. Moreover, it challenges the identification and validation of drug targets and lead candidates for the treatment of many forms of debilitating disorders, including, among others, cancer, allergies, autoimmune and metabolic diseases.	[Tiligada, Ekaterini] Univ Athens, Sch Med, Dept Pharmacol, GR-11527 Athens, Greece; [Tiligada, Ekaterini] Univ Athens, Sch Med, Attikon Gen Univ Hosp, Dept Dermatol & Venereol 2,Allergy Unit D Kaloger, GR-11527 Athens, Greece; [Ishii, Masaru] Osaka Univ, Grad Sch Med & Frontier Biosci, Dept Immunol & Cell Biol, Osaka, Japan; [Riccardi, Carlo] Univ Perugia, Dept Med, I-06100 Perugia, Italy; [Spedding, Michael] Spedding Res Solut SARL, Paris, France; [Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, Bern, Switzerland; [Teixeira, Mauro Martins] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil; [Chovel Cuervo, Mario Landys] Finlay Inst, Havana, Cuba; [Holgate, Stephen T.] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England; [Levi-Schaffer, Francesca] Hebrew Univ Jerusalem, Sch Pharm, Inst Drug Res, Pharmacol Unit,Fac Med, IL-91120 Jerusalem, Israel	Tiligada, E (reprint author), Univ Athens, Sch Med, Dept Pharmacol, M Asias 75, GR-11527 Athens, Greece.	aityliga@med.uoa.gr	Riccardi, Carlo/G-8582-2013; 	Riccardi, Carlo/0000-0001-9257-3997; Simon, Hans-Uwe/0000-0002-9404-7736; Spedding, Michael/0000-0002-1248-8221	Wellcome Trust	The authors thank Dr Doriano Fabbro (PIQUR Therapeutics AG, Basel, Switzerland) and Dr Reinaldo Acevedo (Finlay Institute, Cuba) for their valuable contributions in the preparation of this review. NC-IUPHAR receives financial support from the Wellcome Trust.	Almouzni G, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-487; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1459, DOI 10.1111/bph.12445; Zampeli E, 2009, BRIT J PHARMACOL, V157, P24, DOI 10.1111/j.1476-5381.2009.00151.x; Woodward DF, 2011, PHARMACOL REV, V63, P471, DOI 10.1124/pr.110.003517; Galluzzi L, 2014, ONCOTARGET, V5, P12472; Loriot Y, 2008, NAT CLIN PRACT ONCOL, V5, P268, DOI 10.1038/ncponc1087; Patel P, 2006, EXPERT REV VACCINES, V5, P617, DOI 10.1586/14760584.5.5.617; Akkoc T, 2011, ALLERGY ASTHMA IMMUN, V3, P11, DOI 10.4168/aair.2011.3.1.11; Steinman L, 2012, NAT MED, V18, P59, DOI 10.1038/nm.2625; Chan AC, 2010, NAT REV IMMUNOL, V10, P301, DOI 10.1038/nri2761; Pelaia G, 2012, NAT REV DRUG DISCOV, V11, P958, DOI 10.1038/nrd3792; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1797, DOI 10.1111/bph.12451; Tanaka T, 2012, ANNU REV PHARMACOL, V52, P199, DOI 10.1146/annurev-pharmtox-010611-134715; Tiligada E, 2009, EXPERT OPIN INV DRUG, V18, P1519, DOI 10.1517/14728220903188438; Kenakin T, 2013, NAT REV DRUG DISCOV, V12, P205, DOI 10.1038/nrd3954; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1676, DOI 10.1111/bph.12449; REFF ME, 1994, BLOOD, V83, P435; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212; Rosewich M, 2013, HUM VACC IMMUNOTHER, V9, P1523, DOI 10.4161/hv.24631; Fabbro D, 2015, BRIT J PHARMACOL, V172, P2675, DOI 10.1111/bph.13096; Breedveld FC, 2000, LANCET, V355, P735, DOI 10.1016/S0140-6736(00)01034-5; Gebril A, 2012, EXPERT REV VACCINES, V11, P1139, DOI [10.1586/erv.12.81, 10.1586/ERV.12.81]; Song DH, 2012, IMMUNOL REV, V250, P216, DOI 10.1111/j.1600-065X.2012.01167.x; Corbisier J, 2015, J BIOL CHEM, V290, P9542, DOI 10.1074/jbc.M114.596098; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Rask-Andersen M, 2011, NAT REV DRUG DISCOV, V10, P579, DOI 10.1038/nrd3478; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Thomson AW, 2009, NAT REV IMMUNOL, V9, P324, DOI 10.1038/nri2546; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1652, DOI 10.1111/bph.12448; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Alangari AA, 2010, ANN THORAC MED, V5, P133, DOI 10.4103/1817-1737.65040; Scalapino KJ, 2008, IMMUNOL REV, V223, P143, DOI 10.1111/j.1600-065X.2008.00639.x; Nijmeijer S, 2013, BRIT J PHARMACOL, V170, P78, DOI 10.1111/bph.12117; Nagar B, 2002, CANCER RES, V62, P4236; Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143; Kopf M, 2010, NAT REV DRUG DISCOV, V9, P703, DOI 10.1038/nrd2805; Tiligada E, 2012, J LEUKOCYTE BIOL, V92, P4, DOI 10.1189/jlb.0212093; Beck A, 2010, NAT REV IMMUNOL, V10, P345, DOI 10.1038/nri2747; Bryant CE, 2015, PHARMACOL REV, V67, P462, DOI 10.1124/pr.114.009928; Chen IF, 2011, ACTA PHARM SIN B, V1, P197; Chliva C, 2015, ALLERGY, V70, P457, DOI 10.1111/all.12568; Cohen A, 2006, BRIT J CLIN PHARMACO, V62, P379, DOI 10.1111/j.1365-2125.2006.02760.x; delsCuvillo A, 2006, J INVESTIG ALLERGOL, V16, P3; Dollery CT, 2014, BRIT J PHARMACOL, V171, P2269, DOI 10.1111/bph.12580; Fabbro D, 2015, MOL PHARMACOL, V87, P766, DOI 10.1124/mol.114.095489; Holgate ST, 2013, CURR OPIN PHARMACOL, V13, P345, DOI 10.1016/j.coph.2013.03.008; IUPHAR Immunopharmacology Section, 2015, INTRODUCTION; Kyriakidis K, 2015, INFLAMMATION, V38, P949, DOI 10.1007/s10753-014-0057-1; Leroux-Roels G, 2010, VACCINE, V28S, P25; Marfe Gabriella, 2014, Curr Drug Discov Technol, V11, P145; Moebitz H, 2012, EUR PHARM REV, V17, P41; Parsons M.E., 2006, BRIT J PHARMACOL, V147, P127, DOI DOI 10.1038/SJ.BJP.0706440; Schumacher S, 2014, N-S ARCH PHARMACOL, V387, P1091, DOI 10.1007/s00210-014-1033-x; Siebenhaar F, 2015, ALLERGY, V70, P1, DOI 10.1111/all.12517; Simon D, 2013, J INVEST DERMATOL, V133, P2314, DOI 10.1038/jid.2013.205; Sundberg TB, 2014, CURR OPIN CHEM BIOL, V23, P23, DOI 10.1016/j.cbpa.2014.08.013; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; vansLeeuwen RW, 2014, LANCET ONCOL, V15, pe315; WHO Model Lists of Essential Medicines, 2013, WHO MOD LISTS ESS ME	63	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	SEP	2015	172	17					4217	4227		10.1111/bph.13219		11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CO6VO	WOS:000359295200001		
J	Hano, T; Ohkubo, N; Kono, K; Tanaka, H				Hano, Takeshi; Ohkubo, Nobuyuki; Kono, Kumiko; Tanaka, Hiroyuki			Bioconcentration and Elimination of the Dithiocarbamate Fungicide Polycarbamate in Marine Teleost Fish and Polychaete	BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY			English	Article						Polycarbamate; Bioconcentration; Elimination; Fish; Polychaete	SALMO-GAIRDNERI	We evaluated the bioconcentration and elimination of polycarbamate, a popular antifoulant classified as a dithiocarbamate fungicide, in a marine teleost fish, mummichog (Fundulus heteroclitus), and a polychaete (Perinereis nuntia). Following polycarbamate exposure and depuration, the calculated bioconcentration factor (BCF) and elimination rate constant (k(2)) were 3.1 and 0.17 day(-1) in fish and 1.5-7.8 and 0.13-0.18 day(-1) in the polychaete, indicating that the fungicide has low bioconcentration potential in both organisms. Given the BCF of 3.1, the permissible environmental concentration level of polycarbamate in water was calculated to be 6.1 A mu g L-1 to satisfy the threshold pesticide residue levels in fish permitted by law, which is far below the permissible levels in Hiroshima Bay, Japan. Therefore, we consider that the current polycarbamate contamination level in terms of bioconcentration is not likely to be an alarming issue in coastal environments.	[Hano, Takeshi; Ohkubo, Nobuyuki; Kono, Kumiko; Tanaka, Hiroyuki] Fisheries Res Agcy, Natl Res Inst Fisheries & Environm Inland Sea, Hatsukaichi, Hiroshima 7390452, Japan	Hano, T (reprint author), Fisheries Res Agcy, Natl Res Inst Fisheries & Environm Inland Sea, 2-17-5 Maruishi, Hatsukaichi, Hiroshima 7390452, Japan.	hntks@affrc.go.jp			Fisheries Agency of Japan	We are grateful to Ms. Miki Shoda, Ms. Yumiko Takaba, and Ms. Chiaki Hiramoto (National Research Institute of Fisheries and Environment of Inland Sea, Fisheries Research Agency). This work was supported in part by a Grant-in-aid from the Fisheries Agency of Japan.	van Wezel AP, 2004, AQUAT TOXICOL, V66, P427, DOI 10.1016/j.aquatox.2003.11.003; DAVIES PE, 1985, AQUAT TOXICOL, V7, P93, DOI 10.1016/0166-445X(85)90038-4; Hano T, 2015, CHEMOSPHERE, V131, P225, DOI 10.1016/j.chemosphere.2014.12.015; CURRIE LA, 1995, PURE APPL CHEM, V67, P1699, DOI 10.1351/pac199567101699; Mochida Kazuhiko, 2009, P365, DOI 10.1007/978-4-431-85709-9_21; OECD, 2012, OECD GUID TEST CHEM; Shimizu A, 1997, J FISH BIOL, V51, P724, DOI 10.1006/jfbi.1997.0478; VANLEEUWEN CJ, 1986, TOXICOLOGY, V42, P33, DOI 10.1016/0300-483X(86)90090-9; YAMADA H, 1992, WATER RES, V26, P1589, DOI 10.1016/0043-1354(92)90158-Z	9	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0007-4861	1432-0800		B ENVIRON CONTAM TOX	Bull. Environ. Contam. Toxicol.	SEP	2015	95	3					340	343		10.1007/s00128-015-1552-2		4	Environmental Sciences; Toxicology	Environmental Sciences & Ecology; Toxicology	CP2XO	WOS:000359741300010		
J	Wu, L; Kobayashi, N; Li, ZY; Huang, HY				Wu, Long; Kobayashi, Noriyuki; Li, Zhanyong; Huang, Hongyu			Numerical Study of the Effects of Oxygen Concentration and Fuel Jet Velocity on Thermal Radiation in Methane and Propane Turbulent Diffusion Flames	CANADIAN JOURNAL OF CHEMICAL ENGINEERING			English	Article						thermal radiation; methane; propane flames; turbulent diffusion flame; oxygen concentration	GAS-FIRED FURNACES; SOOT FORMATION; HEAT-TRANSFER; MODELS; TEMPERATURE; PREDICTIONS; EMISSION; INDEX	Thermal radiation is an important mode in combustion and plays a key role in improving energy efficiency and reducing the formation of pollutants in industrial combustion systems. This paper describes the effects of oxygen concentration and fuel (methane and propane) jet velocity on thermal radiation in turbulent diffusion flames via numerical evaluation, using a detailed gas-phase reaction mechanism consisting of 36 species and 219 elementary reactions with the discrete ordinates method. The predictions show close agreement with the experimental results in literature. Specifically, the radiative heat transfer flux and radiation fraction of propane flames were larger than those of methane flames at the same input power because of the increased soot yield in propane flames. In both methane and propane flames, thermal radiation generally increased with oxygen concentration, while at higher oxygen concentrations the degree of radiation increase was lower. Because of the promotion of soot oxidation at higher fuel velocities, the radiant fractions were lower than at lower fuel velocities.	[Wu, Long; Kobayashi, Noriyuki] Nagoya Univ, Dept Chem Engn, Chikusa Ku, Nagoya, Aichi 4648603, Japan; [Li, Zhanyong] Tianjin Univ Sci & Technol, Coll Mech Engn, Tianjin 300222, Peoples R China; [Huang, Hongyu] Chinese Acad Sci, Guangzhou Inst Energy Convers, Guangzhou 510640, Guangdong, Peoples R China	Kobayashi, N (reprint author), Nagoya Univ, Dept Chem Engn, Chikusa Ku, Nagoya, Aichi 4648603, Japan.	kobayashi@energy.gr.jp					ADIGA KC, 1990, FIRE SAFETY J, V16, P443, DOI 10.1016/0379-7112(90)90021-6; Kontogeorgos DA, 2007, INT J HEAT MASS TRAN, V50, P5260, DOI 10.1016/j.ijheatmasstransfer.2007.06.011; Snelling DR, 2004, COMBUST FLAME, V136, P180, DOI 10.1016/j.combustflame.2003.09.013; Wang L, 2005, COMBUST THEOR MODEL, V9, P673, DOI 10.1080/13647830500255551; Wang L, 2005, COMBUST FLAME, V141, P170, DOI 10.1016/j.combustflame.2004.12.015; Liu FS, 2000, J THERMOPHYS HEAT TR, V14, P278, DOI 10.2514/2.6521; SIDEBOTHAM GW, 1992, COMBUST FLAME, V90, P269, DOI 10.1016/0010-2180(92)90088-7; TRUELOVE JS, 1988, J QUANT SPECTROSC RA, V39, P27, DOI 10.1016/0022-4073(88)90016-7; Paul SC, 2010, INT COMMUN HEAT MASS, V37, P1, DOI 10.1016/j.icheatmasstransfer.2009.10.005; Khalilarya S, 2010, THERM SCI, V14, P493, DOI 10.2298/TSCI1002493K; Seong HJ, 2012, COMBUST FLAME, V159, P1864, DOI 10.1016/j.combustflame.2012.01.009; Lee KO, 2000, COMBUST FLAME, V121, P323, DOI 10.1016/S0010-2180(99)00131-5; Saji CB, 2008, INT J HEAT MASS TRAN, V51, P4287, DOI 10.1016/j.ijheatmasstransfer.2008.02.010; Liu FS, 2004, COMBUST FLAME, V138, P136, DOI 10.1016/j.combustflame.2004.04.007; Andersson K, 2008, ENERG FUEL, V22, P1535, DOI 10.1021/cf7004942; Barlow R. S., 2003, RAD MODELS; Baukal J., 1988, OXYGEN ENHANCED COMB, P36; Chandrashekhar S., 1950, RAD TRANSFER; CHARETTE A, 1992, CAN J CHEM ENG, V70, P1198; CHARETTE A, 1989, CAN J CHEM ENG, V67, P378; Ditaranto M, 2011, EXP THERM FLUID SCI, V35, P1343, DOI 10.1016/j.expthermflusci.2011.05.002; FAIRWEATHER M, 1992, COMBUST FLAME, V89, P45, DOI 10.1016/0010-2180(92)90077-3; Fuentes A, 2013, COMBUST FLAME, V160, P786, DOI 10.1016/j.combustflame.2012.12.005; Fujimori T., 2000, P COMBUST INST, V28, P456; GULDER OL, 1995, COMBUST FLAME, V101, P302, DOI 10.1016/0010-2180(94)00217-G; HONNERY DR, 1990, COMBUST FLAME, V82, P426, DOI 10.1016/0010-2180(90)90012-G; HUTNY WP, 1991, INT J HYDROGEN ENERG, V16, P47, DOI 10.1016/0360-3199(91)90059-R; Jun L., 1988, J COMPUT FLUID DYN, V10, P616; Kashir B, 2012, THERM SCI, V16, P1043, DOI 10.2298/TSCI110524122K; Kee R.J., 1986, SAND868246 SAND NAT; Kennedy IM, 1997, PROG ENERG COMBUST, V23, P95, DOI 10.1016/S0360-1285(97)00007-5; Keramida EP, 2000, INT J HEAT MASS TRAN, V43, P1801, DOI 10.1016/S0017-9310(99)00244-6; Kumar P, 2008, INT J HYDROGEN ENERG, V33, P225, DOI 10.1016/j.ijhydene.2007.09.023; Lauder B. E., 1972, LECT MATH MODELS TUR; Liakos HH, 2000, APPL MATH MODEL, V24, P419, DOI 10.1016/S0307-904X(99)00052-9; Liu F, 1998, INT J HEAT MASS TRAN, V41, P3357, DOI 10.1016/S0017-9310(98)00098-2; Liu FS, 2002, J QUANT SPECTROSC RA, V73, P409, DOI 10.1016/S0022-4073(01)00205-9; Magnussen BF, 1976, P COMBUST INST, V16, P719; MODAK AT, 1979, FIRE RES, V1, P339, DOI 10.1016/0379-7112(79)90004-3; Modest M. F., 2003, RAD HEAT TRANSFER, V2 nd, P387; MOSS JB, 1995, COMBUST FLAME, V101, P491, DOI 10.1016/0010-2180(94)00233-I; Neoh K. G., 1981, PARTICULATE CARBON F; Oh KC, 2006, FUEL, V85, P615, DOI 10.1016/j.fuel.2005.08.018; Patankar S. V., 1980, NUMERICAL HEAT TRANS; Smith G. P., 1999, GRI MECH; Spalding D. B., 1980, HTS811 CFDU IMP COLL; Stoomer P., 1995, THESIS DELFT U DELFT; Thurgood CP, 1995, J HEAT TRANS-T ASME, V117, P1068, DOI 10.1115/1.2836285; Walsh K.T., 1998, P COMBUST INST, V27, P615; Wang L, 2002, COMBUST SCI TECHNOL, V174, P45, DOI 10.1080/00102200290021245; Wang L., 2004, THESIS PENNSYLVANIA; Zhubrin SV, 2009, INT J HEAT MASS TRAN, V52, P4125, DOI 10.1016/j.ijheatmasstransfer.2009.03.034	52	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0008-4034	1939-019X		CAN J CHEM ENG	Can. J. Chem. Eng.	SEP	2015	93	9					1567	1576		10.1002/cjce.22256		10	Engineering, Chemical	Engineering	CP2KU	WOS:000359706700010		
J	Enomoto, Y; Inui, N; Imokawa, S; Karayama, M; Hasegawa, H; Ozawa, Y; Matsui, T; Yokomura, K; Suda, T				Enomoto, Yasunori; Inui, Naoki; Imokawa, Shiro; Karayama, Masato; Hasegawa, Hirotsugu; Ozawa, Yuichi; Matsui, Takashi; Yokomura, Koshi; Suda, Takafumi			Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Topotecan; Nogitecan; Interstitial lung disease; Acute exacerbation	IDIOPATHIC PULMONARY-FIBROSIS; JAPANESE PATIENTS; PHASE-II; INTRAVENOUS TOPOTECAN; 2ND-LINE CHEMOTHERAPY; CLINICAL-FEATURES; THERAPY; AMRUBICIN; PNEUMONIAS; DIAGNOSIS	To investigate the safety of intravenous topotecan monotherapy for relapsed small cell lung cancer (SCLC) patients with pre-existing interstitial lung disease (ILD). A total of 77 patients who received topotecan for the treatment of relapsed SCLC between April 2007 and April 2014 were reviewed. Patients with pre-existing ILD were identified using the pretreatment chest computed tomography. The safety of intravenous topotecan for SCLC patients with ILD was retrospectively examined, particularly focusing on topotecan-induced acute exacerbation of ILD (AE-ILD). Twenty-three patients were identified as having pre-existing ILD [median age 74 (range 55-85) years; 21 men]. At the first topotecan administration, two-thirds (65.2 %) had an Eastern Cooperative Oncology Group performance status 0 or 1. Topotecan was administered intravenously as second-line (n = 11) or later chemotherapy (n = 12). The median number of treatment cycles was two (range 1-7). The most common adverse events with grade 3 or 4 were neutropenia in 13 patients (56.5 %) and thrombocytopenia in 10 patients (43.5 %). Febrile neutropenia was observed in six patients (26.1 %) and resulted in one death. AE-ILD occurred in five patients (21.7 %; 95 % confidence interval 4.9-38.5 %) 5-18 days after the last administration of topotecan and was fatal in three cases. Intravenous topotecan monotherapy can be unsafe for relapsed SCLC patients with pre-existing ILD. Clinicians should be cautious regarding topotecan-induced AE-ILD as a lethal complication.	[Enomoto, Yasunori; Hasegawa, Hirotsugu; Ozawa, Yuichi; Matsui, Takashi; Yokomura, Koshi] Seirei Mikatahara Gen Hosp, Dept Resp Med, Resp Dis Ctr, Kita Ku, Hamamatsu, Shizuoka 4338558, Japan; [Inui, Naoki] Hamamatsu Univ Sch Med, Dept Clin Pharmacol & Therapeut, Hamamatsu, Shizuoka 4313192, Japan; [Imokawa, Shiro] Iwata City Hosp, Dept Resp Med, Iwata, Japan; [Karayama, Masato] Hamamatsu Univ Sch Med, Dept Clin Oncol, Hamamatsu, Shizuoka 4313192, Japan; [Enomoto, Yasunori; Inui, Naoki; Karayama, Masato; Suda, Takafumi] Hamamatsu Univ Sch Med, Dept Internal Med 2, Hamamatsu, Shizuoka 4313192, Japan	Enomoto, Y (reprint author), Seirei Mikatahara Gen Hosp, Dept Resp Med, Resp Dis Ctr, Kita Ku, 3453 Mikatahara Cho, Hamamatsu, Shizuoka 4338558, Japan.	yasuyasuyasu29@yahoo.co.jp					Kudoh S, 2008, AM J RESP CRIT CARE, V177, P1348, DOI 10.1164/rccm.200710-1501OC; Minegishi Y, 2009, INTERNAL MED, V48, P665, DOI 10.2169/internalmedicine.48.1650; Togashi Y, 2012, CLIN LUNG CANCER, V13, P304, DOI 10.1016/j.cllc.2011.11.001; Jotte R, 2011, J CLIN ONCOL, V29, P287, DOI 10.1200/JCO.2010.29.8851; Inoue A, 2008, J CLIN ONCOL, V26, P5401, DOI 10.1200/JCO.2008.18.1974; Suzuki H, 2011, J CHEMOTHERAPY, V23, P367; Huber RM, 2006, EUR RESPIR J, V27, P1183, DOI 10.1183/09031936.06.00015605; Collard HR, 2007, AM J RESP CRIT CARE, V176, P636, DOI 10.1164/rccm.200703-463PP; von Pawel J, 2001, J CLIN ONCOL, V19, P1743; von Pawel J, 2014, J CLIN ONCOL, V32, P4012, DOI 10.1200/JCO.2013.54.5392; King TE, 2005, AM J RESP CRIT CARE, V172, P268, DOI 10.1164/rccm.200503-483OE; Eckardt JR, 2007, J CLIN ONCOL, V25, P2086, DOI 10.1200/JCO.2006.08.3998; Miyazaki K, 2010, MED ONCOL, V27, P763, DOI 10.1007/s12032-009-9283-z; Owonikoko TK, 2012, J THORAC ONCOL, V7, P866, DOI 10.1097/JTO.0b013e31824c7f4b; von Pawel J, 1999, J CLIN ONCOL, V17, P658; Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST; Ardizzoni A, 1997, J CLIN ONCOL, V15, P2090; Rossi SE, 2000, RADIOGRAPHICS, V20, P1245; Edgerton CC, 2004, SOUTH MED J, V97, P699, DOI 10.1097/00007611-200407000-00018; Maitland ML, 2006, LUNG CANCER, V54, P243, DOI 10.1016/j.lungcan.2006.07.017; MASUDA N, 1992, J CLIN ONCOL, V10, P1225; Minegishi Y, 2014, LUNG CANCER, V85, P258, DOI 10.1016/j.lungcan.2014.05.016; Natsuizaka M, 2014, AM J RESP CRIT CARE, V190, P773, DOI 10.1164/rccm.201403-0566OC; Pelayo Alvarez M, 2013, COCHRANE DB SYST REV, V11; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Yoh K, 2010, J THORAC ONCOL, V5, P1435, DOI 10.1097/JTO.0b013e3181e369a8; Yoshii N, 2011, ANTI-CANCER DRUG, V22, P563, DOI 10.1097/CAD.0b013e3283473f28	27	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	SEP	2015	76	3					499	505		10.1007/s00280-015-2816-6		7	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CP3YC	WOS:000359817800007		
J	Nishina, T; Kato, T; Yamazaki, K; Yoshino, T; Miyata, Y; Esaki, T; Moriwaki, T; Boku, N; Hyodo, I				Nishina, Tomohiro; Kato, Takeshi; Yamazaki, Kentaro; Yoshino, Takayuki; Miyata, Yoshinori; Esaki, Taito; Moriwaki, Toshikazu; Boku, Narikazu; Hyodo, Ichinosuke			A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						S-1; Leucovorin; Oxaliplatin; SOLA; Colorectal cancer; Bevacizumab	PLUS BEVACIZUMAB; 1ST-LINE THERAPY; FLUOROURACIL; CHEMOTHERAPY; CAPECITABINE; CARCINOMA; TRIAL; I/II	Adding leucovorin to fluorouracil is known to improve response rate and overall survival in first-line chemotherapy for metastatic colorectal cancer (mCRC). The present multicenter phase II study evaluated the efficacy and safety of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA). Patients with unresectable and untreated mCRC received S-1 (40-60 mg bid) plus leucovorin (25 mg bid) orally for 1 week, and oxaliplatin (85 mg/m(2)) and bevacizumab (5 mg/kg) intravenously on day 1, every 2 weeks. Efficacy endpoints, including the response rate (the primary endpoint) and progression-free survival, were assessed by an independent review committee. Of the 29 eligible patients, 25 patients (86 %) had a partial response [95 % confidence interval (CI) 68-96 %] and the remaining four patients showed stable disease with a trend toward tumor shrinkage. The median progression-free survival was 15 months (95 % CI 10-26 months). The median overall survival was not reached after a median follow-up time of 34 months. The 3-year survival rate was 54 %. Curative resections of metastatic lesions were performed in eight patients (28 %). Common grade 3 or 4 adverse events were neutropenia (20 %), hypertension (23 %), anorexia (20 %), fatigue (17 %), diarrhea (10 %), and peripheral sensory neuropathy (53 %). The SOLA therapy showed excellent efficacy and tolerable toxicities except for peripheral sensory neuropathy in patients with mCRC. Since oxaliplatin-induced neuropathy can be alleviated by modifying its administration, SOLA is a promising candidate regimen to be compared with FOLFOX plus bevacizumab in a future phase III trial. JapicCTI-090881.	[Nishina, Tomohiro] Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, Matsuyama, Ehime 7910280, Japan; [Kato, Takeshi] Kansai Rosai Hosp, Dept Surg, Amagasaki, Hyogo, Japan; [Yamazaki, Kentaro] Shizuoka Canc Ctr, Div Gastrointestinal Oncol & Endoscopy, Shizuoka, Japan; [Yoshino, Takayuki] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan; [Miyata, Yoshinori] Saku Cent Hosp, Dept Med Oncol, Saku, Japan; [Esaki, Taito] Kyushu Natl Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan; [Moriwaki, Toshikazu; Hyodo, Ichinosuke] Univ Tsukuba, Div Gastroenterol, Fac Med, Tsukuba, Ibaraki, Japan; [Boku, Narikazu] St Marianna Univ Sch Med, Dept Clin Oncol, Kawasaki, Kanagawa, Japan	Nishina, T (reprint author), Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, 160 Minami Umemoto Machi Kou, Matsuyama, Ehime 7910280, Japan.	tnishina@shikoku-cc.go.jp			Taiho Pharmaceutical Co., Ltd, Tokyo, Japan	We thank the patients; their families; all the investigators who participated in the study; all of the independent data monitoring committee members (Y. Maehara, K. Aiba, and A. Sato); Y. Sakata as a medical adviser; all of the independent review committee members (J. Tanaka, S. Hironaka, and T. Ushimi); T. Tanase, Taiho Pharmaceutical Co., Ltd for statistical analysis; and M. Hiramatsu, Taiho Pharmaceutical Co., Ltd for his support of this report. This study was funded by Taiho Pharmaceutical Co., Ltd, Tokyo, Japan. Employees of Taiho Pharmaceutical Co., Ltd were involved in the study design and the data collection and analysis. They also provided writing assistance.	Doi T, 2010, JPN J CLIN ONCOL, V40, P913, DOI 10.1093/jjco/hyq069; Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091; Yamada Y, 2013, LANCET ONCOL, V14, P1278, DOI 10.1016/S1470-2045(13)70490-X; Shirao K, 2004, CANCER, V100, P2355, DOI 10.1002/cncr.20277; Chuah B, 2011, CANCER SCI, V102, P478, DOI 10.1111/j.1349-7006.2010.01793.x; Folprecht G, 2010, LANCET ONCOL, V11, P38, DOI 10.1016/S1470-2045(09)70330-4; Wong R, 2011, ANN ONCOL, V22, P2042, DOI 10.1093/annonc/mdq714; Okines A, 2009, BRIT J CANCER, V101, P1033, DOI 10.1038/sj.bjc.6605259; Yamada Y, 2008, BRIT J CANCER, V98, P1034, DOI 10.1038/sj.bjc.6604271; Muro K, 2010, LANCET ONCOL, V11, P853, DOI 10.1016/S1470-2045(10)70181-9; Shirasaka T, 2009, JPN J CLIN ONCOL, V39, P2, DOI 10.1093/jjco/hyn127; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Tournigand C, 2006, J CLIN ONCOL, V24, P394, DOI 10.1200/JCO.2005.03.0106; Koizumi W, 2010, ANN ONCOL, V21, P766, DOI 10.1093/annonc/mdp371; Ohtsu A, 2000, BRIT J CANCER, V83, P141; Brienza S, 1995, P AN M AM SOC CLIN, V14, P209; de Gramont A, 2000, J CLIN ONCOL, V18, P2937; Grothey A, 2002, P AN M AM SOC CLIN, V21, p129a; Sommeijer D W, 2013, ASCO M S, V31, P3520; Thirion P, 2004, J Clin Oncol, V22, P3766; Xu R, 2013, J CLIN ONCOL S4, V31; Yamazaki K, 2015, CANCER CHEMOTH PHARM, V75, P569, DOI 10.1007/s00280-015-2676-0	22	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	SEP	2015	76	3					547	553		10.1007/s00280-015-2825-5		7	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CP3YC	WOS:000359817800012		
J	Iwasa, S; Nagashima, K; Yamaguchi, T; Matsumoto, H; Ichikawa, Y; Goto, A; Yasui, H; Kato, K; Okita, NT; Shimada, Y; Yamada, Y				Iwasa, Satoru; Nagashima, Kengo; Yamaguchi, Tatsuro; Matsumoto, Hiroshi; Ichikawa, Yasushi; Goto, Ayumu; Yasui, Hisateru; Kato, Ken; Okita, Natsuko Tsuda; Shimada, Yasuhiro; Yamada, Yasuhide			S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Colorectal cancer; Irinotecan; Phase II; Pooled analysis; S-1	TRIAL; FLUOROURACIL; FLUOROPYRIMIDINE; CARCINOMA; TOXICITY; TIME	S-1, a novel oral prodrug of 5-fluorouracil (5-FU), and irinotecan with or without bevacizumab is known to be effective in metastatic colorectal cancer (mCRC). However, it is not clear whether S-1 and irinotecan confers benefits compared to 5-FU and leucovorin plus oxaliplatin (FOLFOX) in patients with mCRC. Our aim was to compare the efficacy and safety of these regimens. We analyzed 187 patients with previously untreated mCRC who were enrolled in four phase II studies: SIR (S-1 and irinotecan, n = 40), SIRB (S-1 and irinotecan with bevacizumab, n = 51), FOLFOX (5-FU and leucovorin plus oxaliplatin, n = 46), and STOX (stop-and-go strategy of modified FOLFOX-6 with bevacizumab, n = 50). We evaluated efficacy and safety between SIR/SIRB and FOLFOX/STOX. Baseline characteristics were similar in the two groups composed of SIR/SIRB (n = 91) and FOLFOX/STOX (n = 96). The overall response rates were not significantly different between the two groups (65 % in SIR/SIRB vs. 52 % in FOLFOX/STOX, p = 0.125). The median progression-free survival was 10.9 months in SIR/SIRB versus 12.1 months in FOLFOX/STOX (p = 0.59). The median overall survival was 27.3 months in SIR/SIRB versus 26.8 months in FOLFOX/STOX (p = 0.97). Gastrointestinal adverse events were the most common toxicities in SIR/SIRB, while neutropenia and sensory neuropathy were the most common toxicities in FOLFOX/STOX. S-1 and irinotecan with or without bevacizumab was well tolerated and showed similar response rates and survival compared to the FOLFOX regimen. This combination should be considered as an experimental first-line treatment for mCRC.	[Iwasa, Satoru; Kato, Ken; Okita, Natsuko Tsuda; Shimada, Yasuhiro; Yamada, Yasuhide] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Chuo Ku, Tokyo 1040045, Japan; [Nagashima, Kengo] Chiba Univ Hosp, Clin Res Ctr, Chiba, Japan; [Yamaguchi, Tatsuro; Matsumoto, Hiroshi] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Surg, Tokyo, Japan; [Ichikawa, Yasushi; Goto, Ayumu] Yokohama City Univ Grad Sch Med, Dept Clin Oncol, Yokohama, Kanagawa, Japan; [Yasui, Hisateru] Kyoto Med Ctr, Div Med Oncol, Kyoto, Japan	Iwasa, S (reprint author), Natl Canc Ctr, Gastrointestinal Med Oncol Div, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	siwasa@ncc.go.jp			Taiho Pharmaceutical Co., Ltd.; Taiho; Yakult; Daiichi-Sankyo	This work was supported in part by Taiho Pharmaceutical Co., Ltd. Tatsuro Yamaguchi has received speakers' bureau from Taiho and Yakult. Yasushi Ichikawa has received research funding from Taiho and Yakult. Ayumu Goto has received honoraria from Taiho. Hisateru Yasui has received honoraria from Taiho and owns stock in Yakult. Yasuhiro Shimada has received honoraria from Taiho and Yakult, and research funding from Taiho and Yakult and has consulting fees from Taiho. Yasuhide Yamada has received honoraria from Taiho and Yakult, and research funding from Taiho and Daiichi-Sankyo. All other authors declare that they have no conflict of interest relevant to this study. All procedures performed in phase II studies were in accordance with the ethical standards of the institutional review board at each participating center and with the 1964 Declaration of Helsinki and Japanese Good Clinical Practice Guidelines.	Punt CJA, 2004, ANN ONCOL, V15, P1453, DOI 10.1093/annonc/mdh383; Van den Brande J, 2003, BRIT J CANCER, V88, P648, DOI 10.1038/sj.bjc.6600781; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Schwab M, 2008, J CLIN ONCOL, V26, P2131, DOI 10.1200/JCO.2006.10.4182; Yamada Y, 2013, LANCET ONCOL, V14, P1278, DOI 10.1016/S1470-2045(13)70490-X; Shirao K, 2004, CANCER, V100, P2355, DOI 10.1002/cncr.20277; Fuchs CS, 2008, J CLIN ONCOL, V26, P689, DOI 10.1200/JCO.2007.15.5390; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R; Muro K, 2010, LANCET ONCOL, V11, P853, DOI 10.1016/S1470-2045(10)70181-9; Yamada Y, 2003, BRIT J CANCER, V89, P816, DOI 10.1038/sj.bjc.6601224; Ohtsu A, 2000, BRIT J CANCER, V83, P141; Borner MM, 2002, EUR J CANCER, V38, P349, DOI 10.1016/S0959-8049(01)00371-9; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; CAIN KC, 1984, BIOMETRICS, V40, P493, DOI 10.2307/2531402; COOK RD, 1986, J ROY STAT SOC B MET, V48, P133; Goto A, 2006, ANN ONCOL, V17, P968, DOI 10.1093/annonc/mdl066; Hosmer DW, 2008, APPL SURVIVAL ANAL R; Iwasa S, 2012, ANTICANCER RES, V32, P4157; Iwasa S, 2014, J INTEGR ONCOL, V3, P120, DOI [10.4172/2329-6771.1000120, DOI 10.4172/2329-6771.1000120]; Okita NT, 2012, INVEST NEW DRUG, V30, P2026, DOI 10.1007/s10637-011-9779-1; Rubin DB, 1987, MULTIPLE IMPUTATION; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; Sloan JA, 2002, J CLIN ONCOL, V20, P1491, DOI 10.1200/JCO.20.6.1491; Yamada Y, 2012, INVEST NEW DRUG, V30, P1690, DOI 10.1007/s10637-011-9743-0	24	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	SEP	2015	76	3					605	614		10.1007/s00280-015-2834-4		10	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CP3YC	WOS:000359817800018		
J	Goji, T; Kimura, T; Miyamoto, H; Takehara, M; Kagemoto, K; Okada, Y; Okazaki, J; Takaoka, Y; Miyamoto, Y; Mitsui, Y; Matsumoto, S; Sueuchi, T; Tanaka, K; Fujino, Y; Takaoka, T; Kitamura, S; Okamoto, K; Kimura, M; Sogabe, M; Muguruma, N; Okahisa, T; Sato, Y; Sagawa, T; Fujikawa, K; Sato, Y; Ikushima, H; Takayama, T				Goji, Takahiro; Kimura, Tetsuo; Miyamoto, Hiroshi; Takehara, Masanori; Kagemoto, Kaizo; Okada, Yasuyuki; Okazaki, Jun; Takaoka, Yoshifumi; Miyamoto, Yoshihiko; Mitsui, Yasuhiro; Matsumoto, Sayo; Sueuchi, Tatsuhisa; Tanaka, Kumiko; Fujino, Yasuteru; Takaoka, Toshi; Kitamura, Shinji; Okamoto, Koichi; Kimura, Masako; Sogabe, Masahiro; Muguruma, Naoki; Okahisa, Toshiya; Sato, Yasuhiro; Sagawa, Tamotsu; Fujikawa, Koji; Sato, Yasushi; Ikushima, Hitoshi; Takayama, Tetsuji			A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Pancreatic cancer; Gemcitabine; S-1; Chemoradiotherapy; Radiosensitizer	I TRIAL; RADIATION-THERAPY; ADENOCARCINOMA	This study was conducted to identify the maximum-tolerated dose (MTD) of fixed-dose-rate gemcitabine (FDR-gem) administered concurrently with S-1 and radical radiation for locally advanced pancreatic cancer (LAPC) and to provide efficacy and safety data. Patients with unrespectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400 mg/m(2), 5 mg/m(2)/min) on days 1, 8, 22, and 29 and 60 mg/m(2) of S-1 orally on days 1-14, 22-35. A total radiation dose of 50.4 Gy (1.8 Gy/day, 28 fractions) was delivered concurrently. Twenty-five patients were enrolled; all were evaluable for toxicity assessment. In phase I, eight patients were treated in sequential cohorts of three to five patients per dose level. The MTD was reached at level 2, and dose-limiting toxicities were neutropenia and thrombocytopenia. The recommended doses were 300 mg/m(2) of gemcitabine and 60 mg/m(2) of S-1 daily. The overall response rate was 25 % and disease control rate (partial response plus stable disease) was 92 %. The progression-free survival was 11.0 months. The median overall survival and 1-year survival rates were 16.0 months and 73 %, respectively. The combination of FDR-gem and S-1 with radiation is a feasible regimen that shows favorable antitumor activity with an acceptable safety profile in patients with LAPC.	[Goji, Takahiro; Kimura, Tetsuo; Miyamoto, Hiroshi; Takehara, Masanori; Kagemoto, Kaizo; Okada, Yasuyuki; Okazaki, Jun; Takaoka, Yoshifumi; Miyamoto, Yoshihiko; Mitsui, Yasuhiro; Matsumoto, Sayo; Sueuchi, Tatsuhisa; Tanaka, Kumiko; Fujino, Yasuteru; Takaoka, Toshi; Kitamura, Shinji; Okamoto, Koichi; Kimura, Masako; Sogabe, Masahiro; Muguruma, Naoki; Okahisa, Toshiya; Takayama, Tetsuji] Univ Tokushima Grad Sch, Inst Hlth Biosci, Dept Gastroenterol & Oncol, Tokushima 7708503, Japan; [Sato, Yasuhiro; Sagawa, Tamotsu; Fujikawa, Koji] Natl Hosp Org, Dept Gastroenterol, Hokkaido Canc Ctr, Sapporo, Hokkaido 0030804, Japan; [Sato, Yasushi] Sapporo Med Univ, Dept Internal Med 4, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; [Ikushima, Hitoshi] Univ Tokushima Grad Sch, Inst Hlth Biosci, Dept Radiat Therapy Technol, Tokushima 7708503, Japan	Takayama, T (reprint author), Univ Tokushima Grad Sch, Inst Hlth Biosci, Dept Gastroenterol & Oncol, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	takayama@tokushima-u.ac.jp					Ueno H, 2013, J CLIN ONCOL, V31, P1640, DOI 10.1200/JCO.2012.43.3680; Sultana A, 2007, BRIT J CANCER, V96, P1183, DOI 10.1038/sj.bjc.6603719; Epelbaum R, 2002, J SURG ONCOL, V81, P138, DOI 10.1002/jso.10159; MOERTEL CG, 1981, CANCER, V48, P1705, DOI 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]; Sudo K, 2011, INT J RADIAT ONCOL, V80, P119, DOI 10.1016/j.ijrobp.2010.01.027; Ben-Josef E, 2012, INT J RADIAT ONCOL, V84, P1166, DOI 10.1016/j.ijrobp.2012.02.051; Okusaka T, 2004, BRIT J CANCER, V91, P673, DOI 10.1038/sj.bjc.6602001; Fukushima M, 2010, ONCOL REP, V24, P1307, DOI 10.3892/or_00000987; Ikeda M, 2013, INT J RADIAT ONCOL, V85, P163, DOI 10.1016/j.ijrobp.2012.03.059; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Brade A, 2007, INT J RADIAT ONCOL, V67, P1027, DOI 10.1016/j.ijrobp.2006.10.015; Eguchi H, 2014, CANCER CHEMOTH PHARM, V73, P309, DOI 10.1007/s00280-013-2357-9; Loehrer PJ, 2011, J CLIN ONCOL, V29, P4105, DOI 10.1200/JCO.2011.34.8904; Morgan M, 2008, TRANSL ONCOL, V1, P44, DOI 10.1593/tlo.07118; Pipas JM, 2001, INT J RADIAT ONCOL, V50, P1317, DOI 10.1016/S0360-3016(01)01580-2; Shinchi H, 2007, BRIT J CANCER, V96, P1353, DOI 10.1038/sj.bjc.6603735; Wolff RA, 2001, CLIN CANCER RES, V7, P2246; Yeo Theresa Pluth, 2002, Curr Probl Cancer, V26, P176, DOI 10.1067/mcn.2002.129579	19	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	SEP	2015	76	3					615	620		10.1007/s00280-015-2835-3		6	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CP3YC	WOS:000359817800019		
J	Murakami, H; Ikeda, M; Okusaka, T; Inaba, Y; Iguchi, H; Yagawa, K; Yamamoto, N				Murakami, Haruyasu; Ikeda, Masafumi; Okusaka, Takuji; Inaba, Yoshitaka; Iguchi, Haruo; Yagawa, Katsuro; Yamamoto, Nobuyuki			A Phase I study of MEDI-575, a PDGFR alpha monoclonal antibody, in Japanese patients with advanced solid tumors	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						MEDI-575; PDGFR alpha monoclonal antibody; Safety; Pharmacokinetics; Japan	GROWTH-FACTOR-RECEPTOR; CANCER; PROGRESSION; IMATINIB; MODEL	MEDI-575 is a fully human monoclonal antibody that selectively binds to platelet-derived growth factor receptor alpha (PDGFR alpha). This open-label Phase I study assessed the safety and tolerability of MEDI-575 in Japanese patients with advanced solid tumors. The study comprised two parts: Part A, dose escalation; Part B, dose expansion in patients with hepatocellular cancer. In Part A, patients were enrolled into three cohorts: MEDI-575 was administered intravenously over a 21-day treatment cycle at doses of 9 and 15 mg/kg/week (cohorts 1, 2) and 35 mg/kg/3-weekly (cohort 3). In Part B, MEDI-575 25 mg/kg/3-weekly was administered. Secondary measures included assessment of the maximum tolerated dose, pharmacokinetics, immunogenicity and anti-tumor activity. Ten and 12 patients were treated in Parts A and B, respectively. There were no dose-limiting toxicities; the maximum tolerated dose was not determined. Common treatment-related adverse events were fatigue (30 %) and decreased appetite (20 %) in Part A and decreased appetite (33.3 %) in Part B. All treatment-related adverse events were grade 1 or 2 in severity. No patients discontinued MEDI-575 because of an adverse event and there were no patient deaths due to adverse events. MEDI-575 binding with PDGFR alpha resulted in a dose-dependent increase in PDGF-AA ligand, with plateau levels observed within 2 days and sustained during the dosing interval. None of the patients in Part A or B experienced complete or partial responses to treatment. MEDI-575 once weekly and 3-weekly was well tolerated with a favorable pharmacokinetic profile in Japanese patients with advanced solid tumors. ClinicalTrials.gov, NCT01102400.	[Murakami, Haruyasu] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka 4118777, Japan; [Ikeda, Masafumi] Natl Canc Ctr East Hosp, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan; [Okusaka, Takuji] Natl Canc Ctr, Div Hepatobiliary & Pancreat Oncol, Chuo Ku, Tokyo, Japan; [Inaba, Yoshitaka] Aichi Canc Ctr Hosp, Dept Diagnost & Intervent Radiol, Nagoya, Aichi, Japan; [Iguchi, Haruo] Shikoku Canc Ctr, Clin Res Inst, Matsuyama, Ehime, Japan; [Yagawa, Katsuro] AstraZeneca KK, Dept Clin Sci, R&D, Osaka, Japan; [Yamamoto, Nobuyuki] Wakayama Med Univ Sch Med, Dept Internal Med 3, Wakayama, Japan	Murakami, H (reprint author), Shizuoka Canc Ctr, Div Thorac Oncol, 1007 Shimonagakubo, Shizuoka 4118777, Japan.	ha.murakami@scchr.jp			AstraZeneca	This study was sponsored by AstraZeneca. Medical writing assistance was provided by Claire Routley PhD from Mudskipper Business Ltd, funded by AstraZeneca.	Stock P, 2007, MOL CANCER THER, V6, P1932, DOI 10.1158/1535-7163.MCT-06-0720; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Jayson GC, 2005, J CLIN ONCOL, V23, P973, DOI 10.1200/JCO.2005.01.032; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; Quintas-Cardama A, 2007, J CLIN ONCOL, V25, P3908, DOI 10.1200/JCO.2007.12.0329; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007; Ostman A, 2004, CYTOKINE GROWTH F R, V15, P275, DOI 10.1016/j.cytogfr.2004.03.002; Carvalho I, 2005, BREAST CANCER RES, V7, pR788, DOI 10.1186/bcr1304; Tejada ML, 2006, CLIN CANCER RES, V12, P2676, DOI 10.1158/1078-0432.CCR-05-1770; AstraZeneca, 2011, GLOBAL POLICY; Becerra CR, 2014, CANCER CHEMOTH PHARM, V74, P917, DOI 10.1007/s00280-014-2567-9; Buitenhuis Miranda, 2007, Cancer Res, V67, P3759, DOI 10.1158/0008-5472.CAN-06-4183; De WO, 2008, INT J CANCER, V123, P2229; Laing N, 2013, MOL PHARMACOL, V83, P1247, DOI 10.1124/mol.112.084079; Matei D, 2006, ONCOGENE, V25, P2060, DOI 10.1038/sj.onc.1209232; Shikada Y, 2005, CANCER RES, V65, P7241, DOI 10.1158/0008-5472.CAN-04-4171	17	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	SEP	2015	76	3					631	639		10.1007/s00280-015-2832-6		9	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CP3YC	WOS:000359817800021		
J	Hattori, S; Ihara, Y; Kato, CN				Hattori, Shota; Ihara, Yuki; Kato, Chika Nozaki			A Novel Photocatalytic System Constructed Using Eosin Y, Titanium Dioxide, and Keggin-Type Platinum(II)- and Aluminum(III)-Coordinated Polyoxotungstates for Hydrogen Production from Water Under Visible Light Irradiation	CATALYSIS LETTERS			English	Article						Diplatinum(II) complex; Aluminum(III) complex; Polyoxometalate; Hydrogen evolution; Visible light	H-2 EVOLUTION; TIO2; POLYOXOMETALATE; COMPLEX; PHOTOSENSITIZATION; NANOPARTICLES; SENSITIZERS; PHOTOLYSIS; NIOBATE; PT/TIO2	A novel photocatalytic system constructed using Eosin Y, alpha-Keggin-type diplatinum(II)-coordinated tungstophosphate Cs-3[alpha-PW11O39{cis-Pt(NH3)(2)}(2)]center dot 8H(2)O (Cs-Pt-1), alpha-Keggin-type mono-aluminum(III)-coordinated tungstosilicate K-5[alpha-SiW11{Al(OH2)}O-39]center dot 7H(2)O (K-Al-1), and titanium dioxide achieved a steady rate of hydrogen evolution with highly effective utilization of platinum sites from aqueous triethanolamine solution during a long-term visible light irradiation. [GRAPHICS] .	[Hattori, Shota; Ihara, Yuki; Kato, Chika Nozaki] Shizuoka Univ, Dept Chem, Fac Sci, Suruga Ku, Shizuoka 4228529, Japan; [Kato, Chika Nozaki] Shizuoka Univ, Green Chem Res Div, Res Inst Green Sci & Technol, Suruga Ku, Shizuoka 4228529, Japan	Kato, CN (reprint author), Shizuoka Univ, Dept Chem, Fac Sci, Suruga Ku, 836 Ohya, Shizuoka 4228529, Japan.	sckatou@ipc.shizuoka.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan. We also acknowledge Mr. Wataru Unno (Shizuoka University) for the synthesis and characterization of K-Al-1 and TMA-Al-4, and Mr. Daisuke Miyamae (Shizuoka University) for the UV-Vis and NMR measurements.	Abe R, 2010, J PHOTOCH PHOTOBIO C, V11, P179, DOI 10.1016/j.jphotochemrev.2011.02.003; FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0; Maeda K, 2009, J PHYS CHEM C, V113, P7962, DOI 10.1021/jp900842e; Zhao JL, 2014, INT J HYDROGEN ENERG, V39, P18908, DOI 10.1016/j.ijhydene.2014.09.084; Maeda K, 2010, J PHYS CHEM LETT, V1, P2655, DOI 10.1021/jz1007966; Yang JH, 2013, ACCOUNTS CHEM RES, V46, P1900, DOI 10.1021/ar300227e; Fu N, 2009, APPL SURF SCI, V255, P4378, DOI 10.1016/j.apsusc.2008.11.056; Hong JD, 2011, NANOSCALE, V3, P4655, DOI 10.1039/c1nr10628g; Kato CN, 2014, INORG CHEM, V53, P4824, DOI 10.1021/ic402650g; POPE MT, 1991, ANGEW CHEM INT EDIT, V30, P34, DOI 10.1002/anie.199100341; Liu X, 2012, INT J HYDROGEN ENERG, V37, P12150, DOI 10.1016/j.ijhydene.2012.06.028; Li YX, 2008, J MOL CATAL A-CHEM, V282, P117, DOI 10.1016/j.molcata.2007.12.005; Zhang J, 2007, J AM CHEM SOC, V129, P7726, DOI 10.1021/ja071789h; Min SX, 2012, INT J HYDROGEN ENERG, V37, P10564, DOI 10.1016/j.ijhydene.2012.04.072; Kato CN, 2010, DALTON T, V39, P11469, DOI 10.1039/c0dt00722f; Peng TY, 2008, J POWER SOURCES, V180, P498, DOI 10.1016/j.jpowsour.2008.02.002; Ikeda S, 2003, J PHOTOCH PHOTOBIO A, V160, P61, DOI 10.1016/S1010-6030(03)00222-3; Peng TY, 2008, CHEM PHYS LETT, V460, P216, DOI 10.1016/j.cplett.2008.06.001; Abe R, 2013, J AM CHEM SOC, V135, P16872, DOI 10.1021/ja4048637; Watanabe M, 2014, J MATER CHEM A, V2, P12952, DOI 10.1039/c4ta02720e; TEZE A, 1977, J INORG NUCL CHEM, V39, P999, DOI 10.1016/0022-1902(77)80251-0; Liu X, 2013, PHOTOCH PHOTOBIO SCI, V12, P1903, DOI 10.1039/c3pp50167a; Hisatomi T, 2014, CHEM SOC REV, V43, P7520, DOI 10.1039/c3cs60378d; Kato CN, 2013, APPL CATAL A-GEN, V452, P69, DOI 10.1016/j.apcata.2012.12.001; Kato CN, 2012, DALTON T, V41, P10021, DOI 10.1039/c2dt30915g; KIMURA K, 1970, B CHEM SOC JPN, V43, P1329, DOI 10.1246/bcsj.43.1329; Liu X, 2013, INT J HYDROGEN ENERG, V38, P11709, DOI 10.1016/j.ijhydene.2013.06.095; Ma R-H, 2011, HUAXUE SHIJI, V33, P307; Ngweniform P, 2007, J PHOTOCH PHOTOBIO A, V189, P198, DOI 10.1016/j.jphotochem.2007.01.031; Pope M. T., 1983, HETEROPOLY ISOPOLY O; Pope M.T., 1994, POLYOXOMETALATES PLA; Ravotto L, 2014, J PHYS CHEM LETT, V5, P798, DOI 10.1021/jz500160w; Sreethawong T, 2009, J POWER SOURCES, V190, P513, DOI 10.1016/j.jpowsour.2009.01.054; Zheng HQ, 2013, INT J HYDROGEN ENERG, V38, P12938, DOI 10.1016/j.ijhydene.2013.04.138	34	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1011-372X	1572-879X		CATAL LETT	Catal. Lett.	SEP	2015	145	9					1703	1709		10.1007/s10562-015-1574-8		7	Chemistry, Physical	Chemistry	CP3JS	WOS:000359775800006		
J	Nakayama, N; Takahashi, M				Nakayama, Norio; Takahashi, Masayoshi			Catalytic Hydrogenation of Nitrate in Water Using a Pd-Cu/Al2O3 Catalyst and Dilute H-2 Microbubbles	CATALYSIS LETTERS			English	Article						Microbubble; Nitrate; Hydrogen; Hydrogenation; Catalyst; Catalysis	REDOX REACTIONS; DRINKING-WATER; REMOVAL; REDUCTION; PLATINUM; AMMONIA; NITRITE	The catalytic hydrogenation of nitrate was performed in solutions containing 20 mg/dm(3) using a Pd-Cu/Al2O3 catalyst (synthesized with a Cu/Pd ratio of 0.25) together with microbubbles (radii < 50 mu m) of 9.4-43.7 % H-2 in N-2. Significant enhancement of the hydrogenation rate was observed due to the application of the microbubbles. The nitrate conversion factors for microbubble hydrogenation were approximately 1.7-3.8 times greater than those obtained using conventional macrobubbles (radii > 1500 mu m). The application of microbubbles was also effective during hydrogenation in a more concentrated nitrate solution containing 77 mg/dm(3) . [GRAPHICS] .	[Nakayama, Norio; Takahashi, Masayoshi] Natl Inst Adv Ind Sci & Technol, Environm Management Res Inst, Tsukuba, Ibaraki 3058569, Japan	Nakayama, N (reprint author), Natl Inst Adv Ind Sci & Technol, Environm Management Res Inst, 16-1 Onogawa, Tsukuba, Ibaraki 3058569, Japan.	n.nakayama@aist.go.jp; m.taka@aist.go.jp					BARBIER J, 1994, APPL CATAL A-GEN, V116, P179, DOI 10.1016/0926-860X(94)80288-2; HOROLD S, 1993, CATAL TODAY, V17, P21, DOI 10.1016/0920-5861(93)80004-K; Epron F, 2001, J CATAL, V198, P309, DOI 10.1006/jcat.2000.3138; Barrabes N, 2011, APPL CATAL B-ENVIRON, V104, P1, DOI 10.1016/j.apcatb.2011.03.011; Takahashi M, 2007, J PHYS CHEM B, V111, P1343, DOI 10.1021/jp0669254; Gao WL, 2003, APPL CATAL B-ENVIRON, V46, P341, DOI 10.1016/S0926-3373(03)00226-1; Asano M, 2005, MITSUBISHIJUKO GIHOU, V42, P180; Hashimoto K, 2006, HANNOU KOUGAKU, P289; Neyertz C, 2010, APPL CATAL A-GEN, V372, P40, DOI 10.1016/j.apcata.2009.10.001; Pieck CL, 1996, APPL CATAL A-GEN, V134, P319, DOI 10.1016/0926-860X(95)00237-5; Pieck CL, 1995, APPL CATAL A-GEN, V133, P281, DOI 10.1016/0926-860X(95)00174-3; Qin JY, 1998, APPL CATAL B-ENVIRON, V16, P261, DOI 10.1016/S0926-3373(97)00082-9; Theologides CP, 2011, APPL CATAL B-ENVIRON, V102, P54, DOI 10.1016/j.apcatb.2010.11.024; Wang Y, 2009, APPL CATAL A-GEN, V361, P123; Wang Y, 2007, WATER RES, V41, P269, DOI 10.1016/j.watres.2006.10.035	15	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1011-372X	1572-879X		CATAL LETT	Catal. Lett.	SEP	2015	145	9					1756	1763		10.1007/s10562-015-1569-5		8	Chemistry, Physical	Chemistry	CP3JS	WOS:000359775800013		
J	Takaguri, A; Kamato, M; Satoh, Y; Ohtsuki, K; Satoh, K				Takaguri, Akira; Kamato, Maiko; Satoh, Yoshiaki; Ohtsuki, Kazuaki; Satoh, Kumi			Effect of alteration of caveolin-1 expression on doxorubicin-induced apoptosis in H9c2 cardiac cells	CELL BIOLOGY INTERNATIONAL			English	Article						apoptosis; caspase-3; caveolin-1; doxorubicin; MAP kinase family members	INDUCED CARDIOTOXICITY; ACTIVATION; PATHWAY; ERK; PROTEIN; MECHANISMS; KINASE; DEATH; JNK; CARDIOMYOCYTES	Doxorubicin is an anthracycline antibiotic widely used in cancer treatment. Although its antitumor efficacy appears to be dose dependent, its clinical use is greatly restricted by the development of cardiotoxicity associated with apoptosis. Although caveolin-1, the major structural protein in caveolae, can positively or negatively regulate apoptosis depending on the stimulus or cell types, the contribution of caveolin-1 to doxorubicin-induced apoptosis remains unknown. This study was performed to identify the regulatory role of caveolin-1 on doxorubicin-induced apoptosis in H9c2 cardiac cells using a genetic approach. Caveolin-1 knockdown with a short hairpin (sh) RNA adenovirus, but not overexpression of wild-type caveolin-1, resulted in a marked inhibition of doxorubicin-induced caspase-3 cleavage. However, caveolin-1 knockdown tended to protect against doxorubicin-induced decrease in cell viability, but it did not significantly reverse cell death induced by doxorubicin. Doxorubicin stimulated the phosphorylation of p38 and extracellular signal regulated kinase (ERK). Doxorubicin-induced caspase-3 cleavage was inhibited by U0126, a MEK inhibitor or SB203580, a p38 inhibitor. Caveolin-1 knockdown markedly inhibited doxorubicin-induced p-38 phosphorylation but not ERK-mediated p-53 phosphorylation in H9c2 cardiac cells. Our results suggest that reduced caveolin-1 expression plays an anti-apoptotic role in doxorubicin-induced apoptosis but that it is insufficient to prevent such an apoptosis in H9c2 cardiac cells.	[Takaguri, Akira; Kamato, Maiko; Satoh, Yoshiaki; Ohtsuki, Kazuaki; Satoh, Kumi] Hokkaido Pharmaceut Univ, Sch Pharm, Div Pharmacol, Otaru, Hokkaido 0470264, Japan	Satoh, K (reprint author), Hokkaido Pharmaceut Univ, Sch Pharm, Div Pharmacol, 7-1 Katsuraoka, Otaru, Hokkaido 0470264, Japan.	kumi@hokuyakudai.ac.jp			JSPS KAKENHI [25860064]; Hokkaido Pharmaceutical University	Thanks to Dr Allison Bourne for editing assistance. This work was supported in part by the JSPS KAKENHI grant Number 25860064 and the Science Research Promotion Fund and an Education and Research Grant from Hokkaido Pharmaceutical University.	Alvarez S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016100; Gortazar AR, 2013, J BIOL CHEM, V288, P8168, DOI 10.1074/jbc.M112.437921; Das J, 2011, BIOCHEM PHARMACOL, V81, P891, DOI 10.1016/j.bcp.2011.01.008; Pongjit K, 2011, MOL CELL BIOCHEM, V358, P365, DOI 10.1007/s11010-011-0988-x; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Zhang S, 2012, NAT MED, V18, P1639, DOI 10.1038/nm.2919; Ludke ARL, 2009, CAN J PHYSIOL PHARM, V87, P756, DOI 10.1139/Y09-059; Guo RM, 2013, MOL MED REP, V8, P603, DOI 10.3892/mmr.2013.1554; Liu JH, 2008, AM J PHYSIOL-HEART C, V295, pH1956, DOI 10.1152/ajpheart.00407.2008; Brantley-Finley C, 2003, BIOCHEM PHARMACOL, V66, P459, DOI 10.1016/S0006-2952(03)00255-7; Boscher C, 2012, ADV EXP MED BIOL, V729, P29, DOI 10.1007/978-1-4614-1222-9_3; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122; Smith NJ, 2006, HYPERTENSION, V48, P173, DOI 10.1161/01.HYP.0000232641.84521.92; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Callera GE, 2007, CURR OPIN NEPHROL HY, V16, P90, DOI 10.1097/MNH.0b013e328040bfbd; Schleich K, 2013, CELL CYCLE, V12, P193, DOI 10.4161/cc.23464; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Chang WT, 2011, J CELL BIOCHEM, V112, P2873, DOI 10.1002/jcb.23201; Lei MG, 2000, INFECT IMMUN, V68, P5084, DOI 10.1128/IAI.68.9.5084-5089.2000; Kang YJ, 2000, J BIOL CHEM, V275, P13690, DOI 10.1074/jbc.275.18.13690; Sun B, 2012, J CELL BIOCHEM, V113, P473, DOI 10.1002/jcb.23371; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17; Brown L, 2006, J BIOL CHEM, V281, P3832, DOI 10.1074/jbc.M507951200; Hu Weilin, 2013, Cell Microbiol, V15, P1642, DOI 10.1111/cmi.12141; Meyer C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.204; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Peterson TE, 2003, ARTERIOSCL THROM VAS, V23, P1521, DOI 10.1161/01.ATV.0000081743.35125.05; Subramaniam S, 2004, J CELL BIOL, V165, P357, DOI 10.1083/jcb.200403028; Takaguri A, 2011, J MOL CELL CARDIOL, V50, P545, DOI 10.1016/j.yjmcc.2010.12.009; Tencer L, 2008, ANTICANCER RES, V28, P895; Venkatakrishnan CD, 2008, AM J PHYSIOL-HEART C, V294, P1736; Zou HF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039379	36	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-6995	1095-8355		CELL BIOL INT	Cell Biol. Int.	SEP	2015	39	9					1053	1060		10.1002/cbin.10478		8	Cell Biology	Cell Biology	CP2ZA	WOS:000359745400008		
J	Takeda, N; Maemura, K				Takeda, Norihiko; Maemura, Koji			The role of clock genes and circadian rhythm in the development of cardiovascular diseases	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Review						Biological clock; Molecular clock; Myocardial infarction; Endothelial function; Heart; Vasculature; Arrhythmia	PLASMINOGEN-ACTIVATOR INHIBITOR-1; SUDDEN CARDIAC DEATH; MYOCARDIAL-INFARCTION; CONTRACTILE FUNCTION; ENDOTHELIAL FUNCTION; DIURNAL-VARIATION; HEART-DISEASE; VENTRICULAR TACHYARRHYTHMIAS; CARDIOVERTER-DEFIBRILLATOR; BMAL1-DEFICIENT MICE	The time of onset of cardiovascular disorders such as myocardial infarctions or ventricular arrhythmias exhibits a circadian rhythm. Diurnal variations in autonomic nervous activity, plasma cortisol level or renin-angiotensin activity underlie the pathogenesis of cardiovascular diseases. Transcriptional-translational feedback loop of the clock genes constitute a molecular clock system. In addition to the central clock in the suprachiasmatic nucleus, clock genes are also expressed in a circadian fashion in each organ to make up the peripheral clock. The peripheral clock seems to be beneficial for anticipating external stimuli and thus contributes to the maintenance of organ homeostasis. Loss of synchronization between the central and peripheral clocks also augments disease progression. Moreover, accumulating evidence shows that clock genes affect inflammatory and intracellular metabolic signaling. Elucidating the roles of the molecular clock in cardiovascular pathology through the identification of clock controlled genes will help to establish a novel therapeutic approach for cardiovascular disorders.	[Takeda, Norihiko] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; [Maemura, Koji] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cardiovasc Med, Nagasaki 8528501, Japan	Takeda, N (reprint author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	ntakeda-tky@umin.ac.jp; maemura@nagasaki-u.ac.jp			Japan Society for the Promotion of Science, Japan [25461113]	This study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, Japan (to K.M. and N.T. 25461113).	Anea CB, 2010, ARTERIOSCL THROM VAS, V30, P2535, DOI 10.1161/ATVBAHA.110.214379; Anea CB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078626; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; DiTacchio L, 2011, SCIENCE, V333, P1881, DOI 10.1126/science.1206022; Jeyaraj D, 2012, NATURE, V483, P96, DOI 10.1038/nature10852; Eckle T, 2012, NAT MED, V18, P774, DOI 10.1038/nm.2728; Hurd MW, 1998, J BIOL RHYTHM, V13, P430, DOI 10.1177/074873098129000255; Englund A, 1999, J AM COLL CARDIOL, V34, P1560, DOI 10.1016/S0735-1097(99)00369-1; Penev PD, 1998, AM J PHYSIOL-HEART C, V275, pH2334; KURNIK PB, 1995, CIRCULATION, V91, P1341; Lefta M, 2012, AM J PHYSIOL-HEART C, V303, pH475, DOI 10.1152/ajpheart.00238.2012; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Viswambharan H, 2007, CIRCULATION, V115, P2188, DOI 10.1161/CIRCULATIONAHA.106.653303; Takeda N, 2007, J BIOL CHEM, V282, P32561, DOI 10.1074/jbc.M705692200; Grimaldi B, 2010, CELL METAB, V12, P509, DOI 10.1016/j.cmet.2010.10.005; Nguyen KD, 2013, SCIENCE, V341, P1483, DOI 10.1126/science.1240636; Alibhai FJ, 2014, CIRC RES, V114, P1713, DOI 10.1161/CIRCRESAHA.114.302995; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; Schoenhard JA, 2003, J MOL CELL CARDIOL, V35, P473, DOI 10.1016/S0022-2828(03)0051-8; Laposky A, 2005, SLEEP, V28, P395; Hirayama J, 2007, NATURE, V450, P1086, DOI 10.1038/nature06394; Naito Y, 2003, J HYPERTENS, V21, P1107, DOI 10.1097/01.hjh.0000059048.65882.e4; Andrews JL, 2010, P NATL ACAD SCI USA, V107, P19090, DOI 10.1073/pnas.1014523107; Takeda N, 2011, J CARDIOL, V57, P249, DOI 10.1016/j.jjcc.2011.02.006; Anea CB, 2009, CIRCULATION, V119, P1510, DOI 10.1161/CIRCULATIONAHA.108.827477; Durgan DJ, 2006, J BIOL CHEM, V281, P24254, DOI 10.1074/jbc.M601704200; Aguilar-Arnal L, 2013, CURR OPIN CELL BIOL, V25, P170, DOI 10.1016/j.ceb.2013.01.003; Alvarez JD, 2008, J BIOL RHYTHM, V23, P26, DOI 10.1177/0748730407311254; Nonaka H, 2001, CIRCULATION, V104, P1746, DOI 10.1161/hc4001.098048; Sasaki M, 2009, J BIOL CHEM, V284, P25149, DOI 10.1074/jbc.M109.040758; Charloux A, 1999, AM J PHYSIOL-ENDOC M, V276, pE43; Bray MS, 2008, AM J PHYSIOL-HEART C, V294, pH1036, DOI 10.1152/ajpheart.01291.2007; Sato S, 2014, J IMMUNOL, V192, P407, DOI 10.4049/jimmunol.1301982; Durgan DJ, 2011, CHRONOBIOL INT, V28, P187, DOI 10.3109/07420528.2010.550406; Katada S, 2010, NAT STRUCT MOL BIOL, V17, P1414, DOI 10.1038/nsmb.1961; Takeda N, 2010, HYPERTENS RES, V33, P645, DOI 10.1038/hr.2010.68; Bunger MK, 2005, GENESIS, V41, P122, DOI 10.1002/gene.20102; Doi M, 2006, CELL, V125, P497, DOI 10.1016/j.cell.2006.03.033; Sun YM, 2006, J BIOMED SCI, V13, P845, DOI 10.1007/s11373-006-9108-4; Patton KK, 2014, J AM COLL CARDIOL, V63, P2702, DOI 10.1016/j.jacc.2013.11.072; Otto ME, 2004, CIRCULATION, V109, P2507, DOI 10.1161/01.CIR.0000128207.26863.C4; Jensen LD, 2012, CELL REP, V2, P231, DOI 10.1016/j.celrep.2012.07.005; Anea CB, 2012, CIRC RES, V111, P1157, DOI 10.1161/CIRCRESAHA.111.261750; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Liu AC, 2007, CELL, V129, P605, DOI 10.1016/j.cell.2007.02.047; Shi SQ, 2010, CURR BIOL, V20, P316, DOI 10.1016/j.cub.2009.12.034; Partch CL, 2014, TRENDS CELL BIOL, V24, P90, DOI 10.1016/j.tcb.2013.07.002; Bell-Pedersen D, 2005, NAT REV GENET, V6, P544, DOI 10.1038/nrg1633; Bagai K, 2014, SLEEP, V37, P359, DOI 10.5665/sleep.3414; BEHRENS S, 1995, AM HEART J, V130, P79, DOI 10.1016/0002-8703(95)90239-2; BEXTON RS, 1986, BRIT HEART J, V55, P253; BRIDGES AB, 1993, BRIT HEART J, V69, P121; Chalmers JA, 2008, AM J PHYSIOL-REG I, V295, pR1529, DOI 10.1152/ajpregu.90572.2008; Cheng B, 2011, P NATL ACAD SCI USA, V108, P17147, DOI 10.1073/pnas.1112998108; CINCA J, 1990, ANN NY ACAD SCI, V601, P222, DOI 10.1111/j.1749-6632.1990.tb37303.x; Durgan DJ, 2005, AM J PHYSIOL-HEART C, V289, pH1530, DOI 10.1152/ajpheart.00406.2005; Durgan DJ, 2011, J BIOL CHEM, V286, P44606, DOI 10.1074/jbc.M111.278903; FUJITA M, 1987, CIRCULATION, V76, P488; GILLIS AM, 1992, AM J CARDIOL, V69, P1009, DOI 10.1016/0002-9149(92)90855-S; Guney HZ, 1998, CHRONOBIOL INT, V15, P159, DOI 10.3109/07420529808998680; HARTIKAINEN J, 1993, CLIN PHYSIOL, V13, P185, DOI 10.1111/j.1475-097X.1993.tb00379.x; Hemmeryckx B, 2011, ARTERIOSCL THROM VAS, V31, P2552, DOI 10.1161/ATVBAHA.111.229062; Hirayama J, 2005, CURR OPIN GENET DEV, V15, P548, DOI 10.1016/j.gde.2005.07.003; KOBRIN I, 1984, J AM GERIATR SOC, V32, P896; Kozak M, 2003, PACE, V26, P731, DOI 10.1046/j.1460-9592.2003.00124.x; Kung TA, 2007, J MOL CELL CARDIOL, V43, P744, DOI 10.1016/j.yjmcc.2007.08.018; Ma HL, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000235; Maemura K, 2000, J BIOL CHEM, V275, P36847, DOI 10.1074/jbc.C000629200; Maemura K, 2001, ANN NY ACAD SCI, V947, P398; Martino TA, 2008, AM J PHYSIOL-REG I, V294, pR1675, DOI 10.1152/ajpregu.00829.2007; Al Mheid I, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000845; ODA E, 1985, TOHOKU J EXP MED, V145, P419, DOI 10.1620/tjem.145.419; ORTH DN, 1967, J CLIN ENDOCR METAB, V27, P549; Polidarova L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075690; Saito T, 2013, CIRCULATION, V127, P104, DOI 10.1161/CIRCULATIONAHA.112.135608; Schibler U, 2005, EMBO REP, V6, pS9, DOI 10.1038/sj.embor.7400424; Schroder EA, 2013, AM J PHYSIOL-CELL PH, V304, pC954, DOI 10.1152/ajpcell.00383.2012; STEINBACH K, 1982, PACE, V5, P38, DOI 10.1111/j.1540-8159.1982.tb02190.x; STERN N, 1986, J HYPERTENS, V4, P543, DOI 10.1097/00004872-198610000-00005; Westgate EJ, 2008, CIRCULATION, V117, P2087, DOI 10.1161/CIRCULATIONAHA.107.739227; WILLICH SN, 1993, CIRCULATION, V87, P1442; Yamashita T, 2003, CIRCULATION, V107, P1917, DOI 10.1161/01.CIR.0000058752.79734.F0; Young ME, 2001, CIRC RES, V88, P1142, DOI 10.1161/hh1101.091190; Young ME, 2006, AM J PHYSIOL-HEART C, V290, pH1, DOI 10.1152/ajpheart.00582.2005; Young ME, 2014, J BIOL RHYTHM, V29, P257, DOI 10.1177/0748730414543141; Young ME, 2001, CIRC RES, V89, P1199, DOI 10.1161/hh2401.100741; Young ME, 2002, J MOL CELL CARDIOL, V34, P223, DOI 10.1006/jmcc.2001.1504	88	1	1	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1420-682X	1420-9071		CELL MOL LIFE SCI	Cell. Mol. Life Sci.	SEP	2015	72	17					3225	3234		10.1007/s00018-015-1923-1		10	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	CO8UC	WOS:000359446600002		
J	Woolley, H; Kinoshita, I				Woolley, Helen; Kinoshita, Isami			Space, People, Interventions and Time (SPIT): A Model for Understanding Children's Outdoor Play in Post-Disaster Contexts Based On a Case Study from the Triple Disaster Area of Tohoku in North-East Japan	CHILDREN & SOCIETY			English	Article						children; play; disaster; outdoor environments; Japan		Play in the outdoor environment is important for children as part of their childhood and is particularly important for children in a post-disaster situation. This article explores issues around outdoor play opportunities in the Tohoku region of north-east Japan, 13months after the triple disaster of earthquake, tsunami and nuclear power plant failure. A model of space, people, interventions and time (SPIT) is used to understand the situation in this unique case study.	[Woolley, Helen] Univ Sheffield, Dept Landscape, Sheffield S10 2TN, S Yorkshire, England; [Kinoshita, Isami] Chiba Univ, Dept Landscape Architecture, Matsudo, Chiba, Japan	Woolley, H (reprint author), Univ Sheffield, Dept Landscape, Chartered Landscape Architect Reader Landscape Ar, Sheffield S10 2TN, S Yorkshire, England.	h.woolley@sheffield.ac.uk			Daiwa Anglo-Japanese Foundation	Both authors thank the Daiwa Anglo-Japanese Foundation for the small award, which enabled the research reported in this article to take place. The first author is grateful to the second author for making the arrangements for their site visits, interviews and conversations, travel and accommodation during the 10 days they spent in the study area. She is very grateful to Chisato Nagatomo who acted as interpreter. Both authors would like to acknowledge the time given by all the people they met during their journey and particularly thank everyone they interviewed and had conversations with. The first author would also like to acknowledge that the 10-day visit to the Tohoku area was a very moving as well as a significant learning experience.	[Anonymous], 2011, USGS UPD MAGN JAP 20; Boothby N, 2006, Glob Public Health, V1, P87, DOI 10.1080/17441690500324347; Cabinet Office, 2010, WHIT PAP PROT DIS AN; Cole-Hamilton I, 2002, MAKING CASE PLAY GAT; Department of Environment, 1973, CHILDR AT PLAY; Fearn M, 2012, CHILD SOC, V26, P456, DOI 10.1111/j.1099-0860.2011.00357.x; Hart R., 1979, CHILDRENS EXPERIENCE; Hole V., 1966, NATL BUILDING STUDIE; James A., 1998, THEORIZING CHILDHOOD; JMA (Japan Meteorological Agency), 2011, 1 JMA; Lauten AW, 2008, CHILDREN YOUTH ENV, V18, P158; Lester S., 2008, PLAY CHANGE PLAY POL; Matanle P., 2011, LOCAL ENV, V16, P823; Moore R. C., 1986, CHILDHOODS DOMAIN PL; Opie I, 1969, CHILDRENS GAMES STRE; Robson C., 2011, REAL WORLD RES; Senda M., 1992, DESIGN CHILDRENS PLA; Shimbunsha A, 2011, HIGASHI NIHON DAISHI; Silverman WK, 2002, CHILDREN DISASTERS F, P405; Terr LC, 2007, PLAY THERAPY CHILDRE; Webb NB, 2007, PLAY THERAPY CHILDRE; Weissbecker I, 2008, CHILDREN YOUTH ENV, V18, P31; Wheway R, 1997, CHILDS PLAY FACILITA; Woolley H., 2003, URBAN OPEN SPACE; Yin R. K., 2003, APPL SOCIAL RES METH	25	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0951-0605	1099-0860		CHILD SOC	Child. Soc.	SEP	2015	29	5					434	450		10.1111/chso.12072		17	Social Work	Social Work	CO7EV	WOS:000359323300010		
J	Liu, C; Kanamaru, Y; Watanabe, T; Tada, N; Horikoshi, S; Suzuki, Y; Liu, Z; Tomino, Y				Liu, C.; Kanamaru, Y.; Watanabe, T.; Tada, N.; Horikoshi, S.; Suzuki, Y.; Liu, Z.; Tomino, Y.			Targeted IgA Fc receptor I (Fc alpha RI) therapy in the early intervention and treatment of pristane-induced lupus nephritis in mice	CLINICAL AND EXPERIMENTAL IMMUNOLOGY			English	Article						IgA Fc receptor I; MIP-8 alpha; molecular targeting; pristane; systemic lupus erythematosus	BALB/C MICE; ANTIBODY-PRODUCTION; MURINE MODEL; GAMMA ITAM; GLOMERULONEPHRITIS; AUTOANTIBODIES; ERYTHEMATOSUS; INDUCTION; DISEASE; COMPLEX	The Fc receptor I for IgA (FcRI) down-regulates humoral immune responses and modulates the risk of autoimmunity. This study aimed to investigate whether FcRI targeting can affect progression of pristine-induced lupus nephritis. In the first experiment (early intervention), four groups of animals were evaluated: untreated FcRI/FcR transgenic (Tg) mice and Tg mice administered control antibody (Ctr Fab), saline and anti-FcRI Fab [macrophage inflammatory protein (MIP)-8a], respectively, three times a week for 29 weeks, after being injected once intraperitoneally with 05ml pristane. In the second experiment, antibody injection started after the onset of nephritis and was carried out for 2 months, with similar groups as described above. MIP-8a improved proteinuria, decreased the amounts of glomerular injury markers, serum interleukin (IL)-6, IL-1 and monocyte chemoattractant protein (MCP)-1, and F4/80 macrophages in the interstitium and glomeruli, in both experiments. When MIP-8a was used as early intervention, a decrease in mouse serum anti-nuclear antibody (ANA) titres and reduced deposition of immunoglobulins in glomeruli were observed. This effect was associated with reduced serum titres of immunoglobulin (Ig)G2a but not IgG1, IgG2b and IgG3. Furthermore, pathological analysis showed lower glomerular activity index and less fibronectin in MIP-8a treated mice. This study suggests that FcRI targeting could halt disease progression and lupus activation by selective inhibition of cytokine production, leucocyte recruitment and renal inflammation. Our findings provide a basis for the use of FcRI as a molecular target for the treatment of lupus.	[Liu, C.; Kanamaru, Y.; Watanabe, T.; Horikoshi, S.; Suzuki, Y.; Tomino, Y.] Juntendo Univ, Fac Med, Dept Internal Med, Div Nephrol, Tokyo 1138421, Japan; [Liu, C.; Liu, Z.] Nanjing Univ, Natl Clin Res Ctr Kidney Dis, Jinling Hosp, Sch Med, Nanjing 210008, Jiangsu, Peoples R China; [Tada, N.] Juntendo Univ, Fac Med, Res Inst Dis Old Age, Tokyo 1138421, Japan	Tomino, Y (reprint author), Juntendo Univ, Fac Med, Dept Internal Med, Div Nephrol, Tokyo 1138421, Japan.	yasu@juntendo.ac.jp					Lattanzio G, 1997, AM J PATHOL, V151, P689; Richards HB, 1998, J EXP MED, V188, P985, DOI 10.1084/jem.188.5.985; AUSTIN HA, 1983, AM J MED, V75, P382, DOI 10.1016/0002-9343(83)90338-8; Reeves WH, 2009, TRENDS IMMUNOL, V30, P455, DOI 10.1016/j.it.2009.06.003; Bartoe JL, 2000, J NEUROCHEM, V74, P2021, DOI 10.1046/j.1471-4159.2000.0742021.x; Lecocq M, 2013, J IMMUNOL, V190, P2362, DOI 10.4049/jimmunol.1201128; Nacionales DC, 2007, ARTHRITIS RHEUM, V56, P3770, DOI 10.1002/art.23023; Bolland S, 2002, J EXP MED, V195, P1167, DOI 10.1084/jem.20020165; Pasquier B, 2005, IMMUNITY, V22, P31, DOI 10.1016/j.immuni.2004.11.017; Seery JP, 1997, J EXP MED, V186, P1451, DOI 10.1084/jem.186.9.1451; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Kanamaru Y, 2007, EUR J IMMUNOL, V37, P1116, DOI 10.1002/eji.200636826; SATOH M, 1994, J EXP MED, V180, P2341, DOI 10.1084/jem.180.6.2341; Suzuki H, 2011, J AM SOC NEPHROL, V22, P1795, DOI 10.1681/ASN.2011050464; Summers SA, 2010, J AUTOIMMUN, V35, P291, DOI 10.1016/j.jaut.2010.05.004; van der Steen LP, 2012, J IMMUNOL, V189, P1594, DOI 10.4049/jimmunol.1101763; Patten C, 2004, ARTHRITIS RHEUM-US, V50, P3334, DOI 10.1002/art.20507; SATOH M, 1995, P NATL ACAD SCI USA, V92, P10934, DOI 10.1073/pnas.92.24.10934; FINCK BK, 1994, J CLIN INVEST, V94, P585, DOI 10.1172/JCI117373; Satoh M, 2003, J AUTOIMMUN, V21, P1, DOI 10.1016/S0896-8411(03)00083-0; Clynes R, 1998, SCIENCE, V279, P1052, DOI 10.1126/science.279.5353.1052; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Nakamura A, 2000, J EXP MED, V191, P899, DOI 10.1084/jem.191.5.899; Kanamaru Y, 2008, J IMMUNOL, V180, P2669; Kanamaru Y, 2007, BLOOD, V109, P203, DOI 10.1182/blood-2006-06-025882; Kelley VR, 1999, SEMIN NEPHROL, V19, P57; KOFFLER D, 1974, AM J PATHOL, V74, P109; Koffler D, 1971, J Exp Med, V134, P169; Mitani Y, 2001, GENES CELLS, V6, P631, DOI 10.1046/j.1365-2443.2001.00448.x; PIRANI CL, 1964, NEPHRON, V1, P230, DOI 10.1159/000179336; Vuong MT, 2010, PLOS ONE, V5; Watanabe T, 2011, CLIN EXP IMMUNOL, V166, P235, DOI 10.1111/j.1365-2249.2011.04452.x	32	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9104	1365-2249		CLIN EXP IMMUNOL	Clin. Exp. Immunol.	SEP	2015	181	3					407	416		10.1111/cei.12647		10	Immunology	Immunology	CP2UC	WOS:000359731700003		
J	Kato, A; Imai, K; Ochiai, K; Ogata, Y				Kato, Ayako; Imai, Kenichi; Ochiai, Kuniyasu; Ogata, Yorimasa			Prevalence and quantitative analysis of Epstein-Barr virus DNA and Porphyromonas gingivalis associated with Japanese chronic periodontitis patients	CLINICAL ORAL INVESTIGATIONS			English	Article						Chronic periodontitis; Epstein-Barr virus; Periodontopathic bacteria	REAL-TIME PCR; PERIODONTOPATHIC BACTERIA; SALIVARY CYTOMEGALOVIRUS; HERPESVIRUSES; DISEASE; LESIONS; QUANTIFICATION; PATHOGENS; EBV	A number of studies have recently suggested Epstein-Barr virus (EBV) involvement in the pathogenesis of periodontitis. In this study, we investigated the association between major periodontopathic bacteria Porphyromonas gingivalis (P. gingivalis) and EBV in Japanese chronic periodontitis (CP) patients. A group of 25 patients with CP participated in the study along with 13 individuals without periodontitis. Subgingival samples were obtained with paper points. Quantitative real-time polymerase chain reaction (PCR) was used to detect EBV DNA and P. gingivalis. In the CP patients, EBV DNA and P. gingivalis were detected in both 80 % of sites with probing pocket depths (PPD) of a parts per thousand yen5 mm and in 40 and 36 % of sites with PPD a parts per thousand currency sign3 mm, respectively. EBV DNA and P. gingivalis were detected in 50 and 27 % of the sites in periodontally healthy individuals. Coexistence of EBV DNA and P. gingivalis was significantly higher in the deeper PPD sites of CP patients (68 %) than in the PPD sites of the healthy controls (15 %) and shallow PPD sites of CP patients (12 %). PCR-positive deeper PPD sites of CP patients for EBV DNA and P. gingivalis range between 3.74 x 10(3 similar to)2.83 x 10(9) and 2.73 x 10(5)similar to 6.65 x 10(9) (copies/ml), respectively. These results suggest an association between EBV DNA, P. gingivalis, and CP in Japanese individuals. Further studies are required to clarify this association; however, we believe that our enhanced understanding of the pathogenesis of periodontal diseases involving viral infections will lead to new treatments.	[Kato, Ayako; Ogata, Yorimasa] Nihon Univ, Sch Dent Matsudo, Dept Periodontol, Chiba 2718587, Japan; [Imai, Kenichi; Ochiai, Kuniyasu] Nihon Univ, Sch Dent, Dent Res Ctr, Dept Microbiol,Div Immunol & Pathobiol, Tokyo 1028310, Japan; [Ogata, Yorimasa] Nihon Univ, Sch Dent Matsudo, Res Inst Oral Sci, Chiba 2718587, Japan	Ogata, Y (reprint author), Nihon Univ, Sch Dent Matsudo, Dept Periodontol, Chiba 2718587, Japan.	ogata.yorimasa@nihon-u.ac.jp			Nihon University Multidisciplinary Research Grant [25463229]; Ministry of Education, Culture, Sports, Science, and Technology, Japan (MEXT) [S1001024]	This work was supported in part by a Grant-in-Aid for Scientific Research (C; No. 25463229), Nihon University Multidisciplinary Research Grant for 2014, and a grant of Strategic Research Base Development Program for Private Universities from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (MEXT), 2010-2014 (S1001024).	Imai K, 2012, BIOCHIMIE, V94, P839, DOI 10.1016/j.biochi.2011.12.001; Watanabe T, 2011, J BACTERIOL, V193, P4259, DOI 10.1128/JB.05269-11; Sakamoto M, 2001, MICROBIOL IMMUNOL, V45, P39; Idesawa M, 2004, ORAL MICROBIOL IMMUN, V19, P230, DOI 10.1111/j.1399-302X.2004.00144.x; Contreras A, 2000, J PERIODONTAL RES, V35, P3, DOI 10.1034/j.1600-0765.2000.035001003.x; Ximenez-Fyvie LA, 2000, J CLIN PERIODONTOL, V27, P648, DOI 10.1034/j.1600-051x.2000.027009648.x; Saygun I, 2008, J PERIODONTAL RES, V43, P352, DOI 10.1111/j.1600-0765.2007.01043.x; Tao Q, 2006, FRONT BIOSCI, V11, P2672, DOI 10.2741/2000; Chalabi M, 2010, MOL ORAL MICROBIOL, V25, P236, DOI 10.1111/j.2041-1014.2010.00571.x; Slots J, 2011, PERIODONTOL 2000, V55, P48, DOI 10.1111/j.1600-0757.2010.00361.x; Timms JM, 2003, LANCET, V361, P217, DOI 10.1016/S0140-6736(03)12271-4; Toussirot E, 2008, BEST PRACT RES CL RH, V22, P883, DOI 10.1016/j.berh.2008.09.007; Slots J, 2010, PERIODONTOL 2000, V53, P89, DOI 10.1111/j.1600-0757.2009.00325.x; Saygun I, 2005, J PERIODONTAL RES, V40, P187, DOI 10.1111/j.1600-0765.2005.00790.x; Slots J, 2010, PERIODONTOL 2000, V52, P117, DOI 10.1111/j.1600-0757.2009.00308.x; Contreras A, 2000, ORAL MICROBIOL IMMUN, V15, P15, DOI 10.1034/j.1399-302x.2000.150103.x; Slots J, 2006, J PERIODONTAL RES, V41, P235, DOI 10.1111/j.1600-0765.2006.00865.x; Saygun I, 2004, J PERIODONTAL RES, V39, P207, DOI 10.1111/j.1600-0765.2004.00728.x; Kubar A, 2005, J PERIODONTAL RES, V40, P97, DOI 10.1111/j.1600-0765.2005.00770.x; Maeda E, 2009, JPN J RADIOL, V27, P4, DOI 10.1007/s11604-008-0291-2; Haffajee AD, 2005, PERIODONTOL 2000, V38, P9, DOI 10.1111/j.1600-0757.2005.00112.x; Ikuta K, 2000, MICROBES INFECT, V2, P115, DOI 10.1016/S1286-4579(00)00277-X; Imai K, 2012, J ORAL BIOSCI, V54, P164; Kato A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071990; Kinane DF, 2005, J CLIN PERIODONTOL, V32, P130, DOI 10.1111/j.1600-051X.2005.00823.x; Klemenc P, 2005, J CLIN VIROL, V34, P147, DOI 10.1016/j.jcv.2005.03.001; LIN JC, 1993, BLOOD, V81, P3372; LISTGARTEN MA, 1995, J PERIODONTOL, V66, P158; Sahin S, 2009, ORAL MICROBIOL IMMUN, V24, P340, DOI 10.1111/j.1399-302X.2009.00528.x; TAKADA K, 1991, VIRUS GENES, V5, P147, DOI 10.1007/BF00571929; Thorley-Lawson DA, 2004, NEW ENGL J MED, V350, P1328, DOI 10.1056/NEJMra032015; Ting M, 2000, J PERIODONTAL RES, V35, P17, DOI 10.1034/j.1600-0765.2000.035001017.x; Vincent-Bugnas S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080336	33	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1432-6981	1436-3771		CLIN ORAL INVEST	Clin. Oral Investig.	SEP	2015	19	7					1605	1610		10.1007/s00784-014-1387-y		6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CP3YV	WOS:000359819900006		
J	Chen, WW; Newman, C; Liu, ZJ; Kaneko, Y; Omote, K; Masuda, R; Buesching, CD; Macdonald, DW; Xie, ZQ; Zhou, YB				Chen, Wenwen; Newman, Chris; Liu, Zhijin; Kaneko, Yayoi; Omote, Keita; Masuda, Ryuichi; Buesching, Christina D.; Macdonald, David W.; Xie, Zongqiang; Zhou, Youbing			The illegal exploitation of hog badgers (Arctonyx collaris) in China: genetic evidence exposes regional population impacts	CONSERVATION GENETICS RESOURCES			English	Article						Deme; Genetic diversity; Genetic structure; Hunting; Microsatellite; Wildlife trade	MELES-MELES; EURASIAN BADGER; MICROSATELLITE; CONSERVATION; MUSTELIDAE; DIVERSITY; CARNIVORA; MAMMALIA; ECOLOGY; TRADE	Although the impacts of the legal and illegal wildlife trade are broadly recognised for flagship species (e.g., elephant, rhino and tiger), less is known about how exploitation affects more common, and less charismatic species. This is of especial concern in Asia in general, and particularly in China, where demands for wild game species, and derived products are increasing, but a lack of data on illegal bushmeat hunting limits the development of effective species and ecosystem conservation measures. Genetic monitoring provides an informative tool to assess the pressures on regional populations, particularly for species that are difficult to monitor, for example, using arboreal or subterranean refugia. Here, using microsatellite markers, we investigated the effect of hunting on the genetic diversity of a regional population of the hog badger. Samples were collected from hog badgers confiscated from illegal traffickers and local hunters by forest authorities in the market towns of Wufeng and Yuguan, which lie 40 km apart in Hubei Province, China. To isolate novel hog badger microsatellite loci, we constructed a biotin-enriched microsatellite DNA library. Furthermore, we also tested the suitability of microsatellite loci designed for the European badger in the hog badger. Using these microsatellite markers, we found that these seized hog badgers exhibited a high level of genetic diversity-mean alleles per locus (A) were 8.33 and mean expected heterozygosities (H (E)) were 0.77. Despite 40 km separation between sample sites, spatial segregation was not apparent from genetics. This suggests that our confiscated hog badgers belong to the same meta-population. Although limited by a lack of geographical data on the source of these hog badgers, preventing the analysis of isolation by distance effects, hunting likely eroded hog badger population social structure, promoting gene flow among demes. We conclude that the exploitation of this wild source population seems unsustainable.	[Chen, Wenwen; Xie, Zongqiang; Zhou, Youbing] Chinese Acad Sci, Inst Bot, State Key Lab Vegetat & Environm Change, Beijing 100093, Peoples R China; [Chen, Wenwen] Nanjing Univ, Dept Biol, Nanjing 210093, Jiangsu, Peoples R China; [Newman, Chris; Buesching, Christina D.; Macdonald, David W.; Zhou, Youbing] Univ Oxford, Recanati Kaplan Ctr, Dept Zool, Wildlife Conservat Res Unit, Abingdon OX13 5QL, Oxon, England; [Liu, Zhijin] Chinese Acad Sci, Inst Zool, Beijing 100093, Peoples R China; [Kaneko, Yayoi] Tokyo Univ Agr & Technol, Inst Agr, Div Ecosci, Carnivore Ecol & Conservat Res Grp, Tokyo 1838509, Japan; [Omote, Keita; Masuda, Ryuichi] Hokkaido Univ, Grad Sch Sci, Sapporo, Hokkaido 0600810, Japan	Zhou, YB (reprint author), Chinese Acad Sci, Inst Bot, State Key Lab Vegetat & Environm Change, Beijing 100093, Peoples R China.	zhouyb@ibcas.ac.cn			Japan Society for the Promotion of Science [22405003, 26257404]; Special Fund for Public Service - National Environmental Protection Ministry of China [201309039]; Recanati-Kaplan Foundation; Peoples' Trust for Endangered Species	We thank M. Li, B. S. Wang, J. Chen, S. Yuan, G. J. Liu, F. L. Shi, G. H. Jiang and X. Q. Zhu for their assistance during this research. We are grateful to the State Forestry Administration, China, and the Wildlife Conservation Station, Wufeng County Forestry Bureau in Hubei Province, for granting us permission to conduct this study. This work was supported in part by Grants-in-Aid Scientific Research (Nos. 22405003 and 26257404) from the Japan Society for the Promotion of Science and the Special Fund for Public Service sponsored by National Environmental Protection Ministry of China (201309039). DWM gratefully acknowledges the support of the Recanati-Kaplan Foundation and the Peoples' Trust for Endangered Species.	Alacs EA, 2010, FORENSIC SCI MED PAT, V6, P180, DOI 10.1007/s12024-009-9131-7; Annavi G, 2011, CONSERV GENET RESOUR, V3, P515, DOI 10.1007/s12686-011-9392-9; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.2307/2409177; Kalinowski ST, 2007, MOL ECOL, V16, P1099, DOI 10.1111/j.1365-294X.2007.03089.x; Pope LC, 2006, MOL ECOL, V15, P371, DOI 10.1111/j.1365-294X.2005.02815.x; Fa JE, 2002, CONSERV BIOL, V16, P232, DOI 10.1046/j.1523-1739.2002.00275.x; Harris RB, 2002, WILDLIFE SOC B, V30, P634; Excoffier L, 2010, MOL ECOL RESOUR, V10, P564, DOI 10.1111/j.1755-0998.2010.02847.x; Pritchard JK, 2000, GENETICS, V155, P945; [Anonymous], 2012, CONSERV GENET RESOUR, DOI DOI 10.1007/S12686-011-9548-7; Carpenter PJ, 2003, MOL ECOL NOTES, V3, P610, DOI 10.1046/j/1471-8286.2003.00529.x; Zhang L, 2009, ETHOL ECOL EVOL, V21, P89; Domingo-Roura X, 2003, MOL ECOL, V12, P533, DOI 10.1046/j.1365-294X.2003.01707.x; Carter SP, 2007, P R SOC B, V274, P2769, DOI 10.1098/rspb.2007.0998; Zhang L, 2008, BIODIVERS CONSERV, V17, P1493, DOI 10.1007/s10531-008-9358-8; McDonald RA, 2008, TRENDS ECOL EVOL, V23, P53, DOI 10.1016/j.tree.2007.10.011; Frantz AC, 2010, HEREDITY, V104, P493, DOI 10.1038/hdy.2009.136; Van Oosterhout C, 2004, MOL ECOL NOTES, V4, P535, DOI 10.1111/j.1471-8286.2004.00684.x; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; Woodroffe R, 2006, J APPL ECOL, V43, P1, DOI 10.1111/j.1365-2664.2005.01144.x; Amos W, 1998, PHILOS T ROY SOC B, V353, P177, DOI 10.1098/rstb.1998.0200; [Anonymous], 2010, UNDERSTANDING MOTIVA; Zhou YB, 2013, BIOL CONSERV, V165, P18, DOI 10.1016/j.biocon.2013.05.007; Belkhir K., 1996, GENETIX 4 05 LOGICIE, V5000, P1996; Bijlsma R, 2000, MOL ECOL, V9, P2215; Bloor PA, 2001, MICROSATELLITE LIB E; CITES, 2013, CITES APP; Dawnay N, 2008, FORENSIC SCI INT-GEN, V2, P47, DOI 10.1016/j.fsigen.2007.08.006; DeMatteo KE, 2014, INTEGR ZOOL, V9, P623, DOI 10.1111/1749-4877.12113; Helgen KM, 2008, ZOOL J LINN SOC-LOND, V154, P353, DOI 10.1111/j.1096-3642.2008.00416.x; Hu RongLiang, 2012, Chinese Journal of Zoonoses, V28, P487; Lau MWN, 2010, MAMMAL REV, V40, P247, DOI 10.1111/j.1365-2907.2010.00163.x; Liu ZJ, 2013, INTEGR ZOOL, V8, P410, DOI 10.1111/1749-4877.12048; McNeely J.A., 1990, CONSERVING WORLDS BI; Moura AE, 2014, CONSERV GENET, V15, P405, DOI 10.1007/s10592-013-0547-y; Nevo E, 1984, EVOLUTIONARY SIGNIFI; RAYMOND M, 1995, J HERED, V86, P248; ROYLE NJ, 1992, P ROY SOC B-BIOL SCI, V247, P57, DOI 10.1098/rspb.1992.0009; Smith GC, 2008, DEV BIOLOGICALS, V131, P283; State Forestry Administration, 2000, CHECKL TERR WILDL IM; Tuyttens F. A. M., 2000, BEHAV CONSERVATION, P315; Wang S., 2004, CHINA SPECIES RED LI, V1; ZHENG S, 1988, Acta Theriologica Sinica, V8, P65; Zhou YB, 2015, EUR J WILDLIFE RES, V61, P125, DOI 10.1007/s10344-014-0881-5; Zhou YB, 2015, ECOSPHERE, V6, DOI 10.1890/ES14-00155.1; Zhou ZM, 2014, FRONT ECOL ENVIRON, V12, P97, DOI 10.1890/14.WB.001	46	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1877-7252	1877-7260		CONSERV GENET RESOUR	Conserv. Genet. Resour.	SEP	2015	7	3					697	704		10.1007/s12686-015-0467-x		8	Biodiversity Conservation; Genetics & Heredity	Biodiversity & Conservation; Genetics & Heredity	CO9UM	WOS:000359521500022		
J	Itoh, H; Kamimura, S; Hirose, K; Kojima, S				Itoh, Hajime; Kamimura, Satomi; Hirose, Kimiko; Kojima, Shigeaki			Characterization of polymorphic microsatellite markers for the tideland snail Batillaria flectosiphonata	CONSERVATION GENETICS RESOURCES			English	Article						Batillaria flectosiphonata; Microsatellite; Next-generation sequencing	PRIMERS; PROGRAM; PCR	Batillaria flectosiphonata is distributed in the Ryukyu Islands, south-western Japan, and shows genetic differentiation among island groups. This species is vulnerable to environmental fluctuations because the connectivity among the groups is low. Therefore, the conservation of each group is necessary to maintain their genetic diversity. Using next-generation sequencing, 10 microsatellite markers were developed for B. flectosiphonata. In Miyara Bay and the Sakashita River estuary, the numbers of alleles per locus were 1-9 and 1-8, and the expected heterozygosities were 0-0.859 and 0-0.655, respectively.	[Itoh, Hajime; Hirose, Kimiko; Kojima, Shigeaki] Univ Tokyo, Atmosphere & Ocean Res Inst, Kashiwa, Chiba 2778564, Japan; [Kamimura, Satomi] Osaka City Univ, Grad Sch Urban Engn, Sumiyoshi Ku, Sugimoto, Osaka 5588585, Japan	Itoh, H (reprint author), Univ Tokyo, Atmosphere & Ocean Res Inst, 5-1-5 Kashiwanoha, Kashiwa, Chiba 2778564, Japan.	hitou@aori.u-tokyo.ac.jp			Atmosphere and Ocean Research Institute at the University of Tokyo; Japan Science Society	This study was supported by the Interdisciplinary Collaborative Research Program of the Atmosphere and Ocean Research Institute at the University of Tokyo and a Sasakawa Scientific Research Grant from the Japan Science Society. We are also grateful to Junya Hirai at the National Research Institute of Fisheries Science for supporting our research.	Blacket MJ, 2012, MOL ECOL RESOUR, V12, P456, DOI 10.1111/j.1755-0998.2011.03104.x; Meglecz E, 2010, BIOINFORMATICS, V26, P403, DOI 10.1093/bioinformatics/btp670; Holleley CE, 2009, BIOTECHNIQUES, V46, P511, DOI 10.2144/000113156; Kojima S, 2003, ZOOL SCI, V20, P1423, DOI 10.2108/zsj.20.1423; Okinawa Prefecture, 2005, RED DAT OK, V2nd	5	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1877-7252	1877-7260		CONSERV GENET RESOUR	Conserv. Genet. Resour.	SEP	2015	7	3					751	753		10.1007/s12686-015-0452-4		3	Biodiversity Conservation; Genetics & Heredity	Biodiversity & Conservation; Genetics & Heredity	CO9UM	WOS:000359521500035		
J	Numata, T; Jo, R; Kobayashi, Y; Tsuboi, R; Okubo, Y				Numata, Takafumi; Jo, Risa; Kobayashi, Yuko; Tsuboi, Ryoji; Okubo, Yukari			Allergic contact dermatitis caused by adapalene	CONTACT DERMATITIS			English	Editorial Material						acne; adapalene; allergic contact dermatitis; patch test; retinoid	RETINOIC ACID; 0.1-PERCENT; ACNE; GEL		[Numata, Takafumi; Jo, Risa; Kobayashi, Yuko; Tsuboi, Ryoji; Okubo, Yukari] Tokyo Med Univ, Dept Dermatol, Tokyo 1600023, Japan	Numata, T (reprint author), Tokyo Med Univ, Dept Dermatol, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	numata921@gmail.com					BALATO N, 1995, CONTACT DERMATITIS, V32, P51, DOI 10.1111/j.1600-0536.1995.tb00846.x; Gollnick H, 2003, J AM ACAD DERMATOL, V49, pS1, DOI 10.1067/mjd.2003.618; Nast A, 2012, J EUR ACAD DERMATOL, V26, P1, DOI 10.1111/j.1468-3083.2011.04374.x; Clemmensen A, 2007, CONTACT DERMATITIS, V56, P288, DOI 10.1111/j.1600-0536.2006.00988.x; Kawashima M, 2008, J DERMATOL SCI, V49, P241, DOI 10.1016/j.jdermsci.2007.09.012; Griffiths CEM, 1998, BRIT J DERMATOL, V139, P12	6	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-1873	1600-0536		CONTACT DERMATITIS	Contact Dermatitis	SEP	2015	73	3					187	188		10.1111/cod.12410		2	Allergy; Dermatology	Allergy; Dermatology	CO7WD	WOS:000359373100010		
J	Hirohata, A; Hanafusa, T; Mabuchi-Kiyohara, E; Ikegami, R				Hirohata, Ayaki; Hanafusa, Takaaki; Mabuchi-Kiyohara, Eriko; Ikegami, Ryuta			Contact dermatitis caused by efinaconazole solution for treatment of onychomycosis	CONTACT DERMATITIS			English	Editorial Material						alkyl lactate; CAS no. 164650-44-6; efinaconazole; topical antifungal agents			[Hirohata, Ayaki; Hanafusa, Takaaki; Mabuchi-Kiyohara, Eriko; Ikegami, Ryuta] Japan Community Healthcare Org, Osaka Hosp, Dept Dermatol, Osaka 5530003, Japan	Hanafusa, T (reprint author), 4-2-78 Fukushima,Fukushima Ku, Osaka 5530003, Japan.	takafussa0710@gmail.com					Tatsumi Y, 2013, ANTIMICROB AGENTS CH, V57, P2405, DOI 10.1128/AAC.02063-12; Sugiura K, 2014, ANTIMICROB AGENTS CH, V58, P3837, DOI 10.1128/AAC.00111-14; Genova G, 1998, Int J Cosmet Sci, V20, P127, DOI 10.1046/j.1467-2494.1998.171744.x	3	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-1873	1600-0536		CONTACT DERMATITIS	Contact Dermatitis	SEP	2015	73	3					190	U73		10.1111/cod.12414		3	Allergy; Dermatology	Allergy; Dermatology	CO7WD	WOS:000359373100012		
J	Sato, I; Haga, M; Yamada, M				Sato, Ikuya; Haga, Manabu; Yamada, Mamoru			Lost and Gained in Translation: The Role of the "American Model' in the Institution-Building of a Japanese University Press	CULTURAL SOCIOLOGY			English	Article						publishing; publishers; field; institutional translation; organizational identity; organization; organizational model; Scandinavian institutionalism; scholarly publishing; university; university press; Japan; Japanese; American University of Tokyo Press		This paper presents a case study of the early history of the University of Tokyo Press (UTP), which was founded in 1951 as the first university press affiliated with a national university in Japan. We concentrate on how the American model of university publishing was used in inventive and creative ways, not only to build up and manage the UTP but also to create and solidify the emerging institution of university press publishing in Japan. Drawing upon the ideas of Scandinavian institutionalist school of organizational analysis, we contend that a certain translation' of an existing organizational model often constitutes an integral part of institutional entrepreneurship. We also argue that the process of institutional translation is inseparably related to the UTP members' search for workable missions and organizational identity within financial and institutional constraints. The UTP case suggests that to be a successful institutional entrepreneur, one has to be an effective rhetor as well.	[Sato, Ikuya] Hitotsubashi Univ, Kunitachi, Tokyo 1868601, Japan; [Haga, Manabu] Sophia Univ, Tokyo, Japan; [Yamada, Mamoru] Waseda Univ, Tokyo, Japan	Sato, I (reprint author), Hitotsubashi Univ, 2-1 Naka, Kunitachi, Tokyo 1868601, Japan.	ikuya.sato@r.hit-u.ac.jp			JSPS KAKENHI [23530618, 15H03407]	This research was supported by JSPS KAKENHI Grant Numbers23530618 and 15H03407.	AAUP, 2013, ASS AM U PRESS DIR 2; AJUP, 1988, ASS JAP U PRESS 25 A; American Council of Learned Societies, 1979, SCHOL COMM; Green SE, 2004, ACAD MANAGE REV, V29, P653; Suddaby R, 2005, ADMIN SCI QUART, V50, P35, DOI 10.2189/asqu.2005.50.1.35; DIMAGGIO PJ, 1983, AM SOCIOL REV, V48, P147, DOI 10.2307/2095101; MEYER JW, 1977, AM J SOCIOL, V83, P340, DOI 10.1086/226550; Boxenbaum E, 2009, INSTITUTIONAL WORK: ACTORS AND AGENCY IN INSTITUTIONAL STUDIES OF ORGANIZATIONS, P178, DOI 10.1017/CBO9780511596605.007; Zbaracki MJ, 1998, ADMIN SCI QUART, V43, P602, DOI 10.2307/2393677; Pedersen JS, 2006, AM BEHAV SCI, V49, P897, DOI 10.1177/0002764205284798; Bailey H, 1973, SCHOLARLY PUBL, P103; Brown L, 2007, U PUBLISHING DIGITAL; Brown R, 2013, EVERYTHING FOR SALE; Clark Burton R, 1998, CREATING ENTREPRENEU; Czarniawska B., 1996, TRANSLATING ORG CHAN; Czarniawska B, 2005, GLOBAL IDEAS; De Glas F, 1998, POETICS, V25, P379, DOI 10.1016/S0304-422X(98)00005-9; DiMaggio P J, 1988, INST PATTERNS ORGAN, V1, P3; Fukutake Sensei Tsuitobunshu Kankokai, 1990, TAD FUK MEM; Givler P, 2002, SCHOLARLY PUBL, P107; Glynn M. A., 2008, SAGE HDB ORG I, P413; Green SE, 2009, ACAD MANAGE J, V52, P11; Greenwood R., 2012, I THEORY ORG STUDIES; Greenwood R., 2008, SAGE HDB ORG I; Hardy C., 2008, SAGE HDB ORG I, P198; Hatch MJ, 2004, ORG IDENTITY; Ishii K, 1988, MY DAYS U PRESS; Kerr C, 1949, AM U PUBLISHER; Kerr C, 1949, AM U PUBLISHER DIGES; Maruyama M, 1975, SHIGERU NAMBARA MEMO; Meyer JW, 1997, AM J SOCIOL, V103, P144; MEYER S, 1980, SCHOLARLY PUBL, V11, P213; Minowa S, 1983, PUBLISHING HIST; Minowa S, 1973, SCHOLARLY PUBLISHING, pxvi; Nakahira S, 1990, MEMOIR ON PUBLISHING; Nambara S, 1948, U TOKYO NEWSPAP 0115, P1; Powell W, 1985, GETTING INTO PRINT; Powell WW, 1991, NEW I ORG ANAL; Rosenthal A, 1985, BUSINESS BOOK PUBLIS, P344; Sahlin K., 2008, SAGE HDB ORG I, P218; Slaughter S., 1997, ACAD CAPITALISM; Solli R., 2005, GLOBAL IDEAS IDEAS O, P30; Tebbel J, 1987, BETWEEN COVERS; THOMPSON J. B., 2005, BOOKS DIGITAL AGE; Thompson JB, 2010, MERCHANTS OF CULTURE; UTP, 1956, U TOKYO PRESS 5 YEAR; UTP, 1968, 17 ANNIVERSARY BOOKL; UTP, 1991, 40 ANNIVERSARY BOOKL; UTP, 2001, 50 ANNIVERSARY BOOKL; Whetten D.A., 1985, RES ORGAN BEHAV, V7, P263; Xia J, 2008, CHANDOS PUBL SER, P1	51	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1749-9755	1749-9763		CULT SOCIOL-LONDON	Cult. Sociol.	SEP	2015	9	3			SI		347	363		10.1177/1749975515592654		17	Sociology	Sociology	CO8LH	WOS:000359420200004		
J	Matsunobu, S; Sasakura, Y				Matsunobu, Shohei; Sasakura, Yasunori			Time course for tail regression during metamorphosis of the ascidian Ciona intestinalis	DEVELOPMENTAL BIOLOGY			English	Article						Ciona intestinalis; Metamorphosis; Tail regression; Competence; Time course; Memory	ANIMAL CELLULOSE SYNTHASE; TERM-MEMORY FORMATION; HALOCYNTHIA-RORETZI; NITRIC-OXIDE; CYTOPLASMIC FILAMENTS; GENE-EXPRESSION; NERVOUS-SYSTEM; COMPETENCE; LARVAE; EMBRYOS	In most ascidians, the tadpole-like swimming larvae dramatically change their body-plans during metamorphosis and develop into sessile adults. The mechanisms of ascidian metamorphosis have been researched and debated for many years. Until now information on the detailed time course of the initiation and completion of each metamorphic event has not been described. One dramatic and important event in ascidian metamorphosis is tail regression, in which ascidian larvae lose their tails to adjust themselves to sessile life. In the present study, we measured the time associated with tail regression in the ascidian Ciona intestinalis. Larvae are thought to acquire competency for each metamorphic event in certain developmental periods. We show that the timing with which the competence for tail regression is acquired is determined by the time since hatching, and this timing is not affected by the timing of post-hatching events such as adhesion. Because larvae need to adhere to substrates with their papillae to induce tail regression, we measured the duration for which larvae need to remain adhered in order to initiate tail regression and the time needed for the tail to regress. Larvae acquire the ability to adhere to substrates before they acquire tail regression competence. We found that when larvae adhered before they acquired tail regression competence, they were able to remember the experience of adhesion until they acquired the ability to undergo tail regression. The time course of the events associated with tail regression provides a valuable reference, upon which the cellular and molecular mechanisms of ascidian metamorphosis can be elucidated. (C) 2015 Elsevier Inc. All rights reserved.	[Matsunobu, Shohei; Sasakura, Yasunori] Univ Tsukuba, Shimoda Marine Res Ctr, Shizuoka 4150025, Japan	Matsunobu, S (reprint author), Univ Tsukuba, Shimoda Marine Res Ctr, 5-10-1 Shimoda, Shizuoka 4150025, Japan.	matsunobu@shimoda.tsukuba.ac.jp			Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science and Technology (MEXT); Toray Science and Technology Grant; National Bioresource Project	We would like to thank the members of the Shimoda Marine Research Center at the University of Tsukuba for their kind cooperation during our study. We also would like to thank Drs. Shigeki Fujiwara, Nobuo Yamaguchi, Kunifumi Tagawa, and all members of the Department of Zoology, Graduate School of Science, Kyoto University, the Misaki Marine Biological Station, University of Tokyo, the Maizuru Fisher Research Station of Kyoto University, the Marine Biological Laboratory, Graduate school of Science, Hiroshima University for providing us with adult Ciona intestinalis. We are grateful to Dr. Yutaka Iguchi, Laboratory of Biology, Okaya, and Nagano for his kind cooperation with our statistical analyses using R-software. This study was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) and the Ministry of Education, Culture, Sports, Science and Technology (MEXT) to Y.S. Y.S. was supported by a Toray Science and Technology Grant. Further support was provided by grants from the National Bioresource Project.	Akaike H., 1973, 2 INT S INF THEOR, P267; Satoh N, 2003, TRENDS GENET, V19, P376, DOI 10.1016/S0168-9525(03)00144-6; Lemaire P, 2002, DEV BIOL, V252, P151, DOI 10.1006/dbio.2002.0861; Shi YB, 1996, BIOESSAYS, V18, P391, DOI 10.1002/bies.950180509; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Iguchi Y, 2013, EUR J ENTOMOL, V110, P159; Eri R, 1999, DEVELOPMENT, V126, P5809; NISHIDA H, 1987, DEV BIOL, V121, P526, DOI 10.1016/0012-1606(87)90188-6; Bishop CD, 2006, INTEGR COMP BIOL, V46, P662, DOI 10.1093/icb/icl043; Chiba S, 2004, ZOOL SCI, V21, P285, DOI 10.2108/zsj.21.285; Lemaire P, 2011, DEVELOPMENT, V138, P2143, DOI 10.1242/dev.048975; Imai KS, 2004, DEVELOPMENT, V131, P4047, DOI 10.1242/dev.01270; PECHENIK JA, 1993, J EXP MAR BIOL ECOL, V167, P59, DOI 10.1016/0022-0981(93)90184-P; KATZ MJ, 1983, BIOL BULL, V164, P1, DOI 10.2307/1541186; Bishop CD, 2001, J EXP ZOOL, V289, P374, DOI 10.1002/jez.1019; Chambon JP, 2007, DEVELOPMENT, V134, P1203, DOI 10.1242/dev.002220; Miyashita T, 2012, NEURON, V74, P887, DOI 10.1016/j.neuron.2012.03.039; Degnan BM, 1997, DEV GENES EVOL, V206, P370, DOI 10.1007/s004270050066; Chambon JP, 2002, DEVELOPMENT, V129, P3105; Nakashima K, 2004, DEV GENES EVOL, V214, P81, DOI 10.1007/s00427-003-0379-8; BAINBRIDGE SP, 1981, J EMBRYOL EXP MORPH, V66, P57; Delsuc F, 2006, NATURE, V439, P965, DOI 10.1038/nature04336; Wada H, 1998, MOL BIOL EVOL, V15, P1189; CLONEY RA, 1982, AM ZOOL, V22, P817; Knell RJ, 2009, ECOL ENTOMOL, V34, P1, DOI 10.1111/j.1365-2311.2008.01022.x; Bishop CD, 2003, EVOL DEV, V5, P542, DOI 10.1046/j.1525-142X.2003.03059.x; Avila C, 1998, J EXP MAR BIOL ECOL, V231, P81, DOI 10.1016/S0022-0981(98)00093-8; Burnham K. P., 2002, MODEL SELECTION MULT; Chen GQ, 2010, J NEUROSCI, V30, P13066, DOI 10.1523/JNEUROSCI.2378-10.2010; CLONEY RA, 1966, J ULTRA MOL STRUCT R, V14, P300, DOI 10.1016/S0022-5320(66)80051-5; CLONEY RA, 1969, Z ZELLFORSCH MIK ANA, V100, P31, DOI 10.1007/BF00343819; Cloney R.A., 1978, P255; CLONEY RA, 1961, AM ZOOL, V1, P67; Comes S, 2007, DEV BIOL, V306, P772, DOI 10.1016/j.ydbio.2007.04.016; Davidson B, 2001, DEV GENES EVOL, V211, P190, DOI 10.1007/s004270100143; Degnan BM, 2001, BIOLOGY OF ASCIDIANS, P258; Degnan BM, 1999, BIOL BULL-US, V197, P332, DOI 10.2307/1542787; Hirano T, 1997, DEV BIOL, V192, P199, DOI 10.1006/dbio.1997.8772; ISHIKAWA M, 1972, DEV GROWTH DIFFER, V14, P75; Kamiya C, 2014, DEV DYNAM, V243, P1524, DOI 10.1002/dvdy.24176; Kandel E.R., 2004, BIOSCIENCE REP, V24, P477; Karaiskou A., 2014, METAMORHPOSIS SOLITA, DOI [10.1002/dvg.22824, DOI 10.1002/DVG.22824]; Kimura Y, 2003, DEV BIOL, V258, P129, DOI 10.1016/S0012-1606(03)00118-0; Kumano G, 2014, DEV GROWTH DIFFER, V56, P310, DOI 10.1111/dgd.12133; Lange MD, 2012, J PHYSIOL-LONDON, V590, P131, DOI 10.1113/jphysiol.2011.221317; Motulsky H., 2004, FITTING MODELS BIOL; NADEAU L, 1989, J EXP MAR BIOL ECOL, V131, P171, DOI 10.1016/0022-0981(89)90006-3; Nakayama A, 2002, DIFFERENTIATION, V70, P429, DOI 10.1046/j.1432-0436.2002.700805.x; Nakayama A, 2001, DEV GENES EVOL, V211, P184, DOI 10.1007/s004270100133; Nakayama-Ishimura A, 2009, DEV BIOL, V326, P357, DOI 10.1016/j.ydbio.2008.11.026; NICOL D, 1988, DEV BIOL, V130, P721, DOI 10.1016/0012-1606(88)90363-6; Nieuwkoop P., 1994, NORMAL TABLE XENOPUS; Sasakura Y, 2005, P NATL ACAD SCI USA, V102, P15134, DOI 10.1073/pnas.0503640102; Tagawa K, 1997, ZOOL SCI, V14, P297, DOI 10.2108/zsj.14.297; Tarallo R, 2004, DEV DYNAM, V230, P251, DOI 10.1002/dvdy.20055; TATA JR, 1968, DEV BIOL, V18, P415, DOI 10.1016/0012-1606(68)90050-X; Yamada L, 2003, DEV GENES EVOL, V213, P245, DOI 10.1007/s00427-003-0316-x; Zega G, 2005, DEV BIOL, V282, P246, DOI 10.1016/j.ydbio.2005.03.012	58	1	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0012-1606	1095-564X		DEV BIOL	Dev. Biol.	SEP 1	2015	405	1					71	81		10.1016/j.ydbio.2015.06.016		11	Developmental Biology	Developmental Biology	CO9OA	WOS:000359503900007		
J	Dyment, NA; Breidenbach, AP; Schwartz, AG; Russell, RP; Aschbacher-Smith, L; Liu, H; Hagiwara, Y; Jiang, R; Thomopoulos, S; Butler, DL; Rowe, DW				Dyment, Nathaniel A.; Breidenbach, Andrew P.; Schwartz, Andrea G.; Russell, Ryan P.; Aschbacher-Smith, Lindsey; Liu, Han; Hagiwara, Yusuke; Jiang, Rulang; Thomopoulos, Stavros; Butler, David L.; Rowe, David W.			Gdf5 progenitors give rise to fibrocartilage cells that mineralize via hedgehog signaling to form the zonal enthesis	DEVELOPMENTAL BIOLOGY			English	Article						Enthesis; Lineage tracing; GDF5; Fibrocartilage; Collagen; Alkaline phosphatase; Mineralization; Maturation; Hedgehog signaling; Growth; Mouse	TO-BONE ATTACHMENT; GENE-EXPRESSION; STEM-CELLS; TENDON; COLLAGEN; OSTEOARTHRITIS; GROWTH; MICE; CHONDROCYTES; DISORDERS	The sequence of events that leads to the formation of a functionally graded enthesis is not clearly defined. The current study demonstrates that clonal expansion of Gdf5 progenitors contributes to linear growth of the enthesis. Prior to mineralization, Col1+ cells in the enthesis appose Col2+ cells of the underlying primary cartilage. At the onset of enthesis mineralization, cells at the base of the enthesis express alkaline phosphatase, Indian hedgehog, and ColX as they mineralize. The mineralization front then extends towards the tendon midsubstance as cells above the front become encapsulated in mineralized fibrocartilage over time. The hedgehog (Hh) pathway regulates this process, as Hh-responsive Gli1 + cells within the developing enthesis mature from unmineralized to mineralized fibrochondrocytes in response to activated signaling. Hh signaling is required for mineralization, as tissue-specific deletion of its obligate transducer Smoothened in the developing tendon and enthesis cells leads to significant reductions in the apposition of mineralized fibrocartilage. Together, these findings provide a spatiotemporal map of events - from expansion of the embryonic progenitor pool to synthesis of the collagen template and finally mineralization of this template - that leads to the formation of the mature zonal enthesis. These results can inform future tendon-to-bone repair strategies to create a mechanically functional enthesis in which tendon collagen fibers are anchored to bone through mineralized fibrocartilage. (C) 2015 Elsevier Inc. All rights reserved.	[Dyment, Nathaniel A.; Russell, Ryan P.; Rowe, David W.] Univ Connecticut, Ctr Hlth, Ctr Regenerat Med & Skeletal Dev, Sch Dent Med, Farmington, CT 06030 USA; [Breidenbach, Andrew P.; Butler, David L.] Univ Cincinnati, Coll Engn & Appl Sci, Biomed Engn Program, Cincinnati, OH 45221 USA; [Schwartz, Andrea G.; Thomopoulos, Stavros] Washington Univ, Dept Orthopaed Surg, St Louis, MO USA; [Aschbacher-Smith, Lindsey; Liu, Han; Jiang, Rulang] Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA; [Hagiwara, Yusuke] Nippon Med Coll Hosp, Dept Orthopaed Surg, Tokyo, Japan	Dyment, NA (reprint author), Univ Connecticut, Ctr Hlth, Dept Reconstruct Sci, Sch Dent Med, 263 Farmington Ave, Farmington, CT 06030 USA.	dyment@uchc.edu			NIH [R01-AR54713, R01-AR052374, R01-AR055580, T90-DE021989, T32-AR060719]	The authors would like to thank Dr. David Kingsley and Dr. Ronen Schweitzer for graciously providing the GDF5Cre and ScxCre mice, respectively. Thanks to Dr. Kamal Khanna for providing access to the Prairie Ultima IV multiphoton microscope, and Jianping Huang for mouse breeding assistance. This work was supported by NIH Grants R01-AR54713, R01-AR052374, R01-AR055580, T90-DE021989 (support for NAD) and T32-AR060719 (support for AGS).	Amano K, 2014, J BIOL CHEM, V289, P24898, DOI 10.1074/jbc.M114.570507; Blitz E, 2013, DEVELOPMENT, V140, P2680, DOI 10.1242/dev.093906; Kirsch T, 2000, J BIOL CHEM, V275, P35577, DOI 10.1074/jbc.M005648200; Lin AC, 2009, NAT MED, V15, P1421, DOI 10.1038/nm.2055; Mascre G, 2012, NATURE, V489, P257, DOI 10.1038/nature11393; Kaukua N, 2014, NATURE, V513, P551, DOI 10.1038/nature13536; Liu YX, 2012, MECH MATER, V44, P83, DOI 10.1016/j.mechmat.2011.08.005; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]; Benjamin M, 2009, SCAND J MED SCI SPOR, V19, P520, DOI 10.1111/j.1600-0838.2009.00906.x; Karaplis AC, 2012, ENDOCRINOLOGY, V153, P5906, DOI 10.1210/en.2012-1551; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; Wang VM, 2012, J ORTHOP RES, V30, P620, DOI 10.1002/jor.21558; Maye P, 2011, GENESIS, V49, P410, DOI 10.1002/dvg.20733; Lu HH, 2013, ANNU REV BIOMED ENG, V15, P201, DOI 10.1146/annurev-bioeng-071910-124656; Ralphs JR, 1998, J ANAT, V193, P215, DOI 10.1046/j.1469-7580.1998.19320215.x; Galatz L, 2007, J ORTHOP RES, V25, P1621, DOI 10.1002/jor.20441; McGonagle D, 2010, J ANAT, V216, P279, DOI 10.1111/j.1469-7580.2009.01186.x; Liu CF, 2012, TISSUE ENG PT A, V18, P598, DOI [10.1089/ten.TEA.2011.0338, 10.1089/ten.tea.2011.0338]; Sugimoto Y, 2013, DEVELOPMENT, V140, P2280, DOI 10.1242/dev.096354; Soeda T, 2010, GENESIS, V48, P635, DOI 10.1002/dvg.20667; Riley G, 2008, NAT CLIN PRACT RHEUM, V4, P82, DOI 10.1038/ncprheum0700; Sivas F, 2009, CLIN RHEUMATOL, V28, P259, DOI 10.1007/s10067-008-1027-5; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; McGonagle D, 2005, ANN RHEUM DIS, V64, P58, DOI 10.1136/ard.2004.034264; Breidenbach AP, 2015, J ORTHOP RES, V33, P1142, DOI 10.1002/jor.22899; Charvet Benjamin, 2012, Muscles Ligaments Tendons J, V2, P53; Chen L, 2015, BONE, V71, P7, DOI 10.1016/j.bone.2014.09.021; Chokalingam K, 2009, TISSUE ENG PT A, V15, P2807, DOI 10.1089/ten.TEA.2008.0560; Dyment NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096113; Dyment NA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059944; Eyal S, 2015, DEVELOPMENT, V142, P1831, DOI 10.1242/dev.121970; Liu CF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065411; Liu YX, 2014, BIOMECH MODEL MECHAN, V13, P973, DOI 10.1007/s10237-013-0548-2; Rountree RB, 2004, PLOS BIOL, V2, P1815, DOI 10.1371/journal.pbio.0020355; Schwartz AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048630; Schwartz AG, 2015, DEVELOPMENT, V142, P196, DOI 10.1242/dev.112714; Sherlock J., 2012, NAT MED, V18; Shibakawa A, 2005, OSTEOARTHR CARTILAGE, V13, P679, DOI 10.1016/j.joca.2005.04.010; Tatara AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097375; Ushiku C, 2010, J ORTHOP RES, V28, P1338, DOI 10.1002/jor.21105; Yang G, 2014, CELL RES, V24, P1266, DOI 10.1038/cr.2014.111; Zelzer E, 2014, BIRTH DEFECTS RES C, V102, P101, DOI 10.1002/bdrc.21056; Zhou JM, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4437	44	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0012-1606	1095-564X		DEV BIOL	Dev. Biol.	SEP 1	2015	405	1					96	107		10.1016/j.ydbio.2015.06.020		12	Developmental Biology	Developmental Biology	CO9OA	WOS:000359503900009		
J	Nakao, H				Nakao, Hajime			Analyses of interactions among pair-rule genes and the gap gene Kruppel in Bombyx segmentation	DEVELOPMENTAL BIOLOGY			English	Article						Segmentation; Bombyx; Pair-rule gene circuit; Kruppel; RNAi	SHORT-GERM INSECT; TRIBOLIUM-CASTANEUM; EMBRYONIC-DEVELOPMENT; GRYLLUS-BIMACULATUS; DROSOPHILA EMBRYO; PATTERN-FORMATION; SILKWORM; MORI; BLASTODERM; PERIODICITY	In the short-germ insect Tribolium, a pair-rule gene circuit consisting of the Tribolium homologs of even-skipped, runt, and odd-skipped (Tc-eve, Tc-run and Tc-odd, respectively) has been implicated in segment formation. To examine the application of the model to other taxa, I studied the expression and function of pair-rule genes in Bombyx mori, together with a Bombyx homolog of Kruppel (Bm-Kr), a known gap gene. Knockdown embryos of Bombyx homologs of eve, run and odd (Bm-eve, Bin-run and Bm-odd) exhibited asegmental phenotypes similar to those of Tribolium knockdowns. However, pair-rule gene interactions were similar to those of both Tribolium and Drosophila, which, different from Tribolium, shows a hierarchical segmentation mode. Additionally, the Bm-odd expression pattern shares characteristics with those of Drosophila pair-rule genes that receive upstream regulatory input. On the other hand, Bm-Kr knockdowns exhibited a large posterior segment deletion as observed in short-germ insects. However, a detailed analysis of these embryos indicated that Bm-Kr modulates expression of pair-rule genes like in Drosophila, although the mechanisms appear to be different. This suggested hierarchical interactions between Bm-Kr and pair-rule genes. Based on these results, I concluded that the pair-rule gene circuit model that describes Tribolium development is not applicable to Bombyx. (C) 2015 Elsevier Inc. All rights reserved.	Natl Inst Agrobiol Sci, Div Insect Sci, Insect Growth Regulat Res Unit, Tsukuba, Ibaraki 3058634, Japan	Nakao, H (reprint author), Natl Inst Agrobiol Sci, Div Insect Sci, Insect Growth Regulat Res Unit, 1-2 Oowashi, Tsukuba, Ibaraki 3058634, Japan.	nakaoh@nias.affrc.gojp					El-Sherif E, 2012, DEVELOPMENT, V139, P4341, DOI 10.1242/dev.085126; SMALL S, 1992, EMBO J, V11, P4047; Davis GK, 2002, ANNU REV ENTOMOL, V47, P669, DOI 10.1146/annurev.ento.47.091201.145251; Wilson MJ, 2010, DEV BIOL, V339, P200, DOI 10.1016/j.ydbio.2009.12.015; MYOHARA M, 1994, DEVELOPMENT, V120, P2869; Maderspacher F, 1998, DEV GENES EVOL, V208, P558, DOI 10.1007/s004270050215; Nakao H, 2012, DEV BIOL, V371, P293, DOI 10.1016/j.ydbio.2012.08.029; Peel AD, 2005, NAT REV GENET, V6, P905, DOI 10.1038/nrg1724; Choe CP, 2006, P NATL ACAD SCI USA, V103, P6560, DOI 10.1073/pnas.0510440103; AKAM M, 1987, DEVELOPMENT, V101, P1; Nakao H, 2010, J EXP ZOOL PART B, V314B, P224, DOI 10.1002/jez.b.21328; Liu PZ, 2005, EVOL DEV, V7, P629, DOI 10.1111/j.1525-142X.2005.05066.x; Sarrazin AF, 2012, SCIENCE, V336, P338, DOI 10.1126/science.1218256; Beermann A, 2011, DEVELOPMENT, V138, P2793, DOI 10.1242/dev.063644; Bolognesi R, 2008, CURR BIOL, V18, P1624, DOI 10.1016/j.cub.2008.09.057; Bolognesi R, 2009, DEV GENES EVOL, V219, P369, DOI 10.1007/s00427-009-0299-3; Brent AE, 2007, SCIENCE, V315, P1841, DOI 10.1126/science.1137528; Cerny AC, 2005, DEVELOPMENT, V132, P5353, DOI 10.1242/dev.02154; Chipman AD, 2008, DEV BIOL, V319, P160, DOI 10.1016/j.ydbio.2008.02.038; Chipman AD, 2004, CURR BIOL, V14, P1250, DOI 10.1016/j.cub.2004.07.026; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; Liu PZ, 2004, DEVELOPMENT, V131, P4567, DOI 10.1242/dev.01311; Liu WB, 2008, ARCH INSECT BIOCHEM, V69, P47, DOI 10.1002/arch.20261; Lynch JA, 2012, WIRES DEV BIOL, V1, P16, DOI 10.1002/wdev.3; Mito T, 2006, DEV BIOL, V294, P471, DOI 10.1016/j.ydbio.2005.12.057; Miyawaki K, 2004, MECH DEVELOP, V121, P119, DOI 10.1016/j.mod.2004.01.002; NAGY L, 1994, DEV BIOL, V165, P137, DOI 10.1006/dbio.1994.1241; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Pankratz Michael J., 1993, P467; Rosenberg MI, 2014, ELIFE, V3, DOI 10.7554/eLife.01440; Schroeder MD, 2011, DEVELOPMENT, V138, P3067, DOI 10.1242/dev.062141; Shimomura M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-486; TAKESUE S, 1980, J EMBRYOL EXP MORPH, V60, P117; Xu X, 1997, DEV GROWTH DIFFER, V39, P515, DOI 10.1046/j.1440-169X.1997.t01-3-00013.x; Yamaguchi J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025469	37	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0012-1606	1095-564X		DEV BIOL	Dev. Biol.	SEP 1	2015	405	1					149	157		10.1016/j.ydbio.2015.06.012		9	Developmental Biology	Developmental Biology	CO9OA	WOS:000359503900013		
J	Bjornstad, P; Lanaspa, MA; Ishimoto, T; Kosugi, T; Kume, S; Jalal, D; Maahs, DM; Snell-Bergeon, JK; Johnson, RJ; Nakagawa, T				Bjornstad, Petter; Lanaspa, Miguel A.; Ishimoto, Takuji; Kosugi, Tomoki; Kume, Shinji; Jalal, Diana; Maahs, David M.; Snell-Bergeon, Janet K.; Johnson, Richard J.; Nakagawa, Takahiko			Fructose and uric acid in diabetic nephropathy	DIABETOLOGIA			English	Review						Diabetes; Diabetic nephropathy; Fructokinase; Fructose; Glucose; Kidney; Polyol pathway; Review; Tubular injury; Uric acid	CHRONIC-KIDNEY-DISEASE; CORONARY-ARTERY CALCIFICATION; ALDOSE REDUCTASE INHIBITOR; RENAL-FUNCTION LOSS; METABOLIC SYNDROME; TUBULOINTERSTITIAL INJURY; VASCULAR COMPLICATIONS; INDUCED HYPERURICEMIA; RISK-FACTOR; RAT-KIDNEY	Clinical studies have reported associations between serum uric acid levels and the development of diabetic nephropathy, but the underlying mechanisms remain elusive. There is evidence from animal studies that blocking uric acid production protects the kidney from tubulointerstitial injury, which may suggest a causal role for uric acid in the development of diabetic tubular injury. In turn, when fructose, which is endogenously produced in diabetes via the polyol pathway, is metabolised, uric acid is generated from a side-chain reaction driven by ATP depletion and purine nucleotide turnover. For this reason, uric acid derived from endogenous fructose could cause tubulointerstitial injury in diabetes. Accordingly, our research group recently demonstrated that blocking fructose metabolism in a diabetic mouse model mitigated the development of tubulointerstitial injury by lowering tubular uric acid production. In this review we discuss the relationship between uric acid and fructose as a novel mechanism for the development of diabetic tubular injury.	[Bjornstad, Petter; Maahs, David M.; Snell-Bergeon, Janet K.] Univ Colorado Denver, Barbara Davis Ctr Diabet, Aurora, CO USA; [Lanaspa, Miguel A.; Jalal, Diana; Maahs, David M.; Johnson, Richard J.] Univ Colorado Denver, Div Renal Dis & Hypertens, Aurora, CO USA; [Ishimoto, Takuji; Kosugi, Tomoki] Nagoya Univ, Dept Nephrol, Grad Sch Med, Nagoya, Aichi 4648601, Japan; [Kume, Shinji] Shiga Univ Med Sci, Dept Med, Otsu, Shiga 52021, Japan; [Nakagawa, Takahiko] Kyoto Univ, Grad Sch Med, TMK Project, Sakyo Ku, Kyoto 6068507, Japan	Nakagawa, T (reprint author), Kyoto Univ, Grad Sch Med, TMK Project, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	nakagawt@gmail.com			Gout Research Foundation	This work was supported by a fund from the Gout Research Foundation.	Aoyama M, 2012, BIOCHEM BIOPH RES CO, V419, P244, DOI 10.1016/j.bbrc.2012.02.001; Rosolowsky ET, 2008, CLIN J AM SOC NEPHRO, V3, P706, DOI 10.2215/CJN.04271007; Chuengsamarn S, 2014, J DIABETES COMPLICAT, V28, P124, DOI 10.1016/j.jdiacomp.2013.12.002; Altemtam N, 2012, NEPHROL DIAL TRANSPL, V27, P1847, DOI 10.1093/ndt/gfr561; Sun W, 2006, DIABETES, V55, P2757, DOI 10.2337/db06-0138; Krolewski AS, 2014, DIABETES CARE, V37, P226, DOI 10.2337/dc13-0985; Zoppini G, 2012, DIABETES CARE, V35, P99, DOI 10.2337/dc11-1346; Johnson RJ, 2013, DIABETES, V62, P3307, DOI 10.2337/db12-1814; Bjornstad P, 2014, CURR OPIN ENDOCRINOL, V21, P279, DOI 10.1097/MED.0000000000000074; Lanaspa MA, 2012, J BIOL CHEM, V287, P40732, DOI 10.1074/jbc.M112.399899; Kim SM, 2012, NEPHRON EXP NEPHROL, V121, pE109, DOI 10.1159/000343567; Madero M, 2009, AM J KIDNEY DIS, V53, P796, DOI 10.1053/j.ajkd.2008.12.021; Muscelli E, 1996, AM J HYPERTENS, V9, P746, DOI 10.1016/0895-7061(96)00098-2; Musso G, 2012, ANN MED, V44, P375, DOI 10.3109/07853890.2011.560181; Miao Y, 2011, HYPERTENSION, V58, P2, DOI 10.1161/HYPERTENSIONAHA.111.171488; SKEITH MD, 1967, J LAB CLIN MED, V70, P213; Nakagawa T, 2006, AM J PHYSIOL-RENAL, V290, pF625, DOI 10.1152/ajprenal.00140.2005; Kawasaki T, 2002, DIABETES CARE, V25, P353, DOI 10.2337/diacare.25.2.353; Hotta N, 2012, DIABETIC MED, V29, P1529, DOI 10.1111/j.1464-5491.2012.03684.x; Ficociello LH, 2010, DIABETES CARE, V33, P1337, DOI 10.2337/dc10-0227; Jalal DI, 2010, NEPHROL DIAL TRANSPL, V25, P1865, DOI 10.1093/ndt/gfp740; Tseng CH, 2005, KIDNEY INT, V68, P796, DOI 10.1111/j.1523-1755.2005.00459.x; Kosugi T, 2009, AM J PHYSIOL-RENAL, V297, pF481, DOI 10.1152/ajprenal.00092.2009; Hovind P, 2009, DIABETES, V58, P1668, DOI 10.2337/db09-0014; Nakagawa T, 2005, NAT CLIN PRACT NEPHR, V1, P80, DOI 10.1038/ncpneph0019; Behradmanesh S, 2013, J RES MED SCI, V18, P44; LANGFORD HG, 1987, ARCH INTERN MED, V147, P645, DOI 10.1001/archinte.147.4.645; Freitas HS, 2008, ENDOCRINOLOGY, V149, P717, DOI 10.1210/en.2007-1088; Momeni A, 2010, IRAN J KIDNEY DIS, V4, P128; ADAMOPOULOS D, 1977, ACTA ENDOCRINOL-COP, V85, P198; Sturm G, 2008, EXP GERONTOL, V43, P347, DOI 10.1016/j.exger.2008.01.006; Sanchez-Lozada LG, 2012, NEPHRON EXP NEPHROL, V121, pE71, DOI 10.1159/000345509; Perez-Pozo SE, 2010, INT J OBESITY, V34, P454, DOI 10.1038/ijo.2009.259; Iseki K, 2001, HYPERTENS RES, V24, P691, DOI 10.1291/hypres.24.691; EMMERSON BT, 1974, ANN RHEUM DIS, V33, P276, DOI 10.1136/ard.33.3.276; Iseki K, 2004, AM J KIDNEY DIS, V44, P642, DOI 10.1053/j.ajkd.2004.06.006; Nakayama T, 2010, AM J PHYSIOL-RENAL, V298, pF712, DOI 10.1152/ajprenal.00433.2009; Choi JWJ, 2008, ARTHRIT RHEUM-ARTHR, V59, P109, DOI 10.1002/art.23245; Fukui M, 2008, METABOLISM, V57, P625, DOI 10.1016/j.metabol.2007.12.005; TILTON RG, 1995, DIABETES, V44, P234, DOI 10.2337/diabetes.44.2.234; Shinozaki K, 1999, DIABETES, V48, P2437, DOI 10.2337/diabetes.48.12.2437; Orchard TJ, 2010, DIABETOLOGIA, V53, P2312, DOI 10.1007/s00125-010-1860-3; Cirillo P, 2009, J AM SOC NEPHROL, V20, P545, DOI 10.1681/ASN.2008060576; Maahs DM, 2013, CURR DIABETES REP, V13, P550, DOI 10.1007/s11892-013-0381-0; Sautin YY, 2008, NUCLEOS NUCLEOT NUCL, V27, P608, DOI 10.1080/15257770802138558; Glushakova O, 2008, J AM SOC NEPHROL, V19, P1712, DOI 10.1681/ASN.2007121304; Augustin R, 2004, J BIOL CHEM, V279, P16229, DOI 10.1074/jbc.M312226200; Bjornstad P, 2014, J DIABETES COMPLICAT, V28, P298, DOI 10.1016/j.jdiacomp.2013.12.007; Bjornstad P, 2014, ACTA DIABETOL, V51, P783, DOI 10.1007/s00592-014-0611-1; Cherney DZI, 2014, KIDNEY INT, V86, P1057, DOI 10.1038/ki.2014.246; Chino Y, 2014, BIOPHARM DRUG DISPOS, V35, P391, DOI 10.1002/bdd.1909; Collins AJ, 2012, AM J KIDNEY DIS, V59, pe1, DOI DOI 10.1053/J.AJKD.2011.11.015; Collins AJ, 2012, AM J KIDNEY DIS, V59, pEVII, DOI 10.1053/j.ajkd.2011.11.015; Cook DG, 1986, POSTGRAD MED J, V62, P1001; Cox CL, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-68; DOCTOR RB, 1991, J AM SOC NEPHROL, V1, P959; FLATH MC, 1992, DIABETES, V41, P1050, DOI 10.2337/diabetes.41.9.1050; Gersch MS, 2007, AM J PHYSIOL-RENAL, V293, pF1256, DOI 10.1152/ajprenal.00181.2007; GHAHARY A, 1989, DIABETES, V38, P1067, DOI 10.2337/diabetes.38.8.1067; GHAHARY A, 1991, DIABETES, V40, P1391, DOI 10.2337/diabetes.40.11.1391; GINEVRI F, 1993, PEDIATR NEPHROL, V7, P23; Golembiewska E, 2005, ARCH MED RES, V36, P32, DOI 10.1016/j.arcmed.2004.09.003; Kimura T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084996; Lanaspa MA, 2014, J AM SOC NEPHROL, V25, P2526, DOI 10.1681/ASN.2013080901; Liu P, 2014, CLIN ENDOCRINOL OXF, DOI [10.1111/cen.12673, DOI 10.1111/CEN.12673]; LUDVIGSON MA, 1980, DIABETES, V29, P450, DOI 10.2337/diabetes.29.6.450; Lytvyn Y, 2015, AM J PHYSIOL-RENAL, V308, pF77, DOI 10.1152/ajprenal.00555.2014; Maahs DM, 2006, J CLIN ENDOCR METAB, V91, P3757; Ohmura C, 2009, ENDOCR J, V56, P149; GALVAN AQ, 1995, AM J PHYSIOL-ENDOC M, V268, pE1; RAIVIO KO, 1975, METABOLISM, V24, P861, DOI 10.1016/0026-0495(75)90133-X; Ramana K.V., 2011, BIOMOL CONCEPTS, V2, P103, DOI DOI 10.1515/BMC.2011.002; RASCH R, 1984, DIABETOLOGIA, V27, P32; Rasch R, 1997, DIABETOLOGIA, V40, P802, DOI 10.1007/s001250050752; Rodrigues TC, 2010, DIABETES CARE, V33, P2471, DOI 10.2337/dc10-1007; SHICHIRI M, 1990, AM J NEPHROL, V10, P115, DOI 10.1159/000168065; SKEITH MD, 1970, AM J PHYSIOL, V219, P1080; STIRPE F, 1970, LANCET, V2, P1310; TERUBAYASHI H, 1989, KIDNEY INT, V36, P843, DOI 10.1038/ki.1989.270; Verzola D, 2004, J AM SOC NEPHROL, V15, pS85, DOI 10.1097/01.ASN.0000093370.20008.BC; Verzola D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115210; VUORINENMARKKOLA H, 1994, J CLIN ENDOCR METAB, V78, P25, DOI 10.1210/jc.78.1.25; Wang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038285; List JF, 2011, KIDNEY INT, V79, pS20, DOI 10.1038/ki.2010.512; YAMAOKA T, 1995, DIABETOLOGIA, V38, P255, DOI 10.1007/s001250050278	85	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0012-186X	1432-0428		DIABETOLOGIA	Diabetologia	SEP	2015	58	9					1993	2002		10.1007/s00125-015-3650-4		10	Endocrinology & Metabolism	Endocrinology & Metabolism	CO6LS	WOS:000359268800004		
J	Nakamura, T; Sakaguchi, K; So, A; Nakajima, S; Takabe, M; Komada, H; Okuno, Y; Hirota, Y; Nakamura, T; Iida, K; Kajikawa, M; Nagata, M; Ogawa, W; Seino, S				Nakamura, Tomoaki; Sakaguchi, Kazuhiko; So, Anna; Nakajima, Shinsuke; Takabe, Michinori; Komada, Hisako; Okuno, Yoko; Hirota, Yushi; Nakamura, Takehiro; Iida, Keiji; Kajikawa, Michiko; Nagata, Masao; Ogawa, Wataru; Seino, Susumu			Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study	DIABETOLOGIA			English	Article						Basal-bolus insulin therapy; Day-to-day fasting plasma glucose variability; Insulin degludec; Insulin glargine; Type 1 diabetes	BASAL-BOLUS TREATMENT; NPH INSULIN; HOE 901; GLYCEMIC CONTROL; MEALTIME; ASPART; LISPRO; ANALOG; HYPOGLYCEMIA; INFUSION	Aims/hypothesis We compared the effects of insulin degludec (IDeg; Des(B30)LysB29(gamma-Glu N epsilon-hexadecandioyl) human insulin) and insulin glargine (IGlar; A21Gly,B31Arg,B32Arg human insulin) on the day-to-day variability of fasting plasma glucose (FPG) levels in individuals with type 1 diabetes treated with basal-bolus insulin injections. Methods The effects of basal-bolus insulin therapy for 4 weeks with either IDeg or IGlar as the basal insulin in adult C-peptide-negative outpatients with type 1 diabetes were investigated in an open-label, multicentre, randomised, crossover trial. Randomisation was conducted using a centralised allocation process. The primary endpoints were the SD and CV of FPG during the final week of each treatment period. Secondary endpoints included serum glycoalbumin level, daily dose of insulin, intraday glycaemic variability and frequency of severe hypoglycaemia. Results Thirty-six randomised participants (17 in the IDeg/IGlar and 19 in the IGlar/IDeg groups) were recruited, and data for 32 participants who completed the trial were analysed. The mean (7.74 +/- 1.76 vs 8.56 +/- 2.06 mmol/l; p = 0.04) and SD (2.60 +/- 0.97 vs 3.19 +/- 1.36 mmol/l; p = 0.03) of FPG were lower during IDeg treatment than during IGlar treatment, whereas the CV did not differ between the two treatments. The dose of IDeg was smaller than that of IGlar (11.0 +/- 5.2 vs 11.8 +/- 5.6 U/day; p < 0.01), but other secondary endpoints did not differ between the treatments. Conclusions/interpretation IDeg yielded a lower FPG level and smaller day-to-day variability of FPG at a lower daily dose compared with IGlar in participants with type 1 diabetes. IDeg serves as a good option for basal insulin in the treatment of type 1 diabetes.	[Nakamura, Tomoaki; Sakaguchi, Kazuhiko; So, Anna; Nakajima, Shinsuke; Komada, Hisako; Okuno, Yoko; Hirota, Yushi; Ogawa, Wataru] Kobe Univ, Dept Internal Med, Div Diabet & Endocrinol, Grad Sch Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; [Takabe, Michinori] Shinsuma Gen Hosp, Dept Internal Med, Kobe, Hyogo, Japan; [Nakamura, Takehiro] Kobe City Hosp Org, West Hosp, Kobe City Med Ctr, Dept Internal Med, Kobe, Hyogo, Japan; [Iida, Keiji] Hyogo Prefectural Kakogawa Med Ctr, Dept Internal Med, Kakogawa, Hyogo, Japan; [Kajikawa, Michiko] Yodogawa Christians Hosp, Dept Internal Med, Osaka, Japan; [Nagata, Masao] Kakogawa City West Hosp, Dept Internal Med, Kakogawa City Hosp Org, Kakogawa, Hyogo, Japan; [Seino, Susumu] Kobe Univ, Dept Internal Med, Dept Physiol & Cell Biol, Div Mol & Metab Med,Grad Sch Med, Kobe, Hyogo 657, Japan	Sakaguchi, K (reprint author), Kobe Univ, Dept Internal Med, Div Diabet & Endocrinol, Grad Sch Med,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kzhkskgc@med.kobe-u.ac.jp			Novo Nordisk; Sanofi	ToN, KS, SN, MT, YH, TaN, KI, MK, MN, WO and SS have received lecture fees from Novo Nordisk, and KS, SN, MT, YH, TaN, MK, MN, WO and SS have received lecture fees from Sanofi. KS, KI, MK, WO and SS have received research support from Novo Nordisk, and KS and SS have received research support from Sanofi. The remaining authors declare that there is no duality of interest associated with their contribution to this manuscript.	Rossetti P, 2003, DIABETES CARE, V26, P1490, DOI 10.2337/diacare.26.5.1490; Birkeland KI, 2011, DIABETES CARE, V34, P661, DOI 10.2337/dc10-1925; Lepore M, 2000, DIABETES, V49, P2142, DOI 10.2337/diabetes.49.12.2142; Heise T, 2012, DIABETES OBES METAB, V14, P944, DOI 10.1111/j.1463-1326.2012.01638.x; Heller S, 2012, LANCET, V379, P1489, DOI 10.1016/S0140-6736(12)60204-9; Rodbard D, 2009, DIABETES TECHNOL THE, V11, P551, DOI 10.1089/dia.2009.0015; Heise T, 2012, DIABETES OBES METAB, V14, P859, DOI 10.1111/j.1463-1326.2012.01627.x; Jonassen I, 2012, PHARM RES-DORDR, V29, P2104, DOI 10.1007/s11095-012-0739-z; Ratner RE, 2000, DIABETES CARE, V23, P639, DOI 10.2337/diacare.23.5.639; Kuroda A, 2011, DIABETES CARE, V34, P1089, DOI 10.2337/dc10-2149; Bode BW, 2013, DIABETIC MED, V30, P1293, DOI 10.1111/dme.12243; Chatterjee S, 2007, DIABETES RES CLIN PR, V77, P215, DOI 10.1016/j.diabres.2006.11.002; Fulcher GR, 2005, INTERN MED J, V35, P536, DOI 10.1111/j.1445-5994.2005.00902.x; Nakamura T, 2014, J DIABETES INVEST, V5, P48, DOI 10.1111/jdi.12132; Niskanen Leo, 2009, Diabetes Res Clin Pract, V86, pe15, DOI 10.1016/j.diabres.2009.08.005; Pieber TR, 2000, DIABETES CARE, V23, P157, DOI 10.2337/diacare.23.2.157; Porcellati F, 2004, DIABETIC MED, V21, P1213, DOI 10.1111/j.1464-5491.2004.01323.x; Raskin P, 2000, DIABETES CARE, V23, P1666, DOI 10.2337/diacare.23.11.1666; Rosenstock J, 2000, DIABETES CARE, V23, P1137, DOI 10.2337/diacare.23.8.1137	19	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0012-186X	1432-0428		DIABETOLOGIA	Diabetologia	SEP	2015	58	9					2013	2019		10.1007/s00125-015-3648-y		7	Endocrinology & Metabolism	Endocrinology & Metabolism	CO6LS	WOS:000359268800006		
J	Koga, K; Yokoi, H; Mori, K; Kasahara, M; Kuwabara, T; Imamaki, H; Ishii, A; Mori, KP; Kato, Y; Ohno, S; Toda, N; Saleem, MA; Sugawara, A; Nakao, K; Yanagita, M; Mukoyama, M				Koga, Kenichi; Yokoi, Hideki; Mori, Kiyoshi; Kasahara, Masato; Kuwabara, Takashige; Imamaki, Hirotaka; Ishii, Akira; Mori, Keita P.; Kato, Yukiko; Ohno, Shoko; Toda, Naohiro; Saleem, Moin A.; Sugawara, Akira; Nakao, Kazuwa; Yanagita, Motoko; Mukoyama, Masashi			MicroRNA-26a inhibits TGF-beta-induced extracellular matrix protein expression in podocytes by targeting CTGF and is downregulated in diabetic nephropathy	DIABETOLOGIA			English	Article						CTGF; Diabetic nephropathy; MicroRNA; Podocytes; Streptozotocin	TISSUE GROWTH-FACTOR; TUBULOINTERSTITIAL FIBROSIS; GLOMERULAR INJURY; MESANGIAL CELLS; GENE; MECHANISMS; DISEASE; MICE; GLOMERULOSCLEROSIS; TRANSCRIPTION	Aims/hypothesis The accumulation of extracellular matrix (ECM) is a characteristic of diabetic nephropathy, and is partially caused by profibrotic proteins TGF-beta and connective tissue growth factor (CTGF). We aimed to identify microRNAs (miRNAs) targeting CTGF on podocytes in diabetic nephropathy. Methods We investigated miRNAs targeting CTGF on podocytes with miRNA array analysis and identified a candidate miRNA, miR-26a. Using overexpression and silencing of miR-26a in cultured podocytes, we examined changes of ECM and its host genes. We further investigated glomerular miR-26a expression in humans and in mouse models of diabetic nephropathy. Results miR-26a, which was downregulated by TGF-beta 1, was expressed in glomerular cells including podocytes and in tubules by in situ hybridisation. Glomerular miR-26a expression was downregulated by 70% in streptozotocin-induced diabetic mice. Transfection of miR-26a mimics in cultured human podocytes decreased the CTGF protein level by 50%, and directly inhibited CTGF expression in podocytes, as demonstrated by a reporter assay with the 3'-untranslated region of the CTGF gene. This effect was abolished by a mutant plasmid. miR-26a mimics also inhibited TGF-beta 1-induced collagen expression, SMAD-binding activity and expression of its host genes CTDSP2 and CTDSPL. Knockdown of CTDSP2 and CTDSPL increased collagen expression in TGF-beta-stimulated podocytes, suggesting that host genes also regulate TGF-beta/SMAD signalling. Finally, we observed a positive correlation between microdissected glomerular miR-26a expression levels and estimated GFR in patients with diabetic nephropathy. Conclusions/interpretation The downregulation of miR-26a is involved in the progression of diabetic nephropathy both in humans and in mice through enhanced TGF-beta/CTGF signalling.	[Koga, Kenichi; Yokoi, Hideki; Kuwabara, Takashige; Imamaki, Hirotaka; Ishii, Akira; Mori, Keita P.; Kato, Yukiko; Ohno, Shoko; Toda, Naohiro; Yanagita, Motoko; Mukoyama, Masashi] Kyoto Univ, Grad Sch Med, Dept Nephrol, Sakyo Ku, Kyoto 6068507, Japan; [Mori, Kiyoshi; Nakao, Kazuwa] Kyoto Univ, Grad Sch Med, Med Innovat Ctr, Kyoto 6068507, Japan; [Kasahara, Masato] Kyoto Univ Hosp, Inst Adv Clin & Translat Sci, Kyoto 606, Japan; [Kuwabara, Takashige; Mukoyama, Masashi] Kumamoto Univ, Dept Nephrol, Grad Sch Med Sci, Kumamoto, Japan; [Saleem, Moin A.] Univ Bristol, Bristol Childrens Hosp, Acad Renal Unit, Bristol, Avon, England; [Sugawara, Akira] Osaka Red Cross Hosp, Div Nephrol, Osaka, Japan	Yokoi, H (reprint author), Kyoto Univ, Grad Sch Med, Dept Nephrol, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	yokoih@kuhp.kyoto-u.ac.jp			Japanese Ministry of Education, Culture, Sports, Science and Technology; Japanese Ministry of Agriculture, Forestry and Fisheries; Japanese Ministry of Health, Labour and Welfare, Japan Agency for Medical Research and Development (AMED); Fujiwara Memorial Foundation; Takeda Science Foundation	This work was supported in part by research grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology, the Japanese Ministry of Agriculture, Forestry and Fisheries, the Japanese Ministry of Health, Labour and Welfare, Japan Agency for Medical Research and Development (AMED), Fujiwara Memorial Foundation and Takeda Science Foundation.	MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097; Gupta S, 2000, KIDNEY INT, V58, P1389, DOI 10.1046/j.1523-1755.2000.00301.x; Fuchshofer R, 2011, HISTOCHEM CELL BIOL, V136, P301, DOI 10.1007/s00418-011-0844-9; Burns WC, 2006, J AM SOC NEPHROL, V17, P2484, DOI 10.1681/ASN.2006050525; Yokoi H, 2008, KIDNEY INT, V73, P446, DOI 10.1038/sj.ki.5002722; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Liang HH, 2014, MOL THER, V22, P1122, DOI 10.1038/mt.2014.42; Kato M, 2007, P NATL ACAD SCI USA, V104, P3432, DOI 10.1073/pnas.0611192104; Duncan MR, 1999, FASEB J, V13, P1774; Guha M, 2007, FASEB J, V21, P3355, DOI 10.1096/fj.06-6713com; Wolf G, 2005, DIABETES, V54, P1626, DOI 10.2337/diabetes.54.6.1626; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Adler SG, 2010, CLIN J AM SOC NEPHRO, V5, P1420, DOI 10.2215/CJN.09321209; Harvey SJ, 2008, J AM SOC NEPHROL, V19, P2150, DOI 10.1681/ASN.2008020233; Zhu Y, 2012, NUCLEIC ACIDS RES, V40, P4615, DOI 10.1093/nar/gkr1278; Sapkota G, 2006, J BIOL CHEM, V281, P40412, DOI 10.1074/jbc.M610172200; Kato M, 2014, NAT REV NEPHROL, V10, P517, DOI 10.1038/nrneph.2014.116; Leeper NJ, 2011, J CELL PHYSIOL, V226, P1035, DOI 10.1002/jcp.22422; Wei CY, 2013, J CELL PHYSIOL, V228, P1433, DOI 10.1002/jcp.24296; Kato M, 2011, KIDNEY INT, V80, P358, DOI 10.1038/ki.2011.43; Yokoi H, 2004, J AM SOC NEPHROL, V15, P1430, DOI 10.1097/01.ASN.0000130565.69170.85; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Noguchi M, 2007, J BIOL CHEM, V282, P29574, DOI 10.1074/jbc.M705972200; Duisters RF, 2009, CIRC RES, V104, P170, DOI 10.1161/CIRCRESAHA.108.182535; Saleem MA, 2002, J AM SOC NEPHROL, V13; Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101; Kanwar YS, 2011, ANNU REV PATHOL-MECH, V6, P395, DOI 10.1146/annurev.pathol.4.110807.092150; Ogawa Y, 2012, J AM SOC NEPHROL, V23, P1198, DOI 10.1681/ASN.2011100985; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Ichii O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110383; Kanamoto N, 2012, ENDOCRINOLOGY, V153, P492, DOI 10.1210/en.2011-1310; Kasinath BS, 2011, KIDNEY INT, V80, P334, DOI 10.1038/ki.2011.165; Kato M, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003389; Makino Hisashi, 2003, Clin Exp Nephrol, V7, P33, DOI 10.1007/s101570300004; Mu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058622; Okada H, 2008, J AM SOC NEPHROL, V19, P933, DOI 10.1681/ASN.2007060648; Riser BL, 2000, J AM SOC NEPHROL, V11, P25; Roestenberg P, 2006, AM J PHYSIOL-RENAL, V290, pF1344, DOI 10.1152/ajprenal.00174.2005; Su YA, 1997, ONCOGENE, V15, P1289, DOI 10.1038/sj.onc.1201294; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; Yokoi H, 2002, AM J PHYSIOL-RENAL, V282, pF933, DOI 10.1152/ajprenal.00122.2001; Iglesias-de la Cruz MC, 2002, KIDNEY INT, V62, P901, DOI 10.1046/j.1523-1755.2002.00528.x	47	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0012-186X	1432-0428		DIABETOLOGIA	Diabetologia	SEP	2015	58	9					2169	2180		10.1007/s00125-015-3642-4		12	Endocrinology & Metabolism	Endocrinology & Metabolism	CO6LS	WOS:000359268800025		
J	Mura, T; Kawamura, K; Wachino, J; Shibayama, K; Arakawa, Y				Mura, Tatsuki; Kawamura, Kumiko; Wachino, Jun-ichi; Shibayama, Keigo; Arakawa, Yoshichika			Development of a novel chromogenic method, Penta-well test, for rapid prediction of beta(-)lactamase classes produced in clinical Enterobacteriaceae isolates	DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE			English	Article						beta-lactamase; Chromogenic method; Classify; Enterobacteriaceae; Pasta-well test	CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE; LACTAMASE-PRODUCING ENTEROBACTERIACEAE; PHENOTYPIC DETECTION; BETA-LACTAMASES; CEPHALOSPORINS; IDENTIFICATION; URINE; ESBLS	We developed a novel chromogenic method, Penta-well test, which enables the rapid detection and classification of beta-lactamases in clinical Enterobacteriaceae isolates. This test is based on a combination of nitrocefin and 3 beta-lactamase inhibitors specific to classes A. B, and/or C, with nitrocefin hydrolysis by beta-lactamases being assessed by optical density measurements at 490 nm. When the cutoff value for each beta-lactamase class was determined (0.09, 0.4, and 0.55 for class A, class B, and class C beta-lactamase producers, respectively), the sensitivity and specificity of classification were 93.5% and 68.8% for class A, 93.8% and 100% for class B, and 86.7% and 100% for class C. respectively. Moreover, this method allowed accurate beta-lactamase classification in 20 of 23 (87.0%) isolates producing plural class of beta-lactamases. Thus, the Penta-well test can provide information that would be useful in the accurate detection and classification of beta-lactamases produced by causative bacteria. (C) 2015 Elsevier Inc. All rights reserved.	[Mura, Tatsuki; Kawamura, Kumiko] Nagoya Univ, Grad Sch Med, Dept Pathophysiol Lab Sci, Higashi Ku, Nagoya, Aichi 4618673, Japan; [Wachino, Jun-ichi; Arakawa, Yoshichika] Nagoya Univ, Grad Sch Med, Dept Bacteriol, Showa Ku, Nagoya, Aichi 4668550, Japan; [Shibayama, Keigo; Arakawa, Yoshichika] Natl Inst Infect Dis, Dept Bacteriol 2, Tokyo 2080011, Japan	Kawamura, K (reprint author), Nagoya Univ, Grad Sch Med, Dept Pathophysiol Lab Sci, Higashi Ku, 1-1-20 Daikominami, Nagoya, Aichi 4618673, Japan.	mura.tatsuki@h.mbox.nagoya-u.ac.jp; kumiko@met.nagoya-u.ac.jp; wachino@med.nagoya-u.ac.jp; keigo@niid.go.jp; yarakawa@med.nagoya-u.ac.jp	Arakawa, Yoshichika/P-5997-2015		Japanese Ministry of Health, Labour, and Welfare [H21-Shinkou-Ippan-008, H24-Shinkou-Ippan-010]; Ministry of Education, Culture, Sports, Science, and Technology of Japan [25460681]	We thank N Nagano, Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, for providing us a clinical isolate of E. coli producing NDM-1. This study was supported by grants from the Japanese Ministry of Health, Labour, and Welfare (H21-Shinkou-Ippan-008 and H24-Shinkou-Ippan-010) and by a Grant-in-Aid for Scientific Research C (25460681) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Gallah S, 2014, J CLIN MICROBIOL, V52, P3792, DOI 10.1128/JCM.01629-14; Nordmann P, 2012, CLIN MICROBIOL INFEC, V18, P432, DOI 10.1111/j.1469-0691.2012.03815.x; Nordmann P, 2012, EMERG INFECT DIS, V18, P1503, DOI 10.3201/eid1809.120355; Birgy A, 2012, J CLIN MICROBIOL, V50, P1295, DOI 10.1128/JCM.06131-11; Miriagou V, 2010, CLIN MICROBIOL INFEC, V16, P112, DOI 10.1111/j.1469-0691.2009.03116.x; Livermore DM, 2012, J ANTIMICROB CHEMOTH, V67, P1569, DOI 10.1093/jac/dks088; Dortet L, 2014, CLIN MICROBIOL INFEC, V20, P340, DOI 10.1111/1469-0691.12318; Dortet L, 2014, J CLIN MICROBIOL, V52, P3701, DOI 10.1128/JCM.01578-14; Nordmann P, 2012, J CLIN MICROBIOL, V50, P3016, DOI 10.1128/JCM.00859-12; Pournaras S, 2010, J ANTIMICROB CHEMOTH, V65, P1319, DOI 10.1093/jac/dkq124; Poulou A, 2014, J CLIN MICROBIOL, V52, P1483, DOI 10.1128/JCM.03361-13; Dortet L, 2012, ANTIMICROB AGENTS CH, V56, P6437, DOI 10.1128/AAC.01395-12; Renvoise A, 2013, J CLIN MICROBIOL, V51, P4012, DOI 10.1128/JCM.01936-13; Drieux L, 2008, CLIN MICROBIOL INFEC, V14, P90, DOI 10.1111/j.1469-0691.2007.01846.x; Pitout JDD, 2008, LANCET INFECT DIS, V8, P159, DOI 10.1016/S1473-3099(08)70041-0; Hattori T, 2013, JPN J INFECT DIS, V66, P512; Maurer FP, 2015, J CLIN MICROBIOL, V53, P95, DOI 10.1128/JCM.01692-14; Moland ES, 2003, J ANTIMICROB CHEMOTH, V51, P711, DOI 10.1093/jac/dkg124; Morosini MI, 2014, J CLIN MICROBIOL, V52, P1741, DOI 10.1128/JCM.03614-13; Simner PJ, 2014, J CLIN MICROBIOL, V53, P105; Tijet Nathalie, 2013, Antimicrob Agents Chemother, V57, P4578, DOI 10.1128/AAC.00878-13	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0732-8893	1879-0070		DIAGN MICR INFEC DIS	Diagn. Microbiol. Infect. Dis.	SEP	2015	83	1					25	29		10.1016/j.diagmicrobio.2015.06.002		5	Infectious Diseases; Microbiology	Infectious Diseases; Microbiology	CP3CI	WOS:000359754000007		
J	Takesue, Y; Mikamo, H; Kusachi, S; Watanabe, S; Takahashi, K; Yoshinari, T; Ishii, M; Aikawa, N				Takesue, Yoshio; Mikamo, Hiroshige; Kusachi, Shinya; Watanabe, Shinichi; Takahashi, Kenichi; Yoshinari, Tomoko; Ishii, Mikio; Aikawa, Naoki			Correlation between pharmacokinetic/pharmacodynamic indices and clinical outcomes in Japanese patients with skin and soft tissue infections treated with daptomycin: analysis of a phase III study	DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE			English	Article						Daptomycin; Methicillin-resistant Staphylococcus aureus; Pharmacokinetics; Skin and soft tissue infection; Creatine phosphokinase	SAFETY; EFFICACY	The relationships between pharmacokinetic (PK)/pharmacodynamic (PD) indices and outcomes were investigated in patients with skin and soft tissue infection (SSTI) who received daptomycin at 4 mg/kg/day. Efficacy was evaluated in 55 patients from whom Staphylococcus aureus was isolated, with success rates of 94.5% and 69.1% for clinical and microbiological responses, respectively. The odds ratio for the relationship between the area under the day 1 concentration-time curve (AUC(D-24 h)) to the MIC and the probability of clinical success was 1.03 (95% confidence interval [CI] 0.73-1.45), and that for the relationship for probability of microbiological success was 0.94(95% CI 0.81-1.09). In 82 patients in the safety analysis, only 1 met the creatine phosphokinase (CPK) elevation criteria, and this patient's minimum concentration (C-min) of plasma daptomycin was 5.37 mu g/mL No significant relationship was found between peak CPK and C-min (Pearson's correlation coefficient -0.0452). In conclusion, no clear correlation between PK/PD indices and the probability of efficacy or safety events was demonstrated when daptomycin was administered in SSTI patients using the clinically recommended dosage of 4 mg/kg/day. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Takesue, Yoshio] Hyogo Coll Med, Dept Infect Control & Prevent, Nishinomiya, Hyogo 6638501, Japan; [Mikamo, Hiroshige] Aichi Med Univ, Dept Clin Infect Dis, Nagakute, Aichi, Japan; [Kusachi, Shinya] Toho Univ, Ohashi Hosp, Med Ctr, Dept Surg, Tokyo, Japan; [Watanabe, Shinichi] Teikyo Univ, Sch Med, Dept Dermatol, Tokyo 173, Japan; [Takahashi, Kenichi; Yoshinari, Tomoko; Ishii, Mikio] MSD KK, Japan Dev, Tokyo, Japan; [Aikawa, Naoki] Keio Univ, Sch Med, Emergency & Crit Care Med, Tokyo, Japan	Takesue, Y (reprint author), Hyogo Coll Med, Dept Infect Control & Prevent, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	takesuey@hyo-med.ac.jp			MSD K.K., Tokyo, Japan, a group of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Whitehouse Station; Astellas Pharma; Shionogi Co.; Takeda Pharmaceutical Co.; Dainippon Sumitomo Pharma; AstraZeneca K.K.; Daiichi Sankyo Co.; ThermoFisher Scientific K.K. Yoshio Takesue; Hiroshige Mikamo; Shinya Kusachi; Shinnichi Watanabe; Naoki Aikawa served on the Efficacy Adjudication Committee; MSD K.K.	This study was supported by a grant from MSD K.K., Tokyo, Japan, a group of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Whitehouse Station. Yoshio Takesue has received speaker's honoraria from Pfizer Japan, Astellas Pharma, Daiichi Sankyo Co., Meiji Seika Pharma Co., MSD K.K., Taisyo Toyama Pharmaceutical Co., and Dainippon Sumitomo Pharma. Yoshio Takesue has also received grant support from Astellas Pharma, Shionogi & Co., Takeda Pharmaceutical Co., and Dainippon Sumitomo Pharma. Naoki Aikawa is an outside Director of the Board of Astellas Pharma and has received speaker's honoraria from Asahi Kasei Pharma, AstraZeneca K.K., Becton Dickinson and Company Japan, Daiichi Sankyo Co., Meiji Seika Pharma Co., MSD K.K., Ono Pharmaceutical Co., Kyorin Pharmaceutical Co., ThermoFisher Scientific K.K., Taiho Pharmaceutical Co., Nihon Pharmaceutical Co., and Pfizer Japan. Naoki Aikawa has also received consultation fees from AstraZeneca K.K., Daiichi Sankyo Co., and ThermoFisher Scientific K.K. Yoshio Takesue, Hiroshige Mikamo, Shinya Kusachi, Shinnichi Watanabe, and Naoki Aikawa served on the Efficacy Adjudication Committee for this study and received per diem stipends from MSD K.K. for attending meetings of this committee. Tomoko Yoshinari, Mikio Ishi, and Kenichi Takahashi are employees of MSD K.K.	Bhavnani SM, 2010, CLIN INFECT DIS, V50, P1568, DOI 10.1086/652767; Safdar N, 2004, ANTIMICROB AGENTS CH, V48, P63, DOI 10.1128/AAC.48.1.63-68.2004; Dvorchik B, 2004, ANTIMICROB AGENTS CH, V48, P2799, DOI 10.1128/AAC.48.8.2799-2807.2004; Louie A, 2001, ANTIMICROB AGENTS CH, V45, P845, DOI 10.1128/AAC.45.3.845-851.2001; Arbeit RD, 2004, CLIN INFECT DIS, V38, P1673, DOI 10.1086/420818; Aikawa N, 2013, J INFECT CHEMOTHER, V19, P447, DOI 10.1007/s10156-012-0501-9; Dvorchik BH, 2003, ANTIMICROB AGENTS CH, V47, P1318, DOI 10.1128/AAC.47.4.1318-1323.2003; Food and Drug Administration, 2013, GUID IND 2013; Hasegawa S, 2011, ANTIBIOT CHEMOTHER, V27, P135	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0732-8893	1879-0070		DIAGN MICR INFEC DIS	Diagn. Microbiol. Infect. Dis.	SEP	2015	83	1					77	81		10.1016/j.diagmicrobio.2015.05.013		5	Infectious Diseases; Microbiology	Infectious Diseases; Microbiology	CP3CI	WOS:000359754000019		
J	Ohsaki, M; Miyamura, T; Kohiyama, M; Yamashita, T; Yamamoto, M; Nakamura, N				Ohsaki, Makoto; Miyamura, Tomoshi; Kohiyama, Masayuki; Yamashita, Takuzo; Yamamoto, Masashi; Nakamura, Naohiro			Finite-element analysis of laminated rubber bearing of building frame under seismic excitation	EARTHQUAKE ENGINEERING & STRUCTURAL DYNAMICS			English	Article						natural rubber bearing; finite element analysis; base isolation; seismic response; hyper-elasticity; parallel computing	ELASTOMERIC ISOLATION BEARINGS; TIME-DEPENDENT BEHAVIOR; MODEL; ISOLATORS; DEFORMATIONS; STABILITY; STIFFNESS; TENSION; DESIGN; TESTS	Finite element analysis is carried out for a building frame supported by laminated rubber bearings to simultaneously investigate global displacement and local stress responses under seismic excitation. The frame members and the rubber bearings are discretized into hexahedral solid elements with more than 3 million degrees of freedom. The material property of rubber is represented by the Ogden model, and the frame is assumed to remain in elastic range. It is shown that the time histories of non-uniform stress distribution and rocking behavior of the rubber bearings under a frame subjected to seismic excitation can be successfully evaluated, and detailed responses of base and frame can be evaluated through large-scale finite element analysis. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Ohsaki, Makoto] Hiroshima Univ, Dept Architecture, Higashihiroshima 7398527, Japan; [Miyamura, Tomoshi] Nihon Univ, Dept Comp Sci, Koriyama, Fukushima 9638642, Japan; [Miyamura, Tomoshi; Yamashita, Takuzo] Natl Res Inst Earth Sci & Disaster Prevent, Hyogo Earthquake Engn Res Ctr, Miki, Kagawa 6730515, Japan; [Kohiyama, Masayuki] Keio Univ, Dept Syst Design Engn, Yokohama, Kanagawa 2238522, Japan; [Yamamoto, Masashi; Nakamura, Naohiro] Takenaka Res & Dev Inst, Inzai 2701395, Japan	Ohsaki, M (reprint author), Hiroshima Univ, Dept Architecture, 1-4-1 Kagamiyama, Higashihiroshima 7398527, Japan.	ohsaki@hiroshima-u.ac.jp	Ohsaki, Makoto/E-2021-2011		NIED	This study is a part of E-Defense Seismic Experimental Study and Simulation System Development Project conducted by E-Simulator Production Committee (Leader: Prof. Muneo Hori, The University of Tokyo). The authors acknowledge the valuable contribution from the committee members and the financial support by NIED. The contribution by Dr. Tomonobu Ohyama and Mr. Kiyoshi Yuyama at Allied Engineering Corporation for computation and mesh generation is also acknowledged.	Akiba H, 2010, P 7 INT C ENG COMP T; Akiba H, 2006, P INT C HIGH PERF CO; ALI HEM, 1995, J STRUCT ENG-ASCE, V121, P1134, DOI 10.1061/(ASCE)0733-9445(1995)121:7(1134); Bergstrom JS, 1998, J MECH PHYS SOLIDS, V46, P931, DOI 10.1016/S0022-5096(97)00075-6; Osgooei PM, 2014, COMPOS STRUCT, V113, P164, DOI 10.1016/j.compstruct.2014.02.033; Yamamoto M, 2012, EARTHQ ENG STRUCT D, V41, P1845, DOI 10.1002/eqe.2161; Bergstrom JS, 2000, MECH MATER, V32, P627, DOI 10.1016/S0167-6636(00)00028-4; Moon BY, 2002, J MATER PROCESS TECH, V130, P145, DOI 10.1016/S0924-0136(02)00713-6; Miehe C, 2000, J MECH PHYS SOLIDS, V48, P323, DOI 10.1016/S0022-5096(99)00017-4; Cardone D, 2011, B EARTHQ ENG, V9, P1227, DOI 10.1007/s10518-011-9244-8; Cardone D, 2013, EARTHQ ENG STRUCT D, V42, P871, DOI 10.1002/eqe.2250; Abe M, 2004, J STRUCT ENG-ASCE, V130, P1133, DOI 10.1061/(ASCE)0733-9445(2004)130:8(1133); Osgooei PM, 2014, COMPOS STRUCT, V108, P191, DOI 10.1016/j.compstruct.2013.09.008; [Anonymous], 2014, ABAQUS US MAN VER 6; Ogden RW, 1999, P ROY SOC A-MATH PHY, V455, P2861; Toopchi-Nezhad H, 2011, COMPOS STRUCT, V93, P850, DOI 10.1016/j.compstruct.2010.07.009; Gur S, 2014, STRUCT CONTROL HLTH, V21, P449, DOI 10.1002/stc.1576; Buckle I, 2002, J STRUCT ENG-ASCE, V128, P3, DOI 10.1061/(ASCE)0733-9445(2002)128:1(3); Chang CH, 2002, INT J SOLIDS STRUCT, V39, P6055, DOI 10.1016/S0020-7683(02)00471-7; Das A, 2015, STRUCT CONTROL HLTH, V22, P197, DOI 10.1002/stc.1668; Gracia LA, 2010, FINITE ELEM ANAL DES, V46, P357, DOI 10.1016/j.finel.2009.12.002; HARTSMIT.LJ, 1967, INT J ENG SCI, V5, P1, DOI 10.1016/0020-7225(67)90051-1; Iizuka M, 2000, ENG STRUCT, V22, P323, DOI 10.1016/S0141-0296(98)00118-7; Kalpakidis IV, 2010, EARTHQ ENG STRUCT D, V39, P1533, DOI 10.1002/eqe.1039; Kelly JM, 2007, J MECH MATER STRUCT, V2, P1591, DOI 10.2140/jomms.2007.2.1591; Kikuchi M, 2010, EARTHQ ENG STRUCT D, V39, P1513, DOI 10.1002/eqe.1042; KOH CG, 1988, INT J MECH SCI, V30, P933, DOI 10.1016/0020-7403(88)90075-6; Konstantinidis D, 2008, EERC200802 U CAL; Kelly JM, 2011, MECHANICS OF RUBBER BEARINGS FOR SEISMIC AND VIBRATION ISOLATION, P1, DOI 10.1002/9781119971870; Lejeunes S, 2006, ARCH APPL MECH, V76, P311, DOI 10.1007/s00419-006-0030-z; Matsuda A, 2004, J PRESS VESS-T ASME, V126, P134, DOI 10.1115/1.1636784; Matsuda A, 2001, JSME INT J A-SOLID M, V44, P160, DOI 10.1299/jsmea.44.160; Minewaki S., 2009, J STRUCT ENG AIJ, V55, P469; Miyamura T, 2015, EARTHQ ENG STRUCT D, V44, P1449, DOI 10.1002/eqe.2526; Miyamura T., 2011, PROGR NUCL SCI TECHN, V2, P651; Mordini A, 2008, ENG STRUCT, V33, P2239; Mori T, 2010, P ANN M ARCHITECTU B, VB-2, P413; Nagarajaiah S, 1999, J STRUCT ENG-ASCE, V125, P946, DOI 10.1061/(ASCE)0733-9445(1999)125:9(946); OGDEN RW, 1972, PROC R SOC LON SER-A, V328, P567, DOI 10.1098/rspa.1972.0096; Ohsaki M, 2009, EARTHQ ENG STRUCT D, V38, P635, DOI 10.1002/eqe.900; Salomon O, 1999, INT J NUMER METH ENG, V46, P1741, DOI 10.1002/(SICI)1097-0207(19991210)46:10<1741::AID-NME722>3.0.CO;2-H; Suzuki M, 2002, T JAPAN SOC MECH E A, V68, P1010; Takaoka E, 2010, EARTHQ ENG STRUCT D, V40, P551; Warn GP, 2011, ENG STRUCT, V33, P3509, DOI 10.1016/j.engstruct.2011.07.013; Weitzmann R, 2006, EARTHQ ENG STRUCT D, V35, P497, DOI 10.1002/eqe.544; Yamashita T, 2014, J STRUCTURAL CONSTRU, V74, P1481; Yang QR, 2010, J ENG MECH-ASCE, V136, P429, DOI 10.1061/(ASCE)EM.1943-7889.0000007	47	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0098-8847	1096-9845		EARTHQ ENG STRUCT D	Earthq. Eng. Struct. Dyn.	SEP	2015	44	11					1881	1898		10.1002/eqe.2570		18	Engineering, Civil; Engineering, Geological	Engineering	CP0ZQ	WOS:000359606000013		
J	Tsai, YT; Chang, CM; Wang, JY; Hou, MF; Wang, JM; Shiurba, R; Chang, WC; Chang, WC				Tsai, Yao-Ting; Chang, Che-Mai; Wang, Jaw-Yuan; Hou, Ming-Feng; Wang, Ju-Ming; Shiurba, Robert; Chang, Wen-Chang; Chang, Wei-Chiao			Function of DNA methyltransferase 3a in lead (Pb2+)-Induced Cyclooxygenase-2 gene	ENVIRONMENTAL TOXICOLOGY			English	Article						lead; epidermal growth factor receptor; cyclooxygenase-2; DNA methyltransferase 3a	SMOOTH-MUSCLE-CELLS; BLOOD LEAD; CARDIOVASCULAR-DISEASE; CARCINOMA-CELLS; MORTALITY; EXPRESSION; PRESSURE; CANCER; RISK	Lead ions (Pb2+) are toxic industrial pollutants associated with chronic inflammatory diseases in humans and animals. Previously, we found that Pb2+ ions induce COX-2 gene expression via the EGF receptor/nuclear factor-B signal transduction pathway in epidermoid carcinoma cell line A431. In this study, to see whether Pb2+ ions affect COX-2 expression by epigenetic mechanisms, we looked at the mRNAs of DNA methyltransferases (DNMTs) using real-time PCR of total RNA from these cells. Cells exposed to Pb2+ had low levels of DNMT3a mRNA, whereas the levels of DNMT1 and DNMT3b mRNAs remained unchanged. Pretreatment of cells with DNMT inhibitor 5-aza-2'-deoxycytidine (5 M) followed by Pb2+ (1 M) significantly increased levels of COX-2 mRNA compared with cells treated with Pb2+ alone. Overexpression of tumor suppressor gene Rb correlated with an increase in COX-2 mRNA and a decrease in DNMT3a mRNA. Conversely, overexpression of transcription factor E2F1 correlated with a decrease in COX-2 mRNA and an increase in DMNT3a mRNA. Pretreatment with EGFR inhibitors AG1478 and PD153035 significantly limited Pb2+-induced reduction in DNMT3a mRNA. In addition, gene knockdown of DNMT3a with short hairpin RNA correlated with increased COX-2 mRNA induced by Pb2+. Our findings suggest Pb2+ ions induce COX-2 expression indirectly by reducing DNMT3a methylation of the COX-2 promoter via transcription factors Rb and E2F1. (c) 2014 Wiley Periodicals, Inc. Environ Toxicol 30: 1024-1032, 2015.	[Tsai, Yao-Ting; Chang, Che-Mai; Chang, Wei-Chiao] Taipei Med Univ, Sch Pharm, Dept Clin Pharm, Taipei, Taiwan; [Wang, Jaw-Yuan; Hou, Ming-Feng; Chang, Wei-Chiao] Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung, Taiwan; [Wang, Ju-Ming] Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Bioinformat & Biosignal Transduct, Tainan 70101, Taiwan; [Shiurba, Robert] Waseda Univ, Grad Sch Sci & Engn, Integrat Biosci & Biomed Engn, Tokyo, Japan; [Wang, Ju-Ming; Chang, Wen-Chang] Taipei Med Univ, Coll Med, Grad Inst ofMed Sci, Taipei, Taiwan; [Chang, Wei-Chiao] Taipei Med Univ, Wanfang Hosp, Dept Pharm, Taipei, Taiwan; [Chang, Wei-Chiao] Taipei Med Univ, Sch Pharm, Master Program Clin Pharmacogen & Pharmacoprotef, Taipei, Taiwan; [Wang, Jaw-Yuan; Hou, Ming-Feng] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Gastrointestinal & Gen Surg, Kaohsiung, Taiwan; [Wang, Jaw-Yuan; Hou, Ming-Feng] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Grad Inst Clin Med, Kaohsiung, Taiwan; [Hou, Ming-Feng] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Kaohsiung, Taiwan	Chang, WC (reprint author), Taipei Med Univ, Sch Pharm, Dept Clin Pharm, Taipei, Taiwan.	wcc@tmu.edu.tw			Department of Health [DOH102-TD-C-111-002]; National Science Council [NSC101-2628-B-038-001-MY2, NSC101-2320-B-038 -029 -MY3]	Contract grant sponsor: Cancer Research Grant From the Department of Health.; Contract grant number: DOH102-TD-C-111-002; Contract grant sponsor: National Science Council.; Contract grant numbers: NSC101-2628-B-038-001-MY2, NSC101-2320-B-038 -029 -MY3	SCHWARTZ J, 1991, ENVIRON HEALTH PERSP, V91, P71, DOI 10.2307/3430985; Song SH, 2001, CANCER RES, V61, P4628; Lin RK, 2010, CANCER RES, V70, P5807, DOI 10.1158/0008-5472.CAN-09-4161; Lustberg M, 2002, ARCH INTERN MED, V162, P2443, DOI 10.1001/archinte.162.21.2443; Navas-Acien A, 2004, CIRCULATION, V109, P3196, DOI 10.1161/01.CIR.0000130848.18636.B2; Chang WC, 2011, TOXICOLOGY, V279, P45, DOI 10.1016/j.tox.2010.09.004; Meng XY, 2011, DIS ESOPHAGUS, V24, P444, DOI 10.1111/j.1442-2050.2010.01159.x; Chou YH, 2011, TOXICOL LETT, V203, P147, DOI 10.1016/j.toxlet.2011.03.017; Schober SE, 2006, ENVIRON HEALTH PERSP, V114, P1538, DOI 10.1289/ehp.9123; Menke A, 2006, CIRCULATION, V114, P1388, DOI 10.1161/CIRCULATIONAHA.106.628321; Chan CP, 2015, ENVIRON TOXICOL, V30, P129, DOI 10.1002/tox.21878; Cheng YW, 1998, AM J CARDIOL, V82, P594, DOI 10.1016/S0002-9149(98)00402-0; Lin YC, 2015, ENVIRON TOXICOL, V30, P315, DOI 10.1002/tox.21909; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246; Yue X, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-118; Zeller I, 2010, ARTERIOSCL THROM VAS, V30, P1733, DOI 10.1161/ATVBAHA.110.211011	17	1	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1520-4081	1522-7278		ENVIRON TOXICOL	Environ. Toxicol.	SEP	2015	30	9					1024	1032		10.1002/tox.21976		9	Environmental Sciences; Toxicology; Water Resources	Environmental Sciences & Ecology; Toxicology; Water Resources	CP4NN	WOS:000359859100004		
J	Yamanaka, N; Hossain, MM; Yamaoka, Y				Yamanaka, Naoki; Hossain, Md. Motaher; Yamaoka, Yuichi			Molecular mapping of Asian soybean rust resistance in Chinese and Japanese soybean lines, Xiao Jing Huang, Himeshirazu, and Iyodaizu B	EUPHYTICA			English	Article						Allelic variation; Genetic mapping; Glycine max; Phakopsora pachyrhizi; QTL; Resistance gene	PHAKOPSORA-PACHYRHIZI; GENES; CONFIRMATION; GENETICS; ALLELE; LOCUS; RPP2	Asian soybean rust (ASR), caused by the fungus Phakopsora pachyrhizi, is one of the most serious soybean diseases in South America and other tropical and sub-tropical areas. The soybean lines, 'Xiao Jing Huang,' 'Himeshirazu,' and 'Iyodaizu B' were previously identified for their resistance to ASR fungus, while the genetic basis of the resistance has yet to be known. In this study, we mapped the ASR resistance loci in these three lines using three independent mapping populations derived from crosses with an ASR susceptible variety, BRS184. In each population, resistance to ASR appeared to be primarily controlled by a single major gene. The resistance genes with largest effect from Xiao Jing Huang and Himeshirazu were genetically mapped on chromosome 18 corresponding to the same location of known resistant locus, Rpp1. On the other hand, quantitative trait locus analysis mapped the major ASR resistance locus of Iyodaizu B to the region of chromosome 16 where Rpp2 was previously mapped. Genetic mapping with DNA markers and disease reactions of seven candidates carrying Rpp1 to four Brazilian ASR isolates revealed a significant variation in their ASR resistance reaction, indicating that they share different resistance genes tightly linked to each other or different resistant alleles of a single Rpp1 gene. Therefore, these seven soybean lines could be clearly separated into at least two functional groups.	[Yamanaka, Naoki; Hossain, Md. Motaher] JIRCAS, Tsukuba, Ibaraki 3058686, Japan; [Hossain, Md. Motaher] Bangabandhu Sheikh Mujibur Rahman Agr Univ, Gazipur 1706, Bangladesh; [Yamaoka, Yuichi] Univ Tsukuba, Fac Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan	Yamanaka, N (reprint author), JIRCAS, 1-1 Ohwashi, Tsukuba, Ibaraki 3058686, Japan.	naokiy@affrc.go.jp			JIRCAS; JIRCAS Visiting Research Fellowship Program	We thank M. Morishita, T. Mori, and M. Hasegawa (JIRCAS) for their technical assistance, advice, and encouragement. We are grateful to the Brazilian Agricultural Research Corporation (Embrapa) in Brazil, the Jilin Academy of Agricultural Sciences (JAAS) in China, the National Institute of Agrobiological Science (NIAS) and the National Institute of Crop Science (NICS) in Japan for providing seeds of soybean varieties. This study was financially supported and conducted by the JIRCAS research Project "Development of Breeding Technologies toward Improved Production and Stable Supply of Upland Crops." The author, M. M. H. was financially supported by JIRCAS Visiting Research Fellowship Program.	Grant D, 2010, NUCLEIC ACIDS RES, V38, pD843, DOI 10.1093/nar/gkp798; Li SX, 2012, THEOR APPL GENET, V125, P133, DOI 10.1007/s00122-012-1821-y; Yamanaka N, 2013, CROP BREED APPL BIOT, V13, P75, DOI 10.1590/S1984-70332013000100009; Song QJ, 2004, THEOR APPL GENET, V109, P122, DOI 10.1007/s00122-004-1602-3; HARTWIG EE, 1983, CROP SCI, V23, P237; Kim KS, 2012, THEOR APPL GENET, V125, P1339, DOI 10.1007/s00122-012-1932-5; Yamanaka N, 2010, TROP PLANT PATHOL, V35, P153, DOI 10.1590/S1982-56762010000300003; Lemos NG, 2011, EUPHYTICA, V182, P53, DOI 10.1007/s10681-011-0465-3; Garcia A, 2008, THEOR APPL GENET, V117, P545, DOI 10.1007/s00122-008-0798-z; Yamanaka N, 2011, JARQ-JPN AGR RES Q, V45, P385; Akamatsu H, 2013, J GEN PLANT PATHOL, V79, P28, DOI 10.1007/s10327-012-0421-7; Kendrick MD, 2011, PHYTOPATHOLOGY, V101, P535, DOI 10.1094/PHYTO-09-10-0257; Chakraborty N, 2009, CROP SCI, V49, P783, DOI 10.2135/cropsci2008.06.0335; Monteros MJ, 2007, CROP SCI, V47, P829, DOI 10.2135/cropsci06.07.0462; Hyten DL, 2009, CROP SCI, V49, P265, DOI 10.2135/cropsci2008.08.0511; Ribeiro AS, 2007, EUPHYTICA, V157, P15, DOI 10.1007/s10681-007-9404-8; Ray JD, 2009, THEOR APPL GENET, V119, P271, DOI 10.1007/s00122-009-1036-z; Goellner K, 2010, MOL PLANT PATHOL, V11, P169, DOI 10.1111/j.1364-3703.2009.00589.x; Yamaoka Y, 2014, J GEN PLANT PATHOL, V80, P184, DOI 10.1007/s10327-014-0507-5; Levy C, 2005, PLANT DIS, V89, P669, DOI 10.1094/PD-89-0669; Silva DCG, 2008, THEOR APPL GENET, V117, P57, DOI 10.1007/s00122-008-0752-0; Benitez ER, 2008, BREED RES S1, V10, P70; Brogin RL, 2005, THESIS U SAO PAULO; Garcia A, 2011, CROP SCI, V51, P32, DOI 10.2135/cropsci2010.01.0037; Hossain MM, 2015, PLANT PATHOL, V64, P147, DOI 10.1111/ppa.12226; Hyten DL, 2007, CROP SCI, V47, P835, DOI 10.2135/cropsci2006.07.0484; Jeong SC, 2001, THEOR APPL GENET, V103, P406, DOI 10.1007/s001220100567; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; Laperuta LD, 2008, PESQUI AGROPECU BRAS, V43, P1741, DOI 10.1590/S0100-204X2008001200014; Miles M.R., 2006, PLANT HLTH PROGR, DOI [10.1094/PHP-2006-0104-01-RS, DOI 10.1094/PHP-2006-0104-01-RS]; OLIVEIRA A. C. B., 2005, FITOPATOL BRAS, V30, P658; Ray J. D., 2011, Journal of Crop Improvement, V25, P219, DOI 10.1080/15427528.2011.555833; Schneider R, 2008, USING FOLIAR FUNGICI, P72; Wang S, 2007, WINDOWS QTL CARTOGRA; Yamanaka N, 2013, LAB MANUAL STUDIES S; Yamanaka N, 2008, 58 JIRCAS, P99; Yorinori JT, 2008, 58 JIRCAS, P70	37	1	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0014-2336	1573-5060		EUPHYTICA	Euphytica	SEP	2015	205	2					311	324		10.1007/s10681-015-1377-4		14	Agronomy; Plant Sciences; Horticulture	Agriculture; Plant Sciences	CO4MP	WOS:000359135200001		
J	Yamanaka, N; Lemos, NG; Jara, RC; Hossain, MM; Suenaga, K; Yamaoka, Y				Yamanaka, Naoki; Lemos, Noelle Giacomini; Chavez Jara, Romina; Hossain, Md Motaher; Suenaga, Kazuhiro; Yamaoka, Yuichi			Prevention of leaf yellowing in Asian soybean rust infected plants is associated with green cotyledon color and the infection index	EUPHYTICA			English	Article						Glycine max; Phakopsora pachyrhizi; Resistance	PHAKOPSORA-PACHYRHIZI; GAS-EXCHANGE; RESISTANCE; GENES; SENESCENCE; MUTATIONS; NUCLEAR; CHLOROPHYLL; INHERITANCE; PROTEINS	Because the six major known resistance genes to Asian soybean rust (ASR) are pathotype-specific, they rarely offer durable resistance to all ASR pathogens. Thus, other types of resistance such as field resistance or tolerance that confer broad-spectrum resistance to ASR pathogens are required for soybean breeding. The Chinese soybean variety Lu Pi Dou has a green cotyledon color (CC) and a no leaf yellowing (LY) phenotype was previously identified during ASR infection of this strain. This phenotype may reduce yield losses of soybean cultivars infected with ASR infections if it is independent of pathotype-specific major resistance genes and undesirable phenotypes. Thus, to identify associations of LY and CC and other color traits and loci that are linked to the six known ASR resistance genes, recombinant inbred lines (RILs) and backcross (BC) BC2F5 lines were derived from Lu Pi Dou and BRS184 plant strains. Comparisons of LY, CC, and genotypes of simple sequence repeat (SSR) markers revealed that the absence of LY is tightly associated with green CC in accordance with the expression of the genes d1 and d2. However, although variations of LY in RILs with yellow CC predominantly reflected the infection index (IFI), no associations were observed between LY and pubescence color, pod color, seed coat color, or flanking SSR markers for six known ASR resistance loci. An association of LY with CC and IFI was also shown in data from BC populations. Therefore, prevention of LY during ASR infection of Lu Pi Dou was primarily dependent on the double-recessive genotype d1d1d2d2 for CC and secondarily on low IFI.	[Yamanaka, Naoki; Lemos, Noelle Giacomini; Hossain, Md Motaher; Suenaga, Kazuhiro] Japan Int Res Ctr Agr Sci JIRCAS, Tsukuba, Ibaraki 3058686, Japan; [Lemos, Noelle Giacomini] Univ Estadual Maringa, BR-87020900 Maringa, Parana, Brazil; [Chavez Jara, Romina] IPTA, CICM, Capitan Miranda, Itapua, Paraguay; [Hossain, Md Motaher] Bangabandhu Sheikh Mujibur Rahman Agr Univ, Gazipur 1706, Bangladesh; [Yamaoka, Yuichi] Univ Tsukuba, Fac Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan	Yamanaka, N (reprint author), Japan Int Res Ctr Agr Sci JIRCAS, 1-1 Ohwashi, Tsukuba, Ibaraki 3058686, Japan.	naokiy@affrc.go.jp			JIRCAS; JIRCAS Visiting Research Fellowship Program	We thank Mio Morishita, Tomomi Mori, Akiko Takahashi, Sachiko Nishimura, Yukie Muraki, and Iwao Ohyama (JIRCAS) for their technical assistance, advice, and encouragement. We are grateful to the Jilin Academy of Agricultural Sciences (JAAS) in China and the Brazilian Agricultural Research Corporation (Embrapa) for providing seeds of the parental varieties. This study was financially supported and conducted by the JIRCAS research project "Development of Breeding Technologies toward Improved Production and Stable Supply of Upland Crops." The authors N. G. L. and M. M. H. were financially supported by the JIRCAS Visiting Research Fellowship Program.	Grant D, 2010, NUCLEIC ACIDS RES, V38, pD843, DOI 10.1093/nar/gkp798; Li SX, 2012, THEOR APPL GENET, V125, P133, DOI 10.1007/s00122-012-1821-y; Yamanaka N, 2013, CROP BREED APPL BIOT, V13, P75, DOI 10.1590/S1984-70332013000100009; HARTWIG EE, 1983, CROP SCI, V23, P237; Yamanaka N, 2010, TROP PLANT PATHOL, V35, P153, DOI 10.1590/S1982-56762010000300003; Lemos NG, 2011, EUPHYTICA, V182, P53, DOI 10.1007/s10681-011-0465-3; Garcia A, 2008, THEOR APPL GENET, V117, P545, DOI 10.1007/s00122-008-0798-z; Yamanaka N, 2011, JARQ-JPN AGR RES Q, V45, P385; Akamatsu H, 2013, J GEN PLANT PATHOL, V79, P28, DOI 10.1007/s10327-012-0421-7; Hyten DL, 2009, CROP SCI, V49, P265, DOI 10.2135/cropsci2008.08.0511; Ribeiro AS, 2007, EUPHYTICA, V157, P15, DOI 10.1007/s10681-007-9404-8; Goellner K, 2010, MOL PLANT PATHOL, V11, P169, DOI 10.1111/j.1364-3703.2009.00589.x; Hartman GL, 2005, PLANT DIS, V89, P664, DOI 10.1094/PD-89-0664; Silva DCG, 2008, THEOR APPL GENET, V117, P57, DOI 10.1007/s00122-008-0752-0; Arias CAA, 2008, 58 JIRCAS, P29; Brogin RL, 2005, THESIS U SAO PAULO; GUIAMET JJ, 1991, PLANT PHYSIOL, V96, P227, DOI 10.1104/pp.96.1.227; Guiamet JJ, 1996, PHYSIOL PLANTARUM, V96, P655; GUIAMET JJ, 1990, PLANT CELL PHYSIOL, V31, P1123; Hossain MM, 2015, PLANT PATHOL, V64, P147, DOI 10.1111/ppa.12226; Hyten DL, 2007, CROP SCI, V47, P835, DOI 10.2135/cropsci2006.07.0484; Laperuta LD, 2008, PESQUI AGROPECU BRAS, V43, P1741, DOI 10.1590/S0100-204X2008001200014; Luquez VM, 2002, J EXP BOT, V53, P1421, DOI 10.1093/jexbot/53.373.1421; Luquez VM, 2001, ANN BOT-LONDON, V87, P313, DOI 10.1006/anbo.2000.1324; Nakano M, 2014, PLANT CELL PHYSIOL, V55, P1763, DOI 10.1093/pcp/pcu107; OLIVEIRA A. C. B., 2005, FITOPATOL BRAS, V30, P658; Ott Alina, 2013, Plants-Basel, V2, P441, DOI 10.3390/plants2030441; Woodworth CM, 1921, GENETICS, V6, P487; Yamanaka N, 2013, LAB MANUAL STUDIES S; Yorinori JT, 2008, 58 JIRCAS, P70; YOUNG LD, 1978, CROP SCI, V18, P1075	31	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0014-2336	1573-5060		EUPHYTICA	Euphytica	SEP	2015	205	2					475	482		10.1007/s10681-015-1414-3		8	Agronomy; Plant Sciences; Horticulture	Agriculture; Plant Sciences	CO4MP	WOS:000359135200013		
J	Osman, M; He, XY; Singh, RP; Duveiller, E; Lillemo, M; Pereyra, SA; Westerdijk-Hoks, I; Kurushima, M; Yau, SK; Benedettelli, S; Singh, PK				Osman, Mohamed; He, Xinyao; Singh, Ravi P.; Duveiller, Etienne; Lillemo, Morten; Pereyra, Silvia A.; Westerdijk-Hoks, Ingeborg; Kurushima, Masatomo; Yau, Sui-Kwong; Benedettelli, Stefano; Singh, Pawan K.			Phenotypic and genotypic characterization of CIMMYT's 15th international Fusarium head blight screening nursery of wheat	EUPHYTICA			English	Article						FHB screening; Resistance; Fusarium spp.; Triticum aestivum L	TRITICUM-AESTIVUM L.; DEOXYNIVALENOL ACCUMULATION; ANTHER EXTRUSION; SPRING WHEAT; GIBBERELLA-ZEAE; RESISTANCE; GRAMINEARUM; BARLEY; GENE; METAANALYSIS	As an important cereal disease in humid and semi-humid areas, Fusarium head blight (FHB) has caused severe epidemics on wheat (Triticum aestivum L.) in different countries worldwide. By causing both yield loss and quality degradation, FHB presents a two-fold threat to farmers and consumers. Since the beginning of FHB research at the International Maize and Wheat Improvement Centre (CIMMYT) in the early 1980s, a large-scale FHB screening has been conducted to identify and incorporate new resistance genes into elite CIMMYT germplasm. Candidates of the 15th Fusarium head blight screening nursery (FHBSN) were derived from different CIMMYT wheat breeding programs and were tested for 3 years successively in El Batan, Mexico, before being included in the 15th FHBSN set. From 2010 to 2012, a set of 44 out of 2794 lines were gradually selected depending on their FHB indices, pedigree information, and phenological traits like plant height and days to heading. The performance of these lines varied across years under different disease pressure, but they all showed high level of resistance compared to the susceptible checks. In 2013, the nursery was again evaluated in El Batan, as well as in artificially inoculated field trials in Norway, Uruguay, the Netherlands, and Japan (2014), and in naturally infected experiments in Toluca, Mexico, and Canada. Although not all lines demonstrated strong resistance across environments, promising lines with good FHB resistance can still be identified in each location. The genotypes were haplotyped with PCR-based markers for ten loci on seven chromosomes associated with known FHB resistance, and the results suggested that 24 of the genotypes (55 %) carried the 4BS QTL as in Wuhan 1, which was the most frequent QTL in this nursery, and the 7A QTL as in T. dicoccoides was noticed in five (11 %) of the genotypes. The resistance QTLs on chromosomes 3B, 5A and 6B as in Sumai 3 and 3A as in T. dicoccoides were not detected in any of the genotypes denoting the uniqueness of these lines. Fifteen (34 %) of the genotypes may not carry any of the ten QTLs examined. The results provide valuable information that could be successfully utilized by breeders to select resistant parents for crosses since novel resistance sources were detected for better targeted crosses toward diversifying and/or pyramiding FHB resistance.	[Osman, Mohamed; He, Xinyao; Singh, Ravi P.; Duveiller, Etienne; Singh, Pawan K.] CIMMYT, Int Maize & Wheat Improvement Ctr, Mexico City 06600, DF, Mexico; [Osman, Mohamed; Benedettelli, Stefano] Univ Firenze, DISPAA Sez Patol Vegetale & Entomol, I-50144 Florence, Italy; [Lillemo, Morten] Norwegian Univ Life Sci, Dept Plant Sci, N-1432 As, Norway; [Pereyra, Silvia A.] INIA La Estanzuela, Inst Nacl Invest Agr, Colonia Del Sacramento 70000, Uruguay; [Westerdijk-Hoks, Ingeborg] Wiersum Plantbreeding, NL-8250 AB Dronten, Netherlands; [Kurushima, Masatomo] Kitami Agr Expt Stn, Kunneppu, Hokkaido 0991496, Japan; [Yau, Sui-Kwong] Ag Quest Inc, Minto, MB, Canada	Singh, PK (reprint author), CIMMYT, Int Maize & Wheat Improvement Ctr, Apdo Postal 6-641, Mexico City 06600, DF, Mexico.	pk.singh@cgiar.org	Benedettelli, Stefano/M-9760-2015	Benedettelli, Stefano/0000-0002-6035-1801	CGIAR Research Program on Wheat; Research Council of Norway [NFR 208340, NFR 224833]	The helpful assistance of Francisco Lopez and Javier Segura with field trials and Nerida Lozano for her efforts on strain identification and inoculum preparation is highly acknowledged. Financial support by the CGIAR Research Program on Wheat is gratefully acknowledged. Field testing of the 15th FHBSN nursery in Norway was financed through grants from the Research Council of Norway (NFR 208340 and NFR 224833).	Miedaner T, 2008, CROP SCI, V48, P2115, DOI 10.2135/cropsci2008.02.0107; Buerstmayr H, 2002, THEOR APPL GENET, V104, P84, DOI 10.1007/s001220200009; Fernando WGD, 1997, PHYTOPATHOLOGY, V87, P414, DOI 10.1094/PHYTO.1997.87.4.414; Liu SY, 2009, CROP SCI, V49, P1955, DOI 10.2135/cropsci2009.03.0115; Skinnes H, 2010, PLANT BREEDING, V129, P149, DOI 10.1111/j.1439-0523.2009.01731.x; Agostinelli AM, 2012, EUPHYTICA, V186, P115, DOI 10.1007/s10681-011-0499-6; Cuthbert PA, 2007, THEOR APPL GENET, V114, P429, DOI 10.1007/s00122-006-0439-3; Miedaner T, 1997, PLANT BREEDING, V116, P201, DOI 10.1111/j.1439-0523.1997.tb00985.x; Bai GH, 2004, ANNU REV PHYTOPATHOL, V42, P135, DOI 10.1146/annurev.phyto.42.040803.140340; Somers DJ, 2003, GENOME, V46, P555, DOI 10.1139/G03-033; Hilton AJ, 1999, PLANT PATHOL, V48, P202, DOI 10.1046/j.1365-3059.1999.00339.x; Culler MD, 2007, PLANT DIS, V91, P1464, DOI 10.1094/PDIS-91-11-1464; KHONGA EB, 1988, CAN J PLANT PATHOL, V10, P232; Audenaert K, 2009, EUR J PLANT PATHOL, V125, P445, DOI 10.1007/s10658-009-9494-3; Schmolke M, 2005, THEOR APPL GENET, V111, P747, DOI 10.1007/s00122-005-2060-2; Xue S, 2010, THEOR APPL GENET, V121, P147, DOI 10.1007/s00122-010-1298-5; Jansen C, 2005, P NATL ACAD SCI USA, V102, P16892, DOI 10.1073/pnas.0508467102; Paul PA, 2006, PHYTOPATHOLOGY, V96, P951, DOI 10.1094/PHYTO-96-0951; Brunner K, 2009, ANAL BIOANAL CHEM, V395, P1385, DOI 10.1007/s00216-009-3083-3; Li HP, 2005, FEMS MICROBIOL LETT, V243, P505, DOI 10.1016/j.femsle.2005.01.015; Nicholson P, 1998, PHYSIOL MOL PLANT P, V53, P17, DOI 10.1006/pmpp.1998.0170; Srinivasachary, 2009, THEOR APPL GENET, V118, P695, DOI 10.1007/s00122-008-0930-0; Buerstmayr H, 2009, PLANT BREEDING, V128, P1, DOI 10.1111/j.1439-0523.2008.01550.x; McMullen M, 2012, PLANT DIS, V96, P1712, DOI 10.1094/PDIS-03-12-0291-FE; Paul PA, 2005, PHYTOPATHOLOGY, V95, P1225, DOI 10.1094/PHYTO-95-1225; Draeger R, 2007, THEOR APPL GENET, V115, P617, DOI 10.1007/s00122-007-0592-3; Bai GH, 2002, MYCOPATHOLOGIA, V153, P91, DOI 10.1023/A:1014419323550; He XY, 2014, EUPHYTICA, V195, P383, DOI 10.1007/s10681-013-1002-3; Buerstmayr H, 2012, CABI PLANT PROT SER, P236, DOI 10.1079/9781845938185.0236; Holzapfel J, 2008, THEOR APPL GENET, V117, P1119, DOI 10.1007/s00122-008-0850-z; Cuthbert PA, 2006, THEOR APPL GENET, V112, P1465, DOI 10.1007/s00122-006-0249-7; Miedaner T, 2001, PLANT BREEDING, V120, P97, DOI 10.1046/j.1439-0523.2001.00580.x; Schuelke M, 2000, NAT BIOTECHNOL, V18, P233, DOI 10.1038/72708; Mesterhazy A, 1999, PLANT BREEDING, V118, P97, DOI 10.1046/j.1439-0523.1999.118002097.x; Salas B, 1999, PLANT DIS, V83, P667, DOI 10.1094/PDIS.1999.83.7.667; Dubin HJ, 1997, FUSARIUM HEAD SCAB G; Duveiller E, 2008, CEREAL RES COMMUN, V36, P11, DOI 10.1556/CRC.36.2008.Suppl.B.3; Flemmig EL, 2012, THESIS N CAROLINA ST; Graham S, 2009, J PHYTOPATHOL, V157, P580, DOI 10.1111/j.1439-0434.2008.01524.x; Hammer O, 2001, PALAEONTOL ELECTRON, V4, P9, DOI DOI 10.1016/J.BCP.2008.05.025; He X, 2013, FUSARIUM HEAD BLIGHT, P241; He XY, 2013, EUR J PLANT PATHOL, V136, P123, DOI 10.1007/s10658-012-0146-7; He ZH, 2000, P NAT FUS HEAD BLIGH; Nopsa JFH, 2012, CAN J PLANT PATHOL, V34, P380, DOI 10.1080/07060661.2012.695751; Kubo K, 2013, J PHYTOPATHOL, V161, P308, DOI 10.1111/jph.12060; Kumar S, 2007, PHYTOPATHOLOGY, V97, P592, DOI 10.1094/PHYTO-97-5-0592; Leonard K. J., 2003, FUSARIUM HEAD BLIGHT; Lu QX, 2011, CROP SCI, V51, P2430, DOI 10.2135/cropsci2010.12.0671; Lu QX, 2013, THEOR APPL GENET, V126, P317, DOI 10.1007/s00122-012-1981-9; Malihipour A, 2012, PLANT DIS, V96, P1016, DOI 10.1094/PDIS-10-11-0866-RE; McMullen MP, 1994, VISUAL SCALE ESTIMAT, P1095; Mesterhazy A, 2005, EUR J PLANT PATHOL, V112, P267, DOI 10.1007/s10658-005-2853-9; Tamburic-Ilincic L, 2013, P 12 EUR FUS SEM BOR; The Commission of the European Communities, 2006, OFFICIAL J EUROPEA L, V364, P5; VANEEUWIJK FA, 1995, THEOR APPL GENET, V90, P221, DOI 10.1007/BF00222205; WILCOXSON RD, 1992, PLANT DIS, V76, P658; Yan W, 2011, PLANT PATHOL, V60, P506, DOI 10.1111/j.1365-3059.2011.02426.x	57	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0014-2336	1573-5060		EUPHYTICA	Euphytica	SEP	2015	205	2					521	537		10.1007/s10681-015-1425-0		17	Agronomy; Plant Sciences; Horticulture	Agriculture; Plant Sciences	CO4MP	WOS:000359135200017		
J	Onoue, N; Yamada, M; Yamamoto, T; Terakami, S; Nishitani, C; Kunihisa, M; Takada, N; Nishio, S; Sawamura, Y; Saito, T				Onoue, Noriyuki; Yamada, Masahiko; Yamamoto, Toshiya; Terakami, Shingo; Nishitani, Chikako; Kunihisa, Miyuki; Takada, Norio; Nishio, Sogo; Sawamura, Yutaka; Saito, Toshihiro			Kinship and inbreeding estimates based on microsatellite markers in breeding of Japanese pear (Pyrus pyrifolia Nakai)	EUPHYTICA			English	Article						Breeding; Fruit tree; Inbreeding; Kinship; Pear	GENETIC-LINKAGE MAPS; X-DOMESTICA BORKH.; PAIRWISE RELATEDNESS; MOLECULAR MARKERS; SSR MARKERS; COEFFICIENTS; HETEROZYGOSITY; PERSIMMON; IDENTIFICATION; TRAITS	The degree of inbreeding should ideally be determined across the entire genome, but is instead widely measured using the pedigree-based coefficients of kinship (f) for pairs of individuals and of inbreeding (F) for individuals. For fruit trees, this biases the estimates for pairs of cross-parents and crossbred accessions, because f and F do not account for any latent kinship among the parents, particularly when these are local cultivars. Local cultivars are often important genetic resources but usually have an unknown pedigree. Several estimators have been developed for estimating kinship and inbreeding from DNA marker data. Among these, we selected the kinship estimator of Wang (Genet Res 89: 135; 2007) and the inbreeding estimator of Leutenegger et al. (Am J Hum Genet 73: 516; 2003), using 207 simple sequence repeat markers in 73 Japanese pear (Pyrus pyrifolia Nakai) and 3 Chinese pear (Pyrus ussuriensis Maxim.) accessions with high potential as cross-parents in breeding of Japanese pear. Pedigree-based coefficients calculated from accessions with all known great-grandparents were used to compare the performance (measured by root mean square errors and correlations) of the estimators. Most marker kinship estimates matched the expected values for parent-offspring and full-sibling pairs, and indicated latent inbreeding, especially among accessions with f = 0, including local cultivars. Marker estimators highlighted latent inbreeding early in the breeding program. The data presented here will help breeders identify the degree of inbreeding in breeding populations and avoid inbreeding during crossbreeding of Japanese pear.	[Onoue, Noriyuki] NARO Inst Fruit Tree Sci, Grape & Persimmon Res Stn, Higashihiroshima 7392494, Japan; [Yamada, Masahiko; Yamamoto, Toshiya; Terakami, Shingo; Nishitani, Chikako; Kunihisa, Miyuki; Takada, Norio; Nishio, Sogo; Sawamura, Yutaka; Saito, Toshihiro] NARO Inst Fruit Tree Sci, Tsukuba, Ibaraki 3058605, Japan	Onoue, N (reprint author), NARO Inst Fruit Tree Sci, Grape & Persimmon Res Stn, 301-2 Mitsu, Higashihiroshima 7392494, Japan.	noriyuki.onoue@affrc.go.jp					QUELLER DC, 1989, EVOLUTION, V43, P258, DOI 10.2307/2409206; Lynch M, 1999, GENETICS, V152, P1753; Balloux F, 2004, MOL ECOL, V13, P3021, DOI 10.1111/j.1365-294X.2004.02318.x; Toro M, 2002, CONSERV GENET, V3, P309, DOI 10.1023/A:1019921131171; Ritland K, 1996, GENET RES, V67, P175; Guilford P, 1997, THEOR APPL GENET, V94, P249, DOI 10.1007/s001220050407; LI CC, 1993, HUM HERED, V43, P45, DOI 10.1159/000154113; Leutenegger AL, 2003, AM J HUM GENET, V73, P516, DOI 10.1086/378207; Celton JM, 2009, TREE GENET GENOMES, V5, P93, DOI 10.1007/s11295-008-0171-z; Aparicio JM, 2006, MOL ECOL, V15, P4659, DOI 10.1111/j.1365-294X.2006.03111.x; Sato A, 2006, J AM SOC HORTIC SCI, V131, P46; Wang JL, 2002, GENETICS, V160, P1203; HANSCHE PE, 1972, J AM SOC HORTIC SCI, V97, P76; Curik I, 2003, J HERED, V94, P125, DOI 10.1093/jhered/esg029; Slate J, 2004, HEREDITY, V93, P255, DOI 10.1038/sj.hdy.6800485; Iwata H, 2013, BREEDING SCI, V63, P125, DOI 10.1270/jsbbs.63.125; Yamamoto T, 2002, THEOR APPL GENET, V106, P9, DOI 10.1007/s00122-002-0966-5; Liebhard R, 2002, MOL BREEDING, V10, P217, DOI 10.1023/A:1020525906332; HANSCHE PE, 1972, J AM SOC HORTIC SCI, V97, P279; Yamamoto T, 2006, BREEDING SCI, V56, P165, DOI 10.1270/jsbbs.56.165; Wang JL, 2011, MOL ECOL RESOUR, V11, P141, DOI 10.1111/j.1755-0998.2010.02885.x; Yamamoto T, 2013, ACTA HORTIC, V976, P477; Wright S, 1922, AM NAT, V56, P330, DOI 10.1086/279872; Santure AW, 2010, MOL ECOL, V19, P1439, DOI 10.1111/j.1365-294X.2010.04554.x; Milligan BG, 2003, GENETICS, V163, P1153; Wang J, 2007, GENET RES, V89, P135, DOI 10.1017/S0016672307008798; Yamamoto T, 2007, BREEDING SCI, V57, P321, DOI 10.1270/jsbbs.57.321; Ashikawa K, 1973, B TOKYO TO AGR EXPT, V7, P11; BELL RL, 1990, J AM SOC HORTIC SCI, V115, P829; Bink MCAM, 2008, THEOR APPL GENET, V117, P843, DOI 10.1007/s00122-008-0824-1; CALDWELL JD, 1982, J AM SOC HORTIC SCI, V107, P628; COURANJOU J, 1995, SCI HORTIC-AMSTERDAM, V61, P61, DOI 10.1016/0304-4238(94)00727-W; Development Core Team R., 2009, R LANG ENV STAT COMP; Haldane JBS, 1939, ANN EUGENIC, V9, P321; Hedrick P, 2001, EVOLUTION, V55, P1256; Kajiura M, 1967, B HORT RES STATION, V6, P69; Kajiura M, 1974, B FRUIT TREE RES S A, V1, P1; Kajiura M, 1969, B HORT RES STA, V8, P7; Kaneko T, 1997, B TOCHIGI AGR EXP ST, V46, P15; KESTER DE, 1977, J AM SOC HORTIC SCI, V102, P264; Kitaguchi M, 2002, ACTA HORTIC, P311; Kotobuki K, 2004, B NATL I FRUIT TREE, V3, P31; Kotobuki K, 1991, B FRUIT TREE RES STN, V21, P15; Kotobuki K, 2004, B NATL I FRUIT TREE, V3, P41; Kotobuki K, 2004, RECENT RES DEV GENET, V1, P397; Kotobuki K, 1991, B FRUIT TREE RES STN, V21, P1; Kotobuki K, 1994, B FRUIT TREE RES STN, V26, P1; Kotobuki K., 2004, BULL NATL INST FRUIT, V3, P21; Kotobuki K, 2002, B NATL I FRUIT TREE, V1, P11; Kotobuki K, 1991, B FRUIT TREE RES STN, V21, P29; Machida Y., 1976, Journal of the Japanese Society for Horticultural Science (Engei Gakkai Zasshi), V44, P325; Machida Y, 1984, B FRUIT TREE RES STA, V11, P9; MACHIDA Y, 1979, JARQ-JPN AGR RES Q, V13, P234; Maleecot G, 1948, MATH HEREDITE; Moriya S, 2012, TREE GENET GENOMES, V8, P709, DOI 10.1007/s11295-011-0458-3; Nagasawa K, 1971, SHINSEN GENSHOKU KUD, P86; Nagasawa K, 1971, SHINSEN GENSHOKU KUD, P88; Nakajima F, 2002, RES B NATL AGR RES C, V176, P91; Nishitani C, 2009, BREEDING SCI, V59, P391, DOI 10.1270/jsbbs.59.391; Fanizza G., 1973, Vitis, V12, P93; Ruiz-Lopez MJ, 2009, MOL ECOL, V18, P1352, DOI 10.1111/j.1365-294X.2009.04121.x; Saito Toshihiro, 2009, Bulletin of the National Institute of Fruit Tree Science, P11; Sato A, 2008, SCI HORTIC-AMSTERDAM, V117, P85, DOI 10.1016/j.scienta.2008.03.005; Sato Y, 1990, B FRUIT TREE RES STA, V1, P1; Saura M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078314; Sawamura Y, 2008, J JPN SOC HORTIC SCI, V77, P364, DOI 10.2503/jjshs1.77.364; Sawamura Y, 2004, J JPN SOC HORTIC SCI, V73, P511; Silfverberg-Dilworth E, 2006, TREE GENET GENOMES, V2, P202, DOI 10.1007/s11295-006-0045-1; Terakami S, 2009, J JPN SOC HORTIC SCI, V78, P417, DOI 10.2503/jjshs1.78.417; YAMADA M, 1993, JARQ-JPN AGR RES Q, V27, P33; YAMADA M, 1995, J AM SOC HORTIC SCI, V120, P886; YAMADA M, 1994, J AM SOC HORTIC SCI, V119, P1298; Yamada M, 1997, EUPHYTICA, V93, P119, DOI 10.1023/A:1002912325702; Yamada M, 2011, CROSS BREEDING WOODY	74	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0014-2336	1573-5060		EUPHYTICA	Euphytica	SEP	2015	205	2					539	555		10.1007/s10681-015-1427-y		17	Agronomy; Plant Sciences; Horticulture	Agriculture; Plant Sciences	CO4MP	WOS:000359135200018		
J	Sugiyama, M; Kawazu, Y; Fukino, N; Yoshioka, Y; Shimomura, K; Sakata, Y; Okuda, M				Sugiyama, Mitsuhiro; Kawazu, Yoichi; Fukino, Nobuko; Yoshioka, Yosuke; Shimomura, Koichiro; Sakata, Yoshiteru; Okuda, Mitsuru			Mapping of quantitative trait loci for Melon yellow spot virus resistance in cucumber (Cucumis sativus L.)	EUPHYTICA			English	Article						Framework map; MYSV; QTL; Spotted wilt; SSR marker; Tospovirus	POWDERY MILDEW RESISTANCE; RECOMBINANT INBRED LINES; LONG-DISTANCE MOVEMENT; GENETIC-MAP; PLANT-VIRUSES; QTL ANALYSIS; CONSTRUCTION; TOMATO; GENOME; IDENTIFICATION	Melon yellow spot virus (MYSV), a member of the genus Tospovirus, is a devastating thrips-transmitted virus of cucurbits. The cucumber accession 27028930 was found to be resistant to MYSV in our previous study. In the present study, we identified quantitative trait loci (QTLs) conferring resistance to two MYSV isolates, MYSV-FuCu05P and MYSV-S. An F-2 population derived from a cross between accession 27028930 and the susceptible cultivar 'Tokiwa' was used to test for MYSV-FuCu05P resistance and to construct a genetic linkage map. The map contains 7 linkage groups and is comprised of 81 simple sequence repeat (SSR) markers, which span 715 cM, with an average interval between markers of 9.7 cM. Two major QTLs [on chromosomes (Chr.) 1 and 3] and one minor QTL (Chr. 7) contributed by 27028930, and one minor QTL (Chr. 4) contributed by 'Tokiwa' were detected for MYSV-FuCu05P resistance. Another F-2 population from the same cross was used to test for MYSV-S resistance and to construct a genetic linkage map. The latter map also contains 7 linkage groups and is comprised of 76 SSR markers, which span 674 cM with an average interval between markers of 9.8 cM. A resistance gene for MYSV-S was identified on Chr. 3 by linkage analysis. Using independent populations, we demonstrated that SSR markers linked to the major QTLs for MYSV-FuCu05P resistance on Chr. 1 and 3 and an SSR marker linked to a resistance gene for MYSV-S on Chr. 3 could be used to select for MYSV resistance in cucumber breeding.	[Sugiyama, Mitsuhiro; Kawazu, Yoichi; Fukino, Nobuko; Yoshioka, Yosuke; Shimomura, Koichiro; Sakata, Yoshiteru] NARO Inst Vegetable & Tea Sci, Tsu, Mie 5142392, Japan; [Okuda, Mitsuru] NARO Agr Res Ctr, Tsukuba, Ibaraki 3058666, Japan	Kawazu, Y (reprint author), NARO Inst Vegetable & Tea Sci, Tsu, Mie 5142392, Japan.	ykawazu@affrc.go.jp			Ministry of Agriculture, Forestry, and Fisheries of Japan [HOR-1001]	We thank Dr. S. Matsumoto for valuable advice and Dr. T. Sakurai for providing the information on MYSV inoculation. We also thank F. Hori, D. Yamashita, S. Negoro, T. Yamakawa, K. Takeuchi, M. Shindo, M. Wakabayashi, M Sugao, Y. Taki, A. Suzuki, and T. Yamada for their technical assistance. This work was supported by a grant (Genomics-based Technology for Agricultural Improvement, HOR-1001) from the Ministry of Agriculture, Forestry, and Fisheries of Japan.	CLARK MF, 1977, J GEN VIROL, V34, P475, DOI 10.1099/0022-1317-34-3-475; Yuan XJ, 2008, EUPHYTICA, V164, P473, DOI 10.1007/s10681-008-9722-5; Carrington JC, 1996, PLANT CELL, V8, P1669; Fukino N, 2013, MOL BREEDING, V32, P267, DOI 10.1007/s11032-013-9867-3; Chiemsombat P, 2008, ARCH VIROL, V153, P571, DOI 10.1007/s00705-007-0024-3; He XM, 2013, THEOR APPL GENET, V126, P2149, DOI 10.1007/s00122-013-2125-6; Park YH, 2000, GENOME, V43, P1003, DOI 10.1139/gen-43-6-1003; Maule AJ, 2007, MOL PLANT PATHOL, V8, P223, DOI [10.1111/j.1364-3703.2007.00386.x, 10.1111/J.1364-3703.2007.00386.X]; Rehman S, 2009, MOL PLANT MICROBE IN, V22, P330, DOI 10.1094/MPMI-22-3-0330; Amano M, 2013, THEOR APPL GENET, V126, P2983, DOI 10.1007/s00122-013-2187-5; Spassova MI, 2001, MOL BREEDING, V7, P151, DOI 10.1023/A:1011363119763; Huang SW, 2009, NAT GENET, V41, P1275, DOI 10.1038/ng.475; Park Y, 2004, THEOR APPL GENET, V109, P707, DOI 10.1007/s00122-004-1684-y; Zhang WW, 2012, THEOR APPL GENET, V124, P249, DOI 10.1007/s00122-011-1701-x; Sakata Y, 2006, THEOR APPL GENET, V112, P243, DOI 10.1007/s00122-005-0121-1; Fukino N, 2008, BREEDING SCI, V58, P475, DOI 10.1270/jsbbs.58.475; de Ruiter W, 2008, CUCURBITACEAE 2008: PROCEEDINGS OF THE IXTH EUCARPIA MEETING ON GENETICS AND BREEDING OF CUCURBITACEAE, P181; BOITEUX LS, 1993, EUPHYTICA, V67, P89, DOI 10.1007/BF00022729; Caranta C, 2002, THEOR APPL GENET, V104, P586, DOI 10.1007/s001220100753; Cavagnaro PF, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-569; Chen TC, 2008, PLANT PATHOL, V57, P765, DOI 10.1111/j.1365-3059.2007.01791.x; Chisholm ST, 2001, PLANT PHYSIOL, V127, P1667, DOI 10.1104/pp.127.4.1667; Folkertsma RT, 1999, MOL BREEDING, V5, P197, DOI 10.1023/A:1009650424891; Gu Q. S., 2012, New Disease Reports, V25, P7, DOI 10.5197/j.2044-0588.2012.025.007; Kato K, 2000, PHYTOPATHOLOGY, V90, P422, DOI 10.1094/PHYTO.2000.90.4.422; Kato Kimihiko, 1999, Annals of the Phytopathological Society of Japan, V65, P624; Kosambi D. D., 1944, ANN EUGENICS, V12, P172; Kukita Y, 2002, BIOTECHNIQUES, V33, P502; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; Okuda M, 2009, PLANT PROTECTION, V63, P279; Quito-Avila DF, 2014, EUR J PLANT PATHOL, V140, P193, DOI 10.1007/s10658-014-0454-1; Ren Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005795; Sugiyama M, 2009, PLANT BREEDING, V128, P696, DOI 10.1111/j.1439-0523.2008.01617.x; Sugiyama M, 2009, J GEN PLANT PATHOL, V75, P381, DOI 10.1007/s10327-009-0187-8; Takeuchi S., 2001, Japanese Journal of Phytopathology, V67, P46; Wang S, 2012, WINDOWS QTL CARTOGRA; Watcharawongpaiboon N, 2008, PLANT BREEDING, V127, P74, DOI 10.1111/j.1439-0523.2007.01425.x; Wiboonchotikorn N, 2012, AUSTRALAS PLANT PATH, V41, P475, DOI 10.1007/s13313-012-0124-8; Woycicki R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022728; Yang LM, 2013, BMC PLANT BIOL, V13, DOI 10.1186/1471-2229-13-53; Yoshioka Y, 2014, EUPHYTICA, V198, P265, DOI 10.1007/s10681-014-1102-8	41	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0014-2336	1573-5060		EUPHYTICA	Euphytica	SEP	2015	205	2					615	625		10.1007/s10681-015-1444-x		11	Agronomy; Plant Sciences; Horticulture	Agriculture; Plant Sciences	CO4MP	WOS:000359135200023		
J	Miura, H; Takahashi, Y; Maki, Y; Sugino, M				Miura, Hajime; Takahashi, Yoshinori; Maki, Yukimi; Sugino, Megumi			Effects of exercise training on arterial stiffness in older hypertensive females	EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY			English	Article						Exercise training; Hypertension; Pulse wave velocity; Blood pressure	PULSE-WAVE VELOCITY; AEROBIC EXERCISE; BLOOD-PRESSURE; NITRIC-OXIDE; POSTMENOPAUSAL WOMEN; AGE; PATHOPHYSIOLOGY; REDUCTIONS; HUMANS; GENDER	Regular physical exercise is recommended for the prevention and treatment of cardiovascular disease. However, it is unclear whether the effects of exercise training on arterial stiffness are the same in older hypertensive individuals as those observed in older healthy subjects. The aim of this study was to compare the effects of exercise training on arterial stiffness between older hypertensive and healthy females. Ninety-two females with untreated hypertension and 108 healthy females were randomly assigned to either the control group or to participate in a 12-week training program. In the training groups, the subjects engaged in 90 min of training twice a week for 12 weeks. Each training program included recreational activities, six to eight resistance exercises for circuit training and chair-based exercise for the lower extremities. The systolic/diastolic blood pressure (SBP/DBP) and brachial to ankle pulse wave velocity (baPWV) were obtained in the supine position using an automatic pulse wave form analyzer. Compared with that observed in the control group, greater reductions in the baPWV and SBP/DBP were achieved in both training groups (P < 0.05). Furthermore, a significant difference in the delta baPWV values obtained before and after training was noted between the hypertensive (-72.5 +/- A 8.1 cm s(-1)) and healthy females (-131.5 +/- A 107.3 cm s(-1)) who participated in the training program (P < 0.05). These data indicate that exercise training produces fewer improvements in arterial stiffness in older hypertensive females than in older healthy females.	[Miura, Hajime; Maki, Yukimi; Sugino, Megumi] Univ Tokushima, Inst Socioarts & Sci, Appl Physiol Lab, Tokushima 7708502, Japan; [Takahashi, Yoshinori] Inst Tochigi Hlth & Wellness Fdn, Utsunomiya, Tochigi 3210941, Japan	Miura, H (reprint author), Univ Tokushima, Inst Socioarts & Sci, Appl Physiol Lab, 1-1 Minamijyosanjima, Tokushima 7708502, Japan.	hajime-m@tokushima-u.ac.jp			Ministry of Education, Science, Sports and Culture of Japan [15700441]	This study was supported by a grant-in aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (15700441). The authors wish to thank Saori Maruoka, Eri Yoshida, Nao Okumura, Maiko Fujisawa, Sumitaka Mori for their skillful assistance with data collection for this study.	Benetos A, 2002, CIRCULATION, V105, P1202, DOI 10.1161/hc1002.105135; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Chalmers J, 1999, CLIN EXP HYPERTENS, V21, P1009; Matsui Y, 2004, HYPERTENS RES, V27, P851, DOI 10.1291/hypres.27.851; Zieman SJ, 2005, ARTERIOSCL THROM VAS, V25, P932, DOI 10.1161/01.ATV.0000160548.78317.29; Franklin SS, 1997, CIRCULATION, V96, P308; Maeda S, 2001, LIFE SCI, V69, P1005, DOI 10.1016/S0024-3205(01)01192-4; Ferrier KE, 2001, HYPERTENSION, V38, P222; SESSA WC, 1994, CIRC RES, V74, P349; Seals DR, 2001, J AM COLL CARDIOL, V38, P506, DOI 10.1016/S0735-1097(01)01348-1; Tronc F, 1996, ARTERIOSCL THROM VAS, V16, P1256; Sugawara J, 2004, HYPERTENS RES, V27, P897, DOI 10.1291/hypres.27.897; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; Franklin SS, 1999, CIRCULATION, V100, P354; Tanaka H, 2000, CIRCULATION, V102, P1270; Tomiyama H, 2003, ATHEROSCLEROSIS, V166, P303, DOI 10.1016/S0021-9150(02)00332-5; Pescatello LS, 2004, MED SCI SPORT EXER, V36, P533, DOI 10.1249/01.MSS.0000115224.88514.3A; ARAKAWA K, 1993, J HYPERTENS, V11, P223, DOI 10.1097/00004872-199303000-00001; Cheitlin Melvin D, 2003, Am J Geriatr Cardiol, V12, P9, DOI 10.1111/j.1076-7460.2003.01751.x; DUNCAN JJ, 1985, JAMA-J AM MED ASSOC, V254, P2609, DOI 10.1001/jama.254.18.2609; HAGBERG JM, 1989, AM J CARDIOL, V64, P348, DOI 10.1016/0002-9149(89)90533-X; Ishikawa K, 1999, AM J CARDIOL, V84, P192, DOI 10.1016/S0002-9149(99)00233-7; Joffres MR, 1997, AM J HYPERTENS, V10, P1097; KELLEY G, 1994, AM J HYPERTENS, V7, P115; Miura H, 2008, EUR J APPL PHYSIOL, V104, P1039, DOI 10.1007/s00421-008-0860-1; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONTAIN SJ, 1988, HYPERTENSION, V12, P479; Nagamatsu T, 2003, J EPIDEMIOL, V13, P142; O'Sullivan SE, 2000, J AUTONOM NERV SYST, V81, P16, DOI 10.1016/S0165-1838(00)00148-X; Palmer RMJ, 1987, NATURE, V327, P347, DOI DOI 10.1038/327524A0; SEALS DR, 1991, HYPERTENSION, V18, P583; URATA H, 1987, HYPERTENSION, V9, P245	32	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-6319	1439-6327		EUR J APPL PHYSIOL	Eur. J. Appl. Physiol.	SEP	2015	115	9					1847	1854		10.1007/s00421-015-3168-y		8	Physiology; Sport Sciences	Physiology; Sport Sciences	CP2XT	WOS:000359741900003		
J	Tanabe, Y; Maeda, S; Akazawa, N; Zempo-Miyaki, A; Choi, Y; Ra, SG; Imaizumi, A; Otsuka, Y; Nosaka, K				Tanabe, Yoko; Maeda, Seiji; Akazawa, Nobuhiko; Zempo-Miyaki, Asako; Choi, Youngju; Ra, Song-Gyu; Imaizumi, Atsushi; Otsuka, Yoshihiko; Nosaka, Kazunori			Attenuation of indirect markers of eccentric exercise-induced muscle damage by curcumin	EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY			English	Article						Polyphenolic; Elbow flexors; Muscle strength; Muscle soreness; Supplement; Creatine kinase	TART CHERRY JUICE; NF-KAPPA-B; ELBOW FLEXORS; OXIDATIVE STRESS; INFLAMMATORY MEDIATORS; SORENESS; RECOVERY; SUPPLEMENTATION; ACTIVATION; EXPRESSION	Polyphenolic curcumin is known to have potent anti-inflammatory effects; thus the present study investigated the hypothesis that curcumin ingestion would attenuate muscle damage after eccentric exercise. Fourteen untrained young men (24 +/- A 1 years) performed 50 maximal isokinetic (120A degrees/s) eccentric contractions of the elbow flexors of one arm on an isokinetic dynamometer and the same exercise with the other arm 4 weeks later. They took 150 mg of curcumin (theracurmin) or placebo (starch) orally before and 12 h after each eccentric exercise bout in a randomised, crossover design. Maximal voluntary contraction (MVC) torque of the elbow flexors, range of motion of the elbow joint, upper-arm circumference, muscle soreness, serum creatine kinase (CK) activity, and plasma interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) concentration were measured before, immediately after, and 24, 48, 72 and 96 h after each eccentric exercise. Changes in these variables over time were compared between curcumin and placebo conditions by two-way repeated measures ANOVA. MVC torque decreased smaller and recovered faster (e.g., 4 days post-exercise: -31 +/- A 13 % vs. -15 +/- A 15 %), and peak serum CK activity was smaller (peak: 7684 +/- A 8959 IU/L vs. 3398 +/- A 3562 IU/L) for curcumin than placebo condition (P < 0.05). However, no significant differences between conditions were evident for other variables, and no significant changes in IL-6 and TNF-alpha were evident after exercise. It is concluded that theracurmin ingestion attenuates some aspects of muscle damage such as MVC loss and CK activity increase.	[Tanabe, Yoko] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058574, Japan; [Maeda, Seiji; Akazawa, Nobuhiko; Choi, Youngju; Ra, Song-Gyu] Univ Tsukuba, Fac Hlth & Sport Sci, Tsukuba, Ibaraki 3058574, Japan; [Zempo-Miyaki, Asako] Univ Tsukuba, Fac Med, Tsukuba, Ibaraki 3058574, Japan; [Imaizumi, Atsushi; Otsuka, Yoshihiko] Theravalues Corp, Tokyo, Japan; [Nosaka, Kazunori] Edith Cowan Univ, Ctr Exercise & Sports Sci Res, Joondalup, WA, Australia	Maeda, S (reprint author), Univ Tsukuba, Fac Hlth & Sport Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058574, Japan.	maeda@taiiku.tsukuba.ac.jp			Theravalues Corporation	A. I. was a consultant of the Theravalues Corporation, and Y. O. was an employee of the Theravalues Corporation, when the present study was conducted. This study was supported by the company.	Jobin C, 1999, J IMMUNOL, V163, P3474; Aggarwal S, 2006, MOL PHARMACOL, V69, P195, DOI 10.1124/mol.105.017400; Tiidus PM, 1998, CAN J PHYSIOL PHARM, V76, P533, DOI 10.1139/cjpp-76-5-533; Connolly DAJ, 2003, J STRENGTH COND RES, V17, P197; Warren GL, 1999, SPORTS MED, V27, P43, DOI 10.2165/00007256-199927010-00004; Cho JW, 2007, INT J MOL MED, V19, P469; Nosaka K, 2006, INT J SPORT NUTR EXE, V16, P620; Paulsen G, 2012, EXERC IMMUNOL REV, V18, P42; Chen TC, 2006, J STRENGTH COND RES, V20, P108; O'Fallon KS, 2012, INT J SPORT NUTR EXE, V22, P430; Miles MP, 2008, J APPL PHYSIOL, V104, P451, DOI 10.1152/japplphysiol.00572.2007; CLARKSON PM, 1992, MED SCI SPORT EXER, V24, P512; Howatson G, 2010, SCAND J MED SCI SPOR, V20, P843, DOI 10.1111/j.1600-0838.2009.01005.x; Sasaki H, 2011, BIOL PHARM BULL, V34, P660, DOI 10.1248/bpb.34.660; Philippou A, 2009, CLIN CHEM LAB MED, V47, P777, DOI 10.1515/CCLM.2009.163; Evans RK, 2002, MED SCI SPORT EXER, V34, P1892, DOI 10.1249/01.MSS.0000038895.14935.C8; Connolly DAJ, 2006, BRIT J SPORT MED, V40, P679, DOI 10.1136/bjsm.2005.025429; Trappe TA, 2001, J CLIN ENDOCR METAB, V86, P5067, DOI 10.1210/jc.86.10.5067; Trombold JR, 2010, MED SCI SPORT EXER, V42, P493, DOI 10.1249/MSS.0b013e3181b64edd; Kanai M, 2012, CANCER CHEMOTH PHARM, V69, P65, DOI 10.1007/s00280-011-1673-1; Sethi G, 2009, ADV EXP MED BIOL, V647, P37, DOI 10.1007/978-0-387-89520-8_3; Hirose L, 2004, EXERC IMMUNOL REV, V10, P75; Davis JM, 2007, AM J PHYSIOL-REG I, V292, pR2168, DOI 10.1152/ajpregu.00858.2006; Nosaka K, 2002, SCAND J MED SCI SPOR, V12, P337, DOI 10.1034/j.1600-0838.2002.10178.x; Shishodia S, 2007, ADV EXP MED BIOL, V595, P127; Bryer SC, 2006, INT J SPORT NUTR EXE, V16, P270; Raastad T, 2010, MED SCI SPORT EXER, V42, P86, DOI 10.1249/MSS.0b013e3181ac7afa; Moriyuki K, 2010, J PHARMACOL SCI, V114, P225, DOI [10.1254/jphs.101265C, 10.1254/jphs.10126SC]; Depner CM, 2010, EUR J APPL PHYSIOL, V109, P1067, DOI 10.1007/s00421-010-1448-0; Kawanishi N, 2013, BIOCHEM BIOPH RES CO, V441, P573, DOI 10.1016/j.bbrc.2013.10.119; Newton MJ, 2013, J SCI MED SPORT, V16, P166, DOI 10.1016/j.jsams.2012.06.001; Nosaka K, 2002, MED SCI SPORT EXER, V34, P920, DOI 10.1097/00005768-200206000-00003; Usharani P, 2008, DRUGS R&D, V9, P243, DOI 10.2165/00126839-200809040-00004	33	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-6319	1439-6327		EUR J APPL PHYSIOL	Eur. J. Appl. Physiol.	SEP	2015	115	9					1949	1957		10.1007/s00421-015-3170-4		9	Physiology; Sport Sciences	Physiology; Sport Sciences	CP2XT	WOS:000359741900013		
J	Fujii, N; Tsuchiya, SI; Tsuji, B; Watanabe, K; Sasaki, Y; Nishiyasu, T				Fujii, Naoto; Tsuchiya, Sho-Ichiro; Tsuji, Bun; Watanabe, Kazuhito; Sasaki, Yosuke; Nishiyasu, Takeshi			Effect of voluntary hypocapnic hyperventilation on the metabolic response during Wingate anaerobic test	EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY			English	Article						High-intensity exercise; Anaerobic capacity; Respiratory alkalosis; Hypoxia; Training	PULMONARY O-2 UPTAKE; EXERCISE PERFORMANCE; RESPIRATORY ALKALOSIS; SUPRAMAXIMAL EXERCISE; INTENSITY EXERCISE; MODERATE EXERCISE; MUSCLE FATIGUE; POWER OUTPUT; LACTIC-ACID; HYPOXIA	We evaluated whether hypocapnia achieved through voluntary hyperventilation diminishes the increases in oxygen uptake elicited by short-term (e.g., similar to 30 s) all-out exercise without affecting exercise performance. Nine subjects performed 30-s Wingate anaerobic tests (WAnT) in control and hypocapnia trials on separate days in a counterbalanced manner. During the 20-min rest prior to the 30-s WAnT, the subjects in the hypocapnia trial performed voluntary hyperventilation (minute ventilation = 31 L min(-1)), while the subjects in the control trial continued breathing spontaneously (minute ventilation = 14 L min(-1)). The hyperventilation in the hypocapnia trial reduced end-tidal CO2 pressure from 34.8 +/- A 2.5 mmHg at baseline rest to 19.3 +/- A 1.0 mmHg immediately before the 30-s WAnT. In the control trial, end-tidal CO2 pressure at baseline rest (35.9 +/- A 2.5 mmHg) did not differ from that measured immediately before the 30-s WAnT (35.9 +/- A 3.3 mmHg). Oxygen uptake during the 30-s WAnT was lower in the hypocapnia than the control trial (1.55 +/- A 0.52 vs. 1.95 +/- A 0.44 L min(-1)), while the postexercise peak blood lactate concentration was higher in the hypocapnia than control trial (10.4 +/- A 1.9 vs. 9.6 +/- A 1.9 mmol L-1). In contrast, there was no difference in the 5-s peak (842 +/- A 111 vs. 850 +/- A 107 W) or mean (626 +/- A 74 vs. 639 +/- A 80 W) power achieved during the 30-s WAnT between the control and hypocapnia trials. These results suggest that during short-period all-out exercise (e.g., 30-s WAnT), hypocapnia induced by voluntary hyperventilation reduces the aerobic metabolic rate without affecting exercise performance. This implies a compensatory elevation in the anaerobic metabolic rate.	[Fujii, Naoto; Tsuchiya, Sho-Ichiro; Tsuji, Bun; Watanabe, Kazuhito; Sasaki, Yosuke; Nishiyasu, Takeshi] Univ Tsukuba, Inst Hlth & Sport Sci, Tsukuba, Ibaraki 3058574, Japan	Nishiyasu, T (reprint author), Univ Tsukuba, Inst Hlth & Sport Sci, Tsukuba, Ibaraki 3058574, Japan.	nisiyasu@taiiku.tsukuba.ac.jp			Ministry of Education, Culture, Sports, Science and Technology in Japan; Japan Society for the Promotion of Science	We appreciate the subjects participating in the present study. We greatly appreciate the help of Dr. William Goldman for English editing and critical comments. This study was supported by the grants from Ministry of Education, Culture, Sports, Science and Technology in Japan and Japan Society for the Promotion of Science. N. Fujii is the recipient of a research fellowship for young scientists from Japan Society of the Promotion of Science. The current affiliation of N. Fujii is the University of Ottawa, Human and Environmental Physiology Research Unit, School of Human Kinetics, Ottawa, Ontario, Canada, K1N 6N5 (Director, Dr. Glen P Kenny).	PIEPOLI M, 1995, AM J PHYSIOL-HEART C, V269, pH1428; Ogawa T, 2007, EUR J APPL PHYSIOL, V99, P39, DOI 10.1007/s00421-006-0315-5; Weyand PG, 1999, J APPL PHYSIOL, V86, P2059; Calbet JAL, 2003, J APPL PHYSIOL, V94, P668, DOI 10.1152/japplphysiol.00128.2002; Truijens MJ, 2003, J APPL PHYSIOL, V94, P733, DOI 10.1152/japplphysiol.00079.2002; Ainslie PN, 2009, AM J PHYSIOL-REG I, V296, pR1473, DOI 10.1152/ajpregu.91008.2008; Westerblad H, 2002, NEWS PHYSIOL SCI, V17, P17; Cairns SP, 2006, SPORTS MED, V36, P279, DOI 10.2165/00007256-200636040-00001; McNaughton LR, 1992, J SPORT SCI, V10, P415, DOI 10.1080/02640419208729940; Iellamo F, 1999, J APPL PHYSIOL, V86, P174; Borg G., 1975, PHYSICAL WORK EFFORT, P39; BRUCE EN, 1987, J APPL PHYSIOL, V62, P389; Chin LMK, 2007, J PHYSIOL-LONDON, V583, P351, DOI 10.1113/jphysiol.2007.132837; Chin LMK, 2010, J APPL PHYSIOL, V108, P1641, DOI 10.1152/japplphysiol.01346.2009; Chin LMK, 2010, EUR J APPL PHYSIOL, V108, P913, DOI 10.1007/s00421-009-1293-1; Douroudos II, 2006, MED SCI SPORT EXER, V38, P1746, DOI 10.1249/01.mss.0000230210.60957.67; Fujii N., 2012, Gazzetta Medica Italiana Archivio per le Scienze Mediche, V171, P491; Fujimaki T, 1999, ADV EXERC SPORTS PHY, V5, P61; GOLDFINCH J, 1988, EUR J APPL PHYSIOL O, V57, P45, DOI 10.1007/BF00691236; Hayashi N, 1999, AM J PHYSIOL-REG I, V277, pR1274; Inbar O, 1983, J SPORT SCI, V1, P95; KINDERMANN W, 1977, EUR J APPL PHYSIOL O, V37, P197, DOI 10.1007/BF00421775; LeBlanc PJ, 2002, J PHYSIOL-LONDON, V544, P303, DOI 10.1113/jphysiol.2002.022764; Lindinger MI, 2007, J PHYSIOL-LONDON, V581, P419, DOI 10.1113/jphysiol.2007.132209; MCCARTNEY N, 1983, J APPL PHYSIOL, V55, P225; MCLELLAN TM, 1993, EUR J APPL PHYSIOL O, V66, P409, DOI 10.1007/BF00599613; MCLELLAN TM, 1990, EUR J APPL PHYSIOL O, V60, P155, DOI 10.1007/BF00846037; McNaughton L, 1991, J SPORT SCI, V9, P151, DOI 10.1080/02640419108729876; MORROW JA, 1988, EUR J APPL PHYSIOL O, V58, P175, DOI 10.1007/BF00636623; Ogita F, 1999, BIOMECHANICS MED SWI, P423; Ogura Y, 2006, EUR J APPL PHYSIOL, V98, P41, DOI 10.1007/s00421-006-0214-9; WARD SA, 1983, J APPL PHYSIOL, V55, P742	32	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-6319	1439-6327		EUR J APPL PHYSIOL	Eur. J. Appl. Physiol.	SEP	2015	115	9					1967	1974		10.1007/s00421-015-3179-8		8	Physiology; Sport Sciences	Physiology; Sport Sciences	CP2XT	WOS:000359741900015		
J	Togashi, M; Niioka, T; Komatsuda, A; Nara, M; Okuyama, S; Omokawa, A; Abumiya, M; Wakui, H; Takahashi, N; Miura, M				Togashi, Masaru; Niioka, Takenori; Komatsuda, Atsushi; Nara, Mizuho; Okuyama, Shin; Omokawa, Ayumi; Abumiya, Maiko; Wakui, Hideki; Takahashi, Naoto; Miura, Masatomo			Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						Itraconazole; Tacrolimus; CYP3A5 polymorphism; Drug-drug interaction; Connective tissue disease	SINGLE NUCLEOTIDE POLYMORPHISMS; SOLID-ORGAN TRANSPLANTATION; RHEUMATOID-ARTHRITIS; ANTIFUNGAL PROPHYLAXIS; FUNGAL-INFECTIONS; DRUG-INTERACTIONS; LUPUS NEPHRITIS; IN-VITRO; PHARMACOKINETICS; METABOLISM	The aim of this study was to investigate the effect of itraconazole (ITCZ), a potent inhibitor of CYP3A4 and P-glycoprotein, on the blood concentration 12 h after tacrolimus administration (C (12h)) in relation to CYP3A5 6986A > G and ABCB1 3435C > T genotype status in patients with connective tissue disease (CTD). Eighty-one CTD patients taking tacrolimus (PrografA (R)) once daily at night (2100 hours) were enrolled in this study. Whole blood samples were collected 12 h after tacrolimus administration at steady state. The dose-adjusted tacrolimus C (12h) with or without ITCZ co-administration was significantly higher in patients with CYP3A5*3/*3 than in those with the CYP3A5*1 allele [CYP3A5 *1/*1 vs. *1/*3 vs. *3/*3 = 1.67 vs. 2.70 vs. 4.83 ng/mL/mg (P = 0.003) and 0.68 vs. 0.97 vs. 2.20 ng/mL/mg (P < 0.001), respectively], but differences were not observed for ABCB1 genotypes. However, there was no difference in the increase rate of the dose-adjusted C (12h) of tacrolimus between CYP3A5 or ABCB1 genotypes (P = 0.378 and 0.259). On the other hand, reduction of the estimated glomerular filtration rate exhibited a correlation with the C (12h) of tacrolimus after ITCZ co-administration (r = -0.482, P = 0.009). In CYP3A5*3/*3 patients, because the metabolic pathway for tacrolimus occurs only through CYP3A4, the combination with ITCZ seems to lead to a higher risk of acute renal dysfunction. Therefore, we suggest that the target blood tacrolimus concentration be set as low as possible through dose-adjustment for patients with the CYP3A5*3/*3 allele.	[Togashi, Masaru; Komatsuda, Atsushi; Nara, Mizuho; Takahashi, Naoto] Akita Univ, Grad Sch Med, Dept Hematol, Nephrol,Rheumatol, Akita 0108543, Japan; [Niioka, Takenori; Abumiya, Maiko; Miura, Masatomo] Akita Univ Hosp, Dept Pharm, Akita, Japan; [Okuyama, Shin] Akita Univ Hosp, Ctr Kidney Dis & Transplantat, Akita, Japan; [Omokawa, Ayumi] Akita Univ, Grad Sch Med, Dept Gen Internal Med, Akita 0108543, Japan; [Omokawa, Ayumi] Akita Univ, Grad Sch Med, Clin Lab Med, Akita 0108543, Japan; [Wakui, Hideki] Akita Univ, Grad Sch Engn & Resource Sci, Dept Life Sci, Akita 0108543, Japan	Komatsuda, A (reprint author), Akita Univ, Grad Sch Med, Dept Hematol, Nephrol,Rheumatol, 1-1-1 Hondo, Akita 0108543, Japan.	komatsud@med.akita-u.ac.jp			Japan Society for the Promotion of Science, Tokyo, Japan [26460189]	This work was supported by a grant (No. 26460189) from the Japan Society for the Promotion of Science, Tokyo, Japan.	Lee YH, 2011, LUPUS, V20, P636, DOI 10.1177/0961203310389486; Naito T, 2015, CLIN CHIM ACTA, V445, P79, DOI 10.1016/j.cca.2015.03.021; Shirasaka Y, 2013, DRUG METAB DISPOS, V41, P1566, DOI 10.1124/dmd.112.049940; Gorski JC, 2003, CLIN PHARMACOL THER, V74, P275, DOI 10.1016/S0009-9236(03)00187-5; Staatz CE, 2010, CLIN PHARMACOKINET, V49, P207, DOI 10.2165/11317550-000000000-00000; Shon JH, 2005, CLIN PHARMACOL THER, V78, P191, DOI 10.1016/j.clpt.2005.04.012; Miura M, 2011, PHARMACOGENOMICS, V12, P977, DOI [10.2217/pgs.11.33, 10.2217/PGS.11.33]; Cascorbi I, 2001, CLIN PHARMACOL THER, V69, P169, DOI 10.1067/mcp.2001.114164; Lin YS, 2002, MOL PHARMACOL, V62, P162, DOI 10.1124/mol.62.1.162; Staatz CE, 2010, CLIN PHARMACOKINET, V49, P141, DOI 10.2165/11317350-000000000-00000; De BK, 2009, CLIN CHIM ACTA, V410, P25, DOI 10.1016/j.cca.2009.09.009; Christians U, 2002, CLIN PHARMACOKINET, V41, P813, DOI 10.2165/00003088-200241110-00003; Scott LJ, 2003, DRUGS, V63, P1247, DOI 10.2165/00003495-200363120-00006; Lee YH, 2010, SCAND J RHEUMATOL, V39, P271, DOI 10.3109/03009740903501642; Fukuen S, 2002, PHARMACOGENETICS, V12, P331, DOI 10.1097/00008571-200206000-00009; Lass-Florl C, 2011, DRUGS, V71, P2405, DOI 10.2165/11596540-000000000-00000; Isoherranen N, 2004, DRUG METAB DISPOS, V32, P1121, DOI 10.1124/dmd.104.000315; Klotz U, 2009, DRUG METAB REV, V41, P67, DOI 10.1080/03602530902722679; Staatz CE, 2004, CLIN PHARMACOKINET, V43, P623, DOI 10.2165/00003088-200443100-00001; Terrazzino S, 2012, PHARMACOGENET GENOM, V22, P642, DOI 10.1097/FPC.0b013e3283557c74; Boogaerts M, 2001, DRUGS, V61, P39, DOI 10.2165/00003495-200161001-00004; Chandel N, 2009, PHARMACOGENET GENOM, V19, P458, DOI 10.1097/FPC.0b013e32832bd085; Enderby CY, 2014, CLIN TRANSPLANT, V28, P911, DOI 10.1111/ctr.12403; Hesselink DA, 2014, CLIN PHARMACOKINET, V53, P123, DOI 10.1007/s40262-013-0120-3; HUNT CM, 1992, MECH AGEING DEV, V64, P189, DOI 10.1016/0047-6374(92)90106-N; Kramer MR, 2011, CLIN TRANSPL, V25, P163; Kunze KL, 2006, DRUG METAB DISPOS, V34, P583, DOI 10.1124/dmd.105.008508; Miura M, 2011, J CLIN PHARM THER, V36, P208, DOI 10.1111/j.1365-2710.2010.01163.x; Nara M, 2013, EUR J CLIN PHARMACOL, V69, P1321, DOI 10.1007/s00228-013-1471-2; Peng CC, 2012, DRUG METAB DISPOS, V40, P426, DOI 10.1124/dmd.111.042739; Takahashi S, 2011, MOD RHEUMATOL, V21, P282, DOI 10.1007/s10165-010-0398-z; Takeuchi T, 2014, MOD RHEUMATOL, V24, P8, DOI 10.3109/14397595.2013.854074; Tavira B, 2015, J HUM GENET, V60, P273, DOI 10.1038/jhg.2015.12; Templeton I, 2010, CLIN PHARMACOL THER, V88, P499, DOI 10.1038/clpt.2010.119; Tian SY, 2014, J RHEUMATOL, V41, P1998, DOI 10.3899/jrheum.140050; Viscoli C, 2009, DRUGS, V69, P75, DOI 10.2165/11315540-000000000-00000	36	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0031-6970	1432-1041		EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	SEP	2015	71	9					1091	1097		10.1007/s00228-015-1901-4		7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CO8UM	WOS:000359447600008		
J	Ito, M; Miyauchi, A; Kang, S; Hisakado, M; Yoshioka, W; Ide, A; Kudo, T; Nishihara, E; Kihara, M; Ito, Y; Kobayashi, K; Miya, A; Fukata, S; Nakamura, H; Amino, N				Ito, Mitsuru; Miyauchi, Akira; Kang, Shino; Hisakado, Mako; Yoshioka, Waka; Ide, Akane; Kudo, Takumi; Nishihara, Eijun; Kihara, Minoru; Ito, Yasuhiro; Kobayashi, Kaoru; Miya, Akihiro; Fukata, Shuji; Nakamura, Hirotoshi; Amino, Nobuyuki			Effect of the presence of remnant thyroid tissue on the serum thyroid hormone balance in thyroidectomized patients	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							TYPE-2 IODOTHYRONINE DEIODINASE; REPLACEMENT THERAPY; TRIIODOTHYRONINE LEVELS; THYROXINE REPLACEMENT; THYROTROPIN; TSH; HYPOTHYROIDISM; LEVOTHYROXINE; PITUITARY; HEMITHYROIDECTOMY	Objective: We and others recently reported that in total thyroidectomy (TT), serum triiodothyronine (T-3) levels during levothyroxine (L-T-4) therapy were low compared to the preoperative levels, suggesting that the presence of the thyroid tissue affects the balances of serum thyroid hormone levels. However, the effects of remnant thyroid tissue on these balances in thyroidectomized patients have not been established. Methods: We retrospectively studied 253 euthyroid patients with papillary thyroid carcinoma who underwent a TT or hemithyroidectomy (HT). We divided the cases into the TT+supplemental L-T-4 (+L-T-4) group (n=103); the HT+L-T-4 group (n=56); and the HT-alone group (n=94). We compared the postoperative serum levels of free T-4 (FT4) and free T-3 (FT3) and the FT3/FT4 ratio in individual patients with those of controls matched by serum TSH levels. Results: The TT+L-T-4 group had significantly higher FT4 (P < 0.001), lower FT3 (P < 0.01) and lower FT3/FT4 (P < 0.001) levels compared to the controls. The HTCL-T-4 group had FT4, FT3 and FT3/FT4 levels equivalent to those of the controls. The HT-alone group had significantly lower FT4 (P < 0.01), equivalent FT3 (P=0.083), and significantly higher FT3/FT4 (P < 0.001) ratios than the controls. Conclusions: The presence of the remnant thyroid tissue was associated with different thyroid hormone balances in thyroidectomized patients, suggesting that T-3 production by remnant thyroid tissue has a substantial effect on the maintenance of postoperative serum T-3 levels.	[Ito, Mitsuru; Miyauchi, Akira; Kang, Shino; Hisakado, Mako; Yoshioka, Waka; Ide, Akane; Kudo, Takumi; Nishihara, Eijun; Kihara, Minoru; Ito, Yasuhiro; Kobayashi, Kaoru; Miya, Akihiro; Fukata, Shuji; Nakamura, Hirotoshi; Amino, Nobuyuki] Kuma Hosp, Ctr Excellence Thyroid Care, Chuo Ku, Kobe, Hyogo 6500011, Japan	Ito, M (reprint author), Kuma Hosp, Ctr Excellence Thyroid Care, Chuo Ku, 8-2-35 Shimoyamate Dori, Kobe, Hyogo 6500011, Japan.	ito02@kuma-h.or.jp					Alevizaki M, 2005, WIEN KLIN WOCHENSCHR, V117, P636, DOI 10.1007/s00508-005-0421-0; Ito M, 2012, EUR J ENDOCRINOL, V167, P373, DOI 10.1530/EJE-11-1029; EscobarMorreale HF, 1995, J CLIN INVEST, V96, P2828, DOI 10.1172/JCI118353; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Maia AL, 2005, J CLIN INVEST, V115, P2524, DOI 10.1172/JCI25083; RUBIN DB, 1979, J AM STAT ASSOC, V74, P318, DOI 10.2307/2286330; Surks MI, 2004, JAMA-J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228; Miyauchi A, 2008, J CLIN ENDOCR METAB, V93, P2239, DOI 10.1210/jc.2007-2282; Biondi B, 2012, EUR J ENDOCRINOL, V167, P295, DOI 10.1530/EJE-12-0585; GEFFNER DL, 1975, J CLIN INVEST, V55, P224, DOI 10.1172/JCI107925; Gullo D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022552; Hoermann R, 2014, CLIN ENDOCRINOL, V81, P907, DOI 10.1111/cen.12527; Hoermann R, 2015, HORMONE MET IN PRESS, DOI [10.1055/s-0034-1398616, DOI 10.1055/S-0034-1398616)]; Ito M, 2011, EUR J ENDOCRINOL, V164, P95, DOI 10.1530/EJE-10-0736; Jonklaas J, 2014, THYROID, V24, P1670, DOI 10.1089/thy.2014.0028; Jonklaas J, 2008, JAMA-J AM MED ASSOC, V299, P769, DOI 10.1001/jama.299.7.769; Kanou Y, 2007, J CLIN ENDOCR METAB, V92, P1451, DOI 10.1210/jc.2006-1242; Lindblom P, 2001, HORM RES, V55, P81, DOI 10.1159/000049975; LOMBARDI G, 1983, J ENDOCRINOL INVEST, V6, P485; LUM SMC, 1984, J CLIN INVEST, V73, P570, DOI 10.1172/JCI111245; Murakami M, 2001, ENDOCRINOLOGY, V142, P1195, DOI 10.1210/en.142.3.1195; Pilo A, 1990, AM J PHYSIOL, V258, P715; SILVA JE, 1978, J CLIN INVEST, V61, P1247, DOI 10.1172/JCI109041; STURGESS I, 1989, ACTA ENDOCRINOL-COP, V121, P674; Toft Kristensen T, 2014, EUROPEAN THYROID J, V3, P10, DOI [10.1159/000357943, DOI 10.1159/000357943]; TOYODA N, 1992, ENDOCRINOLOGY, V131, P389, DOI 10.1210/en.131.1.389; Verloop H, 2012, J CLIN ENDOCR METAB, V97, P2243, DOI 10.1210/jc.2012-1063; WENNLUND A, 1986, ACTA ENDOCRINOL-COP, V113, P47	28	0	0	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	SEP	2015	173	3					333	340		10.1530/EJE-15-0138		8	Endocrinology & Metabolism	Endocrinology & Metabolism	CO6JO	WOS:000359263200012		
J	Hosokawa, K; Sugimori, N; Katagiri, T; Sasaki, Y; Saito, C; Seiki, Y; Mochizuki, K; Yamazaki, H; Takami, A; Nakao, S				Hosokawa, Kohei; Sugimori, Naomi; Katagiri, Takamasa; Sasaki, Yumi; Saito, Chizuru; Seiki, Yu; Mochizuki, Kanako; Yamazaki, Hirohito; Takami, Akiyoshi; Nakao, Shinji			Increased glycosylphosphatidylinositol-anchored protein-deficient granulocytes define a benign subset of bone marrow failures in patients with trisomy 8	EUROPEAN JOURNAL OF HAEMATOLOGY			English	Article						trisomy 8; bone marrow failure; GPI-AP(-) cells; immunosuppressive therapy	PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; PRIMARY MYELODYSPLASTIC SYNDROMES; ACQUIRED APLASTIC-ANEMIA; CYTOGENETIC ABNORMALITIES; SCORING SYSTEM; IMMUNOSUPPRESSIVE THERAPY; HEMATOPOIETIC-CELLS; MINOR POPULATION; PROGNOSTIC VALUE; MDS	Trisomy 8 (+8), one of the most common chromosomal abnormalities found in patients with myelodysplastic syndromes (MDS), is occasionally seen in patients with otherwise typical aplastic anemia (AA). Although some studies have indicated that the presence of +8 is associated with the immune pathophysiology of bone marrow (BM) failure, its pathophysiology may be heterogeneous. We studied 53 patients (22 with AA and 31 with low-risk MDS) with +8 for the presence of increased glycosylphosphatidylinositol-anchored protein-deficient (GPI-AP(-)) cells, their response to immunosuppressive therapy (IST), and their prognosis. A significant increase in the percentage of GPI-AP(-) cells was found in 14 (26%) of the 53 patients. Of the 26 patients who received IST, including nine with increased GPI-AP(-) cells and 17 without increased GPI-AP(-) cells, 14 (88% with increased GPI-AP(-) cells and 41% without increased GPI-AP(-) cells) improved. The overall and event-free survival rates of the +8 patients with and without increased GPI-AP(-) cells at 5yr were 100% and 100% and 59% and 57%, respectively. Examining the peripheral blood for the presence of increased GPI-AP(-) cells may thus be helpful for choosing the optimal treatment for +8 patients with AA or low-risk MDS.	[Hosokawa, Kohei; Sugimori, Naomi; Sasaki, Yumi; Saito, Chizuru; Seiki, Yu; Mochizuki, Kanako; Yamazaki, Hirohito; Takami, Akiyoshi; Nakao, Shinji] Kanazawa Univ, Grad Sch Med Sci, Cellular Transplantat Biol, Kanazawa, Ishikawa 9208640, Japan; [Katagiri, Takamasa] Kanazawa Univ, Grad Sch Med Sci, Clin Sci Lab, Kanazawa, Ishikawa 9208640, Japan	Nakao, S (reprint author), Kanazawa Univ, Grad Sch Med Sci, Cellular Transplantat Biol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208640, Japan.	snakao8205@staff.kanazawa-u.ac.jp					Wang SA, 2009, HAEMATOL-HEMATOL J, V94, P29, DOI 10.3324/haematol.13601; Araten DJ, 2001, BRIT J HAEMATOL, V115, P360, DOI 10.1046/j.1365-2141.2001.03113.x; Haase D, 2008, ANN HEMATOL, V87, P515, DOI 10.1007/s00277-008-0483-y; Sloand EM, 2007, BLOOD, V109, P2399, DOI 10.1182/blood-2006-01; Haase D, 2007, BLOOD, V110, P4385, DOI 10.1182/blood-2007-03-082404; Saumell S, 2012, BRIT J HAEMATOL, V159, P311, DOI 10.1111/bjh.12035; Yue G, 2008, LEUKEMIA RES, V32, P553, DOI 10.1016/j.leukres.2007.08.006; Gupta V, 2006, BRIT J HAEMATOL, V134, P95, DOI 10.1111/j.1365-2141.2006.06105.x; Wang HB, 2002, BLOOD, V100, P3897, DOI 10.1182/blood-2002-03-0799; Kim SY, 2010, GENE CHROMOSOME CANC, V49, P844, DOI 10.1002/gcc.20793; Araten DJ, 1999, P NATL ACAD SCI USA, V96, P5209, DOI 10.1073/pnas.96.9.5209; Bernasconi P, 2007, BRIT J HAEMATOL, V137, P193, DOI 10.1111/j.1365-2141.2007.06537.x; Greenberg PL, 2012, BLOOD, V120, P2454, DOI 10.1182/blood-2012-03-420489; Greenberg P, 1997, BLOOD, V89, P2079; Schanz J, 2012, J CLIN ONCOL, V30, P820, DOI 10.1200/JCO.2011.35.6394; Sugimori C, 2009, BRIT J HAEMATOL, V147, P102, DOI 10.1111/j.1365-2141.2009.07822.x; Sugimori C, 2006, BLOOD, V107, P1308, DOI 10.1182/blood-2005-06-2485; Hosokawa K, 2012, HAEMATOL-HEMATOL J, V97, P1845, DOI 10.3324/haematol.2011.061127; Sloand EM, 2005, BLOOD, V106, P841, DOI 10.1182/blood-2004-05-2017; Cheson BD, 2006, BLOOD, V108, P419, DOI 10.1182/blood-2005-10-4149; Parker C, 2005, BLOOD, V106, P3699, DOI 10.1182/blood-2005-04-1717; Dunn DE, 1999, ANN INTERN MED, V131, P401; APPELBAUM FR, 1987, EXP HEMATOL, V15, P1134; CAMITTA BM, 1990, AM J PEDIAT HEMATOL, V12, P411; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Katagiri T, 2011, BLOOD, V118, P6601, DOI 10.1182/blood-2011-07-365189; Kulagin A, 2011, BONE MARROW TRANSPL, V46, pS83; LONGO L, 1994, BRIT J HAEMATOL, V87, P401, DOI 10.1111/j.1365-2141.1994.tb04930.x; Maciejewski JP, 2002, BLOOD, V99, P3129, DOI 10.1182/blood.V99.9.3129; Mikhailova N, 1996, HAEMATOLOGICA, V81, P418; PARLIER V, 1992, BRIT J HAEMATOL, V81, P296, DOI 10.1111/j.1365-2141.1992.tb08223.x; Seiki Y, 2013, HAEMATOLOGICA, V98, P901, DOI 10.3324/haematol.2012.066217; Shaffer LG, 2009, INT SYSTEM HUMAN CYT; Sloand EM, 2003, BRIT J HAEMATOL, V123, P173, DOI 10.1046/j.1365-2141.2003.04562.x	34	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0902-4441	1600-0609		EUR J HAEMATOL	Eur. J. Haematol.	SEP	2015	95	3					230	238		10.1111/ejh.12484		9	Hematology	Hematology	CP0XQ	WOS:000359600500006		
J	Onitake, T; Ueno, Y; Tanaka, S; Sagami, S; Hayashi, R; Nagai, K; Hide, M; Chayama, K				Onitake, Toshiko; Ueno, Yoshitaka; Tanaka, Shinji; Sagami, Shintaro; Hayashi, Ryohei; Nagai, Kenta; Hide, Michihiro; Chayama, Kazuaki			Pulverized konjac glucomannan ameliorates oxazolone-induced colitis in mice	EUROPEAN JOURNAL OF NUTRITION			English	Article						Konjac glucomannan; Oxazolone colitis; IL-13; Th1/Th2 balance; NKT cell	INFLAMMATORY-BOWEL-DISEASE; NK-T-CELLS; SPONTANEOUSLY OCCURRING DERMATITIS; ULCERATIVE-COLITIS; NC/NGA MICE; ATOPIC-DERMATITIS; ORAL INTAKE; PARTICLE-SIZE; MURINE MODEL; RATS	Pulverized konjac glucomannan (PKGM) is a natural biologically active compound extracted from konjac, a Japanese traditional food. In the present study, we investigated the role of PKGM in intestinal immunity in a mouse model of oxazolone (OXA)-induced colitis. C57BL/6(B6) mice were fed PKGM or control food from 2 weeks before the induction of OXA colitis. Body weight change, colon length, and histological change in the colon were examined. The mononuclear cells were purified from colon and stimulated with PMA/ionomycin. The levels of TNF-alpha, interferon (IFN)-gamma, interleukin (IL)-4, and IL-13 from the supernatant were measured by ELISA. Oral administration of PKGM prevented the body weight loss and shortening of colon length associated with OXA-induced colitis. Histological analysis revealed that the colonic inflammation was improved by the administration of PKGM. The levels of IL-4 and IL-13, the critical inflammatory cytokines in OXA colitis, derived from mononuclear cells from the lamina propria of the colon were significantly suppressed by PKGM administration. PKGM-fed mice showed a significantly lower IL-4/IFN-gamma ratio in the colonic lamina propria compared with that in control-fed mice. Fluorescence-activated cell sorting analysis revealed that natural killer (NK) 1.1(+) T cells in the liver were significantly decreased in PKGM-fed mice. Finally, the preventive role of PKGM in OXA-induced colitis was not observed in invariant natural killer T cell-deficient mice. PKGM ameliorated OXA-induced colitis in mice. This effect is associated with a decreased population of NK1.1(+) T cells and induction of Th1-polarized immune responses.	[Onitake, Toshiko; Sagami, Shintaro; Hayashi, Ryohei; Nagai, Kenta; Chayama, Kazuaki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Gastroenterol & Metab, Hiroshima, Japan; [Ueno, Yoshitaka; Tanaka, Shinji] Hiroshima Univ Hosp, Dept Endoscopy, Hiroshima, Japan; [Hide, Michihiro] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Dermatol, Integrated Hlth Sci, Hiroshima, Japan	Ueno, Y (reprint author), Hiroshima Univ Hosp, Dept Endoscopy, Hiroshima, Japan.	yueno@hiroshima-u.ac.jp					Fuss IJ, 2004, J CLIN INVEST, V113, P1490, DOI 10.1172/JCI200419836; Kawano T, 1998, P NATL ACAD SCI USA, V95, P5690, DOI 10.1073/pnas.95.10.5690; Wilson MS, 2011, GASTROENTEROLOGY, V140, P254, DOI 10.1053/j.gastro.2010.09.047; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; Baumgart DC, 2007, LANCET, V369, P1627, DOI 10.1016/S0140-6736(07)60750-8; Onishi N, 2005, INT ARCH ALLERGY IMM, V136, P258, DOI 10.1159/000083952; Heller F, 2005, GASTROENTEROLOGY, V129, P550, DOI 10.1053/j.gastro.2005.05.002; Mannon PJ, 2011, GUT, V60, P449, DOI 10.1136/gut.2010.226860; Mudter J, 2008, J CLIN INVEST, V118, P2415, DOI 10.1172/JCI33227; Fuss IJ, 2008, MUCOSAL IMMUNOL, V1, pS31, DOI 10.1038/mi.2008.40; Boirivant M, 1998, J EXP MED, V188, P1929, DOI 10.1084/jem.188.10.1929; Vuksan V, 1999, DIABETES CARE, V22, P913, DOI 10.2337/diacare.22.6.913; Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; Heller F, 2002, IMMUNITY, V17, P629, DOI 10.1016/S1074-7613(02)00453-3; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Chen HL, 2005, NUTRITION, V21, P1059, DOI 10.1016/j.nut.2005.02.008; Wingender G, 2008, AM J PHYSIOL-GASTR L, V294, pG1, DOI 10.1152/ajpgi.00437.2007; Baumgart DC, 2007, LANCET, V369, P1641, DOI 10.1016/S0140-6736(07)60751-X; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; DOI K, 1979, LANCET, V1, P987; EBIHARA K, 1989, J NUTR, V119, P1100; Hoentjen F, 2005, INFLAMM BOWEL DIS, V11, P977, DOI 10.1097/01.MIB.0000183421.02316.d5; Holma R, 2002, SCAND J GASTROENTERO, V37, P1042, DOI 10.1080/003655202320378239; Kimata H, 2006, PEDIATR DERMATOL, V23, P386, DOI 10.1111/j.1525-1470.2006.00268.x; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; MIZUTANI T, 1983, CANCER LETT, V19, P1, DOI 10.1016/0304-3835(83)90127-1; Numata Y, 2005, DIGEST DIS SCI, V50, P1844, DOI 10.1007/s10620-005-2949-2; Okamoto S, 1999, EUR J IMMUNOL, V29, P355, DOI 10.1002/(SICI)1521-4141(199901)29:01<355::AID-IMMU355>3.0.CO;2-G; Onishi N, 2004, BIOFACTORS, V21, P163; Onishi N, 2007, BIOSCI BIOTECH BIOCH, V71, P2551, DOI 10.1271/bbb.70378; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Suzuki H, 2010, INT ARCH ALLERGY IMM, V152, P122, DOI 10.1159/000265533; Uchiyama T, 2008, J HEALTH SCI, V54, P559, DOI 10.1248/jhs.54.559	33	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1436-6207	1436-6215		EUR J NUTR	Eur. J. Nutr.	SEP	2015	54	6					959	969		10.1007/s00394-014-0772-2		11	Nutrition & Dietetics	Nutrition & Dietetics	CP3ZJ	WOS:000359821400009		
J	Ueshima, C; Kataoka, TR; Hirata, M; Koyanagi, I; Honda, T; Tsuruyama, T; Okayama, Y; Seiyama, A; Haga, H				Ueshima, Chiyuki; Kataoka, Tatsuki R.; Hirata, Masahiro; Koyanagi, Itsuko; Honda, Tetsuya; Tsuruyama, Tatsuaki; Okayama, Yoshimichi; Seiyama, Akitoshi; Haga, Hironori			NKp46 regulates the production of serine proteases and IL-22 in human mast cells in urticaria pigmentosa	EXPERIMENTAL DERMATOLOGY			English	Article						chymase; granzyme B; mast cell; NKp46; tryptase	NATURAL-KILLER-CELLS; PROTOONCOGENE C-KIT; INHIBITORY RECEPTOR; T-CELL; MASTOCYTOSIS; ACTIVATION; GAMMA; LINE; IDENTIFICATION; CYTOTOXICITY	NKp46 (natural cytotoxic receptor 1/CD335) is expressed on natural killer cells and Th2-type innate lymphocytes. However, NKp46 expression in human mast cells has not yet been reported. Here, we explored the expression of, and possible role played by, NKp46 in such cells. NKp46 protein was expressed in human mast cells in urticaria pigmentosa principally of the tryptase-positive/chymase-negative type (MCT), but not in human non-neoplastic skin mast cells of the tryptase-positive/chymase-positive (MCTC) type. NKp46 expression was also evident in the human neoplastic mast cell line HMC1.2. NKp46 knockdown changed the phenotype of this cell line from MCT to MCTC and downregulated GrB production, but did not influence IL-22 production. An agonistic anti-NKp46 antibody upregulated production of GrB and IL-22, but did not change the MCT-like phenotype of HMC1.2 cells. NKp46 was thus involved in the production of serine proteases and IL-22 in human mast cells.	[Ueshima, Chiyuki; Kataoka, Tatsuki R.; Hirata, Masahiro; Koyanagi, Itsuko; Tsuruyama, Tatsuaki; Haga, Hironori] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto 6068507, Japan; [Ueshima, Chiyuki; Seiyama, Akitoshi] Kyoto Univ, Grad Sch Med, Human Hlth Sci, Kyoto, Japan; [Honda, Tetsuya] Kyoto Univ Hosp, Dept Dermatol, Kyoto 606, Japan; [Okayama, Yoshimichi] Nihon Univ, Grad Sch Med Sci, Adv Med Res Ctr, Div Mol Cell Immunol & Allergol, Tokyo, Japan	Kataoka, TR (reprint author), Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto 6068507, Japan.	trkataoka@yahoo.co.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan. All patients who provided tissue samples signed the 'Kyoto University Hospital Informed Consent Form for the Non-therapeutic Use of Histopathological Materials', and the signed forms have been uploaded into all electronic health records. The authors thank Ms. K. Ijiri for her secretarial assistance.	Sivori S, 1997, J EXP MED, V186, P1129, DOI 10.1084/jem.186.7.1129; Akin C, 2006, CURR ALLERGY ASTHM R, V6, P282, DOI 10.1007/s11882-006-0061-0; Hitomi K, 2010, NAT IMMUNOL, V11, P601, DOI 10.1038/ni.1886; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Pardo J, 2007, CELL DEATH DIFFER, V14, P1768, DOI 10.1038/sj.cdd.4402183;; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Sanos SL, 2009, NAT IMMUNOL, V10, P83, DOI 10.1038/ni.1684; Okayama Y, 2006, IMMUNOL RES, V34, P97, DOI 10.1385/IR:34:2:97; Kataoka TR, 2010, J IMMUNOL, V184, P2468, DOI 10.4049/jimmunol.0902450; Karra L, 2009, CURR OPIN IMMUNOL, V21, P708, DOI 10.1016/j.coi.2009.09.010; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051; Koyasu S, 2011, CURR OPIN ALLERGY CL, V11, P109, DOI 10.1097/ACI.0b013e3283448808; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Chen X, 2007, P NATL ACAD SCI USA, V104, P6329, DOI 10.1073/pnas.0611655104; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; Satoh-Takayama N, 2008, IMMUNITY, V29, P958, DOI 10.1016/j.immuni.2008.11.001; Guhl S, 2010, EXP DERMATOL, V19, P845, DOI 10.1111/j.1600-0625.2010.01103.x; Pessino A, 1998, J EXP MED, V188, P953, DOI 10.1084/jem.188.5.953; Arnon TI, 2006, SEMIN CANCER BIOL, V16, P348, DOI 10.1016/j.semcancer.2006.07.005; Bensussan A, 2011, J INVEST DERMATOL, V131, P969, DOI 10.1038/jid.2010.404; Chen ZG, 2008, J IMMUNOL, V180, P6085; Freud AG, 2013, AM J CLIN PATHOL, V140, P853, DOI [10.1309/AJCPWGG69MCZOWMM, 10.1309/AJCPWGG69MCZOMM]; Guhl S, 2014, EXP DERMATOL, V23, P933, DOI 10.1111/exd.12558; Hashimoto S, 2002, LEUKEMIA RES, V26, P289, DOI 10.1016/S0145-2126(01)00115-1; Izawa K, 2009, J IMMUNOL, V183, P925, DOI 10.4049/jimmunol.0900552; Kataoka TR, 2005, BLOOD, V105, P1016, DOI 10.1182/bloof-2004-07-2811; Kataoka TR, 2013, ALLERGOL INT, V62, P99, DOI 10.2332/allergolint.12-OA-0450; Kataoka TR, 2004, LAB INVEST, V84, P376, DOI 10.1038/labinvest.3700040; Mizrahi S, 2014, J ALLERGY CLIN IMMUN, V134, P230, DOI 10.1016/j.jaci.2014.03.031; Ortonne N, 2012, EXP DERMATOL, V21, P461, DOI 10.1111/j.1600-0625.2012.01489.x; Ueshima C, 2015, CANC IMMUNOL RES	33	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0906-6705	1600-0625		EXP DERMATOL	Exp. Dermatol.	SEP	2015	24	9					675	679		10.1111/exd.12741		5	Dermatology	Dermatology	CP3LR	WOS:000359781100010		
J	Ohashi, T; Yamamoto, T				Ohashi, Takenobu; Yamamoto, Toshiyuki			Antifibrotic effect of lysophosphatidic acid receptors LPA(1) and LPA(3) antagonist on experimental murine scleroderma induced by bleomycin	EXPERIMENTAL DERMATOLOGY			English	Article						bleomycin; lysophosphatidic acid receptor; mouse model; scleroderma	SYSTEMIC-SCLEROSIS SKIN; ANIMAL-MODEL; MAST-CELLS; PULMONARY-FIBROSIS; ACTIVATION; COLLAGEN; MICE; PATHOGENESIS; FIBROBLASTS; EXPRESSION	The study of lysophosphatidic acid (LPA) receptor has recently focused on its involvement in the pathogenesis of systemic sclerosis (SSc). We examined the inhibitory effects of the antagonist for the LPA receptor, a selective LPA(1) and LPA(3) antagonist (Ki16425), on dermal and lung fibrosis in a mouse model of SSc. Ki16425 was administered intra-dermally after 6h on the same sites as bleomycin injection. Histopathological examination showed that skin lesions were markedly attenuated by treatment with Ki16425 at doses of 1 and 10mg/kg, along with reduced dermal thickness. Hydroxyproline contents in the Ki16425-treated skin showed a decrease of 35% (1mg/kg) and 45% (10mg/kg) compared with those in the oil-injected skin of the controls. The number of mast cells and phospho-Smad2/3-positive spindle cells of the Ki16425-treated skin was significantly decreased compared with that in the controls. Additionally, RT-PCR analysis showed that the mRNA levels of TGF-1, CTGF, MIP-1, IFN- and collagen 1(I) were significantly decreased in both the 1-mg/kg and 10-mg/kg groups of the Ki16425-treated mice compared with those in the controls. Furthermore, treatment with bleomycin and Ki16425 showed reduction in lung fibrosis, and the hydroxyproline contents in the lungs of the Ki16425-treated mice showed a decrease of 25% (1mg/kg) and 32% (10mg/kg) compared with those in the lungs of the controls. Taken together, Ki16425 was found to improve dermal and lung fibrosis in a mouse model of bleomycin-induced murine scleroderma. These results suggest that Ki16425 has the potential to be an effective new treatment for scleroderma.	[Ohashi, Takenobu; Yamamoto, Toshiyuki] Fukushima Med Univ, Dept Dermatol, Fukushima 9601295, Japan	Ohashi, T (reprint author), Fukushima Med Univ, Dept Dermatol, Hikarigaoka 1, Fukushima 9601295, Japan.	ohtk0084@yahoo.co.jp					Alexander S P, 2011, BR J PHARM S1, V158, pS1; Yamamoto T, 1999, J INVEST DERMATOL, V112, P456, DOI 10.1046/j.1523-1747.1999.00528.x; Pradere JP, 2007, J AM SOC NEPHROL, V18, P3110, DOI 10.1681/ASN.2007020196; Yamamoto T, 1999, J RHEUMATOL, V26, P2628; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685; O'Reilly S, 2012, RHEUMATOLOGY, V51, P1540, DOI 10.1093/rheumatology/kes090; Pradere JP, 2008, BBA-MOL CELL BIOL L, V1781, P582, DOI 10.1016/j.bbalip.2008.04.001; Takagawa S, 2003, J INVEST DERMATOL, V121, P41, DOI 10.1046/j.1523-1747.2003.12308.x; Tokumura A, 2009, INT J MED SCI, V6, P168; Yamamoto T, 2000, ARCH DERMATOL RES, V292, P362, DOI 10.1007/s004030000136; Lakos G, 2004, AM J PATHOL, V165, P203, DOI 10.1016/S0002-9440(10)63289-0; Bagga S, 2004, BLOOD, V104, P4080, DOI 10.1182/blood-2004-03-1166; Kissin EY, 2006, ARTHRITIS RHEUM, V54, P3655, DOI 10.1002/art.22186; Hashimoto T, 2006, J PHARMACOL SCI, V100, P82, DOI 10.1254/jphs.FPJ05030X; Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001; Varga J, 2007, J CLIN INVEST, V117, P557, DOI 10.1172/JCI31139; Ohgo S, 2013, EXP DERMATOL, V22, P769, DOI 10.1111/exd.12256; Castelino FV, 2011, ARTHRITIS RHEUM-US, V63, P1405, DOI 10.1002/art.30262; Truchetet ME, 2013, ARTHRITIS RHEUM-US, V65, P1347, DOI 10.1002/art.37860; Sauer B, 2004, J INVEST DERMATOL, V123, P840, DOI 10.1111/j.0022-202X.2004.23458.x; Yamamoto T, 2006, ARCH DERMATOL RES, V297, P333, DOI 10.1007/s00403-005-0635-z; ASHCROFT T, 1988, J CLIN PATHOL, V41, P467, DOI 10.1136/jcp.41.4.467; Bohm M, 2014, EXP DERMATOL, V23, P431, DOI 10.1111/exd.12409; Cabello-Verrugio C, 2011, CELL SIGNAL, V23, P449, DOI 10.1016/j.cellsig.2010.10.019; Chen RB, 2006, STEM CELLS DEV, V15, P797, DOI 10.1089/scd.2006.15.797; Ozbilgin MK, 2003, CLIN RHEUMATOL, V22, P189, DOI 10.1007/s10067-003-0706-5; Pattanaik Debendra, 2010, Discov Med, V10, P161; SEIBOLD JR, 1990, ARTHRITIS RHEUM, V33, P1702, DOI 10.1002/art.1780331114; Watanabe N, 2007, LIFE SCI, V81, P1009, DOI 10.1016/j.lfs.2007.08.013; Willenborg S, 2014, J INVEST DERMATOL, V134, P2005, DOI 10.1038/jid.2014.12; Williams JR, 2009, J BIOL CHEM, V284, P17304, DOI 10.1074/jbc.M109.003194; Yamamoto T, 2001, ARCH DERMATOL RES, V293, P532, DOI 10.1007/PL00007468; Yamamoto T, 2006, INT ARCH ALLERGY IMM, V140, P345, DOI 10.1159/000094242; Yamamoto T, 2002, CLIN IMMUNOL, V102, P77, DOI 10.1006/clim.2001.5138; Yin ZH, 2010, RHEUMATOLOGY, V49, P2290, DOI 10.1093/rheumatology/keq260	36	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0906-6705	1600-0625		EXP DERMATOL	Exp. Dermatol.	SEP	2015	24	9					698	702		10.1111/exd.12752		5	Dermatology	Dermatology	CP3LR	WOS:000359781100014		
J	Wu, ZW; Uchi, H; Morino-Koga, S; Shi, WM; Furue, M				Wu, Zhouwei; Uchi, Hiroshi; Morino-Koga, Saori; Shi, Weimin; Furue, Masutaka			Z-ligustilide ameliorated ultraviolet B-induced oxidative stress and inflammatory cytokine production in human keratinocytes through upregulation of Nrf2/HO-1 and suppression of NF-kappa B pathway	EXPERIMENTAL DERMATOLOGY			English	Article						keratinocytes; NF-B; Nrf2; ultraviolet B; Z-ligustilide	HUMAN EPIDERMAL-KERATINOCYTES; HUMAN SKIN KERATINOCYTES; GENE-EXPRESSION; UVB-RADIATION; MAP KINASES; PC12 CELLS; NRF2; ACTIVATION; PROTECTS; DAMAGE	Ultraviolet B (UVB), a harmful environmental factor, is responsible for a variety of skin disorders including skin inflammation through reactive oxygen species (ROS) and inflammatory mediator production. Here, we investigated the effect of Z-ligustilide (Z-lig), an active ingredient isolated from the medicinal plants Cnidium officinale and Angelica acutiloba, on UVB-induced ROS generation and inflammatory mediator production in normal human epidermal keratinocytes (NHEKs) as well as its underlying mechanisms. Z-lig significantly rescued UVB-induced NHEKs damage in a dosage-dependent manner. Pretreatment of NHEKs with Z-lig inhibited UVB-induced ROS production in NHEKs. Both silencing the nuclear factor E2-related factor 2 (Nrf2) and the supplement of tin protoporphyrin IX (SnPP), a haeme oxygenase-1 (HO-1) inhibitor, cancelled the inhibitory effect of Z-lig on UVB-induced ROS upregulation in NHEKs. Moreover, pretreatment of NHEKs with Z-lig reduced UVB-induced nuclear factor kappa B (NF-B)-dependent inflammatory mediators (IL-6, IL-8 and MCP-1) production at both mRNA and protein level. In the presence of Z-lig, UVB-induced NF-B subunit p65 nuclear translocation was abolished, and the IB degradation was suppressed. Taken together, these findings suggest that Z-lig can suppress UVB-induced ROS generation through Nrf2/HO-1 upregulation and inflammation by suppressing the NF-B pathway, suggesting that Z-lig may be beneficial in protecting skin from UVB exposure.	[Wu, Zhouwei; Shi, Weimin] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Dermatol, Shanghai 200030, Peoples R China; [Wu, Zhouwei; Uchi, Hiroshi; Morino-Koga, Saori; Furue, Masutaka] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka 812, Japan	Shi, WM (reprint author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Dermatol, Shanghai 200030, Peoples R China.	uchihir@dermatol.med.kyushu-u.ac.jp; shiweimin2@gmail.com			National Natural Science Foundation of China [81402587]	National Natural Science Foundation of China (grant nos. 81402587).	Liu GH, 2008, BBA-MOL CELL RES, V1783, P713, DOI 10.1016/j.bbamcr.2008.01.002; Peng HY, 2007, BIOL PHARM BULL, V30, P309, DOI 10.1248/bpb.30.309; Paur I, 2010, FREE RADICAL BIO MED, V48, P1218, DOI 10.1016/j.freeradbiomed.2010.02.005; Checker R, 2012, FREE RADICAL BIO MED, V53, P1421, DOI 10.1016/j.freeradbiomed.2012.08.006; Cho SY, 2003, MOL CELL BIOCHEM, V243, P153, DOI 10.1023/A:1021624520740; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; Wu ZW, 2014, EXP DERMATOL, V23, P260, DOI 10.1111/exd.12360; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Leung TH, 2013, J CLIN INVEST, V123, P5361, DOI 10.1172/JCI70895; Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423; Dietz BM, 2008, CHEM RES TOXICOL, V21, P1939, DOI 10.1021/tx8001274; Kundu JK, 2005, MUTAT RES-FUND MOL M, V591, P123, DOI 10.1016/j.mrfmmm.2005.04.019; Afaq F, 2003, ONCOGENE, V22, P1035, DOI 10.1038/sj.onc.1206206; Buelna-Chontal M, 2013, CELL SIGNAL, V25, P2548, DOI 10.1016/j.cellsig.2013.08.007; Qi HY, 2012, NEUROPHARMACOLOGY, V62, P1659, DOI 10.1016/j.neuropharm.2011.11.012; Hu HB, 2013, NATURE, V494, P371, DOI 10.1038/nature11831; Narayanan BA, 2006, MOL CANCER THER, V5, P1117, DOI 10.1158/1535-7163.MCT-05-0520; Wei Y, 2009, AM J PHYSIOL-CELL PH, V297, pC907, DOI 10.1152/ajpcell.00536.2008; Yu Y, 2008, EXP BRAIN RES, V184, P307, DOI 10.1007/s00221-007-1100-3; Wang J, 2010, ACTA PHARMACOL SIN, V31, P791, DOI 10.1038/aps.2010.71; Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146; Yoshihisa Yoko, 2014, Exp Dermatol, V23, P178, DOI 10.1111/exd.12347; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Chen JS, 2011, ATHEROSCLEROSIS, V214, P301, DOI 10.1016/j.atherosclerosis.2010.11.010; Kregel KC, 2007, AM J PHYSIOL-REG I, V292, pR18, DOI 10.1152/ajpregu.00327.2006; Syed DN, 2012, PHOTOCHEM PHOTOBIOL, V88, P1184, DOI 10.1111/j.1751-1097.2012.01115.x; Bellezza Ilaria, 2010, Cancers (Basel), V2, P483, DOI 10.3390/cancers2020483; English JSC, 2003, BRIT MED BULL, V68, P129, DOI 10.1093/bmb/ldg026; Kim N, 2013, PHYTOTHER RES, V27, P1700, DOI 10.1002/ptr.4924; Kumar KJS, 2013, FOOD CHEM TOXICOL, V59, P55, DOI 10.1016/j.fct.2013.04.055; Lee S, 2014, EXP DERMATOL, V23, P13, DOI 10.1111/exd.12396; Lee S H, 2012, MBIO, V3; Minelli A, 2012, INT J BIOCHEM CELL B, V44, P525, DOI 10.1016/j.biocel.2011.12.006; Monfrecola G, 2013, CLIN EXP DERMATOL, V38, P185, DOI 10.1111/ced.12018; Muta-Takada K, 2009, BIOFACTORS, V35, P435, DOI 10.1002/biof.56; Nishimura K, 2011, EVID-BASED COMPL ALT, V2011; Park G, 2013, BIOL PHARM BULL, V36, P1134, DOI 10.1248/bpb.b13-00101; Peng B, 2013, BRAIN RES, V1520, P168, DOI 10.1016/j.brainres.2013.05.009; Rijnkels JM, 2003, RADIAT RES, V159, P210, DOI 10.1667/0033-7587(2003)159[0210:PBAAUR]2.0.CO;2; Scharffetter-Kochanek K, 2000, EXP GERONTOL, V35, P307, DOI 10.1016/S0531-5565(00)00098-X; Sun Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006588; Svobodova Alena, 2003, Biomedical Papers (Olomouc), V147, P137; Vicentini FTMC, 2011, J DERMATOL SCI, V61, P162, DOI 10.1016/j.jdermsci.2011.01.002	44	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0906-6705	1600-0625		EXP DERMATOL	Exp. Dermatol.	SEP	2015	24	9					703	708		10.1111/exd.12758		6	Dermatology	Dermatology	CP3LR	WOS:000359781100015		
J	Miyazaki, T; Kohno, S				Miyazaki, Taiga; Kohno, Shigeru			Current recommendations and importance of antifungal stewardship for the management of invasive candidiasis	EXPERT REVIEW OF ANTI-INFECTIVE THERAPY			English	Review						antifungal resistance; antifungal stewardship; Candida glabrata; candidemia; echinocandin; invasive candidiasis	BLOOD-STREAM INFECTIONS; INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; CLINICAL-PRACTICE GUIDELINES; LIPOSOMAL AMPHOTERICIN-B; NON-NEUTROPENIC PATIENTS; HOSPITAL RESOURCE UTILIZATION; CENTRAL VENOUS CATHETERS; RISK-FACTORS; ANTIMICROBIAL STEWARDSHIP	Invasive candidiasis can have a major effect on patient prognosis and medical economics. Quickly eliminating the focus of the infection and administering appropriate antifungal therapy are important. Clinical guidelines for invasive candidiasis have been issued in the USA, Europe and recently in Japan. The purpose of this review is to summarize the current recommendations on how to diagnose and treat invasive candidiasis based on the evidence gathered to date and by referencing guidelines from various countries. Echinocandin antifungals play a central role in the prevention and treatment of invasive candidiasis although a recent increase in echinocandin-resistant Candida glabrata is seen as problematic. In the future, promoting the appropriate use of antifungal agents by antifungal stewardship teams will be necessary to suppress adverse effects, appearance of resistant strains and unnecessary medical expenses, as well as improve positive clinical outcomes and prognoses.	[Miyazaki, Taiga; Kohno, Shigeru] Nagasaki Univ, Dept Internal Med 2, Nagasaki 852, Japan; [Miyazaki, Taiga] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Immunol, Div Infect Dis, Nagasaki 852, Japan	Kohno, S (reprint author), Nagasaki Univ, Dept Internal Med 2, Nagasaki 852, Japan.	s-kohno@nagasaki-u.ac.jp			Astellas Pharma Inc.; Dainippon Sumitomo Pharma Co.; MSD (Merck Co.); Pfizer Inc.; Japanese Ministry of Education, Culture, Sports, Science and Technology [24791027, 21390305]; Ministry of Health, Labour and Welfare [H25-shinko-ippan-006]	T Miyazaki received honoraria, consultation fees, and research grants from Astellas Pharma Inc., Dainippon Sumitomo Pharma Co., MSD (Merck & Co.), and Pfizer Inc. S Kohno received honoraria, consultation fees, and research grants from Astellas Pharma Inc., Dainippon Sumitomo Pharma Co., MSD (Merck & Co.), and Pfizer Inc. This work was partially supported by the Grant-in-Aid for Scientific Research (no. 24791027 to T Miyazaki and no. 21390305 to S Kohno) from the Japanese Ministry of Education, Culture, Sports, Science and Technology and by a grant from the Ministry of Health, Labour and Welfare (Research Program on Emerging and Re-emerging Infectious Diseases, H25-shinko-ippan-006 to both authors). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	AbeleHorn M, 1996, INFECTION, V24, P426, DOI 10.1007/BF01713042; Aitken SL, 2014, ANN PHARMACOTHER, V48, P683, DOI 10.1177/1060028014529928; Anaissie EJ, 1996, AM J MED, V101, P170, DOI 10.1016/S0002-9343(96)80072-6; Uppuluri P, 2011, ANTIMICROB AGENTS CH, V55, P3591, DOI 10.1128/AAC.01701-10; Tortorano AM, 2004, EUR J CLIN MICROBIOL, V23, P317, DOI 10.1007/s10096-004-1103-y; Nguyen MH, 2012, CLIN INFECT DIS, V54, P1240, DOI 10.1093/cid/cis200; Toulet D, 2012, J ANTIMICROB CHEMOTH, V67, P430, DOI 10.1093/jac/dkr473; Horn DL, 2010, EUR J CLIN MICROBIOL, V29, P223, DOI 10.1007/s10096-009-0843-0; Jaijakul S, 2012, CLIN INFECT DIS, V55, P521, DOI 10.1093/cid/cis456; Mermel LA, 2009, CLIN INFECT DIS, V49, P1, DOI 10.1086/599376; Kullberg BJ, 2002, EUR J MED RES, V7, P183; Paphitou NI, 2005, MED MYCOL, V43, P235, DOI 10.1080/13693780410001731619; Mondain V, 2013, INFECTION, V41, P621, DOI 10.1007/s15010-013-0431-1; Garnacho-Montero J, 2013, J ANTIMICROB CHEMOTH, V68, P206, DOI 10.1093/jac/dks347; Leon C, 2006, CRIT CARE MED, V34, P730, DOI 10.1097/01.CCM.0000202208.37364.7D; Anaissie EJ, 1998, AM J MED, V104, P238, DOI 10.1016/S0002-9343(98)00030-8; Rodriguez-Adrian LJ, 2003, MEDICINE, V82, P187, DOI 10.1097/00005792-200305000-00005; Rex JH, 2003, CLIN INFECT DIS, V36, P1221, DOI 10.1086/374850; Pfaller MA, 2012, AM J MED, V125, pS3, DOI 10.1016/j.amjmed.2011.11.001; Rodrigues CF, 2014, EUR J CLIN MICROBIOL, V33, P673, DOI 10.1007/s10096-013-2009-3; Morgan J, 2005, INFECT CONT HOSP EP, V26, P540, DOI 10.1086/502581; Almirante B, 2005, J CLIN MICROBIOL, V43, P1829, DOI 10.1128/JCM.43.4.1829-1835.2005; Forrest GN, 2008, J INFECTION, V56, P126, DOI 10.1016/j.jinf.2007.10.014; Shields RK, 2013, ANTIMICROB AGENTS CH, V57, P3528, DOI 10.1128/AAC.00136-13; Ruhnke M, 2011, MYCOSES, V54, P279, DOI 10.1111/j.1439-0507.2011.02040.x; Gudlaugsson O, 2003, CLIN INFECT DIS, V37, P1172, DOI 10.1086/378745; Tumbarello M, 2007, J CLIN MICROBIOL, V45, P1843, DOI 10.1128/JCM.00131-07; Fekkar A, 2014, EUR J CLIN MICROBIOL, V33, P1489, DOI 10.1007/s10096-014-2096-9; Nucci M, 2010, CLIN INFECT DIS, V51, P295, DOI 10.1086/653935; Raad I, 2004, CLIN INFECT DIS, V38, P1119, DOI 10.1086/382874; Cornely OA, 2012, CLIN MICROBIOL INFEC, V18, P19, DOI 10.1111/1469-0691.12039; Alexander BD, 2013, CLIN INFECT DIS, V56, P1724, DOI 10.1093/cid/cit136; Arnold HM, 2010, PHARMACOTHERAPY, V30, P361, DOI 10.1592/phco.30.4.361; Rentz AM, 1998, CLIN INFECT DIS, V27, P781, DOI 10.1086/514955; Garey KW, 2006, CLIN INFECT DIS, V43, P25, DOI 10.1086/504810; Luzzati R, 2000, EUR J CLIN MICROBIOL, V19, P602, DOI 10.1007/s100960000325; Aapro MS, 2011, EUR J CANCER, V47, P8, DOI 10.1016/j.ejca.2010.10.013; Peters BM, 2013, ANTIMICROB AGENTS CH, V57, P74, DOI 10.1128/AAC.01599-12; Andes DR, 2012, CLIN INFECT DIS, V54, P1110, DOI 10.1093/cid/cis021; Holtzman C, 2011, J CLIN MICROBIOL, V49, P1581, DOI 10.1128/JCM.02461-10; Zaoutis TE, 2005, CLIN INFECT DIS, V41, P1232, DOI 10.1086/496922; Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754; Harbarth S, 2002, ARCH SURG-CHICAGO, V137, P1353, DOI 10.1001/archsurg.137.12.1353; Pfaller MA, 2007, CLIN MICROBIOL REV, V20, P133, DOI 10.1128/CMR.00029-06; Silva S, 2012, FEMS MICROBIOL REV, V36, P288, DOI 10.1111/j.1574-6976.2011.00278.x; Pappas PG, 2009, CLIN INFECT DIS, V48, P503, DOI 10.1086/596757; Liu CY, 2009, J INFECTION, V58, P154, DOI 10.1016/j.jinf.2008.12.008; Thompson GR, 2008, ANTIMICROB AGENTS CH, V52, P3783, DOI 10.1128/AAC.00473-08; Patel GP, 2009, AM J THER, V16, P508, DOI 10.1097/MJT.0b013e3181a1afb7; Walraven CJ, 2013, ANTIMICROB AGENTS CH, V57, P1, DOI 10.1128/AAC.01351-12; Gauthier GM, 2005, CLIN INFECT DIS, V41, pE27, DOI 10.1086/431761; Horn DL, 2009, CLIN INFECT DIS, V48, P1695, DOI 10.1086/599039; Hajjeh RA, 2004, J CLIN MICROBIOL, V42, P1519, DOI 10.1128/JCM.42.4.1519-1527.2004; Breit SM, 2005, AM J OPHTHALMOL, V139, P135, DOI 10.1016/j.ajo.2004.08.077; Mora-Duarte J, 2002, NEW ENGL J MED, V347, P2020, DOI 10.1056/NEJMoa021585; Blot SI, 2002, AM J MED, V113, P480, DOI 10.1016/S0002-9343(02)01248-2; Levy MM, 2010, INTENS CARE MED, V36, P222, DOI 10.1007/s00134-009-1738-3; Trofa D, 2008, CLIN MICROBIOL REV, V21, P606, DOI 10.1128/CMR.00013-08; Viscoli C, 1999, CLIN INFECT DIS, V28, P1071, DOI 10.1086/514731; Kullberg BJ, 2005, LANCET, V366, P1435, DOI 10.1016/S0140-6736(05)67490-9; Pappas PG, 2003, CLIN INFECT DIS, V37, P634, DOI 10.1086/376906; Krcmery V, 2002, J HOSP INFECT, V50, P243, DOI 10.1053/jhin.2001.1151; Marr KA, 2000, J INFECT DIS, V181, P309, DOI 10.1086/315193; Pfaller MA, 2013, J CLIN MICROBIOL, V51, P2571, DOI 10.1128/JCM.00308-13; Horn DL, 2007, DIAGN MICR INFEC DIS, V59, P407, DOI 10.1016/j.diagmicrobio.2007.06.008; Leroy O, 2009, CRIT CARE MED, V37, P1612, DOI 10.1097/CCM.0b013e31819efac0; Phillips P, 1997, EUR J CLIN MICROBIOL, V16, P337, DOI 10.1007/BF01726360; Wisplinghoff H, 2004, CLIN INFECT DIS, V39, P309, DOI 10.1086/421946; WENZEL RP, 1995, CLIN INFECT DIS, V20, P1531; Morrell M, 2005, ANTIMICROB AGENTS CH, V49, P3640, DOI 10.1128/AAC.49.9.3640-3645.2005; REX JH, 1994, NEW ENGL J MED, V331, P1325, DOI 10.1056/NEJM199411173312001; Labelle AJ, 2008, CRIT CARE MED, V36, P2967, DOI 10.1097/CCM.0b013e31818b3477; Shorr AF, 2009, CRIT CARE MED, V37, P2519, DOI 10.1097/CCM.0b013e3181a0f95d; Kollef M, 2012, CLIN INFECT DIS, V54, P1739, DOI 10.1093/cid/cis305; Dellit TH, 2007, CLIN INFECT DIS, V44, P159, DOI 10.1086/510393; Lee A, 2007, J CLIN MICROBIOL, V45, P3546, DOI 10.1128/JCM.01555-07; Reboli AC, 2007, NEW ENGL J MED, V356, P2472, DOI 10.1056/NEJMoa066906; Raad I, 2004, ANN INTERN MED, V140, P18; Colombo AL, 2013, BRAZ J INFECT DIS, V17, P283, DOI 10.1016/j.bjid.2013.02.001; Blumberg HM, 2001, CLIN INFECT DIS, V33, P177, DOI 10.1086/321811; Brass EP, 2010, CLIN INFECT DIS, V51, P304, DOI 10.1086/653936; Dellinger RP, 2013, INTENS CARE MED, V39, P165, DOI 10.1007/s00134-012-2769-8; Trick WE, 2002, CLIN INFECT DIS, V35, P627, DOI 10.1086/342300; Kuse ER, 2007, LANCET, V369, P1519, DOI 10.1016/S0140-6736(07)60605-9; Sarria JC, 2005, CLIN INFECT DIS, V40, pE46, DOI 10.1086/427753; Foster N, 2007, J MED MICROBIOL, V56, P1639, DOI 10.1099/jmm.0.47406-0; Pappas PG, 2007, CLIN INFECT DIS, V45, P883, DOI 10.1086/520980; Pfaller MA, 2012, J CLIN MICROBIOL, V50, P1199, DOI 10.1128/JCM.06112-11; Antworth A, 2013, PHARMACOTHERAPY, V33, P137, DOI 10.1002/phar.1186; Arendrup MC, 2014, CURR OPIN INFECT DIS, V27, P484, DOI 10.1097/QCO.0000000000000111; Ben-Ami R, 2008, J CLIN MICROBIOL, V46, P2222, DOI 10.1128/JCM.00214-08; Beyda ND, 2014, CLIN INFECT DIS, V59, P819, DOI 10.1093/cid/ciu407; Bodey GP, 1993, DEFINITIONS CANDIDA, P407; Bow EJ, 2010, CAN J INFECT DIS MED, V21, pE122; De Almeida BM, 2014, SCAND J INFECT DIS, V46, P854, DOI 10.3109/00365548.2014.952246; Castellanos-Ortega A, 2010, CRIT CARE MED, V38, P1036, DOI [10.1097/CCM.0b013e3181d455b6, 10.1097/CCM.0b0bl3e3181d455b6]; Cohen Y, 2010, CRIT CARE MED, V38, P826, DOI 10.1097/CCM.0b013e3181cc4734; Dupont BF, 2009, CRIT CARE, V13, DOI 10.1186/cc8117; Gafter-Gvili A, 2008, MAYO CLIN PROC, V83, P1011, DOI 10.4065/83.9.1011; Griffith M, 2012, EXPERT REV ANTI-INFE, V10, P63, DOI [10.1586/eri.11.153, 10.1586/ERI.11.153]; Harbarth S, 2002, ARCH SURG-CHICAGO, V137, P1359; Hsu DI, 2010, J ANTIMICROB CHEMOTH, V65, P1765, DOI 10.1093/jac/dkq216; Hui M, 2009, J MED MICROBIOL, V58, P396, DOI 10.1099/jmm.0.47842-0; Imtiaz T, 2012, J MED MICROBIOL, V61, P1330, DOI 10.1099/jmm.0.045047-0; Kanji JN, 2013, LEUKEMIA LYMPHOMA, V54, P1479, DOI 10.3109/10428194.2012.745073; Kett DH, 2011, CRIT CARE, V15, DOI 10.1186/cc10514; Lopez-Medrano F, 2013, CLIN MICROBIOL INFEC, V19, P56, DOI 10.1111/j.1469-0691.2012.03891.x; Micallef C, 2015, J ANTIMICROB CHEMOTH, V70, P1908, DOI 10.1093/jac/dkv040; Michalopoulos AS, 2003, CHEST, V124, P2244, DOI 10.1378/chest.124.6.2244; Mikulska M, 2010, CRIT CARE, V14, DOI 10.1186/cc9365; Munoz P, 2000, INT J ANTIMICROB AG, V15, P83, DOI 10.1016/S0924-8579(00)00147-3; Mycoses Forum Task Force on the Guidelines of Deep-Seated Mycoses, 2014, GUID DIAGN MAN DEEP; Mylonakis E, 2015, CLIN INFECT DIS, V60, P892, DOI 10.1093/cid/ciu959; Neely LA, 2013, SCI TRANSL MED, V5; Neoh CF, 2014, INT J ANTIMICROB AG, V43, P207, DOI 10.1016/j.ijantimicag.2013.08.010; NGUYEN MH, 1995, ARCH INTERN MED, V155, P2429, DOI 10.1001/archinte.155.22.2429; Nucci M, 1998, INFECT CONT HOSP EP, V19, P846; Ostrosky-Zeichner L, 2007, EUR J CLIN MICROBIOL, V26, P271, DOI 10.1007/s10096-007-0270-z; Ostrosky-Zeichner L, 2013, CLIN INFECT DIS, V56, P1733, DOI 10.1093/cid/cit140; Parkins MD, 2007, J ANTIMICROB CHEMOTH, V60, P613, DOI 10.1093/jac/dkm212; Pfaller MA, 2002, J CLIN MICROBIOL, V40, P3551, DOI 10.1128/JCM.40.10.3551-3557.2002; Rane HS, 2012, ANTIMICROB AGENTS CH, V56, P4487, DOI 10.1128/AAC.00263-12; Reed EE, 2014, DIAGN MICR INFEC DIS, V78, P157, DOI 10.1016/j.diagmicrobio.2013.11.012; REX JH, 1995, CLIN INFECT DIS, V21, P994; Ruhnke M, 2003, ANN HEMATOL, V82, pS141, DOI 10.1007/s00277-003-0768-0; Shah DN, 2011, J ANTIMICROB CHEMOTH, V66, P2146, DOI 10.1093/jac/dkr244; Shields RK, 2014, ANTIMICROB AGENTS CH, V58, P7601, DOI 10.1128/AAC.04134-14; Shorr AF, 2009, CRIT CARE MED, V37, P2535; Singh-Babak SD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002718; Sinkó János, 2012, Future Microbiol, V7, P1141, DOI 10.2217/fmb.12.93; Suzuki Takashi, 2008, Journal of Infection and Chemotherapy, V14, P204, DOI 10.1007/s10156-008-0612-5; Takazono T, 2011, JPN J INFECT DIS, V64, P116; Takesue Y, 2015, J ANTIMICROB CHEMOTH, V70, P587, DOI 10.1093/jac/dku414; Taur Y, 2010, ANTIMICROB AGENTS CH, V54, P184, DOI 10.1128/AAC.00945-09; The Japanese Society for Medical Mycology, 2013, JSMM CLIN PRACT GUID; Tumbarello M, 2008, J ANTIMICROB CHEMOTH, V62, P1379, DOI 10.1093/jac/dkn381; Valerio M, 2014, J ANTIMICROB CHEMOTH, V69, P1993, DOI 10.1093/jac/dku053; Vardakas KZ, 2009, CLIN MICROBIOL INFEC, V15, P289, DOI 10.1111/j.1469-0691.2008.02653.x; Wingard JR, 2002, CLIN INFECT DIS, V35, P891, DOI 10.1086/342563; Zilberberg MD, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-150	140	0	0	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1478-7210	1744-8336		EXPERT REV ANTI-INFE	Expert Rev. Anti-Infect. Ther.	SEP	2015	13	9					1171	1183		10.1586/14787210.2015.1058157		13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CP0XF	WOS:000359599400010		
J	Tsujii, Y; Kato, M; Inoue, T; Yoshii, S; Nagai, K; Fujinaga, T; Maekawa, A; Hayashi, Y; Akasaka, T; Shinzaki, S; Watabe, K; Nishida, T; Iijima, H; Tsujii, M; Takehara, T				Tsujii, Yoshiki; Kato, Motohiko; Inoue, Takuya; Yoshii, Shunsuke; Nagai, Kengo; Fujinaga, Tetsuji; Maekawa, Akira; Hayashi, Yoshito; Akasaka, Tomofumi; Shinzaki, Shinichiro; Watabe, Kenji; Nishida, Tsutomu; Iijima, Hideki; Tsujii, Masahiko; Takehara, Tetsuo			Integrated diagnostic strategy for the invasion depth of early gastric cancer by conventional endoscopy and EUS	GASTROINTESTINAL ENDOSCOPY			English	Article							ULTRASONOGRAPHY; PROBE	Background: Although conventional endoscopy (CE) and EUS are considered useful for predicting the invasion depth (T-staging) in early gastric cancer (EGC), no effective diagnostic strategy has been established. Objective: To produce simple CE criteria and to elucidate an efficient diagnostic method by combining CE and EUS for accurate T-staging. Design: Single-center retrospective analysis. Setting: Academic university hospital. Patients: Consecutive patients with EGC from April 2007 to March 2012 who underwent CE and EUS before treatment. Interventions: Recorded endoscopic images were independently reviewed by 3 observers. The CE criteria for massive invasion were defined, and their utility and the additional value of EUS were assessed. Main Outcome Measurements: The accuracy of CE based on the criteria and the accuracy of EUS. Results: Two hundred thirty patients were enrolled: 195 with mucosal cancer or cancer in the submucosa less than 500 mm from the muscularis mucosae and 35 with invasive cancers. Multivariate analysis of the CE findings by 1 observer revealed that an irregular surface and a submucosal tumor-like marginal elevation were significantly associated with massive invasion. The simple CE criteria, consisting of those 2 features, had an overall accuracy of 73% to 82% and no significant differences in the diagnostic yield compared with EUS in all observers. CE accurately revealed mucosal cancer, and EUS efficiently salvaged the lesions that were over-diagnosed by CE. With our strategy, which involved the CE criteria and the optimal use of EUS, the comprehensive accuracy exceeded 85% in each observer. Limitations: Retrospective, single-center study. Conclusions: We demonstrated a practical strategy for T-staging in EGC using simple CE criteria and EUS.	[Tsujii, Yoshiki; Kato, Motohiko; Inoue, Takuya; Yoshii, Shunsuke; Nagai, Kengo; Fujinaga, Tetsuji; Maekawa, Akira; Hayashi, Yoshito; Akasaka, Tomofumi; Shinzaki, Shinichiro; Watabe, Kenji; Nishida, Tsutomu; Iijima, Hideki; Tsujii, Masahiko; Takehara, Tetsuo] Osaka Univ Grad Sch Med, Dept Gastroenterol & Hepatol, Suita, Osaka 5650871, Japan; [Kato, Motohiko] Natl Hosp Org, Tokyo Med Ctr, Dept Gastroenterol, Tokyo, Japan; [Akasaka, Tomofumi] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Gastrointestinal Oncol, Osaka, Japan; [Nishida, Tsutomu] Toyonaka City Hosp, Dept Gastroenterol, Toyonaka, Osaka, Japan	Takehara, T (reprint author), Osaka Univ Grad Sch Med, Dept Gastroenterol & Hepatol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Nishida, Tsutomu/0000-0003-4037-9003			Abe S, 2011, GASTRIC CANCER, V14, P35, DOI 10.1007/s10120-011-0002-z; Akashi K, 2006, Int J Gastrointest Cancer, V37, P133; Kim JH, 2007, GASTROINTEST ENDOSC, V66, P901, DOI 10.1016/j.gie.2007.06.012; Akahoshi K, 1998, GASTROINTEST ENDOSC, V48, P470, DOI 10.1016/S0016-5107(98)70087-2; Zeng YK, 2012, ANN SURG, V256, P39, DOI 10.1097/SLA.0b013e3182583e2e; Okada K, 2011, SURG ENDOSC, V25, P841, DOI 10.1007/s00464-010-1279-4; Yanai H, 1999, GUT, V44, P361; Ohashi S, 1999, GUT, V45, P599; Yoshida S, 2005, ABDOM IMAGING, V30, P518, DOI 10.1007/s00261-004-0287-z; Mandai K, 2012, GASTROENT RES PRACT, DOI 10.1155/2012/245390; Choi J, 2010, ENDOSCOPY, V42, P705, DOI 10.1055/s-0030-1255617; SANO T, 1990, DIGEST DIS SCI, V35, P1340, DOI 10.1007/BF01536738; Yanai H, 1997, GASTROINTEST ENDOSC, V46, P212, DOI 10.1016/S0016-5107(97)70088-9; Choi J, 2011, GASTROINTEST ENDOSC, V73, P917, DOI 10.1016/j.gie.2010.11.053; Gotoda T, 2000, GASTRIC CANCER, V3, P219, DOI 10.1007/PL00011720; Iguchi Y, 2009, J GASTROEN HEPATOL, V24, P1733, DOI 10.1111/j.1440-1746.2009.05892.x; Kikuchi D, 2013, GASTROENT RES PRACT, DOI 10.1155/2013/217695; Mouri Ritsuo, 2009, J Clin Gastroenterol, V43, P318, DOI 10.1097/MCG.0b013e3181775966; Park Ji Min, 2011, J Gastric Cancer, V11, P109, DOI 10.5230/jgc.2011.11.2.109; Yamamoto S, 2012, GASTROENT RES PRACT, DOI 10.1155/2012/194530; YASUDA K, 1994, ENDOSCOPY, V26, P816, DOI 10.1055/s-2007-1009117	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	SEP	2015	82	3					452	459		10.1016/j.gie.2015.01.022		8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CP0XX	WOS:000359601300005		
J	Yoshida, N; Hisabe, T; Hirose, R; Ogiso, K; Inada, Y; Konishi, H; Yagi, N; Naito, Y; Aomi, Y; Ninomiya, K; Ikezono, G; Terasawa, M; Yao, KS; Matsui, T; Yanagisawa, A; Itoh, Y				Yoshida, Naohisa; Hisabe, Takashi; Hirose, Ryohei; Ogiso, Kiyoshi; Inada, Yutaka; Konishi, Hideyuki; Yagi, Nobuaki; Naito, Yuji; Aomi, Yoshiaki; Ninomiya, Kazeo; Ikezono, Go; Terasawa, Masaaki; Yao, Kenshi; Matsui, Toshiyuki; Yanagisawa, Akio; Itoh, Yoshito			Improvement in the visibility of colorectal polyps by using blue laser imaging (with video)	GASTROINTESTINAL ENDOSCOPY			English	Article							CONVENTIONAL COLONOSCOPY; ADENOMA DETECTION; CONTROLLED-TRIAL; INVASION DEPTH; WHITE-LIGHT; DIAGNOSIS; SYSTEM; MAGNIFICATION; METAANALYSIS; NEOPLASIA	Background: Fujifilm developed blue laser imaging (BLI) via a laser light source with a narrow-band light observation function. It has a brighter BLI bright mode for tumor detection. Objective: To investigate whether the BLI bright mode can improve the visibility of colorectal polyps compared with white light (WL). Design: We studied 100 colorectal polyps (protruding, 42; flat, 58; size, 2-20 mm) and recorded videos of the polyps by using the BLI bright mode and WL at Kyoto Prefectural University of Medicine and Fukuoka Chikushi University Hospital. The videos were evaluated by 4 expert endoscopists and 4 nonexperts. Each endoscopist evaluated the videos in a randomized order. Each polyp was assigned a visibility score from 4 (excellent visibility) to 1 (poor visibility). Setting: Japanese academic units. Main Outcome Measurements: The visibility scores in each mode and their relationship to the clinical characteristics were analyzed. Results: The mean visibility scores of the BLI bright mode were significantly higher than those of WL for both experts and nonexperts (experts, 3.10 +/- 0.95 vs 2.90 +/- 1.09; P = .00013; nonexperts, 3.04 +/- 0.94 vs 2.78 +/- 1.03; P < .0001). For all nonexperts, the visibility scores of the BLI bright mode were significantly higher than those of WL; however, these scores were significantly higher in only 2 experts. For experts, the mean visibility scores of the BLI bright mode was significantly higher than those of WL for flat polyps, neoplastic polyps, and polyps located on the left side of the colon and the rectum. Limitations: Small sample size and review of videos. Conclusions: Our study showed that polyps were more easily visible with the BLI bright mode compared with WL.	[Yoshida, Naohisa; Hirose, Ryohei; Ogiso, Kiyoshi; Inada, Yutaka; Konishi, Hideyuki; Yagi, Nobuaki; Naito, Yuji; Itoh, Yoshito] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Gastroenterol & Hepatol, Kyoto 6028566, Japan; [Hisabe, Takashi; Aomi, Yoshiaki; Ninomiya, Kazeo; Ikezono, Go; Terasawa, Masaaki; Yao, Kenshi; Matsui, Toshiyuki] Fukuoka Univ, Dept Gastroenterol, Chikushi Hosp, Fukuoka 81401, Japan; [Yanagisawa, Akio] Kyoto Prefectural Univ Med, Dept Pathol, Grad Sch Med Sci, Kyoto 6028566, Japan	Yoshida, N (reprint author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Gastroenterol & Hepatol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	naohisa@koto.kpu-m.ac.jp			AstraZeneca Co, Ltd; Eisai Co, Ltd; Otsuka Pharmaceutical Co, Ltd [J132003243]; MSD KK; Dainippon Sumitomo Pharma Co, Ltd; Chugai Pharmaceutical Co, Ltd; FUJIFILM Medical Co, Ltd; Merck Serono Co; Bristol-Myers KK; Takeda Pharmaceutical Co, Ltd [J132003379, J132003384]	Dr Itoh received support from AstraZeneca Co, Ltd, Eisai Co, Ltd; Otsuka Pharmaceutical Co, Ltd; MSD KK; Dainippon Sumitomo Pharma Co, Ltd; Chugai Pharmaceutical Co, Ltd; FUJIFILM Medical Co, Ltd; Merck Serono Co; and Bristol-Myers KK. Dr Yagi received support from AstraZeneca Co, Ltd; Eisai Co, Ltd; Otsuka Pharmaceutical Co, Ltd; MSD KK; Dainippon Sumitomo Pharma Co, Ltd; Chugai Pharmaceutical Co, Ltd; Fujifilm Medical Co, Ltd; and Merck Serono Co. Dr Naito received support from Otsuka Pharmaceutical Co, Ltd (J132003243) and Takeda Pharmaceutical Co, Ltd (J132003379 and J132003384). All other authors disclosed no financial relationships relevant to this article.	Saito Y, 2010, SURG ENDOSC, V24, P343, DOI 10.1007/s00464-009-0562-8; Rastogi A, 2008, GASTROINTEST ENDOSC, V67, P280, DOI 10.1016/j.gie.2007.07.036; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Matsuda T, 2008, AM J GASTROENTEROL, V103, P1926, DOI 10.1111/j.1572-0241.2008.01931.x; Kanao H, 2009, GASTROINTEST ENDOSC, V69, P631, DOI 10.1016/j.gie.2008.08.028; Su MY, 2006, AM J GASTROENTEROL, V101, P2711, DOI 10.1111/j.1572-0241.2006.00932.x; Yoshida N, 2014, DIGEST ENDOSC, V26, P250, DOI 10.1111/den.12127; Aminalai A, 2010, AM J GASTROENTEROL, V105, P2383, DOI 10.1038/ajg.2010.273; Osawa H, 2014, DIGEST ENDOSC, V26, P105, DOI 10.1111/den.12205; East JE, 2012, COLORECTAL DIS, V14, pE771, DOI 10.1111/codi.12014; Hamilton SR, 2010, PATHOLOGY GENETICS T, P104; Jin XF, 2012, J GASTROEN HEPATOL, V27, P882, DOI 10.1111/j.1440-1746.2011.06987.x; Kaltenbach T, 2008, GUT, V57, P1406, DOI 10.1136/gut.2007.137984; Kudo S, 2001, Gastrointest Endosc Clin N Am, V11, P519; Miyaki R, J CLIN GASTROENTEROL; Pohl J, 2009, GASTROINTEST ENDOSC, V69, P734; Sabbagh LC, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-100; Singh R, 2013, DIGEST ENDOSC, V25, P16, DOI 10.1111/den.12075; Workshop. PitP, 2003, GASTROINTEST ENDOS S, V58, pS3; Yoshida N, 2010, WORLD J GASTROENTERO, V16, P1688, DOI 10.3748/wjg.v16.i14.1688; Yoshida N, 2014, J GASTROENTEROL, V49, P73, DOI 10.1007/s00535-013-0772-7	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	SEP	2015	82	3					542	549		10.1016/j.gie.2015.01.030		8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CP0XX	WOS:000359601300019		
J	Yamaguchi, T; Kuwai, T; Iio, S; Tsuboi, A; Mori, T; Boda, K; Yamashita, K; Yamaguchi, A; Kouno, H; Kohno, H				Yamaguchi, Toshiki; Kuwai, Toshio; Iio, Sumio; Tsuboi, Akiyoshi; Mori, Takeshi; Boda, Kazuki; Yamashita, Ken; Yamaguchi, Atsushi; Kouno, Hirotaka; Kohno, Hiroshi			Endoscopic submucosal dissection using a stag beetle knife for early esophageal cancer in lower esophageal diverticula	GASTROINTESTINAL ENDOSCOPY			English	Editorial Material									[Yamaguchi, Toshiki] Natl Hosp Org Kure Med Ctr, Dept Gastroenterol, Kure, Japan; Chugoku Canc Ctr, Kure, Japan	Yamaguchi, T (reprint author), Natl Hosp Org Kure Med Ctr, Dept Gastroenterol, Kure, Japan.							0	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	SEP	2015	82	3					566	567		10.1016/j.gie.2015.04.009		2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CP0XX	WOS:000359601300022		
J	Nishizawa, T; Uraoka, T; Suzuki, H; Goto, O; Ochiai, Y; Fujimoto, A; Maehata, T; Kanai, T; Yahagi, N				Nishizawa, Toshihiro; Uraoka, Toshio; Suzuki, Hidekazu; Goto, Osamu; Ochiai, Yasutoshi; Fujimoto, Ai; Maehata, Tadateru; Kanai, Takanori; Yahagi, Naohisa			New endoscopic suturing method: slip knot clip suturing	GASTROINTESTINAL ENDOSCOPY			English	Editorial Material									[Nishizawa, Toshihiro] Keio Univ Sch Med, Div Res & Dev Minimally Invas Treatment, Canc Ctr, Div Gastroenterol & Hepatol,Dept Internal Med, Tokyo, Japan; [Uraoka, Toshio] Keio Univ Sch Med, Div Res & Dev Minimally Invas Treatment, Canc Ctr, Div Gastroenterol,Natl Hosp Org,Tokyo Med Ctr, Tokyo, Japan; [Suzuki, Hidekazu; Kanai, Takanori] Keio Univ Sch Med, Div Gastroenterol & Hepatol, Dept Internal Med, Tokyo, Japan; [Goto, Osamu; Ochiai, Yasutoshi; Fujimoto, Ai; Maehata, Tadateru; Yahagi, Naohisa] Keio Univ Sch Med, Div Res & Dev Minimally Invas Treatment, Ctr Canc, Tokyo, Japan	Nishizawa, T (reprint author), Keio Univ Sch Med, Div Res & Dev Minimally Invas Treatment, Canc Ctr, Div Gastroenterol & Hepatol,Dept Internal Med, Tokyo, Japan.		Suzuki, Hidekazu/J-4396-2013					0	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	SEP	2015	82	3					570	571		10.1016/j.gie.2015.04.012		2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CP0XX	WOS:000359601300026		
J	Harada, H; Shimizu, T; Suehiro, S; Katsuyama, Y; Hayasaka, K; Ito, H				Harada, Hideaki; Shimizu, Takanori; Suehiro, Satoshi; Katsuyama, Yasushi; Hayasaka, Kenji; Ito, Hideto			Inverted frontal view method facilitates bile duct cannulation via the intact papilla in patients with Roux-en-Y anastomosis	GASTROINTESTINAL ENDOSCOPY			English	Editorial Material									[Harada, Hideaki; Shimizu, Takanori; Suehiro, Satoshi; Katsuyama, Yasushi; Hayasaka, Kenji] New Tokyo Hosp, Dept Gastroenterol, Chiba, Japan; [Ito, Hideto] New Tokyo Hosp, Dept Surg, Chiba, Japan	Harada, H (reprint author), New Tokyo Hosp, Dept Gastroenterol, Chiba, Japan.							0	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	SEP	2015	82	3					573	574		10.1016/j.gie.2015.04.017		3	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CP0XX	WOS:000359601300029		
J	Sackett, TE; Basiliko, N; Noyce, GL; Winsborough, C; Schurman, J; Ikeda, C; Thomas, SC				Sackett, Tara E.; Basiliko, Nathan; Noyce, Genevieve L.; Winsborough, Carolyn; Schurman, Jonathan; Ikeda, Chihiro; Thomas, Sean C.			Soil and greenhouse gas responses to biochar additions in a temperate hardwood forest	GLOBAL CHANGE BIOLOGY BIOENERGY			English	Article						calcium; carbon dioxide; methane; microbial biomass; microbial respiration; nitrous oxide; nutrients; phosphorus; potassium	SUGAR MAPLE; CENTRAL ONTARIO; PONDEROSA PINE; NUTRIENT; GROWTH; CHARCOAL; RELEASE; CANADA; BLACK; PRODUCTIVITY	Biochar additions can improve soil fertility and sequester carbon, but biochar effects have been investigated primarily in agricultural systems. Biochar from spruce and maple sawdust feedstocks (with and without inorganic phosphorus in a factorial design) were added to plots in a commercially managed temperate hardwood forest stand in central Ontario, Canada; treatments were applied as a top-dressing immediately prior to fall leaf abscission in September 2011. Forests in this region have acidic, sandy soils, and due to nitrogen deposition may exhibit phosphorus, calcium, and magnesium limitation. To investigate short-term impacts of biochar application on soil nutrient supply and greenhouse gas fluxes as compared to phosphorus fertilization, data were collected over the first year after treatment application; linear mixed models were used to analyze data. Two to six weeks after treatment application, there were higher concentrations of potassium in spruce and maple biochar plots, and phosphorus in spruce biochar plots, as compared to the control treatment. There were higher concentrations of calcium, magnesium, and phosphorus in the phosphorus plots. In the following spring and summer (9-12months after treatment application), there were higher soil calcium concentrations in maple biochar plots, and phosphorus plots still had higher soil phosphorus concentrations than control plots. No treatment effects on fluxes of carbon dioxide, methane, or nitrous oxide were detected in the field; however, laboratory incubations after 12months showed higher microbial respiration in soils from maple biochar plots as compared to spruce biochar, despite no effect on microbial biomass. The results suggest that the most important short-term impact of biochar additions in this system is the increased supply of the limiting plant nutrients phosphorus and calcium. We expect that larger changes in mineral soil physical and chemical properties will occur when the surface-applied biochar becomes incorporated into the soil after a few years.	[Sackett, Tara E.; Schurman, Jonathan; Ikeda, Chihiro; Thomas, Sean C.] Univ Toronto, Fac Forestry, Toronto, ON, Canada; [Basiliko, Nathan] Laurentian Univ, Dept Biol, Sudbury, ON P3E 2C6, Canada; [Basiliko, Nathan] Laurentian Univ, Vale Living Lakes Ctr, Sudbury, ON P3E 2C6, Canada; [Basiliko, Nathan; Noyce, Genevieve L.; Winsborough, Carolyn] Univ Toronto, Dept Geog, Toronto, ON M5S 1A1, Canada; [Ikeda, Chihiro] Kyoto Univ, Grad Sch Agr, Kyoto, Kyoto, Japan	Thomas, SC (reprint author), Univ Toronto, Fac Forestry, 33 Willcocks St, Toronto, ON, Canada.	sc.thomas@utoronto.ca			Canadian National Science and Engineering Research Council; Ontario Centres of Excellence	We thank Haliburton Forest and Wildlife Reserve and Dr. Peter Schleifenbaum for field site access, subsidized field housing, and providing equipment, feedstock and personnel for biochar synthesis. Kira Borden, Owen Brokenshire, Malcom Cockwell, Nigel Gale, Matt Garmon, Mary Grunstra, Maciej Jamrozic, Kaitlyn Loukes, Michael McTavish, and Leo Rocca assisted with the pyrolizer, field work, and GC measurements. We thank the two anonymous reviewers who provided valuable comments that greatly improved the manuscript. We acknowledge the Canadian Air and Precipitation Monitoring Network (CAP-MoN) and the NAtChem Database and Analysis Facility (Precipitation data) for access to the nitrate deposition data used in this publication. We thank Western Ag Innovations for providing PRS (TM)-probes at a discount. This project was funded through grants from the Canadian National Science and Engineering Research Council and the Ontario Centres of Excellence.	Amonette J.E., 2009, BIOCHAR ENV MANAGEME, P33; Novak JM, 2009, SOIL SCI, V174, P105, DOI 10.1097/SS.0b013e3181981d9a; Robertson SJ, 2012, CAN J SOIL SCI, V92, P329, DOI 10.4141/CJSS2011-066; Lehmann J, 2007, FRONT ECOL ENVIRON, V5, P381, DOI 10.1890/1540-9295(2007)5[381:BITB]2.0.CO;2; Silber A, 2010, ENVIRON SCI TECHNOL, V44, P9318, DOI 10.1021/es101283d; Lehmann J, 2003, PLANT SOIL, V249, P343, DOI 10.1023/A:1022833116184; SMITH NJH, 1980, ANN ASSOC AM GEOGR, V70, P553, DOI 10.1111/j.1467-8306.1980.tb01332.x; Hart S, 2013, J APPL ECOL, V50, P1197, DOI 10.1111/1365-2664.12136; Biederman LA, 2013, GCB BIOENERGY, V5, P202, DOI 10.1111/gcbb.12037; Wang JM, 2013, BIOGEOSCIENCES, V10, P4371, DOI 10.5194/bg-10-4371-2013; Berglund LM, 2004, SOIL BIOL BIOCHEM, V36, P2067, DOI 10.1016/j.soilbio.2004.06.005; Gradowski T, 2006, FOREST ECOL MANAG, V226, P104, DOI 10.1016/j.foreco.2005.12.062; Spokas KA, 2011, CHEMOSPHERE, V85, P869, DOI 10.1016/j.chemosphere.2011.06.108; Zhao L, 2013, J HAZARD MATER, V256, P1, DOI 10.1016/j.jhazmat.2013.04.015; Atkinson CJ, 2010, PLANT SOIL, V337, P1, DOI 10.1007/s11104-010-0464-5; Lehmann J, 2011, SOIL BIOL BIOCHEM, V43, P1812, DOI 10.1016/j.soilbio.2011.04.022; Jones DL, 2011, SOIL BIOL BIOCHEM, V43, P1723, DOI 10.1016/j.soilbio.2011.04.018; Smith JL, 2010, SOIL BIOL BIOCHEM, V42, P2345, DOI 10.1016/j.soilbio.2010.09.013; Crane-Droesch A, 2013, ENVIRON RES LETT, V8, DOI 10.1088/1748-9326/8/4/044049; Singh B, 2010, AUST J SOIL RES, V48, P516, DOI 10.1071/SR10058; Gundale MJ, 2006, FOREST ECOL MANAG, V231, P86, DOI 10.1016/j.foreco.2006.05.004; DeLuca TH, 2006, SOIL SCI SOC AM J, V70, P448, DOI 10.2136/sssaj2005.0096; Kloss S, 2012, J ENVIRON QUAL, V41, P990, DOI 10.2134/jeq2011.0070; Major J, 2010, GLOBAL CHANGE BIOL, V16, P1366, DOI 10.1111/j.1365-2486.2009.02044.x; Zimmerman AR, 2011, SOIL BIOL BIOCHEM, V43, P1169, DOI 10.1016/j.soilbio.2011.02.005; Quilliam RS, 2012, AGR ECOSYST ENVIRON, V158, P192, DOI 10.1016/j.agee.2012.06.011; Liu XY, 2013, PLANT SOIL, V373, P583, DOI 10.1007/s11104-013-1806-x; Jeffery S, 2011, AGR ECOSYST ENVIRON, V144, P175, DOI 10.1016/j.agee.2011.08.015; Roberts KG, 2010, ENVIRON SCI TECHNOL, V44, P827, DOI 10.1021/es902266r; Gradowski T, 2008, TREE PHYSIOL, V28, P173; Glaser B, 2001, NATURWISSENSCHAFTEN, V88, P37, DOI 10.1007/s001140000193; Brewer CE, 2011, BIOENERG RES, V4, P312, DOI 10.1007/s12155-011-9133-7; Angst TE, 2013, GCB BIOENERGY, V5, P221, DOI 10.1111/gcbb.12023; Wu HW, 2011, IND ENG CHEM RES, V50, P12143, DOI 10.1021/ie200679n; Schulz H, 2012, J PLANT NUTR SOIL SC, V175, P410, DOI 10.1002/jpln.201100143; Yao FX, 2010, CHEMOSPHERE, V80, P724, DOI 10.1016/j.chemosphere.2010.05.026; Major J, 2010, PLANT SOIL, V333, P117, DOI 10.1007/s11104-010-0327-0; Karer J, 2013, AGR FOOD SCI, V22, P390; Ogawa M, 2010, AUST J SOIL RES, V48, P489, DOI 10.1071/SR10006; Cross A, 2011, SOIL BIOL BIOCHEM, V43, P2127, DOI 10.1016/j.soilbio.2011.06.016; Sohi SP, 2010, ADV AGRON, V105, P47, DOI 10.1016/S0065-2113(10)05002-9; Spokas KA, 2012, J ENVIRON QUAL, V41, P973, DOI 10.2134/jeq2011.0069; Nelissen V, 2014, SOIL BIOL BIOCHEM, V70, P244, DOI 10.1016/j.soilbio.2013.12.026; Zimmerman AR, 2010, ENVIRON SCI TECHNOL, V44, P1295, DOI 10.1021/es903140c; WOOD T, 1984, SCIENCE, V223, P391, DOI 10.1126/science.223.4634.391; Borenstein M., 2011, INTRO METAANALYSIS; Calvelo P. R., 2011, ORG GEOCHEM, V42, P1331; Canadian NAtChem, 2014, CAN NAT ATM CHEM PRE; Cayuela ML, 2013, SCI REP-UK, V3, DOI 10.1038/srep01732; Clough TJ, 2013, AGRONOMY, V3, P275, DOI DOI 10.3390/AGR0N0MY3020275; DeLuca T.H., 2009, BIOCHAR ENV MANAGEME, P251; Environment Canada, 2013, 1981 2010 CLIM NORM; Fox J, 2002, R S PLUS COMPANION A, P472; HENDERSHOT WH, 1991, FERT RES, V27, P63, DOI 10.1007/BF01048609; Kim P, 2013, CHEMOSPHERE, V90, P2623, DOI 10.1016/j.chemosphere.2012.11.021; Lehmann J., 2006, MITIGATION ADAPTATIO, V11, P395, DOI DOI 10.1007/S11027-005-9006-5; Lehmann J., 2009, BIOCHAR ENV MANAGEME, P183; Moore JD, 2000, CAN J FOREST RES, V30, P725, DOI 10.1139/cjfr-30-5-725; Mukherjee A, 2013, AGRONOMY, V3, P313, DOI DOI 10.3390/AGR0N0MY3020313; OMNR, 1998, SILV GUID TOL HARDW; Peng YY, 2010, ECOSYSTEMS, V13, P1145, DOI 10.1007/s10021-010-9379-5; Pinheiro J., 2014, R PACKAGE VERSION, V3, P1; Pinheiro J. C., 2000, MIXED EFFECTS MODELS; R Core Team, 2013, R LANG ENV STAT COMP; Sackett TE, 2013, SOIL BIOL BIOCHEM, V57, P459, DOI 10.1016/j.soilbio.2012.08.015; Shaw D. M., 1967, CAN J EARTH SCI, V4, P829; Thomas SC, 2013, SILVICULTURAL MA WIN, P4; VANCE ED, 1987, SOIL BIOL BIOCHEM, V19, P703, DOI 10.1016/0038-0717(87)90052-6; VansZwieten L, 2009, BIOCHAR ENV MANAGEME, P227; Zackrisson O, 1996, OECOLOGIA, V115, P419	70	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1757-1693	1757-1707		GCB BIOENERGY	GCB Bioenergy	SEP	2015	7	5					1062	1074		10.1111/gcbb.12211		13	Agronomy; Biotechnology & Applied Microbiology; Energy & Fuels	Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels	CO7ZU	WOS:000359384500012		
J	Ker, CM; Yang, HJ; Zhang, JX; Shau, YH; Chieh, CJ; Meng, FC; Takazawa, E; You, CF				Ker, Choon-Muar; Yang, Huai-Jen; Zhang, Jianxin; Shau, Yen-Hong; Chieh, Chia-Ju; Meng, Fancong; Takazawa, Eiichi; You, Chen-Feng			Compositional and Sr-Nd-Hf isotopic variations of Baijingsi eclogites from the North Qilian orogen, China: Causes, protolith origins, and tectonic implications	GONDWANA RESEARCH			English	Article						Qilian; Eclogite; Nd isotope; Hf isotope; Protolith; Gondwana	TRACE-ELEMENT FRACTIONATION; UHP METAMORPHIC ROCKS; OCEAN MANTLE DOMAIN; MAUNA-KEA VOLCANO; INDIAN-OCEAN; NW CHINA; CLOSURE TEMPERATURE; SUBDUCTION ZONES; TIBETAN PLATEAU; HIGH-PRESSURE	Eclogites from the Baijingsi area in the North Qilian orogen at NW China were analyzed for major and trace element abundances as well as Sr, Nd, and Hf isotope ratios to evaluate the impacts from subduction processes on these compositional parameters and to reveal the complexity in protolith characteristics. The major element compositions of the Baijingsi eclogites are within the ranges for basalts. However, the absence of systematic variations among major oxides indicates varying extents of metamorphic modifications. Seven samples are characterized by profound Nb and Ta depletions. Six of them form coherent trends in the La versus Th, HFSE, and LREE plots. They are classified as the Group 1 samples. Other eight samples, referred to as the Group 2 samples, define distinct La-Zr and La-Sm trends and have flat variation patterns with slight Th-Nb-Ta-LREE depletions in the primitive mantle-normalized multiple-element diagram. Group 1 dominates the Sr-87/Sr-86-Rb-87/Sr-86, Nd-143/Nd-144-Sm-147/Nd-144 and Hf-176/Hf-177-Lu-176/Hf-177 trends for relatively larger variations in the isotope and abundance ratios. Based on the errorchron ages from the samples, closure temperatures of the isotope systems, and isotope ratio versus 1/X plots (e.g., Sr-87/Sr-86-1/Sr), it is inferred that the Rb-Sr isotope system was subjected to metamorphic modification, whereas the Sm-Nd and Lu-Hf isotope systems mainly reflect protolith characteristics. In addition to the Nb and Ta depletions, the Group 1 samples generally have epsilon(Hf)(510) values (protolith initial at 510 Ma) higher than those of MORB at a given epsilon(Nd)(510), reflecting derivation from relatively high Lu/Hf ratio sources. They also plot within the fields for arc lavas in the Ta/Yb-Th/Yb and Th-Ta-Hf/3 diagrams. All these features are consistent with derivation from protoliths of an arc origin. In contrast, the Group 2 samples have eNd(510) values slightly higher than those of the Group 1 samples at a given epsilon(Hf)(510), plotting on the low epsilon(Nd)(510) margin of the MORB field. They also deviate from the Ta/Yb-Th/Yb trend defined by MORE and OIB toward higher Th/Yb values within the fields of back-arc basin basalts. Therefore, it is inferred that the protoliths of the Group 2 samples were generated as back-arc basin basalts possibly associated with the protoliths of the Group 1 samples in a common supra-subduction zone. The epsilon(Nd)(510)-epsilon(Hf)(510) relationship of the Baijingsi eclogites shows an affinity to the Indian ocean type mantle, implying protolith generation at the southern hemisphere on the margin or a fragment of the Gondwana continent, most likely in the Qilian Block. Based on the current tectonic configuration, a southward subduction is required for protolith generation and might eclogitize the arc protoliths by subduction erosion. Alternatively, the northward subduction in a bidirectional subduction system might become dominant during the amalgamation of the Qilian Block and the North China Craton to eclogitize the arc protoliths in the Qilian Block. Resolving these two possibilities requires more petrological, geochemical, and structural evidence from the North Qilian orogen. (C) 2014 International Association for Gondwana Research. Published by Elsevier B.V. All rights reserved.	[Ker, Choon-Muar; Yang, Huai-Jen; Chieh, Chia-Ju; You, Chen-Feng] Natl Cheng Kung Univ, Dept Earth Sci, Tainan 70101, Taiwan; [Zhang, Jianxin; Meng, Fancong] Chinese Acad Geol Sci, Inst Geol, Beijing 100037, Peoples R China; [Shau, Yen-Hong] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung 80424, Taiwan; [Takazawa, Eiichi] Niigata Univ, Fac Sci, Dept Geol, Niigata 9502181, Japan; [Takazawa, Eiichi] JAMSTEC, Res & Dev Ctr Ocean Drilling Sci, Mantle & Continental Crust Drilling Res, Yokosuka, Kanagawa 2370061, Japan	Yang, HJ (reprint author), Natl Cheng Kung Univ, Dept Earth Sci, Tainan 70101, Taiwan.	hjyang@mail.ncku.edu.tw			National Science Council (NSC) of Taiwan; NSC [96-2116-M-006-007, 97-2116-M-006-008, 98-2116-M-006-013]	The authors thank Hou-Chun Liu for analyzing Hf isotope ratios, Li-Yun Huang for assistance on Sr and Nd isotope analyses, and Yi-Chi Tsau for EDS and SEM works. The authors also thank the insightful discussion with Kuo-An Tung, Yun-Hsin Liu and Tung-Hsin Su. Comments from two anonymous reviewers and editor Wen-Jiao Xiao strengthened the discussion and improved the presentation of this paper. HJY acknowledges the long-term grant support from the National Science Council (NSC) of Taiwan. This research was supported by NSC grants 96-2116-M-006-007, 97-2116-M-006-008, and 98-2116-M-006-013.	Harper GD, 2003, GEOL SOC AM BULL, V115, P771, DOI 10.1130/0016-7606(2003)115<0771:FBAPTI>2.0.CO;2; Song SG, 2004, CHINESE SCI BULL, V49, P848, DOI 10.1360/03wd0517; Zhang JX, 2012, TECTONOPHYSICS, V570, P78, DOI 10.1016/j.tecto.2012.08.018; Yang HJ, 1996, CONTRIB MINERAL PETR, V124, P1, DOI 10.1007/s004100050169; Stern CR, 2011, GONDWANA RES, V20, P284, DOI 10.1016/j.gr.2011.03.006; Eggins SM, 1997, CHEM GEOL, V134, P311, DOI 10.1016/S0009-2541(96)00100-3; Tropper P, 2005, AM MINERAL, V90, P502, DOI 10.2138/am.2005.1806; FREY FA, 1994, GEOCHIM COSMOCHIM AC, V58, P1441, DOI 10.1016/0016-7037(94)90548-7; Kelley KA, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000435; Ganguly J, 1998, SCIENCE, V281, P805, DOI 10.1126/science.281.5378.805; Rudnick RL, 2000, SCIENCE, V287, P278, DOI 10.1126/science.287.5451.278; Tung KA, 2007, CHINESE SCI BULL, V52, P2687, DOI 10.1007/s11434-007-0356-0; Song SG, 2013, GONDWANA RES, V23, P1378, DOI 10.1016/j.gr.2012.02.004; Jahn BM, 1999, INT GEOL REV, V41, P859; Zhang SQ, 2005, J PETROL, V46, P829, DOI 10.1093/petrology/egi002; Kempton PD, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2002GC000320; Jicha BR, 2004, J PETROL, V45, P1845, DOI 10.1093/petrology/egh036; Nebel O, 2007, EARTH PLANET SC LETT, V254, P377, DOI 10.1016/j.epsl.2006.11.046; SALTERS VJM, 1991, EARTH PLANET SC LETT, V104, P364, DOI 10.1016/0012-821X(91)90216-5; Xu JF, 2004, TECTONOPHYSICS, V393, P9, DOI 10.1016/j.tecto.2004.07.028; Gehrels GE, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001876; Wang W, 2010, INT J EARTH SCI, V99, P727, DOI 10.1007/s00531-009-0424-6; DUPRE B, 1983, NATURE, V303, P142, DOI 10.1038/303142a0; RUDNICK RL, 1995, REV GEOPHYS, V33, P267, DOI 10.1029/95RG01302; Yang JS, 2002, TERRA NOVA, V14, P397; Klemme S, 2002, GEOCHIM COSMOCHIM AC, V66, P3109, DOI 10.1016/S0016-7037(02)00859-1; Xiao WJ, 2013, GONDWANA RES, V23, P1316, DOI 10.1016/j.gr.2012.01.012; Song SG, 2009, J ASIAN EARTH SCI, V35, P334, DOI 10.1016/j.jseaes.2008.11.005; Zhang JX, 2007, J METAMORPH GEOL, V25, P285, DOI 10.1111/j.1525-1314.2006.00689.x; Pearce JA, 1999, J PETROL, V40, P1579, DOI 10.1093/petrology/40.11.1579; Yin A, 2007, INT GEOL REV, V49, P681, DOI 10.2747/0020-6814.49.8.681; Liu YJ, 2006, ISL ARC, V15, P187, DOI 10.1111/j.1440-1738.2006.00508.x; HART SR, 1984, NATURE, V309, P753, DOI 10.1038/309753a0; Scherer EE, 2000, GEOCHIM COSMOCHIM AC, V64, P3413, DOI 10.1016/S0016-7037(00)00440-3; Weis D, 2007, GEOCHEM GEOPHY GEOSY, V8, DOI 10.1029/2006GC001473; MEZGER K, 1992, EARTH PLANET SC LETT, V113, P397, DOI 10.1016/0012-821X(92)90141-H; Xiao YY, 2013, LITHOS, V160, P55, DOI 10.1016/j.lithos.2012.11.012; Xiao WJ, 2009, J ASIAN EARTH SCI, V35, P323, DOI 10.1016/j.jseaes.2008.10.001; BURTON KW, 1990, CONTRIB MINERAL PETR, V106, P66, DOI 10.1007/BF00306409; WOOD DA, 1980, EARTH PLANET SC LETT, V50, P11, DOI 10.1016/0012-821X(80)90116-8; John T, 2004, EARTH PLANET SC LETT, V227, P441, DOI 10.1016/j.epsl.2004.09.009; BURTON KW, 1995, EARTH PLANET SC LETT, V133, P199, DOI 10.1016/0012-821X(95)00067-M; Zhang GB, 2008, LITHOS, V104, P99, DOI 10.1016/j.lithos.2007.12.001; Pearce JA, 2006, GEOPH MONOG SERIES, V166, P63; CASTILLO P, 1988, NATURE, V336, P667, DOI 10.1038/336667a0; Tseng CY, 2009, GONDWANA RES, V16, P285, DOI 10.1016/j.gr.2009.04.003; Tung KA, 2013, PRECAMBRIAN RES, V235, P163, DOI 10.1016/j.precamres.2013.06.016; Becker H, 1999, CHEM GEOL, V160, P291, DOI 10.1016/S0009-2541(99)00104-7; Xu WC, 2007, CHINESE SCI BULL, V52, P531, DOI 10.1007/s11434-007-0082-7; Mahoney JJ, 1998, J PETROL, V39, P1285, DOI 10.1093/petrology/39.7.1285; MAHONEY JJ, 1989, J GEOPHYS RES-SOLID, V94, P4033, DOI 10.1029/JB094iB04p04033; Yang HJ, 2003, J PETROL, V44, P603, DOI 10.1093/petrology/44.4.603; HENSEN BJ, 1995, GEOLOGY, V23, P225, DOI 10.1130/0091-7613(1995)023<0225:ROIMIG>2.3.CO;2; HAWKESWORTH CJ, 1986, NATURE, V322, P356, DOI 10.1038/322356a0; Hou QY, 2006, SCI CHINA SER D, V49, P561, DOI 10.1007/s11430-006-0561-8; Xu ZQ, 2006, J ASIAN EARTH SCI, V28, P160, DOI 10.1016/j.jseaes.2005.09.016; Pearce JA, 2007, EARTH PLANET SC LETT, V260, P98, DOI [10.1016/j.epsl.2007.05.023, 10.1016/i.epsl.2007.05.023]; Becker H, 2000, CHEM GEOL, V163, P65, DOI 10.1016/S0009-2541(99)00071-6; Song SG, 2006, J PETROL, V47, P435; Xia LQ, 2003, GEOL SOC AM BULL, V115, P1510, DOI 10.1130/B25269.1; Tseng CY, 2007, CHINESE SCI BULL, V52, P2390, DOI 10.1007/s11434-007-0300-3; Wu CL, 2004, ACTA PETROL SIN, V20, P425; Vervoort JD, 1999, EARTH PLANET SC LETT, V168, P79, DOI 10.1016/S0012-821X(99)00047-3; Woodhead JD, 2001, EARTH PLANET SC LETT, V192, P331, DOI 10.1016/S0012-821X(01)00453-8; Liu YH, 2007, CHEM GEOL, V239, P64, DOI 10.1016/j.chemgeo.2006.12.005; Li SG, 1999, INT GEOL REV, V41, P1114; Kroner U, 2013, GONDWANA RES, V24, P298, DOI 10.1016/j.gr.2013.03.001; Bach W., 2003, GEOCHEMISTRY GEOPHYS, V4; Chauvel C., 1998, MINER MAG A, V62A, P310, DOI 10.1180/minmag.1998.62A.1.163; DODSON MH, 1973, CONTRIB MINERAL PETR, V40, P259, DOI 10.1007/BF00373790; DOSSO L, 1988, EARTH PLANET SC LETT, V88, P47, DOI 10.1016/0012-821X(88)90045-3; El Korh A, 2013, GONDWANA RES, V23, P880, DOI 10.1016/j.gr.2012.07.014; FENG Y. M., 1992, NW GEOSCIENCE, V13, P61; Feng Y.-M., 1996, TECTONICS OROGENESIS, P1; Fu Lipu, 1998, Tethyan Geology, V22, P46; Gehrels G., 2011, TECTONICS, V30, DOI DOI 10.1029/2011TC002868; Hawkins JW, 1995, BACKARC BASINS TECTO, P63; JAGOUTZ E, 1988, GEOCHIM COSMOCHIM AC, V52, P1285, DOI 10.1016/0016-7037(88)90282-7; Jenkin GRT, 2001, GEOCHIM COSMOCHIM AC, V65, P1141, DOI 10.1016/S0016-7037(00)00560-3; Kretz R., 1973, CAN MINERAL, V12, P1; Lee DC, 1999, SCIENCE, V285, P1052, DOI 10.1126/science.285.5430.1052; Liu YH, 2010, TERR ATMOS OCEAN SCI, V21, P277, DOI 10.3319/TAO.2009.06.12.01(TT); MAHONEY J, 1992, J GEOPHYS RES-SOL EA, V97, P19771, DOI 10.1029/92JB01424; MESCHEDE M, 1986, CHEM GEOL, V56, P207, DOI 10.1016/0009-2541(86)90004-5; Munker C., 2001, GEOCHEMISTRY GEOPHYS, V2; Murphy JB, 2006, J GEOL SOC LONDON, V163, P683, DOI 10.1144/0016-764905-108; [潘桂棠 Pan Guitang], 2002, [地质通报, Geological Bulletin of China], V21, P701; Pearce JA, 1982, OROGENIC ANDESITES R, P525; Pertermann M, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2003GC000638; Qiu F.-Q., 1984, GEOLOGICAL PAPERS QI, V14, P41; Smith AD, 2006, J ASIAN EARTH SCI, V28, P133, DOI 10.1016/j.jseaes.2005.09.014; SNEERINGER M, 1984, GEOCHIM COSMOCHIM AC, V48, P1589, DOI 10.1016/0016-7037(84)90329-6; Spear F.S., 1993, MINERALOGICAL SOC AM, V28; Staudigel H., 1996, GEOPHYS MONOGR SER, V96, P19, DOI DOI 10.1029/GM096P0019; Sun S. S., 1989, GEOL SOC SPEC PUBL, V42, P313, DOI DOI 10.1144/GSL.SP.1989.042.01.19; TAKAHASHI T., 1997, RIGAKU DENKI J, V28, P25; Tang HF, 2007, LITHOS, V95, P441, DOI 10.1016/j.lithos.2006.09.007; Tian B., 1994, VERY LOW GRADE METAM, P92; Tung KA, 2012, J ASIAN EARTH SCI, V46, P177, DOI 10.1016/j.jseaes.2011.12.006; Weis D, 1996, J GEOPHYS RES-SOL EA, V101, P13831, DOI 10.1029/96JB00410; WU HQ, 1993, J METAMORPH GEOL, V11, P523; Xia L, 1996, SIGNIFICANCE MARINE; Xu JF, 2002, EARTH PLANET SC LETT, V198, P323, DOI 10.1016/S0012-821X(02)00536-8; Xu YJ, 2010, TECTONOPHYSICS, V495, P337, DOI 10.1016/j.tecto.2010.10.001; Yang HJ, 1996, J GEOPHYS RES-SOL EA, V101, P11747, DOI 10.1029/95JB03465; YANG HJ, 1994, J GEOPHYS RES-SOL EA, V99, P15577, DOI 10.1029/94JB00895; Yang HJ, 1998, J PETROL, V39, P711; Zhao H, 2004, GEOSCIENCE, V18, p64 ; Zirakparvar NA, 2013, GONDWANA RES, V23, P931, DOI 10.1016/j.gr.2012.06.013; Zuo G., 1987, SCI GEOL SINICA, V1, P14	110	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1342-937X	1878-0571		GONDWANA RES	Gondwana Res.	SEP	2015	28	2					721	734		10.1016/j.gr.2014.06.006		14	Geosciences, Multidisciplinary	Geology	CO4ZO	WOS:000359169600014		
J	Moghadam, HS; Li, XH; Ling, XX; Stern, RJ; Khedr, MZ; Chiaradia, M; Ghorbani, G; Arai, S; Tamura, A				Moghadam, Hadi Shafaii; Li, Xian-Hua; Ling, Xiao-Xiao; Stern, Robert J.; Khedr, Mohamed Zaki; Chiaradia, Massimo; Ghorbani, Ghasem; Arai, Shoji; Tamura, Akihiro			Devonian to Permian evolution of the Paleo-Tethys Ocean: New evidence from U-Pb zircon dating and Sr-Nd-Pb isotopes of the Darrehanjir-Mashhad "ophiolites", NE Iran	GONDWANA RESEARCH			English	Article						Paleozoic ophiolites; U-Pb zircon dating; Zircon epsilon Hf(t); Komatiite; Supra-subduction zone-type magmatism	ARC/BACK-ARC ASSEMBLAGES; WESTERN KUNLUN OROGEN; PLATE TECTONIC CYCLE; IGNEOUS ROCKS; CONTINENTAL-MARGIN; SUBDUCTION ZONE; NORTHERN TIBET; BILLION YEARS; CHINA; GEOCHEMISTRY	Middle to Late Paleozoic ophiolites, which are remnants of the Paleo-Tethys Ocean, are aligned in two main zones in northern Iran: Darrehanjir-Fariman-Mashhad, and Rasht in the north and Jandagh-Anarak ophiolites to the south. Our new U-Pb zircon dating results show that the similar to 200 km long Darrehanjir-Mashhad mafic-ultramafic body is not a single ophiolite but a composite igneous complex composed of Permian pillow lavas and pelagic sediments in fault contact with a small outcrop of Devonian intrusive and ultramafic rocks. Darrehanjir intrusive rocks have U-Pb zircon ages of 380.6 +/- 3.7 Ma and 382.9 +/- 3.7 Ma respectively, similar to 100 Ma older than published ages for gabbros and radiolarites intercalated with lavas near Mashhad and Fariman. Mantle peridotites from the Devonian complex contain low Cr# spinel, similar to that in MORB-type peridotites. Devonian Darrehanjir gabbros and Permian Mashhad sequences both have boninitic and calc-alkaline signatures, respectively. The delta O-18(zircon) values from the Devonian ferrodiorite (delta O-18(zircon) similar to 4.6 +/- 0.3 parts per thousand) are slightly lower than the 5.2 to 5.4 parts per thousand expected for MORB-type zircons whereas Devonian plagiogranitic zircons mostly have delta O-18(zircon) <5 parts per thousand, perhaps reflecting involvement of hydrothermally altered crust. Similar, strongly positive values of zircon epsilon Hf(t) for plagiogranite (av. + 14.9) and ferrodiorite (av. + 13.8) indicate melt derivation from depleted asthenosphere. Darrehanjir-Mashhad ophiolitic rocks can be divided into groups with high epsilon Nd (>10.3) and low epsilon Nd (<5.4) for both Permian and Devonian suites. Most Darrehanjir-Mashhad rocks are characterized by radiogenic Pb-207/Pb-204 and Pb-208/Pb-204, indicating the involvement of subducted terrigenous sediments in the source. The Mashhad-Darrehanjir mafic-ultramafic complex demonstrates that this part of Paleo-Tethys evolved from oceanic crust formation above a subduction zone in Devonian time to accretionary convergence in Permian time. Iranian Paleozoic ophiolites and oceanic igneous complexes along with those of the Caucasus and Turkey in the west and Afghanistan, Turkmenistan and Tibet to the east, define a series of diachronous subduction-related marginal basins that were active from at least Early Devonian to Late Permian time. (C) 2014 International Association for Gondwana Research. Published by Elsevier B.V. All rights reserved.	[Moghadam, Hadi Shafaii; Li, Xian-Hua; Ling, Xiao-Xiao] Chinese Acad Sci, Inst Geol & Geophys, State Key Lab Lithospher Evolut, Beijing 100029, Peoples R China; [Moghadam, Hadi Shafaii] Damghan Univ, Sch Earth Sci, Damghan 3671641167, Iran; [Stern, Robert J.] Univ Texas Dallas, Dept Geosci, Richardson, TX 75083 USA; [Khedr, Mohamed Zaki; Arai, Shoji; Tamura, Akihiro] Kanazawa Univ, Dept Earth Sci, Kanazawa, Ishikawa 9201192, Japan; [Khedr, Mohamed Zaki] Kafrelsheikh Univ, Fac Sci, Dept Geol, Kafr Al Sheikh, Egypt; [Chiaradia, Massimo; Ghorbani, Ghasem] Univ Geneva, Dept Mineral, Geneva, Switzerland	Moghadam, HS (reprint author), Chinese Acad Sci, Inst Geol & Geophys, Beijing 100029, Peoples R China.	hadishafaii@mail.iggcas.ac.cn			Chinese Academy of Sciences [XDB03010800]; State Key Laboratory of Lithospheric Evolution, IGG-CAS; project "continental construction in Central Asia" [592]	This research was supported by the "Strategic Priority Research Program (B)" of the Chinese Academy of Sciences (Grant no. XDB03010800) to XHL and the State Key Laboratory of Lithospheric Evolution, IGG-CAS to HSM. We are very grateful to A. Zanchi and Y. Eyuboglu for their constructive reviews of the manuscript. We thank Dr. Inna Safonova (associated editor) for her helpful comments which enhanced the scientific value of this paper. This is a contribution to IGCP#592 project "continental construction in Central Asia". We wish also to acknowledge Y.X. Xiang and Q.L. Li for their assistance during geochemical analyses and SIMS dating.	Aharipour R, 2010, FACIES, V56, P279, DOI 10.1007/s10347-009-0200-x; ALAVI M, 1991, GEOL SOC AM BULL, V103, P983, DOI 10.1130/0016-7606(1991)103<0983:SASCOT>2.3.CO;2; Angiolini L, 2007, GEOLOGY, V35, P1071, DOI 10.1130/G24031A.1; Hauff F, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000421; Meng FC, 2013, GONDWANA RES, V23, P825, DOI 10.1016/j.gr.2012.06.007; Godard M, 2006, CHEM GEOL, V234, P58, DOI 10.1016/j.chemgeo.2006.04.005; SOBOLEV AV, 1993, NATURE, V363, P151, DOI 10.1038/363151a0; USTAOMER T, 1993, GEOL J, V28, P219, DOI 10.1002/gj.3350280303; Le Bas MJ, 2000, J PETROL, V41, P1467; ALABASTER T, 1982, CONTRIB MINERAL PETR, V81, P168, DOI 10.1007/BF00371294; Bagheri S, 2008, TECTONOPHYSICS, V451, P123, DOI 10.1016/j.tecto.2007.11.047; Reagan MK, 2010, GEOCHEM GEOPHY GEOSY, V11, DOI 10.1029/2009GC002871; Xiao WJ, 2005, J GEOL, V113, P687, DOI 10.1086/449326; Pearce JA, 2008, LITHOS, V100, P14, DOI 10.1016/j.lithos.2007.06.016; Grove TL, 2004, EARTH PLANET SC LETT, V219, P173, DOI 10.1016/S0012-821X(04)00002-0; Grimes CB, 2011, CONTRIB MINERAL PETR, V161, P13, DOI 10.1007/s00410-010-0519-x; Safonova I, 2014, INT GEOL REV, V56, P1051, DOI 10.1080/00206814.2014.915586; Karimpour MH, 2010, J ASIAN EARTH SCI, V37, P384, DOI 10.1016/j.jseaes.2009.11.001; Xiao WJ, 2013, GONDWANA RES, V23, P1316, DOI 10.1016/j.gr.2012.01.012; Plank T, 1998, CHEM GEOL, V145, P325, DOI 10.1016/S0009-2541(97)00150-2; Moghadam HS, 2011, GEOL MAG, V148, P762, DOI 10.1017/S0016756811000410; Safonova I, 2011, EPISODES, V34, P186; Dai JG, 2011, CHEM GEOL, V288, P133, DOI 10.1016/j.chemgeo.2011.07.011; Robert AMM, 2014, MAR PETROL GEOL, V57, P68, DOI 10.1016/j.marpetgeo.2014.05.002; THIRLWALL MF, 1994, J PETROL, V35, P819; Zhai QG, 2013, LITHOS, V168, P186, DOI 10.1016/j.lithos.2013.02.005; BOULIN J, 1988, TECTONOPHYSICS, V148, P253, DOI 10.1016/0040-1951(88)90134-5; Zhang CL, 2011, GONDWANA RES, V19, P177, DOI 10.1016/j.gr.2010.03.012; Schwab M, 2004, TECTONICS, V23, DOI 10.1029/2003TC001583; [Anonymous], 1993, GEOL SOC SPEC PUBL; HART SR, 1984, NATURE, V309, P753, DOI 10.1038/309753a0; Yu X, 2011, GONDWANA RES, V20, P485, DOI 10.1016/j.gr.2010.11.009; Jiang YH, 2008, LITHOS, V106, P323, DOI 10.1016/j.lithos.2008.08.004; Stracke A, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2001GC000223; Jian P, 2009, LITHOS, V113, P748, DOI 10.1016/j.lithos.2009.04.004; SNOW JE, 1995, GEOCHIM COSMOCHIM AC, V59, P4219, DOI 10.1016/0016-7037(95)00239-V; Zanchi A, 2009, GEOL SOC SPEC PUBL, V312, P31, DOI 10.1144/SP312.3; JOHNSON KTM, 1990, J GEOPHYS RES-SOLID, V95, P2661, DOI 10.1029/JB095iB03p02661; DICK HJB, 1984, CONTRIB MINERAL PETR, V86, P54, DOI 10.1007/BF00373711; Li XH, 2013, LITHOS, V160, P283, DOI 10.1016/j.lithos.2012.12.016; Reichow MK, 2009, EARTH PLANET SC LETT, V277, P9, DOI 10.1016/j.epsl.2008.09.030; Kusky TM, 2013, GONDWANA RES, V24, P501, DOI 10.1016/j.gr.2013.01.004; Metcalfe I, 2006, GONDWANA RES, V9, P24, DOI 10.1016/j.gr.2005.04.002; PEARCE JA, 1995, ANNU REV EARTH PL SC, V23, P251, DOI 10.1146/annurev.ea.23.050195.001343; Xiao WJ, 2012, J ASIAN EARTH SCI, V49, P1, DOI 10.1016/j.jseaes.2012.03.001; Valley JW, 2003, REV MINERAL GEOCHEM, V53, P343, DOI 10.2113/0530343; Jian P, 2009, LITHOS, V113, P767, DOI 10.1016/j.lithos.2009.04.006; [Anonymous], 1972, GEOTIMES, V17, P22; Muttoni G, 2009, GEOARABIA, V14, P17; Yang JS, 2009, J ASIAN EARTH SCI, V34, P76, DOI 10.1016/j.jseaes.2008.04.001; Garzanti E, 2002, SEDIMENT GEOL, V151, P67, DOI 10.1016/S0037-0738(01)00231-7; Fitton JG, 1997, EARTH PLANET SC LETT, V153, P197, DOI 10.1016/S0012-821X(97)00170-2; Windley BF, 2007, J GEOL SOC LONDON, V164, P31, DOI 10.1144/0016-76492006-022; Valley JW, 2005, CONTRIB MINERAL PETR, V150, P561, DOI 10.1007/s00410-005-0025-8; Su BX, 2011, GONDWANA RES, V20, P516, DOI 10.1016/j.gr.2010.11.015; Mirnejad H, 2013, LITHOS, V170, P105, DOI 10.1016/j.lithos.2013.03.003; Arculus RJ, 2003, J PETROL, V44, P929, DOI 10.1093/petrology/44.5.929; Arndt N, 1998, GEOLOGY, V26, P739, DOI 10.1130/0091-7613(1998)026<0739:WKW>2.3.CO;2; Stampfli GM, 2002, EARTH PLANET SC LETT, V196, P17, DOI 10.1016/S0012-821X(01)00588-X; Boulin J., 1980, REV GEOL DYN GEOG PH, V3, P187; Buchs DM, 2013, LITHOS, V172, P267, DOI 10.1016/j.lithos.2013.02.009; Cavosie A.J., 2009, AM MINERAL, V9, P926; Coleman R.G., 1977, MINERALS ROCKS, V12; Dilek Y., 2003, GEOLOGICAL SOC AM SP, V373, P1, DOI DOI 10.1130/0-8137-2373-6.1; Domeier M., 2014, GEOSCIENCE FRONTIERS, P1; Eftekharnezhad J., 1991, ABHANDLUNGEN GEOLOGI, V38, P89; Gamkrelidze I.P., 1999, P GEOLOGICAL I ACAD, V114, P82; Ghazi M., 2001, EOS T AM GEOPHYS UN, V82; Godard M, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000452; Hawkins J.W., 1994, P ODP SCI RESULTS, V135, P427, DOI DOI 10.2973/ODP.PROC.SR.135.136.1994; He B., 2007, EARTH PLANET SC LETT, V255, P305; Hout F., 2002, J ASIAN EARTH SCI, V21, P307; JOHNSON KTM, 1992, J GEOPHYS RES-SOL EA, V97, P9219, DOI 10.1029/92JB00701; Johnson M.C., 1999, GEOCHEM GEOPHY GEOSY, V1, P1; Kamenetsky VS, 2001, J PETROL, V42, P655, DOI 10.1093/petrology/42.4.655; Karimpour M.H., 2011, J ASIAN EARTH SCI, V37, P384; Kozur H., 1991, GEOL PALAONTOL MITT, V1, P1; Leake B, 1997, CAN MINERAL, V61, P295; Li C., 2014, INT GEOL REV, V68, DOI DOI 10.1080/00206814.2014.9132; Li C., 2014, INT GEOLOGY REV, V68; Liu X., 2013, LITHOS, V189, P185; Maruyama S., 2010, LONDON GEOLOGICAL SO, V338, P55; MCCULLOCH MT, 1981, J GEOPHYS RES, V86, P2721, DOI 10.1029/JB086iB04p02721; Mensing T. M., 2004, ISOTOPES PRINCIPLES; MIYASHIR.A, 1974, AM J SCI, V274, P321; NICOLAS A, 1989, STRUCTURE OPHIOLITES; Nicolas A., 1989, LITHOSPHERE; Zakariadze GS, 2007, GONDWANA RES, V11, P92, DOI 10.1016/j.gr.2006.05.012; PLANK T, 2007, GEOCHEM GEOPHY GEOSY, V8; Rao R., 2007, MINER PETROL, V91, P171; Rolland Y, 2011, GONDWANA RES, V20, P798, DOI 10.1016/j.gr.2011.05.007; ROSS K, 1993, NATURE, V365, P826, DOI 10.1038/365826a0; RUTTNER AW, 1993, GEOL RUNDSCH, V82, P110, DOI 10.1007/BF00563274; Safonova I.Y., 2014, GONDWANA RES, V25, P126; Sengor A. M. C., 1996, TECTONIC EVOLUTION A; Sengor A.M.C., 1988, SPECIAL PUBLICATION, V37; Shafaii Moghadam H., 2015, GONDWANA RES, V25, P575; Moghadam HS, 2014, J ASIAN EARTH SCI, V91, P19, DOI 10.1016/j.jseaes.2014.04.008; Sheikholeslami MR, 2012, J GEODYN, V61, P23, DOI 10.1016/j.jog.2012.06.010; SHERVAIS JW, 1982, EARTH PLANET SC LETT, V59, P101, DOI 10.1016/0012-821X(82)90120-0; Shi RD, 2012, GONDWANA RES, V21, P194, DOI 10.1016/j.gr.2011.05.011; Stakes D.S., 1994, P OCEAN DRILLING PRO, V139, P79; STAMPFLI G, 1991, PALAEOGEOGR PALAEOCL, V87, P373, DOI 10.1016/0031-0182(91)90142-E; Stampfli G.M., 1978, THESIS FAC SCI U GEN; Sun S. S., 1989, GEOL SOC SPEC PUBL, V42, P313, DOI DOI 10.1144/GSL.SP.1989.042.01.19; Treloar P.J., 2009, GEOLOGY, P204; VANDERLAAN SR, 1992, P OCEAN DRILLING PRO, V0125; Zanchetta S, 2009, GEOL SOC SPEC PUBL, V312, P57, DOI 10.1144/SP312.4; Zanchetta S, 2013, GONDWANA RES, V24, P1237, DOI 10.1016/j.gr.2013.02.013; Zhang YT, 2010, GONDWANA RES, V18, P596, DOI 10.1016/j.gr.2010.03.006; Zonenshain L.P., 1990, GEODYNAMICS, V21	111	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1342-937X	1878-0571		GONDWANA RES	Gondwana Res.	SEP	2015	28	2					781	799		10.1016/j.gr.2014.06.009		19	Geosciences, Multidisciplinary	Geology	CO4ZO	WOS:000359169600018		
J	Iba, Y; Sano, S; Rao, X; Fuchs, D; Chen, TG; Weis, R; Sha, JG				Iba, Yasuhiro; Sano, Shin-ichi; Rao, Xin; Fuchs, Dirk; Chen, Tingen; Weis, Robert; Sha, Jingeng			Early Jurassic belemnites from the Gondwana margin of the Southern Hemisphere -Sinemurian record from South Tibet	GONDWANA RESEARCH			English	Article						Belemnites; Sinemurian; Tibet; Gondwana; Southern Hemisphere; Paleobiogeography		Belemnites (Order Belemnitida), a very successful group of Mesozoic coleoid cephalopods, dominated fossil coleoid assemblages throughout the Jurassic and Cretaceous. According to the current view, the phylogenetically earliest known belemnites have been reported from the lowermost Jurassic (Hettangian) of northern Europe. The earliest belemnites are characterized by low diversity and small-sized rostra. Their distribution has until recently been assumed to be restricted to northern Europe until the Pliensbachian. Early belemnites (the Sinobelemnitidae and the Belemnitina) are now also known from the Late Triassic of China and the Hettangian-Sinemurian of Japan, and therefore from the eastern Tethys and western Paleo-Pacific oceans. It has been suggested that the distribution of belemnites became more widespread and expanded to the Southern Hemisphere for the first time in the Toarcian. Here we re-describe a Sinemurian belemnite from South Tibet, which was located at the Gondwana margin at that time. The specimen is characterized by a long rostrum with one deep and long alveolar groove with a splitting surface, whose position cannot be determined as being either dorsal or ventral. This morphological feature allows an assignment of the re-described rostrum to either the Sinobelemnitidae or the Pachybelemnopseina. The Sinemurian belemnite from Tibet represents the earliest firm record of the Belemnitida from the Southern Hemisphere, suggesting that the wide distribution and diversification of this order was established much earlier than previously thought. (C) 2014 Published by Elsevier B.V. on behalf of International Association for Gondwana Research.	[Iba, Yasuhiro; Fuchs, Dirk] Hokkaido Univ, Dept Nat Hist Sci, Kita Ku, Sapporo, Hokkaido 0600810, Japan; [Sano, Shin-ichi] Fukui Prefectural Dinosaur Museum, Fukui 9118601, Japan; [Rao, Xin; Chen, Tingen; Sha, Jingeng] Chinese Acad Sci, Nanjing Inst Geol & Palaeontol, State Key Lab Palaeobiol & Stratig, Nanjing 210008, Jiangsu, Peoples R China; [Weis, Robert] Museum Natl Hist Nat, L-2169 Luxembourg, Luxembourg	Iba, Y (reprint author), Hokkaido Univ, Dept Nat Hist Sci, Kita Ku, N10W8, Sapporo, Hokkaido 0600810, Japan.	iba@mail.sci.hokudai.ac.jp			Japan Society for the Promotion of Science [25800285]; Chinese Academy of Sciences [XDB03010101]	This work was supported by a research grant from the Japan Society for the Promotion of Science (no. 25800285 for Y.I.) and the "Strategic Priority Research Program (B)" of the Chinese Academy of Sciences (no. XDB03010101 for J.S.). We thank Zhouqing Chen for taking photo of the specimen.	Iba Y, 2012, GEOLOGY, V40, P911, DOI 10.1130/G33402.1; Weis Robert, 2012, Palaeodiversity, P13; DOYLE P, 1993, LETHAIA, V26, P65, DOI 10.1111/j.1502-3931.1993.tb01513.x; Rexfort A, 2006, EARTH PLANET SC LETT, V247, P212, DOI 10.1016/j.epsl.2006.04.025; Doyle P, 1997, ALCHERINGA, V21, P219, DOI 10.1080/03115519708619175; Bather F. A., 1888, Annals of Natural History, V(6), P298; Blakey R., 2010, MOLLWEIDE PLATE TECT; Bureau of Geology and Mineral Resources of Xizang Autonomous Region, 1993, GEOLOGICAL MEMORIS 1, V31; Chen T., 1982, PALAEONTOLOGY OF XIZ, V4, P282; Chen T.-e., 1982, Acta Palaeontologica Sinica, V21, P181; Christensen Walter Kegel, 2002, Berliner Palaeobiologische Abhandlungen, V1, P18; Doyle Peter, 1991, Geologica Romana, V27, P347; Doyle P., 1994, University of Kansas Paleontological Contributions New Series, V5, P1; Doyle P., 1993, FOSS REC, V2, P229; Doyle Peter, 1994, Palaeopelagos Special Publication, V1, P109; Doyle P., 1992, MONOGRAPH PALAEONTOG, V145, P50; DOYLE P, 1987, PALAEOGEOGR PALAEOCL, V61, P237, DOI 10.1016/0031-0182(87)90052-6; Howarth M.K., 2013, TREATISE INVERTE B 1, V3B; Iba Y., 2014, PALEONTOLOG IN PRESS; Iba Y, 2011, GEOLOGY, V39, P483, DOI 10.1130/G31724.1; Iba Y., 2014, TREATISE B IN PRESS; Iba Y., 2014, PLOS ONE; Jeletzky J.A., 1980, Geological Survey of Canada Bulletin, V338, P1; Kostak M., 2004, GEOLINES, V18, P59; Mariotti Nino, 2007, Geologica Romana, V40, P1; Mutterlose J, 1998, PALAEOGEOGR PALAEOCL, V144, P161, DOI 10.1016/S0031-0182(98)00081-9; Riegraf W., 1999, PALAEONTOL Z, V73, P56; Riegraf W., 1980, NEUES JB GEOLOGIE PA, V169, P128; Sachs V.N., 1975, T I GEOLOGIYA GEOFIZ, V239, P1; Sanders M.T., 2014, PALAONTOLOG IN PRESS; Stevens G.R., 1964, PALAEONTOLOGY, V7, P606; Wang Y., 1981, PALEONT XIZANG BK, V3, P310; Weis Robert, 2007, Acta Universitatis Carolinae Geologica, V49, P181; Wu S, 1982, CONTRIBUTIONS GEOLOG, V10, P113; Yin J, 2010, JURASSIC AMMONITES T; Yin Jia-run, 1996, Acta Palaeontologica Sinica, V35, P72; Yokoyama M, 1904, J COLL SCI IMP U TOK, V18, P1; Zhang Q, 1985, CONTRIBUTION GEOLOGY, V16, P166; Zhu K.-y., 1984, Acta Palaeontologica Sinica, V23, P300; Zittel K.A.V, 1895, GRUNDZOGE PALAEONTOL	40	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1342-937X	1878-0571		GONDWANA RES	Gondwana Res.	SEP	2015	28	2					882	887		10.1016/j.gr.2014.06.007		6	Geosciences, Multidisciplinary	Geology	CO4ZO	WOS:000359169600025		
J	Masuda, M; Matsuo, M; Aso, T; Kiyohara, H; Rikimaru, F; Kunitake, N; Higaki, Y				Masuda, Muneyuki; Matsuo, Mioko; Aso, Takeichiro; Kiyohara, Hideyuki; Rikimaru, Fumihide; Kunitake, Naonobu; Higaki, Yuichiro			Utility of algorithm-based chemoradioselection in the treatment for advanced hypopharyngeal carcinoma	HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK			English	Article						chemoradioselection; laryngoesophageal dysfunction; therapeutic ratio; toxicity	ADVANCED LARYNGEAL-CANCER; LOCOREGIONALLY ADVANCED HEAD; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED LARYNX; NECK-CANCER; INDUCTION CHEMOTHERAPY; ORGAN PRESERVATION; CONCURRENT CHEMORADIOTHERAPY; RANDOMIZED-TRIAL; FLUOROURACIL	BackgroundCurrent organ-preserving dose-intensified modalities have apparently reached the limit of human tolerance. To optimize the therapeutic ratio, we evaluated the utility of a chemoradioselection strategy for the treatment of advanced hypopharyngeal carcinoma. MethodsFifty-five patients with advanced hypopharyngeal carcinoma were enrolled in our algorithm-based protocol. After 40 Gy of concurrent chemoradiation therapy (CCRT), patients who were chemoradioselected (chemoradioselected group, complete response [CR] at the primary site) received further 30 Gy of CCRT up to 70 Gy, whereas the remaining nonchemoradioselected (nonchemoradioselected group) patients underwent radical surgery. ResultsBased on this algorithm, 27 patients were chemoradioselected and 28 nonchemoradioselected. The 5-year cumulative disease-specific and overall survival (OS) rates were 76% and 65%, respectively. The chemoradioselected group demonstrated favorable laryngoesophageal dysfunction-free survival (77% at 3 years). ConclusionAlthough preliminary, our results indicate that algorithm-based chemoradioselection may provide a novel platform for improving the treatment of advanced hypopharyngeal carcinoma by providing the complete advantages of CCRT and radical surgical resection. (c) 2014 Wiley Periodicals, Inc. Head Neck 37: 1290-1296, 2015	[Masuda, Muneyuki; Matsuo, Mioko; Aso, Takeichiro; Kiyohara, Hideyuki; Rikimaru, Fumihide; Higaki, Yuichiro] Kyushu Natl Canc Ctr, Dept Head & Neck Surg, Minami Ku, Fukuoka 8111395, Japan; [Kunitake, Naonobu] Kyushu Natl Canc Ctr, Dept Radiol, Minami Ku, Fukuoka 8111395, Japan	Masuda, M (reprint author), Kyushu Natl Canc Ctr, Dept Head & Neck Surg, Minami Ku, 3-1-1 Notame, Fukuoka 8111395, Japan.	masuda.m@nk-cc.go.jp			 [24592600]	Contract grant sponsor: This study was supported, in part, by Grants-in-Aid for Scientific Research (C): 24592600 to Muneyuki Masuda.	Posner MR, 2009, ANN ONCOL, V20, P921, DOI 10.1093/annonc/mdn752; Lefebvre JL, 2009, INT J RADIAT ONCOL, V73, P1293, DOI 10.1016/j.ijrobp.2008.10.047; Lefebvre JL, 2009, J NATL CANCER I, V101, P142, DOI 10.1093/jnci/djn460; Argiris A, 2004, CLIN CANCER RES, V10, P1956, DOI 10.1158/1078-0432.CCR-03-1077; Adelstein DJ, 2006, J CLIN ONCOL, V24, P1064, DOI 10.1200/JCO.2005.01.5867; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; Hanna GJ, 2013, ONCOLOGIST, V18, P288, DOI 10.1634/theoncologist.2012-0286; Machtay M, 2008, J CLIN ONCOL, V26, P3582, DOI 10.1200/JCO.2007.14.8841; Urba S, 2006, J CLIN ONCOL, V24, P593, DOI 10.1200/JCO.2005.01.2047; Corry J, 2010, LANCET ONCOL, V11, P287, DOI 10.1016/S1470-2045(09)70384-5; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; Pointreau Y, 2009, J NATL CANCER I, V101, P498, DOI 10.1093/jnci/djp007; Forastiere AA, 2013, J CLIN ONCOL, V31, P845, DOI 10.1200/JCO.2012.43.6097; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; Lorch JH, 2011, LANCET ONCOL, V12, P153, DOI [10.1016/S1470-2045(10)70279-5, 10.1016/S1420-2045(10)20279-5]; Worden FP, 2008, J CLIN ONCOL, V26, P3138, DOI 10.1200/JCO.2007.12.7597; Haddad R, 2013, LANCET ONCOL, V14, P257, DOI 10.1016/S1470-2045(13)70011-1; Cohen EEW, 2012, J CLIN ONCOL, V30; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; Hirata K, 1999, CLIN CANCER RES, V5, P2000; Kumamoto Y, 2002, HEAD NECK-J SCI SPEC, V24, P637, DOI 10.1002/hed.10114; Masuda M, 2013, MOL ONCOL, V7, P14, DOI 10.1016/j.molonc.2012.10.009; Masuda M, 2012, NECK DISSECTION CLIN; Nonoshita T, 2010, J RADIAT RES, V51, P481, DOI 10.1269/jrr.09134; Ohnishi K, 2010, J RADIAT RES, V52, P47; Posner MR, 2010, ANN ONCOL, V21, P246, DOI 10.1093/annonc/mdq291; Psyrri A, 2004, J CLIN ONCOL, V22, P3061, DOI 10.1200/JCO.2004.01.108; WOLF GT, 1991, NEW ENGL J MED, V324, P1685; Worden FP, 2009, LARYNGOSCOPE, V119, P1510, DOI 10.1002/lary.20294	29	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1043-3074	1097-0347		HEAD NECK-J SCI SPEC	Head Neck-J. Sci. Spec. Head Neck	SEP	2015	37	9					1290	1296		10.1002/hed.23759		7	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	CP0ZN	WOS:000359605700013		
J	Singer, S; Araujo, C; Arraras, JI; Baumann, I; Boehm, A; Herlofson, BB; Silva, JC; Chie, WC; Fisher, S; Guntinas-Lichius, O; Hammerlid, E; Irarrazaval, ME; Hjermstad, MJ; Jensen, K; Kiyota, N; Licitra, L; Nicolatou-Galitis, O; Pinto, M; Santos, M; Schmalz, C; Sherman, AC; Tomaszewska, IM; de Leeuw, IV; Yarom, N; Zotti, P; Hofmeister, D				Singer, Susanne; Araujo, Claudia; Arraras, Juan Ignacio; Baumann, Ingo; Boehm, Andreas; Herlofson, Bente Brokstad; Silva, Joaquim Castro; Chie, Wei-Chu; Fisher, Sheila; Guntinas-Lichius, Orlando; Hammerlid, Eva; Irarrazaval, Maria Elisa; Hjermstad, Marianne Jensen; Jensen, Kenneth; Kiyota, Naomi; Licitra, Lisa; Nicolatou-Galitis, Ourania; Pinto, Monica; Santos, Marcos; Schmalz, Claudia; Sherman, Allen C.; Tomaszewska, Iwona M.; de Leeuw, Irma Verdonck; Yarom, Noam; Zotti, Paola; Hofmeister, Dirk		EORTC Qual Life Grp; EORTC Head & Neck Cancer Grp	Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ-H&N Module, Phase III	HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK			English	Article						head and neck neoplasms; larynx; pharynx; oral cavity; multimodal therapies; chemoradiation; quality of life	EUROPEAN-ORGANIZATION; PSYCHOMETRIC VALIDATION; CLINICAL-TRIALS; QUESTIONNAIRE; QLQ-H-AND-N35; QLQ-C30; ONCOLOGY; PROGRESS; VERSION; HEALTH	BackgroundThe objective of this study was to pilot test an updated version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module (EORTC QLQ-H&N60). MethodsPatients with head and neck cancer were asked to complete a list of 60 head and neck cancer-specific items comprising the updated EORTC head and neck module and the core questionnaire EORTC QLQ-C30. Debriefing interviews were conducted to identify any irrelevant items and confusing or upsetting wording. ResultsInterviews were performed with 330 patients from 17 countries, representing different head and neck cancer sites and treatments. Forty-one of the 60 items were retained according to the predefined EORTC criteria for module development, for another 2 items the wording was refined, and 17 items were removed. ConclusionThe preliminary EORTC QLQ-H&N43 can now be used in academic research. Psychometrics will be tested in a larger field study. (c) 2014 Wiley Periodicals, Inc. Head Neck 37: 1358-1367, 2015	[Singer, Susanne] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Med Biostat Epidemiol & Informat, Div Epidemiol & Hlth Serv Res, D-55131 Mainz, Germany; [Araujo, Claudia] Inst Portugues Oncol Francisco Gentil Porto, Dept Surg Oncol, Head & Neck Unit, Oporto, Portugal; [Arraras, Juan Ignacio] Complejo Hosp Navarra, Dept Oncol, Pamplona, Spain; [Baumann, Ingo] Heidelberg Univ, Dept Otolaryngol Head & Neck Surg, Heidelberg, Germany; [Boehm, Andreas] Univ Leipzig, Dept Otolaryngol Head & Neck Surg, D-04109 Leipzig, Germany; [Herlofson, Bente Brokstad] Univ Oslo, Fac Dent, Dept Oral Surg & Oral Med, Oslo, Norway; [Silva, Joaquim Castro] Inst Portugues Oncol Francisco Gentil Porto, Dept Otolaryngol Head & Neck Surg, Oporto, Portugal; [Chie, Wei-Chu] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Coll Publ Hlth, Taipei, Taiwan; [Fisher, Sheila] Univ Leeds, Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England; [Guntinas-Lichius, Orlando] Jena Univ Hosp, Otorhinolaryngol Clin, Jena, Germany; [Hammerlid, Eva] Sahlgrens Univ Hosp, Dept Otolaryngol & Head & Neck Surg, Gothenburg, Sweden; [Irarrazaval, Maria Elisa] Fdn Arturo Lopez Perez, Qual Life Dept, Inst Oncol, Santiago, Chile; [Hjermstad, Marianne Jensen] Univ Oslo, Dept Oncol, Reg Ctr Excellence Palliat Care, Oslo, Norway; [Hjermstad, Marianne Jensen] Norwegian Univ Sci & Technol, European Palliat Care Res Ctr, Dept Canc Res & Mol Med, N-7034 Trondheim, Norway; [Jensen, Kenneth] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark; [Kiyota, Naomi] Kobe Univ Hosp, Dept Med Oncol & Hematol, Kobe, Hyogo, Japan; [Licitra, Lisa] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy; [Nicolatou-Galitis, Ourania] Univ Athens, Sch Dent, Clin Hosp Dent, Dent Oncol Unit, Athens, Greece; [Pinto, Monica] IRCCS, Ist Nazl Studio & Cura Tumori, Fdn Giovanni Pascale, Deapartment Qual Life, Naples, Italy; [Santos, Marcos] Brasilia Univ Hosp, Dept Radiat Oncol, Brasilia, DF, Brazil; [Schmalz, Claudia] Univ Hosp Schleswig Holstein, Dept Radiat Therapy, Kiel, Germany; [Sherman, Allen C.] Univ Arkansas Med Sci, Winthrop P Rockefeller Canc Inst, Div Behav Med, Little Rock, AR 72205 USA; [Tomaszewska, Iwona M.] Jagiellonian Univ, Coll Med, Dept Med Didact, Krakow, Poland; [de Leeuw, Irma Verdonck] Vrije Univ Amsterdam, Med Ctr, Dept Otolaryngol Head & Neck Surg, Amsterdam, Netherlands; [de Leeuw, Irma Verdonck] Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands; [Yarom, Noam] Chaim Sheba Med Ctr, Dept Oral & Maxillofacial Surg, IL-52621 Tel Hashomer, Israel; [Yarom, Noam] Tel Aviv Univ, Sch Dent Med, Dept Oral Pathol & Oral Med, IL-69978 Tel Aviv, Israel; [Zotti, Paola] CRO Aviano, Dept Psychol, Natl Canc Inst, Aviano, Italy; [Hofmeister, Dirk] Univ Leipzig, Dept Med Psychol, D-04109 Leipzig, Germany	Singer, S (reprint author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Med Biostat Epidemiol & Informat, Div Epidemiol & Hlth Serv Res, Obere Zahlbacher Str 69, D-55131 Mainz, Germany.	singers@uni-mainz.de		Chie, Wei-Chu/0000-0001-5584-6554	EORTC Quality of Life Group	Contract grant sponsor: This project was kindly supported by a grant from the EORTC Quality of Life Group.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Arraras JI, 2007, PSYCHO-ONCOL, V16, P249, DOI 10.1002/pon.1047; Singer S, 2013, QUAL LIFE RES, V22, P1927, DOI 10.1007/s11136-012-0325-1; Greimel ER, 2006, CANCER, V107, P1812, DOI 10.1002/cncr.22217; Hanna E, 2004, ARCH OTOLARYNGOL, V130, P875, DOI 10.1001/archotol.130.7.875; Bjordal K, 2000, EUR J CANCER, V36, P1796, DOI 10.1016/S0959-8049(00)00186-6; Curran D, 2007, J CLIN ONCOL, V25, P2191, DOI 10.1200/JCO.2006.08.8005; Bjordal K, 1999, J CLIN ONCOL, V17, P1008; BJORDAL K, 1992, ACTA ONCOL, V31, P311; Bottomley A, 2002, EUR J CANCER, V38, P1611, DOI 10.1016/S0959-8049(02)00125-9; Cull A, 2001, EUR J CANCER, V37, P47, DOI 10.1016/S0959-8049(00)00369-5; Greimel E, 2011, EUR J CANCER, V47, P183, DOI 10.1016/j.ejca.2010.08.014; Guntinas-Lichius O, 2009, J CANCER RES CLIN, V135, P901, DOI 10.1007/s00432-008-0525-9; Hjermstad MJ, 2012, EUR J CANCER, V48, P2203, DOI 10.1016/j.ejca.2012.04.003; Johnson C, 2011, GUIDELINES DEV QUEST; Singer S, 2013, HEAD NECK-J SCI SPEC, V35, P1331, DOI 10.1002/hed.23127; Velikova G., 2012, EJC Supplements, V10, P141	17	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1043-3074	1097-0347		HEAD NECK-J SCI SPEC	Head Neck-J. Sci. Spec. Head Neck	SEP	2015	37	9					1358	1367		10.1002/hed.23762		10	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	CP0ZN	WOS:000359605700022		
J	Kitazawa, Y; Ueta, H; Hunig, T; Sawanobori, Y; Matsuno, K				Kitazawa, Yusuke; Ueta, Hisashi; Huenig, Thomas; Sawanobori, Yasushi; Matsuno, Kenjiro			A novel multicolor immunostaining method using ethynyl deoxyuridine for analysis of in situ immunoproliferative response	HISTOCHEMISTRY AND CELL BIOLOGY			English	Article						EdU; Multicolor immunofluorescence staining; Rat; Immunohistology; Flow cytometry; Immunoproliferative response; T-cell dendritic cell cluster	SECONDARY LYMPHOID ORGANS; REGULATORY T-CELLS; DENDRITIC CELLS; DONOR; VIVO; ANTIBODIES; DISEASES; RAT	Immune responses are generally accompanied by antigen presentation and proliferation and differentiation of antigen-specific lymphocytes (immunoproliferation), but analysis of these events in situ on tissue sections is very difficult. We have developed a new method of simultaneous multicolor immunofluorescence staining for immunohistology and flow cytometry using a thymidine analogue, 5-ethynyl-2'-deoxyuridine (EdU). Because of the small size of azide dye using click chemistry and elimination of DNA denaturation steps, EdU staining allowed for immunofluorescence staining of at least four colors including two different markers on a single-cell surface, which is impossible with the standard 5-bromo-2'-deoxyuridine method. By using two rat models, successfully detected parameters were the cluster of differentiation antigens including phenotypic and functional markers of various immune cells, histocompatibility complex antigens, and even some nuclear transcription factors. Proliferating cells could be further sorted and used for RT-PCR analysis. This method thus enables functional in situ time-kinetic analysis of immunoproliferative responses in a distinct domain of the lymphoid organs, which are quantitatively confirmed by flow cytometry.	[Kitazawa, Yusuke; Ueta, Hisashi; Sawanobori, Yasushi; Matsuno, Kenjiro] Dokkyo Med Univ, Dept Anat Macro, Mibu, Tochigi 3210293, Japan; [Huenig, Thomas] Univ Wurzburg, Inst Virol & Immunobiol, D-97070 Wurzburg, Germany	Matsuno, K (reprint author), Dokkyo Med Univ, Dept Anat Macro, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.	kenjiro@dokkyomed.ac.jp			JSPS KAKENHI [24790200]; Dokkyo Medical University Investigator-Initiated Research [2010-1-5]	This work was supported by JSPS KAKENHI Grant Number 24790200 (Grant-in-Aid for Scientific Research (S)) and a Dokkyo Medical University Investigator-Initiated Research Grant Number 2010-1-5. The authors appreciate the excellent technical support provided by Junko Sakumoto, Keiko Sasaki, Yasuko Nonaka, and Yoko Yamada. The authors also thank Drs. Frans Kroese and Yoshikazu Sado for donating His41 mAb and anti-mouse type IV collagen Ab, respectively, and Dr. Hiromich Tsurui for advising the filter combination of the fluorescence microscope and Dr. Xiaokang Li for valuable discussion concerning effects of CD28SA and Foxp3 response.	KAMPINGA J, 1990, SCAND J IMMUNOL, V31, P699, DOI 10.1111/j.1365-3083.1990.tb02821.x; Guo FZ, 2009, J NEUROSCI, V29, P7256, DOI 10.1523/JNEUROSCI.5653-08.2009; Gottschalk RA, 2012, J IMMUNOL, V188, P976, DOI 10.4049/jimmunol.1102964; Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105; Beyersdorf N, 2005, ANN RHEUM DIS, V64, P91, DOI 10.1136/ard.2005.042564; Zhou S, 2008, INT IMMUNOL, V20, P385, DOI 10.1093/intimm/dxm153; Diermeier-Daucher S, 2009, CYTOM PART A, V75A, P535, DOI 10.1002/cyto.a.20712; Kitazawa Y, 2009, CELL TRANSPLANT, V18, P627; MATSUNO K, 1989, CELL TISSUE RES, V257, P459, DOI 10.1007/BF00221456; Matsuno K, 2010, ARCH HISTOL CYTOL, V73, P1; Park CG, 2012, J IMMUNOL METHODS, V377, P15, DOI 10.1016/j.jim.2011.12.009; Saiki T, 2001, J LEUKOCYTE BIOL, V69, P705; Sawanobori Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109995; Ueta H, 2008, HEPATOLOGY, V47, P1352, DOI [10.1002/hep.22161, 10.1002/bep.22161]	14	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0948-6143	1432-119X		HISTOCHEM CELL BIOL	Histochem. Cell Biol.	SEP	2015	144	3					195	208		10.1007/s00418-015-1329-z		14	Cell Biology; Microscopy	Cell Biology; Microscopy	CP1QJ	WOS:000359650000001		
J	Tsukamoto, M; Niimi, N; Sango, K; Takaku, S; Kanazawa, Y; Utsunomiya, K				Tsukamoto, Masami; Niimi, Naoko; Sango, Kazunori; Takaku, Shizuka; Kanazawa, Yasushi; Utsunomiya, Kazunori			Neurotrophic and neuroprotective properties of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and RhoA	HISTOCHEMISTRY AND CELL BIOLOGY			English	Article						Exendin-4; GLP-1 receptor; Adult DRG neurons; Neurite outgrowth; Survival; Insulin; RhoA; PI3 kinase inhibitor	GLUCAGON-LIKE PEPTIDE-1; MYELIN-ASSOCIATED GLYCOPROTEIN; ENHANCES NEURITE REGENERATION; SENSORY NEURONS; SIGNALING PATHWAY; DIABETIC-NEUROPATHY; ALZHEIMERS-DISEASE; KINASE INHIBITOR; SPINAL-CORD; PC12 CELLS	Glucagon-like peptide-1 (GLP-1) is thought to preserve neurons and glia following axonal injury and neurodegenerative disorders. We investigated the neurotrophic and neuroprotective properties of exendin (Ex)-4, a synthetic GLP-1 receptor (GLP-1R) agonist, on adult rat dorsal root ganglion (DRG) neurons and PC12 cells. GLP-1R was predominantly localized on large and small peptidergic neurons in vivo and in vitro, suggesting the involvement of GLP-1 in both the large and small sensory fiber functions. Ex-4 dose-dependently (1 <= 10 <= 100 nM) promoted neurite outgrowth and neuronal survival at 2 and 7 days in culture, respectively. Treatment with 100 nM Ex-4 restored the reduced neurite outgrowth and viability of DRG neurons caused by the insulin removal from the medium and suppressed the activity of RhoA, an inhibitory regulator for peripheral nerve regeneration, in PC12 cells. Furthermore, these effects were attenuated by co-treatment with phosphatidylinositol-3'-phosphate kinase (PI3K) inhibitor, LY294002. These findings imply that Ex-4 enhances neurite outgrowth and neuronal survival through the activation of PI3K signaling pathway, which negatively regulates RhoA activity. Ex-4 and other GLP-1R agonists may compensate for the reduced insulin effects on neurons, thereby being beneficial for the treatment of diabetic neuropathy.	[Tsukamoto, Masami; Niimi, Naoko; Sango, Kazunori; Takaku, Shizuka; Kanazawa, Yasushi] Tokyo Metropolitan Inst Med Sci, Former Lab Peripheral Nerve Pathophysiol, Dept Sensory & Motor Syst, Diabet Neuropathy Project,Setagaya Ku, Tokyo 1568506, Japan; [Tsukamoto, Masami; Kanazawa, Yasushi; Utsunomiya, Kazunori] Jikei Univ, Sch Med, Dept Internal Med, Div Diabet Metab & Endocrinol,Minato Ku, Tokyo 1058461, Japan	Sango, K (reprint author), Tokyo Metropolitan Inst Med Sci, Former Lab Peripheral Nerve Pathophysiol, Dept Sensory & Motor Syst, Diabet Neuropathy Project,Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan.	sango-kz@igakuken.or.jp			Ministry of Education, Science, Sports and Culture of Japan [25430056]; Nukada Institute for Medical and Biological Research, Chiba, Japan	This study was supported by a Grant-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (Grant Number: 25430056) and the fund from Nukada Institute for Medical and Biological Research, Chiba, Japan. We thank Drs. Kazuhiko Watabe, Hitoshi Kawano, and Junji Yamauchi for their helpful suggestions, Dr. Yasuo Ohashi and Statcom Co., Ltd. for helpful comments on the statistical analyses, Emiko Kawakami, Hiroko Yanagisawa, and the late Kyoko Ajiki for technical assistance, and Enago (www.enago.jp) for the English language review.	Akahori Y, 1997, NEUROREPORT, V8, P2265, DOI 10.1097/00001756-199707070-00034; Matoba K, 2010, BIOCHEM BIOPH RES CO, V402, P725, DOI 10.1016/j.bbrc.2010.10.093; Tarsa L, 2002, P NATL ACAD SCI USA, V99, P1012, DOI 10.1073/pnas.022575999; Holst JJ, 2011, CURR MED RES OPIN, V27, P547, DOI 10.1185/03007995.2010.549466; Liu JH, 2009, ACTA PHARMACOL SIN, V30, P159, DOI 10.1038/aps.2008.25; Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008; Holscher C, 2014, BIOCHEM SOC T, V42, P593, DOI 10.1042/BST20140016; Mielke JG, 2011, PROG MOL BIOL TRANSL, V98, P133, DOI 10.1016/B978-0-12-385506-0.00004-1; Perry T, 2007, EXP NEUROL, V203, P293, DOI 10.1016/j.expneurol.2006.09.028; Jolivalt CG, 2011, DIABETES OBES METAB, V13, P990, DOI 10.1111/j.1463-1326.2011.01431.x; Bomfim TR, 2012, J CLIN INVEST, V122, P1339, DOI 10.1172/JCI57256; Dergham P, 2002, J NEUROSCI, V22, P6570; Auer M, 2011, ANN ANAT, V193, P259, DOI 10.1016/j.aanat.2011.02.015; Yamamoto K, 2013, BIOMED RES INT, DOI 10.1155/2013/315848; Molliver DC, 1997, NEURON, V19, P849, DOI 10.1016/S0896-6273(00)80966-6; Himeno T, 2011, DIABETES, V60, P2397, DOI 10.2337/db10-1462; Kan M, 2012, J NEUROPATH EXP NEUR, V71, P494, DOI 10.1097/NEN.0b013e3182580673; Sango K, 2008, HISTOCHEM CELL BIOL, V130, P669, DOI 10.1007/s00418-008-0484-x; Wang DJ, 2013, DIABETES, V62, P1697, DOI 10.2337/db12-1025; Cho YM, 2014, ANNU REV PHYSIOL, V76, P535, DOI 10.1146/annurev-physiol-021113-170315; Kimura R, 2009, NEUROSCIENCE, V162, P1212, DOI 10.1016/j.neuroscience.2009.05.025; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958; McClean PL, 2011, J NEUROSCI, V31, P6587, DOI 10.1523/JNEUROSCI.0529-11.2011; Aroda VR, 2012, CLIN THER, V34, P1247, DOI 10.1016/j.clinthera.2012.04.013; Harkavyi A, 2010, BRIT J PHARMACOL, V159, P495, DOI 10.1111/j.1476-5381.2009.00486.x; Pierson CR, 2003, J NEUROPATH EXP NEUR, V62, P260; Duarte AI, 2013, BBA-MOL BASIS DIS, V1832, P527, DOI 10.1016/j.bbadis.2013.01.008; Liu WJ, 2011, BRIT J PHARMACOL, V164, P1410, DOI 10.1111/j.1476-5381.2011.01272.x; Baiou D, 2007, J COMP NEUROL, V503, P334, DOI 10.1002/cne.21389; Eickholt BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000869; FERNYHOUGH P, 1993, BRAIN RES, V607, P117, DOI 10.1016/0006-8993(93)91496-F; Gojo A, 2007, EUR J PHARMACOL, V568, P242, DOI 10.1016/j.ejphar.2007.04.011; Grote CW, 2011, EXP DIABETES RES, DOI 10.1155/2011/212571; Kanazawa Y, 2013, EXP NEUROL, V247, P438, DOI 10.1016/j.expneurol.2013.01.012; Nowicki M, 2007, J NEUROSCI RES, V85, P3053, DOI 10.1002/jnr.21422; SANGO K, 1991, NEUROSCI LETT, V129, P277, DOI 10.1016/0304-3940(91)90480-H; Sango K, 2011, J NEUROSCI RES, V89, P898, DOI 10.1002/jnr.22605; Sango K, 2002, LIFE SCI, V71, P2351, DOI 10.1016/S0024-3205(02)02040-4; Sango K, 2012, BASIC PRINCIPLES PER, P31; Sepehr A, 2009, CYTOTECHNOLOGY, V61, P73, DOI 10.1007/s10616-009-9234-8; Sugimoto K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074247; Sugimoto K, 2002, J PERIPHER NERV SYST, V7, P44, DOI 10.1046/j.1529-8027.2002.02005.x; Sun Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035883; Takaku S, 2013, NEUROCHEM INT, V62, P330, DOI 10.1016/j.neuint.2013.01.008; Zhou ZG, 2012, EXP NEUROL, V237, P126, DOI 10.1016/j.expneurol.2012.06.016	46	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0948-6143	1432-119X		HISTOCHEM CELL BIOL	Histochem. Cell Biol.	SEP	2015	144	3					249	259		10.1007/s00418-015-1333-3		11	Cell Biology; Microscopy	Cell Biology; Microscopy	CP1QJ	WOS:000359650000005		
J	Naito, M; Ohashi, A; Takahashi, T				Naito, Masako; Ohashi, Akiko; Takahashi, Tomihisa			Dexamethasone inhibits chondrocyte differentiation by suppression of Wnt/beta-catenin signaling in the chondrogenic cell line ATDC5	HISTOCHEMISTRY AND CELL BIOLOGY			English	Article						Glucocorticoid; Chondrocyte differentiation; Wnt/beta-catenin signaling; sFRP1; beta-Catenin	GLUCOCORTICOID-INDUCED OSTEOPOROSIS; PROMOTES ADIPOCYTE DIFFERENTIATION; MESENCHYMAL PROGENITOR CELLS; EMBRYONIC STEM-CELLS; MUTANT BETA-CATENIN; GROWTH-PLATE; IN-VITRO; EXPRESSION; PATHWAY; OSTEOBLASTS	Glucocorticoids (GCs) regulate proliferation and differentiation in cultured mesenchymal cells through the modulation of various molecules. However, the relationship between growth factor signaling and GCs in differentiating chondrocytes has not been elucidated. In this study, we examined the effects of Wnt/beta-catenin signaling on chondrocyte differentiation and the effects of a GC analogue, dexamethasone (Dex), on Wnt/beta-catenin signaling activity by using a chondrocyte progenitor cell line ATDC5. Western blot analysis and TCF/LEF-optimized promoter EGFP (TOPEGFP) assay showed that both beta-catenin protein levels and TCF/LEF transcription were up-regulated during insulin-transferrin-sodium selenite (ITS)-induced chondrogenic differentiation. Morphological analysis showed that TCF/LEF transcription activity was most prominent in cartilage nodule-like structures. Furthermore, a beta-catenin mutant with constitutive transcriptional activity (Delta N90) showed increased Alcian blue staining intensity and mRNA expression of Sox9, Col2a, aggrecan, Col10, and alkaline phosphatase, even in the absence of ITS stimulation. In contrast, Dex suppressed formation of ITS-induced cartilage nodule-like structures, TCF/LEF-mediated transcription, and beta-catenin protein levels. Real-time PCR analysis showed that Dex increased the mRNA expression levels of secreted frizzled-related protein 1 (sFRP1) and Axin2. Furthermore, treatment with a sFRP1 inhibitor or the Delta N90 beta-catenin mutant transfection attenuated Dex-induced suppression of cartilage matrix production by increasing Sox9 mRNA levels. These results suggest that Dex inhibits chondrocyte differentiation via down-regulation of Wnt/beta-catenin signaling, which promotes chondrocyte differentiation in ATDC5 cells.	[Naito, Masako; Ohashi, Akiko; Takahashi, Tomihisa] Nihon Univ, Sch Dent, Dept Anat, Chiyoda Ku, Tokyo 1018310, Japan; [Naito, Masako; Ohashi, Akiko; Takahashi, Tomihisa] Nihon Univ, Sch Dent, Dent Res Ctr, Div Funct Morphol, Tokyo 1018310, Japan	Naito, M (reprint author), Nihon Univ, Sch Dent, Dept Anat, Chiyoda Ku, 1-8-13 Kanda Surugadai, Tokyo 1018310, Japan.	naitou.masako@nihon-u.ac.jp			dental research center, Nihon University School of Dentistry; Graduate School of Dentistry, Nihon University; Nihon University Multidisciplinary Research Grant; Ministry of Education, Culture, Sports, Science, and Technology, Japan [25870785]	The TOPEGFP reporter plasmid was kindly provided by Dr. M. Oshima (Cancer Research Institute, Kanazawa University, Japan). The pPyCAG-EGFP-IP plasmid vector was kindly provided by Dr. H. Niwa (RIKEN Center for Developmental Biology (CDB), Japan). This work was supported in part by a research grant from the dental research center, Nihon University School of Dentistry, a grant for collaborative research from the Graduate School of Dentistry, Nihon University, a research grant from Nihon University Multidisciplinary Research Grant for 2014, and a Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (M.N., 25870785).	Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007-0910; Dao DY, 2012, J BONE MINER RES, V27, P1680, DOI 10.1002/jbmr.1639; Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652; Siebler T, 2002, BONE, V31, P457, DOI 10.1016/S8756-3282(02)00855-4; Hayashi K, 2009, BIOCHEM BIOPH RES CO, V379, P261, DOI 10.1016/j.bbrc.2008.12.035; Tamamura Y, 2005, J BIOL CHEM, V280, P19185, DOI 10.1074/jbc.M414275200; Gaur T, 2006, J CELL PHYSIOL, V208, P87, DOI 10.1002/jcp.20637; Wang FS, 2009, LIFE SCI, V85, P685, DOI 10.1016/j.lfs.2009.09.009; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Jux C, 1998, ENDOCRINOLOGY, V139, P3296, DOI 10.1210/en.139.7.3296; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Naito M, 2013, CELL TISSUE RES, V354, P761, DOI 10.1007/s00441-013-1696-5; Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198-007-0394-0; Smink JJ, 2003, J ENDOCRINOL, V177, P381, DOI 10.1677/joe.0.1770381; Itoh S, 2012, J BIOL CHEM, V287, P29227, DOI 10.1074/jbc.M112.372086; Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025; Omoteyama K, 2010, BIOCHEM BIOPH RES CO, V403, P242, DOI 10.1016/j.bbrc.2010.11.023; Naito M, 2012, HISTOCHEM CELL BIOL, V138, P833, DOI 10.1007/s00418-012-1007-3; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Mushtaq T, 2002, J ENDOCRINOL, V175, P705, DOI 10.1677/joe.0.1750705; Kato S, 2009, LIFE SCI, V84, P302, DOI 10.1016/j.lfs.2008.12.011; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Nilsson O, 2005, HORM RES, V64, P157, DOI 10.1159/000088791; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Yano F, 2005, BIOCHEM BIOPH RES CO, V333, P1300, DOI 10.1016/j.bbrc.2005.06.041; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210; Fujita T, 2004, J CELL BIOCHEM, V93, P374, DOI 10.1002/jcb.20192; Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Lefebvre V, 2001, OSTEOARTHR CARTILAGE, V9, pS69, DOI 10.1053/joca.2001.0447; Silvestrini G, 2000, BONE, V26, P33, DOI 10.1016/S8756-3282(99)00245-8; Song YW, 2012, RHEUMATOL INT, V32, P3669, DOI 10.1007/s00296-011-2091-8	37	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0948-6143	1432-119X		HISTOCHEM CELL BIOL	Histochem. Cell Biol.	SEP	2015	144	3					261	272		10.1007/s00418-015-1334-2		12	Cell Biology; Microscopy	Cell Biology; Microscopy	CP1QJ	WOS:000359650000006		
J	Fujimoto, M; Basko-Plluska, JL; Shea, CR				Fujimoto, Masakazu; Basko-Plluska, Juliana L.; Shea, Christopher R.			Epstein-Barr virus-encoded RNA in-situ hybridization on non-specific ulcerative skin lesions of immunosuppressed patients	HISTOPATHOLOGY			English	Letter									[Fujimoto, Masakazu; Basko-Plluska, Juliana L.; Shea, Christopher R.] Univ Chicago Med, Dermatol Sect, Dept Med, Chicago, IL 60637 USA; [Fujimoto, Masakazu] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto 606, Japan	Fujimoto, M (reprint author), Univ Chicago Med, Dermatol Sect, Dept Med, Chicago, IL 60637 USA.						Dojcinov SD, 2010, AM J SURG PATHOL, V34, P405, DOI 10.1097/PAS.0b013e3181cf8622; Chai Chiling, 1999, Journal of Cutaneous Pathology, V26, P242, DOI 10.1111/j.1600-0560.1999.tb01837.x; de Paiva GR, 2012, HUM PATHOL, V43, P2241, DOI 10.1016/j.humpath.2012.03.016; Swerdlow S, 2008, WHO CLASSIFICATION T; TeruyaFeldstein J, 1997, BLOOD, V90, P4099	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0309-0167	1365-2559		HISTOPATHOLOGY	Histopathology	SEP	2015	67	3					416	417		10.1111/his.12644		2	Cell Biology; Pathology	Cell Biology; Pathology	CP1WW	WOS:000359669200016		
J	Nishida, A; Minegishi, M; Takeuchi, A; Awano, H; Niba, ETE; Matsuo, M				Nishida, Atsushi; Minegishi, Maki; Takeuchi, Atsuko; Awano, Hiroyuki; Niba, Emma Tabe Eko; Matsuo, Masafumi			Neuronal SH-SY5Y cells use the C-dystrophin promoter coupled with exon 78 skipping and display multiple patterns of alternative splicing including two intronic insertion events	HUMAN GENETICS			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; HUMAN SKELETAL-MUSCLE; MESSENGER-RNA; GENE-EXPRESSION; NEUROBLASTOMA-CELLS; MENTAL-RETARDATION; NONCODING RNA; BRAIN; TRANSCRIPTS; SEQUENCE	Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease caused by mutations in the dystrophin gene. One-third of DMD cases are complicated by mental retardation. Here, we used reverse transcription PCR to analyze the pattern of dystrophin transcripts in neuronal SH-SY5Y cells. Among the three alternative promoters/first exons at the 5'-end, only transcripts containing the brain cortex-specific C1 exon could be amplified. The C-transcript appeared as two products: a major product of the expected size and a minor larger product that contained the cryptic exon 1a between exons C1 and 2. At the 3'-end there was complete exon 78 skipping. Together, these findings indicate that SH-SY5Y cells have neuron-specific characteristics with regard to both promoter activation and alternative splicing. We also revealed partial skipping of exons 9 and 71. Four amplified products were obtained from a fragment covering exons 36-41: a strong expected product, two weak products lacking either exon 37 or exon 38, and a second strong larger product with a 568-bp insertion between exons 40 and 41. The inserted sequence matched the 3'-end of intron 40 perfectly. We concluded that a cryptic splice site was activated in SH-SY5Y cells to create the novel, unusually large, exon 41e (751 bp). In total, we identified seven alternative splicing events in neuronal SH-SY5Y cells, and calculated that 32 dystrophin transcripts could be produced. Our results may provide clues in the analysis of transcriptype-phenotype correlations as regards mental retardation in DMD.	[Nishida, Atsushi; Minegishi, Maki; Niba, Emma Tabe Eko; Matsuo, Masafumi] Kobegakuin Univ, Fac Rehabil, Dept Rehabil Med, Kobe, Hyogo 6512180, Japan; [Minegishi, Maki; Takeuchi, Atsuko] Kobe Pharmaceut Univ, Higashinada Ku, Kobe, Hyogo 6588558, Japan; [Awano, Hiroyuki] Kobe Univ, Grad Sch Med, Dept Pediat, Chuo Ku, Kobe, Hyogo 6500017, Japan	Matsuo, M (reprint author), Kobegakuin Univ, Fac Rehabil, Dept Rehabil Med, 518 Arise, Kobe, Hyogo 6512180, Japan.	mmatsuo@reha.kobegakuin.ac.jp			Exploratory Research from the Japan Society for the Promotion of Science; Health and Labour Sciences Research Grant for Research on Psychiatric and Neurological Diseases and Mental Health; Nervous and Mental Disorders from the Ministry of Health, Labour, and Welfare	This work was supported in part by a Grant-in-Aid for Scientific Research (B) and a Grant-in-Aid for Exploratory Research from the Japan Society for the Promotion of Science; a Health and Labour Sciences Research Grant for Research on Psychiatric and Neurological Diseases and Mental Health; and a research grant for Nervous and Mental Disorders from the Ministry of Health, Labour, and Welfare.	Agholme L, 2014, MOL CELL NEUROSCI, V58, P29, DOI 10.1016/j.mcn.2013.11.001; AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; BIEDLER JL, 1973, CANCER RES, V33, P2643; Xie HR, 2010, CHINESE MED J-PEKING, V123, P1086, DOI 10.3760/cma.j.issn.0366-6999.2010.08.021; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Mikulak J, 2012, J NEUROCHEM, V120, P699, DOI 10.1111/j.1471-4159.2011.07626.x; Daoud F, 2009, HUM MOL GENET, V18, P3779, DOI 10.1093/hmg/ddp320; Wong JJL, 2013, CELL, V154, P583, DOI 10.1016/j.cell.2013.06.052; Mount SM, 2000, AM J HUM GENET, V67, P788, DOI 10.1086/303098; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Barry G, 2014, MOL PSYCHIATR, V19, P410, DOI 10.1038/mp.2013.196; GORECKI DC, 1992, HUM MOL GENET, V1, P505, DOI 10.1093/hmg/1.7.505; BIES RD, 1992, NUCLEIC ACIDS RES, V20, P1725, DOI 10.1093/nar/20.7.1725; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; LIDOV HGW, 1995, HUM MOL GENET, V4, P329, DOI 10.1093/hmg/4.3.329; ROBERTS RG, 1993, HUM MUTAT, V2, P293, DOI 10.1002/humu.1380020409; GORECKI DC, 1995, NEUROREPORT, V6, P893, DOI 10.1097/00001756-199504190-00017; Surono A, 1999, HUM MOL GENET, V8, P493, DOI 10.1093/hmg/8.3.493; Saint Martin A, 2012, FEBS J, V279, P66, DOI 10.1111/j.1742-4658.2011.08399.x; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; Ge Y, 2014, BIOESSAYS, V36, P236, DOI 10.1002/bies.201300156; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Wang ZF, 2008, RNA, V14, P802, DOI 10.1261/rna.876308; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Cyrulnik SE, 2007, J PEDIATR-US, V150, P474, DOI 10.1016/j.jpeds.2006.12.045; Muntoni F, 2003, LANCET NEUROL, V2, P731, DOI 10.1016/S1474-4422(03)00585-4; Wang YX, 2014, NAT GENET, V46, P601, DOI 10.1038/ng.2974; Mehler MF, 2000, BRAIN RES REV, V32, P277, DOI 10.1016/S0165-0173(99)00090-9; Wein N, 2014, NAT MED, V20, P992, DOI 10.1038/nm.3628; Bolisetty MT, 2012, NUCLEIC ACIDS RES, V40, P9244, DOI 10.1093/nar/gks652; Surono A, 1997, BIOCHEM BIOPH RES CO, V239, P895, DOI 10.1006/bbrc.1997.7579; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Castle JC, 2008, NAT GENET, V40, P1416, DOI 10.1038/ng.264; Banihani R, 2015, J CHILD NEUROL, V30, P1472, DOI 10.1177/0883073815570154; Bovolenta M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045328; Clark Brian S., 2014, Frontiers in Genetics, V5, P164, DOI 10.3389/fgene.2014.00164; DSOUZA VN, 1995, HUM MOL GENET, V4, P837, DOI 10.1093/hmg/4.5.837; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; Giliberto Florencia, 2004, Neurological Research, V26, P83; Holder E, 1996, HUM GENET, V97, P232, DOI 10.1007/BF02265272; lannaccone Martina, 2013, Int J Biochem Mol Biol, V4, P102; Malueka RG, 2012, BMC GENET, V31, P13, DOI DOI 10.1186/; MATSUO M, 1991, J CLIN INVEST, V87, P2127, DOI 10.1172/JCI115244; Nishida A, 2015, J HUM GENET, V60, P327, DOI 10.1038/jhg.2015.24; Oltean S, 2013, ONCOGENE IN PRESS, DOI [10.1038/onc.2013.533, DOI 10.1038/ONC.2013.533]; REISS J, 1994, HUM MOL GENET, V3, P295, DOI 10.1093/hmg/3.2.295; ROBERTS RG, 1991, AM J HUM GENET, V49, P298; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shkreta Lulzim, 2013, Cancer Treat Res, V158, P41, DOI 10.1007/978-3-642-31659-3_3; Sironi M, 2002, FEBS LETT, V517, P163, DOI 10.1016/S0014-5793(02)02613-3; Taylor PJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008803; Torelli S, 1996, HUM GENET, V97, P521; Zhang Z, 2007, J HUM GENET, V52, P607, DOI 10.1007/s10038-007-0163-0; Zheng L, 2013, J ALZHEIMERS DIS, V37, P713, DOI 10.3233/JAD-122455	54	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-6717	1432-1203		HUM GENET	Hum. Genet.	SEP	2015	134	9					993	1001		10.1007/s00439-015-1581-2		9	Genetics & Heredity	Genetics & Heredity	CO8EY	WOS:000359399900006		
J	Brownfoot, FC; Tong, S; Hannan, NJ; Binder, NK; Walker, SP; Cannon, P; Hastie, R; Onda, K; Kaitu'u-Lino, TJ				Brownfoot, Fiona C.; Tong, Stephen; Hannan, Natalie J.; Binder, Natalie K.; Walker, Susan P.; Cannon, Ping; Hastie, Roxanne; Onda, Kenji; Kaitu'u-Lino, Tu'uhevaha J.			Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia	HYPERTENSION			English	Article						antioxidants; placenta; pregnancy; pravastatin; preeclampsia; trophoblasts	TYROSINE KINASE 1; SOLUBLE ENDOGLIN; ANTIANGIOGENIC FACTORS; OXIDATIVE STRESS; GROWTH-FACTOR; MOUSE MODEL; PREGNANCY; HYPERTENSION; EXPRESSION; DISEASE	Preeclampsia is a major pregnancy complication where excess placental release of soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin causes maternal endothelial and multisystem organ injury. Clinical trials have commenced examining whether pravastatin can be used to treat preeclampsia. However, the preclinical evidence supporting pravastatin as a treatment is limited to animal models, with almost no studies in human tissues. Therefore, we examined whether pravastatin reduced sFlt-1 and soluble endoglin secretion and decreased endothelial dysfunction in primary human tissues. Pravastatin reduced sFlt-1 secretion from primary endothelial cells, purified cytotrophoblast cells, and placental explants obtained from women with preterm preeclampsia. It increased soluble endoglin secretion from endothelial cells but did not change secretion from placental explants. The regulation of sFlt-1 by pravastatin seemed to be mediated via the 3-hydroxy-3-methylglutaryl-coenzyme A reductase cholesterol synthesis pathway. Pravastatin also reduced markers of endothelial dysfunction, including vascular cell adhesion molecule-1 expression and leukocyte adhesion on endothelial cells and increased endothelial cell migration and invasion. We also treated 4 patients with preterm preeclampsia presenting at <30 weeks of gestation with daily pravastatin. Pravastatin seemed to stabilize blood pressure, proteinuria, and serum uric acid levels. Furthermore, serum sFlt-1 levels decreased. We collected the placentas at delivery and found that pravastatin reduced sFlt-1 secretion. These results indicate that pravastatin reduced sFlt-1 and soluble endoglin production and decreased endothelial dysfunction in primary human tissues. We also present pilot data, suggesting that pravastatin can stabilize clinical and biochemical features of preterm preeclampsia. Our data obtained in human tissues support the concept that pravastatin is a candidate therapeutic for preeclampsia. Clinical Trial Registration URL: http://www.anzctr.org.au. Unique identifier: ACTRN12613000268741.	[Brownfoot, Fiona C.; Tong, Stephen; Hannan, Natalie J.; Binder, Natalie K.; Cannon, Ping; Hastie, Roxanne; Onda, Kenji; Kaitu'u-Lino, Tu'uhevaha J.] Univ Melbourne, Dept Obstet & Gynaecol, Translat Obstet Grp, Heidelberg, Vic 3084, Australia; [Walker, Susan P.] Univ Melbourne, Mercy Hosp Women, Dept Perinatal Med, Heidelberg, Vic 3084, Australia; [Onda, Kenji] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Clin Pharmacol, Hachioji, Tokyo, Japan	Brownfoot, FC (reprint author), Univ Melbourne, Translat Obstet Grp, Mercy Hosp Women, 163 Studley Rd, Heidelberg, Vic 3084, Australia.	Fiona.brownfoot@unimelb.edu.au		Kaitu'u-Lino, Tu'uhevaha/0000-0001-6233-9737; Hannan, Natalie/0000-0001-8446-2250; Walker, Susan Phillipa/0000-0001-9075-4655; Tong, Stephen/0000-0002-2319-0586; Brownfoot, Fiona/0000-0002-1473-5708	National Health and Medical Research Council of Australia (NHMRC) [1048707, 1046484]; Arthur Wilson RANZCOG scholarship; Australian Postgraduate Award; AVANT scholarship; NHMRC [1050765, 1062418, 628927]	This work was funded by the National Health and Medical Research Council of Australia (NHMRC; no. 1048707 and 1046484) and an Arthur Wilson RANZCOG scholarship. F. Brownfoot was supported by an Australian Postgraduate Award and an AVANT scholarship. The NHMRC provided salary support (no. 1050765 to S. Tong, 1062418 to T.J.K. Lino, and 628927 to N.J. Hannan).	Roberts JM, 2013, OBSTET GYNECOL, V122, P1122; Costantine MM, 2010, OBSTET GYNECOL, V116, P114, DOI 10.1097/AOG.0b013e3181e10ebd; Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)17987-2; Levine RJ, 2006, NEW ENGL J MED, V355, P992, DOI 10.1056/NEJMoa055352; Whitehead CL, 2011, BJOG-INT J OBSTET GY, V118, P1268, DOI 10.1111/j.1471-0528.2011.02962.x; Lefkou E, 2014, HYPERTENSION, V63, pE118, DOI 10.1161/HYPERTENSIONAHA.114.03115; Young BC, 2010, ANNU REV PATHOL-MECH, V5, P173, DOI 10.1146/annurev-pathol-121808-102149; Borzychowski AM, 2006, SEMIN FETAL NEONAT M, V11, P309, DOI 10.1016/j.siny.2006.04.001; Godfrey LM, 2012, ANN PHARMACOTHER, V46, P1419, DOI 10.1345/aph.1R202; Simes RJ, 2002, LANCET, V359, P1379; Jebbink J, 2011, HYPERTENSION, V58, P70, DOI 10.1161/HYPERTENSIONAHA.110.164079; Thadhani R, 2011, CIRCULATION, V124, P940, DOI 10.1161/CIRCULATIONAHA.111.034793; Chaiworapongsa T, 2014, NAT REV NEPHROL, V10, P466, DOI 10.1038/nrneph.2014.102; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726; Onda K, 2015, HYPERTENSION, V65, P855, DOI 10.1161/HYPERTENSIONAHA.114.04781; [Anonymous], 2012, STAMP TRIAL PROOF PR; Powe CE, 2011, CIRCULATION, V123, P2856, DOI 10.1161/CIRCULATIONAHA.109.853127; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Nishikawa S, 2000, LIFE SCI, V67, P1447, DOI 10.1016/S0024-3205(00)00736-0; Shaw SM, 2009, CARDIOLOGY, V112, P4, DOI 10.1159/000137692; Bauer AJ, 2013, HYPERTENSION, V61, P1103, DOI 10.1161/HYPERTENSIONAHA.111.00226; Venkatesha S, 2006, NAT MED, V12, P642, DOI 10.1038/nm1429; Kodama Y, 2006, J AM COLL CARDIOL, V48, P43, DOI 10.1016/j.jacc.2006.03.035; Kumasawa K, 2011, P NATL ACAD SCI USA, V108, P1451, DOI 10.1073/pnas.1011293108; Costantine MM, 2013, OBSTET GYNECOL, V121, P349, DOI [http://10.1097/AOG.0b013e31827d8ad5, 10.1097/AOG.0b013e31827d8ad5]; Brownfoot FC, 2014, PLACENTA, V35, P724, DOI 10.1016/j.placenta.2014.06.374; Cudmore M, 2007, CIRCULATION, V115, P1789, DOI 10.1161/CIRCULATIONAHA.106.660134; Fox KA, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.083; Gangooly S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107644; Lecarpentier E, 2012, DRUGS, V72, P773, DOI 10.2165/11632010-000000000-00000; Nachtigal P, 2009, J ATHEROSCLER THROMB, V16, P265; Nanovskaya TN, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.05.038; Nayeri UA, 2014, HYPERTENSION, V63, P1285, DOI 10.1161/HYPERTENSIONAHA.114.03173; Sanchez-Aranguren LC, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00372; Tu'uhevaha J, 2014, PREGNANCY HYPERTENSI, V4, P287; Xu B, 2009, CLIN EXP PHARMACOL P, V36, P839, DOI 10.1111/j.1440-1681.2009.05155.x	37	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0194-911X	1524-4563		HYPERTENSION	Hypertension	SEP	2015	66	3					687	697		10.1161/HYPERTENSIONAHA.115.05445		11	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CP1VO	WOS:000359664700034		
J	Tanaka, M; Kon, K; Tanaka, K				Tanaka, Motoyasu; Kon, Kazuyuki; Tanaka, Kazuo			Range-Sensor-Based Semiautonomous Whole-Body Collision Avoidance of a Snake Robot	IEEE TRANSACTIONS ON CONTROL SYSTEMS TECHNOLOGY			English	Article						Collision avoidance; inspection in narrow spaces; redundancy; snake robot; switching constraints	OBSTACLE; LOCOMOTION; TRACKING	This brief presents a control system for a snake robot based on range sensor data that semiautonomously aids the robot in avoiding collisions with obstacles. In the proposed system, an operator indicates the desired velocity of the first link of the robot using a joystick, and the joint input which accomplishes both the desired velocity of the first link and collision avoidance between subsequent links and obstacles is automatically calculated by the controller, which selects the links needed to be grounded and exploits redundancy. The controller uses real-time data from range sensors for obstacle positions. The experimental system, which has range sensors and the function generating environmental map using simultaneous localization and mapping, was developed with decreasing calculation cost, and experiments were performed to verify the effectiveness of the proposed system in unknown environments.	[Tanaka, Motoyasu; Tanaka, Kazuo] Univ Electrocommun, Dept Mech Engn & Intelligent Syst, Tokyo 1828585, Japan; [Kon, Kazuyuki] Kyoto Univ, Grad Sch Engn, Kyoto 6068501, Japan	Tanaka, M (reprint author), Univ Electrocommun, Dept Mech Engn & Intelligent Syst, Tokyo 1828585, Japan.	mtanaka@uec.ac.jp; kon.kazuyuki.3m@kyoto-u.ac.jp; ktanaka@mce.uec.ac.jp		Tanaka, Motoyasu/0000-0002-3717-8852	Japan Society for the Promotion of Science [26870198]	This work was supported by the Japan Society for the Promotion of Science through the Grants-in-Aid for Scientific Research under Grant 26870198. Recommended by Associate Editor K. Y. Pettersen.	Borenstein J, 2007, J FIELD ROBOT, V24, P601, DOI 10.1002/rob.20196; Wang CC, 2007, INT J ROBOT RES, V26, P889, DOI 10.1177/0278364907081229; Kamegawa T, 2004, IEEE INT CONF ROBOT, P5081, DOI 10.1109/ROBOT.2004.1302523; Transeth AA, 2008, IEEE T ROBOT, V24, P88, DOI 10.1109/TRO.2007.914849; Date H., 2007, P IEEE RSJ INT C INT, P3554; Hirose S., 1993, BIOL INSPIRED ROBOTS; Hitaka Y., 2012, P INT C MECH AUT IEE, P214; Kamel T., 2012, P IEEE EL COMP ENG C, P1; Kano T., 2012, BIOINSPIR BIOMIM, V7; Kimura H., 2002, P IEEE RSJ INT C INT, V1, P823; Kohlbrecher S., 2011, P IEEE INT S SAF SEC, P155; Kouno K, 2013, J ROBOT MECHATRON, V25, P559; Liljeback P, 2010, IEEE T ROBOT, V26, P781, DOI 10.1109/TRO.2010.2056211; Neumann M, 2013, IND ROBOT, V40, P246, DOI 10.1108/01439911311309942; Osuka K., 2003, P IEEE RSJ INT C INT, V4, P3373; Prautsch P., 2000, Transactions of the Institute of Electrical Engineers of Japan, Part D, V120-D; Suzuki K, 2012, IEEE INT C INT ROBOT, P4602, DOI 10.1109/IROS.2012.6385757; Tanaka M, 2014, ADV ROBOTICS, V28, P415, DOI 10.1080/01691864.2013.867285; Tanaka M, 2013, IEEE INT C INT ROBOT, P3285, DOI 10.1109/IROS.2013.6696823; Wu XD, 2013, IEEE T CONTR SYST T, V21, P2443, DOI 10.1109/TCST.2012.2237519; Yagnik D., 2010, P IEEE C MECH EMB SY, P421	21	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1063-6536	1558-0865		IEEE T CONTR SYST T	IEEE Trans. Control Syst. Technol.	SEP	2015	23	5					1927	1934		10.1109/TCST.2014.2382578		8	Automation & Control Systems; Engineering, Electrical & Electronic	Automation & Control Systems; Engineering	CP0BQ	WOS:000359541200019		
J	Yoshida, H; Wada, K				Yoshida, Hidehito; Wada, Keiji			Third-Harmonic Current Suppression for Power Distribution Systems Under Unbalanced Installation of DG Units	IEEE TRANSACTIONS ON INDUSTRIAL ELECTRONICS			English	Article						Harmonic suppression; single-phase distributed generation; third harmonic; three-phase three-wire system	ACTIVE-FILTERS; PERFORMANCE; COMPENSATION; IMPROVEMENT; TOPOLOGY	The ac/dc front-end converter in low-power applications such as household appliances usually contains diode rectifiers equipped with smoothing dc capacitors, which generate a large amount of harmonic current. As a solution for reducing the harmonic current, distributed generation (DG) units with a harmonic compensation function have become an attractive topic. In three-phase three-wire systems, the effect of the third-harmonic current is not serious, because most of the current is zero-sequence current. However, if many single-phase DG units are unevenly installed in three-phase grids, the third-harmonic currents may be serious. This paper shows that conventional harmonic suppression can increase third-harmonic currents in three-phase three-wire grids. To prevent an increase in the harmonic current, a third-harmonic suppression method called the balancing third-harmonic function is proposed. To validate the proposed control strategy, experimental results using a laboratory system are presented.	[Yoshida, Hidehito; Wada, Keiji] Tokyo Metropolitan Univ, Hachioji, Tokyo 1920397, Japan	Yoshida, H (reprint author), Tokyo Metropolitan Univ, Hachioji, Tokyo 1920397, Japan.	yoshida-hidehito@ed.tmu.ac.jp; kj-wada@tmu.ac.jp					Trinh QN, 2014, IEEE T IND ELECTRON, V61, P6528, DOI 10.1109/TIE.2014.2320218; He JW, 2014, IEEE T POWER ELECTR, V29, P642, DOI 10.1109/TPEL.2013.2255895; Fateh B, 2013, IEEE T SMART GRID, V4, P1076, DOI 10.1109/TSG.2013.2241796; Jintakosonwit P, 2003, IEEE T IND APPL, V39, P556, DOI 10.1109/TIA.2003.808959; Akagi H, 2005, P IEEE, V93, P2128, DOI 10.1109/JPROC.2005.859603; Lascu C, 2007, IEEE T POWER ELECTR, V22, P1826, DOI 10.1109/TPEL.2007.904060; Kim S, 2002, IEEE T POWER ELECTR, V17, P48; Singh B, 1999, IEEE T IND ELECTRON, V46, P960, DOI 10.1109/41.793345; He JW, 2012, IEEE T IND ELECTRON, V59, P444, DOI 10.1109/TIE.2011.2141098; Salmeron P, 2010, IEEE T POWER ELECTR, V25, P1923, DOI 10.1109/TPEL.2010.2043687; Castilla M, 2013, IEEE T IND ELECTRON, V60, P1464, DOI 10.1109/TIE.2011.2167734; Asiminoaei L, 2007, IEEE T POWER ELECTR, V22, P247, DOI 10.1109/TPEL.2006.888912; Fujita H, 2009, IEEE T POWER ELECTR, V24, P934, DOI 10.1109/TPEL.2008.2009302; Lee TL, 2015, IEEE T IND ELECTRON, V62, P746, DOI 10.1109/TIE.2014.2347008; Limongi LR, 2008, IEEE POWER ELECTRON, P2894, DOI 10.1109/PESC.2008.4592388; Litran SP, 2014, IEEE T IND ELECTRON, V61, P2648, DOI 10.1109/TIE.2013.2276078; Miret J., 2004, IEEE T POWER ELECTR, V19, P1060; Ribeiro R. L. A., 2012, IEEE T POWER ELECTR, V27, P718, DOI DOI 10.1109/TPEL.2011.2161334; Santos T., 2009, P 35 ANN IEEE IND EL, P3637; Yukihira K., 2013, IEEJ T POWER ENERG B, V133-B, P2	20	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0278-0046	1557-9948		IEEE T IND ELECTRON	IEEE Trans. Ind. Electron.	SEP	2015	62	9					5578	5585		10.1109/TIE.2015.2415766		8	Automation & Control Systems; Engineering, Electrical & Electronic; Instruments & Instrumentation	Automation & Control Systems; Engineering; Instruments & Instrumentation	CP0JE	WOS:000359560800024		
J	Uchiyama, N; Ogawa, Y; Abd El Khalick, M; Sano, S				Uchiyama, Naoki; Ogawa, Yuki; Abd El Khalick, M.; Sano, Shigenori			Energy Saving in Five-Axis Machine Tools Using Synchronous and Contouring Control and Verification by Machining Experiment	IEEE TRANSACTIONS ON INDUSTRIAL ELECTRONICS			English	Article						Contouring control; energy saving; machine tool	MULTIAXIS MOTION SYSTEMS; FEED DRIVE; BIAXIAL SYSTEMS; DESIGN; ROBOTS	This paper deals with a controller design for five-axis machine tools, which typically consist of three translational and two rotary axes. The flexibility to change the relative orientation between a tool and the workpiece in a five-axis machine tool offers many advantages over conventional 3-D machining. Because machine tools operate around the clock in industrial applications all over the world, there is a requirement not only for high-speed and high-precision operation but also for reduced energy consumption. This paper presents a novel controller design that aims to reduce energy consumption in five-axis machine tools. The proposed design is based on a contouring controller that has been proposed for use in high-precision machining in machine tool systems. The design also takes into consideration the relative orientation error between a tool and the workpiece in five-axismachining. The synchronous controller is used to reduce synchronous error between two parallel actuators, which is a cause of significant mechanical damage. The contouring control system has a degree of freedom (DOF) in the direction tangential to the desired contour curve because this directional error does not directly affect the contouring performance, and hence, this DOF is employed for consumed energy reduction in this study. The experimental results of feed drive motion (without machining) demonstrate the effectiveness of the proposed controller, which reduces energy consumption by 13.2%. In addition, after applying to the machining experiment, the effectiveness was increased to 27.9% because of largely reducing the control input variance caused by the machining task.	[Uchiyama, Naoki; Ogawa, Yuki; Sano, Shigenori] Toyohashi Univ Technol, Dept Mech Engn, Toyohashi, Aichi 4418580, Japan; [Abd El Khalick, M.] Assiut Univ, Fac Engn, Dept Mech Engn, Assiut 71515, Egypt	Uchiyama, N (reprint author), Toyohashi Univ Technol, Dept Mech Engn, Toyohashi, Aichi 4418580, Japan.	uchiyama@tut.jp			JSPS KAKENHI [24560131]	This work was supported by JSPS KAKENHI Grant 24560131.	Yeh SS, 2003, IEEE T CONTR SYST T, V11, P375, DOI 10.1109/TCST.2003.810372; Lam D, 2013, IEEE T CONTR SYST T, V21, P552, DOI 10.1109/TCST.2012.2186299; Huang WS, 2010, IEEE T IND ELECTRON, V57, P420, DOI 10.1109/TIE.2009.2034178; Halevi Y, 2011, CIRP ANN-MANUF TECHN, V60, P433, DOI 10.1016/j.cirp.2011.03.032; Mori M, 2011, CIRP ANN-MANUF TECHN, V60, P145, DOI 10.1016/j.cirp.2011.03.099; Cheng MY, 2007, IEEE T IND ELECTRON, V54, P1686, DOI 10.1109/TIE.2007.894691; Uchiyama N, 2009, INT J MACH TOOL MANU, V49, P876, DOI 10.1016/j.ijmachtools.2009.05.004; Hu CX, 2011, IEEE T IND ELECTRON, V58, P5195, DOI 10.1109/TIE.2011.2123859; Chiu GTC, 2001, IEEE T CONTR SYST T, V9, P130, DOI 10.1109/87.896754; Okwudire C, 2013, CIRP ANN-MANUF TECHN, V62, P391, DOI 10.1016/j.cirp.2013.03.139; Chen SL, 2007, IEEE T CONTR SYST T, V15, P1151, DOI [10.1109/TCST.2007.899719, 10.1109/TCS'P.2007.899719]; Chen SL, 2002, IEEE-ASME T MECH, V7, P329, DOI 10.1109/TMECH.2002.802723; Chiu GTC, 1998, J DYN SYST-T ASME, V120, P389, DOI 10.1115/1.2805413; El A. Khalick, 2015, IEEE-ASME T MECH, V20, P572; El A. Khalick, 2012, P AM CONTR C, P4594; El Khalick Mohammad Abd, 2014, IEEE Transactions on Industrial Electronics, V61, DOI 10.1109/TIE.2013.2275975; El Khalick A, 2013, INT J MACH TOOL MANU, V65, P8, DOI 10.1016/j.ijmachtools.2012.07.004; Hsieh MF, 2007, INT J ADV MANUF TECH, V34, P933, DOI 10.1007/s00170-007-1135-4; Hu CX, 2010, IEEE T IND ELECTRON, V57, P1746, DOI 10.1109/TIE.2009.2030769; Kim H, 2014, IEEE T IND ELECTRON, V61, P4771, DOI 10.1109/TIE.2013.2293706; Koren Y, 1980, ASME, V102, P265; KULKARNI PK, 1989, J ENG IND-T ASME, V111, P140; Lo C.-C., 1999, ASME J DYNAMIC SYSTE, V121, P126; McNab R. J., 1998, ASME J DYN SYST MEAS, V122, P375; Neugebauer R., 2011, CIRP J MANUFACTURING, V4, P136; Peng CC, 2007, INT J MACH TOOL MANU, V47, P1542, DOI 10.1016/j.ijmachtools.2006.11.008; Ramesh R, 2005, INT J MACH TOOL MANU, V45, P301, DOI 10.1016/j.ijmachtools.2004.08.008; Sencer B, 2009, J MANUF SCI E-T ASME, V131, DOI 10.1115/1.3123335; Tokekar P, 2011, IEEE INT CONF ROBOT, P1457; Verscheure D, 2008, AMC '08: 10TH INTERNATIONAL WORKSHOP ON ADVANCED MOTION CONTROL, VOLS 1 AND 2, PROCEEDINGS, P727; Wang G., 2005, P INT S LOW POW EL D, P215, DOI 10.1145/1077603.1077656; Wang YB, 2015, IEEE T IND ELECTRON, V62, P1175, DOI 10.1109/TIE.2014.2360077	32	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0278-0046	1557-9948		IEEE T IND ELECTRON	IEEE Trans. Ind. Electron.	SEP	2015	62	9					5608	5618		10.1109/TIE.2015.2437354		11	Automation & Control Systems; Engineering, Electrical & Electronic; Instruments & Instrumentation	Automation & Control Systems; Engineering; Instruments & Instrumentation	CP0JE	WOS:000359560800027		
J	Chen, WH; Ohnishi, K; Guo, L				Chen, Wen-Hua; Ohnishi, Kouhei; Guo, Lei			Advances in Disturbance/Uncertainty Estimation and Attenuation	IEEE TRANSACTIONS ON INDUSTRIAL ELECTRONICS			English	Editorial Material									[Chen, Wen-Hua] Univ Loughborough, Dept Aeronaut & Automot Engn, Loughborough LE11 3TU, Leics, England; [Ohnishi, Kouhei] Keio Univ, Dept Syst Design Engn, Yokohama, Kanagawa 2238522, Japan; [Guo, Lei] Beihang Univ, Sch Automat & Elect Engn, Beijing 100083, Peoples R China	Chen, WH (reprint author), Univ Loughborough, Dept Aeronaut & Automot Engn, Loughborough LE11 3TU, Leics, England.						Ding ZT, 2015, IEEE T IND ELECTRON, V62, P5829, DOI 10.1109/TIE.2015.2442218; Tian BL, 2015, IEEE T IND ELECTRON, V62, P5889, DOI 10.1109/TIE.2015.2442224; Mercorelli P, 2015, IEEE T IND ELECTRON, V62, P5929, DOI 10.1109/TIE.2015.2450725; Ding SH, 2015, IEEE T IND ELECTRON, V62, P5899, DOI 10.1109/TIE.2015.2448064; Gao ZW, 2015, IEEE T IND ELECTRON, V62, P5950, DOI 10.1109/TIE.2015.2421877; Ginoya D, 2015, IEEE T IND ELECTRON, V62, P5817, DOI 10.1109/TIE.2015.2450715; Ichalal D, 2015, IEEE T IND ELECTRON, V62, P5870, DOI 10.1109/TIE.2015.2448055; Katsura S, 2015, IEEE T IND ELECTRON, V62, P5799, DOI 10.1109/TIE.2015.2450737; Li ZJ, 2015, IEEE T IND ELECTRON, V62, P5763, DOI 10.1109/TIE.2015.2447498; Nagatsu Y, 2015, IEEE T IND ELECTRON, V62, P5786, DOI 10.1109/TIE.2015.2448062; Pu ZQ, 2015, IEEE T IND ELECTRON, V62, P5858, DOI 10.1109/TIE.2015.2448060; Ren BB, 2015, IEEE T IND ELECTRON, V62, P5881, DOI 10.1109/TIE.2015.2421884; Ruderman M, 2015, IEEE T IND ELECTRON, V62, P5941, DOI 10.1109/TIE.2015.2435002; Shi P, 2015, IEEE T IND ELECTRON, V62, P5910, DOI 10.1109/TIE.2015.2442221; Sitbon M, 2015, IEEE T IND ELECTRON, V62, P5776, DOI 10.1109/TIE.2015.2434796; Xu DZ, 2015, IEEE T IND ELECTRON, V62, P5919, DOI 10.1109/TIE.2015.2450714; Xue WC, 2015, IEEE T IND ELECTRON, V62, P5847, DOI 10.1109/TIE.2015.2435004; Yang J, 2015, IEEE T IND ELECTRON, V62, P5807, DOI 10.1109/TIE.2015.2450736; Yu JP, 2015, IEEE T IND ELECTRON, V62, P5962, DOI 10.1109/TIE.2015.2418317; Zhang Y, 2015, IEEE T IND ELECTRON, V62, P5971, DOI 10.1109/TIE.2015.2434791; Zhao L, 2015, IEEE T IND ELECTRON, V62, P5838, DOI 10.1109/TIE.2015.2418319	21	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0278-0046	1557-9948		IEEE T IND ELECTRON	IEEE Trans. Ind. Electron.	SEP	2015	62	9					5758	5762		10.1109/TIE.2015.2453347		5	Automation & Control Systems; Engineering, Electrical & Electronic; Instruments & Instrumentation	Automation & Control Systems; Engineering; Instruments & Instrumentation	CP0JE	WOS:000359560800041		
J	Nagatsu, Y; Katsura, S				Nagatsu, Yuki; Katsura, Seiichiro			Design Strategies for Motion Reproduction Based on Environmental Disturbance Compensation	IEEE TRANSACTIONS ON INDUSTRIAL ELECTRONICS			English	Article						Admittance (compliance) control; bilateral control; disturbance observer (DOB); environmental disturbance (EnvD); haptics; motion-copying system; two-degree-of-freedom (2-DOF) control system	CONTROL-SYSTEMS; COPYING SYSTEM; MANIPULATOR; INFORMATION; STABILITY; OBSERVER	This paper proposes a novel motion reproduction method based on environmental disturbance (EnvDs) compensation. The preservation of skillful techniques is an important issue. Although the motion-copying system (MCS) was proposed to deal with this problem, a clear strategy still does not exist for adapting to the environmental variances between the motion saving and reproduction phases. Conventional methods cannot adapt to the difference properly because their control systems are just one-degree-of-freedom (DOF) control systems. In this paper, variances were defined as EnvDs, and the effect on the MCS was demonstrated. A 2-DOF control system structure was developed to compensate for EnvDs. The effectiveness of the proposed system was demonstrated through analysis and experimental results.	[Nagatsu, Yuki; Katsura, Seiichiro] Keio Univ, Dept Syst Design Engn, Yokohama, Kanagawa 2238522, Japan	Nagatsu, Y (reprint author), Keio Univ, Dept Syst Design Engn, Yokohama, Kanagawa 2238522, Japan.	nagatsu@katsura.sd.keio.ac.jp; katsura@sd.keio.ac.jp			Japan Society for the Promotion of Science	This work was supported in part by the Japan Society for the Promotion of Science under Grants-in-Aid for Scientific Research (KAKENHI).	Du GL, 2014, IEEE T IND ELECTRON, V61, P5411, DOI 10.1109/TIE.2014.230178; Yajima S, 2014, IEEE T IND ELECTRON, V61, P3765, DOI 10.1109/TIE.2013.2286086; Ruderman M, 2013, IEEE T IND INFORM, V9, P1130, DOI 10.1109/TII.2012.2222040; Oh S, 2014, IEEE T IND ELECTRON, V61, P985, DOI 10.1109/TIE.2013.2270214; Tesfaye A, 2000, IEEE-ASME T MECH, V5, P32, DOI 10.1109/3516.828587; Natori K, 2008, IEEE T IND INFORM, V4, P185, DOI 10.1109/TII.2008.2002705; Shibata T, 2008, IEEE T IND INFORM, V4, P261, DOI 10.1109/TII.2008.2007847; LAWRENCE DA, 1993, IEEE T ROBOTIC AUTOM, V9, P624, DOI 10.1109/70.258054; Pietrusinski M, 2014, IEEE-ASME T MECH, V19, P490, DOI 10.1109/TMECH.2013.2243915; Ohnishi K, 1996, IEEE-ASME T MECH, V1, P56, DOI 10.1109/3516.491410; Vakanski A, 2012, IEEE T SYST MAN CY B, V42, P1039, DOI 10.1109/TSMCB.2012.2185694; Yokokura Y, 2009, IEEE T IND ELECTRON, V56, P3906, DOI 10.1109/TIE.2009.2027927; Hace A, 2013, IEEE T IND INFORM, V9, P1291, DOI 10.1109/TII.2012.2227267; Iida W., 2004, P 8 IEEE INT WORKSH, P217; Katsura S, 2007, IEEE T IND ELECTRON, V54, P539, DOI 10.1109/TIE.2006.888805; Liu HH, 2011, IEEE T IND INFORM, V7, P389, DOI 10.1109/TII.2011.2158838; Lu R., 2014, IEEE T IND ELECTRON, V61, P3376; Matsui A, 2013, IEEE IND ELEC, P6132, DOI 10.1109/IECON.2013.6700143; Meeussen W., 2007, IEEE T ROBOT, V23, P20; Miyagi T., 2014, P 13 IEEE INT WORKSH, P452; Motioi N., 2014, IEEE T IND ELECTRON, V61, P3765; Nagatsu Y., 2013, P IEEE INT C MECH IC, P546; Nozaki T, 2014, IEEE T IND ELECTRON, V61, P6192, DOI 10.1109/TIE.2014.2308162; Ohishi K., 1983, IPEC-Tokyo Conference Record of the International Power Electronics Conference 1983; Ruderman M., 2014, IEEE T IND ELECTRON, V61, P930; Seki K, 2014, IEEE T IND ELECTRON, V61, P1552, DOI 10.1109/TIE.2013.2259778; Skubic M, 2000, IEEE T ROBOTIC AUTOM, V16, P772, DOI 10.1109/70.897788; Son HI, 2014, IEEE T IND ELECTRON, V61, P6202, DOI 10.1109/TIE.2014.2314058; Suzuki A., 2013, P IEEE INT S IND EL, P1; Tsunashima N., 2010, P 36 ANN C IEEE IND, P1609	30	1	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0278-0046	1557-9948		IEEE T IND ELECTRON	IEEE Trans. Ind. Electron.	SEP	2015	62	9					5786	5798		10.1109/TIE.2015.2448062		13	Automation & Control Systems; Engineering, Electrical & Electronic; Instruments & Instrumentation	Automation & Control Systems; Engineering; Instruments & Instrumentation	CP0JE	WOS:000359560800044		
J	Katsura, S; Onoyama, H				Katsura, Seiichiro; Onoyama, Hiroki			Mixed Reproduction of Physical Human Operation and Data-Based Motions by Frequency Filtering	IEEE TRANSACTIONS ON INDUSTRIAL ELECTRONICS			English	Article						Acceleration control; bilateral control; hybrid control; motion control	COPYING SYSTEM; REHABILITATION	Bilateral control can obtain human motions based on the velocity and force information. Based on the obtained data of human motions, it is possible to reproduce them by position-force hybrid control. The possible applications of the position-force hybrid control can be in the training of experts, rehabilitation, and so on. In the position-force hybrid control, a more adaptive and flexible property is desired since the reproduced motion is strictly affected by the environmental situation in the saved phase. Thus, conventional position-force hybrid control is not sufficient for the training purpose because the reproduced motion is inflexible and its performance is limited. This paper shows a mixed reproduction of physical human operation and data-based motions. In the method, the indexes for human interaction under the automatic reproduction of a saved motion are introduced. The human operationality and the data-based motion reproducibility are stabilized based on frequency filtering. In addition, some comparisons between the conventional method and the proposed method are shown by performance and stability analyses. From these analyses, the effectiveness of the proposed method is confirmed.	[Katsura, Seiichiro; Onoyama, Hiroki] Keio Univ, Fac Sci & Technol, Dept Syst Design Engn, Yokohama, Kanagawa 2238522, Japan	Katsura, S (reprint author), Keio Univ, Fac Sci & Technol, Dept Syst Design Engn, Yokohama, Kanagawa 2238522, Japan.	katsura@sd.keio.ac.jp; onoyama@katsura.sd.keio.ac.jp					Yajima S, 2014, IEEE T IND ELECTRON, V61, P3765, DOI 10.1109/TIE.2013.2286086; Tsunashima N, 2012, IEEE T IND ELECTRON, V59, P1074, DOI 10.1109/TIE.2011.2161247; Lee LH, 2014, IEEE T IND ELECTRON, V61, P4073, DOI 10.1109/TIE.2013.2286565; Lu RQ, 2014, IEEE T IND ELECTRON, V61, P3776, DOI 10.1109/TIE.2013.2275903; LAWRENCE DA, 1993, IEEE T ROBOTIC AUTOM, V9, P624, DOI 10.1109/70.258054; Ogawara K, 2003, IEEE T IND ELECTRON, V50, P667, DOI 10.1109/TIE.2003.814765; Ohnishi K, 1996, IEEE-ASME T MECH, V1, P56, DOI 10.1109/3516.491410; Yokokura Y, 2014, IEEE T IND ELECTRON, V61, P6213, DOI 10.1109/TIE.2014.2308142; Yokokura Y, 2009, IEEE T IND ELECTRON, V56, P3906, DOI 10.1109/TIE.2009.2027927; Haddadi A, 2010, IEEE T HAPTICS, V3, P15, DOI [10.1109/TOH.2009.48, 10.1109/ToH.2009.48]; Hannaford B., 1988, P IEEE INT C ROB AUT, V1, P584; Hogan N, 2004, RESTOR NEUROL NEUROS, V22, P349; Iida W., 2004, P 8 IEEE INT WORKSH, P217; Matsui A., 2013, P IEEE ISIE MAY, P28; Morisawa M., 2002, EPE Journal, V12; Nozaki T., 2014, IEEJ J IND APPL, V3, P1; Ohishi K., 1983, P IEEJ INT POW EL C, P1209; Ohnishi K, 2010, IEEE IND ELECTRON M, V4, P16, DOI 10.1109/MIE.2010.936761; Onoyama H, 2013, IEEE IND ELEC, P5888, DOI 10.1109/IECON.2013.6700100; Onoyama H., 2014, IEEJ J IND APPL, V3, P156; Shimono T., 2006, P IEEE IECON NOV, P5252	21	1	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0278-0046	1557-9948		IEEE T IND ELECTRON	IEEE Trans. Ind. Electron.	SEP	2015	62	9					5799	5806		10.1109/TIE.2015.2450737		8	Automation & Control Systems; Engineering, Electrical & Electronic; Instruments & Instrumentation	Automation & Control Systems; Engineering; Instruments & Instrumentation	CP0JE	WOS:000359560800045		
J	Ruderman, M; Iwasaki, M				Ruderman, Michael; Iwasaki, Makoto			Observer of Nonlinear Friction Dynamics for Motion Control	IEEE TRANSACTIONS ON INDUSTRIAL ELECTRONICS			English	Article						Friction; hysteresis; motion control; non-linearity; observer; presliding; statedynamics; uncertainties	DISTURBANCE-OBSERVER; COMPENSATION; MODEL; SYSTEMS; DRIVES	Kinetic friction in motion control systems is subject to large uncertainties due to the multiple, and often weakly known, internal and external factors such as roughness, thermal and lubricant state of contacting surfaces, varying normal loads, dwell time, wear, and others. The single modeling of friction behavior, even if comprehensive and accurate enough, appears to be insufficient for accurately compensating the friction disturbances, due to their time-and state-varying nature. In this paper, we propose a novel nonlinear friction observer aimed at the motion control. We analyze the uncertainties of viscous and Coulomb friction and derive an asymptotic observer for two-state friction dynamics without assuming a particular dynamic friction model. The linear observer gains prove to be sufficient for achieving an accurate friction estimate with a controllable eigenbehavior. Furthermore, we analyze the friction observer within the linear feedback loop and describe the required system identification and design of controller. An experimental case study accomplished on a rotary actuator system is provided for evaluating both the friction observer and its use for precise positioning.	[Ruderman, Michael] Nagoya Inst Technol, Nagoya, Aichi 4668555, Japan; [Iwasaki, Makoto] Nagoya Inst Technol, Dept Comp Sci & Engn, Nagoya, Aichi 4668555, Japan	Ruderman, M (reprint author), Nagaoka Univ Technol, Nagaoka, Niigata 9402188, Japan.	ruderman@vos.nagaokaut.ac.jp; iwasaki@nitech.ac.jp					Freidovich L, 2010, IEEE T CONTR SYST T, V18, P194, DOI 10.1109/TCST.2008.2010501; Jamaludin Z, 2009, IEEE T IND ELECTRON, V56, P3848, DOI 10.1109/TIE.2009.2017560; Ruderman M, 2014, MECHATRONICS, V24, P407, DOI 10.1016/j.mechatronics.2014.02.009; Chen WH, 2004, IEEE-ASME T MECH, V9, P706, DOI 10.1109/TMECH.2004.839034; DEWIT CC, 1995, IEEE T AUTOMAT CONTR, V40, P419; FRIEDLAND B, 1992, IEEE T AUTOMAT CONTR, V37, P1609, DOI 10.1109/9.256395; Ohnishi K, 1996, IEEE-ASME T MECH, V1, P56, DOI 10.1109/3516.491410; Al-Bender F, 2005, IEEE T AUTOMAT CONTR, V50, P1883, DOI 10.1109/TAC.2005.858676; Kazantzis N, 1998, SYST CONTROL LETT, V34, P241, DOI 10.1016/S0167-6911(98)00017-6; ARMSTRONGHELOUVRY B, 1994, AUTOMATICA, V30, P1083, DOI 10.1016/0005-1098(94)90209-7; Awrejcewicz J., 2005, Applied Mechanics Review, V58, DOI 10.1115/1.2048687; Boegli M, 2014, IEEE-ASME T MECH, V19, P1593, DOI 10.1109/TMECH.2013.2288944; F Al-Bender, 2008, CONTROL SYSTEMS IEEE, V28, P64; Harnoy A, 2008, IEEE CONTR SYST MAG, V28, P82, DOI 10.1109/MCS.2008.929546; HESS DP, 1990, J TRIBOL-T ASME, V112, P147, DOI 10.1115/1.2920220; Ishikawa J, 1998, IEEE-ASME T MECH, V3, P194, DOI 10.1109/3516.712115; Iwasaki M, 1999, IEEE-ASME T MECH, V4, P3, DOI 10.1109/3516.752078; LUENBERG.DG, 1971, IEEE T AUTOMAT CONTR, VAC16, P596, DOI 10.1109/TAC.1971.1099826; Maeda Y, 2013, IEEE T IND ELECTRON, V60, P3865, DOI 10.1109/TIE.2012.2205350; Olsson H, 1996, IEEE DECIS CONTR P, P4345, DOI 10.1109/CDC.1996.577475; Ruderman M., 2014, P IEEE 13 INT WORKSH, P592; Ruderman M, 2014, INT CONF POW ELECTR, P1665, DOI 10.1109/IPEC.2014.6869806; Ruderman M, 2013, MECH SYST SIGNAL PR, V39, P316, DOI 10.1016/j.ymssp.2013.03.010; Ruderman M., 2011, Proceedings of the 2011 IEEE International Conference on Mechatronics (ICM), DOI 10.1109/ICMECH.2011.5971286; Ruderman M, 2014, IEEE T IND ELECTRON, V61, P3727, DOI 10.1109/TIE.2013.2264786; Stribeck R., 1902, VDI Z, V46, P1463; Stribeck R., 1902, VDI Z, V46, P1432; Stribeck R., 1902, VDI Zeitschrift, V46; Symens W, 2005, CHAOS, V15, DOI 10.1063/1.1844992; Zhu HZ, 2015, IEEE-ASME T MECH, V20, P956, DOI 10.1109/TMECH.2014.2337933	30	1	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0278-0046	1557-9948		IEEE T IND ELECTRON	IEEE Trans. Ind. Electron.	SEP	2015	62	9					5941	5949		10.1109/TIE.2015.2435002		9	Automation & Control Systems; Engineering, Electrical & Electronic; Instruments & Instrumentation	Automation & Control Systems; Engineering; Instruments & Instrumentation	CP0JE	WOS:000359560800059		
J	Zhang, Y; Xian, B; Ma, SG				Zhang, Yao; Xian, Bin; Ma, Shugen			Continuous Robust Tracking Control for Magnetic Levitation System With Unidirectional Input Constraint	IEEE TRANSACTIONS ON INDUSTRIAL ELECTRONICS			English	Article						Disturbance-rejection; exponential tracking; magnetic levitation system (MLS); nonlinear robust control; unidirectional control constraint	SLIDING-MODE CONTROL; ONLINE ALGEBRAIC IDENTIFICATION; UNCERTAIN NONLINEAR-SYSTEMS; RISE FEEDBACK-CONTROL; ASYMPTOTIC TRACKING; ADAPTIVE-CONTROL; CONTROL STRATEGY; GPI CONTROL; DISTURBANCE; FEEDFORWARD	In this paper, the exponentially tracking control problem for a magnetic levitation system (MLS) in the presence of parameter uncertainties and external disturbances is investigated. The disturbance/uncertainties-rejecting problem for the MLS is addressed from the view of a continuous nonlinear robust control development. Another problem of the concern is the common unidirectional input constraint in the MLS (i.e., the control input, often referring to the square of the electric current, should be non-negative during the operation of the system). By utilizing an input transformation and augmented dynamics, a virtual control input, which removes the unidirectional constraint, is affinely emerged in the dynamics. A second-order filter is introduced to provide feedback signals for the control development. A novel Lyapunov function guarantees the exponentially tracking stability of the close-loop dynamics. Finally, some numerical simulation and real-time experimental results for tracking of time-varying trajectories are presented to validate the performance of the proposed control design.	[Zhang, Yao; Xian, Bin] Tianjin Univ, Inst Robot & Autonomous Syst, Sch Elect Engn & Automat, Tianjin Key Lab Proc Measurement & Control, Tianjin 300072, Peoples R China; [Ma, Shugen] Ritsumeikan Univ, Kyoto 5258577, Japan; [Ma, Shugen] Tianjin Univ, Tianjin 300072, Peoples R China	Zhang, Y (reprint author), Tianjin Univ, Inst Robot & Autonomous Syst, Sch Elect Engn & Automat, Tianjin Key Lab Proc Measurement & Control, Tianjin 300072, Peoples R China.	xbin@tju.edu.cn			Natural Science Foundation of Tianjin [14JCZDJC31900]	This work was supported by the Natural Science Foundation of Tianjin under Grant 14JCZDJC31900.	Al-Muthairi NE, 2004, MATH PROBL ENG, P93, DOI 10.1155/S1024123X04310033; Laghrouche S, 2007, AUTOMATICA, V43, P531, DOI 10.1016/J.automatica.2006.09.017; Lin FJ, 2007, IEEE T IND ELECTRON, V54, P1752, DOI 10.1109/TIE.2007.894710; SHEVITZ D, 1994, IEEE T AUTOMAT CONTR, V39, P1910, DOI 10.1109/9.317122; Saghafinia A, 2014, INT J ADV MANUF TECH, V71, P57, DOI 10.1007/s00170-013-5398-7; Wai RJ, 2011, IEEE T IND ELECTRON, V58, P629, DOI 10.1109/TIE.2010.2046004; Fischer N, 2014, IEEE T AUTOMAT CONTR, V59, P1094, DOI 10.1109/TAC.2013.2286913; Rote DM, 2002, IEEE T MAGN, V38, P1383, DOI 10.1109/20.996030; Lin CM, 2014, IEEE T IND ELECTRON, V61, P4265, DOI 10.1109/TIE.2013.2288201; Morales R, 2010, INT J CONTROL, V83, P1155, DOI 10.1080/00207171003642196; Zhang ZQ, 2014, IEEE T AUTOMAT CONTR, V59, P1336, DOI 10.1109/TAC.2013.2289704; Morales R, 2011, IEEE T CONTR SYST T, V19, P757, DOI 10.1109/TCST.2010.2057511; Xian B, 2004, IEEE T AUTOMAT CONTR, V49, P1206, DOI 10.1109/TAC.2004.831148; Pilat A, 2012, PRZ ELEKTROTECHNICZN, V88, P282; Chen J, 2008, IEEE T AUTOMAT CONTR, V53, P591, DOI 10.1109/TAC.2008.916658; Morales R, 2014, INT J CONTROL, V87, P1604, DOI 10.1080/00207179.2014.880129; Patre PM, 2010, AUTOMATICA, V46, P140, DOI 10.1016/j.automatica.2009.10.017; Yang ZJ, 2011, IEEE T CONTR SYST T, V19, P256, DOI 10.1109/TCST.2010.2049998; Lin CM, 2011, IEEE SYST J, V5, P278, DOI 10.1109/JSYST.2011.2134530; Lee JD, 2013, IEEE T IND INFORM, V9, P817, DOI 10.1109/TII.2012.2219062; Schuhmann T, 2012, IEEE T IND ELECTRON, V59, P821, DOI 10.1109/TIE.2011.2161056; Yang ZJ, 2004, IEEE T IND ELECTRON, V51, P26, DOI 10.1109/TIE.2003.822095; Gentili L, 2003, AUTOMATICA, V39, P735, DOI 10.1016/S0005-1098(02)00307-2; Behal A, 2001, P AMER CONTR CONF, P3636, DOI 10.1109/ACC.2001.946199; Patre PM, 2008, IEEE T AUTOMAT CONTR, V53, P2180, DOI 10.1109/TAC.2008.930200; Meng ZY, 2013, AUTOMATICA, V49, P2363, DOI 10.1016/j.automatica.2013.04.040; Yang ZJ, 2001, AUTOMATICA, V37, P1125, DOI 10.1016/S0005-1098(01)00063-2; Feemster MG, 2006, IEEE-ASME T MECH, V11, P709, DOI 10.1109/TMECH.2006.886248; Zheng SQ, 2014, IEEE T IND ELECTRON, V61, P7004, DOI 10.1109/TIE.2014.2316226; Baranowski J, 2012, T I MEAS CONTROL, V34, P422, DOI 10.1177/0142331210389650; Bhasin S, 2013, IEEE T AUTOMAT CONTR, V58, P187, DOI 10.1109/TAC.2012.2203452; Fang Y, 2003, PROCEEDINGS OF THE 2003 IEEE INTERNATIONAL SYMPOSIUM ON INTELLIGENT CONTROL, P58; Lin FJ, 2009, IEEE T NEURAL NETWOR, V20, P938, DOI 10.1109/TNN.2009.2014228; Pilat A., 2009, P 14 INT C METH MOD, P164; Qu Z., 1998, ROBUST CONTROL NONLI; West E. V., 2009, J PRECISION ENG, V33, P217; Zhang Y., 2014, P AM CONTR C PORTL O, P2330	37	1	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0278-0046	1557-9948		IEEE T IND ELECTRON	IEEE Trans. Ind. Electron.	SEP	2015	62	9					5971	5980		10.1109/TIE.2015.2434791		10	Automation & Control Systems; Engineering, Electrical & Electronic; Instruments & Instrumentation	Automation & Control Systems; Engineering; Instruments & Instrumentation	CP0JE	WOS:000359560800062		
J	Takamizawa, A; Yanagimachi, S; Tanabe, T; Hagimoto, K; Hirano, I; Watabe, K; Ikegami, T; Hartnett, JG				Takamizawa, Akifumi; Yanagimachi, Shinya; Tanabe, Takehiko; Hagimoto, Ken; Hirano, Iku; Watabe, Ken-ichi; Ikegami, Takeshi; Hartnett, John G.			Preliminary Evaluation of the Cesium Fountain Primary Frequency Standard NMIJ-F2	IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT			English	Article						Atomic fountain clock; primary frequency standard (PFS); uncertainty evaluation	CRYOGENIC-SAPPHIRE-OSCILLATOR; INTERROGATED ATOMIC RESONATOR; 1ST ACCURACY EVALUATION; PULSE-TUBE CRYOCOOLER; UNCERTAINTY EVALUATION; REFERENCE SIGNAL; CLOCK; STABILITY; IEN-CSF1; NIST-F1	We describe the preliminary evaluation of the frequency corrections and their uncertainty in the cesium fountain primary frequency standard (PFS) NMIJ-F2 under development at National Metrology Institute of Japan (NMIJ). In NMIJ-F2, cold atoms generated from a vapor-loaded optical molasses in the (001) configuration are optically pumped to the Zeeman sublevels of m(F) = 0 to increase the number of atoms involved in the Ramsey interrogation. Moreover, a cryocooled sapphire oscillator with ultralow phase noise is employed as the local oscillator to avoid degradation of the frequency stability due to the Dick effect. As a result, we have obtained a very high fractional frequency stability of 9.7 x 10(-14 tau 1/2). As for systematic frequency shifts, the fractional correction for the second-order Zeeman shift is experimentally estimated to be (-165.5 +/- 0.5) x 10(-15) from the first-order Zeeman shift of atoms in m(F) = +1 launched to various heights. The fractional frequency correction for cold-atom collisions is estimated to be (+3.3 +/- 0.4) x 10(-15) by extrapolating the frequency to zero density from the frequencies measured for various nonzero atom numbers. We will soon be able to make a comparison with other atomic fountain PFSs at the 1 x 10(-15) level.	[Takamizawa, Akifumi; Yanagimachi, Shinya; Tanabe, Takehiko; Hagimoto, Ken; Hirano, Iku; Watabe, Ken-ichi; Ikegami, Takeshi] Natl Inst Adv Ind Sci & Technol, Time Stand Sect, Natl Metrol Inst Japan, Tsukuba, Ibaraki 3058563, Japan; [Hartnett, John G.] Univ Adelaide, Sch Phys Sci, Inst Photon & Adv Sensing, Adelaide, SA 5005, Australia	Takamizawa, A (reprint author), Natl Inst Adv Ind Sci & Technol, Time Stand Sect, Natl Metrol Inst Japan, Tsukuba, Ibaraki 3058563, Japan.	akifumi.takamizawa@aist.go.jp					Simon E, 1998, PHYS REV A, V57, P436, DOI 10.1103/PhysRevA.57.436; Li RX, 2010, METROLOGIA, V47, P534, DOI 10.1088/0026-1394/47/5/004; Gerginov V, 2010, METROLOGIA, V47, P65, DOI 10.1088/0026-1394/47/1/008; Szymaniec K, 2013, APPL PHYS B-LASERS O, V111, P527, DOI 10.1007/s00340-013-5368-7; Heavner TP, 2014, METROLOGIA, V51, P174, DOI 10.1088/0026-1394/51/3/174; Hartnett JG, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.4709479; Bauch A, 2012, METROLOGIA, V49, P180, DOI 10.1088/0026-1394/49/3/180; Takamizawa A, 2014, IEEE T ULTRASON FERR, V61, P1463, DOI 10.1109/TUFFC.2014.3060; Weyers S, 2001, METROLOGIA, V38, P343, DOI 10.1088/0026-1394/38/4/7; Santarelli G, 1998, IEEE T ULTRASON FERR, V45, P887, DOI 10.1109/58.710548; Laurent P, 2006, APPL PHYS B-LASERS O, V84, P683, DOI 10.1007/s00340-006-2396-6; Santarelli G, 2009, IEEE T ULTRASON FERR, V56, P1319, DOI 10.1109/TUFFC.2009.1188; Szymaniec K, 2010, METROLOGIA, V47, P363, DOI 10.1088/0026-1394/47/4/003; Guena J, 2012, IEEE T ULTRASON FERR, V59, P391, DOI 10.1109/TUFFC.2012.2208; Donley EA, 2005, REV SCI INSTRUM, V76, DOI 10.1063/1.1930095; Heavner TP, 2005, METROLOGIA, V42, P411, DOI 10.1088/0026-1394/42/5/012; Wynands R, 2005, METROLOGIA, V42, pS64, DOI 10.1088/0026-1394/42/3/S08; Levi F, 2006, METROLOGIA, V43, P545, DOI 10.1088/0026-1394/43/6/010; ITANO WM, 1993, PHYS REV A, V47, P3554, DOI 10.1103/PhysRevA.47.3554; Levi F, 2014, METROLOGIA, V51, P270, DOI 10.1088/0026-1394/51/3/270; Shirley JH, 2006, IEEE T ULTRASON FERR, V53, P2376, DOI 10.1109/TUFFC.2006.186; Audoin C, 1998, IEEE T ULTRASON FERR, V45, P877, DOI 10.1109/58.710546; Domnin YS, 2013, MEAS TECH+, V55, P1155, DOI 10.1007/s11018-012-0102-0; Guena J, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.130801; Hartnett JG, 2010, IEEE T MICROW THEORY, V58, P3580, DOI 10.1109/TMTT.2010.2086551; Hartnett JG, 2014, ELECTRON LETT, V50, P294, DOI 10.1049/el.2013.3481; Jefferts SR, 1998, P IEEE INT FREQ CONT, P6, DOI 10.1109/FREQ.1998.717869; Kumagai M, 2008, METROLOGIA, V45, P139, DOI 10.1088/0026-1394/45/2/003; Kurosu T, 2004, IEEE T INSTRUM MEAS, V53, P466, DOI 10.1109/TIM.2004.823313; Parker TE, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.3682002; Szymaniec K, 2005, METROLOGIA, V42, P49, DOI 10.1088/0026-1394/42/1/007; Takamizawa A., 2010, P 42 ANN PREC TIM TI, P321; Takamizawa A., 2014, P EUR FREQ TIM FOR, P394; Vanier J., 1989, QUANTUM PHYS ATOMIC, V2, P793; Wang C, 2010, CRYOGENICS, V50, P336, DOI 10.1016/j.cryogenics.2010.01.003; Watabe K, 2006, JPN J APPL PHYS 1, V45, P2827, DOI 10.1143/JJAP.45.2827; Watabe K, 2008, JPN J APPL PHYS, V47, P7390, DOI [10.1143/JJAP.47.7390, 10.1143/JAPP.47.7390]; Watabe K, 2005, JPN J APPL PHYS 1, V44, P3283, DOI 10.1143/JJAP.44.3283; Watabe KI, 2006, JPN J APPL PHYS 1, V45, P9234, DOI 10.1143/JJAP.45.9234; Yanagimachi S, 2008, 2008 CONFERENCE ON PRECISION ELECTROMAGNETIC MEASUREMENTS DIGEST, P324, DOI 10.1109/CPEM.2008.4574784; Yanagimachi S, 2005, JPN J APPL PHYS 1, V44, P1468, DOI 10.1143/JJAP.44.1468	41	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9456	1557-9662		IEEE T INSTRUM MEAS	IEEE Trans. Instrum. Meas.	SEP	2015	64	9					2504	2512		10.1109/TIM.2015.2415015		9	Engineering, Electrical & Electronic; Instruments & Instrumentation	Engineering; Instruments & Instrumentation	CP0GX	WOS:000359554900017		
J	Moroi, R; Endo, K; Kinouchi, Y; Shiga, H; Kakuta, Y; Kuroha, M; Kanazawa, Y; Shimodaira, Y; Horiuchi, T; Takahashi, S; Shimosegawa, T				Moroi, Rintaro; Endo, Katsuya; Kinouchi, Yoshitaka; Shiga, Hisashi; Kakuta, Yoichi; Kuroha, Masatake; Kanazawa, Yoshitake; Shimodaira, Yosuke; Horiuchi, Takahiko; Takahashi, Seiichi; Shimosegawa, Tooru			FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity (vol 65, pg 265, 2013)	IMMUNOGENETICS			English	Correction									[Moroi, Rintaro; Endo, Katsuya; Kinouchi, Yoshitaka; Shiga, Hisashi; Kakuta, Yoichi; Kuroha, Masatake; Kanazawa, Yoshitake; Shimodaira, Yosuke; Takahashi, Seiichi; Shimosegawa, Tooru] Tohoku Univ, Grad Sch Med, Div Gastroenterol, Aoba Ku, Sendai, Miyagi 980, Japan; [Horiuchi, Takahiko] Kyushu Univ, Fac Med, Dept Med & Biosyst Sci, Kyushu, Japan	Moroi, R (reprint author), Tohoku Univ, Grad Sch Med, Div Gastroenterol, Aoba Ku, Sendai, Miyagi 980, Japan.	rinta@med.tohoku.ac.jp					Moroi R, 2013, IMMUNOGENETICS, V65, P265, DOI 10.1007/s00251-013-0679-8	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0093-7711	1432-1211		IMMUNOGENETICS	Immunogenetics	SEP	2015	67	9					545	545		10.1007/s00251-015-0861-2		1	Genetics & Heredity; Immunology	Genetics & Heredity; Immunology	CP3ZQ	WOS:000359822200007		
J	Asano, K; Yoshimura, S; Nakane, A				Asano, Krisana; Yoshimura, Sayuri; Nakane, Akio			Adipose Tissue-Derived Mesenchymal Stem Cells Attenuate Staphylococcal Enterotoxin A-Induced Toxic Shock	INFECTION AND IMMUNITY			English	Article							IMMUNOSUPPRESSIVE PROPERTIES; DIFFERENTIATION; MICE; INDUCTION; PROLIFERATION; SUPERANTIGENS; INFECTIONS; EXPANSION; INHIBIT; DISEASE	Adipose tissue-derived stem cells (ASCs), which are mesenchymal stromal cells isolated from adipose tissues, exhibit immunomodulatory effects that are promising for several applications, including the therapeutics of inflammatory diseases. In the present study, the effect of ASCs on bacterial toxin-induced inflammation was investigated. Intraperitoneal administration of ASCs rescued mice from lethal shock induced by staphylococcal enterotoxin A (SEA) potentiated with lipopolysaccharide. In the sera and/or spleens of mice administered ASCs, the production of proinflammatory cytokines, including interferon gamma, tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-2 was reduced. By quantitative real-time PCR, the expression of Foxp3 in the mice administered ASCs was not altered. On the other hand, the expression of IL-12 receptor and STAT4 was decreased with ASC administration. These results imply that the effect of ASCs is not involved in the lineage of regulatory T cells but that these cells may modulate T(H)1 differentiation. This information provides evidence that ASCs have properties that are effective to attenuate SEA-induced toxic shock and should prompt further exploration on other inflammatory diseases caused by bacterial toxins or bacterial infections.	[Asano, Krisana; Yoshimura, Sayuri; Nakane, Akio] Hirosaki Univ, Dept Microbiol & Immunol, Grad Sch Med, Hirosaki, Aomori, Japan	Nakane, A (reprint author), Hirosaki Univ, Dept Microbiol & Immunol, Grad Sch Med, Hirosaki, Aomori, Japan.	a27k03n0@hirosaki-u.ac.jp			JSPS KAKENHI grant [23659217]; Hirosaki University Institutional Research	This study was supported by JSPS KAKENHI grant number 23659217 and a grant for Hirosaki University Institutional Research.	Collins LV, 2002, INFECT IMMUN, V70, P2282, DOI 10.1128/IAI.70.5.2282-2287.2002; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16; Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; Djouad F, 2007, STEM CELLS, V25, P2025, DOI 10.1634/stemcells.2006-0548; STILES BG, 1993, INFECT IMMUN, V61, P5333; Locke M, 2009, ANZ J SURG, V79, P235, DOI 10.1111/j.1445-2197.2009.04852.x; Rasmusson I, 2005, EXP CELL RES, V305, P33, DOI 10.1016/j.yexcr.2004.12.013; Yoo KH, 2009, CELL IMMUNOL, V259, P150, DOI 10.1016/j.cellimm.2009.06.010; Zhou YX, 2011, IMMUNOLOGY, V133, P133, DOI 10.1111/j.1365-2567.2011.03421.x; Fujio K, 2010, ADV IMMUNOL, V105, P99, DOI 10.1016/S0065-2776(10)05004-2; Mattern T, 1998, J IMMUNOL, V160, P3412; Cameron SB, 2001, EUR CYTOKINE NETW, V12, P210; Delalat B, 2009, HEMATOLOGY, V14, P125, DOI 10.1179/102453309X402250; Kubo N, 2012, J GASTROEN HEPATOL, V27, P165, DOI 10.1111/j.1440-1746.2011.06798.x; van der Bogt KEA, 2009, TRANSPLANTATION, V87, P642, DOI 10.1097/TP.0b013e31819609d9; Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006; Yanez R, 2006, STEM CELLS, V24, P2582, DOI 10.1634/stemcells.2006-0228; Blank C, 1997, EUR J IMMUNOL, V27, P825, DOI 10.1002/eji.1830270405; Hu DL, 2003, INFECT IMMUN, V71, P567, DOI 10.1128/IAI.71.1.567-570.2003; Becskei A, 2007, FEBS LETT, V581, P5199, DOI 10.1016/j.febslet.2007.10.007; Blanton MW, 2009, PLAST RECONSTR SURG, V23, P56, DOI DOI 10.1097/PRS; Huss R, 2000, STEM CELLS, V18, P1, DOI 10.1634/stemcells.18-1-1; Kissner TL, 2010, IMMUNOLOGY, V130, P516, DOI 10.1111/j.1365-2567.2010.03249.x; Leto Barone AA, 2013, BIOMED RES INT, P1; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Lu F, 2008, PLAST RECONSTR SURG, V121, P50, DOI 10.1097/01.prs.0000293876.10700.b8; Meyerrose TE, 2007, STEM CELLS, V25, P220, DOI 10.1634/stemcells.2006-0243; Mizuki M, 2002, INFECT IMMUN, V70, P4805, DOI 10.1128/IAI.70.9.4805-4811.2002; MOLLICK JA, 1989, SCIENCE, V244, P817, DOI 10.1126/science.2658055; Siegel G, 2009, TRANSPLANTATION, V87, pS45, DOI 10.1097/TP.0b013e3181a285b0; Ulrich RG, 1995, TRENDS MICROBIOL, V3, P463, DOI 10.1016/S0966-842X(00)89011-3	32	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0019-9567	1098-5522		INFECT IMMUN	Infect. Immun.	SEP	2015	83	9					3490	3496		10.1128/IAI.00730-15		7	Immunology; Infectious Diseases	Immunology; Infectious Diseases	CO8QP	WOS:000359435600014		
J	Takahashi, H; Yanagisawa, T; Kim, KS; Yokoyama, S; Ohnishi, M				Takahashi, Hideyuki; Yanagisawa, Tatsuo; Kim, Kwang Sik; Yokoyama, Shigeyuki; Ohnishi, Makoto			Multiple Functions of Glutamate Uptake via Meningococcal GltT-GltM L-Glutamate ABC Transporter in Neisseria meningitidis Internalization into Human Brain Microvascular Endothelial Cells	INFECTION AND IMMUNITY			English	Article							BACTERIAL MOONLIGHTING PROTEINS; OXIDATIVE STRESS; EPITHELIAL-CELLS; SERUM RESISTANCE; DISEASE; VIRULENCE; GONORRHOEAE; CAPSULE; HOST; LIPOOLIGOSACCHARIDE	We previously reported that Neisseria meningitidis internalization into human brain microvasocular endothelial cells (HBMEC) was triggered by the influx of extracellular L-glutamate via the GltT-GltM L-glutamate ABC transporter, but the underlying mechanism remained unclear. We found that the Delta gltT Delta gltM invasion defect in assay medium (AM) was alleviated in AM without 10% fetal bovine serum (FBS) [AM(-S)]. The alleviation disappeared again in AM(-S) supplemented with 500 mu M glutamate. Glutamate uptake by the Delta gltT Delta gltM mutant was less efficient than that by the wild-type strain, but only upon HBMEC infection. We also observed that both GltT-GltM-dependent invasion and accumulation of ezrin, a key membrane-cytoskeleton linker, were more pronounced when N. meningitidis formed larger colonies on HBMEC under physiological glutamate conditions. These results suggested that GltT-GltM-dependent meningococcal internalization into HBMEC might be induced by the reduced environmental glutamate concentration upon infection. Furthermore, we found that the amount of glutathione within the Delta gltT Delta gltM mutant was much lower than that within the wild-type N. meningitidis strain only upon HBMEC infection and was correlated with intracellular survival. Considering that the L-glutamate obtained via GltT-GltM is utilized as a nutrient in host cells, L-glutamate uptake via GltT-GltM plays multiple roles in N. meningitidis internalization into HBMEC.	[Takahashi, Hideyuki; Ohnishi, Makoto] Natl Inst Infect Dis, Dept Bacteriol 1, Tokyo, Japan; [Yanagisawa, Tatsuo; Yokoyama, Shigeyuki] RIKEN Struct Biol Lab, Yokohama, Kanagawa, Japan; [Kim, Kwang Sik] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, Baltimore, MD 21205 USA	Takahashi, H (reprint author), Natl Inst Infect Dis, Dept Bacteriol 1, Tokyo, Japan.	hideyuki@nih.go.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [24590545, 15K08485]; Platform for Drug Discovery, Informatics, and Structural Life Science; Ministry of Education, Culture, Sports, Science and Technology, Japan	This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (grant no. 24590545 and 15K08485) and by the Platform for Drug Discovery, Informatics, and Structural Life Science, funded by the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Alam J, 2014, J PERIODONTAL IMPLAN, V44, P266, DOI 10.5051/jpis.2014.44.6.266; Lewis LA, 2014, VIRULENCE, V5, P98, DOI 10.4161/viru.26515; Spinosa MR, 2007, INFECT IMMUN, V75, P3594, DOI 10.1128/IAI.01945-06; Brouwer MC, 2010, LANCET INFECT DIS, V10, P262, DOI 10.1016/S1473-3099(10)70045-1; Eugene E, 2002, J CELL SCI, V115, P1231; Fraser C, 2005, P NATL ACAD SCI USA, V102, P1968, DOI 10.1073/pnas.0406993102; Knaust A, 2007, J BACTERIOL, V189, P3246, DOI 10.1128/JB.01966-06; Brown DR, 2010, INFECT IMMUN, V78, P3053, DOI 10.1128/IAI.00099-10; Virji M, 2009, NAT REV MICROBIOL, V7, P274, DOI 10.1038/nrmicro2097; FERNSTROM JD, 1979, AM J CLIN NUTR, V32, P1912; Vogel U, 1999, MOL MICROBIOL, V32, P1133, DOI 10.1046/j.1365-2958.1999.01469.x; Davila S, 2010, NAT GENET, V42, P772, DOI 10.1038/ng.640; Coureuil M, 2010, CELL, V143, P1149, DOI 10.1016/j.cell.2010.11.035; Yazdankhah SP, 2004, J MED MICROBIOL, V53, P821, DOI 10.1099/jmm.0.45529-0; Amon J, 2010, FEMS MICROBIOL REV, V34, P588, DOI 10.1111/j.1574-6976.2010.00216.x; Henderson B, 2011, INFECT IMMUN, V79, P3476, DOI 10.1128/IAI.00179-11; Seib KL, 2006, MICROBIOL MOL BIOL R, V70, P344, DOI 10.1128/MMBR.00044-05; Tala A, 2011, MOL MICROBIOL, V81, P1330, DOI 10.1111/j.1365-2958.2011.07766.x; van Heeswijk WC, 2013, MICROBIOL MOL BIOL R, V77, P628, DOI 10.1128/MMBR.00025-13; Bottero V, 2013, J VIROL, V87, P1733, DOI 10.1128/JVI.02958-12; CARTWRIGHT KAV, 1987, EPIDEMIOL INFECT, V99, P591; HAMMERSCHMIDT S, 1994, MOL MICROBIOL, V11, P885, DOI 10.1111/j.1365-2958.1994.tb00367.x; Hill DJ, 2012, METHODS MOL BIOL, V799, P143, DOI 10.1007/978-1-61779-346-2_9; Takahashi H, 2012, INFECT IMMUN, V80, P4154, DOI 10.1128/IAI.00423-12; Seib KL, 2004, J INFECT DIS, V190, P136, DOI 10.1086/421299; Ricci V, 2014, WORLD J GASTROENTERO, V20, P630, DOI 10.3748/wjg.v20.i3.630; Brissac T, 2012, INFECT IMMUN, V80, P3297, DOI 10.1128/IAI.00369-12; Takahashi H, 2004, J MED MICROBIOL, V53, P657, DOI 10.1099/jmm.0.45541-0; Vandenberg RJ, 2013, PHYSIOL REV, V93, P1621, DOI 10.1152/physrev.00007.2013; Comanducci M, 2002, J EXP MED, V195, P1445, DOI 10.1084/jem.20020407; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Masip L, 2006, ANTIOXID REDOX SIGN, V8, P753, DOI 10.1089/ars.2006.8.753; Di Pietro M, 2015, INT J MOL SCI, V16, P724, DOI 10.3390/ijms16010724; Schoen C, 2008, P NATL ACAD SCI USA, V105, P3473, DOI 10.1073/pnas.0800151105; Codjoe SNA, 2014, INT J ENV RES PUB HE, V11, P6923, DOI 10.3390/ijerph110706923; Merrell DS, 2004, NATURE, V430, P250, DOI 10.1038/nature02760; Caesar JJE, 2014, ELIFE, V3, DOI 10.7554/eLife.04008; CATLIN BW, 1973, J INFECT DIS, V128, P178; Chang Qiuzhi, 2012, Clin Epidemiol, V4, P237, DOI 10.2147/CLEP.S28410; Colicchio R, 2009, INFECT IMMUN, V77, P3578, DOI 10.1128/IAI.01424-08; Dewenter L, 2015, INTEGR BIOL; Hammerschmidt S, 1996, EMBO J, V15, P192; Hammerschmidt S, 1996, MOL MICROBIOL, V20, P1211, DOI 10.1111/j.1365-2958.1996.tb02641.x; Hardy SJ, 2000, MOL MICROBIOL, V36, P817, DOI 10.1046/j.1365-2958.2000.01923.x; He L, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0279-3; Henderson B, 2013, CURR TOP MICROBIOL, V358, P155, DOI 10.1007/82_2011_188; Leduc D, 2010, INFECT IMMUN, V78, P2782, DOI 10.1128/IAI.00149-10; Leibowitz A, 2012, INT J MOL SCI, V13, P10041, DOI 10.3390/ijms130810041; Lu SC, 2013, BBA-GEN SUBJECTS, V1830, P3143, DOI 10.1016/j.bbagen.2012.09.008; Marri PR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011835; Mikaty G, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000314; Monaco C, 2006, INFECT IMMUN, V74, P1725, DOI 10.1128/IAI.74.3.1725-1740.2006; Murray RL, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1062; Plant L, 2006, INFECT IMMUN, V74, P1360, DOI 10.1128/IAI.74.2.1360-1367.2006; Rashid H, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-160; Sa E, 2010, PLOS PATHOG, V6; Sa E, 2009, CELL MICROBIOL, V11, P389; Scarselli M, 2006, MOL MICROBIOL, V61, P631, DOI 10.1111/j.1365-2958.2006.05261.x; Serruto D, 2003, MOL MICROBIOL, V48, P323, DOI 10.1046/j.1365-2958.2003.03420.x; Snyder LAS, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-128; Song J, 2014, NEUROPSYCHOBIOLOGY, V70, P133, DOI 10.1159/000364828; STEPHENS DS, 1993, J INFECT DIS, V167, P475; STEPHENS DS, 1984, INFECT IMMUN, V46, P507; Takahashi H, 2008, INFECT IMMUN, V76, P5777, DOI 10.1128/IAI.00676-08; Takahashi H, 2008, FEMS IMMUNOL MED MIC, V52, P36, DOI 10.1111/j.1574-695X.2007.00342.x; Takahashi H, 2002, MICROBIOL-SGM, V148, P229; Takahashi H, 2011, INFECT IMMUN, V79, P380, DOI 10.1128/IAI.00497-10; Tsai PJ, 1999, METABOLISM, V48, P1455, DOI 10.1016/S0026-0495(99)90159-2; Tunio S.A., 2010, MOL MICROBIOL, V7, P605; Turner DPJ, 2006, INFECT IMMUN, V74, P2957, DOI 10.1128/IAI.74.5.2957-2964.2006; Tzeng YL, 2000, MICROBES INFECT, V2, P687, DOI 10.1016/S1286-4579(00)00356-7; van Ulsen P, 2006, FEMS MICROBIOL REV, V30, P292, DOI 10.1111/j.1574-6976.2005.00013.x; VIRJI M, 1992, MOL MICROBIOL, V6, P2785, DOI 10.1111/j.1365-2958.1992.tb01458.x	73	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0019-9567	1098-5522		INFECT IMMUN	Infect. Immun.	SEP	2015	83	9					3555	3567		10.1128/IAI.00654-15		13	Immunology; Infectious Diseases	Immunology; Infectious Diseases	CO8QP	WOS:000359435600021		
J	Tanaka, N; Levia, D; Igarashi, Y; Nanko, K; Yoshifuji, N; Tanaka, K; Tantasirin, C; Suzuki, M; Kumagai, T				Tanaka, Nobuaki; Levia, Delphis; Igarashi, Yasunori; Nanko, Kazuki; Yoshifuji, Natsuko; Tanaka, Katsunori; Tantasirin, Chatchai; Suzuki, Masakazu; Kumagai, Tomo'omi			Throughfall under a teak plantation in Thailand: a multifactorial analysis on the effects of canopy phenology and meteorological conditions	INTERNATIONAL JOURNAL OF BIOMETEOROLOGY			English	Article						Foliage dynamics; Southeast Asian tropics; Wet canopy evaporation; Canopy interception; Tropical seasonal forest	TROPICAL DECIDUOUS FOREST; BOOSTED REGRESSION TREES; LEAF-AREA INDEX; SPATIAL VARIABILITY; NORTHERN THAILAND; INTERANNUAL VARIATION; WOODED ECOSYSTEMS; RAINFALL; STEMFLOW; STAND	Valuable teak (Tectona grandis Linn. f.) plantations cover vast areas throughout Southeast Asia. This study sought to increase our understanding of throughfall inputs under teak by analyzing the abiotic and biotic factors governing throughfall amounts and ratios in relation to three canopy phenophases (leafless, leafing, and leafed). There was no rain during the brief leaf senescence phenophase in our study. Leveraging detailed field observations, we employed boosted regression tree (BRT) analysis to identify the primary controls on throughfall amount and ratio during each canopy phenophase. Whereas throughfall amounts were always dominated by rainfall magnitude (as expected), throughfall ratios were governed by a suite of predictor variables during each phenophase. The BRT analysis demonstrated that throughfall ratio in the leafless phase was most influenced (in descending order of importance) by air temperature, rainfall amount, maximum wind speed, and rainfall intensity. Throughfall ratio in the leafed phenophase was dominated by rainfall amount. The leafing phenophase was an intermediate case where rainfall amount, air temperature, and vapor pressure deficit were most important. Our results highlight the fact that throughfall ratios are differentially influenced by a suite of meteorological variables during each canopy phenophase. Abiotic variables, such as rainfall amount and air temperature, trumped leaf area index and stand density in their effect on throughfall ratio. The leafing phenophase, while transitional in nature and short in duration, has a detectable and unique impact on water inputs to teak plantations. Further work is needed to better understand the biogeochemistry of leaf emergence in teak plantations.	[Tanaka, Nobuaki] Univ Tokyo, Univ Tokyo Forests, Grad Sch Agr & Life Sci, Ecohydrol Res Inst, Seto, Aichi 4890031, Japan; [Levia, Delphis] Univ Delaware, Dept Geog, Newark, DE 19716 USA; [Levia, Delphis] Univ Delaware, Dept Plant & Soil Sci, Newark, DE 19716 USA; [Levia, Delphis; Igarashi, Yasunori; Kumagai, Tomo'omi] Nagoya Univ, Hydrospher Atmospher Res Ctr, Nagoya, Aichi 4640801, Japan; [Nanko, Kazuki] Forestry & Forest Prod Res Inst, Dept Meteorol Environm, Tsukuba, Ibaraki 3058687, Japan; [Yoshifuji, Natsuko] Kyoto Univ, Grad Sch Agr, Kyoto 6068502, Japan; [Tanaka, Katsunori] Japan Agcy Marine Earth Sci & Technol, Dept Environm Geochem Cycle Res, Kanazawa Ku, Yokohama, Kanagawa 2360001, Japan; [Tantasirin, Chatchai] Kasetsart Univ, Fac Forestry, Bangkok 10900, Thailand; [Suzuki, Masakazu] Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1130023, Japan	Tanaka, N (reprint author), Univ Tokyo, Univ Tokyo Forests, Grad Sch Agr & Life Sci, Ecohydrol Res Inst, Seto, Aichi 4890031, Japan.	tanaka@uf.a.u-tokyo.ac.jp	Kumagai, Tomo'omi/A-4791-2011; Nanko, Kazuki/F-4833-2010	Nanko, Kazuki/0000-0002-1157-9287	Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology (JST) Agency; Ministry of Education, Culture, Sports, Science and Technology in Japan;  [23405028];  [24405031];  [23780161];  [24310018];  [22780139]	This work was funded by the Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology (JST) Agency, the Ministry of Education, Culture, Sports, Science and Technology in Japan through a project titled "Program for risk information on climate change", and Grant-in-Aid for Scientific Research (#23405028, #24405031, #23780161, #24310018, #22780139). We are grateful to Mika Kawamoto for setting up throughfall plot A of this study and also to graduate students from Faculty of Forestry, Kasetsart University, for their assistance in the field. We would like to thank Suwan Pakrat and Srinuan Tunjai for their daily measurements of rainfall and throughfall. David Legates is kindly acknowledged for his input regarding spatial statistics. Finally, we also would like to acknowledge Forestry Industrial Organization (FIO) in Thailand for kind consideration of our research.	McClain ME, 2003, ECOSYSTEMS, V6, P301, DOI 10.1007/s10021-003-0161-9; Aertsen W, 2012, PLANT SOIL, V354, P157, DOI 10.1007/s11104-011-1052-z; Levia DF, 2006, PROG PHYS GEOG, V30, P605, DOI 10.1177/0309133306071145; Cools N, 2014, FOREST ECOL MANAG, V311, P3, DOI 10.1016/j.foreco.2013.06.047; Carlyle-Moses DE, 2014, J FORESTRY RES, V25, P407, DOI 10.1007/s11676-014-0468-8; Martin MP, 2011, BIOGEOSCIENCES, V8, P1053, DOI 10.5194/bg-8-1053-2011; Macinnis-Ng CMO, 2012, BIOGEOCHEMISTRY, V111, P661, DOI 10.1007/s10533-012-9709-0; Zimmermann A, 2014, AGR FOREST METEOROL, V189, P125, DOI 10.1016/j.agrformet.2014.01.014; Carlyle-Moses DE, 2004, J HYDROL, V297, P124, DOI 10.1016/j.jhydrol.2004.04.007; Nanko K, 2006, J HYDROL, V329, P422, DOI 10.1016/j.jhydrol.2006.02.036; Augusto L, 2002, ANN FOR SCI, V59, P233, DOI 10.1051/forest:2002020; Keim RF, 2005, J HYDROL, V314, P263, DOI 10.1016/j.jhydrol.2005.03.021; Kramer I, 2009, ECOHYDROLOGY, V2, P102, DOI 10.1002/eco.44; STOGSDILL WR, 1989, FOREST ECOL MANAG, V29, P105, DOI 10.1016/0378-1127(89)90059-5; Herbst M, 2008, AGR FOREST METEOROL, V148, P1655, DOI 10.1016/j.agrformet.2008.05.011; Staelens J, 2006, J HYDROL, V330, P651, DOI 10.1016/j.jhydrol.2006.04.032; HERWITZ SR, 1987, EARTH SURF PROCESSES, V12, P425, DOI 10.1002/esp.3290120408; ROBSON AJ, 1994, J HYDROL, V158, P107, DOI 10.1016/0022-1694(94)90048-5; Staelens J, 2007, CAN J FOREST RES, V37, P1359, DOI 10.1139/X07-003; De'ath G, 2007, ECOLOGY, V88, P243, DOI 10.1890/0012-9658(2007)88[243:BTFEMA]2.0.CO;2; Wang HX, 2013, FRONT ENV SCI ENG, V7, P579, DOI 10.1007/s11783-013-0524-1; HERWITZ SR, 1995, J HYDROL, V168, P205, DOI 10.1016/0022-1694(94)02643-P; Kato H, 2013, J HYDROL, V504, P1, DOI 10.1016/j.jhydrol.2013.09.028; Elith J, 2008, J ANIM ECOL, V77, P802, DOI 10.1111/j.1365-2656.2008.01390.x; Koch K, 2009, PHILOS T R SOC A, V367, P1487, DOI 10.1098/rsta.2009.0022; Levia DF, 2011, ECOL STUD-ANAL SYNTH, V216, P425, DOI 10.1007/978-94-007-1363-5_21; Yoshifuji N, 2011, ECOHYDROLOGY, V4, P225, DOI 10.1002/eco.219; Bringe K, 2006, PHYTOCHEMISTRY, V67, P161, DOI 10.1016/j.phytochem.2005.10.018; Holst T, 2004, INT J BIOMETEOROL, V48, P192, DOI 10.1007/s00484-004-0201-y; KIMMINS JP, 1973, ECOLOGY, V54, P1008, DOI 10.2307/1935567; Krishnapillay B., 2000, Unasylva (English ed.), V51, P14; Kume T, 2013, ECOHYDROLOGY, V6, P134, DOI 10.1002/eco.1253; LLORENS P, 2003, HYDR MED SEM REG, V278, P101; Loescher HW, 2002, J TROP ECOL, V18, P397, DOI 10.1017/S0266467402002274; LOUSTAU D, 1992, J HYDROL, V138, P449, DOI 10.1016/0022-1694(92)90130-N; MAASS JM, 1995, FOREST ECOL MANAG, V74, P171, DOI 10.1016/0378-1127(94)03485-F; MARSCHNER H., 1995, MINERAL NUTR HIGHER; Nanko K, 2014, HYDROL SCI IN PRESS; PETERSON DL, 1979, FOREST SCI, V25, P582; Raat KJ, 2002, HYDROL EARTH SYST SC, V6, P363; Ridgeway G., 2013, GBM GEN BOOSTED REGR; Ritter A, 2010, AGR FOREST METEOROL, V150, P1102, DOI 10.1016/j.agrformet.2010.04.010; Shinohara Y, 2010, HYDROL PROCESS, V24, P253, DOI 10.1002/hyp.7473; Tanaka N, 2011, HYDROL PROCESS, V25, P384, DOI 10.1002/hyp.7729; Vrugt JA, 2003, WATER RESOUR RES, V39, DOI 10.1029/2003WR002013; Wang Q, 2004, THEOR APPL CLIMATOL, V79, P225, DOI 10.1007/s00704-004-0074-3; Yoshifuji N, 2014, INT J BIOMETEOROL, V58, P2025, DOI 10.1007/s00484-013-0784-2; Zimmermann A, 2009, WATER RESOUR RES, V45, DOI 10.1029/2008WR007470	48	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0020-7128	1432-1254		INT J BIOMETEOROL	Int. J. Biometeorol.	SEP	2015	59	9					1145	1156		10.1007/s00484-014-0926-1		12	Biophysics; Environmental Sciences; Meteorology & Atmospheric Sciences; Physiology	Biophysics; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences; Physiology	CO9ZI	WOS:000359535200001		
J	Lee, S; Fujimura, H; Shimomura, Y; Katsuura, T				Lee, Soomin; Fujimura, Hiroko; Shimomura, Yoshihiro; Katsuura, Tetsuo			Verification of impact of morning showering and mist sauna bathing on human physiological functions and work efficiency during the day	INTERNATIONAL JOURNAL OF BIOMETEOROLOGY			English	Article						Mist sauna; Physiological function; Work efficiency; Morning bathing	SPECTRAL-ANALYSIS; HEART-RATE; EEG; ATTENTION; RESPONSES; RECOVERY; FATIGUE	Recently, a growing number in Japan are switching to taking baths in the morning (morning bathing). However, the effects of the morning bathing on human physiological functions and work efficiency have not yet been revealed. Then, we hypothesized that the effect of morning bathing on physiological functions would be different from those of night bathing. In this study, we measured the physiological functions and work efficiency during the day following the morning bathing (7:10-7:20) including showering, mist sauna bathing, and no bathing as a control. Ten male healthy young adults participated in this study as the subjects. We evaluated the rectal temperature (Tre), skin temperature (Tsk), heart rate (HR), heart rate variability (HRV), blood pressure (BP), the relative power density of the alpha wave (alpha-wave ratio) of electroencephalogram, alpha attenuation coefficient (AAC), and the error rate of the task performance. As a result, we found that the HR after the mist sauna bathing was significantly lower than those after no bathing rest 3 (11:00). Furthermore, we verified that the alpha-wave ratio of the Pz after the mist sauna bathing was significantly lower than those after no bathing during the task 6 (15:00). On the other hand, the alpha-wave ratio of the Pz after the mist sauna bathing was significantly higher than those after showering during the rest 3 (11:00). Tsk after the mist sauna bathing was higher than those after the showering at 9:00 and 15:00. In addition, the error rate of the task performance after the mist sauna bathing was lower than those after no bathing and showering at 14:00. This study concludes that a morning mist sauna is safe and maintains both skin temperature compared to other bathing methods. Moreover, it is presumed that the morning mist sauna bathing improves work efficiency comparing other bathing methods during the task period of the day following the morning bathing.	[Lee, Soomin] Chiba Univ, Ctr Environm Hlth & Field Sci, Kashiwa, Chiba 2770882, Japan; [Fujimura, Hiroko] Tokyo Gas Co Ltd, Urban Res Inst, Tokyo, Japan; [Shimomura, Yoshihiro; Katsuura, Tetsuo] Chiba Univ, Grad Sch Engn, Chiba 12, Japan	Lee, S (reprint author), Chiba Univ, Ctr Environm Hlth & Field Sci, 6-2-1 Kashiwanoha, Kashiwa, Chiba 2770882, Japan.	yisoomin@chiba-u.jp; h_katsumata@tokyo-gas.co.jp; shimomura@faculty.chiba-u.jp; katsu@faculty.chiba-u.jp			Tokyo Gas. Co., Ltd.	The authors wish to thank the subjects for their kind cooperation. This study was supported by a grant from Tokyo Gas. Co., Ltd. We would also like to express our thanks to Tokyo Gas Co., Ltd. The authors declare that they have no conflict of interest.	Capotosto P, 2009, J NEUROSCI, V29, P5863, DOI 10.1523/JNEUROSCI.0539-09.2009; Klimesch W, 2007, BRAIN RES REV, V53, P63, DOI 10.1016/j.brainresrev.2006.06.003; PAGANI M, 1986, CIRC RES, V59, P178; Romei V, 2008, CEREB CORTEX, V18, P2010, DOI 10.1093/cercor/bhm229; Kelly SP, 2009, EUR J NEUROSCI, V30, P2224, DOI [10.1111/j.1460-9568.2009.06980.x, 10.1111/j.1460-9568.2009.6980.x]; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151; Okuda M, 2002, J DERMATOL SCI, V30, P173, DOI 10.1016/S0923-1811(02)00106-8; Yoto Ai, 2007, Journal of Physiological Anthropology, V26, P373, DOI 10.2114/jpa2.26.373; BERARDESCA E, 1995, CONTACT DERMATITIS, V32, P83, DOI 10.1111/j.1600-0536.1995.tb00751.x; Ergen M, 2014, INT J PSYCHOPHYSIOL, DOI [10.1016/j.ijppsycho.2014.08.177, DOI 10.1016/J.IJPPSYCHO.2014.08.177]; Hashiguchi Nobuko, 2002, Journal of Physiological Anthropology and Applied Human Science, V21, P277, DOI 10.2114/jpa.21.277; Iwase S, 2013, HEALTH, V5, P267, DOI [10.4236/health.2013.52036, DOI 10.4236/HEALTH.2013.52036]; JOHNSTON BL, 1981, HEART LUNG, V10, P666; Kawahara Y, 2002, AUTON NERV SYST, V39, P402; Lee S, 2012, J PHYSIOL ANTHROPOL, V31, DOI 10.1186/1880-6805-31-26; Liu Xinxin, 2007, Journal of Physiological Anthropology, V26, P355, DOI 10.2114/jpa2.26.355; Miwa C, 1994, AUTON NERV SYST, V31, P38; Miwa C, 1999, AUTON NERV SYST, V36, P478; Miwa C, 1998, GEN REHABIL, V26, P355; Mizuno K, 2010, MED SCI MONITOR, V16, pCR8; Onaka T, 1995, APPL HUMAN SCI, V14, P235; Sudo M, 1966, AEROSPACE ENV MED, V33, P294; Swan N, 2014, Arch Clin Neuropsychol, V29, P563, DOI 10.1093/arclin/acu038.158; Tochihara Y, 1999, J HUM ENV SYST, V3, P27; VUORI I, 1988, ANN CLIN RES, V20, P249; Watanabe I, 1994, CLIN BODY TEMPERATUR, V14, P35; Yokoi Mari, 2003, Journal of Physiological Anthropology and Applied Human Science, V22, P257, DOI 10.2114/jpa.22.257	27	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0020-7128	1432-1254		INT J BIOMETEOROL	Int. J. Biometeorol.	SEP	2015	59	9					1207	1212		10.1007/s00484-014-0932-3		6	Biophysics; Environmental Sciences; Meteorology & Atmospheric Sciences; Physiology	Biophysics; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences; Physiology	CO9ZI	WOS:000359535200007		
J	Onozuka, D; Hagihara, A				Onozuka, Daisuke; Hagihara, Akihito			Non-stationary dynamics of climate variability in synchronous influenza epidemics in Japan	INTERNATIONAL JOURNAL OF BIOMETEOROLOGY			English	Article						Climate change; El Nino Southern Oscillation; Indian Ocean Dipole; Influenza; Wavelet analysis	RESPIRATORY-TRACT INFECTIONS; NINO-SOUTHERN-OSCILLATION; INDIAN-OCEAN; EL-NINO; RELATIVE-HUMIDITY; WAVELET ANALYSIS; TEMPERATURE; TRANSMISSION; SEASONALITY; VIRUS	Seasonal variation in the incidence of influenza is widely assumed. However, few studies have examined non-stationary relationships between global climate factors and influenza epidemics. We examined the monthly incidence of influenza in Fukuoka, Japan, from 2000 to 2012 using cross-wavelet coherency analysis to assess the patterns of associations between indices for the Indian Ocean Dipole (IOD) and El Nio Southern Oscillation (ENSO). The monthly incidence of influenza showed cycles of 1 year with the IOD and 2 years with ENSO indices (Multivariate, Nio 4, and Nio 3.4). These associations were non-stationary and appeared to have major influences on the synchrony of influenza epidemics. Our study provides quantitative evidence that non-stationary associations have major influences on synchrony between the monthly incidence of influenza and the dynamics of the IOD and ENSO. Our results call for the consideration of non-stationary patterns of association between influenza cases and climatic factors in early warning systems.	[Onozuka, Daisuke; Hagihara, Akihito] Kyushu Univ, Grad Sch Med Sci, Dept Hlth Care Adm & Management, Higashi Ku, Fukuoka 8128582, Japan; [Onozuka, Daisuke] Fukuoka Inst Hlth & Environm Sci, Dept Planning Informat & Adm, Dazaifu, Fukuoka 8180135, Japan	Onozuka, D (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Hlth Care Adm & Management, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	onozukad@hcam.med.kyushu-u.ac.jp	Onozuka, Daisuke/F-5067-2014	Onozuka, Daisuke/0000-0001-9596-9188	Ministry of Health, Labour and Welfare, Japan	The study was supported by grants from the Ministry of Health, Labour and Welfare, Japan and budgets for research of the Department of Public Health and Medical Affairs, Fukuoka Prefectural Government. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akihiko T, 2014, SCI REP-UK, V4, DOI 10.1038/srep05655; Mourtzoukou EG, 2007, INT J TUBERC LUNG D, V11, P938; Tamerius J, 2011, ENVIRON HEALTH PERSP, V119, P439, DOI 10.1289/ehp.1002383; Luo JJ, 2012, P NATL ACAD SCI USA, V109, P18701, DOI 10.1073/pnas.1210239109; Shaman J, 2009, P NATL ACAD SCI USA, V106, P3243, DOI 10.1073/pnas.0806852106; Annamalai H, 2005, J CLIMATE, V18, P302, DOI 10.1175/JCLI-3268.1; Luo JJ, 2010, J CLIMATE, V23, P726, DOI 10.1175/2009JCLI3104.1; Hashizume M, 2009, P NATL ACAD SCI USA, V106, P1857, DOI 10.1073/pnas.0806544106; SALAH B, 1988, EUR RESPIR J, V1, P852; Guan ZY, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016831; du Prel JB, 2009, CLIN INFECT DIS, V49, P861, DOI 10.1086/605435; Ayres JG, 2009, EUR RESPIR J, V34, P295, DOI 10.1183/09031936.00003409; Onozuka D, 2008, EPIDEMIOLOGY, V19, P824, DOI 10.1097/EDE.0b013e3181880eda; Saji NH, 1999, NATURE, V401, P360, DOI 10.1038/43855; Lowen AC, 2008, J VIROL, V82, P5650, DOI 10.1128/JVI.00325-08; Nakamura N, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL040590; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; Maraun D, 2004, NONLINEAR PROC GEOPH, V11, P505; Cox NJ, 1999, LANCET, V354, P1277, DOI 10.1016/S0140-6736(99)01241-6; Steel J, 2011, J VIROL, V85, P1400, DOI 10.1128/JVI.02186-10; Lofgren E, 2007, J VIROL, V81, P5429, DOI 10.1128/JVI.01680-06; SCHAFFER FL, 1976, ARCH VIROL, V51, P263, DOI 10.1007/BF01317930; Hallett TB, 2004, NATURE, V430, P71, DOI 10.1038/nature02708; Cazelles B, 2005, PLOS MED, V2, P313, DOI 10.1371/journal.pmed.0020106; Cazelles B, 2006, PLOS MED, V3, P1212, DOI 10.1371/journal.pmed.0030328; Chaves LF, 2006, PLOS MED, V3, P1320, DOI 10.1371/journal.pmed.0030295; Iseri Y, 2007, MODSIM 2007: INTERNATIONAL CONGRESS ON MODELLING AND SIMULATION, P1533; LeMerre C, 1996, RESP PHYSIOL, V105, P235; Lowen AC, 2007, PLOS PATHOG, V3, P1470, DOI 10.1371/journal.ppat.0030151; Patz JA, 2002, NATURE, V420, P627, DOI 10.1038/420627a; Shaman J, 2013, P NATL ACAD SCI USA, V110, P3689, DOI 10.1073/pnas.1107485109; Shaman J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000316; Viboud C, 2006, PLOS MED, V3, P468, DOI 10.1371/journal.pmed.0030089; Viboud C, 2004, EUR J EPIDEMIOL, V19, P1055, DOI 10.1007/s10654-004-2450-9; WHO, INFL SEAS; Zaraket H, 2008, INFLUENZA OTHER RESP, V2, P127, DOI 10.1111/j.1750-2659.2008.00047.x	36	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0020-7128	1432-1254		INT J BIOMETEOROL	Int. J. Biometeorol.	SEP	2015	59	9					1253	1259		10.1007/s00484-014-0936-z		7	Biophysics; Environmental Sciences; Meteorology & Atmospheric Sciences; Physiology	Biophysics; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences; Physiology	CO9ZI	WOS:000359535200011		
J	Hernandez, M; Hudson, MJ				Hernandez, Mauricio; Hudson, Mark J.			Diagnosis and evaluation of causative factors for the presence of endemic treponemal disease in a Japanese sub-tropical island population from the Tokugawa period	INTERNATIONAL JOURNAL OF PALEOPATHOLOGY			English	Article						Yaws; Treponemal disease; Paleopathology; Ryukyu Islands; Japan	MARIANA ISLANDS; RYUKYU ISLANDS; INHABITANTS; REMAINS; PACIFIC; HEALTH; GUAM	We present a description and differential diagnosis of pathological lesions observed on skeletal elements found during surface surveys of the Nagabaka site on Miyako-jima Island, Japan. The Nagabaka site served as a bone depository during the Early Modern period (c. AD 1600-1870). We evaluated remains via macroscopic inspection to classify infectious lesions according to criteria in Weston (2008). We also obtained CT scans of three bone elements for more extensive lesion analysis and carried out a differential diagnosis utilizing paleopathological literature. Subsequent investigation yielded convincing evidence of treponemal infection on 23 skeletal elements. Based on known geographical spread and morphological comparisons of lesion patterning, we identified yaws as the pathogen most likely responsible, but refrained from calculating site-wide prevalence due to the taphonomical nature of the sample. Lastly, we review treponemal infection rates in other archaeological sites throughout Southeast Asia and Oceania, and assess similar ecological and cultural factors contributing to the observed pathologies. Nagabaka is the northernmost site in the world where yaws has so far been identified. Located between sites between Mainland China and Western Micronesia where this infection has been previously identified, Miyako-jima holds an important geographical position for research into the historical spread of pathogens. (C) 2015 Elsevier Inc. All rights reserved.	[Hernandez, Mauricio] Univ Cambridge, Dept Archaeol & Anthropol, Div Biol Anthropol, Cambridge CB2 3DZ, England; [Hudson, Mark J.] Nishikyushu Univ, Res Inst Sustainable Environm & Cultures, Kanzaki 8428585, Japan	Hernandez, M (reprint author), Univ Cambridge Downing Coll, Regent St, Cambridge CB2 1DQ, England.	mh608@cam.ac.uk			MEXT, Japan [21101005]; Downing College Graduate Travel Grant; Ridgeway-Venn Travel Studentship; Worts Traveling Scholar Fund; JSPS	Grant Sponsorship: Grant-in-aid for Scientific Research on Innovative Areas, MEXT, Japan for the project 'Environmental and cultural changes in the Ryukyu archipelago during prehistoric and proto-historic times' (No. 21101005), Downing College Graduate Travel Grant, Ridgeway-Venn Travel Studentship, Worts Traveling Scholar Fund, and JSPS Core-to-Core Program.	Pettifor JM, 2011, BEST PRACT RES CL EN, V25, P573, DOI 10.1016/j.beem.2011.06.010; Weston DA, 2008, AM J PHYS ANTHROPOL, V137, P48, DOI 10.1002/ajpa.20839; ROTHSCHILD BM, 1993, CLIN INFECT DIS, V17, P198; Gray RD, 2009, SCIENCE, V323, P479, DOI 10.1126/science.1166858; Domett KM, 2006, ARCHAEOL OCEAN, V41, P25; Aufderheide A. C., 1998, CAMBRIDGE ENCY HUMAN, P154, DOI DOI 10.2277/0521552036; Borobia Melendo E. L., 1995, P 4 EUR M PAL ASS BA, P47; Brothwell D R, 1976, Bull Hist Med, V50, P435; Cockburn T., 1967, INFECT DIS THEIR EVO, P84; Cook D. C., 1976, THESIS U CHICAGO US; Dodo Y, 2000, ANTHROPOL SCI, V108, P183; Dodo Y, 1998, ANTHROPOL SCI, V106, P99; Dodo Y, 2001, ANTHROPOL SCI, V109, P183; Douglas MT, 1997, AM J PHYS ANTHROPOL, V104, P291; Hackett C. J., 1936, BOOMERANG LEG YAWS A; Hackett CJ, 1976, DIAGNOSTIC CRITERIA; Harper K. N., 2008, PLOS NEGLECT TROP D, V2, P1; IKEDA J, 1974, Journal of the Anthropological Society of Nippon, V82, P150; Lallo J. W., 1973, THESIS U MIT AMHERST; Leung Angela Ki Che, 1993, P354, DOI 10.1017/CHOL9780521332866.041; Nagabaka Archaeology Project, 2013, PAI MMI NU NAG ISEK, V1; Ortner D. J., 1992, PALEOPATHOLOGY NEWSL, V79, P5; Ortner D.J., 2003, IDENTIFICATION PATHO; Osterholtz A. J., 2014, COMMINGLED DISARTICU, P35; Pellard T., 2015, HDB RYUKYUAN LANGUAG, P13; Pietrusewsky M, 1999, ANTHROPOL SCI, V107, P255; Pietrusewsky M, 1997, AM J PHYS ANTHROPOL, V104, P315; Scheuer L., 2000, DEV JUVENILE OSTEOLO; Steinbock R.T., 1976, PALEOPATHOLOGICAL DI; Stewart T. D., 1967, DIS ANTIQUITY, P307; STEWART T. D., 1952, BULL HIST MED, V26, P538; Stodder A., 1992, AM J PHYS ANTHR S, VS14, P157; Stodder A. L. W., 1991, 89882 PHRI; Stodder A. L. W., 1991, 89757 PHRI; Stodder ALW, 1997, AM J PHYS ANTHROPOL, V104, P363; Suzuki T., 1986, ANTHR STUDIES ORIGIN, P15; Suzuki T., 1984, BULLETIN, V23, P1; Trembly DL, 1996, INT J OSTEOARCHAEOL, V6, P397, DOI 10.1002/(SICI)1099-1212(199609)6:4<397::AID-OA289>3.0.CO;2-#; Willey P., 1997, 50 MIDW ARCH CTR NAT; Zhang Z., 1994, ACTA ANTHR SINICA, V13, P294; Zukeran C, 2002, ANTHROPOL SCI, V110, P421	41	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1879-9817	1879-9825		INT J PALEOPATHOL	Int. J. Paleopathol.	SEP	2015	10						16	25		10.1016/j.ijpp.2015.04.001		10	Paleontology; Pathology	Paleontology; Pathology	CO7GB	WOS:000359326500003		
J	Kawano, H; Levi, C; Inatomi, Y; Pagram, H; Kerr, E; Bivard, A; Spratt, N; Miteff, F; Yonehara, T; Ando, Y; Parsons, M				Kawano, H.; Levi, C.; Inatomi, Y.; Pagram, H.; Kerr, E.; Bivard, A.; Spratt, N.; Miteff, F.; Yonehara, T.; Ando, Y.; Parsons, M.			International bench marking for acute stroke codes: Thrombolytic therapy access in Australia and Japan	INTERNATIONAL JOURNAL OF STROKE			English	Meeting Abstract									[Kawano, H.; Levi, C.; Pagram, H.; Kerr, E.; Bivard, A.; Spratt, N.; Miteff, F.; Parsons, M.] Univ Newcastle, John Hunter Hosp, Dept Neurol, New Lambton Hts, NSW, Australia; [Kawano, H.; Levi, C.; Pagram, H.; Kerr, E.; Bivard, A.; Spratt, N.; Miteff, F.; Parsons, M.] Univ Newcastle, Hunter Med Res Inst, New Lambton Hts, NSW, Australia; [Inatomi, Y.; Yonehara, T.] Saiseikai Kumamoto Hosp, Dept Neurol, Kumamoto, Japan; [Ando, Y.] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Kumamoto, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1747-4930	1747-4949		INT J STROKE	Int. J. Stroke	SEP	2015	10			3	SI		20	20				1	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CO6YR	WOS:000359304400049		
J	Lim, JY; Hackett, ML; Venturelli, PAM; Arima, H; Middleton, S; Olavarria, VV; Brunser, AM; Lavados, PM; Peng, B; Cui, L; Lin, RT; Lee, TH; Pontes-Neto, O; Natsagdorj, L; Watkins, CL; Robinson, TG; Anderson, CS				Lim, J. Y.; Hackett, M. L.; Venturelli, P. A. Munoz; Arima, H.; Middleton, S.; Olavarria, V. V.; Brunser, A. M.; Lavados, P. M.; Peng, B.; Cui, L.; Lin, R-Tay; Lee, T-H; Pontes-Neto, O.; Natsagdorj, L.; Watkins, C. L.; Robinson, T. G.; Anderson, C. S.			Are ups and downs important? Head Position in Stroke Trial (HeadPoST)	INTERNATIONAL JOURNAL OF STROKE			English	Meeting Abstract									[Lim, J. Y.; Hackett, M. L.; Anderson, C. S.] George Inst Global Hlth, Camperdown, NSW, Australia; [Venturelli, P. A. Munoz; Olavarria, V. V.; Brunser, A. M.; Lavados, P. M.] Univ Desarrollo, Clin Alemana Santiago, Santiago, Chile; [Arima, H.] Shiga Univ Med Sci, Ctr Epidemiol Res Asia, Otsu, Shiga 52021, Japan; [Middleton, S.] St Vincents & Mater Hlth Sydney, Nursing Res Inst, Sydney, NSW, Australia; [Middleton, S.] Australian Catholic Univ, Sydney, NSW, Australia; [Peng, B.; Cui, L.] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurol, Beijing 100730, Peoples R China; [Lin, R-Tay] Kaohsiung Med Univ, Chung Ho Mem Hosp, Taipei, Taiwan; [Lee, T-H] Linkou Chang Gung Mem Hosp, Dept Neurol, Taipei, Taiwan; [Pontes-Neto, O.] Univ Sao Paulo, Ribeirao Preto Sch Med, BR-14049 Ribeirao Preto, Brazil; [Natsagdorj, L.] State Third Hosp, Ulaanbaatar, Mongol Peo Rep; [Watkins, C. L.] Univ Cent Lancashire, Sch Hlth, Preston PR1 2HE, Lancs, England; [Robinson, T. G.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; [Robinson, T. G.] Univ Leicester, NIHR Biomed Res Unit Cardiovasc Sci, Leicester, Leics, England			Pontes-Neto, Octavio/G-4294-2012	Pontes-Neto, Octavio/0000-0003-0317-843X				0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1747-4930	1747-4949		INT J STROKE	Int. J. Stroke	SEP	2015	10			3	SI		20	20				1	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CO6YR	WOS:000359304400048		
J	Kato, Y; Hayashi, T; Tanahashi, N; Kobayashi, S				Kato, Y.; Hayashi, T.; Tanahashi, N.; Kobayashi, S.			Cardioembolic stroke is the most serious problem in the ageing society: Japan Standard Stroke Registry Study	INTERNATIONAL JOURNAL OF STROKE			English	Meeting Abstract									[Kato, Y.; Hayashi, T.; Tanahashi, N.; Kobayashi, S.] Saitama Med Univ, Saitama Int Med Ctr, Hidaka, Saitama, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1747-4930	1747-4949		INT J STROKE	Int. J. Stroke	SEP	2015	10			3	SI		66	66				1	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CO6YR	WOS:000359304400182		
J	Nagakane, Y; Yamamoto, Y; Akazawa, K; Yamada, K				Nagakane, Y.; Yamamoto, Y.; Akazawa, K.; Yamada, K.			High-resolution-MRI-verified mural plaque as a predictor for neurological deterioration in small deep infarcts	INTERNATIONAL JOURNAL OF STROKE			English	Meeting Abstract									[Nagakane, Y.; Yamamoto, Y.] Kyoto Second Red Cross Hosp, Neurol, Kyoto, Japan; [Akazawa, K.; Yamada, K.] Kyoto Prefectural Univ Med, Radiol, Kyoto, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1747-4930	1747-4949		INT J STROKE	Int. J. Stroke	SEP	2015	10			3	SI		73	74				2	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CO6YR	WOS:000359304400206		
J	Runge, VM; Aoki, S; Bradley, WG; Chang, KH; Essig, M; Ma, L; Ross, JS; Valavanis, A				Runge, Val M.; Aoki, Shigeki; Bradley, William G., Jr.; Chang, Kee-Hyun; Essig, Marco; Ma, Lin; Ross, Jeffrey S.; Valavanis, Anton			Magnetic Resonance Imaging and Computed Tomography of the Brain-50 Years of Innovation, With a Focus on the Future	INVESTIGATIVE RADIOLOGY			English	Review						brain; magnetic resonance imaging; central nervous system; computed tomography; gadolinium; technology	7 T; INVERSION-RECOVERY; CONTRAST AGENTS; DIFFUSION; ANGIOGRAPHY; QUALITY; SYSTEM; BLOOD; CT; TUMORS	This review focuses specifically on the developments in brain imaging, as opposed to the spine, and specifically conventional, clinical, cross-sectional imaging, looking primarily at advances in magnetic resonance imaging (MRI) and computed tomography (CT). These fields are viewed from a perspective of landmark publications in the last 50 years and subsequently more in depth using sentinel publications from the last 5 years. It is also written from a personal perspective, with the authors having witnessed the evolution of both fields from their initial clinical introduction to their current state. Both CT and MRI have made tremendous advances during this time, regarding not only sensitivity and spatial resolution, but also in terms of the speed of image acquisition. Advances in CT in recent years have focused in part on reduced radiation dose, an important topic for the years to come. Magnetic resonance imaging has seen the development of a plethora of scan techniques, with marked superiority to CT in terms of tissue contrast due to the many parameters that can be assessed, and their intrinsic sensitivity. Future advances in MRI for clinical practice will likely focus both on new acquisition techniques that offer advances in speed and resolution, for example, simultaneous multislice imaging and data sparsity, and on standardization and further automation of image acquisition and analysis. Functional imaging techniques including specifically perfusion and functional magnetic resonance imaging will be further integrated into the workflow to provide pathophysiologic information that influence differential diagnosis, assist treatment decision and planning, and identify and follow treatment-related changes.	[Runge, Val M.] Univ Zurich Hosp, Inst Diagnost & Intervent Radiol, Clin Neuroradiol, CH-8091 Zurich, Switzerland; [Aoki, Shigeki] Juntendo Univ, Dept Radiol, Tokyo, Japan; [Bradley, William G., Jr.] Univ Calif San Diego Hlth Syst, Dept Radiol, San Diego, CA USA; [Chang, Kee-Hyun] Soonchunhyang Univ Hosp, Dept Radiol, Bucheon, South Korea; [Essig, Marco] Univ Manitoba, Dept Radiol, Winnipeg, MB, Canada; [Ma, Lin] Peoples Liberat Army Gen Hosp, Dept Radiol, Beijing, Peoples R China; [Ross, Jeffrey S.] Barrow Neurol Inst, Dept Neuroradiol, Phoenix, AZ 85013 USA; [Valavanis, Anton] Univ Zurich Hosp, Dept Neuroradiol, CH-8091 Zurich, Switzerland	Runge, VM (reprint author), Univ Zurich Hosp, Inst Diagnost & Intervent Radiol, Clin Neuroradiol, Raemistr 100, CH-8091 Zurich, Switzerland.	val.runge@mac.com					Percy DB, 2011, INVEST RADIOL, V46, P718, DOI 10.1097/RLI.0b013e318226c427; Shen YQ, 2015, INVEST RADIOL, V50, P330, DOI 10.1097/RLI.0000000000000132; Kukuk GM, 2010, INVEST RADIOL, V45, P126, DOI 10.1097/RLI.0b013e3181c7bcfe; Cavagna FM, 1997, INVEST RADIOL, V32, P780, DOI 10.1097/00004424-199712000-00009; WESBEY GE, 1984, INVEST RADIOL, V19, P491, DOI 10.1097/00004424-198411000-00005; Bouvy WH, 2014, INVEST RADIOL, V49, P307, DOI 10.1097/RLI.0000000000000027; Schmidt H, 2014, INVEST RADIOL, V49, P373, DOI 10.1097/RLI.0000000000000021; Xu JQ, 2013, NEUROIMAGE, V83, P991, DOI 10.1016/j.neuroimage.2013.07.055; Kwee RM, 2010, INVEST RADIOL, V45, P803, DOI 10.1097/RLI.0b013e3181ed15ff; Reichert M, 2013, INVEST RADIOL, V48, P55, DOI 10.1097/RLI.0b013e318277b1aa; Rohrer M, 2005, INVEST RADIOL, V40, P715, DOI 10.1097/01.rli.0000184756.66360.d3; Bisdas S, 2013, INVEST RADIOL, V48, P295, DOI 10.1097/RLI.0b013e31827188d6; Morhard D, 2010, INVEST RADIOL, V45, P363, DOI 10.1097/RLI.0b013e3181e1956f; Deppe M, 2007, INVEST RADIOL, V42, P338, DOI 10.1097/01.rli.0000261935.41188.39; Johst S, 2012, INVEST RADIOL, V47, P445, DOI 10.1097/RLI.0b013e31824ef21f; Koerte IK, 2011, INVEST RADIOL, V46, P434, DOI 10.1097/RLI.0b013e318210ecf5; BROWN RA, 1979, INVEST RADIOL, V14, P300, DOI 10.1097/00004424-197907000-00006; Graessl A, 2014, INVEST RADIOL, V49, P260, DOI 10.1097/RLI.0000000000000049; Tan H, 2014, INVEST RADIOL, V49, P498, DOI 10.1097/RLI.0000000000000043; Ingrisch M, 2012, INVEST RADIOL, V47, P252, DOI 10.1097/RLI.0b013e31823bfc97; Erb-Eigner K, 2013, INVEST RADIOL, V48, P702, DOI 10.1097/RLI.0b013e31828eea67; Schmitter S, 2014, INVEST RADIOL, V49, P314, DOI 10.1097/RLI.0000000000000033; Kober T, 2012, INVEST RADIOL, V47, P346, DOI 10.1097/RLI.0b013e31824600e9; Cauley SF, 2014, MAGN RESON MED, V72, P93, DOI 10.1002/mrm.24898; Tawfik AM, 2012, INVEST RADIOL, V47, P306, DOI 10.1097/RLI.0b013e31821e3062; Cho ES, 2012, INVEST RADIOL, V47, P142, DOI 10.1097/RLI.0b013e31823076a4; Yang S, 2013, INVEST RADIOL, V48, P113, DOI 10.1097/RLI.0b013e318277f078; Nagel AM, 2011, INVEST RADIOL, V46, P539, DOI 10.1097/RLI.0b013e31821ae918; Ardekani S, 2006, INVEST RADIOL, V41, P806, DOI 10.1097/01.rli.0000242859.75922.be; AXEL L, 1983, INVEST RADIOL, V18, P94, DOI 10.1097/00004424-198301000-00018; Becker HC, 2012, INVEST RADIOL, V47, P202, DOI 10.1097/RLI.0b013e31823a86d5; BELLIVEAU JW, 1992, INVEST RADIOL, V27, pS59; Blaimer M, 2013, MAGN RESON MED, V69, P974, DOI 10.1002/mrm.24685; Bonanno G, 2015, INVEST RADIOL, V50, P135, DOI 10.1097/RLI.0000000000000110; Boss A, 2010, INVEST RADIOL, V45, P270, DOI 10.1097/RLI.0b013e3181dc3671; Christoforidis GA, 2011, INVEST RADIOL, V46, P34, DOI 10.1097/RLI.0b013e3181f0cbc7; de Rotte AAJ, 2014, INVEST RADIOL, V49, P749, DOI 10.1097/RLI.0000000000000079; Dyvorne H, 2014, RADIOLOGY, V275, P245; Filli L, 2015, INVEST RADIOL, V50, P456, DOI 10.1097/RLI.0000000000000151; Frayne R, 2003, INVEST RADIOL, V38, P385, DOI 10.1097/01.rli.0000073442.88269.c9; Fritzsch D, 2014, INVEST RADIOL, V49, P299, DOI 10.1097/RLI.0000000000000010; Gao SJ, 2014, INVEST RADIOL, V49, P593, DOI 10.1097/RLI.0000000000000059; GLENN WV, 1975, INVEST RADIOL, V10, P403, DOI 10.1097/00004424-197509000-00002; Hutter J, 2015, MAGMA; KENT DL, 1992, INVEST RADIOL, V27, P245, DOI 10.1097/00004424-199203000-00014; Koerte I, 2009, INVEST RADIOL, V44, P279, DOI 10.1097/RLI.0b013e31819e9362; Kraff O, 2011, INVEST RADIOL, V46, P246, DOI 10.1097/RLI.0b013e318206cee4; Kroner ESJ, 2012, INVEST RADIOL, V47, P697, DOI 10.1097/RLI.0b013e31826dc174; Lau AZ, 2015, MAGN RESON MED, V73, P995, DOI 10.1002/mrm.25200; Lee JW, 2006, INVEST RADIOL, V41, P553, DOI 10.1097/01.rli.0000221325.03899.48; Muehlmann M, 2013, INVEST RADIOL, V48, P543, DOI 10.1097/RLI.0b013e31828ad504; Nowinski WL, 2013, INVEST RADIOL, V48, P661, DOI 10.1097/RLI.0b013e31828d8403; Nunn AD, 2006, INVEST RADIOL, V41, P206, DOI 10.1097/01.rli.0000191370.52737.75; Nute JL, 2015, INVEST RADIOL, V50, P9, DOI 10.1097/RLI.0000000000000089; Papadakis AE, 2013, INVEST RADIOL, V48, P192, DOI 10.1097/RLI.0b013e31827efc17; Park J, 2012, INVEST RADIOL, V47, P136, DOI 10.1097/RLI.0b013e3182319704; Rapacchi S, 2014, MAGN RESON MED; Rezai AR, 2004, INVEST RADIOL, V39, P300, DOI 10.1097/01.rli.0000124940.02340.ab; Runge VM, 2015, ASNR 53 ANN M EL ED; Saranathan M, 2014, INVEST RADIOL, V49, P290, DOI 10.1097/RLI.0000000000000041; Schubert T, 2014, INVEST RADIOL, V49, P189, DOI 10.1097/RLI.0000000000000013; Sharma SD, 2013, INVEST RADIOL, V48, P638, DOI 10.1097/RLI.0b013e31828a012d; Thierfelder KM, 2015, INVEST RADIOL, V51, P361; Thierfelder KM, 2014, INVEST RADIOL, V49, P236, DOI 10.1097/RLI.0000000000000023; Voglein J, 2011, INVEST RADIOL, V46, P390, DOI 10.1097/RLI.0b013e31820e1511; Yoo SS, 2005, INVEST RADIOL, V40, P110, DOI 10.1097/01.rli.0000149491.69201.cb; Zeineh MM, 2014, INVEST RADIOL, V49, P278, DOI 10.1097/RLI.0000000000000015	67	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0020-9996	1536-0210		INVEST RADIOL	Invest. Radiol.	SEP	2015	50	9					551	556		10.1097/RLI.0000000000000170		6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CP1WU	WOS:000359669000002		
J	Oren, E				Oren, Eitan			Low Levels of Military Threat and High Demand for Increasing Military Spending: The "Puzzle of Chinese Students' Data in the Asian Student Survey of 2008	JAPANESE JOURNAL OF POLITICAL SCIENCE			English	Article							UNITED-STATES; SUPPORT; JAPAN	This article examines perceptions of military and defense expenditure as held by Asian students. By using quantitative data from the Asian Student Survey (1) of 2008 it addresses the following questions: to which areas would Asian students like to see their government allocate more or less resources and, specifically, how supportive of defense and military spending are Asian students. This study finds that data concerning one country have appeared deviant. While designating the strongest will to increase defense and military spending among all countries sampled in the survey, Chinese students from leading universities (N = 800; Pekin and Renmin universities in Beijing; Fudan University and Shanghai Jiao Tong university) also exhibit the lowest levels of perceived military threats. The rest of the paper explores the puzzle' of Chinese students by generating and testing a null hypothesis. In it, Chinese students' high demand for military spending is associated with an aggressive design, whereby anti-foreign, unilateral, and nationalist sentiments coincide. After refuting the null hypothesis, the paper advances an alternative explanation that links students' inclination with the call to modernize the People's Liberation Army.	Univ Tokyo, Tokyo 1138654, Japan	Oren, E (reprint author), Univ Tokyo, Tokyo 1138654, Japan.	eythanoren@gmail.com					Zhao SS, 1998, COMMUNIS POST-COMMUN, V31, P287, DOI 10.1016/S0967-067X(98)00009-9; Zheng BJ, 2005, FOREIGN AFF, V84, P18; [Anonymous], 2011, NY TIMES; [Anonymous], 2005, CHINA DAILY; Cao. go. jp, 2013, SURV JAP REL VAR COU; Chen J, 2001, PUBLIC OPIN QUART, V65, P254, DOI 10.1086/322200; Christiansen B., 1959, ATTITUDES FOREIGN AF; Coleman J., 1973, MATH COLLECTIVE ACTI; Coleman J. S., 1990, FDN SOCIAL THEORY; David Logan, 2013, THE DIPLOMAT    1113; Edward Friedman, 1997, J CONTEMP CHINA, V6, P5, DOI [10.1080/10670569708724263, DOI 10.1080/10670569708724263]; Edward Friedman, 2006, CHINAS RISE TAIWANS; Eitan Oren, 2014, EXPLAINING GOVT SPEN; Elster J., 1986, RATIONAL CHOICE; Friedberg Aaron L., 1993, INT SECURITY, V18, P5, DOI 10.2307/2539204; Friedberg Aaron L, 2011, NY TIMES; GAMSON WA, 1966, PUBLIC OPIN QUART, V30, P187, DOI 10.1086/267399; Gries PH, 2009, INT RELAT ASIA-PAC, V9, P245, DOI 10.1093/irap/lcn028; HAMILTON RF, 1968, AM SOCIOL REV, V33, P439, DOI 10.2307/2091917; HOFSTETTER CR, 1979, ARMED FORCES SOC, V5, P261, DOI 10.1177/0095327X7900500204; Hsia Chang Maria, 2000, RETURN DRAGON CHINAS; Huntington Samuel P., 1991, SURVIVAL, V33, P3, DOI [10.1080/00396339108442570, DOI 10.1080/00396339108442570]; ISN Security Watch, 2013, ISN SECURITY WA 1003; Krasner Stephen D, 2009, POWER STATE SOVEREIG; KRIESBERG L, 1980, J CONFLICT RESOLUT, V24, P79; Ladd Jr E., 1978, PUBLIC OPINION   JUL, P48; PHILLIPS NE, 1973, J CONFLICT RESOLUT, V17, P625, DOI 10.1177/002200277301700403; Reilly J. E., 1979, FOREIGN POLICY, V34, P74; Reuters, 2011, REUTERS         0304; SCOTT WA, 1960, PUBLIC OPIN QUART, V24, P419, DOI 10.1086/266961; Shirk Susan L., 2007, CHINA FRAGILE SUPERP; U. S. Department of Defense, 2011, ANN REP C MIL SEC DE; Yu Gouming, 1998, INT NEWS MEDIA   JAN, P21; Zhao Dingxin, 2003, ASIAN PERSPECT, V27, P5	34	0	0	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	1468-1099	1474-0060		JPN J POLIT SCI	Jpn. J. Polit. Sci.	SEP	2015	16	3					248	269		10.1017/S1468109915000183		22	Political Science	Government & Law	CO6KP	WOS:000359265900002		
J	Hijino, K				Hijino, Ken			Bamboo Shoots and Weak Roots: Organizational Expansion of New Parties in Japan	JAPANESE JOURNAL OF POLITICAL SCIENCE			English	Article							ELECTIONS	Recent research claims that local party organizations are essential for new parties seeking organizational stability and national-level electoral success. Yet new parties which emerged in Japan since the 1990s have failed in building nation-wide networks of local organizations. The article asks how these parties sought to expand locally and why their attempts have been largely unsuccessful. It finds evidence that under certain conditions (in urban areas and multi-member districts, or when controlling local chief executive offices and endowed with inherited resources) new parties have been more successful in standing and winning seats in regional elections. Regions with these favorable conditions are few, however, resulting in the overall weakness of the new parties' local organizations. The study also disconfirms expectations that a party's control of national government should result in their improved representation at the local level. The article contributes to elucidating the incentives and dynamics of building party organizations in terms of local elected offices for newcomer parties in Japan. It hints at similar challenges for entrepreneurial parties with few social roots in other established democracies.	Kyoto Univ, Grad Sch Law, Kyoto 6068501, Japan	Hijino, K (reprint author), Kyoto Univ, Grad Sch Law, Kyoto 6068501, Japan.	hijino@law.kyoto-u.ac.jp					Akiyoshi T, 2013, TITSU CHIH SENKYO NO; Golder M, 2003, COMP POLIT STUD, V36, P432, DOI 10.1177/0010414003251175; Noble GW, 2010, J EAST ASIAN STUD, V10, P239; McElwain KM, 2012, J EAST ASIAN STUD, V12, P323; Carey JM, 1995, ELECT STUD, V14, P417, DOI 10.1016/0261-3794(94)00035-2; Art D, 2007, PARTY POLIT, V13, P331, DOI 10.1177/1354068807075939; Bolleyer N, 2013, NEW PARTIES OLD PART; Brett C. C., 1979, ASIAN SURV; Dalton Russell J., 2002, PARTIES PARTISANS PO; Fenno Jr Richard F., 1973, CONGRESSMEN COMMITTE; Hijino KVL, 2014, PARTY POLIT, V20, P78, DOI 10.1177/1354068811436035; Hijino KVL, 2013, J EAST ASIAN STUD, V13, P107; It A, 2008, MINSHUT YAB TO YAG N; Kataoka M., 1997, JAPANESE POLITICS TO, P20623; Kestel L., 2003, W DEMOCRACIES NEW EX, P13349; Lam P. E., 1996, PAC AFF, P36179; Nishio M., 2007, CHIH BUNKEN KAIKAKU; Ohmura H., 2013, SEIT SOSHIKI NO SEIJ; Park CH, 2000, DAIGISHI NO TSUKURAR; Poguntke T, 2002, ENVIRON POLIT, V11, P133; Reed S. R., 2013, JAPAN DPJ POLITICS T; Reed SR, 2009, PARTY POLIT, V15, P295, DOI 10.1177/1354068808097894; Scheiner Ethan, 2006, DEMOCRACY COMPETITIO; Sunahara Y, 2010, LEVIATHAN, V47, P89; Tsustumi H., 2013, SEIT SOSHIKI NO SEIJ; Uekami T., 2011, MINSHUT NO SOSHIKI T; Weiner R., 2008, POLITICAL REFORM JAP, P15174; Yamaguchi N., 2013, TITSU CHIH SENKYO NO; Yamamoto K., 2010, SEITKAN IDO TO SEIT	29	0	0	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	1468-1099	1474-0060		JPN J POLIT SCI	Jpn. J. Polit. Sci.	SEP	2015	16	3					270	295		10.1017/S1468109915000195		26	Political Science	Government & Law	CO6KP	WOS:000359265900003		
J	Jou, W; Endo, M				Jou, Willy; Endo, Masahisa			Presidentialization of Japanese Politics? Examining Political Leader Evaluations and Vote Choice	JAPANESE JOURNAL OF POLITICAL SCIENCE			English	Article							ELECTION OUTCOMES; PARTY LEADERS; BRITAIN; IMAGES; AUSTRALIA; CANADA; MEDIA	In recent years, the impact of party leaders on voting behavior has attracted increasing attention, leading some scholars to identify a phenomenon of presidentialization'. Many extant studies of this topic in Japan are limited to one or two electoral cycles. In order to trace long-term trends, this paper analyses longitudinal survey data to investigate the existence and magnitude of the effect party leader evaluations exert on vote choice in Japan. Empirical results show that while only dominant and forceful personalities substantially influenced voters' likelihood of supporting their parties in the 1980s and 1990s, by the 2000s assessments of most major party leaders had a significant impact on their parties' electoral performance. In short, party leaders affect vote choice due not to their personalities, but instead to the position they hold. We also test the hypotheses that the association between leader appraisal and voting behavior would be particularly conspicuous among voters who lack party identification and those who are most heavily exposed to media reportage. Analysis reveals that (1) independent voters are not more likely to vote on the basis of leader evaluations than partisans; (2) a leader effect is found more frequently among voters with greater exposure to election coverage on television.	[Jou, Willy] Univ Tsukuba, Inst Contemporary Res Polit & Econ Affairs, Tsukuba, Ibaraki 305, Japan; [Endo, Masahisa] Kochi Univ, Fac Humanities & Econ, Kochi, Kerala, India	Jou, W (reprint author), Univ Tsukuba, Fac Humanities & Social Sci, Tsukuba, Ibaraki 305, Japan.	jouw2015@yahoo.com; endo@kochi-u.ac.jp					Aiji Tanaka, 2009, 2009 NEN NAZE SEIKEN; Amanda Bittner, 2011, PLATFORM PERSONALITY; Andre Blais, 2011, POLITICAL LEADERS DE; Estevez-Abe M, 2006, ASIAN SURV, V46, P632, DOI 10.1525/as.2006.46.4.632; McElwain KM, 2012, J EAST ASIAN STUD, V12, P323; Lobo MC, 2006, ELECT STUD, V25, P270, DOI 10.1016/j.electstud.2005.05.002; Krauss ES, 2005, BRIT J POLIT SCI, V35, P357, DOI 10.1017/S0007123405000190; Anthony King, 2002, LEADERS PERSONALITIE, DOI [10.1093/0199253137.001.0001, DOI 10.1093/0199253137.001.0001]; Anthony Mughan, 1993, BRIT ELECTIONS PARTI, V3, P193, DOI [10.1080/13689889308412931, DOI 10.1080/13689889308412931]; Anthony Mughan, 2000, MEDIA PRESIDENTIALIZ; BEAN C, 1993, COMP POLIT STUD, V26, P111, DOI 10.1177/0010414093026001005; BEAN C, 1989, AM POLIT SCI REV, V83, P1165, DOI 10.2307/1961663; Brian Graetz, 1987, POLITICAL ELITES ANG; BROWN SD, 1988, CAN J POLIT SCI, V21, P729; Butler David, 1974, POLITICAL CHANGE BRI; Campus Donatella and Gianfranco Pasquino, 2006, J CONT EUROPEAN STUD, V14, P25, DOI [10.1080/14782800600617912, DOI 10.1080/14782800600617912]; Clarke Harold D., 1991, ABSENT MANDATE INTER; Combs James E., 1993, NEW PROPAGANDA DICTA; CONOVER PJ, 1989, AM J POLIT SCI, V33, P912, DOI 10.2307/2111115; Dennis Kavanagh, 1995, ELECTION COMPAIGNING; Elisabeth Gidengil, 2001, DO POLITICAL CAMPAIG; Frank Brettschneider, 2002, LEADERS PERSONALITIE; GRAETZ B, 1987, COMP POLIT STUD, V19, P484, DOI 10.1177/0010414087019004002; Harutaka Takenaka, 2006, SHUSHO SHIHAI NIHON; Hermann Schmitt, 2000, AM POL SCI ASS ANN M; Hideo Otake, 2009, POPULISM IN ASIA; Hiroshi Hirano, 2008, LEEDAASIPPU NO HIKAK; Ichiro Miyake, 1989, TOHYO KODO; Ikuo Kabashima, 2001, SENKYO KENKYU, V16, P5; John Bartle, 2002, LEADERS PERSONALITIE; John Curtice, 2005, THE EUROPEAN VOTER; John Curtice, 2011, POLITICAL LEADERS DE; Joseph Massey, 1975, YOUTH POLITICS JAPAN; KAASE M, 1994, INT POLIT SCI REV, V15, P211, DOI 10.1177/019251219401500301; Ken'ichi Ikeda, 2007, SEIJI NO RIARITI TO; Kenji Hayao, 1993, JAPANESE PRIME MINIS; Krauss Ellis S., 2011, RISE FALL JAPANS LDP; Lauri Karvonen, 2010, PERSONALISATION POLI; Lawrence LeDuc, 1994, LEADERS LEADERSHIP C; Lobo MC, 2008, PARTY POLIT, V14, P281, DOI 10.1177/1354068807088123; Maeda Ko, 2009, POLITICAL CHANGE JAP; Maeda Yukio, 2011, SYAKAI KAGAKU KENKYU, V62, P151; Margaret Scammell, 1995, DESIGNER POLITICS EL; MENDELSOHN M, 1994, CAN J POLIT SCI, V27, P81; McAllister Ian, 2004, POLITICAL LEADERS WE; McAllister Ian, 1996, COMP DEMOCRACIES ELE; Mendelsohn M, 1996, J POLIT, V58, P112, DOI 10.2307/2960351; Mori McElwain Kenneth, 2011, SHAKAI KAGAKU KENKYU, V62, P173; Murray Edelman, 1988, CONSTRUCTING POLITIC; NADEAU R, 1994, ELECT STUD, V13, P222, DOI 10.1016/0261-3794(94)90019-1; NADEAU R, 1995, CAN PUBLIC POL, V21, P212, DOI 10.2307/3551594; Pippa Norris, 1999, MESSAGE COMMUNICATIN; Rahat G., 2007, POLIT COMMUN, V24, P65, DOI DOI 10.1080/10584600601128739; Sadafumi Kawato, 1988, HOKUDAI HOGAKU RONSY, V39, P432; Shamir BM, 1994, POLITICAL BEHAV, V16, P265, DOI 10.1007/BF01498880; Shaun Bowler, 1992, ELECTORAL STRATEGIES; Soren Holmberg, 2011, POLITICAL LEADERS DE; STEWART MC, 1992, J POLIT, V54, P447, DOI 10.2307/2132034; Swanson David L., 1996, POLITICS MEDIA MODER; Thomas Poguntke, 2005, PRESIDENTIALIZATION; Tomohito Shinoda, 2000, LEADING JAPAN ROLE P; Toshio Araki, 1983, TOHYO KODO NI OKERU	62	0	0	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	1468-1099	1474-0060		JPN J POLIT SCI	Jpn. J. Polit. Sci.	SEP	2015	16	3					357	387		10.1017/S1468109915000237		31	Political Science	Government & Law	CO6KP	WOS:000359265900007		
J	Inoguchi, T				Inoguchi, Takashi			War Occurrence: Hyper-Insecurity and Multilateral Institutions	JAPANESE JOURNAL OF POLITICAL SCIENCE			English	Article									Univ Niigata Prefecture, Niigata, Japan	Inoguchi, T (reprint author), Univ Niigata Prefecture, Niigata, Japan.	inoguchi@ioc.u-tokyo.ac.jp					Amitai Etizioni, 2014, NEW NORMAL FINDING B; [Anonymous], 2014, JAPAN TIMES, P2; Bellamy Alex J., 2012, MASSACRES MORALITY M; Bonji Ohara, 2015, CHUGOKU NO GUNJI SEN; Chen Weiss Jessica, 2014, POWERFUL PATRIOTS NA; Chikako Ueki Kawakatsu, 2012, HOKUTO AJIA NO NAGAI; Chung Chien-peng, 2014, CONTENTIOUS INTEGRAT; Edward Newman, 2014, ROUTLEDGE HDB CIVIL; Galbraith James K., 2014, END NORMAL GREAT CRI; Homare Endo, 2014, CHUGOKUJIN GA ERANDA, P24; Ikenberry GJ, 2011, PRINC STUD INT HIST, P1; Inoguchi T, 2014, INT AFF, V90, P943, DOI 10.1111/1468-2346.12149; John Mearsheimer, 2005, TRAGEDY GREAT POWER; Junbao Jiefang, 2013, NANKONG YANYU ZHANG; Koichi Furuya, 2014, ASAHI SHIMBUN   0809; Lien Le Thi Quyhn, 2014, JAPANESE J POLITICAL, V15, P523, DOI [10.1017/S1468109914000267, DOI 10.1017/S1468109914000267]; Linda Jacobson, 2014, REPORTS; Mary Kaldor, 2012, NEW OLD WARS ORG VIO, V3rd; Neil Thomas, 2015, THE DIPLOMAT     012; Steven Pinker, 2012, BETTER ANGELS OUR NA; Stockholm International Institute for Peace Research, 2014, SIPRI YB 2014; Takashi Inoguchi, 2014, EUROPEAN REV INT STU, V1, P46; Takashi Inoguchi, 2013, ASIAN SURV, V54, P101; Takashi Inoguchi, 2007, LEGACIES WORLD WAR 2, p138 ; Takashi Inoguchi, 1986, J JAPANESE STUDIES, V12, P95, DOI [10.2307/132448, DOI 10.2307/132448]; Takashi Inoguchi, 2014, KODO, P12; Takashi Inoguchi, 2014, GLOBAL ASIA, V9, P30; Timo Kivimaki, 2014, LONG PEACE E ASIA; Yan Xuetong, 2015, HUANGQIU SHIBAO 0113	29	0	0	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	1468-1099	1474-0060		JPN J POLIT SCI	Jpn. J. Polit. Sci.	SEP	2015	16	3					388	398		10.1017/S1468109915000146		11	Political Science	Government & Law	CO6KP	WOS:000359265900008		
J	Iida, K				Iida, Keisuke			What is the Point of the Ikenberry-Acharya Debate?	JAPANESE JOURNAL OF POLITICAL SCIENCE			English	Article								Since the outbreak of the Great Recession triggered by the Lehman shock in 2008, writings on American decline have proliferated. World-renowned scholars and commentators have all pointed out that the American hegemony or empire is rapidly coming to an end, and that as a consequence the world is in greater turmoil than ever (for example, Zakaria, 2008; Friedman and Mandelbaum, 2011; Kupchan, 2012; Bremmer, 2012). Although there are differences among various works, most commentators predict a bleak prospect for the future.	Univ Tokyo, Grad Sch Law & Polit, Tokyo 1138654, Japan	Iida, K (reprint author), Univ Tokyo, Grad Sch Law & Polit, Tokyo 1138654, Japan.	iida@j.u-tokyo.ac.jp					Acharya Amitav, 2014, END AM WORLD ORDER; Acharya Amitav, 2007, CRAFTING COOPERATION; Acharya Amitav, 2009, WHOSE IDEAS MATTER A; Acharya A, 2004, INT ORGAN, V58, P239, DOI 10.1017/S0020818304582024; BremmerIan A., 2012, EVERY NATION ITSEIF; Breslin S, 2012, ROUTL WARW STUD GLOB, P1; Friedman Thomas L., 2011, USED BE US AM FELL W; Gilpin Robert, 1981, WAR CHANGE WORLD POL; Ikenberry GJ, 2011, PRINC STUD INT HIST, P1; Keohane Robert O., 1984, HEGEMONY COOPERATION; Kindleberger C., 1973, WORLD DEPRESSION 192; KRASNER SD, 1976, WORLD POLIT, V28, P317, DOI 10.2307/2009974; Kupchan Charles A, 2012, NO ONES WORLD W RISI; Zakaria Fareed., 2008, POSTAMERICAN WORLD	14	0	0	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	1468-1099	1474-0060		JPN J POLIT SCI	Jpn. J. Polit. Sci.	SEP	2015	16	3					429	433		10.1017/S1468109915000092		5	Political Science	Government & Law	CO6KP	WOS:000359265900011		
J	Ikeda, Y; Yoshinari, T; Nagasaki, Y				Ikeda, Yutaka; Yoshinari, Tomoki; Nagasaki, Yukio			A novel biointerface that suppresses cell morphological changes by scavenging excess reactive oxygen species	JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A			English	Article						oxidative stress; cell morphology; suppression of cell activation; scaffold; PEG	MESENCHYMAL STEM-CELLS; OXIDATIVE STRESS; BLOOD COMPATIBILITY; HYDROGEN-PEROXIDE; DIFFERENTIATION; ACTIVATION; CULTURE; SURFACE; HL-60; MECHANISMS	During cell cultivation on conventional culture dishes, various events results in strong stresses that lead to the production of bioactive species such as reactive oxygen species (ROS) and nitric oxide. These reactive species cause variable damage to cells and stimulate cellular responses. Here, we report the design of a novel biocompatible surface that decreases stress by not only morphologically modifying the dish surface by using poly(ethylene glycol) tethered chains, but also actively scavenging oxidative stress by using our novel nitroxide radical-containing polymer. A block copolymer, poly(ethylene glycol)-b-poly[(2,2,6,6-tetramethylpiperidine-N-oxyl)aminomethylstyrene] (PEG-b-PMNT) was used to coat the surface of a dish. Differentiation of undifferentiated human leukemia (HL-60) cells was found to be suppressed on the polymer-coated dish. Notably, HL-60 cell cultivation caused apoptosis under high-density conditions, while spontaneous apoptosis was suppressed in cells plated on the PEG-b-PMNT-modified surface, because a healthy mitochondrial membrane potential was maintained. In contrast, low molecular weight antioxidants did not have apparent effects on the maintenance of mitochondria. We attribute this to the lack of cellular internalization of our immobilized polymer and selective scavenging of excessive ROS generated outside of cells. These results demonstrate the utility of our novel biocompatible material for actively scavenging ROS and thus maintaining cellular morphology. (C) 2015 Wiley Periodicals, Inc.	[Ikeda, Yutaka; Yoshinari, Tomoki; Nagasaki, Yukio] Univ Tsukuba, Dept Mat Sci, Grad Sch Pure & Appl Sci, Tsukuba, Ibaraki 3058573, Japan; [Nagasaki, Yukio] Univ Tsukuba, Masters Sch Med Sci, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058573, Japan; [Nagasaki, Yukio] Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton WPI MANA, Satellite Lab, Tsukuba, Ibaraki 3058573, Japan	Nagasaki, Y (reprint author), Univ Tsukuba, Dept Mat Sci, Grad Sch Pure & Appl Sci, Tennodai 1-1-1, Tsukuba, Ibaraki 3058573, Japan.	yukio@nagalabo.jp			 [25220203]	Contract grant sponsor: Grant-in-Aid for Scientific Research S; contract grant number: 25220203	Halliwell B, 2003, FEBS LETT, V540, P3, DOI 10.1016/S0014-5793(03)00235-7; Tormos KV, 2011, CELL METAB, V14, P537, DOI 10.1016/j.cmet.2011.08.007; ISHIHARA K, 1994, J BIOMED MATER RES, V28, P225, DOI 10.1002/jbm.820280213; Jang YY, 2007, BLOOD, V110, P3056, DOI 10.1182/blood-2007-05-087759; Owusu-Ansah E, 2009, NATURE, V461, P537, DOI 10.1038/nature08313; Zhang J, 2011, EMBO J, V30, P4860, DOI 10.1038/emboj.2011.401; OKANO T, 1981, J BIOMED MATER RES, V15, P393, DOI 10.1002/jbm.820150310; Jun JH, 2008, J CELL BIOCHEM, V103, P1246, DOI 10.1002/jcb.21508; Kikuchi A, 2005, J CONTROL RELEASE, V101, P69, DOI 10.1016/j.jconrel.2004.08.026; Liu WE, 2011, BIOMATERIALS, V32, P1796, DOI 10.1016/j.biomaterials.2010.11.029; GINIS I, 1990, BLOOD, V76, P1233; Tada S, 2009, MACROMOL BIOSCI, V9, P63, DOI 10.1002/mabi.200800150; Yoshitomi T, 2009, BIOMACROMOLECULES, V10, P596, DOI 10.1021/bm801278n; Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Yagi H, 2013, J CELL BIOCHEM, V114, P1163, DOI 10.1002/jcb.24459; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; LEE JH, 1995, PROG POLYM SCI, V20, P1043, DOI 10.1016/0079-6700(95)00011-4; Paranjpe A, 2007, FREE RADICAL BIO MED, V43, P1394, DOI 10.1016/j.freeradbiomed.2007.07.011; Stolzing A, 2006, FREE RADICAL BIO MED, V41, P326, DOI 10.1016/j.freeradbiomed.2006.04.018; Berniakovich I, 2012, INT J DEV BIOL, V56, P729, DOI 10.1387/ijdb.120070ji; Fan GK, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-30; Ho JH, 2011, CELL TRANSPLANT, V20, P1209, DOI [10.3727/096368910X546562, 10.3727/0963689109X546562]; Yuan JA, 2004, COLLOID SURFACE B, V36, P27, DOI [10.1016/j.colsurfb.2004.03.017, 10.1016/j.colsurfc.2004.03.017]; Long LH, 2001, BIOCHEM BIOPH RES CO, V286, P991, DOI 10.1006/bbrc.2001.5514; Parasassi T, 2005, CELL DEATH DIFFER, V12, P1285, DOI 10.1038/sj.cdd.4401663; Richard D, 2002, FEBS LETT, V518, P159, DOI 10.1016/S0014-5793(02)02690-X; Saeki K, 1997, J BIOL CHEM, V272, P20003, DOI 10.1074/jbc.272.32.20003; Tanaka M, 2000, BIOMATERIALS, V21, P1471, DOI 10.1016/S0142-9612(00)00031-4; Yoshimoto K, 2009, MACROMOL RAPID COMM, V30, P2136, DOI 10.1002/marc.200900484; Yoshitomi T, 2012, ACTA BIOMATER, V8, P1323, DOI 10.1016/j.actbio.2011.11.029	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1549-3296	1552-4965		J BIOMED MATER RES A	J. Biomed. Mater. Res. Part A	SEP	2015	103	9					2815	2822		10.1002/jbm.a.35419		8	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CO6HO	WOS:000359258000001		
J	Yunoki, S; Hatayama, H; Ebisawa, M; Kondo, E; Yasuda, K				Yunoki, Shunji; Hatayama, Hirosuke; Ebisawa, Mizue; Kondo, Eiji; Yasuda, Kazunori			A novel fabrication method to create a thick collagen bundle composed of uniaxially aligned fibrils: An essential technology for the development of artificial tendon/ligament matrices	JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A			English	Article						collagen; alignment; artificial tendon; shear stress; bundle	ANTERIOR CRUCIATE LIGAMENT; MECHANICAL-PROPERTIES; CROSS-LINKING; ALIGNMENT; CONSTRUCTS; FIBERS; FLOW	In this study, we developed a fabrication method for thick collagen gel bundles comprising uniaxially aligned fibrils of sufficient size for filling defects in ligament tissues. The fabrication involved rotary shearing to dense collagen sols using a rheometer and then warming them from 23 degrees C to 37 degrees C to trigger gelation upon rotation. Gelation due to collagen fibril formation was accelerated by increased concentrations of neutral phosphate buffer, and fibril alignment occurred within 20 s during the early stage of rapid gelation. Fabrication of gels was completed with slippage between gels and the movable upper plate, and well-aligned fibrils along the rotation direction were observed in the marginal regions of disc-shaped gels. Gel thickness could be increased from 1 to 3 mm with homogeneous alignment of fibrils in the entire sample. The alignment of fibrils improved mechanical properties against tensile loads that were placed parallel to the alignment axis. Elongation of cultured fibroblast along the alignment was observed on the gels. The present method will enable the bottom-up fabrication of an artificial tendon for ligament reconstruction and repair. (C) 2015 Wiley Periodicals, Inc.	[Yunoki, Shunji; Hatayama, Hirosuke] Tokyo Metropolitan Ind Technol Res Inst TIRI, Biotechnol Grp, Koto Ku, Tokyo 1350064, Japan; [Ebisawa, Mizue] Tokyo Metropolitan Ind Technol Res Inst TIRI, Opt Radiat & Acoust Technol Grp, Koto Ku, Tokyo 1350064, Japan; [Kondo, Eiji] Hokkaido Univ, Grad Sch Med, Dept Adv Therapeut Res Sports Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; [Yasuda, Kazunori] Hokkaido Univ, Grad Sch Med, Dept Sports Med & Joint Surg, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Yunoki, S (reprint author), Tokyo Metropolitan Ind Technol Res Inst TIRI, Biotechnol Grp, Koto Ku, Tokyo 1350064, Japan.	yunoki.shunji@iri-tokyo.jp			JSPS KAKENHI [20399398]	Contract grant sponsor: JSPS KAKENHI; contract grant number: 20399398	Weadock KS, 1996, J BIOMED MATER RES, V32, P221, DOI 10.1002/(SICI)1097-4636(199610)32:2<221::AID-JBM11>3.0.CO;2-M; Zeugolis DI, 2009, J BIOMED MATER RES A, V89A, P895, DOI 10.1002/jbm.a.32031; Lee CH, 2001, INT J PHARM, V221, P1, DOI 10.1016/S0378-5173(01)00691-3; Smith CW, 1996, J BIOMECH ENG-T ASME, V118, P56, DOI 10.1115/1.2795946; Lanfer B, 2008, BIOMATERIALS, V29, P3888, DOI 10.1016/j.biomaterials.2008.06.016; KATO YP, 1989, BIOMATERIALS, V10, P38, DOI 10.1016/0142-9612(89)90007-0; Baker BM, 2007, BIOMATERIALS, V28, P1967, DOI 10.1016/j.biomaterials.2007.01.004; Lai ES, 2012, REGEN MED, V7, P649, DOI [10.2217/rme.12.48, 10.2217/RME.12.48]; Guo C, 2007, BIOMATERIALS, V28, P1105, DOI 10.1016/j.biomaterials.2006.10.010; Joshi SM, 2009, AM J SPORT MED, V37, P2401, DOI 10.1177/0363546509339915; Silver FH, 2003, J BIOMECH, V36, P1529, DOI 10.1016/S0021-9290(03)00135-0; Saeidi N, 2009, BIOMATERIALS, V30, P6581, DOI 10.1016/j.biomaterials.2009.07.070; Chen S, 2011, ACTA BIOMATER, V7, P644, DOI 10.1016/j.actbio.2010.09.014; TORBET J, 1984, BIOCHEM J, V219, P1057; Cheng XG, 2008, BIOMATERIALS, V29, P3278, DOI 10.1016/j.biomaterials.2008.04.028; Pins GD, 1997, BIOPHYS J, V73, P2164; Noth U, 2005, CYTOTHERAPY, V7, P447, DOI 10.1080/14653240500319093; Carey JL, 2009, J BONE JOINT SURG AM, V91A, P2242, DOI 10.2106/JBJS.I.00610; Saeidi N, 2011, ACTA BIOMATER, V7, P2437, DOI 10.1016/j.actbio.2011.02.038; Benhardt HA, 2009, TISSUE ENG PART B-RE, V15, P467, DOI 10.1089/ten.TEB.2008.0687; Legnani C, 2010, INT ORTHOP, V34, P465, DOI 10.1007/s00264-010-0963-2; Murray MM, 2009, CLIN SPORT MED, V28, P51, DOI 10.1016/j.csm.2008.08.005; Yunoki S, 2008, BIOMACROMOLECULES, V9, P879, DOI 10.1021/bm7012058	23	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1549-3296	1552-4965		J BIOMED MATER RES A	J. Biomed. Mater. Res. Part A	SEP	2015	103	9					3054	3065		10.1002/jbm.a.35440		12	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CO6HO	WOS:000359258000025		
J	Fujiki, H; Sueoka, E; Watanabe, T; Suganuma, M				Fujiki, Hirota; Sueoka, Eisaburo; Watanabe, Tatsuro; Suganuma, Masami			Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY			English	Review						Apoptosis; Cancer stem cells; EGCG; GADD153; NSAID	HUMAN PROSTATE-CANCER; MALIGNANT NEUROBLASTOMA SH-SY5Y; NEGATIVE BREAST-CANCER; EPIGALLOCATECHIN GALLATE; GENE-EXPRESSION; (-)-EPIGALLOCATECHIN GALLATE; IN-VIVO; TUMOR-GROWTH; MDA-MB-231 CELLS; CARCINOMA CELLS	In 2008, we reported that 10 Japanese-size cups of green tea daily, supplemented with tablets of green tea extract (GTE), reduced the recurrence of colorectal adenoma by 51.6 % in patients after polypectomy. Based on these results, we paid special attention to Japanese cancer patients, who consume green tea every day and are administered anticancer drugs. This encouraged us to study whether the combination of green tea catechins and anticancer drugs has the potential to enhance the efficacy of the drugs. The combination of GTE and NSAIDs synergistically inhibited tumor development in rodents through the activation of the GADD153-DR5-TRAIL apoptotic pathway. Since then, this study was further extended by various investigators to the combinations of EGCG and other green tea catechins with anticancer compounds, the latter of which include NSAIDs, phytochemicals, and anticancer drugs. In order to demonstrate whether diversity of the combinations would generally induce synergistic anticancer effects on numerous human cancer cell lines, we studied the results of 42 in vitro combination experiments and the synergistic inhibition of tumor volume of 13 combination experiments using xenograft mouse models, which were previously reported by other investigators. The various combinations of EGCG and anticancer compounds induced similar synergistic anticancer effects for both in vitro and in vivo experiments, and showed an average reduction in tumor volume by 70.3 %. Considering the evidence showing that treatment with EGCG inhibited self-renewal of cancer stem cells, the combination shows a great advantage. Green tea is a cancer preventive for humans, showing a new trend of green tea catechins as synergists with anticancer compounds.	[Fujiki, Hirota; Sueoka, Eisaburo; Watanabe, Tatsuro] Saga Univ, Dept Clin Lab Med, Fac Med, Saga 8498501, Japan; [Suganuma, Masami] Saitama Univ, Grad Sch Sci & Engn, Sakura Ku, Saitama 3388570, Japan	Fujiki, H (reprint author), Saga Univ, Dept Clin Lab Med, Fac Med, Saga 8498501, Japan.	uv4h-fjk@asahi-net.or.jp; masami0306@mail.saitama-u.ac.jp					Suganuma M, 1998, CARCINOGENESIS, V19, P1771, DOI 10.1093/carcin/19.10.1771; Fujiki H, 2012, CANCER LETT, V324, P119, DOI 10.1016/j.canlet.2012.05.012; Saldanha SN, 2014, EXP CELL RES, V324, P40, DOI 10.1016/j.yexcr.2014.01.024; Fujiki H, 2001, MUTAT RES-FUND MOL M, V480, P299, DOI 10.1016/S0027-5107(01)00189-0; Saha A, 2010, CANCER PREV RES, V3, P953, DOI 10.1158/1940-6207.CAPR-09-0247; Davenport A, 2010, INT J MOL MED, V25, P465, DOI 10.3892/ijmm_00000366; Nihal M, 2010, PHARM RES-DORDR, V27, P1103, DOI 10.1007/s11095-010-0054-5; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Scandlyn MJ, 2008, BRIT J CANCER, V99, P1056, DOI 10.1038/sj.bjc.6604634; Hardtner C, 2012, EUR J PHARMACOL, V684, P36, DOI 10.1016/j.ejphar.2012.03.039; Choudhury SR, 2011, CARCINOGENESIS, V32, P1525, DOI 10.1093/carcin/bgr171; Shimizu M, 2008, CANCER EPIDEM BIOMAR, V17, P3020, DOI 10.1158/1055-9965.EPI-08-0528; Suganuma M, 1999, CANCER RES, V59, P44; Stuart EC, 2008, LIFE SCI, V82, P943, DOI 10.1016/j.lfs.2008.02.009; Hsieh TC, 2009, ANTICANCER RES, V29, P4025; Milligan SA, 2009, CLIN CANCER RES, V15, P4885, DOI 10.1158/1078-0432.CCR-09-0109; Zhang X, 2008, INT J CANCER, V123, P1005, DOI 10.1002/ijc.23585; Bannerman B, 2011, CANCER CHEMOTH PHARM, V68, P1145, DOI 10.1007/s00280-011-1591-2; Suganuma M, 2006, INT J CANCER, V119, P33, DOI 10.1002/ijc.21809; Tang SN, 2012, INT J CANCER, V131, P30, DOI 10.1002/ijc.26323; Ghosh AK, 2009, CLIN CANCER RES, V15, P1250, DOI 10.1158/1078-0432.CCR-08-1511; Hsieh TC, 2008, INT J ONCOL, V33, P851, DOI 10.3892/ijo_00000073; Adhami VM, 2007, CLIN CANCER RES, V13, P1611, DOI 10.1158/1078-0432.CCR-06-2269; Nakachi K, 1998, JPN J CANCER RES, V89, P254; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Fujiki H, 2002, CANCER LETT, V188, P9, DOI 10.1016/S0304-3835(02)00379-8; Suganuma M, 2011, CANCER SCI, V102, P317, DOI 10.1111/j.1349-7006.2010.01805.x; Stearns ME, 2011, TRANSL ONCOL, V4, P147, DOI 10.1593/tlo.10286; Chen HP, 2013, EXP CELL RES, V319, P697, DOI 10.1016/j.yexcr.2012.12.026; Nair S, 2010, ACTA PHARMACOL SIN, V31, P1223, DOI 10.1038/aps.2010.147; Shiraishi T, 2005, CANCER RES, V65, P6364, DOI 10.1158/0008-5472.CAN-05-0312; Ahmad KA, 2007, MOL CANCER THER, V6, P1006, DOI 10.1158/1535-7163.MCT-06-0491; Masuda M, 2001, CLIN CANCER RES, V7, P4220; Lee SH, 2013, EUR J CANCER, V49, P3210, DOI 10.1016/j.ejca.2013.06.025; Stuart EC, 2007, INT J ONCOL, V30, P1407; Somers-Edgar TJ, 2008, INT J CANCER, V122, P1966, DOI 10.1002/ijc.23328; Liang G, 2010, INT J ONCOL, V37, P111, DOI 10.3892/ijo_00000659; Nakachi K, 2000, BIOFACTORS, V13, P49; Stearns ME, 2010, AM J PATHOL, V177, P3169, DOI 10.2353/ajpath.2010.100330; Basu A, 2009, INT J ONCOL, V34, P281, DOI 10.3892/ijo_00000150; Chisholm K, 2004, ANTI-CANCER DRUG, V15, P889, DOI 10.1097/00001813-200410000-00010; Das A, 2009, INT J ONCOL, V34, P757, DOI 10.3892/ijo_00000201; Fujiki H, 2012, J CANCER RES CLIN, V138, P1259, DOI 10.1007/s00432-012-1250-y; Haque A, 2014, P AM ASSOC CANC RES, V55, P548; Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274; Mazumder MEH, 2012, ANTICANCER RES, V32, P4851; Mineva ND, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073464; Mohan N, 2011, NEUROCHEM RES, V36, P1383, DOI 10.1007/s11064-011-0463-9; Nair S, 2008, PHARM RES-DORDR, V25, P387, DOI 10.1007/s11095-007-9364-7; Okabe S, 2001, BIOL PHARM BULL, V24, P883, DOI 10.1248/bpb.24.883; Sakata M, 2011, ASIAN PAC J CANCER P, V12, P567; Suganuma M, 2001, J CANCER RES CLIN, V127, P69, DOI 10.1007/s004320000189; Tan M, 2006, BIOMED SCI INSTRUM, V42, P363; Tang Su-Ni, 2010, J Mol Signal, V5, P14, DOI 10.1186/1750-2187-5-14; Wu HJ, 2012, CANCER BIOTHER RADIO, V27, P204, DOI 10.1089/cbr.2011.1103; Wu HT, 2008, BIOSCI BIOTECH BIOCH, V72, P3034, DOI 10.1271/bbb.80422; Xu F, 2003, ACTA PHARMACOL SIN, V24, P163; Yang XW, 2012, HEPATOL RES, V42, P494, DOI 10.1111/j.1872-034X.2011.00947.x; Yokoyama M, 2008, GYNECOL ONCOL, V108, P326, DOI 10.1016/j.ygyno.2007.10.013; Yoshida N, 1992, CANC CELLS TALKED TH, P267; Yoshida T, 2005, CANCER RES, V65, P5662, DOI 10.1158/0008-5472.CAN-05-0693; Zhou DH, 2013, INT J MOL SCI, V14, P12023, DOI 10.3390/ijms140612023	62	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0171-5216	1432-1335		J CANCER RES CLIN	J. Cancer Res. Clin. Oncol.	SEP	2015	141	9					1511	1522		10.1007/s00432-014-1899-5		12	Oncology	Oncology	CP1RY	WOS:000359654100001		
J	Nishikawa, M; Miyake, H; Liu, B; Fujisawa, M				Nishikawa, Masatomo; Miyake, Hideaki; Liu, Bing; Fujisawa, Masato			Expression pattern of autophagy-related markers in non-metastatic clear cell renal cell carcinoma: association with disease recurrence following radical nephrectomy	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY			English	Article						Renal cell carcinoma; Autophagy; Beclin 1; Radical nephrectomy; Prognosis	PROGNOSTIC-SIGNIFICANCE; POOR-PROGNOSIS; CANCER; APOPTOSIS; PROTEINS; BECLIN-1; UPDATE	To evaluate the expression of multiple molecular markers associated with autophagy, a cellular degradation pathway for the clearance of damaged or superfluous proteins and organelles, in clear cell renal cell carcinoma (CCRCC) in order to identify the prognostic significance of these markers in patients undergoing radical nephrectomy. Expression levels of five markers, including autophagy-related gene 5 (Atg5), Atg9, Beclin 1, microtubule-associated protein light chain 3 (LC3), and UNC-51-like kinase 1 (ULK1), in radical nephrectomy specimens from a total of 100 patients with non-metastatic CCRCC were measured by immunohistochemical staining. All the five markers were significantly correlated with some pathological factors reflecting an aggressive phenotype, including the pathological T stage, tumor grade, and microvascular invasion. During the follow-up period of this series (median 58.0 months), disease recurrence developed in 41 of the 100 patients, with a 5-year recurrence-free survival (RFS) rate of 61.3 %. On univariate analysis, expression levels of Atg5 and Beclin 1, in addition to the pathological T stage, microvascular invasion, and preoperative CRP level, were identified as significant predictors of disease recurrence. Of these factors, the expression of Beclin 1 and preoperative CRP level were independently correlated with RFS on multivariate analysis. These findings suggest that the combined assessment of expression levels of autophagy-associated markers, particularly Beclin 1, in radical nephrectomy specimens with conventional prognostic parameters, would contribute to the precise prediction of postoperative disease recurrence in patients with non-metastatic CCRCC.	[Nishikawa, Masatomo; Miyake, Hideaki; Liu, Bing; Fujisawa, Masato] Kobe Univ, Grad Sch Med, Div Urol, Chuo Ku, Kobe, Hyogo 6500017, Japan	Miyake, H (reprint author), Kobe Univ, Grad Sch Med, Div Urol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	hideakimiyake@hotmail.com					Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5; Shen Y, 2008, AUTOPHAGY, V4, P1067; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Jiang S, 2011, CANCER SCI, V102, P1568, DOI 10.1111/j.1349-7006.2011.01964.x; Giatromanolaki A, 2011, GYNECOL ONCOL, V123, P147, DOI 10.1016/j.ygyno.2011.06.023; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Qiu DM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-327; Lee YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081540; Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004; Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583; Klatte T, 2009, CANCER EPIDEM BIOMAR, V18, P894, DOI 10.1158/1055-9965.EPI-08-0786; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Sun M, 2011, EUR UROL, V60, P644, DOI 10.1016/j.eururo.2011.06.041; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Bellmunt J, 2007, BJU INT, V99, P274, DOI 10.1111/j.1464-410X.2006.06589.x; Chowdhury S, 2008, EUR J CANCER, V44, P2152, DOI 10.1016/j.ejca.2008.06.028; Kashyap MK, 2005, BIOMARKERS, V10, P258, DOI 10.1080/13547500500218534; Kim KM, 2012, INT J CANCER, V131, P362; Kurahashi T, 2007, J UROLOGY, V177, P757, DOI 10.1016/j.juro.2006.09.073; Li HY, 2013, CELL BIOCHEM FUNCT, V31, P427, DOI 10.1002/cbf.2917; Mejean A, 2003, J UROLOGY, V169, P821, DOI 10.1097/01.ju.000051378.14270.2a; Nishikawa M., 2014, UROL ONCOL, V32; SHUCH B, 2014, EUR UROL, V67, P85	24	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0171-5216	1432-1335		J CANCER RES CLIN	J. Cancer Res. Clin. Oncol.	SEP	2015	141	9					1585	1591		10.1007/s00432-015-1923-4		7	Oncology	Oncology	CP1RY	WOS:000359654100008		
J	Okuma, Y; Tanuma, J; Kamiryo, H; Kojima, Y; Yotsumoto, M; Ajisawa, A; Uehira, T; Nagai, H; Takeda, Y; Setoguchi, Y; Okada, S				Okuma, Yusuke; Tanuma, Junko; Kamiryo, Hiroshi; Kojima, Yuki; Yotsumoto, Mihoko; Ajisawa, Atsushi; Uehira, Tomoko; Nagai, Hirokazu; Takeda, Yuichiro; Setoguchi, Yasuhiro; Okada, Seiji			A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY			English	Article						Lung cancer; Human immunodeficiency virus; Non-AIDS-defining cancer; Highly active antiretroviral therapy; Epidermal growth factor receptor mutation; Chemotherapy	ACTIVE ANTIRETROVIRAL THERAPY; HIV-POSITIVE PATIENTS; INTENSIVE CHEMOTHERAPY; UNITED-STATES; RISK; AIDS; ERA; COHORT; LYMPHOMA; SURVIVAL	Lung cancer has become a crucial problem among individuals living with the human immunodeficiency virus (HIV) and causes high mortality in Western countries. Japan has an increasing number of newly infected HIV patients, and lung cancer is becoming a theme in this population. However, clinical factors of this particular population in East Asian are unclear given the identification of ethnic differences in lung cancer in the general population. From 1986 to 2013, a retrospective nationwide study involving Japanese patients living with HIV and diagnosed with lung cancer was undertaken. Forty-three lung cancer patients with HIV were identified (median age, 60.0 years; males, 97.7 %; early-stage cancer, 37.2 %; metastatic cancer, 34.9 %), 41 (95.3 %) of whom developed lung cancer in the antiretroviral era. The median CD4-positive T-cell count was 326 cells/A mu L. Adenocarcinoma was the most frequent histology (55.8 %), followed by squamous cell carcinoma (27.9 %). Epidermal growth factor receptor (EGFR) status was examined in 14 patients; five (35.7 %) had EGFR mutations. The median overall survival time was 25.1 months for all stages and 7.9 months for advanced-stage cancer. Using univariate analysis, the only favorable prognostic factor for overall survival was cancer stage (p = 0.02). The incidence of lung cancer among HIV patients in Japan has been increasing in the past decade. The present Japanese cohort showed similar EGFR mutation status similar to that of general population. The ethnic differences known in the general population were seen even in the population living with HIV, implying distinct clinical characteristics and outcomes from those reported in Western countries.	[Okuma, Yusuke] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol, Bunkyo Ku, Tokyo 1138677, Japan; [Okuma, Yusuke] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Resp Med, Bunkyo Ku, Tokyo 1138677, Japan; [Ajisawa, Atsushi] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Infect Dis, Tokyo 1138677, Japan; [Tanuma, Junko] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan; [Takeda, Yuichiro] Natl Ctr Global Hlth & Med, Dept Resp Med, Tokyo, Japan; [Kamiryo, Hiroshi; Uehira, Tomoko] Natl Hosp Org, Osaka Med Ctr, Dept Infect Dis, Osaka, Japan; [Kojima, Yuki; Nagai, Hirokazu] Natl Hosp Org, Nagoya Med Ctr, Dept Hematol, Nagoya, Aichi, Japan; [Yotsumoto, Mihoko] Tokyo Med Univ, Dept Lab Med, Tokyo 1608402, Japan; [Setoguchi, Yasuhiro] Tokyo Med Univ, Dept Resp Med, Tokyo 1608402, Japan; [Okada, Seiji] Kumamoto Univ, Ctr AIDS Res, Kumamoto, Japan	Okuma, Y (reprint author), Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.	y-okuma@cick.jp			Health and Labour Sciences Research Grant from the Japanese Ministry of Health, Labour and Welfare [H25-AIDS-I-002]	This study was supported by a Health and Labour Sciences Research Grant from the Japanese Ministry of Health, Labour and Welfare (Grant Number: H25-AIDS-I-002). The authors thank Makoto Saito, the Senior Biostatistician at the Office for Clinical Research Support in Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, for statistical advice, and the authors would like to thank Enago (www.enago.jp) for the English language review.	Alshafie MT, 1997, BRIT J SURG, V84, P1068, DOI 10.1002/bjs.1800840808; Makinson A, 2010, J THORAC ONCOL, V5, P562, DOI 10.1097/JTO.0b013e3181d3ccf2; Lanoy E, 2011, INT J CANCER, V129, P467, DOI 10.1002/ijc.25903; Ciuleanu T, 2009, LANCET, V374, P1432, DOI 10.1016/S0140-6736(09)61497-5; Tirelli U, 2000, CANCER, V88, P563, DOI 10.1002/(SICI)1097-0142(20000201)88:3<563::AID-CNCR11>3.0.CO;2-D; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Rengan R, 2012, LANCET ONCOL, V13, P1203, DOI 10.1016/S1470-2045(12)70466-7; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Schneider Eileen, 2008, Morbidity and Mortality Weekly Report, V57, P1; Brock MV, 2006, JAIDS-J ACQ IMM DEF, V43, P47, DOI 10.1097/01.qai.0000232260.95288.93; Lavole A, 2009, LUNG CANCER, V65, P345, DOI 10.1016/j.lungcan.2008.11.018; Clifford GM, 2012, BRIT J CANCER, V106, P447, DOI 10.1038/bjc.2011.558; Azzoli CG, 2009, J CLIN ONCOL, V27, P6251, DOI 10.1200/JCO.2009.23.5622; Spano JP, 2004, MED ONCOL, V21, P109, DOI 10.1385/MO:21:2:109; Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Engels EA, 2006, AIDS, V20, P1645, DOI 10.1097/01.aids.0000238411.75324.59; D'Jaen GA, 2010, CLIN LUNG CANCER, V11, P396, DOI 10.3816/CLC.2010.n.051; Bower M, 2003, AIDS, V17, P371, DOI 10.1097/01.aids.0000050788.28043.cf; Galicier L, 2007, BLOOD, V110, P2846, DOI 10.1182/blood-2006-10-051771; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Chaturvedi AK, 2007, AIDS, V21, P207, DOI 10.1097/QAD.0b013e3280118fca; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Crum-Cianflone N, 2009, AIDS, V23, P41, DOI 10.1097/QAD.0b013e328317cc2d; Dal Maso L, 2009, BRIT J CANCER, V100, P840, DOI 10.1038/sj.bjc.6604923; Haiman CA, 2006, NEW ENGL J MED, V354, P333, DOI 10.1056/NEJMoa033250; Grubb JR, 2006, AIDS, V20, P1095, DOI 10.1097/01.aids.0000226949.64600.f9; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Bertolaccini L, 2008, CANC THERAPY, V6, P903; Engsig FN, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-272; Hakimian R, 2007, J THORAC ONCOL, V2, P268; Nakanjako Damalie, 2008, AIDS Res Ther, V5, P23, DOI 10.1186/1742-6405-5-23; Levine AM, 2010, J CLIN ONCOL, V28, P1514, DOI 10.1200/JCO.2009.25.6149; Massera F, 2000, LUNG CANCER-J IASLC, V29, P147, DOI 10.1016/S0169-5002(00)00129-X; Non-small Cell Lung Cancer Collaborative Group, 1995, BMJ-BRIT MED J, V311, P899, DOI DOI 10.1136/BMJ.311.7010.899; Okuma Y, 2012, INT J CLIN ONCOL, V17, P462, DOI 10.1007/s10147-011-0316-1; Okuma Y, 2013, ONKOLOGIE, V36, P586, DOI 10.1159/000355162; Oriol A, 2005, HAEMATOL-HEMATOL J, V90, P990; Oriol A, 2003, HAEMATOLOGICA, V88, P445; Ignatius SH, 2009, J THORAC ONCOL, V4, P1083; Pakkala S, 2012, CANCER-AM CANCER SOC, V118, P164, DOI 10.1002/cncr.26242; Pakkala S, 2010, J THORAC ONCOL, V11, P1864; Petoumenos K, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-51; Robbins HA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju503; SAMET JM, 1988, AM REV RESPIR DIS, V137, P1110; Sanchez X, 1997, J BIOL CHEM, V272, P27529, DOI 10.1074/jbc.272.44.27529; Setiawan VW, 2006, CANCER EPIDEM BIOMAR, V15, P1849, DOI 10.1158/1055.EPI-06-0307; Sigel K, 2013, BRIT J CANCER, V109, P1974, DOI 10.1038/bjc.2013.545; Spitsin S, 2012, CLIN VACCINE IMMUNOL, V19, P752, DOI 10.1128/CVI.00093-12; SRIDHAR KS, 1992, CHEST, V102, P1704, DOI 10.1378/chest.102.6.1704; UNAIDS, 2012, 2012 UNAIDS REP GLOB; Vyzula R, 1996, LUNG CANCER-J IASLC, V15, P325, DOI 10.1016/0169-5002(95)00596-X; Wang ES, 2003, CANCER, V98, P1196, DOI 10.1002/cncr.11628; WHITE CS, 1995, AM J ROENTGENOL, V164, P593; Wistuba II, 1998, JAMA-J AM MED ASSOC, V279, P1554, DOI 10.1001/jama.279.19.1554	57	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0171-5216	1432-1335		J CANCER RES CLIN	J. Cancer Res. Clin. Oncol.	SEP	2015	141	9					1669	1678		10.1007/s00432-015-1956-8		10	Oncology	Oncology	CP1RY	WOS:000359654100017		
J	Miura, A; Fujiwara, T; Osawa, M; Anme, T				Miura, Ayano; Fujiwara, Takeo; Osawa, Maiko; Anme, Tokie			Inverse Correlation of Parental Oxytocin Levels with Autonomy Support in Toddlers	JOURNAL OF CHILD AND FAMILY STUDIES			English	Article						Oxytocin; Parenting; Toddler; Autonomy; Interaction	BEHAVIOR; HUMANS; BRAIN	Oxytocin (OT) has a positive effect on the amount of affectionate and stimulatory involvement parents have with their infants. However, the association between OT and parenting toddlers is unclear in relation to a parenting approach that aims to develop and support child autonomy. Thus, we hypothesized that parental OT might be inversely correlated with parenting that supports autonomy in toddlers. We recruited a convenience sample of 50 women (age range 24-44) and 30 men (age range 31-42) in Japan via community sampling and obtained urine samples to measure OT levels. The Interaction Rating Scale, which evaluates the social competence of children and the parenting skills of caregivers, including autonomy support, was used. Multiple regression analysis that adjusted for covariates (age, number of children, self-rated health, and education) was performed to evaluate the association between OT and parent-toddler interactions. Maternal OT levels were inversely correlated with children's empathy and mothers' respect for autonomy and responsiveness development (p < 0.05). No association between paternal OT levels and father-toddler interactions was found. Maternal OT level is inversely associated with autonomy support for toddlers, but the same is not true for fathers. Further investigation is necessary to determine the causality between OT levels and children's social competence as well as parental behaviors towards toddlers.	[Miura, Ayano; Fujiwara, Takeo; Osawa, Maiko] Natl Res Inst Child Hlth & Dev, Dept Social Med, Setagaya Ku, Tokyo 1578535, Japan; [Anme, Tokie] Univ Tsukuba, Grad Sch Comprehens Human Sci, Int Community Care & Life Span Dev Empowerment Sc, Ibaraki, Japan	Fujiwara, T (reprint author), Natl Res Inst Child Hlth & Dev, Dept Social Med, Setagaya Ku, Tokyo 1578535, Japan.	fujiwara-tk@ncchd.go.jp			National Center for Child Health and Development [21 shi-10]	We thank Hanako Fujiwara, who visited the home and collected samples from the participants. We are also grateful to all the participants and their families. This research was supported by the Research Development Grant for Child Health and Development from the National Center for Child Health and Development (21 shi-10). We would like to thank Dr. Emma L. Barber of the Department of Education for Clinical Research, National Center for Child Health and Development, for editing this manuscript.	AMICO JA, 1987, J CLIN ENDOCR METAB, V64, P340; Strathearn L, 2009, NEUROPSYCHOPHARMACOL, V34, P2655, DOI 10.1038/npp.2009.103; Atzil S, 2011, NEUROPSYCHOPHARMACOL, V36, P2603, DOI 10.1038/npp.2011.172; Gordon I, 2010, BIOL PSYCHIAT, V68, P377, DOI 10.1016/j.biopsych.2010.02.005; Feldman R, 2011, DEVELOPMENTAL SCI, V14, P752, DOI 10.1111/j.1467-7687.2010.01021.x; Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701; Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004; Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107; Schneiderman I, 2012, PSYCHONEUROENDOCRINO, V37, P1277, DOI 10.1016/j.psyneuen.2011.12.021; Knappe S, 2012, J ANXIETY DISORD, V26, P608, DOI 10.1016/j.janxdis.2012.02.014; LINCOLN DW, 1982, J REPROD FERTIL, V65, P571; Snegovskikh V, 2006, ENDOCRIN METAB CLIN, V35, P173, DOI 10.1016/j.ecl.2005.09.012; Gere MK, 2012, J ANXIETY DISORD, V26, P642, DOI 10.1016/j.janxdis.2012.04.003; Joussemet M, 2008, CAN PSYCHOL, V49, P194, DOI 10.1037/a0012754; Riem MME, 2011, BIOL PSYCHIAT, V70, P291, DOI 10.1016/j.biopsych.2011.02.006; Anme T, 2010, J EPIDEMIOL, V20, pS419, DOI 10.2188/jea.JE20090171; Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001; Mitsui S, 2011, HORM BEHAV, V60, P239, DOI 10.1016/j.yhbeh.2011.05.012; Bakermans-Kranenburg MJ, 2008, SOC COGN AFFECT NEUR, V3, P128, DOI 10.1093/scan/nsn004; Barett Helen, 2006, J Fam Health Care, V16, P3; Barnard K., 1994, NURSING CHILD ASSESS; BRADLEY RH, 1977, AM J MENT DEF, V81, P417; Colson E R, 1997, Pediatr Rev, V18, P255, DOI 10.1542/pir.18-8-255; Fujiwara T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052018; Gresham FM, 1990, SOCIAL SKILLS RATING; Holden G. W., 2010, PARENTING; Mori E, 2012, INT J NURS PRACT, V18, P18, DOI 10.1111/j.1440-172X.2012.02025.x; Ryan R. M., 2006, DEV PSYCHOPATHOL, V1, P795; Sudo T, 1978, Horumon To Rinsho, V26, P179; Xing ZX, 2014, J GASTROEN HEPATOL, V29, P463, DOI 10.1111/jgh.12388	30	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1062-1024	1573-2843		J CHILD FAM STUD	J. Child Fam. Stud.	SEP	2015	24	9					2620	2625		10.1007/s10826-014-0064-8		6	Family Studies; Psychology, Developmental; Psychiatry	Family Studies; Psychology; Psychiatry	CO7RA	WOS:000359357400012		
J	Cai, DP; Karasawa-Ohtashiro, Y				Cai, Dapeng; Karasawa-Ohtashiro, Yukio			International cross-ownership of firms and strategic privatization policy	JOURNAL OF ECONOMICS			English	Article						Cross-ownership; Privatization; Mixed enterprises; State ownership	MIXED OLIGOPOLY; TRADE-POLICY; PERFORMANCE; MARKETS; PRIVATE; DUOPOLY; STATE	We consider how the international cross-ownership of firms affects the privatization of a public firm competing with foreign firms. We show that when firms compete a la Cournot in a third market under a linear demand function, the domestic ownership of foreign firms can impede privatization, whereas the foreign ownership of the domestic firm can promote privatization. Moreover, the domestic ownership of foreign firms can render neither complete privatization nor complete nationalization optimal under moderate conditions. Conversely, when firms compete a la Bertrand, we demonstrate that it is always optimal to pursue complete nationalization.	[Cai, Dapeng] Nagoya Univ, Inst Adv Res, Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Karasawa-Ohtashiro, Yukio] Nanzan Univ, Fac Econ, Showa Ku, Nagoya, Aichi 4668673, Japan	Cai, DP (reprint author), Nagoya Univ, Inst Adv Res, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	cai@iar.nagoya-u.ac.jp; yukioko@nanzan-u.ac.jp			JSPS KAKENHI [26780143, 26380325, 26284014, 24530277]; Daiko Foundation; National Social Science Fund of China [14BJY017]	The first author (the corresponding author) acknowledges financial supports from the JSPS KAKENHI (Grant Number 26780143, 26380325, and 26284014), the Daiko Foundation, and the National Social Science Fund of China (Grand Number 14BJY017). The second author acknowledges financial support from the JSPS KAKENHI (Grant Number 24530277). The authors wish to thank Ngo Van Long, Masayuki Okawa, Tsuyoshi Adachi, the managing editor, Dr. Giacomo Corneo, and two anonymous reviewers for their valuable comments. Earlier versions of this paperwere presented at the JSIE 2013 Annual Meeting (Yokohama National University, Japan) and the 14th International Convention of the East Asian Economic Association (Chulalongkorn University, Thailand). The usual disclaimers apply.	Megginson WL, 2001, J ECON LIT, V39, P321, DOI 10.1257/jel.39.2.321; Han L, 2008, FINANZARCHIV, V64, P352, DOI 10.1628/001522108X374179; D'Souza J, 1999, J FINANC, V54, P1397, DOI 10.1111/0022-1082.00150; Pal D, 1998, SOUTHERN ECON J, V65, P264, DOI 10.2307/1060667; Matsumura T, 2005, J ECON, V84, P27, DOI 10.1007/s00712-004-0098-z; HARRIS RG, 1980, CAN J ECON, V13, P125, DOI 10.2307/134624; BRANDER JA, 1985, J INT ECON, V18, P83, DOI 10.1016/0022-1996(85)90006-6; BOARDMAN AE, 1989, J LAW ECON, V32, P1, DOI 10.1086/467167; Boardman AE, 2002, CAN J ADM SCI, V19, P137; Brada JC, 1996, J ECON PERSPECT, V10, P67; Chang W. W., 2005, J INT TRADE ECON DEV, V14, P19, DOI 10.1080/0963819042000333234; Chao C. C., 2006, REV INT ECON, V14, P87, DOI 10.1111/j.1467-9396.2006.00562.x; Corneo G, 1992, 9217 DELT; Corneo Giacomo, 1994, ANN EC STAT, V33, P73; De Fraja G., 1990, J EC SURVEYS, V4, P1; DICK AR, 1993, J INT ECON, V35, P227, DOI 10.1016/0022-1996(93)90018-S; EATON J, 1986, Q J ECON, V101, P383, DOI 10.2307/1891121; Feeney J, 2001, INT ECON REV, V42, P535, DOI 10.1111/1468-2354.00120; Fjell K, 1996, CAN J ECON, V29, P737, DOI 10.2307/136260; Fujiwara K, 2006, EC B, V6, P1; LEE S, 1990, J INT ECON, V29, P173, DOI 10.1016/0022-1996(90)90071-S; Lin MH, 2012, J ECON, V107, P71, DOI 10.1007/s00712-011-0254-4; Long N. V., 2009, CANADIAN J EC, V42, P590; Matsumura T, 1998, J PUBLIC ECON, V70, P473, DOI 10.1016/S0047-2727(98)00051-6; OECD, 2005, CORP GOV STAT OWN EN; VIVES X, 1984, J ECON THEORY, V34, P71, DOI 10.1016/0022-0531(84)90162-5	26	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0931-8658	1617-7134		J ECON	J. Econ.	SEP	2015	116	1					39	62		10.1007/s00712-014-0429-x		24	Economics	Business & Economics	CP1SF	WOS:000359654800003		
J	Hikichi, H; Kondo, N; Kondo, K; Aida, J; Takeda, T; Kawachi, I				Hikichi, Hiroyuki; Kondo, Naoki; Kondo, Katsunori; Aida, Jun; Takeda, Tokunori; Kawachi, Ichiro			Effect of a community intervention programme promoting social interactions on functional disability prevention for older adults: propensity score matching and instrumental variable analyses, JAGES Taketoyo study	JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH			English	Article							PROSPECTIVE COHORT; PARTICIPATION; POPULATION; LIFE; HEALTH; ENGAGEMENT; DEPRESSION; MORTALITY; SYMPTOMS; SURVIVAL	Background The efficacy of promoting social interactions to improve the health of older adults is not fully established due to residual confounding and selection bias. Methods The government of Taketoyo town, Aichi Prefecture, Japan, developed a resident-centred community intervention programme called 'community salons', providing opportunities for social interactions among local older residents. To evaluate the impact of the programme, we conducted questionnaire surveys for all older residents of Taketoyo. We carried out a baseline survey in July 2006 (prior to the introduction of the programme) and assessed the onset of functional disability during March 2012. We analysed the data of 2421 older people. In addition to the standard Cox proportional hazard regression, we conducted Cox regression with propensity score matching (PSM) and an instrumental variable (IV) analysis, using the number of community salons within a radius of 350 m from the participant's home as an instrument. Results In the 5 years after the first salon was launched, the salon participants showed a 6.3% lower incidence of functional disability compared with non-participants. Even adjusting for sex, age, equivalent income, educational attainment, higher level activities of daily living and depression, the Cox adjusted HR for becoming disabled was 0.49 (95% CI 0.33 to 0.72). Similar results were observed using PSM (HR 0.52, 95% CI 0.33 to 0.83) and IV-Cox analysis (HR 0.50, 95% CI 0.34 to 0.74). Conclusions A community health promotion programme focused on increasing social interactions among older adults may be effective in preventing the onset of disability.	[Hikichi, Hiroyuki; Kondo, Katsunori] Chiba Univ, Ctr Prevent Med Sci, Chiba, Japan; [Kondo, Naoki] Univ Tokyo, Sch Publ Hlth, Tokyo, Japan; [Kondo, Katsunori] Nihon Fukushi Univ, Ctr Well Being & Soc, Nagoya, Aichi, Japan; [Aida, Jun] Tohoku Univ, Grad Sch Dens, Dept Int & Community Oral Hlth, Sendai, Miyagi 980, Japan; [Takeda, Tokunori] Seijoh Univ, Fac Rehabil & Care, Tokai, Ibaraki, Japan; [Hikichi, Hiroyuki; Kawachi, Ichiro] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02215 USA	Hikichi, H (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, 401 Pk Dr,Landmark Ctr Room 403-T, Boston, MA 02215 USA.	hikichi@hsph.harvard.edu			MEXT [23243070, 24653150]; Health Labour Sciences Research Grant, Comprehensive Research on Aging and Health [H25-Choju-Ippan-003]	This work was supported by the MEXT-Supported Program for the Strategic Research Foundation at Private University, 2009-2013; Grant-in-Aid for Scientific Research (23243070); Grant-in-Aid for Scientific Challenging Exploratory Research (24653150); and Health Labour Sciences Research Grant, Comprehensive Research on Aging and Health (H25-Choju-Ippan-003).	Aida J, 2013, J EPIDEMIOL COMMUN H, V67, P42, DOI 10.1136/jech-2011-200307; Almeida OP, 1999, INT J GERIATR PSYCH, V14, P858, DOI 10.1002/(SICI)1099-1166(199910)14:10<858::AID-GPS35>3.0.CO;2-8; Bygren LO, 1996, BRIT MED J, V313, P1577; KOYANO W, 1991, ARCH GERONTOL GERIAT, V13, P103, DOI 10.1016/0167-4943(91)90053-S; Kramer AF, 2006, J APPL PHYSIOL, V101, P1237, DOI 10.1152/japplphysiol.000500.2006; Buchman AS, 2009, ARCH INTERN MED, V169, P1139, DOI 10.1001/archinternmed.2009.135; Martinez IL, 2006, J URBAN HEALTH, V83, P941, DOI 10.1007/s11524-006-9058-1; Sato T, 2008, ARCH GERONTOL GERIAT, V47, P327, DOI 10.1016/j.archger.2007.08.015; Glei DA, 2005, INT J EPIDEMIOL, V34, P864, DOI 10.1093/ije/dyi049; James BD, 2011, J GERONTOL A-BIOL, V66, P467, DOI [10.1093/gerona/glq231, 10.1093/gerona/gly231]; Rosso AL, 2013, J AGING HEALTH, V25, P617, DOI 10.1177/0898264313482489; Dishman RK, 2006, OBESITY, V14, P345, DOI 10.1038/oby.2006.46; Glass TA, 1999, BRIT MED J, V319, P478; Kwok TCY, 2011, CLIN INTERV AGING, V6, P269, DOI 10.2147/CIA.S25395; Tobin MC, 2014, RES AUTISM SPECT DIS, V8, P214, DOI 10.1016/j.rasd.2013.12.002; Center for Spatial Information Science TUoT, 2014, GEOC TOOLS UT; Chiao C, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-292; Chiu YC, 2013, INT J NURS STUD, V50, P1314, DOI 10.1016/j.ijnurstu.2013.01.002; De Ridder A, 2011, VALUE HEALTH, V14, P3, DOI 10.1016/j.jval.2010.10.014; Fujiwara Y., 2009, Journal of Intergenerational Relationships, V7, P17, DOI 10.1080/15350770802628901; Ichida Y, 2013, SOC SCI MED, V94, P83, DOI 10.1016/j.socscimed.2013.05.006; International UaH, 2012, AG 21 CENT CEL CHALL; Iwasaki M, 2002, INT J EPIDEMIOL, V31, P1208, DOI 10.1093/ije/31.6.1208; Kamiya Y, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-81; Kanamori S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099638; Khandker S.R., 2010, HDB IMPACT EVALUATIO; Kondo N, 2009, J EPIDEMIOL COMMUN H, V63, P461, DOI 10.1136/jech.2008.078642; Kurimori S, 2006, HEALTH POLICY, V76, P346, DOI 10.1016/j.healthpol.2005.06.017; Luukinen H, 1997, J AM GERIATR SOC, V45, P1302; Ministry-of-Health-Labour-and-Welfare, 2012, KAIG YOB MAN KAIT HL; Ministry-of-Health-Labour-and-Welfare, 2013, SYAK HOS SEID KAIK N; Murayama Y, 2014, AGING MENT HEALTH, P1; Parisi J. M., 2012, ACTIVITIES ADAPTATIO, V36, P242, DOI [10.1080/01924788.2012.702306, DOI 10.1080/01924788.2012.702306]; Sugano Keiko, 2012, Dement Geriatr Cogn Dis Extra, V2, P69, DOI 10.1159/000337224; Takagi D, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-701; Takeuchi K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061741; Thomas KH, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5704; Turner LW, 2002, J WOMEN AGING, V14, P139, DOI 10.1300/J074v14n03_09; Welmer AK, 2012, J AGING PHYS ACTIV, V20, P317; WHO, 2012, 10 FACT AG LIF COURS	40	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0143-005X	1470-2738		J EPIDEMIOL COMMUN H	J. Epidemiol. Community Health	SEP	2015	69	9					905	910		10.1136/jech-2014-205345		6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CO8BF	WOS:000359388800014		
J	Ishigami, G; Iagnemma, K; Overholt, J; Hudas, G				Ishigami, Genya; Iagnemma, Karl; Overholt, Jim; Hudas, Greg			Design, Development, and Mobility Evaluation of an Omnidirectional Mobile Robot for Rough Terrain	JOURNAL OF FIELD ROBOTICS			English	Article							WHEEL; KINEMATICS; ODOMETRY; EXPLORATION; VEHICLES	Omnidirectional vehicles have been widely applied in several areas, but most of them are designed for the case of motion on flat, smooth terrain, and are not feasible for outdoor usage. This paper presents the design and development of an omnidirectional mobile robot that possesses high mobility in rough terrain. The omnidirectional robot consists of a main body with four sets of mobility modules, called an active split offset caster (ASOC). The ASOC module has independently driven dual wheels that produce arbitrary planar translational velocity, enabling the robot to achieve its omnidirectional motion. Each module is connected to the main body via a parallel link with shock absorbers, allowing the robot to conform to uneven terrain. In this paper, the design and development of the ASOC-driven omnidirectional mobile robot for rough terrain are described. A control scheme that considers the kinematics of the omnidirectional mobile robot is presented. The mobility of the robot is also evaluated experimentally based on a metric called the ASOC mobility index. The mobility evaluation test clarifies a design tradeoff between terrain adaptability and omnidirectional mobility due to the shock absorbers. In addition, an odometry improvement technique that can reduce position estimation error due to wheel slippage is proposed. Experimental odometry tests confirmed that the proposed technique is able to improve the odometry accuracy for sharp-turning maneuvers.	[Ishigami, Genya] Keio Univ, Dept Mech Engn, Yokohama, Kanagawa 2238522, Japan; [Iagnemma, Karl] MIT, Mfg & Prod Lab, Cambridge, MA 02139 USA; [Overholt, Jim; Hudas, Greg] US Army Tank Automot Res Dev & Engn Ctr TARDEC, Warren, MI 48397 USA	Ishigami, G (reprint author), Keio Univ, Dept Mech Engn, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2238522, Japan.	ishigami@mech.keio.ac.jp; kdi@mit.edu			U.S. Army Research Office [W911NF-07-1-0540]	This work was supported by the U.S. Army Research Office under Grant No. W911NF-07-1-0540. The authors would like to acknowledge Elvine Pineda and Martin Udengaard, former members in the design and development of the ASOC-driven omnidirectional robot.	AGULLO J, 1987, MECH MACH THEORY, V22, P295, DOI 10.1016/0094-114X(87)90018-8; Moore KL, 2000, IEEE CONTR SYST MAG, V20, P53, DOI 10.1109/37.887449; Udengaard M, 2008, IEEE INT CONF ROBOT, P1666, DOI 10.1109/ROBOT.2008.4543440; PIN FG, 1994, IEEE T ROBOTIC AUTOM, V10, P480, DOI 10.1109/70.313098; Ward CC, 2008, IEEE T ROBOT, V24, P821, DOI 10.1109/TRO.2008.924945; Yu HY, 2004, J MECH DESIGN, V126, P822, DOI 10.1115/1.1767181; Maimone M, 2007, J FIELD ROBOT, V24, P169, DOI 10.1002/rob.20184; Fujisawa S, 1997, IEEE DECIS CONTR P, P3654, DOI 10.1109/CDC.1997.652423; Bauman S., 2010, P 40 AER MECH S NASA, P279; Blumrich J., 1974, US Patent, Patent No. [3,789,947, 3789947]; Borenstein J, 1996, IEEE T ROBOTIC AUTOM, V12, P869, DOI 10.1109/70.544770; Borenstein J, 1998, IEEE T ROBOTIC AUTOM, V14, P963, DOI 10.1109/70.736779; Ferriere L, 1998, IEEE INT CONF ROBOT, P1877; Gfrerrer A, 2008, COMPUT AIDED GEOM D, V25, P784, DOI 10.1016/j.cagd.2008.07.008; Harrison DA, 2008, AEROSP CONF PROC, P1, DOI 10.1109/AERO.2008.4526234; Ilon B., 1975, US Patent, Patent No. [3,876,255, 3876255]; Muir P., 1987, P IEEE INT C ROB AUT; Nister D., 2004, P IEEE COMP SOC C CO, P652, DOI DOI 10.1109/CVPR.2004.1315094; Ojeda L., 2006, IEEE T ROBOTICS, V22, P365; Park T. B., 2002, P IEEE INT C ROB AUT, P732; Smith R., 1987, US Patent, Patent No. [4,715,460, 4715460]; Tadakuma K., 2007, P IEEE INT C INT ROB, P33; Wada M, 1996, IEEE INT CONF ROBOT, P3671, DOI 10.1109/ROBOT.1996.509272; Wada M., 2000, Proceedings 2000 ICRA. Millennium Conference. IEEE International Conference on Robotics and Automation. Symposia Proceedings (Cat. No.00CH37065), DOI 10.1109/ROBOT.2000.844814; West M, 1997, J MECH DESIGN, V119, P153, DOI 10.1115/1.2826230; Williams R., 2002, P ASME DES ENG TECHN, P201; Wong J.Y., 1967, J TERRAMECHANICS, V4, P81, DOI DOI 10.1016/0022-4898(67)90105-X; Wong J.Y., 1967, J TERRAMECHANICS, V4, P7, DOI DOI 10.1016/0022-4898(67)90047-X; Wong JY, 2008, THEORY GROUND VEHICL	29	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1556-4959	1556-4967		J FIELD ROBOT	J. Field Robot.	SEP	2015	32	6					880	896		10.1002/rob.21557		17	Robotics	Robotics	CP1AF	WOS:000359607500003		
J	Jo, B; Banerjee, D				Jo, Byeongnam; Banerjee, Debjyoti			Enhanced Specific Heat Capacity of Molten Salt-Based Carbon Nanotubes Nanomaterials	JOURNAL OF HEAT TRANSFER-TRANSACTIONS OF THE ASME			English	Article						specific heat capacity; nanomaterial; carbon nanotubes; molten salts	THERMAL-CONDUCTIVITY ENHANCEMENT; NANO-FLUIDS; NANOFLUIDS; NANOPARTICLES; SUSPENSIONS; WATER; PARTICLES; MODEL; FLOW	This study aims to investigate the specific heat capacity of a carbonate salt eutecticbased multiwalled carbon nanomaterial (or high temperature nanofluids). The specific heat capacity of the nanomaterials was measured both in solid and liquid phase using a differential scanning calorimetry (DSC). The effect of the carbon nanotube (CNT) concentrations on the specific heat capacity was examined in this study. The carbonate molten salt eutectic with a high melting point around 490 degrees C, which consists of lithium carbonate of 62% and potassium carbonate of 38% by the molar ratio, was used as a base material. Multiwalled CNTs were dispersed in the carbonate salt eutectic. A surfactant, sodium dodecyl sulfate (SDS) was utilized to obtain homogeneous dispersion of CNT into the eutectic. Four different concentrations (0.1, 0.5, 1, and 5 wt.%) of CNT were employed to explore the specific heat capacity enhancement of the nanomaterials as the concentrations of the nanotubes varies. In result, it was observed that the specific heat capacity was enhanced by doping with the nanotubes in both solid and liquid phase. Additionally, the enhancements in the specific heat capacity were increased with increase of the CNT concentration. In order to check the uniformity of dispersion of the nanotubes in the salt, scanning electron microscopy (SEM) images were obtained for pre-DSC and post-DSC samples. Finally, the specific heat capacity results measured in present study were compared with the theoretical prediction.	[Jo, Byeongnam] Univ Tokyo, Nucl Profess Sch, Tokai, Ibaraki 3191188, Japan; [Jo, Byeongnam; Banerjee, Debjyoti] Texas A&M Univ, Dept Mech Engn, College Stn, TX 77843 USA	Jo, B (reprint author), Univ Tokyo, Nucl Profess Sch, Tokai, Ibaraki 3191188, Japan.	jo@vis.t.u-tokyo.ac.jp			Department of Energy (DOE) Solar Energy Program (Golden, CO) [DE-FG36-08GO18154];  [Amd. M001]	For this study, the authors acknowledge the support of the Department of Energy (DOE) Solar Energy Program (Golden, CO) under Grant No. DE-FG36-08GO18154; Amd. M001 (Title: "Molten Salt-Carbon Nanotube Thermal Energy Storage for Concentrating Solar Power Systems").	Das SK, 2003, J HEAT TRANS-T ASME, V125, P567, DOI 10.1115/1.1561080; Murshed SMS, 2005, INT J THERM SCI, V44, P367, DOI 10.1016/j.ijthermalsci.2004.12.005; [Anonymous], 2005, E126995 ASTM; Choi SUS, 2001, APPL PHYS LETT, V79, P2252, DOI 10.1063/1.1408272; Xie H, 2002, INT J THERMOPHYS, V23, P571, DOI 10.1023/A:1015121805842; Shin DH, 2011, J HEAT TRANS-T ASME, V133, DOI 10.1115/1.4002600; Keblinski P, 2002, INT J HEAT MASS TRAN, V45, P855, DOI 10.1016/S0017-9310(01)00175-2; Namburu PK, 2007, MICRO NANO LETT, V2, P67, DOI 10.1049/mnl:20070037; Wang XQ, 2007, INT J THERM SCI, V46, P1, DOI 10.1016/j.ijthermalsci.2006.06.010; [Anonymous], 2005, J APPL PHYS, DOI DOI 10.1063/1.1861145; Buongiorno J, 2006, J HEAT TRANS-T ASME, V128, P240, DOI 10.1115/1.2150834; Jo B, 2015, J SOL ENERG-T ASME, V137, DOI 10.1115/1.4028144; Nelson IC, 2009, J THERMOPHYS HEAT TR, V23, P752, DOI 10.2514/1.31033; Oh SH, 2005, SCIENCE, V310, P661, DOI 10.1126/science.1118611; Eastman JA, 2001, APPL PHYS LETT, V78, P718, DOI 10.1063/1.1341218; Walther JH, 2001, J PHYS CHEM B, V105, P9980, DOI 10.1021/jp011344u; Wang BX, 2006, INT J THERMOPHYS, V27, P139, DOI 10.1007/s10765-006-0022-9; Kim HD, 2007, INT J MULTIPHAS FLOW, V33, P691, DOI 10.1016/j.ijmultiphaseflow.2007.02.007; Jo B, 2014, ACTA MATER, V75, P80, DOI 10.1016/j.actamat.2014.05.005; Zhou SQ, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2890431; Leong KC, 2006, J NANOPART RES, V8, P245, DOI 10.1007/s11051-005-9018-9; Shin D, 2011, INT J HEAT MASS TRAN, V54, P1064, DOI 10.1016/j.ijheatmasstransfer.2010.11.017; Goswami DY, 1998, ENERG SOURCE, V20, P137, DOI 10.1080/00908319808970052; Bridges NJ, 2011, ENERG FUEL, V25, P4862, DOI 10.1021/ef2012084; Vajjha RS, 2009, J HEAT TRANS-T ASME, V131, DOI 10.1115/1.3090813; Kalogirou SA, 2004, PROG ENERG COMBUST, V30, P231, DOI 10.1016/j.pecs.2004.02.001; You SM, 2003, APPL PHYS LETT, V83, P3374, DOI 10.1063/1.1619206; Philip J, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/30/305706; Yu W, 2004, J NANOPART RES, V6, P355, DOI 10.1007/s11051-004-2601-7; Jo B, 2009, J VISUAL-JAPAN, V12, P37; ARAKI N, 1988, INT J THERMOPHYS, V9, P1071, DOI 10.1007/BF01133274; Billings B. H., 1972, AM I PHYS HDB; Dubska L., 1968, VEDA VYZK PRUM POTRA, V18, P79; Jo B., 2010, ASME 2010 4 INT C EN; Kearney D, 2003, J SOL ENERG-T ASME, V125, P170, DOI 10.1115/1.1565087; Kline S. J., 1953, MECH ENG, V75, P3; Li Y, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/15/155405; Shin D., 2010, INT J STRUC IN PRESS, V2, P25; Zhou L-P, 2010, ADV MECH ENG, V2010, P1	39	2	2	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0022-1481	1528-8943		J HEAT TRANS-T ASME	J. Heat Transf.-Trans. ASME	SEP	2015	137	9			SI				091013	10.1115/1.4030226		7	Thermodynamics; Engineering, Mechanical	Thermodynamics; Engineering	CO6YQ	WOS:000359304100015		
J	Kano, I				Kano, Ichiro			Pool Boiling Enhancement by Electrohydrodynamic Force and Diamond Coated Surfaces	JOURNAL OF HEAT TRANSFER-TRANSACTIONS OF THE ASME			English	Article						boiling; critical heat flux; electrohydrodynamic enhancement; heat transfer enhancement; surface roughness	HEAT-TRANSFER; DIELECTRIC LIQUID; GEOMETRY; FLOW	Boiling heat transfer enhancement via compound effect of the electrohydrodynamic (EHD) effect and microstructured surfaces has been experimentally and analytically investigated. A fluorinated dielectric liquid (Asahi Glass Co., Ltd., AE-3000) was selected as the working fluid. Pool boiling heat transfer in the saturated liquid was measured at atmospheric pressure. Microstructured surfaces, which are mainly used for cutting tools, were developed with diamond particles using electrodeposition technique. Four different particle diameters were prepared: 5, 10, 15, and a mixture of 5 and 1.5 mu m. The critical heat flux (CHF) for diamond particle surfaces showed 27-30 W/cm(2) which was 26-40% increase for comparing with a noncoated surface (21.5 W/cm(2)). Upon application of a -5 kV/mm electric field to the microstructured surface (a mixture of 5 and 1.5 mu m particles), a CHF of 70.2 W/cm(2) at a superheat of 21.7 K was obtained. The previous theoretical equation of pool boiling predicted the CHF with electric field and without the electrode within 10%. Also, the CHF enhanced by the diamond coated surfaces was correlated well with the contact angle.	Yamagata Univ, Grad Sch Sci & Engn, Yonezawa, Yamagata 9928510, Japan	Kano, I (reprint author), Yamagata Univ, Grad Sch Sci & Engn, 4-3-16 Jonan, Yonezawa, Yamagata 9928510, Japan.	kano@yz.yamagata-u.ac.jp			JSPS KAKENHI [25420146]; NEDO of Japan [06B44014a]	This work was supported by Grant-in-Aid for Scientific Research (C) from JSPS KAKENHI (Grant No. 25420146) and partially supported by Industrial Technology Research Grant Program in 2006 from NEDO of Japan (Grant No. 06B44014a). The author would like to thank Mr. Tadashi Chika (a former graduate student at Yamagata University) for his support in performing the experiments.	[Anonymous], 1978, ADV HEAT TRANSFER; PICKARD WF, 1963, J APPL PHYS, V34, P246, DOI 10.1063/1.1702592; Das AK, 2007, EXP THERM FLUID SCI, V31, P967, DOI 10.1016/j.expthermflusci.2006.10.006; ALLEN PHG, 1995, HEAT RECOV SYST CHP, V15, P389, DOI 10.1016/0890-4332(95)90050-0; Seyed-Yagoobi J, 2005, J ELECTROSTAT, V63, P861, DOI 10.1016/j.elstat.2005.03.047; Kano I, 2009, IEEE T IND APPL, V45, P59, DOI 10.1109/TIA.2008.2009610; STUETZER OM, 1959, J APPL PHYS, V30, P984, DOI 10.1063/1.1777003; Darabi J, 2003, MICROELECTRON J, V34, P1067, DOI 10.1016/j.mejo.2003.09.010; Darabi J, 2001, J MICROELECTROMECH S, V10, P98, DOI 10.1109/84.911097; Kano I, 2014, J HEAT TRANS-T ASME, V136, DOI 10.1115/1.4027881; Moghaddam S, 2005, J MICROELECTROMECH S, V14, P978, DOI 10.1109/JMEMS.2005.851812; PICKARD WF, 1963, J APPL PHYS, V34, P251, DOI 10.1063/1.1702593; Hristov Y, 2009, HEAT MASS TRANSFER, V45, P999, DOI 10.1007/s00231-007-0286-z; Atten P, 2003, IEEE T DIELECT EL IN, V10, P27, DOI 10.1109/TDEI.2003.1176555; Saville DA, 1997, ANNU REV FLUID MECH, V29, P27, DOI 10.1146/annurev.fluid.29.1.27; Auracher H, 2004, INT J HEAT FLUID FL, V25, P223, DOI 10.1016/j.ijheatfluidflow.2003.11.011; Grassi W., 1993, J ENHANC HEAT TRANSF, V1, P99; Jones T.B., 1995, ELECTROMECHANICS PAR, P24; Kano I, 2013, J HEAT TRANS-T ASME, V135, DOI 10.1115/1.4024390; Kano Ichiro, 2010, Journal of Fluid Science and Technology, V5, DOI 10.1299/jfst.5.123; Lamb H., 1932, HYDRODYNAMICS; Landau L. D., 1984, ELECTROHYDRODYNAMICS, V8, P59; Laohalertdecha S, 2007, RENEW SUST ENERG REV, V11, P858, DOI 10.1016/j.rser.2005.07.002; Luttich T, 2004, INT J THERM SCI, V43, P1125, DOI 10.1016/j.ijthermalsci.2004.04.014; OCONNOR JP, 1995, IEEE T COMPON PACK A, V18, P656, DOI 10.1109/95.465166; Panofsky W. K. H., 1962, CLASSICAL ELECT MAGN, p[111, New York]; Tang Y. S., 1997, BOILING HEART TRANSF, P37; Zuber N., 1958, ASME T, V80, P711	28	0	0	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0022-1481	1528-8943		J HEAT TRANS-T ASME	J. Heat Transf.-Trans. ASME	SEP	2015	137	9			SI				091006	10.1115/1.4030217		9	Thermodynamics; Engineering, Mechanical	Thermodynamics; Engineering	CO6YQ	WOS:000359304100008		
J	Hayashi, S; Murakami, S; Omagari, K; Matsui, T; Iio, E; Isogawa, M; Watanabe, T; Karino, Y; Tanaka, Y				Hayashi, Sanae; Murakami, Shuko; Omagari, Katsumi; Matsui, Takeshi; Iio, Etsuko; Isogawa, Masanori; Watanabe, Tsunamasa; Karino, Yoshiyasu; Tanaka, Yasuhito			Characterization of novel entecavir resistance mutations	JOURNAL OF HEPATOLOGY			English	Article						Hepatitis B virus; Entecavir; Lamivudine; Antiviral resistance; HBV mutations; Viral breakthrough; Hepatitis B treatment; Combination therapy; rtA186T; rtI163V; Entecavir resistance	HEPATITIS-B-VIRUS; NUCLEOSIDE-NAIVE PATIENTS; POLYMERASE; INHIBITION; LAMIVUDINE; MECHANISM; VARIANT; RARE; DNA	Background & Aims: Entecavir (ETV) is approved for the treatment of chronic hepatitis B virus (HBV) infections, but the virus can acquire resistance to the drug. This requires lamivudine resistance mutations (LAMr) and at least one additional mutation. Here, we characterized two novel mutations, rtI163V and rtA186T, associated with viral breakthrough (VBT) in an ETV-refractory patient. Methods: HBV from an ETV-refractory patient was sequenced, and newly identified mutations were inserted into a replication-competent clone by mutagenesis. Clones were analyzed for replication efficacy and susceptibility to ETV in vitro. Chimeric mice with human hepatocytes were inoculated with the patient's serum at VBT, and monitored for viral mutation pattern using a next-generation sequencing approach. Results: RtI163V and rtA186T mutations were detected together with LAMr (rtL180M and rtM204V) at VBT. RtA186T plus LAMr reduced susceptibility to ETV more than 111.1-fold compared with the wild-type clone, while rtI163V plus LAMr resulted in a 20.4-fold reduction. RtA186T significantly reduced viral replication efficacy, while the rtI163V mutation rescued it. Interestingly, the viral mutation pattern in the chimeric mice indicated dominant (or selective) proliferation of a clone containing rtI163V and rtA186T mutations plus LAMr under ETV treatment. Three-dimensional docking simulation indicated that rtA186T reduced the binding affinity of the HBV polymerase to ETV. Conclusions: VBT in this ETV-refractory patient is attributable to the novel ETV resistance mutations rtI163V and rtA186T. RtA186T was apparently responsible for ETV resistance but the selection of a clone with the double mutation plus LAMr suggests that rtI163V is required to sustain viral fitness. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.	[Hayashi, Sanae; Murakami, Shuko; Omagari, Katsumi; Matsui, Takeshi; Iio, Etsuko; Isogawa, Masanori; Watanabe, Tsunamasa; Tanaka, Yasuhito] Nagoya City Univ, Grad Sch Med Sci, Dept Virol, Nagoya, Aichi 4678601, Japan; [Hayashi, Sanae; Murakami, Shuko; Omagari, Katsumi; Matsui, Takeshi; Iio, Etsuko; Isogawa, Masanori; Watanabe, Tsunamasa; Tanaka, Yasuhito] Nagoya City Univ, Grad Sch Med Sci, Liver Unit, Nagoya, Aichi 4678601, Japan; [Matsui, Takeshi] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Hokkaido, Japan; [Karino, Yoshiyasu] Sapporo Kosei Gen Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan	Tanaka, Y (reprint author), Nagoya City Univ, Grad Sch Med Sci, Dept Virol, Mizuho Ku, Kawasumi 1, Nagoya, Aichi 4678601, Japan.	ytanaka@med.nagoya-cu.ac.jp			Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan [H24-Bsou-kanen-ippan-013]; Ministry of Education, Culture, Sports, Science, and Technology [25293176]	This work was supported by Health and Labour Sciences Research Grants (Research on Hepatitis) from the Ministry of Health, Labour and Welfare of Japan (H24-Bsou-kanen-ippan-013), and a grant-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology (25293176).	Amini-Bavil-Olyaee S, 2011, J VIRAL HEPATITIS, V18, P804, DOI 10.1111/j.1365-2893.2010.01378.x; Tenney DJ, 2004, ANTIMICROB AGENTS CH, V48, P3498, DOI 10.1128/AAC.48.9.3498-3507.2004; Sugauchi F, 2001, J GEN VIROL, V82, P883; Brunelle MN, 2007, ANTIMICROB AGENTS CH, V51, P2240, DOI 10.1128/AAC.01440-06; Fukunishi Y, 2005, J MOL GRAPH MODEL, V24, P34, DOI 10.1016/j.jmgm.2005.04.004; Colonno RJ, 2006, HEPATOLOGY, V44, P1656, DOI 10.1002/hep.21422; Locarnini S, 2006, J HEPATOL, V44, P422, DOI 10.1016/j.jhep.2005.11.036; Brunelle MN, 2005, HEPATOLOGY, V41, P1391, DOI 10.1002/hep20723; Seifer M, 1998, ANTIMICROB AGENTS CH, V42, P3200; Song ZL, 2012, WORLD J GASTROENTERO, V18, P7149, DOI 10.3748/wjg.v18.i48.7149; Villet S, 2007, J HEPATOL, V46, P531, DOI 10.1016/j.jhep.2006.11.016; Sugiyama M, 2006, HEPATOLOGY, V44, P915, DOI 10.1002/hep.21345; Menendez-Arias L, 2014, CURR OPIN VIROL, V8, P1, DOI 10.1016/j.coviro.2014.04.005; Innaimo SF, 1997, ANTIMICROB AGENTS CH, V41, P1444; Tatematsu K, 2009, J VIROL, V83, P10538, DOI 10.1128/JVI.00462-09; Tenney DJ, 2009, HEPATOLOGY, V49, P1503, DOI 10.1002/hep.22841; Tanaka Y, 2004, HEPATOLOGY, V40, P747, DOI 10.1002/hep.20365; Mukaide M, 2010, ANTIMICROB AGENTS CH, V54, P882, DOI 10.1128/AAC.01061-09; Tateno C, 2004, AM J PATHOL, V165, P901, DOI 10.1016/S0002-9440(10)63352-4; Langley DR, 2007, J VIROL, V81, P3992, DOI 10.1128/JVI.02395-06; Iv WED, 2003, IN VITRO, V77; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Karayiannis P, 2012, SCI CAIRO, V2012; Kimura T, 2005, J BIOL CHEM, V280, P21713, DOI 10.1074/jbc.M501564200; Lok ASF, 2007, GASTROENTEROLOGY, V132, P1586, DOI 10.1053/j.gastro.2007.02.040; MORIKAMI K, 1992, COMPUT CHEM, V16, P243, DOI 10.1016/0097-8485(92)80010-W; Omagari Katsumi, 2008, Adv Appl Bioinform Chem, V1, P19; Sugiyama M, 2009, GASTROENTEROLOGY, V136, pe3; Walsh AW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009195; Yatsuji H, 2007, J MED VIROL, V79, P1811, DOI 10.1002/jmv.20981	30	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0168-8278	1600-0641		J HEPATOL	J. Hepatol.	SEP	2015	63	3					546	553				8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CP2QI	WOS:000359721700003		
J	Akamatsu, S; Hayes, CN; Ochi, H; Uchida, T; Kan, H; Murakami, E; Abe, H; Tsuge, M; Miki, D; Akiyama, R; Hiraga, N; Imamura, M; Aikata, H; Kawaoka, T; Kawakami, Y; Chayama, K				Akamatsu, Sakura; Hayes, C. Nelson; Ochi, Hidenori; Uchida, Takuro; Kan, Hiromi; Murakami, Eisuke; Abe, Hiromi; Tsuge, Masataka; Miki, Daiki; Akiyama, Rie; Hiraga, Nobuhiko; Imamura, Michio; Aikata, Hiroshi; Kawaoka, Tomokazu; Kawakami, Yoshiiku; Chayama, Kazuaki			Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A	JOURNAL OF HEPATOLOGY			English	Article						Interferon lambda 4; NS5A; ISDR; HCV core protein; Quasispecies; Direct acting antivirals; Daclatasvir; Antiviral resistance; Positive selection; Next generation sequencing	DACLATASVIR PLUS ASUNAPREVIR; HCV GENOTYPE 1B; SUSTAINED VIROLOGICAL RESPONSE; RIBAVIRIN COMBINATION THERAPY; GENOME-WIDE ASSOCIATION; GENETIC-VARIATION; NS5A INHIBITORS; SPONTANEOUS CLEARANCE; IMMUNE-RESPONSES; ALPHA THERAPY	Background & Aims: Single nucleotide polymorphisms within the interferon lambda 4 (IFNL4) locus are strongly associated with spontaneous clearance of hepatitis C virus (HCV) infection and early viral response to interferon therapy. Interaction between host genotype and amino acid substitutions might also influence the risk of antiviral resistance in interferon-free direct acting antiviral (DAA) therapies. Methods: The relationship between IFNL4 genotype and HCV substitutions was analyzed in 929 patients with chronic HCV genotype 1b infection. Ultra-deep sequencing and quasispecies reconstruction was performed on the N-terminal region of NS5A in 57 patients. Results: IFNL4 genotype was strongly associated with HCV NS5A Y93 and core protein substitutions, and the number and diversity of predicted quasispecies was marginally greater in IFNL4 TT/TT patients compared to TT/Delta G, Delta G/Delta G patients. RNA secondary structure prediction of the NS5A region suggests that variable sites are more likely to occupy unpaired, high entropy positions. Conclusions: HCV infection is proposed to induce a more efficient antiviral response in individuals with the IFNL4 TT/TT genotype that results either in viral clearance or selection for viral adaptations. The association between IFNL4 TT/TT genotype and Y93 substitutions may impact the risk of antiviral resistance in NS5A inhibitors in DAA therapy. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.	[Akamatsu, Sakura; Hayes, C. Nelson; Ochi, Hidenori; Uchida, Takuro; Kan, Hiromi; Murakami, Eisuke; Abe, Hiromi; Miki, Daiki; Akiyama, Rie; Hiraga, Nobuhiko; Imamura, Michio; Aikata, Hiroshi; Kawaoka, Tomokazu; Kawakami, Yoshiiku; Chayama, Kazuaki] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Gastroenterol & Metab, Appl Life Sci, Hiroshima 7348551, Japan; [Akamatsu, Sakura; Hayes, C. Nelson; Ochi, Hidenori; Uchida, Takuro; Kan, Hiromi; Murakami, Eisuke; Abe, Hiromi; Tsuge, Masataka; Miki, Daiki; Akiyama, Rie; Hiraga, Nobuhiko; Imamura, Michio; Aikata, Hiroshi; Kawaoka, Tomokazu; Kawakami, Yoshiiku; Chayama, Kazuaki] Hiroshima Univ, Liver Res Project Ctr, Hiroshima 7348551, Japan; [Hayes, C. Nelson; Ochi, Hidenori; Abe, Hiromi; Miki, Daiki; Akiyama, Rie; Hiraga, Nobuhiko; Imamura, Michio; Kawaoka, Tomokazu; Kawakami, Yoshiiku; Chayama, Kazuaki] RIKEN, Ctr Genom Med, Lab Digest Dis, Hiroshima, Japan; [Tsuge, Masataka] Hiroshima Univ, Nat Sci Ctr Basic Res & Dev, Hiroshima 7348551, Japan	Chayama, K (reprint author), Hiroshima Univ, Appl Life Sci Inst Biomed & Hlth Sci, Dept Gastroenterol & Metab, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	chayama@hiroshima-u.ac.jp			Ministry of Health, Labor and Welfare; Ministry of Education, Culture, Sports, Science, and Technology, Government of Japan	This work was supported by Grants-in-Aid for scientific research and development from the Ministry of Health, Labor and Welfare and Ministry of Education, Culture, Sports, Science, and Technology, Government of Japan.	Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Tanaka Y, 2009, NAT GENET, V41, P1105, DOI 10.1038/ng.449; Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309; Honda M, 2010, GASTROENTEROLOGY, V139, P499, DOI 10.1053/j.gastro.2010.04.049; Akuta N, 2006, J MED VIROL, V78, P83, DOI 10.1002/jmv.20507; Akuta N, 2007, J MED VIROL, V79, P1686, DOI 10.1002/jmv.20979; Sarrazin C, 2010, GASTROENTEROLOGY, V138, P447, DOI 10.1053/j.gastro.2009.11.055; Topfer A, 2013, J COMPUT BIOL, V20, P113, DOI 10.1089/cmb.2012.0232; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Fried MW, 2011, J HEPATOL, V55, P69, DOI 10.1016/j.jhep.2010.10.032; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; Prokunina-Olsson L, 2013, NAT GENET, V45, P164, DOI 10.1038/ng.2521; Sheahan T, 2014, CELL HOST MICROBE, V15, P190, DOI 10.1016/j.chom.2014.01.007; Thompson Alexander J, 2010, Gastroenterology, V139, P120, DOI 10.1053/j.gastro.2010.04.013; Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463; ENOMOTO N, 1995, J CLIN INVEST, V96, P224, DOI 10.1172/JCI118025; Kohaar I, 2013, J NATL CANCER I, V105, P69, DOI 10.1093/jnci/djs458; Akuta N, 2014, J MED VIROL, V86, P1314, DOI 10.1002/jmv.23966; Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079; Karino Y, 2013, J HEPATOL, V58, P646, DOI 10.1016/j.jhep.2012.11.012; Hayes CN, 2011, GUT, V60, P261, DOI 10.1136/gut.2010.223495; Lok AS, 2014, J HEPATOL, V60, P490, DOI 10.1016/j.jhep.2013.10.019; Lee C, 2011, ARCH PHARM RES, V34, P1403, DOI 10.1007/s12272-011-0921-6; Suzuki F, 2012, J CLIN VIROL, V54, P352, DOI 10.1016/j.jcv.2012.04.024; Ohnishi Y, 2001, J HUM GENET, V46, P471, DOI 10.1007/s100380170047; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI 10.1093/molbev/mst197; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Suzuki A, 2003, NAT GENET, V34, P395, DOI 10.1038/ng1206; Manns M, 2014, LANCET, V384, P1597, DOI 10.1016/S0140-6736(14)61059-X; Suppiah V, 2009, NAT GENET, V41, P1100, DOI 10.1038/ng.447; O'Brien TR, 2014, J INTERF CYTOK RES, V34, P829, DOI 10.1089/jir.2013.0136; Kumada H, 2014, HEPATOLOGY, V59, P2083, DOI 10.1002/hep.27113; Pawlotsky JM, 2013, J HEPATOL, V59, P375, DOI 10.1016/j.jhep.2013.03.030; Suzuki Y, 2013, J HEPATOL, V58, P655, DOI 10.1016/j.jhep.2012.09.037; Nakamoto S, 2014, WORLD J GASTROENTERO, V20, P2902, DOI 10.3748/wjg.v20.i11.2902; Bernhart SH, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-474; Chayama K, 2015, EXPERT REV GASTROENT, V9, P21, DOI 10.1586/17474124.2015.960394; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; Hayashi K, 2012, J MED VIROL, V84, P438, DOI 10.1002/jmv.23207; Kohler James J, 2014, Infect Drug Resist, V7, P41, DOI 10.2147/IDR.S36247; Kosaka K, 2015, J VIRAL HEPATITIS, V22, P158, DOI 10.1111/jvh.12271; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; Miura M, 2014, HEPATOL RES, V44, pE360, DOI 10.1111/hepr.12316; Poole RM, 2014, DRUGS, V74, P1559, DOI 10.1007/s40265-014-0279-4; Aka PV, 2014, J INFECT DIS, V209, P350, DOI 10.1093/infdis/jit433; Quezada Elizabeth M, 2009, Open Biochem J, V3, P39, DOI 10.2174/1874091X00903010039; Sarasin-Filipowicz M, 2008, P NATL ACAD SCI USA, V105, P7034, DOI 10.1073/pnas.0707882105; Schoggins JW, 2013, CURR TOP MICROBIOL, V369, P219, DOI 10.1007/978-3-642-27340-7_9; Sharafi H, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.22649; Suzuki F, 2010, J CLIN VIROL, V47, P76, DOI 10.1016/j.jcv.2009.09.029; Taguchi T, 2004, J GEN VIROL, V85, P959, DOI 10.1099/vir.0.19513-0; Verbist BMP, 2015, BIOINFORMATICS, V31, P94, DOI 10.1093/bioinformatics/btu587; Ye K, 2008, BIOINFORMATICS, V24, P18, DOI 10.1093/bioinformatics/btm537	53	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0168-8278	1600-0641		J HEPATOL	J. Hepatol.	SEP	2015	63	3					554	563		10.1016/j.jhep.2015.03.033		10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CP2QI	WOS:000359721700004		
J	Lethanh, N; Kaito, K; Kobayashi, K				Lethanh, Nam; Kaito, Kiyoyuki; Kobayashi, Kiyoshi			Infrastructure Deterioration Prediction with a Poisson Hidden Markov Model on Time Series Data	JOURNAL OF INFRASTRUCTURE SYSTEMS			English	Article						Poisson hidden Markov model; Potholes; Pavement management; Bayesian estimation; Markov chain Monte Carlo	OPTIMIZATION; MAINTENANCE; CHAIN	The deterioration of a pavement surface can be described in terms of the presence and severity of distinct distresses, like potholes, cracking, and rutting. Each deterioration process is ordinarily described by a set of pavement indicators (e.g.,number of potholes, percentage of cracks, international roughness index) that are measured during monitoring and inspection activities. Manifestly, there exist statistical correlations among the deterioration processes. For instance, cracks appearing on a road section may contribute to an increase in pothole occurrence, and vice versa. In order to mathematically formulate the statistical interdependency among deterioration processes, a Poisson hidden Markov model is proposed in this paper. The model describes the complex process of pavement deterioration, which includes the frequent occurrence of local damage (e.g.,potholes) as well as the degradation of other pavement indicators (e.g.,cracks, roughness). To model the concurrent frequency of local damage, a stochastic Poisson process is used. At the same time, a Markov chain model is used to depict the degradation of other pavement indicators. A numerical estimation approach using Bayesian statistics with a Markov chain Monte Carlo simulation is developed to derive the values of the model's parameters based on historical information. The applicability of the model was demonstrated through an empirical example using data from a Japanese highway road link.	[Lethanh, Nam] Swiss Fed Inst Technol, Inst Construct & Infrastruct Management, CH-8093 Zurich, Switzerland; [Kaito, Kiyoyuki] Osaka Univ, Grad Sch Engn, Suita, Osaka 5650871, Japan; [Kobayashi, Kiyoshi] Kyoto Univ, Dept Urban Management, Nishikyo Ku, Kyoto 6158540, Japan	Lethanh, N (reprint author), Swiss Fed Inst Technol, Inst Construct & Infrastruct Management, CH-8093 Zurich, Switzerland.	lethanh@ibi.baug.ethz.ch; kaito@ga.eng.osaka-u.ac.jp; kobayashi.kiyoshi.6n@kyoto-u.ac.jp					Anastasopoulos PC, 2011, J INFRASTRUCT SYST, V17, P200, DOI 10.1061/(ASCE)IS.1943-555X.0000057; Kobayashi K, 2012, TRANSPORT RES B-METH, V46, P544, DOI 10.1016/j.trb.2011.11.008; GEMAN S, 1984, IEEE T PATTERN ANAL, V6, P721; Geweke J, 1996, 148 FED RES BANK MIN; GILKS WR, 1992, APPL STAT-J ROY ST C, V41, P337, DOI 10.2307/2347565; Jeff G, 2006, BAYESIAN METHODS SOC; Kaburagi T., 2008, IPSJ DIGITAR COURIER, V4, P193, DOI [10.2197/ipsjdc.4.193, DOI 10.2197/IPSJDC.4.193]; Kaito K., 2007, J CIVIL ENG JSCE, V63, P386; Kobayashi K., 2012, INT J ARCHITECTURE E, V1, P1; Kuhn KD, 2012, J INFRASTRUCT SYST, V18, P270, DOI 10.1061/(ASCE)IS.1943-555X.0000077; Lancaster T., 1990, ECONOMETRIC ANAL TRA; Lovell C. A. K., 2000, STOCHASTIC FRONTIER; MADANAT S, 1995, J TRANSP ENG-ASCE, V121, P267, DOI 10.1061/(ASCE)0733-947X(1995)121:3(267); O'Flaherty C. A, 2002, HIGHWAYS LOCATION DE; Paroli R., 2000, CASUALITY ACTUARIAL, P461; Robelin CA, 2007, J INFRASTRUCT SYST, V13, P195, DOI 10.1061/(ASCE)1076-0342(2007)13:3(195); Robert CP, 2000, J ROY STAT SOC B, V62, P57, DOI 10.1111/1467-9868.00219; Talvitie A, 1999, TRANSPORTATION, V26, P1, DOI 10.1023/A:1005172923602; Thomas O, 2013, J INFRASTRUCT SYST, V19, P186, DOI 10.1061/(ASCE)IS.1943-555X.0000112; Zucchini W, 2009, MONOGR STAT APPL PRO, V110, P3	20	0	0	ASCE-AMER SOC CIVIL ENGINEERS	RESTON	1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA	1076-0342	1943-555X		J INFRASTRUCT SYST	J. Infrastruct. Syst.	SEP	2015	21	3							04014051	10.1061/(ASCE)IS.1943-555X.0000242		10	Engineering, Civil	Engineering	CP2QN	WOS:000359722200009		
J	Helyes, Z; Kun, J; Dobrosi, N; Sandor, K; Nemeth, J; Perkecz, A; Pinter, E; Szabadfi, K; Gaszner, B; Tekus, V; Szolcsanyi, J; Steinhoff, M; Hashimoto, H; Reglodi, D; Biro, T				Helyes, Zsuzsanna; Kun, Jozsef; Dobrosi, Nora; Sandor, Katalin; Nemeth, Jozsef; Perkecz, Aniko; Pinter, Erika; Szabadfi, Krisztina; Gaszner, Balazs; Tekus, Valeria; Szolcsanyi, Janos; Steinhoff, Martin; Hashimoto, Hitoshi; Reglodi, Dora; Biro, Tamas			Pituitary Adenylate Cyclase-Activating Polypeptide Is Upregulated in Murine Skin Inflammation and Mediates Transient Receptor Potential Vanilloid-1-Induced Neurogenic Edema	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Article							GENE-RELATED PEPTIDE; SENSORY NERVE-TERMINALS; IN-VIVO; MULTIPLE-SCLEROSIS; ARTHRITIS MODEL; SPINAL-CORD; PACAP; RAT; MICE; VIP	Although pituitary adenylate cyclase-activating polypeptide (PACAP) was described as a key vasoregulator in human skin, little is known about its expression in mouse skin. As it is important to investigate PACAP signaling in translational mouse dermatitis models, we determined its presence, regulation, and role in neurogenic and non-neurogenic cutaneous inflammatory mechanisms. The mRNA of PACAP and its specific receptor PAC1 was detected with real-time PCR in several skin regions at comparable levels. PACAP-38-immunoreactivity measured with radioimmunoassay was similar in plantar and dorsal paw skin and the ear but significantly smaller in the back skin. PACAP and PAC1 mRNA, as well as PACAP-38 and PAC1 protein expression, significantly increased in the plantar skin after intraplantar administration of capsaicin (50 mu l, 100 mu g ml(-1)), an agonist of the transient receptor potential vanilloid 1 (TRPV1) receptor, evoking chiefly neurogenic inflammation without inflammatory cell accumulation. Intraplantar complete Freund's adjuvant (CFA; 50 mu l, 1 mg ml(-1)) also increased PACAP/PAC1 mRNA but not the PACAP peptide. Capsaicin-induced neurogenic paw edema, but not CFA-evoked non-neurogenic swelling, was significantly smaller in PACAP-deficient mice throughout a 24-hour period. To our knowledge, we provide previously unreported evidence for PACAP and PAC1 expression upregulation during skin inflammation of different mechanisms and for its pro-inflammatory function in neurogenic edema formation.	[Helyes, Zsuzsanna; Kun, Jozsef; Sandor, Katalin; Perkecz, Aniko; Pinter, Erika; Tekus, Valeria; Szolcsanyi, Janos] Univ Pecs, Fac Med, Dept Pharmacol & Pharmacotherapy, H-7624 Pecs, Hungary; [Helyes, Zsuzsanna; Kun, Jozsef; Pinter, Erika; Szabadfi, Krisztina; Tekus, Valeria] Univ Pecs, Janos Szentagothai Res Ctr, H-7624 Pecs, Hungary; [Helyes, Zsuzsanna; Pinter, Erika; Szolcsanyi, Janos] PharmInVivo Ltd, Pecs, Hungary; [Helyes, Zsuzsanna; Kun, Jozsef] Univ Pecs, Sch Med, MTA NAP Pain Res Grp B, H-7624 Pecs, Hungary; [Dobrosi, Nora; Biro, Tamas] Univ Debrecen, Fac Med, Dept Physiol, DE MTA Lendulet Cellular Physiol Res Grp, Debrecen, Hungary; [Dobrosi, Nora; Biro, Tamas] Univ Debrecen, Fac Med, Dept Immunol, Debrecen, Hungary; [Nemeth, Jozsef] Univ Debrecen, Med & Hlth Sci Ctr, Dept Pharmacol & Pharmacotherapy, Debrecen, Hungary; [Szabadfi, Krisztina] Univ Pecs, Fac Sci, Dept Expt Zool & Neurobiol, H-7624 Pecs, Hungary; [Gaszner, Balazs; Reglodi, Dora] Univ Pecs, Fac Med, MTA PTE PACAP Lendlet Res Grp, Dept Anat, H-7624 Pecs, Hungary; [Steinhoff, Martin] Univ Coll Dublin, Charles Clin, Dept Dermatol, Dublin 2, Ireland; [Steinhoff, Martin] Univ Coll Dublin, UCD Charles Inst Translat Dermatol, Dublin 2, Ireland; [Hashimoto, Hitoshi] Osaka Univ, Grad Sch Pharmaceut Sci, Lab Mol Neuropharmacol, Suita, Osaka, Japan; [Hashimoto, Hitoshi] Osaka Univ, United Grad Sch Child Dev, Suita, Osaka, Japan	Helyes, Z (reprint author), Univ Pecs, Dept Pharmacol & Pharmacotherapy, Szigeti U 12, H-7624 Pecs, Hungary.	zsuzsanna.helyes@aok.pte.hu			Hungarian Grants [OTKA 104984, OTKA PD100706, SROP-4.2.2. B-15/KONV-2015-0011]; Arimura Foundation; Hungarian Brain Research Program [KTIA_13_NAP-A-III/5]; Hungarian Academy of Sciences; European Union; State of Hungary - European Social Fund [TAMOP-4.2.4.A/2-11/1-2012-0001]; Japan Society for the Promotion of Science (JSPS) [26293020, 26670122]; Funding Program for Next Generation World-Leading Researchers [LS081]; Uehara Memorial Foundation, Japan; European Social Fund;  [OTKA 101761];  [OTKA 105369];  [TAMOP-4.2.2./A-11/1/KONV-2012-0025]	This work was sponsored by Hungarian Grants OTKA 104984, OTKA PD100706, SROP-4.2.2. B-15/KONV-2015-0011 Supporting Scientific Training of Talented Youth at the University of Pecs 2015, Arimura Foundation, and Hungarian Brain Research Program (grant KTIA_13_NAP-A-III/5). DR and TB are supported by "Lendulet" Program of the Hungarian Academy of Sciences, whereas TB received further support from OTKA 101761, OTKA 105369, and TAMOP-4.2.2./A-11/1/KONV-2012-0025. JK and EP were supported in the form of a scholarship by the European Union and the State of Hungary, co-financed by the European Social Fund in the framework of TAMOP-4.2.4.A/2-11/1-2012-0001 "National Excellence Program." HH was supported in part by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research, KAKENHI, Grant Numbers 26293020 and 26670122, the Funding Program for Next Generation World-Leading Researchers, Grant number LS081, and by a grant for research from Uehara Memorial Foundation, Japan. The project was subsidized by the European Union and co-financed by the European Social Fund. We thank Dr Agnes Kemeny for editing the figures.	Abu-Hamdan MD, 2006, NEUROSCIENCE, V140, P147, DOI 10.1016/j.neuroscience.2006.01.019; Dobrosi N, 2008, FASEB J, V22, P3685, DOI 10.1096/fj.07-104877; Szolcsanyi J, 2004, NEUROPEPTIDES, V38, P377, DOI 10.1016/j.npep.2004.07.005; Geppetti P, 2008, BJU INT, V101, P2, DOI 10.1111/j.1464-410X.2008.07493.x; Armstrong BD, 2008, NEUROSCIENCE, V151, P63, DOI 10.1016/j.neuroscience.200.09.084; MAGGI CA, 1995, PROG NEUROBIOL, V45, P1, DOI 10.1016/0301-0082(94)E0017-B; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Peters EMJ, 2006, J INVEST DERMATOL, V126, P1937, DOI 10.1038/sj.jid.5700429; Abad C, 2011, CURR PHARM DESIGN, V17, P1025; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Hashimoto H, 2006, ANN NY ACAD SCI, V1070, P75, DOI 10.1196/annals.1317.038; Elekes K, 2011, PEPTIDES, V32, P1439, DOI 10.1016/j.peptides.2011.05.008; Fahrenkrug J, 1998, NEUROSCIENCE, V83, P1261, DOI 10.1016/S0306-4522(97)00474-0; Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; Steinhoff M, 1999, REGUL PEPTIDES, V80, P49, DOI 10.1016/S0167-0115(99)00010-5; Azuma YT, 2008, J CELL PHYSIOL, V216, P111, DOI 10.1002/jcp.21381; Reichenstein M, 2008, J MOL NEUROSCI, V36, P330, DOI 10.1007/s12031-008-9116-0; Tamas A, 2012, INT J MOL SCI, V13, P8430, DOI 10.3390/ijms13078430; Schwab VD, 2011, J INVEST DERM SYMP P, V15, P53, DOI 10.1038/jidsymp.2011.6; Willems E, 2008, ANAL BIOCHEM, V379, P127, DOI 10.1016/j.ab.2008.04.036; Ding WH, 2007, J INVEST DERMATOL, V127, P2357, DOI 10.1038/sj.jid.5700858; Toth BI, 2009, FEBS LETT, V583, P1619, DOI 10.1016/j.febslet.2009.04.031; Szolcsanyi J, 1996, PROG BRAIN RES, V113, P343, DOI 10.1016/S0079-6123(08)61097-3; Ohtaki H, 2008, J MOL NEUROSCI, V36, P16, DOI 10.1007/s12031-008-9077-3; Caterina MJ, 1997, NATURE, V389, P816; Helyes Z, 2004, ARTHRITIS RHEUM, V50, P1677, DOI 10.1002/art.20184; Gomariz RP, 2006, ANN NY ACAD SCI, V1070, P51, DOI 10.1196/annals.1317.031; Nemeth J, 2006, NEUROSCIENCE, V143, P223, DOI 10.1016/j.neuroscience.2006.07.028; Reglodi D, 2012, J MOL NEUROSCI, V48, P482, DOI 10.1007/s12031-012-9762-0; Tan YV, 2009, P NATL ACAD SCI USA, V106, P2012, DOI 10.1073/pnas.0812257106; Arimura A, 2007, PEPTIDES, V28, P1617, DOI 10.1016/j.peptides.2007.06.006; Aubdool AA, 2011, J INVEST DERM SYMP P, V15, P33, DOI 10.1038/jidsymp.2011.8; Bodo E, 2004, J INVEST DERMATOL, V123, P410, DOI 10.1111/j.0022-202X.2004.23209.x; Botz B, 2014, ARTHRITIS RHEUMATOL, V66, P2739, DOI 10.1002/art.38772; Cardell LO, 1997, REGUL PEPTIDES, V71, P67, DOI 10.1016/S0167-0115(97)00027-X; Dalsgaard T, 2003, REGUL PEPTIDES, V110, P179, DOI 10.1016/S0167-0115(02)00205-7; De Falco M, 2014, SKIN CANC CURRENT CL, P1; Delgado M, 2003, ANN NY ACAD SCI, V992, P141; Ding WH, 2012, EUR J IMMUNOL, V42, P901, DOI 10.1002/eji.201141958; Dun EC, 1996, BRAIN RES, V721, P233, DOI 10.1016/0006-8993(96)00139-4; Fahrenkrug J, 2000, J CEREBR BLOOD F MET, V20, P1205; Geppetti P, 1996, NEUROGENIC INFLAMMAT; Hannibal J, 2000, CELL TISSUE RES, V299, P59, DOI 10.1007/s004419900124; Helyes Zsuzsanna, 2003, Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, V2, P191, DOI 10.2174/1568014033483806; Helyes Z, 2007, PEPTIDES, V28, P1847, DOI 10.1016/j.peptides.2007.07.001; Jakab B, 2004, J BIOCHEM BIOPH METH, V61, P189, DOI 10.1016/j.jbbm.2004.03.002; Kemeny A, 2010, J MOL NEUROSCI, V42, P443, DOI 10.1007/s12031-010-9368-3; Kodali S, 2003, EUR J IMMUNOL, V33, P3070, DOI 10.1002/eji.200324085; Lenti L, 2009, BRAIN RES, V1283, P50, DOI 10.1016/j.brainres.2009.06.021; MOLLER K, 1993, NEUROSCIENCE, V57, P725, DOI 10.1016/0306-4522(93)90018-B; Moller M, 1999, CELL TISSUE RES, V296, P247, DOI 10.1007/s004410051286; Mulder H, 1999, MOL NEUROBIOL, V19, P229, DOI 10.1007/BF02821715; Nemetz N, 2008, INT J CANCER, V122, P1803, DOI 10.1002/ijc.23308; QIN HY, 1993, J IMMUNOL, V150, P2072; Racz B, 2007, GEN COMP ENDOCR, V153, P115, DOI 10.1016/j.ygcen.2006.12.006; Reglodi D, 2011, CURR PHARM DESIGN, V17, P962; Shimakura SI, 2008, PEPTIDES, V29, P1432, DOI 10.1016/j.peptides.2008.04.009; Szolcsanyi J, 1996, NEUROGENIC INFLAMMAT, P33; Tan YV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061200; Tan YV, 2011, ASN NEURO, V3, P195, DOI 10.1042/AN20110024; Toth BI, 2008, J INVEST DERMATOL, V129, P329; Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370; WARREN JB, 1992, BRIT J PHARMACOL, V106, P331; WARREN JB, 1991, EUR J PHARMACOL, V197, P131, DOI 10.1016/0014-2999(91)90511-N; Wolstenholme GEW, 2008, CIBA F SYMP; Zhang YZ, 1997, REGUL PEPTIDES, V69, P83, DOI 10.1016/S0167-0115(97)02133-2	67	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135	9					2209	2218		10.1038/jid.2015.156		10	Dermatology	Dermatology	CO9JR	WOS:000359492100012		
J	Baba, A; Kitayama, K; Asakura, T; Sezutsu, H; Tanimoto, A; Kanekura, T				Baba, A.; Kitayama, K.; Asakura, T.; Sezutsu, H.; Tanimoto, A.; Kanekura, T.			Silk fibroin produced by transgenic silkworms overexpressing the Arg-Gly-Asp motif accelerates cutaneous wound healing in mice	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Baba, A.; Kanekura, T.] Kagoshima Univ, Grad Sch Med & Dent Sci, Dermatol, Kagoshima 890, Japan; [Kitayama, K.; Asakura, T.] Tokyo Univ Agr & Technol, Biotechnol, Koganei, Tokyo, Japan; [Sezutsu, H.] Natl Inst Agrobiol Sci, Transgen Silkworm Res Unit, Tsukuba, Ibaraki, Japan; [Tanimoto, A.] Kagoshima Univ, Grad Sch Med & Dent Sci, Mol & Cellular Pathol, Kagoshima 890, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		176	S31	S31				1	Dermatology	Dermatology	CP2WW	WOS:000359739400177		
J	Cho, Z; Asai, J; Arita, T; Takenaka, H; Konishi, E; Yanagisawa, A; Katoh, N				Cho, Z.; Asai, J.; Arita, T.; Takenaka, H.; Konishi, E.; Yanagisawa, A.; Katoh, N.			Podoplanin expression in peritumorial keratinocytes predicts aggressive behavior in extramammary Paget's disease	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Cho, Z.; Asai, J.; Arita, T.; Takenaka, H.; Katoh, N.] Kyoto Prefectural Univ Med, Dermatol, Kyoto, Japan; [Konishi, E.; Yanagisawa, A.] Kyoto Prefectural Univ Med, Surg Pathol, Kyoto, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		156	S27	S27				1	Dermatology	Dermatology	CP2WW	WOS:000359739400157		
J	Dai, X; Tohyama, M; Sayama, K				Dai, X.; Tohyama, M.; Sayama, K.			House dust mite allergen triggers IL-31 release from epidermal keratinocytes, via activaing ATP sgnaling and mobilizing intracellular calcium	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Dai, X.; Tohyama, M.; Sayama, K.] Ehime Univ, Grad Sch Med, Toon, Ehime, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		070	S12	S12				1	Dermatology	Dermatology	CP2WW	WOS:000359739400071		
J	Ezure, T; Kosaka, N; Amano, S; Ochiya, T				Ezure, T.; Kosaka, N.; Amano, S.; Ochiya, T.			Aging-associated miRNA Impairs Dermal Fibroblast Function Through Inhibition of TGFB1 Gene Expression: A Potential Regulator of Fibrosis	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Ezure, T.; Amano, S.] Shiseido Res Ctr, Yokohama, Kanagawa, Japan; [Kosaka, N.; Ochiya, T.] Natl Canc Ctr, Tokyo, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		168	S29	S29				1	Dermatology	Dermatology	CP2WW	WOS:000359739400169		
J	Fujii, K; Karpova, M; Asagoe, K; Georgiev, O; Kanekura, T; Iwatsuki, K; Dummer, R; Urosevic-Maiwald, M				Fujii, K.; Karpova, M.; Asagoe, K.; Georgiev, O.; Kanekura, T.; Iwatsuki, K.; Dummer, R.; Urosevic-Maiwald, M.			Versican up-regulation in Sezary cells	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Fujii, K.; Karpova, M.; Asagoe, K.; Dummer, R.; Urosevic-Maiwald, M.] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; [Georgiev, O.] Univ Zurich, Inst Mol Life Sci, Zurich, Switzerland; [Kanekura, T.] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Dermatol, Kagoshima 890, Japan; [Iwatsuki, K.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Dermatol, Okayama 7008530, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		123	S21	S21				1	Dermatology	Dermatology	CP2WW	WOS:000359739400124		
J	Fujimura, T; Furudate, S; Kambayashi, Y; Kakizaki, A; Aiba, S				Fujimura, T.; Furudate, S.; Kambayashi, Y.; Kakizaki, A.; Aiba, S.			Topical administration of imiquimod modifies the profiles of tumor-associated macrophages in B16F10 melanomas.	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Fujimura, T.; Furudate, S.; Kambayashi, Y.; Kakizaki, A.; Aiba, S.] Tohoku Univ, Grad Sch Med, Dept Dermagtol, Sendai, Miyagi 980, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		124	S22	S22				1	Dermatology	Dermatology	CP2WW	WOS:000359739400125		
J	Fujiwara, H				Fujiwara, H.			Epigenetic regulation of epithelial-mesenchymal transition in squamous cell carcinoma of the skin	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Fujiwara, H.] Uonuma Inst Community Med, Dermatol, Minamiuonuma, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		134	S23	S23				1	Dermatology	Dermatology	CP2WW	WOS:000359739400135		
J	Fujiyama, T; Ito, T; Tatsuno, K; Tokura, Y				Fujiyama, T.; Ito, T.; Tatsuno, K.; Tokura, Y.			Topical application of vitamin D3 analogue and corticosteroid to psoriasis plaques synergistically depresses expansion of Th17 cells in the lesional skin	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Fujiyama, T.; Ito, T.; Tatsuno, K.; Tokura, Y.] Hamamatsu Univ Sch Med, Dermatol, Hamamatsu, Shizuoka 4313192, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		206	S36	S36				1	Dermatology	Dermatology	CP2WW	WOS:000359739400207		
J	Furudate, S; Fujimura, T; Kakizaki, A; Kambayashi, Y; Aiba, S				Furudate, S.; Fujimura, T.; Kakizaki, A.; Kambayashi, Y.; Aiba, S.			Tumor-associated macrophages and stromal factors play roles in developing mycosis fungoides in the different stages	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Furudate, S.; Fujimura, T.; Kakizaki, A.; Kambayashi, Y.; Aiba, S.] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi 980, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		450	S78	S78				1	Dermatology	Dermatology	CP2WW	WOS:000359739400450		
J	Hibino, T; Miyai, M; Nakajima, S; Yamamoto-Tanaka, M; Maeda, T; Sakaguchi, M; Kabashima, K; Tsuboi, R				Hibino, T.; Miyai, M.; Nakajima, S.; Yamamoto-Tanaka, M.; Maeda, T.; Sakaguchi, M.; Kabashima, K.; Tsuboi, R.			S100A8 promoted Th1-related gene expression and S100A9 induced Th2 differentiation via activation of GATA-3	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Hibino, T.; Yamamoto-Tanaka, M.; Maeda, T.; Tsuboi, R.] Tokyo Med Univ, Dermatol, Tokyo 1608402, Japan; [Miyai, M.; Sakaguchi, M.] Okayama Univ, Grad Sch Med, Cell Biol, Okayama 7008530, Japan; [Nakajima, S.; Kabashima, K.] Kyoto Univ, Dermatol, Kyoto, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		357	S62	S62				1	Dermatology	Dermatology	CP2WW	WOS:000359739400358		
J	Hidaka, T; Ogawa, E; Kobayashi, E; Suzuki, T; Fujimura, T; Aiba, S; Okuyama, R; Yamamoto, M				Hidaka, T.; Ogawa, E.; Kobayashi, E.; Suzuki, T.; Fujimura, T.; Aiba, S.; Okuyama, R.; Yamamoto, M.			Aryl hydrocarbon receptor activation at keratinocyte leads to atopic dermatitis-like lesion via artemin induction	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Hidaka, T.; Kobayashi, E.; Suzuki, T.; Fujimura, T.; Yamamoto, M.] Tohoku Univ, Med Biochem, Sendai, Miyagi 980, Japan; [Ogawa, E.; Okuyama, R.] Shinshu Univ, Dermatol, Matsumoto, Nagano 390, Japan; [Aiba, S.] Tohoku Univ, Dermatol, Sendai, Miyagi 980, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		007	S2	S2				1	Dermatology	Dermatology	CP2WW	WOS:000359739400008		
J	Hinde, E; Foster, A; Imanishi, A; Schneider, MR; Kawai, K; Matos, TR; Haslam, I; Paus, R				Hinde, E.; Foster, A.; Imanishi, A.; Schneider, M. R.; Kawai, K.; Matos, T. R.; Haslam, I.; Paus, R.			The sebaceous gland shows differential responses to spontaneous and induced cycling	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Hinde, E.; Foster, A.; Imanishi, A.; Haslam, I.; Paus, R.] Univ Manchester, Inst Inflammat & Repair, Manchester, Lancs, England; [Schneider, M. R.] Ludwig Maximilians Univ Munchen, Inst Mol Anim Breeding & Biotechnol, Munich, Germany; [Matos, T. R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA; [Kawai, K.] Kido Hosp, Dept Dermatol, Niigata, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		400	S69	S69				1	Dermatology	Dermatology	CP2WW	WOS:000359739400400		
J	Honda, T; Yamamoto, O; Miyachi, Y; Kabashima, K				Honda, T.; Yamamoto, O.; Miyachi, Y.; Kabashima, K.			Proposal of a novel concept of necroptosis-mediated skin inflammation using an imiquimod-induced psoriasis-like dermatitis model	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Honda, T.; Miyachi, Y.; Kabashima, K.] Kyoto Univ, Dermatol, Kyoto, Japan; [Yamamoto, O.] Tottori Univ, Dermatol, Tottori 680, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		022	S4	S4				1	Dermatology	Dermatology	CP2WW	WOS:000359739400023		
J	Ichihara, A; Jinnin, M; Ogata, A; Niimori, D; Johno, T; Fukushima, S; Ihn, H				Ichihara, A.; Jinnin, M.; Ogata, A.; Niimori, D.; Johno, T.; Fukushima, S.; Ihn, H.			Interleukin-13 induces epidermal spongiosis by let-7f down-regulation and cathepsin C induction in atopic dermatitis	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Ichihara, A.; Jinnin, M.; Ogata, A.; Niimori, D.; Johno, T.; Fukushima, S.; Ihn, H.] Kumamoto Univ, Dermatol & Plast Surg, Kumamoto, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		065	S11	S11				1	Dermatology	Dermatology	CP2WW	WOS:000359739400066		
J	Igawa, K; Yokozeki, H				Igawa, K.; Yokozeki, H.			A trial to clarify the effect of the filaggrin gene mutation to keratinocytes biology by using CRISPR/Cas9 system and human induced pluripotent stem cells	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Igawa, K.; Yokozeki, H.] Tokyo Med & Dent Univ, Dermatol, Tokyo, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		386	S66	S66				1	Dermatology	Dermatology	CP2WW	WOS:000359739400386		
J	Ikushima, H; Taniguchi, T				Ikushima, H.; Taniguchi, T.			Anti-tumor immune system triggered by innate immune pattern recognition of melanoma	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Ikushima, H.; Taniguchi, T.] Univ Tokyo, Tokyo Ctr Integrat Inflammol, Max Planck Univ, Dept Mol Immunol,Inst Ind Sci, Tokyo, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		417	S72	S72				1	Dermatology	Dermatology	CP2WW	WOS:000359739400417		
J	Ito, T; Suzuki, T; Funakoshi, A; Fujiyama, T; Tokura, Y				Ito, T.; Suzuki, T.; Funakoshi, A.; Fujiyama, T.; Tokura, Y.			Plasmacytoid dendritic cells is a key player during the initiation phase of alopecia areata in C3H/HeJ mouse	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Ito, T.; Suzuki, T.; Funakoshi, A.; Fujiyama, T.; Tokura, Y.] Hamamatsu Univ, Sch Med, Dermatol, Hamamatsu, Shizuoka, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		383	S66	S66				1	Dermatology	Dermatology	CP2WW	WOS:000359739400383		
J	Iwasawa, MT; Nakamura, Y; Wakabayashi, S; Saijo, S; Matsue, H				Iwasawa, M. T.; Nakamura, Y.; Wakabayashi, S.; Saijo, S.; Matsue, H.			IL-17 produced by group 3 innate lymphoid cells (ILC3) and gamma delta T cells is pivotal for host defense against epicutaneous candidiasis via neutrophil activation	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Iwasawa, M. T.; Nakamura, Y.; Wakabayashi, S.; Matsue, H.] Chiba Univ, Dermatol, Chiba, Japan; [Saijo, S.] Chiba Univ, Med Mycol Res Canter, Chiba, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		407	S71	S71				1	Dermatology	Dermatology	CP2WW	WOS:000359739400407		
J	Iwata, H; Imafuku, K; Izumi, K; Wada, M; Natsuga, K; Ujiie, H; Nishie, W; Shimizu, H				Iwata, H.; Imafuku, K.; Izumi, K.; Wada, M.; Natsuga, K.; Ujiie, H.; Nishie, W.; Shimizu, H.			Autoantibodies to parts of type XVII collagen outside of the non-collageneous 16A domain lead to mild bullous pemphigoid due to the non-depletion of autoantigen	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Iwata, H.; Imafuku, K.; Izumi, K.; Natsuga, K.; Ujiie, H.; Nishie, W.; Shimizu, H.] Hokkaido Univ, Grad Sch Med, Dermatol, Sapporo, Hokkaido, Japan; [Wada, M.] Hokkaido Univ, Grad Sch Med, Oral Diag & Med, Sapporo, Hokkaido, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		021	S4	S4				1	Dermatology	Dermatology	CP2WW	WOS:000359739400022		
J	Kadono, N; Horigome, T; Nakashima, A; Hasegawa, T; Hirai, Y				Kadono, N.; Horigome, T.; Nakashima, A.; Hasegawa, T.; Hirai, Y.			Involvement of extracellularly extruded syntaxins and heparan sulfate in the differentiation control of epidermal keratinocytes	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Kadono, N.; Horigome, T.; Hirai, Y.] Kwansei Gakuin Univ, Biosci, Sanda, Japan; [Nakashima, A.; Hasegawa, T.] Kobayashi Pharmaceutial Co Ltd, Ibaraki, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		276	S48	S48				1	Dermatology	Dermatology	CP2WW	WOS:000359739400277		
J	Kamiya, K; Sakabe, J; Yamaguchi, H; Suzuki, T; Yatagai, T; Aoshima, M; Ito, T; Tokura, Y				Kamiya, K.; Sakabe, J.; Yamaguchi, H.; Suzuki, T.; Yatagai, T.; Aoshima, M.; Ito, T.; Tokura, Y.			Gross cystic disease fluid protein 15 as a potential marker for decreased sweating in atopic dermatitis	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Kamiya, K.; Sakabe, J.; Yamaguchi, H.; Suzuki, T.; Yatagai, T.; Aoshima, M.; Ito, T.; Tokura, Y.] Hamamatsu Univ Sch Med, Dept Dermatol, Hamamatsu, Shizuoka 4313192, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		188	S33	S33				1	Dermatology	Dermatology	CP2WW	WOS:000359739400189		
J	Kase, Y; Yamagami, J; Wada, N; Takahashi, H; Koyasu, S; Amagai, M				Kase, Y.; Yamagami, J.; Wada, N.; Takahashi, H.; Koyasu, S.; Amagai, M.			Intravenous immunoglobulin regulates anti-desmoglein 3 autoantibody production in B220-antibody-producing cells in mice with pemphigus vulgaris	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Kase, Y.] Japan Blood Prod Org, Cent Res Lab, Kobe, Hyogo, Japan; [Yamagami, J.; Wada, N.; Takahashi, H.; Amagai, M.] Keio Univ, Sch Med, Dept Dermatol, Tokyo, Japan; [Koyasu, S.] RIKEN, Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		004	S1	S1				1	Dermatology	Dermatology	CP2WW	WOS:000359739400005		
J	Kasuya, A; Ohta, I; Tokura, Y				Kasuya, A.; Ohta, I.; Tokura, Y.			Structural and immunological effects of skin cryoablation in a mouse model	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Kasuya, A.; Tokura, Y.] Hamamastu Univ Sch Med, Dermatol, Hamamatsu, Shizuoka, Japan; [Ohta, I.] Hamamastu Univ Sch Med, Res Equipment Ctr, Ultrastruct Morphol Lab, Hamamatsu, Shizuoka, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		177	S31	S31				1	Dermatology	Dermatology	CP2WW	WOS:000359739400178		
J	Kobayashi, T; Matsushita, T; Hamaguchi, Y; Hasegawa, M; Fujimoto, M; Takehara, K				Kobayashi, T.; Matsushita, T.; Hamaguchi, Y.; Hasegawa, M.; Fujimoto, M.; Takehara, K.			B cells Promote Tumor Immunity against B16F10 Melanoma	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Kobayashi, T.; Matsushita, T.; Hamaguchi, Y.; Takehara, K.] Kanazawa Univ, Dept Dermatol, Inst Med Pharmaceut & Hlth Sci, Kanazawa, Ishikawa, Japan; [Hasegawa, M.] Univ Fukui, Dermatol, Fukui 910, Japan; [Fujimoto, M.] Univ Tsukuba, Dermatol, Tsukuba, Ibaraki, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		103	S18	S18				1	Dermatology	Dermatology	CP2WW	WOS:000359739400104		
J	Koga, H; Recke, A; Vidarsson, G; Pas, H; Jonkman, MF; Zillikens, D; Ludwig, R				Koga, H.; Recke, A.; Vidarsson, G.; Pas, H.; Jonkman, M. F.; Zillikens, D.; Ludwig, R.			PDE4 inhibition as potential treatment of epidermolysis bullosa acquisita	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Koga, H.] Kurume Univ, Sch Med, Dept Dermatol, Kurume, Fukuoka 830, Japan; [Recke, A.; Zillikens, D.; Ludwig, R.] Med Univ Lubeck, Inst Expt Dermatol, D-23538 Lubeck, Germany; [Vidarsson, G.] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunohematol, Sanquin Res & Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands; [Pas, H.; Jonkman, M. F.] Univ Groningen, Univ Med Ctr Groningen, Dept Dermatol, Ctr Blistering Dis, Groningen, Netherlands								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		014	S3	S3				1	Dermatology	Dermatology	CP2WW	WOS:000359739400015		
J	Kubo, R; Muramatsu, S; Sagawa, Y; Saito, C; Kasuya, S; Nishioka, A; Nishida, E; Yamazaki, S; Morita, A				Kubo, R.; Muramatsu, S.; Sagawa, Y.; Saito, C.; Kasuya, S.; Nishioka, A.; Nishida, E.; Yamazaki, S.; Morita, A.			Bath-PUVA therapy increases circulating activated regulatory T cells in patients with psoriasis	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Kubo, R.; Muramatsu, S.; Sagawa, Y.; Saito, C.; Kasuya, S.; Nishioka, A.; Nishida, E.; Morita, A.] Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Nagoya, Aichi, Japan; [Yamazaki, S.] Nagoya City Univ, Grad Sch Med Sci, Dept Immunol, Nagoya, Aichi, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		210	S37	S37				1	Dermatology	Dermatology	CP2WW	WOS:000359739400211		
J	Kusuba, N; Kitoh, A; Kabashima, K				Kusuba, N.; Kitoh, A.; Kabashima, K.			The vitamin D analogue MC903 ameliorates imiquimod-induced psoriatic skin lesion through directly inhibiting IL-23 production by Langerhans cells	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Kusuba, N.; Kitoh, A.; Kabashima, K.] Kyoto Univ, Dept Dermatol, Grad Sch Med, Kyoto, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		038	S7	S7				1	Dermatology	Dermatology	CP2WW	WOS:000359739400039		
J	Lee, H; Lee, N; Kim, B; Jung, M; Kim, D; Moniaga, C; Kabashima, K; Choi, E				Lee, H.; Lee, N.; Kim, B.; Jung, M.; Kim, D.; Moniaga, C.; Kabashima, K.; Choi, E.			Neutralization of stratum corneum accelerates the progress from atopic dermatitis to asthma-like lesion in flaky tail mice treated by house dust mite allergen	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Lee, H.; Lee, N.; Kim, B.; Jung, M.; Kim, D.; Choi, E.] Yonsei Univ, Wonju Coll Med, Dept Dermatol, Wonju, South Korea; [Moniaga, C.; Kabashima, K.] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		017	S3	S3				1	Dermatology	Dermatology	CP2WW	WOS:000359739400018		
J	Li, Y; Zhang, J; Wang, J; Hosoi, J; Mandinova, A				Li, Y.; Zhang, J.; Wang, J.; Hosoi, J.; Mandinova, A.			Ex-vivo analyses of localized response to environmental stress in human skin	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Li, Y.; Zhang, J.; Wang, J.; Mandinova, A.] Harvard Univ, Sch Med, MGH, Dermatol, Boston, MA USA; [Hosoi, J.] Shiseido Res Ctr, Yokohama, Kanagawa, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		292	S50	S50				1	Dermatology	Dermatology	CP2WW	WOS:000359739400293		
J	Masahiro, K; Yabe, S; Itoh, M; Okochi, H; Nakagawa, H				Masahiro, K.; Yabe, S.; Itoh, M.; Okochi, H.; Nakagawa, H.			Immortal murine dermal papilla cells introduced by TERT and Bmi1 genes maintain hair inductive activity	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Masahiro, K.; Okochi, H.] Natl Ctr Global Hlth & Med, Regenerat Med Reserch, Shinjuku Ku, Tokyo, Japan; [Yabe, S.; Itoh, M.; Nakagawa, H.] Jikei Univ, Sch Med, Dermatol, Minato Ku, Tokyo, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		391	S67	S67				1	Dermatology	Dermatology	CP2WW	WOS:000359739400391		
J	Masuda, H; Kimura, M; Morita, A				Masuda, H.; Kimura, M.; Morita, A.			Suitable multi-wavelength irradiation for photodynamic therapy using 5-aminolevulinic acid	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Masuda, H.; Morita, A.] Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Nagoya, Aichi, Japan; [Kimura, M.] UHIO INC, Tokyo, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		485	S84	S84				1	Dermatology	Dermatology	CP2WW	WOS:000359739400485		
J	Matsui, T; Hirabayashi, A; Mayuko, S; Toyooka, K; Amagai, M				Matsui, T.; Hirabayashi, A.; Mayuko, S.; Toyooka, K.; Amagai, M.			Initiation of cornification is regulated by Ca2+ and pH in isolated mouse stratum granulosum cells	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Matsui, T.] RIKEN Ctr Integrat Med Sci, Lab Skin Homeostasis, Yokohama, Kanagawa, Japan; [Hirabayashi, A.] Keio Univ, Sch Med, KOSE Endowed Program Skin Care & Allergy Prevent, Tokyo, Japan; [Mayuko, S.; Toyooka, K.] RIKEN Ctr Sustainable Resource Sci, Mass Spectrometry & Microscopy Unit, Yokohama, Kanagawa, Japan; [Amagai, M.] Keio Univ, Sch Med, Dept Dermatol, Tokyo, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		256	S44	S44				1	Dermatology	Dermatology	CP2WW	WOS:000359739400257		
J	Matsushita, T; Hamaguchi, Y; Hasegawa, M; Takehara, K; Fujimoto, M				Matsushita, T.; Hamaguchi, Y.; Hasegawa, M.; Takehara, K.; Fujimoto, M.			Decreased Levels of Regulatory B cells in Patients with Systemic Sclerosis: Association with autoantibody production	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Matsushita, T.; Hamaguchi, Y.; Takehara, K.] Kanazawa Univ, Dermatol, Kanazawa, Ishikawa, Japan; [Hasegawa, M.] Univ Fukui, Dermatol, Fukui 910, Japan; [Fujimoto, M.] Univ Tsukuba, Dermatol, Tsukuba, Ibaraki, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		066	S11	S11				1	Dermatology	Dermatology	CP2WW	WOS:000359739400067		
J	Miyai, M; Sakaguchi, M; Yamamoto-Tanaka, M; Maeda, T; Hiruma, J; Tsuboi, R; Hibino, T				Miyai, M.; Sakaguchi, M.; Yamamoto-Tanaka, M.; Maeda, T.; Hiruma, J.; Tsuboi, R.; Hibino, T.			S100A8/A9 induces skin inflammation and keratinocyte proliferation via neuroplasatin-beta/EMMPRIN heterodimer receptor in atopic dermatitis	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Miyai, M.; Sakaguchi, M.] Okayama Univ, Grad Sch Med, Cell Biol, Okayama 7008530, Japan; [Yamamoto-Tanaka, M.; Maeda, T.; Hiruma, J.; Tsuboi, R.; Hibino, T.] Tokyo Med Univ, Dermatol, Tokyo 1608402, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		048	S8	S8				1	Dermatology	Dermatology	CP2WW	WOS:000359739400049		
J	Mizukami, Y; Sugawara, K; Paus, R; Tsuruta, D				Mizukami, Y.; Sugawara, K.; Paus, R.; Tsuruta, D.			Mucosal type mast cells degranulation and proliferation are stimulated by CRH in situ	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Mizukami, Y.; Sugawara, K.; Tsuruta, D.] Osaka City Univ, Grad Sch Med, Dermatol, Osaka 558, Japan; [Paus, R.] Univ Manchester, Ctr Dermatol, Inst Inflammat & Repair, Manchester, Lancs, England								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		091	S16	S16				1	Dermatology	Dermatology	CP2WW	WOS:000359739400092		
J	Murata, T; Honda, T; Miyachi, Y; Kabashima, K				Murata, T.; Honda, T.; Miyachi, Y.; Kabashima, K.			Non-invasive three-dimensional diagnostic approach to extramammary Paget's disease by two-photon microscopy	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Murata, T.; Honda, T.; Miyachi, Y.; Kabashima, K.] Kyoto Univ, Dermatol, Kyoto, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		135	S23	S23				1	Dermatology	Dermatology	CP2WW	WOS:000359739400136		
J	Nakagawa, S; Nakamura, Y; Katayama, Y; Nunez, G; Matsue, H				Nakagawa, S.; Nakamura, Y.; Katayama, Y.; Nunez, G.; Matsue, H.			Keratinocytes play an essential role on epicutaneous Staphylococcus aureus infection through MyD88	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Nakagawa, S.; Nakamura, Y.; Katayama, Y.; Matsue, H.] Chiba Univ, Dermatol, Chiba, Japan; [Nunez, G.] Univ Michigan, Pathol, Ann Arbor, MI 48109 USA; [Nunez, G.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		015	S3	S3				1	Dermatology	Dermatology	CP2WW	WOS:000359739400016		
J	Nakajima, K; Kataoka, S; Yamamoto, M; Malissen, B; Sano, S				Nakajima, K.; Kataoka, S.; Yamamoto, M.; Malissen, B.; Sano, S.			Langerhans cells migrate to lymph nodes with increased number in mice with Stat3 activation in keratinocytes and are essential for development of psoriasis-like lesion	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Malissen, B.] UM2 Aix Marseille Univ, Ctr Immunol Marseille Luminy, Marseille, France; [Nakajima, K.; Kataoka, S.; Yamamoto, M.; Sano, S.] Kochi Med Sch, Dept Dermatol, Nankoku, Kochi, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		410	S71	S71				1	Dermatology	Dermatology	CP2WW	WOS:000359739400410		
J	Nakamura, K; Jinnin, M; Inoue, K; Fukushima, S; Ihn, H				Nakamura, K.; Jinnin, M.; Inoue, K.; Fukushima, S.; Ihn, H.			Identifying disease-specific molecules of dermatomyositis and lupus erythematosus skin by quantitative proteomics analysis	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Nakamura, K.; Jinnin, M.; Inoue, K.; Fukushima, S.; Ihn, H.] Kumamoto Univ, Fac Life Sci, Dermatol & Plast Surg, Kumamoto, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		029	S5	S5				1	Dermatology	Dermatology	CP2WW	WOS:000359739400030		
J	Nakamura, Y; Inoue, Y; Katayama, Y; Nunez, G; Shimojo, N; Matsue, H				Nakamura, Y.; Inoue, Y.; Katayama, Y.; Nunez, G.; Shimojo, N.; Matsue, H.			Expression ability of RNAIII gene encoding delta-toxin in Staphylococcus aureus isolated from infant skin is associated with atopic dermatitis development	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Nakamura, Y.; Katayama, Y.; Matsue, H.] Chiba Univ, Dermatol, Chiba, Japan; [Inoue, Y.; Shimojo, N.] Chiba Univ, Pediat, Chiba, Japan; [Nunez, G.] Univ Michigan, Pathol, Ann Arbor, MI 48109 USA								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		181	S32	S32				1	Dermatology	Dermatology	CP2WW	WOS:000359739400182		
J	Namiki, T; Yaguchi, T; Nakamura, K; Kawaguchi, M; Tanemura, A; Katayama, I; Yokozeki, H; Kawakami, Y; Hearing, V				Namiki, T.; Yaguchi, T.; Nakamura, K.; Kawaguchi, M.; Tanemura, A.; Katayama, I.; Yokozeki, H.; Kawakami, Y.; Hearing, V.			NUAK2 amplification coupled with PTEN deficiency promote melanoma development via CDK activation	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Namiki, T.; Yokozeki, H.] Tokyo Med & Dent Univ, Dermatol, Tokyo, Japan; [Yaguchi, T.; Nakamura, K.; Kawakami, Y.] Keio Univ, Sch Med, Div Cellular Signaling, Inst Adv Med Res, Tokyo, Japan; [Kawaguchi, M.; Hearing, V.] NCI, Cell Biol Lab, Bethesda, MD 20892 USA; [Tanemura, A.; Katayama, I.] Osaka Univ, Grad Sch Med, Dermatol, Osaka, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		100	S18	S18				1	Dermatology	Dermatology	CP2WW	WOS:000359739400101		
J	Nishida, E; Kubo, R; Morita, A; Muramatsu, S				Nishida, E.; Kubo, R.; Morita, A.; Muramatsu, S.			Incidence of secondary failure and antibody formation to infliximab in Japanese psoriasis patients	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Nishida, E.; Kubo, R.; Morita, A.; Muramatsu, S.] Nagoya City Univ, Geriatr & Environm Dermatol, Nagoya, Aichi, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		232	S40	S40				1	Dermatology	Dermatology	CP2WW	WOS:000359739400233		
J	Ogawa, Y; Kim, J; Morasso, MI; Udey, MC				Ogawa, Y.; Kim, J.; Morasso, M. I.; Udey, M. C.			Macrophages Regulate IL-17-Associated Skin Inflammation in Mice with Dlx3-deficient keratinocytes	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Ogawa, Y.] Yamanashi Sch Med, Dermatol, Yamanashi, Japan; [Kim, J.; Morasso, M. I.] NIAMSD, Skin Biol Lab, Bethesda, MD USA; [Udey, M. C.] NCI, Dermatol Branch, Bethesda, MD 20892 USA								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		427	S74	S74				1	Dermatology	Dermatology	CP2WW	WOS:000359739400427		
J	Ohko, K; Nakajima, K; Sano, S				Ohko, K.; Nakajima, K.; Sano, S.			Keratinocyte-autonomous IL-36/IL-17C loop shapes the psoriasiform phenotype	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Ohko, K.; Nakajima, K.; Sano, S.] Kochi Univ, Nankoku, Kochi, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		026	S5	S5				1	Dermatology	Dermatology	CP2WW	WOS:000359739400027		
J	Okubo, Y; Iwanaga, A; Ikehara, S; Masuyama, R; Utani, A				Okubo, Y.; Iwanaga, A.; Ikehara, S.; Masuyama, R.; Utani, A.			Accelerated calcification in fibroblasts derived from Pseudoxanthoma elasticum-like disorder, GGCX syndrome	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Okubo, Y.; Iwanaga, A.; Ikehara, S.; Utani, A.] Nagasaki Univ, Grad Sch Biomed Sci, Dermatr, Nagasaki 852, Japan; [Masuyama, R.] Nagasaki Univ, Grad Sch Biomed Sci, Mol Bone Biol, Nagasaki 852, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		358	S62	S62				1	Dermatology	Dermatology	CP2WW	WOS:000359739400359		
J	Oshio, T; Komine, M; Tsuda, H; Tominaga, S; Saito, H; Nakae, S; Ohtsuki, M				Oshio, T.; Komine, M.; Tsuda, H.; Tominaga, S.; Saito, H.; Nakae, S.; Ohtsuki, M.			Nuclear expression of IL-33 in skin is positively involved in wound healing in mice	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Oshio, T.; Komine, M.; Tsuda, H.; Tominaga, S.; Ohtsuki, M.] Jichi Med Univ, Shimotsuke, Tochigi, Japan; [Saito, H.] Natl Res Inst Child Hlth & Dev, Tokyo, Japan; [Nakae, S.] Univ Tokyo, Inst Med Sci, Tokyo, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		164	S29	S29				1	Dermatology	Dermatology	CP2WW	WOS:000359739400165		
J	Sakai, T; Hatano, Y; Matsuda-Hirose, H; Zhang, W; Takahashi, D; Jeong, S; Elias, P; Fujiwara, S				Sakai, T.; Hatano, Y.; Matsuda-Hirose, H.; Zhang, W.; Takahashi, D.; Jeong, S.; Elias, P.; Fujiwara, S.			Combined benefits of a protease-activated receptor 2 inhibitor and stratum corneum acidification for murine atopic dermatitis	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Sakai, T.; Hatano, Y.; Matsuda-Hirose, H.; Zhang, W.; Takahashi, D.; Fujiwara, S.] Oita Univ, Fac Med, Dermatol, Yufu, Japan; [Jeong, S.] NeoPharm Co Ltd, Div Appl Res, Taejon, South Korea; [Elias, P.] Univ Calif San Francisco, Dermatol, San Francisco, CA 94143 USA								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		260	S45	S45				1	Dermatology	Dermatology	CP2WW	WOS:000359739400261		
J	Shideler, S; Sugaya, S; Secci, A; Smith, A; Bricmont, P; KOrnyeyeva, E				Shideler, S.; Sugaya, S.; Secci, A.; Smith, A.; Bricmont, P.; KOrnyeyeva, E.			Proof-of-Concept study to investigate efficacy of selective type-4 phosphodiesterase (PDE4) inhibitor OPA-15406 for topical treatment adult subjects with mild to moderate Atopic Dermatitis (AD)	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Shideler, S.] Shideler Dermatol, Carmel, IN USA; [Sugaya, S.] OPCJ, Tokyo, Japan; [Secci, A.; Smith, A.; Bricmont, P.; KOrnyeyeva, E.] OPDC, Princeton, NJ USA								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		025	S5	S5				1	Dermatology	Dermatology	CP2WW	WOS:000359739400026		
J	Shimauchi, T; Blanchet, F; Finsterbusch, K; Czubala, M; Easter, T; Ladell, K; Price, D; Bangham, C; Tokura, Y; Piguet, V				Shimauchi, T.; Blanchet, F.; Finsterbusch, K.; Czubala, M.; Easter, T.; Ladell, K.; Price, D.; Bangham, C.; Tokura, Y.; Piguet, V.			Human T-cell Leukemia Virus type 1 can modulate TLR-induced Dendritic Cells Activation via C-Type Lectin Receptors	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Shimauchi, T.; Blanchet, F.; Finsterbusch, K.; Czubala, M.; Easter, T.; Piguet, V.] Cardiff Univ, Sch Med, Inst Infect & Immun, Dept Dermatol & Wound Healing, Cardiff CF10 3AX, S Glam, Wales; [Ladell, K.; Price, D.] Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff CF10 3AX, S Glam, Wales; [Bangham, C.] Univ London Imperial Coll Sci Technol & Med, Wright Fleming Inst, Inst Infect & Immun, London, England; [Tokura, Y.] Hamamatsu Univ Sch Med, Dept Dermatol, Hamamatsu, Shizuoka 4313192, Japan			Ladell, Kristin/C-8301-2013	Ladell, Kristin/0000-0002-9856-2938				0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		424	S73	S73				1	Dermatology	Dermatology	CP2WW	WOS:000359739400424		
J	Shimizu, S; Moriuchi, R; Miyauchi, T; Hamade, Y; Sakai, T; Yamamoto, S; Nagasaka, A; Shimizu, H				Shimizu, S.; Moriuchi, R.; Miyauchi, T.; Hamade, Y.; Sakai, T.; Yamamoto, S.; Nagasaka, A.; Shimizu, H.			Sudden onset of painful erythemas/infiltrated erythematous plaques is an early clinical indicator of Helicobacter cinaedi bacteremia	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Shimizu, S.; Moriuchi, R.; Miyauchi, T.; Hamade, Y.] Sapporo City Gen Hosp, Dermatol, Sapporo, Hokkaido, Japan; [Sakai, T.; Yamamoto, S.] Sapporo City Gen Hosp, Hematol, Sapporo, Hokkaido, Japan; [Nagasaka, A.] Sapporo City Gen Hosp, Infect Dis, Sapporo, Hokkaido, Japan; [Shimizu, H.] Hokkaido Univ, Dermatol, Sapporo, Hokkaido, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		226	S39	S39				1	Dermatology	Dermatology	CP2WW	WOS:000359739400227		
J	Takaishi, M; Tarutani, M; Takeda, J; Sano, S				Takaishi, M.; Tarutani, M.; Takeda, J.; Sano, S.			Attenuation of human SCC malignancy by introduction of reprogramming factors	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Takaishi, M.; Tarutani, M.; Sano, S.] Kochi Univ, Dept Dermatol, Sch Med, Nankoku, Kochi, Japan; [Takeda, J.] Osaka Univ, Grad Sch Med, Dept Social & Environm Med, Suita, Osaka, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		108	S19	S19				1	Dermatology	Dermatology	CP2WW	WOS:000359739400109		
J	Tokoro, S; Igawa, K; Ugajin, T; Tokura, Y; Katayama, I; Miyachi, Y; Satoh, T; Yokozeki, H				Tokoro, S.; Igawa, K.; Ugajin, T.; Tokura, Y.; Katayama, I.; Miyachi, Y.; Satoh, T.; Yokozeki, H.			A survey of Japanese atopic dermatitis patients - clinical differences between "Intrinsic" and "Extrinsic" subtypes	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Tokoro, S.; Igawa, K.; Ugajin, T.; Yokozeki, H.] Tokyo Med & Dent Univ, Tokyo, Japan; [Tokura, Y.] Hamamatsu Univ, Shizuoka, Japan; [Katayama, I.] Osaka Univ, Osaka, Japan; [Miyachi, Y.] Kyoto Univ, Kyoto, Japan; [Satoh, T.] Natl Def Med Coll, Saitama, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		231	S40	S40				1	Dermatology	Dermatology	CP2WW	WOS:000359739400232		
J	Torii, K; Morita, A				Torii, K.; Morita, A.			UVB irradiation induces HMGB1 in keratinocytes without causing apoptosis	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Torii, K.; Morita, A.] Nagoya City Univ, Grad Sch Med Sci, Geriatr & Environm Dermatol, Nagoya, Aichi, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		472	S82	S82				1	Dermatology	Dermatology	CP2WW	WOS:000359739400472		
J	Tsuda, H; Komine, M; Tominaga, S; Ohtsuki, M				Tsuda, H.; Komine, M.; Tominaga, S.; Ohtsuki, M.			Oncostatin M induces IL-33 through STAT3 pathway in normal human epidermal keratinocytes	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Tsuda, H.; Komine, M.; Ohtsuki, M.] Jichi Med Univ, Dermatol, Shimotsuke, Japan; [Tominaga, S.] JichiMed Univ, Biochem, Shimotsuke, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		426	S74	S74				1	Dermatology	Dermatology	CP2WW	WOS:000359739400426		
J	Tsuji, G; Nakahara, T; Uchi, H; Mitoma, C; Furue, M				Tsuji, G.; Nakahara, T.; Uchi, H.; Mitoma, C.; Furue, M.			Activation of aryl hydrocarbon receptor-nuclear factor erythroid 2-related factor 2 axis by epidermal growth factor receptor inhibitors: a possible mechanism for acneiform eruption	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Tsuji, G.; Mitoma, C.] Kyushu Univ Hosp, Res & Clin Ctr Yusho & Dioxin, Fukuoka 812, Japan; [Nakahara, T.] Kyushu Univ, Div Skin Surface Sensing, Fukuoka 812, Japan; [Uchi, H.; Furue, M.] Kyushu Univ, Dept Dermatol, Fukuoka 812, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		046	S8	S8				1	Dermatology	Dermatology	CP2WW	WOS:000359739400047		
J	Uchida, Y; Bertolini, M; Kanekura, T; Rossi, A; Paus, R				Uchida, Y.; Bertolini, M.; Kanekura, T.; Rossi, A.; Paus, R.			Do gamma delta T cells contribute to human hair biology and pathology?	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Uchida, Y.; Bertolini, M.] Univ Munster, D-48149 Munster, Germany; [Kanekura, T.] Kagoshima Univ, Kagoshima 890, Japan; [Rossi, A.] Univ Roma La Sapienza, Rome, Italy; [Paus, R.] Univ Manchester, Manchester, Lancs, England								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		399	S69	S69				1	Dermatology	Dermatology	CP2WW	WOS:000359739400399		
J	Uchiyama, A; Yamada, K; Buddhini, P; Ogino, S; Yokoyama, Y; Takeuchi, Y; Ishikawa, O; Motegi, S				Uchiyama, A.; Yamada, K.; Buddhini, P.; Ogino, S.; Yokoyama, Y.; Takeuchi, Y.; Ishikawa, O.; Motegi, S.			Protective effect of botulinum toxin A after cutaneous ischemia-reperfusion injury	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Uchiyama, A.; Yamada, K.; Buddhini, P.; Ogino, S.; Yokoyama, Y.; Takeuchi, Y.; Ishikawa, O.; Motegi, S.] Gunma Univ, Grad Sch Med, Dermatol, Maebashi, Gumma 371, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		171	S30	S30				1	Dermatology	Dermatology	CP2WW	WOS:000359739400172		
J	Ugajin, T; Shibama, S; Yamaguchi, T; Yokozeki, H				Ugajin, T.; Shibama, S.; Yamaguchi, T.; Yokozeki, H.			Decreased basophil-derived IL-4 is associated to metal imbalance in patients with prurigo	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Ugajin, T.; Shibama, S.; Yokozeki, H.] Tokyo Med & Dent Univ, Dept Dermatol, Tokyo, Japan; [Yamaguchi, T.] Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Tokyo, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		095	S16	S16				1	Dermatology	Dermatology	CP2WW	WOS:000359739400096		
J	Utsumi, D; Uezato, H; Takahashi, K				Utsumi, D.; Uezato, H.; Takahashi, K.			Contribution of mechanical stress to impaired differentiation and proliferation of lesional keratinocytes in striate palmo-plantar keratoderma caused by haplo-insufficiency of DSG1	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Utsumi, D.; Uezato, H.; Takahashi, K.] Univ Ryukyus, Dermatol, Nakagami, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		350	S60	S60				1	Dermatology	Dermatology	CP2WW	WOS:000359739400351		
J	Watanabe, Y; Yamaguchi, Y; Komitsu, N; Watanabe, T; Aihara, M				Watanabe, Y.; Yamaguchi, Y.; Komitsu, N.; Watanabe, T.; Aihara, M.			Leptin induces secretion of IL-6 by human keratinocytes via decreased expression of caveolin-1	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Watanabe, Y.; Yamaguchi, Y.; Komitsu, N.; Watanabe, T.; Aihara, M.] Yokohama City Univ, Grad Sch Med, Dept Environm Immunodermatol, Yokohama, Kanagawa 232, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		064	S11	S11				1	Dermatology	Dermatology	CP2WW	WOS:000359739400065		
J	Wong, L; Otsuka, A; Yamamoto, Y; Kabashima, K				Wong, L.; Otsuka, A.; Yamamoto, Y.; Kabashima, K.			Epidermal hyperinnervation is mediated by VEGF-A in an imiquimod-induced itchy psoriasiform model	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Wong, L.; Otsuka, A.; Yamamoto, Y.; Kabashima, K.] Kyoto Univ, Grad Sch Med, Kyoto, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		251	S43	S43				1	Dermatology	Dermatology	CP2WW	WOS:000359739400252		
J	Yamada, K; Uchiyama, A; Ogino, S; Perera, B; Yokoyama, Y; Takeuchi, Y; Ishikawa, O; Motegi, S				Yamada, K.; Uchiyama, A.; Ogino, S.; Perera, B.; Yokoyama, Y.; Takeuchi, Y.; Ishikawa, O.; Motegi, S.			MFG-E8 promotes mesenchymal stem cells-induced angiogenesis	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Yamada, K.; Uchiyama, A.; Ogino, S.; Perera, B.; Yokoyama, Y.; Takeuchi, Y.; Ishikawa, O.; Motegi, S.] Gunma Univ, Maebashi, Gumma 371, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		377	S65	S65				1	Dermatology	Dermatology	CP2WW	WOS:000359739400377		
J	Yamaguchi, M; Hamada, T; Morizane, S; Sugaya, M; Iwata, H; Fujii, K; Imada, M; Morishita, K; Ohshima, K; Iwatsuki, K				Yamaguchi, M.; Hamada, T.; Morizane, S.; Sugaya, M.; Iwata, H.; Fujii, K.; Imada, M.; Morishita, K.; Ohshima, K.; Iwatsuki, K.			A novel biomarker, CADM-1/TSLC1 for aggressive Sezary syndrome: comparison with the soluble form in sera	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Yamaguchi, M.; Hamada, T.; Morizane, S.; Iwatsuki, K.] Okayama Univ, Dermatol, Okayama 7008530, Japan; [Sugaya, M.] Univ Tokyo, Dermatol, Tokyo, Japan; [Iwata, H.] Hokkaido Univ, Dermatol, Sapporo, Hokkaido, Japan; [Fujii, K.] Kagoshima Univ, Dermatol, Kagoshima 890, Japan; [Imada, M.] Okayama Univ Hosp, Lab Med, Okayama, Japan; [Morishita, K.] Miyazaki Univ, Med Sci, Miyazaki, Japan; [Ohshima, K.] Kurume Univ, Pathol, Kurume, Fukuoka 830, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		150	S26	S26				1	Dermatology	Dermatology	CP2WW	WOS:000359739400151		
J	Yamaguchi, S; Uezato, H; Takahashi, K				Yamaguchi, S.; Uezato, H.; Takahashi, K.			The decrease of IL-34 is the key mechanism to provoke the disappearance of Langerhans cell in the skin lesion of pellagra	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Yamaguchi, S.; Uezato, H.; Takahashi, K.] Univ Ryukyus, Dermatol, Nishihara, Okinawa 90301, Japan								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		240	S42	S42				1	Dermatology	Dermatology	CP2WW	WOS:000359739400241		
J	Yoshida, K; Ishii, K; Shimizu, A; Yokouchi, M; Amagai, M; Stanley, JR; Ishiko, A				Yoshida, K.; Ishii, K.; Shimizu, A.; Yokouchi, M.; Amagai, M.; Stanley, J. R.; Ishiko, A.			p38 MAPK signaling is necessary for desmoglein1 clustering and enhances pathogenic effect, but is not required for blistering in pemphigus foliaceus	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	45th Annual Meeting of the European-Society-for-Dermatological-Research	SEP 09-12, 2015	Rotterdam, NETHERLANDS	European Soc Dermatol Res					[Yoshida, K.; Ishii, K.; Shimizu, A.; Ishiko, A.] Toho Univ, Sch Med, Dermatol, Tokyo, Japan; [Yokouchi, M.; Amagai, M.] Keio Univ, Sch Med, Dermatol, Tokyo, Japan; [Stanley, J. R.] Univ Penn, Sch Med, Dermatol, Philadelphia, PA 19104 USA								0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X	1523-1747		J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2015	135			2		172	S30	S30				1	Dermatology	Dermatology	CP2WW	WOS:000359739400173		
J	Seki, M; Yoshida, T; Takada, T				Seki, Motohide; Yoshida, Tomohiko; Takada, Takenori			A general method for calculating the optimal leaf longevity from the viewpoint of carbon economy	JOURNAL OF MATHEMATICAL BIOLOGY			English	Article						Leaf lifespan; Optimal strategy; Deciduous; Evergreen; Multiple flushing	USE EFFICIENCY; TREES; PLANT; DYNAMICS; PATTERNS; SPECTRUM; FOREST; LEAVES; SHOOT; AGE	According to the viewpoint of the optimal strategy theory, a tree is expected to shed its leaves when they no longer contribute to maximisation of net carbon gain. Several theoretical models have been proposed in which a tree was assumed to strategically shed an old deteriorated leaf to develop a new leaf. We mathematically refined an index used in a previous theoretical model [Kikuzawa (Am Nat 138:1250-1263, 1991)] so that the index is exactly proportional to a tree's lifelong net carbon gain. We also incorporated a tree's strategy that determines the timing of leaf expansion, and examined three kinds of strategies. Specifically, we assumed that a new leaf is expanded (1) immediately after shedding of an old leaf, (2) only at the beginning of spring, or (3) immediately after shedding of an old leaf if the shedding occurs during a non-winter season and at the beginning of spring otherwise. We derived a measure of optimal leaf longevity maximising the value of an appropriate index reflecting total net carbon gain and show that use of this index yielded results that are qualitatively consistent with empirical records. The model predicted that expanding a new leaf at the beginning of spring than immediately after shedding usually yields higher carbon gain, and combined strategy of the immediate replacement and the spring flushing earned the highest gain. In addition, our numerical analyses suggested that multiple flushing seen in a few species of subtropical zones can be explained in terms of carbon economy.	[Seki, Motohide; Takada, Takenori] Hokkaido Univ, Fac Environm Earth Sci, Kita Ku, Sapporo, Hokkaido 0600810, Japan; [Yoshida, Tomohiko] Hokkaido Univ, Grad Sch Environm Sci, Kita Ku, Sapporo, Hokkaido 0600810, Japan	Seki, M (reprint author), Hokkaido Univ, Fac Environm Earth Sci, Kita Ku, N10W5, Sapporo, Hokkaido 0600810, Japan.	seki.evol@gmail.com			JSPS KAKENHI Grant [24247003, 25340115]	We are grateful to S. Oikawa and K. Kikuzawa for their helpful comments. We also thank A. Ushijima-Akasaka, S. Aiba, K. Umeki, and T. S. Kohyama for acquainting us with suggestive empirical records. This study was supported by JSPS KAKENHI Grant Number 24247003 (T.T.), 25340115 (T.T.).	Wright IJ, 2004, NATURE, V428, P821, DOI 10.1038/nature02403; CHAPIN FS, 1980, ANNU REV ECOL SYST, V11, P233, DOI 10.1146/annurev.es.11.110180.001313; Reich PB, 2014, J ECOL, V102, P275; Kitajima K, 1997, AM J BOT, V84, P702, DOI 10.2307/2445906; Kikuzawa K, 2013, GLOBAL ECOL BIOGEOGR, V22, P982, DOI 10.1111/geb.12042; ACKERLY DD, 1995, OECOLOGIA, V101, P289, DOI 10.1007/BF00328814; Hiremath AJ, 2000, TREE PHYSIOL, V20, P937; KIKUZAWA K, 1991, AM NAT, V138, P1250, DOI 10.1086/285281; REICH PB, 1992, ECOL MONOGR, V62, P365, DOI 10.2307/2937116; CHABOT BF, 1982, ANNU REV ECOL SYST, V13, P229, DOI 10.1146/annurev.es.13.110182.001305; Maynard Smith J., 1973, Nature London, V246, P15; COLEY PD, 1980, NATURE, V284, P545, DOI 10.1038/284545a0; Givnish TJ, 2002, SILVA FENN, V36, P703, DOI 10.14214/sf.535; Anten NPR, 2002, J THEOR BIOL, V217, P15, DOI 10.1006/yjtbi.3022; BENTLEY BL, 1979, ANN BOT-LONDON, V43, P119; GIVNISH T J, 1978, P351; GOWER ST, 1993, TREE PHYSIOL, V12, P327; Harada Y, 1988, PLANT SPEC BIOL, V3, P89, DOI 10.1111/j.1442-1984.1988.tb00174.x; Hikosaka K, 2000, TREE PHYSIOL, V20, P1249; Koike T., 1988, PLANT SPEC BIOL, V3, P77, DOI 10.1111/j.1442-1984.1988.tb00173.x; Nitta I, 1997, PLANT ECOL, V130, P71, DOI 10.1023/A:1009735709258; SAKAI S, 1992, J THEOR BIOL, V154, P77, DOI 10.1016/S0022-5193(05)80189-4; SCHOETTLE AW, 1990, TREE PHYSIOL, V7, P209; Šesták Z., 1985, Photosynthesis during leaf development, P263; Takada T, 2006, EVOL ECOL RES, V8, P605; Xiao Y, 2003, TREE PHYSIOL, V23, P463	26	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0303-6812	1432-1416		J MATH BIOL	J. Math. Biol.	SEP	2015	71	3					669	690		10.1007/s00285-014-0830-7		22	Biology; Mathematical & Computational Biology	Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology	CP0AC	WOS:000359537200007		
J	Tsuzuki, Y				Tsuzuki, Yutaka			Existence and Uniqueness of Solutions to Heat Equations with Hysteresis Coupled with Navier-Stokes Equations in 2D and 3D	JOURNAL OF MATHEMATICAL FLUID MECHANICS			English	Article						Heat equations; hysteresis; Navier-Stokes equations; subdifferential operators	VALUED INTEGRAL-EQUATIONS; FRACTIONAL-POWERS; DOMAINS; TEMPERATURE; THERMOSTATS; OPERATORS; MODEL	This paper is concerned with a system of heat equations with hysteresis and Navier-Stokes equations. In Tsuzuki (J Math Anal Appl 423:877-897, 2015) an existence result is obtained for the problem in a 2-dimensional domain with the Navier-Stokes equation in a weak sense. However the result does not include uniqueness for the problem due to the low regularity for solutions. This paper establishes existence and uniqueness in 2- and 3-dimensional domains with the Navier-Stokes equation in a stronger sense. Moreover this work decides required height of regularity for the initial data by introducing the fractional power of the Stokes operator.	Tokyo Univ Sci, Dept Math, Shinjuku Ku, Tokyo 162, Japan	Tsuzuki, Y (reprint author), Tokyo Univ Sci, Dept Math, Shinjuku Ku, 1-3 Kagurazaka, Tokyo 162, Japan.	yutack1296@gmail.com					GLASHOFF K, 1981, SIAM J MATH ANAL, V12, P477, DOI 10.1137/0512041; Gurevich P, 2011, J DYN DIFFER EQU, V23, P923, DOI 10.1007/s10884-011-9227-0; FUJIWARA D, 1967, P JPN ACAD, V43, P82; Mitrea M, 2008, J FUNCT ANAL, V254, P1522, DOI 10.1016/j.jfa.2007.11.021; GLASHOFF K, 1982, J INTEGRAL EQUAT, V4, P95; Larios A, 2013, J DIFFER EQUATIONS, V255, P2636, DOI 10.1016/j.jde.2013.07.011; Gurevich P, 2009, SIAM J MATH ANAL, V41, P733, DOI 10.1137/080718905; Kenmochi N, 1998, NONLINEAR ANAL-THEOR, V34, P665, DOI 10.1016/S0362-546X(97)00592-0; VISINTIN A, 1986, SIAM J MATH ANAL, V17, P1113, DOI 10.1137/0517079; OTANI M, 1982, J DIFFER EQUATIONS, V46, P268, DOI 10.1016/0022-0396(82)90119-X; Barbu V, 2010, SPRINGER MONOGR MATH, P1, DOI 10.1007/978-1-4419-5542-5; Barbu V., 1976, NONLINEAR SEMIGROUPS; CAZENAVE T., 1998, OXFORD LECT SER MATH, V13; Colli P, 2001, J MATH ANAL APPL, V256, P668, DOI 10.1006/jmaa.2000.7338; Constantin P., 1988, CHICAGO LECT MATH; Demengel F, 2012, UNIVERSITEXT, P1, DOI 10.1007/978-1-4471-2807-6; Fujita H., 1970, P JAPAN ACAD, V46, P1141; Fukao T., 2008, GAKUTO INT SER MATH, V29, P73; Fukao T., 2005, ADV MATH SCI APPL, V15, P29; Fukao T, 2014, DISCRETE CONT DYN-S, V7, P17, DOI 10.3934/dcdss.2014.7.17; Fukao T., 2007, P 6 AIMS INT C DISCR, P399; GIGA Y, 1985, ARCH RATION MECH AN, V89, P251, DOI 10.1007/BF00276874; Guermond J., 2011, J APPL MATH COMPUT, V36, P241; Gurevich P., 2014, MATH BOHEM, V139, P239; Kopfova J, 2002, Z ANGEW MATH PHYS, V53, P676, DOI 10.1007/s00033-002-8176-1; Kubo M, 2004, J DIFFER EQUATIONS, V201, P75, DOI 10.1016/j.jde.2004.02.010; Kubo M., 2005, GAKUTO INT SER MATH, V23, P163; Li D, 2013, DYNAM PART DIFFER EQ, V10, P255; Miao CX, 2013, COMMUN MATH PHYS, V321, P33, DOI 10.1007/s00220-013-1721-2; Morimoto H., 1992, J FS U TOKYO 1A, V39, P61; Simon Jacques, 1987, ANN MAT PUR APPL, V146, P65, DOI 10.1007/BF01762360; Sobajima M., 2012, ADV MATH SCI APPL, V22, P577; Sohr H, 2001, NAVIER STOKES EQUATI; Temam R., 1995, NAVIER STOKES EQUATI; Temam R., 1977, NAVIER STOKES EQUATI; Tsuzuki Y, 2015, J MATH ANAL APPL, V423, P877, DOI 10.1016/j.jmaa.2014.10.038; Tsuzuki Y., 2014, EVOL EQU CONTROL THE, V3, P191	37	0	0	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1422-6928	1422-6952		J MATH FLUID MECH	J. Math. Fluid Mech.	SEP	2015	17	3					577	597		10.1007/s00021-015-0210-0		21	Mathematics, Interdisciplinary Applications; Mechanics; Physics, Fluids & Plasmas	Mathematics; Mechanics; Physics	CP3VT	WOS:000359811500010		
J	Parasuraman, P; Murugan, V; Selvin, JFA; Gromiha, MM; Fukui, K; Veluraja, K				Parasuraman, Ponnusamy; Murugan, Veeramani; Selvin, Jeyasigamani F. A.; Gromiha, M. Michael; Fukui, Kazuhiko; Veluraja, Kasinadar			Theoretical investigation on the glycan-binding specificity of Agrocybe cylindracea galectin using molecular modeling and molecular dynamics simulation studies	JOURNAL OF MOLECULAR RECOGNITION			English	Article						fungal galectin; sialylglycans; molecular dynamics; lectin-carbohydrate interactions; binding specificity; binding free energy; hydrogen bonds; cancer biomarker	ERYTHRINA-CORALLODENDRON LECTIN; SITE-DIRECTED MUTAGENESIS; ANTITUMOR LECTIN; STRUCTURAL BASIS; ACID; RECOGNITION; STABILITY; DATABASE; HEMAGGLUTININS; NEOLECTINS	Galectins are beta-galactoside binding proteins which have the ability to serve as potent antitumor, cancer biomarker, and induce tumor cell apoptosis. Agrocybe cylindracea galectin (ACG) is a fungal galectin which specifically recognizes mu(2,3)-linked sialyllactose at the cell surface that plays extensive roles in the biological recognition processes. To investigate the change in glycan-binding specificity upon mutations, single point and double point site-directed in silico mutations are performed at the binding pocket of ACG. Molecular dynamics (MD) simulation studies are carried out for the wild-type (ACG) and single point (ACG1) and double point (ACG2) mutated ACGs to investigate the dynamics of substituted mutants and their interactions with the receptor sialyllactose. Plausible binding modes are proposed for galectin-sialylglycan complexes based on the analysis of hydrogen bonding interactions, total pair-wise interaction energy between the interacting binding site residues and sialyllactose and binding free energy of the complexes using molecular mechanics-Poisson-Boltzmann surface area. Our result shows that high contribution to the binding in different modes is due to the direct and water-mediated hydrogen bonds. The binding specificity of double point mutant Y59R/N140Q of ACG2 is found to be high, and it has 26 direct and water-mediated hydrogen bonds with a relatively low-binding free energy of -47.52 +/- 5.2kcal/mol. We also observe that the substituted mutant Arg59 is crucial for glycan-binding and for the preference of alpha(2,3)-linked sialyllactose at the binding pocket of ACG2 galectin. When compared with the wild-type and single point mutant, the double point mutant exhibits enhanced affinity towards alpha(2,3)-linked sialyllactose, which can be effectively used as a model for biological cell marker in cancer therapeutics. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Parasuraman, Ponnusamy; Murugan, Veeramani] Manonmaniam Sundaranar Univ, Dept Phys, Tirunelveli 627012, Tamil Nadu, India; [Selvin, Jeyasigamani F. A.] NMSSVN Coll, Dept Phys, Madurai 625019, Tamil Nadu, India; [Gromiha, M. Michael] Indian Inst Technol Madras, Dept Biotechnol, Chennai 600036, Tamil Nadu, India; [Fukui, Kazuhiko] Natl Inst Adv Ind Sci & Technol, Mol Profiling Res Ctr Drug Discovery Molprof, Koto Ku, Tokyo 1350064, Japan; [Veluraja, Kasinadar] VIT Univ, Sch Adv Sci, Vellore 632014, Tamil Nadu, India	Veluraja, K (reprint author), VIT Univ, Sch Adv Sci, Vellore 632014, Tamil Nadu, India.	veluraja.k@vit.ac.in			Department of Biotechnology (DBT), India; National Institute of Advanced Industrial Science and Technology (AIST); Japan Bilateral Project for Junior Research Fellowship [BT/IC/JAPAN(BI)/02/2010]; DBT [BT/BI/25/049/2012]	P.P. and V.M. acknowledge the Department of Biotechnology (DBT), India, and the National Institute of Advanced Industrial Science and Technology (AIST), Japan Bilateral Project for Junior Research Fellowship (BT/IC/JAPAN(BI)/02/2010). All the authors acknowledge the use of DBT funded Bioinformatics Infrastructure Facility (BIF) hosted at the Department of Physics, Manonmaniam Sundaranar University (BT/BI/25/049/2012).	Agostino M, 2012, STRUCTURAL GLYCOBIOL, P111; Vijayan M, 1999, CURR OPIN STRUC BIOL, V9, P707, DOI 10.1016/S0959-440X(99)00034-2; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Gromiha MM, 1999, NUCLEIC ACIDS RES, V27, P286, DOI 10.1093/nar/27.1.286; Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+; [Anonymous], 2009, ESSENT GLYCOBIOLOGY, V2nd, P137; Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h; Chandra NR, 2006, GLYCOBIOLOGY, V16, P938, DOI 10.1093/glycob/cwl012; Yang N, 2009, J MOL BIOL, V387, P694, DOI 10.1016/j.jmb.2009.02.002; Yang N, 2005, J BIOCHEM, V138, P145, DOI 10.1093/jb/mvi109; Wheeler SE, 2010, J AM CHEM SOC, V132, P3304, DOI 10.1021/ja903653j; Walser PJ, 2004, STRUCTURE, V12, P689, DOI 10.1016/j.str.2004.03.002; Rabinovich GA, 2005, BRIT J CANCER, V92, P1188, DOI 10.1038/sj.bjc.6602493; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Kadirvelraj R, 2008, J AM CHEM SOC, V130, P16933, DOI 10.1021/ja8039663; Priyadarzini TRK, 2012, J BIOL CHEM, V287, P34547, DOI 10.1074/jbc.M112.357061; Topham CM, 1997, PROTEIN ENG, V10, P7, DOI 10.1093/protein/10.1.7; GOLDSTEIN IJ, 1980, NATURE, V285, P66, DOI 10.1038/285066b0; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Adar R, 1996, EUR J BIOCHEM, V239, P668, DOI 10.1111/j.1432-1033.1996.0668u.x; Hardt M, 2004, ARCH BIOCHEM BIOPHYS, V426, P286, DOI 10.1016/j.abb.2004.03.017; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441; Arnaud J, 2013, CHEM SOC REV, V42, P4798, DOI 10.1039/c2cs35435g; Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646; Damodaran D, 2008, GLYCOCONJUGATE J, V25, P191, DOI 10.1007/s10719-007-9085-5; Echeverria I, 2011, BIOPHYS J, V100, P2283, DOI 10.1016/j.bpj.2011.03.032; Fadda E, 2010, DRUG DISCOV TODAY, V15, P596, DOI 10.1016/j.drudis.2010.06.001; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HUNTER CA, 1990, J AM CHEM SOC, V112, P5525, DOI 10.1021/ja00170a016; Parthiban V, 2006, NUCLEIC ACIDS RES, V34, pW239, DOI 10.1093/nar/gkl190; Veluraja K, 2005, J BIOMOL STRUCT DYN, V23, P101; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; ARANGO R, 1993, FEBS LETT, V330, P133, DOI 10.1016/0014-5793(93)80258-V; Arnaud J, 2014, ANGEW CHEM INT EDIT, V53, P9267, DOI 10.1002/anie.201404568; Balan Vitaly, 2010, Cancers (Basel), V2, P592, DOI 10.3390/cancers2020592; Ban M, 2005, J MOL BIOL, V351, P695; Case D., 2012, AMBER 12, V1, P3; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Imamura K, 2011, J BIOCHEM, V150, P545, DOI 10.1093/jb/mvr094; JORDAN ET, 1995, EUR J BIOCHEM, V230, P958, DOI 10.1111/j.1432-1033.1995.tb20642.x; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kim M, 1993, GLYCOBIOLOGY, V3, P447; Kumar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059761; Leffler H, 2001, MAMMALIAN CARBOHYDRA, V33, P57; Lis H, 1998, CHEM REV, V98, P637; Mannhold R, 2006, PROTEIN LIGAND INTER; Mehedi Masud M, 2004, BIOORGAN MED CHEM, V12, P1111, DOI 10.1016/j.bmc.2003.12.009; Parasuraman P, 2014, J MOL RECOGNIT, V27, P482, DOI 10.1002/jmr.2369; Perez S, 2014, GLYCOSCI BIOL MED, P1, DOI [10.1007/978-4-431-54836-2_29-1, DOI 10.1007/978-4-431-54836-2_29-1]; Rao VSR, 1998, CONFORMATION CARBOHY; Salomonsson E, 2010, J BIOL CHEM, V285, P35079, DOI 10.1074/jbc.M109.098160; Sarkar A, 2012, STRUCTURAL GLYCOBIOL, P71; Selvin JFA, 2012, J COMPUT AID MOL DES, V26, P375, DOI 10.1007/s10822-012-9563-0; Sharmila DJS, 2004, J BIOMOL STRUCT DYN, V21, P591; Sharon N, 1994, ESSAYS BIOCHEM, V30, P59; Sharon N, 2004, GLYCOBIOLOGY, V14, p53R, DOI 10.1093/glycob/cwh122; Veluraja K, 2010, CARBOHYD RES, V345, P2030, DOI 10.1016/j.carres.2010.06.021; Venkateshwari S, 2012, J STRUCT BIOL, V180, P497, DOI 10.1016/j.jsb.2012.08.003; Yagi F, 1997, GLYCOCONJUGATE J, V14, P281, DOI 10.1023/A:1018558225454; Yan C, 2008, PROTEIN-STRUCT FUNCT, V73, P134	65	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3499	1099-1352		J MOL RECOGNIT	J. Mol. Recognit.	SEP	2015	28	9					528	538		10.1002/jmr.2468		11	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CP0ZI	WOS:000359605200002		
J	Hiyoshi-Taniguchi, K; Oishi, N; Namiki, C; Miyata, J; Murai, T; Cichocki, A; Fukuyama, H				Hiyoshi-Taniguchi, Kazuko; Oishi, Naoya; Namiki, Chihiro; Miyata, Jun; Murai, Toshiya; Cichocki, Andrzej; Fukuyama, Hidenao			The Uncinate Fasciculus as a Predictor of Conversion from Amnestic Mild Cognitive Impairment to Alzheimer Disease	JOURNAL OF NEUROIMAGING			English	Article						DTI; fractional anisotropy; uncinate fasciculus; AD; amnestic mild cognitive impairment	VOXEL-BASED MORPHOMETRY; TEMPORAL STEM; FIBER TRACTS; TRACTOGRAPHY; DAMAGE	BACKGROUND AND PURPOSEAmnestic mild cognitive impairment (aMCI) is associated with the risk of Alzheimer's disease (AD). Although diffusion tensor imaging (DTI)-based fractional anisotropy (FA) analyses have been used to evaluate white matter changes in patients with AD, it remains unknown how FA values change during the conversion of aMCI to AD. This study aimed to elucidate the prediction of conversion to AD and cognitive decline by FA values in uncinate fasciculus (UF) in aMCI patients. METHODSTwenty-two aMCI patients were evaluated for their UF FA values by a tractography-based method with DTI and cognitive performance by neuropsychological testing at baseline and after a 3-year follow-up. Patients were divided into 2 groups after 3 years: 14 aMCI-stable (aMCI-aMCI) and 8 AD-conversion (aMCI-AD). RESULTSAt baseline, FA values in the right UF were significantly lower in the aMCI-AD group than in the aMCI-aMCI group. These values also showed significant correlations with the neuropsychological scores after a 3-year follow-up. The area under the curve of the receiver operation characteristic curves for predicting conversion to AD was .813. CONCLUSIONThese results suggested that FA values in the right UF might be an effective predictor of conversion of aMCI to AD.	[Hiyoshi-Taniguchi, Kazuko; Oishi, Naoya; Fukuyama, Hidenao] Kyoto Univ, Grad Sch Med, Human Brain Res Ctr, Kyoto 6068507, Japan; [Namiki, Chihiro; Miyata, Jun; Murai, Toshiya] Kyoto Univ, Grad Sch Med, Dept Psychiat, Kyoto, Japan; [Cichocki, Andrzej] RIKEN, Brain Sci Inst, Adv Brain Signal Proc, Saitama, Japan; [Cichocki, Andrzej] Polish Acad Sci, Syst Res Inst, PL-00901 Warsaw, Poland	Oishi, N (reprint author), Kyoto Univ, Grad Sch Med, Human Brain Res Ctr, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	noishi@kuhp.kyoto-u.ac.jp			JSPS by MEXT [24791296]	The authors are particularly grateful to Dr. Kawasaki of Tsukuba University and Dr. Islam of RIKEN BSI for their very helpful comments. This study was partly supported by JSPS KAKENHI Grant Number 24791296 for N.O., a "Development of BMI Technologies for Clinical Application" under the Strategic Research Program for Brain Sciences by MEXT for N.O. and T.M., and a Grant-in-Aid for Scientific Research on Innovative Areas, "Glial assembly: a new regulatory machinery of brain function and disorders," for N.O., T.M., and H.F.	Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; EBELING U, 1992, ACTA NEUROCHIR, V115, P143, DOI 10.1007/BF01406373; Kim S, 2011, J CLIN NEUROSCI, V18, P916, DOI 10.1016/j.jocn.2010.12.019; MORRIS JC, 1993, NEUROLOGY, V43, P2412; Ukmar M, 2008, RADIOL MED, V113, P915, DOI 10.1007/s11547-008-0286-1; Kier EL, 2004, AM J NEURORADIOL, V25, P677; Miller SL, 2008, J NEUROL NEUROSUR PS, V79, P630, DOI 10.1136/jnnp.2007.124149; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Pennanen C, 2004, NEUROBIOL AGING, V25, P303, DOI 10.1016/S0197-4580(03)00084-8; Zhuang L, 2012, NEUROLOGY, V79, P748, DOI 10.1212/WNL.0b013e3182661f4d; Fujie S, 2008, DEMENT GERIATR COGN, V26, P432, DOI 10.1159/000165381; Li JP, 2012, NEUROSCI BIOBEHAV R, V36, P757, DOI 10.1016/j.neubiorev.2011.12.001; Morris JC, 1996, NEUROLOGY, V46, P707; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Pennanen C, 2005, J NEUROL NEUROSUR PS, V76, P11, DOI 10.1136/jnnp.2004.035600; Pievani M, 2010, HUM BRAIN MAPP, V31, P1862, DOI 10.1002/hbm.20978; Fellgiebel A, 2008, NEUROPSYCHOLOGIA, V46, P1698, DOI 10.1016/j.neuropsychologia.2007.12.010; Chetelat G, 2002, NEUROREPORT, V13, P1939; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Lyall DM, 2014, NEUROBIOL AGING, V35, pe25; MAHONEY F I, 1965, Md State Med J, V14, P61; MCKHANN G, 1984, NEUROLOGY, V34, P939; Taoka T, 2006, AM J NEURORADIOL, V27, P1040; vansBruggen T, 2012, PSYCHIAT RES, V203, P184; Yasmin H, 2008, NEURORADIOLOGY, V50, P293, DOI 10.1007/s00234-007-0353-7; Zhang J, 2014, BIOMED RES INT, V2014	27	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1051-2284	1552-6569		J NEUROIMAGING	J. Neuroimaging	SEP-OCT	2015	25	5					748	753		10.1111/jon.12196		6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CP3MO	WOS:000359783900007		
J	Watanabe, H; Sobue, G				Watanabe, Hirohisa; Sobue, Gen			Filling in the missing puzzle piece between cardiac MIBG scintigraphy findings and Parkinson's disease pathology	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Editorial Material							SYMPATHETIC-NERVE		[Watanabe, Hirohisa; Sobue, Gen] Nagoya Univ, Brain & Mind Res Ctr, Nagoya, Aichi 4668550, Japan; [Sobue, Gen] Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4668550, Japan	Watanabe, H (reprint author), Nagoya Univ, Brain & Mind Res Ctr, Showa Ku, Nagoya, Aichi 4668550, Japan.	nabe@med.nagoya-u.ac.jp					Orimo S, 2008, BRAIN, V131, P642, DOI 10.1093/brain/awm302; HAKUSUI S, 1994, J AUTONOM NERV SYST, V49, P81, DOI 10.1016/0165-1838(94)90023-X; Nakajima K, 2014, J NUCL CARDIOL, V21, P970, DOI 10.1007/s12350-014-9916-2; Nakamura T, 2010, MOVEMENT DISORD, V25, P1183, DOI 10.1002/mds.23127; Nakamura T, 2007, J NEUROL SCI, V263, P133, DOI 10.1016/j.jns.2007.07.005; Takahashi M, 2015, J NEUROL NEUROSUR PS, V86, P939, DOI 10.1136/jnnp-2015-310686	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2015	86	9					937	937		10.1136/jnnp-2015-310862		1	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	CO9IE	WOS:000359487500066		
J	Takahashi, M; Ikemura, M; Oka, T; Uchihara, T; Wakabayashi, K; Kakita, A; Takahashi, H; Yoshida, M; Toru, S; Kobayashi, T; Orimo, S				Takahashi, Makoto; Ikemura, Masako; Oka, Teruaki; Uchihara, Toshiki; Wakabayashi, Koichi; Kakita, Akiyoshi; Takahashi, Hitoshi; Yoshida, Mari; Toru, Shuta; Kobayashi, Takayoshi; Orimo, Satoshi			Quantitative correlation between cardiac MIBG uptake and remaining axons in the cardiac sympathetic nerve in Lewy body disease	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							I-123-MIBG MYOCARDIAL SCINTIGRAPHY; PARKINSONS-DISEASE; DIAGNOSTIC-ACCURACY; ALZHEIMERS-DISEASE; CEREBRAL TYPE; DENERVATION; BODIES; DEMENTIA; DEGENERATION; SEVERITY	Objectives Reduced cardiac meta-iodobenzylguanidine (MIBG) uptake and loss of cardiac sympathetic axons, as its possible anatomical substrate, were both recognised in Lewy body disease (LBD), while their direct correlation has so far remained speculative. Increasing availability of autopsy-confirmed cases of LBD prompted us to quantify residual cardiac sympathetic axons to establish their relationship to cardiac MIBG uptake. Methods We collected cardiac tissue samples from 23 patients with autopsy-confirmed LBD and two non-LBD control patients who underwent I-123-MIBG cardiac scintigraphy in life. Samples of the left ventricular anterior wall were stained with anti-tyrosine hydroxylase (TH) and anti-neurofilament (NF) antibodies as markers of cardiac nerve axons. We quantified the immunolabelled areas and assessed their correlation to standardised heart to mediastinum (H/M) ratios of I-123-MIBG cardiac scintigraphy. Results Cardiac MIBG uptake in the early and delayed phases was reduced in 90.9% and 95.7% of patients with LBD, respectively. The area of TH-immunoreactive axons correlated significantly with the H/M ratio in the early (p=0.036) as well as in the delayed (p=0.018) phases. The area of NF-immunoreactive axons also correlated with the H/M ratio in the early (p=0.003) as well as in the delayed (p=0.001) phases. Conclusions Tight quantitative correlation between cardiac I-123-MIBG uptake and corresponding loss of sympathetic axons in LBD, as established for the first time by this study, provides a scientific basis to confirm the reliability of MIBG cardiac scintigraphy as a powerful clinical tool to detect loss of these axons as a biomarker for the presence of Lewy body disease.	[Takahashi, Makoto; Orimo, Satoshi] Kanto Cent Hosp, Dept Neurol, Tokyo 1588531, Japan; [Ikemura, Masako; Oka, Teruaki] Kanto Cent Hosp, Div Pathol, Tokyo 1588531, Japan; [Uchihara, Toshiki] Tokyo Metropolitan Inst Med Sci, Lab Struct Neuropathol, Tokyo 113, Japan; [Wakabayashi, Koichi] Hirosaki Univ, Grad Sch Med, Inst Brain Sci, Dept Neuropathol, Hirosaki, Aomori, Japan; [Kakita, Akiyoshi; Takahashi, Hitoshi] Niigata Univ, Brain Res Inst, Dept Pathol, Niigata, Japan; [Yoshida, Mari] Aichi Med Univ, Inst Med Sci Aging, Nagakute, Aichi 48011, Japan; [Toru, Shuta; Kobayashi, Takayoshi] Nakano Gen Hosp, Dept Neurol, Tokyo, Japan	Orimo, S (reprint author), Kanto Cent Hosp, Dept Neurol, Setagaya Ku, 6-25-1 Kami Yoga, Tokyo 1588531, Japan.	orimo@kanto-ctr-hsp.com			JSPS KAKENHI from Ministry of Education, Culture, Sports, Science and Technology [25430057]; Japan Foundation for Neuroscience and Mental Health; Mitsui Life Social Welfare Foundation; Tokyo Metropolitan Institute of Medical Science; Research Committee of CNS Degenerative Diseases; Ministry of Health, Labour and Welfare of Japan; Brain Research Institute, University of Niigata [2014-2508]	TU was funded by Grants-in-Aid for Scientific Research (JSPS KAKENHI 25430057) from the Ministry of Education, Culture, Sports, Science and Technology; a grant from the Japan Foundation for Neuroscience and Mental Health, the Mitsui Life Social Welfare Foundation, and the Tokyo Metropolitan Institute of Medical Science project 'Mechanism for Early Diagnosis and Prevention of Parkinson's disease; and Grants-in-Aid from the Research Committee of CNS Degenerative Diseases, the Ministry of Health, Labour and Welfare of Japan. MY was funded by Grants-in-Aid from the Research Committee of CNS Degenerative Diseases, the Ministry of Health, Labour and Welfare of Japan. AK was funded the by Collaborative Research Project (2014-2508) of the Brain Research Institute, University of Niigata.	Joutsa J, 2014, PARKINSONISM RELAT D, V20, P840, DOI 10.1016/j.parkreldis.2014.04.019; Suzuki M, 2006, J NEUROL SCI, V240, P15, DOI 10.1016/j.jns.2005.08.011; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; Saiki S, 2004, J NEUROL SCI, V220, P105, DOI 10.1016/j.jns.2004.02.018; Orimo S, 2008, ACTA NEUROPATHOL, V116, P575, DOI 10.1007/s00401-008-0428-5; Fujishiro H, 2008, MOVEMENT DISORD, V23, P1085, DOI 10.1002/mds.21989; Zaccai J, 2008, NEUROLOGY, V70, P1042, DOI 10.1212/01.wnl.0000306697.48738.b6; Nelson PT, 2010, J NEUROL, V257, P359, DOI 10.1007/s00415-009-5324-y; Adler CH, 2014, NEUROLOGY, V83, P406, DOI 10.1212/WNL.0000000000000641; Orimo S, 2007, BRAIN PATHOL, V17, P24, DOI 10.1111/j.1750-3639.2006.00032.x; Orimo S, 2012, PARKINSONISM RELAT D, V18, P494, DOI 10.1016/j.parkreldis.2012.01.009; Tijero B, 2013, PARKINSONISM RELAT D, V19, P95, DOI 10.1016/j.parkreldis.2012.08.001; Amino T, 2005, BRAIN PATHOL, V15, P29; Kanazawa T, 2012, BRAIN PATHOL, V22, P67, DOI 10.1111/j.1750-3639.2011.00509.x; Orimo S, 2005, ACTA NEUROPATHOL, V109, P583, DOI 10.1007/s00401-005-0995-7; Orimo S, 2002, J NEUROL NEUROSUR PS, V73, P776, DOI 10.1136/jnnp.73.6.776; Hamada K, 2003, J NEUROL NEUROSUR PS, V74, P423, DOI 10.1136/jnnp.74.4.423; Inui Y, 2014, ANN NUCL MED, V28, P796, DOI 10.1007/s12149-014-0873-2; Jellinger KA, 2009, J NEUROL, V256, pS270, DOI 10.1007/s00415-009-5243-y; Kanazawa T, 2008, BRAIN PATHOL, V18, P415, DOI 10.1111/j.1750-3639.2008.00140.x; Kosaka K, 1996, NEUROPATHOLOGY, V16, P32, DOI 10.1111/j.1440-1789.1996.tb00152.x; Nakajima K, 2014, J NUCL CARDIOL, V21, P970, DOI 10.1007/s12350-014-9916-2; Orimo S, 2005, MOVEMENT DISORD, V20, P1350, DOI 10.1002/mds.20594; Orimo S., 2007, CNS DRUGS, V21, P11; Orimo S, 1999, J NEUROL NEUROSUR PS, V67, P189, DOI 10.1136/jnnp.67.2.189; Yokota O, 2007, NEUROPATHOLOGY, V27, P21, DOI 10.1111/j.1440-1789.2006.00736.x; Yoshita M, 1998, J NEUROL SCI, V155, P60, DOI 10.1016/S0022-510X(97)00278-5; Yoshita M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120540	28	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2015	86	9					939	944		10.1136/jnnp-2015-310686		6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	CO9IE	WOS:000359487500068		
J	Tsujikawa, K; Hasegawa, Y; Yokoi, S; Yasui, K; Nanbu, I; Yanagi, T; Takahashi, A				Tsujikawa, Koyo; Hasegawa, Yasuhiro; Yokoi, Satoshi; Yasui, Keizo; Nanbu, Ichiro; Yanagi, Tsutomu; Takahashi, Akira			Chronological changes of I-123-MIBG myocardial scintigraphy and clinical features of Parkinson's disease	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							NEUROLOGICAL PATIENTS; AUTONOMIC FAILURE; CARDIAC UPTAKE; MIBG; DEGENERATION; I-123-METAIODOBENZYLGUANIDINE; IMPAIRMENT; REDUCTION; DEMENTIA; HEART	Objectives The aim of this study was to investigate chronological changes of I-123-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy and its relation to clinical features in patients with Parkinson's disease (PD), and to characterise patients with PD with normal or mildly low MIBG uptakes at their early stages. Methods The participants were 70 patients with PD who underwent I-123-MIBG myocardial scintigraphy twice or more. A cluster analysis was performed using parameters calculated from heart to mediastinum (H/M) ratio and washout ratio (WR). Results At baseline, the mean early H/M ratio (H/M (E)), delayed H/M ratio (H/M(D)) and WR were 1.83, 1.69 and 41.7%, respectively. After a mean interval of 3.0 years, follow-up studies showed significantly declined H/M(E) (1.69, p<0.001), declined H/M(D) (1.47, p<0.001) and enhanced WR (43.8%, p=0.007). Our longitudinal observations revealed that there existed heterogeneous changes in MIBG uptakes among patients. The cluster analysis classified the patients into two subgroups: 42 patients with markedly low MIBG uptakes at baseline (group A) and 28 patients with normal or mildly low MIBG uptakes at baseline (group B). Group B showed a significantly higher ratio of females, younger age at onset, lower Hoehn and Yahr stage and less demented, compared with group A. Conclusions Follow-up studies of MIBG divided the patients with PD into two major subgroups. A subgroup of patients with PD with normal or mildly low MIBG uptakes at the early stages of illness was characterised by female-dominant, young onset, slow progression in motor dysfunctions and preserved cognitive function.	[Tsujikawa, Koyo; Hasegawa, Yasuhiro; Yasui, Keizo; Takahashi, Akira] Nagoya Daini Red Cross Hosp, Dept Neurol, Nagoya, Aichi 4468650, Japan; [Yokoi, Satoshi] Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi 4648601, Japan; [Nanbu, Ichiro] Nagoya Daini Red Cross Hosp, Dept Radiol, Nagoya, Aichi 4468650, Japan; [Yanagi, Tsutomu] Obu Dementia Care Res & Training Ctr, Aichi, Japan	Hasegawa, Y (reprint author), Nagoya Daini Red Cross Hosp, Dept Neurol, Showa Ku, 2-9 Myoken Cho, Nagoya, Aichi 4468650, Japan.	yhase@nagoya2.jrc.or.jp					American Psychiatric Association, 2000, DIAGN STAT MAN; Buter TC, 2008, NEUROLOGY, V70, P1017, DOI 10.1212/01.wnl.0000306632.43729.24; HIRAYAMA M, 1995, J AUTONOM NERV SYST, V53, P230, DOI 10.1016/0165-1838(95)00002-F; Watanabe M, 2011, EUR J NEUROL, V18, P1010, DOI 10.1111/j.1468-1331.2010.03211.x; Hely MA, 2008, MOVEMENT DISORD, V23, P837, DOI 10.1002/mds.21956; Kitayama M, 2008, J NEUROL SCI, V264, P22, DOI 10.1016/j.jns.2007.07.017; Orimo S, 2001, NEUROLOGY, V57, P1140; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Guidez D, 2014, J NEUROL, V261, P45, DOI 10.1007/s00415-013-7135-4; HAKUSUI S, 1994, J AUTONOM NERV SYST, V49, P81, DOI 10.1016/0165-1838(94)90023-X; Hamada K, 2003, J NEUROL NEUROSUR PS, V74, P423, DOI 10.1136/jnnp.74.4.423; Kishi M, 2011, MOVEMENT DISORD, V26, P563, DOI 10.1002/mds.23464; Orimo Satoshi, 2012, Brain and Nerve (Tokyo), V64, P403; Orimo S, 2003, INTERNAL MED, V42, P127, DOI 10.2169/internalmedicine.42.127; Orimo S, 2007, J NEUROL, V254, P21, DOI 10.1007/s00415-007-4005-y; Orimo S, 1999, J NEUROL NEUROSUR PS, V67, P189, DOI 10.1136/jnnp.67.2.189; Quattrone A, 2008, MOVEMENT DISORD, V23, P21, DOI 10.1002/mds.21701; Satoh A, 1999, J NUCL MED, V40, P371; Sawada H, 2009, EUR J NEUROL, V16, P174, DOI 10.1111/j.1468-1331.2008.02372.x; Stefanelli A, 2013, EUR REV MED PHARMACO, V17, P1326; Yoshita M, 1998, J NEUROL SCI, V155, P60, DOI 10.1016/S0022-510X(97)00278-5	21	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2015	86	9					945	951		10.1136/jnnp-2015-310327		7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	CO9IE	WOS:000359487500069		
J	Obayashi, M; Stevanin, G; Synofzik, M; Monin, ML; Duyckaerts, C; Sato, N; Streichenberger, N; Vighetto, A; Desestret, V; Tesson, C; Wichmann, HE; Illig, T; Huttenlocher, J; Kita, Y; Izumi, Y; Mizusawa, H; Schols, L; Klopstock, T; Brice, A; Ishikawa, K; Durr, A				Obayashi, Masato; Stevanin, Giovanni; Synofzik, Matthis; Monin, Marie-Lorraine; Duyckaerts, Charles; Sato, Nozomu; Streichenberger, Nathalie; Vighetto, Alain; Desestret, Virginie; Tesson, Christelle; Wichmann, H-Erich; Illig, Thomas; Huttenlocher, Johanna; Kita, Yasushi; Izumi, Yuishin; Mizusawa, Hidehiro; Schoels, Ludger; Klopstock, Thomas; Brice, Alexis; Ishikawa, Kinya; Duerr, Alexandra			Spinocerebellar ataxia type 36 exists in diverse populations and can be caused by a short hexanucleotide GGCCTG repeat expansion	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON INVOLVEMENT; GGGGCC REPEAT; RNA FOCI; C9ORF72; TRANSLATION; DISEASE; NEUROPATHOLOGY; INSTABILITY; ORIGIN	Objective Spinocerebellar ataxia 36 (SCA36) is an autosomal-dominant neurodegenerative disorder caused by a large (>650) hexanucleotide GGCCTG repeat expansion in the first intron of the NOP56 gene. The aim of this study is to clarify the prevalence, clinical and genetic features of SCA36. Methods The expansion was tested in 676 unrelated SCA index cases and 727 controls from France, Germany and Japan. Clinical and neuropathological features were investigated in available family members. Results Normal alleles ranged between 5 and 14 hexanucleotide repeats. Expansions were detected in 12 families in France (prevalence: 1.9% of all French SCAs) including one family each with Spanish, Portuguese or Chinese ancestry, in five families in Japan (1.5% of all Japanese SCAs), but were absent in German patients. All the 17 SCA36 families shared one common haplotype for a 7.5 kb pairs region flanking the expansion. While 27 individuals had typically long expansions, three affected individuals harboured small hexanucleotide expansions of 25, 30 and 31 hexanucleotide repeat-units, demonstrating that such a small expansion could cause the disease. All patients showed slowly progressive cerebellar ataxia frequently accompanied by hearing and cognitive impairments, tremor, ptosis and reduced vibration sense, with the age at onset ranging between 39 and 65 years, and clinical features were indistinguishable between individuals with short and typically long expansions. Neuropathology in a presymptomatic case disclosed that Purkinje cells and hypoglossal neurons are affected. Conclusions SCA36 is rare with a worldwide distribution. It can be caused by a short GGCCTG expansion and associates various extracerebellar symptoms.	[Obayashi, Masato; Sato, Nozomu; Mizusawa, Hidehiro; Ishikawa, Kinya] Tokyo Med & Dent Univ, Grad Sch, Dept Neurol & Neurol Sci, Tokyo, Japan; [Stevanin, Giovanni; Monin, Marie-Lorraine; Duyckaerts, Charles; Tesson, Christelle; Brice, Alexis; Duerr, Alexandra] Univ Paris 04, Univ Paris 06, UMR S1127, Paris, France; [Stevanin, Giovanni; Monin, Marie-Lorraine; Duyckaerts, Charles; Tesson, Christelle; Brice, Alexis; Duerr, Alexandra] INSERM, U1127, Paris, France; [Stevanin, Giovanni; Monin, Marie-Lorraine; Duyckaerts, Charles; Tesson, Christelle; Brice, Alexis; Duerr, Alexandra] CNRS, UMR 7225, Paris, France; [Stevanin, Giovanni; Brice, Alexis; Duerr, Alexandra] Grp Hosp Pitie Salpetriere, AP HP, Dept Genet & Cytogenet, F-75013 Paris, France; [Stevanin, Giovanni; Tesson, Christelle] Ecole Prat Hautes Etud, Grp Neurogenet, Paris, France; [Synofzik, Matthis; Schoels, Ludger] Hertie Inst Clin Brain Res, Dept Neurodegenerat Dis, Tubingen, Germany; [Synofzik, Matthis; Schoels, Ludger] Univ Tubingen, German Ctr Neurodegenerat Dis, Tubingen, Germany; [Duyckaerts, Charles] Grp Hosp Pitie Salpetriere, Lab Neuropathol R Escourolle, F-75013 Paris, France; [Streichenberger, Nathalie] Univ Lyon 1, Hosp Civils Lyon, Grp Hosp Est, Pathol & Biochem, F-69365 Lyon, France; [Vighetto, Alain] Hop Pierre Wertheimer, Dept Neurol, Lyon, France; [Desestret, Virginie] Hop Neurol, Hosp Civils Lyon, Neurol D, Bron, France; [Desestret, Virginie] CNRS, UMR 5292, INSERM U1028, Lyon Neurosci Res Ctr, Lyon, France; [Desestret, Virginie] Univ Lyon 1, F-69365 Lyon, France; [Wichmann, H-Erich] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol 1, Neuherberg, Germany; [Wichmann, H-Erich] Univ Munich, Chair Epidemiol, Inst Med Informat Biometry & Epidemiol, Munich, Germany; [Illig, Thomas] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Unit Mol Epidemiol, Neuherberg, Germany; [Huttenlocher, Johanna] Univ Tubingen, Inst Med Genet & Appl Genom, Tubingen, Germany; [Kita, Yasushi] Hyogo Brain & Heart Ctr, Neurol Serv, Himeji, Hyogo, Japan; [Izumi, Yuishin] Univ Tokushima, Grad Sch, Dept Clin Neurosci, Tokushima 770, Japan; [Klopstock, Thomas] Univ Munich, Dept Neurol, Friedrich Baur Inst, D-80539 Munich, Germany; [Klopstock, Thomas] German Network Mitochondrial Disorders NitoNET, Munich, Germany; [Klopstock, Thomas] DZNE German Ctr Neurodegenerat Dis, Munich, Germany; [Klopstock, Thomas] German Ctr Vertigo & Balance Disorders, Munich, Germany	Brice, A (reprint author), Grp Hosp Pitie Salpetriere, Inst Cerveau & Moelle Epiniere, F-75013 Paris, France.	alexis.brice@upmc.fr			Verum Foundation; French association 'Connaitre les Syndromes Cerebelleux'; Programme Hospitalier de Recherche Clinique; Fondation Roger de Spoelberch; Agence Nationale de la Recherche; European Union; Japanese Ministry of Education, Sports and Culture; Strategic Research Program for Brain Sciences; Japan Society for the Promotion of Science (JSPS); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST); Japanese Ministry of Health, Labour and Welfare, Japan; German Federal Ministry of Education and Research (German Center for Vertigo and Balance Disorders) [01 EO 0901]; French Ministry for Research; programme 'Investissements d'avenir' [ANR-10-IAIHU-06]	This study was financially supported by the Verum Foundation (to AB and GS), the French association 'Connaitre les Syndromes Cerebelleux' (to GS and AD), the Programme Hospitalier de Recherche Clinique (to AD), the Fondation Roger de Spoelberch (to AB), the Agence Nationale de la Recherche (to GS), the European Union (7th Framework program, Omics call), the Japanese Ministry of Education, Sports and Culture (KI and HM), the Strategic Research Program for Brain Sciences ('Understanding of molecular and environmental bases for brain health') (HM), the Japan Society for the Promotion of Science (JSPS) (KI and HM), Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST) (HM), the Health and Labour Sciences Research Grants on Ataxic Diseases (KI and HM) of the Japanese Ministry of Health, Labour and Welfare, Japan, and the German Federal Ministry of Education and Research (German Center for Vertigo and Balance Disorders, grant 01 EO 0901, to TK). CT received a fellowship from the French Ministry for Research. This study also benefited from funding from the programme 'Investissements d'avenir' ANR-10-IAIHU-06 (to the Brain and Spine Institute, Paris).	Almeida T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004553; Gomez-Tortosa E, 2013, NEUROLOGY, V80, P366, DOI 10.1212/WNL.0b013e31827f08ea; Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010; Synofzik M, 2011, J MED GENET, V48, P407, DOI 10.1136/jmg.2010.087023; Greco CM, 2006, BRAIN, V129, P243, DOI 10.1093/brain/awh683; Niimi Y, 2013, NEUROPATHOLOGY, V33, P600, DOI 10.1111/neup.12032; Zu T, 2011, P NATL ACAD SCI USA, V108, P260, DOI 10.1073/pnas.1013343108; Ash PEA, 2013, NEURON, V77, P639, DOI 10.1016/j.neuron.2013.02.004; Sugihara K, 2012, MOVEMENT DISORD, V27, P1158, DOI 10.1002/mds.25092; Braak H, 1997, NEUROBIOL AGING, V18, pS85, DOI 10.1016/S0197-4580(97)00062-6; Todd PK, 2013, NEURON, V78, P440, DOI 10.1016/j.neuron.2013.03.026; Kobayashi H, 2011, AM J HUM GENET, V89, P121, DOI 10.1016/j.ajhg.2011.05.015; Wojciechowska M, 2011, HUM MOL GENET, V20, P3811, DOI 10.1093/hmg/ddr299; Al-Chalabi A, 2012, ACTA NEUROPATHOL, V124, P339, DOI 10.1007/s00401-012-1022-4; Parisien M, 2008, NATURE, V452, P51, DOI 10.1038/nature06684; Ikeda Y, 2012, NEUROLOGY, V79, P333, DOI 10.1212/WNL.0b013e318260436f; Lee YC, 2012, ANN NEUROL, V72, P859, DOI 10.1002/ana.23701; Mori K, 2013, SCIENCE, V339, P1335, DOI 10.1126/science.1232927; Boeve BF, 2012, BRAIN, V135, P765, DOI 10.1093/brain/aws004; Lesage S, 2013, BRAIN, V136, P385, DOI 10.1093/brain/aws357; ASHIZAWA T, 1994, AM J HUM GENET, V54, P414; Aziz NA, 2011, EUR J MED GENET, V54, pE413, DOI 10.1016/j.ejmg.2011.04.002; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; Durr A., 2012, LANCET NEUROL, V9, P885; Garcia-Murias M, 2012, BRAIN, V135, P1423, DOI 10.1093/brain/aws069; Ishikawa K, 2011, NEUROLOGY, V77, P1853, DOI 10.1212/WNL.0b013e3182377e3a; Obayashi M, 2012, J HUM GENET, V57, P202, DOI 10.1038/jhg.2012.5; Sato H, 2009, AM J HUM GENET, V85, P544; Serrano-Munuera C, 2013, JAMA NEUROL, V70, P764, DOI 10.1001/jamaneurol.2013.2311; Wheeler VC, 2007, J MED GENET, V44, P695, DOI 10.1136/jmg.2007.050930; White MC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000984	31	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2015	86	9					986	995		10.1136/jnnp-2014-309153		10	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	CO9IE	WOS:000359487500074		
J	Sekijima, Y				Sekijima, Yoshiki			Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Review							SENILE SYSTEMIC AMYLOIDOSIS; WORLD TRANSPLANT REGISTRY; WILD-TYPE TRANSTHYRETIN; TERM-FOLLOW-UP; LIVER-TRANSPLANTATION; HEREDITARY AMYLOIDOSIS; CHOROID-PLEXUS; POLYNEUROPATHY; TAFAMIDIS; FIBRIL	Transthyretin (ATTR) amyloidosis is a life-threatening, gain-of-toxic-function disease characterised by extracellular deposition of amyloid fibrils composed of transthyretin (TTR). TTR protein destabilised by TTR gene mutation is prone to dissociate from its native tetramer to monomer, and to then misfold and aggregate into amyloid fibrils, resulting in autosomal dominant hereditary amyloidosis, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy and familial leptomeningeal amyloidosis. Analogous misfolding of wild-type TTR results in senile systemic amyloidosis, now termed wild-type ATTR amyloidosis, characterised by acquired amyloid disease in the elderly. With the availability of genetic, biochemical and immunohistochemical diagnostic tests, patients with ATTR amyloidosis have been found in many nations; however, misdiagnosis is still common and considerable time is required before correct diagnosis in many cases. The current standard first-line treatment for hereditary ATTR amyloidosis is liver transplantation, which allows suppression of the main source of variant TTR. However, large numbers of patients are not suitable transplant candidates. Recently, the clinical effects of TTR tetramer stabilisers, diflunisal and tafamidis, were demonstrated in randomised clinical trials, and tafamidis has been approved for treatment of hereditary ATTR amyloidosis in European countries and in Japan. Moreover, antisense oligonucleotides and small interfering RNAs for suppression of variant and wild-type TTR synthesis are promising therapeutic approaches to ameliorate ATTR amyloidosis and are currently in phase III clinical trials. These newly developed therapies are expected to be effective for not only hereditary ATTR amyloidosis but also wild-type ATTR amyloidosis.	[Sekijima, Yoshiki] Shinshu Univ, Sch Med, Dept Med Neurol & Rheumatol, Matsumoto, Nagano 3908621, Japan; [Sekijima, Yoshiki] Shinshu Univ, Inst Biomed Sci, Matsumoto, Nagano 3908621, Japan	Sekijima, Y (reprint author), Shinshu Univ, Sch Med, Dept Med Neurol & Rheumatol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	sekijima@shinshu-u.ac.jp			Amyloidosis Research Committee; Ministry of Health, Labour and Welfare, Japan; Group Research Grant for the Pathogenesis and Therapy for Intractable Neuropathy in Japan	The author would like to thank Professor Shu-ichi Ikeda and Prof Jeffery W Kelly for their helpful advice. This study was supported by a grant from Amyloidosis Research Committee, the Ministry of Health, Labour and Welfare, Japan, and a Group Research Grant for the Pathogenesis and Therapy for Intractable Neuropathy in Japan.	Ando E, 1997, BRIT J OPHTHALMOL, V81, P295, DOI 10.1136/bjo.81.4.295; Ando Y, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-31; Lobato L, 2004, AMYLOID, V11, P27, DOI 10.1080/13506120410001673884; Bourgault S, 2011, BIOCHEMISTRY-US, V50, P1001, DOI 10.1021/bi101822y; HOLMGREN G, 1993, LANCET, V341, P1113; Hurshman AR, 2004, BIOCHEMISTRY-US, V43, P7365, DOI 10.1021/bi049621l; Bulawa CE, 2012, P NATL ACAD SCI USA, V109, P9629, DOI 10.1073/pnas.1121005109; Mangione PP, 2014, P NATL ACAD SCI USA, V111, P1539, DOI 10.1073/pnas.1317488111; Bergstrom J, 2005, J PATHOL, V206, P224, DOI 10.1002/path.1759; Jacobson DR, 1997, NEW ENGL J MED, V336, P466, DOI 10.1056/NEJM199702133360703; Sekijima Y, 2011, HUM PATHOL, V42, P1785, DOI 10.1016/j.humpath.2011.03.004; Coelho T, 2012, NEUROLOGY, V79, P785, DOI 10.1212/WNL.0b013e3182661eb1; Ihse E, 2013, AMYLOID, V20, P142, DOI 10.3109/13506129.2013.797890; SCHREIBER G, 1990, AM J PHYSIOL, V258, pR338; Koike H, 2012, J NEUROL NEUROSUR PS, V83, P152, DOI 10.1136/jnnp-2011-301299; Benson MD, 2006, MUSCLE NERVE, V33, P609, DOI 10.1002/mus.20503; Tsuchiya A, 2008, LIVER TRANSPLANT, V14, P563, DOI 10.1002/lt.21395; Coelho T, 2013, NEW ENGL J MED, V369, P819, DOI 10.1056/NEJMoa1208760; Monteiro FA, 2006, J NEUROCHEM, V97, P151, DOI 10.1111/j.1471-4159.2006.03716.x; Sekijima Y, 2005, CELL, V121, P73, DOI 10.1016/j.cell.2005.01.018; Ueda M, 2011, MODERN PATHOL, V24, P1533, DOI 10.1038/modpathol.2011.117; Herlenius G, 2004, TRANSPLANTATION, V77, P64, DOI 10.1097/01.TP.0000092307.98347.CB; Yazaki M, 2000, BIOCHEM BIOPH RES CO, V274, P702, DOI 10.1006/bbrc.2000.3203; Yamashita T, 2005, AMYLOID, V12, P127, DOI 10.1080/13506120500107162; Sousa MM, 2001, J NEUROSCI, V21, P7576; Coelho T, 2013, J NEUROL, V260, P2802, DOI 10.1007/s00415-013-7051-7; Merlini G, 2013, J CARDIOVASC TRANSL, V6, P1011, DOI 10.1007/s12265-013-9512-x; Sorgjerd K, 2008, BIOCHEM BIOPH RES CO, V377, P1072, DOI 10.1016/j.bbrc.2008.10.121; CORNWELL GG, 1983, AM J MED, V75, P618, DOI 10.1016/0002-9343(83)90443-6; Koike H, 2004, NEUROLOGY, V63, P129; Sekijima Y, 2006, AMYLOID, V13, P236, DOI 10.1080/13506120600960882; Tojo K, 2006, NEUROSCI RES, V56, P441, DOI 10.1016/j.neures.2006.08.014; Miller SR, 2004, LAB INVEST, V84, P545, DOI 10.1038/labinvest.3700059; Okamoto S, 2009, LIVER TRANSPLANT, V15, P1229, DOI [10.1002/lt.21817, 10.1002/It.21817]; Reixach N, 2004, P NATL ACAD SCI USA, V101, P2817, DOI 10.1073/pnas.0400062101; Hammarstrom P, 2001, SCIENCE, V293, P2459, DOI 10.1126/science.1062245; Obici L, 2012, AMYLOID, V19, P34, DOI 10.3109/13506129.2012.678508; Bodin K, 2010, NATURE, V468, P93, DOI 10.1038/nature09494; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Yamamoto S, 2007, AM J TRANSPLANT, V7, P2597, DOI 10.1111/j.1600-6143.2007.01969.x; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P2843, DOI 10.1073/pnas.87.7.2843; Yamashita T, 2012, NEUROLOGY, V78, P637, DOI 10.1212/WNL.0b013e318248df18; Wilczek HE, 2011, AMYLOID, V18, P193, DOI 10.3109/13506129.2011.574354072; MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382; Hou X, 2007, J NEUROCHEM, V100, P446, DOI 10.1111/j.1471-4159.2006.04210.x; Ikeda S, 2011, AMYLOID, V18, P211, DOI 10.3109/13506129.2011.623199; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; Zhao L, 2013, BIOCHEMISTRY-US, V52, P1913, DOI 10.1021/bi301313b; EPISKOPOU V, 1993, P NATL ACAD SCI USA, V90, P2375, DOI 10.1073/pnas.90.6.2375; Sekijima Y, 2008, CURR PHARM DESIGN, V14, P3219, DOI 10.2174/138161208786404155; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Benson MD, 2010, AMYLOID, V17, P43, DOI 10.3109/13506129.2010.483121; Ackermann EJ, 2012, AMYLOID, V19, P43, DOI 10.3109/13506129.2012.673140; Sekijima Y, 2014, J CLIN PHARM THER, V39, P225, DOI 10.1111/jcpt.12145; Berk JL, 2013, JAMA-J AM MED ASSOC, V310, P2658, DOI 10.1001/jama.2013.283815; BLAKE CCF, 1974, J MOL BIOL, V88, P1, DOI 10.1016/0022-2836(74)90291-5; IKEDA SI, 1982, NEUROLOGY, V32, P1364; Maia LF, 2015, J NEUROL NEUROSUR PS, V86, P159, DOI 10.1136/jnnp-2014-308107; Sekijima Y, 2015, AMYLOID IN PRESS; Sekijima Y, 2012, GENEREVIEWS GENETEST, P1993; SIMMONS Z, 1993, J NEUROL SCI, V120, P60, DOI 10.1016/0022-510X(93)90025-T; Sipe JD, 2014, AMYLOID, V21, P221, DOI 10.3109/13506129.2014.964858; Su Y, 2012, AMYLOID, V19, P45, DOI 10.3109/13506129.2012.674075; Terazaki H, 2006, LAB INVEST, V86, P23, DOI 10.1038/labinvest.3700365	64	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2015	86	9					1036	1043		10.1136/jnnp-2014-308724		8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	CO9IE	WOS:000359487500081		
J	Kondo, S; Lee, M; Hinoki, T; Hyodo, Y; Kano, F				Kondo, Sosuke; Lee, Moonhee; Hinoki, Tatsuya; Hyodo, Yoshihiro; Kano, Fumihisa			Effect of irradiation damage on hydrothermal corrosion of SiC	JOURNAL OF NUCLEAR MATERIALS			English	Article							SILICON-CARBIDE; WATER; OXIDATION; TEMPERATURES; CERAMICS; BEHAVIOR; OXYGEN; LAYERS; STEAM	The hydrothermal corrosion behavior (320 degrees C, 20 MPa, 168 h) of high-purity chemical-vapor-deposited (CVD) SiC pre-irradiated with 5.1-MeV Si ions at 400 and 800 degrees C and 0.1-2.6 dpa was studied in order to clarify the effects of irradiation damage on SiC corrosion. Regardless of the pre-irradiation conditions, selective corrosion was observed at the grain boundaries and stacking faults even at the unirradiated regions. In contrast to the complete loss of the irradiated regions observed in the specimens irradiated at 400 degrees C during the autoclave test, a number of large grains survived in the case of the specimens irradiated at 800 degrees C. The corrosion rates at the irradiated regions increased with increasing irradiation fluence, with a significant dependence in the lower dpa regime similar to that observed in the point-defect swelling. SiO2 formation was not detected in any case. Cross-sectional scanning transmission electron microscopy (TEM) and electron energy loss spectroscopy (EELS) analyses of the surfaces of the surviving grains revealed oxygen diffusion to a depth of 3.0 nm from the surface. A significant reduction of the oxygen diffusion barrier at the surface was implicated as one of the key mechanisms of the acceleration of the ion-irradiated SiC corrosion rates. (C) 2015 Elsevier B.V. All rights reserved.	[Kondo, Sosuke; Lee, Moonhee; Hinoki, Tatsuya] Kyoto Univ, Inst Adv Energy, Kyoto 6110011, Japan; [Hyodo, Yoshihiro; Kano, Fumihisa] Toshiba Co Ltd, Power & Ind Syst Res & Dev Ctr, Yokohama, Kanagawa 2358523, Japan	Kondo, S (reprint author), Kyoto Univ, Inst Adv Energy, Kyoto 6110011, Japan.	kondo@iae.kyoto-u.ac.jp					Kim WJ, 2003, J MATER SCI LETT, V22, P581, DOI 10.1023/A:1023390111074; Kondo S, 2008, J NUCL MATER, V382, P160, DOI 10.1016/j.jnucmat.2008.08.013; Zhuang D, 2005, MAT SCI ENG R, V48, P1, DOI 10.1016/j.mser.2004.11.002; HIRAYAMA H, 1989, J AM CERAM SOC, V72, P2049, DOI 10.1111/j.1151-2916.1989.tb06029.x; Ziegler JF, 2004, NUCL INSTRUM METH B, V219, P1027, DOI 10.1016/j.nimb.2004.01.208; Muto S, 2004, JPN J APPL PHYS 1, V43, P1076, DOI 10.1143/JJAP.43.1076; Opila EJ, 1999, J AM CERAM SOC, V82, P625; Kondo S, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.075202; Somiya S, 2001, MATER CHEM PHYS, V67, P157, DOI 10.1016/S0254-0584(00)00434-X; Henager CH, 2008, J NUCL MATER, V378, P9, DOI 10.1016/j.jnucmat.2008.03.025; Terrani KA, 2014, J AM CERAM SOC, V97, P2331, DOI 10.1111/jace.13094; Park JY, 2013, J NUCL MATER, V443, P603, DOI 10.1016/j.jnucmat.2013.07.058; Snead LL, 2007, J NUCL MATER, V367, P677, DOI 10.1016/j.jnucmat.2007.03.097; Syvajarvi M, 2000, J CRYST GROWTH, V208, P409, DOI 10.1016/S0022-0248(99)00484-4; Bhattacharya R.S., 1987, J APPL PHYS, P4791; GOGOTSI YG, 1995, J AM CERAM SOC, V78, P1439, DOI 10.1111/j.1151-2916.1995.tb08835.x; IKONIC Z, 1993, PHYS REV B, V48, P17181, DOI 10.1103/PhysRevB.48.17181; Kaneko K, 1999, ACTA MATER, V47, P1281, DOI 10.1016/S1359-6454(98)00423-6; Katoh Y, 2002, J NUCL MATER, V307, P1221, DOI 10.1016/S0022-3115(02)01062-0; Kim D, 2013, OXID MET, V80, P389, DOI 10.1007/s11085-012-9346-y; Kohyama A, 2000, FUSION ENG DES, V51-52, P789, DOI 10.1016/S0920-3796(00)00181-2; Kondo S, 2014, J NUCL MATER, V448, P487, DOI 10.1016/j.jnucmat.2013.09.004; Lindefelt U, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.155204; NUTT SR, 1987, APPL PHYS LETT, V50, P203, DOI 10.1063/1.97661; Ono S., 1991, P JAIF INT C WATER C, P315; Polychroniadis E, 2004, J CRYST GROWTH, V263, P68, DOI 10.1016/j.jcrysgro.2003.10.092; PRICE RJ, 1969, J NUCL MATER, V33, P17, DOI 10.1016/0022-3115(69)90003-8; Swaminathan N, 2012, J APPL PHYS, V111, DOI 10.1063/1.3693036; Tan L, 2009, J NUCL MATER, V394, P95, DOI 10.1016/j.jnucmat.2009.08.008; THOMAS DE, 1974, T AM NUCL SOC, V18, P111; Umeno Y, 2012, PHYS STATUS SOLIDI B, V249, P1229, DOI 10.1002/pssb.201147487; Yano T, 1998, J NUCL MATER, V253, P78, DOI 10.1016/S0022-3115(97)00331-0; Zinkle SJ, 2014, J NUCL MATER, V448, P374, DOI 10.1016/j.jnucmat.2013.12.005	33	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-3115	1873-4820		J NUCL MATER	J. Nucl. Mater.	SEP	2015	464						36	42		10.1016/j.jnucmat.2015.04.034		7	Materials Science, Multidisciplinary; Nuclear Science & Technology; Mining & Mineral Processing	Materials Science; Nuclear Science & Technology; Mining & Mineral Processing	CO4ZZ	WOS:000359170700006		
J	Ohashi, Y; Harada, M; Asanuma, N; Ikeda, Y				Ohashi, Yusuke; Harada, Masayuki; Asanuma, Noriko; Ikeda, Yasuhisa			Feasibility studies on electrochemical recovery of uranium from solid wastes contaminated with uranium using 1-butyl-3-methylimidazorium chloride as an electrolyte	JOURNAL OF NUCLEAR MATERIALS			English	Article							TEMPERATURE IONIC LIQUIDS; EXTRACTION; COMPLEXES; ACTINIDE; ELECTRODEPOSITION; DECONTAMINATION; COORDINATION; SPECTROSCOPY; SEPARATION; CHEMISTRY	In order to examine feasibility of the electrochemical deposition method for recovering uranium from the solid wastes contaminated with uranium using ionic liquid as electrolyte, we have studied the electrochemical behavior of each solution prepared by soaking the spent NaF adsorbents and the steel waste contaminated with uranium in BMICI (1-butyl-3-methyl- imidazolium chloride). The uranyl(VI) species in BMICI solutions were found to be reduced to U(V) irreversibly around -0.8 to -1.3 V vs. Ag/AgCl. The resulting U(V) species is followed by disproportionation to U(VI) and U(IV). Based on the electrochemical data, we have performed potential controlled electrolysis of each solution prepared by soaking the spent NaF adsorbents and steel wastes in BMICI at -1.5 V vs. Ag/AgCl. Black deposit was obtained, and their composition analyses suggest that the deposit is the mixtures of U(IV) and U(VI) compounds containing O, F, Cl, and N elements. From the present study, it is expected that the solid wastes contaminated with uranium can be decontaminated by treating them in BMICI and the dissolved uranium species are recovered electrolytically. (C) 2015 Elsevier B.V. All rights reserved.	[Ohashi, Yusuke] Japan Atom Energy Agcy, Ningyo Toge Environm Engn Ctr, Kagamino, Okayama 7080698, Japan; [Harada, Masayuki; Ikeda, Yasuhisa] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan; [Asanuma, Noriko] Tokai Univ, Sch Engn, Dept Nucl Engn, Hiratsuka, Kanagawa 2591292, Japan	Ohashi, Y (reprint author), Japan Atom Energy Agcy, Ningyo Toge Environm Engn Ctr, 1550 Kamisaibara, Kagamino, Okayama 7080698, Japan.	ohhashi.yusuke@jaea.go.jp					Szabo Z, 2006, COORDIN CHEM REV, V250, P784, DOI 10.1016/j.ccr.2005.10.005; Nockemann P, 2007, INORG CHEM, V46, P11335, DOI 10.1021/ic701752j; Ikeda A, 2002, J NUCL SCI TECHNOL, V39, P1099, DOI 10.3327/jnst.39.1099; Sornein MO, 2006, INORG CHEM, V45, P10419, DOI 10.1021/ic061751q; Ilton ES, 2011, SURF INTERFACE ANAL, V43, P1549, DOI 10.1002/sia.3836; Sun XQ, 2012, CHEM REV, V112, P2100, DOI 10.1021/cr200193x; Giridhar P, 2007, ELECTROCHIM ACTA, V52, P3006, DOI 10.1016/j.electacta.2006.09.038; Binnemans K, 2007, CHEM REV, V107, P2592, DOI 10.1021/cr050979c; Gaillard C, 2007, INORG CHEM, V46, P4815, DOI 10.1021/ic061864+; Earle MJ, 2000, PURE APPL CHEM, V72, P1391, DOI 10.1351/pac200072071391; Panja S, 2012, SEP PURIF TECHNOL, V96, P289, DOI 10.1016/j.seppur.2012.06.015; Francis AJ, 2005, ENVIRON SCI TECHNOL, V39, P5015, DOI 10.1021/es048887c; Pemberton WJ, 2013, ELECTROCHIM ACTA, V93, P264, DOI 10.1016/j.electacta.2013.01.044; Giridhar P, 2008, J ALLOY COMPD, V448, P104, DOI 10.1016/j.jallcom.2007.03.115; Takao K, 2013, INORG CHEM, V52, P3459, DOI 10.1021/ic300807v; Rao CJ, 2011, J NUCL MATER, V408, P25, DOI 10.1016/j.jnucmat.2010.10.022; Gaillard C, 2012, DALTON T, V41, P5476, DOI 10.1039/c2dt30205e; Bera S, 1998, J NUCL MATER, V255, P26, DOI 10.1016/S0022-3115(98)00012-9; Mohapatra PK, 2013, DALTON T, V42, P4343, DOI 10.1039/c3dt32967d; Giridhar P, 2006, RADIOCHIM ACTA, V94, P415, DOI [10.1524/ract.2006.94.8.415, 10.1524/ract.2006.94.8.415d]; Asanuma N, 2007, J NUCL SCI TECHNOL, V44, P368, DOI 10.3327/jnst.44.368; Enda M., 2006, NIHON GENSHIRYOKU GA, V5, P364; HEERMAN L, 1985, J ELECTROANAL CHEM, V193, P289, DOI 10.1016/0022-0728(85)85071-3; Ikeda Y, 2009, J NUCL SCI TECHNOL, V46, P158, DOI 10.3327/jnst.46.158; Kokorin A., 2011, IONIC LIQUIDS APPL P; Mudring A.-V., 2010, EUR J INORG CHEM, V18, P2569; Ogura T, 2012, SCI CHINA CHEM, V55, P1699, DOI 10.1007/s11426-012-4693-8; Ogura T, 2011, INORG CHEM, V50, P10525, DOI 10.1021/ic2015989; Ohno H, 2005, ELECTROCHEMICAL ASPECTS OF IONIC LIQUIDS, P1, DOI 10.1002/0471762512; Rogers R. D., 2002, ASC S SERIES, V818; Rout A, 2012, DESALIN WATER TREAT, V38, P179, DOI 10.5004/dwt.2012.2301; Sornein MO, 2011, J ELECTROANAL CHEM, V661, P49, DOI 10.1016/j.jelechem.2011.07.012; Standards Committee, 2012, J AT ENERGY SOC JPN; TROWBRIDGE LD, 1982, SURF INTERFACE ANAL, V4, P89, DOI 10.1002/sia.740040303; Vasudeva Rao P. R., 2012, Separation Science & Technology, V47, DOI 10.1080/01496395.2011.628733; Wasserscheid P., 2008, IONIC LIQUIDS SYNTHE; Zaima N., 2010, P 13 INT C ENV REM R, V1, P311	37	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-3115	1873-4820		J NUCL MATER	J. Nucl. Mater.	SEP	2015	464						119	127		10.1016/j.jnucmat.2015.04.024		9	Materials Science, Multidisciplinary; Nuclear Science & Technology; Mining & Mineral Processing	Materials Science; Nuclear Science & Technology; Mining & Mineral Processing	CO4ZZ	WOS:000359170700017		
J	Zhan, Q; Zhao, WW; Yang, HG; Hatano, Y; Yuan, XM; Nozaki, T; Zhu, XX				Zhan, Qin; Zhao, Weiwei; Yang, Hongguang; Hatano, Yuji; Yuan, Xiaoming; Nozaki, Teo; Zhu, Xinxin			Formation of alpha-alumina scales in the Fe-Al(Cr) diffusion coating on China low activation martensitic steel	JOURNAL OF NUCLEAR MATERIALS			English	Article							OXIDATION BEHAVIOR; DESIGN	To study the formation mechanism of stable alpha-Al2O3 scales, the oxidation behavior of Fe-Al(Cr) diffusion coating on China low activation martensitic steel has been investigated under the oxygen partial pressure ranging from 1 to 20,000 Pa at 1253 K. A single, continuous Al2O3 scale with the maximum thickness of about 2000 nm was formed on the Fe-Al(Cr) diffusion layer. The phase transformation of alumina scales on the surface of Fe-Al(Cr) layer was studied at different oxidation times ranging from 3 to 180 min. With the increase in oxygen partial pressure, the phase transformation time of alpha-Al2O3 is decreased. The metastable gamma-Al2O3 and transition alpha-(Al0.948Cr0.052)(2)O-3 phases were formed in the earlier oxidation process and finally transformed to the stable alpha-Al2O3 phase, which were detected by grazing incidence angle X-ray diffraction and confirmed by transmission electron microscopy. This implies that Cr shows the third element effect and serves as a template for the nucleation of the stable alpha-Al2O3. (C) 2015 Elsevier B.V. All rights reserved.	[Zhan, Qin; Zhao, Weiwei; Yang, Hongguang; Yuan, Xiaoming; Zhu, Xinxin] China Inst Atom Energy, Beijing 102413, Peoples R China; [Hatano, Yuji; Nozaki, Teo] Toyama Univ, Hydrogen Isotope Res Ctr, Toyama 9308555, Japan	Zhan, Q (reprint author), China Inst Atom Energy, Dept Reactor Engn Res & Design, Tritium Mat & Technol TMT Team, POB 275-55, Beijing 102413, Peoples R China.	zhanqin1983@163.com			National Magnetic Fusion Science Program of China MOST [2014GB111003, 2011GB111006, 2009GB109005]	This work was supported by the National Magnetic Fusion Science Program of China MOST (2014GB111003, 2011GB111006, and 2009GB109005). The authors would like to thank the collaboration of HRC, University of Toyama, and the TMT Team members at CIAE.	Aiello A, 2004, J NUCL MATER, V329, P1398, DOI 10.1016/j.jnucmat.2004.04.205; Pint BA, 1997, OXID MET, V47, P1, DOI 10.1007/BF01682369; Wu Y, 2007, J NUCL MATER, V367, P1410, DOI [10.1016/j.jnucmat.2007.04.031, 10.1016/j.jnucmat.2007.04-031]; BRUMM MW, 1992, CORROS SCI, V33, P1677, DOI 10.1016/0010-938X(92)90002-K; Feng KM, 2006, FUSION ENG DES, V81, P1219, DOI 10.1016/j.fusengdes.2005.09.052; Wulf SE, 2013, FUSION ENG DES, V88, P2530, DOI 10.1016/j.fusengdes.2013.05.060; Asteman H, 2008, CORROS SCI, V50, P1734, DOI 10.1016/j.corsci.2007.12.012; Causey R.A., 2012, COMPREHENSIVE NUCL M, V4, P511; Chabrol C., 2000, FUSION TECHNOL, V3, P37; Grabke H.J., 1999, INTERMETALLICS, V7, P1153; Mao W, 2013, FUSION ENG DES, V88, P2646, DOI 10.1016/j.fusengdes.2013.05.092; Peggy H., 2003, MAT HIGH TEMP, V20, P357; PINT BA, 1994, MRS BULL, V19, P26; Wagner C., 1965, CORROS SCI, V5, P751, DOI 10.1016/S0010-938X(65)80003-8; Xu CH, 2000, SCRIPTA MATER, V42, P975, DOI 10.1016/S1359-6462(00)00327-4; Zhang Y, 2005, SURF COAT TECH, V200, P1231, DOI 10.1016/j.surfcoat.2005.07.081	16	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-3115	1873-4820		J NUCL MATER	J. Nucl. Mater.	SEP	2015	464						135	139		10.1016/j.jnucmat.2015.04.038		5	Materials Science, Multidisciplinary; Nuclear Science & Technology; Mining & Mineral Processing	Materials Science; Nuclear Science & Technology; Mining & Mineral Processing	CO4ZZ	WOS:000359170700019		
J	Shinozuka, K; Esaka, H; Sakasegawa, H; Tanigawa, H				Shinozuka, K.; Esaka, H.; Sakasegawa, H.; Tanigawa, H.			Creep strength and microstructure of F82H steels near tempering temperature	JOURNAL OF NUCLEAR MATERIALS			English	Article							TEST BLANKET MODULES; ITER TEST BLANKET	Creep rupture tests near the tempering temperature were performed, and the creep behavior at high temperatures and the structures of fracture specimens were investigated. Three kinds of F82H test specimens were used: IEA-heat, mod3, and BA07. The time-to-rupture of the BA07 specimens was the longest under all the test conditions. This was because the minimum creep rates of BA07 were smallest, and a large quantity of fine precipitates of MX from the ESR treatment were considered to be effective in providing creep resistance. Although mod.3 specimens showed a high creep resistance under high stress, the timeto-rupture of mod.3 and lEA-heat were almost the same at low stress. This was because the fine tempered martensitic structure was weakened by being subjected to a high temperature for a long period. Therefore, it is considered that a large quantity of fine MX precipitates are effective for creep resistance near the tempering temperature. (C) 2015 Elsevier B.V. All rights reserved.	[Shinozuka, K.; Esaka, H.] Natl Def Acad, Yokosuka, Kanagawa 2398686, Japan; [Sakasegawa, H.; Tanigawa, H.] Japan Atom Energy Agcy, Aomori 0393212, Japan	Shinozuka, K (reprint author), Natl Def Acad, Yokosuka, Kanagawa 2398686, Japan.	kshinozu@nda.ac.jp					Tanigawa H, 2008, FUSION ENG DES, V83, P1471, DOI 10.1016/j.fusengdes.2008.07.024; Sakasegawa H, 2011, FUSION ENG DES, V86, P2541, DOI 10.1016/j.fusengdes.2011.03.087; Tanigawa H, 2011, FUSION ENG DES, V86, P2549, DOI 10.1016/j.fusengdes.2011.04.047; Fukumoto K., 2013, J NUCL MATER, V442, P528; Rieth M, 2009, J NUCL MATER, V386-88, P471, DOI 10.1016/j.jnucmat.2008.12.142; Serizawa H, 2013, J NUCL MATER, V442, pS535, DOI 10.1016/j.jnucmat.2012.12.051; Shiba K, 2004, J NUCL MATER, V329, P243, DOI 10.1016/j.jnucmat.2004.04.018; Shinozuka K, 2009, J NUCL MATER, V384, P1, DOI 10.1016/j.jnucmat.2008.09.006; Tamura M, 2007, J NUCL MATER, V367, P137, DOI 10.1016/j.jnucmat.2007.03.154	9	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-3115	1873-4820		J NUCL MATER	J. Nucl. Mater.	SEP	2015	464						155	159		10.1016/j.jnucmat.2015.04.035		5	Materials Science, Multidisciplinary; Nuclear Science & Technology; Mining & Mineral Processing	Materials Science; Nuclear Science & Technology; Mining & Mineral Processing	CO4ZZ	WOS:000359170700022		
J	Vasudevamurthy, G; Katoh, Y; Aihara, J; Sawa, K; Snead, LL				Vasudevamurthy, G.; Katoh, Y.; Aihara, J.; Sawa, K.; Snead, L. L.			Microstructure and mechanical properties of heat-treated and neutron irradiated TRISO-ZrC coatings	JOURNAL OF NUCLEAR MATERIALS			English	Article							GAS-COOLED REACTOR; HIGH-TEMPERATURE; ZIRCONIUM CARBIDE; TEM/STEM OBSERVATION; FUEL-PARTICLES; LAYER; CARBON; ALLOY	Six developmental sets of as-fabricated and heat-treated, near- and hyper-stoichiometric ZrC coated TRISO particles were subject to fast neutron (E > 0.1 MeV) fluences of 2 and 6 x 10(25) neutrons/m(2) at 800 and 1250 degrees C to assess the effects of irradiation on the coating microstructure and mechanical properties. Pre-irradiation microstructural analysis showed that the all but one of the near-stoichiometric samples fabricated by CVD had a homogenous grain structure while others including the hyper-stoichiometric sample had a distinct tiered band pattern with alternating carbon rich interlayers. The band structure in the near-stoichiometric samples became prominent following the heat treatment and the homogenous grained sample underwent severe grain growth. Post-irradiation observations indicated that neutron irradiation did not have any significant effects on the bulk microstructure of any of the samples regardless of the stoichiometry. Post-irradiation softening and reduction in modulus at the highest dose (6 dpa) were observed in all samples regardless of the composition and structure but were less significant in specimens with a banded microstructure. It was concluded that the carbon interlayers which contributed to the formation of the band structure had played a role in preserving the microstructure and the mechanical properties following both heat treatment and irradiation. Published by Elsevier B.V.	[Vasudevamurthy, G.] Virginia Commonwealth Univ, High Temp Mat Lab, Richmond, VA 23284 USA; [Katoh, Y.; Snead, L. L.] Oak Ridge Natl Lab, Mat Sci & Technol Div, Oak Ridge, TN USA; [Aihara, J.; Sawa, K.] Japan Atom Energy Agcy, Naka, Ibaraki, Japan	Vasudevamurthy, G (reprint author), Virginia Commonwealth Univ, High Temp Mat Lab, Richmond, VA 23284 USA.	gvasudev@vcu.edu			International Nuclear Energy Research Initiative [2006-001-J]; Advanced Gas Reactor projects under aegis of US Department of Energy	This work was supported by the International Nuclear Energy Research Initiative (Project Number: 2006-001-J) and the Advanced Gas Reactor projects under the aegis of the US Department of Energy. The work described above is a collaborative effort involving the Oak Ridge National Laboratory and the Japan Atomic Energy Agency. The authors wish to acknowledge the staff at ORNL-LAMDA, ORNL-IMET facilities for their assistance at various stages of the project. The authors also gratefully acknowledge the assistance rendered by the ORNL's SHaRE user program by allowing the use of XL-30 and JEOL 6500F Scanning electron microscopes for the microstructural observations.	Aihara J, 2009, MATER TRANS, V50, P2631, DOI 10.2320/matertrans.M2009185; Aihara J, 2009, J AM CERAM SOC, V92, P197, DOI 10.1111/j.1551-2916.2008.02822.x; Aihara J, 2007, J AM CERAM SOC, V90, P3968, DOI 10.1111/j.1551-2916.2007.02033.x; ALEXANDER DE, 1991, NUCL INSTRUM METH B, V59, P462, DOI 10.1016/0168-583X(91)95260-K; Andrievskii R.A., 1978, IAN SSSR NEORG MATER, V14, P680; Katoh Y, 2013, J NUCL MATER, V441, P718, DOI 10.1016/j.jnucmat.2013.05.037; Minato K, 2000, J NUCL MATER, V279, P181, DOI 10.1016/S0022-3115(00)00015-5; OGAWA T, 1986, HIGH TEMP SCI, V22, P179; [Anonymous], E11213 ASTM; DAROLIA R, 1976, J MATER SCI, V11, P283, DOI 10.1007/BF00551439; He X.M., 1998, J VAC SCI TECHNOL A, P16; Ikawa J., 1972, LESS COMMON MET, V27, P325; IKAWA K, 1976, J LESS-COMMON MET, V44, P207, DOI 10.1016/0022-5088(76)90133-8; IKAWA K, 1974, J NUCL SCI TECHNOL, V11, P263, DOI 10.3327/jnst.11.263; Keilholtz G.W., 1969, P AM NUCL SOC; Keilholtz G.W., 1968, 4390 ORNL, P113; Kovalchenko M.S., 1973, IAN SSSR NEORG MATER, V9, P321; Little E.A., 1982, EFFECTS RAD MATERIAL, P207, DOI 10.1520/STP34347S; Maki JT, 2007, J NUCL MATER, V371, P270, DOI 10.1016/j.jnucmat.2007.05.019; Ogawa T., 1985, BR NUCL ENERGY SOC L, P163; REYNOLDS GH, 1976, J NUCL MATER, V62, P9, DOI 10.1016/0022-3115(76)90279-8; Snead L.L., 2009, J NUCL MATER, V399, P200; Storms E.K., 1967, REFRACTORY CARBIDES; Valentine K.H., 1977, 5228 ORNL; Versluis R.M., 2008, HTR200858325	25	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-3115	1873-4820		J NUCL MATER	J. Nucl. Mater.	SEP	2015	464						245	255		10.1016/j.jnucmat.2015.04.026		11	Materials Science, Multidisciplinary; Nuclear Science & Technology; Mining & Mineral Processing	Materials Science; Nuclear Science & Technology; Mining & Mineral Processing	CO4ZZ	WOS:000359170700033		
J	Nishi, T; Nakajima, K; Takano, M; Kurata, M; Arita, Y				Nishi, Tsuyoshi; Nakajima, Kunihisa; Takano, Masahide; Kurata, Masaki; Arita, Yuji			Thermal conductivity of U-20 wt.%Pu-2 wt.%Am-10 wt.%Zr alloy	JOURNAL OF NUCLEAR MATERIALS			English	Article							U-PU-ZR; REACTOR-FUELS; TEMPERATURE; DIFFUSIVITY; ACTINIDES; METAL; AM; NP	The authors fabricated U-20 wt.%Pu-2 wt.%Am-10 wt.%Zr alloys and evaluated the heat capacity and thermal conductivity. The heat capacity was measured between 335 and 827 K by a drop calorimetry. The thermal diffusivity was measured between 300 and 1073 K by a laser flash method. The thermal conductivity was evaluated from the measured thermal diffusivity and heat capacity. The thermal conductivity of U-20 wt.%Pu-2 wt.%Am-10 wt.%Zr alloy was slightly higher than literature values of U-Pu-Zr and U-Pu-MA-Zr alloys. The thermal conductivity was formulated for use in practical design for Generation IV fast reactors. (C) 2015 Elsevier B.V. All rights reserved.	[Nishi, Tsuyoshi; Nakajima, Kunihisa; Takano, Masahide; Kurata, Masaki] Japan Atom Energy Agcy, Nucl Sci & Engn Ctr, Tokai, Ibaraki 3191195, Japan; [Nishi, Tsuyoshi] Ibaraki Univ, Dept Mat Sci & Engn, Hitachi, Ibaraki 3168511, Japan; [Arita, Yuji] Univ Fukui, Res Inst Nucl Engn, Tsuruga, Fukui 9140055, Japan	Nishi, T (reprint author), Ibaraki Univ, Dept Mat Sci & Engn, Coll Engn, 4-12-1 Nakanarusawa, Hitachi, Ibaraki 3168511, Japan.	nishi@mx.ibaraki.ac.jp					Kim YS, 2014, J NUCL MATER, V445, P272, DOI 10.1016/j.jnucmat.2013.11.018; MATSUI T, 1989, J NUCL MATER, V167, P152, DOI 10.1016/0022-3115(89)90437-6; JOSELL D, 1995, J APPL PHYS, V78, P6867, DOI 10.1063/1.360452; Iizuka M, 2006, J NUCL MATER, V359, P102, DOI 10.1016/j.jnucmat.2006.08.003; Barin I., 1995, THERMOCHEMICAL DATA, V1995, p[74, 1725, 1851, 1338]; BLANK H, 1986, J LESS-COMMON MET, V121, P583, DOI 10.1016/0022-5088(86)90575-8; Burkes DE, 2010, J NUCL MATER, V396, P49, DOI 10.1016/j.jnucmat.2009.10.053; CEZAIRLIYAN A, 1994, INT J THERMOPHYS, V15, P317, DOI 10.1007/BF01441589; Kato T., 2005, L05010 CRIEPI; KURATA M, 1994, J NUCL MATER, V208, P144, DOI 10.1016/0022-3115(94)90206-2; Nakamura Kinya, 2011, Transactions of the Atomic Energy Society of Japan, V10, DOI 10.3327/taesj.J10.038; Nakamura K., 2011, P GLOB 2011 MAK JAP; Nishi T, 2008, J NUCL MATER, V376, P78, DOI 10.1016/j.jnucmat.2008.01.018; Nishi T, 2006, J NUCL MATER, V355, P114, DOI 10.1016/j.jnucmat.2006.04.008; Nishi T., 2005, JAERI TECH; Ogata T., 2002, J NUCL SCI TECHNOL S, V3, P675; Ohki S., 2000, P 6 OECD NEA INF EXC, P521; SPIRLET JC, 1973, J LESS-COMMON MET, V31, P35, DOI 10.1016/0022-5088(73)90128-8	18	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-3115	1873-4820		J NUCL MATER	J. Nucl. Mater.	SEP	2015	464						270	274		10.1016/j.jnucmat.2015.04.043		5	Materials Science, Multidisciplinary; Nuclear Science & Technology; Mining & Mineral Processing	Materials Science; Nuclear Science & Technology; Mining & Mineral Processing	CO4ZZ	WOS:000359170700036		
J	Komine, N; Kuramoto, A; Yasuda, T; Kawabata, T; Hirano, M; Komiya, S				Komine, Nobuyuki; Kuramoto, Ayako; Yasuda, Toshiyuki; Kawabata, Tatsuya; Hirano, Masafumi; Komiya, Sanshiro			Synthesis of heterodinuclear hydride complexes by oxidative addition of a transition-metal hydride to Pt(0) and Pd(0) complexes	JOURNAL OF ORGANOMETALLIC CHEMISTRY			English	Article						Heterodinuclear hydride complex; Oxidative addition; Reductive elimination; DFT calculation	BETA-HYDROGEN ELIMINATION; INSERTION; CATALYSTS; SELECTIVITY; MOLYBDENUM; PLATINUM; TUNGSTEN; RHENIUM; ALKYNE; PALLADIUM	Heterodinuclear hydridoplatinum and -palladium complexes, (dppe)HPt-MLn (MLn = MoCp(CO)(3) (3a), WCp(CO)(3) (3b)), (dPPe)Pt(mu-H)(mu-CO)Mn(CO)(4) (3c), (dPPe)Pt(mu-F1)(mu-CO)FeCp(CO) (3d), cis-L'2 HPt MLn (5aa: PPh3; ML n = MoCp(CO)(3), 5ba: = PPh3; MLn = WCp(CO)(3), 5ab: = PMePh2; ML n = MoCp(CO)(3), Sac: = PMe2Ph; ML n = MoCp(CO)(3)), (dPPe)Pd(P-14)(1.t-CO)M4 (ML n = MoCP(C0)2 (7a), WCp(C0)2 (M)), (cIPPe)Pd(11-F1)(1.t-CO)Mn(CO)(4) (7c) are prepared by the oxidative addition of mononuclear transition-metal hydride complexes to zero-valent platinum or palladium complexes. The reactions of the heterodinuclear hydride complexes 3a, 3d and 7a with electron deficient alkenes and alkynes such as dimethyl fumarate or DMAD cause reductive elimination at the Pt or Pd center to give the Pt(alkene or alkyne)(dppe) and MHLn suggesting reversibility of this process. The DFT calculations suggest that these reactions are controlled by the thermodynamic stability and the electron rich alkene complex of Pt(0) (or Pd(0)) are preferable to prepare these heterodinuclear hydride complexes by the oxidative addition. (C) 2015 Elsevier BY. All rights reserved.	[Komine, Nobuyuki; Kuramoto, Ayako; Yasuda, Toshiyuki; Kawabata, Tatsuya; Hirano, Masafumi; Komiya, Sanshiro] Tokyo Univ Agr & Technol, Grad Sch Engn, Dept Appl Chem, Koganei, Tokyo 1848588, Japan	Komine, N (reprint author), Tokyo Univ Agr & Technol, Grad Sch Engn, Dept Appl Chem, 2-24-16 Nakacho, Koganei, Tokyo 1848588, Japan.	komine@cc.tuat.ac.jp; komiya@cc.tuat.ac.jp	Komine, Nobuyuki/F-9249-2013; Hirano, Masafumi/C-1054-2013	Komine, Nobuyuki/0000-0003-1744-695X; Hirano, Masafumi/0000-0001-7835-1044	Ministry of Education, Sports, Culture, Science, and Technology (MEXT); Japan Society for the Promotion of Science (JSPS); Tokyo University of Agriculture and Technology; MEXT [18065006, 26105003]; JSPS	We thank the Ministry of Education, Sports, Culture, Science, and Technology (MEXT), Japan Society for the Promotion of Science (JSPS) and Tokyo University of Agriculture and Technology for financial support for this research. A part of this work was supported by Grant-in-Aids for Scientific Research on Priority Areas "Chemistry of Concerto Catalysis" (No. 18065006) and Innovative Areas "3D Active-Site Science" (No. 26105003) by MEXT and JSPS.	Adams RD, 1998, CHEM MET CLUST, P283; Adams RD, 2007, J AM CHEM SOC, V129, P7545, DOI 10.1021/ja070617h; Adams RD, 2006, J AM CHEM SOC, V128, P13672, DOI 10.1021/ja0657152; Jutand A, 1999, ORGANOMETALLICS, V18, P5367, DOI 10.1021/om9906417; TOLMAN CA, 1977, CHEM REV, V77, P313, DOI 10.1021/cr60307a002; Mandal SK, 2010, ACCOUNTS CHEM RES, V43, P248, DOI 10.1021/ar9001729; APPLETON TG, 1973, COORDIN CHEM REV, V10, P335, DOI 10.1016/S0010-8545(00)80238-6; Yoshikai N, 2006, ORGANOMETALLICS, V25, P3867, DOI 10.1021/om060478x; Man ML, 2006, CHEM-EUR J, V12, P1004, DOI 10.1002/chem.200500780; BARS O, 1986, ORGANOMETALLICS, V5, P2021, DOI 10.1021/om00141a015; Bars O., 1982, ANGEW CHEM, V94, P319; BISWAS J, 1988, CATAL REV, V30, P161, DOI 10.1080/01614948808078619; Braunstein P., 1986, NOUV J CHIMO, V9, P221; Braunstein P., 1999, METAL CLUSTERS CHEM; Cotton F. A., 1998, CATALYSIS POLYNUCLEA; FISCHER EO, 1963, INORG SYN, V7, P136, DOI 10.1002/9780470132388.ch38; Hill A. F., 2002, ORGANOTRANSITION MET; Ishii Y, 1997, J AM CHEM SOC, V119, P6448, DOI 10.1021/ja9703887; Jinfelt J. H., 1981, CATALYSIS SCI TECHNO; KIM CM, 1992, J CATAL, V134, P179, DOI 10.1016/0021-9517(92)90220-C; King R. B., 1963, INORG SYNTH, V7, P198; Komine N, 2014, TOP CATAL, V57, P960, DOI 10.1007/s11244-014-0258-8; Komine N, 2008, ORGANOMETALLICS, V27, P2145, DOI 10.1021/om701062g; Komine N, 2000, ORGANOMETALLICS, V19, P5251, DOI 10.1021/om000728o; Komiya S, 2000, J AM CHEM SOC, V122, P170, DOI 10.1021/ja993185m; Komiya S, 2000, J MOL CATAL A-CHEM, V159, P63, DOI 10.1016/S1381-1169(00)00171-0; Kuramoto A, 2006, ORGANOMETALLICS, V25, P311, DOI 10.1021/om0506872; Li LT, 2002, J AM CHEM SOC, V124, P12725, DOI 10.1021/ja0201698; Nakamoto K., 1997, INFRARED RAMAN SPECT, Vfifth, P291; Obora Y, 1996, J AM CHEM SOC, V118, P10922, DOI 10.1021/ja9626392; Ozawa F, 1998, ORGANOMETALLICS, V17, P5630, DOI 10.1021/om980610w; Piper T. S., 1956, J INORG NUCL CHEM, V104, P1956; Qi XJ, 2006, ORGANOMETALLICS, V25, P5879, DOI 10.1021/om0608859; Rath NP, 2007, INORG CHIM ACTA, V360, P2997, DOI 10.1016/j.ica.2007.02.033; Rida M. A., 2003, J MOL CATAL A-CHEM, V202, P87, DOI 10.1016/S1381-1169(03)00234-6; Sanchez-Delgado R. A., 2002, ORGANOMETALLIC MODEL; Shackleton T. A., 1989, ORGANOMETALLICS, V8, P225; Shriver D. F., 1990, CHEM METAL CLUSTER C; SHUM VK, 1985, J CATAL, V96, P371, DOI 10.1016/0021-9517(85)90307-0; Tsuji Y, 1998, ORGANOMETALLICS, V17, P507, DOI 10.1021/om970957j; WALKER HW, 1983, J AM CHEM SOC, V105, P1179, DOI 10.1021/ja00343a017; Yamamoto Y., 2004, MULTIMETALLIC CATALY; Yasuda T, 1998, CHEM LETT, P29	43	0	0	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0022-328X	1872-8561		J ORGANOMET CHEM	J. Organomet. Chem.	SEP 1	2015	792						194	205		10.1016/j.jorganchem.2015.04.048		12	Chemistry, Inorganic & Nuclear; Chemistry, Organic	Chemistry	CO5LV	WOS:000359201500028		
J	Kato, H; Tanaka, G; Masuda, S; Ogasawara, J; Sakurai, T; Kizaki, T; Ohno, H; Izawa, T				Kato, Hisashi; Tanaka, Goki; Masuda, Shinya; Ogasawara, Junetsu; Sakurai, Takuya; Kizaki, Takako; Ohno, Hideki; Izawa, Tetsuya			Melatonin promotes adipogenesis and mitochondrial biogenesis in 3T3-L1 preadipocytes	JOURNAL OF PINEAL RESEARCH			English	Article						3T3-L1; adipogenesis; adiponectin; melatonin; mitochondrial biogenesis	HIGH-FAT DIET; WHITE ADIPOSE-TISSUE; BODY-WEIGHT; C/EBP-BETA; INSULIN SENSITIVITY; METABOLIC SYNDROME; ENERGY-METABOLISM; GENE-EXPRESSION; INDUCED OBESITY; PLASMA LEPTIN	Melatonin is synthesized in the pineal gland, but elicits a wide range of physiological responses in peripheral target tissues. Recent advances suggest that melatonin controls adiposity, resulting in changes in body weight. The aim of this study was to investigate the effect of melatonin on adipogenesis and mitochondrial biogenesis in 3T3-L1 mouse embryo fibroblasts. Melatonin significantly increased the expression of peroxisome proliferator-activated receptor- (PPAR-), a master regulator of adipogenesis, and promoted differentiation into adipocytes. Melatonin-treated cells also formed smaller lipid droplets and abundantly expressed several molecules associated with lipolysis, including adipose triglyceride lipase, perilipin, and comparative gene identification-58. Moreover, the hormone promoted biogenesis of mitochondria, as indicated by fluorescent staining, elevated the citrate synthase activity, and upregulated the expression of PPAR- coactivator 1, nuclear respiratory factor-1, and transcription factor A. The expression of uncoupling protein 1 was also observable both at mRNA and at protein level in melatonin-treated cells. Finally, adiponectin secretion and the expression of adiponectin receptors were enhanced. These results suggest that melatonin promotes adipogenesis, lipolysis, mitochondrial biogenesis, and adiponectin secretion. Thus, melatonin has potential as an anti-obesity agent that may reverse obesity-related disorders.	[Kato, Hisashi; Tanaka, Goki; Izawa, Tetsuya] Doshisha Univ, Grad Sch Hlth & Sports Sci, Kyoto 6100321, Japan; [Masuda, Shinya] Kyoto Med Ctr, Natl Hosp Org, Div Diabet Res, Clin Res Inst, Kyoto, Japan; [Ogasawara, Junetsu; Sakurai, Takuya; Kizaki, Takako; Ohno, Hideki] Kyorin Univ, Dept Mol Predict Med & Sports Sci, Mitaka, Tokyo, Japan; [Izawa, Tetsuya] Doshisha Univ, Fac Hlth & Sports Sci, Kyoto 602, Japan	Izawa, T (reprint author), Doshisha Univ, Grad Sch Hlth & Sports Sci, 1-3 Tatara Miyakodani, Kyoto 6100321, Japan.	tizawa@mail.doshisha.ac.jp			JSPS KAKENHI [23300242]	This work was supported by a grant from JSPS KAKENHI, Grant Number 23300242. We thank Dr. Takeshi Hashimoto for generously donating 3T3-L1 mouse embryo fibroblasts. In addition, we thank Takuya Shibahara, Takumi Kitagawa, and Hisashi Takakura for technical assistance.	Adamczyk-Sowa M, 2013, CELL BIOL INT, V37, P835, DOI 10.1002/cbin.10105; Jimenez-Aranda A, 2013, J PINEAL RES, V55, P416, DOI 10.1111/jpi.12089; Tan DX, 2011, OBES REV, V12, P167, DOI 10.1111/j.1467-789X.2010.00756.x; Agabiti-Rosei C, 2014, J HYPERTENS, V32, P1264, DOI 10.1097/HJH.0000000000000178; Shabalina IG, 2013, CELL REP, V5, P1196, DOI 10.1016/j.celrep.2013.10.044; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Rong JX, 2011, PPAR RES, DOI 10.1155/2011/179454; Nduhirabandi F, 2011, J PINEAL RES, V50, P171, DOI 10.1111/j.1600-079X.2010.00826.x; Cipolla-Neto J, 2014, J PINEAL RES, V56, P371, DOI 10.1111/jpi.12137; Alonso-Vale MIC, 2004, METABOLISM, V53, P500, DOI 10.1016/j.metabol.2003.11.009; Rong JX, 2007, DIABETES, V56, P1751, DOI 10.2337/db06-1135; Zavodnik IB, 2011, J PHYSIOL PHARMACOL, V62, P421; Peschke E, 2006, J PINEAL RES, V40, P135, DOI 10.1111/j.1600-079X.2005.00287.x; Karamanlidis G, 2007, J BIOL CHEM, V282, P24660, DOI 10.1074/jbc.M703101200; Wolden-Hanson T, 2000, ENDOCRINOLOGY, V141, P487, DOI 10.1210/en.141.2.487; Choo HJ, 2006, DIABETOLOGIA, V49, P784, DOI 10.1007/s00125-006-0170-2; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Wang CH, 2013, FEBS J, V280, P1039, DOI 10.1111/febs.12096; Hashimoto T, 2012, J CELL SCI, V125, P6127, DOI 10.1242/jcs.113084; Kitagawa A, 2012, J PINEAL RES, V52, P403, DOI 10.1111/j.1600-079X.2011.00955.x; Jimenez-Aranda A, 2014, J PINEAL RES, V57, P103, DOI 10.1111/jpi.12147; Borges-Silva CN, 2005, J PINEAL RES, V39, P178, DOI 10.1111/j.1600-079X.2005.00241.x; Wilson-Fritch L, 2003, MOL CELL BIOL, V23, P1085, DOI 10.1128/23.3.1085-1094.2003; Harms M, 2013, NAT MED, V19, P1252, DOI 10.1038/nm.3361; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; Koh EH, 2007, DIABETES, V56, P2973, DOI 10.2337/db07-0510; Miyoshi H, 2008, J CELL BIOCHEM, V105, P1430, DOI 10.1002/jcb.21964; She MH, 2009, PHARMACOL RES, V59, P248, DOI 10.1016/j.phrs.2009.01.005; Puchalski SS, 2003, ENDOCRINE, V21, P163, DOI 10.1385/ENDO:21:2:163; Gaidhu MP, 2010, AM J PHYSIOL-CELL PH, V298, pC961, DOI 10.1152/ajpcell.00547.2009; Prunet-Marcassus B, 2003, ENDOCRINOLOGY, V144, P5347, DOI 10.1210/en.2003-0693; Calvo JR, 2013, J PINEAL RES, V55, P103, DOI 10.1111/jpi.12075; Rosen ED, 2000, GENE DEV, V14, P1293; Rasmussen DD, 1999, ENDOCRINOLOGY, V140, P1009, DOI 10.1210/en.140.2.1009; McMullan CJ, 2013, JAMA-J AM MED ASSOC, V309, P1388, DOI 10.1001/jama.2013.2710; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Liang HY, 2006, ADV PHYSIOL EDUC, V30, P145, DOI 10.1152/advan.00052.2006; Huang CL, 2013, BIOCHEM BIOPH RES CO, V438, P211, DOI 10.1016/j.bbrc.2013.07.055; Alonso-Vale MIC, 2009, J PINEAL RES, V47, P221, DOI 10.1111/j.1600-079X.2009.00705.x; Alonso-Vale MIC, 2008, J PINEAL RES, V45, P422, DOI 10.1111/j.1600-079X.2008.00610.x; de Oliveira AC, 2012, ENDOCRINOLOGY, V153, P2178, DOI 10.1210/en.2011-1675; Gonzalez A, 2012, J PINEAL RES, V52, P12, DOI 10.1111/j.1600-079X.2011.00911.x; Kudoh A, 2011, LIFE SCI, V88, P1055, DOI 10.1016/j.lfs.2011.04.001; Larsen S, 2010, J PHYSL, V14, P3349; Maldonado MD, 2006, NEUROENDOCRINOL LETT, V27, P601; Mendes C, 2013, J PINEAL RES, V55, P229, DOI 10.1111/jpi.12065; Morak M, 2012, MOL CELL PROTEOMICS, V11, P1777, DOI 10.1074/mcp.M111.015743; Ntambi JM, 2000, J NUTR, V130, P3122; REITER RJ, 1991, MOL CELL ENDOCRINOL, V79, pC153, DOI 10.1016/0303-7207(91)90087-9; Robeva R, 2008, J PINEAL RES, V44, P52, DOI 10.1111/j.1600-079X.2007.00527.x; Slominski AT, 2014, INT J MOL SCI, V15, P17705, DOI 10.3390/ijms151017705; Zwirska-Korczala K, 2005, J Physiol Pharmacol, V56 Suppl 6, P91; Teodoro BG, 2014, J PINEAL RES, V57, P155, DOI 10.1111/jpi.12157; Yang Baichun, 2004, BMC Pharmacology, V4, P23, DOI 10.1186/1471-2210-4-23; Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162	55	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	SEP	2015	59	2					267	275		10.1111/jpi.12259		9	Endocrinology & Metabolism; Neurosciences; Physiology	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	CO2AQ	WOS:000358958000011		
J	Kikuchi, H; Yoshiuchi, K; Ando, T; Yamamoto, Y				Kikuchi, Hiroe; Yoshiuchi, Kazuhiro; Ando, Tetsuya; Yamamoto, Yoshiharu			Influence of psychological factors on acute exacerbation of tension-type headache: Investigation by ecological momentary assessment	JOURNAL OF PSYCHOSOMATIC RESEARCH			English	Article						Ecological momentary assessment; Psychological stress; Tension-type headache	PRECIPITATING FACTORS; PAPER DIARIES; MIGRAINE; POPULATION; STRESS; PAIN	Objective: In this study, we investigated whether psychological factors were associated with subsequent acute exacerbation of tension-type headache (TTH) in a prospective and ecologically valid manner with computerized ecological momentary assessment. Methods: Eighteen women and five men with TTH wore watch-type computers that acted as an electronic diary for 1 week. The subjects recorded momentary headache intensity, psychological stress, anxiety, and depressive mood with a visual analog scale of 0-100 approximately every 6 h as well as when waking up, when going to bed, and at acute headache exacerbations. Multilevel logistic regression analysis with acute headache exacerbation occurrence as the outcome was conducted. Person-mean centering was applied to psychological factors to disaggregate between- and within-individual association. Results: Momentary psychological stress was associated with subsequent increase in headache exacerbation within 3 h [Odds Ratio (95% CI) = 1.32 (1.07, 1.64) for 10-point increments] while the individual mean of psychological stress was not. Conclusion: These results support the possibility that psychological stress, could trigger acute exacerbations of 1TH. (C) 2015 Elsevier Inc. All rights reserved.	[Kikuchi, Hiroe; Ando, Tetsuya] Natl Inst Mental Hlth, Dept Psychosomat Res, Natl Ctr Neurol & Psychiat, Kodaira, Tokyo 1878553, Japan; [Kikuchi, Hiroe; Yoshiuchi, Kazuhiro] Univ Tokyo, Grad Sch Med, Dept Stress Sci & Psychosomat Med, Tokyo, Japan; [Yamamoto, Yoshiharu] Univ Tokyo, Grad Sch Educ, Educ Physiol Lab, Tokyo, Japan	Kikuchi, H (reprint author), Natl Inst Mental Hlth, Dept Psychosomat Res, Natl Ctr Neurol & Psychiat, 4-1-1 Ogawa Higashi, Kodaira, Tokyo 1878553, Japan.	kikuchih-tky@umin.ac.jp			National Center of Neurology and Psychiatry [20B-7]	This work was partly supported by an Intramural Research Grant (20B-7) for Neurological and Psychiatric Disorders of the National Center of Neurology and Psychiatry (K.Y.).	RASMUSSEN BK, 1993, PAIN, V53, P65, DOI 10.1016/0304-3959(93)90057-V; Spierings ELH, 2001, HEADACHE, V41, P554, DOI 10.1046/j.1526-4610.2001.041006554.x; Zivadinov R, 2003, CEPHALALGIA, V23, P336, DOI 10.1046/j.1468-2982.2003.00544.x; Stone AA, 2002, BRIT MED J, V324, P1193, DOI 10.1136/bmj.324.7347.1193; Lauritsen K, 2004, CONTROL CLIN TRIALS, V25, P585, DOI 10.1016/j.cct.2004.09.001; Leistad RB, 2006, CEPHALALGIA, V26, P64, DOI 10.1111/j.1468-2982.2005.00997.x; Curran PJ, 2011, ANNU REV PSYCHOL, V62, P583, DOI 10.1146/annurev.psych.093008.100356; Cathcart S, 2010, CEPHALALGIA, V30, P285, DOI 10.1111/j.1468-2982.2009.01917.x; CLARK GT, 1995, CEPHALALGIA, V15, P511, DOI 10.1046/j.1468-2982.1995.1506511.x; Fukui I., 1997, JPN J BEHAV THER, V23, P83; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Houle TT, 2012, PAIN, V153, P432; Karli N, 2005, CEPHALALGIA, V25, P444, DOI 10.1111/j.1468-2982.2005.00880.x; Kikuchi H, 2006, CEPHALALGIA, V26, P1335, DOI 10.1111/j.1468-2982.2006.01221.x; Koseoglu E, 2003, CEPHALALGIA, V23, P381, DOI 10.1046/j.1468-2982.2003.00533.x; Marlowe N, 1998, J CLIN PSYCHOL, V54, P247, DOI 10.1002/(SICI)1097-4679(199802)54:2<247::AID-JCLP14>3.0.CO;2-J; Stone Arthur S., 1994, Annals of Behavioral Medicine, V16, P199; Ulrich V, 1996, PAIN, V67, P501, DOI 10.1016/0304-3959(96)03164-8	18	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3999	1879-1360		J PSYCHOSOM RES	J. Psychosomat. Res.	SEP	2015	79	3					239	242		10.1016/j.jpsychores.2015.06.008		4	Psychiatry	Psychiatry	CO6NL	WOS:000359273300012		
J	Cooharojananone, N; Kasamwattanarote, S; Lipikorn, R; Satoh, S				Cooharojananone, Nagul; Kasamwattanarote, Siriwat; Lipikorn, Rajalida; Satoh, Shin'ichi			Automated real-time video surveillance summarization framework	JOURNAL OF REAL-TIME IMAGE PROCESSING			English	Article						Video summarization; Object tracking; Tunnel processing; HOG; Direct shift collision detection; Distance transform; Film map generation; Just-in-time renderer; Dynamic region adaptation; Background subtraction; Foreground extraction		Reviewing video surveillance contents for security monitoring is a time-consuming and time-limiting task. This paper presents a real-time video surveillance summarization framework intended for minimizing the time requirement for time critical tasks, based on compact moving objects in time-space. A tunnel is proposed as an individual time-dimension object. In order to summarize an endless video into a shorter duration without loss of selected targets so as to extend the understanding of any given individual object, this research utilizes three real-time algorithms. Direct shift collision detection (DSCD) is implemented for the extremely fast shifting of tunnels together in time-space. The DSCD summarized video can then be customized by technique from many different approaches. Here, early trajectory searching is applied with the same DSCD technique, and then direct distance transform is used to instantly give the trajectory similarity between tunnels and the user's query. The most important step for identifying each individual object is background subtraction. To this end, dynamic region adaptation (DRA) was used as the background subtraction algorithm to select the best foreground for each object before making a tunnel. DRA also helps DSCD to summarize the video more accurately. The proposed framework is able to provide the results by real-time performance approach without losing the major events of the original video stream.	[Cooharojananone, Nagul; Kasamwattanarote, Siriwat; Lipikorn, Rajalida] Chulalongkorn Univ, Dept Math & Comp Sci, Fac Sci, Bangkok 10330, Thailand; [Satoh, Shin'ichi] Natl Inst Informat, Chiyoda Ku, Tokyo 1018430, Japan	Kasamwattanarote, S (reprint author), Chulalongkorn Univ, Dept Math & Comp Sci, Fac Sci, Bangkok 10330, Thailand.	nagul.c@chula.ac.th; K_siriwatk@hotmail.com; rajalida.l@chula.ac.th; satoh@nii.ac.jp			Thailand Research Fund (TRF); Commission on Higher Education (CHE)	This research was supported by Thailand Research Fund (TRF) and Commission on Higher Education (CHE). The London Gatwick surveillance video files are copyrighted and are provided for research purposes through the TREC Information Retrieval Research Collection, with thanks.	Petrovic N, 2005, MULTIMED TOOLS APPL, V26, P327, DOI 10.1007/s11042-005-0895-9; Pritch Y, 2008, IEEE T PATTERN ANAL, V30, P1971, DOI 10.1109/TPAMI.2008.29; Smith MA, 1997, PROC CVPR IEEE, P775, DOI 10.1109/CVPR.1997.609414; Vlachos M, 2002, PROC INT CONF DATA, P673, DOI 10.1109/ICDE.2002.994784; Dalal N, 2005, PROC CVPR IEEE, P886; Li Z, 2009, IEEE T IMAGE PROCESS, V18, P2572, DOI 10.1109/TIP.2009.2026677; Avidan S., 2007, ACM T GRAPHICS, V26; Berndt D. J., 1996, FINDING PATTERNS TIM, P229; Chen L., 2005, P ACM SIGMOD INT C M, P491, DOI 10.1145/1066157.1066213; Cooharojananone N, 2010, 2010 IEEE 10TH INTERNATIONAL CONFERENCE ON SIGNAL PROCESSING PROCEEDINGS (ICSP2010), VOLS I-III, P932, DOI 10.1109/ICOSP.2010.5655723; Ferman AM, 1997, P SOC PHOTO-OPT INS, V3229, P23, DOI 10.1117/12.290352; Kang H.-W., 2006, P IEEE COMP SOC C CO, V2, P1331; Kasamwattanarote S., 2010, P 11 PAC RIM C ADV M, P136; Kim C., 2000, ACM MULTIMED MM, V1, P303; Peker K. A., 2004, IEEE INT C MULT EXP, V3, P2055; Pelekis N, 2007, INT WORKSHOP TEMPORA, P129; Pritch Y, 2009, AVSS: 2009 6TH IEEE INTERNATIONAL CONFERENCE ON ADVANCED VIDEO AND SIGNAL BASED SURVEILLANCE, P195; Pritch Y., 2007, ICCV, P1; Rav-Acha A., 2006, P IEEE CS C COMP VIS, V1, P435; van Kreveld M., 2007, YOUNG RES FORUM, P229; Vlachos M, 2002, 13TH INTERNATIONAL WORKSHOP ON DATABASE AND EXPERT SYSTEMS APPLICATIONS, PROCEEDINGS, P721	21	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1861-8200	1861-8219		J REAL-TIME IMAGE PR	J. Real-Time Image Process.	SEP	2015	10	3					513	532		10.1007/s11554-012-0280-7		20	Computer Science, Artificial Intelligence; Engineering, Electrical & Electronic; Imaging Science & Photographic Technology	Computer Science; Engineering; Imaging Science & Photographic Technology	CP2ZJ	WOS:000359746300005		
J	Ochi, K; Horiuchi, Y; Horiuchi, K; Iwamoto, T; Morisawa, Y; Sato, K				Ochi, Kensuke; Horiuchi, Yukio; Horiuchi, Koichi; Iwamoto, Takuji; Morisawa, Yasushi; Sato, Kazuki			Shoulder position increases ulnar nerve strain at the elbow of patients with cubital tunnel syndrome	JOURNAL OF SHOULDER AND ELBOW SURGERY			English	Article						Cubital tunnel syndrome; ulnar nerve palsy; nerve strain; shoulder internal rotation; shoulder abduction; elbow flexion test; shoulder internal rotation elbow flexion test; ulnar neuropathy	MEDIAL EPICONDYLECTOMY; FLEXION TEST; EXTRANEURAL PRESSURE; PERIPHERAL-NERVES; DECOMPRESSION; PATHOPHYSIOLOGY; ASSOCIATION; EXCURSION	Background: Previous studies have shown that the shoulder internal rotation elbow flexion (SIREF) test, which is a modified elbow flexion EF) test, has significantly higher sensitivity than the EF test in patients with cubital tunnel syndrome (CubTS). Here, we hypothesized that this increase in sensitivity was due to increase in the ulnar nerve strain around the elbow introduced by the additional shoulder position. Methods: Ulnar nerve strain at the elbow was intraoperatively measured at both the EF test and SIREF test positions in 20 patients with CubTS before simple decompression. Statistical analysis was performed with the Wilcoxon signed rank test at a confidence level of 99% (P < .001). Results: Mean ulnar nerve strain in the EF test position was 18.9% +/- 12.1%, whereas that in the SIREF test position was 24.7% +/- 14.0%. Ulnar nerve strain was higher in the SIREF than in the EF test position in all cases, and the difference was significant (mean, 5.8% +/- 0.9%; 95% confidence interval, 3.90%-7.73%). Conclusion: This study indicated that increased sensitivity in the SIREF test compared with the EF test was due to the increase in ulnar nerve strain around the elbow. To the best of our knowledge, this is the first study showing that shoulder position changes the ulnar nerve strain around the elbow in living patients with CubTS. (C) 2015 Journal of Shoulder and Elbow Surgery Board of Trustees.	[Ochi, Kensuke; Iwamoto, Takuji; Sato, Kazuki] Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, Tokyo 1608582, Japan; [Ochi, Kensuke; Horiuchi, Yukio; Horiuchi, Koichi] Kawasaki Municipal Kawasaki Hosp, Dept Orthopaed Surg, Kawasaki, Kanagawa, Japan; [Morisawa, Yasushi] Saitama Hosp, Natl Hosp Org, Dept Orthopaed Surg, Wako, Saitama, Japan; [Ochi, Kensuke] Tokyo Womens Med Univ, Inst Rheumatol, Dept Orthopaed Surg, Shinjuku Ku, Tokyo, Japan	Ochi, K (reprint author), Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	ochi@1998.jukuin.keio.ac.jp			Japanese Society for Surgery of the Hand [23-1]; Japan Orthopedics and Traumatology Foundation, Inc. [277]	This work was supported in part by an academic research grant from the Japanese Society for Surgery of the Hand (no. 23-1) and the Japan Orthopedics and Traumatology Foundation, Inc. No. 277 to Kensuke Ochi. This study was approved by the Institutional Review Board of Kawasaki Municipal Kawasaki Hospital. However, we do not have a study number because our institute does not provide such numbers for the approval. Koichi Horiuchi is a son of Yukio Horiuchi.	SCHUIND FA, 1995, J HAND SURG-BRIT EUR, V20B, P623, DOI 10.1016/S0266-7681(05)80124-X; Amako M, 2000, J HAND SURG-AM, V25A, P1043, DOI 10.1053/jhsu.2000.17864; Wright TW, 2001, J HAND SURG-AM, V26A, P655, DOI 10.1053/jhsu.2001.26140; ODRISCOLL SW, 1991, J BONE JOINT SURG BR, V73, P613; Palmer BA, 2010, J HAND SURG-AM, V35A, P153, DOI 10.1016/j.jhsa.2009.11.004; Gelberman RH, 1998, J BONE JOINT SURG AM, V80A, P492; Green JR, 1999, J SHOULDER ELB SURG, V8, P466, DOI 10.1016/S1058-2746(99)90078-2; JONES RE, 1979, CLIN ORTHOP RELAT R, P174; Ochi K, 2013, J HAND SURG-EUR VOL, V38, P474, DOI 10.1177/1753193412465234; Iba K, 2006, J HAND SURG-AM, V31A, P553, DOI 10.1016/j.jhsa.2006.01.009; Rempel D, 1999, J BONE JOINT SURG AM, V81A, P1600; Apfelberg D B, 1973, Plast Reconstr Surg, V51, P79; Bozentka DJ, 1998, CLIN ORTHOP RELAT R, P90; BUEHLER MJ, 1988, CLIN ORTHOP RELAT R, P213; Gellman Harris, 2008, Instr Course Lect, V57, P187; Hicks D, 2002, J HAND SURG-AM, V27A, P1026, DOI 10.1053/jhsu.2002.35870; Johnson EW, 1993, PRACTICAL ELECTROMYO, P79; Ochi Kensuke, 2014, Hand Surg, V19, P329, DOI 10.1142/S0218810414500233; Ochi K, 2013, J PLAST SURG HAND SU, V47, P219, DOI 10.3109/2000656X.2012.747962; Ochi K, 2012, J SHOULDER ELB SURG, V21, P777, DOI 10.1016/j.jse.2011.10.015; Ochi K, 2011, J HAND SURG-AM, V36A, P782, DOI 10.1016/j.jhsa.2010.12.019; Ochi K, 2010, J HAND SURG-EUR VOL, V35E, P767, DOI 10.1177/1753193410379559; Ochi K, 2011, J HAND SURG-AM, V36A, P216, DOI 10.1016/j.jhsa.2010.11.013; Toby EB, 1998, J HAND SURG-AM, V23A, P992, DOI 10.1016/S0363-5023(98)80005-1; WILGIS EFS, 1986, HAND CLIN, V2, P761	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	1058-2746			J SHOULDER ELB SURG	J. Shoulder Elbow Surg.	SEP	2015	24	9					1380	1385		10.1016/j.jse.2015.01.014		6	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CO9LI	WOS:000359496900011		
J	Onoue, H; Muraoka, K; Yamaguchi, F				Onoue, Hidetoshi; Muraoka, Kunihide; Yamaguchi, Fumihiko			Posterior coronal shear fracture of the distal humerus in a child	JOURNAL OF SHOULDER AND ELBOW SURGERY			English	Article							INTERNAL-FIXATION; OPEN REDUCTION; CAPITULUM HUMERI; CAPITELLAR		[Onoue, Hidetoshi] Fukuoka Tokushukai Med Ctr, Dept Orthopaed Surg, Kasuga, Fukuoka 8160864, Japan; [Muraoka, Kunihide] Fukuoka Univ, Fac Med, Dept Orthopaed Surg, Fukuoka 81401, Japan; [Yamaguchi, Fumihiko] Fukuoka Rehabil Hosp, Dept Orthopaed Surg, Fukuoka, Japan	Onoue, H (reprint author), Fukuoka Tokushukai Med Ctr, Dept Orthopaed Surg, 4-5 Suku Kita, Kasuga, Fukuoka 8160864, Japan.	hideonou@csf.ne.jp					Ring D, 2003, J BONE JOINT SURG AM, V85A, P232; McKee MD, 1996, J BONE JOINT SURG AM, V78A, P49; Dubberley JH, 2006, J BONE JOINT SURG AM, V88A, P46, DOI 10.2106/JBJS.D.02954; Bryan RS, 1985, ELBOW ITS DISORDERS, P302; FOWLES JV, 1974, J BONE JOINT SURG AM, VA 56, P794; HARALDSSON S, 1959, Acta Orthop Scand Suppl, V38, P1; James BH, 2010, ROCKWOOD WILKINS FRA; KEATS TE, 1966, RADIOLOGY, V87, P904; Letts M, 1997, J PEDIATR ORTHOPED, V17, P315, DOI 10.1097/00004694-199705000-00009; Marsh JL, 2007, J ORTHOP TRAUMA S, V21, pS1, DOI DOI 10.1097/00005131-200711101-00001; Mohan N, 2000, J BONE JOINT SURG BR, V82B, P643, DOI 10.1302/0301-620X.82B5.10435; JOHANSSON J, 1980, CLIN ORTHOP RELAT R, P157; Ruchelsman DE, 2009, J BONE JOINT SURG AM, V91A, P38, DOI 10.2106/JBJS.H.01195	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	1058-2746			J SHOULDER ELB SURG	J. Shoulder Elbow Surg.	SEP	2015	24	9					E264	E270		10.1016/j.jse.2015.06.002		7	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CO9LI	WOS:000359496900004		
J	Nishida, N; Kanchiku, T; Kato, Y; Imajo, Y; Yoshida, Y; Kawano, S; Taguchi, T				Nishida, Norihiro; Kanchiku, Tsukasa; Kato, Yoshihiko; Imajo, Yasuaki; Yoshida, Yuichiro; Kawano, Syunichi; Taguchi, Toshihiko			Cervical ossification of the posterior longitudinal ligament: Biomechanical analysis of the influence of static and dynamic factors	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Cervical myelopathy; Dynamic factor; Finite element method; Static factor; Ossification of the posterior longitudinal ligament	SPINAL-CORD-INJURY; SPONDYLOTIC MYELOPATHY; GRAY-MATTER; PATHOGENESIS; LAMINOPLASTY; COMPRESSION; MECHANISM; FEATURES; WHITE; MODEL	Objective: Cervical myelopathy due to ossification of the posterior longitudinal ligament (OPLL) is induced by static factors, dynamic factors, or a combination of both. We used a three-dimensional finite element method (3D-FEM) to analyze the stress distributions in the cervical spinal cord under static compression, dynamic compression, or a combination of both in the context of OPLL. Methods: Experimental conditions were established for the 3D-FEM spinal cord, lamina, and hill-shaped OPLL. To simulate static compression of the spinal cord, anterior compression at 10, 20, and 30% of the anterior-posterior diameter of the spinal cord was applied by the OPLL. To simulate dynamic compression, the OPLL was rotated 5 degrees, 10 degrees, and 15 degrees in the flexion direction. To simulate combined static and dynamic compression under 10 and 20% anterior static compression, the OPLL was rotated 5 degrees, 10 degrees, and 15 degrees in the flexion direction. Results: The stress distribution in the spinal cord increased following static and dynamic compression by cervical OPLL. However, the stress distribution did not increase throughout the entire spinal cord. For combined static and dynamic compression, the stress distribution increased as the static compression increased, even for a mild range of motion (ROM). Conclusion: Symptoms may appear under static or dynamic compression only. However, under static compression, the stress distribution increases with the ROM of the responsible level and this makes it very likely that symptoms will worsen. We conclude that cervical OPLL myelopathy is induced by static factors, dynamic factors, and a combination of both.	[Nishida, Norihiro; Kanchiku, Tsukasa; Kato, Yoshihiko; Imajo, Yasuaki; Yoshida, Yuichiro; Kawano, Syunichi; Taguchi, Toshihiko] Yamaguchi Univ, Grad Sch Med, Dept Orthoped Surg, Ube, Yamaguchi 7558505, Japan	Nishida, N (reprint author), Yamaguchi Univ, Grad Sch Med, Dept Orthoped Surg, 1-1-1 Minamikogushi, Ube, Yamaguchi 7558505, Japan.	nishida3@yamaguchi-u.ac.jp					Iwasaki M, 2007, SPINE, V32, P647, DOI 10.1097/01.brs.0000257560.91147.86; Matsunaga S, 2002, J NEUROSURG, V96, P168, DOI 10.3171/spi.2002.96.2.0168; Li XF, 2010, SPINE, V35, pE955, DOI 10.1097/BRS.0b013e3181c94cb8; Matsunaga S, 2002, J NEUROSURG, V97, P172, DOI 10.3171/spi.2002.97.2.0172; Morio Y, 1999, SPINAL CORD, V37, P853, DOI 10.1038/sj.sc.3100940; Henderson FC, 2005, NEUROSURGERY, V56, P1101, DOI 10.1227/01.NEU.0000157929.85251.7C; Li XF, 2009, SPINE, V34, P1140, DOI 10.1097/BRS.0b013e31819e2af1; Kato Y, 2010, J NEUROSURG-SPINE, V12, P301, DOI 10.3171/2009.9.SPINE09314; Matsunaga S, 2008, SPINE, V33, P2648, DOI 10.1097/BRS.0b013e31817f988c; Masaki Y, 2007, J SPINAL DISORD TECH, V20, P7, DOI 10.1097/01.bsd.0000211260.28497.35; Fujiyoshi T, 2010, J CLIN NEUROSCI, V17, P320, DOI 10.1016/j.jocn.2009.06.023; Nishida N, 2011, J SPINAL CORD MED, V34, P518, DOI 10.1179/2045772311Y.0000000029; Ichihara K, 2001, J NEUROTRAUM, V18, P361, DOI 10.1089/08977150151071053; OGINO H, 1983, SPINE, V8, P1, DOI 10.1097/00007632-198301000-00001; Azuma Y, 2010, J SPINAL DISORD TECH, V23, P166, DOI 10.1097/BSD.0b013e31819e9066; Cecilia P, 2011, J NEUROTRAUM, V28, P113; Ichihara K, 2003, J NEUROSURG, V99, P278, DOI 10.3171/spi.2003.99.3.0278; Kato Y, 2008, J NEUROSURG-SPINE, V8, P436, DOI 10.3171/SPI/2008/8/5/436; Kato Y, 2009, J SPINAL CORD MED, V32, P555; Koyanagi I, 2004, SURG NEUROL, V62, P286, DOI 10.1016/j.surneu.2003.12.015; Nishida N, 2013, EXP THER MED, V6, P1184, DOI 10.3892/etm.2013.1286; Nishida N, 2012, J SPINAL CORD MED, V35, P256, DOI 10.1179/2045772312Y.0000000024; ONO K, 1977, Spine, V2, P109, DOI 10.1097/00007632-197706000-00004; TUNTURI AR, 1978, J NEUROSURG, V48, P975, DOI 10.3171/jns.1978.48.6.0975	24	0	0	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	SEP	2015	38	5					593	598		10.1179/2045772314Y.0000000221		6	Clinical Neurology	Neurosciences & Neurology	CP4OP	WOS:000359862100006		
J	Arishima, H; Tada, A; Isozaki, M; Kitai, R; Kodera, T; Kikuta, K; Tai, K; Iwasaki, H				Arishima, Hidetaka; Tada, Ayumi; Isozaki, Makoto; Kitai, Ryuhei; Kodera, Toshiaki; Kikuta, Ken-ichiro; Tai, Katsunori; Iwasaki, Hiromichi			Spontaneous spinal epidural hematoma in a patient with acquired Factor X deficiency secondary to systemic amyloid light-chain amyloidosis	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Amyloidosis; Factor X deficiency; Prothrombin complex concentrate; Spinal cord; Spontaneous spinal epidural hematoma	PROTHROMBIN COMPLEX CONCENTRATE; REVERSAL	Background: Spontaneous spinal epidural hematoma (SSEH) is relatively rare. SSEH with anticoagulants including warfarin and rivaroxaban (Factor Xa inhibitor) have been reported; however, SSEH with Factor X deficiency has not been described yet. Methods: Case report. Findings: An 82-year-old woman with acquired Factor X deficiency complained of sudden onset of severe posterior neck pain. Magnetic resonance imaging demonstrated an epidural hematoma from C3 to T3 levels. Because she showed tetraparesis on the third hospital day, we performed surgery. Just before surgery, her prothrombin time-international normalized ratio was 2.49, which was immediately reversed by infusion of prothrombin complex concentrate. The patient safely underwent an emergency laminectomy from C3 to T2, in which the epidural hematoma was evacuated. Post-operatively, the patient recovered completely without rebleeding. Hematologists found acquired deficiency of Factor X in this patient with systemic amyloid light-chain amyloidosis. Conclusion: To our knowledge, this is the first report of a case of SSEH with Factor X deficiency. A blood coagulation disorder should be considered in patients with SSEH.	[Arishima, Hidetaka; Tada, Ayumi; Isozaki, Makoto; Kitai, Ryuhei; Kodera, Toshiaki; Kikuta, Ken-ichiro] Univ Fukui, Dept Neurosurg, Eiheiji, Fukui 9101193, Japan; [Tai, Katsunori; Iwasaki, Hiromichi] Univ Fukui, Dept Med, Div Hematol & Oncol, Eiheiji, Fukui 9101193, Japan	Arishima, H (reprint author), Univ Fukui, Dept Neurosurg, 23-3 Matsuokashimoaizuki, Eiheiji, Fukui 9101193, Japan.	ari@u-fukui.ac.jp					Bowles L, 2009, HAEMOPHILIA, V15, P401, DOI 10.1111/j.1365-2516.2008.01878.x; Peacock WF, 2012, CLIN CARDIOL, V35, P730, DOI 10.1002/clc.22037; ROSE KD, 1990, NEUROSURGERY, V26, P880; Holtas S, 1996, RADIOLOGY, V199, P409; Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017; GROEN RJM, 1990, J NEUROL SCI, V98, P121, DOI 10.1016/0022-510X(90)90253-J; Menegatti M, 2009, SEMIN THROMB HEMOST, V35, P407, DOI 10.1055/s-0029-1225763; Enjeti AK, 2005, HAEMOPHILIA, V11, P535, DOI 10.1111/j.1365-2516.2005.01125.x; Fukuda T, 2012, THROMB HAEMOSTASIS, V107, P253, DOI 10.1160/TH11-09-0668; Makris M, 2010, J THROMB THROMBOLYS, V29, P171, DOI 10.1007/s11239-009-0412-5; Lee G, 2012, HAEMOPHILIA, V18, P655, DOI 10.1111/j.1365-2516.2012.02773.x; Jaeger M, 2012, Eur Spine J, V21 Suppl 4, pS433, DOI 10.1007/s00586-011-2003-3; Kirazli Y, 2004, AM J PHYS MED REHAB, V83, P220, DOI 10.1097/01.PHM.0000107498.91919.44; Scott LJ, 2009, DRUGS, V69, P1977, DOI 10.2165/11203690-000000000-00000	14	0	0	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	SEP	2015	38	5					641	644		10.1179/2045772314Y.0000000230		4	Clinical Neurology	Neurosciences & Neurology	CP4OP	WOS:000359862100011		
J	Chen, T; Narazaki, K; Honda, T; Chen, S; Haeuchi, Y; Nofuji, YY; Matsuo, E; Kumagai, S				Chen, Tao; Narazaki, Kenji; Honda, Takanori; Chen, Sanmei; Haeuchi, Yuki; Nofuji, Yu Y.; Matsuo, Eri; Kumagai, Shuzo			Tri-Axial Accelerometer-Determined Daily Physical Activity and Sedentary Behavior of Suburban Community-Dwelling Older Japanese Adults	JOURNAL OF SPORTS SCIENCE AND MEDICINE			English	Article						Tri-axial accelerometer; physical activity; sedentary behavior; community-based study; older adults	ENERGY-EXPENDITURE; INTENSITY; POPULATION; HEALTH; ASSOCIATION; CHALLENGES; VALIDITY; SCIENCE; DISEASE; CARE	Knowledge regarding accelerometer-derived physical activity (PA) and sedentary behavior (SED) levels is scarce for Japanese older adults. The aims of this study were therefore to 1) describe levels of PA and SED in Japanese community-dwelling older adults, using tri-axial accelerometer; 2) examine the variation of PA and SED with respect to sex, age, and body mass index (BMI). Participants of this study were from the baseline survey of the Sasaguri Genkimon Study, who were 65 years or older and not certified as those requiring long-term care. PA was assessed objectively for seven consecutive days using tri-axial accelerometer. A total of 1,739 participants (median age: 72 years, men: 38.0%) with valid PA data were included. Overall, participants in the present study spent 54.5% of their waking time being sedentary and 45.5% being active, of which 5.4% was moderate-to-vigorous physical activity (MVPA). Women accumulated more minutes of light physical activity (LPA) and MVPA compared with men. In contrast, men spent more time being sedentary. Mean steps per day did not differ between sexes. Furthermore, participants with higher BMI (BMI >= 25) had lower PA levels, and longer SED compared with those with lower BMI (BMI <25). PA levels were lower and SED was longer with age. The present study is the first to demonstrate that the levels of PA and SED differed by sex, age, and BMI in Japanese community-dwelling older adults. In particular, women were more active compared with men, providing unique insight into the current level of PA in older adults. Data presented in the study will enable further investigation of additional determinants of PA and SED in order to develop effective population-based intervention strategies to promote PA and reduce prolonged SED in the Japanese population and possibly other rapidly aging societies.	[Chen, Tao; Honda, Takanori; Chen, Sanmei; Haeuchi, Yuki; Kumagai, Shuzo] Kyushu Univ, Grad Sch Human Environm Studies, Dept Behav & Hlth Sci, Fukuoka 812, Japan; [Narazaki, Kenji] Fukuoka Univ, Cent Res Inst Phys Act, Fukuoka 81401, Japan; [Nofuji, Yu Y.; Matsuo, Eri] Tokyo Metropolitan Inst Gerontol, Tokyo, Japan; [Kumagai, Shuzo] Kyushu Univ, Fac Arts & Sci, Fukuoka 812, Japan	Kumagai, S (reprint author), Kyushu Univ, Grad Sch Human Environm Studies, Dept Behav & Hlth Sci, Fukuoka 812, Japan.	chentwhy@gmail.com; knarazaki@fukuoka-u.ac.jp; honda-t@students.ihs.kyushu-u.ac.jp; chensanmei1987@hotmail.com; yuka_haeuchi@yahoo.co.jp; uyujifuno77@gmail.com; ematsuo@tmig.or.jp; shuzo@ihs.kyushu-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [22240073]; Health and Labour Sciences Research Grants of the Ministry of Health, Labour and Welfare of Japan, Comprehensive Research on Dementia [H25-Ninchisho-Ippan-004]; Sasaguri town, Fukuoka, Japan	We are grateful for the support of the municipal staff of Sasaguri town, especially of Ms. Kumiko Gunjima who helped us coordinate the study. The present study was supported in part by Grants-in-Aid for Scientific Research for Scientific Research (A) (22240073) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by Health and Labour Sciences Research Grants of the Ministry of Health, Labour and Welfare of Japan, Comprehensive Research on Dementia: H25-Ninchisho-Ippan-004, and by a research grant from Sasaguri town, Fukuoka, Japan. As financial sponsors, they had no role in the study design, data analysis, data interpretation, writing of the manuscript or in the decision to submit the manuscript.	Biswas A, 2015, ANN INTERN MED, V162, P123, DOI 10.7326/M14-1651; Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Ohkawara K, 2011, BRIT J NUTR, V105, P1681, DOI 10.1017/S0007114510005441; Meijer EP, 2001, INT J OBESITY, V25, P935, DOI 10.1038/sj.ijo.0801644; Nelson ME, 2007, CIRCULATION, V116, P1094, DOI 10.1161/CIRCULATIONAHA.107.185650; Yasunaga A, 2008, J AGING PHYS ACTIV, V16, P3; Davis MG, 2011, MED SCI SPORT EXER, V43, P647, DOI 10.1249/MSS.0b013e3181f36196; Hendelman D, 2000, MED SCI SPORT EXER, V32, pS442, DOI 10.1097/00005768-200009001-00002; Bassett DR, 2000, MED SCI SPORT EXER, V32, pS471, DOI 10.1097/00005768-200009001-00006; Owen N, 2010, EXERC SPORT SCI REV, V38, P105, DOI 10.1097/JES.0b013e3181e373a2; Oshima Y, 2010, GAIT POSTURE, V31, P370, DOI 10.1016/j.gaitpost.2010.01.005; Crouter SE, 2006, EUR J APPL PHYSIOL, V98, P601, DOI 10.1007/s00421-006-0307-5; Lee IM, 2014, BRIT J SPORT MED, V48, P197, DOI 10.1136/bjsports-2013-093154; Freedson PS, 1998, MED SCI SPORT EXER, V30, P777, DOI 10.1097/00005768-199805000-00021; Arnardottir NY, 2013, AGE AGEING, V42, P222, DOI 10.1093/ageing/afs160; Hansen BH, 2012, MED SCI SPORT EXER, V44, P266, DOI 10.1249/MSS.0b013e31822cb354; Tudor-Locke C, 2013, J GERONTOL A-BIOL, V68, P1426, DOI 10.1093/gerona/glt116; Buman MP, 2010, AM J EPIDEMIOL, V172, P1155, DOI 10.1093/aje/kwq249; Tsutsui T, 2005, J AM GERIATR SOC, V53, P522, DOI 10.1111/j.1532-5415.2005.53175.x; Tamiya N, 2011, LANCET, V378, P1183, DOI 10.1016/S0140-6736(11)61176-8; Brawley LR, 2003, AM J PREV MED, V25, P172, DOI 10.1016/S0749-3797(03)00182-X; Copeland JL, 2009, J AGING PHYS ACTIV, V17, P17; Chomistek AK, 2013, J AM COLL CARDIOL, V61, P2346, DOI 10.1016/j.jacc.2013.03.031; Colbert LH, 2014, J AGING PHYS ACTIV, V22, P571, DOI [10.1123/japa.2012-0257, 10.1123/JAPA.2012-0257]; Evenson KR, 2012, PREV CHRONIC DIS, V9, P1; Jefferis BJ, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-382; Kobayashi T., 2011, 2010 NHK JAPANESE TI; Koster A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037696; Kowalski K, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-148; Lohne-Seiler H, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-284; Midorikawa T, 2007, OBESITY, V15, P3031, DOI 10.1038/oby.2007.361; Narazaki K, 2013, NEUROEPIDEMIOLOGY, V40, P23, DOI 10.1159/000339753; Narazaki K, 2014, J SPORT SCI MED, V13, P590; Osuka Y, 2015, GERIATR GERONTOL INT, V15, P268, DOI 10.1111/ggi.12268; Shephard RJ, 2003, BRIT J SPORT MED, V37, P197, DOI 10.1136/bjsm.37.3.197; Wilcox S., 2002, GENDER PHYS ACTIVITY, P13	36	0	0	JOURNAL SPORTS SCIENCE & MEDICINE	BURSA	MEDICAL FACULTY ULUDAG UNIV, DEPT SPORTS MEDICINE, BURSA, 16059, TURKEY	1303-2968			J SPORT SCI MED	J. Sport. Sci. Med.	SEP	2015	14	3					507	514				8	Sport Sciences	Sport Sciences	CO9KM	WOS:000359494700005		
J	Suwa, M; Nakano, H; Radak, Z; Kumagai, S				Suwa, Masataka; Nakano, Hiroshi; Radak, Zsolt; Kumagai, Shuzo			Effects of Nitric Oxide Synthase Inhibition on Fiber-Type Composition, Mitochondrial Biogenesis, and SIRT1 Expression in Rat Skeletal Muscle	JOURNAL OF SPORTS SCIENCE AND MEDICINE			English	Article						Mitochondrial biogenesis; muscle fiber composition; nitric oxide; nitric oxide synthase; silent information regulator of transcription 1	GLUCOSE-UPTAKE; EXERCISE INCREASES; BLOOD-FLOW; IN-VIVO; PGC-1-ALPHA; CONTRACTION; OXIDATION; AICAR; ENOS; METABOLISM	It was hypothesized that nitric oxide synthases (NOS) regulated SIRT1 expression and lead to a corresponding changes of contractile and metabolic properties in skeletal muscle. The purpose of the present study was to investigate the influence of longterm inhibition of nitric oxide synthases (NOS) on the fiber-type composition, metabolic regulators such as and silent information regulator of transcription 1 (SIRT1) and peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha), and components of mitochondrial biogenesis in the soleus and plantaris muscles of rats. Rats were assigned to two groups: control and NOS inhibitor (N-omega-nitro-L-arginine methyl ester hydrochloride (L-NAME), ingested for 8 weeks in drinking water)-treated groups. The percentage of Type I fibers in the L-NAME group was significantly lower than that in the control group, and the percentage of Type IIA fibers was concomitantly higher in soleus muscle. In plantaris muscle, muscle fiber composition was not altered by L-NAME treatment. L-NAME treatment decreased the cytochrome C protein expression and activity of mitochondrial oxidative enzymes in the plantaris muscle but not in soleus muscle. NOS inhibition reduced the SIRT1 protein expression level in both the soleus and plantaris muscles, whereas it did not affect the PGC-1 alpha protein expression. L-NAME treatment also reduced the glucose transporter 4 protein expression in both muscles. These results suggest that NOS plays a role in maintaining SIRT1 protein expression, muscle fiber composition and components of mitochondrial biogenesis in skeletal muscle.	[Suwa, Masataka] Tohoku Inst Technol, Fac Life Design, Taihaku Ku, Sendai, Miyagi 982, Japan; [Nakano, Hiroshi] Nakamura Gakuen Univ, Fac Educ, Jonan Ku, Fukuoka, Japan; [Radak, Zsolt] Semmelweis Univ, Inst Sport Sci, Fac Phys Educ & Sport Sci, H-1085 Budapest, Hungary; [Kumagai, Shuzo] Kyushu Univ, Fac Arts & Sci, Kasuga, Fukuoka 8168580, Japan; [Kumagai, Shuzo] Kyushu Univ, Grad Sch Human Environm Studies, Kasuga, Fukuoka 8168580, Japan	Kumagai, S (reprint author), Kyushu Univ, Fac Arts & Sci, Kasuga, Fukuoka 8168580, Japan.	suwa-m@tohtech.ac.jp; nakahi@nakamura-u.ac.jp; radak@tf.hu; shuzo@ihs.kyushu-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [20700524]	This work was supported by a Grant-in-Aid for Young Scientists from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 20700524) to MS.	Lau KS, 2000, PHYSIOL GENOMICS, V2, P21; Smith LW, 2002, J APPL PHYSIOL, V92, P2005, DOI 10.1152/japplphysiol.00950.2001; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Calabria E, 2009, P NATL ACAD SCI USA, V106, P13335, DOI 10.1073/pnas.0812911106; Suwa M, 2008, METABOLISM, V57, P986, DOI 10.1016/j.metabol.2008.02.017; Toledo JC, 2012, CHEM RES TOXICOL, V25, P975, DOI 10.1021/tx300042g; Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101; BALON TW, 1994, J APPL PHYSIOL, V77, P2519; Stamler JS, 2001, PHYSIOL REV, V81, P209; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Higaki Y, 2001, DIABETES, V50, P241, DOI 10.2337/diabetes.50.2.241; GOLLNICK PD, 1972, J APPL PHYSIOL, V33, P312; Sellman JE, 2006, J APPL PHYSIOL, V100, P258, DOI 10.1152/japplphysiol.00936.2005; Le Gouill E, 2007, DIABETES, V56, P2690, DOI 10.2337/db06-1228; LAUGHLIN MH, 1982, AM J PHYSIOL, V243, pH296; Drenning JA, 2008, AM J PHYSIOL-CELL PH, V294, pC1088, DOI 10.1152/ajpcell.00523.2007; Wadley GD, 2007, J PHYSIOL-LONDON, V585, P253, DOI 10.1113/jphysiol.2007.141309; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Meissner JD, 2007, J CELL PHYSIOL, V211, P138, DOI 10.1002/jcp.20916; Gurd BJ, 2011, AM J PHYSIOL-REG I, V301, pR67, DOI 10.1152/ajpregu.00417.2010; Benton CR, 2008, J BIOL CHEM, V283, P4228, DOI 10.1074/jbc.M704332200; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Boutant Marie, 2014, Mol Metab, V3, P5, DOI 10.1016/j.molmet.2013.10.006; Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076; Lira VA, 2010, J PHYSIOL-LONDON, V588, P3551, DOI 10.1113/jphysiol.2010.194035; Lira VA, 2007, AM J PHYSIOL-ENDOC M, V293, pE1062, DOI 10.1152/ajpendo.00045.2007; Martins KJB, 2012, J PHYSIOL-LONDON, V590, P1427, DOI 10.1113/jphysiol.2011.223370; McConell GK, 2010, J APPL PHYSIOL, V108, P589, DOI 10.1152/japplphysiol.00377.2009; McConell GK, 2012, AM J PHYSIOL-ENDOC M, V303, pE301, DOI 10.1152/ajpendo.00667.2011; Merry TL, 2010, AM J PHYSIOL-REG I, V299, pR1656, DOI 10.1152/ajpregu.00433.2010; Ojuka EO, 2000, J APPL PHYSIOL, V88, P1072; Pereira Sant'Ana JA, 1997, PFLUGERS ARCH, V435, P151; Punkt K, 2006, HISTOCHEM CELL BIOL, V125, P567, DOI 10.1007/s00418-005-0108-7; Roberts CK, 1999, AM J PHYSIOL-ENDOC M, V277, pE390; Ross RM, 2007, DIABETES, V56, P2885, DOI 10.2337/db07-0745; Schild Lorenz, 2006, FASEB J, V20, P145; Suwa M, 2003, J APPL PHYSIOL, V94, P185, DOI 10.1152/japplphysiol.00295.2002; Suwa M, 2002, INT J OBESITY, V26, P830, DOI 10.1038/sj.ijo.0802007; Suwa M, 2011, METABOLISM, V60, P394, DOI 10.1016/j.metabol.2010.03.003; Suwa M, 2015, J PHYSIOL SCI, V65, P121, DOI 10.1007/s12576-014-0349-0; Wadley GD, 2007, J APPL PHYSIOL, V102, P314, DOI 10.1152/japplphysiol.00549.2006; Wang MX, 2001, NITRIC OXIDE-BIOL CH, V5, P219, DOI 10.1006/niox.2001.0348	46	0	0	JOURNAL SPORTS SCIENCE & MEDICINE	BURSA	MEDICAL FACULTY ULUDAG UNIV, DEPT SPORTS MEDICINE, BURSA, 16059, TURKEY	1303-2968			J SPORT SCI MED	J. Sport. Sci. Med.	SEP	2015	14	3					548	555				8	Sport Sciences	Sport Sciences	CO9KM	WOS:000359494700010		
J	Taufiq, A; Sunaryono; Putra, EGR; Okazawa, A; Watanabe, I; Kojima, N; Pratapa, S; Darminto				Taufiq, Ahmad; Sunaryono; Putra, Edy Giri Rachman; Okazawa, Atsushi; Watanabe, Isao; Kojima, Norimichi; Pratapa, Suminar; Darminto			Nanoscale Clustering and Magnetic Properties of Mn (x) Fe3-x O-4 Particles Prepared from Natural Magnetite	JOURNAL OF SUPERCONDUCTIVITY AND NOVEL MAGNETISM			English	Article						Nanoclusters; MnxFe3-xO4; Coprecipitation; Saturation magnetization; Blocking temperature; Natural magnetite	IRON-OXIDE NANOPARTICLES; FE3O4 NANOPARTICLES; COPRECIPITATION METHOD; HYPERTHERMIA APPLICATIONS; BIOMEDICAL APPLICATIONS; ZNFE2O4 NANOPARTICLES; FERRITE NANOPARTICLES; SUBSTITUTION; FERROFLUIDS; SCATTERING	A series of Mn (x) Fe3-x O-4 (0 a parts per thousand currency sign x a parts per thousand currency sign 1) nanoparticles was successfully synthesized via a simple coprecipitation method. The starting material was a natural magnetite purified from local iron sand. Crystallite nanoparticles were produced by drying without using a high calcination temperature. Rietveld analysis of the X-ray diffractometry (XRD) data for all samples demonstrated that the Mn ions partially substituted the Fe ions in the spinel cubic structure of the Fe3O4 to form Mn (x) Fe3-x O-4 phases. We applied two lognormal spherical and single mass fractal models to the analysis of the small-angle neutron scattering (SANS) data and revealed that the primary Mn (x) Fe3-x O-4 particles ranged in size from 1.5 to 3.8 nm and formed three-dimensional clusters as secondary structures. The samples displayed superparamagnetic behavior, having the saturation magnetization which was most likely influenced by the competing contribution from Mn, the sizes of the primary particles, and their clusters. Further analysis revealed that the zero-field-cooled and field-cooled curves of the Mn (x) Fe3-x O-4 nanoclusters exhibited a superparamagnetic phenomenon with the lowest magnetic blocking temperature approximately 145 K.	[Taufiq, Ahmad; Sunaryono; Pratapa, Suminar; Darminto] Sepuluh Nopember Inst Technol ITS, Fac Math & Nat Sci, Dept Phys, Surabaya 60111, Indonesia; [Taufiq, Ahmad; Sunaryono] State Univ Malang UM, Fac Math & Nat Sci, Dept Phys, Malang 65145, Indonesia; [Putra, Edy Giri Rachman] Natl Nucl Agcy Indonesia BATAN, Ctr Sci & Technol Adv Mat, Tangerang 15314, Indonesia; [Okazawa, Atsushi; Kojima, Norimichi] Univ Tokyo, Grad Sch Arts & Sci, Dept Basic Sci, Tokyo 1538902, Japan; [Watanabe, Isao] RIKEN, Nishina Ctr, Adv Meson Sci Lab, Wako, Saitama 3510198, Japan	Darminto (reprint author), Sepuluh Nopember Inst Technol ITS, Fac Math & Nat Sci, Dept Phys, Surabaya 60111, Indonesia.	darminto@physics.its.ac.id	okazawa, atsushi/O-7339-2015		BPPS Program from the Ministry of Education and Culture, Republic of Indonesia; PKPI Program from the Ministry of Education and Culture, Republic of Indonesia; Penelitian Disertasi Doktor; "Hibah Kompetensi" of DP2M, Ditjen DIKTI	The authors would like to thank Dr. Mauro Porcu for the HRTEM characterization and the University of Tokyo, the RIKEN Nishina Center Japan, and the Neutron Scattering Laboratory at BATAN Serpong for the use of their characterization facilities. This research was partially supported by the BPPS and PKPI Programs from the Ministry of Education and Culture, Republic of Indonesia (A.T. and S.), "Penelitian Disertasi Doktor" (A.T.), and also "Hibah Kompetensi" of DP2M, Ditjen DIKTI, 2013-2015 (D.).	Akbarzadeh A, 2012, NANOSCALE RES LETT, V7, P1, DOI 10.1186/1556-276X-7-144; Amighian J, 2013, J MAGN MAGN MATER, V332, P157, DOI 10.1016/j.jmmm.2012.12.005; Amirabadizadeh A, 2012, J SUPERCOND NOV MAGN, V25, P2763, DOI 10.1007/s10948-011-1259-5; Caruntu D, 2007, J PHYS D APPL PHYS, V40, P5801, DOI 10.1088/0022-3727/40/19/001; Raj BGS, 2015, ELECTROCHIM ACTA, V156, P127, DOI 10.1016/j.electacta.2015.01.052; Shtykova EV, 2007, J PHYS CHEM C, V111, P18078, DOI 10.1021/jp075235c; Putra EGR, 2009, NUCL INSTRUM METH A, V600, P198, DOI 10.1016/j.nima.2008.11.129; WICKHAM DG, 1969, J INORG NUCL CHEM, V31, P313, DOI 10.1016/0022-1902(69)80474-4; Ahalya K, 2014, J MAGN MAGN MATER, V372, P208, DOI 10.1016/j.jmmm.2014.07.030; Liu XD, 2015, MATER RES BULL, V62, P217, DOI 10.1016/j.materresbull.2014.11.022; Doaga A, 2013, MATER CHEM PHYS, V143, P305, DOI 10.1016/j.matchemphys.2013.08.066; Ding YL, 2015, MAT SCI ENG C-MATER, V48, P487, DOI 10.1016/j.msec.2014.12.036; Goya GF, 2003, J APPL PHYS, V94, P3520, DOI 10.1063/1.1599959; Petosa AR, 2010, ENVIRON SCI TECHNOL, V44, P6532, DOI 10.1021/es100598h; Tang SCN, 2013, WATER RES, V47, P2613, DOI 10.1016/j.watres.2013.02.039; Shete PB, 2015, J MAGN MAGN MATER, V377, P406, DOI 10.1016/j.jmmm.2014.10.137; Carta D, 2009, J PHYS CHEM C, V113, P8606, DOI 10.1021/jp901077c; Martinez-Mera I, 2007, MATER LETT, V61, P4447, DOI 10.1016/j.matlet.2007.02.018; Lopez J, 2012, J MAGN MAGN MATER, V324, P394, DOI 10.1016/j.jmmm.2011.07.040; Sharifi I, 2012, J MAGN MAGN MATER, V324, P903, DOI 10.1016/j.jmmm.2011.10.017; Giri J, 2008, J MAGN MAGN MATER, V320, P724, DOI 10.1016/j.jmmm.2007.08.010; Ghaemi N, 2015, CHEM ENG J, V263, P101, DOI 10.1016/j.cej.2014.10.103; Rameshbabu R, 2014, J SUPERCOND NOV MAGN, V27, P1499, DOI 10.1007/s10948-013-2466-z; Bajpai AK, 2013, B MATER SCI, V36, P15, DOI 10.1007/s12034-013-0432-9; Cullity B. D., 2008, INTRO MAGNETIC MAT; Darminto, 2011, AIP C P, P234; Dewhurst C., 2001, GRASANSP GRAPHICAL R; Dutta P, 2009, J APPL PHYS, V105, DOI 10.1063/1.3055272; Gadhvi M, 2004, B MATER SCI, V27, P163, DOI 10.1007/BF02708499; Gamarra LF, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/11/115104; Kim B, 2013, NANOSCALE RES LETT, V8, P1, DOI 10.1186/1556-276X-8-104; Kohlbrecher J., 2011, SOFTWARE PACKAGE SAS; Li ML, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-204; Li YH, 2012, J APPL PHYS, V111, DOI 10.1063/1.3687007; Linh PH, 2014, J SUPERCOND NOV MAGN, V27, P2111, DOI 10.1007/s10948-014-2561-9; Mazo-Zuluaga J., 2008, J APPL PHYS, V103; Meidanchi A, 2015, MAT SCI ENG C-MATER, V46, P394, DOI 10.1016/j.msec.2014.10.062; Niu J. M., 2014, Advanced Materials Research, V900, DOI 10.4028/www.scientific.net/AMR.900.172; Paula FLO, 2007, J APPL CRYSTALLOGR, V40, pS269, DOI 10.1107/S0021889807009181; Pratapa S, 2010, AIP CONF PROC, V1284, P125, DOI 10.1063/1.3515533; Putra E.G.R., 2010, J PHYS C SER, V247; Rumpf K, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-445; Saravanan P, 2002, J MATER SCI LETT, V21, P1135, DOI 10.1023/A:1016527004381; Sari Widya, 2010, AIP Conference Proceedings, V1202, DOI 10.1063/1.3295595; Shen S, 2015, BIOMATERIALS, V39, P67, DOI 10.1016/j.biomaterials.2014.10.064; Simsek T, 2012, J MAGN MAGN MATER, V324, P3924, DOI 10.1016/j.jmmm.2012.06.037; Suzuki M, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.024418; Tackett R, 2008, J MAGN MAGN MATER, V320, P2755, DOI 10.1016/j.jmmm.2008.06.006; TEIXEIRA J, 1988, J APPL CRYSTALLOGR, V21, P781, DOI 10.1107/S0021889888000263; Thakur S, 2015, MATER LETT, V139, P368, DOI 10.1016/j.matlet.2014.10.014; UPADHYAY RV, 1994, J MAGN MAGN MATER, V132, P249, DOI 10.1016/0304-8853(94)90320-4; Wang KM, 2004, J MAGN MAGN MATER, V282, P73, DOI 10.1016/j.jmmm.2004.04.017; Yoon H, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-530; Yusuf SM, 2010, PHYSICA B, V405, P1202, DOI 10.1016/j.physb.2009.11.040; Zelis P.M., 2013, J PHYS APPL PHYS, V46	55	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1557-1939	1557-1947		J SUPERCOND NOV MAGN	J. Supercond. Nov. Magn	SEP	2015	28	9					2855	2863		10.1007/s10948-015-3111-9		9	Physics, Applied; Physics, Condensed Matter	Physics	CO6CS	WOS:000359245400031		
J	Honda, J; Hohashi, N				Honda, Junko; Hohashi, Naohiro			The Environment and Support Needs of Japanese Families on Temporary Work Assignments in the United States	JOURNAL OF TRANSCULTURAL NURSING			English	Article						child-rearing Japanese families; family support; family environment; overseas assignments; Concentric Sphere Family Environment Model (CSFEM); mixed methods approach; ethnonursing; transcultural family health care nursing	DISEASE; HEALTH; MODEL; LUNG	Purpose: This study aimed to describe the environment and the family support needs of families of Japanese nationals rearing children who are temporarily working in the Southwestern United States. Design: Mixed methods were utilized based on the Concentric Sphere Family Environment Model. Data collection occurred over 132 days, with 25 families participating in formal interviews and 40 families completing a written questionnaire survey. Findings/Results: Mutual support from relatives and friends in Japan, and with local Japanese peers, and other themes, six in all, were extracted. Japanese families require intervention for measures related to the global environment in their daily lives. Discussion and Conclusions: The common factor for those families with high intervention needs was the inability to access family external resources that were usually available in Japan. Implication for Practice: The building of peer support and intervention to promote their participation in the community are necessary.	[Honda, Junko; Hohashi, Naohiro] Kobe Univ, Grad Sch Hlth Sci, Kobe, Hyogo 6540142, Japan	Hohashi, N (reprint author), Kobe Univ, Grad Sch Hlth Sci, Fac Hlth Sci, Dept Nursing,Div Family Hlth Care Nursing,Suma Ku, 7-10-2 Tomogaoka, Kobe, Hyogo 6540142, Japan.	naohiro@hohashi.org			Ministry of Education, Culture, Sports, Science and Technology (MEXT) in Japan [18390585, 21390591]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported in part by a Grant-in-Aid for Scientific Research (B) (FYs 2006-2008 and 2009-2011) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) in Japan, granted to the second author (Grant Nos. 18390585 and 21390591).	Al-Baldawi R, 2002, INT CONGR SER, V1241, P271, DOI 10.1016/S0531-5131(02)00649-0; Albright S., 1993, MOVING LIVING ABROAD; Seibold MA, 2011, ANNU REV PHYSIOL, V73, P457, DOI 10.1146/annurev-physiol-012110-142212; Hirayama F, 2010, MOL NUTR FOOD RES, V54, P909, DOI 10.1002/mnfr.200900316; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Grant-Vallone EJ, 2001, INT J INTERCULT REL, V25, P261, DOI 10.1016/S0147-1767(01)00003-7; Caligiuri PM, 1998, J APPL PSYCHOL, V83, P598, DOI 10.1037/0021-9010.83.4.598; Tada N, 2011, J ATHEROSCLER THROMB, V18, P723; Leech NL, 2009, QUAL QUANT, V43, P265, DOI 10.1007/s11135-007-9105-3; Beck C T, 1993, West J Nurs Res, V15, P263, DOI 10.1177/019394599301500212; Cheek R. G., 2000, ACAD MARKETING STUDI, V4, P17; Cheek R. G., 2002, J HLTH MANAGEMENT, V4, P31, DOI [10.1177/097206340200400104, DOI 10.1177/097206340200400104]; Consular and Migration Policy Division Consular Affairs Bureau Ministry of Foreign Affairs of Japan, 2011, ANN REP STAT JAP NAT; Denzin N. K., 2006, SOCIOLOGICAL METHODS; Donenberg GR, 2012, J PEDIATR PSYCHOL, V37, P904, DOI 10.1093/jpepsy/jss056; Emerson Robert M, 2011, WRITING ETHNOGRAPHIC; Fukahori H, 2011, ARCH GERONTOL GERIAT, V53, pE168, DOI 10.1016/j.archger.2010.08.007; Fukuda K. J., 1994, INT STUDIES MANAGEME, V24, P36; Hesse-Biber S. N., 2010, MIXED METHODS RES ME; Hohashi N., 2005, JAP J RES FAM NURS, V10, P105; Hohashi Naohiro, 2012, J Nurs Meas, V20, P212; Hohashi N, 2011, J TRANSCULT NURS, V22, P350, DOI 10.1177/1043659611414200; Hohashi N., 2013, KAZOKU KANKYOU ASESU; Hohashi N., 2010, ATARASHII KAZOKU KAN; Hu JQ, 2003, J FOOD PROD MARK, V9, P31, DOI 10.1300/J038v09n01_04; Kaakinen J. R., 2009, FAMILY HLTH CARE NUR, V4th; Kitamura Kazuya, 2009, Asia Pac Fam Med, V8, P7, DOI 10.1186/1447-056X-8-7; Lei L, 2004, Clin Occup Environ Med, V4, P221, DOI 10.1016/j.coem.2003.12.001; Leininger M., 1985, QUALITATIVE RES METH; Leininger M., 2002, TRANSCULTURAL NURSIN; Leininger M. M., 2006, CULTURE CARE DIVERSI; Roper JM, 2000, ETHNOGRAPHY NURSING; Shimizu Y, 2004, SHONI HOKEN KENKYU, V63, P506; Walsh F., 2006, STRENGTHENING FAMILY; Wright L.M., 2009, BELIEFS ILLNESS MODE; Wright L.M., 2009, NURSES FAMILIES GUID	36	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1043-6596	1552-7832		J TRANSCULT NURS	J. Transcult. Nurs.	SEP	2015	26	4					376	385		10.1177/1043659614526248		10	Nursing	Nursing	CP2VN	WOS:000359735600005		
J	Zhou, LG; Lu, D; Fujita, H				Zhou, Ligang; Lu, Dong; Fujita, Hamido			The performance of corporate financial distress prediction models with features selection guided by domain knowledge and data mining approaches	KNOWLEDGE-BASED SYSTEMS			English	Article						Financial distress prediction; Features selection; Domain knowledge; Data mining	BANKRUPTCY PREDICTION; VARIABLE SELECTION; NEURAL-NETWORKS; HYBRID	Experts in finance and accounting select feature subset for corporate financial distress prediction according to their professional understanding of the characteristics of the features, while researchers in data mining often believe that data alone can tell everything and they use various mining techniques to search the feature subset without considering the financial and accounting meanings of the features. This paper investigates the performance of different financial distress prediction models with features selection approaches based on domain knowledge or data mining techniques. The empirical results show that there is no significant difference between the best classification performance of models with features selection guided by data mining techniques and that by domain knowledge. However, the combination of domain knowledge and genetic algorithm based features selection method can outperform unique domain knowledge and unique data mining based features selection method on AUC performance. (C) 2015 Elsevier B.V. All rights reserved.	[Zhou, Ligang] Macau Univ Sci & Technol, Sch Business, Taipa, Peoples R China; [Lu, Dong] Sichuan Normal Univ, Sch Business, Chengdu, Sichuan Provinc, Peoples R China; [Fujita, Hamido] Iwate Prefectural Univ, Fac Software & Informat Sci, Takizawa, Iwate, Japan	Zhou, LG (reprint author), Macau Univ Sci & Technol, Sch Business, Taipa, Peoples R China.	mrlgzhou@gmail.com; dlu@sicnu.edu.cn; issam@iwate-pu.ac.jp					Altman E., 2007, WORKING PAPER; ALTMAN EI, 1968, J FINANC, V23, P589, DOI 10.2307/2978933; Zhou LG, 2013, KNOWL-BASED SYST, V41, P16, DOI 10.1016/j.knosys.2012.12.007; Zhou LG, 2012, COMPUT MATH APPL, V64, P2484, DOI 10.1016/j.camwa.2012.06.003; Verikas A, 2010, SOFT COMPUT, V14, P995, DOI 10.1007/s00500-009-0490-5; Shumway T, 2001, J BUS, V74, P101, DOI 10.1086/209665; [Anonymous], 2015, TECHNICAL REPORT; WILSON RL, 1994, DECIS SUPPORT SYST, V11, P545, DOI 10.1016/0167-9236(94)90024-8; du Jardin P, 2010, NEUROCOMPUTING, V73, P2047, DOI 10.1016/j.neucom.2009.11.034; Shin KS, 2005, EXPERT SYST APPL, V28, P127, DOI 10.1016/j.eswa.2004.08.009; Ko YC, 2013, KNOWL-BASED SYST, V37, P86, DOI 10.1016/j.knosys.2012.07.010; Tsai CF, 2009, KNOWL-BASED SYST, V22, P120, DOI 10.1016/j.knosys.2008.08.002; Zou H, 2005, J ROY STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x; Charalambous C, 2000, ANN OPER RES, V99, P403, DOI 10.1023/A:1019292321322; Demsar J, 2006, J MACH LEARN RES, V7, P1; Chen HL, 2011, KNOWL-BASED SYST, V24, P1348, DOI 10.1016/j.knosys.2011.06.008; Cho S, 2010, EXPERT SYST APPL, V37, P3482, DOI 10.1016/j.eswa.2009.10.040; Divsalar M, 2011, APPL ARTIF INTELL, V25, P669, DOI 10.1080/08839514.2011.595975; Drezner Z., 2001, J APPL MATH DECISION, V5, P215, DOI 10.1207/S15327612JAMD0504_02; Fawcett T., 2003, ROC GRAPHS NOTES PRA; Gepp A, 2009, J FORECASTING, V29, P536; Guyon I., 2003, Journal of Machine Learning Research, V3, DOI 10.1162/153244303322753616; Guyon I., 2006, FEATURE EXTRACTION F, V207; Hall M., 2009, ACM SIGKDD EXPLORATI, V11, P10, DOI DOI 10.1145/1656274.1656278; Hall MA, 1998, AUST COMP S, V20, P181; Koutroumbas K., 2003, PATTERN RECOGNITION; Lind DA, 2012, STAT TECHNIQUES BUSI; MathWorks, 2012, MATLAB STAT TOOLB US; Mays F.E., 2004, CREDIT SCORING RISK; Kumar PR, 2007, EUR J OPER RES, V180, P1, DOI 10.1016/j.ejor.2006.08.043; Ross S.A., 2002, CORPORATE FINANCE, V7; Walsh C., 2003, KEY MANAGEMENT RATIO; ZMIJEWSKI ME, 1984, J ACCOUNTING RES, V22, P59, DOI 10.2307/2490859	33	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0950-7051	1872-7409		KNOWL-BASED SYST	Knowledge-Based Syst.	SEP	2015	85						52	61		10.1016/j.knosys.2015.04.017		10	Computer Science, Artificial Intelligence	Computer Science	CO7HU	WOS:000359331000004		
J	Hirai, S; Yokoyama, E; Etoh, Y; Seto, J; Ichihara, S; Suzuki, Y; Maeda, E; Sera, N; Horikawa, K; Sato, S; Yamamoto, T				Hirai, S.; Yokoyama, E.; Etoh, Y.; Seto, J.; Ichihara, S.; Suzuki, Y.; Maeda, E.; Sera, N.; Horikawa, K.; Sato, S.; Yamamoto, T.			Putative classification of clades of enterohemorrhagic Escherichia coli O157 using an IS-printing system	LETTERS IN APPLIED MICROBIOLOGY			English	Article						enterohemorrhagic Escherichia coli O157; IS-printing system; population genetic analysis; putative classification of clades; Relative Likelihood	NEW-ZEALAND; STRAINS; IDENTIFICATION; SUBPOPULATIONS; DIVERGENCE; ARGENTINA; VIRULENCE; COMPUTER; BACTERIA; BOVINE	Enterohemorrhagic Escherichia coli O157 (O157) strains can be classified in clades by single nucleotide polymorphisms (SNPs), but this analysis requires significant laboratory effort. As the distribution of insertion sequence (IS) 629 insertions has been reported to be biased among different clades, O157 isolates can be putatively classified in clades by comparison with an IS629 distribution database. A database of the IS629 distribution in O157 strains isolated in Chiba Prefecture and their classification in clades was determined by SNP analysis and IS-printing, an easy and quick analytical tool for IS629 in the O157 genome. The IS629 distribution in O157 strains isolated in Fukuoka and Yamagata Prefectures was determined by IS-printing. These strains were putatively classified in clades by Relative Likelihood calculations that compared the IS-printing data and the IS629 distribution database. Concordance Ratios were calculated, which compared the number of strains putatively classified in a clade by Relative Likelihood to the number of strains classified in that clade by SNP analysis. For the Fukuoka and Yamagata strains, the Concordance Ratios for clades 3, 6 and 8 were 97-100%, for clade 7 about 88%, and for clades 2 and 12 over 90%. In conclusion, O157 clade 2, 3, 6, 7, 8 and 12 strains could be putatively classified by IS-printing. Significance and Impact of the StudyThis study demonstrated that enterohemorrhagic E.coli O157 (O157) strains could be putatively classified in clades using an IS-printing system. IS-printing was previously developed as a relatively quick and easy tool for analysis of insertion sequence 629 in the O157 genome. Since most local government public health institutes in Japan carry out IS-printing for early detection of O157 outbreaks, these data should be useful for putative classification of O157 strains in each area.	[Hirai, S.; Yokoyama, E.] Chiba Prefectural Inst Publ Hlth, Div Bacteriol, Chiba, Chiba 2608715, Japan; [Hirai, S.; Yamamoto, T.] Chiba Univ, Grad Sch Pharmaceut Sci, Dept Microbiol & Mol Genet, Chiba, Japan; [Etoh, Y.; Ichihara, S.; Maeda, E.; Sera, N.; Horikawa, K.] Fukuoka Inst Hlth & Environm Sci, Div Pathol & Bacteriol, Fukuoka, Japan; [Seto, J.; Suzuki, Y.] Yamagata Prefectural Inst Publ Hlth, Dept Microbiol, Yamagata 9900031, Japan; [Sato, S.] Chiba Prefectural Inst Publ Hlth, Chiba, Chiba 2608715, Japan	Hirai, S (reprint author), Chiba Prefectural Inst Publ Hlth, Div Bacteriol, 666-2 Nitona, Chiba, Chiba 2608715, Japan.	s.hri10@pref.chiba.lg.jp			Daido Life Welfare Foundation for Regional Health and Welfare Research	Part of this study was supported by a Grant from the Daido Life Welfare Foundation for Regional Health and Welfare Research in fiscal 2014.	WILLCOX WR, 1973, J GEN MICROBIOL, V77, P317; Yokoyama E, 2011, INFECT GENET EVOL, V11, P78, DOI 10.1016/j.meegid.2010.10.007; Rivas M, 2006, MEDICINA-BUENOS AIRE, V66, P27; Yang Z, 2004, APPL ENVIRON MICROB, V70, P6846, DOI 10.1128/AEM.70.11.6846-6854.2004; Franz E, 2012, J CLIN MICROBIOL, V50, P772, DOI 10.1128/JCM.05964-11; Ooka T, 2009, J CLIN MICROBIOL, V47, P2888, DOI 10.1128/JCM.00792-09; Shaikh N, 2003, J BACTERIOL, V185, P3596, DOI 10.1128/JB.185.12.3596-3605.2003; Hirai S, 2013, INFECT GENET EVOL, V18, P94, DOI 10.1016/j.meegid.2013.05.006; Leotta GA, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-46; Peakall R, 2012, BIOINFORMATICS, V28, P2537, DOI 10.1093/bioinformatics/bts460; BASCOMB S, 1973, J GEN MICROBIOL, V77, P291; Manning SD, 2008, P NATL ACAD SCI USA, V105, P4868, DOI 10.1073/pnas.0710834105; Etoh Y, 2014, INFECT GENET EVOL, V24, P140, DOI 10.1016/j.meegid.2014.03.013; Hirai S, 2014, J APPL MICROBIOL, V117, P1191, DOI 10.1111/jam.12604; Izumiya H, 2015, STUDY REPORT SUPPORT, P169; Jaros P, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-450; Kim JY, 2001, J BACTERIOL, V183, P6885, DOI 10.1128/JB.183.23.6885-6897.2001; Mellor GE, 2012, APPL ENVIRON MICROB, V78, P4724, DOI 10.1128/AEM.00365-12; Yokoyama E, 2012, INFECT GENET EVOL, V12, P1724, DOI 10.1016/j.meegid.2012.07.003	19	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0266-8254	1472-765X		LETT APPL MICROBIOL	Lett. Appl. Microbiol.	SEP	2015	61	3					267	273		10.1111/lam.12448		7	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CP4OO	WOS:000359862000009		
J	Lara, GHB; Takai, S; Sasaki, Y; Kakuda, T; Listoni, FJP; Risseti, RM; de Morais, ABC; Ribeiro, MG				Lara, G. H. B.; Takai, S.; Sasaki, Y.; Kakuda, T.; Listoni, F. J. P.; Risseti, R. M.; de Morais, A. B. C.; Ribeiro, M. G.			VapB type 8 plasmids in Rhodococcus equi isolated from the small intestine of pigs and comparison of selective culture media	LETTERS IN APPLIED MICROBIOLOGY			English	Article						faeces; intermediately virulent; pigs; Rhodococcus equi; Virulence-plasmid profile	BOARS SUS-SCROFA; MOLECULAR EPIDEMIOLOGY; LYMPH-NODES; VIRULENCE PLASMIDS; IDENTIFICATION; BRAZIL; PATHOGENS; ANTIGENS	The virulence-plasmid profile of Rhodococcus equi strains isolated from Suidae and humans is similar. Recent evidence suggests that the consumption of pork products contaminated with faeces might be a potential source of R.equi infections in humans, mainly to patients with rhodococcosis without history of contact with pigs or pig farms. This study investigated the virulence-associated genes (vapA and vapB) and plasmid profiles of R.equi among the 150 samples of small intestinal content obtained from slaughtered pigs. In addition, all samples were subjected to microbiological culture in conventional sheep blood agar and CAZ-NB, TCP and TVP selective media. A total of 40 (267%) of the samples recovered R.equi, with two samples recovering isolates harbouring the VapB type 8 plasmid. Among the 150 pigs sampled herein, CAZ-NB was considered the best selective medium for the isolation of R.equi from faeces. Our results provide evidence that the contamination of slaughtered pig carcasses with pathogenic R.equi might occur through faeces, representing a public health concern. Furthermore, this study is the first description of R.equi strains carrying the VapB plasmid in the gut of pigs. Significance and Impact of the StudyIntermediately virulent (VapB) is a common plasmid-type harboured by R.equi isolated from pigs and humans with AIDS. Curiously, humans with rhodococcosis usually have no history of contact with pigs or pig farms. Virulence-plasmid profile of 40 R.equi isolated among 150 small intestine content samples from pigs revelled two carrying isolates with the VapB type-8 plasmids. Moreover, comparison of three selective culture media shows that CAZ-NB was the best. Our results provide evidence that contamination of slaughtered pig carcasses with pathogenic R.equi might occur through faeces, representing a public health concern. Furthermore, R.equi carrying VapB type-8 plasmids types are described for the first time in the gut of the pig. Significance and Impact of the Study: Intermediately virulent (VapB) is a common plasmid-type harboured by R.equi isolated from pigs and humans with AIDS. Curiously, humans with rhodococcosis usually have no history of contact with pigs or pig farms. Virulence-plasmid profile of 40 R.equi isolated among 150 small intestine content samples from pigs revelled two carrying isolates with the VapB type-8 plasmids. Moreover, comparison of three selective culture media shows that CAZ-NB was the best. Our results provide evidence that contamination of slaughtered pig carcasses with pathogenic R.equi might occur through faeces, representing a public health concern. Furthermore, R.equi carrying VapB type-8 plasmids types are described for the first time in the gut of the pig.	[Lara, G. H. B.; Listoni, F. J. P.; Risseti, R. M.; de Morais, A. B. C.; Ribeiro, M. G.] Univ Estadual Paulista, Sch Vet Med & Anim Sci, Dept Vet Hyg & Publ Hlth, Botucatu, SP, Brazil; [Takai, S.; Sasaki, Y.; Kakuda, T.] Kitasato Univ, Sch Vet Med & Anim Sci, Dept Anim Hyg, Towada, Aomori 034, Japan	Ribeiro, MG (reprint author), Sao Paulo State Univ UNESP, Sch Vet Med & Anim Sci, Dept Vet Hyg & Publ Hlth, POB 560, BR-18618970 Sao Paulo, Brazil.	mgribeiro@fmvz.unesp.br	Lara, Gustavo/K-3758-2015		CNPq (National Council for Scientific and Technological Development) Brazil [472130/2010-2]	We appreciate the funding CNPq (National Council for Scientific and Technological Development) Brazil, protocol 472130/2010-2, for funding this study.	Lara GHB, 2011, RES VET SCI, V90, P185, DOI 10.1016/j.rvsc.2010.06.009; Ribeiro MG, 2011, RES VET SCI, V91, P478, DOI 10.1016/j.rvsc.2010.09.022; Fernandes MC, 2013, BRAZ J MICROBIOL, V44, P485, DOI 10.1590/S1517-83822013005000044; von Bargen K, 2009, FEMS MICROBIOL REV, V33, P870, DOI 10.1111/j.1574-6976.2009.00181.x; Makrai L, 2008, VET MICROBIOL, V131, P318, DOI 10.1016/j.vetmic.2008.04.009; Ribeiro MG, 2005, COMP IMMUNOL MICROB, V28, P53, DOI 10.1016/j.cimid.2004.07.001; Ocampo-Sosa AA, 2007, J INFECT DIS, V196, P763, DOI 10.1086/519688; Takai S, 1997, VET MICROBIOL, V56, P167, DOI 10.1016/S0378-1135(97)00085-0; Komijn RE, 2007, VET MICROBIOL, V120, P352, DOI 10.1016/j.vetmic.2006.10.031; Letek M, 2008, J BACTERIOL, V190, P5797, DOI 10.1128/JB.00468-08; PRESCOTT JF, 1991, CLIN MICROBIOL REV, V4, P20; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Brasil Ministerio da Saude, 2007, PROGR NAC DST AIDS; Costa EO, 2004, MYCOPATHOLOGIA, V158, P81; desVargas A. C, 2013, BMC RES NOTES, V6, P111; Makrai S., 2005, J CLIN MICROBIOL, V43, P1246; Muscatello G, 2007, VET MICROBIOL, V119, P324, DOI 10.1016/j.vetmic.2006.08.022; Quinn PJ, 2011, VET MICROBIOLOGY MIC; Radostits OM, 2007, VET MED TXB DIS CATT; Ribeiro MG, 2011, AM J TROP MED HYG, V85, P510, DOI 10.4269/ajtmh.2011.10-0695; SEKIZAKI T, 1995, GENE, V155, P135, DOI 10.1016/0378-1119(95)00009-U; da Silva P, 2010, MEM I OSWALDO CRUZ, V105, P199, DOI 10.1590/S0074-02762010000200015; Takai S, 1996, J CLIN MICROBIOL, V34, P1034; TAKAI S, 1995, J CLIN MICROBIOL, V33, P1624; Takai S, 2004, J VET MED SCI, V66, P743, DOI 10.1292/jvms.66.743; Takai S, 2003, J INFECT DIS, V188, P1717, DOI 10.1086/379739; Valero-Rello A, 2015, INFECT IMMUN, V83, P2725, DOI 10.1128/IAI.00376-15; Vazquez-Boland JA, 2013, VET MICROBIOL, V167, P9, DOI 10.1016/j.vetmic.2013.06.016	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0266-8254	1472-765X		LETT APPL MICROBIOL	Lett. Appl. Microbiol.	SEP	2015	61	3					306	310		10.1111/lam.12458		5	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CP4OO	WOS:000359862000014		
J	Park, JW; Chen, MS; Colombo, M; Roberts, LR; Schwartz, M; Chen, PJ; Kudo, M; Johnson, P; Wagner, S; Orsini, LS; Sherman, M				Park, Joong-Won; Chen, Minshan; Colombo, Massimo; Roberts, Lewis R.; Schwartz, Myron; Chen, Pei-Jer; Kudo, Masatoshi; Johnson, Philip; Wagner, Samuel; Orsini, Lucinda S.; Sherman, Morris			Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study	LIVER INTERNATIONAL			English	Article						disease management; epidemiology; global trends; liver cancer; observational study; risk factors; treatment patterns	CONSENSUS RECOMMENDATIONS; PROGNOSTIC-FACTORS; CLINICAL-TRIALS; LIVER-CANCER; EPIDEMIOLOGY; SORAFENIB; SURVIVAL; TRENDS; JAPAN	Background & AimsHepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large-scale, longitudinal cohort study undertaken to improve understanding of real-life management of patients with HCC, from diagnosis to death. MethodsData were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with HCC at participating institutions. ResultsForty-two sites in 14 countries contributed final data for 18031 patients. Asia accounted for 67% of patients, Europe for 20% and North America for 13%. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first HCC treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first HCC treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23months for Japan, North America, South Korea, Europe and China respectively (P<0.0001). ConclusionsInitial results from the BRIDGE study confirm previously reported regional trends in patient demographic characteristics and HCC risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier HCC diagnosis worldwide.	[Park, Joong-Won] Natl Canc Ctr, Ctr Liver Canc, Goyang 410769, Gyeonggi, South Korea; [Chen, Minshan] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China; [Colombo, Massimo] Univ Milan, Policlin IRCCS Maggiore Hosp, Milan, Italy; [Roberts, Lewis R.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA; [Schwartz, Myron] Mt Sinai Hosp, New York, NY 10029 USA; [Chen, Pei-Jer] Natl Taiwan Univ, Taipei 10764, Taiwan; [Kudo, Masatoshi] Kinki Univ, Sch Med, Osaka, Osaka 589, Japan; [Johnson, Philip] Univ Birmingham, Birmingham, W Midlands, England; [Wagner, Samuel] Bristol Myers Squibb, Princeton, NJ USA; [Orsini, Lucinda S.] Bristol Myers Squibb, Wallingford, CT USA; [Sherman, Morris] Univ Toronto, Toronto, ON, Canada	Park, JW (reprint author), Natl Canc Ctr, Ctr Liver Canc, 323 Ilsan Ro, Goyang 410769, Gyeonggi, South Korea.	jwpark@ncc.re.kr			Bristol-Myers Squibb	Financial support: Professional medical writing and editorial assistance was provided by StemScientific, funded by Bristol-Myers Squibb.	El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Shiina S, 2012, LIVER INT, V32, P1434, DOI 10.1111/j.1478-3231.2012.02838.x; Chen CJ, 2002, JPN J CLIN ONCOL, V32, pS66, DOI 10.1093/jjco/hye138; Ni YH, 2010, PATHOL BIOL, V58, P296, DOI 10.1016/j.patbio.2009.11.002; Yang JD, 2010, INFECT DIS CLIN N AM, V24, P899, DOI 10.1016/j.idc.2010.07.004; Lencioni R, 2010, ONCOLOGIST, V15, P42, DOI 10.1634/theoncologist.2010-S4-42; MOR V, 1984, CANCER, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W; Omata M, 2010, HEPATOL INT, V4, P439, DOI 10.1007/s12072-010-9165-7; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Carrilho FJ, 2010, CLINICS, V65, P1285, DOI 10.1590/S1807-59322010001200010; Kudo M, 2010, JPN J CLIN ONCOL, V40, pi19, DOI 10.1093/jjco/hyq123; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Shiina S, 2012, AM J GASTROENTEROL, V107, P569, DOI 10.1038/ajg.2011.425; Sloane D, 2006, J NATL MED ASSOC, V98, P1934; Kim HY, 2011, J GASTROEN HEPATOL, V26, P1612, DOI 10.1111/j.1440-1746.2011.06751.x; Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Venook AP, 2010, ONCOLOGIST, V15, P5, DOI 10.1634/theoncologist.2010-S4-05; Makuuchi M, 2008, HEPATOL RES, V38, P37, DOI 10.1111/j.1872-034X.2007.00216.x; Yang JD, 2011, CLIN GASTROENTEROL H, V9, P617, DOI 10.1016/j.cgh.2011.03.027; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Llovet JM, 2008, J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134; Thomas MB, 2010, J CLIN ONCOL, V28, P3994, DOI 10.1200/JCO.2010.28.7805; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Chua TC, 2010, LIVER INT, V30, P166, DOI 10.1111/j.1478-3231.2009.02166.x; Dhanasekaran Renumathy, 2012, Hepat Med, V4, P19, DOI 10.2147/HMER.S16316; Llovet JM, 2012, J HEPATOL, V56, P908; Ferlay J, GLOBOCAN 2012 V1 0 E; Howlader N, 2013, SEER CANC STAT REV 1; Korean Liver Cancer Study G National Cancer Center K, 2009, KOREAN J HEPATOL, V15, P391, DOI DOI 10.3350/KJHEP.2009.15.3.391; Kudo M, 2007, ONCOLOGY-BASEL, V72, P2, DOI 10.1159/000111702; Park J-W, 2012, 2012 ANN M AM SOC CL; Song Peipei, 2013, Liver Cancer, V2, P31, DOI 10.1159/000346220; Su Fu-Hsiung, 2007, Chang Gung Med J, V30, P521; Wei Zhengyu, 2013, Clin Med Insights Oncol, V7, P87, DOI 10.4137/CMO.S7633; Welker MW, 2010, J CHEMOTHERAPY, V22, P205; World Health Organisation, 2011, GLOB STAT REP ALC HL; Yoo KY, 2008, JPN J CLIN ONCOL, V38, P327, DOI 10.1093/jjco/hyn026	40	5	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1478-3223	1478-3231		LIVER INT	Liver Int.	SEP	2015	35	9					2155	2166		10.1111/liv.12818		12	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CP2KI	WOS:000359705500013		
J	Kikuchi-Taura, A; Yura, A; Tsuji, S; Ohshima, S; Kitatoube, A; Shimizu, T; Nii, T; Katayama, M; Teshigawara, S; Yoshimura, M; Kudo-Tanaka, E; Harada, Y; Matsushita, M; Hashimoto, J; Saeki, Y				Kikuchi-Taura, A.; Yura, A.; Tsuji, S.; Ohshima, S.; Kitatoube, A.; Shimizu, T.; Nii, T.; Katayama, M.; Teshigawara, S.; Yoshimura, M.; Kudo-Tanaka, E.; Harada, Y.; Matsushita, M.; Hashimoto, J.; Saeki, Y.			Monocyte CD64 expression as a novel biomarker for the disease activity of systemic lupus erythematosus	LUPUS			English	Article						Hematologic changes; SLEDAI; CD64	INDUCIBLE GENE-EXPRESSION; I INTERFERON; AUTOIMMUNE-DISEASES; ASSOCIATION; BLOOD	Objective: Interferon alpha (IFN-alpha) is a key cytokine associated with systemic lupus erythematosus (SLE). IFN-alpha induces the expression of CD64 on monocytes (mCD64). Although enhanced mCD64 expression has been reported in patients with SLE, it has never been assessed quantitatively. The aim of this study was to investigate whether or not mCD64 expression correlates with SLE disease activity. Methods: The mCD64 expression levels were assessed quantitatively in 40 patients with active or inactive SLE by using flow cytometry. The mCD64 expression levels were subsequently compared with the SLE disease activity index (SLEDAI) and levels of existing SLE activity biomarkers, such as anti-DNA antibody, complements, and so on. Results: The mCD64 expression was significantly higher in active disease than in inactive disease SLE (median molecules/cell, interquartile range: 34,648, 8174-24,932 and 20,865, 6357-21,503, respectively; p<0.001). The levels of mCD64 expression strongly correlated with SLEDAI (r=0.68, p<0.001). Conclusion: The mCD64 expression is a simple and useful biomarker for evaluating disease activity in patients with SLE.	[Kikuchi-Taura, A.; Ohshima, S.; Kitatoube, A.; Saeki, Y.] Osaka Minami Med Ctr, Dept Clin Res, Kawachi Nagano, Osaka 5868521, Japan; [Yura, A.; Tsuji, S.; Shimizu, T.; Nii, T.; Teshigawara, S.; Yoshimura, M.; Kudo-Tanaka, E.; Harada, Y.; Matsushita, M.; Hashimoto, J.] Osaka Minami Med Ctr, Dept Rheumatol & Allergol, Kawachi Nagano, Osaka 5868521, Japan; [Katayama, M.] Osaka Univ, Grad Sch Med, Dept Rheumatol & Allergol, Osaka, Japan	Kikuchi-Taura, A (reprint author), Osaka Minami Med Ctr, Dept Clin Res, 2-1 Kidohigashi Machi, Kawachi Nagano, Osaka 5868521, Japan.	saekiy@ommc-hp.jp			National Hospital Organization of Japan	This work was partly supported by grants from the National Hospital Organization of Japan.	Cooper GS, 1999, ENVIRON HEALTH PERSP, V107, P693, DOI 10.2307/3434329; Zhuang HY, 2005, CLIN IMMUNOL, V117, P238, DOI 10.1016/j.clim.2005.07.009; Malinger G, 2005, ULTRASOUND OBST GYN, V25, P42, DOI 10.1002/uog.1787; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Pascual V, 2006, CURR OPIN IMMUNOL, V18, P676, DOI 10.1016/j.coi.2006.09.014; Banchereau J, 2006, IMMUNITY, V25, P383, DOI 10.1016/j.immuni.2006.08.010; Yang PT, 2008, ANN RHEUM DIS, V67, P429, DOI 10.1136/ard.2007.076117; Mackay IR, 2005, SEMIN LIVER DIS, V25, P239, DOI 10.1055/s-2005-916330; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; Maruyama J, 2010, J RHEUMATOL, V37, P967, DOI 10.3899/jrheum.090662; Feng XB, 2006, ARTHRITIS RHEUM, V54, P2951, DOI 10.1002/art.22044; Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553; BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606; Kamal A, 2014, AUTOIMMUN REV, V13, P1094, DOI 10.1016/j.autrev.2014.08.020; Li Y, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3017; LUPPI P, 1995, J MOL MED-JMM, V73, P381	16	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0961-2033	1477-0962		LUPUS	Lupus	SEP	2015	24	10					1076	1080		10.1177/0961203315579093		5	Rheumatology	Rheumatology	CO8FQ	WOS:000359402200008		
J	Shiga, M; Tangkaratt, V; Sugiyama, M				Shiga, Motoki; Tangkaratt, Voot; Sugiyama, Masashi			Direct conditional probability density estimation with sparse feature selection	MACHINE LEARNING			English	Article						Conditional density estimation; Feature selection; Sparse structured norm	DIMENSION REDUCTION; QUANTILE REGRESSION; INVERSE REGRESSION; ALGORITHM; PATH	Regression is a fundamental problem in statistical data analysis, which aims at estimating the conditional mean of output given input. However, regression is not informative enough if the conditional probability density is multi-modal, asymmetric, and heteroscedastic. To overcome this limitation, various estimators of conditional densities themselves have been developed, and a kernel-based approach called least-squares conditional density estimation (LS-CDE) was demonstrated to be promising. However, LS-CDE still suffers from large estimation error if input contains many irrelevant features. In this paper, we therefore propose an extension of LS-CDE called sparse additive CDE (SA-CDE), which allows automatic feature selection in CDE. SA-CDE applies kernel LS-CDE to each input feature in an additive manner and penalizes the whole solution by a group-sparse regularizer. We also give a subgradient-based optimization method for SA-CDE training that scales well to high-dimensional large data sets. Through experiments with benchmark and humanoid robot transition datasets, we demonstrate the usefulness of SA-CDE in noisy CDE problems.	[Shiga, Motoki] Gifu Univ, Gifu, Gifu 5011193, Japan; [Tangkaratt, Voot; Sugiyama, Masashi] Tokyo Inst Technol, Meguro Ku, Tokyo 1528552, Japan	Shiga, M (reprint author), Gifu Univ, 1-1 Yanagido, Gifu, Gifu 5011193, Japan.	shiga_m@gifu-u.ac.jp; voot@sg.cs.titech.ac.jp; sugi@cs.titech.ac.jp			JSPS KAKENHI [25870322, 23120004]	Motoki Shiga was supported by JSPS KAKENHI 25870322. Masashi Sugiyama was supported by JSPS KAKENHI 23120004 and AOARD. Authors thank Dr. Ichiro Takeuchi, Nagoya Institute of Technology, for kindly providing his source codes.	Yuan M, 2006, J ROY STAT SOC B, V68, P49, DOI 10.1111/j.1467-9868.2005.00532.x; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1; Cook RD, 2005, J AM STAT ASSOC, V100, P410, DOI 10.1198/016214504000001501; Li YJ, 2007, J AM STAT ASSOC, V102, P255, DOI 10.1198/016214506000000979; Takeuchi I, 2009, NEURAL COMPUT, V21, P533, DOI 10.1162/neco.2008.10-07-628; Sugiyama M, 2010, IEICE T INF SYST, VE93D, P583, DOI 10.1587/transinf.E93.D.583; Hastie T, 2004, J MACH LEARN RES, V5, P1391; Fan JQ, 1996, BIOMETRIKA, V83, P189, DOI 10.1093/biomet/83.1.189; Takeuchi I, 2006, J MACH LEARN RES, V7, P1231; Barto A.G., 1998, INTRO REINFORCEMENT; Beck A, 2009, SIAM J IMAGING SCI, V2, P183, DOI 10.1137/080716542; Bishop C. M., 2006, PATTERN RECOGNITION; Cheng G, 2007, ADV ROBOTICS, V21, P1097, DOI 10.1163/156855307781389356; Guyon I., 2003, Journal of Machine Learning Research, V3, DOI 10.1162/153244303322753616; Hall P, 1999, J AM STAT ASSOC, V94, P154, DOI 10.2307/2669691; Hastie T., 2001, ELEMENTS STAT LEARNI; Holmes M. P., 2007, P C UNC ART INT VANC, P175; LI KC, 1991, J AM STAT ASSOC, V86, P316, DOI 10.2307/2290563; Silverman BW, 1986, DENSITY ESTIMATION S; Sra S, 2012, OPTIMIZATION FOR MACHINE LEARNING, P1; Tresp V, 2001, ADV NEUR IN, V13, P654; Weisberg Sanford, 1985, APPL LINEAR REGRESSI; Rasmussen CE, 2005, ADAPT COMPUT MACH LE, P1	23	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0885-6125	1573-0565		MACH LEARN	Mach. Learn.	SEP	2015	100	2-3			SI		161	182		10.1007/s10994-014-5472-x		22	Computer Science, Artificial Intelligence	Computer Science	CP2ZR	WOS:000359747100002		
J	Chen, B; Ting, KM; Washio, T; Haffari, G				Chen, Bo; Ting, Kai Ming; Washio, Takashi; Haffari, Gholamreza			Half-space mass: a maximally robust and efficient data depth method	MACHINE LEARNING			English	Article						Half-space mass; Mass estimation; Data depth; Robustness	LOCATION	Data depth is a statistical method which models data distribution in terms of center-outward ranking rather than density or linear ranking. While there are a lot of academic interests, its applications are hampered by the lack of a method which is both robust and efficient. This paper introduces Half-Space Mass which is a significantly improved version of half-space data depth. Half-Space Mass is the only data depth method which is both robust and efficient, as far as we know. We also reveal four theoretical properties of Half-Space Mass: (i) its resultant mass distribution is concave regardless of the underlying density distribution, (ii) its maximum point is unique which can be considered as median, (iii) the median is maximally robust, and (iv) its estimation extends to a higher dimensional space in which the convex hull of the dataset occupies zero volume. We demonstrate the power of Half-Space Mass through its applications in two tasks. In anomaly detection, being a maximally robust location estimator leads directly to a robust anomaly detector that yields a better detection accuracy than half-space depth; and it runs orders of magnitude faster than depth, an existing maximally robust location estimator. In clustering, the Half-Space Mass version of K-means overcomes three weaknesses of K-means.	[Chen, Bo; Haffari, Gholamreza] Monash Univ, Fac Informat Technol, Clayton, Vic 3168, Australia; [Ting, Kai Ming] Federat Univ Australia, Sch Informat Technol & Engn, Churchill, Vic 3842, Australia; [Washio, Takashi] Osaka Univ, Inst Sci & Ind Res, Ibaraki, Osaka 5670047, Japan	Chen, B (reprint author), Monash Univ, Fac Informat Technol, Clayton, Vic 3168, Australia.	bo.chen@monash.edu; kaiming.ting@federation.edu.au; washio@ar.sanken.osaka-u.ac.jp; gholamreza.haffari@monash.edu			U.S. Air Force Research Laboratory [FA2386-13-1-4043]; JSPS KAKENHI [25240036]; National ICT Australia (NICTA) Machine Learning Collaborative Research Projects; Faculty of Information Technology, Monash University	This project is partially supported by a grant from the U.S. Air Force Research Laboratory, under agreement # FA2386-13-1-4043, awarded to Kai Ming Ting. It is also partially supported by JSPS KAKENHI Grant Number 25240036, awarded to Takashi Washio. Bo Chen and Gholamreza Haffari are grateful to National ICT Australia (NICTA) for their generous funding, as part of the Machine Learning Collaborative Research Projects. Bo Chen is also supported by a scholarship from the Faculty of Information Technology, Monash University.	Agostinelli C, 2011, J STAT PLAN INFER, V141, P817, DOI 10.1016/j.jspi.2010.08.001; Zuo YJ, 2000, ANN STAT, V28, P461; Liu RY, 1999, ANN STAT, V27, P783; Jain AK, 2010, PATTERN RECOGN LETT, V31, P651, DOI 10.1016/j.patrec.2009.09.011; Aloupis G, 2006, DIMACS SER DISCRET M, V72, P147; DONOHO DL, 1992, ANN STAT, V20, P1803, DOI 10.1214/aos/1176348890; Dutta S, 2011, BERNOULLI, V17, P1420, DOI 10.3150/10-BEJ322; Ting KM, 2013, MACH LEARN, V90, P127, DOI 10.1007/s10994-012-5303-x; Franti P, 2006, IEEE T PATTERN ANAL, V28, P1875, DOI 10.1109/TPAMI.2006.227; LOPUHAA HP, 1991, ANN STAT, V19, P229, DOI 10.1214/aos/1176347978; Kroese D. P., 2014, STAT MODELING COMPUT; Lichman M., 2013, UCI MACHINE LEARNING; Mosler K, 2013, ROBUSTNESS COMPLEX D, P17; Tan P.N., 2014, INTRO DATA MINING; Ting K M, 2010, P ACM SIGKDD, P989, DOI 10.1145/1835804.1835929; Tukey JW, 1975, P INT C MATH, V2, P523	16	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0885-6125	1573-0565		MACH LEARN	Mach. Learn.	SEP	2015	100	2-3			SI		677	699		10.1007/s10994-015-5524-x		23	Computer Science, Artificial Intelligence	Computer Science	CP2ZR	WOS:000359747100021		
J	Misumi, I; Naoi, K; Sugawara, K; Gonda, S				Misumi, Ichiko; Naoi, Kazuya; Sugawara, Kentaro; Gonda, Satoshi			Profile surface roughness measurement using metrological atomic force microscope and uncertainty evaluation	MEASUREMENT			English	Article						Surface roughness; Metrological AFM; Calibration; Uncertainty; Traceability	PITCH MEASUREMENTS; CALIBRATION; STANDARDS; AFM	Surface roughness measurements are sometimes performed using an atomic force microscope (AFM) in order to evaluate conditions of thin film fabrication and material surface treatment. Recently precise and reliable surface roughness measurement has been required in order to further improve quality of both thin films and material surfaces. Evaluation method of AFM tip shape is a key technology in the surface roughness measurement using an AFM. An evaluation method of AFM tip shape using a probe examination sample and its evaluation criteria are stipulated in the Japanese Industrial Standard (JIS) R 1683: 2007 "Test method for surface roughness of ceramic thin films by atomic force microscopy''. In this study, profile surface roughness measurements were performed based on JIS R 1683: 2007 and the measurement results are reported. (C) 2015 Elsevier Ltd. All rights reserved.	[Misumi, Ichiko; Naoi, Kazuya; Sugawara, Kentaro; Gonda, Satoshi] Natl Inst Adv Ind Sci & Technol, NMIJ, Tsukuba, Ibaraki 3058563, Japan	Misumi, I (reprint author), Natl Inst Adv Ind Sci & Technol, NMIJ, AIST Tsukuba Cent 3,1-1-1 Umezono, Tsukuba, Ibaraki 3058563, Japan.	misumi.i@aist.go.jp; naoi.k@aist.go.jp; sugawara.k@aist.go.jp; satoshi.gonda@aist.go.jp			National Institute of Advanced Science and Technology (AIST)	This research was mainly supported by the operating support funds of the National Institute of Advanced Science and Technology (AIST).	Misumi I, 2003, MEAS SCI TECHNOL, V14, P463, DOI 10.1088/0957-0233/14/4/309; Gonda S, 1999, REV SCI INSTRUM, V70, P3362, DOI 10.1063/1.1149920; Xu MS, 2009, REV SCI INSTRUM, V80, DOI 10.1063/1.3115182; Itoh H, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2356855; Misumi I, 2006, PRECIS ENG, V30, P13, DOI 10.1016/j.precisioneng.2005.03.002; Dai GL, 2004, MEAS SCI TECHNOL, V15, P2039, DOI 10.1088/0957-0233/15/10/013; Dziomba T., 2013, P NANOSCALE, V2013, P25; Garnaes J, 2003, PRECIS ENG, V27, P91, DOI 10.1016/S0141-6359(02)00184-8; Gonda S., 2007, P 11 INT C METR PROP, P322; [IEC ISO], 2008, GUID EXPR UNC MEAS G; Misumi I, 2008, MEAS SCI TECHNOL, V19, DOI 10.1088/0957-0233/19/4/045101; Misumi I, 2005, MEAS SCI TECHNOL, V16, P2080, DOI 10.1088/0957-0233/16/10/025	12	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0263-2241	1873-412X		MEASUREMENT	Measurement	SEP	2015	73						295	303		10.1016/j.measurement.2015.05.026		9	Engineering, Multidisciplinary; Instruments & Instrumentation	Engineering; Instruments & Instrumentation	CO7AM	WOS:000359309900029		
J	Kudo, R; Okita, K; Okuda, K; Tokuta, Y; Nakano, M; Yamamura, K; Endo, K				Kudo, Ryota; Okita, Kenya; Okuda, Kohei; Tokuta, Yusuke; Nakano, Motohiro; Yamamura, Kazuya; Endo, Katsuyoshi			Simulation-based systematic error compensation for nanoprofiler using normal vector tracing method	MEASUREMENT			English	Article						Nanoprofiler; Normal vector; Aspherical surface; Free-form; High-precision mirror; Calibration		We have developed a nanoprofiler that relies on the use of the normal vector. Our aim was to enable the measurement of the profile of free-form surfaces with high precision. Since the nanoprofiler does not use a reference surface, it should be capable of measuring free-form surfaces with a high degree of accuracy. Repeatability at the sub-nanometer level has been achieved. In this study, with a goal of reducing and evaluating the related uncertainty, we set out to estimate the degree of systematic error. We investigated the effect of the systematic error on the measurement results by computer simulation. Then, by comparing the measured results with those of the simulation, we estimated the systematic error. (C) 2015 Elsevier Ltd. All rights reserved.	[Kudo, Ryota; Yamamura, Kazuya; Endo, Katsuyoshi] Osaka Univ, Res Ctr Ultraprecis Sci & Technol, Suita, Osaka 5650871, Japan; [Okita, Kenya; Okuda, Kohei; Tokuta, Yusuke; Nakano, Motohiro] Osaka Univ, Grad Sch Engn, Dept Precis Sci & Technol, Suita, Osaka 5650871, Japan	Kudo, R (reprint author), Osaka Univ, Res Ctr Ultraprecis Sci & Technol, 2-1 Yamada Oka, Suita, Osaka 5650871, Japan.	kudo@upst.eng.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology [22226005]	This work was carried out at the Ultra Clean Facility, Osaka University. This work was supported by Grants-in-Aid for Scientific Research (No. 22226005) from the Ministry of Education, Culture, Sports, Science, and Technology.	Watanabe T, 2005, J PHYS CONF SER, V13, P240, DOI 10.1088/1742-6596/13/1/056; Tricard M, 2010, CIRP ANN-MANUF TECHN, V59, P547, DOI 10.1016/j.cirp.2010.03.125; Knauer MC, 2004, P SOC PHOTO-OPT INS, V5457, P366, DOI 10.1117/12.545704; YOSHIZUMI K, 1987, APPL OPTICS, V26, P1647, DOI 10.1364/AO.26.001647; Assoufid L, 2001, NUCL INSTRUM METH A, V467, P267, DOI 10.1016/S0168-9002(01)00296-0; Higashi Y., 2007, P SOC PHOTO-OPT INS, V6704; Kudo R, 2014, REV SCI INSTRUM, V85, DOI 10.1063/1.4869473; Takacs P.Z., 2009, HDB OPTICS, V5; Takeuchi H., 2004, WINT TOP M FREE FORM; Usuki K., 2012, SPIE OPTICAL SYSTEM	10	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0263-2241	1873-412X		MEASUREMENT	Measurement	SEP	2015	73						473	479		10.1016/j.measurement.2015.05.047		7	Engineering, Multidisciplinary; Instruments & Instrumentation	Engineering; Instruments & Instrumentation	CO7AM	WOS:000359309900045		
J	Ohtakara, K; Hoshi, H				Ohtakara, Kazuhiro; Hoshi, Hiroaki			Comparison of pencil beam-based homogeneous vs inhomogeneous target dose planning for stereotactic body radiotherapy of peripheral lung tumors through Monte Carlo-based recalculation	MEDICAL DOSIMETRY			English	Article						SBRT; Lung; Target dose homogeneity; Treatment planning	RADIATION-THERAPY SBRT; ISODOSE SURFACE; CANCER; PRESCRIPTION; RADIOSURGERY; VOLUME; ACCELERATOR; EXPERIENCE; COVERAGE	This study was conducted to ascertain whether homogeneous target dose planning is suitable for stereotactic body radiotherapy (SBRT) of peripheral lung cancer under appropriate breath-holding. For 20 peripheral lung tumors, paired dynamic conformal arc plans were generated by only adjusting the leaf margin to the planning target volume (PTV) edge for fulfilling the conditions such that the prescription isodose surface (IDS) encompassing exactly 95% of the PTV (PTV D-95) corresponds to 95% and 80% IDS, normalized to 100% at the PTV isocenter under a pencil beam (PB) algorithm with radiologic path length correction. These plans were recalculated using the x-ray voxel Monte Carlo (XVMC) algorithm under otherwise identical conditions, and then compared. Lesions abutting the parietal pleura or not were defined as edge or island tumors, respectively, and the influences of the target volume and its location relative to the chest wall on the target dose were examined. The median (range) leaf margin required for the 95% and 80% plans was 3.9 mm (1.3 to 5.0) and -1.2 mm (-1.8 to 0.1), respectively. Notably, the latter was significantly correlated negatively with PTV. In the 80% plans, the PTV D-95 was slightly higher under XVMC, whereas the PTV D-98 was significantly lower, irrespective of the dose calculation algorithm used. Other PTV and all gross tumor volume doses were significantly higher, while the lung doses outside the PTV were slightly lower. The target doses increased as a function of PTV and were significantly lower for island tumors than for edge tumors. In conclusion, inhomogeneous target dose planning using smaller leaf margin for a larger tumor volume was deemed suitable in ensuring more sufficient target dose while slightly reducing lung dose. In addition, more inhomogeneous target dose planning using <80% IDS (e.g., 70%) for PTV covering would be preferable for island tumors. (C) 2015 American Association of Medical Dosimetrists.	[Ohtakara, Kazuhiro] Asahi Univ, Murakami Mem Hosp, Dept Radiat Oncol, Gifu 5008523, Japan; [Hoshi, Hiroaki] Gifu Univ, Grad Sch Med, Dept Radiol, Gifu, Japan	Ohtakara, K (reprint author), Asahi Univ, Murakami Mem Hosp, Dept Radiat Oncol, 3-23 Hashimoto Cho, Gifu 5008523, Japan.	ohtakara@murakami.asahi-u.ac.jp			Japanese Society for Promotion of Science (JSPS) KAKENHI	This study was presented in part at the 27th Annual Meeting of Japan 3-D conformal external beam radiotherapy group, February 2014, Tokyo, Japan. This study was supported in part by Grants-in-Aid from the Japanese Society for Promotion of Science (JSPS) KAKENHI.	Matsuo Y, 2007, INT J RADIAT ONCOL, V68, P416, DOI 10.1016/j.ijrobp.2006.12.012; Pettersson N, 2009, RADIOTHER ONCOL, V91, P360, DOI 10.1016/j.radonc.2009.03.022; Shi CY, 2013, MED DOSIM, V38, P287, DOI 10.1016/j.meddos.2013.02.010; Nishimura S, 2014, J THORAC ONCOL, V9, P1370, DOI 10.1097/JTO.0000000000000260; Dunlap NE, 2012, INT J RADIAT ONCOL, V84, P1071, DOI 10.1016/j.ijrobp.2012.01.088; Guckenberger M, 2007, INT J RADIAT ONCOL, V69, P276, DOI 10.1016/j.ijrobp.2007.04.074; Kelsey CR, 2013, SURG ONCOL CLIN N AM, V22, P463, DOI 10.1016/j.soc.2013.02.011; Takeda A, 2009, INT J RADIAT ONCOL, V74, P363, DOI 10.1016/j.ijrobp.2008.08.012; Giraud P, 2000, INT J RADIAT ONCOL, V48, P1015, DOI 10.1016/S0360-3016(00)00750-1; Uematsu M, 1998, CANCER-AM CANCER SOC, V82, P1062, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1062::AID-CNCR8>3.0.CO;2-G; Rassiah-Szegedi P, 2006, ACTA ONCOL, V45, P989, DOI 10.1080/02841860600919225; BLOMGREN H, 1995, ACTA ONCOL, V34, P861; Chatty I. J., 2013, RADIOTHER ONCOL, V109, P498; De La Fuente Herman T., 2010, J APPL CLIN MED PHYS, V11, P158; Disher B, 2013, PHYS MED BIOL, V58, P6641, DOI 10.1088/0031-9155/58/19/6641; Fragoso M, 2010, PHYS MED BIOL, V55, P4445, DOI 10.1088/0031-9155/55/16/S02; Frank SJ, 2003, INT J RADIAT ONCOL, V56, P1308, DOI 10.1016/S0360-3016(03)00337-7; Liu Michael B, 2013, Pract Radiat Oncol, V3, P294, DOI 10.1016/j.prro.2012.09.003; Matsugi Kiyotomo, 2013, Radiol Phys Technol, V6, P233, DOI 10.1007/s12194-012-0193-y; Miura H, 2014, J APPL CLIN MED PHYS, V15, P38; Miura H, 2013, J RADIAT RES, V54, P140, DOI 10.1093/jrr/rrs054; Narabayashi M, 2012, J RADIAT RES, V53, P777, DOI 10.1093/jrr/rrs026; Ohtakara K, 2011, JPN J RADIOL, V29, P630, DOI 10.1007/s11604-011-0606-6; Ohtakara K., 2014, INT J MED PHYS CLIN, V3, P183; Ohtakara K, 2012, RADIOTHER ONCOL, V102, P198, DOI 10.1016/j.radonc.2011.10.012; Ohtakara K, 2012, BRIT J RADIOL, V85, pE223, DOI 10.1259/bjr/36606138; Ohtakara K, 2012, BRIT J RADIOL, V85, pE640, DOI 10.1259/bjr/21015703; Ohtakara K, 2012, BRIT J RADIOL, V85, P69, DOI 10.1259/bjr/20905396; Oku Yohei, 2012, Pract Radiat Oncol, V2, P46, DOI 10.1016/j.prro.2011.06.001; Persson GF, 2012, BRIT J RADIOL, V85, pE654, DOI 10.1259/bjr/76424694; Ross Christopher C, 2011, Pract Radiat Oncol, V1, P126, DOI 10.1016/j.prro.2010.11.002; Schuring D, 2008, RADIAT ONCOL, V3, DOI 10.1186/1748-717X-3-21; Takeda A, 2014, J RADIAT RES, V55, P988, DOI 10.1093/jrr/rru037; Taylor M, 2012, MED DOSIM, V37, P61, DOI 10.1016/j.meddos.2011.01.002; Zhuang TL, 2013, J APPL CLIN MED PHYS, V14, P38; Zimmermann F, 2010, FRONT RADIAT THER ON, V42, P94, DOI 10.1159/000262465	36	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0958-3947	1873-4022		MED DOSIM	Med. Dosim.	FAL	2015	40	3					248	255		10.1016/j.meddos.2015.02.001		8	Oncology; Radiology, Nuclear Medicine & Medical Imaging	Oncology; Radiology, Nuclear Medicine & Medical Imaging	CO8VD	WOS:000359449400016		
J	Baito, K; Imai, S; Matsushita, M; Otani, M; Sato, Y; Kimura, H				Baito, Kyohei; Imai, Satomi; Matsushita, Makoto; Otani, Miku; Sato, Yu; Kimura, Hiroyuki			Biogas production using anaerobic groundwater containing a subterranean microbial community associated with the accretionary prism	MICROBIAL BIOTECHNOLOGY			English	Article							METHANE PRODUCTION; SP-NOV.; FATTY-ACIDS; GEN-NOV.; BACTERIUM; ORIGIN; JAPAN; POPULATION; COCULTURE; DIGESTION	In a deep aquifer associated with an accretionary prism, significant methane (CH4) is produced by a subterranean microbial community. Here, we developed bioreactors for producing CH4 and hydrogen (H-2) using anaerobic groundwater collected from the deep aquifer. To generate CH4, the anaerobic groundwater amended with organic substrates was incubated in the bioreactor. At first, H-2 was detected and accumulated in the gas phase of the bioreactor. After the H-2 decreased, rapid CH4 production was observed. Phylogenetic analysis targeting 16S rRNA genes revealed that the H-2-producing fermentative bacterium and hydrogenotrophic methanogen were predominant in the reactor. The results suggested that syntrophic biodegradation of organic substrates by the H-2-producing fermentative bacterium and the hydrogenotrophic methanogen contributed to the CH4 production. For H-2 production, the anaerobic groundwater, amended with organic substrates and an inhibitor of methanogens (2-bromoethanesulfonate), was incubated in a bioreactor. After incubation for 24h, H-2 was detected from the gas phase of the bioreactor and accumulated. Bacterial 16S rRNA gene analysis suggested the dominance of the H-2-producing fermentative bacterium in the reactor. Our study demonstrated a simple and rapid CH4 and H-2 production utilizing anaerobic groundwater containing an active subterranean microbial community.	[Baito, Kyohei; Imai, Satomi; Matsushita, Makoto; Otani, Miku; Sato, Yu; Kimura, Hiroyuki] Shizuoka Univ, Grad Sch Sci, Dept Geosci, Shizuoka 4228529, Japan; [Kimura, Hiroyuki] Shizuoka Univ, Ctr Integrated Res & Educ Nat Hazards, Shizuoka 4228529, Japan; [Kimura, Hiroyuki] Japan Sci & Technol Agcy JST, PRESTO, Kawaguchi, Saitama, Japan	Kimura, H (reprint author), Shizuoka Univ, Grad Sch Sci, Dept Geosci, Shizuoka 4228529, Japan.	shkimur@ipc.shizuoka.ac.jp			PRESTO, JST	This research was supported by a grant from PRESTO, JST.	Albuquerque L, 2011, INT J SYST EVOL MICR, V61, P2450, DOI 10.1099/ijs.0.028852-0; Shimoyama T, 2009, SCIENCE, V323, P1574, DOI 10.1126/science.1170086; Walker CB, 2012, ISME J, V6, P2045, DOI 10.1038/ismej.2012.60; ZEIKUS JG, 1972, J BACTERIOL, V109, P707; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Li YQ, 2013, BIORESOURCE TECHNOL, V149, P565, DOI 10.1016/j.biortech.2013.09.063; Eder W, 1999, ARCH MICROBIOL, V172, P213, DOI 10.1007/s002030050762; Herve F, 2013, GONDWANA RES, V23, P1122, DOI 10.1016/j.gr.2012.06.016; Hori T, 2006, APPL ENVIRON MICROB, V72, P1623, DOI 10.1128/AEM.72.2.1623-1630.2006; Hillesland KL, 2010, P NATL ACAD SCI USA, V107, P2124, DOI 10.1073/pnas.0908456107; COLLINS MD, 1994, INT J SYST BACTERIOL, V44, P812; IGARI SI, 1989, GEOCHEM J, V23, P139; Sekiguchi Y, 2006, INT J SYST EVOL MICR, V56, P1621, DOI 10.1099/ijs.0.64112-0; Ishii S, 2005, APPL ENVIRON MICROB, V71, P7838, DOI 10.1128/AEM.71.12.7838-7845.2005; Liu XY, 2013, BIORESOURCE TECHNOL, V146, P317, DOI 10.1016/j.biortech.2013.07.096; GOOD IJ, 1953, BIOMETRIKA, V40, P237, DOI 10.2307/2333344; Ogg CD, 2009, INT J SYST EVOL MICR, V59, P964, DOI 10.1099/ijs.0.004218-0; Carrillo-Reyes J, 2014, BIOMASS BIOENERG, V63, P101, DOI 10.1016/j.biombioe.2014.01.050; Davis JS, 1998, J STRUCT GEOL, V20, P639, DOI 10.1016/S0191-8141(98)00001-7; Fagereng, 2011, J STRUCT GEOL, V33, P918; Kaneko M, 2014, ANAL CHEM, V86, P3633, DOI 10.1021/ac500305j; KANO K, 1991, TECTONOPHYSICS, V185, P375, DOI 10.1016/0040-1951(91)90455-2; KHAN AW, 1980, FEMS MICROBIOL LETT, V9, P233, DOI 10.1111/j.1574-6968.1980.tb05643.x; Kimura H, 2013, ENV MICROBIOL REP, V5, P468, DOI 10.1111/1758-2229.12035; Kimura H, 2010, ISME J, V4, P531, DOI 10.1038/ismej.2009.132; Ling FQ, 2013, MICROBES ENVIRON, V28, P50, DOI 10.1264/jsme2.ME12095; Liu YT, 1997, INT J SYST BACTERIOL, V47, P615; Plugge CM, 2002, INT J SYST EVOL MICR, V52, P401, DOI 10.1099/ijs.0.01949-0; Sakata S, 2012, GEOFLUIDS, V12, DOI 10.1111/gfl.12007; Svetlitshnyi V, 1996, INT J SYST BACTERIOL, V46, P1131; Tanabe H., 1996, ISL ARC, V5, P56, DOI 10.1111/j.1440-1738.1996.tb00012.x; Zhong WZ, 2014, BIORESOURCE TECHNOL, V151, P436, DOI 10.1016/j.biortech.2013.10.100	32	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1751-7907	1751-7915		MICROB BIOTECHNOL	Microb. Biotechnol.	SEP	2015	8	5			SI		837	845		10.1111/1751-7915.12179		9	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CP1AC	WOS:000359607200008		
J	Itakura, M; Kaburaki, H; Yamaguchi, M; Tsuru, T				Itakura, M.; Kaburaki, H.; Yamaguchi, M.; Tsuru, T.			Atomistic study on the cross-slip process of a screw < a > dislocation in magnesium	MODELLING AND SIMULATION IN MATERIALS SCIENCE AND ENGINEERING			English	Article						magnesium; dislocation; density functional theory	MOLECULAR-DYNAMICS; PRISMATIC GLIDE; HCP METALS; ALLOYS; SYSTEMS; STRESS; INSITU; MG	The cross-slip process of a screw < a > dislocation from the basal to the prismatic plane in magnesium was studied using the density functional theory and the molecular dynamics calculations. An atomistic method for calculating the total Peierls energy map has been devised to track the transition path of a dissociated and/or constricted screw < a > dislocation in the cross-slip process. The barrier of a screw < a > dislocation from the basal to the prismatic plane is estimated by the density functional theory for the first time to be 61.4 +/- 2.0 meV per Burgers vector length. The activation enthalpy for the cross slip is calculated using a line tension model based on the density functional theory to be 1.4-1.7 eV, which is in reasonable agreement with experiments. On the basis of the results, the effect of temperature on the cross-slip process of the dissociated screw < a > dislocation on the basal plane is studied in detail using the molecular dynamics method with the embedded-atom-method (EAM) interatomic potential, in which the critical resolved shear stress for the cross slip is evaluated. It is confirmed that the bowed-out dislocation line on the prismatic plane consists of slightly dissociated rectilinear segments with connecting jogs at low temperatures and, as the temperature rises, the curved dislocation line becomes smooth with many segments. The motion of an < a > dislocation on the prismatic plane is jerky in the low temperature region, while it is retarded by the formation of the largely dissociated plateau segment above the room temperature. A large reduction of the critical shear stress for the cross slip is obtained when the < a > screw dislocation interacts with a hard-sphere particle placed on the basal plane in the low temperature region.	[Itakura, M.] Japan Atom Energy Agcy, Ctr Computat Sci & E Syst, Kashiwa, Chiba 2770871, Japan; [Kaburaki, H.; Yamaguchi, M.] Japan Atom Energy Agcy, Ctr Computat Sci & E Syst, Tokai, Ibaraki 3191195, Japan; [Tsuru, T.] Japan Atom Energy Agcy, Nucl Sci & Engn Ctr, Tokai, Ibaraki 3191195, Japan	Itakura, M (reprint author), Japan Atom Energy Agcy, Ctr Computat Sci & E Syst, 178-4-4 Wakashiba, Kashiwa, Chiba 2770871, Japan.	itakura.mitsuhiro@jaea.go.jp	Yamaguchi, Masatake/E-3497-2013		Ministry of Education, Sports and Culture, Japan [23109001]; Toyota Motor Corporation	The authors (MI, HK, MY) acknowledge the support by a Grand-in-Aid for Scientific Research on Innovative Areas,'Synchronized Long-Period-Stacking Ordered Structure', from the Ministry of Education, Sports and Culture, Japan (No. 23109001). All the authors acknowledge the financial support by Toyota Motor Corporation. HK acknowledges Dr F Shimizu for adding new functions to the software AtomEye.	Ahmadieh J, 1965, T AM I MIN MET ENG, V233, P1130; Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169; Yoo MH, 2001, MAT SCI ENG A-STRUCT, V319, P87, DOI 10.1016/S0921-5093(01)01027-9; Sun DY, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.024116; COURET A, 1985, ACTA METALL MATER, V33, P1455, DOI 10.1016/0001-6160(85)90046-X; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Shin I, 2014, INT J PLASTICITY, V60, P58, DOI 10.1016/j.ijplas.2014.04.002; Kadoyoshi T, 2007, ACTA MATER, V55, P3073, DOI 10.1016/j.actamat.2007.01.010; AKHTAR A, 1969, ACTA METALL MATER, V17, P1351, DOI 10.1016/0001-6160(69)90152-7; Rodney D, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.094108; YOO MH, 1981, METALL TRANS A, V12, P409, DOI 10.1007/BF02648537; Chino Y, 2008, ACTA MATER, V56, P387, DOI 10.1016/j.actamat.2007.09.036; Cai W, 2003, PHILOS MAG, V83, P539, DOI 10.1080/0141861021000051109; Agnew SR, 2002, METALL MATER TRANS A, V33, P851, DOI 10.1007/s11661-002-0154-x; Koike J, 2003, ACTA MATER, V51, P2055, DOI 10.1016/S1359-6454(03)00005-3; Li J, 2003, MODEL SIMUL MATER SC, V11, P173, DOI 10.1088/0965-0393/11/2/305; COURET A, 1985, ACTA METALL MATER, V33, P1447, DOI 10.1016/0001-6160(85)90045-8; Yasi JA, 2011, ACTA MATER, V59, P5652, DOI 10.1016/j.actamat.2011.05.040; Proville L, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.144106; PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039; Chino Y, 2008, MAT SCI ENG A-STRUCT, V494, P343, DOI 10.1016/j.msea.2008.04.059; Yasi JA, 2009, MODEL SIMUL MATER SC, V17, DOI 10.1088/0965-0393/17/5/055012; Agnew SR, 2010, SCRIPTA MATER, V63, P671, DOI 10.1016/j.scriptamat.2010.06.029; Caillard D, 2014, ACTA MATER, V62, P267, DOI 10.1016/j.actamat.2013.10.007; COURET A, 1991, PHILOS MAG A, V63, P1045; Edagawa K, 1997, PHYS REV B, V55, P6180, DOI 10.1103/PhysRevB.55.6180; Henkelman G, 2002, THEORETICAL METHODS, P269; KRESSE G, 1993, PHYS REV B, V47, P558, DOI 10.1103/PhysRevB.47.558; Sandlobes S, 2013, MAT SCI ENG A-STRUCT, V576, P61, DOI 10.1016/j.msea.2013.03.006; Shin I, 2012, MODEL SIMUL MATER SC, V20, DOI 10.1088/0965-0393/20/1/015006; Ward-Flynn P, 1961, T TMS AIME, V221, P1148; Yoshinaga H., 1963, T JIM, V5, P14	32	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0965-0393	1361-651X		MODEL SIMUL MATER SC	Model. Simul. Mater. Sci. Eng.	SEP	2015	23	6							065002	10.1088/0965-0393/23/6/065002		19	Materials Science, Multidisciplinary; Physics, Applied	Materials Science; Physics	CO7EM	WOS:000359322300002		
J	Namikoshi, T; Fujimoto, S; Yorimitsu, D; Ihoriya, C; Fujimoto, Y; Komai, N; Sasaki, T; Kashihara, N				Namikoshi, Tamehachi; Fujimoto, Sohachi; Yorimitsu, Daisuke; Ihoriya, Chieko; Fujimoto, Yasuo; Komai, Norio; Sasaki, Tamaki; Kashihara, Naoki			Relationship between vascular function indexes, renal arteriolosclerosis, and renal clinical outcomes in chronic kidney disease	NEPHROLOGY			English	Article						arteriolosclerosis; blood pressure; kidney disease; vascular resistance; vascular stiffness	JAPANESE GENERAL-POPULATION; IGA NEPHROPATHY; ARTERIAL STIFFNESS; RESISTIVE INDEX; PULSE PRESSURE; ASSOCIATION; HYPERTENSION; RISK; HEMODIALYSIS; PROGNOSIS	AimHypertension contributes critically to the development of renal arteriolosclerosis in chronic kidney disease (CKD), but the impact of vascular function indexes including central blood pressure on renal arteriolosclerosis has not been investigated. We determined whether vascular function indexes were related to renal arteriolosclerosis and renal clinical outcomes in CKD. MethodsThis cross-sectional study was implemented in our hospital. Subjects were in-patients with CKD aged 20 years who underwent a renal biopsy. Vascular function indexes included central systolic blood pressure (SBP), cardio-ankle vascular index (CAVI), and renal resistive index. Central SBP was measured non-invasively using an automated device. Arteriolosclerosis was assessed histologically. Renal clinical outcomes included estimated glomerular filtration rate using serum creatinine (eGFRcreat) or cystatin C (eGFRcys), and the urinary albumin-creatinine ratio. ResultsAmong vascular function indexes, central SBP was weakly correlated with renal arteriolosclerosis (n=55). Renal arteriolosclerosis was increased in hypertensive or hyperuricaemic patients, and negatively correlated with serum high-density lipoprotein (HDL) cholesterol and eGFRcys, which were independent risk factors for renal arteriolosclerosis in a stepwise multivariate regression analysis. Of the vascular function indexes, CAVI showed the strongest correlation with all renal clinical outcomes. Central SBP was correlated with only urinary albumin-creatinine ratio, while renal resistive index was correlated with eGFRcreat and urinary albumin-creatinine ratio. ConclusionDecreased serum HDL cholesterol was independently and most closely associated with renal arteriolosclerosis. Of the vascular function indexes, CAVI had the greatest impact on renal clinical outcomes, although it was not associated with renal arteriolosclerosis. Summary at a Glance Cross sectional study on 55 patients with biopsy-proven CKD showing cardio-ankle vascular index associated with clinical outcomes (eGFR, ACR). Needs evaluation in prospective study with ESRD.	[Namikoshi, Tamehachi; Fujimoto, Sohachi; Yorimitsu, Daisuke; Ihoriya, Chieko; Fujimoto, Yasuo; Komai, Norio; Sasaki, Tamaki; Kashihara, Naoki] Kawasaki Med Univ, Dept Hypertens & Nephrol, Kurashiki, Okayama 7010192, Japan	Namikoshi, T (reprint author), Kawasaki Med Univ, Dept Hypertens & Nephrol, 577 Matsushima, Kurashiki, Okayama 7010192, Japan.	tnamikoshi@med.kawasaki-m.ac.jp			Kawasaki Medical School	This study was supported by a Research Project Grant from the Kawasaki Medical School. It was registered in the UMINCTR, a clinical trials registry in Japan (UMIN000010214).	Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Horio M, 2013, AM J KIDNEY DIS, V61, P197, DOI 10.1053/j.ajkd.2012.07.007; Myllymaki J, 2005, NEPHROL DIAL TRANSPL, V20, P89, DOI 10.1093/ndt/gfh584; Kubozono T, 2009, J ATHEROSCLER THROMB, V16, P840; Shirai K, 2011, J ATHEROSCLER THROMB, V18, P924; Fogo A, 1997, KIDNEY INT, V51, P244, DOI 10.1038/ki.1997.29; Roman MJ, 2014, HYPERTENSION, V63, P1148, DOI 10.1161/HYPERTENSIONAHA.114.03361; Nakamura K, 2009, J ATHEROSCLER THROMB, V16, P371; Ikee R, 2005, AM J KIDNEY DIS, V46, P603, DOI 10.1053/j.ajkd.2005.06.006; Briet M, 2011, J AM SOC NEPHROL, V22, P967, DOI 10.1681/ASN.2010080863; Takase H, 2013, HYPERTENS RES, V36, P50, DOI 10.1038/hr.2012.122; Kohagura K, 2013, HYPERTENS RES, V36, P43, DOI 10.1038/hr.2012.135; Hashimoto J, 2011, HYPERTENSION, V58, P839, DOI 10.1161/HYPERTENSIONAHA.111.177469; Sugiura T, 2011, CLIN EXP NEPHROL, V15, P114, DOI 10.1007/s10157-010-0371-3; Cohen DL, 2011, INT J NEPHROL, V2011; Hanamura K, 2012, INT J NEPHROL, DOI [10.1155/2012/139565, DOI 10.1155/2012/139565]; Ichihara A, 2008, AM J KIDNEY DIS, V52, P947, DOI 10.1053/j.ajkd.2008.06.007; Ikee R, 2006, HYPERTENS RES, V29, P15, DOI 10.1291/hypres.29.15; Ikee R, 2010, HYPERTENS RES, V33, P499, DOI 10.1038/hr.2010.22; Katafuchi R, 1998, CLIN NEPHROL, V49, P1; National Kidney Foundation, 2002, AM J KIDNEY DIS S, V39, pS1, DOI DOI 10.1053/AJKD.2002.30571.PUBMED:11904577; Nieuwhof C, 1998, AM J KIDNEY DIS, V31, P962, DOI 10.1053/ajkd.1998.v31.pm9631840; Sugiura T, 2009, NEPHROL DIAL TRANSPL, V24, P2780, DOI 10.1093/ndt/gfp121; Takenaka T, 2008, J ATHEROSCLER THROMB, V15, P339; Temmar M, 2010, HYPERTENSION, V55, P327, DOI 10.1161/HYPERTENSIONAHA.109.142851; Tracy Richard E., 2000, International Urology and Nephrology, V32, P109, DOI 10.1023/A:1007119132063; Ueyama K, 2009, HYPERTENS RES, V32, P716, DOI 10.1038/hr.2009.83	27	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5358	1440-1797		NEPHROLOGY	Nephrology	SEP	2015	20	9					585	590		10.1111/nep.12483		6	Urology & Nephrology	Urology & Nephrology	CP4MQ	WOS:000359856600001		
J	Iimori, S; Naito, S; Noda, Y; Nishida, H; Kihira, H; Yui, N; Okado, T; Sasaki, S; Uchida, S; Rai, T				Iimori, Soichiro; Naito, Shotaro; Noda, Yumi; Nishida, Hidenori; Kihira, Hiromi; Yui, Naofumi; Okado, Tomokazu; Sasaki, Sei; Uchida, Shinichi; Rai, Tatemitsu			Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study	NEPHROLOGY			English	Article						anaemia; cardiovascular disease; chronic kidney disease; iron deficiency; mortality	STAGE RENAL-DISEASE; CARDIOVASCULAR-DISEASE; ATHEROSCLEROSIS RISK; PREDIALYSIS PATIENTS; NATIONAL-HEALTH; IRON-DEFICIENCY; ASSOCIATION; DIALYSIS; ERYTHROPOIETIN; OUTCOMES	AimTo investigate the association between iron deficiency anaemia and mortality risk and assess the changes in anaemia and iron status after primary management by a nephrologist. MethodsIn this prospective cohort study, we stratified 951 non-dialysis chronic kidney disease (CKD) G2-G5 patients newly visiting 16 nephrology centres into four groups according to the presence of anaemia with or without iron deficiency. All-cause mortality, cardiovascular (CV)-related mortality, and a change in anaemia and iron status after specialized primary care were the endpoints evaluated. ResultsDuring a median follow-up time of 19 months, the number of all-cause deaths and CV-related deaths were 56 and 26, respectively. Compared with the control group, the groups with isolated anaemia and iron deficiency anaemia had significantly higher all-cause mortalities (isolated anaemia: hazard ratio (HR), 3.37; 95% confidence intervals (CI), 1.76-6.44; iron deficiency anaemia: HR, 3.11; 95% CI, 1.21-8.01) and CV-related mortalities (isolated anaemia: HR, 3.64; 95% CI, 1.36-9.73; iron deficiency anaemia: HR, 3.86; 95% CI, 1.11-13.41). In the isolated anaemia group, erythropoietin-stimulating agent (ESA) prescriptions significantly increased to approximately 70%. However, in patients with both anaemia and iron deficiency, iron prescriptions only increased to 48.1%. ConclusionsIron deficiency anaemia and isolated anaemia were associated with all-cause and CV-related mortality. The absence of relative increase in iron prescriptions suggests that iron deficiency should be accurately assessed and iron supplementation should be appropriately used to manage anaemia in non-dialysis patients with CKD. Summary at a Glance This interesting paper demonstrates the association between anaemia, iron deficiency and increased mortality (both cardiovascular and all-cause mortality) in a cohort of Japanese people with CKD. While the prescription of ESAs increased significantly in a 6-month period, the iron replacement seemed to be less so, suggesting a potential opportunity for future clinical intervention.	[Iimori, Soichiro; Naito, Shotaro; Yui, Naofumi; Okado, Tomokazu; Sasaki, Sei; Uchida, Shinichi; Rai, Tatemitsu] Tokyo Med & Dent Univ, Dept Nephrol, Tokyo 1138519, Japan; [Noda, Yumi] Nakano Gen Hosp, Dept Nephrol, Kanagawa, Japan; [Kihira, Hiromi] Tokyo Metropolitan Tama Med Ctr, Dept Nephrol, Kanagawa, Japan; [Nishida, Hidenori] Hiratsuka Kyosai Hosp, Dept Nephrol, Kanagawa, Japan	Rai, T (reprint author), Tokyo Med & Dent Univ, Dept Nephrol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	trai.kid@tmd.ac.jp			Chugai Pharmaceutical Co., Ltd	The authors are very grateful for the general support of Chugai Pharmaceutical Co., Ltd. The authors thank their clinical staffs, who understood the clinical importance of this study and provided high-quality data. The authors particularly thank all the patients who participated in this study.	Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Fishbane S, 2009, CLIN J AM SOC NEPHRO, V4, P57, DOI 10.2215/CJN.01670408; Langston RD, 2003, KIDNEY INT, V64, P1398, DOI 10.1046/j.1523-1755.2003.00200.x; Kovesdy CP, 2009, CLIN J AM SOC NEPHRO, V4, P435, DOI 10.2215/CJN.03980808; Sarnak MJ, 2002, J AM COLL CARDIOL, V40, P27, DOI 10.1016/S0735-1097(02)01938-1; Abramson JL, 2003, KIDNEY INT, V64, P610, DOI 10.1046/j.1523-1755.2003.00109.x; Xue JL, 2002, AM J KIDNEY DIS, V40, P1153, DOI 10.1053/ajkd.2002.36861; Cases-Amenos A, 2014, NEFROLOGIA, V34, P189, DOI 10.3265/Nefrologia.pre2013.Dec.12261; Dunn LL, 2007, TRENDS CELL BIOL, V17, P93, DOI 10.1016/j.tcb.2006.12.003; Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P121, DOI 10.1093/ndt/gfg458; Minutolo R, 2013, NEPHROL DIAL TRANSPL, V28, P3035, DOI 10.1093/ndt/gft338; Brownlie T, 2004, AM J CLIN NUTR, V79, P437; Jurkovitz CT, 2003, J AM SOC NEPHROL, V14, P2919, DOI 10.1097/01.ASN.0000092138.65211.71; Astor BC, 2002, ARCH INTERN MED, V162, P1401, DOI 10.1001/archinte.162.12.1401; Akizawa T, 2011, CLIN EXP NEPHROL, V15, P248, DOI 10.1007/s10157-010-0396-7; Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x; Keane WF, 2003, KIDNEY INT, V63, P1499, DOI 10.1046/j.1523-1755.2003.00885.x; Dong F, 2005, CLIN SCI, V109, P277, DOI 10.1042/CS20040278; Hayashi T, 2000, AM J KIDNEY DIS, V35, P250, DOI 10.1016/S0272-6386(00)70334-9; Foley RN, 1996, AM J KIDNEY DIS, V28, P53, DOI 10.1016/S0272-6386(96)90130-4; McClellan WM, 2002, J AM SOC NEPHROL, V13, P1928, DOI 10.1097/01.ASN.0000018409.45834.FA; Fink JC, 2001, AM J KIDNEY DIS, V37, P348, DOI 10.1053/ajkd.2001.21305; Iimori S, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-152; Japan Nephrology Society, 2012, NIHON JINZO GAKKAI S, V54, P1034; Japanese Society of Nephrology, 2009, CLIN EXP NEPHROL, V13, P537, DOI 10.1007/s10157-009-0237-8; Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group, 2012, KIDNEY INT S, V2, P279; Portoles J, 1997, AM J KIDNEY DIS, V29, P541, DOI 10.1016/S0272-6386(97)90335-8	27	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5358	1440-1797		NEPHROLOGY	Nephrology	SEP	2015	20	9					601	608		10.1111/nep.12493		8	Urology & Nephrology	Urology & Nephrology	CP4MQ	WOS:000359856600003		
J	Kazama, I; Baba, A; Endo, Y; Toyama, H; Ejima, Y; Matsubara, M; Tachi, M				Kazama, Itsuro; Baba, Asuka; Endo, Yasuhiro; Toyama, Hiroaki; Ejima, Yutaka; Matsubara, Mitsunobu; Tachi, Masahiro			Mast cell involvement in the progression of peritoneal fibrosis in rats with chronic renal failure	NEPHROLOGY			English	Article						chronic renal failure; fibroblast-activating factors; mast cells; peritoneal fibrosis; tranilast	MEMBRANE-SURFACE DEFORMATION; KIDNEY-DISEASE; TRANILAST; MODEL; SCLEROSIS; EXOCYTOSIS; CHYMASE; INJURY	AimPeritoneal fibrosis is a serious complication in patients with end stage renal disease (ESRD), especially those undergoing long-term peritoneal dialysis therapy. Since the peritoneum is a major site of mast cell accumulation, and since mast cells are known to facilitate the progression of organ fibrosis, they would also contribute to the pathogenesis of peritoneal fibrosis. The aim of this study was to reveal the involvement of mast cells in the progression of peritoneal fibrosis in chronic renal failure. MethodsUsing a rat model with chronic renal failure (CRF) resulting from 5/6 nephrectomy, we examined the histopathological features of the rat peritoneum and compared them to those of age-matched sham-operated rat peritoneum. By treating the CRF rats with a potent mast cell stabilizer, tranilast, we also examined the involvement of mast cells in the progression of peritoneal fibrosis. ResultsThe CRF rat peritoneum was characterized by the wide staining of collagen III and an increased number of myofibroblasts, indicating the progression of fibrosis. Compared to sham-operated rat peritoneum, the number of toluidine blue-stained mast cells was significantly higher in the fibrotic peritoneum of CRF rats. The mRNA expression of fibroblast-activating factors and stem cell factor was significantly higher in peritoneal mast cells obtained from CRF rats than in those obtained from sham-operated rats. Treatment with tranilast significantly suppressed the progression of peritoneal fibrosis in CRF rats. ConclusionsThis study demonstrated for the first time that the number of mast cells was significantly increased in the fibrotic peritoneum of CRF rats. The proliferation of mast cells and their increased activity in the peritoneum were thought to be responsible for the progression of peritoneal fibrosis. Summary at a Glance Using a rat model of CKD and peritoneal fibrosis, the authors demonstrated the possible involvement of mast cells in the pathogenesis of peritoneal fibrosis, as indicated by their increased numbers and activity.	[Kazama, Itsuro; Baba, Asuka] Tohoku Univ, Grad Sch Med, Dept Physiol 1, Sendai, Miyagi 9808575, Japan; [Baba, Asuka; Tachi, Masahiro] Tohoku Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Sendai, Miyagi 9808575, Japan; [Matsubara, Mitsunobu] Tohoku Univ, Grad Sch Med, Ctr Translat & Adv Anim Res, Div Mol Med, Sendai, Miyagi 9808575, Japan; [Endo, Yasuhiro; Toyama, Hiroaki; Ejima, Yutaka] Tohoku Univ Hosp, Dept Anesthesiol, Sendai, Miyagi, Japan	Kazama, I (reprint author), Tohoku Univ, Grad Sch Med, Dept Physiol 1, Aoba Ku, Seiryo Cho, Sendai, Miyagi 9808575, Japan.	kazaitsu@med.tohoku.ac.jp			Miyagi Kidney Foundation; MEXT KAKENHI [25860155]	We thank Ms. Fumiko Date, Ms. Miki Yoshizawa and their colleagues at Biomedical Research Core of Tohoku University Graduate School of Medicine for their technical support. This work was supported by Miyagi Kidney Foundation Grant and MEXT KAKENHI Grant Number 25860155.	Rogosnitzky M, 2012, ANTICANCER RES, V32, P2471; Tan SM, 2011, NEPHROL DIAL TRANSPL, V26, P100, DOI 10.1093/ndt/gfq355; Malbec O, 2007, J IMMUNOL, V178, P6465; Blank U, 2007, IMMUNOL REV, V217, P79, DOI 10.1111/j.1600-065X.2007.00503.x; Miyajima A, 2001, J UROLOGY, V165, P1714, DOI 10.1016/S0022-5347(05)66400-2; Kawaguchi Y, 2000, PERITON DIALYSIS INT, V20, pS43; Shiota N, 2005, BRIT J PHARMACOL, V145, P424, DOI 10.1038/sj.bjp.0706209; Margetts PJ, 2002, AM J PATHOL, V160, P2285, DOI 10.1016/S0002-9440(10)61176-5; Doggrell SA, 2005, CAN J PHYSIOL PHARM, V83, P123, DOI 10.1139/Y04-136; Holdsworth SR, 2008, J AM SOC NEPHROL, V19, P2254, DOI 10.1681/ASN.2008010015; Nakamoto H, 2001, PERITON DIALYSIS INT, V21, pS349; Kazama I, 2013, CELL PHYSIOL BIOCHEM, V31, P592, DOI 10.1159/000350079; Combet S, 2001, J AM SOC NEPHROL, V12, P2146; Barreto DV, 2010, KIDNEY INT, V77, P550, DOI 10.1038/ki.2009.503; Williams JD, 2002, J AM SOC NEPHROL, V13, P470; Baba A, 2015, CELL PHYSIOL BIOCHEM, V35, P386, DOI 10.1159/000369704; DULLENS HFJ, 1981, J IMMUNOL METHODS, V40, P367, DOI 10.1016/0022-1759(81)90368-9; Gruber B L, 1995, Int Rev Immunol, V12, P259, DOI 10.3109/08830189509056717; Gruber Barry L, 2003, Curr Rheumatol Rep, V5, P147, DOI 10.1007/s11926-003-0043-3; Hanada M, 2014, J NEUROL SCI, V346, P209, DOI 10.1016/j.jns.2014.08.028; Imai Hiroe, 2003, Adv Perit Dial, V19, P180; Kaysen GA, 2003, J RENAL NUTR, V13, P158, DOI 10.1053/jren.2003.50021; Kazama I, 2012, INT J NEPHROL, V2012; Kazama I, 2014, NEPHRON EXP NEPHROL, V128, P67, DOI 10.1159/000368080; Kelly DJ, 2004, J AM SOC NEPHROL, V15, P2619, DOI 10.1097/01.ASN.0000139066.77892.04; Margetts PJ, 2001, PERITON DIALYSIS INT, V21, pS368; Michimata M, 2003, NEPHRON PHYSIOL, V93, P34; Miyazaki M, 2005, PERITON DIALYSIS INT, V25, pS48; NISHIGAKI T, 1988, VIRCHOWS ARCH B, V55, P311; Patel TS, 2007, AM J KIDNEY DIS, V50, P11, DOI 10.1053/j.ajkd.2007.03.010	30	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5358	1440-1797		NEPHROLOGY	Nephrology	SEP	2015	20	9					609	616		10.1111/nep.12489		8	Urology & Nephrology	Urology & Nephrology	CP4MQ	WOS:000359856600004		
J	Yamada, S; Tsuruya, K; Tokumoto, M; Yoshida, H; Ooboshi, H; Kitazono, T				Yamada, Shunsuke; Tsuruya, Kazuhiko; Tokumoto, Masanori; Yoshida, Hisako; Ooboshi, Hiroaki; Kitazono, Takanari			Factors associated with serum soluble inhibitors of Wnt--catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis	NEPHROLOGY			English	Article						dickkopf-1; peritoneal dialysis; sclerostin; Wnt-beta-catenin signaling	BONE-MINERAL DENSITY; HEMODIALYSIS-PATIENTS; CIRCULATING SCLEROSTIN; RENAL OSTEODYSTROPHY; MULTIPLE-MYELOMA; DISEASE; CKD; METABOLISM; MORTALITY; MARKERS	AimSclerostin and dickkopf-1 (Dkk-1) are soluble inhibitors of Wnt--catenin signaling and are involved in decreased bone formation and bone volume in patients with various bone diseases. The clinical characteristics of sclerostin and Dkk-1 and their impacts on mineral and bone metabolism remain undetermined in patients undergoing peritoneal dialysis (PD). MethodsThis cross-sectional study investigated the association between serum sclerostin and Dkk-1 levels and mineral disorders in 74 outpatients under PD treatment. Levels of sclerostin and Dkk-1 in serum, urine, and peritoneal dialysate were determined using enzyme-linked immunosorbent assay kits. The associations between serum sclerostin and Dkk-1 levels and biochemical parameters were evaluated by linear regression analyses. ResultsMedian serum sclerostin and Dkk-1 levels were 138pmol/L (range, 98.3-195.9pmol/L) and 38.8pmol/L (range, 28.5-47.1pmol/L), respectively. Both sclerostin and Dkk-1 were excreted into urine and peritoneal dialysate. Multivariable linear regression analyses showed that serum sclerostin level was significantly associated with age, sex, parathyroid hormone level, and renal Kt/V. In contrast, serum Dkk-1 level was associated with platelet count and serum fibroblast growth factor 23 level but not with any of the bone metabolic markers. ConclusionSerum sclerostin was associated with serum intact parathyroid hormone, while Dkk-1 was associated with serum fibroblast growth factor 23 in patients undergoing PD. The utility of determining soluble Wnt--catenin inhibitors levels in patients undergoing PD requires further investigation. Summary at a Glance This cross-sectional study investigates the metabolism and association between serum sclerostin and Dkk-1 levels and serum mineral markers in 74 outpatients under PD treatment. Multivariable linear regression analyses show that both serum sclerostin and Dkk-1 level were significantly associated with the serum biomarkers of CKD-MBD, indicating the involvement of soluble Wnt--catenin inhibitors in the pathogenesis of CKD-MBD.	[Yamada, Shunsuke; Tsuruya, Kazuhiko; Kitazono, Takanari] Kyushu Univ, Dept Med & Clin Sci, Fukuoka 8128582, Japan; [Tsuruya, Kazuhiko; Yoshida, Hisako] Kyushu Univ, Grad Sch Med Sci, Dept Integrated Therapy Chron Kidney Dis, Fukuoka 8128582, Japan; [Yamada, Shunsuke; Tokumoto, Masanori; Ooboshi, Hiroaki] Fukuoka Dent Coll, Dept Internal Med, Fukuoka, Japan	Tsuruya, K (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Integrated Therapy Chron Kidney Dis, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	tsuruya@intmed2.med.kyushu-u.ac.jp					Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005-0239; Kanbay M, 2014, J CLIN ENDOCR METAB, V99, pE1854, DOI 10.1210/jc.2014-2042; Cejka D, 2014, J CLIN ENDOCR METAB, V99, P248, DOI 10.1210/jc.2013-2786; Drueke TB, 2011, CLIN J AM SOC NEPHRO, V6, P700, DOI 10.2215/CJN.01370211; Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood-2008-03-145169; Drake MT, 2010, J CLIN ENDOCR METAB, V95, P5056, DOI 10.1210/jc.2010-0720; McNulty M, 2011, J CLIN ENDOCR METAB, V96, pE1159, DOI 10.1210/jc.2011-0254; [Anonymous], 2010, THER APHER DIAL, V14, P489; Thambiah S, 2012, CALCIFIED TISSUE INT, V90, P473, DOI 10.1007/s00223-012-9595-4; PAYNE RB, 1973, BRIT MED J, V4, P643; Kaida H, 2005, ANN NUCL MED, V19, P179, DOI 10.1007/BF02984602; Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/jbmr.090411, 10.1359/JBMR.090411]; Ishimura E, 2014, J CLIN ENDOCR METAB, V99, P4315, DOI 10.1210/jc.2014-2372; Cejka D, 2012, NEPHROL DIAL TRANSPL, V27, P226, DOI 10.1093/ndt/gfr270; Liu XH, 2014, CLIN J AM SOC NEPHRO, V9, P771, DOI 10.2215/CJN.08280813; Amrein K, 2012, J CLIN ENDOCR METAB, V97, P148, DOI 10.1210/jc.2011-2152; Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011-1060; Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood-2008-11-191577; Gennari L, 2012, J CLIN ENDOCR METAB, V97, P1737, DOI 10.1210/jc.2011-2958; Cejka D, 2011, CLIN J AM SOC NEPHRO, V6, P877, DOI 10.2215/CJN.06550810; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010-0067; Fang YF, 2014, J AM SOC NEPHROL, V25, P1760, DOI 10.1681/ASN.2013080818; Sabbagh Y, 2012, J BONE MINER RES, V27, P1757, DOI 10.1002/jbmr.1630; Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002-021105; Pelletier S, 2013, CLIN J AM SOC NEPHRO, V8, P819, DOI 10.2215/CJN.07670712; Bielesz BO, 2014, BLOOD PURIFICAT, V38, P30, DOI 10.1159/000364992; Brandenburg VM, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-219; Jean G, 2013, NEPHROL DIAL TRANSPL, V28, P2932, DOI 10.1093/ndt/gft222; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, KIDNEY INT S, V113, pS1, DOI DOI 10.1038/KI.2009.188; Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182; Noordzij M, 2006, NEPHROL DIAL TRANSPL, V21, P2513, DOI 10.1093/ndt/gfl257; Voorzanger-Rousselot N, 2009, BRIT J HAEMATOL, V145, P264, DOI 10.1111/j.1365-2141.2009.07587.x; Wang AYM, 2007, PERITON DIALYSIS INT, V27, pS223; Yamada S, 2014, THER APHER DIAL, V18, P383, DOI 10.1111/1744-9987.12170	35	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5358	1440-1797		NEPHROLOGY	Nephrology	SEP	2015	20	9					639	645		10.1111/nep.12509		7	Urology & Nephrology	Urology & Nephrology	CP4MQ	WOS:000359856600008		
J	Matsuda, S; Matsuzawa, D; Ishii, D; Tomizawa, H; Sutoh, C; Shimizu, E				Matsuda, Shingo; Matsuzawa, Daisuke; Ishii, Daisuke; Tomizawa, Haruna; Sutoh, Chihiro; Shimizu, Eiji			Sex differences in fear extinction and involvements of extracellular signal-regulated kinase (ERK)	NEUROBIOLOGY OF LEARNING AND MEMORY			English	Article						Fear conditioning; Fear extinction; Spontaneous recovery; Sex differences; ERK	GENERALIZED ANXIETY DISORDER; ACTIVATED PROTEIN-KINASE; LONG-TERM POTENTIATION; NEUROTROPHIC FACTOR; CONTEXTUAL FEAR; PREFRONTAL CORTEX; NEURONAL CIRCUITS; OVARIAN-STEROIDS; CONDITIONED FEAR; SPINE DENSITY	Stress-related disorders, such as post-traumatic stress disorder (PTSD) and panic disorders, are disproportionately prevalent in females. However, the biological mechanism underlying these sex differences in the prevalence rate remains unclear. In the present study, we examined sex differences in fear memory, fear extinction, and spontaneous recovery of fear. We investigated the presence of sex differences in recent and remote fear memory in mice using contextual fear conditioning, as well as sex differences in spontaneous recovery of fear memory using a consecutive fear extinction paradigm. We examined the number of fear extinction days required to prevent spontaneous recovery of fear in either sex. We investigated whether ovariectomy affected fear extinction and spontaneous recovery. We also measured the activation of extracellular signal-regulated kinase (ERK) 1 and 2 in the dorsal hippocampus and the medial prefrontal cortex following fear extinction sessions. In our results, we found no sex difference in recent or remote fear memory. However, females required more fear extinction sessions compared to males to prevent spontaneous recovery. Within-extinction freezing also differed between males and females. Moreover, females required more extinction sessions than males to increase ERK2 phosphorylation in the dorsal hippocampus. Our data suggest that contextual fear extinction was unstable in females compared to males and that such sex differences may be related to the ERK2 phosphorylation in the hippocampus. (C) 2015 Elsevier Inc. All rights reserved.	[Matsuda, Shingo] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Ultrastructural Res, Kodaira, Tokyo 1878502, Japan; [Matsuzawa, Daisuke; Ishii, Daisuke; Tomizawa, Haruna; Sutoh, Chihiro; Shimizu, Eiji] Chiba Univ, Dept Cognit Behav Physiol, Grad Sch Med, Chiba 2608670, Japan; [Matsuzawa, Daisuke; Shimizu, Eiji] Chiba Univ, Res Ctr Child Mental Dev, Grad Sch Med, Chiba 2608670, Japan	Matsuda, S (reprint author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Ultrastructural Res, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878502, Japan.	matsutsuma@gmail.com			 [245315];  [26860912]	This research was supported by the Grant-in-Aid for JSPS Fellows Grant Number 245315 and the Grant-in-Aid for Young scientists (B) Grant Number 26860912.	Tronson NC, 2009, J NEUROSCI, V29, P3387, DOI 10.1523/JNEUROSCI.5619-08.2009; Yonkers KA, 2000, BRIT J PSYCHIAT, V176, P544, DOI 10.1192/bjp.176.6.544; Zhou J, 2005, NEUROENDOCRINOLOGY, V81, P294, DOI 10.1159/000088448; Yonkers KA, 2003, DEPRESS ANXIETY, V17, P173, DOI 10.1002/da.10106; Rodriguez-Ortiz CJ, 2005, LEARN MEMORY, V12, P533, DOI 10.1101/lm.94505; Baker-Andresen D, 2013, LEARN MEMORY, V20, P237, DOI 10.1101/lm.029520.112; Becker JB, 2005, ENDOCRINOLOGY, V146, P1650, DOI 10.1210/en.2004-1142; Dalla C, 2009, PHYSIOL BEHAV, V97, P229, DOI 10.1016/j.physbeh.2009.02.035; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Lopez-Gallardo M, 2012, NEUROSCIENCE, V204, P90, DOI 10.1016/j.neuroscience.2011.09.063; Guedea AL, 2011, MOL CELL NEUROSCI, V47, P137, DOI 10.1016/j.mcn.2011.03.009; Daigle TL, 2008, NEUROPHARMACOLOGY, V54, P36, DOI 10.1016/j.neuropharm.2007.06.005; Satoh Y, 2007, J NEUROSCI, V27, P10765, DOI 10.1523/JNEUROSCI.0117-07.2007; Waters EM, 2009, BRAIN RES, V1290, P1, DOI 10.1016/j.brainres.2009.06.090; Barker JM, 2009, GEN COMP ENDOCR, V164, P77, DOI 10.1016/j.ygcen.2009.05.008; Quirk GJ, 2006, BIOL PSYCHIAT, V60, P337, DOI 10.1016/j.biopsych.2006.03.010; Fenton GE, 2014, LEARN MEMORY, V21, P55, DOI 10.1101/lm.033514.113; Rodriguez-Ortiz CJ, 2008, NEUROBIOL LEARN MEM, V89, P352, DOI 10.1016/j.nlm.2007.10.004; Selcher JC, 2001, LEARN MEMORY, V8, P11, DOI 10.1101/lm.37001; Leray E, 2011, EUR PSYCHIAT, V26, P339, DOI 10.1016/j.eurpsy.2009.12.001; Hugues S, 2004, LEARN MEMORY, V11, P540, DOI 10.1101/lm.77704; Chang YJ, 2009, HIPPOCAMPUS, V19, P1142, DOI 10.1002/hipo.20581; Zhu Z, 2013, HORM BEHAV, V63, P533, DOI 10.1016/j.yhbeh.2013.01.009; Alonso M, 2004, LEARN MEMORY, V11, P172, DOI 10.1101/lm.67804; Choy Y, 2007, CLIN PSYCHOL REV, V27, P266, DOI 10.1016/j.cpr.2006.10.002; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; MAREN S, 1994, BRAIN RES, V661, P25, DOI 10.1016/0006-8993(94)91176-2; Ishikawa S, 2012, EUR J NEUROSCI, V35, P135, DOI 10.1111/j.1460-9568.2011.07921.x; Milad MR, 2010, NEUROSCIENCE, V168, P652, DOI 10.1016/j.neuroscience.2010.04.030; Gibbs RB, 1998, BRAIN RES, V787, P259, DOI 10.1016/S0006-8993(97)01511-4; Herry C, 2010, EUR J NEUROSCI, V31, P599, DOI 10.1111/j.1460-9568.2010.07101.x; Zorawski M, 2006, LEARN MEMORY, V13, P441, DOI 10.1101/lm.189106; English JD, 1996, J BIOL CHEM, V271, P24329; Dalton GD, 2012, BRIT J PHARMACOL, V165, P2497, DOI 10.1111/j.1476-5381.2011.01455.x; Kelley JB, 2009, LEARN MEMORY, V16, P371, DOI 10.1101/lm.1329209; Bowler RM, 2010, AM J IND MED, V53, P1186, DOI 10.1002/ajim.20876; Franklin TB, 2006, PSYCHONEUROENDOCRINO, V31, P38, DOI 10.1016/j.psyneuen.2005.05.008; Karpova A, 2013, CELL, V152, P1119, DOI 10.1016/j.cell.2013.02.002; Milad MR, 2009, NEUROSCIENCE, V164, P887, DOI 10.1016/j.neuroscience.2009.09.011; Baran SE, 2010, LEARN MEMORY, V17, P267, DOI 10.1101/lm.1778010; Fischer A, 2007, NEUROBIOL LEARN MEM, V87, P149, DOI 10.1016/j.nlm.2006.08.003; Herry C, 2008, NATURE, V454, P600, DOI 10.1038/nature07166; Reich CG, 2009, BEHAV BRAIN RES, V203, P264, DOI 10.1016/j.bbr.2009.05.013; Khan MM, 2013, STEROIDS, V78, P614, DOI 10.1016/j.steroids.2012.12.005; Pryce CR, 1999, PHARMACOL BIOCHEM BE, V64, P753, DOI 10.1016/S0091-3057(99)00147-1; Cestari V., 2013, BRAIN RES B; FARR SA, 1995, PHYSIOL BEHAV, V58, P715, DOI 10.1016/0031-9384(95)00124-2; Gresack JE, 2009, NEUROSCIENCE, V159, P451, DOI 10.1016/j.neuroscience.2009.01.009; Hill RA, 2011, BRAIN RES, V1384, P51, DOI 10.1016/j.brainres.2011.01.060; Lebron-Milad K., 2012, BIOL MOOD ANXIETY DI, V2, P2, DOI DOI 10.1186/2045-5380-2-7; Matsuda S, 2010, PROG NEURO-PSYCHOPH, V34, P895, DOI 10.1016/j.pnpbp.2010.04.013; Matsuda S, 2014, NEUROSCI LETT, V578, P139, DOI 10.1016/j.neulet.2014.06.054; Rossato J. I., 2010, P NATL ACAD SCI  NOV, V30; Schiller D., 2013, P NATL ACAD SCI US; Ter Horst J. P., 2012, EUROPEAN J NEUROSCIE; Wiltgen BJ, 2001, BEHAV NEUROSCI, V115, P26, DOI 10.1037/0735-7044.115.1.26; Yang DW, 2004, LIFE SCI, V75, P119, DOI 10.1016/j.lfs.2003.12.004; Zhou J, 2001, NEUROREPORT, V12, P2987, DOI 10.1097/00001756-200109170-00046	58	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1074-7427	1095-9564		NEUROBIOL LEARN MEM	Neurobiol. Learn. Mem.	SEP	2015	123						117	124		10.1016/j.nlm.2015.05.009		8	Behavioral Sciences; Neurosciences; Psychology; Psychology, Multidisciplinary	Behavioral Sciences; Neurosciences & Neurology; Psychology	CO9QR	WOS:000359510900015		
J	Mesic, I; Guzman, YF; Guedea, AL; Jovasevic, V; Corcoran, KA; Leaderbrand, K; Nishimori, K; Contractor, A; Radulovic, J				Mesic, Ivana; Guzman, Yomayra F.; Guedea, Anita L.; Jovasevic, Vladimir; Corcoran, Kevin A.; Leaderbrand, Katherine; Nishimori, Katsuhiko; Contractor, Anis; Radulovic, Jelena			Double Dissociation of the Roles of Metabotropic Glutamate Receptor 5 and Oxytocin Receptor in Discrete Social Behaviors	NEUROPSYCHOPHARMACOLOGY			English	Article							AUTISM SPECTRUM DISORDERS; MGLUR5 ANTAGONIST MPEP; FRAGILE-X-SYNDROME; MOUSE MODEL; KNOCKOUT MICE; RAT-BRAIN; NMDA; SOCIABILITY; FEAR; SYMPTOMS	Social interactions in vertebrates are complex phenomena based on affective and cognitive processes. Multiple brain regions and neurotransmitter systems are involved in the expression of social behaviors, but their individual roles in specific aspects of social interactions are not well understood. Here we investigated how Gq-protein-coupled metabotropic glutamate receptor 5 (mGluR5) and oxytocin receptor (Oxtr) affect social affiliation and social memory. We used conditional genetic approaches in which the genes coding for these receptors were knocked out in the lateral septum by infusion of recombinant adeno-associated viral vectors containing Cre recombinase (AAV-Cre). Social behavior was assessed 2 weeks later using a three-chamber paradigm for sociability and preference for social novelty. Septal deletion of mGluR5 abolished sociability while leaving preference for social novelty intact. In contrast, deletion of Oxtr did not affect sociability but significantly impaired preference for social novelty. Nonsocial behaviors or memories, including novel object recognition or fear conditioning, were not affected by these genetic manipulations. Immunohistochemical analyses of the distribution of mGluR5 and Oxtr revealed non-overlapping localization of these receptors within the lateral septum, suggesting that not only different neurotransmitters but also different neuronal types contribute to sociability versus preference for social novelty. Our findings identify highly specialized roles of lateral septal mGluR5 and Oxtr in the the regulation of discrete social behaviors, and suggest that deficits in social interactions, which accompany many mental illnesses, would benefit from comprehensive treatments targeting different components of social functioning.	[Mesic, Ivana; Guzman, Yomayra F.; Guedea, Anita L.; Jovasevic, Vladimir; Corcoran, Kevin A.; Leaderbrand, Katherine; Radulovic, Jelena] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA; [Nishimori, Katsuhiko] Tohoku Univ, Dept Mol & Cell Biol, Grad Sch Agr Sci, Sendai, Miyagi 980, Japan; [Contractor, Anis] Northwestern Univ, Dept Physiol & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA	Radulovic, J (reprint author), Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, 303 East Chicago Ave,Ward 13-130, Chicago, IL 60611 USA.	j-radulovic@northwestern.edu			NIMH [MH078064, MH092065]; Deutsche Forschungsemeinschaft; Ministry of Education, Culture, Sports, Science, and Technology of Japan	We thank the students Alexandra Garcia and Helen Chen for their help with the behavioral experiments and Dr Jian Xu for providing tissue of knockout mGluR5 mice for validation of the mGluR5 antibodies. This work was supported by NIMH Grants to JR (MH078064) and YFG (MH092065), Deutsche Forschungsemeinschaft fellowship to IM, and 'Integrated research on neuropsychiatric disorder' grant in the Strategic Research Program for Brain Sciences by the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to KN).	Guzman YF, 2013, NAT NEUROSCI, V16, P1185, DOI 10.1038/nn.3465; Tronson NC, 2009, J NEUROSCI, V29, P3387, DOI 10.1523/JNEUROSCI.5619-08.2009; de Vrij FMS, 2008, NEUROBIOL DIS, V31, P127, DOI 10.1016/j.nbd.2008.04.002; Crawley JN, 2007, NEUROPEPTIDES, V41, P145, DOI 10.1016/j.npep.2007.02.002; Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x; Coghlan S, 2012, NEUROSCI BIOBEHAV R, V36, P2044, DOI 10.1016/j.neubiorev.2012.07.005; Nishimori K, 2008, PROG BRAIN RES, V170, P79, DOI 10.1016/S0079-6123(08)00408-1; Hitti FL, 2014, NATURE, V508, P88, DOI 10.1038/nature13028; Ross HE, 2009, FRONT NEUROENDOCRIN, V30, P534, DOI 10.1016/j.yfrne.2009.05.004; Gunaydin LA, 2014, CELL, V157, P1535, DOI 10.1016/j.cell.2014.05.017; Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040; Won H, 2012, NATURE, V486, P261, DOI 10.1038/nature11208; Yap JJ, 2005, PSYCHOPHARMACOLOGY, V179, P230, DOI 10.1007/s00213-004-2023-3; Yan QJ, 2005, NEUROPHARMACOLOGY, V49, P1053, DOI 10.1016/j.neuropharm.2005.06.004; Sankoorikal GMV, 2006, BIOL PSYCHIAT, V59, P415, DOI 10.1016/j.biopsych.2005.07.026; O'Leary DM, 2000, BRIT J PHARMACOL, V131, P1429, DOI 10.1038/sj.bjp.0703715; Movsesyan VA, 2001, J PHARMACOL EXP THER, V296, P41; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; Yang PC, 2014, CURR PHARM DESIGN, V20, P5186; Silverman JL, 2010, NEUROPSYCHOPHARMACOL, V35, P976, DOI 10.1038/npp.2009.201; Xu J, 2009, J NEUROSCI, V29, P3676, DOI 10.1523/JNEUROSCI.5716-08.2009; Lee HJ, 2008, ENDOCRINOLOGY, V149, P3256, DOI 10.1210/en.2007-1710; Nakamoto M, 2007, P NATL ACAD SCI USA, V104, P15537, DOI 10.1073/pnas.0707484104; Insel TR, 1999, BIOL PSYCHIAT, V45, P145, DOI 10.1016/S0006-3223(98)00142-5; Yoshida M, 2009, J NEUROSCI, V29, P2259, DOI 10.1523/JNEUROSCI.5593-08.2009; Cosford NDP, 2003, BIOORG MED CHEM LETT, V13, P351, DOI 10.1016/S0960-894X(02)00997-6; Koros E, 2007, NEUROPSYCHOPHARMACOL, V32, P562, DOI 10.1038/sj.npp.1301133; Moy SS, 2004, GENES BRAIN BEHAV, V3, P287, DOI 10.1111/j.1601-183X.2004.00076.x; Sala M, 2013, J NEUROENDOCRINOL, V25, P107, DOI 10.1111/j.1365-2826.2012.02385.x; Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779; Balconi M, 2014, SOC NEUROSCI-UK, V9, P82, DOI 10.1080/17470919.2013.861361; Teng BL, 2013, NEUROPHARMACOLOGY, V72, P187, DOI 10.1016/j.neuropharm.2013.04.038; Gao C, 2011, J NEUROSCI, V31, P8533, DOI 10.1523/JNEUROSCI.1300-11.2011; Carlson GC, 2012, PHARMACOL BIOCHEM BE, V100, P850, DOI 10.1016/j.pbb.2011.02.003; Thomas AM, 2011, BEHAV BRAIN RES, V223, P310, DOI 10.1016/j.bbr.2011.04.049; Dolen G, 2010, PHARMACOL THERAPEUT, V127, P78, DOI 10.1016/j.pharmthera.2010.02.008; SHIGEMOTO R, 1993, NEUROSCI LETT, V163, P53, DOI 10.1016/0304-3940(93)90227-C; Burket JA, 2011, BRAIN RES BULL, V86, P152, DOI 10.1016/j.brainresbull.2011.08.001; Caldu X, 2007, ANN NY ACAD SCI, V1118, P43, DOI 10.1196/annals.1412.007; Caldwell HK, 2012, ADV EXP MED BIOL, V739, P187, DOI 10.1007/978-1-4614-1704-0_12; Clifton NE, 2013, PSYCHOPHARMACOLOGY, V225, P579, DOI 10.1007/s00213-012-2845-3; Crespi B, 2008, BEHAV BRAIN SCI, V31, P241, DOI 10.1017/S0140525X08004214; Gray J. A., 2000, NEUROPSYCHOLOGY ANXI; Guzman YF, 2014, PSYCHOPHARMACOLOGY, V231, P2097, DOI 10.1007/s00213-013-3356-6; Kaidanovich-Beilin O, 2011, J VIS EXP, V48, P2473; Kiser D, 2012, NEUROSCI BIOBEHAV R, V36, P786, DOI 10.1016/j.neubiorev.2011.12.009; Labrie V, 2008, PSYCHOPHARMACOLOGY, V200, P217, DOI 10.1007/s00213-008-1196-6; PANKSEPP J, 1992, ANN NY ACAD SCI, V652, P243, DOI 10.1111/j.1749-6632.1992.tb34359.x; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Pilakka-Kanthikeel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062241; Pobbe RLH, 2012, HORM BEHAV, V61, P436, DOI 10.1016/j.yhbeh.2011.10.010; Risold PY, 1997, BRAIN RES REV, V24, P115, DOI 10.1016/S0165-0173(97)00009-X; Silverman JL, 2012, SCI TRANSL MED, V4, P131; Tronson NC, 2010, BIOL PSYCHIAT, V68, P1007, DOI 10.1016/j.biopsych.2010.09.004	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	SEP	2015	40	10					2337	2346		10.1038/npp.2015.81		10	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	CO9KE	WOS:000359493700006		
J	Fujihara, K; Miwa, H; Kakizaki, T; Kaneko, R; Mikuni, M; Tanahira, C; Tamamaki, N; Yanagawa, Y				Fujihara, Kazuyuki; Miwa, Hideki; Kakizaki, Toshikazu; Kaneko, Ryosuke; Mikuni, Masahiko; Tanahira, Chiyoko; Tamamaki, Nobuaki; Yanagawa, Yuchio			Glutamate Decarboxylase 67 Deficiency in a Subset of GABAergic Neurons Induces Schizophrenia-Related Phenotypes	NEUROPSYCHOPHARMACOLOGY			English	Article							PARVALBUMIN-IMMUNOREACTIVE NEURONS; PREFRONTAL CORTEX; NMDA RECEPTORS; NUCLEUS-ACCUMBENS; BIPOLAR DISORDER; DENDRITIC SPINE; TRANSGENIC MICE; CEREBRAL-CORTEX; ANIMAL-MODEL; GABA NEURONS	Decreased expression of the GABA synthetic enzyme glutamate decarboxylase 67 (GAD67) in a subset of GABAergic neurons, including parvalbumin (PV)-expressing neurons, has been observed in postmortem brain studies of schizophrenics and in animal models of schizophrenia. However, it is unclear whether and how the perturbations of GAD67-mediated GABA synthesis and signaling contribute to the pathogenesis of schizophrenia. To address this issue, we generated the mice lacking GAD67 primarily in PV neurons and characterized them with focus on schizophrenia-related parameters. We found that heterozygous mutant mice exhibited schizophrenia-related behavioral abnormalities such as deficits in prepulse inhibition, MK-801 sensitivity, and social memory. Furthermore, we observed reduced inhibitory synaptic transmission, altered properties of NMDA receptor-mediated synaptic responses in pyramidal neurons, and increased spine density in hippocampal CA1 apical dendrites, suggesting a possible link between GAD67 deficiency and disturbed glutamatergic excitatory synaptic functions in schizophrenia. Thus, our results indicate that the mice heterozygous for GAD67 deficiency primarily in PV neurons share several neurochemical and behavioral abnormalities with schizophrenia, offering a novel tool for addressing the underlying pathophysiology of schizophrenia.	[Fujihara, Kazuyuki; Miwa, Hideki; Kakizaki, Toshikazu; Kaneko, Ryosuke; Yanagawa, Yuchio] Gunma Univ, Grad Sch Med, Dept Genet & Behav Neurosci, Maebashi, Gumma 3718511, Japan; [Fujihara, Kazuyuki; Miwa, Hideki; Kakizaki, Toshikazu; Kaneko, Ryosuke; Yanagawa, Yuchio] Japan Sci & Technol Agcy JST, Core Res Evolut Sci & Technol, Tokyo, Japan; [Fujihara, Kazuyuki; Mikuni, Masahiko] Gunma Univ, Grad Sch Med, Dept Psychiat & Human Behav, Maebashi, Gumma 3718511, Japan; [Kaneko, Ryosuke] Gunma Univ, Grad Sch Med, Inst Expt Anim Res, Maebashi, Gumma 3718511, Japan; [Tanahira, Chiyoko; Tamamaki, Nobuaki] Kumamoto Univ, Grad Sch Med Sci, Dept Morphol Neural Sci, Kumamoto, Japan	Miwa, H (reprint author), Gunma Univ, Grad Sch Med, Dept Genet & Behav Neurosci, Maebashi, Gumma 3718511, Japan.	hmiwa@gunma-u.ac.jp			Ministry of Education, Science, Sports, Culture, and Technology of Japan; Co-operative Study Program of National Institute for Physiological Sciences, Japan; Takeda Science Foundation; Mitsubishi Pharma Research Foundation; Naito Foundation; Support Program of Gunma University Graduate School of Medicine for Improving Graduate School Education	We thank Drs Yasuhiko Saito and Hiroki Yasuda for their helpful comments on the manuscript and the members of our laboratory for their technical assistance and critical comments. We also thank Dr Minato Nakazawa for statistical advice and the staff at the Institute of Experimental Animal Research, the Gunma University Graduate School of Medicine for technical help. We are grateful to Dr Kunihiko Obata for his encouragement. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, Culture, and Technology of Japan (YY), a grant from the Co-operative Study Program of National Institute for Physiological Sciences, Japan (YY), the Takeda Science Foundation (YY), the Mitsubishi Pharma Research Foundation (HM), the Naito Foundation (KF), and the Support Program of Gunma University Graduate School of Medicine for Improving Graduate School Education (KF).	Nadler JJ, 2004, GENES BRAIN BEHAV, V3, P303, DOI 10.1111/j.1601-183X.2004.00071.x; Schobel SA, 2009, ARCH GEN PSYCHIAT, V66, P938, DOI 10.1001/archgenpsychiatry.2009.115; Lodge DJ, 2009, J NEUROSCI, V29, P2344, DOI 10.1523/JNEUROSCI.5419-08.2009; Mauney SA, 2013, BIOL PSYCHIAT, V74, P427, DOI 10.1016/j.biopsych.2013.05.007; Hashimoto T, 2008, MOL PSYCHIATR, V13, P147, DOI 10.1038/sj.mp.4002011; Glantz LA, 2000, ARCH GEN PSYCHIAT, V57, P65, DOI 10.1001/archpsyc.57.1.65; Volk DW, 2000, ARCH GEN PSYCHIAT, V57, P237, DOI 10.1001/archpsyc.57.3.237; Blaha CD, 1997, EUR J NEUROSCI, V9, P902, DOI 10.1111/j.1460-9568.1997.tb01441.x; Hunt DL, 2012, CURR OPIN NEUROBIOL, V22, P496, DOI 10.1016/j.conb.2012.01.007; KOSAKA T, 1989, BRAIN RES, V483, P158, DOI 10.1016/0006-8993(89)90048-6; Miwa H, 2008, J PHYSIOL-LONDON, V586, P2539, DOI 10.1113/jphysiol.2007.147652; Todtenkopf MS, 1998, SYNAPSE, V29, P323, DOI 10.1002/(SICI)1098-2396(199808)29:4<323::AID-SYN4>3.0.CO;2-7; Paul CM, 2009, BEHAV BRAIN RES, V203, P151, DOI 10.1016/j.bbr.2009.05.022; Obata K, 2008, BIOCHEM BIOPH RES CO, V370, P429, DOI 10.1016/j.bbrc.2008.03.110; Takao K, 2013, NEUROPSYCHOPHARMACOL, V38, P1409, DOI 10.1038/npp.2013.38; Woo TU, 1997, AM J PSYCHIAT, V154, P1013; Insel TR, 2010, NATURE, V468, P187, DOI 10.1038/nature09552; Liu WS, 2001, P NATL ACAD SCI USA, V98, P3477, DOI 10.1073/pnas.051614698; Laruelle M, 1999, J PSYCHOPHARMACOL, V13, P358; Schiller J, 2001, CURR OPIN NEUROBIOL, V11, P343, DOI 10.1016/S0959-4388(00)00217-8; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Braff DL, 2001, PSYCHOPHARMACOLOGY, V156, P234, DOI 10.1007/s002130100810; LAHTI AC, 1995, NEUROPSYCHOPHARMACOL, V13, P9, DOI 10.1016/0893-133X(94)00131-I; KAGI U, 1987, J BIOL CHEM, V262, P7314; Guidotti A, 2000, ARCH GEN PSYCHIAT, V57, P1061, DOI 10.1001/archpsyc.57.11.1061; Legault M, 1999, SYNAPSE, V31, P241, DOI 10.1002/(SICI)1098-2396(19990315)31:4<241::AID-SYN1>3.3.CO;2-R; Hikida T, 2007, P NATL ACAD SCI USA, V104, P14501, DOI 10.1073/pnas.0704774104; Belforte JE, 2010, NAT NEUROSCI, V13, P76, DOI 10.1038/nn.2447; Torrey EF, 2005, BIOL PSYCHIAT, V57, P252, DOI 10.1016/j.biopsych.2004.10.019; Hashimoto T, 2003, J NEUROSCI, V23, P6315; Wen L, 2010, P NATL ACAD SCI USA, V107, P1211, DOI 10.1073/pnas.0910302107; Peleg-Raibstein D, 2008, BEHAV BRAIN RES, V191, P190, DOI 10.1016/j.bbr.2008.03.037; Zhang ZJ, 2002, SCHIZOPHR RES, V55, P1, DOI 10.1016/S0920-9964(01)00188-8; Behrens MM, 2007, SCIENCE, V318, P1645, DOI 10.1126/science.1148045; Piskulic D, 2007, PSYCHIAT RES, V150, P111, DOI 10.1016/j.psychres.2006.03.018; Chattopadhyaya B, 2007, NEURON, V54, P889, DOI 10.1016/j.neuron.2007.05.015; Esclapez M, 1999, J COMP NEUROL, V412, P488; Couture SM, 2006, SCHIZOPHRENIA BULL, V32, pS44, DOI 10.1093/schbul/sb1029; Ben-Ari Y, 2004, TRENDS NEUROSCI, V27, P422, DOI 10.1016/j.tins.2004.05.002; Beasley CL, 1997, SCHIZOPHR RES, V24, P349, DOI 10.1016/S0920-9964(96)00122-3; Brown JA, 2015, MOL PSYCHIATR, DOI [10.1038/mp.2014.192, DOI 10.1038/MP.2014.192]; Bubenikova-Valesova V, 2008, NEUROSCI BIOBEHAV R, V32, P1014, DOI 10.1016/j.neubiorev.2008.03.012; Ducharme G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029754; Hwang IK, 2007, NEUROL RES, V29, P441, DOI 10.1179/016164107X159270; Kirson ED, 1999, J PHYSIOL-LONDON, V521, P99, DOI 10.1111/j.1469-7793.1999.00099.x; Kobayashi Y, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00168; Lazarus MS, 2013, CEREB CORTEX, V25, P1290; Lee FHF, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-20; Pohl V, 1995, DIFFERENTIATION, V59, P235, DOI 10.1046/j.1432-0436.1995.5940235.x; Tanahira C, 2009, NEUROSCI RES, V63, P213, DOI 10.1016/j.neures.2008.12.007	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	SEP	2015	40	10					2475	2486		10.1038/npp.2015.117		12	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	CO9KE	WOS:000359493700020		
J	Kuo, HC; Lee, KS; Na, YQ; Sood, R; Nakaji, S; Kubota, Y; Kuroishi, K				Kuo, Hann-Chorng; Lee, Kyu-Sung; Na, Yanqun; Sood, Rajeev; Nakaji, Shigeru; Kubota, Yosuke; Kuroishi, Kentarou			Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a 3-adrenoceptor agonist, in patients with overactive bladder in Asia	NEUROUROLOGY AND URODYNAMICS			English	Article						clinical trial; efficacy; mirabegron; overactive bladder; phase III; randomized; safety	BETA(3)-ADRENOCEPTOR AGONIST; PHASE-III; METAANALYSIS; EFFICACY; MUSCLE	AimsTo assess the efficacy and safety of mirabegron 50mg once daily compared with placebo and the active control, tolterodine extended-release (ER) 4mg once daily, in patients with symptoms of overactive bladder (OAB) in Taiwan, Korea, China, and India. MethodsA 12-week multinational, randomized, double-blind, parallel-group placebo- and active-controlled trial. The primary efficacy endpoint was change from baseline to final visit in mean number of micturitions/24hr. Secondary endpoints were: mean number of urgency episodes, incontinence episodes and urge incontinence episodes/24hr, mean number of nocturia episodes per night, mean volume voided per micturition, and quality-of-life (QoL) scores as assessed by the King's Health Questionnaire (KHQ). ResultsOf 1,126 patients who were randomized to receive double-blind study drug, 921 patients (300, 311, and 310 in the placebo, mirabegron 50mg, and tolterodine ER 4mg groups, respectively) completed the treatment period. Demographic characteristics were similar across treatment groups. A statistically significant improvement versus placebo in mean number of micturitions/24hr was seen with mirabegron 50mg at all timepoints (P<0.05) as well as final visit (-0.57 with 95% confidence intervals [CIs] of [-1.04, -0.09], P=0.019). There was no significant difference between treatment groups in improvement from baseline to final visit in any of the secondary outcome measures except volume voided per micturition. The overall incidence of drug-related adverse events was 17.2%, 15.8%, and 21.3%, in the placebo, mirabegron 50mg, and tolterodine ER 4mg groups, respectively. ConclusionsMirabegron 50mg once daily for 12 weeks was superior to placebo in reducing the frequency of micturitions in patients with symptoms of OAB in Taiwan, Korea, China, and India. Neurourol. Urodynam. 34:???-???, 2015. (c) 2014 Wiley Periodicals, Inc.	[Kuo, Hann-Chorng] Buddhist Tzu Chi Gen Hosp, Dept Urol, Hualien, Taiwan; [Kuo, Hann-Chorng] Tzu Chi Univ, Hualien, Taiwan; [Lee, Kyu-Sung] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea; [Na, Yanqun] Peking Univ, Peoples Hosp, Dept Urol, Beijing 100871, Peoples R China; [Sood, Rajeev] DR Ram Manohar Lohia Hosp, Dept Urol, New Delhi, India; [Nakaji, Shigeru] PGI MER, New Delhi, India; [Kubota, Yosuke] Astellas Pharma Global Dev, Asian Dev, Tokyo, Japan; [Kuroishi, Kentarou] Astellas Pharma Global Dev, Data Sci, Tokyo, Japan	Kuo, HC (reprint author), Buddhist Tzu Chi Gen Hosp, Dept Urol, 707,Sect 3,Chung Yang Rd, Hualien, Taiwan.	hck@tzuchi.com.tw			Astellas	Grant sponsor: Astellas	Abrams P, 2002, AM J OBSTET GYNECOL, V187, P116, DOI 10.1067/mob.2002.125704; Lee S, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-55; Yamaguchi O, 2002, UROLOGY, V59, P25, DOI 10.1016/S0090-4295(01)01635-1; Kelleher CJ, 2004, BJOG-INT J OBSTET GY, V111, P605, DOI 10.1111/j.1471-0528.2004.00129.x; D'Souza AO, 2008, J MANAGE CARE PHARM, V14, P291; Benner JS, 2010, BJU INT, V105, P1276, DOI 10.1111/j.1464-410X.2009.09036.x; Khullar V, 2013, EUR UROL, V63, P283, DOI 10.1016/j.eururo.2012.10.016; Yamaguchi O, 2007, NEUROUROL URODYNAM, V26, P752, DOI 10.1002/nau.20420; Yamaguchi O, 2014, BJU INT, V113, P951, DOI 10.1111/bju.12649; Herschorn S, 2013, UROLOGY, V82, P313, DOI 10.1016/j.urology.2013.02.077; Brostrom S, 2009, EUR J CLIN PHARMACOL, V65, P309, DOI 10.1007/s00228-008-0600-9; Aizawa N, 2010, NEUROUROL URODYNAM, V29, P771, DOI 10.1002/nau.20826; Irwin DE, 2011, BJU INT, V108, P1132, DOI 10.1111/j.1464-410X.2010.09993.x; Moorthy P, 2004, BJU INT, V93, P528, DOI 10.1111/j.1464-410X.2004.04682.x; Nitti VW, 2013, INT J CLIN PRACT, V67, P619, DOI 10.1111/ijcp.12194; Yamanishi T, 2003, NEUROUROL URODYNAM, V22, P338, DOI 10.1002/nau.10130; Nitti VW, 2013, J UROLOGY, V189, P1388, DOI 10.1016/j.juro.2012.10.017; Chapple CR, 2008, EUR UROL, V54, P543, DOI 10.1016/j.eururo.2008.06.047; Takasu T, 2007, J PHARMACOL EXP THER, V321, P642, DOI 10.1124/jpet.106.115840; Yamaguchi O, 2009, INT J UROL, V16, P126, DOI 10.1111/j.1442-2042.2008.02177.x; Mangera A, 2011, NAT REV UROL, V8, P495, DOI 10.1038/nrurol.2011.99; Nabi G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003781.pub2; Yalcin I, 2004, AM J OBSTET GYNECOL, V191, P194, DOI 10.1016/j.ajog.2004.03.089	23	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0733-2467	1520-6777		NEUROUROL URODYNAM	Neurourol. Urodyn.	SEP	2015	34	7					685	692		10.1002/nau.22645		8	Urology & Nephrology	Urology & Nephrology	CP2MC	WOS:000359710200015		
J	Wang, YC; Wu, HS				Wang, Yuchao; Wu, Hansheng			Adaptive robust backstepping control for a class of uncertain dynamical systems using neural networks	NONLINEAR DYNAMICS			English	Article						Adaptive robust control; Backstepping; Uncertain dynamical systems; Neural networks; Asymptotic stability	VIRTUAL CONTROL COEFFICIENTS; FEEDBACK NONLINEAR-SYSTEMS; SMALL-GAIN APPROACH; H-INFINITY-CONTROL; FUNCTION APPROXIMATION; OUTPUT TRACKING; TIME DELAYS; STABILIZATION; DESIGN	The problem of robust stabilization is considered for a class of nonlinear systems in the presence of structure uncertainties, external disturbances, and unknown time-varying virtual control coefficients. It is supposed that the upper bounds of the external disturbances and the virtual control coefficients are unknown. The unknown structural uncertainties are approximated by using neural networks (NNs). In particular, the prior knowledge about the weights and approximation errors of NNs is not required. The improved adaptation laws with -modification are employed to estimate the unknown parameters, which contain the upper bounds of the external disturbances and the virtual control coefficients, and the norm forms of weights and approximate errors of the NNs. Then, by making use of the updated values of these unknown parameters, a class of backstepping approach-based continuous adaptive robust state feedback controllers is synthesized. It is also shown that the proposed adaptive robust backstepping controller can guarantee the uniform asymptotic stability of such uncertain dynamical systems. Finally, two numerical examples are given to demonstrate the effectiveness of the proposed controller.	[Wang, Yuchao] Prefectural Univ Hiroshima, Grad Sch Comprehens Sci Res, Hiroshima, Hiroshima 7348558, Japan; [Wu, Hansheng] Prefectural Univ Hiroshima, Dept Informat Sci, Hiroshima, Hiroshima 7348558, Japan	Wang, YC (reprint author), Prefectural Univ Hiroshima, Grad Sch Comprehens Sci Res, Hiroshima, Hiroshima 7348558, Japan.	wangyc0918@yahoo.co.jp					Li HX, 2003, IEEE T FUZZY SYST, V11, P24, DOI 10.1109/TFUZZ.2002.806314; Stotsky A, 1997, P AMER CONTR CONF, P1703, DOI 10.1109/ACC.1997.610875; Wu HS, 2004, IEEE T AUTOMAT CONTR, V49, P611, DOI 10.1109/TAC.2004.825634; Yang YS, 2005, IEEE T FUZZY SYST, V13, P104, DOI 10.1109/TFUZZ.2004.839663; Tong SC, 2009, IEEE T FUZZY SYST, V17, P1059, DOI 10.1109/TFUZZ.2009.2021648; Ge SS, 2008, SYST CONTROL LETT, V57, P888, DOI 10.1016/j.sysconle.2008.04.006; Tong SC, 2003, IEEE T FUZZY SYST, V11, P354, DOI 10.1109/TFUZZ.2003.812694; Tong SC, 2009, FUZZY SET SYST, V160, P1749, DOI 10.1016/j.fss.2008.09.004; Huang GB, 2005, IEEE T NEURAL NETWOR, V16, P57, DOI 10.1109/TNN.2004.836241; Ge SS, 2002, AUTOMATICA, V38, P671, DOI 10.1016/S0005-1098(01)00254-0; Bechlioulis CP, 2009, AUTOMATICA, V45, P532, DOI 10.1016/j.automatica.2008.08.012; Yu Y, 2010, INT J CONTROL, V83, P1182, DOI 10.1080/00207171003664117; Tong SC, 2011, IEEE T NEURAL NETWOR, V22, P1073, DOI 10.1109/TNN.2011.2146274; Chen B, 2009, AUTOMATICA, V45, P1530, DOI 10.1016/j.automatica.2009.02.025; Li XF, 2011, NONLINEAR DYNAM, V63, P263, DOI 10.1007/s11071-010-9802-7; Ge SZS, 2004, IEEE T SYST MAN CY B, V34, P499, DOI 10.1109/TSMCB.2003.817055; Ge SS, 2003, IEEE T AUTOMAT CONTR, V48, P1463, DOI 10.1109/TAC.2003.815049; Zhang T, 2000, AUTOMATICA, V36, P1835, DOI 10.1016/S0005-1098(00)00116-3; Leu YG, 1999, IEEE T SYST MAN CY B, V29, P583, DOI 10.1109/3477.790441; Li XF, 2010, NONLINEAR ANAL-REAL, V11, P2215, DOI 10.1016/j.nonrwa.2009.06.011; Jiang ZP, 1998, AUTOMATICA, V34, P825, DOI 10.1016/S0005-1098(98)00018-1; Ferrari S, 2005, IEEE T NEURAL NETWOR, V16, P24, DOI 10.1109/TNN.2004.836233; BROGLIATO B, 1995, AUTOMATICA, V31, P145, DOI 10.1016/0005-1098(94)E0050-R; Freeman R. A., 1992, P IFAC NONL CONTR SY, P307; Hsu CF, 2006, IEEE T NEURAL NETWOR, V17, P1175, DOI 10.1109/TNN.2006.878122; Isidori A., 1995, NONLINEAR CONTROL SY; KHARGONEKAR PP, 1990, IEEE T AUTOMAT CONTR, V35, P356, DOI 10.1109/9.50357; Knanellakopoulos I., 1991, IEEE T AUTOMAT CONTR, V36, P1241; Koofigar HR, 2009, NONLINEAR DYNAM, V56, P13, DOI 10.1007/s11071-008-9375-x; Koshkouei AJ, 2004, ASIAN J CONTROL, V6, P447; Liu Y, 2009, IET CONTROL THEORY A, V3, P813, DOI 10.1049/iet-cta.2008.0329; Ren CE, 2012, NONLINEAR DYNAM, V67, P941, DOI 10.1007/s11071-011-0036-0; Slotine J.J.E., 1991, APPL NONLINEAR CONTR; Wang SY, 2010, NONLINEAR ANAL-REAL, V11, P423, DOI 10.1016/j.nonrwa.2008.11.018; Wang W.Y., 1996, IEEE T SYST MAN CY B, V26, P677; Wu H., 2010, IECON 36 ANN C IEEE, P53, DOI 10.1109/IECON.2010.5675371; Wu HS, 1999, INT J CONTROL, V72, P115, DOI 10.1080/002071799221280; Xie L., 1992, IEEE T AUTOMAT CONTR, V37, P1188; Yang Hongwei, 2011, [Journal of Control Theory and Applications, 控制理论与应用], V9, P220; Yu Y, 2012, IET CONTROL THEORY A, V6, P751, DOI 10.1049/iet-cta.2010.0756; Zainuddin Zarita, 2008, WSEAS Transactions on Mathematics, V7	41	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0924-090X	1573-269X		NONLINEAR DYNAM	Nonlinear Dyn.	SEP	2015	81	4					1597	1610		10.1007/s11071-015-2093-2		14	Engineering, Mechanical; Mechanics	Engineering; Mechanics	CO8JF	WOS:000359414000001		
J	Ikeda, T; Harata, Y; Hiraoka, R				Ikeda, Takashi; Harata, Yuji; Hiraoka, Ryo			Intrinsic localized modes of 1/2-order subharmonic oscillations in nonlinear oscillator arrays	NONLINEAR DYNAMICS			English	Article						Intrinsic localized mode; Nonlinear vibration; 1/2-Order subharmonic oscillation; Frequency response curve; Basin of attraction; Bifurcation set; Hopf bifurcation; Amplitude-modulated motion; Chaotic vibration	CYCLIC SYMMETRY; SYSTEM	1/2-order subharmonic oscillations in an array with nonlinear, identical oscillators are theoretically investigated. Each oscillator is connected by weak, linear springs and subjected to sinusoidal excitation. Van der Pol's method is employed to determine the frequency response curves for 1/2-order subharmonic oscillations when and 3. Frequency response curves for hard- and soft-type nonlinearities of the oscillators are examined and compared with each other. All patterns of oscillations are classified depending on the results of the response curves, and it is determined in which pattern intrinsic localized modes (ILMs) appear. When disturbances are input in order to observe ILMs, basins of attraction demonstrate which pattern of ILMs may occur. Bifurcation sets are also calculated to examine the influence of the connecting spring constants on the response curves and the occurrence of Hopf bifurcations and amplitude-modulated motions (AMMs), including chaotic vibrations. Furthermore, the influence of oscillator imperfections on the response curves is investigated by slightly changing the value of the spring constant. The numerical simulations for and 3 confirm the validity of the frequency response curves and the occurrence of AMMs. ILMs were also observed in the numerical simulations conducted for N = 10.	[Ikeda, Takashi; Harata, Yuji] Hiroshima Univ, Inst Engn, Dept Mech Syst Engn, Higashihiroshima, Hiroshima 7398527, Japan; [Hiraoka, Ryo] Toyo Networks & Syst Integrat Co Ltd, Takatsu Ku, Kawasaki, Kanagawa 2138545, Japan	Ikeda, T (reprint author), Hiroshima Univ, Inst Engn, Dept Mech Syst Engn, 1-4-1 Kagamiyama, Higashihiroshima, Hiroshima 7398527, Japan.	tikeda@hiroshima-u.ac.jp	Ikeda, Takashi/D-6160-2011				SIEVERS AJ, 1988, PHYS REV LETT, V61, P970, DOI 10.1103/PhysRevLett.61.970; Sato M, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.044102; Brent RP, 1973, ALGORITHMS MINIMIZAT; Dick AJ, 2008, NONLINEAR DYNAM, V54, P13, DOI 10.1007/s11071-007-9288-0; Doedel E. J., 1997, CONTINUATION BIFURCA; Flash S., 1998, PHYS REP, V295, P181; Hayashi C, 1964, NONLINEAR OSCILLATIO; Ikeda T., 2013, T ASME J COMP NONLIN, V8; Ikeda T, 2003, NONLINEAR DYNAM, V33, P43, DOI 10.1023/A:1025569028213; Kimura M, 2008, PHYS LETT A, V372, P4592, DOI 10.1016/j.physleta.2008.04.054; KING ME, 1995, NONLINEAR DYNAM, V7, P85; Kivshar YS, 1998, PHYS REV B, V58, P5423, DOI 10.1103/PhysRevB.58.5423; Nayfeh A H, 1979, NONLINEAR OSCILLATIO; Stoker J. J., 2005, NONLINEAR VIBRATIONS; VAKAKIS A, 1993, J APPL MECH-T ASME, V60, P388, DOI 10.1115/1.2900806; VAKAKIS AF, 1993, SIAM J APPL MATH, V53, P265, DOI 10.1137/0153016; WOLF A, 1985, PHYSICA D, V16, P285, DOI 10.1016/0167-2789(85)90011-9	17	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0924-090X	1573-269X		NONLINEAR DYNAM	Nonlinear Dyn.	SEP	2015	81	4					1759	1777		10.1007/s11071-015-2105-2		19	Engineering, Mechanical; Mechanics	Engineering; Mechanics	CO8JF	WOS:000359414000013		
J	Narahara, K				Narahara, Koichi			Characterization of leapfrogging solitary waves in coupled nonlinear transmission lines	NONLINEAR DYNAMICS			English	Article						Nonlinear transmission lines; Leapfrogging pulses; Solitons; Perturbation theory	DE-VRIES EQUATIONS; KDV EQUATIONS; SOLITONS; SYSTEM; STABILITY	Leapfrogging solitary waves are characterized in two capacitively coupled transmission lines that are periodically loaded with Schottky varactors, called coupled nonlinear transmission lines (NLTLs). The coupling implies that a nonlinear solitary wave moving on one of the lines is bounded with the wave moving on the other line, which results in the periodic amplitude/phase oscillation called leapfrogging. In this study, we clarify how the leapfrogging frequency depends on the physical parameters of coupled NLTLs using a numerical model validated through measuring test lines and demonstrate the relaxation of leapfrogging. In addition, coupled Korteweg-de Vries equations are derived by applying the reductive perturbation method to the transmission equations of coupled NLTLs. Using perturbation theory based on the inverse scattering transform, a closed-form expression of leapfrogging frequency is obtained and the parameter values that simulate the properties well are examined. Engineering applications based on leapfrogging are finally discussed.	Kanagawa Inst Technol, Dept Elect & Elect Engn, Atsugi, Kanagawa 2430292, Japan	Narahara, K (reprint author), Kanagawa Inst Technol, Dept Elect & Elect Engn, 1030 Shimoogino, Atsugi, Kanagawa 2430292, Japan.	narahara@ele.kanagawa-it.ac.jp			JSPS KAKENHI [26420296]	This work was partially supported by JSPS KAKENHI Grant Number 26420296.	Zhou YB, 2003, PHYS LETT A, V308, P31, DOI 10.1016/S0375-9601(02)01775-9; Guo R, 2015, NONLINEAR DYNAM, V80, P1221, DOI 10.1007/s11071-015-1938-z; GRIMSHAW R, 1994, PHYS REV LETT, V72, P949, DOI 10.1103/PhysRevLett.72.949; El-Dib YO, 2001, NONLINEAR DYNAM, V24, P399, DOI 10.1023/A:1011125708998; Espinosa-Ceron A., 2012, CHAOS, V22; GEAR JA, 1984, STUD APPL MATH, V70, P235; Gottwald G, 1997, PHYS LETT A, V227, P47, DOI 10.1016/S0375-9601(97)00021-2; Jeffrey A., 1982, ASYMPTOTIC METHODS N; Kintis M, 2007, IEEE MICROW WIREL CO, V17, P454, DOI 10.1109/LMWC.2007.897799; KIVSHAR YS, 1989, REV MOD PHYS, V61, P763, DOI 10.1103/RevModPhys.61.763; KIVSHAR YS, 1989, WAVE MOTION, V11, P261, DOI 10.1016/0165-2125(89)90005-X; Liu A. K., 1980, STUD APPL MATH, V63, P26; LIU AK, 1982, J FLUID MECH, V122, P187, DOI 10.1017/S002211208200216X; Lou SY, 2006, J PHYS A-MATH GEN, V39, P513, DOI 10.1088/0305-4470/39/3/005; MALOMED BA, 1987, WAVE MOTION, V9, P401, DOI 10.1016/0165-2125(87)90029-1; Narahara K., 2009, J INFRARED MILLIM TE, V31, P411; Nitsche M, 2010, J FLUID MECH, V642, P235, DOI 10.1017/S0022112009991819; RODWELL MJW, 1994, P IEEE, V82, P1037, DOI 10.1109/5.293161; Triki H, 2002, OPT COMMUN, V201, P447, DOI 10.1016/S0030-4018(01)01673-X; WEIDMAN PD, 1982, J FLUID MECH, V122, P195, DOI 10.1017/S0022112082002171; Wright JD, 2007, Z ANGEW MATH PHYS, V58, P535, DOI 10.1007/S00033-006-6076-5; Yildirim OO, 2009, IEEE T MICROW THEORY, V57, P2344, DOI 10.1109/TMTT.2009.2029025	22	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0924-090X	1573-269X		NONLINEAR DYNAM	Nonlinear Dyn.	SEP	2015	81	4					1805	1814		10.1007/s11071-015-2108-z		10	Engineering, Mechanical; Mechanics	Engineering; Mechanics	CO8JF	WOS:000359414000016		
J	Shidahara, M; Watabe, H; Tashiro, M; Okamura, N; Furumoto, S; Watanuki, S; Furukawa, K; Arakawa, Y; Funaki, Y; Iwata, R; Gonda, K; Kudo, Y; Arai, H; Ishiwata, K; Yanai, K				Shidahara, Miho; Watabe, Hiroshi; Tashiro, Manabu; Okamura, Nobuyuki; Furumoto, Shozo; Watanuki, Shoichi; Furukawa, Katsutoshi; Arakawa, Yuma; Funaki, Yoshihito; Iwata, Ren; Gonda, Kohsuke; Kudo, Yukitsuka; Arai, Hiroyuki; Ishiwata, Kiichi; Yanai, Kazuhiko			Quantitative kinetic analysis of PET amyloid imaging agents [C-11]BF227 and [F-18]FACT in human brain	NUCLEAR MEDICINE AND BIOLOGY			English	Article						Amyloid imaging; [C-11]BF227; [F-18]FACT; Compartment model	POSITRON-EMISSION-TOMOGRAPHY; MILD COGNITIVE IMPAIRMENT; PITTSBURGH COMPOUND-B; ALZHEIMERS-DISEASE; GRAPHICAL ANALYSIS; BINDING; BETA; F-18-FLUTEMETAMOL; RADIOLIGAND; DERIVATIVES	Introduction: The purpose of this study was to compare two amyloid imaging agents, [C-11]BF227 and [F-18]FACT (derivative from [C-11]BF227) through quantitative pharmacokinetics analysis in human brain. Methods: Positron emission tomography studies were performed on six elderly healthy control (HC) subjects and seven probable Alzheimer's disease (AD) patients with [C-11]BF227 and 10 HC subjects and 10 probable AD patients with [F-18]FACT. Data from nine regions of interest were analyzed by several approaches, namely non-linear least-squared fitting methods with arterial input functions (one-tissue compartment model(1TCM), two-tissue compartment model (2TCM)), Logan plot, and linearized methods with reference region (Reference Logan plot (RefLogan), MRTM0, MRTM2). We also evaluated SUV and SUVR for both tracers. The parameters estimated by several approaches were compared between two tracers for detectability of differences between HC and AD patients. Results: For [C-11]BF227, there were no significant difference of V-T (2TCM, 1TCM) and SUV in all regions (Student t-test; p < 0.05) and significant differences in the DVRs (Logan, RefLogan, and MRTM2) and SUVRs in six neocortical regions (p < 0.05) between the HC and AD groups. For [F-18]FACT, significant differences in DVRs (RefLogan, MRTM0, and MRTM2) were observed in more than four neocortical regions between the HC and AD groups (p < 0.05), and the significant differences were found in SUVRs for two neocortical regions (inferior frontal coretex and lateral temporal coretex). Our results showed that both tracers can clearly distinguish between HC and AD groups although the pharmacokinetics and distribution patterns in brain for two tracers were substantially different. Conclusion: This study revealed that although the PET amyloid imaging agents [C-11]BF227 and [F-18]FACT have similar chemical and biological properties, they have different pharmacokinetics, and caution must be paid for usage of the tracers. (C) 2015 Elsevier Inc. All rights reserved.	[Shidahara, Miho; Arakawa, Yuma; Gonda, Kohsuke] Tohoku Univ, Sch Med, Div Med Phys, Sendai, Miyagi 9808578, Japan; [Shidahara, Miho; Tashiro, Manabu; Watanuki, Shoichi] Tohoku Univ, Div Cyclotron Nucl Med, Cyclotron Radioisotope Ctr, Sendai, Miyagi 9808578, Japan; [Watabe, Hiroshi] Tohoku Univ, Div Radiat Protect & Safety Control, Cyclotron Radioisotope Ctr, Sendai, Miyagi 9808578, Japan; [Okamura, Nobuyuki; Yanai, Kazuhiko] Tohoku Univ, Sch Med, Dept Pharmacol, Sendai, Miyagi 9808578, Japan; [Furumoto, Shozo; Funaki, Yoshihito; Iwata, Ren] Tohoku Univ, Div Radiopharmaceut Chem, Cyclotron Radioisotope Ctr, Sendai, Miyagi 9808578, Japan; [Furukawa, Katsutoshi; Arai, Hiroyuki] Tohoku Univ, Inst Dev Aging & Canc, Dept Geriatr & Gerontol, Div Brain Sci, Sendai, Miyagi 9808578, Japan; [Kudo, Yukitsuka] Tohoku Univ, Inst Dev Aging & Canc, Div Neuroimaging, Sendai, Miyagi 9808578, Japan; [Ishiwata, Kiichi] Tokyo Metropolitan Inst Gerontol, Res Team Neuroimaging, Tokyo, Japan	Watabe, H (reprint author), Tohoku Univ, Div Radiat Protect & Safety Control, Cyclotron Radioisotope Ctr, Aoba Ku, 6-3 Aoba, Sendai, Miyagi 9808578, Japan.	hwatabe@m.tohoku.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japanese Government [24700445, 26293133]	This study was supported in part by Grants-in-Aid of Young Scientists (B) (No. 24700445) and Grant-in-Aid for Scientific Research (B) (No. 26293133) from the Ministry of Education, Culture, Sports, Science and Technology, Japanese Government.	Agdeppa ED, 2001, J NEUROSCI, V21, part. no.; Watabe H, 2006, ANN NUCL MED, V20, P583, DOI 10.1007/BF02984655; Vandenberghe R, 2013, NEUROIMAGE-CLIN, V2, P497, DOI 10.1016/j.nicl.2013.03.014; Nelissen N, 2009, J NUCL MED, V50, P1251, DOI 10.2967/jnumed.109.063305; Furumoto S, 2013, MOL IMAGING BIOL, V15, P497, DOI 10.1007/s11307-012-0608-5; Ono M, 2003, NUCL MED BIOL, V30, P565, DOI 10.1016/S0969-8051(03)00049-0; Price JC, 2005, J CEREBR BLOOD F MET, V25, P1528, DOI 10.1038/sj.jcbfm.9600146; Choi SR, 2009, J NUCL MED, V50, P1887, DOI 10.2967/jnumed.109.065284; Rowe CC, 2008, LANCET NEUROL, V7, P129, DOI 10.1016/S1474-4422(08)70001-2; Vandenberghe R, 2010, ANN NEUROL, V68, P319, DOI 10.1002/ana.22068; Furumoto S, 2007, CURR TOP MED CHEM, V7, P1773, DOI 10.2174/156802607782507402; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431; Nyberg S, 2009, EUR J NUCL MED MOL I, V36, P1859, DOI 10.1007/s00259-009-1182-1; Shidahara M, 2009, NEUROIMAGE, V44, P340, DOI 10.1016/j.neuroimage.2008.09.012; Furukawa K, 2010, J NEUROL, V257, P721, DOI 10.1007/s00415-009-5396-8; LOGAN J, 1990, J CEREBR BLOOD F MET, V10, P740; Waragai M, 2009, J NEUROL SCI, V285, P100, DOI 10.1016/j.jns.2009.06.005; Ito H, 2014, EUR J NUCL MED MOL I, V41, P745, DOI 10.1007/s00259-013-2620-7; Nordberg A, 2004, LANCET NEUROL, V3, P519, DOI 10.1016/S1474-4422(04)00853-1; Mathis CA, 2003, J MED CHEM, V46, P2740, DOI 10.1021/jm030026b; Watabe H, 2000, J CEREBR BLOOD F MET, V20, P899; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834; Fodero-Tavoletti MT, 2009, EUR J PHARMACOL, V617, P54, DOI 10.1016/j.ejphar.2009.06.042; Cselenyi Z., 2012, J NUCL MED, V3, P415; Fujiwara T, 1997, Ann Nucl Med, V11, P307; Ichise M, 2003, J CEREBR BLOOD F MET, V23, P1096; Ishii K, 1997, EUR J NUCL MED, V24, P670; Kaneta T, 2011, ANN NUCL MED, V25, P732, DOI 10.1007/s12149-011-0518-7; Kudo V, 2007, J NUCL MED, V48, P553; lkoma V, 2008, ANN NUCL MED, V22, P1; Munk WE, 2003, NEUROIMAG CLIN N AM, V13, P781; Shao H, 2010, DEMENT GERIATR COGN, V30, P101, DOI 10.1159/000318754; Shidahara M, 2013, EJNMMI RES, V3, DOI 10.1186/2191-219X-3-32; Watanuki S, 2010, ANN NUCL MED, V24, P461, DOI 10.1007/s12149-010-0381-y; Zwan MD, 2015, J NUCL MED, V55, P1305	35	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0969-8051	1872-9614		NUCL MED BIOL	Nucl. Med. Biol.	SEP	2015	42	9					734	744		10.1016/j.nucmedbio.2015.05.001		11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CP3CV	WOS:000359755300007		
J	Moriwaki, Y; Otani, J; Sawada, Y; Okuda, J; Niwano, T; Ntta, T; Ohshima, C				Moriwaki, Yoshihiro; Otani, Jun; Sawada, Yoshiyuki; Okuda, Junzo; Niwano, Toshiyuki; Ntta, Tachiko; Ohshima, Chiaki			Percutaneous transhepatic duodenostomy for a gastrectomy case with CT guidance and real-time visualization by an ultrasound and endoscopy	NUTRITION			English	Article						Percutaneous transhepatic gastrostomy/duodenostomy; Percutaneous endoscopic gastrostomy (PEG)/Duodenostomy; Ultrasound guidance; Hepatic injury	PEG TUBE PLACEMENT; GASTROSTOMY; GASTROJEJUNOSTOMY; EXPERIENCE	After gastrectomy, the remnant stomach, a small stomach behind the lateral segment of the liver, is thought to be a relative contraindication to receiving a percutaneous endoscopy-guided gastrostomy (PEG). We successfully performed a percutaneous duodenostomy in a case with remnant stomach. We used a transhepatic pull method with computed tomography (CT) guidance and real-time visualization by using ultrasound (US) and an endoscopy. The procedure was as follows: 1. Full stretching of the remnant stomach; 2. Insertion of a fine injection needle into the duodenal lumen through the lateral segment of the liver without an intrahepatic vascular and biliary injury using real-time visualization through US; 3. Confirmation of the location of the fine needle using abdominal CT, which showed the fine needle penetrating through the lateral segment and the duodenal lumen; 4. Insertion of the thick needle of the PEG kit just laterally of the fine needle; 5. Confirmation of the location of the thick needle using a repeated CT; 6. Endoscopic confirmation of the location of the two needles; 7. Changing the direction of the thick needle using guidance with endoscopy, inserting the thick needle into the duodenal lumen, and removing the fine needle; 8. Insertion of the guide wire through the thick needle; and 9. Placement of the PEG tube using the pull method. Using a real-time US scan, we detected the puncture of the anterior wall of the duodenum or stomach and avoided intrahepatic major vascular and biliary injuries. (C) 2015 Elsevier Inc. All rights reserved.	[Moriwaki, Yoshihiro; Otani, Jun; Sawada, Yoshiyuki; Okuda, Junzo; Niwano, Toshiyuki] Unnan City Hosp, Dept Surg, Unnan, Shimane, Japan; [Otani, Jun; Sawada, Yoshiyuki; Ntta, Tachiko; Ohshima, Chiaki] Unnan City Hosp, Dept Nutr Support, Unnan, Shimane, Japan	Moriwaki, Y (reprint author), Unnan City Hosp, Dept Surg, Unnan, Shimane, Japan.	Yoshimoriwaki@gmail.com					Gubler C, 2005, GASTROINTEST ENDOSC, V61, P346, DOI 10.1016/S0016-5107(04)02584-2; Loser C, 2005, CLIN NUTR, V24, P848, DOI 10.1016/j.clnu.2005.06.013; de Baere T, 1999, RADIOLOGY, V210, P651; Chaer RA, 2003, GASTROINTEST ENDOSC, V57, P763, DOI 10.1067/mge.2003.201; BELL SD, 1995, RADIOLOGY, V194, P817; Bleck JS, 1998, AM J GASTROENTEROL, V93, P941; KANAZAWA S, 1995, ABDOM IMAGING, V20, P302, DOI 10.1007/BF00203358; PUGASH RA, 1995, CAN ASSOC RADIOL J, V46, P196; Tam A, 2008, CLIN RADIOL, V63, P731, DOI 10.1016/j.crad.2007.09.007; Wiggins TF, 2007, DIGEST DIS SCI, V52, P167, DOI 10.1007/s10620-006-9446-0	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0899-9007	1873-1244		NUTRITION	Nutrition	SEP	2015	31	9					1168	1172		10.1016/j.nut.2015.04.004		5	Nutrition & Dietetics	Nutrition & Dietetics	CO8CQ	WOS:000359393000015		
J	Iwasa, M; Sugimoto, R; Yoshikawa, K; Miyachi, H; Mifuji-Moroka, R; Tanaka, H; Kobayashi, Y; Hasegawa, H; Takei, Y				Iwasa, Motoh; Sugimoto, Ryosuke; Yoshikawa, Kyoko; Miyachi, Hirohide; Mifuji-Moroka, Rumi; Tanaka, Hideaki; Kobayashi, Yoshinao; Hasegawa, Hiroshi; Takei, Yoshiyuki			Change in skeletal muscle mass after administering entecavir in patients with hepatitis B	NUTRITION			English	Article						Cachexia; Hepatitis B; Entecavir; Albumin	LIVER-TRANSPLANTATION; SARCOPENIC OBESITY; CIRRHOSIS	Objective: Cachexia, or disease-related loss of muscle mass, is a complication of chronic liver disease that modifies its clinical course. The aim of this study was to determine whether improvement in liver function and cachexia through control of the hepatitis B virus (HBV) increases skeletal muscle mass. Methods: The blood tests and cross-sectional area (mm(2)) of the psoas major muscle on computed tomography were measured before and after long-term entecavir therapy (median, 39 mo; range, 14-76 mo) in patients with hepatitis B (17 men, 13 women; mean age, 63 +/- 13 y). Results: The anti-HBV effect was good in 30 patients given entecavir, and most patients had undetectable serum HBV-DNA levels (93%) and alanine aminotransferase normalization (83%) within a median of 32 mo. Overall, no significant change in the area of the psoas major muscle was seen in any of the patients, although a significant increase was seen when limited to cases of protein malnutrition defined as serum albumin (Alb) <4 g/dL. A positive correlation was seen for the amount of change (A) in the psoas major muscle and the amount of change (A) in Alb. Conclusions: The present findings suggest that skeletal muscle mass may fluctuate in parallel with Alb levels. An improvement in low muscle mass may thus be expected from antiviral therapy for viral liver disease, especially in patients with cachexia. (C) 2015 Elsevier Inc. All rights reserved.	[Iwasa, Motoh; Sugimoto, Ryosuke; Yoshikawa, Kyoko; Miyachi, Hirohide; Mifuji-Moroka, Rumi; Tanaka, Hideaki; Kobayashi, Yoshinao; Hasegawa, Hiroshi; Takei, Yoshiyuki] Mie Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Tsu, Mie 514, Japan	Iwasa, M (reprint author), Mie Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Tsu, Mie 514, Japan.	motoh@clin.medic.mie-u.ac.jp					Dasarathy J, 2011, LIVER INT, V31, P1250, DOI 10.1111/j.1478-3231.2011.02498.x; Iloeje UH, 2006, GASTROENTEROLOGY, V130, P678, DOI 10.1053/j.gastro.2005.11.016; Shen W, 2004, J APPL PHYSIOL, V97, P2333, DOI 10.1152/japplphysiol.00744.2004; Schutz T, 2012, NUTRITION, V28, P378, DOI 10.1016/j.nut.2011.07.019; Shim JH, 2010, J HEPATOL, V52, P176, DOI 10.1016/j.jhep.2009.11.007; Dasarathy S, 2013, DIGEST DIS SCI, V58, P3103, DOI 10.1007/s10620-013-2791-x; Durand F, 2014, J HEPATOL, V60, P1151, DOI 10.1016/j.jhep.2014.02.026; Biolo G, 2014, CLIN NUTR, V33, P737, DOI 10.1016/j.clnu.2014.03.007; Qiu J, 2013, P NATL ACAD SCI USA, V110, P18162, DOI 10.1073/pnas.1317049110; Yoshizumi T, 2014, HEPATOL RES, V44, P313, DOI 10.1111/hepr.12119	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0899-9007	1873-1244		NUTRITION	Nutrition	SEP	2015	31	9					1173	1174		10.1016/j.nut.2015.04.003		2	Nutrition & Dietetics	Nutrition & Dietetics	CO8CQ	WOS:000359393000016		
J	Carreaud, J; Labruyere, A; Dardar, H; Moisy, F; Duclere, JR; Couderc, V; Bertrand, A; Dutreilh-Colas, M; Delaizir, G; Hayakawa, T; Crunteanu, A; Thomas, P				Carreaud, J.; Labruyere, A.; Dardar, H.; Moisy, F.; Duclere, J. -R.; Couderc, V.; Bertrand, A.; Dutreilh-Colas, M.; Delaizir, G.; Hayakawa, T.; Crunteanu, A.; Thomas, P.			Lasing effects in new Nd3+-doped TeO2-Nb2O5-WO3 bulk glasses	OPTICAL MATERIALS			English	Article						Tellurite glasses; Bulk lasers; Rare earth ions; Nd3+; Laser emission	TUNGSTEN-TELLURITE GLASSES; SPECTROSCOPIC PROPERTIES; MU-M; SUPERCONTINUUM GENERATION; THERMAL-STABILITY; TEO2-RICH PART; UP-CONVERSION; LASER; EMISSION; SYSTEM	This paper demonstrates for the first time continuous wave (cw) and pulsed lasing effects in a 75TeO(2)-20NbO(2.5)-5WO(3) glass doped with 1 mol.% in Nd3+. It is divided into two parts: - The first part treats all the aspects related to the elaboration and the characterization of the materials. Thus, glasses elaborated within the TeO2-Nb2O5-WO3 ternary system show a rather high glass transition temperature T-g similar to 375 degrees C, with an excellent thermal stability of similar to 1.60 degrees C. Compared to glasses synthesized in either TeO2-Nb2O5 or TeO2-WO3 binary systems, glasses fabricated within such system show improved mechanical performances, with larger Young's modulus values. The structural characteristics of the samples, studied by Raman spectroscopy, are also presented. Linear optical properties (refractive index and extinction coefficient) are accessed by spectroscopic ellipsometry. As well, the optical transmission of the various bulk glasses is measured, in the case of both uncoated and coated glasses. In particular, specific anti-reflective coatings at 808 nm (laser diode pump wavelength) and 1064 nm (laser emission wavelength) are respectively deposited on the two surfaces of the sample in order to minimize the losses due to Fresnel reflections at the two glass/air interfaces. In addition, another specific surface treatment (R-max at 1064 nm) was employed to serve as the back mirror of the laser cavity. The optical transmission data testified to the real efficiency of all these coatings. Finally, the photoluminescence properties (emission and excitation spectra, and luminescence decay curve) of the Nd3+-doped glasses, measured at room temperature for bulk samples, and as a function of temperature for powder glasses, are discussed. - The second part is focused on evidencing (cw) and pulsed lasing effects in such coated bulk lasers. Cylindric samples of only a few millimeters in height and in diameter were tested and led to a laser emission around 1064 nm, characterized by a very low pump power threshold of similar to 5 mW, but with a limited slope efficiency (similar to 4.6%). The spectral characteristics were also measured and some anisotropic enlargement of the laser emission band toward longer wavelength was noticed with increasing the pump power. Finally, monomodal or multimodal laser emission was evidenced, depending again on the pump power. (C) 2015 Elsevier B.V. All rights reserved.	[Carreaud, J.; Dardar, H.; Moisy, F.; Duclere, J. -R.; Bertrand, A.; Dutreilh-Colas, M.; Delaizir, G.; Thomas, P.] Univ Limoges, UMR CNRS 7315, Ctr Europeen Ceram, Lab Sci Proc Ceram & Traitements Surface, F-87068 Limoges, France; [Labruyere, A.; Dardar, H.; Couderc, V.; Crunteanu, A.] Univ Limoges, UMR CNRS 7252, Inst XLIM, F-87060 Limoges, France; [Hayakawa, T.] Nagoya Inst Technol, Dept Frontier Mat, Field Adv Energy Convers, Showa Ku, Nagoya, Aichi 4668555, Japan	Duclere, JR (reprint author), Univ Limoges, UMR CNRS 7315, Ctr Europeen Ceram, Lab Sci Proc Ceram & Traitements Surface, 12 Rue Atlantis, F-87068 Limoges, France.	jean-rene.duclere@unilim.fr			Conseil Regional du Limousin; National Agency of the Research [ANR-10-LABX-0074-01, ANR-13-BS08-0008-01]	Some of the authors wish to thank the Conseil Regional du Limousin for its financial support. This work benefited also of a financial support from the French state managed by the National Agency of the Research under both the 'Future Investments' program referred as Labex Sigma-Lim (noANR-10-LABX-0074-01) and the HOLIGRALE Project (noANR-13-BS08-0008-01). Finally, some of the authors wish as well to thank both F. Gouraud and Dr. J.-C. Orlianges for their technical assistance in measuring the mechanical properties and in the acquisition of the spectroscopic ellipsometry data, respectively.	Achenbach J. D., 1984, WAVE PROPAGATION ELA; Miguel A, 2013, OPT EXPRESS, V21, P9298, DOI 10.1364/OE.21.009298; Carreaud J, 2012, LASER PHYS LETT, V9, P344, DOI 10.7452/lapl.201110140; Gandhi Y, 2010, J ALLOY COMPD, V508, P278, DOI 10.1016/j.jallcom.2010.08.137; Guo YY, 2013, SPECTROCHIM ACTA A, V111, P150, DOI 10.1016/j.saa.2013.03.089; Lei N, 1996, OPT COMMUN, V127, P263, DOI 10.1016/0030-4018(96)00099-5; KIM SH, 1993, J AM CERAM SOC, V76, P2486, DOI 10.1111/j.1151-2916.1993.tb03970.x; Price JHV, 2012, OPT FIBER TECHNOL, V18, P327, DOI 10.1016/j.yofte.2012.07.013; MICHEL JC, 1978, REV PHYS APPL, V13, P859, DOI 10.1051/rphysap:019780013012085900; Jha A, 2012, PROG MATER SCI, V57, P1426, DOI 10.1016/j.pmatsci.2012.04.003; Iparraguirre I, 2007, J NON-CRYST SOLIDS, V353, P990, DOI 10.1016/j.jnoncrysol.2006.12.103; Zhou B, 2013, J LUMIN, V137, P132, DOI 10.1016/j.jlumin.2012.12.045; Dai SX, 2005, SPECTROCHIM ACTA A, V62, P431, DOI 10.1016/j.saa.2005.01.011; He LN, 2013, LASER PHOTONICS REV, V7, P60, DOI 10.1002/lpor.201100032; Fusari F, 2010, OPT EXPRESS, V18, P22090, DOI 10.1364/OE.18.022090; Richards B, 2010, LASER PHYS LETT, V7, P177, DOI 10.1002/lapl.200910131; Kalaycioglu H, 2008, OPT COMMUN, V281, P6056, DOI 10.1016/j.optcom.2008.08.053; Ersundu AE, 2010, J ALLOY COMPD, V508, P266, DOI 10.1016/j.jallcom.2010.08.120; WANG JS, 1994, OPT LETT, V19, P1448, DOI 10.1364/OL.19.001448; Savelii I, 2011, OPT MATER, V33, P1661, DOI 10.1016/j.optmat.2011.05.010; Wang J. S., 1994, Optical Materials, V3, DOI 10.1016/0925-3467(94)90004-3; Balashov I. F., 1990, Journal of Applied Spectroscopy, V52, DOI 10.1007/BF00664538; Balda R, 2009, OPT EXPRESS, V17, P8781, DOI 10.1364/OE.17.008781; Bell MJV, 2014, J OPT SOC AM B, V31, P1590, DOI 10.1364/JOSAB.31.001590; Blanchandin S, 1999, J MATER CHEM, V9, P1785, DOI 10.1039/a900788a; Blanchandin S, 1999, J MATER SCI, V34, P4285, DOI 10.1023/A:1004667223028; Boetti NG, 2012, J LUMIN, V132, P1265, DOI 10.1016/j.jlumin.2011.12.057; Cankaya H, 2010, APPL PHYS B-LASERS O, V99, P121, DOI 10.1007/s00340-009-3752-0; Damak K, 2012, J NON-CRYST SOLIDS, V358, P2974, DOI 10.1016/j.jnoncrysol.2012.07.027; El-Mallawany R. A. H, 2012, TELLURITE GLASSES HD; Feng X, 1999, J NON-CRYST SOLIDS, V256, P372, DOI 10.1016/S0022-3093(99)00476-7; Fusari F, 2010, OPT MATER, V32, P1007, DOI 10.1016/j.optmat.2010.02.020; Ghribi N, 2015, J ALLOY COMPD, V622, P333, DOI 10.1016/j.jallcom.2014.10.063; Ghribi N, 2015, SOLID STATE SCI, V40, P20, DOI 10.1016/j.solidstatesciences.2014.12.009; Jan N. A. Mat, 2013, Nano Hybrids, V3, DOI 10.4028/www.scientific.net/NH.3.81; Jiang C, 1999, MATER LETT, V41, P209, DOI 10.1016/S0167-577X(99)00132-9; Kolsky H., 1963, STRESS WAVES SOLIDS; Krautkramer K., 1969, ULTRASONIC TESTING M; Luo Y. R., 2002, HDB BOND DISSOCIATIO; Narro-Garcia R, 2013, J LUMIN, V134, P528, DOI 10.1016/j.jlumin.2012.07.034; Fusari F, 2008, OPT EXPRESS, V16, P19146, DOI 10.1364/OE.16.019146; Richards BDO, 2011, PROC SPIE, V8039, DOI 10.1117/12.886722; Wang G.-N., 2004, J INORG MATER, V5, P997; Wang XM, 2008, SPECTROCHIM ACTA A, V70, P99, DOI 10.1016/j.saa.2007.07.013; [Xu Shiqing 徐时清], 2004, Chinese Optics Letters, V2, P106; Yen W.M., 2006, FUNDAMENTALS PHOSPHO	46	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	SEP	2015	47						99	107		10.1016/j.optmat.2015.06.055		9	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CO4YJ	WOS:000359166500018		
J	Starobor, A; Yasyhara, R; Snetkov, I; Mironov, E; Palashov, O				Starobor, Aleksey; Yasyhara, Ryo; Snetkov, Ilya; Mironov, Evgeniy; Palashov, Oleg			TSAG-based cryogenic Faraday isolator	OPTICAL MATERIALS			English	Article						Thermal effects; Thermally induced depolarization; Faraday isolator; Magnetooptical materials	TERBIUM GALLIUM GARNET; SCANDIUM-ALUMINUM GARNET; INDUCED MODAL DISTORTIONS; SINGLE-CRYSTALS; INDUCED DEPOLARIZATION; POWER LASERS; GROWTH; CERAMICS; COMPENSATION; ROTATORS	Thermooptical and magnetooptical properties of novel magnetoactive crystal terbium-scandium aluminum garnet were investigated at temperature range 80-300 K. It is shown that Verdet constant increases inversely proportional to temperature, and thermally induced depolarization, and the optical power of the thermal lens is reduced significantly with cooling from 290 K to 80K. According to estimates, TSAG crystals in [111] orientation allow to create a cryogenic Faraday isolator provides a degree of isolation of 30 dB with the laser power exceeds similar to 6 kW, it is estimated that the transition to the [001] orientation allows to provide degree of isolation of 30 dB at a laser power higher than 400 kW. (C) 2015 Elsevier B.V. All rights reserved.	[Starobor, Aleksey; Snetkov, Ilya; Mironov, Evgeniy; Palashov, Oleg] RAS, Inst Appl Phys, Nonlinear Dynam & Opt Dept, Nizhnii Novgorod 603098, Russia; [Yasyhara, Ryo] Natl Inst Nat Sci, Natl Inst Fus Sci, Toki, Gifu 5095292, Japan	Starobor, A (reprint author), RAS, Inst Appl Phys, Nonlinear Dynam & Opt Dept, Nizhnii Novgorod 603098, Russia.	astarobor@mail.ru			Government of the Russian Federation [14.B25.31.0024]	This work was supported by the mega-grant of the Government of the Russian Federation No. 14.B25.31.0024 executed at the Institute of Applied Physics RAS.	Khazanov EA, 1999, IEEE J QUANTUM ELECT, V35, P1116, DOI 10.1109/3.777210; BRANDLE CD, 1973, J CRYST GROWTH, V20, P1, DOI 10.1016/0022-0248(73)90029-8; Mironov EA, 2014, OPT EXPRESS, V22, P23226, DOI 10.1364/OE.22.023226; Zheleznov DS, 2012, J OPT SOC AM B, V29, P786; Malshakov AN, 1997, APPL OPTICS, V36, P6403, DOI 10.1364/AO.36.006403; Mueller G, 2002, CLASSICAL QUANT GRAV, V19, P1793, DOI 10.1088/0264-9381/19/7/376; Yasuhara R, 2007, OPT EXPRESS, V15, P11255, DOI 10.1364/OE.15.011255; Vasyliev V, 2012, OPT EXPRESS, V20, P14460, DOI 10.1364/OE.20.014460; Snetkov IL, 2013, OPT EXPRESS, V21, P21254, DOI 10.1364/OE.21.021254; Mukhin I, 2009, OPT COMMUN, V282, P1969, DOI 10.1016/j.optcom.2009.02.008; Kagan MA, 2004, APPL OPTICS, V43, P6030, DOI 10.1364/AO.43.006030; Lin H, 2011, OPT MATER, V33, P1833, DOI 10.1016/j.optmat.2011.06.017; Chen Z, 2015, MATER LETT, V145, P171, DOI 10.1016/j.matlet.2015.01.108; Yasuhara R, 2013, OPT LETT, V38, P1751, DOI 10.1364/OL.38.001751; Zheleznov DS, 2010, QUANTUM ELECTRON+, V40, P276, DOI 10.1070/QE2010v040n03ABEH014247; Chen Z, 2015, OPT LETT, V40, P820, DOI 10.1364/OL.40.000820; Khazanov EA, 1999, QUANTUM ELECTRON+, V29, P59, DOI 10.1070/QE1999v029n01ABEH001412; Pawlak DA, 2001, J CRYST GROWTH, V226, P341, DOI 10.1016/S0022-0248(01)01378-1; Chen C., 2015, J MATER SCI, V12, P2; Ganschow S, 1997, P SOC PHOTO-OPT INS, V3178, P55, DOI 10.1117/12.280704; Guo FY, 2014, J CRYST GROWTH, V397, P19, DOI 10.1016/j.jcrysgro.2014.04.002; Guo FY, 2012, OPT MATER, V35, P227, DOI 10.1016/j.optmat.2012.08.009; Kagamitani Y, 2002, JPN J APPL PHYS 1, V41, P6020, DOI 10.1143/JJAP.41.6020; Kagamitani Y, 2004, J MATER RES, V19, P579, DOI 10.1557/jmr.2004.19.2.579; Kang JB, 2014, OPT MATER, V36, P1266, DOI 10.1016/j.optmat.2014.03.013; Khazanov E, 2004, IEEE J QUANTUM ELECT, V40, P1500, DOI 10.1109/JQE.2004.834766; Mironov E., 2014, APPL; Snetkov Ilya, 2011, Opt Express, V19, P6366, DOI 10.1364/OE.19.006366; Snetkov I.L., 2015, THERMOOPTICAL MAGNET; Starobor A., 2014, OPT MATER EXPRESS, V4, P2127; Starobor AV, 2011, J OPT SOC AM B, V28, P1409; Veber P, 2015, CRYSTENGCOMM, V17, P492, DOI 10.1039/c4ce02006e; Zelenogorsky VV, 2006, APPL OPTICS, V45, P4092, DOI 10.1364/AO.45.004092	33	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	SEP	2015	47						112	117		10.1016/j.optmat.2015.07.013		6	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CO4YJ	WOS:000359166500020		
J	Arita, R; Minami, Y; Cadatal-Raduban, M; Pham, MH; Empizo, MJF; Luong, MV; Hori, T; Takabatake, M; Fukuda, K; Mori, K; Yamanoi, K; Shimizu, T; Sarukura, N; Fukuda, K; Kawaguchi, N; Yokota, Y; Yoshikawa, A				Arita, Ren; Minami, Yuki; Cadatal-Raduban, Marilou; Pham, Minh Hong; Empizo, Melvin John Fernandez; Luong, Mui Viet; Hori, Tatsuhiro; Takabatake, Masahiro; Fukuda, Kazuhito; Mori, Kazuyuki; Yamanoi, Kohei; Shimizu, Toshihiko; Sarukura, Nobuhiko; Fukuda, Kentaro; Kawaguchi, Noriaki; Yokota, Yuui; Yoshikawa, Akira			Significant blue-shift in photoluminescence excitation spectra of Nd3+:LaF3 potential laser medium at low-temperature	OPTICAL MATERIALS			English	Article						Nd3+:LaF3; Fluoride crystal; Vacuum ultraviolet; Temperature dependent; Laser material	VACUUM-ULTRAVIOLET-LASER; NM; TRIFLUORIDES; SPECTROSCOPY; SCINTILLATOR; EMISSION; PULSES	Temperature-dependent optical properties of bulk Nd3+:LaF3 crystals are reported. A blue-shift in the photoluminescence excitation (PLE) spectrum is observed at 30 K. The 173.2-nm emission peak wavelength at 300 K shifted to 172.8 nm at 30 K, consistent with the 6-nm blue-shift in transmission edge and 2437-cm(-1) increase in the lowest energy level of the 4f(2)5d configuration. Thermal broadening of the 5d-4f emission bands with increasing temperature is also observed as the dip at around 178.5 nm present at 30K disappears at 300 K. A smaller spectral overlap between the PLE and emission spectra is observed as temperature is decreased. Our results suggest that absorption cross-section at the peak fluorescence wavelength is expected to decrease at 30 K. (C) 2015 Elsevier B.V. All rights reserved.	[Arita, Ren; Minami, Yuki; Cadatal-Raduban, Marilou; Pham, Minh Hong; Empizo, Melvin John Fernandez; Luong, Mui Viet; Hori, Tatsuhiro; Takabatake, Masahiro; Fukuda, Kazuhito; Mori, Kazuyuki; Yamanoi, Kohei; Shimizu, Toshihiko; Sarukura, Nobuhiko] Osaka Univ, Inst Laser Engn, Suita, Osaka 5650871, Japan; [Cadatal-Raduban, Marilou] Massey Univ, Inst Nat & Math Sci, Ctr Theoret Chem & Phys, Auckland 0632, New Zealand; [Cadatal-Raduban, Marilou; Pham, Minh Hong] Osaka Univ, Inst Acad Initiat, Suita, Osaka 5650871, Japan; [Pham, Minh Hong] Viet Nam Acad Sci & Technol, Inst Phys, Hanoi, Vietnam; [Fukuda, Kentaro; Kawaguchi, Noriaki; Yoshikawa, Akira] Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan; [Yokota, Yuui] Tohoku Univ, New Ind Creat Hatchery Ctr, Sendai, Miyagi 9808579, Japan	Arita, R (reprint author), Osaka Univ, Inst Laser Engn, 2-6 Yamadaoka, Suita, Osaka 5650871, Japan.	arita-r@ile.osaka-u.ac.jp	Shimizu, Toshihiko/F-5079-2015; Sarukura, Nobuhiko/F-3276-2015; Yamanoi, Kohei/B-2150-2013	Shimizu, Toshihiko/0000-0001-6712-3804; Sarukura, Nobuhiko/0000-0003-2353-645X; Yamanoi, Kohei/0000-0003-4492-4099			Aleksanyan E, 2010, OPT COMMUN, V283, P49, DOI 10.1016/j.optcom.2009.09.067; Jones DJ, 1999, J MATER RES, V14, P4337, DOI 10.1557/JMR.1999.0587; Cadatal M, 2007, JPN J APPL PHYS 2, V46, pL985, DOI 10.1143/JJAP.46.L985; Cadatal M, 2009, J LUMIN, V129, P1629, DOI 10.1016/j.jlumin.2009.01.025; Dorenbos P, 1996, J LUMIN, V69, P229, DOI 10.1016/S0022-2313(96)00095-6; DUBINSKII MA, 1992, J OPT SOC AM B, V9, P1148, DOI 10.1364/JOSAB.9.001148; DUBINSKII MA, 1992, OPT COMMUN, V88, P122, DOI 10.1016/0030-4018(92)90497-F; Fukui K, 1998, J SYNCHROTRON RADIAT, V5, P836, DOI 10.1107/S0909049598000430; Govorkov S.V., 1998, ADV SOLID STATE LASE; JOHNSON SA, 1967, J OPT SOC AM, V57, P734, DOI 10.1364/JOSA.57.000734; LAUFER AH, 1965, J OPT SOC AM, V55, P64, DOI 10.1364/JOSA.55.000064; Liu ZL, 2001, IEEE J SEL TOP QUANT, V7, P542, DOI 10.1109/2944.974225; Nakazato T, 2010, IEEE T NUCL SCI, V57, P1208, DOI 10.1109/TNS.2010.2041362; Shinzato Y., 2013, APPL PHYS EXP, V6; Sugimura H, 2005, JPN J APPL PHYS 1, V44, P5185, DOI 10.1143/JJAP.44.5185; WAYNANT RW, 1982, APPL PHYS B-PHOTO, V28, P205; Yamanoi K, 2013, OPT MATER, V35, P2030, DOI 10.1016/j.optmat.2012.09.033; Yanagida T, 2011, NUCL INSTRUM METH A, V659, P258, DOI 10.1016/j.nima.2011.08.056; YANG KH, 1978, PHYS REV B, V17, P4246, DOI 10.1103/PhysRevB.17.4246; YANG KH, 1976, APPL PHYS LETT, V29, P499, DOI 10.1063/1.89137	20	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	SEP	2015	47						462	464		10.1016/j.optmat.2015.06.020		3	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CO4YJ	WOS:000359166500072		
J	Okamoto, T; Sasaki, R; Kataoka, T; Kumasaka, A; Kaibuchi, N; Naganawa, T; Fukada, K; Ando, T				Okamoto, Toshihiro; Sasaki, Ryo; Kataoka, Toshiyuki; Kumasaka, Akira; Kaibuchi, Nobuyuki; Naganawa, Takuya; Fukada, Kenji; Ando, Tomohiro			Dermoscopy imaging findings in the normal Oral Mucosa	ORAL ONCOLOGY			English	Letter									[Okamoto, Toshihiro; Sasaki, Ryo; Kataoka, Toshiyuki; Kumasaka, Akira; Kaibuchi, Nobuyuki; Naganawa, Takuya; Fukada, Kenji; Ando, Tomohiro] Tokyo Womens Med Univ, Sch Med, Dept Oral & Maxillofacial Surg, Shinjuku Ku, Tokyo, Japan	Okamoto, T (reprint author), Tokyo Womens Med Univ, Sch Med, Dept Oral & Maxillofacial Surg, Shinjuku Ku, Tokyo, Japan.	okamoto@oms.twmu.ac.jp					Barbara D, 2014, POSTEP DERM ALERGOL, VXXXI, P222; Ken K, 2010, DERMATOL RES PRACT, V10, P1155; Luana VM, 2012, J DERMATOL, V39, P397; Manabu M., 2006, J DERMATOL, V2, P96; Masaru T, 2006, J DERMATOL, V33, P513; Takano JH, 2010, INT J ORAL MAX SURG, V39, P208, DOI 10.1016/j.ijom.2010.01.007; Tamar HS, 2012, J DERMATOL CASE REP, V1, P1; Vincenzo DG, 2003, ORAL ONCOL, V39, P534; Zoe A, 2012, J DERMATOL CASE REP, P57	9	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1368-8375	1879-0593		ORAL ONCOL	Oral Oncol.	SEP	2015	51	9					E69	E70		10.1016/j.oraloncology.2015.06.007		2	Oncology; Dentistry, Oral Surgery & Medicine	Oncology; Dentistry, Oral Surgery & Medicine	CO6YT	WOS:000359304800003		
J	Tsukutani, Y; Hagino, H; Ito, Y; Nagashima, H				Tsukutani, Y.; Hagino, H.; Ito, Y.; Nagashima, H.			Epidemiology of fragility fractures in Sakaiminato, Japan: incidence, secular trends, and prognosis	OSTEOPOROSIS INTERNATIONAL			English	Article						Fragility fractures; Incidence rates; Osteoporosis; Prognosis	PROXIMAL HUMERAL FRACTURES; HIP FRACTURE; OSTEOPOROTIC FRACTURES; VERTEBRAL FRACTURE; WRIST FRACTURES; WOMEN; RISK; POPULATION; DENSITY; NETHERLANDS	A Summary We investigated the incidence of fragility fractures from 2010 to 2012 in Sakaiminato, Japan. The incidence rates of limb fractures in Sakaiminato were lower than in Caucasian populations but had increased relative to data obtained in Japan in the 1990s. Clinical vertebral fractures occurred at higher rates in Sakaiminato than in Caucasian populations. Introduction To elucidate the incidence and prognosis of fragility fractures in Sakaiminato, Japan. Methods A survey of all hip, distal radius, proximal humerus, and clinical vertebral fractures was performed from 2010 to 2012 in patients aged 50 or older in Sakaiminato city, Tottori prefecture, Japan. The age- and gender-specific incidence rates (per 100,000 person-years) were calculated based on the population of Sakaiminato city each year. The incidence rates of hip, distal radius, and proximal humerus fractures were compared with previous reports. We conducted a follow-up study assessing patients within 1 year following their initial treatment at two Sakaiminato hospitals. Results The age-adjusted incidence rates in population aged 50 years or older (per 100,000 person-years) of hip, distal radius, proximal humerus, and clinical vertebral fractures were, respectively, 217, 82, 26, and 412 in males and 567, 432, 96, and 1229 in females. Age-specific incidence rates of hip, distal radius, and proximal humerus fractures all increased since the 1990s. Our study also revealed that anti-osteoporotic pharmacotherapy was prescribed 1 year post-fracture at rates of 29, 20, 30, and 50 % for patients with hip, distal radius, proximal humerus, and clinical vertebral fractures, respectively. Conclusions The incidence rates of limb fractures in Sakaiminato were substantially lower than Caucasian populations in northern Europe but had increased relative to data obtained in Japan in the 1990s. Unlike upper and lower limb fractures, clinical vertebral fractures occurred at higher rates in our study population than in other Asian and North European countries.	[Tsukutani, Y.; Nagashima, H.] Tottori Univ, Fac Med, Dept Orthoped Surg, Yonago, Tottori 6838504, Japan; [Hagino, H.] Tottori Univ, Sch Hlth Sci, Tottori 680, Japan; [Ito, Y.] Ome Keiyu Hosp, Tokyo, Japan	Tsukutani, Y (reprint author), Tottori Univ, Fac Med, Dept Orthoped Surg, 36-1 Nishi Cho, Yonago, Tottori 6838504, Japan.	tukuyasu@med.tottori-u.ac.jp			Asahi Kasei Pharma Corp.; Astellas Pharma Inc.; Banyu Pharmaceutical Co. Ltd.; Chugai Pharmaceutical Co. Ltd.; Eisai Co. Ltd.; Eli Lilly Japan K.K.; Mitsubishi Tanabe Pharma Corp.; Ono Pharmaceutical Co. Ltd.; Pfizer Inc.; Takeda Pharmaceutical Co. Ltd.; Teijin Pharma Ltd.	Yasuto Tsukutani and Yasuyo Ito declare that they have no conflict of interest. Hiroshi Hagino and Hideki Nagashima have received consulting fees from Asahi Kasei Pharma Corp., Astellas Pharma Inc., Banyu Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teijin Pharma Ltd.	Brauer CA, 2009, JAMA-J AM MED ASSOC, V302, P1573, DOI 10.1001/jama.2009.1462; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Boufous S, 2006, BONE, V39, P1144, DOI 10.1016/j.bone.2006.05.011; Fujiwara S, 2003, J BONE MINER RES, V18, P1547, DOI 10.1359/jbmr.2003.18.8.1547; Duan YB, 1999, J BONE MINER RES, V14, P1796, DOI 10.1359/jbmr.1999.14.10.1796; GILSANZ V, 1994, RADIOLOGY, V190, P678; Rabenda V, 2008, J BONE JOINT SURG AM, V90A, P2142, DOI 10.2106/JBJS.G.00864; Rozental TD, 2008, J BONE JOINT SURG AM, V90A, P953, DOI 10.2106/JBJS.G.01121; Chang KP, 2004, J BONE MINER RES, V19, P532, DOI 10.1359/JBMR.040109; Palvanen M, 2006, CLIN ORTHOP RELAT R, P87, DOI 10.1097/01.blo.0000194672.79634.78; Melton L, 2009, OSTEOPOROSIS INT, V20, P687, DOI 10.1007/s00198-008-0742-8; [Anonymous], 1957, BERICHTE OHARA I LAN, V11, p12e21; Kanis JA, 2000, OSTEOPOROSIS INT, V11, P669, DOI 10.1007/s001980070064; Dimai HP, 2013, OSTEOPOROSIS INT, V24, P2413, DOI 10.1007/s00198-013-2339-0; Ruyssen-Witrand A, 2007, OSTEOPOROSIS INT, V18, P1271, DOI 10.1007/s00198-007-0356-6; Hagino H, 1999, BONE, V24, P265, DOI 10.1016/S8756-3282(98)00175-6; de Putter CE, 2013, INJURY, V44, P421, DOI 10.1016/j.injury.2012.10.025; Oskam J, 1998, INJURY, V29, P353, DOI 10.1016/S0020-1383(97)00212-X; Siggeirsdottir K, 2014, OSTEOPOROSIS INT, V25, P211, DOI 10.1007/s00198-013-2422-6; Cauley JA, 2014, NAT REV ENDOCRINOL, V10, P338, DOI 10.1038/nrendo.2014.51; Kannus P, 2006, J BONE MINER RES, V21, P1836, DOI 10.1359/JBMR.060815; Amin S, 2014, J BONE MINER RES, V29, P581, DOI 10.1002/jbmr.2072; Baba T, 2015, OSTEOPOROS INT; Bjorgul K, 2007, INT ORTHOP, V31, P665, DOI 10.1007/s00264-006-0251-3; Bow CH, 2012, OSTEOPOROSIS INT, V23, P879, DOI 10.1007/s00198-011-1627-9; Chan DC, 2013, CALCIFIED TISSUE INT, V93, P397; Chau PH, 2013, AGE AGEING, V42, P229, DOI 10.1093/ageing/afs177; Finkelstein JS, 2002, J CLIN ENDOCR METAB, V87, P3057, DOI 10.1210/jc.87.7.3057; Goettsch WG, 2007, PHARMACOEPIDEM DR S, V16, P166, DOI 10.1002/pds.1245; Hagino H, 2009, OSTEOPOROSIS INT, V20, P543, DOI 10.1007/s00198-008-0685-0; Hagino H, 2012, CALCIFIED TISSUE INT, V90, P14, DOI 10.1007/s00223-011-9545-6; Jonsson B, 1999, ACTA ORTHOP SCAND, V70, P129, DOI 10.3109/17453679909011249; Kaastad TS, 1998, BONE, V22, P175, DOI 10.1016/S8756-3282(97)00247-0; Koh LKH, 2001, OSTEOPOROSIS INT, V12, P311, DOI 10.1007/s001980170121; Lippuner K, 2009, OSTEOPOROSIS INT, V20, P1131, DOI 10.1007/s00198-008-0779-8; Lonnroos E, 2006, BONE, V39, P623, DOI 10.1016/j.bone.2006.03.001; Morales-Torres J, 2004, OSTEOPOROSIS INT, V15, P625, DOI 10.1007/s00198-004-1596-3; Pentek M, 2008, OSTEOPOROSIS INT, V19, P243, DOI 10.1007/s00198-007-0453-6; Roerholt C, 2009, OSTEOPOROSIS INT, V20, P299, DOI 10.1007/s00198-008-0651-x; Sakuma M, 2013, J BONE MINER METAB; Solomon DH, 2014, J BONE MINER RES; Yan L, 1999, BONE, V24, P151, DOI 10.1016/S8756-3282(98)00168-9	42	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0937-941X	1433-2965		OSTEOPOROSIS INT	Osteoporosis Int.	SEP	2015	26	9					2249	2255		10.1007/s00198-015-3124-z		7	Endocrinology & Metabolism	Endocrinology & Metabolism	CO9EI	WOS:000359475200003		
J	Harvey, NC; Kanis, JA; Oden, A; Nakamura, T; Shiraki, M; Sugimoto, T; Kuroda, T; Johansson, H; McCloskey, EV				Harvey, N. C.; Kanis, J. A.; Oden, A.; Nakamura, T.; Shiraki, M.; Sugimoto, T.; Kuroda, T.; Johansson, H.; McCloskey, E. V.			Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX	OSTEOPOROSIS INTERNATIONAL			English	Article						Epidemiology; FRAX; Osteoporosis; Randomised controlled trial; Teriparatide; Vertebral fracture	BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; PRIMARY OSTEOPOROSIS; VERTEBRAL FRACTURES; RISK; BAZEDOXIFENE; REDUCTION; TRIAL	The aim of this study was to determine the efficacy of once-weekly teriparatide as a function of baseline fracture risk. Treatment with once-weekly teriparatide was associated with a statistically significant 79 % decrease in vertebral fractures, and in the cohort as a whole, efficacy was not related to baseline fracture risk. Introduction Previous studies have suggested that the efficacy of some interventions may be greater in the segment of the population at highest fracture risk as assessed by the FRAXA(R) algorithms. The aim of the present study was to determine whether the antifracture efficacy of weekly teriparatide was dependent on the magnitude of fracture risk. Methods Baseline fracture probabilities (using FRAX) were computed from the primary data of a phase 3 study (TOWER) of the effects of weekly teriparatide in 542 men and postmenopausal women with osteoporosis. The outcome variable comprised morphometric vertebral fractures. Interactions between fracture probability and efficacy were explored by Poisson regression. Results The 10-year probability of major osteoporotic fractures (without BMD) ranged from 7.2 to 42.2 %. FRAX-based hip fracture probabilities ranged from 0.9 to 29.3 %. Treatment with teriparatide was associated with a 79 % (95 % CI 52-91 %) decrease in vertebral fractures assessed by semiquantitative morphometry. Relative risk reductions for the effect of teriparatide on the fracture outcome did not change significantly across the range of fracture probabilities (p=0.28). In a subgroup analysis of 346 (64 %) participants who had FRAX probabilities calculated with the inclusion of BMD, there was a small but significant interaction (p=0.028) between efficacy and baseline fracture probability such that high fracture probabilities were associated with lower efficacy. Conclusion Weekly teriparatide significantly decreased the risk of morphometric vertebral fractures in men and postmenopausal women with osteoporosis. Overall, the efficacy of teriparatide was not dependent on the level of fracture risk assessed by FRAX in the cohort as a whole.	[Harvey, N. C.] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton SO16 6YD, Hants, England; [Kanis, J. A.; Oden, A.; Johansson, H.; McCloskey, E. V.] Univ Sheffield, Ctr Metab Bone Dis, Sheffield S10 2RX, S Yorkshire, England; [Nakamura, T.] Natl Ctr Global Hlth & Med, Shinjuku Ku, Tokyo 1628655, Japan; [Shiraki, M.] Res Inst & Practice Involut Dis, Azumino, Nagano 3998101, Japan; [Sugimoto, T.] Shimane Univ, Fac Med, Internal Med 1, Izumo, Shimane 6938501, Japan; [Kuroda, T.] Asahi Kasei Pharma Corp, Med Affairs Dept, Chiyoda Ku, Tokyo 1018101, Japan	Kanis, JA (reprint author), Univ Sheffield, Ctr Metab Bone Dis, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	w.j.pontefract@sheffield.ac.uk			ActiveSignal; Alliance for Better Bone Health; AMGEN; Bayer; Consilient Healthcare; GE Lunar; Hologic; Internis Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Servier; Tethys; UCB; Univadis; Chugai Pharmaceutical; Teijin Pharma; Asahi Kasei Pharma; Daiichi Sankyo; Chugai; Daiichi-Sankyo-Co.; Eli Lilly Japan; Eli Lilly; lecture fees	NH has received consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare, and Internis Pharma. JA Kanis has received consulting fees, advisory board fees, lecture fees, and/or grant support from the majority of companies concerned with skeletal metabolism. EVM has received consultancy, lecture fees, research grant support, and/or honoraria from ActiveSignal, Alliance for Better Bone Health, AMGEN, Bayer, Consilient Healthcare, GE Lunar, Hologic, Internis Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Servier, Tethys, UCB, and Univadis. TN received research grants and/or consulting fees from Chugai Pharmaceutical, Teijin Pharma, Asahi Kasei Pharma, and Daiichi Sankyo. MS received consulting fees from Chugai, Daiichi Sankyo, Asahi Kasei Pharma, Teijin Pharma, and MSD. TS received consulting fee and/or research grant from Asahi-Kasei Pharma, Daiichi-Sankyo-Co., Eli Lilly Japan, and Pfizer. TK is an employee of Asahi Kasei Pharma Corporation. Anders Oden and Helena Johansson declare that they have no conflict of interest.	Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093; Kanis JA, 2010, BONE, V47, P729, DOI 10.1016/j.bone.2010.06.009; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; McCloskey EV, 2012, J BONE MINER RES, V27, P1480, DOI 10.1002/jbmr.1606; Nakamura T, 2012, J CLIN ENDOCR METAB, V97, P3097, DOI 10.1210/jc.2011-3479; Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501; Genant HK, 1996, J BONE MINER RES, V11, P984; McCloskey EV, 2009, OSTEOPOROSIS INT, V20, P811, DOI 10.1007/s00198-008-0786-9; MCCLOSKEY EV, 1993, OSTEOPOROSIS INT, V3, P138, DOI 10.1007/BF01623275; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198-007-0543-5; REEVE J, 1980, BRIT MED J, V280, P1340; Kim K, 2014, OSTEOPOROSIS INT, V25, P325, DOI 10.1007/s00198-013-2521-4; Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198-012-2074-y; Kanis JA, 2009, BONE, V44, P1049, DOI 10.1016/j.bone.2009.02.014; Breslow NE, 1987, IARC SCI PUBL, VII, P131; Committee for Medicinal Products for Human Use (CHMP), 2006, CPMPEWP55295 CHMP; Devogelaer Jean-Pierre, 2010, Curr Osteoporos Rep, V8, P154, DOI 10.1007/s11914-010-0024-1; Fujita T, 2014, CALCIFIED TISSUE INT, V94, P170, DOI 10.1007/s00223-013-9777-8; Kanis J., 2008, TECHNICAL REPORT; Kanis JA, 2011, OSTEOPOROSIS INT, V22, P2347, DOI 10.1007/s00198-010-1474-0; Lu Y, 2001, OSTEOPOROSIS INT, V12, P438, DOI 10.1007/s001980170087; Nakano T, 2013, J BONE MINER METAB, V9; Resmini G, 2011, AGING CLIN EXP RES, V23, P30; Shrader SP, 2005, ANN PHARMACOTHER, V39, P1511, DOI 10.1345/aph.1G146; Vescini Fabio, 2012, Clin Cases Miner Bone Metab, V9, P31	25	1	1	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0937-941X	1433-2965		OSTEOPOROSIS INT	Osteoporosis Int.	SEP	2015	26	9					2347	2353		10.1007/s00198-015-3129-7		7	Endocrinology & Metabolism	Endocrinology & Metabolism	CO9EI	WOS:000359475200015		
J	Takenaka, T; Yamanaka, T; Yoshida, M; Suzuki, H				Takenaka, T.; Yamanaka, T.; Yoshida, M.; Suzuki, H.			Unexpected action of lanthanum carbonate	OSTEOPOROSIS INTERNATIONAL			English	Letter							CALCIUM-SENSING RECEPTOR; CHRONIC KIDNEY-DISEASE		[Takenaka, T.; Yamanaka, T.; Yoshida, M.] Int Univ Hlth & Welf, Clin Res Ctr, Sanno Hosp, Tokyo 1060042, Japan; [Takenaka, T.; Yamanaka, T.; Yoshida, M.] Int Univ Hlth & Welf, Chemotherapy Res Inst, Tokyo 1060042, Japan; [Suzuki, H.] Saitama Med Univ, Saitama, Japan	Takenaka, T (reprint author), Int Univ Hlth & Welf, Clin Res Ctr, Sanno Hosp, 8-10-16 Akasaka Minato, Tokyo 1060042, Japan.	takenaka@iuhw.ac.jp					Slatopolsky E, 1996, J CLIN INVEST, V97, P2534, DOI 10.1172/JCI118701; Jamal SA, 2013, LANCET, V382, P1268, DOI 10.1016/S0140-6736(13)60897-1; Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744-9987.12058; Canaff L, 2002, J BIOL CHEM, V277, P30337, DOI 10.1074/jbc.M201804200; Carrillo-Lopez N, 2010, NEPHROL DIAL TRANSPL, V25, P2930, DOI 10.1093/ndt/gfq124	5	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0937-941X	1433-2965		OSTEOPOROSIS INT	Osteoporosis Int.	SEP	2015	26	9					2385	2386		10.1007/s00198-015-3155-5		2	Endocrinology & Metabolism	Endocrinology & Metabolism	CO9EI	WOS:000359475200020		
J	Yamanaka, Y; Kitagawa, J; Nakamaru, H				Yamanaka, Yoichiro; Kitagawa, Junichi; Nakamaru, Hiroki			Effect of Surface Free Energy of Film Laminated Steel Sheets on Content Release Properties	PACKAGING TECHNOLOGY AND SCIENCE			English	Article						surface free energy; content release properties; laminated steel sheet; PET film		Polyethylene terephthalate (PET) sheets that are now widely used in beverage cans have excellent properties of formability, corrosion resistance and adhesion to steel sheets. To expand their application, we have sought to develop a new PET film laminated steel sheet for use in food cans. Content release properties are necessary for easy removal of the can contents in food can applications. However, PET film laminated steel sheets have poor content release properties. Investigations of these properties have revealed dependence on the strength of adhesion between the films and can contents. The surface free energy of PET films has been inferred to be the main factor in poor content release properties. Therefore, using films with widely diverse surface free energy values, we studied the effects of surface free energy on the content release properties of materials in contact with cans. The results showed that these properties are closely related to the surface free energy of the film material, and that materials with surface free energy of less than 23mN/m or greater than 44mN/m show excellent properties for processed meat products with high protein content. The material with PET film coated with mixture of polyester resin and fatty acid is the most promising material for use in food cans in this study. The work has also shown that content release properties can be expressed as a function of adhesion in water between a material and protein. Reducing adhesion can significantly improve content release properties.	[Yamanaka, Yoichiro; Kitagawa, Junichi; Nakamaru, Hiroki] JFE Steel Corp, Steel Res Lab, Fukuyama, Hiroshima 7218510, Japan	Yamanaka, Y (reprint author), JFE Steel Corp, Steel Res Lab, 1 Kokan Cho, Fukuyama, Hiroshima 7218510, Japan.	yo-yamanaka@jfe-steel.co.jp					OWENS DK, 1969, J APPL POLYM SCI, V13, P1741, DOI 10.1002/app.1969.070130815; Cherrys B, 1981, POLYM SURFACES, P161; Days M, 1972, J APPL POLYM SCI, V16, P175; Dommershuijzen H, 2005, PACKAG TECHNOL SCI, V18, P303, DOI 10.1002/pts.701; Fowkess F., 1964, IND ENG CHEM, V56, P77; Holland BJ, 2002, POLYMER, V43, P1797, DOI 10.1016/S0032-3861(01)00773-X; Horiguchis H, 1968, SEKIGAI ZUSETU SORAN, P224; Ikada Y, 1984, POLYM BIOMATERIALS, P135; Ikadas Y, 1997, J ADHESION SOC JAPAN, V15, P9; Ikadas Y, 1989, IYOU KOUBUNNSI ZAIRY, P77; Miyazawas T, 1996, J SURFACE FINISHING, V47, P677; Moris M, 1978, CANNERS J, V57, P268; Okiyamas T, 1995, PLASTIC FILM, P196; PAUL L, 1981, J COLLOID INTERF SCI, V84, P546, DOI 10.1016/0021-9797(81)90245-9; TANAKA A, 1985, TETSU TO HAGANE, V71, P1252; Yamanakas Y, 2007, JFE TECHNICAL REPORT, V9, P16	16	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-3214	1099-1522		PACKAG TECHNOL SCI	Packag. Technol. Sci.	SEP	2015	28	9					811	821		10.1002/pts.2144		11	Engineering, Manufacturing; Food Science & Technology	Engineering; Food Science & Technology	CP0YB	WOS:000359601700005		
J	Fahkri, H; Zhang, BB; Fajol, A; Hernando, N; Elvira, B; Mannheim, JG; Pichler, BJ; Daniel, C; Amann, K; Hirao, A; Haight, J; Mak, TW; Lang, F; Foller, M				Fahkri, Hajar; Zhang, Bingbing; Fajol, Abul; Hernando, Nati; Elvira, Bernat; Mannheim, Julia G.; Pichler, Bernd J.; Daniel, Christoph; Amann, Kerstin; Hirao, Atsushi; Haight, Jillian; Mak, Tak W.; Lang, Florian; Foeller, Michael			Checkpoint kinase Chk2 controls renal Cyp27b1 expression, calcitriol formation, and calcium-phosphate metabolism	PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY			English	Article						PTH/vitD/FGF23; Calcium/phosphate metabolism; Klotho; ATM	GROWTH-FACTOR 23; VITAMIN-D METABOLISM; MOLECULAR-MECHANISMS; GENE-EXPRESSION; HUMAN MONOCYTES; PHOSPHORUS; KIDNEY; MICE; COTRANSPORTER; FGF23	Checkpoint kinase 2 (Chk2) is the main effector kinase of ataxia telangiectasia mutated (ATM) and responsible for cell cycle regulation. ATM signaling has been shown to upregulate interferon-regulating factor-1 (IRF-1), a transcription factor also expressed in the kidney. Calcitriol (1,25 (OH)(2)D-3), a major regulator of mineral metabolism, is generated by 25-hydroxyvitamin D 1 alpha-hydroxylase in the kidney. Since 25-hydroxyvitamin D 1 alpha-hydroxylase expression is enhanced by IRF-1, the present study explored the role of Chk2 for calcitriol formation and mineral metabolism. Chk2-deficient mice (chk2 (-/-)) were compared to wild-type mice (chk2 (+/+)). Transcript levels of renal 25-hydroxyvitamin D 1 alpha-hydroxylase, Chk2, and IRF-1 were determined by RT-PCR; Klotho expression by Western blotting; bone density by mu CT analysis; serum or plasma 1,25 (OH)(2)D-3, PTH, and C-terminal FGF23 concentrations by immunoassays; and serum, fecal, and urinary calcium and phosphate concentrations by photometry. The renal expression of IRF-1 and 25-hydroxyvitamin D 1 alpha-hydroxylase as well as serum 1,25 (OH)(2)D-3 and FGF23 levels were significantly lower in chk2 (-/-) mice compared to chk2 (+/+) mice. Plasma PTH was not different between the genotypes. Renal calcium and phosphate excretion were significantly higher in chk2 (-/-) mice than in chk2 (+/+) mice despite hypophosphatemia and normocalcemia. Bone density was not different between the genotypes. We conclude that Chk2 regulates renal 25-hydroxyvitamin D 1 alpha-hydroxylase expression thereby impacting on calcium and phosphate metabolism.	[Fahkri, Hajar; Zhang, Bingbing; Fajol, Abul; Elvira, Bernat; Lang, Florian; Foeller, Michael] Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; [Hernando, Nati] Univ Zurich, Inst Physiol, Zurich, Switzerland; [Hernando, Nati] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland; [Mannheim, Julia G.; Pichler, Bernd J.] Univ Tubingen, Werner Siemens Imaging Ctr, Dept Preclin Imaging & Radiopharm, D-72076 Tubingen, Germany; [Daniel, Christoph; Amann, Kerstin] Univ Hosp Erlangen, Dept Nephropathol, Erlangen, Germany; [Hirao, Atsushi] Kanazawa Univ, Canc Res Inst, Div Mol Genet, Ctr Canc & Stem Cell Res, Kanazawa, Ishikawa 920, Japan; [Haight, Jillian; Mak, Tak W.; Foeller, Michael] Univ Hlth Network, Ontario Canc Inst, Campbell Family Inst Breast Canc Res, Toronto, ON, Canada	Foller, M (reprint author), Univ Tubingen, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	michael.foeller@uni-tuebingen.de			Deutsche Forschungsgemeinschaft [Fo 695/1-1, Fo 695/2-1, La 315/15-1]; Deutscher Akademischer Austauschdienst	The authors acknowledge the meticulous preparation of the manuscript by Lejla Subasic and Tanja Loch and the technical support by Elfriede Faber. This study was supported by Deutsche Forschungsgemeinschaft (Fo 695/1-1, Fo 695/2-1, and La 315/15-1) and Deutscher Akademischer Austauschdienst.	Silverstein DM, 2003, KIDNEY INT, V64, P25, DOI 10.1046/j.1523-1755.2003.00067.x; Rasheed N, 2006, HUM MOL GENET, V15, P1938, DOI 10.1093/hmg/ddl116; Lanske B, 2007, CURR OPIN NEPHROL HY, V16, P311, DOI 10.1097/MNH.0b013e3281c55eca; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; STOLL R, 1979, BIOCHEM J, V180, P465; Zhang MYH, 2002, ENDOCRINOLOGY, V143, P587, DOI 10.1210/en.143.2.587; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.18.6521-6532.2002; Braam B, 2003, EUR J PHARMACOL, V464, P87, DOI 10.1016/S0014-2999(03)01382-7; Lane NE, 2013, J BONE MINER RES, V28, P2325, DOI 10.1002/jbmr.1985; Bacchetta J, 2013, J BONE MINER RES, V28, P46, DOI 10.1002/jbmr.1740; Haussler MR, 2013, CALCIFIED TISSUE INT, V92, P77, DOI 10.1007/s00223-012-9619-0; Biber J, 2007, NAT PROTOC, V2, P1356, DOI 10.1038/nprot.2007.156; Wolf M, 2013, J BONE MINER RES, V28, P1793, DOI 10.1002/jbmr.1923; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Ackermann TF, 2011, CELL PHYSIOL BIOCHEM, V28, P137, DOI 10.1159/000331722; Capuano P, 2005, AM J PHYSIOL-CELL PH, V288, pC429, DOI 10.1152/ajpcell.00331.2004; Thanasoula M, 2012, EMBO J, V31, P3398, DOI 10.1038/emboj.2012.191; Ali Q, 2010, MOL CELL BIOCHEM, V344, P65, DOI 10.1007/s11010-010-0529-z; Perwad F, 2011, MOL CELL ENDOCRINOL, V347, P17, DOI 10.1016/j.mce.2011.08.030; Kuro-O M, 2012, CURR OPIN NEPHROL HY, V21, P362, DOI 10.1097/MNH.0b013e32835422ad; Jobson AG, 2009, J PHARMACOL EXP THER, V331, P816, DOI 10.1124/jpet.109.154997; Dusso AS, 2005, AM J PHYSIOL-RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004; Nowik M, 2008, PFLUG ARCH EUR J PHY, V457, P539, DOI 10.1007/s00424-008-0530-5; Chen Y, 2008, FRONT BIOSCI, V13, P5016; Martin A, 2012, PHYSIOL REV, V92, P131, DOI 10.1152/physrev.00002.2011; Kumar R, 2012, ARCH BIOCHEM BIOPHYS, V523, P77, DOI 10.1016/j.abb.2012.03.003; Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251; Arima K, 2002, AM J PHYSIOL-GASTR L, V283, pG426, DOI 10.1152/ajpgi.00319.2001; Bhandaru M, 2011, KIDNEY INT, V80, P61, DOI 10.1038/ki.2011.67; Bourgeois S, 2013, PFLUG ARCH EUR J PHY, V465, P1557, DOI 10.1007/s00424-013-1298-9; BUSHINSKY DA, 1989, AM J PHYSIOL, V256, pF285; Chen G, 1996, J BIOL CHEM, V271, P33693; Chin MY, 2003, EXP MOL PATHOL, V75, P131, DOI 10.1016/S0014-4800(03)00088-1; DeLuca H F, 1980, Ann N Y Acad Sci, V355, P1, DOI 10.1111/j.1749-6632.1980.tb21323.x; Foller M, 2011, J AM SOC NEPHROL, V22, P873, DOI 10.1681/ASN.2010070757; Itamochi H, 2014, INT J GYNECOL CANCER, V24, P61, DOI 10.1097/IGC.0000000000000014; Lukas C, 2001, CANCER RES, V61, P4990; Marks J, 2008, J AM SOC NEPHROL, V19, P2313, DOI 10.1681/ASN.2008030315; Ohata Y, 2014, J BONE MINER RES, V29, P1627, DOI 10.1002/jbmr.2186; Pamment J, 2002, ONCOGENE, V21, P7776, DOI 10.1038/sj.onc.1205981; Prie D, 2010, CLIN J AM SOC NEPHRO, V5, P1717, DOI 10.2215/CJN.02680310; Shinki T, 1997, P NATL ACAD SCI USA, V94, P12920, DOI 10.1073/pnas.94.24.12920; Silver J, 1999, Kidney Int Suppl, V73, pS2; Stoffels K, 2006, J BONE MINER RES, V21, P37, DOI 10.1359/JBMR.050908; Umbach AT, 2014, KIDNEY INT; Wang YX, 2009, J AM SOC NEPHROL, V20, P1544, DOI 10.1681/ASN.2008080843; Xu H, 2003, AM J PHYSIOL-GASTR L, V285, pG1317, DOI 10.1152/ajpgi.00172.2003; Xu H, 2001, AM J PHYSIOL-CELL PH, V280, pC628; Zehnder D, 1999, J AM SOC NEPHROL, V10, P2465	50	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0031-6768	1432-2013		PFLUG ARCH EUR J PHY	Pflugers Arch.	SEP	2015	467	9					1871	1880		10.1007/s00424-014-1625-9		10	Physiology	Physiology	CP3WE	WOS:000359812600002		
J	Nishimoto, R; Kashio, M; Tominaga, M				Nishimoto, Rei; Kashio, Makiko; Tominaga, Makoto			Propofol-induced pain sensation involves multiple mechanisms in sensory neurons	PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY			English	Article						Propofol; TRPV1; TRPA1; Voltage-gated Ca2+ channel; GABA(A) receptor	ROOT GANGLION NEURONS; ION-CHANNEL TRPA1; GABA(A) RECEPTORS; CAPSAICIN RECEPTOR; GENERAL-ANESTHETICS; COVALENT MODIFICATION; MOLECULAR TARGETS; DIRECT ACTIVATION; TRPV1; INJECTION	Propofol, a commonly used intravenous anesthetic agent, is known to at times cause pain sensation upon injection in humans. However, the molecular mechanisms underlying this effect are not fully understood. Although propofol was reported to activate human transient receptor potential ankyrin 1 (TRPA1) in this regard, its action on human TRP vanilloid 1 (TRPV1), another nociceptive receptor, is unknown. Furthermore, whether propofol activates TRPV1 in rodents is controversial. Here, we show that propofol activates human and mouse TRPA1. In contrast, we did not observe propofol-evoked human TRPV1 activation, while the ability of propofol to activate mouse TRPV1 was very small. We also found that propofol caused increases in intracellular Ca2+ concentrations in a considerable portion of dorsal root ganglion (DRG) cells from mice lacking both TRPV1 and TRPA1, indicating the existence of TRPV1- and TRPA1-independent mechanisms for propofol action. In addition, propofol produced action potential generation in a type A gamma-amino butyric acid (GABA(A)) receptor-dependent manner. Finally, we found that both T-type and L-type Ca2+ channels are activated downstream of GABA(A) receptor activation by propofol. Thus, we conclude that propofol may cause pain sensation through multiple mechanisms involving not only TRPV1 and TRPA1 but also voltage-gated channels downstream of GABA(A) receptor activation.	[Nishimoto, Rei; Tominaga, Makoto] Grad Univ Adv Studies SOKENDAI, Dept Physiol Sci, Okazaki, Aichi 4448585, Japan; [Nishimoto, Rei; Kashio, Makiko; Tominaga, Makoto] Natl Inst Physiol Sci, Div Cell Signaling, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan	Tominaga, M (reprint author), Natl Inst Physiol Sci, Div Cell Signaling, Okazaki Inst Integrat Biosci, Higashiyama 5-1, Okazaki, Aichi 4448787, Japan.	tominaga@nips.ac.jp			Ministry of Education, Culture, Sports, Science and Technology in Japan	We would like to thank Dr. Junichi Nabekura (Division of Homeostatic Development, National Institute for Physiological Sciences, Okazaki, Japan), Dr. Motohiro Nishida (Division of Cardiocirculatory Signaling, National Institute for Physiological Sciences, Okazaki, Japan), Dr. Hidemasa Furue (Division of Neural Signaling, National Institute for Physiological Sciences, Okazaki, Japan), and Dr. Hitoshi Ishibashi (School of Allied Health Sciences, Kitasato University, Kanagawa, Japan) for their helpful suggestion and discussion. This work was supported by grants to Makoto Tominaga from the Ministry of Education, Culture, Sports, Science and Technology in Japan.	Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Coull JAM, 2003, NATURE, V424, P938, DOI 10.1038/nature01868; Yevenes GE, 2011, BRIT J PHARMACOL, V164, P224, DOI 10.1111/j.1476-5381.2011.01471.x; Mao SH, 2012, J NEUROPHYSIOL, V108, P834, DOI 10.1152/jn.00970.2011; Cao E, 2013, NEURON, V77, P667, DOI 10.1016/j.neuron.2012.12.016; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Matta JA, 2008, P NATL ACAD SCI USA, V105, P8784, DOI 10.1073/pnas.0711038105; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Kakazu Y, 1999, J NEUROSCI, V19, P2843; Zurborg S, 2007, NAT NEUROSCI, V10, P277, DOI 10.1038/nn1843; Lee SP, 2008, BRIT J PHARMACOL, V153, P1739, DOI 10.1038/bjp.2008.85; Usala M, 2003, BRIT J PHARMACOL, V140, P1045, DOI 10.1038/sj.bjp.0705540; Fischer MJM, 2010, J BIOL CHEM, V285, P34781, DOI 10.1074/jbc.M110.143958; Moriyama T, 2003, J NEUROSCI, V23, P6058; Aptel H, 2007, MOL CELL NEUROSCI, V36, P293, DOI 10.1016/j.mcn.2007.07.009; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Caterina MJ, 1997, NATURE, V389, P816; Mohammadi B, 2001, EUR J PHARMACOL, V421, P85, DOI 10.1016/S0014-2999(01)01033-0; Alkire MT, 2008, SCIENCE, V322, P876, DOI 10.1126/science.1149213; Klein RM, 2008, J BIOL CHEM, V283, P26208, DOI 10.1074/jbc.M801912200; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Garcia PS, 2010, CURR NEUROPHARMACOL, V8, P2, DOI 10.2174/157015910790909502; Franks NP, 2006, BRIT J PHARMACOL, V147, pS72, DOI 10.1038/sj.bjp.0706441; SCROGGS RS, 1992, J PHYSIOL-LONDON, V445, P639; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; Chung MK, 2011, ADV EXP MED BIOL, V704, P615, DOI 10.1007/978-94-007-0265-3_33; Wang YY, 2008, J BIOL CHEM, V283, P32691, DOI 10.1074/jbc.M803568200; Macpherson LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544; Stein AT, 2006, J GEN PHYSIOL, V128, P509, DOI 10.1085/jgp.200609576; AULT B, 1994, NEUROPHARMACOLOGY, V33, P109, DOI 10.1016/0028-3908(94)90104-X; Carlton SM, 1999, NEUROSCIENCE, V93, P713, DOI 10.1016/S0306-4522(99)00101-3; Doenicke AW, 1996, ANESTH ANALG, V82, P472, DOI 10.1097/00000539-199603000-00007; DUNDEE JW, 1979, BRIT J ANAESTH, V51, P641, DOI 10.1093/bja/51.7.641; Funk K, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-32; Jalota L, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d1110; Jurd Rachel, 2003, FASEB Journal, V17, P250; KLEMENT W, 1991, BRIT J ANAESTH, V67, P281, DOI 10.1093/bja/67.3.281; Kurganov E, 2014, PFLUG ARCH EUR J PHY, V466, P1873, DOI 10.1007/s00424-013-1420-z; Mandadi S, 2006, PAIN, V123, P106, DOI 10.1016/j.pain.2006.02.016; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; ORSER BA, 1994, J NEUROSCI, V14, P7747; Rosenbaum T, 2004, J GEN PHYSIOL, V123, P53, DOI 10.1085/jgp.200308906; Stein V, 2003, NEURON, V37, P375, DOI 10.1016/S0896-6273(03)00056-4; Tan CH, 1998, ANAESTHESIA, V53, P468, DOI 10.1046/j.1365-2044.1998.00405.x; Zeller A, 2005, FASEB J, V19, P1677, DOI 10.1096/fj.04-3443fje	46	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0031-6768	1432-2013		PFLUG ARCH EUR J PHY	Pflugers Arch.	SEP	2015	467	9					2011	2020		10.1007/s00424-014-1620-1		10	Physiology	Physiology	CP3WE	WOS:000359812600012		
J	Bakayan, A; Domingo, B; Miyawaki, A; Llopis, J				Bakayan, Adil; Domingo, Beatriz; Miyawaki, Atsushi; Llopis, Juan			Imaging Ca2+ activity in mammalian cells and zebrafish with a novel red-emitting aequorin variant	PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY			English	Article						Bioluminescence; Resonance energy transfer; Calcium; Aequorin; Coelenterazine; Red fluorescent protein	YELLOW FLUORESCENT PROTEINS; IN-VIVO; BIOLUMINESCENT REPORTERS; PHOTOPROTEIN AEQUORIN; ENERGY-TRANSFER; MONOMERIC RED; CALCIUM; COMPARTMENTS; SENSITIVITY	Ca2+ monitoring with aequorin is an established bioluminescence technique, whereby the photoprotein emits blue light when it binds to Ca2+. However, aequorin's blue emission and low quantum yield limit its application for in vivo imaging because blue-green light is greatly attenuated in animal tissues. In earlier work, aequorin was molecularly fused with green, yellow, and red fluorescent proteins, producing an emission shift through bioluminescence resonance energy transfer (BRET). We have previously shown that the chimera tandem dimer Tomato-aequorin (tdTA) emits red light in mammalian cells and across the skin and other tissues of mice [1]. In this work, we varied the configuration of the linker in tdTA to maximize energy transfer. One variant, named Redquorin, improved BRET from aequorin to tdTomato to almost a maximum value, and the emission above 575 nm exceeded 73 % of total counts. By pairing Redquorin with appropriate synthetic coelenterazines, agonist-induced and spontaneous Ca2+ oscillations in single HEK-293 cells were imaged. In addition, we also imaged Ca2+ transients associated with twitching behavior in developing zebrafish embryos expressing Redquorin during the segmentation period. Furthermore, the emission profile of Redquorin resulted in significant luminescence crossing a blood sample, a highly absorbing tissue. This new tool will facilitate in vivo imaging of Ca2+ from deep tissues of animals.	[Bakayan, Adil; Domingo, Beatriz; Llopis, Juan] Univ Castilla La Mancha, CRIB, Albacete 02008, Spain; [Bakayan, Adil; Domingo, Beatriz; Llopis, Juan] Univ Castilla La Mancha, Fac Med Albacete, Albacete 02008, Spain; [Miyawaki, Atsushi] RIKEN, Lab Cell Funct Dynam, Brain Sci Inst, Wako, Saitama 3510198, Japan	Llopis, J (reprint author), Univ Castilla La Mancha, CRIB, C Almansa 14, Albacete 02008, Spain.	Juan.Llopis@uclm.es		Domingo, Beatriz/0000-0001-9430-4803	Spanish Ministry of Science and Innovation [MICINN/FEDER BFU2008-03288, MINECO/FEDER BFU2012-39548-C02-01]	This work was supported by grants from the Spanish Ministry of Science and Innovation MICINN/FEDER BFU2008-03288 and MINECO/FEDER BFU2012-39548-C02-01. We thank Pilar Alfaro, Carmen Cifuentes, and Sandrine Picaud for technical assistance. This article is dedicated to the memory of Dr. Philippe Brulet.	Baubet V, 2000, P NATL ACAD SCI USA, V97, P7260, DOI 10.1073/pnas.97.13.7260; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Lin MZ, 2009, CHEM BIOL, V16, P1169, DOI 10.1016/j.chembiol.2009.10.009; Dikici E, 2009, PROTEIN ENG DES SEL, V22, P243, DOI 10.1093/protein/gzn083; Brini M, 2008, METHODS, V46, P160, DOI 10.1016/j.ymeth.2008.09.011; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; SHIMOMURA O, 1993, CELL CALCIUM, V14, P373, DOI 10.1016/0143-4160(93)90041-4; Shimozono S, 2006, BIOCHEMISTRY-US, V45, P6267, DOI 10.1021/bi060093i; Curie T, 2007, MOL IMAGING, V6, P30, DOI 10.2310/7290.2006.00033; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Brini M, 1999, MICROSC RES TECHNIQ, V46, P380, DOI 10.1002/(SICI)1097-0029(19990915)46:6<380::AID-JEMT6>3.0.CO;2-Y; SHIMOMURA O, 1989, BIOCHEM J, V261, P913; KENYON GS, 1985, BRAIN, V108, P771, DOI 10.1093/brain/108.3.771; Manjarres IM, 2008, PFLUG ARCH EUR J PHY, V455, P961, DOI 10.1007/s00424-007-0349-5; Rowe L, 2008, PROTEIN ENG DES SEL, V21, P73, DOI 10.1093/protein/gzm073; Zhao H, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2032388; Bakayan A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019520; Cheung CY, 2011, INT J DEV BIOL, V55, P153, DOI 10.1387/ijdb.103160cc; Domingo B, 2007, MICROSC RES TECHNIQ, V70, P1010, DOI 10.1002/jemt.20509; Gorokhovatsky AY, 2004, BIOCHEM BIOPH RES CO, V320, P703, DOI 10.1016/j.bbrc.2004.06.014; Horikawa K, 2010, NAT METHODS, V7, P729, DOI 10.1038/nmeth.1488; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V187, P1091, DOI 10.1016/0006-291X(92)91309-E; Martin JR, 2008, J NEUROGENET, V22, P285, DOI 10.1080/01677060802298517; Mencoboni M, 2008, CLIN MED ONCOL, V2, P353; Najafpour MM, 2008, ACTA CRYSTALLOGR E, V65, po193, DOI [10.1107/S1600536808035678, DOI 10.1107/S1600536808035678]; PRASHER D, 1985, BIOCHEM BIOPH RES CO, V126, P1259, DOI 10.1016/0006-291X(85)90321-3; Robert V, 2000, METHOD ENZYMOL, V327, P440; Rogers KL, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2937236; Roncali E, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2976426; Saavalainen PM, 2008, EUR J PAEDIATR NEURO, V12, P246, DOI 10.1016/j.ejpn.2007.08.007; Stepanyuk GA, 2005, FEBS LETT, V579, P1008, DOI 10.1016/j.febslet.2005.01.004; Tong JF, 1999, BIOCHEM J, V343, P39, DOI 10.1042/0264-6021:3430039; Tsuzuki K, 2005, J BIOL CHEM, V280, P34324, DOI 10.1074/jbc.M505303200; Webb SE, 2010, METHOD CELL BIOL, V99, P263, DOI [10.1016/B978-0-12-374841-6.00010-4, 10.1016/S0091-679X(10)99010-9]	34	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0031-6768	1432-2013		PFLUG ARCH EUR J PHY	Pflugers Arch.	SEP	2015	467	9					2031	2042		10.1007/s00424-014-1639-3		12	Physiology	Physiology	CP3WE	WOS:000359812600014		
J	Khokon, MAR; Salam, MA; Jammes, F; Ye, W; Hossain, MA; Uraji, M; Nakamura, Y; Mori, IC; Kwak, JM; Murata, Y				Khokon, Md. A. R.; Salam, M. A.; Jammes, F.; Ye, W.; Hossain, M. A.; Uraji, M.; Nakamura, Y.; Mori, I. C.; Kwak, J. M.; Murata, Y.			Two guard cell mitogen-activated protein kinases, MPK9 and MPK12, function in methyl jasmonate-induced stomatal closure in Arabidopsis thaliana	PLANT BIOLOGY			English	Article						[Ca2+](cyt) oscillations; cytosolic alkalisation; guard cell; mitogen-activated protein kinase; methyl jasmonate; reactive oxygen species; S-type anion channels	OXYGEN SPECIES PRODUCTION; ANION CHANNEL SLAC1; ABSCISIC-ACID; MAP KINASE; CYTOSOLIC CALCIUM; SIGNAL-TRANSDUCTION; PHOSPHATASE PAIR; ION-CHANNEL; ABA; ROLES	Methyl jasmonate (MeJA) and abscisic acid (ABA) signalling cascades share several signalling components in guard cells. We previously showed that two guard cell-preferential mitogen-activated protein kinases (MAPKs), MPK9 and MPK12, positively regulate ABA signalling in Arabidopsis thaliana. In this study, we examined whether these two MAP kinases function in MeJA signalling using genetic mutants for MPK9 and MPK12 combined with a pharmacological approach. MeJA induced stomatal closure in mpk9-1 and mpk12-1 single mutants as well as wild-type plants, but not in mpk9-1 mpk12-1 double mutants. Consistently, the MAPKK inhibitor PD98059 inhibited the MeJA-induced stomatal closure in wild-type plants. MeJA elicited reactive oxygen species (ROS) production and cytosolic alkalisation in guard cells of the mpk9-1, mpk12-1 and mpk9-1 mpk12-1 mutants, as well in wild-type plants. Furthermore, MeJA triggered elevation of cytosolic Ca2+ concentration ([Ca2+](cyt)) in the mpk9-1 mpk12-1 double mutant as well as wild-type plants. Activation of S-type anion channels by MeJA was impaired in mpk9-1 mpk12-1. Together, these results indicate that MPK9 and MPK12 function upstream of S-type anion channel activation and downstream of ROS production, cytosolic alkalisation and [Ca2+](cyt) elevation in guard cell MeJA signalling, suggesting that MPK9 and MPK12 are key regulators mediating both ABA and MeJA signalling in guard cells.	[Khokon, Md. A. R.; Salam, M. A.; Ye, W.; Hossain, M. A.; Uraji, M.; Nakamura, Y.; Murata, Y.] Okayama Univ, Grad Sch Environm & Life Sci, Okayama 7008530, Japan; [Jammes, F.] Pomona Coll, Dept Biol, Claremont, CA 91711 USA; [Mori, I. C.] Okayama Univ, Inst Plant Sci & Resources, Kurashiki, Okayama, Japan; [Kwak, J. M.] Daegu Kyungbuk Inst Sci & Technol, Ctr Plant Aging Res, Inst Basic Sci, Dept New Biol, Taegu, South Korea	Murata, Y (reprint author), Okayama Univ, Grad Sch Environm & Life Sci, Okayama 7008530, Japan.	muta@cc.okayama-u.ac.jp			Asahi Glass Foundation; Novartis Foundation (Japan) for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology of Japan;  [IBS-R013-G2-2014-a00]	This research was supported in part by The Asahi Glass Foundation, Novartis Foundation (Japan) for the Promotion of Science, Grant-in-Aid for Young Scientists, and Grants for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan to Y.M., and in part by project IBS-R013-G2-2014-a00 to J.M.K.	Akter N, 2010, BIOSCI BIOTECH BIOCH, V74, P2504, DOI 10.1271/bbb.100513; Munemasa S, 2007, PLANT PHYSIOL, V143, P1398, DOI 10.1104/pp.106.091298; Pedley KF, 2005, CURR OPIN PLANT BIOL, V8, P541, DOI 10.1016/j.pbi.2005.07.006; SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; Munemasa S, 2011, PLANT PHYSIOL, V155, P553, DOI 10.1104/pp.110.162750; Suhita D, 2003, PLANT SCI, V164, P481, DOI 10.1016/S0168-9452(02)00432-6; Lee SC, 2009, P NATL ACAD SCI USA, V106, P21419, DOI 10.1073/pnas.0910601106; Jonak C, 2002, CURR OPIN PLANT BIOL, V5, P415, DOI 10.1016/S1369-5266(02)00285-6; Negi J, 2008, NATURE, V452, P483, DOI 10.1038/nature06720; Kwak JM, 2003, EMBO J, V22, P2623, DOI 10.1093/emboj/cdg277; Salam MA, 2013, PLANT BIOLOGY, V15, P436, DOI 10.1111/j.1438-8677.2012.00671.x; Jammes F, 2009, P NATL ACAD SCI USA, V106, P20520, DOI 10.1073/pnas.0907205106; Desikan R, 2001, PLANT PHYSIOL, V126, P1579, DOI 10.1104/pp.126.4.1579; Gehring CA, 1997, ANN BOT-LONDON, V80, P485, DOI 10.1006/anbo.1997.0471; Vahisalu T, 2008, NATURE, V452, P487, DOI 10.1038/nature06608; Geiger D, 2009, P NATL ACAD SCI USA, V106, P21425, DOI 10.1073/pnas.0912021106; Suhita D, 2004, PLANT PHYSIOL, V134, P1536, DOI 10.1104/pp.103.032250; Zhang AY, 2006, PLANT PHYSIOL, V141, P475, DOI 10.1104/pp.105.075416; Geiger D, 2010, P NATL ACAD SCI USA, V107, P8023, DOI 10.1073/pnas.0912030107; Pei ZM, 1999, PLANT PHYSIOL, V121, P977, DOI 10.1104/pp.121.3.977; Segonzac C, 2011, PLANT PHYSIOL, V156, P687, DOI 10.1104/pp.110.171249; Zhu SY, 2007, PLANT CELL, V19, P3019, DOI 10.1105/tpc.107.050666; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Suza WP, 2008, PLANTA, V227, P1221, DOI 10.1007/s00425-008-0694-4; Islam MM, 2010, PLANT CELL PHYSIOL, V51, P302, DOI 10.1093/pcp/pcq001; Fonseca S, 2009, NAT CHEM BIOL, V5, P344, DOI 10.1038/nchembio.161; Hettenhausen C, 2012, PLANT PHYSIOL, V158, P759, DOI 10.1104/pp.111.190074; Hossain MA, 2011, PLANT PHYSIOL, V156, P430, DOI 10.1104/pp.111.172254; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Takahashi F, 2011, MOL CELL, V41, P649, DOI 10.1016/j.molcel.2011.02.029; Yan JB, 2009, PLANT CELL, V21, P2220, DOI 10.1105/tpc.109.065730; Desikan R, 1999, J EXP BOT, V50, P1863, DOI 10.1093/jexbot/50.341.1863; Hossain MA, 2011, J PLANT PHYSIOL, V168, P1901, DOI 10.1016/j.jplph.2011.05.004; Islam MM, 2010, PLANT CELL PHYSIOL, V51, P1721, DOI 10.1093/pcp/pcq131; Kwak J. M., 2008, ARABIDOPSIS BOOK, V6, P1; Liechti R, 2002, SCIENCE, V296, P1649, DOI 10.1126/science.1071547; Ligterink W, 2000, RES PRO CEL, V27, P11; Mori IC, 2006, PLOS BIOL, V4, P1749, DOI 10.1371/journal.pbio.0040327; RAGHAVENDRA AS, 1987, PLANT PHYSIOL, V83, P732, DOI 10.1104/pp.83.4.732; Saito N, 2008, PLANT CELL PHYSIOL, V49, P1396, DOI 10.1093/pcp/pcn106; Salam MA, 2012, BIOSCI BIOTECH BIOCH, V76, P1785, DOI 10.1271/bbb.120228	42	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1435-8603	1438-8677		PLANT BIOLOGY	Plant Biol.	SEP	2015	17	5					946	952		10.1111/plb.12321		7	Plant Sciences	Plant Sciences	CP0ZE	WOS:000359604800003		
J	Ogata, T; Okada, H; Kawaide, H; Takahashi, H; Seo, S; Mitsuhara, I; Matsushita, Y				Ogata, T.; Okada, H.; Kawaide, H.; Takahashi, H.; Seo, S.; Mitsuhara, I.; Matsushita, Y.			Involvement of NtERF3 in the cell death signalling pathway mediated by SIPK/WIPK and WRKY1 in tobacco plants	PLANT BIOLOGY			English	Article						Ethylene response factor; hypersensitive reaction; N gene; salicylic acid-induced protein kinase; tobacco (Nicotiana tabacum); tobacco mosaic virus; WRKY	ACTIVATED PROTEIN-KINASE; ETHYLENE-RESPONSIVE ELEMENT; SYSTEMIC ACQUIRED-RESISTANCE; TRANSCRIPTION FACTOR FAMILY; GENOME-WIDE ANALYSIS; DISEASE RESISTANCE; DEFENSE RESPONSES; SALICYLIC-ACID; MOSAIC-VIRUS; HYPERSENSITIVE RESPONSE	We previously reported that one of the ethylene response factors (ERFs), NtERF3, and other members of the subgroup VIII-a ERFs of the AP2/ERF family exhibit cell death-inducing ability in tobacco leaves. In this study, we focused on the involvement of NtERF3 in a cell death signalling pathway in tobacco plants, particularly downstream of NtSIPK/NtWIPK and NtWRKY1, which are mitogen-activated protein kinases and a phosphorylation substrate of NtSIPK, respectively. An ERF-associated amphiphilic repression (EAR) motif-deficient NtERF3b mutant (NtERF3bEAR) that lacked cell death-inducing ability suppressed the induction of cell death caused by NtERF3a. The transient co-expression of NtERF3bEAR suppressed the hypersensitive reaction (HR)-like cell death induced by NtSIPK and NtWRKY1. The induction of cell death by NtSIPK and NtWRKY1 was also inhibited in transgenic plants expressing NtERF3bEAR. Analysis of gene expression, ethylene production and cell death symptoms in salicylic acid-deficient tobacco plants suggested the existence of some feedback regulation in the HR cell death signalling pathway mediated by SIPK/WIPK and WRKY1. Overall, these results suggest that NtERF3 functions downstream of NtSIPK/NtWIPK and NtWRKY1 in a cell death signalling pathway, with some feedback regulation.	[Ogata, T.; Okada, H.; Matsushita, Y.] Tokyo Univ Agr & Technol, Ctr Gene Res, Fuchu, Tokyo 1838509, Japan; [Kawaide, H.] Tokyo Univ Agr & Technol, Inst Agr, Fuchu, Tokyo 1838509, Japan; [Takahashi, H.] Tohoku Univ, Grad Sch Agr Sci, Dept Life Sci, Sendai, Miyagi 980, Japan; [Seo, S.; Mitsuhara, I.] Natl Inst Agrobiol Sci, Plant Microbe Interact Res Unit, Tsukuba, Ibaraki, Japan	Matsushita, Y (reprint author), Tokyo Univ Agr & Technol, Ctr Gene Res, Fuchu, Tokyo 1838509, Japan.	ymatsu@cc.tuat.ac.jp			Japan Society for the Promotion of Science (JSPS) [19580045]; Collaborative Research Ring of Tokyo University of Agriculture and Technology (TUAT); TUAT Foundation;  [23-8011]	We thank Dr Yuichiro Watanabe of Tokyo University for plasmids pTocJ-GFP and pTogJ. We are grateful to Dr Tetsuo Meshi for the NahG-expressing transgenic nn tobacco line SN25. We also thank Osamu Hashiguchi for assistance with the early steps of NtSIPK cloning. This study was supported partly by a Grant-in-Aid for Scientific Research (C) (to Y. M., no. 19580045) from the Japan Society for the Promotion of Science (JSPS) and a Grant-in-Aid for JSPS Fellows (to T. O., no. 23-8011), as well as research grants (to Y. M.) from the Collaborative Research Ring of Tokyo University of Agriculture and Technology (TUAT) and the TUAT Foundation. The authors have no conflicts of interest to declare.	Century K, 2008, PLANT PHYSIOL, V147, P20, DOI 10.1104/pp.108.117887; Zhou F, 2004, PLANT J, V39, P920, DOI 10.1111/j.1365-313X.2004.02180.x; Matsui K, 2008, PLANT J, V55, P954, DOI 10.1111/j.1365-313X.2008.03565.x; Sharma MK, 2010, MOL GENET GENOMICS, V284, P455, DOI 10.1007/s00438-010-0580-1; Liu YD, 2004, PLANT CELL, V16, P3386, DOI 10.1105/tpc.104.026609; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Berrocal-Lobo M, 2002, PLANT J, V29, P23, DOI 10.1046/j.1365-313x.2002.01191.x; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; Kazan K, 2006, TRENDS PLANT SCI, V11, P109, DOI 10.1016/j.tplants.2006.01.004; Onate-Sanchez L, 2007, PLANT PHYSIOL, V143, P400, DOI 10.1104/pp.106.086637; Bethke G, 2009, P NATL ACAD SCI USA, V106, DOI 10.1073/pnas.0810206106; Ohtsubo N, 1999, PLANT CELL PHYSIOL, V40, P808; Ohta M, 2001, PLANT CELL, V13, P1959, DOI 10.1105/tpc.13.8.1959; Ohta M, 2000, PLANT J, V22, P29, DOI 10.1046/j.1365-313x.2000.00709.x; Hiratsu K, 2003, PLANT J, V34, P733, DOI 10.1046/j.1365-313X.2003.01759.x; Nomura H, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1926; Mitsuda N, 2011, METHODS MOL BIOL, V754, P87, DOI 10.1007/978-1-61779-154-3_5; Ogata T, 2013, PLANT SCI, V209, P12, DOI 10.1016/j.plantsci.2013.04.003; Chandra-Shekara AC, 2006, PLANT J, V45, P320, DOI 10.1111/j.1365-313X.2005.02618.x; Park JM, 2001, PLANT CELL, V13, P1035, DOI 10.1105/tpc.13.5.1035; Zhang ZJ, 2009, PLANT PHYSIOL, V150, P365, DOI 10.1104/pp.109.135830; Kagale S, 2011, EPIGENETICS-US, V6, P141, DOI 10.4161/epi.6.2.13627; Takabatake R, 2007, PLANT CELL PHYSIOL, V48, P498, DOI 10.1093/pcp/pcm021; Paponov IA, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-126; Lacomme C, 1999, P NATL ACAD SCI USA, V96, P7956, DOI 10.1073/pnas.96.14.7956; Gu YQ, 2002, PLANT CELL, V14, P817, DOI 10.1105/tpc.000794; Yang KY, 2001, P NATL ACAD SCI USA, V98, P741, DOI 10.1073/pnas.98.2.741; Jin HL, 2003, PLANT J, V33, P719, DOI 10.1046/j.1365-313X.2003.01664.x; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; Liu YL, 2004, PLANT J, V38, P800, DOI 10.1111/j.1365-313X.2004.02085.x; Erickson FL, 1999, PLANT J, V18, P67, DOI 10.1046/j.1365-313X.1999.00426.x; Onate-Sanchez L, 2002, PLANT PHYSIOL, V128, P1313, DOI 10.1104/pp.010862; Shirano Y, 2002, PLANT CELL, V14, P3149, DOI 10.1105/tpc.005348; Soosaar JLM, 2005, NAT REV MICROBIOL, V3, P789, DOI 10.1038/nrmicro1239; Xiao SY, 2003, PLANT CELL, V15, P33, DOI 10.1105/tpc.006940; Mur LAJ, 2008, J EXP BOT, V59, P501, DOI 10.1093/jxb/erm239; Dodds PN, 2010, NAT REV GENET, V11, P539, DOI 10.1038/nrg2812; Rushton PJ, 2010, TRENDS PLANT SCI, V15, P247, DOI 10.1016/j.tplants.2010.02.006; Knoester M, 1998, P NATL ACAD SCI USA, V95, P1933, DOI 10.1073/pnas.95.4.1933; Sharoni AM, 2011, PLANT CELL PHYSIOL, V52, P344, DOI 10.1093/pcp/pcq196; Overmyer K, 2003, TRENDS PLANT SCI, V8, P335, DOI 10.1016/S1360-1385(03)00135-3; Mizoi J, 2012, BBA-GENE REGUL MECH, V1819, P86, DOI 10.1016/j.bbagrm.2011.08.004; Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286; Menke FLH, 2005, MOL PLANT MICROBE IN, V18, P1027, DOI 10.1094/MPMI-18-1027; Nakano T, 2006, PLANT PHYSIOL, V140, P411, DOI 10.1104/pp.105.073783; Ikeda M, 2009, PLANT CELL PHYSIOL, V50, P970, DOI 10.1093/pcp/pcp048; Kagale S, 2010, PLANT PHYSIOL, V152, P1109, DOI 10.1104/pp.109.151704; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; Nishiuchi T, 2004, J BIOL CHEM, V279, P55355, DOI 10.1074/jbc.M409674200; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.2307/3869993; Mitsuda N, 2009, PLANT CELL PHYSIOL, V50, P1232, DOI 10.1093/pcp/pcp075; Du H, 1997, MOL PLANT MICROBE IN, V10, P922, DOI 10.1094/MPMI.1997.10.7.922; Fischer U, 2004, MOL PLANT MICROBE IN, V17, P1162, DOI 10.1094/MPMI.2004.17.10.1162; He P, 2007, CELL MICROBIOL, V9, P1385, DOI 10.1111/j.1462-5822.2007.00944.x; Hori K., 2003, PLANT BIOTECHNOL, V20, P129, DOI 10.5511/plantbiotechnology.20.129; Kagale Sateesh, 2010, Plant Signal Behav, V5, P691, DOI 10.4161/psb.5.6.11576; Kobayashi M, 2010, MOL PLANT MICROBE IN, V23, P1032, DOI 10.1094/MPMI-23-8-1032; Koyama T., 2012, CURR BIOTECHNOL, V1, P23; Liu MC, 2013, PLANT J, V76, P406, DOI 10.1111/tpj.12305; Nishiuchi T, 2002, PLANT MOL BIOL, V49, P473, DOI 10.1023/A:1015553232309; Ogata T, 2012, J GEN PLANT PATHOL, V78, P8, DOI 10.1007/s10327-011-0355-5; Seo S, 2007, PLANT J, V49, P899, DOI 10.1111/j.1365-313X.2006.03003.x; Suzuki K, 1998, PLANT J, V15, P657, DOI 10.1046/j.1365-313x.1998.00243.x; vansVerk M. C., 2011, BMC PLANT BIOL, V11, P89; Zhang SQ, 2001, PLANT CELL, V13, P1877, DOI 10.1105/tpc.13.8.1877; Zhang Z., 1998, P NATL ACAD SCI USA, V95, P7433; Zhu Y, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000844	67	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1435-8603	1438-8677		PLANT BIOLOGY	Plant Biol.	SEP	2015	17	5					962	972		10.1111/plb.12349		11	Plant Sciences	Plant Sciences	CP0ZE	WOS:000359604800005		
J	Atapaththu, KSS; Miyagi, A; Atsuzawa, K; Kaneko, Y; Kawai-Yamada, M; Asaeda, T				Atapaththu, K. S. S.; Miyagi, A.; Atsuzawa, K.; Kaneko, Y.; Kawai-Yamada, M.; Asaeda, T.			Effects of water turbulence on variations in cell ultrastructure and metabolism of amino acids in the submersed macrophyte, Elodea nuttallii (Planch.) H. St. John	PLANT BIOLOGY			English	Article						Amino acids; asparagine; Elodea nuttallii; starch granules; turbulence	L-ASCORBIC-ACID; AQUATIC MACROPHYTES; STARCH ACCUMULATION; CALCIUM-OXALATE; OXALIC-ACID; STRESS; PLANTS; LEAVES; GROWTH; CALMODULIN	The interactions between macrophytes and water movement are not yet fully understood, and the causes responsible for the metabolic and ultrastructural variations in plant cells as a consequence of turbulence are largely unknown. In the present study, growth, metabolism and ultrastructural changes were evaluated in the aquatic macrophyte Elodea nuttallii, after exposure to turbulence for 30days. The turbulence was generated with a vertically oscillating horizontal grid. The turbulence reduced plant growth, plasmolysed leaf cells and strengthened cell walls, and plants exposed to turbulence accumulated starch granules in stem chloroplasts. The size of the starch granules increased with the magnitude of the turbulence. Using capillary electrophoresis-mass spectrometry (CE-MS), analysis of the metabolome found metabolite accumulation in response to the turbulence. Asparagine was the dominant amino acid that was concentrated in stressed plants, and organic acids such as citrate, ascorbate, oxalate and -amino butyric acid (GABA) also accumulated in response to turbulence. These results indicate that turbulence caused severe stress that affected plant growth, cell ultrastructure and some metabolic functions of E.nuttallii. Our findings offer insights to explain the effects of water movement on the functions of aquatic plants.	[Atapaththu, K. S. S.; Miyagi, A.; Kawai-Yamada, M.; Asaeda, T.] Saitama Univ, Dept Environm Sci & Technol, Sakura Ku, Saitama 3388770, Japan; [Atsuzawa, K.] Saitama Univ, Comprehens Anal Ctr Sci, Sakura Ku, Saitama 3388770, Japan; [Kaneko, Y.] Saitama Univ, Grad Sch Sci & Engn, Fac Educ, Biol Sect,Sakura Ku, Saitama 3388770, Japan	Asaeda, T (reprint author), Saitama Univ, Dept Environm Sci & Technol, Sakura Ku, 255 Shimo Okubo, Saitama 3388770, Japan.	asaeda@mail.saitama-u.ac.jp	Miyagi, Atsuko/N-8621-2015		River Foundation; Japan Society for the Promotion Science; Ministry of Education, Culture, Sports, Science and Technology, Japan	A Research Grant-in-Aid from the River Foundation, Japan Society for the Promotion Science and the Ministry of Education, Culture, Sports, Science and Technology, Japan, financially supported this research.	Anoop VM, 2003, PLANT PHYSIOL, V132, P2205, DOI 10.1104/pp.103.023903; Lea PJ, 2007, ANN APPL BIOL, V150, P1, DOI 10.1111/j.1744-7348.2006.00104.x; Less H, 2008, PLANT PHYSIOL, V147, P316, DOI 10.1104/pp.108.115733; NAIDU BP, 1991, PHYTOCHEMISTRY, V30, P407, DOI 10.1016/0031-9422(91)83693-F; Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701; Dinakar C, 2012, PLANT SCI, V182, P29, DOI 10.1016/j.plantsci.2011.01.018; Miyagi A, 2013, METABOLOMICS, V9, P590, DOI 10.1007/s11306-012-0486-5; BROUQUISSE R, 1992, PLANTA, V188, P384, DOI 10.1007/BF00192806; Gill SS, 2010, PLANT PHYSIOL BIOCH, V48, P909, DOI 10.1016/j.plaphy.2010.08.016; Krasensky J, 2012, J EXP BOT, V63, P1593, DOI 10.1093/jxb/err460; Liu CL, 2011, J INTEGR PLANT BIOL, V53, P608, DOI 10.1111/j.1744-7909.2011.01049.x; Wang XC, 2013, MOL CELL PROTEOMICS, V12, P2174, DOI 10.1074/mcp.M112.022475; Nepf HM, 2012, J HYDRAUL RES, V50, P262, DOI 10.1080/00221686.2012.696559; Mittler R, 2004, TRENDS PLANT SCI, V9, P490, DOI 10.1016/j.tplants.2004.08.009; Martinelli T, 2007, J EXP BOT, V58, P3037, DOI 10.1093/jxb/erm161; Rhodes D, 1999, BOOK SOIL P, P319; Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359; OPARKA KJ, 1994, NEW PHYTOL, V126, P571, DOI 10.1111/j.1469-8137.1994.tb02952.x; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; WALLACE W, 1984, PLANT PHYSIOL, V75, P170, DOI 10.1104/pp.75.1.170; Maggio A, 2002, PLANT J, V31, P699, DOI 10.1046/j.1365-313X.2002.01389.x; Bornette G, 2011, AQUAT SCI, V73, P1, DOI 10.1007/s00027-010-0162-7; Braam J, 2005, NEW PHYTOL, V165, P373, DOI 10.1111/j.1469-8137.2004.01263.x; Bohnert HJ, 1999, SCI HORTIC-AMSTERDAM, V78, P237; Chehab EW, 2009, J EXP BOT, V60, P43, DOI 10.1093/jxb/ern315; ARIOVICH D, 1983, PLANT CELL ENVIRON, V6, P657; Asaeda T, 2010, RIVER RES APPL, V26, P1153, DOI 10.1002/rra.1322; Atapaththu KSS, 2015, HYDROBIOLOGIA, V747, P217, DOI 10.1007/s10750-014-2141-9; Borek S, 2013, J PLANT GROWTH REGUL, V32, P471, DOI [10.1007/s00344-012-9313-5, 10.1007]; BRAAM J, 1992, CELL CALCIUM, V13, P457, DOI 10.1016/0143-4160(92)90058-Z; Champika Ellawala K., 2011, FLORA, V206, P1085; Durand-Smet P, 2014, BIOPHYS J, V107, P2237, DOI 10.1016/j.bpj.2014.10.023; Ellawala C, 2011, AQUAT ECOL, V45, P417, DOI 10.1007/s10452-011-9364-x; Ellawala C, 2013, HYDROBIOLOGIA, V709, P173, DOI 10.1007/s10750-013-1447-3; Elzenga JTM, 1997, J EXP BOT, V48, P2055, DOI 10.1093/jexbot/48.317.2055; Folkard A.M., 2011, ENG COMPUTATIONAL ME, V164, P3; Franceschi V. R., 1995, OXALATE BIOSYNTHESIS; Green JC, 2005, AQUAT ECOL, V39, P1, DOI 10.1007/s10452-004-1913-0; JANAUER GA, 1977, Z PFLANZENPHYSIOL, V82, P45; Kadono Y., 2004, GLOBAL ENV RES, V8, P163; Keates SE, 2000, PHYTOCHEMISTRY, V53, P433, DOI 10.1016/S0031-9422(99)00448-3; Kostman TA, 2001, PLANT PHYSIOL, V125, P634, DOI 10.1104/pp.125.2.634; Larcher W, 2003, PHYSL PLANT ECOLOGY, P513; LING V, 1994, PLANT CELL, V6, P1135; Luttge U., 1983, GROWTH FUNCTIONING L, P413; MADSEN TV, 1993, PLANT CELL ENVIRON, V16, P317, DOI 10.1111/j.1365-3040.1993.tb00875.x; Miyagi A, 2010, METABOLOMICS, V6, P146, DOI 10.1007/s11306-009-0186-y; Neumann G, 2000, ANN BOT-LONDON, V85, P909, DOI 10.1006/anbo.2000.1135; Seki Y, 2014, PLANT BIOLOGY, V16, P258, DOI 10.1111/plb.12008; WAMPLE RL, 1983, PLANT PHYSIOL, V73, P195, DOI 10.1104/pp.73.1.195; WESTLAKE DF, 1967, J EXP BOT, V18, P187, DOI 10.1093/jxb/18.2.187; Zaman T, 2013, FLORA, V208, P211, DOI 10.1016/j.flora.2013.02.009	52	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1435-8603	1438-8677		PLANT BIOLOGY	Plant Biol.	SEP	2015	17	5					997	1004		10.1111/plb.12346		8	Plant Sciences	Plant Sciences	CP0ZE	WOS:000359604800009		
J	Hossan, MS; Rahman, MA; Tauer, K; Minami, H; Ahmad, H				Hossan, M. Shamim; Rahman, M. Abdur; Tauer, Klaus; Minami, Hideto; Ahmad, Hasan			A generalized technique for the encapsulation of nano-sized NiO particles by styrene-2-hydroxyethyl methacrylate copolymer	POLYMERS FOR ADVANCED TECHNOLOGIES			English	Article						NiO; nanoparticles; encapsulation; composite; colloidal stability	NANOSIZED NICKEL-OXIDE; POLY(VINYL ALCOHOL); COMPOSITE-PARTICLES; MAGNETIC-PROPERTIES; NANOPARTICLES; POLYMERIZATION; NANOCOMPOSITE; MICROSPHERES; CATALYSTS; SILICA	Encapsulation of nickel oxide (NiO) particles is of great interest to the researchers as such modification produces remarkable improvement in properties and versatility in application potential. In this investigation, nano-sized NiO particles were first prepared by calcination of nickel hydroxide precursor obtained using a simple liquid-phase process. The produced NiO particles were stabilized with oleic acid and then treated with tetraethylorthosilicate to produce NiO/SiO2 composite seed particles. Finally tri-layered inorganic/organic composite particles were prepared by seeded copolymerization of styrene and 2-hydroxyethyl methacrylate (HEMA) in the presence of NiO/SiO2 composite seed particles. The produced composite particles named as NiO/SiO2/P(S-HEMA) were colloidally stable, and the obtained particles were characterized by Fourier transform infrared spectroscopy, scanning electron microscopy, X-ray diffraction, X-ray photoelectron spectroscopy and thermogravimetric analyses. Copyright (C) 2015 John Wiley & Sons, Ltd.	[Hossan, M. Shamim; Rahman, M. Abdur; Ahmad, Hasan] Rajshahi Univ, Dept Chem, Rajshahi 6205, Bangladesh; [Tauer, Klaus] Max Planck Inst Colloid & Interfaces, D-14476 Golm, Germany; [Minami, Hideto] Kobe Univ, Grad Sch Engn, Kobe, Hyogo 6578501, Japan	Ahmad, H (reprint author), Rajshahi Univ, Dept Chem, Rajshahi 6205, Bangladesh.	samarhass@yahoo.com	Minami, Hideto/E-2890-2010				Andres P. R., 1996, SCIENCE, V273, P1690; Ichiyanagi Y, 2003, PHYSICA B, V329, P862, DOI 10.1016/S0921-4526(02)02578-4; Cheng XJ, 2006, J POLYM SCI POL CHEM, V44, P3807, DOI 10.1002/pola.21472; Caruso F, 2001, ADV MATER, V13, P11, DOI 10.1002/1521-4095(200101)13:1<11::AID-ADMA11>3.0.CO;2-N; Chandrappa KG, 2012, MATER CORROS, V63, P445, DOI 10.1002/maco.201005966; Varghese B, 2008, CHEM MATER, V20, P3360, DOI 10.1021/cm703512k; Kim SI, 2013, ACS APPL MATER INTER, V5, P1596, DOI 10.1021/am3021894; PERENBOOM JAAJ, 1981, PHYS REP, V78, P173, DOI 10.1016/0370-1573(81)90194-0; Kuhlenbeck H, 2013, CHEM REV, V113, P3986, DOI 10.1021/cr300312n; Adair JH, 1998, MAT SCI ENG R, V23, P139, DOI 10.1016/S0927-796X(98)80001-6; Song XF, 2008, J AM CERAM SOC, V91, P3465, DOI 10.1111/j.1551-2916.2008.02667.x; Himstedt HH, 2011, LANGMUIR, V27, P5574, DOI 10.1021/la200223g; Bhowmik K, 2014, LANGMUIR, V30, P3209, DOI 10.1021/la500156e; Shambharkar BH, 2011, J APPL POLYM SCI, V122, P1905, DOI 10.1002/app.34286; Poizot P, 2000, NATURE, V407, P496; Krumova M, 2000, POLYMER, V41, P9265, DOI 10.1016/S0032-3861(00)00287-1; Fominykh K, 2014, ADV FUNCT MATER, V24, P3123, DOI 10.1002/adfm.201303600; Ahmad H, 2003, COLLOID POLYM SCI, V281, P988, DOI 10.1007/s00396-003-0862-9; Lee JE, 2010, J AM CHEM SOC, V132, P552, DOI 10.1021/ja905793q; Luo Z, 2011, ANGEW CHEM INT EDIT, V50, P640, DOI 10.1002/anie.201005061; Karthik K, 2011, J ALLOY COMPD, V509, P181, DOI 10.1016/j.jallcom.2010.09.033; Liu H, 2011, J MATER CHEM, V21, P3046, DOI 10.1039/c0jm03132a; Luo SR, 2013, RSC ADV, V3, P12671, DOI 10.1039/c3ra41771a; Wang CB, 2005, CATAL LETT, V101, P241, DOI 10.1007/s10562-005-4899-x; Bargava R. N., 1996, J LUMIN, V70, P85; Chen H, 2013, EUR J INORG CHEM, P1105, DOI 10.1002/ejic.201201309; Deki S, 2003, CHEM MATER, V15, P4916, DOI 10.1021/cm021754a; Gandhi S, 2010, J APPL POLYM SCI, V118, P1666, DOI 10.1002/app.32570; Garcia-Cerda LA, 2009, J MATER SCI, V44, P4553, DOI 10.1007/s10853-009-3690-6; Hao Y, 2013, J POLYM SCI POL CHEM, V51, P2150, DOI 10.1002/pola.26617; Hossan M. S., 2013, AM J POLYM SCI, V3, P83; Kamath VP, 2002, J PHYS CHEM B, V106, P7729; Kim JW, 2002, COLLOID POLYM SCI, V280, P584, DOI 10.1007/s00396-002-0655-6; Kim TW, 2008, ADV MATER, V20, P539, DOI 10.1002/adma.200701677; Ling DS, 2014, CHEM-EUR J, V20, P7916, DOI 10.1002/chem.201403071; Manoharan VN, 2003, SCIENCE, V301, P483, DOI 10.1126/science.1086189; Nandapure B. I., 2013, ADV MAT LETT, V4, P134; Rahman MA, 2013, POLYM ADVAN TECHNOL, V24, P174, DOI 10.1002/pat.3067; Rahman MA, 2012, POLYM ADVAN TECHNOL, V23, P1187, DOI 10.1002/pat.2026; Song GP, 2005, COLLOID POLYM SCI, V283, P677, DOI 10.1007/s00396-004-1205-1; Syed-Hassan SSA, 2011, APPL CATAL A-GEN, V405, P166, DOI 10.1016/j.apcata.2011.08.008; Tang Q, 2010, POLYM ADVAN TECHNOL, V21, P802, DOI 10.1002/pat.1505; THOMAS JM, 1988, J PURE APPL CHEM, V60, P1517; Xiao-Yan G, 2007, MATER LETT, V61, P621, DOI 10.1016/j.matlet.2006.05.026	44	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1042-7147	1099-1581		POLYM ADVAN TECHNOL	Polym. Adv. Technol.	SEP	2015	26	9					1047	1052		10.1002/pat.3521		6	Polymer Science	Polymer Science	CP1HV	WOS:000359627800001		
J	Nakashima, R; Watanabe, C; Maeda, E; Yoshikawa, T; Matsuda, I; Miki, S; Yokosawa, K				Nakashima, Ryoichi; Watanabe, Chisaki; Maeda, Eriko; Yoshikawa, Takeharu; Matsuda, Izuru; Miki, Soichiro; Yokosawa, Kazuhiko			The effect of expert knowledge on medical search: medical experts have specialized abilities for detecting serious lesions	PSYCHOLOGICAL RESEARCH-PSYCHOLOGISCHE FORSCHUNG			English	Article							VISUAL-SEARCH; CORRECTABLE SEARCH; DECISION-MAKING; RARE TARGETS; ERROR RATES; LIFE-SPAN; PREVALENCE; PERCEPTION; SIMILARITY; ATTENTION	How does domain-specific knowledge influence the experts' performance in their domain of expertise? Specifically, can visual search experts find, with uniform efficiency, any type of target in their domain of expertise? We examined whether acquired knowledge of target importance influences an expert's visual search performance. In some professional searches (e.g., medical screenings), certain targets are rare; one aim of this study was to examine the extent to which experts miss such targets in their searches. In one experiment, radiologists (medical experts) engaged in a medical lesion search task in which both the importance (i.e., seriousness/gravity) and the prevalence of targets varied. Results showed decreased target detection rates in the low prevalence conditions (i.e., the prevalence effect). Also, experts were better at detecting important (versus unimportant) lesions. Results of an experiment using novices ruled out the possibility that decreased performance with unimportant targets was due to low target noticeability/visibility. Overall, the findings suggest that radiologists do not have a generalized ability to detect any type of lesion; instead, they have acquired a specialized ability to detect only those important lesions relevant for effective medical practices.	[Nakashima, Ryoichi; Watanabe, Chisaki; Yokosawa, Kazuhiko] Univ Tokyo, Grad Sch Humanities & Soc, Dept Psychol, Bunkyo Ku, Tokyo 1130033, Japan; [Maeda, Eriko; Yoshikawa, Takeharu; Matsuda, Izuru; Miki, Soichiro] Tokyo Univ Hosp, Tokyo 113, Japan	Nakashima, R (reprint author), Univ Tokyo, Grad Sch Humanities & Soc, Dept Psychol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	one.island.one@gmail.com					ALLARD F, 1980, Journal of Sport Psychology, V2, P14; Asano M, 2008, PSYCHOLOGIA, V51, P126, DOI 10.2117/psysoc.2008.126; Krupinski EA, 2010, ATTEN PERCEPT PSYCHO, V72, P1205, DOI 10.3758/APP.72.5.1205; Wolfe JM, 2007, J EXP PSYCHOL GEN, V136, P623, DOI 10.1037/0096-3445.136.4.623; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; VOSS JF, 1980, J VERB LEARN VERB BE, V19, P651, DOI 10.1016/S0022-5371(80)90343-6; Palmer J, 2005, J VISION, V5, P376, DOI 10.1167/5.5.1; Wolfe JM, 2010, CURR BIOL, V20, P121, DOI 10.1016/j.cub.2009.11.066; Nieuwenhuis S, 2011, NAT NEUROSCI, V14, P1105, DOI 10.1038/nn.2886; Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366; Menneer T, 2007, APPL COGNITIVE PSYCH, V21, P915, DOI 10.1002/acp.1305; Fleck MS, 2007, PSYCHOL SCI, V18, P943, DOI 10.1111/j.1467-9280.2007.02006.x; Hickey C, 2011, VIS COGN, V19, P117, DOI 10.1080/13506285.2010.503946; Wolfe JM, 2005, NATURE, V435, P439, DOI 10.1038/435439a; Hommel B, 2004, DEV PSYCHOL, V40, P545, DOI 10.1037/0012-1649.40.4.545; CHASE WG, 1973, COGNITIVE PSYCHOL, V4, P55, DOI 10.1016/0010-0285(73)90004-2; Trick LM, 1998, COGNITIVE DEV, V13, P369, DOI 10.1016/S0885-2014(98)90016-8; Evans KK, 2011, ARCH PATHOL LAB MED, V135, P1557, DOI 10.5858/arpa.2010-0739-OA; Warm JS, 2008, HUM FACTORS, V50, P433, DOI 10.1518/001872008X312152; Fleck MS, 2010, J EXP PSYCHOL-APPL, V16, P60, DOI 10.1037/a0018629; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Hickey C, 2010, J NEUROSCI, V30, P11096, DOI 10.1523/JNEUROSCI.1026-10.2010; Menneer T, 2009, J EXP PSYCHOL-APPL, V15, P125, DOI 10.1037/a0015331; KUNDEL HL, 1978, INVEST RADIOL, V13, P175, DOI 10.1097/00004424-197805000-00001; Bedard J, 1992, CURRENT DIRECTIONS P, V1, P135, DOI DOI 10.1111/1467-8721.EP10769799; Berbaum K. S., 2010, HDB MED IMAGE PERCEP, P107; Bowditch R., 1996, CYTOLETTER, V3, P22; Brawley OW, 2005, J CLIN ONCOL, V23, P293, DOI 10.1200/JCO.2005.06.107; CARMODY DP, 1981, PERCEPT PSYCHOPHYS, V29, P594, DOI 10.3758/BF03207377; Chase W. G., 1982, PSYCHOL LEARN MOTIV, V16, P1, DOI 10.1016/S0079-7421(08)60546-0; Davies DR, 1982, PSYCHOL VIGILANCE; DeMay RM, 1997, ARCH PATHOL LAB MED, V121, P229; Evans KK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064366; Evans KK, 2011, ATTEN PERCEPT PSYCHO, V73, P30, DOI 10.3758/s13414-010-0022-5; Evans KK, 2013, PSYCHON B REV, V20, P1170, DOI 10.3758/s13423-013-0459-3; Humphrey DG, 1997, PSYCHOL AGING, V12, P704, DOI 10.1037//0882-7974.12.4.704; Ishibashi K, 2012, ATTEN PERCEPT PSYCHO, V74, P115, DOI 10.3758/s13414-011-0225-4; Kundel Harold L, 2006, J Am Coll Radiol, V3, P402, DOI 10.1016/j.jacr.2006.02.023; Macmillan NA, 1991, DETECTION THEORY USE; Maeda E, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-607; Menneer T., 2004, COGNITIVE TECHNOLOGY, V9, P22; Nakashima R., 2013, FRONT PSYCHOL, V4, P1; Neider MB, 2006, VISION RES, V46, P2217, DOI 10.1016/j.visres.2006.01.006; OESTMANN JW, 1988, RADIOLOGY, V166, P451; Rich AN, 2008, J VISION, V8, DOI 10.1167/8.15.15; Sowden PT, 2000, J EXP PSYCHOL HUMAN, V26, P379; Van Wert MJ, 2009, ATTEN PERCEPT PSYCHO, V71, P541, DOI 10.3758/APP.71.3.541; Wolfe J., 2013, J VISION, V13, P1, DOI DOI 10.1167/13.3.33; Yantis S, 2012, NEBR SYM MOTIV, V59, P91, DOI 10.1007/978-1-4614-4794-8_5; Zenger B, 1997, J EXP PSYCHOL HUMAN, V23, P1783, DOI 10.1037//0096-1523.23.6.1783	50	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-0727	1430-2772		PSYCHOL RES-PSYCH FO	Psychol. Res.-Psychol. Forsch.	SEP	2015	79	5					729	738		10.1007/s00426-014-0616-y		10	Psychology, Experimental	Psychology	CP1TN	WOS:000359659000003		
J	Ikuto, T; Ishizaka, S				Ikuto, Takaya; Ishizaka, Satoshi			ENTANGLEMENT AND SWAP OF QUANTUM STATES IN TWO QUBITS	QUANTUM INFORMATION & COMPUTATION			English	Article						entanglement; asymmetry; LOCC; SLOCC; PPT operations	DISTILLABLE ENTANGLEMENT; MATRICES	Suppose that two distant parties Alice and Bob share an entangled state PAD, and they want to exchange the subsystems of PAD by local operations and classical communication (LOCC). In general, this LOCC task (i.e. the LOGO transformation of rho(AB) -> V rho ABV with V being a swap operator) is impossible deterministically, but becomes possible probabilistically. In this paper, we study how the optimal probability is related to the amount of entanglement in the framework of positive partial transposed (PPT) operations, and numerically show a remarkable class of states whose probability is the smallest among every state in two quantum bits.	[Ikuto, Takaya; Ishizaka, Satoshi] Hiroshima Univ, Grad Sch Integrated Arts & Sci, Higashihiroshima 7398521, Japan	Ikuto, T (reprint author), Hiroshima Univ, Grad Sch Integrated Arts & Sci, Higashihiroshima 7398521, Japan.				JSPS KAKENHI [23246071, 24540405]	This work was supported by JSPS KAKENHI Grants No. 23246071 and No.24540405.	CHOI MD, 1975, LINEAR ALGEBRA APPL, V10, P285, DOI 10.1016/0024-3795(75)90075-0; Rains EM, 1999, PHYS REV A, V60, P173, DOI 10.1103/PhysRevA.60.173; DEPILLIS J, 1967, PAC J MATH, V23, P129; Rains EM, 2001, IEEE T INFORM THEORY, V47, P2921, DOI 10.1109/18.959270; Zyczkowski K, 1998, PHYS REV A, V58, P883, DOI 10.1103/PhysRevA.58.883; Plenio MB, 2007, QUANTUM INF COMPUT, V7, P1; ZYCZKOWSKI K, 1994, J PHYS A-MATH GEN, V27, P4235, DOI 10.1088/0305-4470/27/12/028; Peres A, 1996, PHYS REV LETT, V77, P1413, DOI 10.1103/PhysRevLett.77.1413; Borchers B., COMPUTER CODE CSDP V; Boyd S, 2004, CONVEX OPTIMIZATION; Horodecki K, 2010, QUANTUM INF COMPUT, V10, P901; Jamio lkowski A., 1972, REP MATH PHYS, V3, P275, DOI DOI 10.1016/0034-4877(72)90011-0; Kent A, 1999, PHYS REV LETT, V83, P2656, DOI 10.1103/PhysRevLett.83.2656; Ishizaka S, 2005, PHYS REV A, V71, DOI 10.1103/PhysRevA.71.052303	14	0	0	RINTON PRESS, INC	PARAMUS	565 EDMUND TERRACE, PARAMUS, NJ 07652 USA	1533-7146			QUANTUM INF COMPUT	Quantum Inform. Comput.	SEP	2015	15	11-12					923	931				9	Computer Science, Theory & Methods; Physics, Particles & Fields; Physics, Mathematical	Computer Science; Physics	CO5CQ	WOS:000359177600003		
J	Konno, N; Takei, M				Konno, Norio; Takei, Masato			THE NON-UNIFORM STATIONARY MEASURE FOR DISCRETE-TIME QUANTUM WALKS IN ONE DIMENSION	QUANTUM INFORMATION & COMPUTATION			English	Article						Quantum walk; stationary measure; uniform measure		We consider stationary measures of the one-dimensional discrete-time quantum walks (QWs) with two chiralities, which is defined by a 2 x 2 unitary matrix U. In our previous paper [15], we proved that any uniform measure becomes the stationary measure of the QW by solving the corresponding eigenvalue problem. This paper reports that non-uniform measures are also stationary measures of the QW except when U is diagonal. For diagonal matrices, we show that any stationary measure is uniform. Moreover, we prove that any uniform measure becomes a stationary measure for more general QWs not by solving the eigenvalue problem but by a simple argument.	[Konno, Norio; Takei, Masato] Yokohama Natl Univ, Fac Engn, Dept Appllied Math, Yokohama, Kanagawa 2408501, Japan	Konno, N (reprint author), Yokohama Natl Univ, Fac Engn, Dept Appllied Math, 79-5 Tokiwadai, Yokohama, Kanagawa 2408501, Japan.	konno@ynu.ac.jp; takei@ynu.ac.jp			Japan Society for the Promotion of Science [24540116]	We would like to thank Kei Saito for useful discussions. This work was partially supported by the Grant-in-Aid for Scientific Research (C) of Japan Society for the Promotion of Science (Grant No.24540116).	Ambaims A., 2001, P 33 ANN ACM S THEOR, P37, DOI 10.1145/380752.380757; Kempe J, 2003, CONTEMP PHYS, V44, P307, DOI 10.1080/00107151031000110776; Kendon V, 2007, MATH STRUCT COMP SCI, V17, P1169, DOI 10.1017/S0960129507006354; Cantero MJ, 2012, QUANTUM INF PROCESS, V11, P1149, DOI 10.1007/s11128-012-0448-x; Endo S., 2014, ARXIV14098134; Endo T., 2014, YOKOHAMA MATH J, V60, P49; Konno N., 2014, YOKOHAMA MATH J, V60, P33; Konno N, 2008, LECT NOTES MATH, V1954, P309; Konno N, 2013, QUANTUM INF PROCESS, V12, P33, DOI 10.1007/s11128-011-0353-8; Konno N, 2014, QUANTUM INF PROCESS, V13, P1103, DOI 10.1007/s11128-013-0714-6; Manouchehri K., 2013, PHYS IMPLEMENTATION; Portugal R., 2013, QUANTUM WALKS SEARCH; Venegas-Andraca SE, 2012, QUANTUM INF PROCESS, V11, P1015, DOI 10.1007/s11128-012-0432-5; Venegas-Andraca S. E., 2008, QUANTUM WALKS COMPUT; Wojcik A, 2012, PHYS REV A, V85, DOI 10.1103/PhysRevA.85.012329	15	0	0	RINTON PRESS, INC	PARAMUS	565 EDMUND TERRACE, PARAMUS, NJ 07652 USA	1533-7146			QUANTUM INF COMPUT	Quantum Inform. Comput.	SEP	2015	15	11-12					1060	1075				16	Computer Science, Theory & Methods; Physics, Particles & Fields; Physics, Mathematical	Computer Science; Physics	CO5CQ	WOS:000359177600012		
J	Shinotsuka, H; Tanuma, S; Powell, CJ; Penn, DR				Shinotsuka, H.; Tanuma, S.; Powell, C. J.; Penn, D. R.			Calculations of electron inelastic mean free paths. X. Data for 41 elemental solids over the 50eV to 200keV range with the relativistic full Penn algorithm	SURFACE AND INTERFACE ANALYSIS			English	Article						electron inelastic mean free path; elemental solids; relativistic full Penn algorithm; IMFP; relativistic TPP-2M	OPTICAL-DATA; ENERGIES; SPECTROSCOPY; HOLOGRAPHY; MATTER; IMFPS; MODEL	We have calculated inelastic mean free paths (IMFPs) for 41 elemental solids (Li, Be, graphite, diamond, glassy C, Na, Mg, Al, Si, K, Sc, Ti, V, Cr, Fe, Co, Ni, Cu, Ge, Y, Nb, Mo, Ru, Rh, Pd, Ag, In, Sn, Cs, Gd, Tb, Dy, Hf, Ta, W, Re, Os, Ir, Pt, Au, and Bi) for electron energies from 50eV to 200keV. The IMFPs were calculated from measured energy loss functions for each solid with a relativistic version of the full Penn algorithm. The calculated IMFPs could be fitted to a modified form of the relativistic Bethe equation for inelastic scattering of electrons in matter for energies from 50eV to 200keV. The average root-mean-square (RMS) deviation in these fits was 0.68%. The IMFPs were also compared with IMFPs from a relativistic version of our predictive Tanuma, and Powell and Penn (TPP-2M) equation that was developed from a modified form of the relativistic Bethe equation. In these comparisons, the average RMS deviation was 11.9% for energies between 50eV and 200keV. This RMS deviation is almost the same as that found previously in a similar comparison for the 50eV to 30keV range (12.3%). Relatively large RMS deviations were found for diamond, graphite, and cesium as in our previous comparisons. If these three elements were excluded in the comparisons, the average RMS deviation was 8.9% between 50eV and 200keV. The relativistic TPP-2M equation can thus be used to estimate IMFPs in solid materials for energies between 50eV and 200keV. We found satisfactory agreement between our calculated IMFPs and those from recent calculations and from measurements at energies of 100 and 200keV. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Shinotsuka, H.; Tanuma, S.] Natl Inst Mat Sci, Tsukuba, Ibaraki 3050047, Japan; [Powell, C. J.; Penn, D. R.] NIST, Gaithersburg, MD 20899 USA	Tanuma, S (reprint author), Natl Inst Mat Sci, 1-2-1 Sengen, Tsukuba, Ibaraki 3050047, Japan.	tanuma.shigeo@nims.go.jp					TANUMA S, 1991, SURF INTERFACE ANAL, V17, P911, DOI 10.1002/sia.740171304; Tanuma S, 2011, SURF INTERFACE ANAL, V43, P689, DOI 10.1002/sia.3522; Tanuma S, 2005, SURF INTERFACE ANAL, V37, P833, DOI 10.1002/sia.2102; TANUMA S, 1988, SURF INTERFACE ANAL, V11, P577, DOI 10.1002/sia.740111107; MCCARTNEY MR, 1994, ULTRAMICROSCOPY, V53, P283, DOI 10.1016/0304-3991(94)90040-X; Tanuma S, 2005, SURF INTERFACE ANAL, V37, P1, DOI 10.1002/sia.1997; FernandezVarea JM, 1996, NUCL INSTRUM METH B, V108, P35, DOI 10.1016/0168-583X(95)01055-6; INOKUTI M, 1971, REV MOD PHYS, V43, P297, DOI 10.1103/RevModPhys.43.297; TANUMA S, 1993, SURF INTERFACE ANAL, V20, P77, DOI 10.1002/sia.740200112; PENN DR, 1987, PHYS REV B, V35, P482, DOI 10.1103/PhysRevB.35.482; Fernandez-Varea JM, 2005, NUCL INSTRUM METH B, V229, P187, DOI 10.1016/j.nimb.2004.12.002; TANUMA S, 1994, SURF INTERFACE ANAL, V21, P165, DOI 10.1002/sia.740210302; Tanuma S, 2003, SURF INTERFACE ANAL, V35, P268, DOI 10.1002/sia.1526; Powell CJ, 2010, J ELECTRON SPECTROSC, V178, P331, DOI 10.1016/j.elspec.2009.05.004; Arakawa E. T., 1991, HDB OPTICAL CONSTANT, VII, P421; Bethe H, 1930, ANN PHYS-BERLIN, V5, P325; Cullen D.E., 1997, EVALUATED PHOTON DAT, V6, P1997; Egerton RF, 2011, ELECT ENERGY LOSS SP; FANO U, 1954, PHYS REV, V95, P1198, DOI 10.1103/PhysRev.95.1198; Iakoubovskii K, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.104102; Lindhard J., 1954, VIDENSK SELSK MAT FY, V28, P1; Powell C. J., 2005, NUCL INSTRUM METH A, V601, P54; Shinotsuka H, 2012, NUCL INSTRUM METH B, V270, P75, DOI 10.1016/j.nimb.2011.09.016; TANUMA S, 1990, J ELECTRON SPECTROSC, V52, P285, DOI 10.1016/0368-2048(90)85024-4; TANUMA S, 1993, J ELECTRON SPECTROSC, V62, P95, DOI 10.1016/0368-2048(93)80008-A; Tanuma S., 1991, SURF INTERFACE ANAL, V17, P929; Wang YG, 2003, CHINESE PHYS LETT, V20, P888; Werner WSM, 2001, J ELECTRON SPECTROSC, V113, P127, DOI 10.1016/S0368-2048(00)00280-2; Werner WSM, 2000, SURF SCI, V470, pL123, DOI 10.1016/S0039-6028(00)00858-X	29	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0142-2421	1096-9918		SURF INTERFACE ANAL	Surf. Interface Anal.	SEP	2015	47	9					871	888		10.1002/sia.5789		18	Chemistry, Physical	Chemistry	CP1HG	WOS:000359626300003		
J	Meguro, M; Mizuguchi, T; Kawamoto, M; Ota, S; Ishii, M; Nishidate, T; Okita, K; Kimura, Y; Hirata, K				Meguro, Makoto; Mizuguchi, Toru; Kawamoto, Masaki; Ota, Shigenori; Ishii, Masayuki; Nishidate, Toshihiko; Okita, Kenji; Kimura, Yasutoshi; Hirata, Koichi			Clinical comparison of laparoscopic and open liver resection after propensity matching selection	SURGERY			English	Article							LONG-TERM-SURVIVAL; HEPATOCELLULAR-CARCINOMA; BLOOD-TRANSFUSION; OPEN HEPATECTOMY; PROGNOSIS; SCORE; CLASSIFICATION; EXPERIENCE; CRITERIA; OUTCOMES	Background. This study aimed to compare the radicality for and clinical advantages of laparoscopic liver resection, which is increasingly used, and the corresponding open procedure by propensity score matching analysis. Methods. We analyzed 260 hepatocellular carcinoma patients who underwent initial liver resection at our department between January 2003 and June 2011, including 60 laparoscopic (the Lap group) and 200 open cases (the Open group). Propensity scores were calculated for each patient via the use of various clinicopathologic features as covariates, and patients' survival was compared. Results. The Lap group had more women and patients of advanced age (n = 60) than the Open group (n = 200). Tumor size (2.3 cm vs 3.5 cm median), multiple tumors (18.3% vs 41.0%), vascular invasion (15.0% vs 36.5%), poor differentiation status (11.2% vs 24.5%), intraoperative bleeding (110 mL vs 420 mL; median), and operative time (277 minutes vs 312 minutes; median) were significantly more favorable in the Lap group than in the Open group because of a selection bias of the patients (Lap vs Open). The postoperative recurrence-free and overall survival rates were greater in the Lap group than in the Open group; however, when 35 patients from each group were analyzed after propensity scare matching of clinicopathologic characteristics of the patients, intraoperative bleeding was lesser in the Lap group. The recurrence-free survival rates at 1, 3, and 5 years were 75.0%, 43.8%, and 43.8%, respectively, in the Lap group and 73.6%, 49.3%, and 37.2%, respectively, in the Open group, which indicated no significant differences (P = .954). Similarly, the overall survival rates at 1, 3, and 5 years were 93.9%, 82.1%, and 82.1%, respectively, in the Lap group and 94.3%, 85.2%, and 61.8%, respectively, in the Open group, indicating no significant differences between the 2 groups (P = .672). Conclusion. Our results indicate that laparoscopic liver resection is comparable with the corresponding open procedure in clinical safety and prognostic efficacy.	[Meguro, Makoto; Mizuguchi, Toru; Kawamoto, Masaki; Ota, Shigenori; Ishii, Masayuki; Nishidate, Toshihiko; Okita, Kenji; Kimura, Yasutoshi; Hirata, Koichi] Sapporo Med Univ, Sch Med, Dept Surg Surg Oncol & Sci, Sapporo, Hokkaido 0608543, Japan	Meguro, M (reprint author), Sapporo Med Univ, Sch Med, Dept Surg Surg Oncol & Sci, Chuo Ku, South-1,West-16, Sapporo, Hokkaido 0608543, Japan.	meguro@sapmed.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [24791437, 26461920, 13377023, 23591993]; Yuasa Memorial Foundation	Supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (grant nos. 24791437 and 26461920 to M. Meguro, no. 13377023 to K. Hirata, and no. 23591993 to T. Mizuguchi). A grant from the Yuasa Memorial Foundation was awarded to T. Mizuguchi.	El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Fan ST, 1999, ARCH SURG-CHICAGO, V134, P1124, DOI 10.1001/archsurg.134.10.1124; Mizuguchi T, 2014, SURG TODAY, V44, P1, DOI 10.1007/s00595-013-0534-4; Imamura H, 2005, J HEPATO-BILIARY-PAN, V12, P16, DOI 10.1007/s00534-004-0965-9; Kudo M, 2003, J GASTROENTEROL, V38, P207, DOI 10.1007/s005350300038; Buell JF, 2008, ANN SURG, V248, P475, DOI 10.1097/SLA.0b013e318185e647; Kim H, 2014, SURG ENDOSC, V28, P950, DOI 10.1007/s00464-013-3254-3; Feng K, 2012, J HEPATOL, V57, P794, DOI [10.1016/j.jhep.2012.05.007, 10.1016/j.jhep.2012.07.022]; Kuroda S, 2012, WORLD J SURG, V36, P651, DOI 10.1007/s00268-012-1425-3; Mizuguchi T, 2011, J GASTROINTEST SURG, V15, P1433, DOI 10.1007/s11605-011-1566-y; Eguchi S, 2008, SURGERY, V143, P469, DOI 10.1016/j.surg.2007.12.003; Tranchart H, 2010, SURG ENDOSC, V24, P1170, DOI 10.1007/s00464-009-0745-3; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Reddy SK, 2012, HEPATOLOGY, V55, P1809, DOI 10.1002/hep.25536; Truant S, 2011, SURG ENDOSC, V25, P3668, DOI 10.1007/s00464-011-1775-1; Kaneko H, 2005, J HEPATO-BILIARY-PAN, V12, P438, DOI 10.1007/s00534-005-1028-6; Balzan S, 2005, ANN SURG, V242, P824, DOI 10.1097/01.sla.0000189131.90876.9e; Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2; Chow PKH, 2012, J GASTROEN HEPATOL, V27, P452, DOI 10.1111/j.1440-1746.2011.07034.x; Cheung TT, 2013, ANN SURG, V257, P506, DOI 10.1097/SLA.0b013e31827b947a; Hu BS, 2011, WORLD J GASTROENTERO, V17, P4725, DOI 10.3748/wjg.v17.i42.4725; Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786; Pringle JH, 1908, ANN SURG, V48, P541, DOI 10.1097/00000658-190810000-00005; Nitta H, 2010, ANN SURG, V251, P450, DOI 10.1097/SLA.0b013e3181cf87da; [Anonymous], 2010, AJCC CANC STAGING MA; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Starley BQ, 2010, HEPATOLOGY, V51, P1820, DOI 10.1002/hep.23594; Rao A, 2012, AM J SURG, V204, P222, DOI 10.1016/j.amjsurg.2011.08.013; Vauthey JN, 2010, HPB, V12, P289, DOI 10.1111/j.1477-2574.2010.00181.x; Mayinuer A, 2013, ANN SURG ONCOL, V20, P305, DOI 10.1245/s10434-012-2395-2; Reddy SK, 2011, WORLD J SURG, V35, P1478, DOI 10.1007/s00268-010-0906-5; Manghisi G, 1998, HEPATOLOGY, V28, P751; Fleming TR, 1990, J ACQ IMMUN DEF SYND, V3, P82; Gustafson JD, 2012, SURG ENDOSC, V26, P468, DOI 10.1007/s00464-011-1902-z; Ho CM, 2013, SURG ENDOSC, V27, P1820, DOI 10.1007/s00464-012-2624-6; Kobayashi S, 2013, SURG ENDOSC, V27, P610, DOI 10.1007/s00464-012-2499-6; Koffron AJ, 2007, ANN SURG, V246, P385, DOI 10.1097/SLA.0b013e318146996c; Lee KF, 2011, WORLD J SURG, V35, P2268, DOI 10.1007/s00268-011-1212-6; Mizuguchi T, 2011, SURG TODAY, V41, P39, DOI 10.1007/s00595-010-4337-6; Mizuguchi T, 2012, HEPATO-GASTROENTEROL, V59, P551, DOI 10.5754/hge10052; Morise Zenichi, 2013, World J Hepatol, V5, P487, DOI 10.4254/wjh.v5.i9.487; Sugita S, 2008, EJSO-EUR J SURG ONC, V34, P339, DOI 10.1016/j.ejso.2007.02.010	44	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	SEP	2015	158	3					573	587		10.1016/j.surg.2015.02.031		15	Surgery	Surgery	CP3CS	WOS:000359755000001		
J	Nishikawa, T; Sunami, E; Tanaka, T; Tanaka, J; Kiyomatsu, T; Kawai, K; Hata, K; Kazama, S; Nozawa, H; Ishihara, S; Watanabe, T				Nishikawa, Takeshi; Sunami, Eiji; Tanaka, Toshiaki; Tanaka, Junichiro; Kiyomatsu, Tomomitsu; Kawai, Kazushige; Hata, Keisuke; Kazama, Shinsuke; Nozawa, Hiroaki; Ishihara, Soichiro; Watanabe, Toshiaki			Incidence and prognostic significance of positive peritoneal lavage in colorectal cancer	SURGERY TODAY			English	Review						Peritoneal lavage; Colorectal cancer; Survival; Recurrence	CURATIVE RESECTION; WASHING CYTOLOGY; GASTRIC-CARCINOMA; PANCREATIC-CANCER; MALIGNANT-CELLS; TUMOR-CELLS; RECURRENCE; FLUID; RISK; ADENOCARCINOMA	The significance of peritoneal lavage cytology as a prognostic marker has been examined in various types of cancer. However, the meaning of positive peritoneal lavage cytology in colorectal cancer is still controversial. The aim of this review is to evaluate the prognostic significance of positive peritoneal lavage cytology in colorectal cancer. An English literature search was performed on all studies published between 1998 and 2014 that compared the detection of peritoneal free cancer cells with survival or recurrence. Eighteen articles met the inclusion criteria. All studies employed one (or more) of the three techniques used to detect free cancer cells in the peritoneal cavity: (1) conventional cytology, (2) immunocytochemistry or (3) polymerase chain reaction. The incidence of positive peritoneal lavage cytology ranged from 2.2 to 47.2 % across the studies. The factors correlated with positive peritoneal lavage cytology were tumor penetration and metastases (lymph node, liver and peritoneum). In nine studies, positive lavage findings were associated with a worse survival, and it was associated with increased recurrence in 13 studies. Positive peritoneal lavage cytology seems to be an indicator of a poor prognosis in colorectal cancer patients. Further studies are needed to clarify the prognostic impact of peritoneal lavage cytology, by comparing the different methods used for the collection of the peritoneal lavage.	[Nishikawa, Takeshi; Sunami, Eiji; Tanaka, Toshiaki; Tanaka, Junichiro; Kiyomatsu, Tomomitsu; Kawai, Kazushige; Hata, Keisuke; Kazama, Shinsuke; Nozawa, Hiroaki; Ishihara, Soichiro; Watanabe, Toshiaki] Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, Tokyo 1138655, Japan	Watanabe, T (reprint author), Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	takn-tky@umin.ac.jp; toshwatanabe@yahoo.co.jp					Lloyd JM, 2006, CLIN CANCER RES, V12, P417, DOI 10.1158/1078-0432.CCR-05-1473; UMPLEBY HC, 1984, BRIT J SURG, V71, P659, DOI 10.1002/bjs.1800710902; Kanellos I, 2006, COLORECTAL DIS, V8, P436, DOI 10.1111/j.1463-1318.2006.00991.x; Homma Y, 2014, SURG TODAY, V44, P1084, DOI 10.1007/s00595-013-0689-z; Gozalan U, 2007, AM J SURG, V193, P672, DOI 10.1016/j.amjsurg.2006.10.020; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Nath J, 2008, BRIT J SURG, V95, P721, DOI 10.1002/bjs.6107; Rekhraj S, 2008, ANN SURG ONCOL, V15, P60, DOI 10.1245/s10434-007-9591-5; Bosch B, 2003, BRIT J SURG, V90, P882, DOI 10.1002/bjs.4129; ZISELMAN EM, 1984, ACTA CYTOL, V28, P105; Hayes N, 1999, BRIT J CANCER, V79, P520, DOI 10.1038/sj.bjc.6690081; Hase K, 1998, DIS COLON RECTUM, V41, P1134, DOI 10.1007/BF02239435; Noura S, 2011, ANN SURG ONCOL, V18, P396, DOI 10.1245/s10434-010-1319-2; Hara M, 2007, CLIN EXP METASTAS, V24, P179, DOI 10.1007/s10585-007-9067-9; Fucso M, 1994, CURR SURG, V51, P527; Fujii S, 2009, INT J COLORECTAL DIS, V24, P907, DOI 10.1007/s00384-009-0733-z; Ishikawa O, 2003, ANN SURG, V238, P103, DOI 10.1097/01.SLA.0000074982.51763.d6; Kamiyama H, 2009, J SURG ONCOL, V100, P69, DOI 10.1002/jso.21291; Kasamatsu T, 2009, GYNECOL ONCOL, V115, P488, DOI 10.1016/j.ygyno.2009.08.020; Katoh H, 2009, BRIT J SURG, V96, P769, DOI 10.1002/bjs.6622; Kobayashi H, 2013, INT J CLIN ONCOL, V18, P411, DOI 10.1007/s10147-012-0394-8; Kodera Y, 1999, J SURG ONCOL, V72, P60, DOI 10.1002/(SICI)1096-9098(199910)72:2<60::AID-JSO3>3.0.CO;2-1; Kuji S, 2014, J GYNECOL ONCOL, V25, P90, DOI 10.3802/jgo.2014.25.2.90; LEATHER AJM, 1994, DIS COLON RECTUM, V37, P814, DOI 10.1007/BF02050147; Lee IK, 2009, ANN SURG ONCOL, V16, P861, DOI 10.1245/s10434-008-0294-3; LEI SZ, 1994, ARCH SURG-CHICAGO, V129, P639; Matsuda K, 2013, SURG TODAY, V43, P984, DOI 10.1007/s00595-012-0348-9; MICHELASSI F, 1990, SURGERY, V108, P787; Nishikawa T, 2009, DIS COLON RECTUM, V52, P2016, DOI 10.1007/DCR.0b013e3181b4c46e; Noura S, 2009, DIS COLON RECTUM, V52, P1312, DOI 10.1007/DCR.0b013e3181a745a4; Ozawa H, 2014, SURG TODAY, V44, P1643, DOI 10.1007/s00595-013-0735-x; Rossi Del Monte S, 2012, J SURG ONCOL, V106, P17; Temesi R, 2012, WORLD J SURG, V36, P2714, DOI 10.1007/s00268-012-1713-y; Vogel P, 2000, DIS COLON RECTUM, V43, P92, DOI 10.1007/BF02237250; WARSHAW AL, 1991, AM J SURG, V161, P26, DOI 10.1016/0002-9610(91)90356-I; Wind P, 1999, SCAND J GASTROENTERO, V34, P606; Yamamoto S, 2003, JPN J CLIN ONCOL, V33, P33, DOI 10.1093/jjco/hyg007	37	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1073	1081		10.1007/s00595-014-1066-2		9	Surgery	Surgery	CP1UE	WOS:000359660900001		
J	Kodera, Y; Kobayashi, D; Tanaka, C; Fujiwara, M				Kodera, Yasuhiro; Kobayashi, Daisuke; Tanaka, Chie; Fujiwara, Michitaka			Gastric adenocarcinoma with para-aortic lymph node metastasis: a borderline resectable cancer?	SURGERY TODAY			English	Review						Gastric cancer; Para-aortic lymph nodes; Lymphadenectomy; Neoadjuvant chemotherapy	NEOADJUVANT CHEMOTHERAPY; PHASE-II; CURATIVE RESECTION; LIVER METASTASES; CLINICAL-TRIAL; CISPLATIN; S-1; D2; LYMPHADENECTOMY; DISSECTION	Dissection of the para-aortic lymph nodes (PAN) had once been enthusiastically explored at dedicated centers throughout Japan. Reflecting the results of a randomized trial, however, the current standard surgery for advanced resectable gastric cancer does not include systematic dissection of the PAN. Gastric cancer with PAN metastases, currently considered distant metastases, is classified as Stage IV, and according to the algorithm of the Japanese guidelines, is not indicated for surgery with curative intent. Historical data indicates, however, that a certain proportion of long-term survivors can be introduced among patients with PAN metastasis through D2 + PAN dissection. The Japan Clinical Oncology Group launched a series of phase II trials exploring a strategy employing neoadjuvant chemotherapy followed by D2 + PAN dissection for patients radiologically diagnosed to harbor metastases to the PAN. The campaign was successful, with 57 % of these patients surviving for 5 years after two cycles of neoadjuvant S-1/CDDP followed by surgery. This strategy is now the tentative standard, mentioned in the 4th version of the Japanese Gastric Cancer Treatment Guidelines as one of the current clinical questions, and could be replaced by a more powerful combination chemotherapy or treatment employing more or longer cycles of chemotherapy in the future. The relevance of the strategy consisting of neoadjuvant chemotherapy followed by D2 + PAN dissection and its fundamental difference from the concept of conversion therapy are discussed herein with reference to the literature.	[Kodera, Yasuhiro; Kobayashi, Daisuke; Tanaka, Chie; Fujiwara, Michitaka] Nagoya Univ, Grad Sch Med, Dept Surg Gastroenterol, Showa Ku, Nagoya, Aichi 4668550, Japan	Kodera, Y (reprint author), Nagoya Univ, Grad Sch Med, Dept Surg Gastroenterol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	ykodera@med.nagoya-u.ac.jp			Taiho Pharmaceutical Company; Chugai Pharmaceutical Company; Yakult Honsha Co. Ltd; Bristol-Myers Squibb; Eli Lilly Japan KK; Pfizer Japan	Yasuhiro Kodera has received research Grants from Taiho Pharmaceutical Company, Chugai Pharmaceutical Company, Yakult Honsha Co. Ltd, Bristol-Myers Squibb, Eli Lilly Japan KK, and Pfizer Japan, and received lecture fees from Taiho Pharmaceutical Company and Chugai Pharmaceutical Company.	Ohtsu A, 1999, J CLIN ONCOL, V17, P2915; Leone F, 2013, CANCER-AM CANCER SOC, V119, P3429, DOI 10.1002/cncr.28223; Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI [10.1016/S1470-2045(08)70035-4, 10.1016/S1470-204S(08)70035-4]; Bang YJ, 2010, LANCET, V376, P1302; Koizumi W, 2003, BRIT J CANCER, V89, P2207, DOI 10.1038/sj.bjc.6601413; Sasako M, 2008, NEW ENGL J MED, V359, P453, DOI 10.1056/NEJMoa0707035; Marrelli D, 2011, ANN SURG ONCOL, V18, P2265, DOI 10.1245/s10434-010-1541-y; Sano T, 2011, GASTRIC CANCER, V14, P97, DOI 10.1007/s10120-011-0040-6; Yoshikawa T, 2014, ANN SURG ONCOL, V21, P213, DOI 10.1245/s10434-013-3055-x; Katayama H, 2012, JPN J CLIN ONCOL, V42, P556, DOI 10.1093/jjco/hys054; Tsuburaya A, 2014, BRIT J SURG, V101, P653, DOI 10.1002/bjs.9484; Takashima S, 2005, SURG TODAY, V35, P425, DOI 10.1007/s00595-004-2976-1; Lowy AM, 1999, ANN SURG, V229, P303, DOI 10.1097/00000658-199903000-00001; Yonemura Y, 2008, INT J CLIN ONCOL, V13, P132, DOI 10.1007/s10147-007-0727-1; FELDMAN LD, 1986, CANCER RES, V46, P2578; Kulig J, 2007, AM J SURG, V193, P10, DOI 10.1016/j.amjsurg.2006.04.018; Kunisaki C, 2006, ANN SURG ONCOL, V13, P659, DOI 10.1245/ASO.2006.07.015; Koizumi W, 2012, CANCER CHEMOTH PHARM, V69, P407, DOI 10.1007/s00280-011-1701-1; D'Angelica M, 2004, ANN SURG, V240, P808, DOI 10.1097/01.sla.0000143245.28656.15; Yoshikawa T, 2014, SURG TODAY, V44, P11, DOI 10.1007/s00595-013-0529-1; Folprecht G, 2014, ANN ONCOL, V25, P1018, DOI 10.1093/annonc/mdu088; Becker K, 2003, CANCER, V98, P1521, DOI 10.1002/cncr.11660; Kodera Y, 2014, GASTRIC CANCER, V17, P206, DOI 10.1007/s10120-013-0299-x; Hasegawa S, 2013, ANN SURG ONCOL, V20, P2016, DOI 10.1245/s10434-012-2817-1; Yoshikawa T, 2009, BRIT J SURG, V96, P1015, DOI 10.1002/bjs.6665; Varadhachary GR, 2006, ANN SURG ONCOL, V13, P1035, DOI 10.1245/ASO.2006.08.011; Fujimura T, 2009, ONCOL REP, V22, P509, DOI 10.3892/or_00000464; Kodera Y, 2008, MANAGEMENT GASTRIC C, P149; Kurokawa Y, 2014, GASTRIC CANCER, V17, P514, DOI 10.1007/s10120-013-0294-2; Matsumoto T, 2015, GASTRIC CANCER, V18, P467, DOI 10.1007/s10120-014-0398-3; Nakamura K, 2015, GASTRIC CANCER, V18, P597, DOI 10.1007/s10120-014-0401-z; Oyama K, 2012, J SURG ONCOL, V105, P535, DOI 10.1002/jso.22125; Park IH, 2011, CANCER CHEMOTH PHARM, V67, P127, DOI 10.1007/s00280-010-1296-y; Roviello F, 2010, EJSO-EUR J SURG ONC, V36, P439, DOI 10.1016/j.ejso.2010.03.008; SAWAI K, 1994, J SURG ONCOL, V56, P221, DOI 10.1002/jso.2930560404; Tanizawa Y, 2012, JPN J CANC CHEMOTHER, V39, P2469; Tokunaga M, 2010, ANN SURG ONCOL, V17, P2031, DOI 10.1245/s10434-010-0969-4; Van Cutsem W, 2014, GASTRIC CANCER, DOI [10.1007/s10120-014-0402-y, DOI 10.1007/S10120-014-0402-Y]; Wang Y, 2014, CANCER CHEMOTH PHARM, V73, P1155, DOI 10.1007/s00280-014-2449-1; Yoshida M, 2004, JPN J CLIN ONCOL, V34, P654, DOI 10.1093/jjco/hyh120	40	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1082	1090		10.1007/s00595-014-1067-1		9	Surgery	Surgery	CP1UE	WOS:000359660900002		
J	Tomimaru, Y; Wada, H; Eguchi, H; Tomokuni, A; Hama, N; Kawamoto, K; Marubashi, S; Umeshita, K; Doki, Y; Mori, M; Wakasa, K; Nagano, H				Tomimaru, Yoshito; Wada, Hiroshi; Eguchi, Hidetoshi; Tomokuni, Akira; Hama, Naoki; Kawamoto, Koichi; Marubashi, Shigeru; Umeshita, Koji; Doki, Yuichiro; Mori, Masaki; Wakasa, Kenichi; Nagano, Hiroaki			Clinical significance of surgical resection of metastatic lymph nodes from hepatocellular carcinoma	SURGERY TODAY			English	Article						Hepatocellular carcinoma; Lymph node metastasis; Surgery	SUBCUTANEOUS INTERFERON-ALPHA; HEPATIC RESECTION; INTRAARTERIAL 5-FLUOROURACIL; COMBINATION CHEMOTHERAPY; TUMOR THROMBUS; THERAPY; RECURRENCE; SURGERY; LYMPHADENECTOMY; RADIOTHERAPY	The clinical significance of the surgical resection of metastatic lymph nodes (LN) from patients with hepatocellular carcinoma (HCC) remains controversial. The aim of this study was to evaluate the significance of the surgical resection of LN metastasis of HCC. Among 961 patients who underwent surgical resection for HCC in our hospital, LN metastasis was identified in 38 patients. In these patients, the metastatic LN were removed completely in 22 patients (complete removal group), and incompletely or not removed in 16 patients (control group). The long-term prognosis after LN metastasis was compared between the two groups. The overall survival rate after LN metastasis was significantly better in the complete removal group (1-, 3- and 5-year: 71.2, 58.0 and 49.7 %, respectively) than in the control group (45.9, 23.0 and 15.3 %, respectively, p = 0.0477). LN metastasis was not the cause of death in any of the patients in the complete removal group, whereas it was a cause in some patients in the control group. No local LN recurrence was identified in the complete removal group. The present results suggest that the complete removal of metastatic LN from HCC is clinically beneficial in selected patients.	[Tomimaru, Yoshito; Wada, Hiroshi; Eguchi, Hidetoshi; Tomokuni, Akira; Hama, Naoki; Kawamoto, Koichi; Marubashi, Shigeru; Doki, Yuichiro; Mori, Masaki; Nagano, Hiroaki] Osaka Univ, Grad Sch Med, Dept Surg, Suita, Osaka 5650871, Japan; [Umeshita, Koji] Osaka Univ, Grad Sch Med, Div Hlth Sci, Suita, Osaka 5650871, Japan; [Wakasa, Kenichi] Osaka City Univ Hosp, Dept Pathol, Osaka, Japan	Nagano, H (reprint author), Osaka Univ, Grad Sch Med, Dept Surg, 2-2 Yamadaoka E-2, Suita, Osaka 5650871, Japan.	hnagano@gesurg.med.osaka-u.ac.jp					Abe T, 2002, AM J CLIN ONCOL-CANC, V25, P318, DOI 10.1097/00000421-200206000-00024; Ercolani G, 2004, ANN SURG, V239, P202, DOI 10.1097/01.sla.0000109154.00020.e0; Yamashita H, 2007, J GASTROEN HEPATOL, V22, P523, DOI 10.1111/j.1440-1746.2006.04450.x; Marsh JW, 2000, CANCER, V88, P538, DOI 10.1002/(SICI)1097-0142(20000201)88:3<538::AID-CNCR7>3.0.CO;2-H; EDMONDSON HA, 1954, CANCER, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Park YJ, 2006, J GASTROENTEROL, V41, P1099, DOI 10.1007/s00535-006-1895-x; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Nagano H, 2007, CANCER, V110, P2493, DOI 10.1002/cncr.23033; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Uenishi T, 2000, SURG TODAY, V30, P892; MILLER DL, 1987, AM HEART J, V114, P906, DOI 10.1016/0002-8703(87)90808-8; Sakon M, 2002, CANCER, V94, P435, DOI 10.1002/cncr.10246; WATANABE J, 1994, JPN J CLIN ONCOL, V24, P37; Yang YB, 2007, SURGERY, V141, P196, DOI 10.1016/j.surg.2006.06.033; Ota H, 2005, BRIT J CANCER, V93, P557, DOI 10.1038/sj.bjc.6602742; YUKI K, 1990, CANCER, V66, P2174, DOI 10.1002/1097-0142(19901115)66:10<2174::AID-CNCR2820661022>3.0.CO;2-A; Poon RTP, 2001, ANN SURG, V234, P63, DOI 10.1097/00000658-200107000-00010; Zeng ZC, 2005, INT J RADIAT ONCOL, V63, P1067, DOI 10.1016/j.ijrobp.2005.03.058; Minagawa M, 2003, ANN SURG, V238, P703, DOI 10.1097/01.sla.0000094549.11754.e6; Sun HC, 2007, J SURG ONCOL, V96, P37, DOI 10.1002/jso.20772; Arii S, 1998, J Hepatobiliary Pancreat Surg, V5, P86, DOI 10.1007/PL00009956; Kobayashi T, 2013, SURG TODAY, V43, P1347, DOI 10.1007/s00595-012-0473-5; LAU WY, 1994, SURG ONCOL, V3, P161, DOI 10.1016/0960-7404(94)90045-0; Nagano H, 2007, HEPATO-GASTROENTEROL, V54, P172; NAGAO T, 1987, ANN SURG, V205, P33, DOI 10.1097/00000658-198701000-00006; Nakamura M, 2008, CANCER, V112, P1765, DOI 10.1002/cncr.23356; Nakamura M, 2006, J GASTROENTEROL, V41, P1120, DOI 10.1007/s00535-006-1907-x; Toyoda H, 1996, J GASTROEN HEPATOL, V11, P959, DOI 10.1111/j.1440-1746.1996.tb01854.x; Ueno M, 2014, SURG TODAY, V44, P1651, DOI 10.1007/s00595-013-0739-6; UNE Y, 1994, SURG TODAY, V24, P606; Yamamoto K, 1997, ARCH SURG-CHICAGO, V132, P120; Yamasaki T, 2001, CANCER, V91, P1342, DOI 10.1002/1097-0142(20010401)91:7<1342::AID-CNCR1137>3.0.CO;2-0	33	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1112	1120		10.1007/s00595-014-1028-8		9	Surgery	Surgery	CP1UE	WOS:000359660900005		
J	Toyooka, S; Soh, J; Yamamoto, H; Yamane, M; Hattori, S; Shien, K; Miyoshi, K; Sugimoto, S; Oto, T; Miyoshi, S				Toyooka, Shinichi; Soh, Junichi; Yamamoto, Hiromasa; Yamane, Masaomi; Hattori, Shigeru; Shien, Kazuhiko; Miyoshi, Kentaroh; Sugimoto, Seiichiro; Oto, Takahiro; Miyoshi, Shinichiro			Extended sleeve lobectomy after induction chemoradiotherapy for non-small cell lung cancer	SURGERY TODAY			English	Article						Sleeve lobectomy; Lung cancer; Chemoradiotherapy; Induction therapy	BRONCHOPLEURAL FISTULA; RISK-FACTOR; PNEUMONECTOMY; MANAGEMENT; CISPLATIN; DOCETAXEL; RESECTION; SURGERY; LOBE	Extended sleeve lobectomy is a challenging surgery. While induction chemoradiotherapy (ChRT) followed by surgery is one of the therapeutic strategies used for locally advanced non-small cell lung cancer (NSCLC), ChRT can impair the anastomotic healing potential. We herein present our experience with cases who underwent an extended sleeve lobectomy after induction ChRT. The medical records of patients who underwent a surgery for NSCLC after ChRT were reviewed. Between December 2007 and January 2013, nine patients underwent an extended sleeve lobectomy; the left lingular division and lower lobe in four patients, the right upper lobe and trachea in one patient, the carina and trachea in one patient, the right middle and lower lobes in one patient, the right upper and middle lobes and carina in one patient and the right upper lobe and superior segment of the lower lobe in one patient. While no postoperative 90-day deaths occurred, one case developed a bronchopleural fistula on postoperative day (POD) 25 and one case developed a bronchovascular fistula on POD 163. No cases of local recurrence developed. Our experience suggests that an extended sleeve lobectomy after induction ChRT is feasible, but careful patient selection and perioperative management are mandatory.	[Toyooka, Shinichi; Soh, Junichi; Yamamoto, Hiromasa; Yamane, Masaomi; Hattori, Shigeru; Shien, Kazuhiko; Miyoshi, Kentaroh; Sugimoto, Seiichiro; Oto, Takahiro; Miyoshi, Shinichiro] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Thorac Surg, Kita Ku, Okayama 7008558, Japan; [Toyooka, Shinichi; Shien, Kazuhiko] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Genom Med, Okayama 7008558, Japan	Toyooka, S (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Thorac Surg, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	toyooka@md.okayama-u.ac.jp	Shien, Kazuhiko/B-8560-2012	Shien, Kazuhiko/0000-0002-4959-4220			Venuta F, 2009, J THORAC CARDIOV SUR, V138, P1185, DOI 10.1016/j.jtcvs.2009.07.043; Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Ferguson MK, 2003, ANN THORAC SURG, V76, P1782, DOI 10.1016/S0003-4975(03)01243-8; Imai K, 2014, SURG TODAY, V44, P1197, DOI 10.1007/s00595-013-0660-z; Toyooka S, 2012, INTERACT CARDIOV TH, V14, P565, DOI 10.1093/icvts/ivs028; Rea F, 2008, EUR J CARDIO-THORAC, V34, P488, DOI 10.1016/j.ejcts.2008.05.027; Deslauriers J, 2004, ANN THORAC SURG, V77, P1152, DOI 10.1016/j/athoracsur.2003.07.040; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; ASAMURA H, 1992, J THORAC CARDIOV SUR, V104, P1456; Park JS, 2010, J THORAC ONCOL, V5, P517, DOI 10.1097/JTO.0b013e3181d0a44b; Katayama H, 2004, BRIT J CANCER, V90, P979, DOI 10.1038/sj.bjc.6601624; DAVIS SD, 1992, AM J ROENTGENOL, V159, P1157; Jichen QV, 2009, ANN THORAC SURG, V88, P1589, DOI 10.1016/j.athoracsur.2009.06.024; MAEDA M, 1986, INT SURG, V71, P221; Miyoshi S, 2006, J THORAC CARDIOV SUR, V132, P978, DOI 10.1016/j.jtevs.2006.05.055; Okada M, 1999, J THORAC CARDIOVASC, V118, P13; Okada M, 1999, J THORAC CARDIOV SUR, V118, P710, DOI 10.1016/S0022-5223(99)70017-6; ROSWIT B, 1977, AM J ROENTGENOL, V129, P127; Shiraishi T, 2014, SURG TODAY, V44, P123, DOI 10.1007/s00595-013-0520-x; THOMAS C P, 1956, J R Coll Surg Edinb, V1, P169; Toyooka S, 2013, EUR J CARDIO-THORAC, V43, P568, DOI 10.1093/ejcts/ezs323; Toyooka S, 2013, EUR J CARDIO-THORAC, V43, P182, DOI 10.1093/ejcts/ezs379	22	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1121	1126		10.1007/s00595-014-1025-y		6	Surgery	Surgery	CP1UE	WOS:000359660900006		
J	Kozu, Y; Oh, S; Takamochi, K; Suzuki, K				Kozu, Yoshiki; Oh, Shiaki; Takamochi, Kazuya; Suzuki, Kenji			Surgical outcomes of pulmonary metastases from esophageal carcinoma diagnosed by both pathological and clinical criteria	SURGERY TODAY			English	Article						Esophageal carcinoma; Pulmonary metastasis; Surgical resection; Clinical criteria; Squamous cell carcinoma	SQUAMOUS-CELL CARCINOMA; 2ND PRIMARY TUMORS; COMPLETE RESECTION; COLORECTAL-CARCINOMA; PROGNOSTIC-FACTORS; LUNG METASTASES; NECK; HEAD; CANCER; RECURRENCE	This investigation was performed to examine the surgical outcomes of pulmonary metastases from esophageal carcinoma (EC) diagnosed by both pathological and clinical criteria. Based on the pathological criteria, we identified 22 patients who had undergone pulmonary metastasectomy for EC between 1997 and 2011. Thehistological type of EC was squamous cell carcinoma (SCC) in all patients. After specific clinical criteria were applied, seven patients suspected of having primary lung SCC were excluded. The surgical outcomes of the remaining 15 patients were reviewed. The overall survival (OS) was calculated as the period from pulmonary resection until death or the date of the last follow-up. The 1-, 3- and 4-year OS rates of the 15 patients were 93, 44 and 0 % respectively, with a median OS of 32 months. A larger diameter of the pulmonary metastasis was marginally associated with a poorer OS (p = 0.087); however, none of the parameters were significant prognostic factors. The median OS of patients who underwent surgical resection for pulmonary metastases from EC was comparable to that in previous reports, even after excluding patients clinically suspected of having a second primary lung SCC. The poor long-term survival might indicate that our clinical criteria are helpful in selecting true metastatic patients, considering the aggressive clinical course of metastatic EC.	[Kozu, Yoshiki; Oh, Shiaki; Takamochi, Kazuya; Suzuki, Kenji] Juntendo Univ, Sch Med, Div & Dept Gen Thorac Surg, Bunkyo Ku, Tokyo 1138431, Japan	Suzuki, K (reprint author), Juntendo Univ, Sch Med, Div & Dept Gen Thorac Surg, Bunkyo Ku, 1-3 Hongo 3 Chome, Tokyo 1138431, Japan.	y-kozu@juntendo-urayasu.jp; kjsuzuki@juntendo.ac.jp			Ministry of Health, Labour and Welfare, Japan; Smoking Research Foundation	This work was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare, Japan, and the Smoking Research Foundation.	Leong PP, 1998, J NATL CANCER I, V90, P972, DOI 10.1093/jnci/90.13.972; Geurts TW, 2005, CLIN CANCER RES, V11, P6608, DOI 10.1158/1078-0432.CCR-05-0257; Mariette C, 2003, CANCER, V97, P1616, DOI 10.1002/cncr.11228; Kobayashi Y, 2013, SURG TODAY, V43, P1382, DOI 10.1007/s00595-012-0432-1; Lou FR, 2013, J THORAC ONCOL, V8, P1558, DOI 10.1097/01.JTO.0000437420.38972.fb; Ichikawa H, 2011, SURGERY, V149, P164, DOI 10.1016/j.surg.2010.07.047; Ohba T, 2012, SURG TODAY, V42, P526, DOI 10.1007/s00595-011-0090-8; Abate E, 2010, J AM COLL SURGEONS, V210, P428, DOI 10.1016/j.jamcollsurg.2010.01.006; SCHWARTZ LH, 1994, CANCER, V74, P1933, DOI 10.1002/1097-0142(19941001)74:7<1933::AID-CNCR2820740718>3.0.CO;2-X; Saito Y, 2002, J THORAC CARDIOV SUR, V124, P1007, DOI 10.1067/mtc.2002.125165; Shiono S, 2008, J THORAC ONCOL, V3, P1046, DOI 10.1097/JTO.0b013e318183aa0c; Pfannschmidt J, 2003, J THORAC CARDIOV SUR, V126, P732, DOI 10.1016/S0022-5223(03)000587-7; Chen Fengshi, 2008, Interact Cardiovasc Thorac Surg, V7, P809, DOI 10.1510/icvts.2008.180778; CHUNG KY, 1993, CANCER RES, V53, P1676; FINLEY RK, 1992, AM J SURG, V164, P594, DOI 10.1016/S0002-9610(05)80714-7; Hirosawa T, 2013, SURG TODAY, V43, P494, DOI 10.1007/s00595-012-0373-8; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; Jiao XL, 2002, ANN THORAC SURG, V74, P278, DOI 10.1016/S0003-4975(01)03376-8; JONES AS, 1995, CANCER, V75, P1343, DOI 10.1002/1097-0142(19950315)75:6<1343::AID-CNCR2820750617>3.0.CO;2-T; Kozu Y, 2011, J CARDIOTHORAC SURG, V6, DOI 10.1186/1749-8090-6-135; Matsui T, 2014, SURG TODAY, V44, P702, DOI 10.1007/s00595-013-0769-0; Takemura M, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-103	22	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1127	1133		10.1007/s00595-014-1036-8		7	Surgery	Surgery	CP1UE	WOS:000359660900007		
J	Mikami, J; Kurokawa, Y; Miyazaki, Y; Takahashi, T; Yamasaki, M; Miyata, H; Nakajima, K; Takiguchi, S; Mori, M; Doki, Y				Mikami, Jota; Kurokawa, Yukinori; Miyazaki, Yasuhiro; Takahashi, Tsuyoshi; Yamasaki, Makoto; Miyata, Hiroshi; Nakajima, Kiyokazu; Takiguchi, Shuji; Mori, Masaki; Doki, Yuichiro			Postoperative gastrectomy outcomes in octogenarians with gastric cancer	SURGERY TODAY			English	Article						Gastric cancer; Gastrectomy; Elderly patient; Older persons; Oldest-old persons	QUALITY-OF-LIFE; ELDERLY-PATIENTS; DISTAL GASTRECTOMY; SURGERY; COMPLICATIONS; MORTALITY; PROGNOSIS; MORBIDITY; AGE	It is controversial whether the treatment strategy for gastric cancer should be different for elderly patients. We herein evaluated the feasibility of gastrectomy and the risk factors for postoperative complications in octogenarians with gastric cancer. We retrospectively collected data on 441 consecutive patients who underwent total or subtotal gastrectomy for gastric cancer. We divided all of the patients into two groups: the octogenarian group (n = 47), consisting of patients aged 80-89 years, and the younger group (n = 394), consisting of patients under 80 years of age. The postoperative complication rate was 23.1 % (91/394) in the younger group and 36.2 % (17/47) in the octogenarian group (P = 0.049). Octogenarian patients had significantly lower preoperative serum albumin levels (P < 0.001) and higher ASA scores (P < 0.001). Although the rate of each major complication was similar between the two groups, there was a trend toward a higher rate of other miscellaneous complications, mostly non-surgical complications, in the octogenarian group (P = 0.077). A multivariate analysis of the patients in the octogenarian group revealed that only total gastrectomy was a significant risk factor for postoperative complications (P = 0.035). Octogenarian patients with gastric cancer experienced more complications than younger patients. Therefore, closer monitoring is needed for octogenarian patients who will receive total gastrectomy.	[Mikami, Jota; Kurokawa, Yukinori; Miyazaki, Yasuhiro; Takahashi, Tsuyoshi; Yamasaki, Makoto; Miyata, Hiroshi; Nakajima, Kiyokazu; Takiguchi, Shuji; Mori, Masaki; Doki, Yuichiro] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Osaka, Japan	Kurokawa, Y (reprint author), Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Osaka, Japan.	ykurokawa@gesurg.med.osaka-u.ac.jp					Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Endo S, 2011, GASTRIC CANCER, V14, P139, DOI 10.1007/s10120-011-0022-8; Katai H, 2004, SURG ONCOL, V13, P235, DOI 10.1016/j.suronc.2004.09.007; Kumagai K, 2012, SURG TODAY, V42, P411, DOI 10.1007/s00595-012-0159-z; Hayashi T, 2012, WORLD J SURG, V36, P2139, DOI 10.1007/s00268-012-1653-6; Saif MW, 2010, EJSO-EUR J SURG ONC, V36, P709, DOI 10.1016/j.ejso.2010.05.023; Takeshita H, 2013, WORLD J SURG, V37, P2891, DOI 10.1007/s00268-013-2210-7; Park DJ, 2005, BRIT J SURG, V92, P1099, DOI 10.1002/bjs.4952; Hotta T, 2001, SURG TODAY, V31, P774; Liang YX, 2013, WORLD J GASTROENTERO, V19, P6568, DOI 10.3748/wjg.v19.i39.6568; Pisanu A, 2007, TUMORI, V93, P478; Orsenigo E, 2007, GASTRIC CANCER, V10, P39, DOI 10.1007/s10120-006-0409-0; Gretschel S, 2006, WORLD J SURG, V30, P1468, DOI 10.1007/s00268-005-0633-5; Gunther K, 2000, SURG TODAY, V30, P700; Imano M, 2014, SURG TODAY, V44, P399, DOI 10.1007/s00595-013-0603-8; Japanese Gastric Cancer Association, 2011, GASTRIC CANCER, V14, P113, DOI [10.1007/s10120-011-0042-4, DOI 10.1007/S10120-011-0042-4]]; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Kumagai K, 2014, GASTRIC CANCER, V17, P548, DOI 10.1007/s10120-013-0292-4; Matsushita I, 2002, J CLIN GASTROENTEROL, V35, P29, DOI 10.1097/01.MCG.0000017268.40643.2A; Ramesh HS, 2005, WORLD J SURG ONCOL, V3, P17, DOI 10.1186/1477-7819-3-17; Sasada S, 2008, HEPATO-GASTROENTEROL, V55, P1931; Takayama T, 2014, SURG TODAY IN PRESS; UN, 2009, WORLD POP AG; World health organization, 2004, CAUS OF DEATH	24	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1134	1138		10.1007/s00595-014-1087-x		5	Surgery	Surgery	CP1UE	WOS:000359660900008		
J	Omura, N; Yano, F; Tsuboi, K; Hoshino, M; Yamamoto, SR; Akimoto, S; Ishibashi, Y; Kashiwagi, H; Yanaga, K				Omura, Nobuo; Yano, Fumiaki; Tsuboi, Kazuto; Hoshino, Masato; Yamamoto, Se Ryung; Akimoto, Shunsuke; Ishibashi, Yoshio; Kashiwagi, Hideyuki; Yanaga, Katsuhiko			Short-term surgical outcomes of reduced port surgery for esophageal achalasia	SURGERY TODAY			English	Article						Esophageal achalasia; Reduced port surgery; Single-incision laparoscopic surgery; Surgical outcome; Laparoscopic myotomy	LAPAROSCOPIC HELLER MYOTOMY; SINGLE-INCISION; DOR FUNDOPLICATION; METAANALYSIS; EXPERIENCE	To clarify the feasibility and utility of reduced port surgery (RPS) for achalasia. Between September 2005 and June 2013, 359 patients with esophageal achalasia, excluding cases of reoperation, underwent laparoscopic Heller myotomy and Dor fundoplication (LHD) according to our clinical pathway. Three-hundred and twenty-seven patients underwent LHD with five incisions (conventional approach), while the other 32 patients underwent RPS, including eight via SILS. The clinical data were collected in a prospective fashion and retrospectively reviewed. We selected 24 patients matched for gender, age and morphologic type with patients in the RPS group from among the 327 patients (C group). The surgical outcomes were compared between the C and RPS groups. There were no significant differences between the two groups in the duration of symptoms, dysphagia score, chest pain score, shape of the distal esophagus and esophageal clearance. The operative time was significantly longer in the RPS group than in the C group (p < 0.001). There were no significant differences between the two groups in the length of postoperative hospital stay or rates of bleeding, mucosal injury of the esophagus and/or stomach and postoperative complications. The symptom scores significantly improved after surgery in both groups (p < 0.001). Furthermore, there were no significant differences between the C group and RPS group in terms of the postoperative symptom scores or satisfaction scores after surgery. The surgical outcomes of RPS for achalasia are comparable to those obtained with the conventional method.	[Omura, Nobuo; Yano, Fumiaki; Tsuboi, Kazuto; Hoshino, Masato; Yamamoto, Se Ryung; Akimoto, Shunsuke; Ishibashi, Yoshio; Kashiwagi, Hideyuki; Yanaga, Katsuhiko] Jikei Univ, Dept Surg, Sch Med, Minato Ku, Tokyo 1058461, Japan	Omura, N (reprint author), Jikei Univ, Dept Surg, Sch Med, Minato Ku, 3-25-8 Nishishinbashi, Tokyo 1058461, Japan.	surgomura@jikei.ac.jp					Omura N, 2011, SURG ENDOSC, V25, P1048, DOI 10.1007/s00464-010-1314-5; Khajanchee YS, 2005, ARCH SURG-CHICAGO, V140, P827, DOI 10.1001/archsurg.140.9.827; Qiu JG, 2013, J LAPAROENDOSC ADV S, V23, P815, DOI 10.1089/lap.2013.0040; Cai YL, 2013, WORLD J GASTROENTERO, V19, P5165, DOI 10.3748/wjg.v19.i31.5165; Zaninotto G, 2008, ANN SURG, V248, P986, DOI 10.1097/SLA.0b013e3181907bdd; Mattioli S, 2010, J THORAC CARDIOV SUR, V140, P962, DOI 10.1016/j.jtcvs.2010.07.053; Fan Y, 2014, J SURG RES, V186, P354, DOI 10.1016/j.jss.2013.09.010; Kwag SJ, 2013, AM J SURG, V206, P320, DOI 10.1016/j.amjsurg.2012.11.007; Barry L, 2011, SURG ENDOSC, V25, P1766, DOI 10.1007/s00464-010-1454-7; Burpee SE, 2005, SURG ENDOSC, V19, P9, DOI 10.1007/s00464-004-8932-8; Katada N, 2014, SURG TODAY, V44, P732, DOI 10.1007/s00595-013-0640-3; Kobayashi M, 2011, J PEDIATR SURG, V46, P2200, DOI 10.1016/j.jpedsurg.2011.07.027; Kostic SV, 2000, J THORAC CARDIOV SUR, V120, P935, DOI 10.1067/mtc.2000.110463; Mittermair R, 2013, J MINIM ACCESS SURG, V9, P104, DOI 10.4103/0972-9941.115367; Miyazaki Y, 2014, SURG TODAY, V44, P668, DOI 10.1007/s00595-013-0617-2; Nakajima J, 2011, SURG TODAY, V41, P1543, DOI 10.1007/s00595-010-4533-4; Omura N, 2006, SURG ENDOSC, V20, P210, DOI 10.1007/s00464-005-0365-5; Rossetti G, 2005, ANN SURG, V241, P614, DOI 10.1097/01.sla.0000157271.69192.96; SHIMI S, 1991, Journal of the Royal College of Surgeons of Edinburgh, V36, P152; Takata Akihiro, 2014, Asian J Endosc Surg, V7, P25, DOI 10.1111/ases.12069; Tsiaoussis J, 2007, AM J SURG, V193, P26, DOI 10.1016/j.amjsurg.2006.10.008; Yamada Hidehisa, 2013, Int J Surg Case Rep, V4, P1, DOI 10.1016/j.ijscr.2012.09.003; Yano Fumiaki, 2012, Surg Today, V42, P299, DOI 10.1007/s00595-011-0089-1	23	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1139	1143		10.1007/s00595-014-1109-8		5	Surgery	Surgery	CP1UE	WOS:000359660900009		
J	Nishi, H; Miyata, H; Motomura, N; Toda, K; Miyagawa, S; Sawa, Y; Takamoto, S				Nishi, Hiroyuki; Miyata, Hiroaki; Motomura, Noboru; Toda, Koichi; Miyagawa, Shigeru; Sawa, Yoshiki; Takamoto, Shinichi			Propensity-matched analysis of minimally invasive mitral valve repair using a nationwide surgical database	SURGERY TODAY			English	Article						Mitral valve; Surgery; Valvular diseases	STERNOTOMY APPROACH; CARDIAC-SURGERY; PORT-ACCESS; REGURGITATION; OPERATIONS; OUTCOMES; RECONSTRUCTION; SOCIETY; VOLUME; JAPAN	The aim of this study was to compare the cases of minimally invasive mitral valve surgery (MICS-mitral) performed using right mini-thoracotomy (RT) with those performed using median sternotomy (MS). Between 2008 and 2012, 6137 patients underwent isolated mitral valve repair at 210 institutions and were registered in the Japan Adult Cardiovascular Surgery Database. We compared 756 who underwent MICS-mitral via RT to 5381 MS patients and performed a one-to-one matched analysis based on the estimated propensity score. The in-hospital mortality was similar between both groups (RT vs. MS: 0.5 vs. 1.1 %). Although the incidence of postoperative stroke, renal failure, and prolonged ventilation was similar, the number of patients with mediastinitis was greater in the MS group (RT vs. MS: 0 vs. 0.7 %, p < 0.01). Reexploration for bleeding was more frequent in the RT group (RT vs. MS: 2.9 vs. 1.4 %, p < 0.01). Mortality and morbidity occurred at a higher rate in low-volume institutions. The propensity analysis showed that the operation-related times were significantly longer in the RT group, while the length of hospital stay was shorter. In a propensity analysis of patients < 60 years of age, there was no in-hospital mortality. MICS-mitral via RT was successful without compromising the clinical outcomes. Although the operation time and postoperative bleeding should be improved, an RT approach is safe in appropriately selected patients, especially those < 60 years of age or treated in a high-volume center.	[Nishi, Hiroyuki; Toda, Koichi; Miyagawa, Shigeru; Sawa, Yoshiki] Osaka Univ, Dept Cardiovasc Surg, Grad Sch Med, Suita, Osaka 5650871, Japan; [Miyata, Hiroaki; Motomura, Noboru; Takamoto, Shinichi] Japan Cardiovasc Surg Database Org, Tokyo, Japan	Sawa, Y (reprint author), Osaka Univ, Dept Cardiovasc Surg, Grad Sch Med, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	sawa-p@surg1.med.osaka-u.ac.jp					Amano Jun, 2013, Gen Thorac Cardiovasc Surg, V61, P578, DOI 10.1007/s11748-013-0289-2; Dogan S, 2005, ANN THORAC SURG, V79, P492, DOI 10.1016/j.athoracsur.2004.08.066; Goldstone AB, 2013, J THORAC CARDIOV SUR, V145, P748, DOI 10.1016/j.jtcvs.2012.09.093; Cohn LH, 1997, ANN SURG, V226, P421, DOI 10.1097/00000658-199710000-00003; Novick RJ, 2002, ANN THORAC SURG, V73, P358; Mohr FW, 1998, J THORAC CARDIOV SUR, V115, P567, DOI 10.1016/S0022-5223(98)70320-4; Galloway AC, 2009, ANN THORAC SURG, V88, P1180, DOI 10.1016/j.athoracsur.2009.05.023; Motomura N, 2008, ANN THORAC SURG, V86, P1866, DOI 10.1016/j.athoracsur.2008.08.001; Holzhey DM, 2013, CIRCULATION, V128, P483, DOI 10.1161/CIRCULATIONAHA.112.001402; Gammie JS, 2010, ANN THORAC SURG, V90, P1401, DOI 10.1016/j.athoracsur.2010.05.055; Woo YJ, 2006, SURGERY, V140, P263, DOI 10.1016/j.surg.2006.05.003; Modi P, 2008, EUR J CARDIO-THORAC, V34, P943, DOI 10.1016/j.ejcts.2008.07.057; Schmitto JD, 2010, J AM COLL CARDIOL, V56, P455, DOI 10.1016/j.jacc.2010.03.053; Enriquez-Sarano M, 2005, NEW ENGL J MED, V352, P875, DOI 10.1056/NEJMoa041451; McClure RS, 2013, J THORAC CARDIOV SUR, V145, P1199, DOI 10.1016/j.jtcvs.2012.12.070; Svensson LG, 2010, J THORAC CARDIOV SUR, V139, P926, DOI 10.1016/j.jtcvs.2009.09.038; Beckmann A, 2014, THORAC CARDIOV SURG, V62, P5, DOI 10.1055/s-0033-1361953; Casselman FP, 2003, CIRCULATION, V108, P48, DOI 10.1161/01.cir.0000087391.49121.ce; Cheng Davy C H, 2011, Innovations (Phila), V6, P84, DOI 10.1097/IMI.0b013e3182167feb; Falk Volkmar, 2011, Innovations (Phila), V6, P66, DOI 10.1097/IMI.0b013e318216be5c; Grossi EA, 2001, J THORAC CARDIOV SUR, V121, P708, DOI 10.1067/mtc.2001.112626; Holzhey DM, 2011, ANN THORAC SURG, V91, P401, DOI 10.1016/j.athoracsur.2010.08.006; Iribarne A, 2010, ANN THORAC SURG, V90, P1471, DOI 10.1016/j.athoracsur.2010.06.034; Jiang ZL, 2014, SURG TODAY, V44, P2086, DOI 10.1007/s00595-013-0816-x; Manabe S, 2013, CIRC J, V77, P2038, DOI 10.1253/circj.CJ-12-1600; Miyata H, 2008, J THORAC CARDIOV SUR, V135, P1306, DOI 10.1016/j.jtcvs.2007.10.079; Murashita T, 2013, CIRC J, V77, P2050, DOI 10.1253/circj.CJ-13-0089; Richardson Lydia, 2008, Interact Cardiovasc Thorac Surg, V7, P678, DOI 10.1510/icvts.2008.180182; Suri RM, 2012, CURR CARDIOL REP, V14, P171, DOI 10.1007/s11886-011-0244-8; Woo Y Joseph, 2007, Semin Thorac Cardiovasc Surg, V19, P289, DOI 10.1053/j.semtcvs.2007.10.005	30	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1144	1152		10.1007/s00595-015-1210-7		9	Surgery	Surgery	CP1UE	WOS:000359660900010		
J	Tachibana, K; Higami, T; Miyaki, Y; Nakagima, T; Ito, T; Takagi, N				Tachibana, Kazutoshi; Higami, Tetsuya; Miyaki, Yasuko; Nakagima, Tomohiro; Ito, Toshiro; Takagi, Nobuyuki			Impact of novel intraoperative evaluation for mitral valve regurgitation: the retrograde cardio-protective beating test	SURGERY TODAY			English	Article						Mitral valvuloplasty; Mitral valve regurgitation; Intraoperative evaluation; Beating heart	BLOOD CARDIOPLEGIA; MYOCARDIAL PROTECTION; LEAFLET PROLAPSE; REPAIR; SURGERY; SURVIVAL; HEART; WARM	The saline injection test is commonly employed during mitral valvuloplasty. However, discrepancies in regurgitation between the naked eye findings during the saline injection test and the postoperative echocardiographic findings have been noted. Here, we describe the new retrograde cardio-protective beating test (RC-beating test) which allows direct transatrial evaluation of the valve in the fully loaded, beating heart under cross-clamping by means of the retrograde perfusion of warm oxygenated blood into the coronary sinus. From January 2006 to June 2012, 63 patients (mean age, 59 +/- A 15 years) with degenerative mitral valve regurgitation underwent mitral valve repair with application of this novel evaluation. In 20 of the 63 patients (31.8 %), minor residual leaks that were not remarkable in the saline injection test were detected during the RC-beating test and were completely corrected. Almost all patients (n = 61, 96.8 %) revealed no mitral regurgitation on intraoperative transesophageal echocardiography. The results of the RC-beating test were satisfactory, and discrepancies were not recognized at all between this evaluation and the postoperative echocardiographic findings. The ultrastructure of the mitochondria showed significant myocardial preservation. The RC-beating test is a simpler and more accurate evaluation for mitral valve repair than the saline injection test. This novel evaluation enables a safe and more complete mitral valve repair.	[Tachibana, Kazutoshi; Higami, Tetsuya; Miyaki, Yasuko; Nakagima, Tomohiro; Ito, Toshiro; Takagi, Nobuyuki] Sapporo Med Univ & Hosp, Dept Cardiovasc Surg, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	Tachibana, K (reprint author), Sapporo Med Univ & Hosp, Dept Cardiovasc Surg, Chuo Ku, S-1 W-16, Sapporo, Hokkaido 0608543, Japan.	aad72150@pop17.odn.ne.jp					CARPENTIER A, 1983, J THORAC CARDIOV SUR, V86, P323; JENNINGS RB, 1974, CIRC RES, V35, P156; Suri RM, 2006, ANN THORAC SURG, V82, P819, DOI 10.1016/j.athoracsur.2006.03.091; Castillo JG, 2012, J THORAC CARDIOV SUR, V144, P308, DOI 10.1016/j.jtcvs.2011.12.054; FLAMENG W, 1980, J THORAC CARDIOV SUR, V79, P413; ANTUNES MJ, 1992, EUR J CARDIO-THORAC, V6, pS13, DOI 10.1016/1010-7940(92)90016-Q; BECK CS, 1948, JAMA-J AM MED ASSOC, V137, P436; Bezon Eric, 2006, Interact Cardiovasc Thorac Surg, V5, P403, DOI 10.1510/icvts.2006.131276; Deja MA, 2009, J THORAC CARDIOV SUR, V137, P997, DOI 10.1016/j.jtcvs.2008.08.068; FIX J, 1993, CIRCULATION, V88, P39; Flameng WJ, 2003, J THORAC CARDIOV SUR, V125, P121, DOI 10.1067/mtc.2003.77; Gogbashian A, 2006, AM HEART J, V151, P1325, DOI 10.1016/j.ahj.2005.07.003; Guyton A.C., 2000, TXB MED PHYSL, P223; Kasegawa H, 2006, ANN THORAC SURG, V81, P1625, DOI 10.1016/j.athoracsur.2005.11.032; Louagie YAG, 2004, ANN THORAC SURG, V77, P664, DOI 10.1016/S0003-4975(03)01522-4; Nonaka M, 2008, EUR J CARDIO-THORAC, V34, P755, DOI 10.1016/j.ejcts.2008.04.052; RAINIO P, 1995, J THORAC CARDIOV SUR, V110, P81, DOI 10.1016/S0022-5223(05)80012-1; Tachibana K, 2013, EUR J CARDIO-THORAC, V44, P375, DOI 10.1093/ejcts/ezs691; TASDEMIR O, 1993, ANN THORAC SURG, V56, P305	19	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1153	1159		10.1007/s00595-014-1062-6		7	Surgery	Surgery	CP1UE	WOS:000359660900011		
J	Murakami, K; Naka, S; Shiomi, H; Akabori, H; Kurumi, Y; Morikawa, S; Tani, T				Murakami, Koichiro; Naka, Shigeyuki; Shiomi, Hisanori; Akabori, Hiroya; Kurumi, Yoshimasa; Morikawa, Shigehiro; Tani, Tohru			Initial experiences with MR Image-guided laparoscopic microwave coagulation therapy for hepatic tumors	SURGERY TODAY			English	Article						Microwave; Liver; Ablation; Magnetic resonance; Laparoscopy	HEPATOCELLULAR-CARCINOMA; LIVER-TUMORS; RADIOFREQUENCY ABLATION; THERMOCOAGULATION; DEVICES; TISSUE; SYSTEM	Percutaneous thermal ablation is used for treating hepatic tumors. Recent advances in laparoscopy and imaging modalities have led to the development of a novel image-guided minimally invasive loco-regional treatment. The aim of this trial was to apply laparoscopic assistance to magnetic resonance (MR) image-guided thermoablation instead of ultrasonography, because of its various advantages. Patients with hepatic tumors and liver cirrhosis underwent magnetic resonance (MR) image-guided laparoscopic microwave coagulation therapy using a borescope and endoscopic forceps. Six cases of laparoscopic microwave coagulation treatment using MR image guidance were successfully performed between January 2000 and December 2008. Tumors were detected, punctured, and ablated in an open-configured MR scanner. A total of nine hepatocellular carcinoma nodules were preoperatively identified in S3, S5 and S6 (mean diameter = 20.8 +/- A 5.4 mm). MR-guided microwave coagulation was laparoscopically achieved in all patients without any significant complications that required invasive treatment. The mean length of the operation was 275.3 +/- A 60.5 min, and the mean postsurgical hospital stay was 10.0 +/- A 2.3 days. Postoperative confirmation scanning was performed without moving the patients. MR-guided laparoscopic microwave coagulation therapy is an effective treatment for hepatic tumors adjacent to other organs, as it allows for more accurate detection of lesions and for tumors to be treated safely while avoiding adjacent organs. It is less invasive than conventional procedures, because the MR real-time guidance enabled continuous monitoring throughout the procedure.	[Murakami, Koichiro; Tani, Tohru] Shiga Univ Med Sci, Biomed Innovat Ctr, Otsu, Shiga 5022121, Japan; [Murakami, Koichiro; Naka, Shigeyuki; Shiomi, Hisanori; Akabori, Hiroya] Shiga Univ Med Sci, Dept Surg, Otsu, Shiga 5022121, Japan; [Kurumi, Yoshimasa] Shiga Univ Med Sci, Dept Comprehens Surg, Otsu, Shiga 5022121, Japan; [Morikawa, Shigehiro] Shiga Univ Med Sci, Dept Fundamental Nursing, Otsu, Shiga 5022121, Japan	Murakami, K (reprint author), Shiga Univ Med Sci, Biomed Innovat Ctr, Seta Tsukinowa Cho, Otsu, Shiga 5022121, Japan.	emkami@belle.shiga-med.ac.jp					Jolesz FA, 1998, JMRI-J MAGN RESON IM, V8, P8, DOI 10.1002/jmri.1880080105; Simo KA, 2011, J SURG ONCOL, V104, P822, DOI 10.1002/jso.21933; Seki S, 2005, ENDOSCOPY, V37, P1220, DOI 10.1055/s-921035; MURAKAMI R, 1995, AM J ROENTGENOL, V164, P1159; Poon RTP, 2002, ANN SURG, V235, P466, DOI 10.1097/00000658-200204000-00004; Ido K, 2001, J GASTROENTEROL, V36, P145, DOI 10.1007/s005350170121; Brace Christopher L., 2010, Critical Reviews in Biomedical Engineering, V38, P65; Imura S, 2014, SURG TODAY, V44, P1214, DOI 10.1007/s00595-013-0668-4; Laeseke PF, 2009, J VASC INTERV RADIOL, V20, P1224, DOI 10.1016/j.jvir.2009.05.029; Shiomi H, 2008, AM J SURG, V195, P854, DOI 10.1016/j.amjsurg.2007.08.056; Cillio U, 2013, PLOS ONE, V8, P1; Gilbert JC, 1997, EUR RADIOL, V7, P1165; Head HW, 2004, GASTROENTEROLOGY, V127, P167; Kurumi Y, 2007, INT J CLIN ONCOL, V12, P85, DOI 10.1007/s10147-006-0653-7; Mack MG, 2001, ABDOM IMAGING, V26, P369, DOI 10.1007/s002610000197; Morikawa S, 2003, ACAD RADIOL, V10, P1442, DOI 10.1016/S1076-6332(03)00508-7; Morikawa S, 2002, J MAGN RESON IMAGING, V16, P576, DOI 10.1002/jmri.10198; Morikawa S, 2004, CARDIOVASC INTER RAD, V27, P370, DOI 10.1007/s00270-003-0079-9; Morikawa S, 2003, ACAD RADIOL, V10, P180, DOI 10.1016/S1076-6332(03)80043-0; MOSCATEL MA, 1995, JMRI-J MAGN RESON IM, V5, P369, DOI 10.1002/jmri.1880050324; Mukaisho K, 2002, DIGEST DIS SCI, V47, P2441, DOI 10.1023/A:1020539421508; Murakami Koichiro, 2008, Magn Reson Med Sci, V7, P105, DOI 10.2463/mrms.7.105; Ng KK, 2005, SURG ONCOL, V14, P41, DOI 10.1016/j.suronc.2005.01.001; Okamoto T, 2014, SURG TODAY; Rossi S, 1995, Cancer J Sci Am, V1, P73; Santambrogio R, 2008, J Ultrasound, V11, P1, DOI 10.1016/j.jus.2007.12.003; Sato Koichiro, 2005, Magn Reson Med Sci, V4, P89, DOI 10.2463/mrms.4.89; Seifert JK, 1998, J ROY COLL SURG EDIN, V43, P141; Stattner S, 2014, SURG TODAY; Tabuse K, 1979, Nihon Geka Hokan, V48, P160; Yamaguchi T, 2005, DIGEST DIS SCI, V50, P1347, DOI 10.1007/s10620-005-2786-3	31	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1173	1178		10.1007/s00595-014-1042-x		6	Surgery	Surgery	CP1UE	WOS:000359660900014		
J	Taniguchi, T; Kawaguchi, K; Fukui, T; Nishimura, M; Yokoi, K				Taniguchi, Tetsuo; Kawaguchi, Koji; Fukui, Takayuki; Nishimura, Masashi; Yokoi, Kohei			Primary malignant melanoma of the thymus: report of a case	SURGERY TODAY			English	Article						Malignant melanoma; Mediastinum; Positron emission tomography		A 61-year-old male was admitted to our hospital complaining of bloody sputum. A chest roentgenogram revealed a clearly demarcated mass located in the anterior mediastinum. Positron emission tomography revealed abnormal accumulation of F-18-fluorodeoxy glucose only in the anterior mediastinal tumor. A computed tomography-guided needle aspiration biopsy was performed, and the tumor was diagnosed as a malignant melanoma. Although the skin, eyeballs, oral cavity, nasal cavity, etc., were closely evaluated, no other lesion of malignant melanoma was detected except the mediastinal tumor. Hence, this tumor was diagnosed as a primary malignant melanoma. We performed total thymectomy, including the tumor, and combined resection of the adhesive bilateral lungs, pericardium and left brachiocephalic vein. Because the tumor was histologically surrounded by thymus tissue, we diagnosed it as a primary mediastinal malignant melanoma that originated in the thymus. Although the patient's postoperative course was uneventful, he complained of back pain 5 months after the operation. Multiple bone metastases were found, and he received chemotherapy and radiotherapy, and is currently alive with disease 14 months after the primary treatment.	[Taniguchi, Tetsuo; Kawaguchi, Koji; Fukui, Takayuki; Yokoi, Kohei] Nagoya Univ, Grad Sch Med, Dept Thorac Surg, Showa Ku, Nagoya, Aichi 4668550, Japan; [Nishimura, Masashi] Tosei Gen Hosp, Dept Thorac Surg, Seto, Japan	Taniguchi, T (reprint author), Nagoya Univ, Grad Sch Med, Dept Thorac Surg, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	ttani@med.nagoya-u.ac.jp					Bichakjian CK, 2011, J AM ACAD DERMATOL, V65, P1032, DOI 10.1016/j.jaad.2011.04.031; DASGUPTA TK, 1969, SURG GYNECOL OBSTETR, V128, P841; Karuppiah Saravana V, 2006, Jpn J Thorac Cardiovasc Surg, V54, P396, DOI 10.1007/s11748-006-0004-7; Moehrle M, 2001, EUR J OBSTET GYN R B, V99, P268, DOI 10.1016/S0301-2115(01)00407-9; Parker JR, 1999, MODERN PATHOL, V12, P329; Shimizu J, 2000, AUST NZ J SURG, V70, P753, DOI 10.1046/j.1440-1622.2000.01952.x; Vlodavsky E, 2000, AM J SURG PATHOL, V24, P747, DOI 10.1097/00000478-200005000-00015; Wilson RW, 1997, AM J SURG PATHOL, V21, P196	8	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1187	1189		10.1007/s00595-014-0998-x		3	Surgery	Surgery	CP1UE	WOS:000359660900016		
J	Kashiyama, N; Toda, K; Miyagawa, S; Nishi, H; Yoshikawa, Y; Fukushima, S; Yoshioka, D; Masashi, K; Saito, T; Sawa, Y				Kashiyama, Noriyuki; Toda, Koichi; Miyagawa, Shigeru; Nishi, Hiroyuki; Yoshikawa, Yasushi; Fukushima, Satsuki; Yoshioka, Daisuke; Masashi, Kawamura; Saito, Tetsuya; Sawa, Yoshiki			Off-pump coronary artery bypass grafting via median sternotomy in a patient with a history of esophagectomy with substernal gastric tube reconstruction: report of a case	SURGERY TODAY			English	Article						OPCAB; Esophagectomy; Substernal gastric tube reconstruction		We performed successful off-pump coronary artery bypass grafting (OPCAB) in a patient with unstable angina caused by triple-vessel disease, who had undergone esophagectomy with substernal gastric tube reconstruction for esophageal cancer 40 years earlier. Preoperative multidetector-row computed tomography was done to evaluate the course of the gastric tube and also that of the gastroepiploic artery, which feeds the gastric tube. Following careful sternal re-entry and adequate dissection, OPCAB was performed safely via a median sternotomy without injuring the gastric tube or causing hemodynamic instability. The patient had an uneventful early postoperative course.	[Kashiyama, Noriyuki; Toda, Koichi; Miyagawa, Shigeru; Nishi, Hiroyuki; Yoshikawa, Yasushi; Fukushima, Satsuki; Yoshioka, Daisuke; Masashi, Kawamura; Saito, Tetsuya; Sawa, Yoshiki] Osaka Univ, Grad Sch Med, Dept Cardiovasc Surg, Suita, Osaka 5650087, Japan	Sawa, Y (reprint author), Osaka Univ, Grad Sch Med, Dept Cardiovasc Surg, Yamadaoka 2-2, Suita, Osaka 5650087, Japan.	sawa-p@surg1.med.osaka-u.ac.jp					Oezcelik A, 2013, J GASTROINTEST SURG, V17, P1032, DOI 10.1007/s11605-013-2177-6; Hirose H, 1999, EUR J CARDIO-THORAC, V15, P729, DOI 10.1016/S1010-7940(99)00065-2; Iemura J, 2000, JPN CIRC J, V64, P404, DOI 10.1253/jcj.64.404; Iida M, 2014, ANN THORAC CARDIOVAS, V20, P754, DOI 10.5761/atcs.cr.12.01968; Nishi H, 2009, ANN THORAC SURG, V88, P667, DOI 10.1016/j.athoracsur.2008.12.077; Safi H J, 1994, Cardiovasc Surg, V2, P415; TAJIMA K, 1993, ANN THORAC SURG, V55, P625; Zhang YY, 2012, CHINESE MED J-PEKING, V125, P2062, DOI 10.3760/ema.j.issn.0366-6999.2012.11.039	8	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1190	1193		10.1007/s00595-014-1057-3		4	Surgery	Surgery	CP1UE	WOS:000359660900017		
J	Haratake, N; Yamazaki, K; Shikada, Y				Haratake, Naoki; Yamazaki, Koji; Shikada, Yasunori			Diaphragmatic hernia caused by heterotopic endometriosis in Chilaiditi syndrome: report of a case	SURGERY TODAY			English	Article						Diaphragm hernias; Endometriosis; Chilaiditi syndrome		A 50-year-old Japanese female was admitted to our hospital because of ileus due to Chilaiditi syndrome. Her symptoms did not improve with conservative therapy, so chest and abdominal computed tomography (CT) was performed on the fifth day after hospital admission. A diagnosis of incarceration of a right diaphragmatic hernia was established in the coronal view of CT, and emergency surgery was performed. A dilated loop of small intestine was seen in the right thoracic cavity, which was strangulated by the 2-cm defect in the diaphragm. Primary closure of the diaphragm was performed. Approximately 80 cm of the terminal ileum showed obvious ischemic changes, and it was cut and reconstructed. Postoperatively, the patient made an uneventful recovery and was discharged on the 15th postoperative day. A histological examination of the specimen of the diaphragm around the hernia orifice showed the presence of a small cystiform glandular system with hemorrhage and congestion. These findings indicated that heterotopic endometriosis was present in the diaphragm. This report describes the first known case of right diaphragmatic hernia secondary to heterotopic endometriosis in a patient with Chilaiditi syndrome. The clinical course and management of affected patients and a literature review of these three unusual conditions are discussed.	[Haratake, Naoki; Yamazaki, Koji; Shikada, Yasunori] Saiseikai Fukuoka Gen Hosp, Dept Gen Surg, Fukuoka 8100001, Japan	Haratake, N (reprint author), Saiseikai Fukuoka Gen Hosp, Dept Gen Surg, Fukuoka 8100001, Japan.	nao_para169km@yahoo.co.jp					Chatra Priyank S, 2012, J Radiol Case Rep, V6, P25, DOI 10.3941/jrcr.v6i1.614; Cooper MJW, 1999, MED J AUSTRALIA, V171, P142; Hanna WC, 2008, ANN THORAC SURG, V85, P1044, DOI 10.1016/j.athoracsur.2007.10.084; NEWMAN BM, 1986, ARCH SURG-CHICAGO, V121, P813; Soufi M, 2013, WORLD J EMERG SURG, V8, DOI 10.1186/1749-7922-8-2	5	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1194	1196		10.1007/s00595-014-1001-6		3	Surgery	Surgery	CP1UE	WOS:000359660900018		
J	Sakamoto, K; Ando, K; Noma, D				Sakamoto, Kazuhiro; Ando, Kohei; Noma, Daisuke			Pulmonary chondromatous hamartoma with pleural dissemination: report of a case	SURGERY TODAY			English	Article						Thoracoscopy; Pleura; Lung benign lesion		We herein describe a very rare case of pulmonary hamartoma with pleural dissemination. A 77-year-old male was referred to our department for a further investigation of an abnormal chest radiograph. Chest computed tomography showed a 15 mm nodule in the left lung with small pleural nodules. Thoracoscopic resection of the nodules was performed, as the possibility of malignancy could not be ruled out. The intraoperative findings revealed a white nodule with a lumpy surface in the left lower lobe that had penetrated the visceral pleura. Several smaller nodules were found on the pleural surface. Pathologically, the pulmonary and pleural nodules were chondromatous hamartomas.	[Sakamoto, Kazuhiro; Ando, Kohei; Noma, Daisuke] Natl Hosp Org Yokohama Med Ctr, Dept Resp Surg, Totsuka Ku, Yokohama, Kanagawa 2458575, Japan	Sakamoto, K (reprint author), Natl Hosp Org Yokohama Med Ctr, Dept Resp Surg, Totsuka Ku, 3-60-2 Harajuku, Yokohama, Kanagawa 2458575, Japan.	yksakamoto2@yahoo.co.jp					Amano Jun, 2013, Gen Thorac Cardiovasc Surg, V61, P578, DOI 10.1007/s11748-013-0289-2; HANSEN CP, 1992, J THORAC CARDIOV SUR, V104, P674; Iguchi K, 2007, JJLC, V47, P285; Smith MA, 2006, ANN THORAC SURG, V81, P1824, DOI 10.1016/j.athoracsur.2005.11.010; Teramoto K, 2007, SURG TODAY, V37, P1087, DOI 10.1007/s00595-007-3552-2; Tomiyasu Makiko, 2002, Ann Thorac Cardiovasc Surg, V8, P42	6	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1197	1199		10.1007/s00595-014-1006-1		3	Surgery	Surgery	CP1UE	WOS:000359660900019		
J	Arai, H; Rino, Y; Fushimi, K; Goda, M; Yoshioka, E; Okudela, K; Yukawa, N; Masuda, M				Arai, Hiromasa; Rino, Yasushi; Fushimi, Ken-ichi; Goda, Masami; Yoshioka, Emi; Okudela, Koji; Yukawa, Norio; Masuda, Munetaka			Pericardial ectopic thymoma presenting with cardiac tamponade: report of a case	SURGERY TODAY			English	Article						Thymoma; Pericardium; Ectopic; Cardiac tamponade		Ectopic thymoma arising from organs other than the thymus, such as the neck, trachea, thyroid, lung and pericardium, is rare. To date, there have been only seven other cases of pericardial thymoma reported in the English literature. We herein report a case of pericardial ectopic thymoma that presented with cardiac tamponade. A 72-year-old Japanese male noticed body weight gain and leg edema. Chest computed tomography (CT) revealed pericardial effusion and an irregularly shaped mass in the pericardial space compressing the right atrium. He was considered to have cardiac tamponade due to a paracardiac tumor that developed following acute cardiac failure. The intraoperative frozen diagnosis was thymoma. Pericardectomy of the thickened pericardium, tumorectomy and thymectomy via a median sternotomy were performed. The final pathological diagnosis was pericardial ectopic thymoma associated with constrictive pericarditis. The differential diagnosis and complete resection of mediastinal tumors such as this rare case of thymoma are important to obtain a better prognosis, as patients with such tumors often present in a state of shock.	[Arai, Hiromasa; Rino, Yasushi; Fushimi, Ken-ichi; Goda, Masami; Yukawa, Norio; Masuda, Munetaka] Yokohama City Univ, Grad Sch Med, Dept Surg, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; [Yoshioka, Emi; Okudela, Koji] Yokohama City Univ, Grad Sch Med, Dept Pathol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Arai, H (reprint author), Yokohama City Univ, Grad Sch Med, Dept Surg, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	hiromasa@jg7.so-net.ne.jp					Amano Jun, 2013, Gen Thorac Cardiovasc Surg, V61, P578, DOI 10.1007/s11748-013-0289-2; Engels EA, 2010, J THORAC ONCOL, V5, pS260, DOI 10.1097/JTO.0b013e3181f1f62d; Deveci MS, 2001, HISTOPATHOLOGY, V38, P479; Duwe BV, 2005, CHEST, V128, P2893, DOI 10.1378/chest.128.4.2893; Azoulay S, 2005, VIRCHOWS ARCH, V446, P185, DOI 10.1007/s00428-004-1093-2; Hami BB, 1996, ANN PATHOL, V16, P445; Iiceto S, 1984, AM HEART J, V107, P605; Mirra M, 1997, ARCH PATHOL LAB MED, V121, P59; Okamoto Minoru, 2013, Gen Thorac Cardiovasc Surg, V61, P723, DOI 10.1007/s11748-012-0186-0; Shimosato Y, 2010, TUMORS MEDIASTINUM A, V11, P1; Skoutelis Kostas, 2009, Cases J, V2, P9149, DOI 10.1186/1757-1626-2-9149; Theodore S, 2004, IJTCVS, V20, P102, DOI 10.1007/s12055-004-0054-3	12	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	SEP	2015	45	9					1200	1204		10.1007/s00595-014-1000-7		5	Surgery	Surgery	CP1UE	WOS:000359660900020		
J	Miura, YF; Matsui, H; Inoue, K; Hoshino, J; Ikegami, K				Miura, Yasuhiro F.; Matsui, Haruki; Inoue, Kyoko; Hoshino, Jun-ichi; Ikegami, Keiichi			Structure and properties of the highly conductive Langmuir-Blodgett films based on ditetradecyldimethylammonium-Au(dmit)(2) salt	SYNTHETIC METALS			English	Article						Langmuir-Blodgett films; Ditetradecyldimethylammonium-Au(dmit)(2) (dmit=1,3-dithiol-2-thione-4,5-dithiolate) [2C(14)N(+)-Me-2-Au(dmit)(2)] salt; Electro-oxidation; Metallic conducting property	MOLECULAR SUPERCONDUCTOR; TEMPERATURE-DEPENDENCE; METALLIC CONDUCTIVITY; X-RAY; TRIDECYLMETHYLAMMONIUM-AU(DMIT)2; SPECTROSCOPY; COMPLEXES; THICKNESS; TRANSPORT; PRESSURE	The Langmuir-Blodgett (LB) film based on ditetradecyldimethylammonium-Au(dmit)(2) (dmit =1,3-dithiol-2-thione-4,5-dithiolate) [2C(14)N(+)Me(2)-Au(dmit)(2)] salt exhibits a high room-temperature conductivity of 40 S/cm (4.0 x 10(3) S/m) after electro-oxidation. Since the optical transmittance of the 20-layered LB film is more than 80 % in the whole visible region, the thin-film system attracts much attention both from the technological and scientific point of views. Although the electro-oxidation plays a key role to realize the high conductivity, the induced changes in structure and properties of the film had not been fully elucidated. Here we present a comprehensive study on the structure and properties of the 2C(14)N(+)Me(2)-Au(dmit)(2) LB film utilizing UV-visible spectroscopy, FT-IR spectroscopy, AFM and XRD. The oxidation of the Au(dmit)(2) anions solely proceeds in the earlier stage, while the anion oxidation and a morphological change proceed simultaneously in the later stage. Associated with the electro-oxidation, a broad band appears in a wide IR region and the change in the spectral weight [Delta integral Adk(cm(-1))] coincides well with the conductance indicating that conduction electrons are generated by the charge transfer. The order of the hydrocarbon chains improves by the electro-oxidation. The as-deposited film consists of insulating domains with d = 3.2 nm, while the insulating domains with d = 3.2 nm and highly conductive domains with d = 2.9 nm coexist in the electro-oxidized film. The heterogeneity is considered to be the origin of the percolation-type conduction. (C) 2015 Elsevier B.V. All rights reserved.	[Miura, Yasuhiro F.; Matsui, Haruki; Inoue, Kyoko; Hoshino, Jun-ichi] Toin Univ Yokohama, Grad Sch Engn, Aoba Ku, Yokohama, Kanagawa 2258503, Japan; [Ikegami, Keiichi] Natl Inst Adv Ind Sci & Technol, Res Inst Chem Proc Technol, Tsukuba, Ibaraki 3058568, Japan	Miura, YF (reprint author), Toin Univ Yokohama, Grad Sch Engn, Aoba Ku, 1614 Kurogane Cho, Yokohama, Kanagawa 2258503, Japan.	yfmiura@toin.ac.jp; xa42357@sb4.so-net.ne.jp; inoue.maz.ax@gmail.com; j.h0shl.223@gmail.com			University-Industry Joint Research Project for Private University: matching fund subsidy from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); MEXT [22560011]	We would like to thank the late Prof. Michio Sugi and Prof. Shinichi Morita for helpful comments and discussion in early stage of this work. We also would like to thank Mr. Masaaki Kitao and Mr. Souichiro Kobayashi for their technical assistance. Y.F.M. would like to thank Dr. Kazumasa Honda for structural analyses of the bulk crystal. This work was supported in part by the University-Industry Joint Research Project for Private University: matching fund subsidy from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), 2007-2010 and Gant-in-Aid for Scientific Research from MEXT under Grant No. 22560011.	UMEMURA J, 1980, BIOCHIM BIOPHYS ACTA, V602, P32, DOI 10.1016/0005-2736(80)90287-4; STEIMECKE G, 1979, PHOSPHORUS SULFUR, V7, P49; Brett C.M.A., 1993, ELECTROCHEMISTRY PRI, P82; BROSSARD L, 1986, CR ACAD SCI II, V302, P205; Brossard L., 1988, SYNTHETIC MET, V27, P157, DOI 10.1016/0379-6779(88)90139-7; Clark R.A., 1990, PHYS CHEM ORGANIC SU, V51, P28; de Caro D, 2008, J PHYS-CONDENS MAT, V20, DOI 10.1088/0953-8984/20/18/184012; FUKUI T, 1980, PHYS REV B, V22, P4898, DOI 10.1103/PhysRevB.22.4898; IKEGAMI K, 1995, JPN J APPL PHYS 2, V34, pL1227; Ishiguro T., 1997, ORGANIC SUPERCONDUCT, V2nd, P237; ISOTALO H, 1995, PHYS REV B, V51, P1809, DOI 10.1103/PhysRevB.51.1809; KOBAYASHI A, 1991, CHEM LETT, P2163, DOI 10.1246/cl.1991.2163; KOBAYASHI A, 1987, CHEM LETT, P1819, DOI 10.1246/cl.1987.1819; KOTOV AI, 1991, SYNTHETIC MET, V42, P2355, DOI 10.1016/0379-6779(91)91380-S; Liu HL, 1996, PHYS REV B, V53, P10557, DOI 10.1103/PhysRevB.53.10557; MATSUBAYASHI G, 1990, J CHEM SOC DALTON, P3535, DOI 10.1039/dt9900003535; Matsui H., 2007, T MAT RES SOC JPN, V32, P341; Miura YF, 1998, JPN J APPL PHYS 2, V37, pL1481, DOI 10.1143/JJAP.37.L1481; MIURA YF, 1991, JPN J APPL PHYS 1, V30, P3503, DOI 10.1143/JJAP.30.3503; Miura YF, 2011, JPN J APPL PHYS, V50, DOI 10.1143/JJAP.50.038001; Miura YF, 2000, SOLID STATE COMMUN, V113, P603, DOI 10.1016/S0038-1098(99)00559-1; Miura YF, 2008, JPN J APPL PHYS, V47, P8884, DOI 10.1143/JJAP.47.8884; Morita S, 2004, J PHYS CHEM B, V108, P19354, DOI 10.1021/jp040403b; Myrzakozha DA, 1999, LANGMUIR, V15, P3601, DOI 10.1021/la981016u; NAKAMURA T, 1989, THIN SOLID FILMS, V179, P183, DOI 10.1016/0040-6090(89)90181-8; Nakamura T., 1988, SYNT MET, V27, P601, DOI 10.1016/0379-6779(88)90206-8; NAKAMURA T, 1994, J PHYS CHEM-US, V98, P1882, DOI 10.1021/j100058a028; NAKAMURA T, 1989, CHEM LETT, P367, DOI 10.1246/cl.1989.367; Nakamura T., 1997, HDB ORGANIC CONDUCTI, P727; Ogasawara K, 1996, JPN J APPL PHYS 2, V35, pL571, DOI 10.1143/JJAP.35.L571; Ohnuki H, 1997, PHYS REV B, V55, P10225; Ramakumar R, 1997, PHYS REV B, V56, P795, DOI 10.1103/PhysRevB.56.795; Savy JP, 2007, EPL-EUROPHYS LETT, V78, DOI 10.1209/0295-5075/78/37005; Swietlik R, 1996, J PHYS I, V6, P1643, DOI 10.1051/jp1:1996180; TAJIMA H, 1993, CHEM LETT, P1235, DOI 10.1246/cl.1993.1235; TAJIMA H, 1993, SOLID STATE COMMUN, V86, P7, DOI 10.1016/0038-1098(93)90237-H; Ulman A., 1991, INTRO ULTRATHIN ORGA; VISWANATHAN R, 1995, PHYS REV LETT, V75, P4433, DOI 10.1103/PhysRevLett.75.4433; WANG P, 1993, J PHYS CHEM-US, V97, P2926, DOI 10.1021/j100114a016; Yartsev V. M., 1990, Reviews of Solid State Science, V4	40	0	0	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0379-6779			SYNTHETIC MET	Synth. Met.	SEP	2015	207						54	64		10.1016/j.synthmet.2015.05.019		11	Materials Science, Multidisciplinary; Physics, Condensed Matter; Polymer Science	Materials Science; Physics; Polymer Science	CO9NQ	WOS:000359502900009		
J	Imae, I; Korai, K; Ooyama, Y; Komaguchi, K; Harima, Y				Imae, Ichiro; Korai, Keisuke; Ooyama, Yousuke; Komaguchi, Kenji; Harima, Yutaka			Synthesis of novel dyes having EDOT-containing oligothiophenes as pi-linker for panchromatic dye-sensitized solar cells	SYNTHETIC METALS			English	Article						Dye-sensitized solar cells; Donor-pi-acceptor (D-pi-A) dyes; Oligothiophene; 3,4-Ethylenedioxythiophene (EDOT)	ORGANIC-DYES; PHOTOVOLTAIC PERFORMANCE; TIO2 FILMS; 3,4-ETHYLENEDIOXYTHIOPHENE; ELECTRODES; CONVERSION; MOLECULES; LIGHT	Novel donor-pi-acceptor (D-pi-A) dyes composed of oligothiophenes having 3,4-ethylenedioxythiophene (EDOT) as a pi-linker have been synthesized. The introduction of EDOT unit in oligothiophenes and the elongation of pi-conjugation length of oligothiophenes led to a red-shift of absorption bands of the D-pi-A dyes. It was found that a D-pi-A dye having EDOT-containing quaterthiophene exhibited the excellent light-harvesting ability up to 800 nm. (C) 2015 Elsevier B.V. All rights reserved.	[Imae, Ichiro; Korai, Keisuke; Ooyama, Yousuke; Komaguchi, Kenji; Harima, Yutaka] Hiroshima Univ, Grad Sch Engn, Dept Appl Chem, Higashihiroshima 7398527, Japan	Imae, I (reprint author), Hiroshima Univ, Grad Sch Engn, Dept Appl Chem, 1-4-1 Kagamiyama, Higashihiroshima 7398527, Japan.	imae@hiroshima-u.ac.jp					Yang CH, 2012, ELECTROCHIM ACTA, V69, P256, DOI 10.1016/j.electacta.2012.02.100; Planells M, 2011, ENERG ENVIRON SCI, V4, P1820, DOI 10.1039/c1ee01060c; Hagfeldt A, 2010, CHEM REV, V110, P6595, DOI 10.1021/cr900356p; Imae I, 2015, J SOLID STATE ELECTR, V19, P71, DOI 10.1007/s10008-014-2579-8; Imae I, 2014, RSC ADV, V4, P2501, DOI 10.1039/c3ra44129f; NAZEERUDDIN MK, 1993, J AM CHEM SOC, V115, P6382, DOI 10.1021/ja00067a063; Wu YZ, 2013, CHEM SOC REV, V42, P2039, DOI 10.1039/c2cs35346f; Xu MF, 2009, J PHYS CHEM C, V113, P2966, DOI 10.1021/jp809319x; Liang M, 2013, CHEM SOC REV, V42, P3453, DOI 10.1039/c3cs35372a; Yum JH, 2007, J AM CHEM SOC, V129, P10320, DOI 10.1021/ja0731470; Zhang SF, 2013, ENERG ENVIRON SCI, V6, P1443, DOI 10.1039/c3ee24453a; Shen P, 2009, DYES PIGMENTS, V83, P187, DOI 10.1016/j.dyepig.2009.04.005; Chi Y, 2015, CHEM-ASIAN J, V10, P1098, DOI 10.1002/asia.201403261; Li WQ, 2013, DYES PIGMENTS, V99, P176, DOI 10.1016/j.dyepig.2013.04.031; OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0; Imae I, 2012, MATER CHEM PHYS, V131, P752, DOI 10.1016/j.matchemphys.2011.10.046; Hara K, 2004, LANGMUIR, V20, P4205, DOI 10.1021/la0357615; Ooyama Y, 2009, EUR J ORG CHEM, P2903, DOI 10.1002/ejoc.200900236; Thomas KRJ, 2008, CHEM MATER, V20, P1830, DOI 10.1021/cm702631r; He JJ, 2002, J AM CHEM SOC, V124, P4922, DOI 10.1021/ja0178012; HAGFELDT A, 1995, CHEM REV, V95, P49, DOI 10.1021/cr00033a003; Ooyama Y, 2012, CHEMPHYSCHEM, V13, P4032, DOI 10.1002/cphc.201200218; Pavlishchuk VV, 2000, INORG CHIM ACTA, V298, P97, DOI 10.1016/S0020-1693(99)00407-7; Yen YS, 2012, J MATER CHEM, V22, P8734, DOI 10.1039/c2jm30362k; Frisch M. J., 2009, GAUSSIAN 09 REVISION; Imae I., 2014, OPEN J POLYM CHEM, V4, P83; Liu WH, 2008, CHEM COMMUN, P5152, DOI 10.1039/b808535h; Manfredi N, 2014, EUR J ORG CHEM, P7069, DOI 10.1002/ejoc.201402422	28	0	0	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0379-6779			SYNTHETIC MET	Synth. Met.	SEP	2015	207						65	71		10.1016/j.synthmet.2015.06.009		7	Materials Science, Multidisciplinary; Physics, Condensed Matter; Polymer Science	Materials Science; Physics; Polymer Science	CO9NQ	WOS:000359502900010		
J	Lutsey, PL; McClelland, RL; Duprez, D; Shea, S; Shahar, E; Nagayoshi, M; Budoff, M; Kaufman, JD; Redline, S				Lutsey, Pamela L.; McClelland, Robyn L.; Duprez, Daniel; Shea, Steven; Shahar, Eyal; Nagayoshi, Mako; Budoff, Matthew; Kaufman, Joel D.; Redline, Susan			Objectively measured sleep characteristics and prevalence of coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis Sleep study	THORAX			English	Article							POSITIVE AIRWAY PRESSURE; AMERICAN-HEART-ASSOCIATION; CARDIOVASCULAR-DISEASE; APNEA-HYPOPNEA; HEALTH; DURATION; STROKE; RISK; MESA; THERAPY	Background We tested whether objectively measured indices of obstructive sleep apnoea (OSA) and sleep quality are associated with coronary artery calcification (CAC) prevalence independent of obesity, a classic confounder. Methods 1465 Multi-Ethnic Study of Atherosclerosis participants (mean age 68 years), who were free of clinical cardiovascular disease, had both coronary CT and in-home polysomnography and actigraphy performed. OSA categories were defined by the Apnea-Hypopnea Index (AHI). Prevalence ratios (PRs) for CAC >0 and >400 (high burden) were calculated. Results Participants with severe OSA (AHI >= 30; 14.6%) were more likely to have prevalent CAC, relative to those with no evidence of OSA, after adjustment for demographics and smoking status (PR 1.16; 95% CI 1.06 to 1.26), body mass index (1.11; 1.02 to 1.21) and traditional cardiovascular risk factors (1.10; 1.01 to 1.19). Other markers of hypoxaemia tended to be associated with a higher prevalence of CAC >0. For CAC > 400, a higher prevalence was observed with both a higher arousal index and less slow-wave sleep. Overall, associations were somewhat stronger among younger participants, but did not vary by sex or race/ethnicity. Conclusions In this population-based multi-ethnic sample, severe OSA was associated with subclinical coronary artery disease (CAC > 0), independent of obesity and traditional cardiovascular risk factors. Furthermore, the associations of the arousal index and slow-wave sleep with high CAC burden suggest that higher nightly sympathetic nervous system activation is also a risk factor. These findings highlight the potential importance of measuring disturbances in OSA as well as sleep fragmentation as possible risk factors for coronary artery disease.	[Lutsey, Pamela L.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA; [McClelland, Robyn L.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Duprez, Daniel] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Shea, Steven] Columbia Univ, Dept Med, New York, NY USA; [Shea, Steven] Columbia Univ, Dept Epidemiol, New York, NY USA; [Shahar, Eyal] Univ Arizona, Div Epidemiol & Biostat, Tucson, AZ USA; [Nagayoshi, Mako] Nagasaki Univ, Dept Community Med, Nagasaki 852, Japan; [Budoff, Matthew] Univ Calif Los Angeles, Dept Med, Torrance, CA USA; [Kaufman, Joel D.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA; [Redline, Susan] Brigham & Womens Hosp, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA; [Redline, Susan] Harvard Univ, Sch Med, Boston, MA USA	Lutsey, PL (reprint author), Univ Minnesota, Div Epidemiol & Community Hlth, 1300 S 2nd St,Suite 300, Minneapolis, MN 55454 USA.	Lutsey@umn.edu	Kaufman, Joel/B-5761-2008	Kaufman, Joel/0000-0003-4174-9037	NHBLI [N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169]; NCRR [UL1-TR-000040, UL1-RR-025005]; U.S. Environmental Protection Agency (EPA) [RD831697];  [R01HL098433]	This research was supported by contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the NHBLI, and by grants UL1-TR-000040, UL1-RR-025005 from NCRR, R01HL098433 (MESA Sleep). This publication was also developed under a STAR research assistance agreement, No. RD831697 (MESA Air), awarded by the U.S. Environmental Protection Agency (EPA), which has not been formally reviewed by the EPA. The views expressed in this document are those of the authors and the EPA does not endorse any products or commercial services mentioned in this publication.	Amlander C, 2009, BASICS SLEEP GUIDE; Kronmal RA, 2007, CIRCULATION, V115, P2722, DOI 10.1161/CIRCULATIONHA.106.674143; Weinreich G, 2013, ATHEROSCLEROSIS, V231, P191, DOI 10.1016/j.atherosclerosis.2013.09.011; Weinstock TG, 2012, SLEEP, V35, P617, DOI 10.5665/sleep.1816; Sorajja D, 2008, CHEST, V133, P927, DOI 10.1378/chest.07-2544; Chen XL, 2015, SLEEP, V38, P877, DOI 10.5665/sleep.4732; Mensah GA, 2005, CIRCULATION, V111, P1233, DOI 10.1161/01.CIR.0000158136.76824.04; Lauderdale DS, 2006, AM J EPIDEMIOL, V164, P5, DOI 10.1093/aje/kwj199; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; Martinez-Garcia MA, 2012, AM J RESP CRIT CARE, V186, P909, DOI 10.1164/rccm.201203-0448OC; Fung MM, 2011, HYPERTENSION, V58, P596, DOI 10.1161/HYPERTENSIONAHA.111.174409; Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113; Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC; Drager LF, 2011, OBESITY, V19, P2167, DOI 10.1038/oby.2011.240; King CR, 2008, JAMA-J AM MED ASSOC, V300, P2859, DOI 10.1001/jama.2008.867; Reis JP, 2013, JAMA-J AM MED ASSOC, V310, P280, DOI 10.1001/jama.2013.7833; Folsom AR, 2008, ARCH INTERN MED, V168, P1333, DOI 10.1001/archinte.168.12.1333; Drager LF, 2013, AM J RESP CRIT CARE, V188, P240, DOI 10.1164/rccm.201209-1688OC; Hoyos CM, 2012, THORAX, V67, P1081, DOI 10.1136/thoraxjnl-2011-201420; Laugsand LE, 2011, CIRCULATION, V124, P2073, DOI 10.1161/CIRCULATIONAHA.111.025858; Cappuccio FP, 2011, EUR HEART J, V32, P1484, DOI 10.1093/eurheartj/ehr007; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Aronow WS, 2011, J AM COLL CARDIOL, V57, P2037, DOI 10.1016/j.jacc.2011.01.008; Somers VK, 2008, CIRCULATION, V118, P1080, DOI 10.1161/CIRCULATIONAHA.107.189375; Tasali E, 2008, P NATL ACAD SCI USA, V105, P1044, DOI 10.1073/pnas.0706446105; Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801; Matthews KA, 2011, SLEEP, V34, P711, DOI 10.5665/SLEEP.1032; Redline S, 1998, SLEEP, V21, P759; Arik B, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-9; EEG arousals: Scoring rules and examples, 1992, SLEEP, V15, P173; Kim S, 2010, J BACTERIOL, V192, P575, DOI 10.1128/JB.01052-09; Silber Michael H, 2007, J Clin Sleep Med, V3, P121; Silva Graciela E, 2007, J Clin Sleep Med, V3, P622; Steiropoulos P, 2009, SLEEP, V32, P537	34	3	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376	1468-3296		THORAX	Thorax	SEP	2015	70	9					880	887		10.1136/thoraxjnl-2015-206871		8	Respiratory System	Respiratory System	CP3UR	WOS:000359808600013		
J	Yamada, E; Demachi-Okamura, A; Kondo, S; Akatsuka, Y; Suzuki, S; Shibata, K; Kikkawa, F; Kuzushima, K				Yamada, E.; Demachi-Okamura, A.; Kondo, S.; Akatsuka, Y.; Suzuki, S.; Shibata, K.; Kikkawa, F.; Kuzushima, K.			Identification of a naturally processed HLA-Cw7-binding peptide that cross-reacts with HLA-A24-restricted ovarian cancer-specific CTLs	TISSUE ANTIGENS			English	Article						alloreactivity; antigen-presenting cells; cytotoxic T-lymphocyte; HLA-A*24:02; HLA-Cw*07:02; ovarian cancer	T-CELL ALLORECOGNITION; MAJOR HISTOCOMPATIBILITY COMPLEX; ADOPTIVE IMMUNOTHERAPY; HUMAN-MELANOMA; GENE-THERAPY; CLASS-I; HLA-C; ANTIGEN; LYMPHOCYTES; EPITOPES	Here, we describe an human leukocyte antigen (HLA)-A*24:02-restricted cytotoxic T-lymphocyte (CTL) clone, 1G3, established from naive CD8(+) T-lymphocytes obtained from a healthy donor stimulated with HLA-modified TOV21G, an ovarian cancer cell line. The 1G3 clone responds not only to ovarian cancer cells in the context of HLA-A*24:02 but also to allogeneic HLA-Cw*07:02 molecules through cross-reactive T-cell receptor recognition. Expression screening using a complementary DNA library constructed from TOV21G messenger RNA revealed that this alloreactivity was mediated through the nine-mer peptide VRTPYTMSY, derived from RNA-binding motif protein 4. To our knowledge, this study presents the first example of the allorecognition of an HLA-Cw molecule by HLA-A-restricted T-cells, thereby revealing a naturally processed epitope peptide. These findings provide the structural bases for the allorecognition of human T-cells. In addition, this study suggests that unexpected alloresponses occur in certain HLA combinations, and further study is needed to understand the mechanisms of alloreactivity for better prediction of alloresponses in clinical settings.	[Yamada, E.; Demachi-Okamura, A.; Akatsuka, Y.; Kuzushima, K.] Aichi Canc Ctr, Res Inst, Div Immunol, Nagoya, Aichi 4648681, Japan; [Yamada, E.; Suzuki, S.; Shibata, K.; Kikkawa, F.] Grad Sch Med, Dept Gynecol, Nagoya, Aichi, Japan; [Kondo, S.] Aichi Canc Ctr Hosp, Dept Gynecol Oncol, Nagoya, Aichi 464, Japan; [Akatsuka, Y.] Fujita Hlth Univ, Dept Hematol & Oncol, Toyoake, Aichi, Japan; [Kuzushima, K.] Nagoya Univ, Grad Sch Med, Dept Cellular Oncol, Nagoya, Aichi 4648601, Japan	Kuzushima, K (reprint author), Aichi Canc Ctr, Res Inst, Div Immunol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	kkuzushi@aichi-cc.jp			Japan Society for the Promotion of Science, Japan; Takeda Science Foundation, Japan	The authors would like to thank Ms. Hiramatsu K. for the production of HLA-tetramers and Ms. Tamaki H. and Asai H. for administrative assistance. The authors would also like to thank Dr. J. Kigawa (Department of Obstetrics and Gynecology, Tottori University, Tottori, Japan) for providing KOC7C cells and Dr. H. Miyoshi (Department of Physiology, Keio University School of Medicine) for providing the lentivirus vectors. This work was supported through funding from the Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, Japan, and the Takeda Science Foundation, Japan.	Amir AL, 2011, BLOOD, V118, P6733, DOI 10.1182/blood-2011-05-354787; Amir AL, 2010, BLOOD, V115, P3146, DOI 10.1182/blood-2009-07-234906; Macdonald WA, 2009, IMMUNITY, V31, P897, DOI 10.1016/j.immuni.2009.09.025; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Apps R, 2013, SCIENCE, V340, P87, DOI 10.1126/science.1232685; Markus MA, 2009, INT J BIOCHEM CELL B, V41, P740, DOI 10.1016/j.biocel.2008.05.027; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Wooldridge L, 2012, J BIOL CHEM, V287, P1168, DOI 10.1074/jbc.M111.289488; Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191; Yin L, 2011, IMMUNITY, V35, P23, DOI 10.1016/j.immuni.2011.04.017; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Schumacher TNM, 2002, NAT REV IMMUNOL, V2, P512, DOI 10.1038/nri841; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Blais ME, 2011, IMMUNOLOGY, V133, P1, DOI 10.1111/j.1365-2567.2011.03422.x; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; Linette GP, 2013, BLOOD, V122, P863, DOI 10.1182/blood-2013-03-490565; Parkhurst MR, 2011, MOL THER, V19, P620, DOI 10.1038/mt.2010.272; Felix NJ, 2007, NAT REV IMMUNOL, V7, P942, DOI 10.1038/nri2200; Nagata Y, 1997, J IMMUNOL, V159, P1336; Krogsgaard M, 2005, NAT IMMUNOL, V6, P239, DOI 10.1038/ni1173; Cieri N, 2014, IMMUNOL REV, V257, P165, DOI 10.1111/imr.12130; Kuzushima K, 2001, BLOOD, V98, P1872, DOI 10.1182/blood.V98.6.1872; Sugaya M, 2002, CHEST, V122, P282, DOI 10.1378/chest.122.1.282; Archbold JK, 2008, MOL IMMUNOL, V45, P583, DOI 10.1016/j.molimm.2006.05.018; Brooks YS, 2009, J BIOL CHEM, V284, P18033, DOI 10.1074/jbc.M109.006999; Cameron B.J., 2013, SCI TRANSL MED, V5, P197, DOI DOI 10.1126/SCITRANSLMED.3006034; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Demachi-Okamura A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047126; Ennis FA, 1997, VIROLOGY, V238, P380, DOI 10.1006/viro.1997.8827; Kalos M, 2013, IMMUNITY, V39, P49, DOI 10.1016/j.immuni.2013.07.002; Kondo E, 2004, BLOOD, V103, P630, DOI 10.1182/blood-2003-03-0824; Kondo S, 2013, HUM IMMUNOL, V74, P1103, DOI 10.1016/j.humimm.2013.06.030; Kuzushima K, 1999, BLOOD, V94, P3094; Morice A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012120; Nagata Yoshika, 2005, Clin Cancer Res, V11, P5265, DOI 10.1158/1078-0432.CCR-04-2542; Sugaya M, 2007, INT J CANCER, V120, P1055, DOI 10.1002/ijc.22396; Whitelegg A, 2004, TISSUE ANTIGENS, V63, P101, DOI 10.1111/j.1399-0039.2004.00188.x; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	39	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-2815	1399-0039		TISSUE ANTIGENS	Tissue Antigens	SEP	2015	86	3					164	171		10.1111/tan.12607		8	Cell Biology; Immunology; Pathology	Cell Biology; Immunology; Pathology	CP1YM	WOS:000359673800003		
J	Kongmaroeng, C; Romphruk, A; Puapairoj, C; Leelayuwat, C; Kulski, JK; Inoko, H; Dunn, DS; Romphruk, AV				Kongmaroeng, C.; Romphruk, A.; Puapairoj, C.; Leelayuwat, C.; Kulski, J. K.; Inoko, H.; Dunn, D. S.; Romphruk, A. V.			HLA alleles and haplotypes in Burmese (Myanmarese) and Karen in Thailand	TISSUE ANTIGENS			English	Article						Burmese; haplotype frequency; human leukocyte antigen; Karen; Southeast Asian	SYSTEMIC-LUPUS-ERYTHEMATOSUS; STEVENS-JOHNSON SYNDROME; CLASS-I; HLA-B-ASTERISK-1502 ALLELE; LINKAGE DISEQUILIBRIUM; POPULATION; HLA-DRB1; CARBAMAZEPINE; ASSOCIATION; DNA	This is the first report on human leukocyte antigen (HLA) allele and haplotype frequencies at three class I loci and two class II loci in unrelated healthy individuals from two ethnic groups, 170 Burmese and 200 Karen, originally from Burma (Myanmar), but sampled while residing in Thailand. Overall, the HLA allele and haplotype frequencies detected by polymerase chain reaction sequence-specific primer (PCR-SSP) at five loci (A, B, C, DRB1 and DRQB1) at low resolution showed distinct differences between the Burmese and Karen. In Burmese, five HLA-B*15 haplotypes with different HLA-A and HLA-DR/DQ combinations were detected with three of these not previously reported in other Asian populations. The data are important in the fields of anthropology, transplantation and disease-association studies.	[Kongmaroeng, C.] Huachiew Chalermprakiet Univ, Fac Med Technol, Dept Blood Bank, Samut Prakarn, Thailand; [Romphruk, A.; Leelayuwat, C.] Khon Kaen Univ, Fac Associated Med Sci, Dept Clin Immunol & Transfus Sci, Khon Kaen 40002, Thailand; [Romphruk, A.; Leelayuwat, C.; Romphruk, A. V.] Khon Kaen Univ, Fac Associated Med Sci, Ctr Res & Dev, Khon Kaen 40002, Thailand; [Romphruk, A.; Leelayuwat, C.; Romphruk, A. V.] Khon Kaen Univ, Fac Associated Med Sci, Med Diagnost Labs, Khon Kaen 40002, Thailand; [Puapairoj, C.; Romphruk, A. V.] Khon Kaen Univ, Fac Med, Ctr Blood Transfus, Khon Kaen 40002, Thailand; [Kulski, J. K.] Univ Western Australia, Ctr Forens Sci, Nedlands, WA 6009, Australia; [Inoko, H.] Tokai Univ, Sch Med, Div Mol Life Sci, Dept Genet Informat, Tokyo 151, Japan; [Dunn, D. S.] Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA 6150, Australia	Romphruk, AV (reprint author), Khon Kaen Univ, Fac Med, Ctr Blood Transfus, Khon Kaen 40002, Thailand.	aromphruk@kku.ac.th			Graduate School, Khon Kaen University; Centre for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University Thailand; Department of Genetic Information, Division of Molecular Life Science, Tokai University, Japan	This research was supported by a grant from Graduate School, Khon Kaen University, The Centre for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University Thailand and the Department of Genetic Information, Division of Molecular Life Science, Tokai University, Japan.	Kulkantrakorn K, 2012, PAIN PRACT, V12, P202, DOI 10.1111/j.1533-2500.2011.00479.x; Itoh Y, 2005, IMMUNOGENETICS, V57, P717, DOI 10.1007/s00251-005-0048-3; Yang KL, 2009, HUM IMMUNOL, V70, P269, DOI 10.1016/j.humimm.2009.01.015; Romphruk AV, 2010, TISSUE ANTIGENS, V75, P701, DOI 10.1111/j.1399-0039.2010.01448.x; BOWTELL DDL, 1987, ANAL BIOCHEM, V162, P463, DOI 10.1016/0003-2697(87)90421-0; Locharernkul C, 2008, EPILEPSIA, V49, P2087, DOI 10.1111/j.1528-1167.2008.01719.x; Excoffier L, 2010, MOL ECOL RESOUR, V10, P564, DOI 10.1111/j.1755-0998.2010.02847.x; Trachtenberg E, 2007, TISSUE ANTIGENS, V70, P455, DOI 10.1111/j.1399-0039.2007.00932.x; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Hoa BK, 2008, TISSUE ANTIGENS, V71, P127, DOI 10.1111/j.1399-0039.2007.00982.x; Dhaliwal JS, 2007, ASIAN PAC J ALLERGY, V25, P47; Shiina T, 2009, J HUM GENET, V54, P15, DOI 10.1038/jhg.2008.5; Man CBL, 2007, EPILEPSIA, V48, P1015, DOI 10.1111/j.1528-1167.2007.01022.x; Lim KS, 2008, NEUROL ASIA, V13, P15; Erlich HA, 2001, IMMUNITY, V14, P347, DOI 10.1016/S1074-7613(01)00115-7; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; Slatkin M, 1996, HEREDITY, V76, P377, DOI 10.1038/hdy.1996.55; Tassaneeyakul W, 2010, EPILEPSIA, V51, P926, DOI [10.1111/j.1528-1167.2010.02533.x, 10.1111/j.1528-1167.2009.02533.x]; Chandanayingyong D, 1997, HUM IMMUNOL, V53, P174, DOI 10.1016/S0198-8859(96)00284-4; Chang YW, 1997, HUM IMMUNOL, V56, P125, DOI 10.1016/S0198-8859(97)00108-0; Charron D J, 1996, Curr Opin Hematol, V3, P416; Chiewsilp Pimol, 1997, Journal of the Medical Association of Thailand, V80, pS30; Di D, 2014, AM J PHYS ANTHROPOL, V145, P81; Di D, 2011, IMMUNOGENETICS, V66, P153; IMANISHI T, 1992, J MOL EVOL, V35, P196; Kongmaroeng C, 2009, TISSUE ANTIGENS, V74, P164, DOI 10.1111/j.1399-0039.2009.01281.x; Lu LY, 1997, ARTHRITIS RHEUM, V40, P1138, DOI 10.1002/art.1780400619; Miao KR, 2007, INT J IMMUNOGENET, V34, P419, DOI 10.1111/j.1744-313X.2007.00713.x; Parker DM, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0712-5; Raymond M, 1995, EVOLUTION, V49, P1283; Rhodes D A, 1999, Rev Immunogenet, V1, P21; Robinson J, 2009, NUCLEIC ACIDS RES, V37, pD1013, DOI 10.1093/nar/gkn662; Romphruk AV, 1999, EUR J IMMUNOGENET, V26, P129, DOI 10.1046/j.1365-2370.1999.00133.x; Shen Y, 2014, J IMMUNOL RES, V2014; Sirikong M, 2002, TISSUE ANTIGENS, V59, P113, DOI 10.1034/j.1399-0039.2002.590206.x; Srithawong S, 2015, J HUM GENET, V60, P371, DOI 10.1038/jhg.2015.32; Tonks S, 1996, 12 INT HIST WORKSH L; Yuliwulandari R, 2009, TISSUE ANTIGENS, V73, P46, DOI 10.1111/j.1399-0039.2008.01178.x	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-2815	1399-0039		TISSUE ANTIGENS	Tissue Antigens	SEP	2015	86	3					199	204		10.1111/tan.12637		6	Cell Biology; Immunology; Pathology	Cell Biology; Immunology; Pathology	CP1YM	WOS:000359673800008		
J	Tanaka, T; Murakami, K; Kumata, A; Kawai, Y				Tanaka, Takashi; Murakami, Kaori; Kumata, Atsushi; Kawai, Yasuo			Influence of drying temperature on the migration of cesium chloride initially dissolved in the liquid water of sugi (Cryptomeria japonica D. Don) sapwood	WOOD SCIENCE AND TECHNOLOGY			English	Article							LOW-MOLECULAR SUGARS; PINUS-SYLVESTRIS L; WOOD; AIR; RADIOCESIUM; HEARTWOOD; ACCIDENT; KILN	A method to be potentially used for radiocesium decontamination from timber harvested in Fukushima region, where fallout from the Fukushima Daiichi nuclear disaster was deposited, involves drying the timber and planing away the contaminated wood. The objective of this study was to investigate the influence of drying temperature on the migration of cesium dissolved in the liquid water of sugi (Cryptomeria japonica D. Don) sapwood during the drying process. Small specimens of sugi sapwood impregnated with aqueous cesium chloride (CsCl) solution were dried at 20 or 90 A degrees C, and the migration of CsCl during drying was examined by means of X-ray imaging. The results of this study indicate that the drying of sugi sapwood at any temperature causes surface accumulation of dissolved cesium, which is affected by both the drying temperature and grain orientation of the surface. Statistical analysis confirmed that a high drying temperature causes greater surface accumulation of CsCl during drying. It is recommended to use higher temperatures to dry sugi sapwood when employing the drying/planing method for radiocesium decontamination from timber.	[Tanaka, Takashi] Shizuoka Univ, Grad Sch Agr, Shizuoka 4228529, Japan; [Murakami, Kaori] Fukushima Prefectural Forestry Res Ctr, Koriyama, Fukushima, Japan; [Kumata, Atsushi] Fukushima Prefectural Ken Nan Agr & Forestry Off, Shirakawa, Japan; [Kawai, Yasuo] Akita Prefectural Univ, Inst Wood Technol, Noshiro, Akita, Japan	Tanaka, T (reprint author), Shizuoka Univ, Grad Sch Agr, Shizuoka 4228529, Japan.	attanak@ipc.shizuoka.ac.jp			JSPS KAKENHI [24780170]; LIXIL JS Foundation [12-66]	This work was supported by JSPS KAKENHI Grant Number 24780170 and LIXIL JS Foundation Research Grant No. 12-66. We thank Drs. Katsuhiko Takata and Shigeru Yamauchi at Akita Prefectural University for donating sugi samples and providing CsCl, respectively.	Kuroda K, 2013, J ENVIRON RADIOACTIV, V122, P37, DOI 10.1016/j.jenvrad.2013.02.019; TERZIEV N, 1995, HOLZFORSCHUNG, V49, P565, DOI 10.1515/hfsg.1995.49.6.565; Salin JG, 2008, DRY TECHNOL, V26, P560, DOI 10.1080/07373930801944747; Tanaka K, 2013, J RADIOANAL NUCL CH, V295, P1927, DOI 10.1007/s10967-012-2160-9; Hasegawa H, 2009, J ENVIRON RADIOACTIV, V100, P54, DOI 10.1016/j.jenvrad.2008.10.011; Hubbell J. H., 2004, TABLES XRAY MASS ATT; Ida T, 2008, J FLUX GROWTH, V3, P2; King B., 1974, Material und Organismen, V9, P241; Kreber B, 1997, HOLZ ROH WERKST, V55, P215, DOI 10.1007/BF02990551; Matsumura J, 2005, J WOOD SCI, V51, P328, DOI 10.1007/s10086-004-0668-5; Salin J.-G., 2006, Wood Materials Science and Engineering, V1, DOI 10.1080/17480270600900841; Salin JG, 2008, P COST ACT E53 C 29, P135; Salin J.-G., 2006, Wood Materials Science and Engineering, V1, DOI 10.1080/17480270600630927; Tanaka T, 2015, MADERAS-CIENC TECNOL, V17, P17, DOI 10.4067/S0718-221X2015005000002; Tanaka T, 2014, HOLZFORSCHUNG, V68, P591, DOI 10.1515/hf-2013-0188; TERZIEV N, 1993, HOLZFORSCHUNG, V47, P3, DOI 10.1515/hfsg.1993.47.1.3; THEANDER O, 1993, WOOD SCI TECHNOL, V27, P381; WIBERG P, 1995, HOLZ ROH WERKST, V53, P402; Wiberg P, 1999, HOLZ ROH WERKST, V57, P137, DOI 10.1007/s001070050029	19	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0043-7719	1432-5225		WOOD SCI TECHNOL	Wood Sci. Technol.	SEP	2015	49	5					915	924		10.1007/s00226-015-0746-4		10	Forestry; Materials Science, Paper & Wood	Forestry; Materials Science	CO7ZL	WOS:000359383200003		
J	Penkhrue, W; Khanongnuch, C; Masaki, K; Pathom-aree, W; Punyodom, W; Lumyong, S				Penkhrue, Watsana; Khanongnuch, Chartchai; Masaki, Kazuo; Pathom-aree, Wasu; Punyodom, Winita; Lumyong, Saisamorn			Isolation and screening of biopolymer-degrading microorganisms from northern Thailand	WORLD JOURNAL OF MICROBIOLOGY & BIOTECHNOLOGY			English	Article						Polylactic acid; Polycaprolactone; Poly(butylene succinate); Biodegradation; Bioplastic; Thailand; Amycolatopsis sp.; Remediation	CUTINASE-LIKE ENZYME; AMYCOLATOPSIS SP; POLY(L-LACTIDE) DEGRADATION; BIODEGRADABLE PLASTICS; ACID) DEPOLYMERASE; FILAMENTOUS FUNGI; SP. NOV.; SOIL; BACTERIUM; GENE	Forty agricultural soils were collected from Chiang Mai and Lampang provinces in northern Thailand. Bacteria, actinomycetes and fungi were isolated and screened for their ability to degrade polylactic acid (PLA), polycaprolactone (PCL) and poly(butylene succinate) (PBS) by the agar diffusion method. Sixty-seven actinomycetes, seven bacteria and five fungal isolates were obtained. The majority of actinomycetes were Streptomyces based on morphological characteristic, chemotaxonomy and 16S rRNA gene data. Seventy-nine microorganisms were isolated from 40 soil samples. Twenty-six isolates showed PLA-degradation (32.9 %), 44 isolates showed PBS-degradation (55.7 %) and 58 isolates showed PCL-degradation (73.4 %). Interestingly, 16 isolates (20.2 %) could degrade all three types of bioplastics used in this study. The Amycolatopsis sp. strain SCM_MK2-4 showed the highest enzyme activity for both PLA and PCL, 0.046 and 0.023 U/mL, respectively. Moreover, this strain produced protease, esterase and lipase on agar plates. Approximately, 36.7 % of the PLA film was degraded by Amycolatopsis sp. SCM_MK2-4 after 7 days of cultivation at 30 A degrees C in culture broth.	[Penkhrue, Watsana; Pathom-aree, Wasu; Lumyong, Saisamorn] Chiang Mai Univ, Dept Biol, Fac Sci, Chiang Mai 50200, Thailand; [Khanongnuch, Chartchai] Chiang Mai Univ, Fac Agroind, Div Biotechnol, Chiang Mai 50100, Thailand; [Masaki, Kazuo] Natl Res Inst Brewing NRIB, Hiroshima 7390046, Japan; [Punyodom, Winita] Chiang Mai Univ, Dept Chem, Fac Sci, Chiang Mai 50200, Thailand	Lumyong, S (reprint author), Chiang Mai Univ, Dept Biol, Fac Sci, 239 Huay Kaew Rd, Chiang Mai 50200, Thailand.	watsanapenkhrue@gmail.com; scboi009@gmail.com			Royal Golden Jubilee Ph.D. Program [PHD/0142/2553]	This research was supported by The Royal Golden Jubilee Ph.D. Program (PHD/0142/2553). The National Research University Project under Thailand's Office of the Higher Education Commission and The Graduate School, Chiang Mai University are thankfully acknowledged. The authors wish to thank Dr. Robert J. McGovern (The Graduate School, Chiang Mai University, Chiang Mai, Thailand) for valuable comments and improving the English text.	Akutsu-Shigeno Y, 2003, APPL ENVIRON MICROB, V69, P2498, DOI 10.1128/AEM.69.5.2498.2504.2003; Chomchoei A, 2011, INT J SYST EVOL MICR, V61, P839, DOI 10.1099/ijs.0.023564-0; Kim OS, 2012, INT J SYST EVOL MICR, V62, P716, DOI 10.1099/ijs.0.038075-0; Zheng Y, 2005, CRIT REV BIOTECHNOL, V25, P243, DOI 10.1080/07388550500346359; Hsu KJ, 2012, BOT STUD, V53, P307; Tokiwa Y, 2004, BIOTECHNOL LETT, V26, P771, DOI 10.1023/B:BILE.0000025927.31028.e3; Shinozaki Y, 2013, APPL MICROBIOL BIOT, V97, P8591, DOI 10.1007/s00253-012-4673-0; Maeda H, 2005, APPL MICROBIOL BIOT, V67, P778, DOI 10.1007/s00253-004-1853-6; REEVE MS, 1994, MACROMOLECULES, V27, P825, DOI 10.1021/ma00081a030; Nakayama A, 1998, POLYMER, V39, P1213, DOI 10.1016/S0032-3861(97)00401-1; Sukkhum S, 2009, J GEN APPL MICROBIOL, V55, P459; EDWARDS U, 1989, NUCLEIC ACIDS RES, V17, P7843, DOI 10.1093/nar/17.19.7843; Tokiwa Y, 2009, INT J MOL SCI, V10, P3722, DOI 10.3390/ijms10093722; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI 10.1093/molbev/mst197; Tokiwa Y, 2004, BIOTECHNOL LETT, V26, P1181, DOI 10.1023/B:BILE.0000036599.15302.e5; Tokiwa Y, 2006, APPL MICROBIOL BIOT, V72, P244, DOI 10.1007/s00253-006-0488-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Kim SB, 1998, INT J SYST BACTERIOL, V48, P59; Masaki K, 2005, APPL ENVIRON MICROB, V71, P7548, DOI 10.1128/AEM.71.11.7548-7550.2005; HASEGAWA T, 1983, J GEN APPL MICROBIOL, V29, P319, DOI 10.2323/jgam.29.319; TOKIWA Y, 1977, NATURE, V270, P76, DOI 10.1038/270076a0; Barnett HL, 1987, ILLUSTRATED GENERA I; BENEDICT CV, 1983, J APPL POLYM SCI, V28, P327, DOI 10.1002/app.1983.070280128; Chua TK, 2013, AMB EXPRESS, V3, DOI 10.1186/2191-0855-3-8; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Girdthep S, 2015, POLYM INT, V64, P203, DOI 10.1002/pi.4775; Hayase N, 2004, J BIOSCI BIOENG, V97, P131; Hoang KC, 2007, WORLD J MICROB BIOT, V23, P201, DOI 10.1007/s11274-006-9212-7; Holt JG, 1994, BERGEYS MANUAL DETER; Ikura Y, 1999, J GEN APPL MICROBIOL, V45, P247, DOI 10.2323/jgam.45.247; Jarerat A, 2001, MACROMOL BIOSCI, V1, P136, DOI 10.1002/1616-5195(20010601)1:4<136::AID-MABI136>3.3.CO;2-V; Jarerat A, 2002, MACROMOL BIOSCI, V2, P420, DOI 10.1002/mabi.200290001; Jarerat A, 2003, BIOTECHNOL LETT, V25, P2035, DOI 10.1023/B:BILE.0000004398.38799.29; Jarerat A, 2003, BIOTECHNOL LETT, V25, P401, DOI 10.1023/A:1022450431193; Kelly K. L., 1964, INTERSOCIETY COLOR C; KENNEDY AC, 1995, PLANT SOIL, V170, P75, DOI 10.1007/BF02183056; Kim MN, 2010, J APPL POLYM SCI, V117, P67, DOI 10.1002/app.31950; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Lee SH, 2010, INT BIODETER BIODEGR, V64, P184, DOI 10.1016/j.ibiod.2010.01.002; Li F, 2011, WORLD J MICROB BIOT, V27, P2591, DOI 10.1007/s11274-011-0731-5; Lim HA, 2005, BIOTECHNOL LETT, V27, P459, DOI 10.1007/s10529-005-2217-8; Nakamura K, 2001, APPL ENVIRON MICROB, V67, P345, DOI 10.1128/AEM.67.1.345-353.2001; Nakayama A, 1997, J APPL POLYM SCI, V66, P741, DOI 10.1002/(SICI)1097-4628(19971024)66:4<741::AID-APP14>3.0.CO;2-U; Nishida H., 1993, J ENV POLYM DEGRADE, P227, DOI DOI 10.1007/BF01458031; Oda Y, 1997, FEMS MICROBIOL LETT, V152, P339, DOI 10.1016/S0378-1097(97)00222-X; ODA Y, 1995, J FERMENT BIOENG, V80, P265, DOI 10.1016/0922-338X(95)90827-M; Plastics-Europe, 2015, AN EUR PLAST PROD DE; Pranamuda H, 1997, APPL ENVIRON MICROB, V63, P1637; Pranamuda H, 1999, BIOTECHNOL LETT, V21, P901, DOI 10.1023/A:1005547326434; Pranamuda H, 2001, MACROMOL BIOSCI, V1, P25, DOI 10.1002/1616-5195(200101)1:1<25::AID-MABI25>3.3.CO;2-V; Sambrook J, 2001, MOL CLONING LAB MANU; Sanchez JG, 2000, BIOTECHNOL LETT, V22, P849, DOI 10.1023/A:1005603112688; Sekiguchi T, 2010, JAMSTEC REP RES DAV, V11, P33, DOI [10.5918/jamstecr.11.33, DOI 10.5918/JAMSTECR.11.33]; SHIRLING E. B., 1966, INT J SYST BACTERIOL, V16, P313; Stackebrandt E., 2006, MICROBIOL TODAY, V33, P152; Sukkhum S, 2011, AFR J MICROBIOL RES, V5, P2575; Szumigaj J, 2008, POL J ENVIRON STUD, V17, P335; Teeraphatpornchai T, 2003, BIOTECHNOL LETT, V25, P23, DOI 10.1023/A:1021713711160; Tokiwa Y, 1997, WORLD J MICROB BIOT, V14, P133, DOI [10.1023/A:1008897121993, DOI 10.1023/A:1008897121993]; Tomita K, 2003, POLYM DEGRAD STABIL, V81, P167, DOI 10.1016/S0141-3910(03)00086-7; Tomita K, 1999, J BIOSCI BIOENG, V87, P752, DOI 10.1016/S1389-1723(99)80148-0; Torres A, 1996, APPL ENVIRON MICROB, V62, P2393; Uchida H, 2000, FEMS MICROBIOL LETT, V189, P25, DOI 10.1016/S0378-1097(00)00246-9; White TJ, 1990, PCR PROTOCOLS GUIDE; Williams D., 1981, ENG MED, V10, P5	65	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0959-3993	1573-0972		WORLD J MICROB BIOT	World J. Microbiol. Biotechnol.	SEP	2015	31	9					1431	1442		10.1007/s11274-015-1895-1		12	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CO8AX	WOS:000359388000013		
J	Sugino, K; Nagahama, M; Kitagawa, W; Shibuya, H; Ohkuwa, K; Uruno, T; Suzuki, A; Akaishi, J; Masaki, C; Matsuzu, K; Ito, K				Sugino, Kiminori; Nagahama, Mitsuji; Kitagawa, Wataru; Shibuya, Hiroshi; Ohkuwa, Keiko; Uruno, Takashi; Suzuki, Akifumi; Akaishi, Junko; Masaki, Chie; Matsuzu, Ken-ichi; Ito, Koichi			Papillary Thyroid Carcinoma in Children and Adolescents: Long-Term Follow-Up and Clinical Characteristics	WORLD JOURNAL OF SURGERY			English	Article							PULMONARY METASTASES; SURGICAL APPROACH; FREE SURVIVAL; CANCER; CHILDHOOD; RECURRENCE; SURGERY; RISK; INSTITUTION; RADIOIODINE	The aim of this study was to analyze the clinical features and clinical outcomes of papillary thyroid carcinoma (PTC) in the pediatric and adolescent population treated in our institution. The subjects were 227 PTC patients 20 years of age or under treated initially between 1979 and 2012. Their mean age at diagnosis was 18-year old (range 7-20 years). Patient characteristics and outcomes in the period before 1999 and the period after 2000 were compared. Cause-specific survival (CSS) rates and disease-free survival (DFS) rates were calculated by the Kaplan-Meier method. Two patients died of their disease and 45 patients had recurrent disease (36 in lymph node, seven in a remnant thyroid, and 11 in the form of distant metastasis). The 10-, 20-, and 30-CSS rates were 99.3, 99.3, and 96.5 %, respectively, and the 10-, 20-, and 30-DFS were 83.6, 70.7, and 64.0 %, respectively. Gender and preoperative lymph node metastasis were identified as significant factors related to DFS in the multivariate analysis. After the year 2000, there were significantly more patients with a small primary tumor size, significantly more patients without distant metastasis at presentation and significantly more patients without extrathyroidal invasion. The number of patients with advanced cancer has been declining in recent years. Lobectomy with prophylactic unilateral central neck dissection is considered acceptable for patients without the risk factors for recurrence.	[Sugino, Kiminori; Nagahama, Mitsuji; Kitagawa, Wataru; Shibuya, Hiroshi; Ohkuwa, Keiko; Uruno, Takashi; Suzuki, Akifumi; Akaishi, Junko; Masaki, Chie; Matsuzu, Ken-ichi; Ito, Koichi] Ito Hosp, Dept Surg, Shibuya Ku, Tokyo 1508308, Japan	Sugino, K (reprint author), Ito Hosp, Dept Surg, Shibuya Ku, 4-3-6 Jingumae, Tokyo 1508308, Japan.	k-sugino@ito-hospital.jp					Collini P, 2006, AM J SURG PATHOL, V30, P1420, DOI 10.1097/01.pas.0000213264.07597.9a; Hay ID, 2010, WORLD J SURG, V34, P1192, DOI 10.1007/s00268-009-0364-0; Demidchik YE, 2006, ANN SURG, V243, P525, DOI 10.1097/01.sla.0000205977.74806.0b; Thompson GB, 2004, WORLD J SURG, V28, P1187, DOI 10.1007/s00268-004-7605-z; Dinauer C, 2007, ENDOCRIN METAB CLIN, V36, P779, DOI 10.1016/j.ecl.2007.04.002; Adam MA, 2014, ANN SURG, V260, P601, DOI 10.1097/SLA.0000000000000925; Pawelczak M, 2010, THYROID, V20, P1095, DOI 10.1089/thy.2009.0446; Haigh PI, 2005, ANN SURG ONCOL, V12, P81, DOI 10.1245/ASO.2005.03.027; Borson-Chazot F, 2004, WORLD J SURG, V28, P1088, DOI 10.1007/s00268-004-7630-y; O'Gorman CS, 2010, THYROID, V20, P375, DOI 10.1089/thy.2009.0386; Brierley JD, 1997, CANCER, V79, P2414; Jarzab B, 2005, ENDOCR-RELAT CANCER, V12, P773, DOI 10.1677/erc.1.00880; Dinauer CAW, 1998, CLIN ENDOCRINOL, V49, P619; van Santen HM, 2004, EUR J CANCER, V40, P1743, DOI 10.1016/j.ejca.2004.03.006; ZIMMERMAN D, 1988, SURGERY, V104, P1157; Rachmiel M, 2006, J PEDIATR ENDOCR MET, V19, P1377; Wada N, 2009, ANN SURG ONCOL, V16, P3442, DOI 10.1245/s10434-009-0673-4; Rivkees SA, 2011, ENDOCR REV, V32, P798, DOI 10.1210/er.2011-0011; LAQUAGLIA MP, 1988, SURGERY, V104, P1149; Brink JS, 2000, SURGERY, V128, P881, DOI 10.1067/msy.2000.109728; Carty SE, 2009, THYROID, V19, P1153, DOI 10.1089/thy.2009.0159; Astl J, 2004, INT J PEDIATR OTORHI, V68, P1273, DOI 10.1016/j.ijporl.2004.04.024; Balazs G, 1996, SURG TODAY, V26, P536; Ben Arush MW, 2000, PEDIATR HEMAT ONCOL, V17, P85; Chaukar DA, 2005, J SURG ONCOL, V92, P130, DOI 10.1002/jso.20339; Dinauer CAW, 1999, J PEDIATR SURG, V34, P1799; Handkiewicz-Junak D, 2007, J NUCL MED, V48, P879, DOI 10.2967/jnumed.106.035535; Iyer P, 2014, THYROID, V24, P169, DOI 10.1089/thy.2012.0468; Loh KC, 1997, J CLIN ENDOCR METAB, V82, P3553, DOI 10.1210/jc.82.11.3553; Massimino M, 2006, PEDIATR BLOOD CANCER, V46, P307, DOI 10.1002/pbc.20438; Matsuzu K, 2014, WORLD J SURG, V38, P68, DOI 10.1007/s00268-013-2224-1; Wada N, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-306	32	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	SEP	2015	39	9					2259	2265		10.1007/s00268-015-3042-4		7	Surgery	Surgery	CO8UO	WOS:000359447800021		
J	Murakami, Y; Satoi, S; Sho, M; Motoi, F; Matsumoto, I; Kawai, M; Honda, G; Uemura, K; Yanagimoto, H; Shinzeki, M; Kurata, M; Kinoshita, S; Yamaue, H; Unno, M				Murakami, Yoshiaki; Satoi, Sohei; Sho, Masayuki; Motoi, Fuyuhiko; Matsumoto, Ippei; Kawai, Manabu; Honda, Goro; Uemura, Kenichiro; Yanagimoto, Hiroaki; Shinzeki, Makoto; Kurata, Masanao; Kinoshita, Shoichi; Yamaue, Hiroki; Unno, Michiaki			National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival	WORLD JOURNAL OF SURGERY			English	Article							INTERNATIONAL STUDY-GROUP; NEOADJUVANT GEMCITABINE; CONSENSUS STATEMENT; VEIN RESECTION; HEAD CARCINOMA; PHASE-II; CHEMOTHERAPY; ADENOCARCINOMA; OXALIPLATIN; SURGERY	The aim of this study was to evaluate the validity of preoperative resectability status, as defined by the National Comprehensive Cancer Network (NCCN), from the viewpoint of overall survival. A total of consecutive 704 patients with pancreatic head carcinoma who underwent pancreatoduodenectomy with upfront surgery at seven Japanese hospitals between 2001 and 2012 were evaluated retrospectively. According to the NCCN definition of preoperative resectability status, tumors were divided into resectable tumors without vascular contact (R group), resectable tumors with portal or superior mesenteric vein (PV/SMV) contact of a parts per thousand broken vertical bar 180A degrees (R-PV group), borderline resectable(BR) tumors with PV/SMV contact of > 180A degrees (BR-PV group), and BR tumors with arterial contact (BR-A group). The relationship between the NCCN definition of preoperative resectability status and overall survival was analyzed. Of the 704 patients, 389, 114, 145, and 56 were classified into the R group, the R-PV group, the BR-PV group, and the BR-A group, respectively. Overall survival of the BR-PV and BR-A groups was significantly worse than that of the R group and R-PV groups (P < 0.05), although there was no significant difference in overall survival between the R group and the R-PV group (P = 0.310). Multivariate analysis revealed that PV/SMV contact of > 180A degrees (P = 0.008) and arterial contact (P < 0.001) were independent prognostic factors of overall survival. From the viewpoint of overall survival, the NCCN definition of preoperative resectability status was valid.	[Murakami, Yoshiaki; Uemura, Kenichiro] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Surg, Minami Ku, Hiroshima 7348551, Japan; [Satoi, Sohei; Yanagimoto, Hiroaki] Kansai Med Univ, Dept Surg, Hirakata, Osaka 5731010, Japan; [Sho, Masayuki; Kinoshita, Shoichi] Nara Med Univ, Dept Surg, Kashihara, Nara 6348522, Japan; [Motoi, Fuyuhiko; Unno, Michiaki] Tohoku Univ, Grad Sch Med, Div Gastroenterol Surg, Dept Surg,Aoba Ku, Sendai, Miyagi 9808574, Japan; [Matsumoto, Ippei; Shinzeki, Makoto] Kobe Univ, Grad Sch Med, Div Hepatobiliary Pancreat Surg, Chuo Ku, Kobe, Hyogo 6500017, Japan; [Kawai, Manabu; Yamaue, Hiroki] Wakayama Med Univ, Dept Surg 2, Sch Med, Wakayama 6418510, Japan; [Honda, Goro; Kurata, Masanao] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Surg, Bunkyo Ku, Tokyo 1138677, Japan	Murakami, Y (reprint author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Surg, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	mura777@hiroshima-u.ac.jp					Shinchi H, 2012, J HEPATO-BIL-PAN SCI, V19, P152, DOI 10.1007/s00534-011-0400-y; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Yamada S, 2013, PANCREAS, V42, P1004, DOI 10.1097/MPA.0b013e31827b2d7c; Murakami Y, 2013, J SURG ONCOL, V107, P414, DOI 10.1002/jso.23229; Nakao A, 2006, WORLD J SURG, V30, P976, DOI 10.1007/s00268-005-0438-6; Bassi C, 2005, SURGERY, V138, P8, DOI 10.1016/j.surg.2005.05.001; Kaneoka Y, 2009, SURGERY, V145, P417, DOI 10.1016/j.surg.2008.12.009; Kim EJ, 2013, CANCER-AM CANCER SOC, V119, P2692, DOI 10.1002/cncr.28117; Miura JT, 2013, ANN SURG ONCOL, V20, P4338, DOI 10.1245/s10434-013-3237-6; Wang JS, 2012, CANCER-AM CANCER SOC, V118, P3801, DOI 10.1002/cncr.26717; Callery MP, 2009, ANN SURG ONCOL, V16, P1727, DOI 10.1245/s10434-009-0408-6; Katz MHG, 2012, CANCER-AM CANCER SOC, V118, P5749, DOI 10.1002/cncr.27636; Kato H, 2013, J HEPATO-BIL-PAN SCI, V20, P601, DOI 10.1007/s00534-013-0595-1; Bockhorn M, 2014, SURGERY, V155, P977, DOI 10.1016/j.surg.2014.02.001; Murakami Y, 2012, J SURG ONCOL, V106, P174, DOI 10.1002/jso.23068; Ishii H, 2010, JPN J CLIN ONCOL, V40, P573, DOI 10.1093/jjco/hyq011; Katz MHG, 2008, J AM COLL SURGEONS, V206, P833, DOI 10.1016/j.jamcollsurg.2007.12.020; Lee JL, 2012, SURGERY, V152, P851, DOI 10.1016/j.surg.2012.03.010; National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology, 2015, PANCR AD VERS 1; Sahora K, 2011, SURGERY, V149, P311, DOI 10.1016/j.surg.2010.07.048; Shimada K, 2006, ANN SURG ONCOL, V13, P1569, DOI 10.1245/s10434-006-9143-4; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sobin LH, 2010, INT UNION CANC UICC; Sudo K, 2012, INT J RADIAT ONCOL, V80, P119; Takahashi S, 2011, J HEPATO-BIL-PAN SCI, V18, P567, DOI 10.1007/s00534-011-0371-z	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	SEP	2015	39	9					2306	2314		10.1007/s00268-015-3096-3		9	Surgery	Surgery	CO8UO	WOS:000359447800028		
J	Hiyoshi, M; Fujii, Y; Kondo, K; Imamura, N; Nagano, M; Ohuchida, J				Hiyoshi, Masahide; Fujii, Yoshiro; Kondo, Kazuhiro; Imamura, Naoya; Nagano, Motoaki; Ohuchida, Jiro			Stent Placement for Portal Vein Stenosis After Pancreaticoduodenectomy	WORLD JOURNAL OF SURGERY			English	Article							INTRAOPERATIVE RADIATION-THERAPY; PEDIATRIC LIVER-TRANSPLANTATION; BLEEDING JEJUNAL VARICES; VENOUS STENOSIS; HYPERTENSION; RECURRENCE; PREVENTION; VENOPLASTY; OCCLUSION; RESECTION	Portal vein (PV) stenosis is a worrisome late complication following pancreaticoduodenectomy (PD) that causes intestinal bleeding from varices, which must be diagnosed correctly and treated promptly. Recent reports advocate the usefulness of stent placement to improve PV stenosis. We evaluated the cause, diagnosis, and treatment method of PV stenosis after PD and the duration of stent patency in our institution. Intestinal bleeding caused by PV stenosis occurred in 5 (2.4 %) of 205 patients. A computed tomography scan was useful to diagnose this complication. Four of 5 patients with PV stenosis underwent percutaneous transhepatic PV stent placement. The duration of stent patency was 21-41 months, and no rebleeding occurred. Percutaneous stent placement is viable, less invasive option than laparotomy for the management of PV stenosis after PD.	[Hiyoshi, Masahide; Fujii, Yoshiro; Kondo, Kazuhiro; Imamura, Naoya; Nagano, Motoaki; Ohuchida, Jiro] Miyazaki Univ, Sch Med, Dept Surg Oncol & Regulat Organ Funct, Kiyotake, Miyazaki, Japan	Hiyoshi, M (reprint author), Miyazaki Univ, Sch Med, Dept Surg Oncol & Regulat Organ Funct, 5200 Kihara, Kiyotake, Miyazaki, Japan.	mhiyoshi@med.miyazaki-u.ac.jp					Agarwal A, 2008, J MED IMAG RADIAT ON, V52, P4, DOI 10.1111/j.1440-1673.2007.01903.x; Zhou ZQ, 2014, ANZ J SURG, V84, P346, DOI 10.1111/ans.12046; Hiyoshi M, 2013, WORLD J SURG, V37, P2436, DOI 10.1007/s00268-013-2149-8; Sakai M, 2005, HEPATO-GASTROENTEROL, V52, P749; Ota S, 2005, J HEPATO-BILIARY-PAN, V12, P88, DOI 10.1007/s00534-004-0941-4; Kim KR, 2011, AM J ROENTGENOL, V196, pW446, DOI 10.2214/AJR.10.5274; Tsuruga Y, 2013, WORLD J GASTROENTERO, V19, P2569, DOI 10.3748/wjg.v19.i16.2569; Hwang S, 2007, J GASTROINTEST SURG, V11, P333, DOI 10.1007/s11605-006-0058-y; Wei BJ, 2009, WORLD J GASTROENTERO, V15, P1880, DOI 10.3748/wjg.15.1880; Shibata T, 2005, RADIOLOGY, V235, P1078, DOI 10.1148/radiol.2353040489; Gubler C, 2012, ENDOSCOPY, V44, P776, DOI 10.1055/s-0032-1309834; Woodrum DA, 2009, J VASC INTERV RADIOL, V20, P593, DOI 10.1016/j.jvir.2009.02.010; Saeki Y, 2013, SURG TODAY, V43, P550, DOI 10.1007/s00595-012-0243-4; Hiraoka K, 2001, SURG TODAY, V31, P1008; Bosch J, 2003, LANCET, V361, P952, DOI 10.1016/S0140-6736(03)12778-X; Reiberger T, 2013, GUT, V62, P1634, DOI 10.1136/gutjnl-2012-304038; Orlandini M, 2014, J PEDIAT-BRAZIL, V90, P169, DOI 10.1016/j.jped.2013.08.010; Yamakado K, 2001, J VASC INTERV RADIOL, V12, P1407, DOI 10.1016/S1051-0443(07)61699-6; Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008; Chijiiwa K, 2009, J HEPATO-BILIARY-PAN, V16, P49, DOI 10.1007/s00534-008-0004-3; Ichihara T, 2007, WORLD J GASTROENTERO, V13, P970; Kawano Y, 2009, TRANSPL INT, V22, P1151, DOI 10.1111/j.1432-2277.2009.00932.x; Lee DH, 2013, AM J ROENTGENOL, V200, P1261, DOI 10.2214/AJR.12.9172; Mitsunaga S, 2006, INT J RADIAT ONCOL, V64, P730, DOI 10.1016/j.ijrob.2005.08.022; Olcott E W, 1990, J Vasc Interv Radiol, V1, P17, DOI 10.1016/S1051-0443(90)72496-7; Park SW, 2007, CARDIOVASC INTER RAD, V30, P719, DOI 10.1007/s00270-007-9001-1; Sakurai K, 2014, INT SURG, V99, P91, DOI 10.9738/INTSURG-D-13-00128.1; Shimizu Y, 2005, J GASTROEN HEPATOL, V20, P1235, DOI 10.1111/j.1400-1746.2005.03913.x; Woo David H, 2007, Tech Vasc Interv Radiol, V10, P233, DOI 10.1053/j.tvir.2007.09.017; Yamashita Y, 2004, SURG TODAY, V34, P925, DOI 10.1007/s00595-004-2848-8; Yamazaki S, 2005, HEPATO-GASTROENTEROL, V52, P191	31	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	SEP	2015	39	9					2315	2322		10.1007/s00268-015-3094-5		8	Surgery	Surgery	CO8UO	WOS:000359447800029		
J	Otsuka, S; Kaneoka, Y; Maeda, A; Takayama, Y; Fukami, Y; Isogai, M				Otsuka, Shimpei; Kaneoka, Yuji; Maeda, Atsuyuki; Takayama, Yuichi; Fukami, Yasuyuki; Isogai, Masatoshi			One-Stage Colectomy with Intraoperative Colonic Irrigation for Acute Left-Sided Malignant Colonic Obstruction	WORLD JOURNAL OF SURGERY			English	Article							LARGE-BOWEL OBSTRUCTION; COLORECTAL-CANCER; EMERGENCY-SURGERY; PRIMARY ANASTOMOSIS; BRIDGE; MANAGEMENT; STENTS; METAANALYSIS; COLONOSCOPY; OUTCOMES	One-stage colectomy with intraoperative colonic irrigation (OCICI) may be useful in early resolution of acute left-sided malignant colonic obstruction (ALMCO). However, the clinical benefit of this technique has not been fully investigated. Between January 2007 and July 2014, 451 patients underwent left hemicolectomy or sigmoidectomy for colon cancer, of whom 25 underwent OCICI for ALMCO. The medical records of the patients who underwent OCICI for ALMCO were compared to 174 medical records of a control population (without ALMCO) who were matched for tumor characteristics. There were no statistically significant differences between the two groups in regard to age, sex, American Society of Anesthesiologists Physical Status, location of tumor, preoperative CEA levels, and previous abdominal surgeries. The OCICI for ALMCO group was associated with a longer operation time (153 +/- A 33 vs. 111 +/- A 47 min, p < 0.001). However, no significant differences were found in patient morbidity, the duration of the postoperative hospital stay, or the tumor pathology between the two groups. Univariate and multivariate analyses indicated that OCICI for ALMCO did not increase the risk of postoperative morbidity in patients with left-sided colon cancer. OCICI for ALMCO did not increase the rate of morbidity or prolong the hospital stay duration compared to treatment of a control population.	[Otsuka, Shimpei; Kaneoka, Yuji; Maeda, Atsuyuki; Takayama, Yuichi; Fukami, Yasuyuki; Isogai, Masatoshi] Ogaki Municipal Hosp, Dept Surg, Ogaki, Gifu 5038502, Japan	Otsuka, S (reprint author), Ogaki Municipal Hosp, Dept Surg, 4-86 Minaminokawa Cho, Ogaki, Gifu 5038502, Japan.	shiootsuka@gmail.com; y-kaneoka@omh.ogaki.gifu.jp					Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; PEARCE NW, 1992, BRIT J SURG, V79, P839, DOI 10.1002/bjs.1800790844; Alcantara M, 2011, WORLD J SURG, V35, P1904, DOI 10.1007/s00268-011-1139-y; Khot UP, 2002, BRIT J SURG, V89, P1096, DOI 10.1046/j.1365-2168.2002.02148.x; Mella J, 1997, BRIT J SURG, V84, P1731; van den Berg MW, 2014, BRIT J SURG, V101, P867, DOI 10.1002/bjs.9521; Sasaki K, 2012, DIS COLON RECTUM, V55, P72, DOI 10.1097/DCR.0b013e318239be5e; Tan CJ, 2012, BRIT J SURG, V99, P469, DOI 10.1002/bjs.8689; BARILLARI P, 1992, INT SURG, V77, P251; DEANS GT, 1994, BRIT J SURG, V81, P1270, DOI 10.1002/bjs.1800810905; Fukami Y, 2009, SURG TODAY, V39, P265, DOI 10.1007/s00595-008-3817-4; Gorissen KJ, 2013, BRIT J SURG, V100, P1805, DOI 10.1002/bjs.9297; Huang X, 2014, J GASTROINTEST SURG, V18, P584, DOI 10.1007/s11605-013-2344-9; Kam MH, 2009, INT J COLORECTAL DIS, V24, P1031, DOI 10.1007/s00384-009-0723-1; Kavanagh DO, 2013, DIS COLON RECTUM, V56, P433, DOI 10.1097/DCR.0b013e3182760506; Marudiachalam K, 2007, BRIT J SURG, V94, P1151, DOI 10.1002/bjs.5790; Nelson H, 2004, NEW ENGL J MED, V350, P2050; Park UC, 2004, INT J COLORECTAL DIS, V19, P487, DOI 10.1007/s00384-004-0584-6; POLLOCK AV, 1987, DIS COLON RECTUM, V30, P171, DOI 10.1007/BF02554331; Sabbagh C, 2013, SURG ENDOSC, V27, P3622, DOI 10.1007/s00464-013-2934-3; Sabbagh C, 2013, ANN SURG, V258, P107, DOI 10.1097/SLA.0b013e31827e30ce; SERPELL JW, 1989, BRIT J SURG, V76, P965, DOI 10.1002/bjs.1800760932; Shigeta K, 2014, J GASTROINTEST SURG, V18, P1507, DOI 10.1007/s11605-014-2541-1; Shingu Y, 2013, SURG ENDOSC, V27, P3359, DOI 10.1007/s00464-013-2917-4; Sobin LH, 2010, TNM CLASSIFICATION M; Turan M, 2002, SURG TODAY, V32, P959	26	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	SEP	2015	39	9					2336	2342		10.1007/s00268-015-3078-5		7	Surgery	Surgery	CO8UO	WOS:000359447800032		
